# ::tok We present a model in which activation of the MAPK cascade signals via c @-@ fos/c @-@ jun family members to activate alpha 2 integrin gene expression .
# ::alignments 0-1.1 1-1 3-1.2 6-1.2.1.1 7-1.2.1.1.1.r 9-1.2.1.1.1.1.1.1 10-1.2.1.1.1 11-1.2.1 13-1.2.1.2.1.1.1.1.1.1 13-1.2.1.2.1.1.2.1.1.1 17-1.2.1.2.1.1.2.1.1.1 18-1.2.1.2.1.1.1 18-1.2.1.2.1.1.2 19-1.2.1.2 21-1.2.1.3 22-1.2.1.3.1.1.1.1 23-1.2.1.3.1.1.1.2 24-1.2.1.3.1.1.1.3 25-1.2.1.2.1.1.1.1 25-1.2.1.2.1.1.2.1 25-1.2.1.3.1.1 26-1.2.1.3.1
# ::id bel_pmid_1002_9589_23800
(p2 / present-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (m / model~e.3
            :location-of (s / signal-01~e.11
                  :ARG0 (a / activate-01~e.6
                        :ARG1~e.7 (c / cascade~e.10
                              :mod (p / pathway
                                    :name (n / name :op1 "MAPK"~e.9))))
                  :instrument (m2 / member~e.19
                        :ARG1-of (i / include-91
                              :ARG2 (a2 / and
                                    :op1 (f / family~e.18
                                          :mod (g2 / gene~e.25
                                                :name (n2 / name :op1 "c-fos"~e.13)))
                                    :op2 (f2 / family~e.18
                                          :mod (g3 / gene~e.25
                                                :name (n3 / name :op1 "c-jun"~e.13,17))))))
                  :purpose (a3 / activate-01~e.21
                        :ARG1 (e / express-03~e.26
                              :ARG1 (g / gene~e.25
                                    :name (n4 / name
                                          :op1 "alpha"~e.22
                                          :op2 "2"~e.23
                                          :op3 "integrin"~e.24)))))))

# ::tok In addition , constitutive activation of the pathway via expression of the constitutively active mutants of MAPKK1 or MAPKK2 induced the expression of the platelet @/@ megakaryocytic @-@ specific genes alpha IIb and eta 3 .
# ::alignments 0-1.1.2.1 1-1.1.2.1 3-1.1.1.2 4-1.1.1 4-1.1.1.3.1.4 5-1.1.1.1.r 7-1.1.1.1 9-1.1.1.3 12-1.1.1.2 14-1.1.1.3.1.3 16-1.1.1.3.1.1.1.1 17-1.1.1.3.1 18-1.1.1.3.1.2.1.1 19-1.1 21-1.1.1.3 21-1.1.2 22-1.1.2.1.r 24-1.1.2.1.3.1.1.1 26-1.1.2.1.3.1.2.1.1 28-1.1.2.1.3 29-1.1.2.1.1 29-1.1.2.1.2 30-1.1.2.1.1.1.1 31-1.1.2.1.1.1.2 32-1 32-1.1.2.1
# ::id bel_pmid_1002_9589_23888
(a / and~e.32
      :op2 (i / induce-01~e.19
            :ARG0 (a2 / activate-01~e.4
                  :ARG1~e.5 (p / pathway~e.7)
                  :mod (c / constitutive~e.3,12)
                  :manner (e / express-03~e.9,21
                        :ARG2 (o / or~e.17
                              :op1 (e2 / enzyme
                                    :name (n / name :op1 "MAPKK1"~e.16))
                              :op2 (e3 / enzyme
                                    :name (n2 / name :op1 "MAPKK2"~e.18))
                              :ARG1-of (m2 / mutate-01~e.14)
                              :ARG1-of (a4 / activate-01~e.4
                                    :mod c))))
            :ARG1 (e4 / express-03~e.21
                  :ARG1~e.22 (a5 / and~e.0,1,32
                        :op1 (g / gene~e.29
                              :name (n3 / name :op1 "alpha"~e.30 :op2 "IIb"~e.31))
                        :op2 (g2 / gene~e.29
                              :name (n4 / name :op1 "beta3"))
                        :mod (s / specific~e.28
                              :topic (c3 / cell
                                    :name (n5 / name :op1 "platelet"~e.24)
                                    :source (c4 / cell
                                          :name (n6 / name :op1 "megakaryocyte"~e.26))))))))

# ::tok Using these methods , we found that JAK2 was essential for signal transduction but that loss of TYK2 made no appreciable difference in tyrosine phosphorylation of downstream molecules , including Mpl , STAT3 , and Shc ( 33 ) .....In fact , tyrosine phosphorylation of STATs and DNA binding assays seem to be almost interchangeable measures of transcriptional activity .
# ::alignments 0-1.1.4 1-1.1.4.1.1 2-1.1.4.1 4-1.1.1 5-1.1 6-1.1.2.r 7-1.1.2.1.1.1.1 8-1.1.2.1.1.r 9-1.1.2.1 11-1.1.2.1.2.1 13-1.1.2 15-1.1.2.2.1 16-1.1.2.2.1.1.r 17-1.1.2.2.1.1.1.1 18-1.1.2.2 19-1.1.2.2.2.1.r 20-1.1.2.2.2.2 20-1.2.1.3.2.2 21-1.1.2.2.2 21-1.1.2.2.2.1 21-1.1.2.2.2.1.r 22-1.2.2 23-1.2.1.1.1.1.1 24-1.1.2.2.3 25-1.1.2.2.3.1.r 26-1.1.2.2.3.1.2.1 27-1.1.2.2.3.1.2 29-1.1.2.2.3.1.2.2 30-1.1.2.2.3.1.2.2.1.1.1.1 32-1.1.2.2.3.1.2.2.1.2.1.1 34-1.1.2.2.3.1.2.2.1 35-1.1.2.2.3.1.2.2.1.3.1.1 37-1.1.3.1.1.1 40-1.2.2 42-1.1.2.2.3.1.1.1 42-1.2.1.1.1.1.1 43-1.2.1.1 46-1.2.1 47-1.2.1.2.1.1 48-1.2.1.2.1 49-1.2.1.2 50-1.2 53-1.2.1.3.2.1 55-1.2.1.3
# ::id bel_pmid_1008_0909_21272
(m / multi-sentence
      :snt1 (f / find-01~e.5
            :ARG0 (w / we~e.4)
            :ARG1~e.6 (c / contrast-01~e.13
                  :ARG1 (e / essential~e.9
                        :domain~e.8 (e2 / enzyme
                              :name (n / name :op1 "JAK2"~e.7))
                        :purpose (t / transduct-00
                              :ARG1 (s / signal-01~e.11)))
                  :ARG2 (m2 / make-01~e.18
                        :ARG0 (l / lose-01~e.15
                              :ARG1~e.16 (e3 / enzyme
                                    :name (n2 / name :op1 "TYK2"~e.17)))
                        :ARG1 (d / difference~e.21
                              :polarity~e.19,21 "-"~e.21
                              :mod (a / appreciable~e.20))
                        :ARG3 (p / phosphorylate-01~e.24
                              :ARG1~e.25 (a2 / amino-acid
                                    :name (n3 / name :op1 "tyrosine"~e.42)
                                    :part-of (m5 / molecule~e.27
                                          :location (d2 / downstream~e.26)
                                          :ARG2-of (i / include-01~e.29
                                                :ARG1 (a3 / and~e.34
                                                      :op1 (p2 / protein
                                                            :name (n4 / name :op1 "Mpl"~e.30))
                                                      :op2 (p3 / protein
                                                            :name (n5 / name :op1 "STAT3"~e.32))
                                                      :op3 (p4 / protein
                                                            :name (n6 / name :op1 "Shc"~e.35)))))))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p5 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "33"~e.37)))
            :manner (u / use-01~e.0
                  :ARG1 (m3 / method~e.2
                        :mod (t2 / this~e.1))))
      :snt2 (s3 / seem-01~e.50
            :ARG1 (a4 / and~e.46
                  :op1 (p6 / phosphorylate-01~e.43
                        :ARG1 (a5 / amino-acid
                              :name (n7 / name :op1 "tyrosine"~e.23,42)
                              :part-of (p7 / protein
                                    :name (n8 / name :op1 "STAT"))))
                  :op2 (a6 / assay-00~e.49
                        :ARG1 (b / bind-01~e.48
                              :ARG1 (d4 / DNA~e.47)))
                  :ARG2-of (m4 / measure-01~e.55
                        :ARG1 (a7 / act-01
                              :ARG1 (t3 / transcribe-01))
                        :mod (i3 / interchange-01
                              :mod (a8 / almost~e.53)
                              :mod (p8 / possible~e.20))))
            :mod (i2 / in-fact~e.22,40)))

# ::tok It has been difficult to interpret the physiologic role of STAT signaling in megakaryocyte development . In multiple cell lines it was reported that TPO induced activation of both STAT3 and STAT5 ( 5A and 5B ) ( 26 , 28?30 , 37 , 38 ) ....However , when purified murine megakaryocyte extracts were examined , we found that STAT3 was much more pronounced in both tyrosine phosphorylation and DNA binding activity than STAT5 ( 32 )
# ::alignments 2-1.1.1.r 3-1.1 5-1.1.1 7-1.1.1.1.1 8-1.1.1.1 9-1.1.1.1.2.r 10-1.1.1.1.2.1.1.1 11-1.1.1.1.2 12-1.1.1.1.3.r 13-1.1.1.1.3.1.1.1 14-1.1.1.1.3 17-1.2.3.1 18-1.2.3 19-1.2.3 22-1.2 23-1.2.1.r 24-1.2.1.1.1.1 25-1.2.1 26-1.2.1.2 27-1.2.1.2.1.r 28-1.2.1.2.1.3 29-1.2.1.2.1.1.1.1 30-1.2.1.2.1 30-1.2.2.1 31-1.2.1.2.1.2.1.1 33-1.2.2.1.1.1 34-1.2.2.1 34-1.2.2.1.3.1.1 35-1.2.2.1.2.1 38-1.2.2.1.3.1.1.1 42-1.2.2.1.3.1.1.4 44-1.2.2.1.3.1.1.5 48-1.3.1.3.r 49-1.3.1.3.1.1.2 50-1.3.1.3.1.1.1.1 51-1.3.1.3.1.1.1 52-1.3.1.3.1 52-1.3.1.3.1.1 52-1.3.1.3.1.1.r 54-1.3.1.3 56-1.3.1.1 57-1.3.1 58-1.3.1.2.r 59-1.3.1.2.1.1.1 60-1.3.1.2.1.r 61-1.3.1.2.2.1 62-1.3.1.2.2 63-1.3.1.2 64-1.3.1.2.3.r 65-1.3.1.2.3.3 66-1.3.1.2.3.1.1.1.1 67-1.3.1.2.3.1 68-1.3.1.2.3 69-1.3.1.2.3.2.1.1 70-1.3.1.2.3.2.1 71-1.3.1.2.3.2 72-1.3.1.2.4.r 73-1.3.1.2.4.1.1 75-1.3.2.1.1.1
# ::id bel_pmid_1008_0909_24618
(m / multi-sentence
      :snt1 (d / difficult~e.3
            :domain~e.2 (i / interpret-01~e.5
                  :ARG1 (r / role~e.8
                        :mod (p2 / physiologic~e.7)
                        :poss~e.9 (s / signal-01~e.11
                              :ARG0 (p3 / protein
                                    :name (n / name :op1 "STAT"~e.10)))
                        :purpose~e.12 (d2 / develop-02~e.14
                              :ARG1 (c / cell
                                    :name (n2 / name :op1 "megakaryocyte"~e.13))))))
      :snt2 (r2 / report-01~e.22
            :ARG1~e.23 (i2 / induce-01~e.25
                  :ARG0 (p4 / protein
                        :name (n3 / name :op1 "TPO"~e.24))
                  :ARG1 (a / activate-01~e.26
                        :ARG1~e.27 (a2 / and~e.30
                              :op1 (p5 / protein
                                    :name (n4 / name :op1 "STAT3"~e.29))
                              :op2 (p6 / protein
                                    :name (n5 / name :op1 "STAT5"~e.31))
                              :mod (b / both~e.28))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (a3 / and~e.30,34
                        :op1 (f / figure :mod "5A"~e.33)
                        :op2 (f2 / figure :mod "5B"~e.35)
                        :op3 (p7 / publication
                              :ARG1-of (c2 / cite-01
                                    :ARG2 (a4 / and~e.34
                                          :op1 "26"~e.38
                                          :op2 "28"
                                          :op3 "30"
                                          :op4 "37"~e.42
                                          :op5 "38"~e.44)))))
            :location (c5 / cell-line~e.18,19
                  :quant (m5 / multiple~e.17)))
      :snt3 (c6 / contrast-01
            :ARG2 (f3 / find-01~e.57
                  :ARG0 (w / we~e.56)
                  :ARG1~e.58 (p8 / pronounced~e.63
                        :domain~e.60 (p9 / protein
                              :name (n6 / name :op1 "STAT3"~e.59))
                        :degree (m2 / more~e.62
                              :quant (m3 / much~e.61))
                        :condition~e.64 (a5 / and~e.68
                              :op1 (p10 / phosphorylate-01~e.67
                                    :ARG1 (a6 / amino-acid
                                          :name (n7 / name :op1 "tyrosine"~e.66)))
                              :op2 (a7 / activity~e.71
                                    :ARG0-of (b2 / bind-01~e.70
                                          :ARG1 (d4 / DNA~e.69)))
                              :mod (b3 / both~e.65))
                        :compared-to~e.72 (p11 / protein
                              :name (n8 / name :op1 "STAT5"~e.73)))
                  :time~e.48 (e / examine-01~e.54
                        :ARG1 (t / thing~e.52
                              :ARG1-of~e.52 (e2 / extract-01~e.52
                                    :ARG2 (m6 / megakaryocyte~e.51
                                          :mod (m4 / murine~e.50))
                                    :ARG1-of (p13 / purify-01~e.49)))))
            :ARG1-of (d5 / describe-01
                  :ARG0 (p12 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "32"~e.75)))))

# ::tok Activation of MEK1 and MEK2 involves phosphorylation upon conserved serine residues ( Ser @-@ 218 and Ser @-@ 222 on MEK1 , Ser @-@ 222 and Ser @-@ 226 on MEK2
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1 3-1.1.1 4-1.1.1.2.1.1 5-1 6-1.2 8-1.2.1.2 9-1.2.1.1.1.1 9-1.2.1.3.1.1.1.2.1 9-1.2.1.3.1.1.2.2.1 9-1.2.1.3.1.2.1.2.1 9-1.2.1.3.1.2.2.2.1 10-1.2.1 14-1.2.1.3.1.1.1.1 15-1.2.1.3.1 15-1.2.1.3.1.1 15-1.2.1.3.1.1.r 15-1.2.1.3.1.2 18-1.2.1.3.1.1.2.1 18-1.2.1.3.1.2.1.1 20-1.1.1.1.1.1 24-1.2.1.3.1.1.2.1 24-1.2.1.3.1.2.1.1 25-1.2.1.3.1 25-1.2.1.3.1.1 25-1.2.1.3.1.1.r 25-1.2.1.3.1.2 28-1.2.1.3.1.2.2.1 29-1.2.1.3.1.2.r 30-1.2.1.3.1.2.3
# ::id bel_pmid_1008_5062_23884
(i / involve-01~e.5
      :ARG0 (a2 / activate-01~e.0
            :ARG1~e.1 (a3 / and~e.3
                  :op1 (e / enzyme
                        :name (n2 / name :op1 "MEK1"~e.2,20))
                  :op2 (e2 / enzyme
                        :name (n3 / name :op1 "MEK2"~e.4))))
      :ARG1 (p2 / phosphorylate-01~e.6
            :ARG1 (r / residue~e.10
                  :mod (a4 / amino-acid
                        :name (n4 / name :op1 "serine"~e.9))
                  :ARG1-of (c / conserve-01~e.8)
                  :ARG1-of (m / mean-01
                        :ARG2 (a5 / and~e.15,25
                              :op1~e.15,25 (a6 / and~e.15,25
                                    :op1 (a7 / amino-acid
                                          :mod "218"~e.14
                                          :name (n5 / name :op1 "serine"~e.9))
                                    :op2 (a8 / amino-acid
                                          :mod "222"~e.18,24
                                          :name (n6 / name :op1 "serine"~e.9))
                                    :part-of e)
                              :op2~e.29 (a9 / and~e.15,25
                                    :op1 (a10 / amino-acid
                                          :mod "222"~e.18,24
                                          :name (n7 / name :op1 "serine"~e.9))
                                    :op2 (a11 / amino-acid
                                          :mod "226"~e.28
                                          :name (n8 / name :op1 "serine"~e.9))
                                    :part-of e2~e.30))))))

# ::tok c @-@ Cbl is tyrosine @-@ phosphorylated , binds to Fyn upon insulin stimulation , and is translocated to small invaginations of the plasma membrane , called caveolae , after insulin stimulation
# ::alignments 0-1.1.1.2.1.1 2-1.1.1.2.1.1 4-1.1.1.1.1 6-1.1 8-1.2 9-1.2.2.r 10-1.2.2.1.1 12-1.2.3.1 13-1.2.3 15-1 19-1.3.2.2 20-1.3.2 21-1.3.2.1.r 23-1.3.2.1.1 24-1.3.2.1 26-1.3.2.1.2 27-1.3.2.1.2.1 29-1.3.3 30-1.3.3.1 31-1.3.3.1
# ::id bel_pmid_1019_4465_17324
(a / and~e.15
      :op1 (p / phosphorylate-01~e.6
            :ARG1 (a2 / amino-acid
                  :name (n2 / name :op1 "tyrosine"~e.4)
                  :part-of (p3 / protein
                        :name (n / name :op1 "c-Cbl"~e.0,2))))
      :op2 (b / bind-01~e.8
            :ARG1 p3
            :ARG2~e.9 (e / enzyme
                  :name (n3 / name :op1 "Fyn"~e.10))
            :condition (s / stimulate-01~e.13
                  :ARG2 (i2 / insulin~e.12)))
      :op3 (t / translocate-00
            :ARG1 p3
            :location (i / invaginate-00~e.20
                  :ARG1~e.21 (m / membrane~e.24
                        :mod (p2 / plasma~e.23)
                        :ARG1-of (c / call-01~e.26
                              :ARG2 (c2 / caveolae~e.27)))
                  :mod (s2 / small~e.19))
            :time (a3 / after~e.29
                  :op1 s~e.30,31)))

# ::tok Insulin and IGF @-@ 1 stimulation also promote association between IRS @-@ 1 and aVb3 integrin ( vitronectin receptor )
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1.1.2.1.1 4-1.1.1.2.1.1 5-1.1 6-1.3 7-1 8-1.2 10-1.2.2.1.1 12-1.2.2.1.1 14-1.2.3.1.1 15-1.2.3 17-1.2.3.2.1.1.1.1 18-1.2.3.2.1
# ::id bel_pmid_1019_4465_17346
(p / promote-01~e.7
      :ARG0 (s / stimulate-01~e.5
            :ARG1 (a2 / and~e.1
                  :op1 (i / insulin~e.0)
                  :op2 (p3 / protein
                        :name (n2 / name :op1 "IGF-1"~e.2,4))))
      :ARG1 (a3 / associate-01~e.8
            :ARG0 a2
            :ARG1 (p2 / protein
                  :name (n3 / name :op1 "IRS-1"~e.10,12))
            :ARG2 (i2 / integrin~e.15
                  :name (n4 / name :op1 "aVb3"~e.14)
                  :ARG1-of (d / describe-01
                        :ARG2 (r / receptor~e.18
                              :mod (p4 / protein
                                    :name (n / name :op1 "vitronectin"~e.17))))))
      :mod (a / also~e.6))

# ::tok Thiazolidinediones ( TZDs ) , the class of insulin sensitizers that act through the nuclear receptor PPAR @-@ g , increase CAP expression levels and c @-@ Cbl phosphorylation significantly in adipocytes ( 54 ) , possibly contributing to their insulin sensitizing effect
# ::alignments 6-1.1.1 7-1.1.1.1.r 8-1.1.1.1.1.1 11-1.1.1.1 11-1.1.1.1.2 11-1.1.1.1.2.r 14-1.1.1.1.2.1.2 15-1.1.1.1.2.1 16-1.1.1.1.2.1.1.1 18-1.1.1.1.2.1.1.1 20-1 21-1.2.1.1.1.1.1 22-1.2.1.1 23-1.2.1 24-1.2 25-1.2.2.1.1.1 27-1.2.2.1.1.1 28-1.2.2 29-1.3 33-1.5.1.1.1 36-1.6.2 37-1.6 40-1.1.1.1.1.1 41-1.1.1.1.1 41-1.6.1.1 42-1.6.1
# ::id bel_pmid_1019_4465_17828
(i / increase-01~e.20
      :ARG0 (t / thiazolidinedione
            :mod (c / class~e.6
                  :mod~e.7 (m / molecular-physical-entity~e.11
                        :ARG0-of (s / sensitize-01~e.41
                              :ARG1 (i2 / insulin~e.8,40))
                        :ARG0-of~e.11 (a / act-01~e.11
                              :instrument (r / receptor~e.15
                                    :name (n2 / name :op1 "PPAR-g"~e.16,18)
                                    :mod (n / nucleus~e.14))))))
      :ARG1 (a2 / and~e.24
            :op1 (l / level~e.23
                  :degree-of (e / express-03~e.22
                        :ARG2 (p5 / protein
                              :name (n6 / name :op1 "CAP"~e.21))))
            :op2 (p3 / phosphorylate-01~e.28
                  :ARG1 (p6 / protein
                        :name (n4 / name :op1 "c-Cbl"~e.25,27))))
      :degree (s2 / significant~e.29)
      :location (c2 / cell
            :name (n5 / name :op1 "adipocyte"))
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c4 / cite-01 :ARG2 "54"~e.33)))
      :ARG0-of (c3 / contribute-01~e.37
            :ARG1 (a3 / affect-01~e.42
                  :ARG1 (s3 / sensitize-01~e.41
                        :ARG0 t
                        :ARG1 i2))
            :mod (p / possible~e.36)))

# ::tok Interestingly , this NPXY sequence is also a receptor internalization motif found in many members of the tyrosine kinase receptor family , the low @-@ density lipoprotein receptor ( 11 @-@ 13 ) , and the transferrin receptor ( 14 ) , all of which are internalized in a ligand @-@ dependent fashion .
# ::alignments 2-1.2.2 3-1.2.1.1 4-1.2 5-1.2.r 6-1.5 8-1.1.1 9-1.1 10-1 11-1.3 12-1.3.1.r 13-1.3.1.1 14-1.3.1 17-1.3.1.2.1.1.1.1 18-1.3.1.2.1.1.1.2 19-1.3.1.2.1.1.1.3 20-1.3.1.2.1 23-1.3.1.4.1.1.1 25-1.3.1.4.1.1.1 26-1.3.1.4.1.1.2 27-1.3.1.4.1.1.3 29-1.3.1.4.1.2.1.1.1.1 31-1.3.1.4.1.2.1.1.1.2 34-1.3.1.4 36-1.3.1.4.2.1.1 37-1.3.1.4.2.1.2 39-1.3.1.4.2.2.1.1.1 46-1.3.1.3 47-1.3.1.3.1.r 49-1.3.1.3.1.1 51-1.3.1.3.1
# ::id bel_pmid_1019_4465_19902
(m / motif~e.10
      :ARG0-of (i / internalize-01~e.9
            :ARG1 (r / receptor~e.8))
      :domain~e.5 (d / dna-sequence~e.4
            :name (n / name :op1 "NPXY"~e.3)
            :mod (t / this~e.2))
      :ARG1-of (f2 / find-01~e.11
            :location~e.12 (m2 / member~e.14
                  :quant (m3 / many~e.13)
                  :ARG1-of (i2 / include-91
                        :ARG2 (f3 / family~e.20
                              :mod (p / protein
                                    :name (n2 / name
                                          :op1 "tyrosine"~e.17
                                          :op2 "kinase"~e.18
                                          :op3 "receptor"~e.19))))
                  :ARG1-of (i4 / internalize-01~e.46
                        :manner~e.47 (d4 / depend-01~e.51
                              :ARG1 (l / ligand~e.49)))
                  :example (a / and~e.34
                        :op1 (p2 / protein
                              :name (n3 / name
                                    :op1 "low-density"~e.23,25
                                    :op2 "lipoprotein"~e.26
                                    :op3 "receptor"~e.27)
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p3 / publication
                                          :ARG1-of (c / cite-01
                                                :ARG2 (v / value-interval :op1 "11"~e.29 :op2 "13"~e.31)))))
                        :op2 (p4 / protein
                              :name (n4 / name :op1 "transferrin"~e.36 :op2 "receptor"~e.37)
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (p5 / publication
                                          :ARG1-of (c2 / cite-01 :ARG2 "14"~e.39)))))))
      :ARG2-of (i3 / interest-01)
      :mod (a2 / also~e.6))

# ::tok Csk has been reported to associate with IRS @-@ 1 through its SH2 domain and promote dephosphorylation of the focal adhesion kinase ( FAK ) in an insulin @-@ dependent manner ( 56 ) .
# ::alignments 0-1.1.1.1.2.1.1 3-1 5-1.1.1 6-1.1.1.2.r 7-1.1.1.2.1.1 9-1.1.1.2.1.1 12-1.1.1.1.1.1 13-1.1.1.1.1.2 14-1.1 15-1.1.2 16-1.1.2.2 17-1.1.2.2.1.r 19-1.1.2.2.1.1.1 20-1.1.2.2.1.1.2 21-1.1.2.2.1.1.3 27-1.1.2.2.2.1 29-1.1.2.2.2 30-1.1.2.2.2.r 32-1.2.1.1.1
# ::id bel_pmid_1019_4465_19968
(r / report-01~e.3
      :ARG1 (a / and~e.14
            :op1 (a2 / associate-01~e.5
                  :ARG1 (p6 / protein-segment
                        :name (n6 / name :op1 "SH2"~e.12 :op2 "domain"~e.13)
                        :part-of (p / protein
                              :name (n / name :op1 "Csk"~e.0)))
                  :ARG2~e.6 (p2 / protein
                        :name (n2 / name :op1 "IRS-1"~e.7,9)))
            :op2 (p3 / promote-01~e.15
                  :ARG0 p
                  :ARG1 (d2 / dephosphorylate-01~e.16
                        :ARG1~e.17 (p4 / protein
                              :name (n4 / name
                                    :op1 "focal"~e.19
                                    :op2 "adhesion"~e.20
                                    :op3 "kinase"~e.21))
                        :manner~e.30 (d4 / depend-01~e.29
                              :ARG1 (i / insulin~e.27)))))
      :ARG1-of (d5 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c / cite-01 :ARG2 "56"~e.32))))

# ::tok In smooth muscle cells , blocking ligand occupancy of aVb3 integrin reduces IGF @-@ 1 @-@ induced IRS @-@ 1 phosphorylation
# ::alignments 1-1.3.1.1 2-1.3.1 3-1.3 5-1.1 6-1.1.1.1 9-1.1.1.2.1.1 10-1.1.1.2 11-1 12-1.2.2.1.1.1 14-1.2.2.1.1.1 16-1.2.2 17-1.2.1.1.1 19-1.2.1.1.1 20-1.2
# ::id bel_pmid_1019_4465_20030
(r / reduce-01~e.11
      :ARG0 (b / block-01~e.5
            :ARG1 (o / occupy-01
                  :ARG0 (l / ligand~e.6)
                  :ARG1 (i2 / integrin~e.10
                        :name (n / name :op1 "aVb3"~e.9))))
      :ARG1 (p / phosphorylate-01~e.20
            :ARG1 (p2 / protein
                  :name (n2 / name :op1 "IRS-1"~e.17,19))
            :ARG1-of (i / induce-01~e.16
                  :ARG0 (p3 / protein
                        :name (n3 / name :op1 "IGF-1"~e.12,14))))
      :location (c / cell~e.3
            :mod (m / muscle~e.2
                  :mod (s / smooth~e.1))))

# ::tok Nck associates with IRS @-@ 1 ( 45 ) , many different tyrosine kinases , several serine @/@ threonine kinases through its SH2 domain , as well as Sos through its SH3 domains
# ::alignments 0-1.1.2.1.1 1-1 10-1.2.1.2 11-1.2.1 11-1.2.1.3 11-1.2.1.3.r 12-1.2.1.1.1 13-1.2.1.1.2 15-1.2.2.3 16-1.2.2.1.1.1 18-1.2.2.2.1.1 19-1.2.1.1.2 19-1.2.2.1.1.2 19-1.2.2.2.1.2 22-1.1.1.1 23-1.1.1.2 27-1.2.r 28-1.2.3.2.1.1 31-1.2.3.1.1 32-1.2.3.1.2
# ::id bel_pmid_1019_4465_20066
(a / associate-01~e.1
      :ARG1 (p3 / protein-segment
            :name (n8 / name :op1 "SH2"~e.22 :op2 "domain"~e.23)
            :part-of (p / protein
                  :name (n / name :op1 "Nck"~e.0)))
      :ARG2~e.27 (a2 / and
            :op1 (e / enzyme~e.11
                  :name (n2 / name :op1 "tyrosine"~e.12 :op2 "kinase"~e.13,19)
                  :quant (m / many~e.10)
                  :ARG1-of~e.11 (d / differ-02~e.11))
            :op2 (o / or
                  :op1 (e2 / enzyme
                        :name (n3 / name :op1 "serine"~e.16 :op2 "kinase"~e.19))
                  :op2 (e3 / enzyme
                        :name (n4 / name :op1 "threonine"~e.18 :op2 "kinase"~e.19))
                  :quant (s / several~e.15))
            :op3 (p4 / protein-segment
                  :name (n9 / name :op1 "SH3"~e.31 :op2 "domain"~e.32)
                  :part-of (p2 / protein
                        :name (n6 / name :op1 "Sos"~e.28)))))

# ::tok Gab @-@ 1 is heavily phosphorylated by the epidermal growth factor receptor , but poorly by the insulin receptor
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 4-1.1.3 5-1.1 5-1.2 9-1.1.2.1.1 10-1.1.2.1.2 11-1.2.2 13-1 14-1.2.3 17-1.2.2.1 18-1.2.2
# ::id bel_pmid_1019_4465_21192
(c / contrast-01~e.13
      :ARG1 (p / phosphorylate-01~e.5
            :ARG1 (p4 / protein
                  :name (n2 / name :op1 "Gab-1"~e.0,2))
            :ARG2 (e2 / enzyme
                  :name (n / name :op1 "growth"~e.9 :op2 "factor"~e.10)
                  :mod (e / epidermis))
            :degree (h2 / heavy~e.4))
      :ARG2 (p2 / phosphorylate-01~e.5
            :ARG1 p4
            :ARG2 (r / receptor~e.11,18
                  :mod (i / insulin~e.17))
            :degree (p3 / poor~e.14)))

# ::tok Recently , it was shown that Fyn is one of the kinases responsible for the phosphorylation of caveolin
# ::alignments 0-1.2 4-1 5-1.1.r 6-1.1.1.1 11-1.1.2.1 12-1.1.2.1.1 13-1.1.2.1.1.1.r 15-1.1.2.1.1.1 16-1.1.2.1.1.1.1.r 17-1.1.2.1.1.1.1.1.1
# ::id bel_pmid_1019_4465.21226
(s / show-01~e.4
      :ARG1~e.5 (e / enzyme
            :name (n / name :op1 "Fyn"~e.6)
            :ARG1-of (i / include-91
                  :ARG2 (k / kinase~e.11
                        :ARG0-of (r / responsible-01~e.12
                              :ARG1~e.13 (p / phosphorylate-01~e.15
                                    :ARG1~e.16 (p2 / protein
                                          :name (n2 / name :op1 "caveolin"~e.17)))))))
      :time (r2 / recent~e.0))

# ::tok It also contains an additional binding site located in the phosphorylated kinase activation loop of the insulin receptor but is only very slightly phosphorylated by insulin receptor .
# ::alignments 0-1.1.1 1-1.1.3 2-1.1 4-1.1.2.2 5-1.1.2.3 6-1.1.2 7-1.1.2.1 10-1.1.2.1.1.1.1.1 11-1.1.2.1.1.1.1 12-1.1.2.1.1.1 13-1.1.2.1.1 14-1.1.2.1.1.2.r 16-1.1.2.1.1.2.1 17-1.1.2.1.1.2 18-1 19-1.1.2.1 20-1.2.3.2 21-1.2.3.1 22-1.2.3 23-1.2 24-1.2.2.r 25-1.2.2 26-1.2.2
# ::id bel_pmid_1019_4465_21256
(h / have-concession-91~e.18
      :ARG1 (c / contain-01~e.2
            :ARG0 (i / it~e.0)
            :ARG1 (p3 / protein-segment~e.6
                  :ARG1-of (b2 / be-located-at-91~e.7,19
                        :ARG2 (l2 / loop~e.13
                              :ARG0-of (a / activate-01~e.12
                                    :ARG1 (k / kinase~e.11
                                          :ARG3-of (p / phosphorylate-01~e.10)))
                              :poss~e.14 (r2 / receptor~e.17
                                    :mod (i2 / insulin~e.16))))
                  :mod (a2 / additional~e.4)
                  :ARG1-of (b / bind-01~e.5))
            :mod (a3 / also~e.1))
      :ARG2 (p2 / phosphorylate-01~e.23
            :ARG1 i
            :ARG2~e.24 r2~e.25,26
            :degree (s2 / slight~e.22
                  :degree (v / very~e.21)
                  :mod (o / only~e.20))))

# ::tok Crk has been reported to associate with tyrosine @-@ phosphorylated proteins , such as p130Cas and paxillin ( 42 , 43 ) , involved in the rearrangement of cytoskeletal components , through its SH2 domain .
# ::alignments 0-1.1.1.1.1 3-1 5-1.1 6-1.1.2.4.2.r 7-1.1.2.2.1.1 9-1.1.2.3 10-1.1.2 12-1.1.2.1.r 13-1.1.2.1.r 14-1.1.2.1.1.1.1 15-1.1.2.1 15-1.1.2.1.3.1.1.1 16-1.1.2.1.2.1.1 18-1.1.2.1.3.1.1.1.1 20-1.1.2.1.3.1.1.1.2 23-1.1.2.4 24-1.1.2.4.1.r 26-1.1.2.4.1 29-1.1.2.4.1.1 32-1.1.2.4.2.2 32-1.1.2.4.2.2.r 33-1.1.2.4.2.1.1 34-1.1.2.4.2.1.2
# ::id bel_pmid_1019_4465_22614
(r / report-01~e.3
      :ARG1 (a / associate-01~e.5
            :ARG1 (p / protein
                  :name (n / name :op1 "Crk"~e.0))
            :ARG2 (p2 / protein~e.10
                  :example~e.12,13 (a3 / and~e.15
                        :op1 (p4 / protein
                              :name (n3 / name :op1 "p130Cas"~e.14))
                        :op2 (p5 / protein
                              :name (n4 / name :op1 "paxillin"~e.16))
                        :ARG1-of (d / describe-01
                              :ARG0 (p6 / publication
                                    :ARG1-of (c / cite-01
                                          :ARG2 (a4 / and~e.15 :op1 "42"~e.18 :op2 "43"~e.20)))))
                  :part (a2 / amino-acid
                        :name (n2 / name :op1 "tyrosine"~e.7))
                  :ARG1-of (p3 / phosphorylate-01~e.9)
                  :ARG1-of (i / involve-01~e.23
                        :ARG2~e.24 (r2 / rearrange-01~e.26
                              :ARG1 (c2 / component~e.29
                                    :part-of (c3 / cytoskeleton)))
                        :instrument~e.6 (p7 / protein-segment
                              :name (n5 / name :op1 "SH2"~e.33 :op2 "domain"~e.34)
                              :part-of~e.32 p~e.32)))))

# ::tok c @-@ Cbl associated protein ( CAP ) that has three sequential SH3 domains is specifically expressed in insulin @-@ responsive cell types and associates with both c @- Cbl and the insulin receptor
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 3-1.1.1.1.2 3-1.2 4-1.1.1.1.3 9-1.1.1 9-1.1.1.2 9-1.1.1.2.r 10-1.1.1.2.1.1 11-1.1.1.2.1.3 12-1.1.1.2.1.2.1 13-1.1.1.2.1.2.2 15-1.1.3 16-1.1 17-1.1.2.r 18-1.1.2.1.1.1 20-1.1.2.1.1 21-1.1.2.1 22-1.1.2 23-1 24-1.2 27-1.2.2.1.1.1 29-1.2.2.1.1.1 30-1.2.2 32-1.2.2.2.1 33-1.2.2.2
# ::id bel_pmid_1019_4465_22706
(a / and~e.23
      :op1 (e / express-03~e.16
            :ARG2 (p / protein~e.9
                  :name (n / name
                        :op1 "c-Cbl"~e.0,2
                        :op2 "associated"~e.3
                        :op3 "protein"~e.4)
                  :ARG0-of~e.9 (h / have-03~e.9
                        :ARG1 (p2 / protein-segment
                              :quant "3"~e.10
                              :name (n2 / name :op1 "SH3"~e.12 :op2 "domain"~e.13)
                              :mod (s / sequential~e.11))))
            :ARG3~e.17 (t / type~e.22
                  :mod (c / cell~e.21
                        :ARG1-of (r / respond-01~e.20
                              :ARG0 (i / insulin~e.18))))
            :manner (s2 / specific~e.15))
      :op2 (a2 / associate-01~e.3,24
            :ARG1 p
            :ARG2 (a3 / and~e.30
                  :op1 (p3 / protein
                        :name (n3 / name :op1 "c-Cbl"~e.27,29))
                  :op2 (r2 / receptor~e.33
                        :mod i~e.32))))

# ::tok Recently , phosphorylated p62 dok was demonstrated to associate with the GTPase @-@ activating protein ( GAP ) for Ras .
# ::alignments 0-1.2 2-1.1.1.2 6-1 8-1.1 9-1.1.2.r 11-1.1.2.1.1 13-1.1.2.1.1 14-1.1.2.1.2 18-1.1.3.r 19-1.1.3.1.1
# ::id bel_pmid_1019_4465_22914
(d / demonstrate-01~e.6
      :ARG1 (a / associate-01~e.8
            :ARG1 (p / protein
                  :name (n2 / name :op1 "p62dok")
                  :ARG3-of (p2 / phosphorylate-01~e.2))
            :ARG2~e.9 (p3 / protein
                  :name (n3 / name :op1 "GTPase-activating"~e.11,13 :op2 "protein"~e.14))
            :beneficiary~e.18 (e / enzyme
                  :name (n / name :op1 "Ras"~e.19)))
      :time (r / recent~e.0))

# ::tok In the case of insulin , it is unclear whether SHIP associates with IRS proteins or the insulin receptor , although a recent report has demonstrated SHIP association with IRS @-@ 2 in response to erythropoietin
# ::alignments 4-1.1.1 7-1.1.2.2.r 8-1.1.2 8-1.1.2.1 8-1.1.2.1.r 9-1.1.2.2.1 9-1.1.2.2.1.r 10-1.1.2.2.2.1.1 11-1.1.2.2 12-1.1.2.2.3.r 13-1.1.2.2.3.1.1.1 14-1.1.2.2.2 14-1.1.2.2.3.1 14-1.2.2.2 15-1.1.2.2.3 17-1.1.2.2.3.2.1 18-1.1.2.2.3.2 20-1 22-1.2.1.1 23-1.2.1 25-1.2 26-1.1.2.2.2.1.1 27-1.2.2 29-1.2.2.2.1.1 31-1.2.2.2.1.1 32-1.2.2.3.r 33-1.2.2.3 34-1.2.2.3.1.r 35-1.2.2.3.1
# ::id bel_pmid_1019_4465_23034
(h / have-concession-91~e.20
      :ARG1 (e / exemplify-01
            :ARG0 (i / insulin~e.4)
            :ARG1 (c / clear~e.8
                  :polarity~e.8 "-"~e.8
                  :domain~e.7 (a / associate-01~e.11
                        :mode~e.9 "interrogative"~e.9
                        :ARG1 (p2 / protein~e.14
                              :name (n3 / name :op1 "SHIP"~e.10,26))
                        :ARG2~e.12 (o / or~e.15
                              :op1 (p / protein~e.14
                                    :name (n2 / name :op1 "IRS"~e.13))
                              :op2 (r / receptor~e.18
                                    :mod i~e.17)))))
      :ARG2 (d / demonstrate-01~e.25
            :ARG0 (r2 / report~e.23
                  :time (r3 / recent~e.22))
            :ARG1 (a2 / associate-01~e.27
                  :ARG1 p
                  :ARG2 (p3 / protein~e.14
                        :name (n4 / name :op1 "IRS-2"~e.29,31))
                  :ARG2-of~e.32 (r4 / respond-01~e.33
                        :ARG1~e.34 (e2 / erythropoietin~e.35)))))

# ::tok The SH2 domain of the adaptor protein Grb @- 2 and the SH2 domain of the phosphotyrosine phosphatase SHP @-@ 2 bind other sequences , including pYVNI , pYIDL , and pYASI sequences ( 1 ) .
# ::alignments 1-1.1.1.1.1 1-1.1.2.1.1 2-1.1.1.1.2 2-1.1.2.1.2 5-1.1.1.2.2 6-1.1.1 6-1.1.1.2 6-1.1.1.2.r 6-1.1.2 6-1.1.2.2 6-1.1.2.2.r 6-1.2.1.1.1 6-1.2.1.1.2 6-1.2.1.1.3 9-1.1.2.2.1.3 12-1.1.2.1.1 13-1.1.2.1.2 16-1.1.2.2.1.1 17-1.1.2.2.1.2 18-1.1.2.2.1.3 20-1.1.2.2.1.3 21-1 22-1.2.2 23-1.2 25-1.2.1 26-1.2.1.1.1.1.1 28-1.2.1.1.2.1.1 30-1.2.1.1 31-1.2.1.1.3.1.1 32-1.2 34-1.3.1.1.1
# ::id bel_pmid_1019_4465_23202
(b / bind-01~e.21
      :ARG1 (a / and
            :op1 (p7 / protein-segment~e.6
                  :name (n8 / name :op1 "SH2"~e.1 :op2 "domain"~e.2)
                  :part-of~e.6 (p / protein~e.6
                        :name (n2 / name :op1 "Grb2")
                        :mod (a2 / adaptor~e.5)))
            :op2 (p8 / protein-segment~e.6
                  :name (n / name :op1 "SH2"~e.1,12 :op2 "domain"~e.2,13)
                  :part-of~e.6 (p2 / protein~e.6
                        :name (n4 / name
                              :op1 "phosphotyrosine"~e.16
                              :op2 "phosphatase"~e.17
                              :op3 "SHP-2"~e.9,18,20))))
      :ARG2 (s / sequence~e.23,32
            :ARG2-of (i / include-91~e.25
                  :ARG1 (a3 / and~e.30
                        :op1 (p3 / protein-segment~e.6
                              :name (n5 / name :op1 "pYVNI"~e.26))
                        :op2 (p4 / protein-segment~e.6
                              :name (n6 / name :op1 "pYIDL"~e.28))
                        :op2 (p5 / protein-segment~e.6
                              :name (n7 / name :op1 "pYASI"~e.31))))
            :mod (o / other~e.22))
      :ARG1-of (d3 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c / cite-01 :ARG2 "1"~e.34))))

# ::tok Since an inhibitor against SERCA induces apoptosis in some cell lines ( 76 ) , the IRS @/@ SERCA complex might be involved in an insulin and IGF @-@ 1 @-@ dependent antiapoptotic effect .
# ::alignments 0-1 2-1.1.1 2-1.1.1.1 2-1.1.1.1.r 4-1.1.1.1.1.1.1 5-1.1 6-1.1.2 7-1.1.4.r 8-1.1.4.1 9-1.1.4 10-1.1.4 12-1.1.3.1.1.1 16-1.2.1.1.1.1.1 18-1.2.1.1.2 19-1.2.1.1 20-1.2 21-1.2.1.r 22-1.2.1 23-1.2.1.2.r 25-1.2.1.2.2.1.1 26-1.2.1.2.2.1 27-1.2.1.2.2.1.2.1.1 29-1.2.1.2.2.1.2.1.1 31-1.2.1.2.2 32-1.2.1.2.1 33-1.2.1.2
# ::id bel_pmid_1019_4465_23382
(c / cause-01~e.0
      :ARG0 (i2 / induce-01~e.5
            :ARG0 (m2 / molecular-physical-entity~e.2
                  :ARG0-of~e.2 (i / inhibit-01~e.2
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "SERCA"~e.4))))
            :ARG1 (a / apoptosis~e.6)
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c4 / cite-01 :ARG2 "76"~e.12)))
            :location~e.7 (c3 / cell-line~e.9,10
                  :mod (s / some~e.8)))
      :ARG1 (p / possible~e.20
            :domain~e.21 (i3 / involve-01~e.22
                  :ARG1 (m / macro-molecular-complex~e.19
                        :part (p4 / protein
                              :name (n2 / name :op1 "IRS"~e.16))
                        :part p2~e.18)
                  :ARG2~e.23 (a2 / affect-01~e.33
                        :ARG0 (a3 / antiapoptotic~e.32)
                        :ARG0-of (d2 / depend-01~e.31
                              :ARG1 (a4 / and~e.26
                                    :op1 (i4 / insulin~e.25)
                                    :op2 (p6 / protein
                                          :name (n5 / name :op1 "IGF-1"~e.27,29))))))))

# ::tok Grb @-@ IR is a recently discovered SH2 domain protein that may translocate from the cytosol to the plasma membrane and bind directly to the tyrosine @-@ phosphorylated insulin receptor
# ::alignments 0-1.3.1.1 2-1.3.1.1 3-1.3.r 5-1.2.1 6-1.2 7-1.1.1.1 8-1.1.1.2 9-1 11-1.4.3 12-1.4 13-1.4.2.r 15-1.4.2 16-1.4.1.r 18-1.4.1.1 19-1.4.1 21-1.5 22-1.5.2 22-1.5.2.r 23-1.5.1.r 25-1.5.1.2.1.1 27-1.5.1.1.1 28-1.5.1.1 29-1.5.1
# ::id bel_pmid_1019_4465_23752
(p6 / protein~e.9
      :part (p5 / protein-segment
            :name (n2 / name :op1 "SH2"~e.7 :op2 "domain"~e.8))
      :ARG1-of (d2 / discover-01~e.6
            :time (r / recent~e.5))
      :domain~e.3 (p2 / protein
            :name (n / name :op1 "Grb-IR"~e.0,2))
      :ARG1-of (t / translocate-00~e.12
            :ARG2~e.16 (m / membrane~e.19
                  :mod (p3 / plasma~e.18))
            :source~e.13 (c / cytosol~e.15)
            :mod (p / possible~e.11))
      :ARG1-of (b / bind-01~e.21
            :ARG2~e.23 (r2 / receptor~e.29
                  :mod (i / insulin~e.28
                        :ARG1-of (p4 / phosphorylate-01~e.27))
                  :part (a2 / amino-acid
                        :name (n4 / name :op1 "tyrosine"~e.25)))
            :manner~e.22 (d3 / direct~e.22)
            :mod p))

# ::tok The physiological substrates for SHP @- 2 are not known , but overexpression of SHP @-@ 2 modulates cell adhesion and migration , as well as insulin activation of the Ras @/@ MAP @-@ kinase pathway Several isoforms of 14 @-@ 3 @-@ 3 proteins ( b , e, and z ) have also been shown to associate with IRS @-@ 1 , presumably through one of the several RXRXXpS motifs of IRS @-@ 1 .
# ::alignments 1-1.1.1.2.1 2-1.1.1.2 4-1.1.1.2.2.1.1 6-1.1.1.2.2.1.1 8-1.1.1.1 8-1.1.1.1.r 9-1.1.1 11-1.1 14-1.1.1.2.2.1.1 16-1.1.1.2.2.1.1 17-1.1.2.1 18-1.1.2.1.2.1.1.1 20-1.1.2.1.2.1 21-1.1.2.1.2.1.2 25-1.1.2.1.2.r 26-1.1.2.1.2.2.1 27-1.1.2.1.2.2 28-1.1.2.1.2.2.2.r 30-1.1.2.1.2.2.2.1.1 32-1.1.2.1.2.2.2.1.1 34-1.1.2.1.2.2.2.1.1 35-1.1.2.1.2.2.2 36-1.2.1.1.3 39-1.2.1.1.1.1.1 39-1.2.1.1.2.1.1.1.1 39-1.2.1.1.2.1.2.1.1 39-1.2.1.1.2.1.3.1.1 41-1.2.1.1.1.1.1 41-1.2.1.1.2.1.1.1.1 41-1.2.1.1.2.1.2.1.1 41-1.2.1.1.2.1.3.1.1 43-1.2.1.1.1.1.1 43-1.2.1.1.2.1.1.1.1 43-1.2.1.1.2.1.2.1.1 43-1.2.1.1.2.1.3.1.1 44-1.1.1.2.2 44-1.2.1.1.1 44-1.2.1.1.2.1.1 44-1.2.1.1.2.1.2 44-1.2.1.1.2.1.3 44-1.2.1.2 49-1.2.1.1.2.1 53-1.2.2 55-1.2 57-1.2.1 58-1.2.1.3.r 59-1.2.1.2.1.1 61-1.2.1.2.1.1 63-1.2.1.3.2 65-1.2.1.2.1.1 68-1.2.1.1.3 69-1.2.1.3.1.1.1.1 70-1.2.1.3 70-1.2.1.3.1.1 72-1.2.1.2.1.1 74-1.2.1.2.1.1
# ::id bel_pmid_1019_4465_23766
(m3 / multi-sentence
      :snt1 (c / contrast-01~e.11
            :ARG1 (k / know-01~e.9
                  :polarity~e.8 "-"~e.8
                  :ARG1 (s / substrate~e.2
                        :mod (p2 / physiology~e.1)
                        :topic (p3 / protein~e.44
                              :name (n2 / name :op1 "SHP-2"~e.4,6,14,16))))
            :ARG2 (a / and
                  :op1 (m / modulate-01~e.17
                        :ARG0 (o2 / overexpress-00
                              :ARG2 p3)
                        :ARG1~e.25 (a4 / and
                              :op1 (a2 / and~e.20
                                    :op1 (a3 / adhere-01
                                          :ARG1 (c2 / cell~e.18))
                                    :op2 (m2 / migrate-01~e.21
                                          :ARG0 c2))
                              :op2 (a5 / activate-01~e.27
                                    :ARG0 (i3 / insulin~e.26)
                                    :ARG1~e.28 (p4 / pathway~e.35
                                          :name (n3 / name :op1 "Ras/MAP-kinase"~e.30,32,34)))))))
      :snt2 (s2 / show-01~e.55
            :ARG1 (a8 / associate-01~e.57
                  :ARG1 (i / isoform
                        :mod (p / protein~e.44
                              :name (n / name :op1 "14-3-3"~e.39,41,43))
                        :ARG1-of (d / describe-01
                              :ARG2 (a7 / and~e.49
                                    :op1 (p5 / protein~e.44
                                          :name (n4 / name :op1 "14-3-3β"~e.39,41,43))
                                    :op2 (p8 / protein~e.44
                                          :name (n5 / name :op1 "14-3-3ε"~e.39,41,43))
                                    :op3 (p9 / protein~e.44
                                          :name (n8 / name :op1 "14-3-3ζ"~e.39,41,43))))
                        :quant (s3 / several~e.36,68))
                  :ARG2 (p6 / protein~e.44
                        :name (n6 / name :op1 "IRS-1"~e.59,61,65,72,74))
                  :instrument~e.58 (m5 / motif~e.70
                        :ARG1-of (i2 / include-91
                              :ARG2 (m4 / motif~e.70
                                    :name (n7 / name :op1 "RXRXXpS"~e.69)
                                    :part-of p6))
                        :ARG1-of (p7 / presume-01~e.63)))
            :mod (a6 / also~e.53)))

# ::tok TNF @-@ a appears to impair insulin signaling by increasing serine phosphorylation of IRS @-@ 1. Serine @-@ phosphorylated IRS @-@ 1 inhibits insulin receptor tyrosine kinase activity , which leads to impaired downstream signaling
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.1 5-1.1.1 6-1.1.1.2.1 7-1.1.1.2 8-1.1.1.3.r 9-1.1.1.3 10-1.1.1.3.2.1.1.1 11-1.1.1.3.2 13-1.1.1.3.2.1.2.1.1 13-1.2.1.1.2.1.1 16-1.1.1.3.2.1.1.1 16-1.2.1.1.1.1 18-1.2.1 19-1.2.1.1.2.1.1 21-1.2.1.1.2.1.1 22-1.2 23-1.2.2.1.2 24-1.2.2.1.1.1 25-1.2.2.1.1.2 26-1.2.2.1.1.3 27-1.2.2 30-1.2.3 31-1.2.3.1.r 32-1.2.3.1.2 33-1.2.3.1.1 34-1.2.3.1
# ::id bel_pmid_1019_4465_23768
(m / multi-sentence
      :snt1 (a2 / appear-02~e.3
            :ARG1 (i / impair-01~e.5
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "TNF-a"~e.0,2))
                  :ARG1 (s / signal-01~e.7
                        :ARG1 (i5 / insulin~e.6))
                  :manner~e.8 (i2 / increase-01~e.9
                        :ARG0 p2
                        :ARG1 (p3 / phosphorylate-01~e.11
                              :ARG1 (a / amino-acid
                                    :name (n / name :op1 "serine"~e.10,16)
                                    :part-of (p4 / protein
                                          :name (n4 / name :op1 "IRS-1"~e.13)))))))
      :snt2 (i3 / inhibit-01~e.22
            :ARG0 (p6 / phosphorylate-01~e.18
                  :ARG1 (a4 / amino-acid
                        :name (n6 / name :op1 "serine"~e.16)
                        :part-of (p5 / protein
                              :name (n3 / name :op1 "IRS-1"~e.13,19,21))))
            :ARG1 (a3 / act-02~e.27
                  :ARG1 (p / protein
                        :name (n5 / name
                              :op1 "receptor"~e.24
                              :op2 "tyrosine"~e.25
                              :op3 "kinase"~e.26)
                        :mod (i6 / insulin~e.23)))
            :ARG0-of (l / lead-03~e.30
                  :ARG2~e.31 (s2 / signal-01~e.34
                        :location (d / downstream~e.33)
                        :ARG1-of (i4 / impair-01~e.32)))))

# ::tok other SH2 proteins , such as Crk ( adaptor ) , Nck ( adaptor ) , Fyn ( tyrosine kinase ) , and Csk ( tyrosine kinase ) , bind to tyrosine residues on IRS proteins through their specific SH2 domains .
# ::alignments 0-1.1.3 1-1.1.1.1 2-1.1 4-1.1.2.r 5-1.1.2.r 6-1.1.2.1.1.1 8-1.1.2.1.2.1 11-1.1.2.2.1.1 13-1.1.2.1.2.1 16-1.1.2.3.1.1 18-1.1.2.3.2.1.1.1 19-1.1.2.3.2.1.1.2 22-1.1.2 23-1.1.2.4.1.1 25-1.1.2.3.2.1.1.1 26-1.1.2.3.2.1.1.2 29-1 30-1.2.r 31-1.2.1.1.1 32-1.2 33-1.2.2.r 34-1.2.2.2.1.1 35-1.1.2.1 35-1.1.2.2 35-1.1.2.3 35-1.1.2.4 35-1.2.2 35-1.2.2.2 35-1.2.2.2.r 38-1.2.2.3 39-1.1.1.1 39-1.2.2.1.1 40-1.1.1.2 40-1.2.2.1.2
# ::id bel_pmid_1019_4465_23770
(b / bind-01~e.29
      :ARG1 (p / protein-segment~e.2
            :name (n / name :op1 "SH2"~e.1,39 :op2 "domain"~e.40)
            :example~e.4,5 (a / and~e.22
                  :op1 (p2 / protein~e.35
                        :name (n2 / name :op1 "Crk"~e.6)
                        :ARG1-of (d / describe-01
                              :ARG2 (a2 / adaptor~e.8,13)))
                  :op2 (p3 / protein~e.35
                        :name (n3 / name :op1 "Nck"~e.11)
                        :ARG1-of (d2 / describe-01
                              :ARG2 a2))
                  :op3 (p4 / protein~e.35
                        :name (n4 / name :op1 "Fyn"~e.16)
                        :ARG1-of (d3 / describe-01
                              :ARG2 (e / enyzme
                                    :name (n6 / name :op1 "tyrosine"~e.18,25 :op2 "kinase"~e.19,26))))
                  :op4 (p5 / protein~e.35
                        :name (n5 / name :op1 "Csk"~e.23)
                        :ARG1-of (d4 / describe-01
                              :ARG2 e)))
            :mod (o / other~e.0))
      :ARG2~e.30 (r / residue~e.32
            :mod (a4 / amino-acid
                  :name (n7 / name :op1 "tyrosine"~e.31))
            :part-of~e.33 (p7 / protein-segment~e.35
                  :name (n9 / name :op1 "SH2"~e.39 :op2 "domain"~e.40)
                  :part-of~e.35 (p6 / protein~e.35
                        :name (n8 / name :op1 "IRS"~e.34))
                  :mod (s / specific~e.38))))

# ::tok Fyn is not activated directly by the insulin receptor , but rather by interaction with IRS @-@ 1 ( 49 ) and another insulin receptor substrate , c @-@ Cbl ( 50 ) .
# ::alignments 0-1.1.3.1.1 2-1.1.1 2-1.1.1.r 3-1.1 3-1.2 4-1.1.4 4-1.1.4.r 5-1.1.2.r 7-1.1.2.1 8-1.1.2 10-1 12-1.2.1.r 13-1.2.1 14-1.2.1.2.r 15-1.2.1.2.1.1.1 17-1.2.1.2.1.1.1 19-1.2.1.2.1.2.1.1.1 21-1.2.1.2 22-1.2.1.2.2.4 23-1.2.1.2.2.1.1 24-1.2.1.2.2.1 25-1.2.1.2.2 27-1.2.1.2.2.3.1.1.1 29-1.2.1.2.2.3.1.1.1 31-1.2.1.2.2.2.1.1.1
# ::id bel_pmid_1019_4465_23772
(c3 / contrast-01~e.10
      :ARG1 (a / activate-01~e.3
            :polarity~e.2 "-"~e.2
            :ARG0~e.5 (r / receptor~e.8
                  :mod (i / insulin~e.7))
            :ARG1 (p / protein
                  :name (n2 / name :op1 "Fyn"~e.0))
            :manner~e.4 (d / direct~e.4))
      :ARG2 (a2 / activate-01~e.3
            :ARG0~e.12 (i2 / interact-01~e.13
                  :ARG0 p
                  :ARG1~e.14 (a3 / and~e.21
                        :op1 (p2 / protein
                              :name (n3 / name :op1 "IRS-1"~e.15,17)
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p3 / publication
                                          :ARG1-of (c / cite-01 :ARG2 "49"~e.19))))
                        :op2 (s / substrate~e.25
                              :mod (r2 / receptor~e.24
                                    :mod i~e.23)
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (p4 / publication
                                          :ARG1-of (c2 / cite-01 :ARG2 "50"~e.31)))
                              :ARG0-of (m / mean-01
                                    :ARG1 (p5 / protein
                                          :name (n / name :op1 "c-Cbl"~e.27,29)))
                              :mod (a4 / another~e.22))))
            :ARG1 p))

# ::tok Recently , b1 integrins have also been reported to enhance IRS @-@ 1 phosphorylation and interaction , but not glucose transport , with downstream molecules such as PI3 @-@ kinase and Akt ( 74 ) . These results suggest that integrins and insulin @/@ IGF @-@ 1 receptor signaling pathways converge at an early point in the signaling cascade around the IRS proteins .
# ::alignments 0-1.1.2 2-1.1.1.1.1.1.1 5-1.1.4 7-1.1 9-1.1.1.1 9-1.1.1.2 10-1.1.1.1.2.1.1.1.1 12-1.1.1.1.2.1.1.1.1 13-1.1.1.1.2.1 14-1.1.1.1.2 15-1.1.1.1.2.2 17-1.1.1 18-1.1.1.2.1 18-1.1.1.2.1.r 19-1.1.1.2.2.1.1.1 20-1.1.1.2.2 22-1.1.1.2.3.r 23-1.1.1.2.3 24-1.1.1.2.3 25-1.1.1.2.3 26-1.1.1.2.3 27-1.1.1.2.3 28-1.1.1.2.3 29-1.1.1.2.3 30-1.1.1.2.3 31-1.1.1.2.3 33-1.1.3.1.1.1 36-1.2.1.2 37-1.2.1 37-1.2.1.1 37-1.2.1.1.r 38-1.2 42-1.2.2.2.1.1 44-1.2.2.2.1.1 46-1.2.2.2.1.1 47-1.2.2.2.1.2 47-1.2.2.2.2.1 48-1.2.2.2.2 49-1.2.2.2 50-1.2.2 51-1.2.2.3.r 53-1.2.2.3.1 54-1.2.2.3 55-1.2.2.3.2.r 57-1.2.2.3.2.1 58-1.2.2.3.2 59-1.2.2.3.2.2 61-1.2.2.3.2.2.1.1.1 62-1.1.1.1.1 62-1.1.1.1.2.1.1 62-1.1.1.1.2.2.2.2.2 62-1.1.1.2.2.1 62-1.2.2.1 62-1.2.2.3.2.2.1
# ::id bel_pmid_1019_4465_23788
(m / multi-sentence
      :snt1 (r / report-01~e.7
            :ARG1 (c / contrast-01~e.17
                  :ARG1 (e / enhance-01~e.9
                        :ARG0 (p12 / protein~e.62
                              :name (n / name :op1 "b1"~e.2 :op2 "integrin"))
                        :ARG1 (a / and~e.14
                              :op1 (p3 / phosphorylate-01~e.13
                                    :ARG1 (p4 / protein~e.62
                                          :name (n2 / name :op1 "IRS-1"~e.10,12)))
                              :op2 (i / interact-01~e.15
                                    :ARG0 p4
                                    :ARG1 (m2 / molecule
                                          :mod (d / downstream)
                                          :example (a2 / and
                                                :op1 (e3 / enzyme
                                                      :name (n4 / name :op1 "PI3-kinase"))
                                                :op2 (p5 / protein~e.62
                                                      :name (n5 / name :op1 "Akt")))))))
                  :ARG2 (e2 / enhance-01~e.9
                        :polarity~e.18 "-"~e.18
                        :ARG0 (t2 / transport-01~e.20
                              :ARG1 (p / protein~e.62
                                    :name (n3 / name :op1 "glucose"~e.19)))
                        :ARG1~e.22 a~e.23,24,25,26,27,28,29,30,31))
            :time (r2 / recent~e.0)
            :ARG1-of (d2 / describe-01
                  :ARG0 (p6 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "74"~e.33)))
            :mod (a5 / also~e.5))
      :snt2 (s / suggest-01~e.38
            :ARG0 (t3 / thing~e.37
                  :ARG2-of~e.37 (r3 / result-01~e.37)
                  :mod (t / this~e.36))
            :ARG1 (c3 / converge-01~e.50
                  :ARG0 (p10 / protein~e.62
                        :name (n8 / name :op1 "integrin"))
                  :ARG1 (p9 / pathway~e.49
                        :name (n6 / name :op1 "insulin/IGF-1"~e.42,44,46 :op2 "receptor"~e.47)
                        :ARG0-of (s3 / signal-01~e.48
                              :mod (r5 / receptor~e.47)))
                  :time~e.51 (p7 / point~e.54
                        :mod (e4 / early~e.53)
                        :subevent-of~e.55 (c4 / cascade~e.58
                              :subevent (s2 / signal-01~e.57)
                              :location (a4 / around~e.59
                                    :op1 (p8 / protein~e.62
                                          :name (n7 / name :op1 "IRS"~e.61))))))))

# ::tok PC @-@ 1 is a membrane glycoprotein with ectonucleotide pyrophosphatase activity that seems to act as an intrinsic inhibitor of insulin receptor tyrosine kinase activity
# ::alignments 0-1.4.1.1 2-1.4.1.1 3-1.4.r 5-1.1 6-1 8-1.2.1.1.1.1 9-1.2.1.1.1.2 10-1.2.1 12-1.3.2 14-1.3 15-1.3.1.r 17-1.3.1.3 18-1.3.1 20-1.3.1.2.1.2 21-1.3.1.2.1.1.1 22-1.3.1.2.1.1.2 23-1.3.1.2.1.1.3 24-1.2.1 24-1.3.1.2
# ::id bel_pmid_1019_4465_24722
(g / glycoprotein~e.6
      :mod (m / membrane~e.5)
      :ARG0-of (h2 / have-03
            :ARG1 (a / act-02~e.10,24
                  :ARG1 (e / enzyme
                        :name (n3 / name :op1 "ectonucleotide"~e.8 :op2 "pyrophosphatase"~e.9))))
      :ARG0-of (a2 / act-01~e.14
            :ARG1~e.15 (i2 / inhibit-01~e.18
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "PC-1"~e.0,2))
                  :ARG1 (a3 / act-02~e.24
                        :ARG0 (p3 / protein
                              :name (n4 / name
                                    :op1 "receptor"~e.21
                                    :op2 "tyrosine"~e.22
                                    :op3 "kinase"~e.23)
                              :mod (i / insulin~e.20)))
                  :mod (i3 / intrinsic~e.17))
            :ARG1-of (s / seem-01~e.12))
      :domain~e.3 p2)

# ::tok It has been reported that PC @-@ 1 overexpression in skeletal muscle of obese subjects explains downregulation of insulin receptor tyrosine phosphorylation
# ::alignments 3-1 4-1.1.r 5-1.1.1.1.1.1 7-1.1.1.1.1.1 10-1.1.1.2.1 11-1.1.1.2 12-1.1.1.2.2.r 13-1.1.1.2.2.1 14-1.1.1.2.2 15-1.1 16-1.1.2 17-1.1.2.1.r 18-1.1.2.1.1.1.1 19-1.1.2.1.1.1.2 20-1.1.2.1.1.1.3 21-1.1.2.1
# ::id bel_pmid_1019_4465_24724
(r / report-01~e.3
      :ARG1~e.4 (e / explain-01~e.15
            :ARG0 (o3 / overexpress-00
                  :ARG2 (e3 / enzyme
                        :name (n / name :op1 "PC-1"~e.5,7))
                  :location (m / muscle~e.11
                        :mod (s / skeletal~e.10)
                        :part-of~e.12 (s2 / subject~e.14
                              :mod (o2 / obese~e.13))))
            :ARG1 (d / downregulate-01~e.16
                  :ARG1~e.17 (p / phosphorylate-01~e.21
                        :ARG1 (p2 / protein
                              :name (n2 / name
                                    :op1 "insulin"~e.18
                                    :op2 "receptor"~e.19
                                    :op3 "tyrosine"~e.20))))))

# ::tok Inhibition of MEK1 also led to reduced expression of alpha @-@ enolase , phosphoglycerate kinase , elongation factor 2 and heterogeneous nuclear ribonucleoprotein A3 , the latter two being detected as truncated proteins .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1 3-1.3 4-1 5-1.2.r 6-1.2.2 7-1.2 8-1.2.1.r 9-1.2.1.1.1.1 11-1.2.1.1.1.1 13-1.2.1.2.1.1 14-1.2.1.2.1.2 16-1.2.1.3.1.1 17-1.2.1.3.1.2 18-1.2.1.3.1.3 19-1.2.1 20-1.2.1.4.1.1 21-1.2.1.4.1.2 22-1.2.1.4.1.3 23-1.2.1.4.1.4 27-1.2.1.3.2.2.1 29-1.2.1.3.2 30-1.2.1.3.2.1.r 31-1.2.1.3.2.1.1 32-1.2.1.3.2.1
# ::id bel_pmid_1022_8560_5928
(l / lead-03~e.4
      :ARG0 (i / inhibit-01~e.0
            :ARG1~e.1 (e / enzyme
                  :name (n / name :op1 "MEK1"~e.2)))
      :ARG2~e.5 (e2 / express-03~e.7
            :ARG1~e.8 (a / and~e.19
                  :op1 (e3 / enzyme
                        :name (n2 / name :op1 "alpha-enolase"~e.9,11))
                  :op2 (e4 / enzyme
                        :name (n3 / name :op1 "phosphoglycerate"~e.13 :op2 "kinase"~e.14))
                  :op3 (p / protein
                        :name (n4 / name
                              :op1 "elongation"~e.16
                              :op2 "factor"~e.17
                              :op3 "2"~e.18)
                        :ARG0-of (d / detect-01~e.29
                              :ARG1~e.30 (p3 / protein~e.32
                                    :ARG1-of (t / truncate-01~e.31))
                              :ord (o / ordinal-entity :value "-2"~e.27)))
                  :op4 (p2 / protein
                        :name (n5 / name
                              :op1 "heterogeneous"~e.20
                              :op2 "nuclear"~e.21
                              :op3 "ribonucleoprotein"~e.22
                              :op4 "A3"~e.23)
                        :ARG0-of d))
            :ARG1-of (r / reduce-01~e.6))
      :mod (a2 / also~e.3))

# ::tok expression of MLK3 strongly activated SAPK ? to the same extent seen with the established JNK @/@ SAPK activator arsenite ( 45 )
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1 3-1.3 3-1.3.r 4-1 5-1.2.1.1 9-1.4.2 10-1.4.r 11-1.4 12-1.4.1.r 14-1.4.1.2 15-1.4.1.1.1.1.1 17-1.4.1.1.1.1.1 18-1.4.1.1 19-1.4.1 21-1.5.1.1.1
# ::id bel_pmid_1023_2608_16572
(a / activate-01~e.4
      :ARG0 (e / express-03~e.0
            :ARG2~e.1 (e2 / enzyme
                  :name (n / name :op1 "MLK3"~e.2)))
      :ARG1 (p / protein
            :name (n2 / name :op1 "SAPK"~e.5))
      :manner~e.3 (s / strong~e.3)
      :extent~e.10 (s2 / see-01~e.11
            :ARG1~e.12 (a2 / arsenite~e.19
                  :ARG0-of (a3 / activate-01~e.18
                        :ARG1 (p2 / pathway
                              :name (n3 / name :op1 "JNK/SAPK"~e.15,17)))
                  :ARG1-of (e3 / establish-01~e.14))
            :ARG1-of (s3 / same-01~e.9))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c / cite-01 :ARG2 "45"~e.21))))

# ::tok Using a coupled assay , we were able to show that MLK3 @-@ mediated phosphorylation of SEK1 resulted in activation because GST @-@ SEK1 is able to phosphorylate recombinant SAPK ? ( Fig . 5D )
# ::alignments 0-1.2 2-1.2.2.1 3-1.2.2 5-1.1.1 6-1.1.r 7-1 9-1.1 10-1.1.2.r 11-1.1.2.1.2.1.1.1 13-1.1.2.1.2 14-1.1.2.1 15-1.1.2.1.1.r 16-1.1.2.1.1.1.1 17-1.1.2 18-1.1.2.2.r 19-1.1.2.2 20-1.1.2.3 21-1.1.2.3.1.1.2.1.1 23-1.1.2.3.1.1.2.1.1 24-1.1.2.3.1.1.r 25-1.1.2.3.1 27-1.1.2.3.1.1 29-1.1.2.3.1.1.1.1.1 34-1.3.1.1
# ::id bel_pmid_1023_2608_23890
(p / possible~e.7
      :domain~e.6 (s / show-01~e.9
            :ARG0 (w / we~e.5)
            :ARG1~e.10 (r / result-01~e.17
                  :ARG1 (p3 / phosphorylate-01~e.14
                        :ARG1~e.15 (p4 / protein
                              :name (n / name :op1 "SEK1"~e.16))
                        :ARG1-of (m / mediate-01~e.13
                              :ARG0 (e / enzyme
                                    :name (n2 / name :op1 "MLK3"~e.11))))
                  :ARG2~e.18 (a / activate-01~e.19)
                  :ARG1-of (c / cause-01~e.20
                        :ARG0 (p5 / possible~e.25
                              :domain~e.24 (p2 / phosphorylate-01~e.27
                                    :ARG1 (p6 / protein
                                          :name (n3 / name :op1 "SAPK"~e.29)
                                          :ARG3-of (r2 / recombine-01))
                                    :ARG2 (p7 / protein
                                          :name (n4 / name :op1 "GST-SEK1"~e.21,23)))))))
      :manner (u / use-01~e.0
            :ARG0 w
            :ARG1 (a2 / assay-00~e.3
                  :ARG1-of (c2 / couple-01~e.2)))
      :ARG1-of (d / describe-01
            :ARG2 (f / figure :mod "5D"~e.34)))

# ::tok Wild type , but not KD , MLK3 was able to phosphorylate His @-@ MEK1 ( Fig . 5A ) ? and GST @-@ SEK1 ( Fig . 5B ) ? in vitro .
# ::alignments 0-1.1.1.2.2 1-1.1.1.2.2 3-1 4-1.2.1 4-1.2.1.r 4-1.2.2.2.2.1 4-1.2.2.2.2.1.r 7-1.1.1.2.1.1 7-1.2.2.2.1.1 8-1.1.1.r 8-1.2.2.r 9-1.1 9-1.2 11-1.1.1 11-1.2.2 12-1.1.1.1.1.1.1 14-1.1.1.1.1.1.2 18-1.1.1.1.1.2.1.1 21-1.1.1.1 22-1.1.1.1.2.1.1 24-1.1.1.1.2.1.1 28-1.1.1.1.2.2.1.1 31-1.1.1.3 32-1.1.1.3
# ::id bel_pmid_1023_2608_23894
(c / contrast-01~e.3
      :ARG1 (p / possible~e.9
            :domain~e.8 (p2 / phosphorylate-01~e.11
                  :ARG1 (a2 / and~e.21
                        :op1 (p3 / protein
                              :name (n / name :op1 "His"~e.12 :op2 "MEK1"~e.14)
                              :ARG1-of (d / describe-01
                                    :ARG2 (f / figure :mod "5A"~e.18)))
                        :op2 (p4 / protein
                              :name (n2 / name :op1 "GST-SEK1"~e.22,24)
                              :ARG1-of (d2 / describe-01
                                    :ARG2 (f2 / figure :mod "5B"~e.28))))
                  :ARG2 (e / enzyme
                        :name (n3 / name :op1 "MLK3"~e.7)
                        :mod (w / wild-type~e.0,1))
                  :manner (i / in-vitro~e.31,32)))
      :ARG2 (p5 / possible~e.9
            :polarity~e.4 "-"~e.4
            :domain~e.8 (p6 / phosphorylate-01~e.11
                  :ARG1 a2
                  :ARG2 (e2 / enzyme
                        :name (n5 / name :op1 "MLK3"~e.7)
                        :ARG0-of (f3 / function-01
                              :polarity~e.4 "-"~e.4
                              :ARG1 (k / kinase))))))

# ::tok In support of these data , we also show that MEK1 is highly phosphorylated in vivo on Ser 217 @/@ 221 in MLK3 @-@ transformed fibroblasts
# ::alignments 0-1.2.3 1-1.3 2-1.3.1.r 3-1.3.1.1 4-1.3.1 6-1.1 7-1.4 8-1 10-1.2.1.1.3.1.1 12-1.2.2 13-1.2 14-1.2.3 15-1.2.3 18-1.2.1.1.1 20-1.2.1.2.1 21-1.2.3 21-1.2.4.r 22-1.2.4.1.1.1.1 24-1.2.4.1 25-1.2.4
# ::id bel_pmid_1023_2608_5936
(s / show-01~e.8
      :ARG0 (w / we~e.6)
      :ARG1 (p / phosphorylate-01~e.13
            :ARG1 (s2 / slash
                  :op1 (a / amino-acid
                        :mod "217"~e.18
                        :name (n2 / name :op1 "serine")
                        :part-of (p2 / protein
                              :name (n5 / name :op1 "MEK1"~e.10)))
                  :op2 (a3 / amino-acid
                        :mod "221"~e.20
                        :name (n4 / name :op1 "serine")
                        :part-of p2))
            :degree (h / high~e.12)
            :manner (i / in-vivo~e.0,14,15,21)
            :location~e.21 (f / fibroblast~e.25
                  :ARG1-of (t / transform-01~e.24
                        :ARG0 (e2 / enzyme
                              :name (n3 / name :op1 "MLK3"~e.22)))))
      :purpose (s3 / support-01~e.1
            :ARG1~e.2 (d / data~e.4
                  :mod (t2 / this~e.3)))
      :mod (a2 / also~e.7))

# ::tok Thrombin receptor mediated signal transduction could induce the expressions of IL6 and G @-@ CSF , and increase inflammatory events in the cavum articulare via NF-êB activation
# ::alignments 0-1.1.1.1.2.1.1.1 1-1.1.1.1.2.1 2-1.1.1.1.2 3-1.1.1.1.1 4-1.1.1.1 5-1 6-1.1.1 8-1.1.1.2 9-1.1.1.2.1.r 10-1.1.1.2.1.1.1.1 11-1.1.1.2.1 12-1.1.1.2.1.2.1.1 14-1.1.1.2.1.2.1.1 16-1.1 17-1.1.2 18-1.1.2.2.1 19-1.1.2.2 20-1.1.2.3.r 22-1.1.2.3 23-1.1.2.3.1 26-1.1.2.4
# ::id bel_pmid_1034_3541_18504
(p / possible~e.5
      :domain (a / and~e.16
            :op1 (i / induce-01~e.6
                  :ARG0 (t / transduce-00~e.4
                        :ARG1 (s / signal-01~e.3)
                        :ARG1-of (m / mediate-01~e.2
                              :ARG0 (r / receptor~e.1
                                    :name (n / name :op1 "thrombin"~e.0))))
                  :ARG1 (e / express-03~e.8
                        :ARG2~e.9 (a2 / and~e.11
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "IL6"~e.10))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "G-CSF"~e.12,14)))))
            :op2 (i2 / increase-01~e.17
                  :ARG0 t
                  :ARG1 (e2 / event~e.19
                        :mod (i3 / inflame-01~e.18))
                  :location~e.20 (c / cavum~e.22
                        :mod (a3 / articulare~e.23))
                  :manner (a4 / activate-01~e.26
                        :ARG1 (p4 / protein
                              :name (n4 / name :op1 "NF-κB"))))))

# ::tok The levels of IL6 and of G @-@ CSF mRNAs showed a time dependent increase during two to eight hours after thrombin stimulation....Cytokines were measured by enzyme linked immunosorbent assay ( ELISA ) in the supernatants of cultured rheumatoid synovial fibroblasts stimulated by thrombin
# ::alignments 1-1.1.1.1 1-1.1.1.2 3-1.1.1.1.1.2.1.1 4-1.1.1 6-1.1.1.2.1.2.1.1 8-1.1.1.2.1.2.1.1 9-1.1.1.1.1.1.1 9-1.1.1.2.1.1.1 10-1.1 12-1.1.2.1.1 12-1.1.2.2.1 12-1.1.2.2.2 13-1.1.2.1 14-1.1.2 15-1.1.2.3.r 16-1.1.2.2.1.1 18-1.1.2.2.2.1 19-1.1.2.2.1.2 20-1.1.2.3 21-1.1.2.3.1.1.1.1 24-1.2 25-1.2.2.r 26-1.2.2.1.1 27-1.2.2.1.2 28-1.2.2.1.3 29-1.2.2.1.4 31-1.2.2.2.1.1.1 33-1.2.3.r 35-1.2.3 36-1.2.3.1.r 37-1.2.3.1 38-1.2.3.1.1.2 39-1.2.3.1.1.1 40-1.2.3.1.1 41-1.1.2.3.1 41-1.2.3.2 43-1.1.2.3.1.1.1.1
# ::id bel_pmid_1034_3541_23056
(m / multi-sentence
      :snt1 (s / show-01~e.10
            :ARG0 (a / and~e.4
                  :op1 (l / level~e.1
                        :quant-of (r / rna
                              :name (n / name :op1 "mRNA"~e.9)
                              :part-of (g / gene
                                    :name (n2 / name :op1 "IL6"~e.3))))
                  :op2 (l2 / level~e.1
                        :quant-of (r2 / rna
                              :name (n3 / name :op1 "mRNA"~e.9)
                              :part-of (g2 / gene
                                    :name (n4 / name :op1 "G-CSF"~e.6,8)))))
            :ARG1 (i / increase-01~e.14
                  :ARG0-of (d / depend-01~e.13
                        :ARG1 (t / time~e.12))
                  :duration (b / between
                        :op1 (t2 / temporal-quantity~e.12
                              :quant "2"~e.16
                              :unit (h / hour~e.19))
                        :op2 (t3 / temporal-quantity~e.12
                              :quant "8"~e.18
                              :unit h))
                  :time~e.15 (a2 / after~e.20
                        :op1 (s2 / stimulate-01~e.41
                              :ARG1 (e / enzyme
                                    :name (n5 / name :op1 "thrombin"~e.21,43))))))
      :snt2 (m2 / measure-01~e.24
            :ARG1 (p / protein
                  :name (n8 / name :op1 "cytokine"))
            :instrument~e.25 (t4 / thing
                  :name (n6 / name
                        :op1 "enzyme"~e.26
                        :op2 "linked"~e.27
                        :op3 "immunosorbent"~e.28
                        :op4 "assay"~e.29)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (t5 / thing
                              :name (n7 / name :op1 "ELISA"~e.31))))
            :location~e.33 (s3 / supernatant~e.35
                  :part-of~e.36 (c2 / culture-01~e.37
                        :ARG1 (f / fibroblast~e.40
                              :location (s4 / synovia~e.39)
                              :mod (r3 / rheumatoid~e.38)))
                  :ARG1-of (s5 / stimulate-01~e.41
                        :ARG0 e))))

# ::tok Thrombin receptor mediated signal transduction could induce the expressions of IL6 and G @-@ CSF , and increase inflammatory events in the cavum articulare via NF-êB activation
# ::alignments 0-1.1.1.1.2.1.1.1 1-1.1.1.1.2.1 2-1.1.1.1.2 3-1.1.1.1.1 4-1.1.1.1 5-1 6-1.1.1 8-1.1.1.2 9-1.1.1.2.1.r 10-1.1.1.2.1.1.1.1 11-1.1.1.2.1 12-1.1.1.2.1.2.1.1 14-1.1.1.2.1.2.1.1 16-1.1 17-1.1.2 18-1.1.2.2.1 19-1.1.2.2 20-1.1.2.3.r 22-1.1.2.3 23-1.1.2.3.1 26-1.1.2.4
# ::id bel_pmid_1034_3541_35586
(p / possible~e.5
      :domain (a / and~e.16
            :op1 (i / induce-01~e.6
                  :ARG0 (t / transduce-00~e.4
                        :ARG1 (s / signal-01~e.3)
                        :ARG1-of (m / mediate-01~e.2
                              :ARG0 (r / receptor~e.1
                                    :name (n / name :op1 "thrombin"~e.0))))
                  :ARG1 (e / express-03~e.8
                        :ARG2~e.9 (a2 / and~e.11
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "IL6"~e.10))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "G-CSF"~e.12,14)))))
            :op2 (i2 / increase-01~e.17
                  :ARG0 t
                  :ARG1 (e2 / event~e.19
                        :mod (i3 / inflame-01~e.18))
                  :location~e.20 (c / cavum~e.22
                        :mod (a3 / articulare~e.23))
                  :manner (a4 / activate-01~e.26
                        :ARG1 (p4 / protein
                              :name (n4 / name :op1 "NF-κB"))))))

# ::tok Thrombin receptor mediated signal transduction could induce the expressions of IL6 and G @-@ CSF , and increase inflammatory events in the cavum articulare via NF @-@ kappa B activation
# ::alignments 0-1.1.1.1.2.1.1.1 1-1.1.1.1.2.1 2-1.1.1.1.2 3-1.1.1.1.1 4-1.1.1.1 5-1 6-1.1.1 8-1.1.1.2 9-1.1.1.2.1.r 10-1.1.1.2.1.1.1.1 11-1.1.1.2.1 12-1.1.1.2.1.2.1.1 14-1.1.1.2.1.2.1.1 16-1.1 17-1.1.2 18-1.1.2.2.1 19-1.1.2.2 20-1.1.2.3.r 22-1.1.2.3 23-1.1.2.3.1 25-1.1.2.4.1.1.1 27-1.1.2.4.1.1.1 28-1.1.2.4.1.1.1 29-1.1.2.4
# ::id bel_pmid_1034_3541_46
(p / possible~e.5
      :domain (a / and~e.16
            :op1 (i / induce-01~e.6
                  :ARG0 (t / transduce-00~e.4
                        :ARG1 (s / signal-01~e.3)
                        :ARG1-of (m / mediate-01~e.2
                              :ARG0 (r / receptor~e.1
                                    :name (n / name :op1 "thrombin"~e.0))))
                  :ARG1 (e / express-03~e.8
                        :ARG2~e.9 (a2 / and~e.11
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "IL6"~e.10))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "G-CSF"~e.12,14)))))
            :op2 (i2 / increase-01~e.17
                  :ARG0 t
                  :ARG1 (e2 / event~e.19
                        :mod (i3 / inflame-01~e.18))
                  :location~e.20 (c / cavum~e.22
                        :mod (a3 / articulare~e.23))
                  :manner (a4 / activate-01~e.29
                        :ARG1 (p4 / protein
                              :name (n4 / name :op1 "NF-kappa-B"~e.25,27,28))))))

# ::tok Further , the expression of the catalytically inactive mutants of Ha @-@ Ras , RhoA , c @-@ Raf , and Erk2 or addition of the Mek1 @-@ specific inhibitor PD 098059 abrogated the stimulation of the urokinase promoter by HGF/SF .
# ::alignments 3-1.1.2.1 7-1.1.2.1.1.2.1 8-1.1.2.1.1 9-1.1.2.1.1.1.r 10-1.1.2.1.1.1.1.1.1 12-1.1.2.1.1.1.1.1.1 14-1.1.2.1.1.1.2.1.1 16-1.1.2.1.1.1.3.1.1 18-1.1.2.1.1.1.3.1.1 20-1.1.2.1.1.1 21-1.1.2.1.1.1.4.1.1 22-1.1.2 23-1.1.2.2 24-1.1.2.2.1.r 26-1.1.2.2.1.2.1.1.1.1 28-1.1.2.2.1.2.1 29-1.1.2.2.1 29-1.1.2.2.1.2 29-1.1.2.2.1.2.r 30-1.1.2.2.1.1.1 31-1.1.2.2.1.1.1 32-1.1 34-1.1.1 35-1.1.1.2.r 37-1.1.1.2.1.1.1.1 39-1.1.1.1.r 40-1.1.1.1.1.1
# ::id bel_pmid_1034_7197_20912
(a / and
      :op2 (a2 / abrogate-01~e.32
            :ARG1 (s / stimulate-01~e.34
                  :ARG0~e.39 (p / protein
                        :name (n / name :op1 "HGF/SF"~e.40))
                  :ARG1~e.35 (m / molecular-physical-entity
                        :ARG0-of (p2 / promote-01
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "urokinase"~e.37)))))
            :ARG2 (o / or~e.22
                  :op1 (e2 / express-03~e.3
                        :ARG2 (m2 / mutate-01~e.8
                              :ARG1~e.9 (a3 / and~e.20
                                    :op1 (p3 / protein
                                          :name (n3 / name :op1 "Ha-Ras"~e.10,12))
                                    :op2 (p4 / protein
                                          :name (n4 / name :op1 "RhoA"~e.14))
                                    :op3 (e3 / enzyme
                                          :name (n5 / name :op1 "c-Raf"~e.16,18))
                                    :op3 (e4 / enzyme
                                          :name (n6 / name :op1 "Erk2"~e.21)))
                              :ARG1-of (a4 / activate-01
                                    :polarity "-"~e.7
                                    :manner (c / catalytic))))
                  :op2 (a5 / add-02~e.23
                        :ARG1~e.24 (m3 / molecular-physical-entity~e.29
                              :name (n7 / name :op1 "PD-098059"~e.30,31)
                              :ARG0-of~e.29 (i / inhibit-01~e.29
                                    :mod (s2 / specific~e.28
                                          :topic (e5 / enzyme
                                                :name (n8 / name :op1 "Mek1"~e.26)))))))))

# ::tok Induction of the urokinase promoter by HGF @/@ SF via the Met receptor was blocked by co @-@ expression of a dominant @-@ negative Grb2 and Sos1 expression construct .
# ::alignments 3-1.2.2.1.1.1.1 6-1.2.1.1.1 8-1.2.1.1.1 11-1.2.3.1.1 12-1.2.3 14-1 15-1.1.r 16-1.1 18-1.1 19-1.1.1.r 21-1.1.1.1.1 21-1.1.1.1.1.3 21-1.1.1.1.1.3.r 24-1.1.1.1.1.1.1 25-1.1.1.1 26-1.1.1.1.2.1.1.1 27-1.1.1.1.2 28-1.1.1
# ::id bel_pmid_1034_7197_8888
(b / block-01~e.14
      :ARG0~e.15 (c / co-express-00~e.16,18
            :ARG2~e.19 (c2 / construct-01~e.28
                  :ARG1 (a / and~e.25
                        :op1 (p / protein~e.21
                              :name (n / name :op1 "Grb2"~e.24)
                              :ARG2-of (m / mutate-01 :mod "-/-")
                              :ARG0-of~e.21 (d / dominate-01~e.21))
                        :op2 (e / express-03~e.27
                              :ARG2 (p2 / protein
                                    :name (n2 / name :op1 "Sos1"~e.26))))))
      :ARG1 (i / induct-01
            :ARG0 (p3 / protein
                  :name (n3 / name :op1 "HGF/SF"~e.6,8))
            :ARG1 (m2 / molecular-physical-entity
                  :ARG0-of (p4 / promote-01
                        :ARG1 (e2 / enzyme
                              :name (n4 / name :op1 "urokinase"~e.3))))
            :medium (r / receptor~e.12
                  :name (n5 / name :op1 "Met"~e.11))))

# ::tok c @-@ Raf @-@ 1 kinase was identified as an intracellular target of a signal transduction cascade initiated by binding of TNF @-@ alpha to TNFR @-@ I .
# ::alignments 0-1.1.1.1 2-1.1.1.1 4-1.1.1.1 5-1.1.1.2 7-1 8-1.2.r 10-1.2.3 11-1.2 12-1.2.1.r 14-1.2.1.1.1 16-1.2.1 17-1.2.1.2 18-1.2.1.2.1.r 19-1.2.1.2.1 20-1.2.1.2.1.1.r 21-1.2.1.2.1.1.1.1 23-1.2.1.2.1.1.1.1 24-1.2.1.2.1.2.r 25-1.2.1.2.1.2.1.1 27-1.2.1.2.1.2.1.1
# ::id bel_pmid_1035_9574_24516
(i / identify-01~e.7
      :ARG1 (e / enzyme
            :name (n / name :op1 "c-Raf-1"~e.0,2,4 :op2 "kinase"~e.5))
      :ARG2~e.8 (t / target-01~e.11
            :ARG0~e.12 (c / cascade-01~e.16
                  :ARG0-of (t2 / transduct-00
                        :ARG1 (s / signal-01~e.14))
                  :ARG1-of (i2 / initiate-01~e.17
                        :ARG2~e.18 (b / bind-01~e.19
                              :ARG1~e.20 (p / protein
                                    :name (n2 / name :op1 "TNF-alpha"~e.21,23))
                              :ARG2~e.24 (p2 / protein
                                    :name (n3 / name :op1 "TNFR-I"~e.25,27)))))
            :ARG1 e
            :location (i3 / intracellular~e.10)))

# ::tok Gadd45 was also able to physically interact with Cdc2 , but not Cyclin B1. Addition of Gadd45 to immunoprecipitated Cdc2 @/@ Cyclin B1 in vitro led to a dissociation of this complex , and thus may represent a new checkpoint mechanism whereby Cdc2 @/@ Cyclin B1 can be inhibited .
# ::alignments 0-1.1.1.1.1.1.1 1-1.1.1.1.r 2-1.1.1.2 3-1.1.1 3-1.1.2 5-1.1.1.1.3 5-1.1.1.1.3.r 6-1.1.1.1 6-1.1.2.1 7-1.2.3.1.1.1.3.r 8-1.1.1.1.2.1.1 8-1.2.1.2.1.1.1 10-1.1 11-1.1.2.1.1 11-1.1.2.1.1.r 12-1.1.2.1.3.1.1 12-1.2.1.2.2.1.1 14-1.2.1 15-1.2.1.1.r 16-1.2.1.1.1.1 19-1.2.1.2.1.1.1 21-1.2.1.2.2.1.1 22-1.2.1.2.2.1.1 23-1.2.1.3 24-1.2.1.3 25-1.2 26-1.2.2.r 26-1.2.3 28-1.2.2 30-1.2.2.2.1 31-1.2.1.2 31-1.2.2.2 34-1.2.3 35-1.2.3.1 36-1.2.3.1.1 38-1.2.3.1.1.1.2 39-1.2.3.1.1.1.1 40-1.2.3.1.1.1 42-1.2.1.2.1.1.1 44-1.2.1.2.2.1.1 45-1.2.1.2.2.1.1 46-1.2.3.1.1.1.3 47-1.2.3.1.1.1.3.1.r 48-1.2.3.1.1.1.3.1
# ::id bel_pmid_1036_2260_5288
(m / multi-sentence
      :snt1 (c / contrast-01~e.10
            :ARG1 (p / possible~e.3
                  :domain~e.1 (i / interact-01~e.6
                        :ARG0 (p2 / protein
                              :name (n / name :op1 "Gadd45"~e.0))
                        :ARG1 (m2 / molecular-physical-entity
                              :name (n2 / name :op1 "Cdc2"~e.8))
                        :manner~e.5 (p3 / physical~e.5))
                  :mod (a / also~e.2))
            :ARG2 (p4 / possible~e.3
                  :domain (i2 / interact-01~e.6
                        :polarity~e.11 "-"~e.11
                        :ARG0 p2
                        :ARG1 (p5 / protein
                              :name (n3 / name :op1 "Cyclin-B1"~e.12))
                        :manner p3)))
      :snt2 (l / lead-03~e.25
            :ARG0 (a2 / add-02~e.14
                  :ARG1~e.15 (p6 / protein
                        :name (n4 / name :op1 "Gadd45"~e.16))
                  :ARG2 (m3 / macro-molecular-complex~e.31
                        :part (m4 / molecular-physical-entity
                              :name (n5 / name :op1 "Cdc2"~e.8,19,42))
                        :part (p7 / protein
                              :name (n6 / name :op1 "Cyclin-B1"~e.12,21,22,44,45))
                        :ARG1-of (i3 / immunoprecipitate-00))
                  :manner (i4 / in-vitro~e.23,24))
            :ARG2~e.26 (d / dissociate-01~e.28
                  :ARG0 a2
                  :ARG1 (c2 / complex~e.31
                        :mod (t / this~e.30)))
            :ARG0-of (c3 / cause-01~e.26,34
                  :ARG1 (p8 / possible~e.35
                        :domain (r / represent-01~e.36
                              :ARG0 (m5 / mechanism~e.40
                                    :mod (c4 / checkpoint~e.39)
                                    :mod (n7 / new~e.38)
                                    :instrument-of~e.7 (p9 / possible~e.46
                                          :domain~e.47 (i5 / inhibit-01~e.48
                                                :ARG1 m3)))
                              :ARG1 a2)))))

# ::tok Treatment with TNF @-@ a significantly decreased the intracellular GSH content of HS @-@ 24 cells . Pretreatment of this culture with DMSO recovered the TNF @-@ a @-@ induced decrease in GSH ( Table 1 ) .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1 5-1.1.3 5-1.1.3.r 6-1.1 8-1.1.2.2.2 9-1.1.2.1.1 10-1.1.2 10-1.1.2.2 10-1.1.2.2.r 11-1.1.2.2.1.r 12-1.1.2.2.1.1.1 14-1.1.2.2.1.1.1 15-1.1.2.2.1 19-1.2.1.1.1 20-1.2.1.1 22-1.2.1.2.1.1 23-1.2 25-1.2.2.2.1.1.1 29-1.2.2.2 30-1.2.2 31-1.2.2.1.r 32-1.2.2.1.1.1 34-1.2.3.1 35-1.2.3.1.1
# ::id bel_pmid_1036_2713_15636
(m / multi-sentence
      :snt1 (d / decrease-01~e.6
            :ARG0 (t / treat-04~e.0
                  :ARG2~e.1 (p / protein
                        :name (n / name :op1 "TNF-α"~e.2)))
            :ARG1 (m2 / molecular-physical-entity~e.10
                  :name (n2 / name :op1 "GSH"~e.9)
                  :ARG1-of~e.10 (c / contain-01~e.10
                        :ARG0~e.11 (c2 / cell~e.15
                              :name (n3 / name :op1 "HS-24"~e.12,14))
                        :location (i / intracellular~e.8)))
            :manner~e.5 (s / significant~e.5))
      :snt2 (r / recover-02~e.23
            :ARG0 (p2 / pretreat-00
                  :ARG1 (c3 / culture~e.20
                        :mod (t2 / this~e.19))
                  :ARG2 (m3 / molecular-physical-entity
                        :name (n4 / name :op1 "DMSO"~e.22)))
            :ARG1 (d2 / decrease-01~e.30
                  :ARG1~e.31 (m4 / molecular-physical-entity
                        :name (n5 / name :op1 "GSH"~e.32))
                  :ARG1-of (i2 / induce-01~e.29
                        :ARG0 (p3 / protein
                              :name (n6 / name :op1 "TNF-α"~e.25))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (t3 / table~e.34 :mod "1"~e.35))))

# ::tok TNF @-@ a ( 200 U/ml ) significantly increased the levels of IL @-@ 6 mRNA in HS @-@ 24 cells and DMSO ( 1.0 %) markedly reduced those induced with the cytokine ( Fig . 5E ) .
# ::alignments 0-1.1.1.1.1 4-1.1.1.2.1 7-1.1.4 7-1.1.4.r 8-1.1 10-1.1.2 10-1.2.2 12-1.1.2.1.2.1.1 14-1.1.2.1.2.1.1 15-1.1.2.1.1.1 16-1.1.3.r 17-1.1.3.1.1 19-1.1.3.1.1 20-1.1.3 21-1 22-1.2.1.1.1 24-1.2.1.2.1 26-1.2.3 26-1.2.3.r 27-1.2 29-1.2.2.2 30-1.2.2.2.1.r 32-1.2.2.2.1.1.1 36-1.3.1.1
# ::id bel_pmid_1036_2713_15640
(a / and~e.21
      :op1 (i / increase-01~e.8
            :ARG0 (p / protein
                  :name (n / name :op1 "TNF-α"~e.0)
                  :quant (c / concentration-quantity
                        :quant "200"~e.4
                        :unit (u / unit-per-milliliter)))
            :ARG1 (l / level~e.10
                  :quant-of (r / rna
                        :name (n2 / name :op1 "mRNA"~e.15)
                        :part-of (g / gene
                              :name (n5 / name :op1 "IL-6"~e.12,14))))
            :location~e.16 (c2 / cell~e.20
                  :name (n3 / name :op1 "HS-24"~e.17,19))
            :manner~e.7 (s / significant~e.7))
      :op2 (r2 / reduce-01~e.27
            :ARG0 (m / molecular-physical-entity
                  :name (n4 / name :op1 "DMSO"~e.22)
                  :quant (p2 / percentage-entity :quant "1.0"~e.24))
            :ARG1 (l2 / level~e.10
                  :quant-of r
                  :ARG1-of (i2 / induce-01~e.29
                        :ARG0~e.30 (p3 / protein
                              :name (n6 / name :op1 "cytokine"~e.32))))
            :manner~e.26 (m2 / marked~e.26))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "5E"~e.36)))

# ::tok An XO enzyme activity of 5.0 mU @/@ ml led to a twofold increase in IL @-@ 6 secretion in NHBE cells . And incubation of HS @-@ 24 cells with XO ( 20 mU/ml ) induced a 1.8 @-@ fold increase in IL @-@ 6 production
# ::alignments 1-1.2.1.1.2.1.1 2-1.1.1.1 2-1.1.2.2.1 2-1.2.1.1.2 2-1.2.1.2.2.1 4-1.1.2.3 5-1.1.1.2.1 9-1.1 13-1.1.2 14-1.1.2.2.r 15-1.1.2.2.1.1.1 17-1.1.2.2.1.1.1 18-1.1.2.2 19-1.1.2.4.r 20-1.1.2.4.1.1 21-1.1.2.4 23-1.2 24-1.2.1.1 25-1.2.1.1.1.r 26-1.2.1.1.1.1.1 28-1.2.1.1.1.1.1 29-1.2.1.1.1 31-1.1.1.1.1.1 31-1.2.1.1.2.1.1 33-1.2.1.1.2.2.1 36-1.2.1 38-1.2.1.2.3.1 41-1.2.1.2 42-1.2.1.2.2.r 43-1.2.1.2.2.1.1.1 45-1.2.1.2.2.1.1.1 46-1.2.1.2.2
# ::id bel_pmid_1036_2713_18726
(m / multi-sentence
      :snt1 (l / lead-03~e.9
            :ARG0 (a / act-01
                  :ARG1 (e / enzyme~e.2
                        :name (n / name :op1 "XO"~e.31))
                  :quant (c / concentration-quantity
                        :quant "5.0"~e.5
                        :unit (m2 / milliunit-per-milliliter)))
            :ARG2 (i / increase-01~e.13
                  :ARG0 a
                  :ARG1~e.14 (s / secrete-01~e.18
                        :ARG1 (p / protein~e.2
                              :name (n2 / name :op1 "IL-6"~e.15,17)))
                  :ARG2 (p2 / product-of~e.4 :op1 "2")
                  :location~e.19 (c2 / cell~e.21
                        :name (n3 / name :op1 "NHBE"~e.20))))
      :snt2 (a2 / and~e.23
            :op2 (i2 / induce-01~e.36
                  :ARG0 (i3 / incubate-01~e.24
                        :ARG1~e.25 (c3 / cell~e.29
                              :name (n4 / name :op1 "HS-24"~e.26,28))
                        :ARG2 (e2 / enzyme~e.2
                              :name (n5 / name :op1 "XO"~e.1,31)
                              :quant (c4 / concentration-quantity
                                    :quant "20"~e.33
                                    :unit (m3 / milliunit-per-milliliter))))
                  :ARG1 (i4 / increase-01~e.41
                        :ARG0 i3
                        :ARG1~e.42 (p3 / produce-01~e.46
                              :ARG1 (p4 / protein~e.2
                                    :name (n6 / name :op1 "IL-6"~e.43,45)))
                        :ARG2 (p5 / product-of :op1 "1.8"~e.38)))))

# ::tok SOD ( 250 U/ml ) significantly suppressed the IL @-@ 6 production and IL @-@ 6 mRNA expression induced by XO , whereas catalase ( 500 U/ml ) did not modulate the IL @-@ 6 response to XO ( Fig . 4 ) .
# ::alignments 0-1.1.1.1.1 2-1.1.1.2.1 5-1.1.3 5-1.1.3.r 6-1.1 8-1.1.2.1.1.1.1 8-1.1.2.2.1.2.1.1 10-1.1.2.1.1.1.1 10-1.1.2.2.1.2.1.1 11-1.1.2.1 12-1.1.2 13-1.1.2.1.1.1.1 13-1.1.2.2.1.2.1.1 15-1.1.2.1.1.1.1 15-1.1.2.2.1.2.1.1 16-1.1.2.2.1.1.1 17-1.1.2.2 18-1.1.2.3 19-1.1.2.3.1.r 20-1.1.2.3.1.1.1 22-1 23-1.2.2.1.1 25-1.2.2.2.1 29-1.2.1 29-1.2.1.r 30-1.2 32-1.1.2.1.1.1.1 34-1.1.2.1.1.1.1 35-1.2.3 36-1.2.3.2.r 37-1.2.3.2 41-1.3.1.1
# ::id bel_pmid_1036_2713_24360
(c / contrast-01~e.22
      :ARG1 (s / suppress-01~e.6
            :ARG0 (e / enzyme
                  :name (n / name :op1 "SOD"~e.0)
                  :quant (c2 / concentration-quantity
                        :quant "250"~e.2
                        :unit (u / unit-per-milliliter)))
            :ARG1 (a / and~e.12
                  :op1 (p / produce-01~e.11
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "IL-6"~e.8,10,13,15,32,34)))
                  :op2 (e2 / express-03~e.17
                        :ARG1 (r / rna
                              :name (n3 / name :op1 "mRNA"~e.16)
                              :part-of (g / gene
                                    :name (n5 / name :op1 "IL-6"~e.8,10,13,15))))
                  :ARG1-of (i / induce-01~e.18
                        :ARG0~e.19 (e3 / enzyme
                              :name (n4 / name :op1 "XO"~e.20))))
            :manner~e.5 (s2 / significant~e.5))
      :ARG2 (m / modulate-01~e.30
            :polarity~e.29 "-"~e.29
            :ARG0 (e4 / enzyme
                  :name (n6 / name :op1 "catalase"~e.23)
                  :quant (c3 / concentration-quantity
                        :quant "500"~e.25
                        :unit u))
            :ARG1 (r2 / respond-01~e.35
                  :ARG0 p2
                  :ARG1~e.36 e3~e.37))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4"~e.41)))

# ::tok TNF @-@ a significantly increased the production of IL @-@ 6 in WI @-@ 38 @-@ 40 cells . However , DMSO was not able to inhibit the TNF @-@ a @-@ induced IL @-@ 6 enhancement in both protein and mRNA levels ( Fig . 7 ) . These results suggest that ROIs may not be involved in the production of IL @-@ 6 in human lung fibroblasts
# ::alignments 0-1.1.1.1.1 3-1.1.4 3-1.1.4.r 4-1.1 6-1.1.2 7-1.1.2.1.r 8-1.1.2.1.1.1 10-1.1.2.1.1.1 11-1.1.3.r 12-1.1.3.1.1 14-1.1.3.1.1 16-1.1.3.1.1 17-1.1.3 19-1.2 21-1.2.1.2.1.1.1 22-1.2.1.2.r 23-1.2.1.1 23-1.2.1.1.r 24-1.2.1 26-1.2.1.2 28-1.2.1.2.2.2.1.1.1 32-1.2.1.2.2.2 33-1.2.1.2.2.1.1.1 35-1.2.1.2.2.1.1.1 36-1.2.1.2.2 39-1.2.1.2.2.3.1.1 40-1.2.1.2.2.3 41-1.2.1.2.2.3.2.1.1.1 42-1.2.1.2.2.3.1 42-1.2.1.2.2.3.2 46-1.2.2.1.1 49-1.3.1.2 50-1.3.1 50-1.3.1.1 50-1.3.1.1.r 51-1.3 54-1.3.2 55-1.3.2.1 55-1.3.2.1.r 56-1.3.2.2.r 57-1.3.2.2 58-1.3.2.2.2.r 60-1.3.2.2.2 61-1.3.2.2.2.1.r 62-1.3.2.2.2.1.1.1 64-1.3.2.2.2.1.1.1 65-1.3.2.2.2.2.r 66-1.3.2.2.2.2.1.1 67-1.3.2.2.2.2.1 68-1.3.2.2.2.2
# ::id bel_pmid_1036_2713_24536
(m / multi-sentence
      :snt1 (i / increase-01~e.4
            :ARG0 (p / protein
                  :name (n / name :op1 "TNF-α"~e.0))
            :ARG1 (p2 / produce-01~e.6
                  :ARG1~e.7 (p3 / protein
                        :name (n2 / name :op1 "IL-6"~e.8,10)))
            :location~e.11 (c / cell~e.17
                  :name (n3 / name :op1 "WI-38-40"~e.12,14,16))
            :manner~e.3 (s / significant~e.3))
      :snt2 (h / have-concession-91~e.19
            :ARG1 (p4 / possible~e.24
                  :polarity~e.23 "-"~e.23
                  :domain~e.22 (i2 / inhibit-01~e.26
                        :ARG0 (m2 / molecular-physical-entity
                              :name (n4 / name :op1 "DMSO"~e.21))
                        :ARG1 (e / enhance-01~e.36
                              :ARG1 (p5 / protein
                                    :name (n5 / name :op1 "IL-6"~e.33,35))
                              :ARG1-of (i3 / induce-01~e.32
                                    :ARG0 (p6 / protein
                                          :name (n6 / name :op1 "TNF-α"~e.28)))
                              :location (a / and~e.40
                                    :op1 (l / level~e.42
                                          :mod (p7 / protein~e.39))
                                    :op2 (l2 / level~e.42
                                          :mod (r / rna
                                                :name (n7 / name :op1 "mRNA"~e.41)))))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "7"~e.46)))
      :snt3 (s2 / suggest-01~e.51
            :ARG0 (t / thing~e.50
                  :ARG2-of~e.50 (r2 / result-01~e.50)
                  :mod (t2 / this~e.49))
            :ARG1 (p8 / possible~e.54
                  :polarity~e.55 "-"~e.55
                  :domain~e.56 (i4 / involve-01~e.57
                        :ARG1 (m3 / molecular-physical-entity
                              :name (n8 / name :op1 "ROI"))
                        :ARG2~e.58 (p9 / produce-01~e.60
                              :ARG1~e.61 (p10 / protein
                                    :name (n9 / name :op1 "IL-6"~e.62,64))
                              :location~e.65 (f2 / fibroblast~e.68
                                    :part-of (l3 / lung~e.67
                                          :part-of (h2 / human~e.66))))))))

# ::tok TNF @-@ a was dose dependently capable of inducing IL @-@ 6 release from NHBE and HS @-@ 24 cells ( Fig . 5 , A and C ) .
# ::alignments 0-1.1.1.1.1 3-1.1.r 4-1.2.2 8-1.1 9-1.1.2.1.1.1 11-1.1.2.1.1.1 12-1.1.2 14-1.1.2.2.1.1.1 15-1.1.2.2 16-1.1.2.2.2.1.1 18-1.1.2.2.2.1.1 19-1.1.2.2.1 19-1.1.2.2.2 26-1.1.2.2 26-1.3.1
# ::id bel_pmid_1036_2713_24538
(p / possible
      :domain~e.3 (i / induce-01~e.8
            :ARG0 (p2 / protein
                  :name (n / name :op1 "TNF-α"~e.0))
            :ARG1 (r / release-01~e.12
                  :ARG1 (p3 / protein
                        :name (n2 / name :op1 "IL-6"~e.9,11))
                  :ARG2 (a / and~e.15,26
                        :op1 (c / cell~e.19
                              :name (n3 / name :op1 "NHBE"~e.14))
                        :op2 (c2 / cell~e.19
                              :name (n4 / name :op1 "HS-24"~e.16,18)))))
      :manner (d / depend-01
            :ARG0 p2
            :ARG1 (d2 / dose~e.4))
      :ARG1-of (d3 / describe-01
            :ARG0 (a2 / and~e.26
                  :op1 (f / figure :mod "5A")
                  :op2 (f2 / figure :mod "5C"))))

# ::tok As shown in Fig. 3A , stimulation with XO resulted in a significant increase in the levels of IL @-@ 6 at 12 and 24 h compared with those with 0.7 mM X alone ( P , 0.0001 ) . Consistent with these protein data , stimulation of HS @-@ 24 cells with XO caused the maximum elevation in IL @-@ 6 mRNAlevels at 6 h , whereas XO did not modulate control GAPDH transcript levels ( Fig . 3B ) .
# ::alignments 0-1.1.2.2.r 1-1.1.3 4-1.1.3.1.1 6-1.1.1 7-1.1.1.1.r 8-1.1.1.1.1.1 9-1.1 12-1.1.2.3 13-1.1.2 14-1.1.2.1.r 16-1.1.2.1 17-1.1.2.1.1.r 18-1.1.2.1.1.1.1 20-1.1.2.1.1.1.1 22-1.1.2.2.1.1 23-1.1.2.2 24-1.1.2.2.2.1 26-1.1.1.2 28-1.1.1.2.1.2 30-1.1.1.2.1.1.2.1 32-1.1.1.2.1.1.1.1 33-1.1.1.2.1.1.3 37-1.1.1.2.1.3.1.1 40-1.2.3 41-1.2.3.1.r 42-1.2.3.1.2 43-1.2.3.1.1 44-1.2.3.1 46-1.1.1.2.1 46-1.2.1.1 47-1.2.1.1.1.r 48-1.2.1.1.1.1.1 50-1.2.1.1.1.1.1 51-1.2.1.1.1 52-1.2.1.1.2.r 53-1.2.1.1.2.1.1 54-1.2.1 56-1.2.1.2.2 57-1.2.1.2 59-1.2.1.2.1.1.2.1.1 61-1.2.1.2.1.1.2.1.1 61-1.2.1.2.3.1 64-1.2.1.2.1.1.2.1.1 64-1.2.1.2.3.1 67-1.2 68-1.2.2.2 70-1.2.2.1 70-1.2.2.1.r 71-1.2.2 72-1.2.2.3.1 72-1.2.2.3.1.3 72-1.2.2.3.1.3.r 73-1.2.2.3.1.1.1 75-1.2.1.2.1 75-1.2.2.3 79-1.2.4.1.1
# ::id bel_pmid_1036_2713_24690
(m / multi-sentence
      :snt1 (r / result-01~e.9
            :ARG1 (s / stimulate-01~e.6
                  :ARG2~e.7 (e / enzyme
                        :name (n / name :op1 "XO"~e.8))
                  :ARG1-of (c / compare-01~e.26
                        :ARG2 (s2 / stimulate-01~e.46
                              :ARG2 (m2 / molecular-physical-entity
                                    :name (n2 / name :op1 "X"~e.32)
                                    :quant (c2 / concentration-quantity
                                          :quant "0.7"~e.30
                                          :unit (m3 / millimolar))
                                    :mod (a / alone~e.33))
                              :mod (t / that~e.28)
                              :value (p / probability
                                    :degree (l / less-than :quant "0.0001"~e.37)))))
            :ARG2 (i / increase-01~e.13
                  :ARG1~e.14 (l2 / level~e.16
                        :quant-of~e.17 (p2 / protein
                              :name (n3 / name :op1 "IL-6"~e.18,20)))
                  :time~e.0 (a2 / and~e.23
                        :op1 (t2 / temporal-quantity
                              :quant "12"~e.22
                              :unit (h / hour))
                        :op2 (t3 / temporal-quantity
                              :quant "24"~e.24
                              :unit h))
                  :mod (s3 / significant~e.12))
            :ARG1-of (s4 / show-01~e.1
                  :ARG0 (f / figure :mod "3A"~e.4)))
      :snt2 (c3 / contrast-01~e.67
            :ARG1 (c4 / cause-01~e.54
                  :ARG0 (s5 / stimulate-01~e.46
                        :ARG1~e.47 (c5 / cell~e.51
                              :name (n4 / name :op1 "HS-24"~e.48,50))
                        :ARG2~e.52 (e2 / enzyme
                              :name (n5 / name :op1 "XO"~e.53)))
                  :ARG1 (e3 / elevate-01~e.57
                        :ARG1 (l3 / level~e.75
                              :mod (r2 / rna
                                    :name (n6 / name :op1 "mRNA")
                                    :part-of (g / gene
                                          :name (n7 / name :op1 "IL-6"~e.59,61,64))))
                        :degree (m4 / maximum~e.56)
                        :quant (t4 / temporal-quantity
                              :quant "6"~e.61,64
                              :unit (h2 / hour))))
            :ARG2 (m5 / modulate-01~e.71
                  :polarity~e.70 "-"~e.70
                  :ARG0 e2~e.68
                  :ARG1 (l4 / level~e.75
                        :quant-of (e4 / enzyme~e.72
                              :name (n8 / name :op1 "GAPDH"~e.73)
                              :ARG1-of (t5 / transcribe-01)
                              :ARG0-of~e.72 (c6 / control-01~e.72))))
            :ARG1-of (c7 / consistent-01~e.40
                  :ARG2~e.41 (d / data~e.44
                        :mod (p3 / protein~e.43)
                        :mod (t6 / this~e.42)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f2 / figure :mod "3B"~e.79))))

# ::tok TNF @-@ a significantly increased the production of IL @-@ 6 in WI @-@ 38 @-@ 40 cells . However , DMSO was not able to inhibit the TNF @-@ a @-@ induced IL @-@ 6 enhancement in both protein and mRNA levels ( Fig . 7 ) . These results suggest that ROIs may not be involved in the production of IL @-@ 6 in human lung fibroblasts
# ::alignments 0-1.1.1.1.1 3-1.1.4 3-1.1.4.r 4-1.1 6-1.1.2 7-1.1.2.1.r 8-1.1.2.1.1.1 10-1.1.2.1.1.1 11-1.1.3.r 12-1.1.3.1.1 14-1.1.3.1.1 16-1.1.3.1.1 17-1.1.3 19-1.2 21-1.2.1.2.1.1.1 22-1.2.1.2.r 23-1.2.1.1 23-1.2.1.1.r 24-1.2.1 26-1.2.1.2 28-1.2.1.2.2.2.1.1.1 32-1.2.1.2.2.2 33-1.2.1.2.2.1.1.1 35-1.2.1.2.2.1.1.1 36-1.2.1.2.2 39-1.2.1.2.2.3.1.1 40-1.2.1.2.2.3 41-1.2.1.2.2.3.2.1.1.1 42-1.2.1.2.2.3.1 42-1.2.1.2.2.3.2 46-1.2.2.1.1 49-1.3.1.2 50-1.3.1 50-1.3.1.1 50-1.3.1.1.r 51-1.3 54-1.3.2 55-1.3.2.1 55-1.3.2.1.r 56-1.3.2.2.r 57-1.3.2.2 58-1.3.2.2.2.r 60-1.3.2.2.2 61-1.3.2.2.2.1.r 62-1.3.2.2.2.1.1.1 64-1.3.2.2.2.1.1.1 65-1.3.2.2.2.2.r 66-1.3.2.2.2.2.1.1 67-1.3.2.2.2.2.1 68-1.3.2.2.2.2
# ::id bel_pmid_1036_2713_39152
(m / multi-sentence
      :snt1 (i / increase-01~e.4
            :ARG0 (p / protein
                  :name (n / name :op1 "TNF-α"~e.0))
            :ARG1 (p2 / produce-01~e.6
                  :ARG1~e.7 (p3 / protein
                        :name (n2 / name :op1 "IL-6"~e.8,10)))
            :location~e.11 (c / cell~e.17
                  :name (n3 / name :op1 "WI-38-40"~e.12,14,16))
            :manner~e.3 (s / significant~e.3))
      :snt2 (h / have-concession-91~e.19
            :ARG1 (p4 / possible~e.24
                  :polarity~e.23 "-"~e.23
                  :domain~e.22 (i2 / inhibit-01~e.26
                        :ARG0 (m2 / molecular-physical-entity
                              :name (n4 / name :op1 "DMSO"~e.21))
                        :ARG1 (e / enhance-01~e.36
                              :ARG1 (p5 / protein
                                    :name (n5 / name :op1 "IL-6"~e.33,35))
                              :ARG1-of (i3 / induce-01~e.32
                                    :ARG0 (p6 / protein
                                          :name (n6 / name :op1 "TNF-α"~e.28)))
                              :location (a / and~e.40
                                    :op1 (l / level~e.42
                                          :quant-of (p7 / protein~e.39))
                                    :op2 (l2 / level~e.42
                                          :quant-of (r / rna
                                                :name (n7 / name :op1 "mRNA"~e.41)))))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "7"~e.46)))
      :snt3 (s2 / suggest-01~e.51
            :ARG0 (t / thing~e.50
                  :ARG2-of~e.50 (r2 / result-01~e.50)
                  :mod (t2 / this~e.49))
            :ARG1 (p8 / possible~e.54
                  :polarity~e.55 "-"~e.55
                  :domain~e.56 (i4 / involve-01~e.57
                        :ARG1 (m3 / molecular-physical-entity
                              :name (n8 / name :op1 "ROI"))
                        :ARG2~e.58 (p9 / produce-01~e.60
                              :ARG1~e.61 (p10 / protein
                                    :name (n9 / name :op1 "IL-6"~e.62,64))
                              :location~e.65 (f2 / fibroblast~e.68
                                    :part-of (l3 / lung~e.67
                                          :part-of (h2 / human~e.66))))))))

# ::tok TNF @-@ a was dose dependently capable of inducing IL @-@ 6 release from NHBE and HS @-@ 24 cells ( Fig . 5 , A and C ) .
# ::alignments 0-1.1.1.1.1 3-1.1.r 4-1.2.2 8-1.1 9-1.1.2.1.1.1 11-1.1.2.1.1.1 12-1.1.2 14-1.1.2.2.1.1.1 15-1.1.2.2 16-1.1.2.2.2.1.1 18-1.1.2.2.2.1.1 19-1.1.2.2.1 19-1.1.2.2.2 26-1.1.2.2 26-1.3.1
# ::id bel_pmid_1036_2713_39154
(p / possible
      :domain~e.3 (i / induce-01~e.8
            :ARG0 (p2 / protein
                  :name (n / name :op1 "TNF-α"~e.0))
            :ARG1 (r / release-01~e.12
                  :ARG1 (p3 / protein
                        :name (n2 / name :op1 "IL-6"~e.9,11))
                  :ARG2 (a / and~e.15,26
                        :op1 (c / cell~e.19
                              :name (n3 / name :op1 "NHBE"~e.14))
                        :op2 (c2 / cell~e.19
                              :name (n4 / name :op1 "HS-24"~e.16,18)))))
      :manner (d / depend-01
            :ARG0 p2
            :ARG1 (d2 / dose~e.4))
      :ARG1-of (d3 / describe-01
            :ARG0 (a2 / and~e.26
                  :op1 (f / figure :mod "5A")
                  :op2 (f2 / figure :mod "5C"))))

# ::tok Northern blot analysis documented that two transcription factor genes chosen for further study , c @-@ myc promoter @-@ binding protein ( MBP @-@ 1 ) and X @-@ box binding protein 1 ( XBP @-@ 1 ) , were up @-@ regulated in U266 cells about 3 @-@ fold relative to the cell cycle @-@ dependent beta @-@ actin gene 12 h after IL @-@ 6 treatment .
# ::alignments 0-1.1.1.1.1 1-1.1.1.1.2 2-1.1 3-1 5-1.2.1.1 6-1.2.1.2.1 7-1.2.1.2.2 8-1.2.1 9-1.2.1.3 10-1.2.1.3.1.r 11-1.2.1.3.1.1 12-1.2.1.3.1 14-1.2.1.4.1.1.1.1.1.1 16-1.2.1.4.1.1.1.1.1.1 17-1.2.1.4.1.1.1.1 19-1.2.1.4.1.1.1 20-1.2.1.4.1.1 22-1.2.1.4.1.1.2.1.1.1 24-1.2.1.4.1.1.2.1.1.1 24-1.2.1.4.1.2.1.1 26-1.2.1.4.1 27-1.2.1.4.1.2.2.1.1.1 29-1.2.1.4.1.2.2.1.1.1 30-1.2.1.4.1.2.2 31-1.2.1.4.1.2.1.1 32-1.2.1.4.1.2.1.1 32-1.2.1.4.1.2.3.1.1.1 34-1.2.1.4.1.2.3.1.1.1 36-1.2.1.4.1.1.2.1.1.1 36-1.2.1.4.1.2.1.1 36-1.2.1.4.1.2.3.1.1.1 44-1.2.2.1.1 45-1.2.5.1.2.1.1 46-1.2.3.2 47-1.2.3.1 53-1.2.5.1.2.1.1 54-1.2.5.1.2.1 56-1.2.5.1.2 57-1.2.5.1.1.1 59-1.2.5.1.1.1 60-1.2.5.1 61-1.2.4.2.1 63-1.2.4 64-1.2.4.1.1.1.1 66-1.2.4.1.1.1.1 67-1.2.4.1
# ::id bel_pmid_1037_5612_23694
(d / document-01~e.3
      :ARG0 (a / analyze-01~e.2
            :instrument (t / thing
                  :name (n / name :op1 "northern"~e.0 :op2 "blot"~e.1)))
      :ARG1 (u / upregulate-01
            :ARG1 (g / gene~e.8
                  :quant "2"~e.5
                  :name (n2 / name :op1 "transcription"~e.6 :op2 "factor"~e.7)
                  :ARG1-of (c / choose-01~e.9
                        :ARG4~e.10 (s / study-01~e.12
                              :degree (f / further~e.11)))
                  :ARG1-of (m / mean-01
                        :ARG2 (a2 / and~e.26
                              :op1 (p / protein~e.20
                                    :ARG0-of (b / bind-01~e.19
                                          :ARG1 (p2 / promoter~e.17
                                                :name (n3 / name :op1 "c-myc"~e.14,16)))
                                    :ARG1-of (d2 / describe-01
                                          :ARG0 (p3 / protein
                                                :name (n4 / name :op1 "MBP-1"~e.22,24,36))))
                              :op2 (p4 / protein
                                    :name (n5 / name :op1 "protein-1"~e.24,31,32,36)
                                    :ARG0-of (b2 / bind-01~e.30
                                          :ARG1 (m2 / molecular-physical-entity
                                                :name (n6 / name :op1 "X-box"~e.27,29)))
                                    :ARG1-of (d3 / describe-01
                                          :ARG0 (p5 / protein
                                                :name (n7 / name :op1 "XBP-1"~e.32,34,36)))))))
            :location (c2 / cell
                  :name (n8 / name :op1 "U266"~e.44))
            :degree (p6 / product-of
                  :op1 "3"~e.47
                  :mod (a3 / about~e.46))
            :time (a4 / after~e.63
                  :op1 (t2 / treat-04~e.67
                        :ARG2 (p7 / protein
                              :name (n9 / name :op1 "IL-6"~e.64,66)))
                  :quant (t3 / temporal-quantity
                        :quant "12"~e.61
                        :unit (h / hour)))
            :ARG1-of (r / relate-01
                  :ARG2 (g2 / gene~e.60
                        :name (n10 / name :op1 "beta-actin"~e.57,59)
                        :ARG0-of (d4 / depend-01~e.56
                              :ARG1 (c3 / cycle~e.54
                                    :mod (c4 / cell~e.45,53)))))))

# ::tok Signaling by the IL @-@ 6 receptor is mediated through the signal transducing subunit gp130 and involves the activation of Janus @-@ associated kinases ( JAKs ) , signal transducer and activator of transcription 3 ( STAT3 ) , and mitogen @-@ activated protein ( MAP ) kinase .
# ::alignments 0-1.1.1 3-1.1.1.1.1.1 5-1.1.1.1.1.1 6-1.1.1.1 8-1.1 11-1.1.1 11-1.1.2.2.1.1 12-1.1.2.2.1 13-1.1.2.2 14-1.1.2.1.1 15-1 16-1.2 18-1.2.1 19-1.2.1.1.2.1.5 19-1.2.1.1.r 20-1.2.1.1.1.1.1 22-1.2.1.1.1.1.1 23-1.2.1.1.1.1.2 23-1.2.1.1.3.1.3 28-1.2.1.1.2.1.1 29-1.2.1.1.2.1.2 30-1.2.1.1.2.1.3 31-1.2.1.1.2.1.4 32-1.2.1.1.2.1.5 33-1.2.1.1.2.1.6 34-1.2.1.1.2.1.6 36-1.2.1.1.2.2.1.1.1 39-1.2.1.1 40-1.2.1.1.3.1.1 42-1.2.1.1.3.1.1 43-1.2.1.1.3.1.2 45-1.2.1.1.3.2.1.1.1 47-1.2.1.1.1.1.2
# ::id bel_pmid_1040_9724_18580
(a / and~e.15
      :op1 (m / mediate-01~e.8
            :ARG1 (s / signal-01~e.0,11
                  :ARG0 (r / receptor~e.6
                        :name (n / name :op1 "IL-6"~e.3,5)))
            :medium (p / protein
                  :name (n2 / name :op1 "gp130"~e.14)
                  :mod (s2 / subunit~e.13
                        :ARG0-of (t / transduce-00~e.12
                              :ARG1 (s3 / signal-01~e.11)))))
      :op2 (i / involve-01~e.16
            :ARG1 (a2 / activate-01~e.18
                  :ARG1~e.19 (a3 / and~e.39
                        :op1 (e / enzyme
                              :name (n3 / name :op1 "Janus-associated"~e.20,22 :op2 "kinase"~e.23,47)
                              :ARG1-of (d / describe-01
                                    :ARG0 (e2 / enzyme
                                          :name (n4 / name :op1 "JAK"))))
                        :op2 (p2 / protein
                              :name (n5 / name
                                    :op1 "signal"~e.28
                                    :op2 "transducer"~e.29
                                    :op3 "and"~e.30
                                    :op4 "activator"~e.31
                                    :op5 "of"~e.19,32
                                    :op6 "transcription-3"~e.33,34)
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p3 / protein
                                          :name (n6 / name :op1 "STAT3"~e.36))))
                        :op3 (e3 / enzyme
                              :name (n7 / name
                                    :op1 "mitogen-activated"~e.40,42
                                    :op2 "protein"~e.43
                                    :op3 "kinase"~e.23)
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (e4 / enzyme
                                          :name (n8 / name :op1 "MAP"~e.45))))))
            :ARG2 s))

# ::tok This study shows that in hepatoma cells , the recruitment and tyrosine phosphorylation of SHP @-@ 2 , but not SHC , is the primary signaling event associated with the activation of MAP kinases ( ERK1 @/@ 2 ) by gp130 .
# ::alignments 0-1.1.1 1-1.1 2-1 4-1.2.r 5-1.2.4.2.1.1 6-1.2.4.2 9-1.2.3.1 9-1.2.3.3.1.1 10-1.2.3 11-1.2.3.2.2 12-1.2.3.2 12-1.2.3.3.1.2 13-1.2.3.1.1.r 14-1.2.3.1.1.1.1 16-1.2.3.1.1.1.1 18-1.2.3.3 19-1.2.3.3.1.1.1 19-1.2.3.3.1.1.1.r 19-1.2.3.3.1.2.1 19-1.2.3.3.1.2.1.r 20-1.2.3.3.1.1.2.1.1 22-1.2.3.r 24-1.2.2 25-1.2.1 26-1.2 27-1.2.4 28-1.2.4.1.r 30-1.2.4.1 31-1.2.4.1.2.r 32-1.2.4.1.2.1.1.1 33-1.2.4.1.2 35-1.2.4.1.2.2.1.1.1 37-1.2.4.1.2.2.1.1.1 39-1.2.4.1.1.r 40-1.2.4.1.1.1.1
# ::id bel_pmid_1040_9724_23704
(s / show-01~e.2
      :ARG0 (s2 / study-01~e.1
            :mod (t / this~e.0))
      :ARG1~e.4 (e / event~e.26
            :ARG0-of (s3 / signal-01~e.25)
            :mod (p / primary~e.24)
            :domain~e.22 (a / and~e.10
                  :op1 (r / recruit-01~e.9
                        :ARG1~e.13 (p2 / protein
                              :name (n / name :op1 "SHP-2"~e.14,16)))
                  :op2 (p3 / phosphorylate-01~e.12
                        :ARG1 p2
                        :ARG2 (t2 / tyrosine~e.11))
                  :ARG1-of (c / contrast-01~e.18
                        :ARG2 (a2 / and
                              :op1 (r2 / recruit-01~e.9
                                    :polarity~e.19 "-"~e.19
                                    :ARG1 (p4 / protein
                                          :name (n2 / name :op1 "SHC"~e.20)))
                              :op2 (p5 / phosphorylate-01~e.12
                                    :polarity~e.19 "-"~e.19
                                    :ARG1 p4
                                    :ARG2 t2))))
            :ARG1-of (a3 / associate-01~e.27
                  :ARG2~e.28 (a4 / activate-01~e.30
                        :ARG0~e.39 (p6 / protein
                              :name (n3 / name :op1 "gp130"~e.40))
                        :ARG1~e.31 (k / kinase~e.33
                              :mod (p7 / protein
                                    :name (n4 / name :op1 "MAP"~e.32))
                              :ARG1-of (d / describe-01
                                    :ARG0 (e2 / enzyme
                                          :name (n5 / name :op1 "ERK1/2"~e.35,37)))))
                  :location (c2 / cell~e.6
                        :name (n6 / name :op1 "hepatoma"~e.5)))))

# ::tok Signaling by the IL @-@ 6 receptor is mediated through the signal transducing subunit gp130 and involves the activation of Janus @-@ associated kinases ( JAKs ) , signal transducer and activator of transcription 3 ( STAT3 ) , and mitogen @-@ activated protein ( MAP ) kinase .
# ::alignments 0-1.1.1 3-1.1.1.1.1.1 5-1.1.1.1.1.1 6-1.1.1.1 8-1.1 11-1.1.1 11-1.1.2.2.1.1 12-1.1.2.2.1 13-1.1.2.2 14-1.1.2.1.1 15-1 16-1.2 18-1.2.1 19-1.2.1.1.2.1.5 19-1.2.1.1.r 20-1.2.1.1.1.1.1 22-1.2.1.1.1.1.1 23-1.2.1.1.1.1.2 23-1.2.1.1.3.1.3 28-1.2.1.1.2.1.1 29-1.2.1.1.2.1.2 30-1.2.1.1.2.1.3 31-1.2.1.1.2.1.4 32-1.2.1.1.2.1.5 33-1.2.1.1.2.1.6 34-1.2.1.1.2.1.6 36-1.2.1.1.2.2.1.1.1 39-1.2.1.1 40-1.2.1.1.3.1.1 42-1.2.1.1.3.1.1 43-1.2.1.1.3.1.2 45-1.2.1.1.3.2.1.1.1 47-1.2.1.1.1.1.2
# ::id bel_pmid_1040_9724_52
(a / and~e.15
      :op1 (m / mediate-01~e.8
            :ARG1 (s / signal-01~e.0,11
                  :ARG0 (r / receptor~e.6
                        :name (n / name :op1 "IL-6"~e.3,5)))
            :medium (p / protein
                  :name (n2 / name :op1 "gp130"~e.14)
                  :mod (s2 / subunit~e.13
                        :ARG0-of (t / transduce-00~e.12
                              :ARG1 (s3 / signal-01~e.11)))))
      :op2 (i / involve-01~e.16
            :ARG1 (a2 / activate-01~e.18
                  :ARG1~e.19 (a3 / and~e.39
                        :op1 (e / enzyme
                              :name (n3 / name :op1 "Janus-associated"~e.20,22 :op2 "kinase"~e.23,47)
                              :ARG1-of (d / describe-01
                                    :ARG0 (e2 / enzyme
                                          :name (n4 / name :op1 "JAK"))))
                        :op2 (p2 / protein
                              :name (n5 / name
                                    :op1 "signal"~e.28
                                    :op2 "transducer"~e.29
                                    :op3 "and"~e.30
                                    :op4 "activator"~e.31
                                    :op5 "of"~e.19,32
                                    :op6 "transcription-3"~e.33,34)
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p3 / protein
                                          :name (n6 / name :op1 "STAT3"~e.36))))
                        :op3 (e3 / enzyme
                              :name (n7 / name
                                    :op1 "mitogen-activated"~e.40,42
                                    :op2 "protein"~e.43
                                    :op3 "kinase"~e.23)
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (e4 / enzyme
                                          :name (n8 / name :op1 "MAP"~e.45))))))
            :ARG2 s))

# ::tok <A4> c @-@ Abl binds to p53 in response to 1 @-@ b @-@ d @-@ arabinofuransylcytosine or methylmethanesulfonate ( Yuan et al. , 1996 ) ; this interaction does not require c @-@ Abl kinase activity . Moreover , c @-@ Abl kinase activity does not require p53. Binding of c @-@ Abl to p53 inhibits the Mdm2 @-@ mediated degradation of p53 ( Sionov et al. , 1999 ) .
# ::alignments 1-1.2.1.2.1.1.1 1-1.3.1.1.1.1 3-1.2.1.2.1.1.1 3-1.3.1.1.1.1 4-1.1.1 5-1.1.1.2.r 6-1.1.1.2.1.1 7-1.1.1.3.r 8-1.1.1.3 9-1.1.1.3.1.r 10-1.1.1.3.1.1.1.1 12-1.1.1.3.1.1.1.1 14-1.1.1.3.1.1.1.1 17-1.1.1.3.1 18-1.1.1.3.1.2.1.1 20-1.1.1.4.1.1.1.1.1 21-1.1.1.4.1.1 22-1.1.1.4.1.1.2.1 24-1.1.1.4.1.2.1 27-1.1.2.2.1 28-1.1.2.2 30-1.1.2.1 30-1.1.2.1.r 31-1.1.2 32-1.1.1.1.1.1 34-1.1.1.1.1.1 35-1.1.1.1 36-1.1.2.3 40-1.2.1.2.1.1.1 40-1.3.1.1.1.1 42-1.2.1.2.1.1.1 42-1.3.1.1.1.1 43-1.2.1.2.1 44-1.1.2.3 44-1.2.1.2 46-1.2.1.1 46-1.2.1.1.r 47-1.1.2 47-1.2.1 49-1.3.1 51-1.2.1.2.1.1.1 51-1.3.1.1.1.1 53-1.2.1.2.1.1.1 53-1.3.1.1.1.1 55-1.2.1.3.1.1 55-1.3.1.2.1.1 56-1.3 58-1.3.2.2.1.1.1 60-1.3.2.2 61-1.3.2 62-1.3.1.2.r 63-1.3.1.2.1.1 65-1.3.3.1.1.1.1.1 66-1.1 66-1.2 66-1.3.3.1.1 67-1.3.3.1.1.2.1 69-1.3.3.1.2.1
# ::id bel_pmid_1043_6023_17968
(m / multi-sentence
      :snt1 (a / and~e.66
            :op1 (b / bind-01~e.4
                  :ARG1 (k2 / kinase~e.35
                        :name (n / name :op1 "c-Abl"~e.32,34))
                  :ARG2~e.5 (p2 / protein
                        :name (n2 / name :op1 "p53"~e.6))
                  :ARG2-of~e.7 (r / respond-01~e.8
                        :ARG1~e.9 (o / or~e.17
                              :op1 (s / small-molecule
                                    :name (n3 / name :op1 "1-b-d-arabinofuranosylcytosine"~e.10,12,14))
                              :op2 (s2 / small-molecule
                                    :name (n4 / name :op1 "methylmethanesulfonate"~e.18))))
                  :ARG1-of (d3 / describe-01
                        :ARG0 (p3 / publication-91
                              :ARG0 (a2 / and~e.21
                                    :op1 (p4 / person
                                          :name (n5 / name :op1 "Yuan"~e.20))
                                    :op2 (p5 / person
                                          :mod (o2 / other~e.22)))
                              :time (d4 / date-entity :year "1996"~e.24))))
            :op2 (r2 / require-01~e.31,47
                  :polarity~e.30 "-"~e.30
                  :ARG0 (i / interact-01~e.28
                        :mod (t / this~e.27))
                  :ARG1 (a3 / act-02~e.36,44
                        :ARG0 k2)))
      :snt2 (a4 / and~e.66
            :op2 (r3 / require-01~e.47
                  :polarity~e.46 "-"~e.46
                  :ARG0 (a5 / act-02~e.44
                        :ARG0 (k3 / kinase~e.43
                              :name (n6 / name :op1 "c-Abl"~e.1,3,40,42,51,53)))
                  :ARG1 (p7 / protein
                        :name (n7 / name :op1 "p53"~e.55))))
      :snt3 (i2 / inhibit-01~e.56
            :ARG0 (b2 / bind-01~e.49
                  :ARG1 (p8 / protein
                        :name (n8 / name :op1 "c-Abl"~e.1,3,40,42,51,53))
                  :ARG2~e.62 (p9 / protein
                        :name (n9 / name :op1 "p53"~e.55,63)))
            :ARG1 (d / degrade-01~e.61
                  :ARG1 p9
                  :ARG1-of (m2 / mediate-01~e.60
                        :ARG0 (p10 / protein
                              :name (n10 / name :op1 "Mdm2"~e.58))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p11 / publication-91
                        :ARG0 (a6 / and~e.66
                              :op1 (p12 / person
                                    :name (n11 / name :op1 "Sionov"~e.65))
                              :op2 (p13 / person
                                    :mod (o3 / other~e.67)))
                        :time (d5 / date-entity :year "1999"~e.69))))
      :ARG1-of (d6 / describe-01
            :ARG2 (a7 / A4)))

# ::tok <B8> c @-@ Abl phosphorylates DNA @-@ PK in the C @-@ terminal region ( amino acids 3414?3850 ) ( Jin et al. , 1997 ) . c @-@ Abl @-@ dependent phosphorylation of DNA @-@ PK is stimulated by IR ( Kharbanda et al. , 1997 ) . c @-@ Abl does not phosphorylate Ku ( Kharbanda et al. , 1997 ) .
# ::alignments 1-1.1.2.1.1 1-1.2.2.2.1.1.1 1-1.3.3.1.1 3-1.1.2.1.1 3-1.2.2.2.1.1.1 3-1.3.3.1.1 4-1.1 4-1.2.2 5-1.1.1.2.1.1 5-1.2.2.1.1.1 7-1.1.1.2.1.1 7-1.2.2.1.1.1 10-1.1.1.1.1 10-1.1.2.1.1 10-1.2.2.2.1.1.1 10-1.3.3.1.1 12-1.1.1.1.1 15-1.1.1.3.1 15-1.1.1.3.2 16-1.1.1.3.1 16-1.1.1.3.2 20-1.1.3.1.1.1.1.1 21-1.1.3.1.1 21-1.2.3.1.1 21-1.3.4.1.1 22-1.1.3.1.1.2.1 22-1.2.3.1.1.2.1 22-1.3.4.1.1.2.1 24-1.1.3.1.2.1 24-1.2.3.1.2.1 24-1.3.4.1.2.1 27-1.1.2.1.1 27-1.2.2.2.1.1.1 27-1.3.3.1.1 29-1.1.2.1.1 29-1.2.2.2.1.1.1 29-1.3.3.1.1 31-1.2.2.2 32-1.2.2 33-1.2.2.1.r 34-1.2.2.1.1.1 36-1.2.2.1.1.1 38-1.2 42-1.2.3.1.1.1.1.1 42-1.3.4.1.1.1.1.1 43-1.1.3.1.1 43-1.2.3.1.1 43-1.3.4.1.1 44-1.1.3.1.1.2.1 44-1.2.3.1.1.2.1 44-1.3.4.1.1.2.1 46-1.1.3.1.2.1 46-1.2.3.1.2.1 46-1.3.4.1.2.1 49-1.1.2.1.1 49-1.3.3.1.1 51-1.1.2.1.1 51-1.3.3.1.1 53-1.3.1 53-1.3.1.r 54-1.3 55-1.3.2.1.1 57-1.2.3.1.1.1.1.1 57-1.3.4.1.1.1.1.1 58-1.1.3.1.1 58-1.2.3.1.1 58-1.3.4.1.1 59-1.1.3.1.1.2.1 59-1.2.3.1.1.2.1 59-1.3.4.1.1.2.1 61-1.1.3.1.2.1 61-1.2.3.1.2.1 61-1.3.4.1.2.1
# ::id bel_pmid_1043_6023_18176
(m / multi-sentence
      :snt1 (p / phosphorylate-01~e.4
            :ARG1 (p3 / protein-segment
                  :name (n3 / name :op1 "C-terminus"~e.10,12)
                  :part-of (e / enzyme
                        :name (n2 / name :op1 "DNA-PK"~e.5,7))
                  :mod (b / between
                        :op1 (a / amino-acid~e.15,16 :value "3414")
                        :op2 (a2 / amino-acid~e.15,16 :value "3850")))
            :ARG2 (p2 / protein
                  :name (n / name :op1 "c-Abl"~e.1,3,10,27,29,49,51))
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication-91
                        :ARG0 (a3 / and~e.21,43,58
                              :op1 (p5 / person
                                    :name (n4 / name :op1 "Jin"~e.20))
                              :op2 (p6 / person
                                    :mod (o / other~e.22,44,59)))
                        :time (d2 / date-entity :year "1997"~e.24,46,61))))
      :snt2 (s / stimulate-01~e.38
            :ARG0 (r / radiation
                  :ARG0-of (i / ionize-01))
            :ARG1 (p7 / phosphorylate-01~e.4,32
                  :ARG1~e.33 (e2 / enzyme
                        :name (n5 / name :op1 "DNA-PK"~e.5,7,34,36))
                  :ARG0-of (d3 / depend-01~e.31
                        :ARG1 (p9 / protein
                              :name (n6 / name :op1 "c-Abl"~e.1,3,10,27,29))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p10 / publication-91
                        :ARG0 (a4 / and~e.21,43,58
                              :op1 (p11 / person
                                    :name (n7 / name :op1 "Kharbanda"~e.42,57))
                              :op2 (p12 / person
                                    :mod (o2 / other~e.22,44,59)))
                        :time (d5 / date-entity :year "1997"~e.24,46,61))))
      :snt3 (p13 / phosphorylate-01~e.54
            :polarity~e.53 "-"~e.53
            :ARG1 (p15 / protein
                  :name (n9 / name :op1 "Ku"~e.55))
            :ARG2 (p14 / protein
                  :name (n8 / name :op1 "c-Abl"~e.1,3,10,27,29,49,51))
            :ARG1-of (d6 / describe-01
                  :ARG0 (p16 / publication-91
                        :ARG0 (a5 / and~e.21,43,58
                              :op1 (p17 / person
                                    :name (n10 / name :op1 "Kharbanda"~e.42,57))
                              :op2 (p18 / person
                                    :mod (o3 / other~e.22,44,59)))
                        :time (d7 / date-entity :year "1997"~e.24,46,61))))
      :ARG1-of (d8 / describe-01
            :ARG2 (b2 / B8)))

# ::tok <N12> Rad51 binds to c @-@ Abl directly ( Yuan et al. , 1998 ) . c @-@ Abl phosphorylates Rad51 Tyr54 , as a consequence of which the binding of Rad51 to ssDNA is inhibited ( Yuan et al. , 1998 ) . IR induces c @-@ Abl @-@ dependent phosphorylation of Rad51 ( Yuan et al. , 1998 ) .
# ::alignments 1-1.1.1.1.1 1-1.2.1.3.1.1 2-1.1 3-1.1.2.r 4-1.1.2.1.1 6-1.1.2.1.1 7-1.1.3 7-1.1.3.r 9-1.1.4.1.1.1.1.1 9-1.2.4.1.1.1.1.1 9-1.3.3.1.1.1.1.1 10-1.1.4.1.1 10-1.2.4.1.1 10-1.3.3.1.1 11-1.1.4.1.1.2.1 11-1.2.4.1.1.2.1 11-1.3.3.1.1.2.1 13-1.1.4.1.2.1 13-1.2.4.1.2.1 13-1.3.3.1.2.1 16-1.1.2.1.1 16-1.2.2.1.1 18-1.1.2.1.1 18-1.2.2.1.1 19-1.2 20-1.2.1.3.1.1 23-1.2.3 23-1.2.4.1.2.r 24-1.2.3 25-1.2.3 29-1.2.3.1.1 30-1.2.3.1.1.1.r 31-1.2.3.1.1.1 32-1.2.3 35-1.2.3.1 37-1.1.4.1.1.1.1.1 37-1.2.4.1.1.1.1.1 37-1.3.3.1.1.1.1.1 38-1.1.4.1.1 38-1.2.4.1.1 38-1.3.3.1.1 39-1.1.4.1.1.2.1 39-1.2.4.1.1.2.1 39-1.3.3.1.1.2.1 41-1.1.4.1.2.1 41-1.2.4.1.2.1 41-1.3.3.1.2.1 45-1.3 46-1.3.2.2.1.1.1 48-1.3.2.2.1.1.1 50-1.3.2.2 51-1.3.2 53-1.1.1.1.1 53-1.2.1.3.1.1 53-1.3.2.1.1.1 55-1.1.4.1.1.1.1.1 55-1.2.4.1.1.1.1.1 55-1.3.3.1.1.1.1.1 56-1.1.4.1.1 56-1.2.4.1.1 56-1.3.3.1.1 57-1.1.4.1.1.2.1 57-1.2.4.1.1.2.1 57-1.3.3.1.1.2.1 59-1.1.4.1.2.1 59-1.2.4.1.2.1 59-1.3.3.1.2.1
# ::id bel_pmid_1043_6023_18178
(m / multi-sentence
      :snt1 (b / bind-01~e.2
            :ARG1 (p / protein
                  :name (n / name :op1 "Rad51"~e.1,53))
            :ARG2~e.3 (p2 / protein
                  :name (n2 / name :op1 "c-Abl"~e.4,6,16,18))
            :manner~e.7 (d / direct~e.7)
            :ARG1-of (d2 / describe-01
                  :ARG0 (p3 / publication-91
                        :ARG0 (a / and~e.10,38,56
                              :op1 (p4 / person
                                    :name (n3 / name :op1 "Yuan"~e.9,37,55))
                              :op2 (p5 / person
                                    :mod (o / other~e.11,39,57)))
                        :time (d3 / date-entity :year "1998"~e.13,41,59))))
      :snt2 (p6 / phosphorylate-01~e.19
            :ARG1 (a4 / amino-acid
                  :mod "54"
                  :name (n13 / name :op1 "tyrosine")
                  :part-of (p8 / protein
                        :name (n5 / name :op1 "Rad51"~e.1,20,53)))
            :ARG2 (p9 / protein
                  :name (n6 / name :op1 "c-Abl"~e.16,18))
            :ARG0-of (c / cause-01~e.23,24,25,32
                  :ARG1 (i / inhibit-01~e.35
                        :ARG1 (b2 / bind-01~e.29
                              :ARG1~e.30 p8~e.31
                              :ARG2 (d5 / DNA
                                    :mod (s / strand
                                          :mod (s2 / single))))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p10 / publication-91
                        :ARG0 (a2 / and~e.10,38,56
                              :op1 (p11 / person
                                    :name (n7 / name :op1 "Yuan"~e.9,37,55))
                              :op2 (p12 / person
                                    :mod (o2 / other~e.11,39,57)))
                        :time~e.23 (d6 / date-entity :year "1998"~e.13,41,59))))
      :snt3 (i2 / induce-01~e.45
            :ARG0 (r / radiation
                  :ARG0-of (i3 / ionize-01))
            :ARG1 (p14 / phosphorylate-01~e.51
                  :ARG1 (p15 / protein
                        :name (n9 / name :op1 "Rad51"~e.53))
                  :ARG0-of (d7 / depend-01~e.50
                        :ARG1 (p16 / protein
                              :name (n10 / name :op1 "c-Abl"~e.46,48))))
            :ARG1-of (d8 / describe-01
                  :ARG0 (p17 / publication-91
                        :ARG0 (a3 / and~e.10,38,56
                              :op1 (p18 / person
                                    :name (n11 / name :op1 "Yuan"~e.9,37,55))
                              :op2 (p19 / person
                                    :mod (o3 / other~e.11,39,57)))
                        :time (d9 / date-entity :year "1998"~e.13,41,59))))
      :ARG1-of (d10 / describe-01
            :ARG2 (n12 / N12)))

# ::tok <p30> p53 is rapidly degraded by the process of ubiquitiation and proteasome . <p31> mdm2 stimulates p53 degradation
# ::alignments 1-1.1.2.1.1 3-1.1.3 3-1.1.3.r 4-1.1 5-1.1.1.r 7-1.1.1.1 10-1.1.1 11-1.1.1.2.1.1 14-1.2.1.1.1 15-1.2 16-1.2.2.1.1.1 17-1.2.2
# ::id bel_pmid_1043_6023_18610
(m / multi-sentence
      :snt1 (d / degrade-01~e.4
            :ARG0~e.5 (a / and~e.10
                  :op1 (p2 / process~e.7
                        :mod (u / ubiquitinate-01
                              :ARG1 (p / protein
                                    :name (n / name :op1 "p53"~e.1))))
                  :op2 (m2 / macro-molecular-complex
                        :name (n2 / name :op1 "proteasome"~e.11)))
            :ARG1 p
            :manner~e.3 (r / rapid~e.3)
            :ARG1-of (d3 / describe-01
                  :ARG2 (p5 / p30)))
      :snt2 (s / stimulate-01~e.15
            :ARG0 (p3 / protein
                  :name (n3 / name :op1 "mdm2"~e.14))
            :ARG1 (d2 / degrade-01~e.17
                  :ARG1 (p4 / protein
                        :name (n4 / name :op1 "p53"~e.16)))
            :ARG1-of (d4 / describe-01
                  :ARG2 (p6 / p31))))

# ::tok <A8> c @-@ Abl tyrosine kinase activity is blocked by pRb , which binds to the c @-@ Abl kinase domain ( Welch and Wang , 1995 ) .
# ::alignments 1-1.2.1.1.1 3-1.2.1.1.1 4-1.2.1.2.1.1 5-1.2.1 6-1.2 8-1 9-1.1.r 10-1.1.1.1 13-1.1 13-1.1.2 13-1.1.2.r 14-1.1.2.1.r 16-1.1.2.1.1 17-1.1.2.1.1 18-1.1.2.1.1 19-1.1.2.1.1 20-1.1.2.1 22-1.3.1.1.1.1.1 23-1.3.1.1 24-1.3.1.1.2.1.1 26-1.3.1.2.1
# ::id bel_pmid_1043_6023_19908
(b / block-01~e.8
      :ARG0~e.9 (p3 / protein~e.13
            :name (n3 / name :op1 "pRb"~e.10)
            :ARG1-of~e.13 (b2 / bind-01~e.13
                  :ARG2~e.14 (d / domain~e.20
                        :part-of k2~e.16,17,18,19)))
      :ARG1 (a / act-02~e.6
            :ARG0 (k2 / kinase~e.5
                  :name (n6 / name :op1 "c-Abl"~e.1,3)
                  :mod (a4 / amino-acid
                        :name (n / name :op1 "tyrosine"~e.4))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a2 / and~e.23
                        :op1 (p5 / person
                              :name (n4 / name :op1 "Welch"~e.22))
                        :op2 (p6 / person
                              :name (n5 / name :op1 "Wang"~e.24)))
                  :time (d3 / date-entity :year "1995"~e.26)))
      :ARG1-of (d4 / describe-01
            :ARG2 (a3 / A8)))

# ::tok <s10> Cyclin A : Cdk2 and Cyclin A : Cdc2 phosphorylate RPA2; the major site for Cdc2 has been mapped to Ser29 ( Niu et al.,1997 ) .
# ::alignments 1-1.1.2.1.1.1.1 2-1.1.2.1.1.1.2 4-1.1.2.1.2.1.1 6-1.1.2.1.1.1.1 7-1.1.2.1.1.1.2 9-1.1.2.2.2.1.1 10-1.1 13-1.2.1.1 14-1.2.1 15-1.2.1.2.r 16-1.2.1.2 19-1.2 23-1.3.1.1.1.1.1 24-1 24-1.3.1.1
# ::id bel_pmid_1043_6023_19942
(a / and~e.24
      :op1 (p / phosphorylate-01~e.10
            :ARG1 (p3 / protein
                  :name (n4 / name :op1 "RPA2"))
            :ARG2 (a2 / and
                  :op1 (m / macro-molecular-complex
                        :part (p2 / protein
                              :name (n / name :op1 "Cyclin"~e.1,6 :op2 "A"~e.2,7))
                        :part (e / enzyme
                              :name (n2 / name :op1 "Cdk2"~e.4)))
                  :op2 (m2 / macro-molecular-complex
                        :part p2
                        :part (e2 / enzyme
                              :name (n3 / name :op1 "Cdc2"~e.9)))))
      :op2 (m3 / map-02~e.19
            :ARG1 (p4 / protein-segment~e.14
                  :mod (m4 / major~e.13)
                  :part-of~e.15 e2~e.16)
            :ARG2 (a3 / amino-acid
                  :mod "29"
                  :name (n5 / name :op1 "serine")))
      :ARG1-of (d / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a4 / and~e.24
                        :op1 (p6 / person
                              :name (n6 / name :op1 "Niu"~e.23))
                        :op2 (p7 / person
                              :mod (o / other)))
                  :time (d2 / date-entity :year "1997")))
      :ARG1-of (d3 / describe-01
            :ARG2 (s / s10)))

# ::tok <r11> Cyclin D binds PCNA directly and inhibits PCNA @-@ dependent replication ( Matsuoka et al. , 1994; Pagano et al. , 1994 ) .
# ::alignments 1-1.1.1.1.1 2-1.1.1.1.2 3-1.1 4-1.1.2.1.1 5-1.1.3 5-1.1.3.r 6-1 6-1.3.1 6-1.3.1.1.1 7-1.2 8-1.2.2.1.1 10-1.2.2.1 11-1.2.2 13-1.3.1.1.1.1.1.1 14-1.3.1.1.1 15-1.3.1.1.1.2.1 18-1.3.1.2.1.1.1.1 19-1.3.1 19-1.3.1.1.1 19-1.3.1.2.1 20-1.3.1.1.1.2.1 22-1.3.1.1.2.1
# ::id bel_pmid_1043_6023_19946
(a / and~e.6
      :op1 (b / bind-01~e.3
            :ARG1 (p / protein
                  :name (n / name :op1 "Cyclin"~e.1 :op2 "D"~e.2))
            :ARG2 (p2 / protein
                  :name (n2 / name :op1 "PCNA"~e.4))
            :manner~e.5 (d / direct~e.5))
      :op2 (i / inhibit-01~e.7
            :ARG0 p
            :ARG1 (r / replicate-01~e.11
                  :ARG0-of (d2 / depend-01~e.10
                        :ARG1 p2~e.8)))
      :ARG1-of (d3 / describe-01
            :ARG0 (a2 / and~e.6,19
                  :op1 (p3 / publication-91
                        :ARG0 (a3 / and~e.6,14,19
                              :op1 (p4 / person
                                    :name (n3 / name :op1 "Matsuoka"~e.13))
                              :op2 (p5 / person
                                    :mod (o / other~e.15,20)))
                        :time (d4 / date-entity :year "1994"~e.22))
                  :op2 (p6 / publication-91
                        :ARG0 (a4 / and~e.19
                              :op1 (p7 / person
                                    :name (n4 / name :op1 "Pagano"~e.18))
                              :op2 p5)
                        :time d4)))
      :ARG1-of (d5 / describe-01
            :ARG2 (r2 / r11)))

# ::tok <r2> DPase a @-@ primase may be regulated by phosphorylation of its p68 subunit by Cyclin A : Cdk2 , which reduces and Cyclin E : Cdk2 which increases its DNA initiation activity ( Voitenleitner et al. , 1999 ) .
# ::alignments 4-1.1.2.1.3 5-1 6-1.1.r 7-1.1 8-1.1.1.r 9-1.1.1 10-1.1.1.1.r 11-1.1.1.1.2 11-1.1.1.1.2.r 12-1.1.1.1.1.1 14-1.1.1.2.r 15-1.1.1.2.1.1.1.1 16-1.1.1.2.1.1.1.2 18-1.1.1.2.1.2.1.1 21-1.1.1.2.1 21-1.1.1.2.1.3 21-1.1.1.2.1.3.r 22-1.1.1.2 23-1.1.1.2.2.1.1.1 24-1.1.1.2.2.1.1.2 26-1.1.1.2.2.3 28-1.1.1.2.2 28-1.1.1.2.2.2 28-1.1.1.2.2.2.r 30-1.1.1.2.1.3.1.2.1 30-1.1.2.1.1 31-1.1.1.2.1.3.1.2 34-1.2.1.1.1.1.1 35-1.2.1.1 36-1.2.1.1.2.1 38-1.2.1.2.1
# ::id bel_pmid_1043_6023_19948
(p / possible~e.5
      :domain~e.6 (r / regulate-01~e.7
            :ARG0~e.8 (p2 / phosphorylate-01~e.9
                  :ARG1~e.10 (p3 / protein-segment
                        :name (n2 / name :op1 "p68"~e.12)
                        :part-of~e.11 e~e.11)
                  :ARG2~e.14 (a / and~e.22
                        :op1 (m / macro-molecular-complex~e.21
                              :part (p4 / protein
                                    :name (n3 / name :op1 "Cyclin"~e.15 :op2 "A"~e.16))
                              :part (p5 / protein
                                    :name (n4 / name :op1 "Cdk2"~e.18))
                              :ARG0-of~e.21 (r2 / reduce-01~e.21
                                    :ARG1 (a2 / act-01
                                          :ARG0 (e / enzyme
                                                :name (n / name
                                                      :op1 "DNA"~e.30
                                                      :op2 "polymerase"
                                                      :op3 "alpha-primase"~e.4))
                                          :ARG1 (i / initiate-01~e.31
                                                :ARG1 (d / DNA~e.30)))))
                        :op2 (m2 / macro-molecular-complex~e.28
                              :part (p6 / protein
                                    :name (n5 / name :op1 "Cyclin"~e.23 :op2 "E"~e.24))
                              :ARG0-of~e.28 (i2 / increase-01~e.28
                                    :ARG1 a2)
                              :part p5~e.26)))
            :ARG1 e)
      :ARG1-of (d2 / describe-01
            :ARG0 (p8 / publication-91
                  :ARG0 (a3 / and~e.35
                        :op1 (p9 / person
                              :name (n7 / name :op1 "Voitenleitner"~e.34))
                        :op2 (p10 / person
                              :mod (o / other~e.36)))
                  :time (d3 / date-entity :year "1999"~e.38)))
      :ARG1-of (d4 / describe-01
            :ARG2 (r3 / r2)))

# ::tok <C13> Cyclin E has a half @-@ life of ~30 min . It is degraded by way of the ubiquitin ? proteasome pathway subsequent to phosphorylation ( possibly autophosphorylation ) at threonine @-@ 380 ( Clurman et al. , 1996; Won and Reed , 1996 ) . However , it can be stabilized by binding to Cdk2 .
# ::alignments 1-1.1.1.1.1 1-1.2.1.1.1 1-1.3.1.1.2.1.1 2-1.1.1.1.2 2-1.2.1.1.2 2-1.3.1.1.2.1.2 5-1.1.2.1 7-1.1 7-1.1.2 7-1.1.2.r 14-1.2 17-1.2.2.r 19-1.2.2.1.1 21-1.2.2.1.2 22-1.2.2 23-1.2.3 23-1.2.3.r 24-1.2.3.1.r 25-1.2.3.1 25-1.2.3.1.2.1 27-1.2.3.1.2.1.2 30-1.2.3.1.1.r 31-1.2.3.1.1.2.1 33-1.2.3.1.1.1 35-1.2.4.1.1.1.1.1.1 36-1.2.4.1.1.1 37-1.2.4.1.1.1.2.1 40-1.2.4.1.2.1.1.1.1 41-1.2.4.1.2.1 42-1.2.4.1.2.1.2.1.1 44-1.2.4.1.1.2.1 47-1.3 50-1.3.1 51-1.3.1.1.r 52-1.3.1.1 53-1.3.1.1.1.r 54-1.3.1.1.1 55-1.3.1.1.1.2.r 56-1.3.1.1.1.2.1.1
# ::id bel_pmid_1043_6023_19950
(m / multi-sentence
      :snt1 (l / live-01~e.7
            :ARG0 (p3 / protein
                  :name (n2 / name :op1 "Cyclin"~e.1 :op2 "E"~e.2))
            :ARG1~e.7 (l2 / life~e.7
                  :mod (h / half~e.5))
            :duration (a / approximately
                  :op1 (t / temporal-quantity
                        :quant "30"
                        :unit (m2 / minute))))
      :snt2 (d2 / degrade-01~e.14
            :ARG1 (p4 / protein
                  :name (n3 / name :op1 "Cyclin"~e.1 :op2 "E"~e.2))
            :ARG2~e.17 (p5 / pathway~e.22
                  :name (n4 / name :op1 "ubiquitin"~e.19 :op2 "proteasome"~e.21))
            :time~e.23 (s / subsequent~e.23
                  :op1~e.24 (p6 / phosphorylate-01~e.25
                        :ARG1~e.30 (a2 / amino-acid
                              :mod "380"~e.33
                              :name (n5 / name :op1 "threonine"~e.31)
                              :part-of p4)
                        :ARG1-of (m3 / mean-01
                              :ARG2 (p7 / phosphorylate-01~e.25
                                    :ARG2 p4
                                    :mod (p8 / possible~e.27)))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (a3 / and
                        :op1 (p9 / publication-91
                              :ARG0 (a4 / and~e.36
                                    :op1 (p10 / person
                                          :name (n6 / name :op1 "Clurman"~e.35))
                                    :op2 (p11 / person
                                          :mod (o / other~e.37)))
                              :time (d4 / date-entity :year "1996"~e.44))
                        :op2 (p12 / publication-91
                              :ARG0 (a5 / and~e.41
                                    :op1 (p13 / person
                                          :name (n7 / name :op1 "Won"~e.40))
                                    :op2 (p14 / person
                                          :name (n8 / name :op1 "Reed"~e.42)))
                              :time d4))))
      :snt3 (c / contrast-01~e.47
            :ARG2 (p15 / possible~e.50
                  :domain~e.51 (s3 / stabilize-01~e.52
                        :ARG0~e.53 (b / bind-01~e.54
                              :ARG1 (p16 / protein
                                    :name (n9 / name :op1 "Cyclin"~e.1 :op2 "E"~e.2))
                              :ARG2~e.55 (e / enzyme
                                    :name (n10 / name :op1 "Cdk2"~e.56)))
                        :ARG1 p16)))
      :ARG1-of (d / describe-01
            :ARG2 (c2 / C13)))

# ::tok <C40> Ser216 @-@ phosphorylated Cdc25C is recognized and bound by 14 @-@ 3 @-@ 3 protein family members ( Peng et al. , 1997 , 1998 ) . Ser216 phosphorylation and 14 @-@ 3 @-@ 3 binding probably sequester Cdc25C and thus prevent it from interacting with Cdk1 in vivo ( Peng et al. , 1997 ) . 14 @-@ 3 @-@ 3s is localized to the cytoplasm and may be the means by which Cdc25C is sequestered outside of the nucleus ( Hermeking et al. , 1997 ) .
# ::alignments 3-1.1.1.2.2.3 3-1.2.1.1.1 4-1.1.1.2.1.1 4-1.2.1.1.1.1.3.1.1 5-1.3.1 6-1.1.1 7-1.1 7-1.1.3.1.1 7-1.1.3.1.2 8-1.1.2 9-1.1.2.2.r 10-1.1.2.2.1.1.1.1 12-1.1.2.2.1.1.1.1 14-1.1.2.2.1.1.1.1 15-1.1.2.2.1.1 15-1.2.1.1.2.2 15-1.3.1.1 16-1.1.2.2.1.1.2 17-1.1.2.2 19-1.1.3.1.1.1.1.1 20-1.1.3.1.1 20-1.1.3.1.2 21-1.1.3.1.1.2.1 23-1.1.3.1.2.1.1 25-1.1.3.1.2.2.1 29-1.2.1.1.1 30-1.1.3.1.1 30-1.1.3.1.2 30-1.2.1.1 30-1.2.2.1.1 31-1.2.1.1.2.2.1.1 31-1.3.1.1.1.1 33-1.2.1.1.2.2.1.1 33-1.3.1.1.1.1 35-1.2.1.1.2.2.1.1 35-1.3.1.1.1.1 36-1.2.1.1.2 37-1.2 38-1.2.1 39-1.2.1.1.1.1.3.1.1 40-1.2.1.1 42-1.2.1.3 43-1.2.1.3.1.1 45-1.2.1.3.1 46-1.2.1.3.1.2.r 47-1.2.1.3.1.2.1.1 48-1.2.1.3.1.3 49-1.2.1.3.1.3 51-1.1.3.1.1.1.1.1 51-1.2.2.1.1.1.1.1 52-1.1.3.1.1 52-1.1.3.1.2 52-1.2.2.1.1 52-1.3 53-1.1.3.1.1.2.1 53-1.2.2.1.1.2.1 55-1.1.3.1.2.1.1 55-1.2.2.1.2.1 58-1.3.1.1.1.1 60-1.3.1.1.1.1 63-1.2.1.r 63-1.3.1 67-1.3.1.2 68-1.3 68-1.3.3.1.1 69-1.3.2 70-1.3.2.1.r 75-1.3.2.1.2.1.1 76-1.3.2.1.r 77-1.3.2.1 78-1.3.2.1.3 79-1.3.2.1.3.1.r 81-1.3.2.1.3.1 83-1.3.3.1.1.1.1.1 84-1.1.3.1.1 84-1.1.3.1.2 84-1.2.2.1.1 84-1.3 84-1.3.3.1.1 85-1.1.3.1.1.2.1 85-1.2.2.1.1.2.1 85-1.3.3.1.1.2.1 87-1.1.3.1.2.1.1 87-1.2.2.1.2.1 87-1.3.3.1.2.1
# ::id bel_pmid_1043_6023_19952
(m / multi-sentence
      :snt1 (a / and~e.7
            :op1 (r / recognize-01~e.6
                  :ARG0 (m2 / member~e.17
                        :ARG1-of (i / include-91
                              :ARG2 (p3 / protein~e.15
                                    :name (n3 / name :op1 "14-3-3"~e.10,12,14)
                                    :mod (f / family~e.16))))
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Cdc25C"~e.4)
                        :part (a2 / amino-acid
                              :mod "216"
                              :name (n2 / name :op1 "serine")
                              :ARG1-of (p2 / phosphorylate-01~e.3))))
            :op2 (b / bind-01~e.8
                  :ARG1 e
                  :ARG2~e.9 m2)
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication-91
                        :ARG0 (a3 / and~e.7,20,30,52,84
                              :op1 (p5 / person
                                    :name (n4 / name :op1 "Peng"~e.19,51))
                              :op2 (p6 / person
                                    :mod (o / other~e.21,53,85)))
                        :time (a4 / and~e.7,20,30,52,84
                              :op1 (d2 / date-entity :year "1997"~e.23,55,87)
                              :op2 (d3 / date-entity :year "1998"~e.25)))))
      :snt2 (p7 / probable~e.37
            :domain~e.63 (s / sequester-01~e.38
                  :ARG0 (a5 / and~e.30,40
                        :op1 (p8 / phosphorylate-01~e.3,29
                              :ARG1 (a6 / amino-acid
                                    :mod "216"
                                    :name (n5 / name :op1 "serine")
                                    :part-of (e2 / enzyme
                                          :name (n6 / name :op1 "Cdc25C"~e.4,39))))
                        :op2 (b2 / bind-01~e.36
                              :ARG1 e2
                              :ARG2 (p10 / protein~e.15
                                    :name (n7 / name :op1 "14-3-3"~e.31,33,35))))
                  :ARG1 e2
                  :ARG0-of (p11 / prevent-01~e.42
                        :ARG1 (i2 / interact-01~e.45
                              :ARG0 e2~e.43
                              :ARG1~e.46 (e3 / enzyme
                                    :name (n8 / name :op1 "Cdk1"~e.47))
                              :manner (i3 / in-vivo~e.48,49))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p13 / publication-91
                        :ARG0 (a7 / and~e.30,52,84
                              :op1 (p14 / person
                                    :name (n9 / name :op1 "Peng"~e.51))
                              :op2 (p15 / person
                                    :mod (o2 / other~e.53,85)))
                        :time (d5 / date-entity :year "1997"~e.55,87))))
      :snt3 (a8 / and~e.52,68,84
            :op1 (b3 / be-located-at-91~e.5,63
                  :ARG1 (p16 / protein~e.15
                        :name (n10 / name :op1 "14-3-3"~e.31,33,35,58,60))
                  :ARG2 (c / cytoplasm~e.67))
            :op2 (p17 / possible~e.69
                  :domain~e.70,76 (s2 / sequester-01~e.77
                        :ARG0 p16
                        :ARG1 (e4 / enzyme
                              :name (n11 / name :op1 "Cdc25C"~e.75))
                        :location (o3 / outside~e.78
                              :op1~e.79 (n12 / nucleus~e.81))))
            :ARG1-of (d6 / describe-01
                  :ARG0 (p19 / publication-91
                        :ARG0 (a9 / and~e.68,84
                              :op1 (p20 / person
                                    :name (n13 / name :op1 "Hermeking"~e.83))
                              :op2 (p21 / person
                                    :mod (o4 / other~e.85)))
                        :time (d7 / date-entity :year "1997"~e.87))))
      :ARG1-of (d8 / describe-01
            :ARG2 (c2 / C40)))

# ::tok <C36> Cdc25C is activated by hyperphosphorylation of the Nterminal domain ( Gabrielli et al. , 1997 ) , which can be phosphorylated by Cyclin B : Cdk1 ( Hoffman et al. , 1993 ) .
# ::alignments 1-1.1.2.1.1 3-1.1 11-1.1.3.1.1.1.1.1 12-1.1.3.1.1 13-1.1.3.1.1.2.1 15-1.1.3.1.2.1 19-1.2 20-1.2.1.r 21-1.1.1 21-1.2.1 22-1.2.1.1.r 23-1.2.1.1.1.1.1 24-1.2.1.1.1.1.2 26-1.2.1.1.2.1.1 28-1.2.2.1.1.1.1.1 29-1 29-1.1.3.1.1 29-1.2.2.1.1 30-1.1.3.1.1.2.1 32-1.2.2.1.2.1
# ::id bel_pmid_1043_6023_19958
(a3 / and~e.29
      :op1 (a / activate-01~e.3
            :ARG0 (p2 / phosphorylate-01~e.21
                  :ARG1 (p3 / protein-segment
                        :name (n2 / name :op1 "N-terminus")
                        :part-of (e / enzyme
                              :name (n / name :op1 "Cdc25C"~e.1)))
                  :degree (h / hyper))
            :ARG1 e
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication-91
                        :ARG0 (a2 / and~e.12,29
                              :op1 (p5 / person
                                    :name (n3 / name :op1 "Gabrielli"~e.11))
                              :op2 (p6 / person
                                    :mod (o / other~e.13,30)))
                        :time (d2 / date-entity :year "1997"~e.15))))
      :op2 (p7 / possible~e.19
            :domain~e.20 (p8 / phosphorylate-01~e.21
                  :ARG0~e.22 (m / macro-molecular-complex
                        :part (p9 / protein
                              :name (n4 / name :op1 "Cyclin"~e.23 :op2 "B"~e.24))
                        :part (e2 / enzyme
                              :name (n5 / name :op1 "Cdk1"~e.26)))
                  :ARG1 p3)
            :ARG1-of (d3 / describe-01
                  :ARG0 (p11 / publication-91
                        :ARG0 (a4 / and~e.29
                              :op1 (p12 / person
                                    :name (n6 / name :op1 "Hoffman"~e.28))
                              :op2 p6)
                        :time (d4 / date-entity :year "1993"~e.32))))
      :ARG1-of (d5 / describe-01
            :ARG2 (c / C36)))

# ::tok <E14> The interaction with HDAC1 enhances transcriptional repression by pocket proteins ( Brehm et al. , 1998; Ferreira et al. , 1998; Luo et al. , 1998 ) . HDAC1:RB1^taof( RB1 ) HDAC1:NOLC1^taof( RB1 ) HDAC1:RBL1^taof( RB1 )
# ::alignments 2-1.1.1 4-1.1.1.1.1.1 4-1.2.1.2.1.1 5-1.1 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1.1 10-1.1.2.1 12-1.1.3.1.1.1.1.1.1 13-1.1.3.1.1.1 14-1.1.3.1.1.1.2.1 17-1.1.3.1.2.1.1.1.1 18-1.1.3.1 18-1.1.3.1.1.1 18-1.1.3.1.2.1 18-1.1.3.1.3.1 19-1.1.3.1.3.1.2 22-1.1.3.1.3.1.1.1.1 23-1.1.3.1 23-1.1.3.1.1.1 23-1.1.3.1.2.1 23-1.1.3.1.3.1 23-1.2 24-1.1.3.1.1.1.2.1 26-1.1.3.1.1.2.1 30-1.2.1.1.1.1 33-1.2.1.1.1.1 36-1.2.1.1.1.1
# ::id bel_pmid_1043_6023_20010
(m / multi-sentence
      :snt1 (e / enhance-01~e.5
            :ARG0 (i / interact-01~e.2
                  :ARG1 (e4 / enzyme
                        :name (n / name :op1 "HDAC1"~e.4)))
            :ARG1 (r / repress-01~e.7
                  :ARG0~e.8 (p2 / protein~e.10
                        :mod (p3 / pocket~e.9))
                  :ARG1 (t / transcribe-01))
            :ARG1-of (d / describe-01
                  :ARG0 (a / and~e.18,23
                        :op1 (p4 / publication-91
                              :ARG0 (a2 / and~e.13,18,23
                                    :op1 (p5 / person
                                          :name (n2 / name :op1 "Brehm"~e.12))
                                    :op2 (p6 / person
                                          :mod (o / other~e.14,24)))
                              :time (d2 / date-entity :year "1998"~e.26))
                        :op2 (p7 / publication-91
                              :ARG0 (a3 / and~e.18,23
                                    :op1 (p8 / person
                                          :name (n3 / name :op1 "Ferreira"~e.17))
                                    :op2 p6)
                              :time d2)
                        :op3 (p9 / publication-91
                              :ARG0 (a4 / and~e.18,23
                                    :op1 (p10 / person
                                          :name (n4 / name :op1 "Luo"~e.22))
                                    :op2 p6~e.19)
                              :time d2)))
            :ARG1-of (d3 / describe-01
                  :ARG2 (e2 / E14)))
      :snt2 (a5 / and~e.23
            :op1 (m2 / macro-molecular-complex
                  :part (p11 / protein
                        :name (n5 / name :op1 "RB1"~e.30,33,36))
                  :part (e3 / enzyme
                        :name (n8 / name :op1 "HDAC1"~e.4)))
            :op2 (m3 / macro-molecular-complex
                  :part (p12 / protein
                        :name (n6 / name :op1 "NOLC1"))
                  :part e3)
            :op3 (m4 / macro-molecular-complex
                  :part (p13 / protein
                        :name (n7 / name :op1 "RBL1"))
                  :part e3)))

# ::tok <B10> HMG1 or 2 competes with Ku for binding to DNA @-@ PK and stimulates DNA @-@ dependent kinase activity in vitro in the absence of Ku ( Yumoto et al. , 1998 ) .
# ::alignments 1-1.1.1.1.1.1 2-1.1.1 4-1.1 5-1.1.2.r 6-1.1.2.1.1 7-1.1.3.r 8-1.1.3 9-1.1.3.2.r 10-1.1.3.2 11-1.1.3.2 12-1.1.3.2 14-1.2 15-1.2.2.1.1.1 19-1.2.2 20-1.2.2.2 21-1.2.2.2 22-1.2.2.2 22-1.2.2.3.r 24-1.2.2.3 25-1.2.2.3.1.r 26-1.2.2.3.1 28-1.3.1.1.1.1.1 29-1 29-1.3.1.1 30-1.3.1.1.2.1 32-1.3.1.2.1
# ::id bel_pmid_1043_6023_20014
(a / and~e.29
      :op1 (c / compete-01~e.4
            :ARG0 (o / or~e.2
                  :op1 (p / protein
                        :name (n / name :op1 "HMG1"~e.1))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "HMG2")))
            :ARG1~e.5 (p3 / protein
                  :name (n3 / name :op1 "Ku"~e.6))
            :ARG2~e.7 (b / bind-01~e.8
                  :ARG1 o
                  :ARG2~e.9 e~e.10,11,12))
      :op2 (s / stimulate-01~e.14
            :ARG0 o
            :ARG1 (a2 / act-02~e.19
                  :ARG0 (e / enzyme
                        :name (n5 / name :op1 "DNA-PK"~e.15))
                  :manner (i / in-vitro~e.20,21,22)
                  :condition~e.22 (a3 / absent-01~e.24
                        :ARG1~e.25 p3~e.26)))
      :ARG1-of (d3 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a4 / and~e.29
                        :op1 (p5 / person
                              :name (n4 / name :op1 "Yumoto"~e.28))
                        :op2 (p6 / person
                              :mod (o2 / other~e.30)))
                  :time (d4 / date-entity :year "1998"~e.32)))
      :ARG1-of (d5 / describe-01
            :ARG2 (b2 / B10)))

# ::tok <B4> The kinase activity of DNA @-@ PK is stimulated by binding to dsDNA ends ; however , the stimulation is greater in the complex with Ku ( Yaneva et al. , 1997; West et al. , 1998 ) .
# ::alignments 2-1.1.2.1 3-1.1.2 5-1.1.1.2.1 5-1.1.2.1.1.1 7-1.1.2.1.1.1 9-1.1 10-1.1.1.r 11-1.1.1 14-1.1.1.2 16-1 19-1.2 21-1.2.1 21-1.2.1.1 21-1.2.1.1.r 24-1.2.2.1 26-1.2.2.2.1.1 28-1.3.1.1.1.1.1.1 29-1.3.1.1.1 30-1.3.1.1.1.2.1 33-1.3.1.2.1.1.1.1 34-1.3.1 34-1.3.1.1.1 34-1.3.1.2.1 35-1.3.1.1.1.2.1 37-1.3.1.2.2.1
# ::id bel_pmid_1043_6023_20114
(c / contrast-01~e.16
      :ARG1 (s / stimulate-01~e.9
            :ARG0~e.10 (b / bind-01~e.11
                  :ARG1 (k2 / kinase~e.2
                        :name (n / name :op1 "DNA-PK"~e.5,7))
                  :ARG2 (e / end~e.14
                        :part-of (d / DNA~e.5
                              :mod (s2 / strand
                                    :mod (d2 / double)))))
            :ARG1 (a / act-02~e.3
                  :ARG0 k2))
      :ARG2 (s3 / stimulate-01~e.19
            :mod (g / great~e.21
                  :degree~e.21 (m / more~e.21))
            :condition (h / have-part-91
                  :ARG1 (m2 / macro-molecular-complex~e.24
                        :part k2)
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "Ku"~e.26))))
      :ARG1-of (d3 / describe-01
            :ARG0 (a2 / and~e.34
                  :op1 (p3 / publication-91
                        :ARG0 (a3 / and~e.29,34
                              :op1 (p4 / person
                                    :name (n3 / name :op1 "Yaneva"~e.28))
                              :op2 (p5 / person
                                    :mod (o / other~e.30,35)))
                        :time (d4 / date-entity :year "1997"))
                  :op2 (p6 / publication-91
                        :ARG0 (a4 / and~e.34
                              :op1 (p7 / person
                                    :name (n4 / name :op1 "West"~e.33))
                              :op2 p5)
                        :time (d5 / date-entity :year "1998"~e.37))))
      :ARG1-of (d6 / describe-01
            :ARG2 (b2 / B4)))

# ::tok <E16> pRb binds and activates C/EBP ( Chen et al. , 1996a , b ) . The binding of C/EBP to its DNA recognition elements is enhanced .
# ::alignments 1-1.1.1.1.1.1 1-1.2.1.2.2.1.1 2-1.1.1 3-1.1 3-1.1.3.1 3-1.1.3.1.1.1 4-1.1.2 5-1.2.1.1.1.1 7-1.1.3.1.1.1.1.1.1 8-1.1.3.1.1.1 9-1.1.3.1.1.1.2.1 17-1.2.1 19-1.2.1.1.1.1 22-1.2.1.2.1.1 23-1.2.1.2.1 24-1.2.1.2 26-1.2
# ::id bel_pmid_1043_6023_20124
(m / multi-sentence
      :snt1 (a / and~e.3
            :op1 (b / bind-01~e.2
                  :ARG1 (p / protein
                        :name (n / name :op1 "pRb"~e.1))
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "C/EPB")))
            :op2 (a2 / activate-01~e.4
                  :ARG0 p
                  :ARG1 p2)
            :ARG1-of (d / describe-01
                  :ARG0 (a4 / and~e.3
                        :op1 (p3 / publication-91
                              :ARG0 (a3 / and~e.3,8
                                    :op1 (p4 / person
                                          :name (n3 / name :op1 "Chen"~e.7))
                                    :op2 (p5 / person
                                          :mod (o / other~e.9)))
                              :time (d2 / date-entity :year "1996"))
                        :op2 (f / figure
                              :mod a)
                        :op3 (f2 / figure
                              :mod b))))
      :snt2 (e / enhance-01~e.26
            :ARG1 (b2 / bind-01~e.17
                  :ARG1 (p6 / protein
                        :name (n4 / name :op1 "C/EBP"~e.5,19))
                  :ARG2 (e2 / element~e.24
                        :ARG0-of (r / recognize-01~e.23
                              :ARG1 (d3 / DNA~e.22))
                        :part-of (p7 / protein
                              :name (n5 / name :op1 "pRb"~e.1)))))
      :ARG1-of (d4 / describe-01
            :ARG2 (e3 / E16)))

# ::tok <s7> The binding of RPA to p53 inhibits the binding of RPA to ssDNA ( Dutta et al. , 1993 ) and the binding of p53 to its promoter sites ( Miller et al. , 1997 ) .
# ::alignments 2-1.1 4-1.1.1.1.1 6-1.1.2.1.1 7-1 9-1.1 10-1.2.r 11-1.2.1.1 15-1.2.1.3.1.1.1.1.1 16-1.2.1.3.1.1 17-1.2.1.3.1.1.2.1 19-1.2.1.3.1.2.1 21-1.2 23-1.2.1 23-1.2.2 25-1.1.2.1.1 26-1.2.2.1.r 27-1.2.2.1 29-1.2.2.2 31-1.2.2.3.1.1.1.1.1 32-1.2.2.3.1.1 33-1.2.2.3.1.1.2.1 35-1.2.2.3.1.2.1
# ::id bel_pmid_1043_6023_20132
(i / inhibit-01~e.7
      :ARG0 (b / bind-01~e.2,9
            :ARG1 (p / protein
                  :name (n / name :op1 "RPA"~e.4))
            :ARG2 (p2 / protein
                  :name (n2 / name :op1 "p53"~e.6,25)))
      :ARG1~e.10 (a / and~e.21
            :op1 (b2 / bind-01~e.23
                  :ARG1 p~e.11
                  :ARG2 (d / DNA
                        :mod (s / strand
                              :mod (s2 / single)))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p3 / publication-91
                              :ARG0 (a2 / and~e.16
                                    :op1 (p4 / person
                                          :name (n3 / name :op1 "Dutta"~e.15))
                                    :op2 (p5 / person
                                          :mod (o / other~e.17)))
                              :time (d4 / date-entity :year "1993"~e.19))))
            :op2 (b3 / bind-01~e.23
                  :ARG1~e.26 p2~e.27
                  :ARG2 (p6 / protein-segment~e.29
                        :part-of (m / molecular-physical-entity
                              :ARG0-of (p7 / promote-01
                                    :ARG1 p2)))
                  :ARG1-of (d3 / describe-01
                        :ARG0 (p8 / publication-91
                              :ARG0 (a3 / and~e.32
                                    :op1 (p9 / person
                                          :name (n4 / name :op1 "Miller"~e.31))
                                    :op2 (p10 / person
                                          :mod (o2 / other~e.33)))
                              :time (d5 / date-entity :year "1997"~e.35)))))
      :ARG1-of (d6 / describe-01
            :ARG2 (s3 / s7)))

# ::tok <E27> p107 inhibits Sp1 @-@ dependent transcription . Binding of p107 to Sp1 seems to inhibit the binding of Sp1 to DNA ( Datta et al. , 1995 ) .
# ::alignments 1-1.1.1.1.1 1-1.2.1.1.1.1.1 2-1.1 3-1.1.2.1.1.1.1 5-1.1.2.1 6-1.1.2 8-1.2.1.2 10-1.2.1.1.1.1.1 12-1.2.1.1.2.1.1 13-1.2 15-1.2.1 17-1.2.1.1 17-1.2.1.2 18-1.2.1.2.1.r 19-1.2.1.2.1 20-1.2.1.2.2.r 21-1.2.1.2.2 23-1.2.2.1.1.1.1.1 24-1.2.2.1.1 25-1.2.2.1.1.2.1 27-1.2.2.1.2.1
# ::id bel_pmid_1043_6023_20152
(m / multi-sentence
      :snt1 (i / inhibit-01~e.2
            :ARG0 (p / protein
                  :name (n / name :op1 "p107"~e.1))
            :ARG1 (t / transcribe-01~e.6
                  :ARG0-of (d / depend-01~e.5
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "Sp1"~e.3)))))
      :snt2 (s / seem-01~e.13
            :ARG1 (i2 / inhibit-01~e.15
                  :ARG0 (b / bind-01~e.17
                        :ARG1 (p4 / protein
                              :name (n4 / name :op1 "p107"~e.1,10))
                        :ARG2 (p3 / protein
                              :name (n3 / name :op1 "Sp1"~e.12)))
                  :ARG1 (b2 / bind-01~e.8,17
                        :ARG1~e.18 p3~e.19
                        :ARG2~e.20 (d2 / DNA~e.21)))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p5 / publication-91
                        :ARG0 (a / and~e.24
                              :op1 (p6 / person
                                    :name (n5 / name :op1 "Datta"~e.23))
                              :op2 (p7 / person
                                    :mod (o / other~e.25)))
                        :time (d4 / date-entity :year "1995"~e.27))))
      :ARG1-of (d5 / describe-01
            :ARG2 (e / E27)))

# ::tok <p17> Ser392 phosphorylation of P53 increases 10 @-@ fold the association constant for tetramerization , but this effect is reversed by Ser315 phosphorylation . The tetramerization activates P53 for specific DNA binding and transcription
# ::alignments 2-1.1.1.1 3-1.1.1.1.1.r 3-1.1.1.3 4-1.1.1.1.1.3.1.1 5-1.1.1 6-1.1.1.3.1 10-1.1.1.2.1 11-1.1.1.2 15-1.1 17-1.1.2.2 19-1.1.2 22-1.1.2.1 26-1.2 27-1.2.2.1.1 28-1.2.3.r 29-1.2.3.1.2 30-1.2.3.1.1 31-1.2.3.1 32-1.2.3 33-1.2.3.2
# ::id bel_pmid_1043_6023_20166
(m / multi-sentence
      :snt1 (c / contrast-01~e.15
            :ARG1 (i / increase-01~e.5
                  :ARG0 (p / phosphorylate-01~e.2
                        :ARG1~e.3 (a / amino-acid
                              :mod "392"
                              :name (n / name :op1 "serine")
                              :part-of (p2 / protein
                                    :name (n2 / name :op1 "P53"~e.4))))
                  :ARG1 (c2 / constant~e.11
                        :value-of (a2 / associate-01~e.10)
                        :topic (t / tetramerize-00))
                  :ARG2 (p3 / product-of~e.3 :op1 "10"~e.6))
            :ARG2 (r / reverse-01~e.19
                  :ARG0 (p4 / phosphorylate-01~e.22
                        :ARG1 (a3 / amino-acid
                              :mod "315"
                              :name (n3 / name :op1 "serine")
                              :part-of p2))
                  :ARG1 (e / effect-01~e.17
                        :ARG1 i)))
      :snt2 (a4 / activate-01~e.26
            :ARG0 (t3 / tetramerize-00)
            :ARG1 (p5 / protein
                  :name (n4 / name :op1 "P53"~e.27))
            :purpose~e.28 (a5 / and~e.32
                  :op1 (b / bind-01~e.31
                        :ARG1 (d / DNA~e.30)
                        :mod (s / specific~e.29))
                  :op2 (t4 / transcribe-01~e.33
                        :ARG1 d
                        :mod s)))
      :ARG1-of (d2 / describe-01
            :ARG2 (p6 / p17)))

# ::tok <p10> PKC phosphorylates P53 at Serine378 <p11> The Cdk7:CycH : p36 ( CAK ) component of TFIIH phosphorylates p53 at sites which may include 372,376 , 378 , 392 [serine residues]
# ::alignments 1-1.1.2.1.1 2-1.1 2-1.2 3-1.1.1.3.1.1 10-1.2.2.4.1.1 12-1.2.2.1.1 16-1.2.2.5.1.1 17-1.2 18-1.2.1.1.1.1 20-1.2.1 22-1.2.1.2.2 23-1.2.1.2 26-1.1.1.1 26-1.2.1.2.1.3.1.1 28-1.2.1.2.1.4.1.1
# ::id bel_pmid_1043_6023_21014
(m / multi-sentence
      :snt1 (p / phosphorylate-01~e.2
            :ARG1 (a / amino-acid
                  :mod "378"~e.26
                  :name (n2 / name :op1 "serine")
                  :part-of (p2 / protein
                        :name (n3 / name :op1 "P53"~e.3)))
            :ARG2 (e / enzyme
                  :name (n / name :op1 "PKC"~e.1)))
      :snt2 (p3 / phosphorylate-01~e.2,17
            :ARG1 (p7 / protein-segment~e.20
                  :part-of (p8 / protein
                        :name (n8 / name :op1 "p53"~e.18))
                  :ARG2-of (i / include-91~e.23
                        :ARG1 (a2 / and
                              :op1 (r / residue
                                    :mod (a3 / amino-acid
                                          :mod "372"
                                          :name (n10 / name :op1 "serine")))
                              :op2 (r2 / residue
                                    :mod (a4 / amino-acid
                                          :mod "376"
                                          :name (n11 / name :op1 "serine")))
                              :op3 (r3 / residue
                                    :mod (a5 / amino-acid
                                          :mod "378"~e.26
                                          :name (n12 / name :op1 "serine")))
                              :op4 (r4 / residue
                                    :mod (a6 / amino-acid
                                          :mod "392"~e.28
                                          :name (n13 / name :op1 "serine"))))
                        :mod (p10 / possible~e.22)))
            :ARG2 (m3 / macro-molecular-complex
                  :name (n7 / name :op1 "CAK"~e.12)
                  :part (p4 / protein
                        :name (n4 / name :op1 "Cdk7"))
                  :part (p5 / protein
                        :name (n5 / name :op1 "CycH"))
                  :part (p6 / protein
                        :name (n6 / name :op1 "p36"~e.10))
                  :part-of (p9 / protein
                        :name (n9 / name :op1 "TFIIH"~e.16))))
      :ARG1-of (d / describe-01
            :ARG2 (p11 / p10)))

# ::tok <A7> c @-@ Abl binds and tyrosine phosphorylates paxillin in an adhesion @-@ dependent manner ( Lewis and Schwartz , 1998 ) .
# ::alignments 1-1.1.1.1.1 3-1.1.1.1.1 4-1.1 5-1 5-1.4.1.1 6-1.2.2.1.1 7-1.2 8-1.1.2.1.1 13-1.3 16-1.4.1.1.1.1.1 17-1.4.1.1 18-1.4.1.1.2.1.1 20-1.4.1.2.1
# ::id bel_pmid_1043_6023_21100
(a / and~e.5
      :op1 (b / bind-01~e.4
            :ARG1 (p2 / protein
                  :name (n / name :op1 "c-Abl"~e.1,3))
            :ARG2 (p3 / protein
                  :name (n3 / name :op1 "paxillin"~e.8)))
      :op2 (p / phosphorylate-01~e.7
            :ARG1 p3
            :ARG2 (a2 / amino-acid
                  :name (n2 / name :op1 "tyrosine"~e.6)))
      :ARG0-of (d / depend-01~e.13
            :ARG1 (a3 / adhere-01))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a4 / and~e.5,17
                        :op1 (p5 / person
                              :name (n4 / name :op1 "Lewis"~e.16))
                        :op2 (p6 / person
                              :name (n5 / name :op1 "Schwartz"~e.18)))
                  :time (d3 / date-entity :year "1998"~e.20)))
      :ARG1-of (d4 / describe-01
            :ARG2 (a5 / A7)))

# ::tok <A2> ATM phosphorylates c @-@ Abl on Ser465 and thereby activates the kinase ( Baskaran et al. , 1997b ) . <A3> Phosphorylation by ATM activates c @-@ Abl ( Baskaran et al. , 1997b ) . c @-@ Abl tyrosine kinase activity is stimulated in response to ionizing radiation ( IR ) , 1 @-@ b @-@ d @-@ arabinofuransylcytosine , camptothecin , or etoposide ( Yuan et al. , 1996 , 1998 ) .
# ::alignments 1-1.1.2.1.1 1-1.2.1.2.1.1 2-1.1 2-1.2.1 3-1.1.1.3.1.1 3-1.2.2.1.1 3-1.3.1.1.1.1 5-1.1.1.3.1.1 5-1.2.2.1.1 5-1.3.1.1.1.1 8-1.1.4.1 8-1.1.4.1.1.1 8-1.2.3.1 8-1.2.3.1.1.1 10-1.2 12-1.1.1.3 12-1.2.2 14-1.1.4.1.1.1.1.1.1 14-1.2.3.1.1.1.1.1.1 15-1.1.4.1 15-1.1.4.1.1.1 15-1.2.3.1 15-1.2.3.1.1.1 16-1.1.4.1.1.1.2.1 16-1.2.3.1.1.1.2.1 22-1.1 23-1.1.2.r 24-1.1.2.1.1 25-1.1.3 26-1.1.1.3.1.1 26-1.2.2.1.1 26-1.3.1.1.1.1 28-1.1.1.3.1.1 28-1.2.2.1.1 28-1.3.1.1.1.1 30-1.1.4.1.1.1.1.1.1 30-1.2.3.1.1.1.1.1.1 31-1.1.4.1 31-1.1.4.1.1.1 31-1.2.3.1 31-1.2.3.1.1.1 32-1.1.4.1.1.1.2.1 32-1.2.3.1.1.1.2.1 37-1.1.1.3.1.1 37-1.2.2.1.1 37-1.3.1.1.1.1 39-1.1.1.3.1.1 39-1.2.2.1.1 39-1.3.1.1.1.1 40-1.3.1.1.2.1.1 41-1.3.1.1 42-1.3.1 44-1.3 45-1.3.2.r 46-1.3.2 47-1.3.2.1.r 48-1.3.2.1.1.1 49-1.3.2.1.1 51-1.3.2.1.1.2.1 54-1.3.2.1.2.1.1 56-1.1.4.1.2.1 56-1.2.3.1.2.1 56-1.3.2.1.2.1.1 58-1.3.2.1.2.1.1 62-1.3.2.1.3.1.1 64-1.3.2.1 65-1.3.2.1.4.1.1 67-1.3.3.1.1.1.1.1 68-1.3.3.1.1 68-1.3.3.1.2 69-1.3.3.1.1.2.1 71-1.3.3.1.2.1.1 73-1.3.3.1.2.2.1
# ::id bel_pmid_1043_6023_21124
(m / multi-sentence
      :snt1 (p / phosphorylate-01~e.2,22
            :ARG1 (a / amino-acid
                  :mod "465"
                  :name (n2 / name :op1 "serine")
                  :part-of (k2 / kinase~e.12
                        :name (n3 / name :op1 "c-Abl"~e.3,5,26,28,37,39)))
            :ARG2~e.23 (e / enzyme
                  :name (n / name :op1 "ATM"~e.1,24))
            :ARG0-of (a2 / activate-01~e.25
                  :ARG1 k2)
            :ARG1-of (d / describe-01
                  :ARG0 (a4 / and~e.8,15,31
                        :op1 (p4 / publication-91
                              :ARG0 (a3 / and~e.8,15,31
                                    :op1 (p5 / person
                                          :name (n4 / name :op1 "Baskaran"~e.14,30))
                                    :op3 (p6 / person
                                          :mod (o / other~e.16,32)))
                              :time (d2 / date-entity :year "1997"))
                        :op2 (f / figure
                              :mod (b / b~e.56))))
            :ARG1-of (d8 / describe-01
                  :ARG2 (a11 / A2)))
      :snt2 (a5 / activate-01~e.10
            :ARG0 (p7 / phosphorylate-01~e.2
                  :ARG1 (k3 / kinase~e.12
                        :name (n6 / name :op1 "c-Abl"~e.3,5,26,28,37,39))
                  :ARG2 (p8 / protein
                        :name (n5 / name :op1 "ATM"~e.1)))
            :ARG1 k3
            :ARG1-of (d3 / describe-01
                  :ARG0 (a6 / and~e.8,15,31
                        :op1 (p10 / publication-91
                              :ARG0 (a7 / and~e.8,15,31
                                    :op1 (p11 / person
                                          :name (n7 / name :op1 "Baskaran"~e.14,30))
                                    :op2 (p12 / person
                                          :mod (o2 / other~e.16,32)))
                              :time (d4 / date-entity :year "1997"))
                        :op2 (f2 / figure
                              :mod (b2 / b~e.56))))
            :ARG1-of (d9 / describe-01
                  :ARG2 (a12 / A3)))
      :snt3 (s / stimulate-01~e.44
            :ARG1 (a8 / act-02~e.42
                  :ARG0 (k / kinase~e.41
                        :name (n8 / name :op1 "c-Abl"~e.3,5,26,28,37,39)
                        :mod (a13 / amino-acid
                              :name (n13 / name :op1 "tyrosine"~e.40))))
            :ARG2-of~e.45 (r / respond-01~e.46
                  :ARG1~e.47 (o3 / or~e.64
                        :op1 (r2 / radiation~e.49
                              :ARG0-of (i / ionize-01~e.48)
                              :ARG1-of (l / label-01 :ARG2 "IR"~e.51))
                        :op2 (s2 / small-molecule
                              :name (n9 / name :op1 "1-b-d-arabinofuranosylcytosine"~e.54,56,58))
                        :op3 (s3 / small-molecule
                              :name (n10 / name :op1 "camptothecin"~e.62))
                        :op4 (s4 / small-molecule
                              :name (n11 / name :op1 "etoposide"~e.65))))
            :ARG1-of (d5 / describe-01
                  :ARG0 (p14 / publication-91
                        :ARG0 (a9 / and~e.68
                              :op1 (p15 / person
                                    :name (n12 / name :op1 "Yuan"~e.67))
                              :op2 (p16 / person
                                    :mod (o4 / other~e.69)))
                        :time (a10 / and~e.68
                              :op1 (d6 / date-entity :year "1996"~e.71)
                              :op2 (d7 / date-entity :year "1998"~e.73))))))

# ::tok <C39> Cdc25C Ser216 also binds and is phosphorylated by CTAK1 ( Peng et al. , 1998 ) . Cdc25C Ser216 is phosphorylated throughout interphase but not in mitosis ( Peng et al. , 1997 ) .
# ::alignments 1-1.1.1.1.3.1.1 1-1.2.1.3.1.1 3-1.1.1.3 4-1.1.1 5-1.1 5-1.1.3.1.1 7-1.1.2 8-1.1.2.2.r 9-1.1.2.2.1.1 11-1.1.3.1.1.1.1.1 12-1.1 12-1.1.3.1.1 13-1.1.3.1.1.2.1 15-1.1.3.1.2.1 18-1.2.1.3.1.1 21-1.2 21-1.2.3.1 23-1.2.2 24-1.2.3 25-1.2.3.1.1 25-1.2.3.1.1.r 26-1.2.3.1.3.r 27-1.2.3.1.3 29-1.2.4.1.1.1.1.1 30-1.2.4.1.1 31-1.2.4.1.1.2.1 33-1.2.4.1.2.1
# ::id bel_pmid_1043_6023_21372
(m / multi-sentence
      :snt1 (a / and~e.5,12
            :op1 (b / bind-01~e.4
                  :ARG1 (a2 / amino-acid
                        :mod "216"
                        :name (n / name :op1 "serine")
                        :part-of (e2 / enzyme
                              :name (n2 / name :op1 "Cdc25C"~e.1)))
                  :ARG2 (p3 / protein
                        :name (n3 / name :op1 "CTAK1"~e.9))
                  :mod (a6 / also~e.3))
            :op2 (p / phosphorylate-01~e.7
                  :ARG1 a2
                  :ARG2~e.8 p3)
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication-91
                        :ARG0 (a3 / and~e.5,12
                              :op1 (p5 / person
                                    :name (n4 / name :op1 "Peng"~e.11))
                              :op2 (p6 / person
                                    :mod (o / other~e.13)))
                        :time (d2 / date-entity :year "1998"~e.15))))
      :snt2 (p7 / phosphorylate-01~e.21
            :ARG1 (a4 / amino-acid
                  :mod "216"
                  :name (n5 / name :op1 "serine")
                  :part-of (e / enzyme
                        :name (n6 / name :op1 "Cdc25C"~e.1,18)))
            :duration (i / interphase~e.23)
            :ARG1-of (c / contrast-01~e.24
                  :ARG2 (p9 / phosphorylate-01~e.21
                        :polarity~e.25 "-"~e.25
                        :ARG1 a4
                        :time~e.26 (m2 / mitosis~e.27)))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p10 / publication-91
                        :ARG0 (a5 / and~e.30
                              :op1 (p11 / person
                                    :name (n7 / name :op1 "Peng"~e.29))
                              :op2 (p12 / person
                                    :mod (o2 / other~e.31)))
                        :time (d4 / date-entity :year "1997"~e.33))))
      :ARG1-of (d5 / describe-01
            :ARG2 (c2 / C39)))

# ::tok <C41> Cyclin B is degraded late in mitosis through the ubiquitin @-@ protein ligase ( E3 ) activity of the anaphase @-@ promoting complex , which is probably activated by phosphorylation by Plk1 ( Glover et al. , 1998 ) .
# ::alignments 1-1.2.1.1 2-1.2.1.2 4-1 5-1.3 6-1.4.r 7-1.4 10-1.1.2.1.1 12-1.1.2.1.1 13-1.1.2.1.2 15-1.1.2.2.1 20-1.1.1.1.1 22-1.1.1.1.1 23-1.1.1.1.2 27-1.1.1.2.2 28-1.1.1.2 29-1.1.1.2.1.r 30-1.1.1.2.1 31-1.1.1.2.1.1.r 32-1.1.1.2.1.1.1.1 34-1.5.1.1.1.1.1 35-1.5.1.1 36-1.5.1.1.2.1 38-1.5.2.1
# ::id bel_pmid_1043_6023_21412
(d / degrade-01~e.4
      :ARG0 (a / act-01
            :ARG0 (m / macro-molecular-complex
                  :name (n2 / name :op1 "anaphase-promoting"~e.20,22 :op2 "complex"~e.23)
                  :ARG1-of (a2 / activate-01~e.28
                        :ARG0~e.29 (p3 / phosphorylate-01~e.30
                              :ARG2~e.31 (e / enzyme
                                    :name (n4 / name :op1 "Plk1"~e.32)))
                        :mod (p4 / probable~e.27)))
            :ARG1 (p2 / protein
                  :name (n3 / name :op1 "ubiquitin-protein"~e.10,12 :op2 "ligase"~e.13)
                  :ARG1-of (l2 / label-01 :ARG2 "E3"~e.15)))
      :ARG1 (p / protein
            :name (n / name :op1 "Cyclin"~e.1 :op2 "B"~e.2))
      :time (l / late~e.5)
      :time~e.6 (m2 / mitosis~e.7)
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a3 / and~e.35
                        :op1 (p6 / person
                              :name (n5 / name :op1 "Glover"~e.34))
                        :op2 (p7 / person
                              :mod (o / other~e.36))))
            :time (d3 / date-entity :year "1998"~e.38))
      :ARG1-of (d4 / describe-01
            :ARG2 (c / C14)))

# ::tok <C37> The Cdc25C N @-@ terminal domain can also be phosphorylated by Plk1 ( Hamanaka et al. , 1994 ) . During mitosis , Plk1 , by way of its polo boxes , localizes progressively to the centromeres , spindle poles , centrosomes , and spindle midzone or midbody ( Glover et al. , 1998; Lee et al. , 1998c ) .
# ::alignments 2-1.1.1.1.2.1.1 3-1.1.1.1.1.1 5-1.1.1.1.1.1 7-1.1 8-1.1.2 9-1.1.1.r 10-1.1.1 11-1.1.1.2.r 12-1.1.1.2.1.1 14-1.1.3.1.1.1.1.1 15-1.1.3.1.1 16-1.1.3.1.1.2.1 18-1.1.3.1.2.1 21-1.1.3.1.2.r 21-1.2.5.r 22-1.2.5 24-1.2.1.1.1 27-1.2.3.r 29-1.2.6.2 29-1.2.6.2.r 30-1.2.6.1.1 31-1.2.6.1.2 34-1.2.3 37-1.2.2.1 39-1.2.2.2.1 40-1.2.2.2 42-1.2.2.3 44-1.2.2 45-1.2.2.4.1.1 46-1.2.2.4.1 47-1.2.2.4 48-1.2.2.4.2 50-1.2.4.1.1.1.1.1.1 51-1.2.4.1 51-1.2.4.1.1.1 51-1.2.4.1.2.1 52-1.2.4.1.1.1.2.1 55-1.2.4.1.2.1.1.1.1 56-1.2.4.1 56-1.2.4.1.2.1 57-1.2.4.1.1.1.2.1
# ::id bel_pmid_1043_6023_21414
(m / multi-sentence
      :snt1 (p / possible~e.7
            :domain~e.9 (p2 / phosphorylate-01~e.10
                  :ARG1 (p3 / protein-segment
                        :name (n / name :op1 "N-terminus"~e.3,5)
                        :part-of (e3 / enzyme
                              :name (n2 / name :op1 "Cdc25C"~e.2)))
                  :ARG2~e.11 (e / enzyme
                        :name (n3 / name :op1 "Plk1"~e.12)))
            :mod (a / also~e.8)
            :ARG1-of (d / describe-01
                  :ARG0 (p5 / publication-91
                        :ARG0 (a2 / and~e.15
                              :op1 (p6 / person
                                    :name (n4 / name :op1 "Hamanaka"~e.14))
                              :op2 (p7 / person
                                    :mod (o / other~e.16)))
                        :time~e.21 (d2 / date-entity :year "1994"~e.18))))
      :snt2 (b / be-located-at-91
            :ARG1 (e2 / enzyme
                  :name (n7 / name :op1 "Plk1"~e.24))
            :ARG2 (a6 / and~e.44
                  :op1 (c2 / centromere~e.37)
                  :op2 (p15 / pole~e.40
                        :part-of (s / spindle~e.39))
                  :op3 (c3 / centrosome~e.42)
                  :op4 (o3 / or~e.47
                        :op1 (m3 / midzone~e.46
                              :part-of s~e.45)
                        :op2 (m4 / midbody~e.48
                              :part-of s)))
            :manner~e.27 (p8 / progressive~e.34)
            :ARG1-of (d3 / describe-01
                  :ARG0 (a3 / and~e.51,56
                        :op1 (p9 / publication-91
                              :ARG0 (a4 / and~e.51
                                    :op1 (p10 / person
                                          :name (n5 / name :op1 "Glover"~e.50))
                                    :op2 (p11 / person
                                          :mod (o2 / other~e.52,57)))
                              :time (d4 / date-entity :year "1998"))
                        :op2 (p12 / publication-91
                              :ARG0 (a5 / and~e.51,56
                                    :op1 (p13 / person
                                          :name (n6 / name :op1 "Lee"~e.55))
                                    :op2 p11)
                              :time d4)
                        :op3 (f / figure
                              :mod (c / c))))
            :time~e.21 (m2 / mitosis~e.22)
            :instrument (p14 / protein-segment
                  :name (n8 / name :op1 "polo"~e.30 :op2 "box"~e.31)
                  :part-of~e.29 e2~e.29))
      :ARG1-of (d5 / describe-01
            :ARG2 (c4 / C37)))

# ::tok <B5> DNA @-@ PK phosphorylates itself , thereby blocking its interaction with Ku : DNA complex and inhibiting its kinase activity ; it also phosphorylates Ku70 . Ku80 , but without effect ( Chan and Lees @-@ Miller , 1996 ) .
# ::alignments 1-1.1.1.1 3-1.1.1.1 4-1 8-1.3 9-1.3.1.1 9-1.3.1.1.r 10-1.3.1 12-1.3.1.2.1.1.1 14-1.1.1.1 14-1.3.1.2.2 15-1.3.1.2 15-1.5.1.1 16-1.6.1.1 17-1.4 18-1.4.1.1 18-1.4.1.1.r 19-1.4.1.2 23-1.5.1.4 24-1.5.1 25-1.5.1.1.1.1.1 27-1.5.1.1.2.1.1 29-1.5 30-1.5.1.3.1 30-1.5.1.3.1.r 31-1.5.1.3 33-1.6.1.1.1.1.1 34-1.6.1.1 35-1.6.1.1.2.1.1 37-1.6.1.1.2.1.1 39-1.6.1.2.1
# ::id bel_pmid_1043_6023_21440
(p / phosphorylate-01~e.4
      :ARG1 (e / enzyme
            :name (n / name :op1 "DNA-PK"~e.1,3,14))
      :ARG2 e
      :ARG0-of (b / block-01~e.8
            :ARG1 (i / interact-01~e.10
                  :ARG0~e.9 e~e.9
                  :ARG1 (m / macro-molecular-complex~e.15
                        :part (p2 / protein
                              :name (n2 / name :op1 "Ku"~e.12))
                        :part (d / DNA~e.14))))
      :ARG0-of (i2 / inhibit-01~e.17
            :ARG1 (a / act-01
                  :ARG0~e.18 e~e.18
                  :ARG1 (k / kinase~e.19)))
      :ARG1-of (c / contrast-01~e.29
            :ARG2 (p3 / phosphorylate-01~e.24
                  :ARG1 (m2 / macro-molecular-complex~e.15
                        :part (p4 / protein
                              :name (n3 / name :op1 "Ku70"~e.25))
                        :part (p5 / protein
                              :name (n4 / name :op1 "Ku80"~e.27)))
                  :ARG2 e
                  :ARG0-of (e2 / effect-01~e.31 :polarity~e.30 "-"~e.30)
                  :mod (a3 / also~e.23)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p6 / publication-91
                  :ARG0 (a2 / and~e.16,34
                        :op1 (p7 / person
                              :name (n5 / name :op1 "Chan"~e.33))
                        :op2 (p8 / person
                              :name (n6 / name :op1 "Lees-Miller"~e.35,37)))
                  :time (d3 / date-entity :year "1996"~e.39)))
      :ARG1-of (d4 / describe-01
            :ARG2 (b2 / B5)))

# ::tok <C27> p45Skp2 inhibits Cdk2 kinase activity and blocks phosphorylation of Cdk2 by Wee1 or CAK ( Yam et al. , 1999 ) . Similarly to p21Cip1 , two molecules of p45Skp2 seem to be required to inhibit Cdk2. Binding to p45Skp2 is mutually exclusive with p21 cip1 .
# ::alignments 1-1.1.1.1.1.1 1-1.3.1.1.1.1 2-1.1.1 3-1.1.1.2.1.1.1 4-1.1.1.2.1 5-1.1.1.2 6-1.1 6-1.1.3.1.1 7-1.1.2 8-1.1.2.2 10-1.2.1.1.1.1.1 11-1.1.2.2.2.r 12-1.1.2.2.2.1.1.1 13-1.1.2.2.2 14-1.1.2.2.2.2.1.1 16-1.1.3.1.1.1.1.1 17-1.1.3.1.1 18-1.1.3.1.1.2.1 20-1.1.3.1.2.1 23-1.2.1.3 25-1.2.1.3.1.1.1 25-1.3.2.1.1 27-1.2.1.2.1 28-1.2.1.2 29-1.2.1.2.2.r 30-1.2.1.2.2.1.1 31-1.2 34-1.2.1 36-1.2.1.1 38-1.3.1 39-1.3.1.1.r 40-1.3.1.1.1.1 42-1.3.3 42-1.3.3.r
# ::id bel_pmid_1043_6023_21494
(m / multi-sentence
      :snt1 (a / and~e.6
            :op1 (i / inhibit-01~e.2
                  :ARG0 (p / protein
                        :name (n / name :op1 "p45Skp2"~e.1))
                  :ARG1 (a2 / act-02~e.5
                        :ARG0 (k / kinase~e.4
                              :name (n2 / name :op1 "Cdk2"~e.3))))
            :op2 (b / block-01~e.7
                  :ARG0 p
                  :ARG1 (p2 / phosphorylate-01~e.8
                        :ARG1 k
                        :ARG2~e.11 (o / or~e.13
                              :op1 (e / enzyme
                                    :name (n3 / name :op1 "Wee1"~e.12))
                              :op2 (e2 / enzyme
                                    :name (n4 / name :op1 "CAK"~e.14)))))
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication-91
                        :ARG0 (a3 / and~e.6,17
                              :op1 (p4 / person
                                    :name (n5 / name :op1 "Yam"~e.16))
                              :op2 (p5 / person
                                    :mod (o2 / other~e.18)))
                        :time (d2 / date-entity :year "1999"~e.20))))
      :snt2 (s / seem-01~e.31
            :ARG1 (r / require-01~e.34
                  :ARG0 (i2 / inhibit-01~e.36
                        :ARG1 (e4 / enzyme
                              :name (n6 / name :op1 "Cdk2"~e.10)))
                  :ARG1 (m2 / molecule~e.28
                        :quant "2"~e.27
                        :mod~e.29 (p7 / protein
                              :name (n7 / name :op1 "p45Skp2"~e.30)))
                  :ARG1-of (r2 / resemble-01~e.23
                        :ARG2 (p8 / protein
                              :name (n8 / name :op1 "p21Cip1"~e.25)))))
      :snt3 (e3 / exclude-01
            :ARG0 (b2 / bind-01~e.38
                  :ARG2~e.39 (p9 / protein
                        :name (n9 / name :op1 "p45Skp2"~e.1,40)))
            :ARG2 (p10 / protein
                  :name (n10 / name :op1 "p21cip1"~e.25))
            :manner~e.42 (m3 / mutual~e.42))
      :ARG1-of (d3 / describe-01
            :ARG2 (c / C27)))

# ::tok <C17> Phosphorylation of Thr14 or Tyr15 in Cdk1 reduces kinase activity 10 @-@ fold ; phosphorylation of both sites reduces activity 100 @-@ fold ( Liu et al. , 1997 ) .
# ::alignments 1-1.1.1 4-1.1.1.1 7-1.1.1.1.1.3.1.1 8-1.1 9-1.1.2.1 10-1.1.2 11-1.1.3.1 15-1.1.1 15-1.2.1 16-1.1.3 19-1.1 19-1.2 20-1.1.2 21-1.2.3.1 25-1.3.1.1.1.1.1 26-1 26-1.2.1.1 26-1.3.1.1 27-1.3.1.1.2.1 29-1.3.1.2.1
# ::id bel_pmid_1043_6023_22542
(a / and~e.26
      :op1 (r / reduce-01~e.8,19
            :ARG0 (p / phosphorylate-01~e.1,15
                  :ARG1 (o / or~e.4
                        :op1 (a2 / amino-acid
                              :mod "14"
                              :name (n / name :op1 "threonine")
                              :part-of (k2 / kinase
                                    :name (n3 / name :op1 "Cdk1"~e.7)))
                        :op1 (a3 / amino-acid
                              :mod "15"
                              :name (n2 / name :op1 "tyrosine")
                              :part-of k2)))
            :ARG1 (a4 / act-02~e.10,20
                  :ARG0 k2~e.9)
            :ARG2 (p2 / product-of~e.16 :op1 "10"~e.11))
      :op2 (r2 / reduce-01~e.19
            :ARG0 (p3 / phosphorylate-01~e.15
                  :ARG1 (a5 / and~e.26
                        :op1 a2
                        :op2 a3))
            :ARG1 a4
            :ARG2 (p4 / product-of :op1 "100"~e.21))
      :ARG1-of (d / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a6 / and~e.26
                        :op1 (p6 / person
                              :name (n4 / name :op1 "Liu"~e.25))
                        :op2 (p7 / person
                              :mod (o2 / other~e.27)))
                  :time (d2 / date-entity :year "1997"~e.29)))
      :ARG1-of (d3 / describe-01
            :ARG2 (c / C17)))

# ::tok <C21> p27Kip1 can be phosphorylated by Cyclin E @- or Cyclin A @-@ dependent kinases and thereby may be targeted for degradation ( Sheaff et al. , 1997 ) .
# ::alignments 1-1.1.1.1.1 2-1 3-1.1.r 4-1.1 5-1.1.2.r 6-1.1.2.1.1.1.1.1 7-1.1.2.1.1.1.1.2 9-1.1.2 10-1.1.2.2.1.1.1.1 11-1.1.2.2.1.1.1.2 13-1.1.2.1.1 13-1.1.2.2.1 14-1.1.2.1 14-1.1.2.2 15-1.3.1.1 17-1.2.1 18-1.2.1.1.r 19-1.2.1.1 20-1.2.1.1.2.r 21-1.2.1.1.2 23-1.3.1.1.1.1.1 24-1.3.1.1 25-1.3.1.1.2.1 27-1.3.1.2.1
# ::id bel_pmid_1043_6023_22720
(p / possible~e.2
      :domain~e.3 (p2 / phosphorylate-01~e.4
            :ARG1 (p3 / protein
                  :name (n / name :op1 "p27Kip1"~e.1))
            :ARG2~e.5 (o / or~e.9
                  :op1 (k / kinase~e.14
                        :ARG0-of (d / depend-01~e.13
                              :ARG1 (p4 / protein
                                    :name (n2 / name :op1 "Cyclin"~e.6 :op2 "E"~e.7))))
                  :op2 (k2 / kinase~e.14
                        :ARG0-of (d2 / depend-01~e.13
                              :ARG1 (p5 / protein
                                    :name (n3 / name :op1 "Cyclin"~e.10 :op2 "A"~e.11))))))
      :ARG0-of (c / cause-01
            :ARG1 (p6 / possible~e.17
                  :domain~e.18 (t / target-01~e.19
                        :ARG1 p3
                        :purpose~e.20 (d3 / degrade-01~e.21
                              :ARG1 p3))))
      :ARG1-of (d4 / describe-01
            :ARG0 (p7 / publication-91
                  :ARG0 (a / and~e.15,24
                        :op1 (p8 / person
                              :name (n4 / name :op1 "Sheaff"~e.23))
                        :op2 (p9 / person
                              :mod (o2 / other~e.25)))
                  :time (d5 / date-entity :year "1997"~e.27)))
      :ARG1-of (d6 / describe-01
            :ARG2 (c2 / C21)))

# ::tok <C9> Cyclin D1 has a short half @-@ life ( , 30 min ) , regardless of whether free or Cdk4 @-@ bound . Rapid degradation of Cyclin D1 requires phosphorylation at threonine @-@ 286 ( kinase unknown , but not Cdk2 or Cdk4 ) ; degradation is by way of the ubiquitin @-@ proteasome pathway ( Diehl et al. , 1997 ) .
# ::alignments 1-1.2.1.1.1.1 2-1.2.1.1.1.2 5-1.1.2.2 6-1.1.2.1 8-1.1 8-1.1.2 8-1.1.2.r 11-1.1.2.3.1 18-1.1.3.1 19-1.1.3 20-1.1.3.2.2.1.1 22-1.1.3.2 24-1.2.1.3 25-1.2.1 27-1.2.1.1.1.1 28-1.2.1.1.1.2 29-1.2 30-1.2.2 31-1.2.2.1.r 32-1.2.2.1.2.1 34-1.2.2.1.1 36-1.2.2.2 36-1.2.2.2.2.1.1 36-1.2.2.2.2.1.2 37-1.2.2.2.1 37-1.2.2.2.1.1 37-1.2.2.2.2.1.1.1 37-1.2.2.2.2.1.2.1 39-1.2.2.2.2 40-1.2.2.2.1.1.r 40-1.2.2.2.2.1.1.1.r 40-1.2.2.2.2.1.2.1.r 41-1.2.2.2.2.1.1.2.1 42-1.2.2.2.2.1 43-1.2.2.2.2.1.2.2.1 46-1.2.1 50-1.2.1.2.r 52-1.2.1.2.1.1 54-1.2.1.2.1.1 55-1.2.1.2 57-1.2.3.1.1.1.1.1 58-1.2.3.1.1 59-1.2.3.1.1.2.1 61-1.2.3.1.2.1
# ::id bel_pmid_1043_6023_22724
(m / multi-sentence
      :snt1 (l / live-01~e.8
            :ARG0 (p / protein
                  :name (n / name :op1 "Cyclin" :op2 "D"))
            :ARG1~e.8 (l2 / life~e.8
                  :mod (h / half~e.6)
                  :mod (s / short~e.5)
                  :duration (t / temporal-quantity
                        :quant "30"~e.11
                        :unit (m2 / minute)))
            :concession (o / or~e.19
                  :op1 (f / free-04~e.18
                        :ARG1 p)
                  :op2 (b / bind-01~e.22
                        :ARG1 p
                        :ARG2 (e / enzyme
                              :name (n2 / name :op1 "Cdk4"~e.20)))))
      :snt2 (r / require-01~e.29
            :ARG0 (d / degrade-01~e.25,46
                  :ARG1 (p3 / protein
                        :name (n3 / name :op1 "Cyclin"~e.1,27 :op2 "D1"~e.2,28))
                  :ARG2~e.50 (p5 / pathway~e.55
                        :name (n7 / name :op1 "ubiquitin-proteasome"~e.52,54))
                  :mod (r2 / rapid~e.24))
            :ARG1 (p4 / phosphorylate-01~e.30
                  :ARG1~e.31 (a2 / amino-acid
                        :mod "286"~e.34
                        :name (n4 / name :op1 "threonine"~e.32)
                        :part-of p3)
                  :ARG2 (k / kinase~e.36
                        :ARG1-of (k2 / know-01~e.37 :polarity~e.40 "-"~e.37)
                        :ARG1-of (c / contrast-01~e.39
                              :ARG2 (o2 / or~e.42
                                    :op1 (k3 / kinase~e.36
                                          :polarity~e.40 "-"~e.37
                                          :name (n5 / name :op1 "Cdk2"~e.41))
                                    :op2 (k4 / kinase~e.36
                                          :polarity~e.40 "-"~e.37
                                          :name (n6 / name :op1 "Cdk4"~e.43))))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p6 / publication-91
                        :ARG0 (a / and~e.58
                              :op1 (p7 / person
                                    :name (n8 / name :op1 "Diehl"~e.57))
                              :op2 (p8 / person
                                    :mod (o3 / other~e.59)))
                        :time (d3 / date-entity :year "1997"~e.61))))
      :ARG1-of (d4 / describe-01
            :ARG2 (c2 / C9)))

# ::tok <C11b> DMTF1 activates transcription from the p19ARF promoter and induces cell cycle arrest and p21Cip1 accumulation in a p19ARF @- and p53 @-@ dependent manner ( Inoue et al. , 1999 ) . Another DMTF1 @-@ regulated gene is CD13 @/@ aminopeptidase N , which is activated cooperatively by DMTF1 and c @-@ Myb ; its activation by DMTF1 is inhibited by cyclin D independent of Cdk4 @/@ 6 .
# ::alignments 1-1.1.1.1.1.1 2-1.1.1 3-1.1.1.2 4-1.1.1.2.1.r 6-1.1.1.2.1.1.1.1.1 8-1.1 8-1.1.3.1.1 9-1.1.2 10-1.1.2.2.1.1.1 11-1.1.2.2.1.1 12-1.1.2.2.1 13-1.1.2.2 14-1.1.2.2.2.1.1.1 15-1.1.2.2.2 16-1.1.2.3.r 18-1.1.2.3.1.1 20-1.1.2.3.1 20-1.1.3.1.1 21-1.1.2.3.1.2.1.1 23-1.1.2.3 24-1.2.1.3.3.2.r 26-1.1.3.1.1.1.1.1 27-1.1.3.1.1 28-1.1.3.1.1.2.1 30-1.1.3.1.2.1 33-1.2.1.1 34-1.2.1.2.1.1.1 36-1.2.1.2 37-1.2.1 38-1.2.1.3.r 39-1.2.1.3.1.1 41-1.2.1.3.2.1.1.1 42-1.2.1.3.2.1.1.2 45-1.2.1.3.r 46-1.2.1.3.3 47-1.2.1.3.3.2 48-1.2.1.3.3.1.r 49-1.2.1.3.3.1.1 50-1.2.2.2.2 51-1.2.2.2.2 52-1.2.2.2.2 53-1.2.2.2.2 56-1.2.2.2 57-1.2.2.2.1.r 58-1.2.2.2.1 59-1.2.1.3.r 60-1.2.2 61-1.2.2.1.r 62-1.2.2.1.1.1 63-1.2.2.1.1.2 64-1.2.2.3 64-1.2.2.3.1 64-1.2.2.3.1.r 65-1.2.2.3.2.r 66-1.2.2.3.2.1.1 68-1.2.2.3.2.1.1
# ::id bel_pmid_1043_6023_22908
(m / multi-sentence
      :snt1 (a / and~e.8
            :op1 (a2 / activate-01~e.2
                  :ARG0 (p / protein
                        :name (n / name :op1 "DMTF1"~e.1))
                  :ARG1 (t / transcribe-01~e.3
                        :ARG0~e.4 (m2 / molecular-physical-entity
                              :ARG0-of (p2 / promote-01
                                    :ARG1 (p3 / protein
                                          :name (n2 / name :op1 "p19ARF"~e.6))))))
            :op2 (i / induce-01~e.9
                  :ARG0 p
                  :ARG1 (a3 / and~e.13
                        :op1 (a4 / arrest-02~e.12
                              :ARG1 (c / cycle~e.11
                                    :mod (c2 / cell~e.10)))
                        :op2 (a5 / accumulate-01~e.15
                              :ARG1 (p4 / protein
                                    :name (n3 / name :op1 "p21Cip1"~e.14))))
                  :ARG0-of~e.16 (d / depend-01~e.23
                        :ARG1 (a6 / and~e.20
                              :op1 p3~e.18
                              :op2 (p6 / protein
                                    :name (n5 / name :op1 "p53"~e.21)))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p7 / publication-91
                        :ARG0 (a7 / and~e.8,20,27
                              :op1 (p8 / person
                                    :name (n6 / name :op1 "Inoue"~e.26))
                              :op2 (p9 / person
                                    :mod (o / other~e.28)))
                        :time (d3 / date-entity :year "1999"~e.30))))
      :snt2 (a8 / and
            :op1 (g3 / gene~e.37
                  :mod (a9 / another~e.33)
                  :ARG1-of (r / regulate-01~e.36
                        :ARG0 (p10 / protein
                              :name (n9 / name :op1 "DMTF1"~e.34)))
                  :domain~e.38,45,59 (g / gene
                        :name (n7 / name :op1 "CD13"~e.39)
                        :ARG1-of (m3 / mean-01
                              :ARG2 (g2 / gene
                                    :name (n8 / name :op1 "aminopeptidase"~e.41 :op2 "N"~e.42)))
                        :ARG1-of (a10 / activate-01~e.46
                              :ARG0~e.48 (a11 / and
                                    :op1 p10~e.49
                                    :op2 (p11 / protein
                                          :name (n10 / name :op1 "c-Myb")))
                              :manner~e.24 (c3 / cooperate-01~e.47))))
            :op2 (i2 / inhibit-01~e.60
                  :ARG0~e.61 (p12 / protein
                        :name (n11 / name :op1 "cyclin"~e.62 :op2 "D"~e.63))
                  :ARG1 (a12 / activate-01~e.56
                        :ARG0~e.57 p10~e.58
                        :ARG1 g~e.50,51,52,53)
                  :ARG0-of (d4 / depend-01~e.64
                        :polarity~e.64 "-"~e.64
                        :ARG1~e.65 (e / enzyme
                              :name (n12 / name :op1 "Cdk4/6"~e.66,68)))))
      :ARG1-of (d5 / describe-01
            :ARG2 (c4 / C11b)))

# ::tok <h5> p300 binds to the transactivation domain of E2F1 ( Lee et al. , 1998a ) . E2F1 and p53 may be reciprocally regulated by their mutual dependence on coactivation by limiting amounts of p300 ( Lee et al. , 1998a ) .
# ::alignments 1-1.1.1.1.1 2-1.1 3-1.1.2.r 5-1.1.2.2 8-1.1.2.1.1.1 8-1.2.1.2.1.1.1 10-1.1.3.1.1.1.1.1.1 10-1.2.2.1.1.1.1.1.1 11-1.1.3.1 11-1.1.3.1.1.1 11-1.2.1.2 11-1.2.2.1 11-1.2.2.1.1.1 12-1.1.3.1.1.1.2.1 12-1.2.2.1.1.1.2.1 17-1.1.2.1.1.1 17-1.2.1.2.1.1.1 18-1.1.3.1 18-1.1.3.1.1.1 18-1.2.1.2 18-1.2.2.1 18-1.2.2.1.1.1 19-1.2.1.2.2.1.1 20-1.2 21-1.2.1.r 22-1.2.1.3 22-1.2.1.3.r 23-1.2.1 24-1.2.1.1.r 25-1.2.1.1.1 25-1.2.1.1.1.r 27-1.2.1.1 28-1.2.1.1.2.r 29-1.2.1.1.2 30-1.2.1.1.2.1.r 31-1.2.1.1.2.1 32-1.2.1.1.2.1.1 34-1.1.1.1.1 34-1.2.1.1.2.1.1.1.1.1 36-1.1.3.1.1.1.1.1.1 36-1.2.2.1.1.1.1.1.1 37-1.1.3.1 37-1.1.3.1.1.1 37-1.2.2.1 37-1.2.2.1.1.1 38-1.1.3.1.1.1.2.1 38-1.2.2.1.1.1.2.1
# ::id bel_pmid_1043_6023_23028
(m / multi-sentence
      :snt1 (b / bind-01~e.2
            :ARG1 (p / protein
                  :name (n / name :op1 "p300"~e.1,34))
            :ARG2~e.3 (p2 / protein-segment
                  :part-of (p3 / protein
                        :name (n2 / name :op1 "E2F1"~e.8,17))
                  :location-of (t / transactivate-00~e.5))
            :ARG1-of (d / describe-01
                  :ARG0 (a2 / and~e.11,18,37
                        :op1 (p4 / publication-91
                              :ARG0 (a / and~e.11,18,37
                                    :op1 (p5 / person
                                          :name (n3 / name :op1 "Lee"~e.10,36))
                                    :op2 (p6 / person
                                          :mod (o / other~e.12,38))
                                    :op2 (f / figure
                                          :mod (a8 / a)))
                              :time (d2 / date-entity :year "1998")))))
      :snt1 (p7 / possible~e.20
            :domain~e.21 (r / regulate-01~e.23
                  :ARG0~e.24 (d3 / depend-01~e.27
                        :ARG0~e.25 a3~e.25
                        :ARG1~e.28 (c / coactivate-00~e.29
                              :manner~e.30 (l / limit-01~e.31
                                    :ARG1 (a4 / amount~e.32
                                          :quant-of (p10 / protein
                                                :name (n6 / name :op1 "p300"~e.34))))))
                  :ARG1 (a3 / and~e.11,18
                        :op1 (p8 / protein
                              :name (n4 / name :op1 "E2F1"~e.8,17))
                        :op2 (p9 / protein
                              :name (n5 / name :op1 "p53"~e.19)))
                  :manner~e.22 (r2 / reciprocal~e.22))
            :ARG1-of (d4 / describe-01
                  :ARG0 (a5 / and~e.11,18,37
                        :op1 (p11 / publication-91
                              :ARG0 (a7 / and~e.11,18,37
                                    :op1 (p12 / person
                                          :name (n7 / name :op1 "Lee"~e.10,36))
                                    :op2 (p13 / person
                                          :mod (o2 / other~e.12,38)))
                              :time (d5 / date-entity :year "1998"))
                        :op2 (f2 / figure
                              :mod (a6 / a)))))
      :ARG1-of (d6 / describe-01
            :ARG2 (h / h5)))

# ::tok <p24> P300 coactivates P53 @-@ activated promotors , including p21 , Bax , and Mdm2. <p25> P300 binds the transactivation domain in the Nterminal region of p53 - this interaction is involved in the coactivation of p53 by p300
# ::alignments 1-1.1.1.1.1 1-1.2.1.1.1.1 2-1.1 3-1.1.2.2.1.1.1 5-1.1.2.2 8-1.1.2.3 9-1.1.2.3.1.1.1.1 11-1.1.2.3.1.2.1.1 13-1.1.2.3.1 13-1.2 16-1.1.1.1.1 16-1.2.1.1.1.1 17-1.2.2.1.1 18-1.2.2.1.1 19-1.2.2.1.1 20-1.2.2.1.1 21-1.2.2.1.1 22-1.2.2.1.1 23-1.2.2.1.1 24-1.2.2.1.1 25-1.2.2.1.1 26-1.2.2.1.1 29-1.2.2.1 31-1.2.2 34-1.1 34-1.2.2.2 36-1.2.1.2.2.2.1.1 37-1.1.1.r 38-1.1.1.1.1
# ::id bel_pmid_1043_6023_23030
(m / multi-sentence
      :snt1 (c / coactivate-00~e.2,34
            :ARG0~e.37 (p / protein
                  :name (n / name :op1 "p300"~e.1,16,38))
            :ARG1 (m2 / molecular-physical-entity
                  :ARG0-of (p2 / promote-01)
                  :ARG1-of (a / activate-01~e.5
                        :ARG0 (p3 / protein
                              :name (n2 / name :op1 "p53"~e.3)))
                  :ARG2-of (i / include-91~e.8
                        :ARG1 (a2 / and~e.13
                              :op1 (p4 / protein
                                    :name (n3 / name :op1 "p21"~e.9))
                              :op2 (p5 / protein
                                    :name (n4 / name :op1 "Bax"~e.11))
                              :op2 (p6 / protein
                                    :name (n5 / name :op1 "Mdm2")))))
            :ARG1-of (d / describe-01
                  :ARG2 (p11 / p24)))
      :snt2 (a3 / and~e.13
            :op1 (b / bind-01
                  :ARG1 (p7 / protein
                        :name (n6 / name :op1 "p300"~e.1,16))
                  :ARG2 (p8 / protein-segment
                        :location-of (t / transactivate-00)
                        :part-of (p9 / protein-segment
                              :name (n7 / name :op1 "N-terminus")
                              :part-of (p10 / protein
                                    :name (n8 / name :op1 "p53"~e.36)))))
            :op2 (i2 / involve-01~e.31
                  :ARG1 (i3 / interact-01~e.29
                        :mod b~e.17,18,19,20,21,22,23,24,25,26)
                  :ARG2 (c2 / coactivate-00~e.34
                        :ARG0 p7
                        :ARG1 p10))
            :ARG1-of (d2 / describe-01
                  :ARG2 (p12 / p25))))

# ::tok <p52> HMG1 binds p53 and enhances p53 binding to DNA , asl well as p53 @-@ mediated transcriptional activation
# ::alignments 1-1.1.1.1.1 2-1.1 3-1.1.2.1.1 4-1 5-1.2 6-1.2.2.1.1 7-1.2.2.1 8-1.2.2.1.2.r 9-1.2.2.1.2 14-1.1.2.1.1 16-1.2.2.2.2 18-1.2.2.2
# ::id bel_pmid_1043_6023_23244
(a / and~e.4
      :op1 (b / bind-01~e.2
            :ARG1 (p / protein
                  :name (n / name :op1 "HMG1"~e.1))
            :ARG2 (p2 / protein
                  :name (n2 / name :op1 "p53"~e.3,14)))
      :op2 (e / enhance-01~e.5
            :ARG0 p
            :ARG1 (a2 / and
                  :op1 (b2 / bind-01~e.7
                        :ARG1 p2~e.6
                        :ARG2~e.8 (d / DNA~e.9))
                  :op2 (a3 / activate-01~e.18
                        :ARG1 (t / transcribe-01)
                        :ARG1-of (m / mediate-01~e.16
                              :ARG0 p2))))
      :ARG1-of (d2 / describe-01
            :ARG2 (p3 / p52)))

# ::tok <r8> PCNA binds DNA ligase I ; the complex may function to join Okazaki fragments during DNA replication ( Levin et al.,1997 ) .
# ::alignments 1-1.1.1.1.1 2-1.1 3-1.1.2.1.1 4-1.1.2.1.2 5-1.1.2.1.3 8-1.2.1.1 9-1.2 10-1.2.1 12-1.2.1.2 13-1.2.1.2.2.1.1 14-1.2.1.2.2.1.2 15-1.2.1.2.3.r 16-1.2.1.2.3.1 17-1.2.1.2.3 19-1.3.1.1.1.1.1 20-1 20-1.3.1.1
# ::id bel_pmid_1043_6023_23872
(a / and~e.20
      :op1 (b / bind-01~e.2
            :ARG1 (p / protein
                  :name (n / name :op1 "PCNA"~e.1))
            :ARG2 (e / enzyme
                  :name (n2 / name
                        :op1 "DNA"~e.3
                        :op2 "ligase"~e.4
                        :op3 "I"~e.5)))
      :op2 (p2 / possible~e.9
            :domain (f / function-01~e.10
                  :ARG0 (c / complex~e.8)
                  :ARG1 (j / join-01~e.12
                        :ARG1 c
                        :ARG2 (p3 / protein-segment
                              :name (n3 / name :op1 "Okazaki"~e.13 :op2 "fragment"~e.14))
                        :time~e.15 (r / replicate-01~e.17
                              :ARG1 (d / DNA~e.16)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a2 / and~e.20
                        :op1 (p5 / person
                              :name (n4 / name :op1 "Levin"~e.19))
                        :op2 (p6 / person
                              :mod (o / other)))
                  :time (d3 / date-entity :year "1997")))
      :ARG1-of (d4 / describe-01
            :ARG2 (r2 / r8)))

# ::tok Max blocks transcriptional activation from the E @-@ cadherin promoter by c @-@ Myc , presumably because it blocks the binding between c @-@ Myc and AP2 .
# ::alignments 0-1.1.1.1 1-1 3-1.2 6-1.2.2.1.1.1.1.1 8-1.2.2.1.1.1.1.1 10-1.2.1.r 11-1.2.1.1.1 13-1.2.1.1.1 16-1.3 18-1.3.1 20-1.3.1.2 22-1.3.1.2.1 23-1.3.1.2.1 24-1.3.1.2.1 26-1.3.1.2.2.1.1
# ::id bel_pmid_1043_6023_23902
(b / block-01~e.1
      :ARG0 (p / protein
            :name (n / name :op1 "Max"~e.0))
      :ARG1 (a / activate-01~e.3
            :ARG0~e.10 (p4 / protein
                  :name (n3 / name :op1 "c-Myc"~e.11,13))
            :ARG1 (t / transcribe-01
                  :ARG0 (m / molecular-physical-entity
                        :ARG0-of (p2 / promote-01
                              :ARG1 (p3 / protein
                                    :name (n2 / name :op1 "E-cadherin"~e.6,8))))))
      :ARG1-of (c / cause-01~e.16
            :ARG0 (b2 / block-01~e.18
                  :ARG0 p
                  :ARG1 (b3 / bind-01~e.20
                        :ARG1 p4~e.22,23,24
                        :ARG2 (p5 / protein
                              :name (n4 / name :op1 "AP2"~e.26))))))

# ::tok <p29> mdm2 inhibits p53 @-@ mediated transactivation ; it inhibits the expression of p53 dependent genes
# ::alignments 1-1.1.1.1.1 2-1.1 3-1.1.2.1.1.1.1 5-1.1.2.1 6-1.1.2 9-1.1 9-1.2 11-1.2.2 12-1.2.2.1.r 13-1.2.2.1.1.1 14-1.2.2.1.1 15-1.2.2.1
# ::id bel_pmid_1043_6023_23914
(a / and
      :op1 (i / inhibit-01~e.2,9
            :ARG0 (p / protein
                  :name (n / name :op1 "mdm2"~e.1))
            :ARG1 (t / transactivate-00~e.6
                  :ARG1-of (m / mediate-01~e.5
                        :ARG0 (p2 / protein
                              :name (n2 / name :op1 "p53"~e.3)))))
      :op2 (i2 / inhibit-01~e.9
            :ARG0 p
            :ARG1 (e / express-03~e.11
                  :ARG1~e.12 (g / gene~e.15
                        :ARG0-of (d / depend-01~e.14
                              :ARG1 p2~e.13))))
      :ARG1-of (d2 / describe-01
            :ARG2 (p3 / p29)))

# ::tok <A9> Phosphorylation of pRb disrupts the c @-@ Abl : pRb complex and releases active c @-@ Abl ( Welch and Wang , 1995 ) .
# ::alignments 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1 4-1.1 6-1.1.2.1.1.1 8-1.1.2.1.1.1 10-1.1.2.2 11-1.1.2 12-1 12-1.3.1.1 13-1.2 15-1.1.2.1.1.1 15-1.2.2.1.1 17-1.1.2.1.1.1 17-1.2.2.1.1 19-1.3.1.1.1.1.1 20-1.3.1.1 21-1.3.1.1.2.1.1 23-1.3.1.2.1
# ::id bel_pmid_1043_6023_24262
(a / and~e.12
      :op1 (d / disrupt-01~e.4
            :ARG0 (p / phosphorylate-01~e.1
                  :ARG1~e.2 (p2 / protein
                        :name (n / name :op1 "pRb"~e.3)))
            :ARG1 (m / macro-molecular-complex~e.11
                  :part (p3 / protein
                        :name (n2 / name :op1 "c-Abl"~e.6,8,15,17))
                  :part p2~e.10))
      :op2 (r / release-01~e.13
            :ARG0 p
            :ARG1 (p4 / protein
                  :name (n3 / name :op1 "c-Abl"~e.15,17)
                  :ARG1-of (a2 / activate-01)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a3 / and~e.12,20
                        :op1 (p6 / person
                              :name (n4 / name :op1 "Welch"~e.19))
                        :op2 (p7 / person
                              :name (n5 / name :op1 "Wang"~e.21)))
                  :time (d3 / date-entity :year "1995"~e.23)))
      :ARG1-of (d4 / describe-01
            :ARG2 (a4 / A9)))

# ::tok <E21> The p107 promoter contains E2F recognition elements and can be repressed by pRb or p107 ( Zhu et al. , 1995 ) .
# ::alignments 2-1.1.1.1.1.1.1 4-1.1 5-1.1.2.1.1.1.1 6-1.1.2.1 7-1.1.2 8-1 8-1.3.1.1 9-1.2 10-1.2.1.r 11-1.2.1 12-1.2.1.1.r 13-1.2.1.1.1.1.1 14-1.2.1.1 15-1.2.1.1.2 17-1.3.1.1.1.1.1 18-1.3.1.1 19-1.3.1.1.2.1 21-1.3.1.2.1
# ::id bel_pmid_1043_6023_24268
(a / and~e.8
      :op1 (c / contain-01~e.4
            :ARG0 (m / molecular-physical-entity
                  :ARG0-of (p / promote-01
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "p107"~e.2))))
            :ARG1 (e / element~e.7
                  :ARG0-of (r / recognize-01~e.6
                        :ARG1 (p3 / protein
                              :name (n2 / name :op1 "E2F"~e.5)))))
      :op2 (p4 / possible~e.9
            :domain~e.10 (r2 / repress-01~e.11
                  :ARG0~e.12 (o / or~e.14
                        :op1 (p5 / protein
                              :name (n3 / name :op1 "pRb"~e.13))
                        :op2 p2~e.15)
                  :ARG1 m))
      :ARG1-of (d / describe-01
            :ARG0 (p6 / publication-91
                  :ARG0 (a2 / and~e.8,18
                        :op1 (p7 / person
                              :name (n4 / name :op1 "Zhu"~e.17))
                        :op2 (p8 / person
                              :mod (o2 / other~e.19)))
                  :time (d2 / date-entity :year "1995"~e.21)))
      :ARG1-of (d3 / describe-01
            :ARG2 (e2 / E21)))

# ::tok <r4> Clamp @-@ loader RF @-@ C loads PCNA onto the DNA ( Kelman , 1997 ) . RF @-@ C interacts with the C @-@ terminal side of PCNA ( Mossi et al. , 1997 ) .
# ::alignments 1-1.1.1.2.1 4-1.1.1.1.1 6-1.1.1.1.1 7-1.1 7-1.1.1 7-1.1.1.2 7-1.1.1.2.r 7-1.1.1.r 8-1.1.3.1.1 11-1.1.2 13-1.1.4.1.1.1.1 15-1.1.4.1.2.1 18-1.2.1.1.1 20-1.2.1.1.1 21-1.2 24-1.2.1.1.1 24-1.2.2.1.1 26-1.2.2.1.1 29-1.2.2.2.1.1 31-1.2.3.1.1.1.1.1 32-1.2.3.1.1 33-1.2.3.1.1.2.1 35-1.1.4.1.2.1 35-1.2.3.1.2.1
# ::id bel_pmid_1043_6023_24294
(m / multi-sentence
      :snt1 (l / load-01~e.7
            :ARG0~e.7 (m2 / macro-molecular-complex~e.7
                  :name (n / name :op2 "RF-C"~e.4,6)
                  :ARG0-of~e.7 (l2 / load-01~e.7
                        :ARG1 (c / clamp~e.1)))
            :ARG1 (d / DNA~e.11)
            :ARG2 (p / protein
                  :name (n2 / name :op1 "PCNA"~e.8))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p2 / publication-91
                        :ARG0 (p3 / person
                              :name (n3 / name :op1 "Kelman"~e.13))
                        :time (d3 / date-entity :year "1997"~e.15,35))))
      :snt2 (i / interact-01~e.21
            :ARG0 (m3 / macro-molecular-complex
                  :name (n4 / name :op1 "RF-C"~e.18,20,24))
            :ARG1 (p4 / protein-segment
                  :name (n5 / name :op1 "C-terminus"~e.24,26)
                  :part-of (p5 / protein
                        :name (n6 / name :op1 "PCNA"~e.29)))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p6 / publication-91
                        :ARG0 (a / and~e.32
                              :op1 (p7 / person
                                    :name (n7 / name :op1 "Mossi"~e.31))
                              :op2 (p8 / person
                                    :mod (o / other~e.33)))
                        :time (d5 / date-entity :year "1997"~e.35))))
      :ARG1-of (d6 / describe-01
            :ARG2 (r / r4)))

# ::tok <s16> DNA @-@ PK can bind to RPA ( Shao et al. , 1999 ) . <s17> Phosphorylation of RPA2 by DNA @-@ PK impairs the binding of RPA to DNA @-@ PK ( Shao et al. , 1999 ) .
# ::alignments 1-1.2.1.2.1.1 3-1.2.1.2.1.1 4-1.1 5-1.1.1 6-1.1.1.2.r 7-1.1.1.2.1.1 9-1.1.2.1.1.1.1.1 9-1.2.3.1.1.1.1.1 10-1.1.2.1.1 10-1.2.3.1.1 11-1.1.2.1.1.2.1 11-1.2.3.1.1.2.1 13-1.1.2.1.2.1 13-1.2.3.1.2.1 17-1.2.1 18-1.2.1.1.r 19-1.2.1.1.1.1 21-1.2.1.2.1.1 23-1.2.1.2.1.1 24-1.2 26-1.2.2 28-1.1.1.2.1.1 28-1.2.2.1.1.1 29-1.1.1.1.r 30-1.1.1.1.1.1 32-1.1.1.1.1.1 34-1.1.2.1.1.1.1.1 34-1.2.3.1.1.1.1.1 35-1.1.2.1.1 35-1.2.3.1.1 36-1.1.2.1.1.2.1 36-1.2.3.1.1.2.1 38-1.1.2.1.2.1 38-1.2.3.1.2.1
# ::id bel_pmid_1043_6023_24302
(m / multi-sentence
      :snt1 (p / possible~e.4
            :domain (b / bind-01~e.5
                  :ARG1~e.29 (e / enzyme
                        :name (n / name :op1 "DNA-PK"~e.30,32))
                  :ARG2~e.6 (p2 / protein
                        :name (n2 / name :op1 "RPA"~e.7,28)))
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication-91
                        :ARG0 (a / and~e.10,35
                              :op1 (p4 / person
                                    :name (n3 / name :op1 "Shao"~e.9,34))
                              :op2 (p5 / person
                                    :mod (o / other~e.11,36)))
                        :time (d2 / date-entity :year "1999"~e.13,38)))
            :ARG1-of (d5 / describe-01
                  :ARG2 (s / s16)))
      :snt2 (i / impair-01~e.24
            :ARG0 (p6 / phosphorylate-01~e.17
                  :ARG1~e.18 (p7 / protein
                        :name (n4 / name :op1 "RPA2"~e.19))
                  :ARG2 (e2 / enzyme
                        :name (n5 / name :op1 "DNA-PK"~e.1,3,21,23)))
            :ARG1 (b2 / bind-01~e.26
                  :ARG1 (p8 / protein
                        :name (n6 / name :op1 "RPA"~e.28))
                  :ARG2 e2)
            :ARG1-of (d3 / describe-01
                  :ARG0 (p9 / publication-91
                        :ARG0 (a2 / and~e.10,35
                              :op1 (p10 / person
                                    :name (n7 / name :op1 "Shao"~e.9,34))
                              :op2 (p11 / person
                                    :mod (o2 / other~e.11,36)))
                        :time (d4 / date-entity :year "1999"~e.13,38)))
            :ARG1-of (d6 / describe-01
                  :ARG2 (s2 / s17))))

# ::tok <C29> p19Skp1 , through its F @-@ box motif , may link Cyclin A to the ubiquitin ? proteasome protein degradation device ( Bai et al. , 1996 ) .
# ::alignments 1-1.1.1.1.1 5-1.1.3.1.1 7-1.1.3.1.1 8-1.1.3.1.2 10-1 11-1.1 12-1.1.2.1.1.1 13-1.1.2.1.1.2 14-1.1.2.r 16-1.1.2.2.1.1.1.1 18-1.1.2.2.1.1.1.1 19-1.1.1 19-1.1.2.1 19-1.1.2.2.1.1 20-1.1.2.2.1 21-1.1.2.2 23-1.2.1.1.1.1.1 24-1.1.2 24-1.2.1.1 25-1.2.1.1.2.1 27-1.2.1.2.1
# ::id bel_pmid_1043_6023_24340
(p2 / possible~e.10
      :domain (l / link-01~e.11
            :ARG0 (p3 / protein~e.19
                  :name (n2 / name :op1 "p19Skp1"~e.1))
            :ARG1~e.14 (a / and~e.24
                  :op1 (p5 / protein~e.19
                        :name (n4 / name :op1 "Cyclin"~e.12 :op2 "A"~e.13))
                  :op2 (d3 / device~e.21
                        :ARG2-of (d4 / degrade-01~e.20
                              :ARG1 (p6 / protein~e.19
                                    :name (n5 / name :op1 "ubiquitin/proteasome"~e.16,18)))))
            :ARG2 (p4 / protein-segment
                  :name (n3 / name :op1 "F-box"~e.5,7 :op2 "motif"~e.8)))
      :ARG1-of (d / describe-01
            :ARG0 (p / publication-91
                  :ARG0 (a2 / and~e.24
                        :op1 (p7 / person
                              :name (n / name :op1 "Bai"~e.23))
                        :op2 (p8 / person
                              :mod (o / other~e.25)))
                  :time (d2 / date-entity :year "1996"~e.27)))
      :ARG1-of (d5 / describe-01
            :ARG2 (c / C29)))

# ::tok <p4> Unknown Phosphatase dephosphorylates P53 at Thr18 <p5> Phosphorylation of Ser18 ( note discrepancy with Thr18 above ) prevents stable binding of p53 to Mdm2 - other sites may be involved in this process
# ::alignments 1-1.1.2.1 1-1.1.2.1.1 1-1.1.2.1.1.r 2-1.1.2 4-1.1.1.3.1.1 8-1.2.1.2 12-1.2.1.2.1.3.2 16-1.2.1.2.1.3.1.3.1 18-1.2.1 19-1.2.1.1.3 20-1.2.1.1 21-1.2.1.1.1.r 22-1.2.1.1.1.1.1 23-1.2.1.1.2.r 24-1.2.1.1.2.1.1 26-1.2.2.1.1.1 27-1.2.2.1.1 28-1.2.2 29-1.2.2.1.r 30-1.2.2.1 31-1.2.2.1.2.r 32-1.2.2.1.2.1 33-1.2.2.1.2
# ::id bel_pmid_1043_6023_24616
(m / multi-sentence
      :snt1 (d / dephosphorylate-01
            :ARG1 (a / amino-acid
                  :mod "18"
                  :name (n / name :op1 "threonine")
                  :part-of (p2 / protein
                        :name (n2 / name :op1 "P53"~e.4)))
            :ARG2 (p / phosphatase~e.2
                  :ARG1-of (k / know-01~e.1 :polarity~e.1 "-"~e.1))
            :ARG1-of (d3 / describe-01
                  :ARG2 (p9 / p4)))
      :snt2 (a2 / and
            :op1 (p3 / prevent-01~e.18
                  :ARG1 (b / bind-01~e.20
                        :ARG1~e.21 (p5 / protein
                              :name (n4 / name :op1 "p53"~e.22))
                        :ARG2~e.23 (p6 / protein
                              :name (n5 / name :op1 "Mdm2"~e.24))
                        :mod (s / stable~e.19))
                  :ARG3 (p4 / phosphorylate-01~e.8
                        :ARG1 (a3 / amino-acid
                              :mod "18"
                              :name (n3 / name :op1 "serine")
                              :ARG1-of (c / contrast-01
                                    :ARG2 (a4 / amino-acid
                                          :mod "18"
                                          :name (n6 / name :op1 "threonine")
                                          :ARG1-of (d2 / describe-01
                                                :medium (a5 / above~e.16)))
                                    :ARG1-of (n7 / note-01~e.12
                                          :mode "imperative"
                                          :ARG0 (y / you))))))
            :op2 (p7 / possible~e.28
                  :domain~e.29 (i / involve-01~e.30
                        :ARG1 (s2 / site~e.27
                              :mod (o / other~e.26))
                        :ARG2~e.31 (p8 / process~e.33
                              :mod (t / this~e.32))))
            :ARG1-of (d4 / describe-01
                  :ARG2 (p10 / p5))))

# ::tok <s18> KARP1 stimulates DNA @-@ PK activity and may function in complex with DNA @-@ PK and Ku ( Mysung et al. , 1997; Myung et al. , 1998 ) ( also see P50 ) .
# ::alignments 1-1.1.1.1.1 2-1.1 3-1.1.2.1.1.1 5-1.1.2.1.1.1 6-1.1.2 7-1 7-1.3.1 7-1.3.1.1.1 8-1.2 9-1.2.1 10-1.2.1.2.r 11-1.2.1.2 12-1.2.1.2.1.r 13-1.2.1.2.1 14-1.2.1.2.1 15-1.2.1.2.1 16-1 16-1.3.1 16-1.3.1.1.1 17-1.2.1.2.2.1.1 19-1.3.1.1.1.1.1.1 20-1.3.1.1.1 21-1.3.1.1.1.2.1 24-1.3.1.2.1.1.1.1 25-1.3.1 25-1.3.1.1.1 25-1.3.1.2.1 26-1.3.1.1.1.2.1 28-1.3.1.2.2.1 32-1.3.1.3 32-1.3.1.3.2 32-1.3.1.3.2.r 33-1.3.1.3.1.1
# ::id bel_pmid_1043_6023_24698
(a2 / and~e.7,16
      :op1 (s / stimulate-01~e.2
            :ARG0 (p / protein
                  :name (n / name :op1 "KARP1"~e.1))
            :ARG1 (a / act-02~e.6
                  :ARG0 (e / enzyme
                        :name (n2 / name :op1 "DNA-PK"~e.3,5))))
      :op2 (p2 / possible~e.8
            :domain (f / function-01~e.9
                  :ARG0 p
                  :ARG1~e.10 (m2 / macro-molecular-complex~e.11
                        :part~e.12 e~e.13,14,15
                        :part (p3 / protein
                              :name (n3 / name :op1 "Ku"~e.17))
                        :part p)))
      :ARG1-of (d / describe-01
            :ARG0 (a3 / and~e.7,16,25
                  :op1 (p5 / publication-91
                        :ARG0 (a4 / and~e.7,16,20,25
                              :op1 (p6 / person
                                    :name (n4 / name :op1 "Mysung"~e.19))
                              :op2 (p7 / person
                                    :mod (o / other~e.21,26)))
                        :time (d2 / date-entity :year "1997"))
                  :op2 (p8 / publication-91
                        :ARG0 (a5 / and~e.25
                              :op1 (p9 / person
                                    :name (n5 / name :op1 "Myung"~e.24))
                              :op2 p7)
                        :time (d3 / date-entity :year "1998"~e.28))
                  :op3 (p4 / publication~e.32
                        :ARG1-of (c / cite-01 :ARG2 "P50"~e.33)
                        :ARG1-of~e.32 (s2 / see-01~e.32
                              :mode "imperative"
                              :ARG0 (y / you)))))
      :ARG1-of (d4 / describe-01
            :ARG2 (s3 / s18)))

# ::tok In the case of Cdk1 , these inhibitory phosphorylations are removed by dual @-@ action phosphatase Cdc25C , which is in turn activated by phosphorylations ( C18 ) introduced by mammalian polo @-@ like kinase 1 ( Plk1 ) ( C37 ) and @/@ or Cdk1 ( C36 ) . Cdc25C can be phosphorylated at Ser216 by Chk1 ( C38 ) or C @-@ TAK1 ( C39 ) . Ser216 phosphorylation generates a binding site for 14 @-@ 3 @-@ 3 , and this binding inhibits the phosphatase ( C40 ) .
# ::alignments 0-1.1.1.3.2 4-1.1.3.1.1 6-1.1.2.1 8-1.1.2 10-1.1 12-1.1.1.2.1 14-1.1.1.2 15-1.1.1 16-1.1.1.1.1 20-1.1.1.3.2 21-1.1.1.3.2 22-1.1.1.3 23-1.1.1.3.1.r 24-1.1.1.3.1 26-1.1.1.3.1.2.1 28-1.1.1.3.1.1 31-1.1.1.3.1.1.1.1.1.1 33-1.1.1.3.1.1.1.1.1.1 34-1.1.1.3.1.1.1.1 34-1.1.1.3.1.1.1.1.1.2 35-1.1.1.3.1.1.1.1.1.3 40-1.1.1.3.1.1.1.1.3.1 42-1.1.1.3.1.1.1 44-1.1.1.3.1.1.1 45-1.1.1.3.1.1.1.2.1.1 47-1.1.1.3.1.1.1.2.2.1 50-1.2.1.1.3.1.1 51-1.2 52-1.2.1.r 53-1.2.1 56-1.2.1.2.r 57-1.2.1.2.1.1.1 59-1.2.1.2.1.2.1 61-1.2.1.2 62-1.2.1.2.2.1.1 64-1.2.1.2.2.1.1 66-1.2.1.2.2.2.1 70-1.3.1 71-1.3 73-1.3.2.1 74-1.3.2 76-1.3.2.1.1.1.1 78-1.3.2.1.1.1.1 80-1.3.2.1.1.1.1 82-1.1.1.3.1.1.1 83-1.1.2.1 84-1.3.2.1 85-1.1.2.2 85-1.3.2.1.2 87-1.3.2.1.2.1 89-1.3.2.1.2.1.1.1
# ::id bel_pmid_1043_6023_24712
(m / multi-sentence
      :snt1 (r / remove-01~e.10
            :ARG0 (p14 / phosphatase~e.15
                  :name (n / name :op2 "Cdc25C"~e.16)
                  :ARG0-of (a / act-01~e.14
                        :mod (d / dual~e.12))
                  :ARG1-of (a2 / activate-01~e.22
                        :ARG0~e.23 (p2 / phosphorylate-01~e.24
                              :ARG1-of (i3 / introduce-02~e.28
                                    :ARG0 (a3 / and-or~e.42,44,82
                                          :op1 (k / kinase~e.34
                                                :name (n4 / name
                                                      :op1 "polo-like"~e.31,33
                                                      :op2 "kinase"~e.34
                                                      :op3 "1"~e.35)
                                                :mod (m3 / mammal)
                                                :ARG1-of (l2 / label-01 :ARG2 "C37"~e.40))
                                          :op2 (e / enzyme
                                                :name (n3 / name :op1 "Cdk1"~e.45)
                                                :ARG1-of (l3 / label-01 :ARG2 "C36"~e.47))))
                              :ARG1-of (l / label-01 :ARG2 "C18"~e.26))
                        :mod (i2 / in-turn~e.0,20,21)))
            :ARG1 (p / phosphorylate-01~e.8
                  :mod (t / this~e.6,83)
                  :ARG0-of (i / inhibit-01~e.85))
            :topic (e2 / enzyme
                  :name (n2 / name :op1 "Cdk1"~e.4)))
      :snt2 (p5 / possible~e.51
            :domain~e.52 (p6 / phosphorylate-01~e.53
                  :ARG1 (a4 / amino-acid
                        :mod "216"
                        :name (n5 / name :op1 "serine")
                        :part-of (e5 / enzyme
                              :name (n6 / name :op1 "Cdc25C"~e.50)))
                  :ARG2~e.56 (o / or~e.61
                        :op1 (e3 / enzyme
                              :name (n7 / name :op1 "Chk1"~e.57)
                              :ARG1-of (l4 / label-01 :ARG2 "C38"~e.59))
                        :op2 (e4 / enzyme
                              :name (n8 / name :op1 "C-TAK1"~e.62,64)
                              :ARG1-of (l5 / label-01 :ARG2 "C39"~e.66)))))
      :snt3 (g / generate-01~e.71
            :ARG0 (p10 / phosphorylate-01~e.70
                  :ARG1 (a5 / amino-acid
                        :mod "216"
                        :name (n9 / name :op1 "serine")))
            :ARG1 (p11 / protein-segment~e.74
                  :ARG1-of (b / bind-01~e.73,84
                        :ARG2 (p12 / protein
                              :name (n10 / name :op1 "14-3-3"~e.76,78,80))
                        :ARG0-of (i4 / inhibit-01~e.85
                              :ARG1 (p13 / phosphatase~e.87
                                    :ARG1-of (l6 / label-01 :ARG2 "C40"~e.89)))))))

# ::tok <C18> Dephosphorylation of Cdk1 Thr14 and Tyr15 sites is carried out by Cdc25C , which must itself be activated by phosphorylation in its N @-@ terminal domain ( Jackman and Pines , 1997 ) . Cdc25C activity is high in mitosis during mitosis and low during interphase .
# ::alignments 1-1.1.2 2-1.1.2.1.r 3-1.1.2.1.1.3.1.1 5-1.1.2.1 5-1.1.3.1.1 7-1.1.1.2.1.1 9-1.1 10-1.1 12-1.1.1.1.1 15-1.1.1.2.2 18-1.1.1.2 20-1.1.1.2.1 21-1.1.1.2.1.1.2.r 22-1.1.1.2.1.1.2 23-1.1.1.2.1.1.1.1 25-1.1.1.2.1.1.1.1 26-1.1.1.2.1.1.1.2 28-1.1.3.1.1.1.1.1 29-1.1.3.1.1 30-1.1.3.1.1.2.1.1 32-1.1.3.1.2.1 35-1.2.1.1.1.1 36-1.2.1 36-1.2.2 38-1.2.1.3 40-1.2.1.2 41-1.2.1.2.r 42-1.2.1.2 43-1.2 44-1.2.2.3 45-1.2.2.2.r 46-1.2.2.2
# ::id bel_pmid_1043_6023_24714
(m / multi-sentence
      :snt1 (c / carry-03~e.9,10
            :ARG0 (e / enzyme
                  :name (n4 / name :op1 "Cdc25C"~e.12)
                  :ARG1-of (a4 / activate-01~e.18
                        :ARG0 (p3 / phosphorylate-01~e.20
                              :ARG1 (p4 / protein-segment~e.7
                                    :name (n5 / name :op1 "N-terminus"~e.23,25 :op2 "domain"~e.26)
                                    :part-of~e.21 e~e.22))
                        :ARG2-of (o / obligate-01~e.15)))
            :ARG1 (d / dephosphorylate-01~e.1
                  :ARG1~e.2 (a / and~e.5
                        :op1 (a2 / amino-acid
                              :mod "14"
                              :name (n / name :op1 "threonine")
                              :part-of (e2 / enzyme
                                    :name (n3 / name :op1 "Cdk1"~e.3)))
                        :op2 (a3 / amino-acid
                              :mod "15"
                              :name (n2 / name :op1 "tyrosine")
                              :part-of e2)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p5 / publication-91
                        :ARG0 (a5 / and~e.5,29
                              :op1 (p6 / person
                                    :name (n6 / name :op1 "Jackman"~e.28))
                              :op2 (p7 / person
                                    :name (n7 / name :op1 "Pines"~e.30)))
                        :time (d3 / date-entity :year "1997"~e.32))))
      :snt2 (a6 / and~e.43
            :op1 (a8 / act-02~e.36
                  :ARG0 (e3 / enzyme
                        :name (n8 / name :op1 "Cdc25C"~e.35))
                  :time~e.41 (m2 / mitosis~e.40,42)
                  :mod (h / high~e.38))
            :op2 (a7 / act-02~e.36
                  :ARG0 e3
                  :time~e.45 (i / interphase~e.46)
                  :mod (l / low~e.44)))
      :ARG1-of (d4 / describe-01
            :ARG2 (c2 / C18)))

# ::tok <C35> Cdc25A may be transcriptionally activated by c @-@ Myc ; the Myc : Max heterodimer binds to elements in the Cdc25A gene and activates its transcription ( Galaktionov et al. , 1996 ) .
# ::alignments 1-1.1.1.2.1.1 2-1.1 3-1.1.1.r 5-1.1.1 7-1.1.1.1.1.1 9-1.2.1.1.1.1 12-1.2.1.1.1.1 14-1.2.1.2.1.1 15-1.2.1.3 16-1.2 17-1.2.2.r 18-1.2.2 19-1.2.2.1.r 21-1.2.2.1 22-1.2.2.1 23-1 23-1.4.1.1 24-1.1.1 24-1.3 26-1.1.1.3 26-1.3.2 28-1.4.1.1.1.1.1 29-1.4.1.1 30-1.4.1.1.2.1 32-1.4.1.2.1
# ::id bel_pmid_1043_6023_32164
(a / and~e.23
      :op1 (p / possible~e.2
            :domain~e.3 (a2 / activate-01~e.5,24
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "c-Myc"~e.7))
                  :ARG1 (g / gene
                        :name (n / name :op1 "Cdc25A"~e.1))
                  :manner (t / transcribe-01~e.26)))
      :op2 (b / bind-01~e.16
            :ARG1 (m / macro-molecular-complex
                  :part (p3 / protein
                        :name (n3 / name :op1 "Myc"~e.9,12))
                  :part (p4 / protein
                        :name (n4 / name :op1 "Max"~e.14))
                  :mod (h / heterodimer~e.15))
            :ARG2~e.17 (e / element~e.18
                  :part-of~e.19 g~e.21,22))
      :op3 (a3 / activate-01~e.24
            :ARG0 m
            :ARG1 (t2 / transcribe-01~e.26
                  :ARG1 g))
      :ARG1-of (d / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a4 / and~e.23,29
                        :op1 (p6 / person
                              :name (n6 / name :op1 "Galaktionov"~e.28))
                        :op2 (p7 / person
                              :mod (o / other~e.30)))
                  :time (d2 / date-entity :year "1996"~e.32)))
      :ARG1-of (d3 / describe-01
            :ARG2 (c / C35)))

# ::tok <C1> The Cyclin D1 promoter is activated by E2F4 , but it is repressed by E2F1 via pRb ( Watanabe et al. , 1998 ) . In pRb deficient cells , E2F1 stimulates this promoter . An Sp1 site close to the E2F element also participates in the regulation . ( Overexpression of pRb can increase the expression of Cyclin D1 by an unknown mechanism [Watanabe et al. , 1998].)
# ::alignments 2-1.1.1.2.1.1.1.1 2-1.4.1.2.1.1.1 3-1.1.1.2.1.1.1.2 3-1.4.1.2.1.1.2 5-1.4.1.r 6-1.1.1 7-1.1.1.1.r 8-1.1.1.1.1.1 10-1.1 11-1.1.2.2 13-1.1.2 15-1.1.2.1.1.1 15-1.2.1.1.1 17-1.1.2.3.1.1 17-1.2.3.1.1.1.1 17-1.4.1.1.1.1.1 19-1.1.3.1.1.1.1.1 19-1.4.2.1.1.1.1.1 20-1.1.3.1.1 20-1.4.2.1.1 21-1.1.3.1.1.2.1 21-1.4.2.1.1.2.1 23-1.1.3.1.2.1 23-1.4.2.1.2.1 27-1.1.2.3.1.1 27-1.2.3.1.1.1.1 27-1.4.1.1.1.1.1 29-1.2.3 31-1.2.1.1.1 32-1.2 33-1.2.2.2 37-1.3.1.1.1.1 38-1.3.1 39-1.3.1.2 40-1.3.1.2.1.r 42-1.3.1.2.1.1.1.1 43-1.3.1.2.1 44-1.3.3 45-1.3 46-1.3.2.r 48-1.3.2 51-1.4.1.2 53-1.4.1.1.1.1.1 54-1.4 55-1.4.1 57-1.4.1.2 58-1.4.1.2.1.r 59-1.4.1.2.1.1.1 60-1.4.1.2.1.1.2 61-1.4.1.3.r 63-1.4.1.3.1 63-1.4.1.3.1.1 63-1.4.1.3.1.1.r 64-1.4.1.3 66-1.1.3.1.1 66-1.4.2.1.1 67-1.1.3.1.1.2.1 67-1.4.2.1.1.2.1
# ::id bel_pmid_1043_6023_32260
(m / multi-sentence
      :snt1 (c / contrast-01~e.10
            :ARG1 (a / activate-01~e.6
                  :ARG0~e.7 (p3 / protein
                        :name (n2 / name :op1 "E2F4"~e.8))
                  :ARG1 (m2 / molecular-physical-entity
                        :ARG0-of (p / promote-01
                              :ARG1 (p2 / protein
                                    :name (n / name :op1 "Cyclin"~e.2 :op2 "D1"~e.3)))))
            :ARG2 (r / repress-01~e.13
                  :ARG0 (p4 / protein
                        :name (n3 / name :op1 "E2F1"~e.15))
                  :ARG1 m2~e.11
                  :instrument (p5 / protein
                        :name (n4 / name :op1 "pRb"~e.17,27)))
            :ARG1-of (d / describe-01
                  :ARG0 (p6 / publication-91
                        :ARG0 (a2 / and~e.20,66
                              :op1 (p7 / person
                                    :name (n5 / name :op1 "Watanabe"~e.19))
                              :op2 (p8 / person
                                    :mod (o / other~e.21,67)))
                        :time (d2 / date-entity :year "1998"~e.23))))
      :snt2 (s / stimulate-01~e.32
            :ARG0 (p9 / protein
                  :name (n6 / name :op1 "E2F1"~e.15,31))
            :ARG1 (m3 / molecular-physical-entity
                  :ARG0-of (p10 / promote-01)
                  :mod (t / this~e.33))
            :location (c2 / cell~e.29
                  :ARG0-of (l / lack-01
                        :ARG1 (p11 / protein
                              :name (n7 / name :op1 "pRb"~e.17,27)))))
      :snt3 (p12 / participate-01~e.45
            :ARG0 (p13 / protein-segment~e.38
                  :part-of (p14 / protein
                        :name (n8 / name :op1 "Sp1"~e.37))
                  :ARG1-of (c3 / close-10~e.39
                        :ARG2~e.40 (e / element~e.43
                              :part-of (p15 / protein
                                    :name (n9 / name :op1 "E2F"~e.42)))))
            :ARG1~e.46 (r2 / regulate-01~e.48)
            :mod (a3 / also~e.44))
      :snt4 (p16 / possible~e.54
            :domain~e.5 (i / increase-01~e.55
                  :ARG0 (o2 / overexpress-00
                        :ARG1 (p17 / protein
                              :name (n10 / name :op1 "pRb"~e.17,27,53)))
                  :ARG1 (e2 / express-03~e.51,57
                        :ARG2~e.58 (p18 / protein
                              :name (n11 / name :op1 "Cyclin"~e.2,59 :op2 "D1"~e.3,60)))
                  :manner~e.61 (m4 / mechanism~e.64
                        :ARG1-of (k / know-01~e.63 :polarity~e.63 "-"~e.63)))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p19 / publication-91
                        :ARG0 (a4 / and~e.20,66
                              :op1 (p20 / person
                                    :name (n12 / name :op1 "Watanabe"~e.19))
                              :op2 (p21 / person
                                    :mod (o3 / other~e.21,67)))
                        :time (d4 / date-entity :year "1998"~e.23))))
      :ARG1-of (d5 / describe-01
            :ARG2 (c4 / C1)))

# ::tok <E15> E2F @-@ regulated genes include many that are involved in cell cycle progression and control . Individual genes are differently regulated . Dyhydrofolate reductase ( DHFR ) is activated via the E2F transactivation domain , whereas B @-@ myb , Cyclin E , E2F @-@ 1 , E2F @-@ 2 , and Cdc2 are regulated via the repression domain of pRb family proteins ( Dyson , 1998 ) .
# ::alignments 1-1.1.2.1.1.1.1 3-1.1.2.1 4-1.1.1 4-1.1.2 5-1.1 5-1.3.2.1.2.1 6-1.1.1.1 9-1.1.1.2 10-1.1.1.2.1.r 11-1.1.1.2.1.1.1.1 12-1.1.1.2.1.1.1 13-1.1.1.2.1.1 14-1.1.1.2.1 15-1.1.1.2.1.2 17-1.2.1.1 18-1.2.1 20-1.2.2 21-1.2 23-1.3.1.2.1.1 24-1.3.1.2.1.2 29-1.3.1 32-1.3.1.1.2.1.1 33-1.3.1.1.1 34-1.3.1.1 36-1.3 37-1.3.2.2.1.1.1 39-1.3.2.2.1.1.1 41-1.3.2.2.2.1.1 42-1.3.2.2.2.1.2 44-1.3.2.2.3.1.1 44-1.3.2.2.4.1.1 46-1.3.2.2.3.1.1 48-1.3.2.2.3.1.1 48-1.3.2.2.4.1.1 50-1.3.2.2.4.1.1 52-1.3.2.2 53-1.3.2.2.5.1.1 55-1.3.2 58-1.3.2.1.1 59-1.3.2.1 60-1.3.2.1.2.r 61-1.3.2.1.2.1.1.1.1 62-1.3.2.1.2.1.1.2 63-1.3.2.1.2 65-1.3.3.1.1.1.1 67-1.3.3.1.2.1
# ::id bel_pmid_1043_6023_32488
(m / multi-sentence
      :snt1 (i / include-91~e.5
            :ARG1 (g2 / gene~e.4
                  :quant (m2 / many~e.6)
                  :ARG1-of (i2 / involve-01~e.9
                        :ARG2~e.10 (a / and~e.14
                              :op1 (p2 / progression~e.13
                                    :mod (c / cycle~e.12
                                          :mod (c2 / cell~e.11)))
                              :op2 (c3 / control-01~e.15
                                    :ARG1 c))))
            :ARG2 (g / gene~e.4
                  :ARG1-of (r / regulate-01~e.3
                        :ARG0 (p / protein
                              :name (n / name :op1 "E2F"~e.1)))))
      :snt2 (r2 / regulate-01~e.21
            :ARG1 (g3 / gene~e.18
                  :mod (i3 / individual~e.17))
            :manner (d / differ-02~e.20))
      :snt3 (c4 / contrast-01~e.36
            :ARG1 (a2 / activate-01~e.29
                  :ARG0 (d2 / domain~e.34
                        :ARG0-of (t / transactivate-00~e.33)
                        :part-of (p3 / protein
                              :name (n4 / name :op1 "E2F"~e.32)))
                  :ARG1 (g4 / gene
                        :name (n2 / name :op1 "dyhydrofolate"~e.23 :op2 "reductase"~e.24)))
            :ARG2 (r3 / regulate-01~e.55
                  :ARG0 (d3 / domain~e.59
                        :ARG0-of (r4 / repress-01~e.58)
                        :part-of~e.60 (p4 / protein~e.63
                              :ARG1-of (i4 / include-91~e.5
                                    :ARG2 (p5 / protein
                                          :name (n10 / name :op1 "pRb"~e.61)
                                          :mod (f / family~e.62)))))
                  :ARG1 (a3 / and~e.52
                        :op1 (g6 / gene
                              :name (n5 / name :op1 "B-myb"~e.37,39))
                        :op2 (g7 / gene
                              :name (n6 / name :op1 "Cyclin"~e.41 :op2 "E"~e.42))
                        :op3 (g8 / gene
                              :name (n7 / name :op1 "E2F-1"~e.44,46,48))
                        :op4 (g9 / gene
                              :name (n8 / name :op1 "E2F-2"~e.44,48,50))
                        :op5 (g10 / gene
                              :name (n9 / name :op1 "Cdc2"~e.53))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p6 / publication-91
                        :ARG0 (p7 / person
                              :name (n11 / name :op1 "Dyson"~e.65))
                        :time (d5 / date-entity :year "1998"~e.67))))
      :ARG1-of (d6 / describe-01
            :ARG2 (e / E15)))

# ::tok <r12> p53 binds and transiently transactivates the PCNA promoter ( when p53 reaches high levels , transactivation seems to stop ) ( Shivakumar et al. , 1995; Morris et al. , 1996; Xu and Morris , 1999 ) .
# ::alignments 1-1.1.1.1.1 2-1.1 3-1 3-1.4.1 4-1.2.3 4-1.2.3.r 5-1.2 7-1.1.2.1.1.1.1 10-1.4.1.1.2.r 10-1.4.1.2.2.r 11-1.3.2.1 12-1.3.2 13-1.3.2.2.1 14-1.3.2.2 16-1.2 17-1.3 19-1.3.1 22-1.4.1.1.1.1.1.1 23-1.4.1.1.1 24-1.4.1.1.1.2.1 27-1.4.1.2.1.1.1.1 28-1.4.1 28-1.4.1.1.1 28-1.4.1.2.1 28-1.4.1.3.1 29-1.4.1.1.1.2.1 32-1.4.1.3.1.1.1.1 33-1.4.1 33-1.4.1.1.1 33-1.4.1.2.1 33-1.4.1.3.1 34-1.4.1.3.1.2 36-1.4.1.3.2.1
# ::id bel_pmid_1043_6023_32562
(a / and~e.3
      :op1 (b / bind-01~e.2
            :ARG1 (p / protein
                  :name (n / name :op1 "p53"~e.1))
            :ARG2 (m / molecular-physical-entity
                  :ARG0-of (p2 / promote-01
                        :ARG1 (p3 / protein
                              :name (n2 / name :op1 "PCNA"~e.7)))))
      :op2 (t / transactivate-00~e.5,16
            :ARG0 p
            :ARG1 m
            :manner~e.4 (t2 / transient~e.4))
      :op3 (s / seem-01~e.17
            :ARG1 (s2 / stop-01~e.19
                  :ARG1 t)
            :condition (r / reach-01~e.12
                  :ARG0 p~e.11
                  :ARG1 (l / level~e.14
                        :mod (h / high~e.13))))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.3,28,33
                  :op1 (p4 / publication-91
                        :ARG0 (a3 / and~e.23,28,33
                              :op1 (p5 / person
                                    :name (n3 / name :op1 "Shivakumar"~e.22))
                              :op2 (p6 / person
                                    :mod (o / other~e.24,29)))
                        :time~e.10 (d2 / date-entity :year "1995"))
                  :op2 (p7 / publication-91
                        :ARG0 (a4 / and~e.28,33
                              :op1 (p8 / person
                                    :name (n4 / name :op1 "Morris"~e.27))
                              :op2 p6)
                        :time~e.10 (d3 / date-entity :year "1996"))
                  :op3 (p9 / publication-91
                        :ARG0 (a5 / and~e.28,33
                              :op1 (p10 / person
                                    :name (n5 / name :op1 "Xu"~e.32))
                              :op2 p8~e.34)
                        :time (d4 / date-entity :year "1999"~e.36))))
      :ARG1-of (d5 / describe-01
            :ARG2 (r2 / r12)))

# ::tok <p2> ATM phosphorylates P53 at Ser15
# ::alignments 1-1.2.1.1 2-1 3-1.1.3.1.1
# ::id bel_pmid_1043_6023_36686
(p / phosphorylate-01~e.2
      :ARG1 (a / amino-acid
            :mod "15"
            :name (n2 / name :op1 "serine")
            :part-of (p3 / protein
                  :name (n3 / name :op1 "P53"~e.3)))
      :ARG2 (p2 / protein
            :name (n / name :op1 "ATM"~e.1))
      :ARG1-of (d / describe-01
            :ARG2 (p4 / p2)))

# ::tok <p6> DNA @-@ PK phosphorylates P53 at Ser15 and Ser37 dependent on DNA double @-@ strand ends
# ::alignments 1-1.2.1.1 3-1.2.1.1 4-1 5-1.1.1.3.1.1 8-1.1 10-1.3 11-1.3.1.r 12-1.3.1.1 13-1.3.1.1.1.1 15-1.3.1.1.1 16-1.3.1
# ::id bel_pmid_1043_6023_37166
(p / phosphorylate-01~e.4
      :ARG1 (a / and~e.8
            :op1 (a2 / amino-acid
                  :mod "15"
                  :name (n2 / name :op1 "serine")
                  :part-of (p2 / protein
                        :name (n3 / name :op1 "P53"~e.5)))
            :op2 (a3 / amino-acid
                  :mod "37"
                  :name (n4 / name :op1 "serine")
                  :part-of p2))
      :ARG2 (e / enzyme
            :name (n / name :op1 "DNA-PK"~e.1,3))
      :ARG0-of (d / depend-01~e.10
            :ARG1~e.11 (e2 / end~e.16
                  :part-of (d2 / DNA~e.12
                        :mod (s / strand~e.15
                              :mod (d3 / double~e.13)))))
      :ARG1-of (d4 / describe-01
            :ARG2 (p3 / p6)))

# ::tok <p47> p53 binds BRCA1. This binding enhances the transcriptional activity of P53
# ::alignments 1-1.1.1.1.1 1-1.2.2.1.1.1 2-1.1 2-1.2.1 4-1.2.1.1 5-1.2.1 6-1.2 11-1.1.1.1.1 11-1.2.2.1.1.1
# ::id bel_pmid_1043_6023_37792
(m / multi-sentence
      :snt1 (b / bind-01~e.2
            :ARG1 (p / protein
                  :name (n / name :op1 "p53"~e.1,11))
            :ARG2 (p2 / protein
                  :name (n2 / name :op1 "BRCA1")))
      :snt2 (e / enhance-01~e.6
            :ARG0 (b2 / bind-01~e.2,5
                  :mod (t / this~e.4))
            :ARG1 (a / act-01
                  :ARG0 (p3 / protein
                        :name (n3 / name :op1 "P53"~e.1,11))
                  :ARG1 (t2 / transcribe-01)))
      :ARG1-of (d / describe-01
            :ARG2 (p4 / p47)))

# ::tok <C31> Cyclin D : Cdk4 phosphorylates pRb at a subset of sites , P( D ) , but this does not suffice to abrogate the inhibition of E2F . <C32> Cyclin E : Cdk2 phosphorylates pRb at additional sites , P( E ) , after the Cyclin D : Cdk4 @-@ specific sites have been phosphorylated . ( Cyclin E , in addition to acting on pRb , has actions that can induce S phase independent of pRb [Lukas et al. , 1997; Lundberg and Weinberg , 1998].)
# ::alignments 1-1.1.2.1.1.1 2-1.1.2.1.1.2 4-1.1.2.2.1.1 5-1.2 6-1.1.1.2.1.1 6-1.2.1.1.1.1 9-1.1.1.1.1 11-1.2.1 14-1.1.1.3.1 17-1.1.3 20-1.1.3.1.1 20-1.1.3.1.1.r 21-1.1.3.1 23-1.1.3.1.3 25-1.1.3.1.3.1 26-1.1.3.1.3.1.1.r 27-1.1.3.1.3.1.1.1.1 30-1.2.2.1.1.1 31-1.2.2.1.1.2 33-1.2.2.2.1.1 34-1.2 35-1.2.1.1.1.1 37-1.2.1.2 38-1.2.1 41-1.2.1.4.1 44-1.2.3 46-1.2.3.1.2.1.1.1 47-1.2.3.1.2.1.1.2 49-1.2.3.1.2.2.1.1 51-1.2.3.1.1.1 52-1.1.1 52-1.2.3.1.1 53-1.1.3 55-1.1 55-1.2.3.1 58-1.3.2.1.1.1.1.1 59-1.3.2.1.1.1.1.2 61-1.3 61-1.3.3.1 61-1.3.3.1.1.1 62-1.3 62-1.3.3.1 62-1.3.3.1.1.1 64-1.3.1 66-1.3.2.1.3.2.1.1 69-1.3.2.1.1 71-1.3.2 72-1.3.2.1 73-1.3.2.1.2.1.1 74-1.3.2.1.2.1.2 75-1.3.2.1.3 75-1.3.2.1.3.1 75-1.3.2.1.3.1.r 77-1.3.2.1.3.2.1.1 79-1.3 79-1.3.3.1 79-1.3.3.1.1.1 80-1.3.3.1.1.1.2.1 83-1.3.3.1.2.1.2.1.1 84-1.3.3.1.2.1 85-1.3.3.1.2.1.1.1.1
# ::id bel_pmid_1043_6023_37884
(m / multi-sentence
      :snt1 (p / phosphorylate-01~e.55
            :ARG1 (s / site~e.52
                  :ARG1-of (i / include-91
                        :ARG2 (s2 / subset~e.9))
                  :part-of (p4 / protein
                        :name (n3 / name :op1 "pRb"~e.6))
                  :ARG1-of (l / label-01 :ARG2 "D"~e.14)
                  :ARG1-of (m3 / mean-01 :ARG2 "P"))
            :ARG2 (m2 / macro-molecular-complex
                  :part (p2 / protein
                        :name (n / name :op1 "Cyclin"~e.1 :op2 "D"~e.2))
                  :part (e2 / enzyme
                        :name (n2 / name :op1 "Cdk4"~e.4)))
            :ARG2-of (h / have-concession-91~e.17,53
                  :ARG1 (s3 / suffice-01~e.21
                        :polarity~e.20 "-"~e.20
                        :ARG0 p
                        :ARG1 (a / abrogate-01~e.23
                              :ARG1 (i2 / inhibit-01~e.25
                                    :ARG1~e.26 (p5 / protein
                                          :name (n4 / name :op1 "E2F"~e.27))))))
            :ARG1-of (d5 / describe-01
                  :ARG2 (c / C31)))
      :snt2 (p6 / phosphorylate-01~e.5,34
            :ARG1 (p9 / protein-segment~e.11,38
                  :part-of (p10 / protein
                        :name (n7 / name :op1 "pRb"~e.6,35))
                  :mod (a2 / additional~e.37)
                  :ARG1-of (m5 / mean-01 :ARG2 "P")
                  :ARG1-of (l2 / label-01 :ARG2 "E"~e.41))
            :ARG2 (m4 / macro-molecular-complex
                  :part (p7 / protein
                        :name (n5 / name :op1 "Cyclin"~e.30 :op2 "E"~e.31))
                  :part (e3 / enzyme
                        :name (n6 / name :op1 "Cdk2"~e.33)))
            :time (a3 / after~e.44
                  :op1 (p11 / phosphorylate-01~e.55
                        :ARG1 (p12 / protein-segment~e.52
                              :mod (s4 / specific~e.51))
                        :part-of (m6 / macro-molecular-complex
                              :part-of (p13 / protein
                                    :name (n8 / name :op1 "Cyclin"~e.46 :op2 "D"~e.47))
                              :part-of (e4 / enzyme
                                    :name (n9 / name :op1 "Cdk4"~e.49)))))
            :ARG1-of (d6 / describe-01
                  :ARG2 (c2 / C32)))
      :snt3 (a5 / and~e.61,62,79
            :op1 (a6 / act-02~e.64
                  :ARG0 (p16 / protein
                        :name (n10 / name :op1 "Cyclin"~e.58 :op2 "E"~e.59)))
            :op2 (p15 / possible~e.71
                  :domain (i3 / induce-01~e.72
                        :ARG0 (a4 / act-02~e.69
                              :ARG0 p16)
                        :ARG1 (e / event
                              :name (n15 / name :op1 "S"~e.73 :op2 "phase"~e.74))
                        :ARG0-of (d / depend-01~e.75
                              :polarity~e.75 "-"~e.75
                              :ARG1 (p18 / protein
                                    :name (n11 / name :op1 "pRb"~e.66,77)))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a7 / and~e.61,62,79
                        :op1 (p19 / publication-91
                              :ARG0 (a8 / and~e.61,62,79
                                    :op1 (p20 / person
                                          :name (n12 / name :op1 "Lukas"))
                                    :op2 (p21 / person
                                          :mod (o / other~e.80)))
                              :time (d3 / date-entity :year "1997"))
                        :op2 (p22 / publication-91
                              :ARG0 (a9 / and~e.84
                                    :op1 (p24 / person
                                          :name (n14 / name :op1 "Weinberg"~e.85))
                                    :op1 (p23 / person
                                          :name (n13 / name :op1 "Lundberg"~e.83)))
                              :time (d4 / date-entity :year "1998"))))))

# ::tok Treatment of ECs with an NO donor , S @-@ nitroso @-@ N @-@ acetylpenicillamine ( SNAP ) or 3 @-@ morpholinosydnonimine ( SIN @-@ 1 ) , inhibited this shear stress @-@ induced Egr @-@ 1 expression .
# ::alignments 0-1.1 3-1.1.2.r 5-1.1.2.1.1.1 6-1.1.2 6-1.1.2.1 6-1.1.2.1.r 8-1.1.2.1.1.2.1.1.1 10-1.1.2.1.1.2.1.1.1 12-1.1.2.1.1.2.1.1.1 14-1.1.2.1.1.2.1.1.1 16-1.1.2.1.1.2.1.2.1.1 18-1.1.2.1.1.2 19-1.1.2.1.1.2.2.1.1 21-1.1.2.1.1.2.2.1.1 23-1.1.2.1.1.2.2.2.1.1 25-1.1.2.1.1.2.2.2.1.1 28-1 29-1.2.2 30-1.2.1.2.1.1 31-1.2.1.2.1 33-1.2.1.2 34-1.2.1.1.1 36-1.2.1.1.1 37-1.2
# ::id bel_pmid_1043_6166_18636
(i3 / inhibit-01~e.28
      :ARG0 (t / treat-03~e.0
            :ARG1 (c / cell
                  :name (n / name :op1 "EC"))
            :ARG3~e.3 (t3 / thing~e.6
                  :ARG0-of~e.6 (d / donate-01~e.6
                        :ARG1 (n2 / name
                              :op1 "NO"~e.5
                              :example (o / or~e.18
                                    :op1 (a / amino-acid
                                          :name (n3 / name :op1 "S-nitroso-N-acetylpenicillamine"~e.8,10,12,14)
                                          :ARG1-of (m / mean-01
                                                :ARG2 (n4 / name :op1 "SNAP"~e.16)))
                                    :op2 (a2 / amino-acid
                                          :name (n5 / name :op1 "3-morpholinosydnonimine"~e.19,21)
                                          :ARG1-of (m2 / mean-01
                                                :ARG2 (n6 / name :op1 "SIN-1"~e.23,25))))))))
      :ARG1 (e / express-03~e.37
            :ARG2 (p2 / protein
                  :name (n7 / name :op1 "Egr-1"~e.34,36)
                  :ARG1-of (i2 / induce-01~e.33
                        :ARG0 (s / stress-01~e.31
                              :mod (s2 / shear-01~e.30))))
            :mod (t2 / this~e.29)))

# ::tok NO modulation of the signaling pathway was shown by its inhibitory effect on shear stress @-@ induced ERK1 @/@ ERK2 phosphorylation and activity .
# ::alignments 0-1.2.1.1 1-1.2 2-1.2.2.r 4-1.2.2.1 5-1.2.2 7-1 8-1.1.r 9-1.1.1 9-1.1.1.r 11-1.1 12-1.1.2.r 13-1.1.2.1.1.3.1.1 14-1.1.2.1.1.3.1 16-1.1.2.1.1.3 17-1.1.2.1.1.1.1.1 19-1.1.2.1.1.2.1.1 20-1.1.2.1 21-1.1.2
# ::id bel_pmid_1043_6166_3510
(s / show-01~e.7
      :ARG0~e.8 (e / effect-01~e.11
            :ARG0~e.9 m2~e.9
            :ARG1~e.12 (a / and~e.21
                  :op1 (p / phosphorylate-01~e.20
                        :ARG0 (s3 / slash
                              :op1 (e2 / enzyme
                                    :name (n2 / name :op1 "ERK1"~e.17))
                              :op2 (e3 / enzyme
                                    :name (n3 / name :op1 "ERK2"~e.19))
                              :ARG1-of (i2 / induce-01~e.16
                                    :ARG0 (s4 / stress-01~e.14
                                          :mod (s5 / shear-01~e.13)))))
                  :op2 (a2 / act-01
                        :ARG0 s3))
            :mod (i / inhibit-01))
      :ARG1 (m2 / modulate-01~e.1
            :ARG0 (n / name :op1 "NO"~e.0)
            :ARG1~e.2 (p2 / pathway~e.5
                  :ARG0-of (s2 / signal-01~e.4))))

# ::tok The FAK and Fyn @/@ Shc pathways . Integrins activate various protein tyrosine kinases , including focal adhesion kinase ( FAK ) , Srcfamily kinases , and Abl , and a serine @-@ threonine kinase , integrin @-@ linked kinase ( ILK ) ( 4 , 7 ) .
# ::alignments 1-1.1.1.1.1 2-1.1 3-1.1.2.1.1 5-1.1.2.1.1 6-1.1.1 6-1.1.2 9-1.2 10-1.2.2.1.3 11-1.2.2.1.1.1 12-1.2.2.1.1.2 13-1.2.2.1.1.3 15-1.2.2.1.2 16-1.2.2.1.2.1.1.1.1 17-1.2.2.1.2.1.1.1.2 18-1.2.2.1.2.1.1.1.3 20-1.2.2.1.2.1.1.2.1.1 24-1.2.2.1.2.1.2 26-1.2.2.1.2.1 27-1.2.2.1.2.1.3.1.1 29-1.2.2.1.2.1 31-1.2.2.2.1.1 33-1.2.2.2.1.1 34-1.2.2.2.1.2 34-1.2.2.2.2.1.1.2 36-1.2.1.1.1 38-1.2.2.2.2.1.1.1 39-1.2.2.2.2.1.1.2 41-1.2.2.2.2.1.2.1.1 44-1.2.3.1.1.1.1 46-1.2.3.1.1.1.2
# ::id bel_pmid_1044_6041_18010
(m / multi-sentence
      :snt1 (a / and~e.2
            :op1 (p / pathway~e.6
                  :name (n / name :op1 "FAK"~e.1))
            :op2 (p2 / pathway~e.6
                  :name (n2 / name :op1 "Fyn/Shc"~e.3,5)))
      :snt2 (a2 / activate-01~e.9
            :ARG0 (m4 / molecular-physical-entity
                  :name (n3 / name :op1 "integrin"~e.36))
            :ARG1 (a3 / and
                  :op1 (e3 / enzyme
                        :name (n10 / name
                              :op1 "protein"~e.11
                              :op2 "tyrosine"~e.12
                              :op3 "kinases"~e.13)
                        :ARG2-of (i2 / include-91~e.15
                              :ARG1 (a4 / and~e.26,29
                                    :op1 (e2 / enzyme
                                          :name (n4 / name
                                                :op1 "focal"~e.16
                                                :op2 "adhesion"~e.17
                                                :op3 "kinase"~e.18)
                                          :ARG1-of (m2 / mean-01
                                                :ARG2 (n5 / name :op1 "FAK"~e.20)))
                                    :op2 (k / kinase~e.24
                                          :part-of (f / family
                                                :mod (p3 / protein
                                                      :name (n9 / name :op1 "Scr"))))
                                    :op3 (p4 / protein
                                          :name (n6 / name :op1 "Abl"~e.27))))
                        :mod (v2 / various~e.10))
                  :op2 (e / enzyme
                        :name (n7 / name :op1 "serine-threonine"~e.31,33 :op2 "kinase"~e.34)
                        :ARG1-of (m5 / mean-01
                              :ARG2 (p5 / protein
                                    :name (n8 / name :op1 "integrin-linked"~e.38 :op2 "kinase"~e.34,39)
                                    :ARG1-of (m3 / mean-01
                                          :ARG2 (n11 / name :op1 "ILK"~e.41))))))
            :ARG1-of (d / describe-01
                  :ARG0 (p6 / publication
                        :ARG1-of (c / cite-01
                              :ARG2 (a5 / and :op1 "4"~e.44 :op2 "7"~e.46))))))

# ::tok ( 38 ) . Integrins also stimulate the p70 S6 @- kinase , which may promote cyclin D1 translation ( 39 ) . Finally , anchorage to the ECM is necessary for the down @-@ regulation of the Cdk 2 inhibitors p21 and p27 and , thus , the activation of cyclin E @-@ Cdk 2
# ::alignments 1-1.1.1.1.1 5-1.2.3 6-1.2 8-1.2.2.1.1 9-1.2.2.1.2 11-1.2.2.1.3 14-1.2.4.2 15-1.2.4 16-1.2.4.1.1.1.1 17-1.2.4.1.1.1.2 18-1.2.4.1 20-1.2.5.1.1.1 23-1.3.3 26-1.3.4 28-1.3.2.1.1.1 30-1.3 38-1.3.4.1.1.1.2 39-1.3.4.1.1.1.3 40-1.3.1.1.1 40-1.3.1.1.1.2 40-1.3.1.1.1.2.r 40-1.3.1.1.2 40-1.3.1.1.2.2 40-1.3.1.1.2.2.r 41-1.3.1.1.1.1.1 42-1.3.1.1 43-1.3.1.1.2.1.1 44-1.3.1.1 46-1.3.4 49-1.3.4.1 51-1.3.4.1.1.1.1 52-1.3.4.1.1.1.2 54-1.3.1.1.1.2.1.1.1 55-1.3.1.1.1.2.1.1.2
# ::id bel_pmid_1044_6041_18016
(m / multi-sentence
      :snt1 (d2 / describe-01
            :ARG0 (p / publication
                  :ARG1-of (c / cite-01 :ARG2 "38"~e.1)))
      :snt2 (s / stimulate-01~e.6
            :ARG0 (m2 / molecular-physical-entity
                  :name (n10 / name :op1 "integrin"))
            :ARG2 (e / enzyme
                  :name (n2 / name
                        :op1 "p70"~e.8
                        :op2 "S6"~e.9
                        :op3 "kinase"~e.11))
            :mod (a / also~e.5)
            :ARG0-of (p2 / promote-01~e.15
                  :ARG1 (t2 / translate-01~e.18
                        :ARG1 (p4 / protein
                              :name (n3 / name :op1 "cyclin"~e.16 :op2 "D1"~e.17)))
                  :mod (p3 / possible~e.14))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p5 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "39"~e.20))))
      :snt3 (n / need-01~e.30
            :ARG0 (d4 / downregulate-01
                  :ARG1 (a3 / and~e.42,44
                        :op1 (p6 / protein~e.40
                              :name (n6 / name :op1 "p21"~e.41)
                              :ARG0-of~e.40 (i / inhibit-01~e.40
                                    :ARG1 (e2 / enzyme
                                          :name (n7 / name :op1 "Cdk"~e.54 :op2 "2"~e.55))))
                        :op2 (p7 / protein~e.40
                              :name (n8 / name :op1 "p27"~e.43)
                              :ARG0-of~e.40 (i3 / inhibit-01~e.40
                                    :ARG1 e2))))
            :ARG1 (a2 / anchor-01
                  :ARG1 (m3 / molecular-physical-entity
                        :name (n11 / name :op1 "ECM"~e.28)))
            :time (f / final~e.23)
            :ARG0-of (c3 / cause-01~e.26,46
                  :ARG1 (a4 / activate-01~e.49
                        :ARG1 (e3 / enzyme
                              :name (n9 / name
                                    :op1 "cyclin"~e.51
                                    :op2 "E-Cdk"~e.38,52
                                    :op3 "2"~e.39))))))

# ::tok PTP @-@ PEST has a COOH @-@ terminal extension that anchors it to the cytosolic aspect of the endoplasmic reticulum . Integrin @-@ mediated adhesion activates calpain , a protease that cleaves this extension and allows the phosphatase to relocate to focal adhesions ( 21 ) .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 3-1.1 5-1.1.2.1.1.1 7-1.1.2.1.1.1 8-1.1.2 10-1.1.2.2 11-1.1.2.2.1 12-1.1.2.2.2.r 14-1.1.2.2.2.1 15-1.1.2.2.2 19-1.1.2.2.2.2 21-1.2.1.1.1.1.1 23-1.2.1.1 24-1.2.2.3.1.2.1.2 25-1.2 26-1.2.2.1.1 29-1.2.2 31-1.2.2.2 32-1.2.2.2.1.1 33-1.2.2.2.1 35-1.2.2.3 37-1.2.2.3.1.1.1.1 39-1.2.2.3.1 41-1.2.2.3.1.2.1.1 42-1.2.2.3.1.2.1.2 44-1.2.3.1.1.1
# ::id bel_pmid_1044_6041_18018
(m / multi-sentence
      :snt1 (h / have-03~e.3
            :ARG0 (e4 / enzyme
                  :name (n / name :op1 "PTP-PEST"~e.0,2))
            :ARG1 (e / extend-01~e.8
                  :mod (p2 / protein-segment
                        :name (n2 / name :op1 "COOH-terminus"~e.5,7))
                  :ARG0-of (a / anchor-01~e.10
                        :ARG1 e4~e.11
                        :location~e.12 (a2 / aspect~e.15
                              :mod (c / cytosol~e.14)
                              :part-of (r / reticulum~e.19
                                    :mod (e2 / endoplasm))))))
      :snt2 (a3 / activate-01~e.25
            :ARG0 (a4 / adhere-01
                  :ARG1-of (m2 / mediate-01~e.23
                        :ARG0 (m3 / molecular-physical-entity
                              :name (n5 / name :op1 "integrin"~e.21))))
            :ARG1 (p / protease~e.29
                  :name (n6 / name :op1 "calpain"~e.26)
                  :ARG0-of (c2 / cleave-01~e.31
                        :ARG1 (e5 / extend-01~e.33
                              :mod (t / this~e.32)))
                  :ARG0-of (a5 / allow-01~e.35
                        :ARG1 (r2 / relocate-01~e.39
                              :ARG1 (e3 / enzyme
                                    :name (n4 / name :op1 "phosphatase"~e.37))
                              :ARG2 (m4 / molecular-physical-entity
                                    :name (n3 / name :op1 "focal"~e.41 :op2 "adhesion"~e.24,42)))))
            :ARG1-of (d / describe-01
                  :ARG0 (p5 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "21"~e.44)))))

# ::tok Whereas FAK is phosphorylated on tyrosine upon assembly of focal adhesions , it becomes phosphorylated on serine and disassociates from Src and p130CAS during mitosis ( 14 ) . These events may loosen cell @-@ substrate contacts and allow cells to divide and move apart .
# ::alignments 0-1.1 1-1.1.1.1.2.1.1 3-1.1.1 5-1.1.1.1.1.1 7-1.1.1.2 8-1.1.1.2.1.r 9-1.1.1.2.1.1.1 10-1.1.1.2.1.1.2 13-1.1.2.1 14-1.1.2.1.1 15-1.1.2.1.1.1.r 16-1.1.2.1.1.1.1.1 17-1.1.2 18-1.1.2.2 19-1.1.2.2.2.r 20-1.1.2.2.2.1.1.1 22-1.1.2.2.2.2.1.1 23-1.1.2.2.3.r 24-1.1.2.2.3 26-1.1.3.1.1.1 29-1.2.1.1.1.1 30-1.2.1.1.1 31-1.2.1 32-1.2.1.1 33-1.2.1.1.2.1 35-1.2.1.1.2.2 36-1.2.1.1.2 37-1.2 38-1.2.2 39-1.2.2.2.1.1 41-1.2.2.2.1 42-1.2.2.2 43-1.2.2.2.2 44-1.2.2.2.2.2
# ::id bel_pmid_1044_6041_18060
(m / multi-sentence
      :snt1 (c / contrast-01~e.0
            :ARG1 (p / phosphorylate-01~e.3
                  :ARG1 (a2 / amino-acid
                        :name (n3 / name :op1 "tyrosine"~e.5)
                        :part-of (p2 / protein
                              :name (n2 / name :op1 "FAK"~e.1)))
                  :time (a3 / assemble~e.7
                        :mod~e.8 (m4 / molecular-physical-entity
                              :name (n6 / name :op1 "focal"~e.9 :op2 "adhesion"~e.10))))
            :ARG2 (a6 / and~e.17
                  :op1 (b / become-01~e.13
                        :ARG1 (p3 / phosphorylate-01~e.14
                              :ARG1~e.15 (a / amino-acid
                                    :name (n / name :op1 "serine"~e.16)
                                    :part-of p2)))
                  :op2 (d2 / disassociate-01~e.18
                        :ARG1 p2
                        :ARG2~e.19 (a5 / and
                              :op1 (p4 / protein
                                    :name (n4 / name :op1 "Src"~e.20))
                              :op2 (p5 / protein
                                    :name (n5 / name :op1 "p130CAS"~e.22)))
                        :time~e.23 (m2 / mitosis~e.24)))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p6 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "14"~e.26))))
      :snt2 (a7 / and~e.37
            :op1 (p7 / possible~e.31
                  :domain (l / loosen-01~e.32
                        :ARG0 (e / event~e.30
                              :mod (t / this~e.29))
                        :ARG1 (c3 / contact-01~e.36
                              :ARG0 (c4 / cell~e.33)
                              :ARG1 (s / substrate~e.35))))
            :op2 (a8 / allow-01~e.38
                  :ARG0 e
                  :ARG1 (a9 / and~e.42
                        :op1 (d4 / divide-02~e.41
                              :ARG0 (c5 / cell~e.39))
                        :op2 (m3 / move-01~e.43
                              :ARG1 c5
                              :mod (a10 / apart~e.44))))))

# ::tok Certain integrins may regulate proliferation by additional mechanisms . For example , the a6b1 integrin may in part promote exit from the cell cycle in myoblasts , because the cytoplasmic domain of a6 inhibits paxillin signaling ( 44 ) .
# ::alignments 0-1.2.1.1.2 2-1.2 3-1.2.1 4-1.2.1.2 5-1.2.1.3.r 6-1.2.1.3.1 7-1.2.1.3 9-1.1.3 10-1.1.3 13-1.1.2.1.1.1.1 14-1.1.2.1.1.1.2 14-1.2.1.1.1.1 15-1.1.2 17-1.1.2.1.3 18-1.1.2.1 19-1.1.2.1.2 20-1.1.2.1.2.1.r 22-1.1.2.1.2.1.1 23-1.1.2.1.2.1 27-1.1 29-1.1.1.1.1 30-1.1.1.1 33-1.1.1 34-1.1.1.2.1.1.1 35-1.1.1.2 37-1.1.4.1.1.1
# ::id bel_pmid_1044_6041_18334
(m / multi-sentence
      :snt2 (c2 / cause-01~e.27
            :ARG0 (i3 / inhibit-01~e.33
                  :ARG0 (d2 / domain~e.30
                        :mod (c5 / cytoplasm~e.29)
                        :part-of (m5 / molecular-physical-entity
                              :name (n2 / name :op1 "a6b1"~e.13 :op2 "integrin"~e.14)))
                  :ARG1 (s / signal-01~e.35
                        :ARG0 (p5 / protein
                              :name (n3 / name :op1 "paxillin"~e.34))))
            :ARG1 (p / possible~e.15
                  :domain (p3 / promote-01~e.18
                        :ARG0 m5
                        :ARG1 (e2 / exit-01~e.19
                              :ARG1~e.20 (c3 / cycle~e.23
                                    :mod (c4 / cell~e.22)
                                    :location (m3 / myoblast)))
                        :mod (p4 / part~e.17)))
            :ARG0-of (e / exemplify-01~e.9,10)
            :ARG1-of (d3 / describe-01
                  :ARG0 (p7 / publication
                        :ARG1-of (c6 / cite-01 :ARG2 "44"~e.37))))
      :snt1 (p8 / possible~e.2
            :domain (r / regulate-01~e.3
                  :ARG0 (m4 / molecular-physical-entity
                        :name (n / name :op1 "integrin"~e.14)
                        :mod (c / certain~e.0))
                  :ARG1 (p2 / proliferate-01~e.4)
                  :instrument~e.5 (m2 / mechanism~e.7
                        :mod (a / additional~e.6)))))

# ::tok For example , avb3 associates with the PDGF receptor , and fibroblasts show greater proliferation in response to PDGFb when adhering to the avb3 ligand vitronectin than when they adhere to the b1 integrin ligand collagen ( 26 ) .
# ::alignments 0-1.3 1-1.3 3-1.1.1.1.1 4-1.1 5-1.1.2.r 7-1.1.2.1.1 8-1.1.2.1.2 10-1 11-1.2.1.1.1 12-1.2 13-1.2.2.1 13-1.2.2.1.1 13-1.2.2.1.1.r 14-1.2.2 15-1.2.3.r 16-1.2.3 17-1.2.3.1.r 18-1.2.3.1.1.1 19-1.2.4.r 20-1.2.4 20-1.2.4.3 23-1.2.4.2.2.1.1 24-1.2.4.2.2 25-1.2.4.2.1.1 26-1.2.4.3.r 27-1.2.4.r 29-1.2.4 29-1.2.4.3 30-1.2.4.3.2.r 32-1.2.4.3.2.2.1.1 33-1.2.4.3.2.2.1.2 34-1.2.4.3.2.2 35-1.2.4.3.2.1.1 37-1.4.1.1.1
# ::id bel_pmid_1044_6041_18348
(a / and~e.10
      :op1 (a2 / associate-01~e.4
            :ARG1 (m2 / molecular-physical-entity
                  :name (n9 / name :op1 "avb3"~e.3))
            :ARG2~e.5 (m3 / molecular-physical-entity
                  :name (n5 / name :op1 "PDGF"~e.7 :op2 "receptor"~e.8)))
      :op2 (s / show-01~e.12
            :ARG0 (c / cell
                  :name (n2 / name :op1 "fibroblast"~e.11))
            :ARG1 (p / proliferate-01~e.14
                  :mod (g2 / great~e.13
                        :degree~e.13 (m / more~e.13)))
            :ARG2-of~e.15 (r2 / respond-01~e.16
                  :ARG1~e.17 (p2 / protein
                        :name (n3 / name :op1 "PDGFb"~e.18)))
            :time~e.19,27 (a4 / adhere-01~e.20,29
                  :ARG1 p2
                  :ARG2 (p3 / protein
                        :name (n6 / name :op1 "vitronectin"~e.25)
                        :mod (l / ligand~e.24
                              :name (n7 / name :op1 "avb3"~e.23)))
                  :compared-to~e.26 (a5 / adhere-01~e.20,29
                        :ARG1 p2
                        :ARG2~e.30 (p5 / protein
                              :name (n4 / name :op1 "collagen"~e.35)
                              :mod (l2 / ligand~e.34
                                    :name (n8 / name :op1 "b1"~e.32 :op2 "integrin"~e.33))))))
      :ARG0-of (e / exemplify-01~e.0,1)
      :ARG1-of (d / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "26"~e.37))))

# ::tok In addition to activating FAK , some b1 and av integrins also activate the tyrosine kinase Fyn and , through it , the adapter protein Shc ( 4 ) .
# ::alignments 0-1.2 1-1 1-1.2 1-1.2.r 3-1.1 3-1.2.1 3-1.2.3 4-1.1.1.1.1 6-1.2.1.1.2 7-1.2.1.1.1.1 8-1.2 9-1.2.2.1.1.1 11-1.2.1.3 12-1.2.1 12-1.2.2 14-1.2.1.2.1.1 15-1.2.1.2.1.2 16-1.2.1.2.1.3 17-1.2 23-1.2.3.1.2 24-1.1.1 24-1.2.3.1 25-1.2.3.1.1.1 27-1.3.1.1.1
# ::id bel_pmid_1044_6041_18586
(a / and~e.1
      :op1 (a2 / activate-01~e.3
            :ARG1 (p / protein~e.24
                  :name (n / name :op1 "FAK"~e.4)))
      :op2~e.1 (a3 / and~e.0,1,8,17
            :op1 (a4 / activate-01~e.3,12
                  :ARG0 (i / integrin
                        :name (n2 / name :op1 "b1"~e.7)
                        :quant (s / some~e.6))
                  :ARG1 (e / enzyme
                        :name (n3 / name
                              :op1 "tyrosine"~e.14
                              :op2 "kinase"~e.15
                              :op3 "Fyn"~e.16))
                  :mod (a5 / also~e.11))
            :op2 (a6 / activate-01~e.12
                  :ARG0 (i2 / integrin
                        :name (n4 / name :op1 "av"~e.9)
                        :quant s)
                  :ARG1 e
                  :mod a5)
            :ARG0-of (a7 / activate-01~e.3
                  :ARG1 (p2 / protein~e.24
                        :name (n5 / name :op1 "Shc"~e.25)
                        :mod (a8 / adapter~e.23))))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c / cite-01 :ARG2 "4"~e.27))))

# ::tok Rac promotes cell cycle progression , an effect that correlates with its ability to organize the cytoskeleton and promote spreading , rather than with its ability to activate MAP kinases ( 63 ) .
# ::alignments 0-1.1.1.1 1-1 2-1.2.1.1 3-1.2.1 4-1.2 7-1.3 9-1.3.1 10-1.3.1.1.r 11-1.3.1.1.1 11-1.3.1.1.1.r 12-1.3.1.1 13-1.3.1.1.2.r 14-1.3.1.1.2.1 16-1.3.1.1.2.1.2 17-1.3.1.1.2 18-1.3.1.1.2.2 19-1.3.1.1.2.2.1 24-1.3.1.1.3.1.1 24-1.3.1.1.3.1.1.r 25-1.3.1.1.3.1 27-1.3.1.1.3.1.2 28-1.3.1.1.3.1.2.2.1.1 29-1.3.1.1.3.1.2.2.1.2 31-1.4.1.1.1
# ::id bel_pmid_1044_6041_20870
(p / promote-01~e.1
      :ARG0 (e / enzyme
            :name (n / name :op1 "Rac"~e.0))
      :ARG1 (p2 / progress-01~e.4
            :ARG1 (c / cycle~e.3
                  :mod (c2 / cell~e.2)))
      :ARG1-of (e2 / effect-01~e.7
            :ARG1-of (c3 / correlate-01~e.9
                  :ARG2~e.10 (c6 / capable-01~e.12
                        :ARG1~e.11 e~e.11
                        :ARG2~e.13 (a4 / and~e.17
                              :op1 (o / organize-01~e.14
                                    :ARG0 e
                                    :ARG1 (c4 / cytoskeleton~e.16))
                              :op2 (p3 / promote-01~e.18
                                    :ARG1 (s / spread-01~e.19)))
                        :ARG1-of (i / instead-of-91
                              :ARG2 (c7 / capable-01~e.25
                                    :ARG1~e.24 e~e.24
                                    :ARG2 (a3 / activate-01~e.27
                                          :ARG0 e
                                          :ARG1 (e3 / enzyme
                                                :name (n2 / name :op1 "MAP"~e.28 :op2 "kinases"~e.29))))))))
      :ARG1-of (d / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c5 / cite-01 :ARG2 "63"~e.31))))

# ::tok Yes and Lck are known to be enriched in rafts and may mediate the activation of Shc when Fyn is not expressed .
# ::alignments 0-1.1.1.1.1.1.1 2-1.1.1.1.2.1.1 4-1.1 7-1.1.1 8-1.1.1.2.r 9-1.1.1.2 10-1 11-1.2 12-1.2.1 14-1.2.1.2 15-1.2.1.2.1.r 16-1.2.1.2.1.1.1 17-1.2.1.3.r 18-1.2.1.3.2.1.1 20-1.2.1.3.1 20-1.2.1.3.1.r 21-1.2.1.3
# ::id bel_pmid_1044_6041_21282
(a2 / and~e.10
      :op1 (k / know-01~e.4
            :ARG1 (e3 / enrich-01~e.7
                  :ARG1 (a / and
                        :op1 (e / enzyme
                              :name (n / name :op1 "Yes"~e.0))
                        :op2 (e2 / enzyme
                              :name (n2 / name :op1 "Lck"~e.2)))
                  :ARG2~e.8 (r / raft~e.9)))
      :op2 (p / possible~e.11
            :domain (m / mediate-01~e.12
                  :ARG0 a
                  :ARG1 (a3 / activate-01~e.14
                        :ARG1~e.15 (p2 / protein
                              :name (n3 / name :op1 "Shc"~e.16)))
                  :time~e.17 (e4 / express-03~e.21
                        :polarity~e.20 "-"~e.20
                        :ARG2 (e5 / enzyme
                              :name (n4 / name :op1 "Fyn"~e.18))))))

# ::tok Integrin signaling may be needed for the transcription of cyclin D1 , because the cyclin D1 promoter is coordinately regulated by JNK and ERK ( 37 ) ( Fig . 4 ) .
# ::alignments 0-1.2.1.2.1.1.1 1-1.2.1.2 2-1.2 3-1.2.1.r 4-1.2.1 5-1.2.1.1.r 7-1.2.1.1 8-1.2.1.1.1.r 9-1.2.1.1.1.1.1 10-1.2.1.1.1.1.2 12-1 14-1.2.1.1.1.1.1 15-1.2.1.1.1.1.2 17-1.2.1.r 18-1.1.3 19-1.1 20-1.1.1.r 21-1.1.1.1.1.1 22-1.1.1 23-1.1.1.2.1.1 25-1.3.1.1.1 30-1.4.1.1
# ::id bel_pmid_1044_6041_21342
(c / cause-01~e.12
      :ARG0 (r / regulate-01~e.19
            :ARG0~e.20 (a / and~e.22
                  :op1 (e2 / enzyme
                        :name (n4 / name :op1 "JNK"~e.21))
                  :op2 (e3 / enzyme
                        :name (n5 / name :op1 "ERK"~e.23)))
            :ARG1 (p2 / promote-01
                  :ARG1 (p / protein
                        :name (n3 / name :op1 "cyclin"~e.9,14 :op2 "D1"~e.10,15)))
            :manner (c2 / coordinate-01~e.18))
      :ARG1 (p4 / possible~e.2
            :domain~e.3,17 (n2 / need-01~e.4
                  :ARG0~e.5 (t / transcribe-01~e.7
                        :ARG1~e.8 p)
                  :ARG1 (s / signal-01~e.1
                        :ARG0 (m / molecular-physical-entity
                              :name (n / name :op1 "integrin"~e.0)))))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "37"~e.25)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4"~e.30)))

# ::tok Activated JNK enters the nucleus and phosphorylates the transcription factor c @-@ Jun , which combines with c @-@ Fos to form the AP @-@ 1 transcription factor complex .
# ::alignments 0-1.1.1.2 1-1.1.1.1.1 2-1.1 4-1.1.2 5-1 6-1.2 8-1.2.1 8-1.2.1.2 8-1.2.1.2.r 9-1.2.1.3 10-1.2.1.1.1 12-1.2.1.1.1 15-1.2.1.4 16-1.2.1.4.1.r 17-1.2.1.4.1.1.1 19-1.2.1.4.1.1.1 23-1.2.1.4.2.2.1.1 25-1.2.1.4.2.2.1.1 26-1.2.1.4.2.2 26-1.2.1.4.2.2.2 26-1.2.1.4.2.2.2.r 27-1.2.1.4.2.1 28-1.2.1.4.2
# ::id bel_pmid_1044_6041_21364
(a / and~e.5
      :op1 (e / enter-01~e.2
            :ARG0 (e2 / enzyme
                  :name (n / name :op1 "JNK"~e.1)
                  :ARG1-of (a2 / activate-01~e.0))
            :ARG1 (n2 / nucleus~e.4))
      :op2 (p / phosphorylate-01~e.6
            :ARG1 (p2 / protein~e.8
                  :name (n3 / name :op1 "c-Jun"~e.10,12)
                  :ARG1-of~e.8 (t / transcribe-01~e.8)
                  :mod (f / factor~e.9)
                  :ARG1-of (c / combine-01~e.15
                        :ARG2~e.16 (p3 / protein
                              :name (n4 / name :op1 "c-Fos"~e.17,19))
                        :ARG3 (c2 / complex~e.28
                              :mod (f2 / factor~e.27)
                              :mod (p4 / protein~e.26
                                    :name (n5 / name :op1 "AP-1"~e.23,25)
                                    :ARG1-of~e.26 (t2 / transcribe-01~e.26)))))
            :ARG2 e2))

# ::tok Several integrins have been found to associate laterally with the oligomeric membrane protein caveolin @-@ 1 , at least in primary cells ( 4 , 5 ) . Although the biochemical nature of this interaction is not known , inhibiting caveolin expression suppresses the formation of focal adhesions and integrin signaling ( 4 , 5 ) .
# ::alignments 0-1.1.1.1.2 4-1.1 6-1.1.1 7-1.1.1.3 7-1.1.1.3.r 11-1.1.1.2.2 12-1.1.1.2 12-1.2.1.1.1 13-1.1.1.2.1.1 15-1.1.1.2.1.1 17-1.1.1.4.2 18-1.1.1.4.2 20-1.1.1.4.1 21-1.1.1.4 23-1.1.2.1.1.1.1 25-1.1.2.1.1.1.2 28-1.2 30-1.2.2.2.1 31-1.2.2.2 32-1.2.2.2.2.r 33-1.2.2.2.2.1 34-1.2.2.2.2 36-1.2.2.1 36-1.2.2.1.r 37-1.2.2 39-1.2.1 40-1.2.1.1.1.1.1 41-1.2.1.1 42-1.2.1.2 44-1.2.1.2.1 45-1.2.1.2.1.1.r 46-1.2.1.2.1.1.1.1.1 47-1.2.1.2.1.1.1.1.2 48-1.2.1.2.1.1 49-1.1.1.1.1.1 50-1.2.1.2.1.1.2 52-1.2.3.1.1.1.1 54-1.1.2.1.1.1.2 54-1.2.3.1.1.1.2
# ::id bel_pmid_1044_6041_22694
(m / multi-sentence
      :snt1 (f / find-01~e.4
            :ARG1 (a2 / associate-01~e.6
                  :ARG1 (m3 / molecular-physical-entity
                        :name (n3 / name :op1 "integrin"~e.49)
                        :quant (s4 / several~e.0))
                  :ARG2 (p / protein~e.12
                        :name (n / name :op1 "caveolin-1"~e.13,15)
                        :mod (m2 / membrane~e.11
                              :mod (o / oligomer)))
                  :manner~e.7 (l / lateral~e.7)
                  :location (c / cell~e.21
                        :mod (p2 / primary~e.20)
                        :mod (a / at-least~e.17,18)))
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c2 / cite-01
                              :ARG2 (a3 / and :op1 "4"~e.23 :op2 "5"~e.25,54)))))
      :snt2 (h / have-concession-91~e.28
            :ARG1 (i3 / inhibit-01~e.39
                  :ARG1 (e / express-03~e.41
                        :ARG2 (p5 / protein~e.12
                              :name (n4 / name :op1 "caveolin"~e.40)))
                  :ARG0-of (s2 / suppress-01~e.42
                        :ARG1 (f2 / form-01~e.44
                              :ARG1~e.45 (a4 / and~e.48
                                    :op1 (m4 / molecular-physical-entity
                                          :name (n5 / name :op1 "focal"~e.46 :op2 "adhesion"~e.47))
                                    :op2 (s3 / signal-01~e.50
                                          :ARG0 (i4 / integrin))))))
            :ARG2 (k / know-01~e.37
                  :polarity~e.36 "-"~e.36
                  :ARG1 (n2 / nature~e.31
                        :mod (b / biochemistry~e.30)
                        :poss~e.32 (i2 / interact-01~e.34
                              :mod (t / this~e.33))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p4 / publication
                        :ARG1-of (c3 / cite-01
                              :ARG2 (a6 / and :op1 "4"~e.52 :op2 "5"~e.54))))))

# ::tok IAP , an immunoglobulin superfamily transmembrane protein , cooperates with b3 integrins in binding thrombospondin to cells , and it also activates an inhibitory trimeric guanine nucleotide @- binding protein ( 29 ) .
# ::alignments 0-1.1.1.2.1 3-1.1.1.1.1 4-1.1.1.1.2 5-1.1.1.1.3 6-1.1.1 8-1.1 10-1.1.2.1.1 13-1.1.3 14-1.1.3.1.1.1 16-1.1.3.2 18-1 19-1.2.1 20-1.2.3 21-1.2 24-1.2.2.2 25-1.2.2.1.1 26-1.2.2.1.2 28-1.1.3 28-1.2.2.1.2 29-1.1.3.1 29-1.2.2 31-1.3.1.1.1
# ::id bel_pmid_1044_6041_24492
(a / and~e.18
      :op1 (c / cooperate-01~e.8
            :ARG0 (p6 / protein~e.6
                  :name (n5 / name
                        :op1 "immunoglobulin"~e.3
                        :op2 "superfamily"~e.4
                        :op3 "transmembrane"~e.5)
                  :ARG1-of (m / mean-01
                        :ARG2 (i / IAP~e.0)))
            :ARG1 (i2 / integrin
                  :name (n2 / name :op1 "b3"~e.10))
            :ARG2 (b / bind-01~e.13,28
                  :ARG1 (p3 / protein~e.29
                        :name (n3 / name :op1 "thrombospondin"~e.14))
                  :ARG2 (c2 / cell~e.16)))
      :op2 (a2 / activate-01~e.21
            :ARG0 p6~e.19
            :ARG1 (p4 / protein~e.29
                  :name (n4 / name :op1 "guanine"~e.25 :op2 "nucleotide-binding"~e.26,28)
                  :mod (t2 / trimeric~e.24)
                  :ARG0-of (i3 / inhibit-01))
            :mod (a3 / also~e.20))
      :ARG1-of (d / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "29"~e.31))))

# ::tok The FAK and Shc pathways are regulated both positively and negatively by tyrosine phosphatases . Integrin @-@ mediated activation of ERK is suppressed in cells that lack the re @- ceptor @-@ type protein tyrosine phosphatase a or the cytosolic phosphatase SHP @-@ 2 ( 19 ) . These enzymes dephosphorylate the negative regulatory site in Src @-@ family kinases and thus , presumably , amplify both FAK and Shc signaling .
# ::alignments 1-1.3.1.1.1.1.1 2-1.3 2-1.3.1.1 3-1.3.1.1.2.1.1 4-1.2.4.1.1.1.1 4-1.2.4.1.1.2.1 4-1.3.1.1.1 4-1.3.1.1.2 12-1.3.1.2.1.1 13-1.3.1.2.1.2 15-1.1.1.2.1.1.1 17-1.1.1.2 18-1.1.1 19-1.1.1.1.r 20-1.1.1.1.1.1 22-1.1 23-1.1.2.r 24-1.1.2 26-1.1.2.1 32-1.1.2.1.1.1.1 33-1.1.2.1.1.1.2.1.1 34-1.1.2.1.1.1.2.1.2 35-1.1.2.1.1.1.2.1.3 36-1.1.2.1.1.1.2.1.4 37-1.1.2.1.1 39-1.1.2.1.1.2.2 40-1.1.2.1.1.2.1.1 41-1.1.2.1.1.2.1.2 43-1.1.2.1.1.2.1.2 45-1.1.3.1.1.1 48-1.2.2.1 49-1.2.2 50-1.2 54-1.2.1 55-1.2.3.r 56-1.2.3.1.1.1.1 58-1.2.3.1 59-1.2.3 61-1.2.4 63-1.2.4.2 65-1.2.4.1 67-1.2.4.1.1.1.1.1.1 68-1.2.4.1.1 69-1.2.4.1.1.2.1.1.1 70-1.2.4.1.1.1 70-1.2.4.1.1.2
# ::id bel_pmid_1044_6041_24730
(m / multi-sentence
      :snt2 (s / suppress-01~e.22
            :ARG1 (a3 / activate-01~e.18
                  :ARG1~e.19 (e / enzyme
                        :name (n / name :op1 "ERK"~e.20))
                  :ARG1-of (m2 / mediate-01~e.17
                        :ARG0 (m3 / molecular-physical-entity
                              :name (n5 / name :op1 "integrin"~e.15))))
            :location~e.23 (c / cell~e.24
                  :ARG0-of (l / lack-01~e.26
                        :ARG1 (o / or~e.37
                              :op1 (r2 / receptor
                                    :mod (t / type~e.32)
                                    :domain (e5 / enzyme
                                          :name (n8 / name
                                                :op1 "protein"~e.33
                                                :op2 "tyrosine"~e.34
                                                :op3 "phosphatase"~e.35
                                                :op4 "a"~e.36)))
                              :op2 (e4 / enzyme
                                    :name (n7 / name :op1 "phosphatase"~e.40 :op2 "SHP-2"~e.41,43)
                                    :mod (c2 / cytosol~e.39)))))
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "19"~e.45))))
      :snt3 (d2 / dephosphorylate-01~e.50
            :ARG1 (s2 / site~e.54
                  :ARG1-of (d3 / downregulate-01))
            :ARG2 (e3 / enzyme~e.49
                  :mod (t2 / this~e.48))
            :ARG3~e.55 (k / kinase~e.59
                  :part-of (f / family~e.58
                        :mod (p3 / protein
                              :name (n6 / name :op1 "Src"~e.56))))
            :ARG0-of (c4 / cause-01~e.61
                  :ARG1 (a4 / amplify-01~e.65
                        :ARG1 (a2 / and~e.68
                              :op1 (s3 / signal-01~e.70
                                    :ARG0 (p6 / pathway~e.4
                                          :name (n9 / name :op1 "FAK"~e.67)))
                              :op2 (s4 / signal-01~e.70
                                    :ARG0 (p7 / pathway~e.4
                                          :name (n10 / name :op1 "Shc"~e.69)))))
                  :ARG1-of (p5 / presume-01~e.63)))
      :snt1 (a6 / and~e.2
            :op1 (u / upregulate-01
                  :ARG1 (a / and~e.2
                        :op1 (p / pathway~e.4
                              :name (n2 / name :op1 "FAK"~e.1))
                        :op2 (p2 / pathway~e.4
                              :name (n3 / name :op1 "Shc"~e.3)))
                  :ARG2 (e2 / enzyme
                        :name (n4 / name :op1 "tyrosine"~e.12 :op2 "phosphatases"~e.13)))
            :op2 (d4 / downregulate-01
                  :ARG1 a
                  :ARG2 e2)))

# ::tok Two cytoplasmic protein tyrosine phosphatases , PTP @-@ PEST and PTP @-@ 1B , target p130CAS and may specifically inhibit some of the signals downstream of FAK ( 20 ) .
# ::alignments 0-1.1.1.1 1-1.1.1.3 2-1.1.1.2.1 3-1.1.1.2.2 4-1.1.1.2.3 6-1.1.1.4.1.1.1 6-1.1.1.4.2.1.1 8-1.1.1.4.1.1.1 9-1.1.1.4 10-1.1.1.4.1.1.1 10-1.1.1.4.2.1.1 12-1.1.1.4.2.1.1 14-1.1 15-1.1.2.1.1 16-1 17-1.2 18-1.2.1.2 19-1.2.1 20-1.2.1.1.1.1 23-1.2.1.1 24-1.2.1.1.2.2 26-1.2.1.1.2.1.1.1 28-1.3.1.1.1
# ::id bel_pmid_1044_6041_39480
(a / and~e.16
      :op1 (t / target-01~e.14
            :ARG0 (e / enzyme
                  :quant "2"~e.0
                  :name (n / name
                        :op1 "protein"~e.2
                        :op2 "tyrosine"~e.3
                        :op3 "phosphatases"~e.4)
                  :mod (c / cytoplasm~e.1)
                  :example (a2 / and~e.9
                        :op1 (e2 / enzyme
                              :name (n2 / name :op1 "PTP-PEST"~e.6,8,10))
                        :op2 (e3 / enzyme
                              :name (n3 / name :op1 "PTP-1B"~e.6,10,12))))
            :ARG1 (p / protein
                  :name (n4 / name :op1 "p130CAS"~e.15)))
      :op2 (p2 / possible~e.17
            :domain (i / inhibit-01~e.19
                  :ARG1 (s / signal-01~e.23
                        :ARG2-of (i2 / include-91
                              :ARG3 (s2 / some~e.20))
                        :location (r / relative-position
                              :op1 (p3 / pathway
                                    :name (n5 / name :op1 "FAK"~e.26))
                              :direction (d2 / downstream~e.24)))
                  :manner (s3 / specific~e.18)))
      :ARG1-of (d3 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "20"~e.28))))

# ::tok Stat3 is activated by phosphorylation on Tyr @-@ 705 , which leads to dimer formation , nuclear translocation , and regulation of gene expression .
# ::alignments 0-1.2.1.1 2-1 3-1.1.r 4-1.1 8-1.1.1.1 11-1.3 12-1.3.1.r 13-1.3.1.1.1.1.1 14-1.3.1.1 16-1.3.1.2.1 17-1.3.1.2 19-1.3.1 20-1.3.1.3 21-1.3.1.3.1.r 22-1.3.1.3.1.1 23-1.3.1.3.1
# ::id bel_pmid_1044_6219_2808
(a / activate-01~e.2
      :ARG0~e.3 (p3 / phosphorylate-01~e.4
            :ARG1 (a2 / amino-acid
                  :mod "705"~e.8
                  :name (n2 / name :op1 "tyrosine")))
      :ARG1 (p2 / protein
            :name (n / name :op1 "Stat3"~e.0))
      :ARG0-of (l / lead-01~e.11
            :ARG4~e.12 (a3 / and~e.19
                  :op1 (f / form-01~e.14
                        :ARG1 (m / macro-molecular-complex
                              :name (n3 / name :op1 "dimer"~e.13)))
                  :op2 (t / translocate-00~e.17
                        :mod (n4 / nucleus~e.16))
                  :op3 (r / regulate-01~e.20
                        :ARG1~e.21 (e / express-03~e.23
                              :ARG2 (g / gene~e.22))))))

# ::tok Here , we report that Stat3 was specifically associated with PKC delta in vivo in an IL @-@ 6 @-@ dependent manner in several cell types . Furthermore , Stat3 was phosphorylated by PKC delta in vivo on Ser @-@ 727,
# ::alignments 0-1.1.3 2-1.1.1 3-1.1 4-1.1.2.r 5-1.1.2.1.1.1 7-1.1.2.3 8-1.1.2 9-1.1.2.2.r 10-1.1.2.2.1.1 11-1.1.2.2.1.2 12-1.1.2.4 13-1.1.2.4 14-1.1.2.4 14-1.1.2.6.r 16-1.1.2.6.1.1.1 18-1.1.2.6.1.1.1 20-1.1.2.6 21-1.1.2.3.r 21-1.1.2.4.r 22-1.1.2.4 22-1.1.2.5.r 23-1.1.2.5.2 24-1.1.2.5.1 25-1.1.2.5 29-1.1.2.1.1.1 29-1.2.1.1.3.1.1 31-1.2.1 33-1.1.2.2.1.1 34-1.1.2.2.1.2 35-1.1.2.4 35-1.2.1.2.2 36-1.1.2.4 36-1.2.1.2.2
# ::id bel_pmid_1044_6219_5996
(m / multi-sentence
      :snt1 (r / report-01~e.3
            :ARG0 (w / we~e.2)
            :ARG1~e.4 (a / associate-01~e.8
                  :ARG1 (p / protein
                        :name (n / name :op1 "Stat3"~e.5,29))
                  :ARG2~e.9 (e / enzyme
                        :name (n2 / name :op1 "PKC"~e.10,33 :op2 "delta"~e.11,34))
                  :manner~e.21 (s / specific~e.7)
                  :manner~e.21 (i / in-vivo~e.12,13,14,22,35,36)
                  :location~e.22 (t / type~e.25
                        :mod (c / cell~e.24)
                        :quant (s2 / several~e.23))
                  :manner~e.14 (d / depend-01~e.20
                        :ARG1 (p4 / protein
                              :name (n6 / name :op1 "IL-6"~e.16,18))))
            :location (h / here~e.0))
      :snt2 (a3 / and
            :op2 (p2 / phosphorylate-01~e.31
                  :ARG1 (a2 / amino-acid
                        :mod "727"
                        :name (n5 / name :op1 "serine")
                        :part-of (p3 / protein
                              :name (n3 / name :op1 "Stat3"~e.29)))
                  :ARG2 (e2 / enzyme
                        :name (n4 / name :op1 "PKA" :op2 "delta")
                        :manner (i2 / in-vivo~e.35,36)))))

# ::tok Finally , we showed that the phosphorylation of Stat3 by PKC delta led to a negative regulation of Stat3 DNA binding and transcriptional activity .
# ::alignments 0-1.3 2-1.1 3-1 4-1.2.r 6-1.2.1 7-1.2.1.1.r 8-1.2.1.1.1.1 9-1.2.1.2.r 10-1.2.1.2.1.1 11-1.2.1.2.1.2 12-1.2 18-1.2.1.1.1.1 18-1.2.2.1.1.1.1 19-1.2.2.1.1.2.1 20-1.2.2.1.1.2 21-1.2.2
# ::id bel_pmid_1044_6219_5998
(s / show-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1~e.4 (l / lead-01~e.12
            :ARG0 (p2 / phosphorylate-01~e.6
                  :ARG1~e.7 (p3 / protein
                        :name (n / name :op1 "Stat3"~e.8,18))
                  :ARG2~e.9 (e / enzyme
                        :name (n2 / name :op1 "PKC"~e.10 :op2 "delta"~e.11)))
            :ARG4 (a / and~e.21
                  :op1 (d / downregulate-01
                        :ARG1 (p4 / protein
                              :name (n3 / name :op1 "Stat3"~e.18)
                              :ARG0-of (b / bind-01~e.20
                                    :ARG1 (d2 / DNA~e.19))))
                  :op2 (a2 / act-01
                        :ARG1 (t / transcribe-01))))
      :time (f / final~e.0))

# ::tok Here , we report that Stat3 was specifically associated with PKC delta in vivo in an IL @-@ 6 @-@ dependent manner in several cell types .
# ::alignments 0-1.3 2-1.1 3-1 4-1.2.r 5-1.2.1.1.1 7-1.2.4 8-1.2 9-1.2.2.r 10-1.2.2.1.1 11-1.2.2.1.2 12-1.2.3 13-1.2.3 14-1.2.3 14-1.2.6.r 16-1.2.6.1.1.1 18-1.2.6.1.1.1 20-1.2.6 21-1.2.3.r 21-1.2.4.r 22-1.2.3 22-1.2.5.r 23-1.2.5.1.1 24-1.2.5.1 25-1.2.5
# ::id bel_pmid_1044_6219_7272
(r / report-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1~e.4 (a / associate-01~e.8
            :ARG1 (p / protein
                  :name (n / name :op1 "Stat3"~e.5))
            :ARG2~e.9 (e / enzyme
                  :name (n2 / name :op1 "PKC"~e.10 :op2 "delta"~e.11))
            :manner~e.21 (i / in-vivo~e.12,13,14,22)
            :manner~e.21 (s / specific~e.7)
            :location~e.22 (t / type~e.25
                  :mod (c / cell~e.24
                        :quant (s2 / several~e.23)))
            :manner~e.14 (d / depend-01~e.20
                  :ARG1 (p2 / protein
                        :name (n3 / name :op1 "IL-6"~e.16,18))))
      :location (h / here~e.0))

# ::tok interleukin @-@ 17 induces time @-@ dependent stimulation of tyrosine phosphorylation of JAK 1 , 2 and 3 , Tyk 2 and STAT 1 , 2, 3 and 4 within 0.5 to 30 min
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1 4-1.2.1.9.1 4-1.2.1.9.2 4-1.2.2.1 6-1.2.2 7-1.2 8-1.2.1.r 9-1.2.1.1.1.1.1 9-1.2.1.2.1.1.1 9-1.2.1.3.1.1.1 9-1.2.1.4.1.1.1 9-1.2.1.5.1.1.1 9-1.2.1.6.1.1.1 9-1.2.1.7.1.1.1 9-1.2.1.8.1.1.1 10-1.2.1.1 10-1.2.1.2 10-1.2.1.3 10-1.2.1.4 10-1.2.1.5 10-1.2.1.6 10-1.2.1.7 10-1.2.1.8 11-1.2.1.1.1.r 12-1.2.1.1.1.2.1.1 13-1.2.1.1.1.2.1.2 15-1.2.1.2.1.2.1.2 15-1.2.1.6.1.2.1.2 16-1.2.1 17-1.2.1.3.1.2.1.2 17-1.2.1.7.1.2.1.2 19-1.2.1.4.1.2.1.1 20-1.2.1.4.1.2.1.2 21-1.2.1 22-1.2.1.5.1.2.1.1 23-1.2.1.5.1.2.1.2 26-1.2.1.3.1.2.1.2 26-1.2.1.7.1.2.1.2 27-1.2.1 28-1.2.1.8.1.2.1.2 30-1.2.1.9.1.1 32-1.2.1.9.2.1
# ::id bel_pmid_1044_8060_23506
(i / induce-01~e.3
      :ARG0 (p2 / protein
            :name (n / name :op1 "interleukin-17"~e.0,2))
      :ARG1 (s / stimulate-01~e.7
            :ARG1~e.8 (a3 / and~e.16,21,27
                  :op1 (p / phosphorylate-01~e.10
                        :ARG1~e.11 (a / amino-acid
                              :name (n2 / name :op1 "tyrosine"~e.9)
                              :part-of (e / enzyme
                                    :name (n3 / name :op1 "JAK"~e.12 :op2 "1"~e.13))))
                  :op2 (p3 / phosphorylate-01~e.10
                        :ARG1 (a2 / amino-acid
                              :name (n4 / name :op1 "tyrosine"~e.9)
                              :part-of (e2 / enzyme
                                    :name (n5 / name :op1 "JAK" :op2 "2"~e.15))))
                  :op3 (p4 / phosphorylate-01~e.10
                        :ARG1 (a4 / amino-acid
                              :name (n6 / name :op1 "tyrosine"~e.9)
                              :part-of (e3 / enzyme
                                    :name (n7 / name :op1 "JAK" :op2 "3"~e.17,26))))
                  :op4 (p5 / phosphorylate-01~e.10
                        :ARG1 (a5 / amino-acid
                              :name (n8 / name :op1 "tyrosine"~e.9)
                              :part-of (e4 / enzyme
                                    :name (n9 / name :op1 "Tyk"~e.19 :op2 "2"~e.20))))
                  :op5 (p6 / phosphorylate-01~e.10
                        :ARG1 (a6 / amino-acid
                              :name (n10 / name :op1 "tyrosine"~e.9)
                              :part-of (p7 / protein
                                    :name (n11 / name :op1 "STAT"~e.22 :op2 "1"~e.23))))
                  :op6 (p8 / phosphorylate-01~e.10
                        :ARG1 (a7 / amino-acid
                              :name (n12 / name :op1 "tyrosine"~e.9)
                              :part-of (p9 / protein
                                    :name (n13 / name :op1 "STAT" :op2 "2"~e.15))))
                  :op7 (p10 / phosphorylate-01~e.10
                        :ARG1 (a8 / amino-acid
                              :name (n14 / name :op1 "tyrosine"~e.9)
                              :part-of (p11 / protein
                                    :name (n15 / name :op1 "STAT" :op2 "3"~e.17,26))))
                  :op8 (p12 / phosphorylate-01~e.10
                        :ARG1 (a9 / amino-acid
                              :name (n16 / name :op1 "tyrosine"~e.9)
                              :part-of (p13 / protein
                                    :name (n17 / name :op1 "STAT" :op2 "4"~e.28))))
                  :duration (v / value-interval
                        :op1 (t2 / temporal-quantity~e.4
                              :quant "0.5"~e.30
                              :unit (m / minute))
                        :op2 (t3 / temporal-quantity~e.4
                              :quant "30"~e.32
                              :unit (m2 / minute))))
            :ARG0-of (d / depend-01~e.6
                  :ARG1 (t / time~e.4))))

# ::tok In @-@ gel tryptic fragmentation and mass spectroscopy identified the major IL @-@ 6 @-@ dependent STAT3 @-@ co @-@ shifted p60 protein as the chaperone GRP58 @/@ ER @-@ 60/ERp57 .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.1.1.1.1.2 4-1.1.1 5-1.1 6-1.1.2.1 7-1.1.2 8-1 10-1.2.2.1.2.2 11-1.2.2.1.2.1.1.1 13-1.2.2.1.2.1.1.1 15-1.2.2.1.2 16-1.2.2.1.1.1 18-1.2.2 20-1.2.2 21-1.2.1.1 22-1.2 22-1.2.2.1 22-1.2.2.1.2.1 23-1.3.r 25-1.3 26-1.3.1.1 28-1.3.1.1
# ::id bel_pmid_1046_4281_23680
(i / identify-01~e.8
      :ARG0 (a / and~e.5
            :op1 (f / fragment-01~e.4
                  :instrument (p / product
                        :name (n2 / name :op1 "In-gel"~e.0,2 :op2 "tryptic"~e.3)))
            :op2 (s / spectroscopy~e.7
                  :mod (m2 / mass~e.6)))
      :ARG1 (p3 / protein~e.22
            :name (n3 / name :op1 "p60"~e.21)
            :ARG1-of (c / co-shift-00~e.18,20
                  :ARG0 (p2 / protein~e.22
                        :name (n / name :op1 "STAT3"~e.16)
                        :ARG0-of (d / depend-01~e.15
                              :ARG1 (p4 / protein~e.22
                                    :name (n4 / name :op1 "IL-6"~e.11,13))
                              :mod (m / major~e.10)))))
      :ARG2~e.23 (c2 / chaperone~e.25
            :name (n8 / name :op1 "GRP58/ER-60/ERp57"~e.26,28)))

# ::tok Ariadne : GRP58 is a major target for tyrosine phosphorylation by the Lyn kinase ( 76 ) , a kinase that can be activated by IL @-@ 6 through gp130 signaling
# ::alignments 0-1.1.1.1.1 2-1.1.2.1.1.1 5-1.1.2.2 6-1.1.2 7-1.1.2.3.r 8-1.1.2.3.1.1.1 9-1.1.2.3 10-1.1.2.3.2.r 12-1.1.2.3.2.1.1 13-1.1.2.3.2 15-1.1.3.1.1.1 19-1.1.2.3.2 21-1.2 22-1.2.1.r 23-1.2.1 24-1.2.1.1.r 25-1.2.1.1.1.1 27-1.2.1.1.1.1 29-1.2.1.3.1.1.1 30-1.2.1.3
# ::id bel_pmid_1046_4281_38530
(a2 / and
      :op1 (s / say-01
            :ARG0 (j / journal
                  :name (n / name :op1 "Ariadne"~e.0))
            :ARG1 (t / target-01~e.6
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "GRP58"~e.2))
                  :mod (m / major~e.5)
                  :purpose~e.7 (p3 / phosphorylate-01~e.9
                        :ARG1 (a / amino-acid
                              :name (n3 / name :op1 "tyrosine"~e.8))
                        :ARG2~e.10 (k / kinase~e.13,19
                              :name (n4 / name :op1 "Lyn"~e.12))))
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "76"~e.15))))
      :op2 (p5 / possible~e.21
            :domain~e.22 (a3 / activate-01~e.23
                  :ARG0~e.24 (p6 / protein
                        :name (n5 / name :op1 "IL-6"~e.25,27))
                  :ARG1 k
                  :manner (s2 / signal-01~e.30
                        :ARG0 (p7 / protein
                              :name (n6 / name :op1 "gp130"~e.29))))))

# ::tok Moreover , in human lymphoid cell lines of B @- and T @-@ cell origin ( Raji , Jurkat , and NC @-@ 37 ) , IL @-@ 6 stimulated production of MMP @-@ 9 and MMP @-@ 2 but not TIMP @-@ 1. In the Matrigel invasion assay IL @-@ 6 significantly upregulated transmigration of Raji and Jurkat cells , which in turn was inhibited by recombinant human TIMP @-@ 1 and anti @-@ MMP @-@ 9 and MMP @-@ 2 antibodies .
# ::alignments 2-1.1.4.2.2 3-1.2.1.1.3.2 4-1.2.1.1.3.1 5-1.2.1.1.3 5-1.2.1.1.3.3.1.1.1 6-1.2.1.1.3 7-1.2.1.1.3.3.r 8-1.2.1.1.3.3.1.1.1 10-1.2.1.1.3.3 11-1.2.1.1.3.3.2.1.1 13-1.2.1.1.3.3.1.1.1 13-1.2.1.1.3.3.2.1.1 16-1.2.1.1.3.3.3.1.1.1.1 18-1.2.1.1.3.3.3.1.2.1.1 20-1.2.1.1.3.3 21-1.2.1.1.3.3.3.1.3.1.1 23-1.2.1.1.3.3.3.1.3.1.1 26-1.2.1.1.1.1.1 28-1.2.1.1.1.1.1 29-1.2.1.1 29-1.2.1.2 30-1.2.1.1.2 30-1.2.1.2.3 31-1.2.1.1.2.1.r 32-1.2.1.1.2.1.1.1.1 32-1.2.1.1.2.1.2.1.1 34-1.2.1.1.2.1.1.1.1 35-1.2.1.1.2.1 36-1.2.1.1.2.1.1.1.1 36-1.2.1.1.2.1.2.1.1 38-1.2.1.1.2.1.2.1.1 39-1.2.1 40-1.2.1.2.1 40-1.2.1.2.1.r 41-1.1.4.2.1.1.1.1 41-1.2.1.2.3.1.1.1 44-1.1.4.2.2 46-1.1.4.1.1.1.1 47-1.1.4.1 48-1.1.4 49-1.1.1.1.1 51-1.1.1.1.1 52-1.1.3 52-1.1.3.r 56-1.1.2.1.1.1.1 57-1.1.2.1 58-1.1.2.1.2.1.1 59-1.1.2.1.1 59-1.1.2.1.2 59-1.2.1.1.3.3.1 59-1.2.1.1.3.3.2 59-1.2.1.1.3.3.3.1.1 59-1.2.1.1.3.3.3.1.2 59-1.2.1.1.3.3.3.1.3 62-1.1.4.2.2 63-1.1.4.2.2 65-1.1.4.2 68-1.1.4.2.1.5 69-1.1.4.2.1.1.1.1 71-1.1.4.2.1.1.1.1 72-1.1.4.2.1 73-1.1.4.2.1.2.1 73-1.1.4.2.1.3.1 75-1.1.4.2.1.2.1.1.1.1 75-1.1.4.2.1.3.1.1.1.1 77-1.1.4.2.1.2.1.1.1.1 78-1.1.4.2.1 79-1.1.4.2.1.2.1.1.1.1 79-1.1.4.2.1.3.1.1.1.1 81-1.1.4.2.1.3.1.1.1.1 82-1.1.4.2.1.2 82-1.1.4.2.1.3
# ::id bel_pmid_1047_7738_7276
(m2 / multi-sentence
      :snt2 (u / upregulate-01
            :ARG0 (p5 / protein
                  :name (n13 / name :op1 "IL-6"~e.49,51))
            :ARG1 (t / transmigrate-00
                  :ARG1 (a6 / and~e.57
                        :op1 (c10 / cell~e.59
                              :name (n14 / name :op1 "Raji"~e.56))
                        :op2 (c11 / cell~e.59
                              :name (n15 / name :op1 "Jurkat"~e.58))))
            :manner~e.52 (s3 / significant~e.52)
            :time (a7 / assay-00~e.48
                  :manner (i / invade-01~e.47
                        :ARG0 (p4 / protein
                              :name (n10 / name :op1 "Matrigel"~e.46)))
                  :ARG1-of (i2 / inhibit-01~e.65
                        :ARG0 (a8 / and~e.72,78
                              :op1 (g2 / gene
                                    :name (n16 / name :op1 "TIMP-1"~e.41,69,71))
                              :op2 (a10 / antibody~e.82
                                    :ARG0-of (c8 / counter-01~e.73
                                          :ARG1 (e3 / enzyme
                                                :name (n11 / name :op1 "MMP-9"~e.75,77,79))))
                              :op3 (a11 / antibody~e.82
                                    :ARG0-of (c9 / counter-01~e.73
                                          :ARG1 (e4 / enzyme
                                                :name (n12 / name :op1 "MMP-2"~e.75,79,81))))
                              :ARG1-of (r / recombine-01)
                              :mod (h2 / human~e.68))
                        :mod (i3 / in-turn~e.2,44,62,63))))
      :snt1 (a2 / and
            :op2 (c / contrast-01~e.39
                  :ARG1 (s / stimulate-01~e.29
                        :ARG0 (p3 / protein
                              :name (n4 / name :op1 "IL-6"~e.26,28))
                        :ARG1 (p / produce-01~e.30
                              :ARG1~e.31 (a3 / and~e.35
                                    :op1 (e / enzyme
                                          :name (n / name :op1 "MMP-9"~e.32,34,36))
                                    :op2 (e2 / enzyme
                                          :name (n2 / name :op1 "MMP-2"~e.32,36,38))))
                        :location (c2 / cell-line~e.5,6
                              :mod (l / lymph~e.4)
                              :part-of (h / human~e.3)
                              :source~e.7 (a4 / and~e.10,20
                                    :op1 (c3 / cell~e.59
                                          :name (n5 / name :op1 "B-cell"~e.5,8,13))
                                    :op2 (c4 / cell~e.59
                                          :name (n6 / name :op1 "T-cell"~e.11,13))
                                    :ARG1-of (m / mean-01
                                          :ARG2 (a5 / and
                                                :op1 (c5 / cell~e.59
                                                      :name (n7 / name :op1 "Raji"~e.16))
                                                :op2 (c6 / cell~e.59
                                                      :name (n8 / name :op1 "Jurkat"~e.18))
                                                :op3 (c7 / cell~e.59
                                                      :name (n9 / name :op1 "NC-37"~e.21,23)))))))
                  :ARG2 (s2 / stimulate-01~e.29
                        :polarity~e.40 "-"~e.40
                        :ARG0 p3
                        :ARG1 (p2 / produce-01~e.30
                              :ARG1 (g / gene
                                    :name (n3 / name :op1 "TIMP-1"~e.41)))))))

# ::tok Furthermore , the anti @-@ CD38 agonist antibody expectedly inhibited bone resorption in the pit assay and elevated interleukin @-@ 6 ( IL @-@ 6 ) secretion . IL @-@ 6 , in turn , enhanced CD38 mRNA expression
# ::alignments 3-1.1.1.1.1.2 5-1.1.1.1.1.2.1.1.1 6-1.1.1.1.1.1 7-1.1.1.1.1 9-1.1.1.1 10-1.1.1.1.2.1 12-1.2.3 14-1.1.1.1.2.2.1 15-1.1.1.1.2.2 16-1.1.1 17-1.1.1.2 18-1.1.1.2.2.1.1.1 20-1.1.1.2.2.1.1.1 20-1.2.1.1.1 22-1.2.1.1.1 24-1.1.1.2.2.1.1.1 24-1.2.1.1.1 26-1.1.1.2.2 28-1.2.1.1.1 30-1.2.1.1.1 32-1.2.3 33-1.2.3 35-1.2 36-1.2.2.1.2.1.1 37-1.2.2.1.1.1 38-1.2.2
# ::id bel_pmid_1047_7767_22748
(m3 / multi-sentence
      :snt1 (a2 / and
            :op2 (a6 / and~e.16
                  :op1 (i / inhibit-01~e.9
                        :ARG0 (a3 / antibody~e.7
                              :mod (a4 / agonist~e.6)
                              :ARG0-of (c / counter-01~e.3
                                    :ARG1 (p5 / protein
                                          :name (n / name :op1 "CD38"~e.5))))
                        :ARG1 (r / resorb-00
                              :ARG1 (b / bone~e.10)
                              :location (a / assay-00~e.15
                                    :mod (p / pit~e.14)))
                        :ARG1-of (e / expect-01))
                  :op2 (e2 / elevate-01~e.17
                        :ARG0 a3
                        :ARG1 (s / secrete-01~e.26
                              :ARG0 (e5 / enzyme
                                    :name (n3 / name :op1 "interleukin-6"~e.18,20,24))))))
      :snt2 (e3 / enhance-01~e.35
            :ARG0 (p6 / protein
                  :name (n6 / name :op1 "IL-6"~e.20,22,24,28,30))
            :ARG1 (e4 / express-03~e.38
                  :ARG2 (r3 / rna
                        :name (n5 / name :op1 "mRNA"~e.37)
                        :mod (p4 / protein
                              :name (n4 / name :op1 "CD38"~e.36))))
            :mod (i2 / in-turn~e.12,32,33)))

# ::tok Raf @-@ 1 phosphorylates and activates MEK @-@ 1 , a kinase that activates the extracellular signal regulated kinases ( ERK )
# ::alignments 0-1.1.2.1.1 2-1.1.2.1.1 3-1.1 4-1 5-1.2 6-1.2.2.1.1 8-1.2.2.1.1 13-1.2.2 13-1.2.2.2 13-1.2.2.2.r 15-1.2.2.2.1.1.1 16-1.2.2.2.1.1.2 17-1.2.2.2.1.1.3 18-1.2.2.2.1.1.4 20-1.2.2.2.1.2.1.1.1
# ::id bel_pmid_1049_0027_36928
(a / and~e.4
      :op1 (p / phosphorylate-01~e.3
            :ARG1 (e3 / enzyme~e.13
                  :name (n7 / name :op1 "MEK-1"~e.6,8)
                  :ARG0-of~e.13 (a3 / activate-01~e.13
                        :ARG1 (e4 / enzyme
                              :name (n3 / name
                                    :op1 "extracellular"~e.15
                                    :op2 "signal"~e.16
                                    :op3 "regulated"~e.17
                                    :op4 "kinases"~e.18)
                              :ARG1-of (m / mean-01
                                    :ARG2 (e / enzyme
                                          :name (n / name :op1 "ERK"~e.20))))))
            :ARG2 (e2 / enzyme
                  :name (n2 / name :op1 "Raf-1"~e.0,2)))
      :op2 (a2 / activate-01~e.5
            :ARG0 e2
            :ARG1 e3))

# ::tok Human SAA2 promoter Early experiments in which a human SAA2 genomic clone was transiently transfected into mouse L cells established that A @-@ SAA expression is enhanced by IL @-@ 1 beta , TNF @-@ alpha , IL @-@ 6 and IFN @-@ gamma [ 146 , 147 ].
# ::alignments 0-1.1.1.1.1.2 1-1.1.1.1.1.1.1 3-1.1.3 4-1.1 8-1.1.2.1.2 9-1.1.2.1.1 10-1.1.2.1.3 11-1.1.2.1 13-1.1.2.3 13-1.1.2.3.r 14-1.1.2 15-1.1.2.2.r 16-1.1.2.2.2 17-1.1.2.2.1.1 18-1.1.2.2 19-1 20-1.2.r 21-1.2.2.1.1.1 23-1.2.2.1.1.1 24-1.2.2 26-1.2 27-1.2.1.r 28-1.2.1.1.1.1 28-1.2.1.3.1.1 33-1.2.1.2.1.1 35-1.2.1.2.1.1 37-1.2.1.1.1.1 37-1.2.1.3.1.1 39-1.2.1.3.1.1 40-1.2.1 41-1.2.1.4.1.1 43-1.2.1.4.1.1 45-1.3.1.1.1.1 47-1.3.1.1.1.2
# ::id bel_pmid_1050_4381_28150
(e / establish-01~e.19
      :ARG0 (e3 / experiment-01~e.4
            :ARG1 (m / molecular-physical-entity
                  :ARG0-of (p7 / promote-01
                        :ARG1 (g / gene
                              :name (n6 / name :op1 "SAA2"~e.1)
                              :mod h~e.0)))
            :ARG2 (t / transfect-00~e.14
                  :ARG1 (c4 / clone-01~e.11
                        :ARG1 g~e.9
                        :mod (h / human~e.8)
                        :mod (g2 / genomic~e.10))
                  :ARG2~e.15 (c5 / cell~e.18
                        :name (n7 / name :op1 "L"~e.17)
                        :source (m2 / mouse~e.16))
                  :manner~e.13 (t2 / transient~e.13))
            :time (e4 / early~e.3))
      :ARG1~e.20 (e2 / enhance-01~e.26
            :ARG0~e.27 (a / and~e.40
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "IL-1beta"~e.28,37))
                  :op2 (p5 / protein
                        :name (n3 / name :op1 "TNF-alpha"~e.33,35))
                  :op3 (p3 / protein
                        :name (n4 / name :op1 "IL-6"~e.28,37,39))
                  :op4 (p4 / protein
                        :name (n5 / name :op1 "IFN-gamma"~e.41,43)))
            :ARG1 (e5 / express-03~e.24
                  :ARG2 (p / protein
                        :name (n / name :op1 "A-SAA"~e.21,23))))
      :ARG1-of (d / describe-01
            :ARG0 (p8 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (a2 / and :op1 "146"~e.45 :op2 "147"~e.47)))))

# ::tok The mouse Mincle proximal promoter region contains an indispensable NF @-@ IL6 binding element , demonstrating that Mincle is a direct target of NF @-@ IL6 .
# ::alignments 1-1.1.1.1.1.1.2 2-1.1.1.1.1.1.1.1 3-1.1.1.1.2 5-1.1 6-1 8-1.2.2 9-1.2.1.1.1.1 11-1.2.1.1.1.1 12-1.2.1 13-1.2 15-1.3 16-1.3.1.r 17-1.3.1.2 18-1.1.1 20-1.3.1.3 21-1.3.1 22-1.3.1.1.r 23-1.3.1.1 24-1.3.1.1 25-1.3.1.1
# ::id bel_pmid_1052_8209_11148
(c / contain-01~e.6
      :ARG0 (r / region~e.5
            :ARG2-of (b2 / be-located-at-91~e.18
                  :ARG1 (m / molecular-physical-entity
                        :ARG0-of (p / promote-01
                              :ARG1 (g / gene
                                    :name (n3 / name :op1 "Mincle"~e.2)
                                    :mod (m3 / mouse~e.1)))
                        :mod (p2 / proximal~e.3))))
      :ARG1 (e / element~e.13
            :ARG1-of (b / bind-01~e.12
                  :ARG2 (p4 / protein
                        :name (n / name :op1 "NF-IL6"~e.9,11)))
            :ARG1-of (i / indispensable-41~e.8))
      :ARG0-of (d2 / demonstrate-01~e.15
            :ARG1~e.16 (t / target-01~e.21
                  :ARG0~e.22 p4~e.23,24,25
                  :ARG1 g~e.17
                  :mod (d3 / direct~e.20))))

# ::tok Mincle mRNA expression was strongly induced in response to several inflammatory stimuli , such as LPS , TNF @-@ alpha , IL @-@ 6 , and IFN @-@ gamma in wild @-@ type macrophages .
# ::alignments 0-1.1.1.2.1.1 1-1.1.1.1.1 2-1.1 4-1.2 4-1.2.r 5-1 6-1.3.r 7-1.3 8-1.3.1.r 9-1.3.1.2 10-1.3.1.1 11-1.3.1 13-1.3.1.3.r 14-1.3.1.3.r 15-1.3.1.3.1.1.1 17-1.3.1.3.2.1.1 19-1.3.1.3.2.1.1 21-1.3.1.3.3.1.1 23-1.3.1.3.3.1.1 25-1.3.1.3 26-1.3.1.3.4.1.1 28-1.3.1.3.4.1.1 30-1.3.1.3.5.2 32-1.3.1.3.5.2 33-1.3.1.3.5.1.1
# ::id bel_pmid_1052_8209_9080
(i3 / induce-01~e.5
      :ARG1 (e / express-03~e.2
            :ARG2 (r / rna
                  :name (n / name :op1 "mRNA"~e.1)
                  :mod (g / gene
                        :name (n6 / name :op1 "Mincle"~e.0))))
      :manner~e.4 (s3 / strong~e.4)
      :ARG2-of~e.6 (r2 / respond-01~e.7
            :ARG1~e.8 (s / stimulus~e.11
                  :ARG1-of (i2 / inflame-01~e.10)
                  :quant (s4 / several~e.9)
                  :example~e.13,14 (a / and~e.25
                        :op1 (m / molecular-physical-entity
                              :name (n5 / name :op1 "LPS"~e.15))
                        :op2 (p3 / protein
                              :name (n2 / name :op1 "TNF-alpha"~e.17,19))
                        :op3 (p / protein
                              :name (n3 / name :op1 "IL-6"~e.21,23))
                        :op4 (p2 / protein
                              :name (n4 / name :op1 "IFN-gamma"~e.26,28))
                        :location (c3 / cell
                              :name (n7 / name :op1 "macrophage"~e.33)
                              :mod (w / wild-type~e.30,32))))))

# ::tok Transcriptional interference between PPARalpha and both c @-@ Jun and p65 occurs reciprocally , since c @-@ Jun and p65 also inhibit PPARalpha @-@ mediated activation of a PPAR response element @-@ driven promoter .
# ::alignments 1-1.2 3-1.1.2.2.1.1.1 6-1.1.1.1.1.1 8-1.1.1.1.1.1 10-1.1.1.2.1.1 12-1.2.2 12-1.2.2.r 14-1 15-1.1.1.1.1.1 17-1.1.1.1.1.1 18-1.1.1 19-1.1.1.2.1.1 20-1.1.3 21-1.1 22-1.1.2.2.1.1.1 24-1.1.2.2 25-1.1.2 26-1.1.2.1.r 28-1.1.2.1.1.1.1.1 29-1.1.2.1.1.1.2.1.1 30-1.1.2.1.1.1.2.1 32-1.1.2.1.1.1 32-1.1.2.1.1.1.2 32-1.1.2.1.1.1.2.r
# ::id bel_pmid_1054_2237_10870
(c / cause-01~e.14
      :ARG0 (i2 / inhibit-01~e.21
            :ARG0 (a / and~e.18
                  :op1 (p2 / protein
                        :name (n3 / name :op1 "c-Jun"~e.6,8,15,17))
                  :op2 (p3 / protein
                        :name (n4 / name :op1 "p65"~e.10,19)))
            :ARG1 (a2 / activate-01~e.25
                  :ARG0~e.26 (m2 / molecular-physical-entity
                        :ARG0-of (p / promote-01
                              :ARG1 (p4 / protein~e.32
                                    :name (n2 / name :op1 "PPAR"~e.28)
                                    :ARG1-of~e.32 (d2 / drive-02~e.32
                                          :ARG0 (e / element~e.30
                                                :ARG2-of (r / respond-01~e.29))))))
                  :ARG1-of (m / mediate-01~e.24
                        :ARG0 (d / dna-sequence
                              :name (n / name :op1 "PPARalpha"~e.3,22))))
            :mod (a5 / also~e.20))
      :ARG1 (i / interfere-01~e.1
            :ARG1 (a3 / and
                  :op1 d
                  :op2 (a4 / and
                        :op1 p2
                        :op2 p3))
            :manner~e.12 (r2 / reciprocal~e.12)
            :mod (t / transcribe-01)))

# ::tok LPS stimulation resulted in a significant increase of IL @-@ 6 production ( approximately 3 @-@ fold ) in wild @-@ type mice aortas , in agreement with previous observations ( 26 ) . However , this increase was much greater in aortas isolated from the PPARa 2 @/@ 2 mice ( 12 @-@ fold , p , 0.03 ) .
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 2-1.1 3-1.1.2.r 5-1.1.2.3 6-1.1.2 7-1.1.2.1.r 8-1.1.2.1.1.1.1 10-1.1.2.1.1.1.1 11-1.1.2.1 13-1.1.2.2 14-1.1.2.2.1.1 19-1.1.2.2.1.2 20-1.1.2.2.1.2 21-1.1.2.2.1.2 22-1.1.2.2.1.2 23-1.1.2.2.1.2 25-1.1.3.r 26-1.1.3 27-1.1.3.1.r 28-1.1.3.1.1 29-1.1.3.1 31-1.1.4.1.1.1 34-1.2 36-1.2.1.2.3 37-1.2.1.2 38-1.2.1.2.r 39-1.2.1.1.1 40-1.2.1 40-1.2.1.1 40-1.2.1.1.r 41-1.2.1.2.2.r 42-1.2.1.2.2 43-1.2.1.2.2.1 44-1.2.1.2.2.1.1.r 46-1.2.1.2.2.1.1.2.1.1 47-1.2.1.2.2.1.1.1 49-1.2.1.2.2.1.1.1 50-1.2.1.2.2.1.1 52-1.2.1.2.1.1
# ::id bel_pmid_1054_2237_15954
(m7 / multi-sentence
      :snt1 (r / result-01~e.2
            :ARG1 (s / stimulate-01~e.1
                  :ARG1 (m6 / molecular-physical-entity
                        :name (n3 / name :op1 "LPS"~e.0)))
            :ARG2~e.3 (i3 / increase-01~e.6
                  :ARG1~e.7 (p / produce-01~e.11
                        :ARG1 (p2 / protein
                              :name (n4 / name :op1 "IL-6"~e.8,10))
                        :ARG3 (a5 / aorta
                              :part-of (m5 / mouse
                                    :mod (w / wild-type))))
                  :ARG2 (a / approximately~e.13
                        :op1 (p6 / product-of
                              :op1 "3"~e.14
                              :op2 p~e.19,20,21,22,23))
                  :degree (s3 / significant~e.5))
            :ARG0-of~e.25 (a6 / agree-01~e.26
                  :ARG1~e.27 (o / observe-02~e.29
                        :time (p3 / previous~e.28)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p4 / publication
                        :ARG1-of (c / cite-01 :ARG2 "26"~e.31))))
      :snt2 (h / have-concession-91~e.34
            :ARG1 (g / great~e.40
                  :degree~e.40 (m / more~e.40
                        :degree (m2 / much~e.39))
                  :domain~e.38 (i / increase-01~e.37
                        :ARG2 (p7 / product-of :op1 "12"~e.52)
                        :location~e.41 (a2 / aorta~e.42
                              :ARG1-of (i2 / isolate-01~e.43
                                    :ARG2~e.44 (m3 / mouse~e.50
                                          :quant "2/2"~e.47,49
                                          :mod (p5 / protein
                                                :name (n / name :op1 "PPARa"~e.46)))))
                        :mod (t / this~e.36)))))

# ::tok Cotransfection of c @-@ Jun and c @-@ Fos also strongly activated the wild @-@ type human IL @-@ 6 promoter ( Fig . 3B ) .
# ::alignments 2-1.1.1.1.1.1 2-1.1.1.2.1.1 4-1.1.1.1.1.1 5-1.1.1 6-1.1.1.1.1.1 6-1.1.1.2.1.1 8-1.1.1.2.1.1 9-1.5 10-1.4 10-1.4.r 11-1 13-1.2.3 15-1.2.3 16-1.2.2 17-1.2.1.1.1.1 19-1.2.1.1.1.1 24-1.3.1.1
# ::id bel_pmid_1054_2237_20000
(a / activate-01~e.11
      :ARG0 (c / cotransfect-00
            :ARG1 (a2 / and~e.5
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "c-Jun"~e.2,4,6))
                  :op2 (p3 / protein
                        :name (n3 / name :op1 "c-Fos"~e.2,6,8))))
      :ARG1 (m / molecular-physical-entity
            :ARG0-of (p / promote-01
                  :ARG1 (p4 / protein
                        :name (n / name :op1 "IL-6"~e.17,19)))
            :mod (h / human~e.16)
            :mod (w / wild-type~e.13,15))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "3B"~e.24))
      :manner~e.10 (s / strong~e.10)
      :mod (a3 / also~e.9))

# ::tok Cotransfection of c @-@ Jun and c @-@ Fos also strongly activated the wild @-@ type human IL @-@ 6 promoter ( Fig . 3 B ) .
# ::alignments 2-1.1.1.1.1.1 2-1.1.1.2.1.1 4-1.1.1.1.1.1 5-1.1.1 6-1.1.1.1.1.1 6-1.1.1.2.1.1 8-1.1.1.2.1.1 9-1.4 10-1.3 10-1.3.r 11-1 13-1.2.1 15-1.2.1 16-1.2.3 17-1.2.2.1.1.1 19-1.2.2.1.1.1
# ::id bel_pmid_1054_2237_23142
(a / activate-01~e.11
      :ARG0 (c / cotransfect-00
            :ARG1 (a3 / and~e.5
                  :op1 (p / protein
                        :name (n / name :op1 "c-Jun"~e.2,4,6))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "c-Fos"~e.2,6,8))))
      :ARG1 (m / molecular-physical-entity
            :mod (w / wild-type~e.13,15)
            :ARG0-of (p3 / promote-01
                  :ARG1 (p4 / protein
                        :name (n3 / name :op1 "IL-6"~e.17,19)))
            :mod (h / human~e.16))
      :manner~e.10 (s / strong~e.10)
      :mod (a2 / also~e.9)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "3B")))

# ::tok Cotransfection of the p65 NF @-@ kB subunit resulted in a strong activation of wild @-@ type IL @-@ 6 promoter activity ( 11 @-@ fold ) ( Fig . 3A ) .
# ::alignments 3-1.1.1.1.1 4-1.1.1.2.1.1 6-1.1.1.2.1.1 7-1.1.1 8-1 9-1.2.r 11-1.2.2 12-1.2 13-1.2.1.2.1 14-1.2.1.1.2 16-1.2.1.1.2 17-1.2.1.1.1.1.1.1 19-1.2.1.1.1.1.1.1 21-1.2.1 23-1.2.1.2.1.1 30-1.3.1.1.1
# ::id bel_pmid_1054_2237_24282
(r2 / result-01~e.8
      :ARG1 (c2 / cotransfect-00
            :ARG1 (s / subunit~e.7
                  :name (n / name :op1 "p65"~e.3)
                  :part-of (p2 / protein
                        :name (n2 / name :op1 "NF-kB"~e.4,6))))
      :ARG2~e.9 (a / activate-01~e.12
            :ARG1 (a2 / act-02~e.21
                  :ARG0 (m2 / molecular-physical-entity
                        :ARG0-of (p3 / promote-01
                              :ARG1 (p4 / protein
                                    :name (n3 / name :op1 "IL-6"~e.17,19)))
                        :mod (w / wild-type~e.14,16)
                        :ARG1-of (m3 / mean-01))
                  :ARG1-of (i / increase-01
                        :ARG2 (p / product-of~e.13 :op1 "11"~e.23)))
            :mod (s2 / strong~e.11))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :name (n4 / name :op1 "3A"~e.30))))

# ::tok Devchand et al. ( 11 ) showed that absence of PPARa expression in mice prolonged the inflammatory response .
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2.1 4-1.3.1.1.1 6-1 7-1.2.r 8-1.2.1 9-1.2.1.1.r 10-1.2.1.1.1.1.1 11-1.2.1.1 12-1.2.1.1.2.r 13-1.2.1.1.2 14-1.2 16-1.2.2.1 17-1.2.2
# ::id bel_pmid_1054_2237_30022
(s / show-01~e.6
      :ARG0 (a2 / and~e.1
            :op1 (p3 / person
                  :name (n / name :op1 "Devchand"~e.0))
            :op2 (p4 / person
                  :mod (o / other~e.2)))
      :ARG1~e.7 (p5 / prolong-01~e.14
            :ARG0 (a3 / absent-01~e.8
                  :ARG1~e.9 (e / express-03~e.11
                        :ARG2 (p6 / protein
                              :name (n2 / name :op1 "PPARa"~e.10))
                        :ARG3~e.12 (m / mouse~e.13))
                  :ARG2 m)
            :ARG1 (r / respond-01~e.17
                  :mod (i / inflame-01~e.16)))
      :ARG1-of (d / describe-01
            :ARG0 (p / publication
                  :ARG1-of (c / cite-01 :ARG2 "11"~e.4))))

# ::tok Furthermore , activation of PPARalpha represses both c @-@ Jun @- and p65 @-@ induced transcription of the human IL @-@ 6 promoter .
# ::alignments 2-1.1.1 3-1.1.1.1.r 4-1.1.1.1.1.1 5-1.1 7-1.1.2.1.1.1.1 9-1.1.2.1.1.1.1 11-1.1.2 12-1.1.2.2.1.1.1 15-1.1.2.1 15-1.1.2.2 16-1.1.2.1.2.r 18-1.1.2.1.2.2 19-1.1.2.1.2.1.1.1.1 21-1.1.2.1.2.1.1.1.1
# ::id bel_pmid_1054_2237_32350
(a / and
      :op2 (r / repress-01~e.5
            :ARG0 (a2 / activate-01~e.2
                  :ARG1~e.3 (p5 / protein
                        :name (n / name :op1 "PPARalpha"~e.4)))
            :ARG1 (a4 / and~e.11
                  :op1 (t2 / transcribe-01~e.15
                        :ARG0 (p / protein
                              :name (n2 / name :op1 "c-Jun"~e.7,9))
                        :ARG1~e.16 (m / molecular-physical-entity
                              :ARG0-of (p3 / promote-01
                                    :ARG1 (p4 / protein
                                          :name (n4 / name :op1 "IL-6"~e.19,21)))
                              :mod (h / human~e.18)))
                  :op2 (t3 / transcribe-01~e.15
                        :ARG0 (p2 / protein
                              :name (n3 / name :op1 "p65"~e.12))
                        :ARG1 m))))

# ::tok Here , we show that aortic explants isolated from PPARalpha @-@ null mice display an exacerbated response to inflammatory stimuli , such as lipopolysaccharide ( LPS ) , as demonstrated by increased IL @-@ 6 secretion .
# ::alignments 0-1.3 2-1.1 3-1 7-1.2.1.2 8-1.2.1.2.1.r 9-1.2.1.2.1.1.1.1 12-1.2.1.2.1 15-1.2.3 16-1.2 17-1.2.2.r 18-1.2.2.1 19-1.2.2 21-1.2.2.2.r 22-1.2.2.2.r 23-1.2.2.2.1.1.1.1 28-1.4.r 29-1.4 30-1.4.1.r 31-1.4.1.2 32-1.4.1.1.1.1 34-1.4.1.1.1.1 35-1.4.1
# ::id bel_pmid_1054_2237_33684
(s / show-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1 (r2 / respond-01~e.16
            :ARG0 (e / explant
                  :mod (a / aorta)
                  :ARG1-of (i / isolate-01~e.7
                        :ARG2~e.8 (m / mouse~e.12
                              :mod (p2 / protein
                                    :name (n / name :op1 "PPARalpha"~e.9)
                                    :ARG2-of (m4 / mutate-01 :mod "-/-")))))
            :ARG1~e.17 (s2 / stimulus~e.19
                  :ARG1-of (i2 / inflame-01~e.18)
                  :example~e.21,22 (l / lipopolysaccharide
                        :ARG1-of (m2 / mean-01
                              :ARG2 (m3 / molecular-physical-entity
                                    :name (n3 / name :op1 "Lipopolysaccharide"~e.23)))))
            :ARG1-of (e2 / exacerbate-01~e.15))
      :location (h / here~e.0)
      :ARG1-of~e.28 (d / demonstrate-01~e.29
            :ARG0~e.30 (s4 / secrete-01~e.35
                  :ARG1 (p / protein
                        :name (n4 / name :op1 "IL-6"~e.32,34))
                  :ARG1-of (i3 / increase-01~e.31))))

# ::tok IL @-@ 6 controls macrophage and T cell activation , SMC proliferation , and migration and is a major regulator of the acute phase response ( 5 ) .
# ::alignments 0-1.2.1.1.1 2-1.2.1.1.1 3-1.1 4-1.1.2.1.1.1.1 5-1.1.2 6-1.1.2.2.1.1.1 7-1.1.2.1.1 7-1.1.2.2.1 8-1.1.2.1 8-1.1.2.2 10-1.1.2.3.1.1.1 11-1.1.2.3 13-1.1.2 14-1.1.2.4 15-1.1.2 18-1.2.3 19-1.2 20-1.2.2.r 22-1.2.2.1.1.1 23-1.2.2.1.1.2 24-1.2.2 26-1.3.1.1.1
# ::id bel_pmid_1054_2237_38526
(a / and
      :op1 (c / control-01~e.3
            :ARG0 (p5 / protein
                  :name (n / name :op1 "IL-6"~e.0,2))
            :ARG1 (a2 / and~e.5,13,15
                  :op1 (a5 / activate-01~e.8
                        :ARG1 (c4 / cell~e.7
                              :name (n4 / name :op1 "macrophage"~e.4)))
                  :op2 (a3 / activate-01~e.8
                        :ARG1 (c3 / cell-line~e.7
                              :name (n2 / name :op1 "T"~e.6)))
                  :op3 (p2 / proliferate-01~e.11
                        :ARG0 (m2 / molecular-physical-entity
                              :name (n3 / name :op1 "SMC"~e.10)))
                  :op4 (m3 / migrate-01~e.14
                        :ARG0 m2)))
      :op2 (r / regulate-01~e.19
            :ARG0 p5
            :ARG1~e.20 (r2 / respond-01~e.24
                  :ARG0 (p3 / protein
                        :name (n5 / name :op1 "acute"~e.22 :op2 "phase"~e.23)))
            :mod (m / major~e.18))
      :ARG1-of (d / describe-01
            :ARG0 (p / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "5"~e.26))))

# ::tok RIP2 is a serine @-@ threonine kinase associated with the tumor necrosis factor ( TNF ) receptor complex and is implicated in the activation of NF @-@ kappaB and cell death in mammalian cells .
# ::alignments 0-1.1.1.1.1 1-1.1.1.r 3-1.1.2.1.1 5-1.1.3.1.1 6-1.1 7-1.1.4 8-1.1.4.1.r 10-1.1.4.1.1.1 11-1.1.4.1.1.2 12-1.1.4.1.1.3 14-1.1.4.1.3.1.1.1.1 19-1.1.1.r 20-1.2.1 21-1.2.1.2.r 23-1.2.1.2.1 24-1.2.1.2.1.2.r 25-1.2.1.2.1.2.1.1 28-1.2.1.2 29-1.2.1.2.2.1 29-1.2.1.2.2.2 30-1.2.1.2.2 33-1.2.1.2.2.1
# ::id bel_pmid_1055_9258_21454
(a / and
      :op1 (k / kinase~e.6
            :domain~e.1,19 (e / enzyme
                  :name (n / name :op1 "RIP2"~e.0))
            :mod (a2 / amino-acid
                  :name (n2 / name :op1 "serine"~e.3))
            :mod (a3 / amino-acid
                  :name (n3 / name :op1 "threonine"~e.5))
            :ARG1-of (a4 / associate-01~e.7
                  :ARG2~e.8 (p5 / protein
                        :name (n9 / name
                              :op1 "tumor"~e.10
                              :op2 "necrosis"~e.11
                              :op3 "factor"~e.12)
                        :ARG0-of (r / receive-01)
                        :mod (p4 / protein
                              :ARG1-of (m / mean-01
                                    :ARG2 (p3 / protein
                                          :name (n5 / name :op1 "TNF"~e.14)))))))
      :op2 (a5 / and
            :op2 (i / implicate-01~e.20
                  :ARG1 e
                  :ARG2~e.21 (a6 / and~e.28
                        :op1 (a7 / activate-01~e.23
                              :ARG0 e
                              :ARG1~e.24 (p2 / protein
                                    :name (n6 / name :op1 "NF-kB"~e.25)))
                        :op2 (d / die-01~e.30
                              :ARG1 (c3 / cell~e.29,33)
                              :location (c4 / cell~e.29
                                    :mod (m2 / mammal)))))))

# ::tok Kinase @-@ defective point and deletion variants of RIP2 also significantly blocked the activation of ERK2 by TNFalpha but not epidermal growth factor .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.1.1.1.1.2 4-1.1.1 5-1.1.1.2.1 6-1.1.1.2 7-1.1.1.2.2.r 8-1.1.1.2.2.1.1 9-1.1.3 10-1.1.4 11-1.1 11-1.2 13-1.1.2 14-1.1.2.2.r 15-1.1.2.2.1.1 16-1.1.2.1.r 17-1.1.2.1.1.1 18-1 19-1.2.1 19-1.2.1.r 20-1.2.2.1.1 21-1.2.2.1.2 22-1.2.2.1.3
# ::id bel_pmid_1055_9258_21456
(c2 / contrast-01~e.18
      :ARG1 (b2 / block-01~e.11
            :ARG0 (a2 / and~e.4
                  :op1 (m / molecular-physical-entity
                        :name (n2 / name :op1 "kinase-defective"~e.0,2 :op2 "point"~e.3))
                  :op2 (v / variant~e.6
                        :ARG0-of (d / delete-01~e.5)
                        :mod~e.7 (e / enzyme
                              :name (n3 / name :op1 "RIP2"~e.8))))
            :ARG1 (a3 / activate-01~e.13
                  :ARG0~e.16 (c / cell
                        :name (n5 / name :op1 "TNFalpha"~e.17))
                  :ARG1~e.14 (e2 / enzyme
                        :name (n4 / name :op1 "ERK2"~e.15)))
            :mod (a / also~e.9)
            :degree (s / significant~e.10))
      :ARG2 (b3 / block-01~e.11
            :polarity~e.19 "-"~e.19
            :ARG1 (p / protein
                  :name (n / name
                        :op1 "epidermal"~e.20
                        :op2 "growth"~e.21
                        :op3 "factor"~e.22))))

# ::tok Here we show that RIP2 activates the extracellular signal @-@ regulated kinase ( ERK ) pathway and that the kinase activity of RIP2 appears to be important in this process .
# ::alignments 0-1.3 1-1.1 2-1 3-1.2.r 4-1.2.1.1.1.1 5-1.2.1 7-1.2.1.2.1.2 8-1.2.1.2.1.3 10-1.2.1.2.1.3 11-1.2.1.2.1.4 15-1.2.1.2.1.1 16-1.2 19-1.2.1.2.1.4 19-1.2.2.1.1.2 20-1.2.2.1.1 21-1.2.2.1.1.1.r 22-1.2.2.1.1.1 23-1.2.2 25-1.2.2.1.1.r 26-1.2.2.1 27-1.2.2.1.2.r 28-1.2.2.1.2.1 29-1.2.2.1.2
# ::id bel_pmid_1055_9258_6012
(s / show-01~e.2
      :ARG0 (w / we~e.1)
      :ARG1~e.3 (a / and~e.16
            :op1 (a2 / activate-01~e.5
                  :ARG0 (e3 / enzyme
                        :name (n / name :op1 "RIP2"~e.4))
                  :ARG1 (e4 / enzyme
                        :name (n3 / name
                              :op1 "pathway"~e.15
                              :op2 "extracellular"~e.7
                              :op3 "signal-regulated"~e.8,10
                              :op4 "kinase"~e.11,19)))
            :op2 (a3 / appear-02~e.23
                  :ARG1 (i / important~e.26
                        :domain~e.25 (a4 / act-02~e.20
                              :ARG0~e.21 e3~e.22
                              :ARG1 (k / kinase~e.19))
                        :purpose~e.27 (p2 / process~e.29
                              :mod (t / this~e.28)))))
      :location (h / here~e.0))

# ::tok RIP2 activates AP @-@ 1 and serum response element regulated expression by inducing the activation of the Elk1 transcription factor .
# ::alignments 0-1.2.1.1.1.1 1-1.2.1 2-1.2.1.2.1.1.1 4-1.2.1.2.1.1.1 5-1.2.1.2 6-1.2.1.2.2.1.1.1.1 7-1.2.1.2.2.1.1.1 8-1.2.1.2.2.1.1 9-1.2.1.2.2.1 10-1.2.1.2.2 12-1.2 14-1 15-1.1.r 17-1.1.1.1.1.1 18-1.1.1 19-1.1
# ::id bel_pmid_1055_9258_6014
(a4 / activate-01~e.14
      :ARG1~e.15 (f / factor~e.19
            :ARG0-of (t / transcribe-01~e.18
                  :ARG1 (g / gene
                        :name (n / name :op1 "Elk1"~e.17))))
      :ARG0-of (i / induce-01~e.12
            :ARG1 (a2 / activate-01~e.1
                  :ARG0 (e3 / enzyme
                        :name (n3 / name :op1 "RIP2"~e.0))
                  :ARG1 (a3 / and~e.5
                        :op1 (m / molecular-physical-entity
                              :name (n2 / name :op1 "AP-1"~e.2,4))
                        :op2 (e / express-03~e.10
                              :ARG1-of (r / regulate-01~e.9
                                    :ARG0 (e2 / element~e.8
                                          :ARG2-of (r2 / respond-01~e.7
                                                :ARG0 (s / serum~e.6)))))))))

# ::tok The haematopoietic protein tyrosine phosphatase ( HePTP ) is a negative regulator of the MAP kinases Erk1 , Erk2 and p38 .
# ::alignments 1-1.2.2 2-1.2.1.1 3-1.2.1.2 4-1.2.1.3 6-1.2.3.1.1.1 8-1.2.r 14-1.1.1.1.1 15-1.1.1 16-1.1.1.2.1.1.1.1 18-1.1.1.2.1.2.1.1 19-1.1.1.2.1 20-1.1.1.2.1.3.1.1
# ::id bel_pmid_1055_9944_7830
(m / molecular-physical-entity
      :ARG0-of (d / downregulate-01
            :ARG1 (k / kinase~e.15
                  :name (n3 / name :op1 "MAP"~e.14)
                  :ARG1-of (m4 / mean-01
                        :ARG2 (a / and~e.19
                              :op1 (e / enzyme
                                    :name (n4 / name :op1 "Erk1"~e.16))
                              :op2 (e2 / enzyme
                                    :name (n5 / name :op1 "Erk2"~e.18))
                              :op3 (e3 / enzyme
                                    :name (n6 / name :op1 "p38"~e.20))))))
      :domain~e.8 (e4 / enzyme
            :name (n7 / name
                  :op1 "protein"~e.2
                  :op2 "tyrosine"~e.3
                  :op3 "phosphatase"~e.4)
            :mod (h / haematopoietic~e.1)
            :ARG1-of (m2 / mean-01
                  :ARG2 (e5 / enzyme
                        :name (n / name :op1 "HePTP"~e.6)))))

# ::tok We have shown that the inflammatory cytokines , interleukin @-@ 6 ( IL @-@ 6 ) and heme @-@ induced HO @-@ 1 gene expression , were suppressed by dexamethasone ( Dex ) in a sustained manner .
# ::alignments 0-1.1 2-1 3-1.2.r 5-1.2.2.1 5-1.2.2.1.2 5-1.2.2.1.2.r 8-1.2.2.2.1.1 10-1.2.2.2.1.1 10-1.2.2.2.2.1.1.1 12-1.2.2.2.2.1.1.1 14-1.2.2.2.1.1 14-1.2.2.2.2.1.1.1 16-1.2.2 17-1.2.2.3.2.1 19-1.2.2.3.2 20-1.2.2.3.1.1.1 22-1.2.2.3.1.1.1 23-1.2.2.3.1 24-1.2.2.3 27-1.2 28-1.2.1.r 29-1.2.1 31-1.2.1.1.1.1.1 35-1.2.3 36-1.2.3.r
# ::id bel_pmid_1056_4544_10930
(s / show-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1~e.3 (s2 / suppress-01~e.27
            :ARG0~e.28 (d / dexamethasone~e.29
                  :ARG1-of (m / mean-01
                        :ARG2 (m2 / molecular-physical-entity
                              :name (n / name :op1 "Dex"~e.31))))
            :ARG1 (a / and~e.16
                  :op1 (p2 / protein~e.5
                        :name (n5 / name :op1 "cytokine")
                        :ARG0-of~e.5 (i / inflame-01~e.5))
                  :op2 (e / enzyme
                        :name (n2 / name :op1 "interleukin-6"~e.8,10,14)
                        :ARG1-of (m4 / mean-01
                              :ARG2 (e2 / enzyme
                                    :name (n3 / name :op1 "IL-6"~e.10,12,14))))
                  :op3 (e3 / express-03~e.24
                        :ARG2 (g / gene~e.23
                              :name (n4 / name :op1 "HO-1"~e.20,22))
                        :ARG1-of (i3 / induce-01~e.19
                              :ARG0 (h / heme~e.17))))
            :manner~e.36 (s3 / sustain-01~e.35)))

# ::tok STAT3 @-@ specific probe inhibited nuclear binding protein to the putative HO @-@ 1 @-@ STAT3 sequence . This suggests that IL @-@ 6 induction of human HO @-@ 1 is mediated via the JAK @-@ STAT pathway and that Dex inhibition of gene expression is carried out by activation of a transcriptional protein in competition with the STAT3 binding site .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.2 3-1.1.1 4-1.1 5-1.1.2.2 6-1.1.2.1 7-1.1.2 8-1.1.2.1.1.r 10-1.1.2.1.1.2 11-1.1.2.1.1.1.1 13-1.1.2.1.1.1.1 15-1.1.2.1.1.1.1 16-1.1.2.1.1 18-1.2.1 19-1.2 20-1.2.2.r 21-1.2.2.1.1.1.1.1 23-1.2.2.1.1.1.1.1 24-1.2.2.1.1 25-1.2.2.1.1.2.r 26-1.2.2.1.1.2.2 27-1.2.2.1.1.2.1.1 29-1.2.2.1.1.2.1.1 31-1.2.2.1 34-1.2.2.1.2.1.1 36-1.2.2.1.2.1.1 37-1.2.2.1.2 38-1.2.2 39-1.2.2.r 40-1.2.2.2.2.1.1.1 41-1.2.2.2.2 42-1.2.2.2.2.2.r 43-1.2.2.2.2.2.1 44-1.2.2.2.2.2 46-1.2.2.2 47-1.2.2.2 48-1.2.2.2.1.r 49-1.2.2.2.1 53-1.2.2.2.1.1 54-1.2.2.2.1.2.r 55-1.2.2.2.1.2 56-1.2.2.2.1.2.1.r 58-1.2.2.2.1.2.1.1.1.1.1 59-1.2.2.2.1.2.1.1 60-1.2.2.2.1.2.1
# ::id bel_pmid_1056_4544_11020
(m3 / multi-sentence
      :snt1 (i / inhibit-01~e.4
            :ARG0 (p / probe-01~e.3
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "STAT3"~e.0))
                  :mod (s2 / specific~e.2))
            :ARG1 (p3 / protein~e.7
                  :ARG1-of (b / bind-01~e.6
                        :ARG2~e.8 (d / dna-sequence~e.16
                              :name (n3 / name :op1 "HO-1-STAT3"~e.11,13,15)
                              :ARG1-of (t / think-01~e.10)))
                  :mod (n2 / nucleus~e.5)))
      :snt2 (s4 / suggest-01~e.19
            :ARG0 (t3 / this~e.18)
            :ARG1~e.20,39 (a / and~e.38
                  :op1 (m / mediate-01~e.31
                        :ARG1 (i2 / induce-01~e.24
                              :ARG0 (p4 / protein
                                    :name (n4 / name :op1 "IL-6"~e.21,23))
                              :ARG1~e.25 (g / gene
                                    :name (n5 / name :op1 "HO-1"~e.27,29)
                                    :mod (h / human~e.26)))
                        :manner (p5 / pathway~e.37
                              :name (n6 / name :op1 "JAK-STAT"~e.34,36)))
                  :op2 (c / carry-03~e.46,47
                        :ARG0~e.48 (a2 / activate-01~e.49
                              :ARG1 (p6 / protein~e.53
                                    :ARG0-of (t2 / transcribe-01))
                              :ARG0-of~e.54 (c2 / compete-01~e.55
                                    :ARG1~e.56 (s3 / site~e.60
                                          :ARG0-of (b2 / bind-01~e.59
                                                :ARG1 (p7 / protein
                                                      :name (n8 / name :op1 "STAT3"~e.58))))))
                        :ARG1 (i3 / inhibit-01~e.41
                              :ARG0 (m2 / molecular-physical-entity
                                    :name (n7 / name :op1 "Dex"~e.40))
                              :ARG1~e.42 (e / express-03~e.44
                                    :ARG2 (g2 / gene~e.43)))))))

# ::tok Endothelial cells treated with heme ( 10 microM ) and IL @-@ 6 ( 25 ng/ml ) , increased HO @-@ 1 mRNA 15 @- and 60 @-@ fold , respectively .
# ::alignments 1-1.1 2-1.1.2 3-1.1.2.1.r 4-1.1.2.1.1 6-1.1.2.1.1.1.1 9-1.1.2.1 10-1.1.2.1.2.1.1 12-1.1.2.1.2.1.1 14-1.1.2.1.2.2.1 18-1 19-1.2.2.1.1 21-1.2.2.1.1 22-1.2.1.1 23-1.3.1.1 25-1.3 26-1.3.2.1 30-1.4 30-1.4.r
# ::id bel_pmid_1056_4544_7290
(i / increase-01~e.18
      :ARG0 (c / cell~e.1
            :mod (e / endothelin)
            :ARG1-of (t / treat-04~e.2
                  :ARG2~e.3 (a / and~e.9
                        :op1 (h / heme~e.4
                              :quant (c2 / concentration-quantity
                                    :quant "10"~e.6
                                    :unit (m / micromole)))
                        :op2 (g / gene
                              :name (n / name :op1 "IL-6"~e.10,12)
                              :quant (c3 / concentration-quantity
                                    :quant "25"~e.14
                                    :unit (n5 / nanogram-per-milliliter))))))
      :ARG1 (r3 / rna
            :name (n3 / name :op1 "mRNA"~e.22)
            :mod (g2 / gene
                  :name (n2 / name :op1 "HO-1"~e.19,21)))
      :ARG2 (a3 / and~e.25
            :op1 (p / product-of :op1 "15"~e.23)
            :op2 (p2 / product-of :op1 "60"~e.26))
      :manner~e.30 (r2 / respective~e.30))

# ::tok In PBMC , LPS significantly induced G @-@ CSF and interleukin ( IL )-1 , an inducer of G @-@ CSF . Both were partly inhibited by IL @-@ 4 , IL @-@ 6 and IL @-@ 10 .
# ::alignments 1-1.1.3.1.1 3-1.1.1.1.1 4-1.1.4 5-1.1 5-1.1.2.2.2 6-1.1.2.1.1.1 8-1.1.2.1.1.1 9-1.1.2 10-1.1.2.2.1.1 12-1.2.1.1.1.1 12-1.2.1.2.1.1 12-1.2.1.3.1.1 18-1.1.2.1.1.1 20-1.1.2.1.1.1 22-1.2.2 25-1.2 27-1.2.1.1.1.1 27-1.2.1.2.1.1 27-1.2.1.3.1.1 29-1.2.1.1.1.1 31-1.2.1.1.1.1 31-1.2.1.2.1.1 31-1.2.1.3.1.1 33-1.2.1.2.1.1 34-1.2.1 35-1.2.1.1.1.1 35-1.2.1.2.1.1 35-1.2.1.3.1.1 37-1.2.1.3.1.1
# ::id bel_pmid_1056_4547_3474
(m2 / multi-sentence
      :snt1 (i / induce-01~e.5
            :ARG0 (m3 / molecular-physical-entity
                  :name (n2 / name :op1 "LPS"~e.3))
            :ARG1 (a2 / and~e.9
                  :op1 (p / protein
                        :name (n3 / name :op1 "G-CSF"~e.6,8,18,20))
                  :op2 (e / enzyme
                        :name (n4 / name :op1 "interleukin-1"~e.10)
                        :ARG0-of (i4 / induce-01~e.5
                              :ARG1 p)))
            :location (c / cell
                  :name (n / name :op1 "PBMC"~e.1))
            :degree (s / significant~e.4))
      :snt2 (i2 / inhibit-01~e.25
            :ARG0 (a3 / and~e.34
                  :op1 (p4 / protein
                        :name (n6 / name :op1 "IL-4"~e.12,27,29,31,35))
                  :op2 (p5 / protein
                        :name (n7 / name :op1 "IL-6"~e.12,27,31,33,35))
                  :op3 (p6 / protein
                        :name (n8 / name :op1 "IL-10"~e.12,27,31,35,37)))
            :ARG1 (b / both~e.22)
            :degree (p7 / part)))

# ::tok Supernatants of monocytes stimulated with the F( ab ')2 preparation of anti @-@ U1 @-@ RNP antibodies enhanced the amounts of both Il @-@ 1 alpha and IL @-@ 6 associated with HPAECs almost as effectively as those stimulated with intact autoantibody molecules .
# ::alignments 0-1.1 0-1.2.1.3.2.1 1-1.1.1.r 2-1.1.1 3-1.1.2 9-1.1.2.1 9-1.1.2.1.1 9-1.1.2.1.1.r 10-1.1.2.1.1.1.r 11-1.1.2.1.1.1.1 13-1.1.2.1.1.1.1.1.1.1 15-1.1.2.1.1.1.1.1.1.1 16-1.1.2.1.1.1 17-1 19-1.2 22-1.2.1.1.1.1 22-1.2.1.2.1.1 26-1.2.1 27-1.2.1.1.1.1 27-1.2.1.2.1.1 29-1.2.1.2.1.1 30-1.2.1.3 33-1.2.1.3.2.2 35-1.2.1.3.2 35-1.2.1.3.2.r 36-1.2.1.3.2.1.1.r 37-1.2.1.3.2.1.1 38-1.2.1.3.2.1.2 39-1.2.1.3.2.1.2.1.r 40-1.2.1.3.2.1.2.1.2 41-1.2.1.3.2.1.2.1.1 42-1.2.1.3.2.1.2.1
# ::id bel_pmid_1060_9069_24352
(e / enhance-01~e.17
      :ARG0 (s / supernatant~e.0
            :mod~e.1 (m / monocyte~e.2)
            :ARG1-of (s2 / stimulate-01~e.3
                  :ARG0 (t / thing~e.9
                        :ARG1-of~e.9 (p / prepare-01~e.9
                              :ARG2~e.10 (a / antibody~e.16
                                    :ARG0-of (c2 / counter-01~e.11
                                          :ARG1 (p4 / protein
                                                :name (n2 / name :op1 "U1-RNP"~e.13,15))))
                              :mod (m3 / molecular-physical-entity
                                    :name (n / name :op1 "F(ab')2"))))))
      :ARG1 (a2 / amount-01~e.19
            :ARG1 (a3 / and~e.26
                  :op1 (p2 / protein
                        :name (n3 / name :op1 "IL-1 alpha"~e.22,27))
                  :op2 (p3 / protein
                        :name (n4 / name :op1 "IL-6"~e.22,27,29))
                  :ARG1-of (a4 / associate-01~e.30
                        :ARG2 (c / cell
                              :name (n5 / name :op1 "HPAEC"))
                        :manner~e.35 (e3 / effective~e.35
                              :compared-to (s3 / supernatant~e.0
                                    :mod~e.36 (t2 / that~e.37)
                                    :ARG1-of (s4 / stimulate-01~e.38
                                          :ARG0~e.39 (m2 / molecule~e.42
                                                :mod (a5 / autoantibody~e.41)
                                                :mod (i / intact~e.40))))
                              :degree (a6 / almost~e.33))))))

# ::tok Rac3V12 expression significantly increased the incorporation of BrdUrd into nascent DNA ( Fig . 3 ) , emphasizing that transfection of active Rac3 drives epithelial cell proliferation .
# ::alignments 1-1.1.1 2-1.1.3 3-1.1 5-1.1.2 6-1.1.2.1.r 7-1.1.2.1.1.1 10-1.1.2.2 14-1.1.4.1.1 17-1.2 18-1.2.1.r 19-1.2.1.1 20-1.2.1.1.1.r 21-1.2.1.1.1.2 22-1.2.1.1.1.1.1 23-1.2.1 24-1.2.1.2.1.1 25-1.2.1.2.1 26-1.2.1.2
# ::id bel_pmid_1061_8392_20884
(c2 / cause-01
      :ARG0 (i2 / increase-01~e.3
            :ARG0 (e3 / express-03~e.1
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "Rac")
                        :ARG2-of (m / mutate-01 :value "V12")))
            :ARG1 (i3 / incorporate-01~e.5
                  :ARG1~e.6 (m2 / molecular-physical-entity
                        :name (n4 / name :op1 "BrdUrd"~e.7))
                  :location (d2 / DNA~e.10
                        :ARG1-of (b / birth-01)))
            :degree (s / significant~e.2)
            :ARG1-of (d3 / describe-01
                  :ARG0 (f / figure :mod "3"~e.14)))
      :ARG1 (e / emphasize-01~e.17
            :ARG1~e.18 (d / drive-02~e.23
                  :ARG0 (t / transfect-00~e.19
                        :ARG1~e.20 (p3 / protein
                              :name (n / name :op1 "Rac3"~e.22)
                              :mod (a / active~e.21)))
                  :ARG1 (p / proliferate-01~e.26
                        :ARG0 (c / cell~e.25
                              :mod (e2 / epithelium~e.24))))))

# ::tok Expression of either dominant @-@ negative Rac3N17 or PBD F107 almost completely blocked Pak and JNK activities , demonstrating that Rac3 is upstream of these proteins ( Fig . 4B ) .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.3 3-1.1.1.1.5 5-1.1.1.1.4 7-1.1.1.1 8-1.1.1.1.2.1.1 9-1.1.1.1.2.2.1 10-1.1.3.1 11-1.1.3 12-1.1 13-1.1.2.1.1.1.1 14-1.1.2.1 15-1.1.2.1.2.1.1 16-1.1.2 18-1.2 20-1.2.1 21-1.2.2 22-1.2.2.2 23-1.2.2.2.1.r 24-1.2.2.2.1.1 25-1.2.2.2.1 29-1.3.1.1
# ::id bel_pmid_1061_8392_20886
(c / cause-01
      :ARG0 (b / block-01~e.12
            :ARG0 (e / express-03~e.0
                  :ARG2~e.1 (o / or~e.7
                        :op1 (e2 / enzyme
                              :name (n / name :op1 "Rac3")
                              :ARG2-of (m / mutate-01 :value "N17"))
                        :op2 (p2 / protein-segment
                              :name (n2 / name :op1 "PBD"~e.8)
                              :ARG2-of (m2 / mutate-01 :value "F107"~e.9))
                        :mod (e6 / either~e.2)
                        :mod (n6 / negative~e.5)
                        :ARG0-of (d3 / dominate-01~e.3)))
            :ARG1 (a2 / act-02~e.16
                  :ARG0 (a3 / and~e.14
                        :op1 (e4 / enzyme
                              :name (n3 / name :op1 "Pak"~e.13))
                        :op2 (e5 / enzyme
                              :name (n4 / name :op1 "JNK"~e.15))))
            :degree (c2 / complete~e.11
                  :mod (a / almost~e.10)))
      :ARG1 (d / demonstrate-01~e.18
            :ARG0 e~e.20
            :ARG1 (b2 / be-located-at-91~e.21
                  :ARG1 e2
                  :ARG2 (u / upstream~e.22
                        :mod~e.23 (p / protein~e.25
                              :mod (t / this~e.24)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4B"~e.29)))

# ::tok Pak activity was increased 4 @- to 6 @-@ fold in the three cell lines containing active Rac3 ( Fig . 4A ) . This increased kinase activity was mainly associated with the Pak2 isoform , which can phosphorylate and positively regulate Raf @-@ 1 activity , another key component in cell proliferation ( 38 @-@ 40 )
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 3-1.1 4-1.1.2.1.1 7-1.1.2.2.1 12-1.1.4.1 13-1.1.4 14-1.1.4 15-1.1.4.2 16-1.2.1 17-1.1.4.2.1.1.1 21-1.1.3.1.1 25-1.1 25-1.2.1.2 26-1.2.1.1 27-1.2.1 29-1.2.3 30-1.2 31-1.2.2.r 33-1.2.2.1.1.1 34-1.2.2 37-1.2.2.2.2 38-1.2.2.2 42-1.2.2.2.1.1.1.1 44-1.2.2.2.1.1.1.1 45-1.2.2.2.1 47-1.2.2.2.1.1.2.3 48-1.2.2.2.1.1.2.1 49-1.2.2.2.1.1.2 50-1.2.2.2.1.1.2.2.r 51-1.2.2.2.1.1.2.2.1 52-1.2.2.2.1.1.2.2 54-1.2.4.1.1.1.1 56-1.2.4.1.1.1.2
# ::id bel_pmid_1061_8392_20888
(m2 / multi-sentence
      :snt1 (i / increase-01~e.3,25
            :ARG1 (a2 / act-02~e.1
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "Pak"~e.0)))
            :ARG2 (a9 / and
                  :op1 (p3 / product-of :op1 "4"~e.4)
                  :op2 (p7 / product-of :op1 "6"~e.7))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "4A"~e.21))
            :location (c / cell-line~e.13,14
                  :quant "3"~e.12
                  :ARG0-of (c2 / contain-01~e.15
                        :ARG1 (p6 / protein
                              :name (n2 / name :op1 "Rac3"~e.17)
                              :ARG1-of (a3 / activate-01)))))
      :snt2 (a4 / associate-01~e.30
            :ARG1 (a5 / act-02~e.16,27
                  :ARG0 (k / kinase~e.26)
                  :ARG1-of (i2 / increase-01~e.25))
            :ARG2~e.31 (i3 / isoform~e.34
                  :mod (e2 / enzyme
                        :name (n3 / name :op1 "Pak2"~e.33))
                  :ARG2-of (p2 / phosphorylate-01~e.38
                        :ARG1 (a7 / act-02~e.45
                              :ARG0 (e3 / enzyme
                                    :name (n4 / name :op1 "Raf-1"~e.42,44)
                                    :mod (c3 / component~e.49
                                          :mod (k2 / key~e.48)
                                          :topic~e.50 (p4 / proliferate-01~e.52
                                                :ARG0 (c4 / cell~e.51))
                                          :mod (a8 / another~e.47))))
                        :mod (p / possible~e.37))
                  :ARG2-of (u / upregulate-01
                        :ARG1 a7))
            :mod (m / main~e.29)
            :ARG1-of (d2 / describe-01
                  :ARG0 (p5 / publication
                        :ARG1-of (c5 / cite-01
                              :ARG2 (b / between :op1 "38"~e.54 :op2 "40"~e.56))))))

# ::tok The activation of STAT3 by the cytokine receptor gp130 is required for both the G1 to S cell cycle transition and antiapoptosis . #[JL] IL6ST is gp130
# ::alignments 1-1.1.1 2-1.1.1.2.r 3-1.1.1.2.1.1 4-1.1.1.1.r 6-1.1.1.1.2.1.1.1 7-1.1.1.1.2.1.1.2 8-1.1.1.1.1.1 10-1.1 14-1.1.2.1.2 16-1.1.2.1.1 17-1.1.2.1.3.1 18-1.1.2.1.3 19-1.1.2.1 20-1.1.2 24-1.2.2.1.1 25-1.2.2.r 26-1.2.1.1
# ::id bel_pmid_1062_6893_23710
(m / multi-sentence
      :snt1 (r / require-01~e.10
            :ARG1 (a / activate-01~e.1
                  :ARG0~e.4 (p2 / protein
                        :name (n2 / name :op1 "gp130"~e.8)
                        :ARG1-of (i / include-91
                              :ARG2 (p5 / protein
                                    :name (n5 / name :op1 "cytokine"~e.6 :op2 "receptor"~e.7))))
                  :ARG1~e.2 (p / protein
                        :name (n / name :op1 "STAT3"~e.3)))
            :ARG2 (a2 / and~e.20
                  :op1 (t / transition-01~e.19
                        :ARG2 (s / S~e.16)
                        :ARG3 (g / G1~e.14)
                        :subevent-of (c2 / cycle~e.18
                              :mod (c3 / cell~e.17)))
                  :op2 (a3 / apoptosis :polarity "-")))
      :snt2 (p3 / protein
            :name (n3 / name :op1 "gp130"~e.26)
            :domain~e.25 (p4 / protein
                  :name (n4 / name :op1 "IL6ST"~e.24))))

# ::tok In this paper we demonstrate that expression of CD72 down @-@ modulates both extracellular signal @-@ related kinase ( ERK ) activation and Ca2+ mobilization induced by BCR ligation in the mouse B lymphoma line K46^mA , whereas BCR @-@ mediated ERK activation was not reduced by the ITIM @-@ mutated form of CD72 .
# ::alignments 1-1.3.1 2-1.3 3-1.1 4-1 5-1.2.r 6-1.2.1 7-1.2.1.1.r 8-1.2.1.1.1.1 9-1.2 11-1.2 13-1.2.2.1.1.1.1 14-1.2.2.1.1.1.2 16-1.2.2.1.1.1.2 17-1.2.2.1.1.1.3 19-1.2.2.1.1.2.1.1.1 21-1.2.2.1 22-1.2.2 23-1.2.2.2.1.1.1 24-1.2.2.2 25-1.2.2.3 27-1.2.2.3.1.1.1.1 29-1.2.2.3.2.r 31-1.2.2.3.2.2 32-1.2.2.3.2.3.1.1 33-1.2.2.3.2.3.2 34-1.2.2.3.2 35-1.2.2.3.2.1.1 37-1.2.3 38-1.2.3.1.3.2.1 40-1.2.3.1.3.2 41-1.2.3.1.3.1 42-1.2.3.1.3 44-1.2.3.1.1 44-1.2.3.1.1.r 45-1.2.3.1 46-1.2.3.1.2.r 48-1.2.3.1.2.2.1.1.1 50-1.2.3.1.2.2 53-1.2.1.1.1.1 53-1.2.3.1.2.1.1
# ::id bel_pmid_1064_0734_39802
(d / demonstrate-01~e.4
      :ARG0 (w / we~e.3)
      :ARG1~e.5 (d2 / down-modulate-00~e.9,11
            :ARG0 (e2 / express-03~e.6
                  :ARG2~e.7 (p2 / protein
                        :name (n2 / name :op1 "CD72"~e.8,53)))
            :ARG1 (a / and~e.22
                  :op1 (a2 / activate-01~e.21
                        :ARG1 (e4 / enzyme
                              :name (n3 / name
                                    :op1 "extracellular"~e.13
                                    :op2 "signal-related"~e.14,16
                                    :op3 "kinase"~e.17)
                              :ARG1-of (d3 / describe-01
                                    :ARG2 (e3 / enzyme
                                          :name (n4 / name :op1 "ERK"~e.19)))))
                  :op2 (m / mobilize-01~e.24
                        :ARG1 (s / small-molecule
                              :name (n5 / name :op1 "Ca2+"~e.23)))
                  :ARG1-of (i / induce-01~e.25
                        :ARG0 (l / ligate-01
                              :ARG1 (p3 / protein
                                    :name (n6 / name :op1 "BCR"~e.27)))
                        :location~e.29 (c / cell-line~e.34
                              :name (n7 / name :op1 "K46^mA"~e.35)
                              :mod (m2 / mouse~e.31)
                              :consist-of (c3 / cell
                                    :name (n / name :op1 "B"~e.32)
                                    :part-of (l2 / lymphoma~e.33)))))
            :ARG1-of (c2 / contrast-01~e.37
                  :ARG2 (r / reduce-01~e.45
                        :polarity~e.44 "-"~e.44
                        :ARG0~e.46 (p4 / protein
                              :name (n8 / name :op1 "CD72"~e.53)
                              :ARG2-of (m4 / mutate-01~e.50
                                    :ARG0 (p5 / protein-segment
                                          :name (n9 / name :op1 "ITIM"~e.48))))
                        :ARG1 (a3 / activate-01~e.42
                              :ARG1 e3~e.41
                              :ARG1-of (m3 / mediate-01~e.40
                                    :ARG0 p3~e.38)))))
      :medium (p / paper~e.2
            :mod (t / this~e.1)))

# ::tok Results CD72 negatively regulates both ERK activation and Ca2+ mobilization induced by BCR ligation in the K46^mk B lymphoma cells To investigate the signaling function of CD72 , we assessed CD72 expression on the surface of B cell lines by flow cytometry .
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 1-1.2.2.1.1 5-1.2.1.1.1.1.1 6-1.2.1.1 7-1.2.1 8-1.2.1.2.1.1.1 9-1.2.1.2 10-1.2.1.3 12-1.2.1.3.1.1.1.1 16-1.2.3.1.1 17-1.2.3.2.1.1 18-1.2.3.2.2 19-1.2.3 19-1.2.3.2 19-1.2.3.2.r 21-1.3.4 23-1.3.4.2.2 24-1.3.4.2 25-1.3.4.2.1.r 26-1.3.4.2.1 28-1.3.1 29-1.3 30-1.3.2.1.1.1 31-1.3.2 32-1.3.2.2.r 34-1.3.2.2 35-1.3.2.2.1.r 36-1.3.2.2.1.1.1.1 37-1.3.2.2.1 38-1.3.2.2.1 39-1.3.3.r 40-1.3.3.1 41-1.3.3
# ::id bel_pmid_1064_0734_39804
(m / multi-sentence
      :snt1 (t / thing~e.0
            :ARG2-of~e.0 (r / result-01~e.0))
      :snt1 (d / downregulate-01
            :ARG1 (a / and~e.7
                  :op1 (a2 / activate-01~e.6
                        :ARG1 (e2 / enzyme
                              :name (n4 / name :op1 "ERK"~e.5)))
                  :op2 (m2 / mobilize-01~e.9
                        :ARG1 (s / small-molecule
                              :name (n5 / name :op1 "Ca2+"~e.8)))
                  :ARG1-of (i / induce-01~e.10
                        :ARG0 (l / ligate-01
                              :ARG1 (p2 / protein
                                    :name (n6 / name :op1 "BCR"~e.12)))))
            :ARG2 (p / protein
                  :name (n3 / name :op1 "CD72"~e.1))
            :location (c / cell-line~e.19
                  :name (n7 / name :op1 "K46^mk"~e.16)
                  :consist-of~e.19 (c5 / cell~e.19
                        :name (n9 / name :op1 "B"~e.17)
                        :part-of (l2 / lymphoma~e.18))))
      :snt3 (a3 / assess-01~e.29
            :ARG0 (w / we~e.28)
            :ARG1 (e3 / express-03~e.31
                  :ARG2 (p3 / protein
                        :name (n8 / name :op1 "CD72"~e.30))
                  :location~e.32 (s2 / surface~e.34
                        :part-of~e.35 (c2 / cell-line~e.37,38
                              :consist-of (c4 / cell
                                    :name (n / name :op1 "B"~e.36)))))
            :instrument~e.39 (c3 / cytometry~e.41
                  :mod (f / flow~e.40))
            :purpose (i2 / investigate-01~e.21
                  :ARG0 w
                  :ARG1 (f2 / function-01~e.24
                        :ARG0~e.25 p3~e.26
                        :ARG1 (s3 / signal-01~e.23)))))

# ::tok However , both of the CD72 transfectants showed reduced phosphorylation of ERK1 and ERK2 compared to that of the parent cells regardless of the duration of Ag stimulation .
# ::alignments 0-1 2-1.1.1.1 5-1.1.1.2.1.1.1 7-1.1 8-1.1.2.2 9-1.1.2 10-1.1.2.1.r 11-1.1.2.1.1.1.1 12-1.1.2.1 13-1.1.2.1.2.1.1 14-1.1.2.2.1.r 19-1.1.2.2.1.1 20-1.1.2.2.1 27-1.1.2.2.2.1
# ::id bel_pmid_1064_0734_39810
(h / have-concession-91~e.0
      :ARG1 (s2 / show-01~e.7
            :ARG0 (m / molecular-physical-entity
                  :mod (b / both~e.2)
                  :ARG1-of (t / transfect-00
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "CD72"~e.5))))
            :ARG1 (p / phosphorylate-01~e.9
                  :ARG1~e.10 (a / and~e.12
                        :op1 (e / enzyme
                              :name (n3 / name :op1 "ERK1"~e.11))
                        :op2 (e2 / enzyme
                              :name (n4 / name :op1 "ERK2"~e.13)))
                  :ARG1-of (r / reduce-01~e.8
                        :compared-to~e.14 (c3 / cell~e.20
                              :mod (p4 / parent~e.19))
                        :concession (t2 / temporal-quantity
                              :duration-of (s / stimulate-01~e.27
                                    :ARG2 (a2 / antigen)))))))

# ::tok Taken together , expression of CD72 most probably down @-@ modu @-@ lates phosphorylation of ERK induced by BCR signaling .
# ::alignments 0-1.2 1-1.2.1 3-1.1.2.1 4-1.1.2.1.1.r 5-1.1.2.1.1.1.1 6-1.1.1 7-1.1 8-1.1.2 13-1.1.2.2 14-1.1.2.2.1.r 15-1.1.2.2.1.1.1 16-1.1.2.2.2 17-1.1.2.2.2.1.r 18-1.1.2.2.2.1.1.1.1 19-1.1.2.2.2.1
# ::id bel_pmid_1064_0734_39812
(h / have-condition-91
      :ARG1 (p3 / probable~e.7
            :degree (m / most~e.6)
            :domain (d / down-modulate-00~e.8
                  :ARG0 (e2 / express-03~e.3
                        :ARG2~e.4 (p2 / protein
                              :name (n2 / name :op1 "CD72"~e.5)))
                  :ARG1 (p / phosphorylate-01~e.13
                        :ARG1~e.14 (e / enzyme
                              :name (n / name :op1 "ERK"~e.15))
                        :ARG1-of (i / induce-01~e.16
                              :ARG0~e.17 (s / signal-01~e.19
                                    :ARG0 (p4 / protein
                                          :name (n3 / name :op1 "BCR"~e.18)))))))
      :ARG2 (t / take-01~e.0
            :mod (t2 / together~e.1)))

# ::tok Indeed , in vitro kinase assay showed that the activity of ERK2 in Ag @-@ stimulated K46^mA CD72 transfectants was lower than that of Ag @-@ stimulated K46^mA ( Fig . 3 ) .
# ::alignments 0-1.3 2-1.1.2 3-1.1.2 4-1.1.1 5-1.1 6-1 10-1.2.r 11-1.2.2.1.1.1 12-1.1.2 15-1.2.2.2.1.2 16-1.2.2.2.1.1.1 17-1.2.2.2.2.1.1.1 19-1.2.2.r 20-1.2 20-1.2.1 20-1.2.1.r 21-1.2.3.r 26-1.2.3.1 27-1.2.3.1 31-1.4.1.1
# ::id bel_pmid_1064_0734_39814
(s / show-01~e.6
      :ARG0 (a / assay-00~e.5
            :mod (k / kinase~e.4)
            :manner (i / in-vitro~e.2,3,12))
      :ARG1~e.10 (l / low~e.20
            :degree~e.20 (m / more~e.20)
            :domain~e.19 (a2 / act-01
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "ERK2"~e.11))
                  :location (m2 / molecular-physical-entity
                        :part-of (c2 / cell-line
                              :name (n4 / name :op1 "K46^mA"~e.16)
                              :ARG1-of (s2 / stimulate-01~e.15
                                    :ARG2 (a4 / antigen)))
                        :ARG1-of (t / transfect-00
                              :ARG2 (p / protein
                                    :name (n3 / name :op1 "CD72"~e.17)))))
            :compared-to~e.21 (a3 / act-01
                  :location c2~e.26,27))
      :mod (i2 / indeed~e.0)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "3"~e.31)))

# ::tok However , the CD72 transfectants showed less increase in the intracellular Ca2+ concentration than the parent K46^mA cells did .
# ::alignments 0-1 3-1.1.1.1.1.1.1 5-1.1 6-1.1.2.2 7-1.1.2 8-1.1.2.1.r 10-1.1.2.1.2 11-1.1.2.1.1.1.1 12-1.1.2.1 13-1.1.2.2.1.r 15-1.1.2.2.1.2 16-1.1.2.2.1.1.1 17-1.1.2.2.1
# ::id bel_pmid_1064_0734_39818
(h / have-concession-91~e.0
      :ARG1 (s / show-01~e.5
            :ARG0 (m / molecular-physical-entity
                  :ARG1-of (t / transfect-00
                        :ARG2 (p / protein
                              :name (n2 / name :op1 "CD72"~e.3))))
            :ARG1 (i / increase-01~e.7
                  :ARG1~e.8 (c3 / concentrate-02~e.12
                        :ARG0 (s2 / small-molecule
                              :name (n3 / name :op1 "Ca2+"~e.11))
                        :mod (i2 / intracellular~e.10))
                  :ARG2 (l / less~e.6
                        :compared-to~e.13 (c4 / cell-line~e.17
                              :name (n4 / name :op1 "K46^mA"~e.16)
                              :mod (p2 / parent~e.15))))))

# ::tok Thus , expression of CD72 appears to negatively regulate BCR @-@ mediated Ca2+ mobilization in K46^mA cells .
# ::alignments 2-1.1.1.2 3-1.1.1.2.1.r 4-1.1.1.2.1.1.1 5-1.1 9-1.1.1.1.2.1.1.1 11-1.1.1.1.2 12-1.1.1.1.1.1.1 13-1.1.1.1 15-1.1.1.3.1.1 16-1.1.1.3
# ::id bel_pmid_1064_0734_39820
(i / infer-01
      :ARG1 (a / appear-02~e.5
            :ARG1 (d / downregulate-01
                  :ARG1 (m / mobilize-01~e.13
                        :ARG1 (s / small-molecule
                              :name (n3 / name :op1 "Ca2+"~e.12))
                        :ARG1-of (m2 / mediate-01~e.11
                              :ARG0 (p2 / protein
                                    :name (n4 / name :op1 "BCR"~e.9))))
                  :ARG2 (e / express-03~e.2
                        :ARG2~e.3 (p / protein
                              :name (n / name :op1 "CD72"~e.4)))
                  :location (c / cell-line~e.16
                        :name (n5 / name :op1 "K46^mA"~e.15)))))

# ::tok Taken together , CD72 down @-@ modulates both ERK activation and Ca2+ mobilization induced by BCR ligation , strongly suggesting that CD72 negatively regulates BCR signaling in K46^mA cells .
# ::alignments 0-1.2 1-1.2.1 3-1.1.1.1.1 4-1.1 6-1.1 8-1.1.2.1.1.1.1 9-1.1.2.1 10-1.1.2 11-1.1.2.2.1.1.1 12-1.1.2.2 13-1.1.2.3 15-1.1.2.3.1.1.1.1 18-1.1.3.2 18-1.1.3.2.r 19-1.1.3 21-1.1.1.1.1 24-1.1.3.1.1.1 25-1.1.3.1.1 27-1.1.3.1.3.1.1 28-1.1.3.1.3
# ::id bel_pmid_1064_0734_39822
(h / have-condition-91
      :ARG1 (d / down-modulate-00~e.4,6
            :ARG0 (p / protein
                  :name (n2 / name :op1 "CD72"~e.3,21))
            :ARG1 (a / and~e.10
                  :op1 (a2 / activate-01~e.9
                        :ARG1 (e2 / enzyme
                              :name (n3 / name :op1 "ERK"~e.8)))
                  :op2 (m / mobilize-01~e.12
                        :ARG1 (s / small-molecule
                              :name (n4 / name :op1 "Ca2+"~e.11)))
                  :ARG1-of (i / induce-01~e.13
                        :ARG0 (l / ligate-01
                              :ARG1 (p2 / protein
                                    :name (n5 / name :op1 "BCR"~e.15)))))
            :ARG0-of (s2 / suggest-01~e.19
                  :ARG1 (d2 / downregulate-01
                        :ARG1 (s4 / signal-01~e.25
                              :ARG0 p2~e.24)
                        :ARG2 p
                        :location (c / cell-line~e.28
                              :name (n6 / name :op1 "K46^mA"~e.27)))
                  :manner~e.18 (s3 / strong~e.18)))
      :ARG2 (t / take-01~e.0
            :mod (t2 / together~e.1)))

# ::tok Western blotting of total cell lysates using anti @-@ phospho @-@ ERK Ab showed that both ERK1 and ERK2 were phosphorylated by either BCR ligation alone or coligation of BCR and CD72 ( Fig . 6B ) .
# ::alignments 0-1.1.1.1 1-1.1.1.2 3-1.1.2.2 4-1.1.2.1 7-1.1.3.1 11-1.1.3.1.1.1.1 13-1 16-1.2.1.1.1.1 17-1.2.1 18-1.2.1.2.1.1 20-1.1.3.1.1.2 20-1.2 23-1.2.2.1.1.1.1 25-1.2.2.1.2 26-1.2.2 29-1.2.2.2.1 31-1.2.2.2.2.1.1 35-1.3.1.1
# ::id bel_pmid_1064_0734_39824
(s / show-01~e.13
      :ARG0 (t / thing
            :name (n2 / name :op1 "Western"~e.0 :op2 "blotting"~e.1)
            :mod (l / lysate
                  :mod (c / cell~e.4)
                  :quant (t2 / total~e.3))
            :instrument (a / antibody
                  :ARG0-of (c2 / counter-01~e.7
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "ERK"~e.11)
                              :ARG3-of (p / phosphorylate-01~e.20)))))
      :ARG1 (p2 / phosphorylate-01~e.20
            :ARG1 (a2 / and~e.17
                  :op1 (e2 / enzyme
                        :name (n3 / name :op1 "ERK1"~e.16))
                  :op2 (e3 / enzyme
                        :name (n4 / name :op1 "ERK2"~e.18)))
            :ARG2 (o / or~e.26
                  :op1 (l2 / ligate-01
                        :ARG1 (p3 / protein
                              :name (n5 / name :op1 "BCR"~e.23))
                        :mod (a3 / alone~e.25))
                  :op2 (l3 / ligate-01
                        :ARG1 p3~e.29
                        :ARG3 (p4 / protein
                              :name (n6 / name :op1 "CD72"~e.31))
                        :mod (t3 / together))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6B"~e.35)))

# ::tok However , BCR ligation induced stronger ERK phosphorylation than coligation of CD72 with BCR did , indicating that BCR ligation @-@ induced phosphorylation of ERK is down @-@ modulated when CD72 is coligated with BCR .
# ::alignments 0-1 2-1.1.1.1.1.1 4-1.1 5-1.1.2.2 5-1.1.2.2.1 5-1.1.2.2.1.r 6-1.1.2.1.1.1 7-1.1.2 8-1.1.2.2.2.r 11-1.1.2.2.2.1.1.1 13-1.1.1.1.1.1 16-1.1.3 18-1.1.1.1.1.1 21-1.1 21-1.1.3.1.1.2 22-1.1.2 22-1.1.3.1.1 24-1.1.2.1.1.1 26-1.1.3.1 28-1.1.3.1 29-1.1.3.1.2.r 30-1.1.3.1.2 34-1.1.2.2.2.2
# ::id bel_pmid_1064_0734_39826
(h / have-concession-91~e.0
      :ARG1 (i / induce-01~e.4,21
            :ARG0 (l / ligate-01
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "BCR"~e.2,13,18)))
            :ARG1 (p / phosphorylate-01~e.7,22
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "ERK"~e.6,24))
                  :mod (s / strong~e.5
                        :degree~e.5 (m / more~e.5)
                        :compared-to~e.8 (l2 / ligate-01
                              :ARG1 (p3 / protein
                                    :name (n3 / name :op1 "CD72"~e.11))
                              :ARG3 p2~e.34
                              :mod (t / together))))
            :ARG0-of (i2 / indicate-01~e.16
                  :ARG1 (d / down-modulate-00~e.26,28
                        :ARG1 (p4 / phosphorylate-01~e.22
                              :ARG1 e
                              :ARG1-of (i3 / induce-01~e.21
                                    :ARG0 l))
                        :time~e.29 l2~e.30))))

# ::tok Phosphorylation of both ERK1 and ERK2 induced by coligation of BCR and CD72 was weaker than that induced by BCR ligation alone ( Fig . 6 C ) , indicating that coligation with CD72 reduced BCR ligation @-@ mediated phosphorylation of ERK in DBA/2 spleen cells .
# ::alignments 0-1.2 0-1.3 3-1.2.1.1.1.1 4-1.2.1 5-1.2.1.2.1.1 6-1.2.2 6-1.3.1 9-1.2.2.r 10-1.2.2.1.1.1.1 12-1.2.2.1.2.1.1 13-1.2.r 14-1 14-1.1 14-1.1.r 15-1.3.r 17-1.2.2 19-1.3.1.1.1 21-1.3.1.1.2 29-1.5 32-1.5.1.r 33-1.5.1.1 34-1.5.1 35-1.5.1.1 38-1.5.1.2.2 39-1.5.1.2 40-1.5.1.2.1.r 41-1.5.1.2.1.1.1 42-1.5.1.2.3.r 43-1.5.1.2.3.1.1.1 44-1.5.1.2.3.1 45-1.5.1.2.3
# ::id bel_pmid_1064_0734_39828
(w / weak~e.14
      :degree~e.14 (m / more~e.14)
      :domain~e.13 (p / phosphorylate-01~e.0
            :ARG1 (a / and~e.4
                  :op1 (e2 / enzyme
                        :name (n2 / name :op1 "ERK1"~e.3))
                  :op2 (e3 / enzyme
                        :name (n3 / name :op1 "ERK2"~e.5)))
            :ARG1-of~e.9 (i / induce-01~e.6,17
                  :ARG0 (l / ligate-01
                        :ARG1 (p2 / protein
                              :name (n4 / name :op1 "BCR"~e.10))
                        :ARG3 (p3 / protein
                              :name (n5 / name :op1 "CD72"~e.12))
                        :mod (t / together))))
      :compared-to~e.15 (p4 / phosphorylate-01~e.0
            :ARG1-of (i2 / induce-01~e.6
                  :ARG0 (l2 / ligate-01
                        :ARG1 p2~e.19
                        :mod (a2 / alone~e.21))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6C"))
      :ARG0-of (i3 / indicate-01~e.29
            :ARG1~e.32 (r / reduce-01~e.34
                  :ARG0 l~e.33,35
                  :ARG1 (p5 / phosphorylate-01~e.39
                        :ARG1~e.40 (e / enzyme
                              :name (n / name :op1 "ERK"~e.41))
                        :ARG1-of (m2 / mediate-01~e.38
                              :ARG0 l2)
                        :location~e.42 (c / cell~e.45
                              :part-of (s / spleen~e.44
                                    :poss (m3 / mouse :mod "DBA/2"~e.43)))))))

# ::tok Coligation of CD72 with BCR showed a reduced Ca2+ flux compared to that with BCR ligation alone in spleen B cells ( Fig . 6D ) .
# ::alignments 2-1.1.1.1.1 4-1.1.2.1.1 5-1 7-1.2.2 8-1.2.1.1.1 9-1.2 9-1.2.3 10-1.2.3.r 11-1.2.3.1 14-1.2.3.1.1.1 16-1.2.3.1.1.2 17-1.3.r 18-1.3.2 19-1.3.1.1 20-1.3 24-1.4.1.1
# ::id bel_pmid_1064_0734_39830
(s / show-01~e.5
      :ARG0 (l / ligate-01
            :ARG1 (p / protein
                  :name (n / name :op1 "CD72"~e.2))
            :ARG3 (p2 / protein
                  :name (n2 / name :op1 "BCR"~e.4))
            :mod (t / together))
      :ARG1 (f / flux~e.9
            :quant-of (s2 / small-molecule
                  :name (n3 / name :op1 "Ca2+"~e.8))
            :ARG1-of (r / reduce-01~e.7)
            :compared-to~e.10 (f2 / flux~e.9
                  :ARG1-of (c / cause-01~e.11
                        :ARG0 (l2 / ligate-01
                              :ARG1 p2~e.14
                              :mod (a / alone~e.16)))))
      :location~e.17 (c2 / cell~e.20
            :name (n4 / name :op1 "B"~e.19)
            :part-of (s3 / spleen~e.18))
      :ARG1-of (d / describe-01
            :ARG0 (f3 / figure :mod "6D"~e.24)))

# ::tok Taken together , these results indicate that coligation with CD72 negatively regulates BCR @-@ induced ERK activation and Ca2+ concentration in normal spleen B cells .
# ::alignments 0-1.2 1-1.1.2.2.2 3-1.1.1.2 4-1.1.1 4-1.1.1.1 4-1.1.1.1.r 5-1.1 9-1.1.2.2.1.1.1 12-1.1.2.1.1.2.1.1.1 14-1.1.2.1.1.2 15-1.1.2.1.1.1.1.1 16-1.1.2.1.1 17-1.1.2.1 18-1.1.2.1.2.1.1.1 19-1.1.2.1.2 21-1.1.2.3.2 22-1.1.2.3.3 23-1.1.2.3.1.1 24-1.1.2.3
# ::id bel_pmid_1064_0734_39832
(h / have-condition-91
      :ARG1 (i / indicate-01~e.5
            :ARG0 (t / thing~e.4
                  :ARG1-of~e.4 (r / result-01~e.4)
                  :mod (t2 / this~e.3))
            :ARG1 (d / downregulate-01
                  :ARG1 (a2 / and~e.17
                        :op1 (a / activate-01~e.16
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "ERK"~e.15))
                              :ARG1-of (i2 / induce-01~e.14
                                    :ARG0 (p2 / protein
                                          :name (n4 / name :op1 "BCR"~e.12))))
                        :op2 (c / concentrate-02~e.19
                              :ARG1 (s / small-molecule
                                    :name (n5 / name :op1 "Ca2+"~e.18))))
                  :ARG2 (l / ligate-01
                        :ARG3 (p / protein
                              :name (n3 / name :op1 "CD72"~e.9))
                        :mod (t3 / together~e.1))
                  :location (c2 / cell~e.24
                        :name (n6 / name :op1 "B"~e.23)
                        :mod (n7 / normal~e.21)
                        :part-of (s2 / spleen~e.22))))
      :ARG2 (t4 / take-01~e.0
            :mod t3))

# ::tok Furthermore , the hCdc14 phosphatases were found to dephosphorylate p53 specifically at the p34( Cdc2 )/clb phosphorylation site ( p53 @-@ phosphor @-@ Ser( 315 )).
# ::alignments 3-1.1.1.2.1.1 4-1.1.1.2.1.2 6-1.1 8-1.1.1 9-1.1.1.1.3.1.1 10-1.1.1.3 16-1.1.1.1.1 17-1.1.1.1 19-1.1.1.1.2.1.4 24-1.1.1.1.2.1.1
# ::id bel_pmid_1064_4693_7794
(a / and
      :op2 (f / find-01~e.6
            :ARG1 (d / dephosphorylate-01~e.8
                  :ARG1 (p3 / protein-segment~e.17
                        :ARG1-of (p / phosphorylate-01~e.16
                              :ARG2 (e / enzyme
                                    :name (n3 / name :op1 "p34Cdc2/clb")))
                        :ARG1-of (d2 / describe-01
                              :ARG2 (a2 / amino-acid
                                    :mod "315"~e.24
                                    :name (n4 / name :op1 "serine")
                                    :ARG1-of p
                                    :part-of p2~e.19))
                        :part-of (p2 / protein
                              :name (n / name :op1 "p53"~e.9)))
                  :ARG2 (e2 / enzyme
                        :name (n2 / name :op1 "hCdc14"~e.3 :op2 "phosphatase"~e.4))
                  :manner (s / specific~e.10))))

# ::tok Overexpression of mutant FGFR3 resulted in IL @-@ 6 independence , decreased apoptosis , and an enhanced proliferative response to IL @-@ 6 .
# ::alignments 2-1.1.1 2-1.1.1.2 2-1.1.1.2.r 3-1.1.1.1.1 4-1 5-1.2.r 6-1.2.1.2.1.1 8-1.2.1.2.1.1 9-1.2.1 9-1.2.1.1 9-1.2.1.1.r 11-1.2.2.1 12-1.2.2 14-1.2 16-1.2.3.3 18-1.2.3 19-1.2.3.1.r 20-1.2.3.1 21-1.2.3.1 22-1.2.3.1
# ::id bel_pmid_1064_8414_21216
(r / result-01~e.4
      :ARG1 (o / overexpress-00
            :ARG2 (p / protein~e.2
                  :name (n / name :op1 "FGFR3"~e.3)
                  :ARG1-of~e.2 (m / mutate-01~e.2)))
      :ARG2~e.5 (a / and~e.14
            :op1 (d / depend-01~e.9
                  :polarity~e.9 "-"~e.9
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "IL-6"~e.6,8)))
            :op2 (a2 / apoptosis~e.12
                  :ARG1-of (d2 / decrease-01~e.11))
            :op3 (r2 / respond-01~e.18
                  :ARG1~e.19 p2~e.20,21,22
                  :mod (p3 / proliferate-01)
                  :ARG1-of (e / enhance-01~e.16))))

# ::tok B9 clones expressing either wild @-@ type FGFR3 at high levels or mutant FGFR3 displayed increased phosphorylation of STAT3 and higher levels of bcl @-@ x( L ) expression than did parental B9 cells after cytokine withdrawal .
# ::alignments 0-1.1.1 1-1.1 2-1.1.2 4-1.1.2.1.1.2 6-1.1.2.1.1.2 7-1.1.2.1.1.1.1 7-1.1.2.1.2.1.1 9-1.1.2.1.1.3.1 10-1.1.2.1.1.3 11-1.1.2.1 12-1.1.2.1.2 12-1.1.2.1.2.2 12-1.1.2.1.2.2.r 13-1.1.2.1.1.1.1 13-1.1.2.1.2.1.1 14-1 15-1.2.1.2 16-1.2.1 17-1.2.1.1.r 18-1.2.1.1.1.1 19-1.2 20-1.2.2.1 20-1.2.2.1.1 20-1.2.2.1.1.r 21-1.2.2 22-1.2.2.2.r 23-1.2.2.2.1.1.1 28-1.2.2.2 29-1.2.3.r 31-1.2.3.2 32-1.2.3.1.1 33-1.2.3 34-1.2.3.3 35-1.2.3.3.1.1.1.1 36-1.2.3.3.1
# ::id bel_pmid_1064_8414_21218
(d / display-01~e.14
      :ARG0 (c3 / clone-01~e.1
            :ARG1 c2~e.0
            :ARG3-of (e / express-03~e.2
                  :ARG2 (o / or~e.11
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "FGFR3"~e.7,13)
                              :mod (w / wild-type~e.4,6)
                              :degree (l / level~e.10
                                    :mod (h2 / high~e.9)))
                        :op2 (p3 / protein~e.12
                              :name (n3 / name :op1 "FGFR3"~e.7,13)
                              :ARG1-of~e.12 (m2 / mutate-01~e.12)))))
      :ARG1 (a / and~e.19
            :op1 (p / phosphorylate-01~e.16
                  :ARG1~e.17 (p4 / protein
                        :name (n4 / name :op1 "STAT3"~e.18))
                  :ARG1-of (i / increase-01~e.15))
            :op2 (l2 / level~e.21
                  :mod (h / high~e.20
                        :degree~e.20 (m / more~e.20))
                  :degree-of~e.22 (e2 / express-03~e.28
                        :ARG2 (p5 / protein
                              :name (n5 / name :op1 "bcl-xL"~e.23))))
            :compared-to~e.29 (c2 / cell~e.33
                  :name (n6 / name :op1 "B9"~e.32)
                  :mod (p6 / parental~e.31)
                  :time (a2 / after~e.34
                        :op1 (w2 / withdraw-01~e.36
                              :ARG1 (p7 / protein
                                    :name (n7 / name :op1 "cytokine"~e.35)))))))

# ::tok Furthermore , Erk @-@ 2 phosphorylated threonine 1179 and serine 1185 ( and to a lesser extent , serine 395 ) in vitro , suggesting the importance of this pathway for SRC @-@ 1 regulation .
# ::alignments 2-1.1.2.1.1 4-1.1.2.1.1 5-1.1 6-1.1.1.1.2.1 7-1.1.1.1.1 8-1.1.1 9-1.1.1.2.2.1 9-1.1.1.3.2.1 10-1.1.1.2.1 13-1.1.1.r 15-1.1.1.3.3.1 15-1.1.1.3.3.1.1 15-1.1.1.3.3.1.1.r 16-1.1.1.3.3 18-1.1.1.3.2.1 19-1.1.1.3.1 21-1.1.3 22-1.1.3 24-1.1.4 26-1.1.4.1 27-1.1.4.1.1.r 28-1.1.4.1.1.1 29-1.1.4.1.1 30-1.1.4.1.2.r 31-1.1.4.1.2.1.1.1 33-1.1.4.1.2.1.1.1 34-1.1.4.1.2
# ::id bel_pmid_1066_0621_21334
(a3 / and
      :op2 (p / phosphorylate-01~e.5
            :ARG1~e.13 (a4 / and~e.8
                  :op1 (a / amino-acid
                        :mod "1179"~e.7
                        :name (n / name :op1 "threonine"~e.6))
                  :op2 (a2 / amino-acid
                        :mod "1185"~e.10
                        :name (n2 / name :op1 "serine"~e.9))
                  :op3 (a5 / amino-acid
                        :mod "395"~e.19
                        :name (n4 / name :op1 "serine"~e.9,18)
                        :degree (e2 / extent~e.16
                              :mod (l / less~e.15
                                    :degree~e.15 (m / more~e.15)))))
            :ARG2 (e / enzyme
                  :name (n3 / name :op1 "Erk-2"~e.2,4))
            :manner (i / in-vitro~e.21,22)
            :ARG0-of (s / suggest-01~e.24
                  :ARG1 (i2 / importance~e.26
                        :poss~e.27 (p2 / pathway~e.29
                              :mod (t / this~e.28))
                        :purpose~e.30 (r / regulate-01~e.34
                              :ARG1 (p3 / protein
                                    :name (n5 / name :op1 "SRC-1"~e.31,33)))))))

# ::tok Treatment of cells expressing SRC @-@ 1 with epidermal growth factor enhanced the ligand @-@ dependent , progesterone receptor @-@ mediated activation of a target reporter gene . These results identify phosphorylation as a regulatory modification of SRC @-@ 1 and provide a basis upon which to identify signaling pathways that regulate SRC @-@ 1 function and , consequently , modify steroid @/@ nuclear receptor action .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1 3-1.1.1.1.1 4-1.1.1.1.1.1.1.1 6-1.1.1.1.1.1.1.1 7-1.1.1.2.r 8-1.1.1.2.1.1 9-1.1.1.2.1.2 10-1.1.1.2.1.3 11-1.1 13-1.1.2.2.1 15-1.1.2.2 17-1.1.2.3.1.1.1 18-1.1.2.3.1.1.2 20-1.1.2.3 21-1.1.2 22-1.1.2.1.r 24-1.1.2.1 24-1.1.2.1.2 24-1.1.2.1.2.r 25-1.1.2.1.1.1 26-1.1.2.1.1.2 28-1.2.1.1.2 29-1.2.1.1 29-1.2.1.1.1 29-1.2.1.1.1.r 30-1.2.1 31-1.2.1.2 32-1.2.1.3.r 34-1.2.1.3.2 35-1.2.1.3 36-1.2.1.3.1.r 37-1.2.1.3.1.1.1 39-1.2.1.3.1.1.1 40-1.2 41-1.2.2 43-1.2.2.2 47-1.2.2.3 48-1.2.2.3.1.1 49-1.2.2.3.1 51-1.2.2.3.1.2 52-1.2.2.3.1.2.1.1 53-1.2.2.3.1.2.1.1 54-1.2.2.3.1.2.1.1 55-1.2.2.3.1.3.2.1 58-1.2.2.3.1.3.2 60-1.2.2.3.1.3 61-1.2.2.3.1.3.1.1.1.1 63-1.2.2.3.1.3.1.1.1.1 64-1.2.2.3.1.3.1.1.1.2 65-1.2.2.3.1.3.1
# ::id bel_pmid_1066_0621_6864
(m / multi-sentence
      :snt1 (e / enhance-01~e.11
            :ARG0 (t / treat-04~e.0
                  :ARG1~e.1 (c / cell~e.2
                        :ARG3-of (e2 / express-03~e.3
                              :ARG2 (p3 / protein
                                    :name (n2 / name :op1 "SRC-1"~e.4,6))))
                  :ARG2~e.7 (p8 / protein
                        :name (n / name
                              :op1 "epidermal"~e.8
                              :op2 "growth"~e.9
                              :op3 "factor"~e.10)))
            :ARG1 (a2 / activate-01~e.21
                  :ARG1~e.22 (g / gene~e.24
                        :name (n4 / name :op1 "reporter"~e.25 :op2 "gene"~e.26)
                        :ARG1-of~e.24 (t2 / target-01~e.24))
                  :ARG0-of (d / depend-01~e.15
                        :ARG1 (l / ligand~e.13))
                  :ARG1-of (m2 / mediate-01~e.20
                        :ARG0 (p4 / protein
                              :name (n3 / name :op1 "progesterone"~e.17 :op2 "receptor"~e.18)))))
      :snt2 (a3 / and~e.40
            :op1 (i / identify-01~e.30
                  :ARG0 (t3 / thing~e.29
                        :ARG1-of~e.29 (r2 / result-01~e.29)
                        :mod (t4 / this~e.28))
                  :ARG1 (p2 / phosphorylate-01~e.31)
                  :ARG2~e.32 (m3 / modify-01~e.35
                        :ARG1~e.36 (p / protein
                              :name (n5 / name :op1 "SRC-1"~e.37,39))
                        :ARG0-of (r / regulate-01~e.34)))
            :op2 (p5 / provide-01~e.41
                  :ARG0 t3
                  :ARG1 (b / basis~e.43)
                  :purpose (i2 / identify-01~e.47
                        :ARG1 (p6 / pathway~e.49
                              :ARG0-of (s2 / signal-01~e.48)
                              :ARG0-of (r3 / regulate-01~e.51
                                    :ARG1 (f / function-01
                                          :ARG0 p~e.52,53,54))
                              :ARG0-of (m4 / modify-01~e.60
                                    :ARG1 (a4 / act-01~e.65
                                          :ARG0 (p7 / protein
                                                :name (n6 / name :op1 "steroid/nuclear"~e.61,63 :op2 "receptor"~e.64)))
                                    :ARG1-of (c2 / cause-01~e.58
                                          :ARG0 r3~e.55)))))))

# ::tok overexpressions of cyclin D1 or bcl @-@ 2 inhibited only differentiation or apoptosis , respectively
# ::alignments 2-1.1.1.1.1.1 3-1.1.1.1.1.2 4-1.1.1 5-1.1.1.2.1.1 7-1.1.1.2.1.1 8-1 9-1.3 10-1.2.1 11-1.2 12-1.2.2 14-1.4 14-1.4.r
# ::id bel_pmid_1066_6199_2154
(i / inhibit-01~e.8
      :ARG0 (o3 / overexpress-00
            :ARG2 (o4 / or~e.4
                  :op1 (p / protein
                        :name (n / name :op1 "cyclin"~e.2 :op2 "D1"~e.3))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "bcl-2"~e.5,7))))
      :ARG1 (o2 / or~e.11
            :op1 (d / differentiate-01~e.10)
            :op2 (a / apoptosis~e.12))
      :mod (o / only~e.9)
      :manner~e.14 (r / respective~e.14))

# ::tok Although STAT3 is essential for IL @-@ 6 @-@ induced macrophage differentiation of M1 cells , GATA @-@ 1 had little or no effect on tyrosine phosphorylation , DNA binding , and transcriptional activities of STAT3 in Western blot analysis , electropholic mobility shift assay ( EMSA ) , and luciferase assays .
# ::alignments 0-1 1-1.2.1 2-1.2.1.r 3-1.2 4-1.2.2.r 5-1.2.2.2.1.1.1 7-1.2.2.2.1.1.1 9-1.2.2.2 10-1.2.2.3 11-1.2.2 12-1.2.2.1.r 13-1.2.2.1.1.1 14-1.2.2.1 16-1.1.1.1.1.1 18-1.1.1.1.1.1 20-1.1.1.3 21-1.1 22-1.1.2.1 22-1.1.2.1.r 23-1.1.1 23-1.1.2 24-1.1.1.2.r 25-1.1.1.2.1.1.1.1 26-1.1.1.2.1 28-1.1.1.2.2.1 29-1.1.1.2.2 31-1.1.1.2 35-1.1.1.2.3.1.1.1 36-1.1.3.r 37-1.1.3.1.1.1 38-1.1.3.1.1.2 39-1.1.3.1.1.3 41-1.1.3.2.1.1 42-1.1.3.2.1.2 43-1.1.3.2.1.3 44-1.1.3.2.1.4 46-1.1.3.2.2.1.1.1 50-1.1.3.3.1.1 51-1.1.3.3.1.2
# ::id bel_pmid_1066_6199_28424
(h / have-concession-91~e.0
      :ARG1 (o2 / or~e.21
            :op1 (a / affect-01~e.23
                  :ARG0 (p2 / protein
                        :name (n / name :op1 "GATA-1"~e.16,18))
                  :ARG1~e.24 (a2 / and~e.31
                        :op1 (p / phosphorylate-01~e.26
                              :ARG1 (a3 / amino-acid
                                    :name (n3 / name :op1 "tyrosine"~e.25)))
                        :op2 (b / bind-01~e.29
                              :ARG1 (d / DNA~e.28))
                        :op3 (a4 / act-01
                              :ARG0 (p3 / protein
                                    :name (n4 / name :op1 "STAT3"~e.35))
                              :ARG1 (t / transcribe-01)))
                  :degree (l / little~e.20))
            :op2 (a6 / affect-01~e.23
                  :polarity~e.22 "-"~e.22
                  :ARG0 p2
                  :ARG1 a2)
            :time~e.36 (a5 / and
                  :op1 (t2 / thing
                        :name (n5 / name
                              :op1 "Western"~e.37
                              :op2 "blot"~e.38
                              :op3 "analysis"~e.39))
                  :op2 (t3 / thing
                        :name (n6 / name
                              :op1 "electropholic"~e.41
                              :op2 "mobility"~e.42
                              :op3 "shift"~e.43
                              :op4 "assay"~e.44)
                        :ARG1-of (d2 / describe-01
                              :ARG2 (t4 / thing
                                    :name (n7 / name :op1 "EMSA"~e.46))))
                  :op3 (t5 / thing
                        :name (n8 / name :op1 "luciferase"~e.50 :op2 "assay"~e.51))))
      :ARG2 (e / essential~e.3
            :domain~e.2 p3~e.1
            :purpose~e.4 (d3 / differentiate-01~e.11
                  :ARG1~e.12 (c2 / cell~e.14
                        :name (n10 / name :op1 "M1"~e.13))
                  :ARG1-of (i2 / induce-01~e.9
                        :ARG0 (p4 / protein
                              :name (n11 / name :op1 "IL-6"~e.5,7)))
                  :mod (m / macrophage~e.10))))

# ::tok During IL @-@ 6 @-@ induced macrophage differentiation of M1 cells , IL @-@ 6 down @-@ regulated cyclin D1 expression and induced p19( INK4D ) expression , leading to reduction in cdk4 activities . In contrast , sustained expression of cyclin D1 and a significantly lesser amount of p19( INK4D ) induction were observed in IL @-@ 6 @-@ treated M1 cells overexpressing GATA @-@ 1 .
# ::alignments 0-1.1.4.r 1-1.1.4.2.1 2-1.1.4.2.1 3-1.1.4.2.1 5-1.1.4.2 6-1.1.4.3 7-1.1.4 8-1.1.4.1.r 9-1.1.4.1.1.1 10-1.1.4.1 12-1.1.1.2.1.1 14-1.1.1.2.1.1 18-1.1.1.1.1.1.1 19-1.1.1.1.1.1.2 20-1.1.1.1 20-1.1.2.2 21-1.1 22-1.1.2 26-1.1.1.1 26-1.1.2.2 28-1.1.3 29-1.1.3.1.r 30-1.1.3.1 32-1.1.3.1.1.1.1.1 36-1.2 38-1.2.1.1.1.2 39-1.2.1.1.1 40-1.2.1.1.1.1.r 41-1.2.1.1.1.1.1.1 42-1.2.1.1.1.1.1.2 43-1.2.1.1 45-1.2.1.1.2.1.1 45-1.2.1.1.2.1.1.r 46-1.2.1.1.2.1 46-1.2.1.1.2.1.2 46-1.2.1.1.2.1.2.r 47-1.2.1.1.2 52-1.2.1.1.2.2 54-1.2.1 55-1.2.1.2.r 56-1.2.1.2.2.1.1.1 58-1.2.1.2.2.1.1.1 60-1.2.1.2.2 61-1.2.1.2.1.1 62-1.2.1.2 64-1.2.1.2.3.1.1.1 66-1.2.1.2.3.1.1.1
# ::id bel_pmid_1066_6199_38222
(m / multi-sentence
      :snt1 (a / and~e.21
            :op1 (d / downregulate-01
                  :ARG1 (e / express-03~e.20,26
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "cyclin"~e.18 :op2 "D1"~e.19)))
                  :ARG2 (p / protein
                        :name (n / name :op1 "IL-6"~e.12,14)))
            :op2 (i / induce-01~e.22
                  :ARG0 p
                  :ARG1 (e2 / express-03~e.20,26
                        :ARG1 (g / gene
                              :name (n7 / name :op1 "p19INK4D"))))
            :ARG0-of (l / lead-03~e.28
                  :ARG2~e.29 (r / reduce-01~e.30
                        :ARG1 (a2 / act-01
                              :ARG0 (e3 / enzyme
                                    :name (n3 / name :op1 "cdk4"~e.32)))))
            :time~e.0 (d2 / differentiate-01~e.7
                  :ARG1~e.8 (c / cell~e.10
                        :name (n4 / name :op1 "M1"~e.9))
                  :ARG1-of (i2 / induce-01~e.5
                        :ARG0 p~e.1,2,3)
                  :mod (m2 / macrophage~e.6)))
      :snt2 (c3 / contrast-01~e.36
            :ARG2 (o / observe-01~e.54
                  :ARG1 (a3 / and~e.43
                        :op1 (e4 / express-03~e.39
                              :ARG1~e.40 (p3 / protein
                                    :name (n6 / name :op1 "cyclin"~e.41 :op2 "D1"~e.42))
                              :ARG1-of (s / sustain-01~e.38))
                        :op2 (a4 / amount~e.47
                              :mod (l2 / less~e.46
                                    :manner~e.45 (s2 / significant~e.45)
                                    :degree~e.46 (m3 / more~e.46))
                              :degree-of (i4 / induce-01~e.52
                                    :ARG1 (g2 / gene
                                          :name (n8 / name :op1 "p19INK4D")))))
                  :location~e.55 (c4 / cell~e.62
                        :name (n9 / name :op1 "M1"~e.61)
                        :ARG1-of (t / treat-04~e.60
                              :ARG2 (p4 / protein
                                    :name (n10 / name :op1 "IL-6"~e.56,58)))
                        :ARG3-of (o2 / overexpress-00
                              :ARG2 (p5 / protein
                                    :name (n11 / name :op1 "GATA-1"~e.64,66)))))))

# ::tok p44MAPK @/@ extracellular signal @-@ regulated kinase 1 ( ERK1 ) and p42 MAPK @/@ ERK2 are activated by IL @-@ 3 , colocalize with mitochondrial Bcl2 , and can directly phosphorylate Bcl2 on Ser @-@ 70 in a stauro @-@ resistant manner both in vitro and in vivo
# ::alignments 0-1.1.2.1.1.1 2-1.1.2.1.2.1.1.1 3-1.1.2.1.2.1.1.2 5-1.1.2.1.2.1.1.2 6-1.1.2.1.2.1.1.3 7-1.1.2.1.2.1.1.4 9-1.1.2.1.2.1.2.1.1.1 15-1.1.2.2.2.1.1.1 17-1.1 18-1.1.1.r 19-1.1.1.1.1 21-1.1.1.1.1 23-1.2 26-1.2.2.1.1 28-1 29-1.3 30-1.3.1.5 31-1.3.1 32-1.3.1.1.3 36-1.3.1.1.1 37-1.3.1.3.r 37-1.3.1.4.1 39-1.3.1.3.1.1.1 41-1.3.1.3 42-1.3.1.4.r 42-1.3.1.5.r 44-1.3.1.4.1 45-1.3.1.4.1 46-1.3.1.4 47-1.3.1.4.1 47-1.3.1.4.2 48-1.3.1.4.2
# ::id bel_pmid_1067_7502_21952
(a / and~e.28
      :op1 (a2 / activate-01~e.17
            :ARG0~e.18 (p / protein
                  :name (n6 / name :op1 "IL-3"~e.19,21))
            :ARG1 (a3 / and
                  :op1 (e / enzyme
                        :name (n / name :op1 "p44MAPK"~e.0)
                        :ARG1-of (m / mean-01
                              :ARG2 (e2 / enzyme
                                    :name (n2 / name
                                          :op1 "extracellular"~e.2
                                          :op2 "signal-regulated"~e.3,5
                                          :op3 "kinase"~e.6
                                          :op4 "1"~e.7)
                                    :ARG1-of (d / describe-01
                                          :ARG2 (e3 / enzyme
                                                :name (n3 / name :op1 "ERK1"~e.9))))))
                  :op2 (e4 / enzyme
                        :name (n4 / name :op1 "p42MAPK")
                        :ARG1-of (m2 / mean-01
                              :ARG2 (e5 / enzyme
                                    :name (n5 / name :op1 "ERK2"~e.15))))))
      :op2 (c / colocalize-00~e.23
            :ARG1 a3
            :ARG2 (p2 / protein
                  :name (n7 / name :op1 "Bcl2"~e.26)
                  :part-of (m3 / mitochondrion)))
      :op3 (p3 / possible~e.29
            :domain (p4 / phosphorylate-01~e.31
                  :ARG1 (a4 / amino-acid
                        :mod "70"~e.36
                        :name (n8 / name :op1 "serine")
                        :part-of p2~e.32)
                  :ARG2 a3
                  :manner~e.37 (r / resist-01~e.41
                        :ARG1 (s / small-molecule
                              :name (n9 / name :op1 "stauro"~e.39)))
                  :manner~e.42 (a5 / and~e.46
                        :op1 (i / in-vitro~e.37,44,45,47)
                        :op2 (i2 / in-vivo~e.47,48))
                  :manner~e.42 (d2 / direct~e.30))))

# ::tok High concentrations of stauro of up to 1 microM only partially inhibit IL @-@ 3 @-@ stimulated Bcl2 phosphorylation but completely block PKC @-@ mediated Bcl2 phosphorylation in vitro
# ::alignments 0-1.1.1.2 1-1.1.1 1-1.1.1.3.1 2-1.1.1.1.r 3-1.1.1.1.1.1 4-1.1.1.3.r 5-1.1.1.3 6-1.1.1.3 7-1.1.1.3.1.1 9-1.1.4 11-1.1 12-1.1.2.2.1.1.1 14-1.1.2.2.1.1.1 16-1.1.2.2 17-1.1.2.1.1.1 18-1.1.2 19-1 20-1.2.3 20-1.2.3.r 21-1.2 22-1.2.2.2.1.1.1 24-1.2.2.2 25-1.2.2.1 26-1.2.2 27-1.2.4 28-1.2.4
# ::id bel_pmid_1067_7502_3614
(c / contrast-01~e.19
      :ARG1 (i / inhibit-01~e.11
            :ARG0 (c2 / concentrate-02~e.1
                  :ARG0~e.2 (s / small-molecule
                        :name (n4 / name :op1 "stauro"~e.3))
                  :mod (h / high~e.0)
                  :quant~e.4 (u / up-to~e.5,6
                        :op1 (c4 / concentration-entity~e.1
                              :quant "1"~e.7
                              :unit (m2 / micromolar))))
            :ARG1 (p3 / phosphorylate-01~e.18
                  :ARG1 (p4 / protein
                        :name (n / name :op1 "Bcl2"~e.17))
                  :ARG1-of (s2 / stimulate-01~e.16
                        :ARG0 (p5 / protein
                              :name (n2 / name :op1 "IL-3"~e.12,14))))
            :manner (p2 / part)
            :mod (o / only~e.9))
      :ARG2 (b / block-01~e.21
            :ARG0 c2
            :ARG1 (p / phosphorylate-01~e.26
                  :ARG1 p4~e.25
                  :ARG1-of (m / mediate-01~e.24
                        :ARG0 (e / enzyme
                              :name (n3 / name :op1 "PKC"~e.22))))
            :manner~e.20 (c3 / complete~e.20)
            :manner (i2 / in-vitro~e.27,28)))

# ::tok By using a refined model of megakaryocytic differentiation , we found that either TPO stimulation or Ha @-@ Ras G12V expression could up @-@ regulate the expression of cyclin D1 and cyclin D2 in addition to cyclin D3 , and that , when cdc2 activity was suppressed , each of cyclin D1 , cyclin D2 , and cyclin D3 expression was able to induce megakaryocytic differentiation with a similar efficiency .
# ::alignments 1-1.3 3-1.3.1.1 4-1.3.1 5-1.3.1.2.r 6-1.3.1.2 7-1.3.1.2 9-1.1 10-1 13-1.2.1.1.2.1.1.1.1 14-1.2.1.1.2.1 15-1.2.1.1.2 16-1.2.1.1.2.2.1.1.1 18-1.2.1.1.2.2.1.1.1 19-1.2.1.1.2.2.1.2.1 20-1.2.1.1.2.2 21-1.2.2 26-1.2.2.1.1.1 28-1.2.2.1.1.1.1.1.1 29-1.2.2.1.1.1.1.1.2 30-1.2.2.1.1 31-1.2.2.1.1.2.1.1.1 32-1.2.2.1.1.2.1.1.2 33-1.2.2.1.1 34-1.2.2.1.1 36-1.2.2.1.1.3.1.1.1 37-1.2.2.1.1.3.1.1.2 39-1.2.2.1.1 42-1.2.2.2.r 43-1.2.2.2.1.1.1.1 46-1.2.2.2 48-1.2.2.1.1.4 50-1.2.2.1.1.1.1.1.1 51-1.2.2.1.1.1.1.1.2 53-1.2.2.1.1.2.1.1.1 54-1.2.2.1.1.2.1.1.2 56-1.2.2.1.1 57-1.2.2.1.1.3.1.1.1 58-1.2.2.1.1.3.1.1.2 59-1.2.2.1.1.1 59-1.2.2.1.1.2 59-1.2.2.1.1.3 60-1.2.2.1.r 61-1.2.1 61-1.2.2 63-1.2.2.1 64-1.2.2.1.2.1.1.1 65-1.2.2.1.2 66-1.2.2.1.3.r 68-1.2.2.1.3.1 69-1.2.2.1.3
# ::id bel_pmid_1068_1535_24496
(f / find-01~e.10
      :ARG0 (w / we~e.9)
      :ARG1 (a / and
            :op1 (p2 / possible~e.61
                  :domain (u / upregulate-01
                        :ARG1 (a3 / and~e.30,33,34,39,56
                              :op1 (e3 / express-03~e.26,59
                                    :ARG2 (p9 / protein
                                          :name (n6 / name :op1 "cyclin"~e.28,50 :op2 "D1"~e.29,51)))
                              :op2 (e4 / express-03~e.59
                                    :ARG2 (p10 / protein
                                          :name (n7 / name :op1 "cyclin"~e.31,53 :op2 "D2"~e.32,54)))
                              :op3 (e5 / express-03~e.59
                                    :ARG2 (p11 / protein
                                          :name (n8 / name :op1 "cyclin"~e.36,57 :op2 "D3"~e.37,58)))
                              :mod (e6 / each~e.48))
                        :ARG2 (o / or~e.15
                              :op1 (s / stimulate-01~e.14
                                    :ARG1 (p3 / protein
                                          :name (n / name :op1 "TPO"~e.13)))
                              :op2 (e / express-03~e.20
                                    :ARG2 (p4 / protein
                                          :name (n2 / name :op1 "Ha-Ras"~e.16,18)
                                          :ARG2-of (m / mutate-01 :value "G12V"~e.19))))))
            :op2 (p8 / possible~e.21,61
                  :domain~e.60 (i / induce-01~e.63
                        :ARG0 a3
                        :ARG1 (d / differentiate-01~e.65
                              :ARG1 (c / cell
                                    :name (n10 / name :op1 "megakaryocyte"~e.64)))
                        :manner~e.66 (e7 / efficient-41~e.69
                              :ARG1-of (r2 / resemble-01~e.68)))
                  :time~e.42 (s2 / suppress-01~e.46
                        :ARG1 (a4 / act-01
                              :ARG0 (e8 / enzyme
                                    :name (n9 / name :op1 "cdc2"~e.43))))))
      :manner (u2 / use-01~e.1
            :ARG1 (m3 / model~e.4
                  :ARG1-of (r / refine-01~e.3)
                  :topic~e.5 d~e.6,7)))

# ::tok We found that TPO stimulation or Ha @-@ Ras G12V expression led to up @-@ regulation of cyclin D1 , cyclin D2 , and cyclin D3 expression .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1.1.1 4-1.2.1.1 5-1.2.1 6-1.2.1.2.1.1.1 8-1.2.1.2.1.1.1 9-1.2.1.2.1.2.1 10-1.2.1.2 11-1.2 17-1.2.2.1.1.1.1.1 18-1.2.2.1.1.1.1.2 20-1.2.2.1.2.1.1.1 21-1.2.2.1.2.1.1.2 23-1.2.2.1 24-1.2.2.1.3.1.1.1 25-1.2.2.1.3.1.1.2 26-1.2.2.1.1 26-1.2.2.1.2 26-1.2.2.1.3
# ::id bel_pmid_1068_1535_5746
(f / find-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (l / lead-03~e.11
            :ARG0 (o / or~e.5
                  :op1 (s / stimulate-01~e.4
                        :ARG1 (p / protein
                              :name (n / name :op1 "TPO"~e.3)))
                  :op2 (e / express-03~e.10
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "Ha-Ras"~e.6,8)
                              :ARG2-of (m / mutate-01 :value "G12V"~e.9))))
            :ARG2 (u / upregulate-01
                  :ARG1 (a2 / and~e.23
                        :op1 (e2 / express-03~e.26
                              :ARG2 (p3 / protein
                                    :name (n3 / name :op1 "cyclin"~e.17 :op2 "D1"~e.18)))
                        :op2 (e3 / express-03~e.26
                              :ARG2 (p4 / protein
                                    :name (n4 / name :op1 "cyclin"~e.20 :op2 "D2"~e.21)))
                        :op3 (e4 / express-03~e.26
                              :ARG2 (p5 / protein
                                    :name (n5 / name :op1 "cyclin"~e.24 :op2 "D3"~e.25)))))))

# ::tok which are dual @-@ specificity ( serine/threonine and tyrosine ) kinases that regulate downstream responses to a broad range of mitogenic , apoptotic , and differentiation @-@ inducing stimuli [368 @-@ 372]. Interestingly , MEK1 but not MEK2 is stimulated by H2O2 treatment , suggesting that only MEK1 is redox @-@ sensitive [154].
# ::alignments 2-1.1.1.1.2 4-1.1.1.1 7-1.1.1.1.1.1 8-1.1.1.1.1.1.2.1.1 10-1.1.1 12-1.1 13-1.1.3 14-1.1.2 15-1.1.2.1.r 17-1.1.2.1.2 18-1.1.2.1 19-1.1.2.1.1.r 20-1.1.2.1.1.1 22-1.1.2.1.1.2 25-1.1.2.1.1.3.1 27-1.1.2.1.1.3 28-1.1.2.1.1 34-1.2.1.2.1.1 35-1.2 36-1.2.2.1 36-1.2.2.1.r 37-1.2.2.3.1.1 39-1.2.1 39-1.2.2 40-1.2.1.1.r 41-1.2.1.1.1 42-1.2.1.1 44-1.2.4 45-1.2.4.1.r 46-1.2.4.1.3 47-1.2.4.1.1 49-1.2.4.1.2 51-1.2.4.1
# ::id bel_pmid_1069_9758_15770
(m / multi-sentence
      :snt1 (r / regulate-01~e.12
            :ARG0 (k / kinase~e.10
                  :mod (s7 / specificity~e.4
                        :ARG1-of (m2 / mean-01
                              :ARG2 (a / and~e.7
                                    :op1 (s / slash
                                          :op1 (a2 / amino-acid
                                                :name (n / name :op1 "serine"))
                                          :op2 (a3 / amino-acid
                                                :name (n2 / name :op1 "theronine")))
                                    :op2 (a4 / amino-acid
                                          :name (n3 / name :op1 "tyrosine"~e.8))))
                        :mod (d / dual~e.2)))
            :ARG1 (r2 / respond-01~e.14
                  :ARG1~e.15 (r5 / range~e.18
                        :mod~e.19 (s5 / stimulus~e.28
                              :mod (m3 / mitogenic~e.20)
                              :mod (a6 / apoptotic~e.22)
                              :ARG0-of (i / induce-01~e.27
                                    :ARG1 (d3 / differentiate-01~e.25)))
                        :mod (b / broad~e.17)))
            :direction (d2 / downstream~e.13)
            :ARG1-of (d4 / describe-01
                  :ARG0 (p / publication
                        :ARG1-of (c / cite-01
                              :ARG2 (v / value-interval :op1 "368" :op2 "372")))))
      :snt2 (c2 / contrast-01~e.35
            :ARG1 (s2 / stimulate-01~e.39
                  :ARG0~e.40 (t / treat-04~e.42
                        :ARG2 (h / H2O2~e.41))
                  :ARG1 (e / enzyme
                        :name (n4 / name :op1 "MEK1"~e.34)))
            :ARG2 (s3 / stimulate-01~e.39
                  :polarity~e.36 "-"~e.36
                  :ARG0 t
                  :ARG1 (e2 / enzyme
                        :name (n5 / name :op1 "MEK2"~e.37)))
            :ARG2-of (i2 / interest-01)
            :ARG0-of (s4 / suggest-01~e.44
                  :ARG1~e.45 (s6 / sensitive-03~e.51
                        :ARG0 e~e.47
                        :ARG1 (r3 / redox~e.49)
                        :mod (o / only~e.46))
                  :ARG2-of (i3 / interest-01)
                  :ARG1-of (d5 / describe-01
                        :ARG0 (p2 / publication
                              :ARG1-of (c3 / cite-01 :ARG2 "154"))))))

# ::tok Additionally , several studies have shown that antioxidant enzymes and mimics also block NF @-@ kB activation by various stimuli . For example , overexpression of peroxiredoxin [247] or thioredoxin [111] blocks NF @-@ kB activation by H2O2 .
# ::alignments 0-1.1.3 2-1.1.1.1 3-1.1.1 5-1.1 6-1.1.2.r 7-1.1.2.1.1.1 8-1.1.2.1.1 9-1.1.2.1 10-1.1.2.1.2 11-1.1.2.4 12-1.1.2 13-1.1.2.2.1.1.1 15-1.1.2.2.1.1.1 16-1.1.2.2 17-1.1.2.3.r 18-1.1.2.3.1 19-1.1.2.3 21-1.2.4 22-1.2.4 26-1.2.1.1.1.1.1 28-1.2.1 29-1.2.1.2.1.1.1 31-1.2 32-1.2.2.1.1.1 34-1.2.2.1.1.1 35-1.2.2 36-1.2.3.r 37-1.2.3
# ::id bel_pmid_1069_9758_24188
(m / multi-sentence
      :snt1 (s / show-01~e.5
            :ARG0 (s2 / study-01~e.3
                  :quant (s3 / several~e.2))
            :ARG1~e.6 (b / block-01~e.12
                  :ARG0 (a7 / and~e.9
                        :op1 (e2 / enzyme~e.8
                              :mod (a2 / antioxidant~e.7))
                        :op2 (m2 / mimic-01~e.10))
                  :ARG1 (a4 / activate-01~e.16
                        :ARG1 (p / protein
                              :name (n / name :op1 "NF-kB"~e.13,15)))
                  :ARG3~e.17 (s4 / stimulus~e.19
                        :mod (v / various~e.18))
                  :mod (a / also~e.11))
            :mod (a6 / additional~e.0))
      :snt2 (b3 / block-01~e.31
            :ARG0 (o4 / or~e.28
                  :op1 (o2 / overexpress-00
                        :ARG2 (e4 / enzyme
                              :name (n2 / name :op1 "peroxiredoxin"~e.26))
                        :ARG1-of (d / describe-01
                              :ARG0 (p2 / publication
                                    :ARG1-of (c / cite-01 :ARG2 "247"))))
                  :op2 (o3 / overexpress-00
                        :ARG2 (p4 / protein
                              :name (n4 / name :op1 "thioredoxin"~e.29))
                        :ARG1-of (d2 / describe-01
                              :ARG0 (p5 / publication
                                    :ARG1-of (c2 / cite-01 :ARG2 "111")))))
            :ARG1 (a5 / activate-01~e.35
                  :ARG1 (p3 / protein
                        :name (n3 / name :op1 "NF-kB"~e.32,34)))
            :ARG3~e.36 (h / H2O2~e.37)
            :ARG0-of (e / exemplify-01~e.21,22)))

# ::tok Furthermore , in many types of cells , antioxidants diminish or completely eliminate NF @-@ kB activation ( Table 1 ) . For example , H2O2 , UV , and ionizing radiation have all been observed to stimulate degradation of IkB ( Table 1 ) . Conversely , antioxidants and reductants such as BHA , NGA , a @-@ tocopherol , NAC , and PDTC decrease NF @-@ kB activity and translocation [12,253].
# ::alignments 3-1.1.1.3.2 4-1.1.1.3 5-1.1.1.3.1.r 6-1.1.1.3.1 8-1.1.1.1.1 9-1.1.1.1 10-1.1.1 11-1.1.1.2.3 12-1.1.1.2 13-1.1.1.1.2.1.1.1 15-1.1.1.1.2.1.1.1 16-1.1.1.1.2 18-1.1.2.1 18-1.2.2.1 19-1.1.2.1.1 19-1.2.2.1.1 23-1.2.3 25-1.2.1.1.1 27-1.2.1.1.2 29-1.2.1.1 30-1.2.1.1.3.1 31-1.2.1.1.3 33-1.2.1.1.4 35-1.2 37-1.2.1 38-1.2.1.2 39-1.2.1.2.1.r 40-1.2.1.2.1.1.1 42-1.1.2.1 42-1.2.2.1 43-1.1.2.1.1 43-1.2.2.1.1 48-1.3.1.1.1 48-1.3.1.1.1.1.1 48-1.3.1.1.1.1.2 49-1.3.1.1.1.1 51-1.3.1.1.1.1.r 52-1.3.1.1.1.1.r 53-1.3.1.1.1.1.1.1.1 55-1.3.1.1.1.1.2.1.1 57-1.3.1.1.2.1.1.1.1 59-1.3.1.1.2.1.1.1.1 61-1.3.1.1.2.1.2.1.1 63-1.3.1.1.2.1 64-1.3.1.1.2.1.3.1.1 65-1.3.1 66-1.3.1.2.1.1.1.1 68-1.3.1.2.1.1.1.1 70-1.3.1.1.2.1 70-1.3.1.2 70-1.3.1.3.1.1.1 71-1.3.1.2.2
# ::id bel_pmid_1069_9758_34686
(m / multi-sentence
      :snt1 (a / and
            :op2 (o / or~e.10
                  :op1 (d / diminish-01~e.9
                        :ARG0 (a10 / antioxidant~e.8)
                        :ARG1 (a2 / activate-01~e.16
                              :ARG1 (p / protein
                                    :name (n2 / name :op1 "NF-kB"~e.13,15))))
                  :op2 (e2 / eliminate-01~e.12
                        :ARG0 (m2 / molecular-physical-entity)
                        :ARG1 a2
                        :degree (c4 / complete~e.11))
                  :location (t / type~e.4
                        :mod~e.5 (c / cell~e.6)
                        :quant (m3 / many~e.3)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (t2 / table~e.18,42 :mod "1"~e.19,43)))
      :snt2 (o2 / observe-01~e.35
            :ARG1 (s / stimulate-01~e.37
                  :ARG0 (a3 / and~e.29
                        :op1 (h / H2O2~e.25)
                        :op2 (u / UV~e.27)
                        :op3 (r / radiate-01~e.31
                              :ARG0-of (i / ionize-01~e.30))
                        :mod (a11 / all~e.33))
                  :ARG1 (d3 / degrade-01~e.38
                        :ARG1~e.39 (e3 / enzyme
                              :name (n3 / name :op1 "IkB"~e.40))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (t3 / table~e.18,42 :mod "1"~e.19,43))
            :ARG0-of (e / exemplify-01~e.23))
      :snt3 (c2 / contrast-01
            :ARG2 (d5 / decrease-01~e.65
                  :ARG0 (a12 / and
                        :op1 (a7 / antioxidant~e.48
                              :example~e.51,52 (a13 / and~e.49
                                    :op1 (a14 / antioxidant~e.48
                                          :name (n / name :op1 "BHA"~e.53))
                                    :op2 (a15 / antioxidant~e.48
                                          :name (n12 / name :op1 "NGA"~e.55))))
                        :op2 (r2 / reductant
                              :example (a6 / and~e.63,70
                                    :op1 (r3 / reductant
                                          :name (n4 / name :op1 "a-tocopherol"~e.57,59))
                                    :op2 (r4 / reductant
                                          :name (n6 / name :op1 "NAC"~e.61))
                                    :op3 (r5 / reductant
                                          :name (n7 / name :op1 "PDTC"~e.64)))))
                  :ARG1 (a4 / and~e.70
                        :op1 (a8 / act-01
                              :ARG0 (p2 / protein
                                    :name (n11 / name :op1 "NF-kB"~e.66,68)))
                        :op2 (t4 / translocate-00~e.71
                              :ARG0 p2))
                  :ARG1-of (d7 / describe-01
                        :ARG0 (p3 / publication
                              :ARG1-of (c3 / cite-01
                                    :ARG2 (a9 / and~e.70 :op1 "12" :op2 "253")))))))

# ::tok Once activated , Raf @-@ 1 phosphorylates serines in the catalytic sites of MKK @/@ MEK [345,367]. MKK1 @/@ MEK1 and MKK2 @/@ MEK2 activate members of the MAP kinase family ( ERK @-@ 1/ERK @-@ 2 ) ,
# ::alignments 0-1.2.2.2.1.2.1.1 1-1.1.3 3-1.1.2.1.1 5-1.1.2.1.1 6-1.1 7-1.1.1.1.1 10-1.1.1.2.2 11-1.1.1.2 13-1.1.1.2.1.1.1.1 15-1.1.1.2.1.2.1.1 17-1.2.1.1.1.1.1 19-1.2.1.1.2.1.1 20-1.2.1 21-1.2.1.2.1.1.1 23-1.2.1.2.2.1.1 24-1.2 25-1.2.2 26-1.2.2.1.r 28-1.2.2.1.1.1.1 29-1.2.2.1.1.1.2 30-1.2.2.1 32-1.2.2.2.1.1.1.1 32-1.2.2.2.1.2.1.1 36-1.2.2.2.1.2.1.1
# ::id bel_pmid_1069_9758_36926
(m / multi-sentence
      :snt1 (p / phosphorylate-01~e.6
            :ARG1 (a / amino-acid
                  :name (n2 / name :op1 "serine"~e.7)
                  :part-of (p3 / protein-segment~e.11
                        :part-of (s2 / slash
                              :op1 (e5 / enzyme
                                    :name (n6 / name :op1 "MKK"~e.13))
                              :op2 (e6 / enzyme
                                    :name (n7 / name :op1 "MEK"~e.15)))
                        :mod (c / catalysis~e.10)))
            :ARG2 (e / enzyme
                  :name (n / name :op1 "Raf-1"~e.3,5))
            :time (a2 / activate-01~e.1
                  :ARG1 e)
            :ARG1-of (d / describe-01
                  :ARG0 (p2 / publication
                        :ARG1-of (c2 / cite-01
                              :ARG2 (a3 / and :op1 "345" :op2 "367")))))
      :snt2 (a5 / activate-01~e.24
            :ARG0 (a7 / and~e.20
                  :op1 (s3 / slash
                        :op1 (e4 / enzyme
                              :name (n5 / name :op1 "MKK1"~e.17))
                        :op2 (e2 / enzyme
                              :name (n3 / name :op1 "MEK1"~e.19)))
                  :op2 (s5 / slash
                        :op1 (e9 / enzyme
                              :name (n10 / name :op1 "MKK2"~e.21))
                        :op2 (e10 / enzyme
                              :name (n11 / name :op1 "MEK2"~e.23))))
            :ARG1 (m2 / member~e.25
                  :part-of~e.26 (f / family~e.30
                        :mod (e3 / enzyme
                              :name (n4 / name :op1 "MAP"~e.28 :op2 "kinase"~e.29)))
                  :ARG1-of (m3 / mean-01
                        :ARG2 (s4 / slash
                              :op1 (e7 / enzyme
                                    :name (n8 / name :op1 "ERK-1"~e.32))
                              :op2 (e8 / enzyme
                                    :name (n9 / name :op1 "1/ERK-2"~e.0,32,36)))))))

# ::tok Eosinophils Human Superoxide production Human Transmigration through epithelial cells Human Transmigration through Matrigel Human CD11b @/@ CD18 ( Mac @-@ 1 ) translocation , degranulation Human IL @-@ 8 release
# ::alignments 0-1.1.1.2.1.1 1-1.1.1.1 2-1.1.1 3-1.1 4-1.2.2 4-1.3.1.2 4-1.3.2 7-1.2.1.1 8-1.2.1 9-1.2.2 9-1.3.1.2 9-1.3.2 12-1.3.1.1.1 13-1.2.2 13-1.3.1.2 13-1.3.2 14-1.4.1.1.1.1.1 16-1.4.1.1.2.1.1 18-1.4.1.1.3.1.1.1 20-1.4.1.1.3.1.1.1 22-1.4.1 25-1.4.2.1.1.2 26-1.4.2.1.1.1.1 28-1.4.2.1.1.1.1 29-1.4.2.1
# ::id bel_pmid_1072_9607_18666
(m / multi-sentence
      :snt1 (p / produce-01~e.3
            :ARG1 (s / superoxide~e.2
                  :mod (h / human~e.1)
                  :mod (c / cell
                        :name (n / name :op1 "eosinophil"~e.0))))
      :snt2 (t / transmigrate-00
            :ARG1 (c2 / cell~e.8
                  :mod (e / epithelium~e.7))
            :mod (h5 / human~e.4,9,13))
      :snt3 (t2 / transmigrate-00
            :ARG1 (t3 / thing
                  :name (n3 / name :op1 "Matrigel"~e.12)
                  :mod (h3 / human~e.4,9,13))
            :mod (h2 / human~e.4,9,13))
      :snt4 (a / and
            :op1 (t4 / translocate-00~e.22
                  :ARG0 (m2 / macro-molecular-complex
                        :part (p2 / protein
                              :name (n4 / name :op1 "CD11b"~e.14))
                        :part (p3 / protein
                              :name (n5 / name :op1 "CD18"~e.16))
                        :ARG1-of (m3 / mean-01
                              :ARG2 (m4 / molecular-physical-entity
                                    :name (n2 / name :op1 "Mac-1"~e.18,20)))))
            :op2 (d / degranulate-00
                  :ARG1 (r / release-01~e.29
                        :ARG0 (p4 / protein
                              :name (n6 / name :op1 "IL-8"~e.26,28)
                              :mod (h4 / human~e.25))))))

# ::tok Activation of tyrosine kinases Fyn and Lyn , but not Lck , also occurred within 2 min after PAF stimulation in the cells
# ::alignments 0-1.1 0-1.2 1-1.1.1.r 2-1.1.1.1.1.1 3-1.1.1.1.1.2 4-1.1.1.1.1.3 5-1.1.1 6-1.1.1.2.1.3 8-1 9-1.2.1 9-1.2.1.r 10-1.2.2.1.1 12-1.1.3 15-1.1.2.2.1.1 17-1.1.2 18-1.1.2.1.1.1.1 19-1.1.2.1 20-1.1.2.1.2.r 22-1.1.2.1.2
# ::id bel_pmid_1072_9607_19486
(c3 / contrast-01~e.8
      :ARG1 (a3 / activate-01~e.0
            :ARG1~e.1 (a / and~e.5
                  :op1 (e / enzyme
                        :name (n / name
                              :op1 "tyrosine"~e.2
                              :op2 "kinases"~e.3
                              :op3 "Fyn"~e.4))
                  :op2 (e2 / enzyme
                        :name (n2 / name
                              :op1 "tyrosine"
                              :op2 "kinases"
                              :op3 "Lyn"~e.6)))
            :time (a6 / after~e.17
                  :op1 (s / stimulate-01~e.19
                        :ARG1 (m / molecular-physical-entity
                              :name (n4 / name :op1 "PAF"~e.18))
                        :location~e.20 (c2 / cell~e.22))
                  :quant (u / up-to
                        :op1 (t / temporal-quantity
                              :quant "2"~e.15
                              :unit (m2 / minute))))
            :mod (a2 / also~e.12))
      :ARG2 (a5 / activate-01~e.0
            :polarity~e.9 "-"~e.9
            :ARG1 (e3 / enzyme
                  :name (n3 / name :op1 "Lck"~e.10))))

# ::tok PAFR promoter 2 contained AP @-@ 2 and Sp @-@ 1 binding sites we demonstrated that PAF activates p44ERK1 @/@ p42ERK2 in CHO cells stably expressing PAF receptor
# ::alignments 2-1.1.1.1 2-1.1.2.1.1.1.1.1.1 3-1.1 4-1.1.2.1.1.1.1.1.1 6-1.1.2.1.1.1.1.1.1 7-1.1.2.1 8-1.1.2.1.2.1.1.1.1 10-1.1.2.1.2.1.1.1.1 11-1.1.2 11-1.1.2.1.1.1 11-1.1.2.1.2.1 12-1.1.2.1.1 12-1.1.2.1.2 13-1.2.1 14-1.2 15-1.2.2.r 16-1.2.2.1.1.1 17-1.2.2 18-1.2.2.2.1.1.1 20-1.2.2.2.2.1.1 21-1.2.2.3.r 22-1.2.2.3.1.1 23-1.2.2.3 24-1.2.2.3.2.2 24-1.2.2.3.2.2.r 25-1.2.2.3.2 26-1.1.1.2.1.1.1 26-1.2.2.1.1.1 27-1.1.1.2.1 27-1.2.2.1
# ::id bel_pmid_1072_9607_19488
(m3 / multi-sentence
      :snt1 (c2 / contain-01~e.3
            :ARG0 (m4 / molecular-physical-entity
                  :mod "2"~e.2
                  :ARG0-of (p / promote-01
                        :ARG1 (r3 / receptor~e.27
                              :name (n7 / name :op1 "PAF"~e.26))))
            :ARG1 (b / bind-01~e.11
                  :ARG1 (a2 / and~e.7
                        :op1 (p4 / protein-segment~e.12
                              :ARG1-of (b2 / bind-01~e.11
                                    :ARG2 (p2 / protein
                                          :name (n6 / name :op1 "AP-2"~e.2,4,6))))
                        :op2 (p5 / protein-segment~e.12
                              :ARG1-of (b3 / bind-01~e.11
                                    :ARG2 (p3 / protein
                                          :name (n8 / name :op1 "Sp-1"~e.8,10)))))))
      :snt2 (d / demonstrate-01~e.14
            :ARG0 (w / we~e.13)
            :ARG1~e.15 (a / activate-01~e.17
                  :ARG0 (r2 / receptor~e.27
                        :name (n / name :op1 "PAF"~e.16,26))
                  :ARG1 (m2 / macro-molecular-complex
                        :part (e / enzyme
                              :name (n2 / name :op1 "p44ERK1"~e.18))
                        :part (e2 / enzyme
                              :name (n3 / name :op1 "p42ERK2"~e.20)))
                  :location~e.21 (c / cell~e.23
                        :name (n4 / name :op1 "CHO"~e.22)
                        :ARG1-of (e3 / express-03~e.25
                              :ARG2 r2
                              :manner~e.24 (s / stable~e.24))))))

# ::tok PAF induced tyrosine phosphorylation and activation of focal adhesion kinase ( FAK ) in human endothelial cells derived from vein umbilical cord
# ::alignments 0-1.1.1.1 1-1 2-1.2.1.1.1.1 3-1.2.1 4-1.2 5-1.2.2 6-1.2.2.1.r 7-1.2.2.1.1.1 8-1.2.2.1.1.2 9-1.2.2.1.1.3 13-1.3.r 14-1.3.2 15-1.3.1 16-1.3 17-1.3.3 18-1.3.3.1.r 19-1.3.3.1.2 20-1.3.3.1.1 21-1.3.3.1
# ::id bel_pmid_1072_9607_19490
(i / induce-01~e.1
      :ARG0 (m / molecular-physical-entity
            :name (n / name :op1 "PAF"~e.0))
      :ARG1 (a / and~e.4
            :op1 (p / phosphorylate-01~e.3
                  :ARG1 (a2 / amino-acid
                        :name (n2 / name :op1 "tyrosine"~e.2)
                        :part-of (e / enzyme
                              :name (n3 / name
                                    :op1 "focal"~e.7
                                    :op2 "adhesion"~e.8
                                    :op3 "kinase"~e.9))))
            :op2 (a3 / activate-01~e.5
                  :ARG1~e.6 e))
      :location~e.13 (c / cell~e.16
            :mod (e2 / endothelium~e.15)
            :mod (h / human~e.14)
            :ARG1-of (d / derive-01~e.17
                  :ARG2~e.18 (c2 / cord~e.21
                        :mod (n4 / navel~e.20)
                        :mod (v / vein~e.19)))))

# ::tok Suppression of the PAF effects by calphostin C , a PKC inhibitor , suggests that PKC is an upstream activator of FAK
# ::alignments 0-1.1 1-1.1.1.r 3-1.1.1.2.1.1 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1 7-1.1.1.1.1.1 10-1.1.1.1.2.1.1.1.1.1 11-1.1.1.1.2.1 11-1.1.1.1.2.1.1 11-1.1.1.1.2.1.1.r 13-1 14-1.2.r 15-1.2.1 18-1.2.3 19-1.2 20-1.2.2.r 21-1.2.2.1.1
# ::id bel_pmid_1072_9607_22074
(s / suggest-01~e.13
      :ARG0 (s2 / suppress-01~e.0
            :ARG1~e.1 (e / effect-01~e.4
                  :ARG0~e.5 (c / calphostin~e.6
                        :name (n2 / name :op1 "C"~e.7)
                        :ARG1-of (m2 / mean-01
                              :ARG2 (m3 / molecular-physical-entity~e.11
                                    :ARG0-of~e.11 (i2 / inhibit-01~e.11
                                          :ARG1 (e2 / enzyme
                                                :name (n3 / name :op1 "PKC"~e.10))))))
                  :ARG1 (m / molecular-physical-entity
                        :name (n / name :op1 "PAF"~e.3))))
      :ARG1~e.14 (a2 / activate-01~e.19
            :ARG0 e2~e.15
            :ARG1~e.20 (e3 / enzyme
                  :name (n4 / name :op1 "FAK"~e.21))
            :direction (u / upstream~e.18)))

# ::tok transforming growth factor @-@ b2 ( TGF @-@ b2 ) was shown to upregulate the transcription rate of PAFR transcript 1 in Ramos human lymphoblastoid cells
# ::alignments 0-1.1.2.1.1 1-1.1.2.1.2 2-1.1.2.1.3 4-1.1.2.1.3 4-1.1.2.2.1.1.1 6-1.1.2.2.1.1.1 8-1.1.2.1.3 8-1.1.2.2.1.1.1 11-1 13-1.1 15-1.1.1.1 16-1.1.1 17-1.1.1.1.1.r 18-1.1.1.1.1.1.1 19-1.1.1.1.1.1.2 20-1.1.1.1.1.1.3 21-1.1.3.r 22-1.1.3.1.1 23-1.1.3.1.2 24-1.1.3.1.3 25-1.1.3
# ::id bel_pmid_1072_9607_31242
(s / show-01~e.11
      :ARG1 (u / upregulate-01~e.13
            :ARG1 (r / rate~e.16
                  :degree-of (t2 / transcribe-01~e.15
                        :ARG0~e.17 (m2 / molecular-physical-entity
                              :name (n2 / name
                                    :op1 "PAFR"~e.18
                                    :op2 "transcript"~e.19
                                    :op3 "1"~e.20))))
            :ARG2 (p2 / protein
                  :name (n3 / name
                        :op1 "transforming"~e.0
                        :op2 "growth"~e.1
                        :op3 "factor-b2"~e.2,4,8)
                  :ARG1-of (m / mean-01
                        :ARG2 (p / protein
                              :name (n / name :op1 "TGF-b2"~e.4,6,8))))
            :location~e.21 (c / cell~e.25
                  :name (n4 / name
                        :op1 "Ramos"~e.22
                        :op2 "human"~e.23
                        :op3 "lymphoblastoid"~e.24))))

# ::tok These results are consistent with our previous data showing that PAF is able to translocate PKCa and PKCe from cytosol to plasma membrane
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 4-1.2.r 5-1.2.1 5-1.2.1.r 6-1.2.2 7-1.2 8-1.3 9-1.3.1.r 10-1.3.1.1.1.1.1 11-1.3.1.1.r 12-1.3.1 13-1.3.1.1.4.r 14-1.3.1.1 15-1.3.1.1.2.1.1.1 16-1.3.1.1.2 17-1.3.1.1.2.2.1.1 18-1.3.1.1.3.r 19-1.3.1.1.3 20-1.3.1.1.4.r 21-1.3.1.1.4.1 22-1.3.1.1.4
# ::id bel_pmid_1072_9607_86
(c / consistent-01~e.3
      :ARG1 (t3 / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t / this~e.0))
      :ARG2~e.4 (d / data~e.7
            :poss~e.5 (w / we~e.5)
            :time (p2 / previous~e.6))
      :ARG0-of (s / show-01~e.8
            :ARG1~e.9 (p / possible~e.12
                  :domain~e.11 (t2 / translocate-00~e.14
                        :ARG0 (m / molecular-physical-entity
                              :name (n / name :op1 "PAF"~e.10))
                        :ARG1 (a / and~e.16
                              :op1 (e / enzyme
                                    :name (n2 / name :op1 "PKCa"~e.15))
                              :op2 (e2 / enzyme
                                    :name (n3 / name :op1 "PKCe"~e.17)))
                        :source~e.18 (c2 / cytosol~e.19)
                        :destination~e.13,20 (m2 / membrane~e.22
                              :mod (p3 / plasma~e.21))))))

# ::tok Activation of the GFAP gene promoter by IL @-@ 11 and related cytokines Previous studies have shown that stimulation of gp130 molecules on neuroepithelial cells by LIF , CNTF , or the IL @-@ 6/sIL @-@ 6R complex induces activation of the GFAP gene promoter ( Bonni et al. , 1997 ; Nakashima et al. , 1999 b ) .
# ::alignments 0-1.2 3-1.2.2.1.1.1.1 4-1.2.2.1.1 6-1.2.1.r 7-1.2.1.1.1.1 9-1.2.1.1.1.1 11-1.2.1.2.2 13-1.1.1.1 14-1.1.1 16-1.1 17-1.1.2.r 18-1.1.2.1 19-1.1.2.1.1.r 20-1.1.2.1.1.1.1 21-1.1.2.2.1 21-1.2.2 24-1.1.2.1.2 25-1.1.2.1.3.r 26-1.1.2.1.3.1.1.1 28-1.1.2.1.3.2.1.1 32-1.1.2.1.3.3.1.1.1 36-1.1.2.1.3.3.2.1.1 37-1.1.2.1.3.3 38-1.1.2 39-1.1.2.2 42-1.1.2.2.1.1.1.1.1 43-1.1.2.2.1.1.1 46-1.1.3.1.1.1.1.1.1 47-1.1.3.1.1.1 48-1.1.3.1.1.1.2.1 50-1.1.3.1.1.2.1 52-1.1.3.1.2.1.1.1.1 53-1.1.3.1 53-1.1.3.1.2.1 53-1.2.1 54-1.1.3.1.2.1.2.1 56-1.1.3.1.2.2.1
# ::id bel_pmid_1073_7606_22816
(m / multi-sentence
      :snt2 (s2 / show-01~e.16
            :ARG0 (s3 / study-01~e.14
                  :time (p9 / previous~e.13))
            :ARG1~e.17 (i / induce-01~e.38
                  :ARG0 (s / stimulate-01~e.18
                        :ARG0~e.19 (p5 / protein
                              :name (n5 / name :op1 "gp130"~e.20))
                        :ARG1 (c / cell~e.24
                              :name (n6 / name :op1 "neuroepithelium"))
                        :ARG2~e.25 (a4 / and
                              :op1 (p4 / protein
                                    :name (n4 / name :op1 "LIF"~e.26))
                              :op2 (p6 / protein
                                    :name (n7 / name :op1 "CNTF"~e.28))
                              :op3 (m3 / macro-molecular-complex~e.37
                                    :part (p7 / protein
                                          :name (n8 / name :op1 "IL-6"~e.32))
                                    :part (p8 / protein
                                          :name (n9 / name :op1 "sIL-6R"~e.36)))))
                  :ARG1 (a3 / activate-01~e.39
                        :ARG1 (m4 / molecular-physical-entity~e.21
                              :ARG0-of (p10 / promote-01
                                    :ARG1 (g2 / gene~e.43
                                          :name (n10 / name :op1 "GFAP"~e.42))))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (a7 / and~e.53
                        :op1 (p11 / publication-91
                              :ARG0 (a5 / and~e.47
                                    :op1 (p12 / person
                                          :name (n11 / name :op1 "Bonni"~e.46))
                                    :op2 (p13 / person
                                          :mod (o / other~e.48)))
                              :time (d / date-entity :year "1997"~e.50))
                        :op2 (p14 / publication-91
                              :ARG0 (a6 / and~e.53
                                    :op1 (p15 / person
                                          :name (n12 / name :op1 "Nakashima"~e.52))
                                    :op2 (p16 / person
                                          :mod (o2 / other~e.54)))
                              :time (d2 / date-entity :year "1999"~e.56)))))
      :snt1 (a2 / activate-01~e.0
            :ARG0~e.6 (a8 / and~e.53
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "IL-11"~e.7,9))
                  :op2 (p3 / protein
                        :name (n3 / name :op1 "cytokine")
                        :ARG1-of (r / relate-01~e.11)))
            :ARG1 (m2 / molecular-physical-entity~e.21
                  :ARG0-of (p / promote-01
                        :ARG1 (g / gene~e.4
                              :name (n / name :op1 "GFAP"~e.3))))))

# ::tok We have further identified , in the GFAP promoter region , a STAT3 site at which nucleotide substitutions almost completely abolished the IL @-@ 11 @-@ induced GFAP promoter activation .
# ::alignments 0-1.1 2-1.4 3-1 5-1.3.r 7-1.3.2.1.1.1.1.1 9-1.5 12-1.2.1.1.1 13-1.2 16-1.3.1.1 17-1.3.1 18-1.3.3.1 19-1.3.3 19-1.3.3.r 20-1.3 22-1.3.2.2.1.1.1 24-1.3.2.2.1.1.1 26-1.3.2.2 27-1.3.2.1.1.1.1.1 29-1.3.2
# ::id bel_pmid_1073_7606_7132
(i / identify-01~e.3
      :ARG0 (w / we~e.0)
      :ARG1 (p3 / protein-segment~e.13
            :part-of (p / protein
                  :name (n / name :op1 "STAT3"~e.12)))
      :ARG2~e.5 (a / abolish-01~e.20
            :ARG0 (s2 / substitute-01~e.17
                  :ARG1 (n3 / nucleotide~e.16))
            :ARG1 (a3 / activate-01~e.29
                  :ARG1 (m2 / molecular-physical-entity
                        :ARG0-of (p4 / promote-01
                              :ARG1 (p5 / protein
                                    :name (n4 / name :op1 "GFAP"~e.7,27))))
                  :ARG1-of (i2 / induce-01~e.26
                        :ARG0 (p6 / protein
                              :name (n5 / name :op1 "IL-11"~e.22,24))))
            :manner~e.19 (c / complete~e.19
                  :degree (a2 / almost~e.18)))
      :degree (f / further~e.2)
      :location (r / region~e.9
            :part-of (m / molecular-physical-entity
                  :ARG0-of (p2 / promote-01
                        :ARG1 p5))))

# ::tok As shown in Fig. 3A in normal cells , IR causes activation of Chk2 @/@ Cds1 ( lane 2 ) , and this activation is inhibited by prior treatment of cells with caffeine ( lane 4 ) .
# ::alignments 0-1.2.1.3.r 1-1.3 4-1.3.1.1 6-1.4.1 7-1.4 9-1.1.1.1.1 10-1.1 11-1.1.2 13-1.1.2.1.1.1.1 15-1.1.2.1.2.1.1 17-1.1.3.1 18-1.1.3.1.1 23-1.1.2 25-1.2 27-1.2.1.3 28-1.2.1 29-1.2.1.1.r 30-1.2.1.1 31-1.2.1.2.r 32-1.2.1.2 34-1.2.3.1 35-1.2.3.1.1
# ::id bel_pmid_1074_4722_15494
(a / and
      :op1 (c / cause-01~e.10
            :ARG0 (t / thing
                  :name (n / name :op1 "IR"~e.9))
            :ARG1 (a2 / activate-01~e.11,23
                  :ARG1 (m / macro-molecular-complex
                        :part (e / enzyme
                              :name (n2 / name :op1 "Chk2"~e.13))
                        :part (e2 / enzyme
                              :name (n3 / name :op1 "Cds1"~e.15))))
            :ARG1-of (d2 / describe-01
                  :ARG2 (l / lane~e.17 :mod "2"~e.18)))
      :op1 (i / inhibit-01~e.25
            :ARG0 (t2 / treat-03~e.28
                  :ARG1~e.29 (c2 / cell~e.30)
                  :ARG3~e.31 (c3 / caffeine~e.32)
                  :time~e.0 (p / prior~e.27))
            :ARG1 a2
            :ARG1-of (d / describe-01
                  :ARG2 (l2 / lane~e.34 :mod "4"~e.35)))
      :ARG1-of (s / show-01~e.1
            :location (f / figure :mod "3A"~e.4))
      :location (c4 / cell~e.7
            :mod (n4 / normal~e.6)))

# ::tok Immediately after IR , an increase in serine 216 @-@ phosphorylated Cdc25C was observed in the nuclear fraction ( Fig . 1B , lane 2 ) , and prior treatment of cells with caffeine inhibited this increase ( Fig . 1B , lane 4 ) .
# ::alignments 0-1.1.3.2 1-1.1.3 2-1.1.3.1.1.1 5-1.1.1 6-1.1.1.1.r 7-1.1.1.1.2.2.1 8-1.1.1.1.2.1 10-1.1.1.1.2.3 11-1.1.1.1.1.1 13-1.1 14-1.1.2.r 16-1.1.2.1 17-1.1.2 21-1.1.4.1.1.1 23-1.1.4.1.2 24-1.1.4.1.2.1 27-1 27-1.1.4.1 28-1.2.1.3 29-1.2.1 30-1.2.1.1.r 31-1.2.1.1 32-1.2.1.2.r 33-1.2.1.2 34-1.2 36-1.2.2 40-1.2.3.1.1.1 42-1.2.3.1.2 43-1.2.3.1.2.1
# ::id bel_pmid_1074_4722_15496
(a2 / and~e.27
      :op1 (o / observe-01~e.13
            :ARG1 (i / increase-01~e.5
                  :ARG1~e.6 (e / enzyme
                        :name (n3 / name :op1 "Cdc25C"~e.11)
                        :part (a3 / amino-acid
                              :mod "216"~e.8
                              :name (n2 / name :op1 "serine"~e.7)
                              :ARG0-of (p / phosphorylate-01~e.10))))
            :location~e.14 (f / fraction-01~e.17
                  :mod (n4 / nucleus~e.16))
            :time (a / after~e.1
                  :op1 (t / thing
                        :name (n / name :op1 "IR"~e.2))
                  :mod (i2 / immediate~e.0))
            :ARG1-of (d / describe-01
                  :ARG0 (a4 / and~e.27
                        :op1 (f2 / figure :mod "1B"~e.21)
                        :op2 (l / lane~e.23 :mod "2"~e.24))))
      :op2 (i3 / inhibit-01~e.34
            :ARG0 (t2 / treat-03~e.29
                  :ARG1~e.30 (c / cell~e.31)
                  :ARG3~e.32 (c2 / caffeine~e.33)
                  :time (p2 / prior~e.28))
            :ARG1 i~e.36
            :ARG1-of (d2 / describe-01
                  :ARG0 (a5 / and
                        :op1 (f3 / figure :mod "1B"~e.40)
                        :op2 (l2 / lane~e.42 :mod "4"~e.43)))))

# ::tok As shown in Fig. 6A , ATM immunoprecipitated from irradiated cells was more active than that from unirradiated cells , and both the basal and radiationinduced ATM activities were inhibited by caffeine with an IC50 at around 200 M.
# ::alignments 1-1.3 4-1.3.1.1 6-1.2.2.1.1.1.1 6-1.2.2.2.1.1.1 8-1.1.1.2.1.r 8-1.1.2.2.r 9-1.1.1.2.1.1 9-1.1.2.2.1 9-1.1.2.2.1.1 9-1.1.2.2.1.1.r 10-1.1.1.2.1 10-1.1.2.2 12-1.1.1.2.2.1 13-1.1.1.2.2 14-1.1.2.r 16-1.1.1.2.1.r 16-1.1.2.2.r 17-1.1.1.2.1.1 17-1.1.2.2.1 17-1.1.2.2.1.1 17-1.1.2.2.1.1.r 18-1.1.1.2.1 18-1.1.2.2 20-1 23-1.2.2.1.1.2 24-1 24-1.2.2 26-1.1.1.1.1 26-1.1.2.1.1.1 26-1.2.2.1.1.1.1 26-1.2.2.2.1.1.1 27-1.1.1.2.2 29-1.2 30-1.2.1.r 31-1.2.1 32-1.2.3.r 34-1.2.3.1.1 36-1.2.3.2 37-1.2.3.2.1.1
# ::id bel_pmid_1074_4722_15498
(a2 / and~e.20,24
      :op1 (a6 / activate-01
            :ARG1 (e / enzyme
                  :name (n / name :op1 "ATM"~e.26)
                  :ARG1-of (i / immunoprecipitate-00
                        :source~e.8,16 (c / cell~e.10,18
                              :ARG1-of (i2 / irradiate-01~e.9,17))
                        :mod (a3 / active~e.13,27
                              :degree (m2 / more~e.12))))
            :compared-to~e.14 (i3 / immunoprecipitate-00
                  :ARG1 (e2 / enzyme
                        :name (n2 / name :op1 "ATM"~e.26))
                  :source~e.8,16 (c2 / cell~e.10,18
                        :ARG1-of (i8 / irradiate-01~e.9,17 :polarity~e.9,17 "-"~e.9,17))))
      :op2 (i5 / inhibit-01~e.29
            :ARG0~e.30 (c3 / caffeine~e.31)
            :ARG1 (a5 / and~e.24
                  :op1 (a7 / act-01
                        :ARG0 (e3 / enzyme
                              :name (n3 / name :op1 "ATM"~e.6,26)
                              :mod (b / basal~e.23)))
                  :op2 (a8 / act-01
                        :ARG0 (e4 / enzyme
                              :name (n4 / name :op1 "ATM"~e.6,26))
                        :ARG1-of (i6 / induce-01
                              :ARG0 (r / radiate-01))))
            :instrument~e.32 (t / thing
                  :name (n5 / name :op1 "IC50"~e.34)
                  :quant (a / around~e.36
                        :op1 (c4 / concentration-quantity
                              :quant "200"~e.37
                              :unit (m / molar)))))
      :ARG1-of (s / show-01~e.1
            :location (f / figure :mod "6A"~e.4)))

# ::tok However , no such activation was found in A @-@ T cells indicating that caffeine inhibited the ATM @-@ dependent Chk2 @/@ Cds1 activation ( Fig . 3A , lanes 6 and 8 ) .
# ::alignments 0-1 2-1.1.1.1 2-1.1.1.1.r 3-1.1.1.2 4-1.1.1 6-1.1 7-1.1.2.r 8-1.1.2.1.1 10-1.1.2.1.1 11-1.1.2 12-1.1.3 13-1.1.3.1.r 14-1.1.3.1.1 15-1.1.3.1 17-1.1.3.1.2.1.1.1 19-1.1.3.1.2.1 19-1.1.3.1.2.1.2 19-1.1.3.1.2.1.2.r 20-1.1.3.1.2.1.2.1.1.1.1 22-1.1.3.1.2.1.2.1.2.1.1 23-1.1.3.1.2 27-1.2.1.1.1 29-1.2.1.2.1 29-1.2.1.2.2 30-1.2.1.2.1.1 31-1.2.1.2 32-1.2.1.2.2.1
# ::id bel_pmid_1074_4722_15500
(h / have-concession-91~e.0
      :ARG1 (f / find-01~e.6
            :ARG1 (a / activate-01~e.4
                  :polarity~e.2 "-"~e.2
                  :mod (s / such~e.3))
            :location~e.7 (c / cell~e.11
                  :name (n / name :op1 "A-T"~e.8,10))
            :ARG0-of (i / indicate-01~e.12
                  :ARG1~e.13 (i2 / inhibit-01~e.15
                        :ARG0 (c2 / caffeine~e.14)
                        :ARG1 (a2 / activate-01~e.23
                              :ARG1 (e / enzyme~e.19
                                    :name (n2 / name :op1 "ATM"~e.17)
                                    :ARG0-of~e.19 (d / depend-01~e.19
                                          :ARG1 (m / macro-molecular-complex
                                                :part (e2 / enzyme
                                                      :name (n3 / name :op1 "Chk2"~e.20))
                                                :part (e3 / enzyme
                                                      :name (n4 / name :op1 "Cds1"~e.22)))))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a3 / and
                  :op1 (f2 / figure :mod "3A"~e.27)
                  :op2 (a4 / and~e.31
                        :op1 (l / lane~e.29 :op1 "6"~e.30)
                        :op2 (l2 / lane~e.29 :mod "8"~e.32)))))

# ::tok Substitution of threonine 68 by alanine in the full @-@ length kinase @-@ dead Chk2 dramatically reduced but did not abolish the ATM phosphorylation of Chk2 @/@ Cds1 in vitro ( Fig . 4B ; threonine 68 accounts for approximately 70 % of the total phosphorylation ) .
# ::alignments 0-1.1.1.1 2-1.1.1.1.2.1.1 2-1.2.1.2.1 3-1.2.1.1 4-1.1.1.1.1.r 5-1.1.1.1.1.1.1 6-1.1.1.1.3.r 6-1.1.1.2.3 8-1.1.1.1.3.2.2.1 10-1.1.1.1.3.2.2.1 11-1.1.1.1.3.2.2 14-1.1.1.1.3.1.1 14-1.1.1.2.1.1.1.1 15-1.1.1.3 16-1.1.1 17-1.1 19-1.1.2.1 20-1.1.2 22-1.1.2.2 23-1.1.2.2 24-1.1.2.2 25-1.1.2.2 26-1.1.2.2 27-1.1.2.2 28-1.1.2.2 29-1.1.2.2 33-1.1.3.1.1 35-1.2.1.2.1 36-1.2.1.1 37-1.2 39-1.2.1.3.2 40-1.2.1.3.2.1.1 41-1.2.1.3.2.1 44-1.2.1.3.1 45-1.2.1.3.1.1
# ::id bel_pmid_1074_4722_21126
(m / multi-sentence
      :snt1 (c / contrast-01~e.17
            :ARG1 (r / reduce-01~e.16
                  :ARG0 (s / substitute-01~e.0
                        :ARG1~e.4 (a2 / amino-acid
                              :name (n2 / name :op1 "alanine"~e.5))
                        :ARG3 (a / amino-acid
                              :name (n / name :op1 "threonine"~e.2))
                        :location~e.6 (e / enzyme
                              :name (n3 / name :op1 "Chk2"~e.14)
                              :ARG0-of (f3 / function-01
                                    :polarity "-"
                                    :ARG1 (k / kinase~e.11
                                          :mod (f / full-length~e.8,10)))))
                  :ARG1 (p3 / phosphorylate-01
                        :ARG1 (m2 / macro-molecular-complex
                              :part (e2 / enzyme
                                    :name (n4 / name :op1 "Chk2"~e.14))
                              :part (e4 / enzyme
                                    :name (n6 / name :op1 "cds1")))
                        :ARG2 (e3 / enzyme
                              :name (n5 / name :op1 "ATM"))
                        :manner (i / in-vitro~e.6))
                  :manner (d2 / dramatic~e.15))
            :ARG2 (a3 / abolish-01~e.20
                  :ARG0 s~e.19
                  :ARG1 p3~e.22,23,24,25,26,27,28,29)
            :ARG1-of (d3 / describe-01
                  :ARG0 (f2 / figure :mod "4B"~e.33)))
      :snt2 (a4 / account-01~e.37
            :ARG1 (a5 / amino-acid
                  :mod "68"~e.3,36
                  :name (n7 / name :op1 "threonine"~e.2,35)
                  :ARG1-of (i2 / include-91
                        :ARG2 (t / total-01~e.44
                              :ARG1 (p2 / phosphorylate-01~e.45))
                        :ARG3 (a7 / approximately~e.39
                              :quant (p / percentage-entity~e.41 :value "70"~e.40))))))

# ::tok Serine 15 in the N terminus of p53 has been shown to be the preferred ATM phosphorylation site ( 27 , 29 , 30 ) . As shown in Fig. 7A , ATM immunoprecipitated from irradiated cells was more active than that from control cells , and both ATM activities were inhibited by caffeine with IC50 at around 200 M.
# ::alignments 0-1.1.1.3.2.1 1-1.1.1.3.1 4-1.1.1.3.3.1.1 5-1.1.1.3.3.1.2 7-1.1.1.3.3.2.1.1 9-1.1.1.3.r 10-1.1 12-1.1.1.3.r 14-1.1.1.2 15-1.1.1.1.1.1.1 16-1.1.1.1 17-1.1.1 19-1.1.2.1.1.1.1 21-1.1.2.1.1.1.2 23-1.1.2.1.1.1.3 27-1.1 27-1.2.3 30-1.2.3.1.1 32-1.2.1.1.1.1 32-1.2.2.2.1.1.1 34-1.2.1.2.1.r 35-1.2.1.2.1.1 36-1.2.1.2.1 38-1.2.1.2.2.1 39-1.2.1.2.2 40-1.2.1.3.r 42-1.2.1.3.2.r 43-1.2.1.3.2.1 44-1.2.1.3.2 46-1.2 47-1.2.2.2.2 48-1.2.1.3.1.1.1 48-1.2.2.2.1.1.1 49-1.2.2.2 51-1.2.2 52-1.2.2.1.r 53-1.2.2.1 54-1.2.2.3.r 55-1.2.2.3.1.1 57-1.2.2.3.2 58-1.2.2.3.2.1.1
# ::id bel_pmid_1074_4722_21132
(m2 / multi-sentence
      :snt1 (s / show-01~e.10,27
            :ARG1 (p / protein-segment~e.17
                  :ARG1-of (p5 / phosphorylate-01~e.16
                        :ARG2 (e / enzyme
                              :name (n5 / name :op1 "ATM"~e.15)))
                  :ARG1-of (p4 / prefer-01~e.14)
                  :domain~e.9,12 (a3 / amino-acid
                        :mod "15"~e.1
                        :name (n2 / name :op1 "serine"~e.0)
                        :part-of (p2 / protein-segment
                              :name (n3 / name :op1 "N"~e.4 :op2 "terminus"~e.5)
                              :part-of (p3 / protein
                                    :name (n4 / name :op1 "p53"~e.7)))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p6 / publication
                        :ARG1-of (c / cite-01
                              :ARG2 (a4 / and
                                    :op1 "27"~e.19
                                    :op2 "29"~e.21
                                    :op3 "30"~e.23)))))
      :snt2 (a2 / and~e.46
            :op1 (a7 / activate-01
                  :ARG1 (e2 / enzyme
                        :name (n / name :op1 "ATM"~e.32))
                  :ARG1-of (i / immunoprecipitate-00
                        :source~e.34 (c2 / cell~e.36
                              :ARG1-of (i2 / irradiate-01~e.35))
                        :mod (a5 / active~e.39
                              :degree (m3 / more~e.38)))
                  :compared-to~e.40 (i3 / immunoprecipitate-00
                        :ARG1 (e3 / enzyme
                              :name (n6 / name :op1 "ATM"~e.48))
                        :source~e.42 (c3 / cell~e.44
                              :mod (c5 / control-01~e.43))))
            :op2 (i4 / inhibit-01~e.51
                  :ARG0~e.52 (c4 / caffeine~e.53)
                  :ARG1 (a6 / activity~e.49
                        :mod (e4 / enzyme
                              :name (n7 / name :op1 "ATM"~e.32,48))
                        :mod (b / both~e.47))
                  :instrument~e.54 (t / thing
                        :name (n8 / name :op1 "IC50"~e.55)
                        :quant (a / around~e.57
                              :op1 (c6 / concentration-quantity
                                    :quant "200"~e.58
                                    :unit (m / molar)))))
            :ARG1-of (s3 / show-01~e.27
                  :location (f / figure :mod "7A"~e.30))))

# ::tok Both Chk1 and Chk2 @/@ Cds1 have been shown to localize to the nucleus and to phosphorylate serine 216 of Cdc25C in vitro ( 13 , 15 ) ( 18–21 ) .
# ::alignments 1-1.1.1.1.1.1.1 3-1.1.1.1.2.1.1.1 5-1.1.1.1.2.2.1.1 7-1.1.1 8-1 13-1.1.1.2 14-1.1 16-1.1.2 17-1.1.2.1.2.1 18-1.1.2.1.1 20-1.1.2.1.3.1.1 21-1.1.2.3 22-1.1.2.3 24-1.2.1.1.1.1.1 26-1.2.1.1.1.1.2
# ::id bel_pmid_1074_4722_21168
(s / show-01~e.8
      :ARG1 (a2 / and~e.14
            :op1 (b / be-located-at-91~e.7
                  :ARG1 (a5 / and
                        :op1 (e / enzyme
                              :name (n2 / name :op1 "Chk1"~e.1))
                        :op2 (m / macro-molecular-complex
                              :part (e2 / enzyme
                                    :name (n3 / name :op1 "Chk2"~e.3))
                              :part (e3 / enzyme
                                    :name (n4 / name :op1 "Cds1"~e.5))))
                  :ARG2 (n5 / nucleus~e.13))
            :op2 (p / phosphorylate-01~e.16
                  :ARG1 (a / amino-acid
                        :mod "216"~e.18
                        :name (n / name :op1 "serine"~e.17)
                        :part-of (e4 / enzyme
                              :name (n6 / name :op1 "Cdc25C"~e.20)))
                  :ARG2 a5
                  :manner (i / in-vitro~e.21,22)))
      :ARG1-of (d2 / describe-01
            :ARG0 (a4 / and
                  :op1 (p2 / publication
                        :ARG1-of (c / cite-01
                              :ARG2 (a3 / and :op1 "13"~e.24 :op2 "15"~e.26)))
                  :op2 (p3 / publication
                        :ARG1-of (c2 / cite-01
                              :ARG2 (v / value-interval :op1 "18" :op2 "21"))))))

# ::tok As shown in the Western blot ( Fig . 1A , lane 3 ) , the phospho @-@ S216 antibody recognized Cdc25C that was incubated with a wild type Chk2 in the in vitro kinase assay but failed to recognize unphosphorylated Cdc25C , incubated with a kinase @-@ dead mutant ( D347A ) ( Fig . 1A , lane 2 ) .
# ::alignments 0-1.1.2.2.2.r 1-1.3 2-1.1.2.2.2.2 2-1.3.1.r 4-1.3.1.1.1 5-1.3.1.1.2 9-1.3.2.1.1.1 11-1.3.2.1.2 12-1.3.2.1.2.1 16-1.1.1.1.1 18-1.1.1.1.1 19-1.1.1 20-1.1 21-1.1.2.1.1 24-1.1.2.2 25-1.1.2.2.1.r 27-1.1.2.2.1.2 28-1.1.2.2.1.2 29-1.1.2.2.1.1.1 30-1.1.2.2.2.2 32-1.1.2.2.2.2 33-1.1.2.2.2.2 34-1.1.2.2.2.1 35-1.1.2.2.2 36-1 37-1.2 39-1.2.2 41-1.2.2.2.1.1 43-1.2.2.2.3 44-1.2.2.2.3.1.r 46-1.2.2.2.3.1.2.2 49-1.2.2.2.3.1 49-1.2.2.2.3.1.1 49-1.2.2.2.3.1.1.r 51-1.2.2.2.3.1.1.1 56-1.2.3.1.1.1 58-1.2.3.1.2 59-1.2.3.1.2.1
# ::id bel_pmid_1074_4722_21170
(c / contrast-01~e.36
      :ARG1 (r / recognize-01~e.20
            :ARG0 (a / antibody~e.19
                  :name (n2 / name :op1 "phospho-S216"~e.16,18))
            :ARG1 (e / enzyme
                  :name (n3 / name :op1 "Cdc25C"~e.21)
                  :ARG1-of (i / incubate-01~e.24
                        :ARG2~e.25 (e2 / enzyme
                              :name (n4 / name :op1 "Chk2"~e.29)
                              :mod (w / wild-type~e.27,28))
                        :time~e.0 (a3 / assay-00~e.35
                              :ARG1 (k / kinase~e.34)
                              :manner (i2 / in-vitro~e.2,30,32,33)))))
      :ARG2 (f2 / fail-01~e.37
            :ARG1 a
            :ARG2 (r2 / recognize-01~e.39
                  :ARG0 a
                  :ARG1 (e3 / enzyme
                        :name (n5 / name :op1 "Cdc25C"~e.41)
                        :ARG1-of (p / phosphorylate-01 :polarity "-")
                        :ARG1-of (i3 / incubate-01~e.43
                              :ARG2~e.44 (m2 / molecular-physical-entity~e.49
                                    :ARG2-of~e.49 (m / mutate-01~e.49 :value "D347A"~e.51)
                                    :ARG0-of (f / function-01
                                          :polarity "-"
                                          :ARG1 (k2 / kinase~e.46))))))
            :ARG1-of (d / describe-01
                  :ARG0 (a2 / and
                        :op1 (f3 / figure :mod "1A"~e.56)
                        :op2 (l / lane~e.58 :mod "2"~e.59))))
      :ARG1-of (s / show-01~e.1
            :location~e.2 (t2 / thing
                  :name (n6 / name :op1 "Western"~e.4 :op2 "blot"~e.5))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a4 / and
                        :op1 (f4 / figure :mod "1A"~e.9)
                        :op2 (l2 / lane~e.11 :mod "3"~e.12)))))

# ::tok As shown in Fig. 5B , immediately after -@ irradiation , the amount of threonine 68 @- phosphorylated Chk2 increased ( lane 2 ) , and prior treatment of cells with caffeine markedly reduced this increase ( lane 4 ) .
# ::alignments 0-1.1.3.r 0-1.2.1.3.r 1-1.3 4-1.4.1 6-1.2.2 7-1.2.2 8-1.2.2 9-1.2.2 10-1.2.2 11-1.2.2 12-1.2.2 13-1.2.2 14-1.2.2 15-1.2.2 16-1.2.2 17-1.2.2 18-1.2.2 19-1.2.2 20-1.2.2 21-1.2.2 22-1.2.2 25-1 26-1.2.1.3 27-1.2.1 28-1.2.1.1.r 29-1.2.1.1 30-1.2.1.2.r 31-1.2.1.2 32-1.2.3 32-1.2.3.r 33-1.2 35-1.2.2 37-1.2.4.1 38-1.2.4.1.1
# ::id bel_pmid_1074_4722_88
(a5 / and~e.25
      :op1 (i / increase-01
            :ARG1 (a3 / amount
                  :quant-of (e / enzyme
                        :name (n2 / name :op1 "Chk2")
                        :part (a / amino-acid
                              :mod "68"
                              :name (n / name :op1 "threonine")
                              :ARG1-of (p / phosphorylate-01))))
            :ARG1-of (d / describe-01
                  :ARG2 (l / lane :mod "2"))
            :time~e.0 (a4 / after
                  :op1 (i2 / irradiate-01)
                  :mod (i3 / immediate)))
      :op2 (r / reduce-01~e.33
            :ARG0 (t / treat-03~e.27
                  :ARG1~e.28 (c / cell~e.29)
                  :ARG3~e.30 (c2 / caffeine~e.31)
                  :time~e.0 (p2 / prior~e.26))
            :ARG1 i~e.6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,35
            :manner~e.32 (m2 / marked~e.32)
            :ARG1-of (d2 / describe-01
                  :ARG2 (l2 / lane~e.37 :mod "4"~e.38)))
      :ARG1-of (s / show-01~e.1)
      :location (f / figure :mod "5B"~e.4))

# ::tok We found that STAT3 , but not STAT5 , was activated in response to IGF @-@ I in 293T cells cotransfected with IGF @-@ IR and STAT expression vectors . Moreover , tyrosine phosphorylation of STAT3 , JAK1 , and JAK2 was increased upon IGF @-@ I stimulation of endogenous IGF @-@ IR in 293T cells transfected with the respective STAT or JAK expression vector .
# ::alignments 0-1.2.1 1-1.2 2-1.2.2.r 3-1.2.2.1.1.1.1 5-1.2.2 6-1.2.2.2.1 6-1.2.2.2.1.r 7-1.2.2.2.2.1.1 10-1.2.2.1 10-1.2.2.2 11-1.2.2.1.2.r 12-1.2.2.1.2 13-1.2.2.1.2.1.r 14-1.2.2.1.2.1.1.1 14-1.2.2.1.2.1.2.2.1.1.1.1 16-1.2.2.1.2.1.1.1 18-1.2.2.1.2.1.2.1.1 19-1.2.2.1.2.1.2 22-1.2.2.1.2.1.1.1 22-1.2.2.1.2.1.2.2.1.1.1.1 24-1.2.2.1.2.1.2.2.1.1.1.1 25-1.2.2.1.2.1.2.2.1 26-1.2.2.1.2.1.2.2.1.2.1.1.1.1 27-1.2.2.1.2.1.2.2.1.2.1 28-1.2.2.1.2.1.2.2.1.2 32-1.1.1.1.1.1.1.1 32-1.1.1.1.1.2.1.1 32-1.1.1.1.1.3.1.1 33-1.1.1.1 34-1.1.1.1.1.r 35-1.1.1.1.1.1.2.1.1 37-1.1.1.1.1.2.2.1.1 39-1.1.1.1.1 40-1.1.1.1.1.3.2.1.1 42-1.1.1 44-1.1.1.2.1.1.1 46-1.1.1.2.1.1.1 47-1.1.1.2 48-1.1.1.2.2.r 49-1.1.1.2.2.2 50-1.1.1.2.2.1.1 52-1.1.1.2.2.1.1 54-1.1.1.2.2.3.1.1 55-1.1.1.2.2.3 56-1.1.1.2.2.3.2 57-1.1.1.2.2.3.2.1.r 59-1.1.1.2.2.3.2.1.1.1.1.2 60-1.1.1.2.2.3.2.1.1.1.1.1.1 61-1.1.1.2.2.3.2.1 62-1.1.1.2.2.3.2.1.2.1.1.1.1 63-1.1.1.2.2.3.2.1.1.1 63-1.1.1.2.2.3.2.1.2.1 64-1.1.1.2.2.3.2.1.1 64-1.1.1.2.2.3.2.1.2
# ::id bel_pmid_1074_7872_20016
(m / multi-sentence
      :snt2 (a4 / and
            :op2 (i / increase-01~e.42
                  :ARG1 (p / phosphorylate-01~e.33
                        :ARG1~e.34 (a5 / and~e.39
                              :op1 (a6 / amino-acid
                                    :name (n7 / name :op1 "tyrosine"~e.32)
                                    :part-of (p6 / protein
                                          :name (n8 / name :op1 "STAT3"~e.35)))
                              :op2 (a7 / amino-acid
                                    :name (n16 / name :op1 "tyrosine"~e.32)
                                    :part-of (p7 / protein
                                          :name (n9 / name :op1 "JAK1"~e.37)))
                              :op3 (a8 / amino-acid
                                    :name (n17 / name :op1 "tyrosine"~e.32)
                                    :part-of (p8 / protein
                                          :name (n10 / name :op1 "JAK2"~e.40)))))
                  :time (s / stimulate-01~e.47
                        :ARG0 (p9 / protein
                              :name (n11 / name :op1 "IGF-I"~e.44,46))
                        :ARG1~e.48 (e3 / enzyme
                              :name (n12 / name :op1 "IGF-IR"~e.50,52)
                              :mod (m2 / monocot~e.49)
                              :location (c5 / cell~e.55
                                    :name (n13 / name :op1 "293T"~e.54)
                                    :ARG1-of (t / transfect-00~e.56
                                          :ARG2~e.57 (o / or~e.61
                                                :op1 (v3 / vector~e.64
                                                      :ARG1-of (e5 / express-03~e.63
                                                            :ARG2 (p10 / protein
                                                                  :name (n14 / name :op1 "STAT"~e.60)
                                                                  :mod (r2 / respective~e.59))))
                                                :op2 (v2 / vector~e.64
                                                      :ARG1-of (e4 / express-03~e.63
                                                            :ARG2 (p11 / protein
                                                                  :name (n15 / name :op1 "JAK"~e.62)))))))))))
      :snt1 (f / find-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1~e.2 (c / contrast-01~e.5
                  :ARG1 (a / activate-01~e.10
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "STAT3"~e.3))
                        :ARG2-of~e.11 (r / respond-01~e.12
                              :ARG1~e.13 (p3 / protein
                                    :name (n2 / name :op1 "IGF-I"~e.14,16,22)
                                    :location (c2 / cell~e.19
                                          :name (n3 / name :op1 "293T"~e.18)
                                          :ARG1-of (c4 / contransfect-00
                                                :ARG2 (a2 / and~e.25
                                                      :op1 (e / enzyme
                                                            :name (n4 / name :op1 "IGF-IR"~e.14,22,24))
                                                      :op2 (v / vector~e.28
                                                            :ARG1-of (e2 / express-03~e.27
                                                                  :ARG2 (p4 / protein
                                                                        :name (n5 / name :op1 "STAT"~e.26))))))))))
                  :ARG2 (a3 / activate-01~e.10
                        :polarity~e.6 "-"~e.6
                        :ARG1 (p5 / protein
                              :name (n6 / name :op1 "STAT5"~e.7))
                        :ARG2-of r))))

# ::tok tyrosine phosphorylation of STAT3 , JAK1 , and JAK2 was increased upon IGF @-@ I stimulation of endogenous IGF @-@ IR in 293T cells transfected with the respective STAT or JAK expression vector .
# ::alignments 0-1.1.1.1.1.1 0-1.1.1.2.1.1 0-1.1.1.3.1.1 1-1.1 2-1.1.1.r 3-1.1.1.1.2.1.1 5-1.1.1.2.2.1.1 7-1.1.1 8-1.1.1.3.2.1.1 10-1 12-1.2.1.1.1 14-1.2.1.1.1 15-1.2 16-1.2.2.r 17-1.2.2.2 18-1.2.2.1.1 20-1.2.2.1.1 22-1.2.2.3.1.1 23-1.2.2.3 24-1.2.2.3.2 25-1.2.2.3.2.1.r 27-1.2.2.3.2.1.1.1.1.2 28-1.2.2.3.2.1.1.1.1.1.1 29-1.2.2.3.2.1 30-1.2.2.3.2.1.2.1.1.1.1 31-1.2.2.3.2.1.1.1 31-1.2.2.3.2.1.2.1 32-1.2.2.3.2.1.1 32-1.2.2.3.2.1.2
# ::id bel_pmid_1074_7872_21236
(i / increase-01~e.10
      :ARG1 (p / phosphorylate-01~e.1
            :ARG1~e.2 (a2 / and~e.7
                  :op1 (a / amino-acid
                        :name (n / name :op1 "tyrosine"~e.0)
                        :part-of (p2 / protein
                              :name (n2 / name :op1 "STAT3"~e.3)))
                  :op2 (a3 / amino-acid
                        :name (n10 / name :op1 "tyrosine"~e.0)
                        :part-of (p3 / protein
                              :name (n3 / name :op1 "JAK1"~e.5)))
                  :op3 (a4 / amino-acid
                        :name (n11 / name :op1 "tyrosine"~e.0)
                        :part-of (p7 / protein
                              :name (n9 / name :op1 "JAK2"~e.8)))))
      :time (s / stimulate-01~e.15
            :ARG0 (p4 / protein
                  :name (n4 / name :op1 "IGF-I"~e.12,14))
            :ARG1~e.16 (e / enzyme
                  :name (n5 / name :op1 "IGF-IR"~e.18,20)
                  :mod (m / monocot~e.17)
                  :location (c / cell~e.23
                        :name (n6 / name :op1 "293T"~e.22)
                        :ARG1-of (t / transfect-00~e.24
                              :ARG2~e.25 (o / or~e.29
                                    :op1 (v2 / vector~e.32
                                          :ARG1-of (e3 / express-03~e.31
                                                :ARG2 (p5 / protein
                                                      :name (n7 / name :op1 "STAT"~e.28)
                                                      :mod (r / respective~e.27))))
                                    :op2 (v / vector~e.32
                                          :ARG1-of (e2 / express-03~e.31
                                                :ARG2 (p6 / protein
                                                      :name (n8 / name :op1 "JAK"~e.30))))))))))

# ::tok STAT3 , but not STAT5 , was activated in response to IGF @-@ I in 293T cells cotransfected with IGF @-@ IR and STAT expression vectors .
# ::alignments 0-1.1.1.1.1 2-1 3-1.2.1 3-1.2.1.r 4-1.2.2.1.1 7-1.1 7-1.2 8-1.1.2.r 9-1.1.2 10-1.1.2.1.r 11-1.1.2.1.1.1 13-1.1.2.1.1.1 15-1.1.2.1.2.1.1 16-1.1.2.1.2 19-1.1.2.1.2.2.1.1.1.1.1.1 21-1.1.2.1.2.2.1.1.1.1.1.1 22-1.1.2.1.2.2.1 23-1.1.2.1.2.2.1.2.1.1.1.1 24-1.1.2.1.2.2.1.1.1 24-1.1.2.1.2.2.1.2.1 25-1.1.2.1.2.2.1.1 25-1.1.2.1.2.2.1.2
# ::id bel_pmid_1074_7872_21238
(c / contrast-01~e.2
      :ARG1 (a / activate-01~e.7
            :ARG1 (p / protein
                  :name (n / name :op1 "STAT3"~e.0))
            :ARG2-of~e.8 (r / respond-01~e.9
                  :ARG1~e.10 (p2 / protein
                        :name (n2 / name :op1 "IGF-I"~e.11,13)
                        :location (c2 / cell~e.16
                              :name (n3 / name :op1 "293T"~e.15)
                              :ARG1-of (c3 / cotransfect-00
                                    :ARG2 (a2 / and~e.22
                                          :op1 (v2 / vector~e.25
                                                :ARG1-of (e2 / express-03~e.24
                                                      :ARG2 (p3 / protein
                                                            :name (n4 / name :op1 "IGF-IR"~e.19,21))))
                                          :op2 (v / vector~e.25
                                                :ARG1-of (e / express-03~e.24
                                                      :ARG2 (p4 / protein
                                                            :name (n5 / name :op1 "STAT"~e.23))))))))))
      :ARG2 (a3 / activate-01~e.7
            :polarity~e.3 "-"~e.3
            :ARG1 (p5 / protein
                  :name (n6 / name :op1 "STAT5"~e.4))
            :ARG2-of r))

# ::tok Dominant @-@ negative JAK1 or JAK2 was able to block the IGF @-@ IR @-@ mediated tyrosine phosphorylation of STAT3 in 293T cells .
# ::alignments 3-1.1.1.1.1.1 4-1.1.1 5-1.1.1.2.1.1 6-1.1.r 7-1 9-1.1 11-1.1.2.4.1.1.1 13-1.1.2.4.1.1.1 15-1.1.2.4 16-1.1.2.1.1.1 17-1.1.2 18-1.1.2.2.r 19-1.1.2.2.1.1 20-1.1.2.3.r 21-1.1.2.3.1.1 22-1.1.2.3
# ::id bel_pmid_1074_7872_21262
(p3 / possible~e.7
      :domain~e.6 (b / block-01~e.9
            :ARG0 (o / or~e.4
                  :op1 (p4 / protein
                        :name (n / name :op1 "JAK1"~e.3)
                        :ARG2-of (m2 / mutate-01 :mod "-/-"))
                  :op2 (p / protein
                        :name (n7 / name :op1 "JAK2"~e.5)
                        :ARG2-of (m3 / mutate-01 :mod "-/-")))
            :ARG1 (p2 / phosphorylate-01~e.17
                  :ARG0 (a2 / amino-acid
                        :name (n4 / name :op1 "tyrosine"~e.16))
                  :ARG1~e.18 (p6 / protein
                        :name (n5 / name :op1 "STAT3"~e.19))
                  :location~e.20 (c / cell~e.22
                        :name (n6 / name :op1 "293T"~e.21))
                  :ARG1-of (m / mediate-01~e.15
                        :ARG0 (p5 / protein
                              :name (n3 / name :op1 "IGF-IR"~e.11,13))))))

# ::tok Inhibition of SHP2 activation leads to increased SOCS3 @-@ mRNA levels , whereas increased expression of SOCS3 results in a reduction of SHP2 phosphorylation after activation of the interleukin @-@ 6 signal transduction pathway .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1.1 3-1.1.1.1 4-1.1 5-1.1.2.r 6-1.1.2.1 7-1.1.2.2.2.1.1 9-1.1.2.2.1.1 10-1.1.2 12-1 13-1.1.2.1 13-1.2.1.2 14-1.2.1 15-1.2.1.1.r 16-1.2.1.1 17-1.2 18-1.2.2.r 20-1.2.2 21-1.2.2.2.r 22-1.2.2.2.1 23-1.2.2.2 24-1.2.3 25-1.2.3.1 26-1.2.3.1.1.r 28-1.2.3.1.1.1.1.1.1.1 30-1.2.3.1.1.1.1.1.1.1 31-1.2.3.1.1.1.1 33-1.2.3.1.1
# ::id bel_pmid_1077_7583_7596
(c / contrast-01~e.12
      :ARG1 (l / lead-03~e.4
            :ARG0 (i / inhibit-01~e.0
                  :ARG1~e.1 (a / activate-01~e.3
                        :ARG1 (e3 / enzyme
                              :name (n3 / name :op1 "SHP2"~e.2))))
            :ARG2~e.5 (l2 / level~e.10
                  :ARG1-of (i2 / increase-01~e.6,13)
                  :quant-of (r / rna
                        :name (n / name :op1 "mRNA"~e.9)
                        :mod (p / protein
                              :name (n2 / name :op1 "SOCS3"~e.7)))))
      :ARG2 (r2 / result-01~e.17
            :ARG1 (e / express-03~e.14
                  :ARG2~e.15 p~e.16
                  :ARG1-of (i3 / increase-01~e.13))
            :ARG2~e.18 (r3 / reduce-01~e.20
                  :ARG0 e
                  :ARG2~e.21 (p3 / phosphorylate-01~e.23
                        :ARG1 e3~e.22))
            :time (a2 / after~e.24
                  :op1 (a3 / activate-01~e.25
                        :ARG1~e.26 (p4 / pathway~e.33
                              :ARG0-of (t / transduct-00
                                    :ARG1 (s / signal-01~e.31
                                          :mod (e2 / enzyme
                                                :name (n4 / name :op1 "interleukin-6"~e.28,30)))))))))

# ::tok In situ end @-@ labeling detection showed that apoptotic cell death was significantly increased in cells with 5 @-@ day treatment of antisense H @-@ ras oligodeoxynucleotide ( 34.0 +/- 4.5 %) in comparing with cells without treatment ( 2.5 +/- 1.2 % , t = 13.434 , P < 0.01 ) or treated with non @-@ specific antisense oligodeoxynucleotide ( 4.8 +/- 1.4 % , t = 12.453 , P < 0.01 ) at the corresponding time .
# ::alignments 0-1.1.2 1-1.1.2 2-1.1.1.1 4-1.1.1 5-1.1 6-1 7-1.2.r 8-1.2.1.1 9-1.2.1 12-1.2.2 13-1.2 14-1.1.2 14-1.2.3.r 15-1.2.3 16-1.2.3.1.r 17-1.2.3.1.2.1 19-1.2.3.1.2.2 20-1.2.3.1 21-1.2.3.1.1.r 22-1.2.3.1.1.2.2 23-1.2.3.1.1.2.1.1 25-1.2.3.1.1.2.1.1 26-1.2.3.1.1.1.1 30-1.2.3.1.1.4.1 32-1.1.2 33-1.2.4.r 35-1.2.4.1 35-1.2.4.2 36-1.2.4.1.1.1 37-1.2.4.2.1 41-1.2.4.1.4.1 42-1.2.3.1.1.4 42-1.2.4.1.4 46-1.2.4.1.2.1 50-1.2.4.1.3.1.1 52-1.2.4 53-1.2.4.1.1 55-1.2.1.2.1 55-1.2.4.2.1.1.2.1.1 55-1.2.4.2.1.1.2.1.1.r 57-1.2.4.2.1.1.2.1 58-1.2.4.2.1.1.2 59-1.2.4.2.1.1.1.1 63-1.2.4.2.2.1 64-1.2.4.2.2 68-1.2.4.2.3.1 72-1.2.4.2.4 76-1.2.4.3.1 77-1.2.3.1.2 77-1.2.4.3 77-1.2.4.3.r
# ::id bel_pmid_1079_1191_20850
(s / show-01~e.6
      :ARG0 (d / detect-01~e.5
            :ARG2 (l / label-01~e.4
                  :mod (e2 / end~e.2))
            :mod (i / in-situ~e.0,1,14,32))
      :ARG1~e.7 (i2 / increase-01~e.13
            :ARG1 (c / cell~e.9
                  :mod (a / apoptotic~e.8)
                  :ARG0-of (f / function-01 :polarity "-"~e.55))
            :degree (s2 / significant~e.12)
            :location~e.14 (c2 / cell~e.15
                  :ARG1-of~e.16 (t / treat-04~e.20
                        :ARG2~e.21 (m / molecular-physical-entity
                              :name (n / name :op1 "oligodeoxynucleotide"~e.26)
                              :mod (e / enzyme
                                    :name (n2 / name :op1 "H-ras"~e.23,25)
                                    :mod (a2 / antisense~e.22))
                              :quant (c6 / concentration-quantity
                                    :quant "34"
                                    :unit (m3 / micromolar))
                              :quant (p2 / percentage-entity~e.42 :value "4.5"~e.30))
                        :duration (t2 / temporal-quantity~e.77
                              :quant "5"~e.17
                              :unit (d3 / day~e.19))))
            :compared-to~e.33 (o / or~e.52
                  :op1 (c3 / cell~e.35
                        :ARG1-of (t3 / treat-04~e.53 :polarity "-"~e.36)
                        :quant (t6 / temperature-quantity :value "13.434"~e.46)
                        :value (p / probability
                              :quant (l2 / less-than :op1 "0.01"~e.50))
                        :quant (p4 / percentage-entity~e.42 :value "1.2"~e.41))
                  :op2 (c4 / cell~e.35
                        :ARG1-of (t4 / treat-04~e.37
                              :ARG2 (m2 / molecular-physical-entity
                                    :name (n3 / name :op1 "oligodeoxynucleotide"~e.59)
                                    :mod (a3 / antisense~e.58
                                          :mod (s3 / specific~e.57 :polarity~e.55 "-"~e.55))))
                        :quant (p3 / percentage-entity~e.64 :value "1.4"~e.63)
                        :quant (c7 / concentration-quantity
                              :quant "12.453"~e.68
                              :unit (m4 / micromolar))
                        :value p~e.72)
                  :time~e.77 (t5 / time~e.77
                        :ARG1-of (c5 / correspond-02~e.76)))))

# ::tok \" Negative regulation of growth hormone receptor @/@ JAK2 signaling by signal regulatory protein alpha.\"
# ::alignments 2-1.2.1.2 4-1.1.1.1.1 5-1.1.1.1.2 6-1.1.1.1.3 8-1.1.2.1.1 9-1.2.1.1 11-1.2.1.1 12-1.2.1.2 13-1.2.1.3
# ::id bel_pmid_1084_2184_19138
(d / downregulate-01
      :ARG1 (m / macro-molecular-complex
            :part (p / protein
                  :name (n2 / name
                        :op1 "growth"~e.4
                        :op2 "hormone"~e.5
                        :op3 "receptor"~e.6))
            :part (p2 / protein
                  :name (n3 / name :op1 "JAK2"~e.8)))
      :ARG2 (p3 / protein
            :name (n / name
                  :op1 "signal"~e.9,11
                  :op2 "regulatory"~e.2,12
                  :op3 "protein"~e.13
                  :op4 "alpha"))
      :ARG2-of (c / cite-01))

# ::tok FGFs activate the endogenous FGFRs leading to the formation of a Grb2/FRS2/Shp2 complex and activation of MAP kinase .
# ::alignments 1-1 3-1.2.2 5-1.2.3 6-1.2.3.1.r 8-1.2.3.1.1 12-1.2.3.1.1.2 13-1.2.3.1 14-1.2.3.1.2 15-1.2.3.1.2.2.r 16-1.2.3.1.2.2.1.1 17-1.2.3.1.2.2
# ::id bel_pmid_1085_1026_6144
(a / activate-01~e.1
      :ARG0 (p / protein
            :name (n / name :op1 "FGF"))
      :ARG1 (p2 / protein
            :name (n2 / name :op1 "FGFR")
            :mod (m2 / monocot~e.3)
            :ARG0-of (l / lead-03~e.5
                  :ARG2~e.6 (a2 / and~e.13
                        :op1 (f / form-01~e.8
                              :ARG0 p2
                              :ARG1 (m / macro-molecular-complex~e.12
                                    :part (p3 / protein
                                          :name (n3 / name :op1 "Grb2"))
                                    :part (p4 / protein
                                          :name (n4 / name :op1 "FRS2"))
                                    :part (p5 / protein
                                          :name (n5 / name :op1 "Shp2"))))
                        :op2 (a3 / activate-01~e.14
                              :ARG0 p2
                              :ARG1~e.15 (k / kinase~e.17
                                    :name (n6 / name :op1 "MAP"~e.16)))))))

# ::tok However , immature osteoblasts respond to FGF treatment with increased proliferation , whereas in differentiating cells FGF does not induce DNA synthesis but causes apoptosis .
# ::alignments 0-1 0-1.1 0-1.1.r 2-1.1.1.1.1 2-1.1.1.1.1.1 2-1.1.1.1.1.1.r 3-1.1.1.1 4-1.1.1 5-1.1.1.2.r 6-1.1.1.2.2.1.1 7-1.1.1.2 8-1.1.1.3.r 9-1.1.1.3.2 10-1.1.1.3 12-1.1.2 14-1.1.2.1.4 15-1.1.2.1.4.2 16-1.1.2.1.4.1 18-1.1.2.1.1 18-1.1.2.1.1.r 19-1.1.2.1 20-1.1.2.1.3.1 22-1.1.2 23-1.1.2.2 24-1.1.2.2.2
# ::id bel_pmid_1085_1026_8692
(h / have-concession-91~e.0
      :ARG1~e.0 (c2 / contrast-01~e.0
            :ARG1 (r / respond-01~e.4
                  :ARG0 (o / osteoblast~e.3
                        :ARG1-of (m / mature-01~e.2 :polarity~e.2 "-"~e.2))
                  :ARG1~e.5 (t / treat-04~e.7
                        :ARG1 o
                        :ARG2 (p / protein
                              :name (n / name :op1 "FGF"~e.6)))
                  :ARG2~e.8 (p2 / proliferate-01~e.10
                        :ARG0 o
                        :ARG1-of (i2 / increase-01~e.9)))
            :ARG2 (c3 / contrast-01~e.12,22
                  :ARG1 (i / induce-01~e.19
                        :polarity~e.18 "-"~e.18
                        :ARG0 p
                        :ARG1 (s / synthesize-01
                              :ARG1 (d / DNA~e.20))
                        :time (d2 / differentiate-01~e.14
                              :ARG0 p~e.16
                              :ARG1 (c5 / cell~e.15)))
                  :ARG2 (c4 / cause-01~e.23
                        :ARG0 p
                        :ARG1 (a / apoptosis~e.24)))))

# ::tok When either primary or OB1 osteoblasts are induced to differentiate , FGF signaling inhibits expression of alkaline phosphatase , and blocks mineralization .
# ::alignments 0-1.3.r 1-1.3.1.3 2-1.3.1.1.1 3-1.3.1 5-1.3.1.1 5-1.3.1.2 7-1.3 9-1.3.2 11-1.1.1.1.1 12-1.1.1.1.2 13-1.1 14-1.1.2 15-1.1.2.1.r 16-1.1.2.1.1.1 17-1.1.2.1.1.2 19-1 20-1.2
# ::id bel_pmid_1085_1026_8694
(a / and~e.19
      :op1 (i2 / inhibit-01~e.13
            :ARG0 (p2 / protein
                  :name (n / name :op1 "FGF"~e.11 :op2 "signaling"~e.12))
            :ARG1 (e2 / express-03~e.14
                  :ARG1~e.15 (e3 / enzyme
                        :name (n3 / name :op1 "alkaline"~e.16 :op2 "phosphatase"~e.17))))
      :op2 (b / block-01~e.20
            :ARG0 p2
            :ARG1 (m / mineralize-01))
      :time~e.0 (i / induce-01~e.7
            :ARG1 (o / or~e.3
                  :op1 (o3 / osteoblast~e.5
                        :mod (p / primary~e.2))
                  :op2 (o2 / osteoblast~e.5
                        :mod (d2 / dna-sequence
                              :name (n2 / name :op1 "OP1")))
                  :mod (e / either~e.1))
            :purpose (d / differentiate-01~e.9
                  :ARG0 o)))

# ::tok IL @-@ 2 @-@ mediated hetero @-@ dimerization of its receptor triggers a rapid increase in the recruitment of Jak3 and activation of both Jak1 and Jak3
# ::alignments 0-1.1.3.1.1.1 2-1.1.3.1.1.1 4-1.1.3 5-1.1.2 7-1.1 10-1.1.1 11-1 13-1.2.2 14-1.2 15-1.2.1.r 17-1.2.1.1 18-1.2.1.1.1.r 19-1.2.1.1.1.1.1 20-1.2.1 21-1.2.1.2 24-1.2.1.2.1.1.1.1 25-1.2.1 26-1.2.1.2.1.2
# ::id bel_pmid_1085_1055_19244
(t / trigger-01~e.11
      :ARG0 (d / dimerize-00~e.7
            :ARG1 (r3 / receptor~e.10)
            :mod (h / hetero~e.5)
            :ARG1-of (m / mediate-01~e.4
                  :ARG0 (p3 / protein
                        :name (n2 / name :op1 "IL-2"~e.0,2))))
      :ARG1 (i / increase-01~e.14
            :ARG1~e.15 (a / and~e.20,25
                  :op1 (r2 / recruit-01~e.17
                        :ARG1~e.18 (p / protein
                              :name (n / name :op1 "Jak3"~e.19)))
                  :op2 (a2 / activate-01~e.21
                        :ARG1 (a3 / and
                              :op1 (p2 / protein
                                    :name (n3 / name :op1 "Jak1"~e.24))
                              :op2 p~e.26)))
            :manner (r / rapid~e.13)))

# ::tok We and others have shown that IL @-@ 6 induces growth in MM cells via the MAPK pathway , which includes activation of protein @-@ tyrosine phosphatase SHP2 ( 16 , 28 )
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.1 4-1 5-1.2.r 6-1.2.1.1.1 8-1.2.1.1.1 9-1.2 10-1.2.2 13-1.2.2.1 16-1.2.2.2.1.1 17-1.2.2.2 20-1.2.2.2.2 21-1.2.2.2.2.1 23-1.2.1 23-1.2.2.2.2.1.1 25-1.2.2.2.2.1.1 26-1.2.2.2.2.1.1 27-1.2.2.2.2.1.1.1.1 29-1.3.1.1.1.1 31-1.3.1.1.1.2
# ::id bel_pmid_1088_0513_23686
(s / show-01~e.4
      :ARG0 (a2 / and~e.1
            :op1 (w / we~e.0)
            :op2 (p2 / person
                  :mod (o / other~e.2)))
      :ARG1~e.5 (i2 / induce-01~e.9
            :ARG0 (p3 / protein~e.23
                  :name (n / name :op1 "IL-6"~e.6,8))
            :ARG1 (g / grow-01~e.10
                  :ARG1 (c2 / cell~e.13
                        :name (n2 / name :op1 "multiple" :op2 "myeloma"))
                  :instrument (p4 / pathway~e.17
                        :name (n3 / name :op1 "MAPK"~e.16)
                        :ARG2-of (i / include-01~e.20
                              :ARG1 (a3 / activate-01~e.21
                                    :ARG1 (p6 / protein-tyrosine-phosphatase~e.23,25,26
                                          :name (n6 / name :op1 "SHP2"~e.27)))))))
      :ARG1-of (d / describe-01
            :ARG0 (p / publication
                  :ARG1-of (c / cite-01
                        :ARG2 (a / and :op1 "16"~e.29 :op2 "28"~e.31)))))

# ::tok We show that IL @-@ 6 triggers selective activation of SHP2 and its association with RAFTK in Dex @-@ treated MM cells .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1 5-1.2.1.1.1 6-1.2 7-1.2.2.1.3 8-1.2.2.1 9-1.2.2.1.2.r 10-1.2.2.1.2.1.1 11-1.2.2 13-1.2.2.2 14-1.2.2.2.2.r 15-1.2.2.2.2.1.1 16-1.2.2.2.3.r 17-1.2.2.2.3.2.1.1.1 19-1.2.2.2.3.2 21-1.2.2.2.3
# ::id bel_pmid_1088_0513_7274
(s / show-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (t / trigger-01~e.6
            :ARG0 (p / protein
                  :name (n2 / name :op1 "IL-6"~e.3,5))
            :ARG1 (a / and~e.11
                  :op1 (a2 / activate-01~e.8
                        :ARG0 p
                        :ARG1~e.9 (e / enzyme
                              :name (n / name :op1 "SHP2"~e.10))
                        :mod (s2 / selective~e.7))
                  :op2 (a3 / associate-01~e.13
                        :ARG1 e
                        :ARG2~e.14 (e2 / enzyme
                              :name (n3 / name :op1 "RAFTK"~e.15))
                        :location~e.16 (c / cell~e.21
                              :name (n5 / name :op1 "multiple" :op2 "myeloma")
                              :ARG1-of (t2 / treat-04~e.19
                                    :ARG2 (m / molecular-physical-entity
                                          :name (n4 / name :op1 "Dex"~e.17))))))))

# ::tok We show here that activated ACK1 , a nonreceptor tyrosine kinase that belongs to the focal adhesion kinase family , causes tyrosine phosphorylation of Ras @-@ GRF1 .
# ::alignments 0-1.1 1-1 2-1.3 3-1.2.r 4-1.2.1.4 5-1.2.1.1.1 8-1.2.1 9-1.2.1 10-1.2.1 12-1.2.1.2 13-1.2.1.2.1.r 15-1.2.1.2.1.1.1.1 16-1.2.1.2.1.1.1.2 17-1.2.1.2.1.1.1.3 18-1.2.1.2.1 20-1.2 21-1.2.2.1.1.1 22-1.2.2 24-1.2.2.1.2.1.1 26-1.2.2.1.2.1.1
# ::id bel_pmid_1088_2715_21490
(s / show-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.3 (c / cause-01~e.20
            :ARG0 (n5 / nonreceptor-tyrosine-kinase~e.8,9,10
                  :name (n4 / name :op1 "ACK1"~e.5)
                  :ARG0-of (b / belong-01~e.12
                        :ARG1~e.13 (f / family~e.18
                              :mod (p3 / protein
                                    :name (n3 / name
                                          :op1 "focal"~e.15
                                          :op2 "adhesion"~e.16
                                          :op3 "kinase"~e.17))))
                  :ARG0-of (r / receive-01 :polarity "-")
                  :ARG1-of (a2 / activate-01~e.4))
            :ARG1 (p / phosphorylate-01~e.22
                  :ARG1 (a / amino-acid
                        :name (n / name :op1 "tyrosine"~e.21)
                        :part-of (p2 / protein
                              :name (n2 / name :op1 "Ras-GRF1"~e.24,26)))))
      :location (h / here~e.2))

# ::tok GEF activity of Ras @-@ GRF1 toward Ha @-@ Ras , as defined by in vitro GDP binding and release assays , was augmented after tyrosine phosphorylation by ACK1 .
# ::alignments 0-1.1.1.1.1 1-1.1 3-1.1.2.1.1 3-1.1.3.1.1 5-1.1.2.1.1 7-1.1.3.1.1 9-1.1.2.1.1 9-1.1.3.1.1 11-1.1.4.r 11-1.2.r 12-1.1.4 13-1.1.4.1.r 14-1.1.4.1.1.2 15-1.1.4.1.1.2 16-1.1.4.1.1.1.1.1 17-1.1.4.1.1 18-1.1.4.1 19-1.1.4.1.2.1 20-1.1.4.1.2 23-1 24-1.2 25-1.2.1.1.1.1 26-1.2.1 27-1.2.1.2.r 28-1.2.1.2.1.1
# ::id bel_pmid_1088_2715_4484
(a / augment-01~e.23
      :ARG1 (a3 / act-02~e.1
            :ARG0 (s / small-molecule
                  :name (n3 / name :op1 "GEF"~e.0))
            :ARG1 (p2 / protein
                  :name (n4 / name :op1 "Ras-GRF1"~e.3,5,9))
            :location (g / gene
                  :name (n5 / name :op1 "Ha-Ras"~e.3,7,9))
            :manner~e.11 (d / define-01~e.12
                  :ARG0~e.13 (a4 / and~e.18
                        :op1 (b / bind-01~e.17
                              :ARG1 (s2 / small-molecule
                                    :name (n6 / name :op1 "GDP"~e.16))
                              :manner (i / in-vitro~e.14,15))
                        :op2 (a5 / assay-00~e.20
                              :manner (r / release~e.19)))
                  :ARG1 a3))
      :time~e.11 (a6 / after~e.24
            :op1 (p / phosphorylate-01~e.26
                  :ARG1 (a2 / amino-acid
                        :name (n2 / name :op1 "tyrosine"~e.25))
                  :ARG2~e.27 (e / enzyme
                        :name (n / name :op1 "ACK1"~e.28)))))

# ::tok Ras @-@ GRF1 acts as a GEF for Rac when tyrosine @-@ phosphorylated following G protein @-@ coupled receptor stimulation .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1 4-1.2.r 4-1.3.r 6-1.2.1.1 8-1.5.1.1 9-1.3.r 10-1.3.1.1.1 12-1.3 13-1.4 14-1.4.1.1.1.1.1.1 15-1.1 15-1.4.1.1.1.1 15-1.5 17-1.4.1.1.1 18-1.4.1.1 19-1.4.1
# ::id bel_pmid_1088_2715_4486
(a / act-01~e.3
      :ARG0 (p / protein~e.15
            :name (n / name :op1 "Ras-GRF1"~e.0,2))
      :ARG1~e.4 (s / small-molecule
            :name (n2 / name :op1 "GEF"~e.6))
      :time~e.4,9 (p3 / phosphorylate-01~e.12
            :ARG1 (a2 / amino-acid
                  :name (n4 / name :op1 "tyrosine"~e.10)
                  :part-of p))
      :ARG1-of (f / follow-01~e.13
            :ARG2 (s2 / stimulate-01~e.19
                  :ARG1 (r / receptor~e.18
                        :ARG1-of (c / couple-01~e.17
                              :ARG2 (p4 / protein~e.15
                                    :name (n5 / name :op1 "G"~e.14))))))
      :beneficiary (p2 / protein~e.15
            :name (n3 / name :op1 "Rac"~e.8)))

# ::tok Stimulation by IL @-@ 18 strongly enhanced tyrosine phosphorylation of STAT3 and of the mitogen @-@ activated protein kinases ( MAPK ) p44 erk @-@ 1 and p42 erk @-@ 2 .
# ::alignments 0-1.1 2-1.1.1.1.1 4-1.1.1.1.1 5-1.3 6-1 7-1.2.1.1.1.1 7-1.2.1.2.1.1.1 7-1.2.1.2.2.1.1 8-1.2 9-1.2.1.r 10-1.2.1.1.2.1.1 11-1.2.1 11-1.2.1.2 11-1.2.1.2.r 14-1.2.1.2.1.2 14-1.2.1.2.2.2 16-1.2.1.2.1.2 16-1.2.1.2.2.2 17-1.1.1 17-1.2.1.1.2 17-1.2.1.2.1.2 17-1.2.1.2.2.2 18-1.2.1.2.1.2 18-1.2.1.2.2.2 25-1.2.1.2.1.2.1.1 26-1.2.1.2 30-1.2.1.2.2.2.1.1
# ::id bel_pmid_1090_3731_2472
(e / enhance-01~e.6
      :ARG0 (s2 / stimulate-01~e.0
            :ARG2 (p5 / protein~e.17
                  :name (n4 / name :op1 "IL-18"~e.2,4)))
      :ARG1 (p / phosphorylate-01~e.8
            :ARG1~e.9 (a / and~e.11
                  :op1 (a3 / amino-acid
                        :name (n6 / name :op1 "tyrosine"~e.7)
                        :part-of (p6 / protein~e.17
                              :name (n5 / name :op1 "STAT3"~e.10)))
                  :op2~e.11 (a2 / and~e.11,26
                        :op1 (a4 / amino-acid
                              :name (n3 / name :op1 "tyrosine"~e.7)
                              :part-of (m / mitogen-activated-protein-kinase~e.14,16,17,18
                                    :name (n2 / name :op1 "p44erk-1"~e.25)))
                        :op2 (a5 / amino-acid
                              :name (n7 / name :op1 "tyrosine"~e.7)
                              :part-of (m2 / mitogen-activated-protein-kinase~e.14,16,17,18
                                    :name (n / name :op1 "p42erk-2"~e.30))))))
      :degree (s / strong~e.5))

# ::tok MAPK activation appears to play a prominent role in IL @-@ 18 signaling , being involved in transcription and translation of IL @-@ 18 @-@ induced IFN @-@ gamma mRNA and IL @-@ 18 @-@ induced cytolytic effects .
# ::alignments 0-1.2.1.1.1.1.1 1-1.2.1.1 2-1.2 4-1.2.1 6-1.2.1.2.1 7-1.2.1.2 8-1.2.1.3.r 9-1.2.1.3.1.1.1 11-1.2.1.3.1.1.1 12-1.2.1.3 15-1.1 16-1.1.2.r 17-1.1.2.1 18-1.1.2 19-1.1.2.2 21-1.1.2.1.2.3.1 22-1.1.2.1.2.3.1 23-1.1.2.1.2.3.1 25-1.1.2.1.2.3 26-1.1.2.1.2.2.1.1 28-1.1.2.1.2.2.1.1 29-1.1.2.1.2.1.1 30-1.1.2 31-1.1.2.1.2.3.1 32-1.1.2.1.2.3.1 33-1.1.2.1.2.3.1 35-1.1.2.3.2 36-1.1.2.3.1 37-1.1.2.3
# ::id bel_pmid_1090_3731_37032
(c / cause-01
      :ARG0 (i / involve-01~e.15
            :ARG1 (a2 / activate-01~e.1
                  :ARG0 (p / pathway
                        :name (n / name :op1 "MAPK"~e.0)))
            :ARG2~e.16 (a3 / and~e.18,30
                  :op1 (t / transcribe-01~e.17
                        :ARG0 a2
                        :ARG1 (r2 / rna
                              :name (n3 / name :op1 "mRNA"~e.29)
                              :mod (p5 / protein
                                    :name (n4 / name :op1 "IFN-gamma"~e.26,28))
                              :ARG1-of (i2 / induce-01~e.25
                                    :ARG0 p4~e.21,22,23,31,32,33)))
                  :op2 (t2 / translate-01~e.19
                        :ARG0 a2
                        :ARG1 r2)
                  :op3 (e / effect-01~e.37
                        :ARG1 (c2 / cytolysis~e.36)
                        :ARG1-of i2~e.35)))
      :ARG1 (a / appear-01~e.2
            :ARG1 (p2 / play-02~e.4
                  :ARG0 a2
                  :ARG1 (r / role~e.7
                        :mod (p3 / prominent~e.6))
                  :topic~e.8 (s / signal-01~e.12
                        :ARG1 (p4 / protein
                              :name (n2 / name :op1 "IL-18"~e.9,11))))))

# ::tok Our previous study indicated that IGF @-@ 1 could significantly increase IL @-@ 6 mRNA expression and protein production in PHA @- activated cord blood MNC ( 12 ) .
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1.2 2-1.1 3-1 4-1.2.r 5-1.2.1.1.1.1 7-1.2.1.1.1.1 8-1.2 9-1.2.1.3 10-1.2.1 11-1.2.1.2.1.1.2.1.1 13-1.2.1.2.1.1.2.1.1 14-1.2.1.2.1.1.1.1 15-1.2.1.2.1 16-1.2.1.2 17-1.2.1.2.2.1 18-1.2.1.2.2 19-1.2.1.2.2.2.r 20-1.2.1.2.2.2.2.1.1.1 22-1.2.1.2.2.2.2 23-1.2.1.2.2.2.3.1 24-1.2.1.2.2.2.3 25-1.2.1.2.2.2.1.1 27-1.3.1.1.1
# ::id bel_pmid_1090_3734_23408
(i / indicate-01~e.3
      :ARG0 (s / study-01~e.2
            :ARG0~e.0 (w / we~e.0)
            :time (p / previous~e.1))
      :ARG1~e.4 (p5 / possible~e.8
            :domain (i2 / increase-01~e.10
                  :ARG0 (p2 / protein
                        :name (n3 / name :op1 "IGF-1"~e.5,7))
                  :ARG1 (a / and~e.16
                        :op1 (e / express-03~e.15
                              :ARG2 (r / rna
                                    :name (n2 / name :op1 "mRNA"~e.14)
                                    :mod (p4 / protein
                                          :name (n / name :op1 "IL-6"~e.11,13))))
                        :op2 (p3 / produce-01~e.18
                              :ARG1 (p6 / protein~e.17)
                              :ARG3~e.19 (c3 / cell
                                    :name (n4 / name :op1 "MNC"~e.25)
                                    :ARG1-of (a2 / activate-01~e.22
                                          :ARG0 (p7 / protein
                                                :name (n5 / name :op1 "PHA"~e.20)))
                                    :mod (b / blood~e.24
                                          :location (c / cord~e.23)))))
                  :degree (s2 / significant~e.9)))
      :ARG1-of (d / describe-01
            :ARG0 (p8 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "12"~e.27))))

# ::tok Moreover , cord blood T cells cultured with IGF @-@ 1 and PHA had a higher resistance to anti @-@ Fas @-@ induced apoptosis as compared with PHA @-@ activated cord blood T cells . IGF @-@ 1 also significantly inhibited PHA @-@ induced Fas expression on cord blood T cells
# ::alignments 2-1.2.2.2.2.1 3-1.2.2.2.2 4-1.1.1.1.1.1 4-1.2.2.2.1.1 5-1.1.1.1 6-1.1.1.1.2 7-1.1.1.1.2.1.r 8-1.1.1.1.2.1.1.1.1 10-1.1.1.1.2.1.1.1.1 11-1.1.1.1.2.1 12-1.1.1.1.2.1.2.1.1 15-1.1.1.4 15-1.1.1.4.1 15-1.1.1.4.1.r 16-1.1.1 17-1.1.1.2.r 18-1.1.1.2.1 20-1.1.1.2.1.1 22-1.1.1.2.2 23-1.1.1.2 25-1.1.1.3.r 27-1.1.1.3.2.1 29-1.1.1.3.2 30-1.1.1.1.2.2.1 31-1.1.1.1.2.2 32-1.1.1.1.1.1 32-1.1.1.3.1.1 33-1.1.1.3 35-1.2.1.1.1 37-1.2.1.1.1 38-1.2.3 39-1.2.4 40-1.2 41-1.2.2.3.1.1.1 43-1.2.2.3 44-1.2.2.1.1.1 45-1.2.2 47-1.2.2.2.2.1 48-1.2.2.2.2 49-1.2.2.2.1.1 50-1.2.2.2
# ::id bel_pmid_1090_3734_4380
(m / multi-sentence
      :snt1 (a2 / and
            :op2 (r / resist-01~e.16
                  :ARG0 (c4 / cell~e.5
                        :name (n4 / name :op1 "T"~e.4,32)
                        :ARG1-of (c3 / culture-01~e.6
                              :ARG0~e.7 (a6 / and~e.11
                                    :op1 (p2 / protein
                                          :name (n5 / name :op1 "IGF-1"~e.8,10))
                                    :op2 (p3 / protein
                                          :name (n6 / name :op1 "PHA"~e.12)))
                              :mod (b2 / blood~e.31
                                    :location (c5 / cord~e.30))))
                  :ARG1~e.17 (a4 / apoptosis~e.23
                        :ARG0-of (c6 / counter-01~e.18
                              :ARG1 e2~e.20)
                        :ARG1-of (i3 / induce-01~e.22))
                  :compared-to~e.25 (c7 / cell~e.33
                        :name (n7 / name :op1 "T"~e.32)
                        :ARG1-of (a5 / activate-01~e.29
                              :ARG0 p3~e.27)
                        :mod b2)
                  :degree (h / high~e.15
                        :degree~e.15 (m2 / more~e.15))))
      :snt2 (i / inhibit-01~e.40
            :ARG0 (p4 / protein
                  :name (n8 / name :op1 "IGF-1"~e.35,37))
            :ARG1 (e / express-03~e.45
                  :ARG1 (e2 / enzyme
                        :name (n2 / name :op1 "Fas"~e.44))
                  :ARG3 (c / cell~e.50
                        :name (n3 / name :op1 "T"~e.4,49)
                        :mod (b / blood~e.3,48
                              :location (c2 / cord~e.2,47)))
                  :ARG1-of (i2 / induce-01~e.43
                        :ARG0 (p / protein
                              :name (n / name :op1 "PHA"~e.41))))
            :mod (a / also~e.38)
            :degree (s / significant~e.39)))

# ::tok constitutively active kinases within the ERK1 @/@ 2 pathway ( MEKK1 , MEK1 ) or the p38 pathway ( ASK1 , MEKK1 , MKK3 ) are potent activators of the MMP @-@ 1 promoter
# ::alignments 0-1.1.1.1.1 0-1.1.1.1.1.r 2-1.1.1 5-1.1.1.2.1.1.1 7-1.1.1.2.1.1.1 8-1.1.1.2.1 10-1.1.1.2.1.2.1.1.1.1 12-1.1.1.2.1.2.1.2.1.1 14-1.1 14-1.1.1.2 16-1.1.1.2.2.1.1 17-1.1.1.2.2 19-1.1.1.2.2.2.1.1.1.1 21-1.1.1.2.2.2.1.2 23-1.1.1.2.2.2.1.3.1.1 26-1.3 27-1 27-1.1.1.1 28-1.2.r 30-1.2.1.1.1.1 32-1.2.1.1.1.1
# ::id bel_pmid_1091_2795_5930
(a / activate-01~e.27
      :ARG0 (o / or~e.14
            :op1 (k / kinase~e.2
                  :ARG1-of (a2 / activate-01~e.27
                        :manner~e.0 (c / constitutive~e.0))
                  :location (o2 / or~e.14
                        :op1 (p4 / pathway~e.8
                              :name (n3 / name :op1 "ERK1/2"~e.5,7)
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (a3 / and
                                          :op1 (e5 / enzyme
                                                :name (n5 / name :op1 "MEKK1"~e.10))
                                          :op2 (e6 / enzyme
                                                :name (n6 / name :op1 "MEK1"~e.12)))))
                        :op2 (p3 / pathway~e.17
                              :name (n2 / name :op1 "p38"~e.16)
                              :ARG1-of (m3 / mean-01
                                    :ARG2 (a4 / and
                                          :op1 (e2 / enzyme
                                                :name (n7 / name :op1 "ASK1"~e.19))
                                          :op2 e5~e.21
                                          :op3 (e4 / enzyme
                                                :name (n9 / name :op1 "MKK3"~e.23))))))))
      :ARG1~e.28 (m / molecular-physical-entity
            :ARG0-of (p2 / promote-01
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "MMP-1"~e.30,32))))
      :mod (p / potent~e.26))

# ::tok TGF @-@ b1 also stimulates H2O2 production in bovine pulmonary artery endothelial cells ( 22 ) , vascular endothelial cells ( 23 ) , mouse osteoblastic cells ( 24 ) , and human lung fibroblast ( HLF ) cells ( 25 , 26 ) .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1.3 4-1 5-1.2.1.1.1 6-1.2 7-1.4.r 8-1.4.1.3.2 10-1.4.1.3 11-1.4.1.2 12-1.4.1 14-1.4.1.1.1.1.1 17-1.4.2.3 18-1.4.2.2 19-1.4.2 21-1.4.2.1.1.1.1 24-1.4.3.3 26-1.4.3 28-1.4.3.1.1.1.1 31-1.4 32-1.4.4.2.1 33-1.4.1.3.1 33-1.4.4.2 34-1.4.4.3 38-1.4.4 40-1.4.4.1.1.1.1.1 42-1.4.4.1.1.1.1.2
# ::id bel_pmid_1092_5306_24430
(s / stimulate-01~e.4
      :ARG0 (p5 / protein
            :name (n / name :op1 "TGF-b1"~e.0,2))
      :ARG1 (p / produce-01~e.6
            :ARG1 (m2 / molecular-physical-entity
                  :name (n2 / name :op1 "H2O2"~e.5)))
      :mod (a / also~e.3)
      :location~e.7 (a2 / and~e.31
            :op1 (c / cell~e.12
                  :ARG1-of (d / describe-01
                        :ARG0 (p2 / publication
                              :ARG1-of (c8 / cite-01 :ARG2 "22"~e.14)))
                  :mod (e / endothelium~e.11)
                  :part-of (a3 / artery~e.10
                        :mod (l2 / lung~e.33)
                        :mod (b / Bos~e.8)))
            :op2 (c2 / cell~e.19
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p3 / publication
                              :ARG1-of (c7 / cite-01 :ARG2 "23"~e.21)))
                  :mod e~e.18
                  :part-of (v / vessel~e.17))
            :op3 (c3 / cell~e.26
                  :ARG1-of (d3 / describe-01
                        :ARG0 (p4 / publication
                              :ARG1-of (c6 / cite-01 :ARG2 "24"~e.28)))
                  :mod (o / osteoblast)
                  :part-of (m3 / mouse~e.24))
            :op4 (c4 / cell~e.38
                  :ARG1-of (d5 / describe-01
                        :ARG0 (p6 / publication
                              :ARG1-of (c5 / cite-01
                                    :ARG2 (a4 / and :op1 "25"~e.40 :op2 "26"~e.42))))
                  :part-of (l / lung~e.33
                        :mod (h / human~e.32))
                  :mod (f / fibroblast~e.34))))

# ::tok TGF @-@ b1 ( 1 ng/ml )-induced intracellular ROS levels in HLF cells were measured with DCFH @-@ DA and laser @-@ scanning confocal microscopy...As shown in Fig. 1 , A and B , DCF fluorescence displayed a rapid increase with maximal intensity at 5 min after treatment and was followed by a decline in fluorescence to the basal level by 20 min .
# ::alignments 0-1.1.1.4.1.1.1 2-1.1.1.4.1.1.1 4-1.1.1.4.1.2.1 7-1.1.1.3 8-1.1.1.1.1.1 9-1.1.1 10-1.1.1.2.r 11-1.1.1.2.1.1 12-1.1.1.2 14-1.1 15-1.1.2.r 16-1.1.2.1.1.1 18-1.1.2.1.1.1 19-1.1.2 20-1.1.2.2.2.1 22-1.1.2.2.2 23-1.1.2.2.1 25-1.2.3 28-1.1.1.4.1.2.1 31-1.2 31-1.2.3.1 34-1.2.1.1.1.1.1.1 35-1.2.1.1.1 36-1.2.1 38-1.2.1.1.2 39-1.2.1.1 40-1.2.1.1.3.r 41-1.2.1.1.3.1 42-1.2.1.1.3 44-1.2.1.1.4.2.1.3.1 46-1.2.1.1.4 46-1.2.1.1.4.2 46-1.2.1.1.4.2.r 46-1.2.2.1.3 47-1.2.1.1.4.2.1 47-1.2.2.1.3.1 48-1.2 50-1.2.2 51-1.2.2.1.r 53-1.2.2.1 54-1.2.2.1.1.r 55-1.2.2.1.1 56-1.2.2.1.2.r 58-1.2.2.1.2.1 59-1.2.2.1.2 60-1.2.2.1.3.1.1.r 61-1.2.2.1.3.1.1.1
# ::id bel_pmid_1092_5306_24432
(m / multi-sentence
      :snt1 (m2 / measure-01~e.14
            :ARG1 (l / level~e.9
                  :quant-of (m3 / molecular-physical-entity
                        :name (n / name :op1 "ROS"~e.8))
                  :location~e.10 (c / cell~e.12
                        :name (n2 / name :op1 "HLF"~e.11))
                  :mod (i / intracellular~e.7)
                  :ARG1-of (i2 / induce-01
                        :ARG0 (p / protein
                              :name (n3 / name :op1 "TGF-b1"~e.0,2)
                              :quant (c2 / concentration-quantity
                                    :quant "1"~e.4,28
                                    :unit (n4 / nanogram-per-milliliter)))))
            :ARG2~e.15 (a / and~e.19
                  :op1 (m5 / molecular-physical-entity
                        :name (n5 / name :op1 "DCFH-DA"~e.16,18))
                  :op2 (m6 / microscope
                        :mod (c3 / confocal~e.23)
                        :ARG2-of (s / scan-01~e.22
                              :ARG0 (l2 / laser~e.20)))))
      :snt2 (a2 / and~e.31,48
            :op1 (d / display-01~e.36
                  :ARG1 (i3 / increase-01~e.39
                        :ARG1 (f4 / fluorescence~e.35
                              :mod (m7 / molecular-physical-entity
                                    :name (n6 / name :op1 "DCF"~e.34)))
                        :mod (r / rapid~e.38)
                        :mod~e.40 (i4 / intense~e.42
                              :degree (m8 / maximal~e.41))
                        :time (a5 / after~e.46
                              :unit (m9 / minute)
                              :time~e.46 (a4 / after~e.46
                                    :op1 (t2 / treat-04~e.47
                                          :ARG1 f4
                                          :ARG2 m7
                                          :quant (t / temporal-quantity
                                                :quant "5"~e.44
                                                :unit (m4 / minute)))))))
            :op2 (f / follow-01~e.50
                  :ARG1~e.51 (d3 / decline-01~e.53
                        :ARG1~e.54 (f5 / fluorescence~e.55)
                        :degree~e.56 (l3 / level~e.59
                              :mod (b / basal~e.58))
                        :time (a7 / after~e.46
                              :op1 (t3 / treat-04~e.47
                                    :quant~e.60 (t4 / temporal-quantity
                                          :quant "20"~e.61
                                          :unit (m11 / minute)))))
                  :ARG2 f4)
            :ARG1-of (s2 / show-01~e.25
                  :ARG0 (a3 / and~e.31
                        :op1 (f2 / figure :mod "1A")
                        :op2 (f3 / figure :mod "1B")))))

# ::tok Also , stimulation with TGF @-@ b1 ( 1 ng/ml ) caused a time @-@ dependent increase in IL @-@ 6 protein accumulation in the culture supernatants ( Fig . 2C ) .
# ::alignments 0-1.4 2-1.1 4-1.1.1.1.1 6-1.1.1.1.1 8-1.1.1.2.1 11-1 13-1.2.2.1 15-1.2.2 16-1.2 17-1.2.1.r 18-1.2.1.1.1.1 20-1.2.1.1.1.1 21-1.1.1 21-1.2.1.1 22-1.2.1 23-1.2.3.r 25-1.2.3.1 26-1.2.3 30-1.3.1.1
# ::id bel_pmid_1092_5306_24450
(c / cause-01~e.11
      :ARG0 (s / stimulate-01~e.2
            :ARG2 (p2 / protein~e.21
                  :name (n / name :op1 "TGF-b1"~e.4,6)
                  :quant (c2 / concentration-quantity
                        :quant "1"~e.8
                        :unit (n2 / nanogram-per-milliliter))))
      :ARG1 (i / increase-01~e.16
            :ARG1~e.17 (a2 / accumulate-01~e.22
                  :ARG0 (p / protein~e.21
                        :name (n3 / name :op1 "IL-6"~e.18,20)))
            :ARG0-of (d2 / depend-01~e.15
                  :ARG1 (t / time~e.13))
            :location~e.23 (s2 / supernatant~e.26
                  :mod (c3 / culture~e.25)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2C"~e.30))
      :mod (a / also~e.0))

# ::tok The amount of 1 ng @/@ ml TGF @-@ b1 was sufficient to induce the IL @-@ 6 mRNA ( Fig . 2A ) . TGF @-@ b1 ( 1 ng/ml ) treatment produced a progressive increase in IL @-@ 6 mRNA concentrations , beginning as early as 30 min , peaking at 12 h , and decreasing after 24 h ( Fig . 2B ) .
# ::alignments 1-1.1.1 3-1.1.1.2.1 7-1.1.1.1.1.1 9-1.1.1.1.1.1 11-1.1 13-1.1.2 15-1.1.2.2.2.1.1 17-1.1.2.2.2.1.1 18-1.1.2.2.1.1 22-1.1.3.1.1 25-1.2.1.1.1.1 27-1.2.1.1.1.1 29-1.2.1.1.2.1 32-1.2.1 33-1.2 36-1.2.2 38-1.2.2.1.1.2.1.1 40-1.2.2.1.1.2.1.1 41-1.2.2.1.1.1.1 42-1.1.1.2 42-1.2.1.1.2 42-1.2.2.1 44-1.2.2.2 45-1.2.2.2.1.r 46-1.2.2.2.1 47-1.2.2.2.1.1.r 47-1.2.2.2.1.r 48-1.2.2.2.1.1.1 51-1.2.2.3 53-1.2.2.3.1.1.1 57-1.2.2.4 58-1.2.2.3.1 58-1.2.2.4.1 59-1.2.2.4.1.1.1 64-1.2.3.1.1
# ::id bel_pmid_1092_5306_24464
(m / multi-sentence
      :snt1 (s / suffice-01~e.11
            :ARG0 (a / amount-01~e.1
                  :ARG1 (m2 / molecular-physical-entity
                        :name (n / name :op1 "TGF-b1"~e.7,9))
                  :ARG2 (c / concentration-quantity~e.42
                        :quant "1"~e.3
                        :unit (n2 / nanogram-per-milliliter)))
            :ARG1 (i / induce-01~e.13
                  :ARG0 a
                  :ARG1 (r / rna
                        :name (n4 / name :op1 "mRNA"~e.18)
                        :mod (p / protein
                              :name (n3 / name :op1 "IL-6"~e.15,17))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "2A"~e.22)))
      :snt2 (p2 / produce-01~e.33
            :ARG0 (t / treat-04~e.32
                  :ARG2 (m3 / molecular-physical-entity
                        :name (n6 / name :op1 "TGF-b1"~e.25,27)
                        :quant (c2 / concentration-quantity~e.42
                              :quant "1"~e.29
                              :unit (n5 / nanogram-per-milliliter))))
            :ARG1 (i2 / increase-01~e.36
                  :ARG1 (c3 / concentrate-02~e.42
                        :ARG1 (r2 / rna
                              :name (n7 / name :op1 "mRNA"~e.41)
                              :mod (p3 / protein
                                    :name (n8 / name :op1 "IL-6"~e.38,40))))
                  :ARG0-of (b / begin-01~e.44
                        :time~e.45,47 (e / early~e.46
                              :op1~e.47 (t2 / temporal-quantity
                                    :quant "30"~e.48
                                    :unit (m4 / minute))))
                  :ARG1-of (p4 / peak-01~e.51
                        :time (a3 / after~e.58
                              :op1 (t3 / temporal-quantity
                                    :quant "12"~e.53
                                    :unit (h / hour))))
                  :ARG1-of (d3 / decrease-01~e.57
                        :time (a2 / after~e.58
                              :op1 (t4 / temporal-quantity
                                    :quant "24"~e.59
                                    :unit (h2 / hour))))
                  :ARG1-of (p5 / progress-01))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f2 / figure :mod "2B"~e.64))))

# ::tok Our results indicate that autocrine secretion of PRL stimulates tyrosine phosphorylation of ErbB @-@ 2 by Jak2 , provides docking sites for Grb2 and stimulates Ras @-@ MAP kinase cascade , thereby causing unrestricted cellular proliferation .
# ::alignments 0-1.1.2 0-1.1.2.r 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1.2.r 4-1.2.1.1.1 5-1.2.1.1 6-1.2.1.1.2.r 7-1.2.1.1.2.1.1 8-1.2.1 9-1.2.1.2.1.1.1 10-1.2.1.2 12-1.2.1.2.1.2.1.1 14-1.2.1.2.1.2.1.1 15-1.2.1.2.2.r 16-1.2.1.2.2.1.1 18-1.2.2 19-1.2.2.2.1 20-1.2.2.2 21-1.2.2.3.r 22-1.2.2.3.1.1 23-1.2 24-1.2.1 24-1.2.3 25-1.2.3.2.1.1.1 27-1.2.3.2.1.1.1 28-1.2.3.2.1 29-1.2.3.2 32-1.2.4 33-1.2.4.1.2.1 34-1.2.4.1.1 35-1.2.4.1
# ::id bel_pmid_1093_8266_21268
(i / indicate-01~e.2
      :ARG0 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :poss~e.0 (w / we~e.0))
      :ARG1~e.3 (a / and~e.23
            :op1 (s / stimulate-01~e.8,24
                  :ARG0 (s3 / secrete-01~e.5
                        :ARG0 (a2 / autocrine~e.4)
                        :ARG1~e.6 (p4 / protein
                              :name (n / name :op1 "PRL"~e.7)))
                  :ARG1 (p3 / phosphorylate-01~e.10
                        :ARG1 (a3 / amino-acid
                              :name (n2 / name :op1 "tyrosine"~e.9)
                              :part-of (p5 / protein
                                    :name (n3 / name :op1 "ErbB-2"~e.12,14)))
                        :ARG2~e.15 (p7 / protein
                              :name (n4 / name :op1 "Jak2"~e.16))))
            :op2 (p / provide-01~e.18
                  :ARG0 a2
                  :ARG1 (s4 / site~e.20
                        :ARG0-of (d / dock-01~e.19))
                  :ARG2~e.21 (e2 / enzyme
                        :name (n5 / name :op1 "Grb2"~e.22)))
            :op3 (s2 / stimulate-01~e.24
                  :ARG0 a2
                  :ARG1 (c3 / cascade-01~e.29
                        :ARG1 (k / kinase~e.28
                              :name (n6 / name :op1 "Ras-MAP"~e.25,27))))
            :ARG0-of (c / cause-01~e.32
                  :ARG1 (p2 / proliferate-01~e.35
                        :ARG0 (c2 / cell~e.34)
                        :ARG1-of (r2 / restrict-01 :polarity "-"~e.33)))))

# ::tok inhibition of MAPK14 activity also interfered with stabilization of EPO mRNA in human hepatoma cells undergoing hypoxic stress
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1 3-1.1.1 4-1.3 5-1 6-1.2.r 7-1.2 9-1.2.1.2.1.1 10-1.2.1.1.1 11-1.2.2.r 12-1.2.2.2 13-1.2.2.1 14-1.2.2 16-1.2.2.3.1 17-1.2.2.3
# ::id bel_pmid_1094_3842_21324
(i / interfere-01~e.5
      :ARG0 (i2 / inhibit-01~e.0
            :ARG1~e.1 (a / act-02~e.3
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "MAPK14"~e.2))))
      :ARG1~e.6 (s / stabilize-01~e.7
            :ARG1 (r / rna
                  :name (n2 / name :op1 "mRNA"~e.10)
                  :mod (m / molecular-physical-entity
                        :name (n3 / name :op1 "EPO"~e.9)))
            :location~e.11 (c / cell~e.14
                  :mod (h / hepatoma~e.13)
                  :mod (h2 / human~e.12)
                  :ARG1-of (s2 / stress-01~e.17
                        :mod (h3 / hypoxic~e.16))))
      :mod (a2 / also~e.4))

# ::tok Consistent with the earlier results , p42 @/@ 44 MAPK and its upstream kinase MEK1 @/@ 2 were activated in a time @-@ dependent manner by the induction of Pak1 ( Fig . 3C ) .
# ::alignments 0-1.4 1-1.4.1.r 3-1.4.1.1.1 3-1.4.1.1.1.1 3-1.4.1.1.1.1.r 4-1.4.1 4-1.4.1.1 4-1.4.1.1.r 6-1.2.1.1.1.1 9-1.2.1.1.1.2 9-1.2.1.2.1.2 10-1.2 11-1.2.2.4 11-1.2.2.4.r 12-1.2.2.3 13-1.2.1.1 13-1.2.1.2 13-1.2.2.1 13-1.2.2.2 14-1.2.2.1.1.1 18-1 21-1.3.1 23-1.3 24-1.3.r 29-1.1.1.1.1 33-1.4.2.1.1
# ::id bel_pmid_1094_5974_21384
(a3 / activate-01~e.18
      :ARG0 (i / induct-01
            :ARG1 (e2 / enzyme
                  :name (n / name :op1 "Pak1"~e.29)))
      :ARG1 (a2 / and~e.10
            :op1 (s / slash
                  :op1 (k2 / kinase~e.13
                        :name (n3 / name :op1 "p42"~e.6 :op2 "MAPK"~e.9))
                  :op2 (k4 / kinase~e.13
                        :name (n4 / name :op1 "p44" :op2 "MAPK"~e.9)))
            :op2 (s2 / slash
                  :op1 (k5 / kinase~e.13
                        :name (n2 / name :op1 "MEK1"~e.14))
                  :op2 (k6 / kinase~e.13
                        :name (n6 / name :op1 "MEK2"))
                  :location (u / upstream~e.12)
                  :poss~e.11 s~e.11))
      :manner~e.24 (d / depend-01~e.23
            :ARG1 (t2 / time~e.21))
      :ARG1-of (c / consistent-01~e.0
            :ARG2~e.1 (t / thing~e.4
                  :ARG2-of~e.4 (r / result-01~e.4
                        :time (e / early~e.3
                              :degree~e.3 (m / more~e.3))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "3C"~e.33))))

# ::tok Jaffe et al. [22,23] reported IL @-@ 5 and IL @-@ 13 production from human lung mast cells following IgE @-@ mediated activation .
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2.1 4-1 5-1.2.1.1.1.1 5-1.2.1.2.1.1 7-1.2.1.1.1.1 8-1.2.1 9-1.2.1.1.1.1 9-1.2.1.2.1.1 11-1.2.1.2.1.1 12-1.2 13-1.2.2.r 14-1.2.2.2.1 15-1.2.2.2 16-1.2.2.1 17-1.2.2 18-1.2.3 19-1.2.3.1.1.1.1.1 21-1.2.3.1.1 22-1.2.3.1
# ::id bel_pmid_1097_1465_18050
(r / report-01~e.4
      :ARG0 (a / and~e.1
            :op1 (p / person
                  :name (n / name :op1 "Jaffe"~e.0))
            :op2 (p2 / person
                  :mod (o / other~e.2)))
      :ARG1 (p4 / produce-01~e.12
            :ARG1 (a3 / and~e.8
                  :op1 (p5 / protein
                        :name (n2 / name :op1 "IL-5"~e.5,7,9))
                  :op2 (p6 / protein
                        :name (n3 / name :op1 "IL-13"~e.5,9,11)))
            :ARG2~e.13 (c2 / cell~e.17
                  :mod (m / mast~e.16)
                  :part-of (l / lung~e.15
                        :mod (h / human~e.14)))
            :ARG1-of (f / follow-01~e.18
                  :ARG2 (a4 / activate-01~e.22
                        :ARG1-of (m2 / mediate-01~e.21
                              :ARG0 (m3 / molecular-physical-entity
                                    :name (n4 / name :op1 "IgE"~e.19))))))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 (a2 / and :op1 "22" :op2 "23")))))

# ::tok Using immunocytochemistry , Bradding et al. [1±4] reported that interleukin ( IL )-4 , IL @-@ 5 , IL @-@ 6 , and tumour necrosis factor ( TNF )-a were present within mast cells in nasal and bronchial mucosa taken from both normal subjects and patients with allergic perennial rhinitis ,
# ::alignments 0-1.1 1-1.1.2 3-1.2.1.1.1.1 4-1.1.3.1.1.1.2 4-1.2.1 5-1.2.1.2.1 7-1.2 11-1.2.2.1.1.1.1 11-1.2.2.1.2.1.1 11-1.2.2.1.3.1.1 14-1.2.2.1.1.1.1 14-1.2.2.1.2.1.1 14-1.2.2.1.3.1.1 16-1.2.2.1.2.1.1 18-1.2.2.1.1.1.1 18-1.2.2.1.2.1.1 18-1.2.2.1.3.1.1 20-1.2.2.1.3.1.1 22-1.2.2.1 23-1.2.2.1.4.1.1 24-1.2.2.1.4.1.2 25-1.2.2.1.4.1.3 29-1.2.2 32-1.2.2.2.1 33-1.2.2.2 36-1.2.2.2.1.1.1 37-1.2.2.2.1.1.1.2.1 38-1.2.2.2.1.1.1.1 38-1.2.2.2.1.1.1.2 39-1.2.2.2.1.1.1.3 42-1.2.2.2.1.1.1.3.1.1.1 43-1.2.2.2.1.1.1.3.1.1 44-1.2.2.2.1.1.1.3.1 45-1.2.2.2.1.1.1.3.1.2 46-1.2.2.2.1.1.1.3.1.2.1.r 47-1.2.2.2.1.1.1.3.1.2.1 48-1.2.2.2.1.1.1.3.1.2.1.1.1.1 49-1.2.2.2.1.1.1.3.1.2.1.1.1.2
# ::id bel_pmid_1097_1465_18052
(c / cause-01
      :ARG0 (u / use-01~e.0
            :ARG0 (a / and~e.4
                  :op1 (p / person
                        :name (n / name :op1 "Bradding"~e.3))
                  :op2 (p2 / person
                        :mod (o / other~e.5)))
            :ARG1 (i / immunocytochemistry~e.1)
            :ARG1-of (d2 / describe-01
                  :ARG0 (p8 / publication
                        :ARG1-of (c3 / cite-01
                              :ARG2 (o2 / or
                                    :op1 "1"
                                    :op2 (a6 / and~e.4 :op1 "1" :op2 "4"))))))
      :ARG1 (r / report-01~e.7
            :ARG0 a
            :ARG1 (b / be-located-at-91~e.29
                  :ARG1 (a2 / and~e.22
                        :op1 (p4 / protein
                              :name (n4 / name :op1 "IL-4"~e.11,14,18))
                        :op2 (p5 / protein
                              :name (n5 / name :op1 "IL-5"~e.11,14,16,18))
                        :op3 (p6 / protein
                              :name (n6 / name :op1 "IL-6"~e.11,14,18,20))
                        :op4 (p7 / protein
                              :name (n7 / name
                                    :op1 "tumour"~e.23
                                    :op2 "necrosis"~e.24
                                    :op3 "factor"~e.25)))
                  :ARG2 (c2 / cell~e.33
                        :mod (m / mast~e.32
                              :ARG1-of (b2 / be-located-at-91
                                    :ARG2 (a4 / and~e.36
                                          :op1 (m2 / mucosa~e.38
                                                :mod (n8 / nose))
                                          :op2 (m3 / mucosa~e.38
                                                :mod (b3 / bronchus~e.37))
                                          :ARG1-of (t / take-01~e.39
                                                :ARG2 (a3 / and~e.44
                                                      :op1 (s / subject~e.43
                                                            :mod (n2 / normal~e.42))
                                                      :op2 (p3 / patient~e.45
                                                            :ARG1-of~e.46 (a5 / allergic-01~e.47
                                                                  :ARG2 (d / disease
                                                                        :name (n3 / name :op1 "perennial"~e.48 :op2 "rhinitis"~e.49)))))))))))))

# ::tok STAM2 is downstream of the Jak family of kinases since coexpression of STAM2 with Jak1 or Jak2 but not an unrelated Tec family kinase , Etk , resulted in its tyrosine phosphorylation .
# ::alignments 0-1.2.1 1-1.2 2-1.2.2.2 5-1.2.2.1.1.1.1 6-1.1.2.2.2 8-1.1.2.2 9-1 12-1.1.1.1.1.1.1 14-1.1.1.1.2.1.1.1 15-1.1.1.1.2 16-1.1.1.1.2.2.1.1 17-1.1 18-1.1.2.1.r 18-1.1.2.2.3.1.r 20-1.1.2.1 20-1.1.2.2.3 20-1.1.2.2.3.1 21-1.1.2.2.2.1.1.1 22-1.1.2.2.2 22-1.2.2.1 23-1.1.2.2 23-1.2.2.1.2 25-1.1.2.2.1.1 27-1.1.1 27-1.1.2 28-1.1.1.2.r 29-1.1.1.2.1.2 29-1.1.1.2.1.2.r 30-1.1.1.2.1.1.1 31-1.1.1.2
# ::id bel_pmid_1099_3906_5890
(c4 / cause-01~e.9
      :ARG0 (c5 / contrast-01~e.17
            :ARG1 (r / result-01~e.27
                  :ARG1 (c3 / coexpress-00
                        :ARG0 (p5 / protein
                              :name (n3 / name :op1 "STAM2"~e.12))
                        :ARG1 (o / or~e.15
                              :op1 (p / protein
                                    :name (n / name :op1 "Jak1"~e.14))
                              :op2 (p2 / protein
                                    :name (n2 / name :op1 "Jak2"~e.16))))
                  :ARG2~e.28 (p4 / phosphorylate-01~e.31
                        :ARG1 (a / amino-acid
                              :name (n5 / name :op1 "tyrosine"~e.30)
                              :part-of~e.29 p5~e.29)))
            :ARG2 (r2 / result-01~e.27
                  :polarity~e.18 "-"~e.20
                  :ARG1 (k2 / kinase~e.8,23
                        :name (n7 / name :op1 "Etk"~e.25)
                        :part-of (f2 / family~e.6,22
                              :mod (p6 / protein
                                    :name (n6 / name :op1 "Tec"~e.21))
                              :mod (k / kinase~e.23))
                        :ARG1-of (r3 / relate-01~e.20 :polarity~e.18 "-"~e.20))
                  :ARG2 p4))
      :ARG1 (b / be-located-at-91~e.1
            :ARG1 p5~e.0
            :ARG2 (r4 / relative-position
                  :op1 (f / family~e.22
                        :mod (p3 / protein
                              :name (n4 / name :op1 "Jak"~e.5))
                        :mod k)
                  :direction (d / downstream~e.2))))

# ::tok Tyrosine phosphorylation of STAM2 is induced by growth factors such as epidermal growth factor and platelet @-@ derived growth factor as well as by cytokines like IL @-@ 3 .
# ::alignments 0-1.2.1.1.1 1-1.2 3-1.2.1.2.1.1 5-1 6-1.1.r 7-1.1.1.1 8-1.1.1.2 9-1.1.2.3.2.r 9-1.1.2.r 10-1.1.2.3.2.r 10-1.1.2.r 11-1.1.2.1.1.1 12-1.1.2.1.1.2 13-1.1.2.1.1.3 14-1.1.2 15-1.1.2.2.1.1 17-1.1.2.2.1.1 18-1.1.2.2.1.2 19-1.1.2.2.1.3 25-1.1.2.3.2.r 25-1.1.2.r 26-1.1.2.3.2.1.1 28-1.1.2.3.2.1.1
# ::id bel_pmid_1099_3906_6852
(i / induce-01~e.5
      :ARG0~e.6 (p2 / protein
            :name (n3 / name :op1 "growth"~e.7 :op2 "factor"~e.8)
            :example~e.9,10,25 (a2 / and~e.14
                  :op1 (p3 / protein
                        :name (n7 / name
                              :op1 "epidermal"~e.11
                              :op2 "growth"~e.12
                              :op3 "factor"~e.13))
                  :op2 (p4 / protein
                        :name (n6 / name
                              :op1 "platelet-derived"~e.15,17
                              :op2 "growth"~e.18
                              :op3 "factor"~e.19))
                  :op2 (p5 / protein
                        :name (n5 / name :op1 "cytokine")
                        :example~e.9,10,25 (p6 / protein
                              :name (n4 / name :op1 "IL-3"~e.26,28)))))
      :ARG1 (p8 / phosphorylate-01~e.1
            :ARG1 (a / amino-acid
                  :name (n / name :op1 "tyrosine"~e.0)
                  :part-of (p / protein
                        :name (n2 / name :op1 "STAM2"~e.3)))))

# ::tok Finally , overexpression of wild type STAM2 led to an increase in IL @-@ 2 @-@ mediated induction of c @-@ Myc promoter activation indicating that it potentiates cytokine receptor signaling .
# ::alignments 0-1.3 4-1.1.1.2 5-1.1.1.2 6-1.1.1.1.1 7-1 10-1.2 12-1.2.1.2.1.1.1 14-1.2.1.2.1.1.1 16-1.2.1.2 19-1.2.1.1.1.1.1.1.1 21-1.2.1.1.1.1.1.1.1 23-1.2.1.1 24-1.4 25-1.4.1.r 26-1.4.1.1 27-1.4.1 28-1.4.1.2.1.1.1.1 29-1.4.1.2.1 30-1.4.1.2
# ::id bel_pmid_1099_3906_7612
(l / lead-03~e.7
      :ARG0 (o / overexpress-00
            :ARG1 (p5 / protein
                  :name (n / name :op1 "STAM2"~e.6)
                  :mod (w / wild-type~e.4,5)))
      :ARG2 (i / increase-01~e.10
            :ARG1 (i2 / induct-01
                  :ARG1 (a / activate-01~e.23
                        :ARG1 (m2 / molecular-physical-entity
                              :ARG0-of (p2 / promote-01
                                    :ARG1 (p6 / protein
                                          :name (n3 / name :op1 "c-Myc"~e.19,21)))))
                  :ARG1-of (m / mediate-01~e.16
                        :ARG0 (p / protein
                              :name (n2 / name :op1 "IL-2"~e.12,14)))))
      :time (f / final~e.0)
      :ARG0-of (i3 / indicate-01~e.24
            :ARG1~e.25 (p3 / potentiate-00~e.27
                  :ARG0 o~e.26
                  :ARG1 (s / signal-01~e.30
                        :ARG0 (r / receptor~e.29
                              :mod (p4 / protein
                                    :name (n4 / name :op1 "cytokine"~e.28)))))))

# ::tok At days 8 , 11 , 20 , 23 , and 26 after disease induction , splenocytes from CCR2 @-@ deficient mice also proliferated less robustly to Ag and secreted lower levels of IFN-{gamma} and IL @-@ 6 than splenocytes from wild @-@ type controls
# ::alignments 2-1.3.1 4-1.3.2 6-1.3.3 8-1.3.4 11-1.3.5 12-1.4 13-1.4.1.1 17-1.1.1.2.r 18-1.1.1.2.1.1.1 21-1.1.1.2 21-1.2.2.1.2.2.2 22-1.1.3 23-1.1 24-1.1.2.1 25-1.1.2 25-1.1.2.r 27-1.1.4.1.1.1 28-1 29-1.2 30-1.2.2.1.2 30-1.2.2.1.2.1 30-1.2.2.1.2.1.r 31-1.2.2.1 31-1.2.2.2 34-1.2.2 35-1.2.2.2.1.1.1 37-1.2.2.2.1.1.1 38-1.2.2.2.2 40-1.1.1.2.r 40-1.2.2.1.2.2.2.2.r 40-1.2.2.1.2.2.r 41-1.2.2.1.2.2.2.2 43-1.2.2.1.2.2.2.2 44-1.2.2.1.2.2.2.1
# ::id bel_pmid_1101_5448_18896
(a / and~e.28
      :op1 (p / proliferate-01~e.23
            :ARG0 (c / cell
                  :name (n / name :op1 "splenocyte")
                  :source~e.17,40 (m / mouse~e.21
                        :mod (p2 / protein
                              :name (n2 / name :op1 "CCR2"~e.18)
                              :ARG2-of (m2 / mutate-01 :mod "-/-"))))
            :manner~e.25 (r / robust~e.25
                  :degree (l / less~e.24))
            :mod (a2 / also~e.22)
            :ARG1-of (r2 / result-01
                  :ARG2 (m3 / molecular-physical-entity
                        :name (n5 / name :op1 "Ag"~e.27))))
      :op2 (s / secrete-01~e.29
            :ARG0 c
            :ARG1 (a4 / and~e.34
                  :op1 (l2 / level~e.31
                        :quant-of (p3 / protein
                              :name (n3 / name :op1 "IFN-γ"))
                        :mod (l3 / low~e.30
                              :degree~e.30 (m4 / more~e.30)
                              :compared-to~e.40 (c2 / cell
                                    :name (n6 / name :op1 "splenocyte")
                                    :source (m5 / mouse~e.21
                                          :ARG2-of (c3 / control-01~e.44)
                                          :mod~e.40 (w / wild-type~e.41,43)))))
                  :op2 (l4 / level~e.31
                        :quant-of (p4 / protein
                              :name (n4 / name :op1 "IL-6"~e.35,37))
                        :mod l3~e.38)))
      :time (d / date-entity
            :day "8"~e.2
            :day "11"~e.4
            :day "20"~e.6
            :day "23"~e.8
            :day "26"~e.11)
      :time (a5 / after~e.12
            :op1 (i / induct-01
                  :ARG1 (d2 / disease~e.13))))

# ::tok Additionally , T cells from CCR2(-/)- immunized mice showed decreased antigen @-@ induced proliferation and production of IFN @-@ gamma compared with wild @-@ type immunized controls , suggesting that CCR2 enhances the T helper cell type 1 immune response in EAE .
# ::alignments 2-1.1.1.1.1 3-1.1.1 4-1.1.1.2.r 6-1.1.1.2.1 7-1.1.1.2 7-1.1.2.3.1.1 8-1.1 9-1.1.2.3 10-1.1.2.1.1.1 12-1.1.2.1.1 13-1.1.2.1 14-1.1.2 15-1.1.2.2 16-1.1.2.2.1.r 17-1.1.2.2.1.1.1 19-1.1.2.2.1.1.1 20-1.1.2.3.1 21-1.1.2.3.1.1.3.r 22-1.1.2.3.1.1.3 24-1.1.2.3.1.2.1.2.1.2 25-1.1.2.3.1.1.2 26-1.1.2.3.1.1.1 28-1.1.2.3.1.2 30-1.1.1.2.2.1.1 31-1.1.2.3.1.2.1 33-1.1.2.3.1.2.1.2.1.1.1 34-1.1.2.3.1.2.1.2.1.1.1 35-1.1.2.3.1.2.1.2.1 36-1.1.2.3.1.2.1.2.1.2 37-1.1.2.3.1.2.1.2.1.2.1 38-1.1.2.3.1.2.1.2.2 39-1.1.2.3.1.2.1.2 40-1.1.2.3.1.2.1.2.3.r 41-1.1.2.3.1.2.1.2.3.1.1
# ::id bel_pmid_1101_5448_8236
(a / and
      :op2 (s / show-01~e.8
            :ARG0 (c / cell~e.3
                  :name (n / name :op1 "T"~e.2)
                  :source~e.4 (m / mouse~e.7
                        :ARG1-of (i / immunize-01~e.6)
                        :mod (p / protein
                              :name (n2 / name :op1 "CCR2"~e.30)
                              :ARG2-of (m2 / mutate-01 :mod "-/-"))))
            :ARG1 (a2 / and~e.14
                  :op1 (p2 / proliferate-01~e.13
                        :ARG1-of (i2 / induce-01~e.12
                              :ARG0 (a3 / antigen~e.10)))
                  :op2 (p3 / produce-01~e.15
                        :ARG1~e.16 (p4 / protein
                              :name (n3 / name :op1 "IFN-gamma"~e.17,19)))
                  :ARG1-of (d / decrease-01~e.9
                        :ARG1-of (c2 / compare-01~e.20
                              :ARG2 (m3 / mouse~e.7
                                    :ARG2-of (c3 / control-01~e.26)
                                    :ARG1-of i~e.25
                                    :mod~e.21 (w / wild-type~e.22))
                              :ARG0-of (s2 / suggest-01~e.28
                                    :ARG1 (e / enhance-01~e.31
                                          :ARG0 p
                                          :ARG1 (r / respond-01~e.39
                                                :ARG0 (c4 / cell~e.35
                                                      :name (n4 / name :op1 "T-helper"~e.33,34)
                                                      :mod (t / type~e.24,36 :mod "1"~e.37))
                                                :mod (i3 / immune~e.38)
                                                :topic~e.40 (d2 / disease
                                                      :name (n5 / name :op1 "EAE"~e.41))))))))))

# ::tok GnT @-@ V transcription was stimulated by several oncogenes including src , her -@ 2/ neu , H @- ras , and v @- sis ( 9 , 10 , 11 ) , and this overexpression was regulated through the ras @-@ raf @-@ ets pathways .
# ::alignments 0-1.1.2.1.1.1 2-1.1.2.1.1.1 5-1.1 6-1.1.1.r 7-1.1.1.1 8-1.1.1 9-1.1.1.2 10-1.1.1.2.1.1.1.1 12-1.1.1.2.1.2.1.1 15-1.1.1.2.1.2.1.1 17-1.1.1.2.1.3.1.1 19-1.1.1.2.1.3.1.1 21-1.1.1.2.1 22-1.1.1.2.1.4.1.1 24-1.1.1.2.1.4.1.1 26-1.1.3.1.1.1 28-1.1.3.1.2.1 30-1.1.3.1.3.1 33-1 33-1.1.3.1 34-1.2.2.1 37-1.2 40-1.2.1.1.1 42-1.2.1.1.1 44-1.2.1.1.1 45-1.2.1
# ::id bel_pmid_1102_9459_20858
(a / and~e.33
      :op1 (s / stimulate-01~e.5
            :ARG0~e.6 (o / oncogene~e.8
                  :mod (s2 / several~e.7)
                  :ARG2-of (i / include-91~e.9
                        :ARG1 (a2 / and~e.21
                              :op1 (g / gene
                                    :name (n / name :op1 "src"~e.10))
                              :op2 (g2 / gene
                                    :name (n2 / name :op1 "her-2/neu"~e.12,15))
                              :op3 (g3 / gene
                                    :name (n3 / name :op1 "H-ras"~e.17,19))
                              :op4 (g4 / gene
                                    :name (n4 / name :op1 "v-sis"~e.22,24)))))
            :ARG1 (t / transcript-00
                  :ARG1 (e / enzyme
                        :name (n5 / name :op1 "GnT-V"~e.0,2)))
            :ARG1-of (d / describe-01
                  :ARG0 (a3 / and~e.33
                        :op1 (f / figure :mod "9"~e.26)
                        :op2 (f2 / figure :mod "10"~e.28)
                        :op3 (f3 / figure :mod "11"~e.30))))
      :op2 (r / regulate-01~e.37
            :ARG0 (p / pathway~e.45
                  :name (n6 / name :op1 "ras-raf-ets"~e.40,42,44))
            :ARG1 (o2 / overexpress-00
                  :mod (t2 / this~e.34))))

# ::tok Each of three Ki @-@ ras( G12V ) transfectants responded to TGF @-@ beta1 by an increase in proliferation and by decreasing the abundance of the Cdk inhibitor p21 and the tumor suppressor PTEN , whereas each of three wild @-@ type Ki @-@ ras transfectants remained unresponsive to TGF @-@ beta1 .
# ::alignments 0-1.1.1.3 0-1.2.1.3 2-1.1.1.1 2-1.2.1.1 3-1.1.1.2.1.1.1 3-1.2.1.2.1.1.1 6-1.1.1.2.1.2.1 9-1.1 10-1.1.2.r 11-1.1.2.1.1 14-1.1.3.r 16-1.1.3.1 17-1.1.3.1.1.r 18-1.1.3.1.1 19-1.1.3 21-1.1.3.2 23-1.1.3.2.1 24-1.1.3.2.1.1.r 26-1.1.3.2.1.1.1.2.1.1.1 27-1.1.3.2.1.1.1 27-1.1.3.2.1.1.1.2 27-1.1.3.2.1.1.1.2.r 28-1.1.3.2.1.1.1.1.1 29-1.1.3.2.1.1 31-1.1.3.2.1.1.2.2 33-1.1.3.2.1.1.2.1.1.1 35-1 36-1.1.1.3 36-1.2.1.3 38-1.1.1.1 38-1.2.1.1 39-1.2.1.4 41-1.2.1.4 42-1.2.1.2.1.1.1 44-1.2.1.2.1.1.1 46-1.2 47-1.2.2 47-1.2.2.1 47-1.2.2.1.r 48-1.2.2.3.r 49-1.2.2.3
# ::id bel_pmid_1102_9459_21486
(c / contrast-01~e.35
      :ARG1 (r / respond-01~e.9
            :ARG0 (c2 / cell
                  :quant "3"~e.2,38
                  :ARG3-of (t / transfect-00
                        :ARG2 (p / protein
                              :name (n / name :op1 "Ki-ras"~e.3)
                              :ARG2-of (m / mutate-01 :value "G12V"~e.6)))
                  :mod (e / each~e.0,36))
            :ARG1~e.10 (p2 / protein
                  :name (n3 / name :op1 "TGF-β1"~e.11))
            :ARG2~e.14 (a / and~e.19
                  :op1 (i / increase-01~e.16
                        :ARG1~e.17 (p3 / proliferate-01~e.18))
                  :op2 (d / decrease-01~e.21
                        :ARG1 (a2 / abound-01~e.23
                              :ARG1~e.24 (a3 / and~e.29
                                    :op1 (p4 / protein~e.27
                                          :name (n4 / name :op1 "p21"~e.28)
                                          :ARG0-of~e.27 (i2 / inhibit-01~e.27
                                                :ARG1 (e2 / enzyme
                                                      :name (n5 / name :op1 "Cdk"~e.26))))
                                    :op2 (s / suppress-01
                                          :ARG0 (g / gene
                                                :name (n6 / name :op1 "PTEN"~e.33))
                                          :ARG1 (t2 / tumor~e.31)))))))
      :ARG2 (r2 / remain-01~e.46
            :ARG1 (c3 / cell
                  :quant "3"~e.2,38
                  :ARG3-of (t3 / transfect-00
                        :ARG2 (p5 / protein
                              :name (n7 / name :op1 "Ki-ras"~e.3,42,44)))
                  :mod (e3 / each~e.0,36)
                  :mod (w / wild-type~e.39,41))
            :ARG3 (r3 / respond-01~e.47
                  :polarity~e.47 "-"~e.47
                  :ARG0 c3
                  :ARG1~e.48 p2~e.49)))

# ::tok The wild @-@ type Ki @-@ ras transfectants lack functional TGF @-@ beta receptors , whereas all three Ki @-@ ras( G12V ) transfectants expressed functional TGF @-@ beta receptors that bound ( 125 ) I @-@ TGF @-@ beta1 .
# ::alignments 1-1.1.1.1.1.2 3-1.1.1.1.1.2 4-1.1.1.1.1.1.1 6-1.1.1.1.1.1.1 8-1.1 9-1.1.2.2 10-1.1.2.1.1 13-1.1.2 15-1 16-1.2.2.3 17-1.2.2.1 18-1.2.2.2.1.1.1 21-1.2.2.2.1.2.1 24-1.2 25-1.1.2.2 26-1.1.2.1.1 26-1.2.1.1.1 29-1.2.1 31-1.2.1.3 35-1.2.1.2 37-1.1.2.1.1 37-1.2.1.1.1 37-1.2.1.3.1.1.1
# ::id bel_pmid_1102_9459_7644
(c / contrast-01~e.15
      :ARG1 (l / lack-01~e.8
            :ARG0 (c2 / cell
                  :ARG3-of (t / transfect-00
                        :ARG2 (p / protein
                              :name (n / name :op1 "Ki-ras"~e.4,6)
                              :mod (w / wild-type~e.1,3))))
            :ARG1 (r / receptor~e.13
                  :name (n2 / name :op1 "TGF-β"~e.10,26,37)
                  :mod (f / function-01~e.9,25)))
      :ARG2 (e / express-03~e.24
            :ARG2 (r2 / receptor~e.29
                  :name (n3 / name :op1 "TGF-β"~e.26,37)
                  :mod f~e.35
                  :ARG1-of (b / bind-01~e.31
                        :ARG2 (p2 / protein
                              :name (n4 / name :op1 "(125)I-TGF-β1"~e.37))))
            :ARG3 (c3 / cell
                  :quant "3"~e.17
                  :ARG3-of (t2 / transfect-00
                        :ARG2 (p3 / protein
                              :name (n5 / name :op1 "Ki-ras"~e.18)
                              :ARG2-of (m / mutate-01 :value "G12V"~e.21)))
                  :mod (a / all~e.16))))

# ::tok SIRP is a transmembrane protein that is now known to bind to integrin @-@ associated protein . It appears to bind directly to JAK2 by a process that does not require tyrosyl phosphorylation , although is itself highly phosphorylated on tyrosines in response to GH . The phosphorylated SIRP recruits one or more molecules of the tyrosine phosphatase SHP2 that , in turn , de @-@ phosphorylates SIRP and most likely JAK2 .
# ::alignments 0-1.1.1.1.1.1 0-1.3.1.1.1 3-1.1.1.1.2 4-1.1.1.1 7-1.1.2 8-1.1 10-1.1.1 11-1.1.1.2.r 12-1.1.1.2.1.1.1.1 14-1.1.1.2.1 15-1.1.1.2 18-1.2 20-1.2.1 21-1.2.1.3 21-1.2.1.3.r 22-1.2.1.2.r 23-1.2.1.2.1.1 24-1.2.1.4.r 26-1.2.1.4 29-1.2.1.4.1.1 29-1.2.1.4.1.1.r 30-1.2.1.4.1 31-1.2.1.4.1.2.1.1.1 32-1.2.1.4.1.2 32-1.3.1 32-1.3.1.2 32-1.3.1.2.r 34-1.2.2.r 37-1.2.2.2 38-1.2.2 40-1.2.2.1.1.1 41-1.3.2.1.2.1.3 42-1.2.2.3 42-1.3.2.1 42-1.3.2.1.2 42-1.3.2.1.2.r 43-1.2.2.3.1.r 44-1.2.2.3.1.1.1 47-1.2.2 48-1.2.1.1.1.1 48-1.3.1.1.1 49-1.3 50-1.3.2.2.1 51-1.3.2.2 52-1.3.2.2.2 53-1.3.2 56-1.3.2.1.1.1 57-1.3.2.1.1.2 58-1.3.2.1.1.3 61-1.3.2.1.2.1.3 62-1.3.2.1.2.1.3 66-1.2.1.4.1.2 67-1.2.1.1.1.1 67-1.3.1.1.1 68-1.3.2.1.2.1.2 69-1.3.2.1.2.1.2.2.2.1 70-1.3.2.1.2.1.2.2.2 71-1.2.1.2.1.1 71-1.3.2.1.2.1.2.2.1.1
# ::id bel_pmid_1103_6942_20042
(m / multi-sentence
      :snt1 (k / know-02~e.8
            :ARG3 (b / bind-01~e.10
                  :ARG1 (p / protein~e.4
                        :name (n / name :op1 "SIRP"~e.0)
                        :mod (t / transmembrane~e.3))
                  :ARG2~e.11 (p2 / protein~e.15
                        :ARG1-of (a / associate-01~e.14
                              :ARG2 (p3 / protein
                                    :name (n2 / name :op1 "integrin"~e.12)))))
            :time (n3 / now~e.7))
      :snt2 (a2 / appear-02~e.18
            :ARG1 (b2 / bind-01~e.20
                  :ARG1 (p4 / protein
                        :name (n5 / name :op1 "SIRP"~e.48,67))
                  :ARG2~e.22 (e / enzyme
                        :name (n4 / name :op1 "JAK2"~e.23,71))
                  :manner~e.21 (d / direct~e.21)
                  :manner~e.24 (p5 / process-01~e.26
                        :ARG0-of (r / require-01~e.30
                              :polarity~e.29 "-"~e.29
                              :ARG1 (p6 / phosphorylate-01~e.32,66
                                    :ARG1 (m2 / molecular-physical-entity
                                          :name (n6 / name :op1 "tyrosyl"~e.31))))))
            :concession~e.34 (p7 / phosphorylate-01~e.38,47
                  :ARG1 (a3 / amino-acid
                        :name (n7 / name :op1 "tyrosine"~e.40)
                        :part-of p4)
                  :degree (h / high~e.37)
                  :ARG2-of (r2 / respond-01~e.42
                        :ARG1~e.43 (m3 / molecular-physical-entity
                              :name (n8 / name :op1 "GH"~e.44)))))
      :snt3 (r3 / recruit-01~e.49
            :ARG0 (p8 / protein~e.32
                  :name (n9 / name :op1 "SIRP"~e.0,48,67)
                  :ARG1-of~e.32 (p9 / phosphorylate-01~e.32))
            :ARG1 (m4 / molecule~e.53
                  :mod (e2 / enzyme~e.42
                        :name (n10 / name
                              :op1 "tyrosine"~e.56
                              :op2 "phosphatase"~e.57
                              :op3 "SHP2"~e.58)
                        :ARG1-of~e.42 (r4 / respond-01~e.42
                              :ARG2 (d2 / dephosphorylate-01
                                    :ARG0 e2
                                    :ARG1 (a4 / and~e.68
                                          :op1 p8
                                          :op2 (e3 / enzyme
                                                :name (n11 / name :op1 "JAK2"~e.71)
                                                :mod (l / likely~e.70
                                                      :degree (m5 / most~e.69))))
                                    :mod (i / in-turn~e.41,61,62))))
                  :quant (o / or~e.51
                        :op1 "1"~e.50
                        :op2 (m6 / more~e.52)))))

# ::tok Estrogen rapidly activates the mitogen @-@ activated protein kinases , Erk @-@ 1 and Erk @-@ 2 , via an as yet unknown mechanism . requires the expression of the G protein @-@ coupled receptor homolog , GPR30. We show that 17 beta @-@ estradiol activates Erk @-@ 1/-2 not only in MCF @-@ 7 cells , which express both estrogen receptor alpha ( ER alpha ) and ER beta , but
# ::alignments 0-1.1.1 1-1.1.3 1-1.1.3.r 2-1.1 2-1.1.2.3.2 4-1.1.2.3.2.1 6-1.1.2.3.2 7-1.1.2.3.1.1 8-1.1.2.3.1.2 10-1.1.2.1.1.1 10-1.1.2.2.1.1 12-1.1.2.1.1.1 13-1.1.2 14-1.1.2.1.1.1 14-1.1.2.2.1.1 16-1.1.2.2.1.1 20-1.1.4.r 21-1.1.4.1.2 22-1.1.4.1 22-1.1.4.1.1 22-1.1.4.1.1.r 23-1.1.4 25-1.2 27-1.2.1 28-1.2.1.1.r 30-1.2.1.1.1.1 31-1.2.1.1.1.2 33-1.2.1.1.1.2 34-1.2.1.1.1.3 35-1.2.1.1.1.4 38-1.3.1 39-1.3 44-1.3.2.1.1.1 45-1.3.2 46-1.3.2.2.1.1 49-1.3.2.3.2.1 49-1.3.2.3.2.1.r 50-1.3.2.3.2 52-1.3.2.3.1.1 54-1.3.2.3.1.1 55-1.3.2.3 58-1.3.2.3.3 60-1.3.2.3.3.1.1.1.1 61-1.3.2.3.3.1.1.1.2 67-1.3.2.3.3.1
# ::id bel_pmid_1104_3579_19856
(m / multi-sentence
      :snt1 (a / activate-01~e.2
            :ARG0 (e / estrogen~e.0)
            :ARG1 (a2 / and~e.13
                  :op1 (e2 / enzyme
                        :name (n / name :op1 "Erk-1"~e.10,12,14))
                  :op2 (e3 / enzyme
                        :name (n2 / name :op1 "Erk-2"~e.10,14,16))
                  :domain (e4 / enzyme
                        :name (n3 / name :op1 "protein"~e.7 :op2 "kinase"~e.8)
                        :ARG1-of (a3 / activate-01~e.2,6
                              :ARG0 (m2 / mitogen~e.4))))
            :manner~e.1 (r / rapid~e.1)
            :manner~e.20 (m3 / mechanism~e.23
                  :ARG1-of (k / know-01~e.22
                        :polarity~e.22 "-"~e.22
                        :mod (y / yet~e.21))))
      :snt2 (r2 / require-01~e.25
            :ARG1 (e5 / express-03~e.27
                  :ARG2~e.28 (p / protein
                        :name (n4 / name
                              :op1 "G"~e.30
                              :op2 "protein-coupled"~e.31,33
                              :op3 "receptor"~e.34
                              :op4 "homolog"~e.35)
                        :ARG1-of (d / describe-01
                              :ARG0 (p2 / protein
                                    :name (n5 / name :op1 "GPR30"))))))
      :snt3 (s / show-01~e.39
            :ARG0 (w / we~e.38)
            :ARG1 (a4 / activate-01~e.45
                  :ARG0 (m4 / molecular-physical-entity
                        :name (n6 / name :op1 "17β-estradiol"~e.44))
                  :ARG1 (e6 / enzyme
                        :name (n7 / name :op1 "Erk-1/-2"~e.46))
                  :location (c / cell~e.55
                        :name (n8 / name :op1 "MCF-7"~e.52,54)
                        :mod (o / only~e.50 :polarity~e.49 "-"~e.49)
                        :ARG2-of (e7 / express-03~e.58
                              :ARG1 (a5 / and~e.67
                                    :op1 (p3 / protein
                                          :name (n9 / name
                                                :op1 "estrogen"~e.60
                                                :op2 "receptor"~e.61
                                                :op3 "α")
                                          :ARG1-of (d2 / describe-01
                                                :ARG0 (p4 / protein
                                                      :name (n10 / name :op1 "ERα"))))
                                    :op2 (p5 / protein
                                          :name (n11 / name :op1 "ERβ"))))))))

# ::tok Consistent with acting through a G protein @-@ coupled receptor , estradiol signaling to Erk @-@ 1/-2 occurred via a Gbetagamma @-@ dependent , pertussis toxin @-@ sensitive pathway that required Src @-@ related tyrosine kinase activity and tyrosine phosphorylation of tyrosine 317 of the Shc adapter protein .
# ::alignments 0-1.4 1-1.4.1.1.r 2-1.3.3.1.1 2-1.4.1 5-1.4.1.1.1.1.1.1 6-1.4.1.1.1.1 8-1.4.1.1.1 9-1.4.1.1 11-1.1.1.1 12-1 13-1.2.r 14-1.2.1.1 22-1.3.1 24-1.3.2.1.1.1 25-1.3.2.1.1.2 27-1.3.2 28-1.3 30-1.3.3 31-1.3.3.1.1.2.1.1.1 33-1.3.3.1.1.2 34-1.3.3.1.1.1.1.1 35-1.3.3.1.1.1.1.2 37-1.3.3.1 39-1.3.3.1.2 40-1.3.3.1.2.1.r 41-1.3.3.1.2.1.2.1 42-1.3.3.1.2.1.1 45-1.3.3.1.2.1.3.1.1 46-1.3.3.1.2.1.3.1.2 47-1.3.1.1.1 47-1.3.1.1.2 47-1.3.3.1.1.2.1 47-1.3.3.1.2.1.3
# ::id bel_pmid_1104_3579_5226
(s / signal-01~e.12
      :ARG0 (m / molecular-physical-entity
            :name (n / name :op1 "estradiol"~e.11))
      :ARG2~e.13 (e / enzyme
            :name (n2 / name :op1 "Erk-1/-2"~e.14))
      :manner (p / pathway~e.28
            :ARG0-of (d / depend-01~e.22
                  :ARG1 (m2 / macro-molecular-complex
                        :part (p2 / protein~e.47
                              :name (n3 / name :op1 "Gβ"))
                        :part (p3 / protein~e.47
                              :name (n4 / name :op1 "Gγ"))))
            :ARG0-of (s2 / sensitive-03~e.27
                  :ARG1 (m3 / molecular-physical-entity
                        :name (n5 / name :op1 "pertussis"~e.24 :op2 "toxin"~e.25)))
            :ARG0-of (r / require-01~e.30
                  :ARG1 (a / and~e.37
                        :op1 (a2 / act-01~e.2
                              :ARG0 (e2 / enzyme
                                    :name (n6 / name :op1 "tyrosine"~e.34 :op2 "kinase"~e.35))
                              :ARG1-of (r2 / relate-01~e.33
                                    :ARG2 (p4 / protein~e.47
                                          :name (n7 / name :op1 "Src"~e.31))))
                        :op2 (p5 / phosphorylate-01~e.39
                              :ARG1~e.40 (a3 / amino-acid
                                    :mod "317"~e.42
                                    :name (n8 / name :op1 "tyrosine"~e.41)
                                    :part-of (p6 / protein~e.47
                                          :name (n9 / name :op1 "Shc"~e.45 :op2 "adapter"~e.46)))))))
      :ARG1-of (c / consistent-01~e.0
            :ARG2 (a4 / act-01~e.2
                  :instrument~e.1 (r3 / receptor~e.9
                        :ARG1-of (c2 / couple-01~e.8
                              :ARG2 (p7 / protein~e.6
                                    :name (n10 / name :op1 "G"~e.5)))))))

# ::tok Reinforcing this idea , estradiol signaling to Erk @-@ 1/-2 was dependent upon trans @-@ activation of the epidermal growth factor ( EGF ) receptor via release of heparan @-@ bound EGF ( HB @-@ EGF ) .
# ::alignments 0-1.3 1-1.3.1.1 2-1.3.1 4-1.1.1.1.1 5-1.1 6-1.1.2.r 7-1.1.2.1.1 11-1 13-1.2.2 15-1.2 16-1.2.1.r 18-1.2.1.1.1 19-1.2.1.1.2 20-1.2.1.1.3 22-1.2.1.2.1.1.1 24-1.2.1 24-1.2.1.2.1 26-1.2.3 30-1.2.3.1 31-1.2.3.1.3.1.1.1 33-1.2.3.1.3.1.1.1 35-1.2.1.2.1.1.1
# ::id bel_pmid_1104_3579_5228
(d / depend-01~e.11
      :ARG0 (s / signal-01~e.5
            :ARG0 (m / molecular-physical-entity
                  :name (n / name :op1 "estradiol"~e.4))
            :ARG2~e.6 (e / enzyme
                  :name (n2 / name :op1 "Erk-1/-2"~e.7)))
      :ARG1 (a / activate-01~e.15
            :ARG1~e.16 (r / receptor~e.24
                  :name (n3 / name
                        :op1 "epidermal"~e.18
                        :op2 "growth"~e.19
                        :op3 "factor"~e.20)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (r2 / receptor~e.24
                              :name (n4 / name :op1 "EGF"~e.22,35))))
            :mod (t / trans~e.13)
            :manner (r3 / release-01~e.26
                  :ARG1 (b / bind-01~e.30
                        :ARG1 r2
                        :ARG2 (h / heparin)
                        :ARG1-of (d3 / describe-01
                              :ARG0 (p / protein
                                    :name (n5 / name :op1 "HB-EGF"~e.31,33))))))
      :ARG2-of (r4 / reinforce-01~e.0
            :ARG1 (i / idea~e.2
                  :mod (t2 / this~e.1))))

# ::tok Correspondingly , in vitro kinase assays showed that N17Rac1 inhibited the kinase activities of MEK1 @/@ 2 and ERK1 @/@ 2 stimulated by target signals ( Fig . 4b ) .
# ::alignments 0-1.3 2-1.1.2 3-1.1.2 4-1.1.1 5-1.1 6-1 7-1.2.r 8-1.2.1.1.1 9-1.2 11-1.2.2.2 14-1.2.2.1.1.1.1 16-1.2.2.1.1.1.1 16-1.2.2.1.2.1.1 17-1.2.2.1 18-1.2.2.1.2.1.1 20-1.2.2.1.1.1.1 20-1.2.2.1.2.1.1 21-1.2.2.3 22-1.2.2.3.1.r 23-1.2.2.3.1.1 24-1.2.2.3.1 28-1.4.1.1
# ::id bel_pmid_1106_2502_20878
(s / show-01~e.6
      :ARG0 (a / assay~e.5
            :mod (k / kinase~e.4)
            :manner (i / in-vitro~e.2,3))
      :ARG1~e.7 (i2 / inhibit-01~e.9
            :ARG0 (m / molecular-physical-entity
                  :name (n / name :op1 "N17Rac1"~e.8))
            :ARG1 (a2 / act-01
                  :ARG0 (a3 / and~e.17
                        :op1 (e / enzyme
                              :name (n2 / name :op1 "MEK1/2"~e.14,16,20))
                        :op2 (e2 / enzyme
                              :name (n3 / name :op1 "ERK1/2"~e.16,18,20)))
                  :ARG1 k~e.11
                  :ARG1-of (s2 / stimulate-01~e.21
                        :ARG0~e.22 (s3 / signal-01~e.24
                              :ARG1-of (t / target-01~e.23)))))
      :ARG1-of (c / correspond-02~e.0)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4b"~e.28)))

# ::tok Introduction of N17Rac1 into NK92 cells totally blocked PAK1 activation triggered by target ligation , whereas introduction of V12Rac1 strongly stimulated PAK1 activity even in the absence of target cells ( Fig . 7d ) .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1 3-1.1.1.2.r 4-1.1.1.2.1.1 5-1.1.1.2 6-1.1.3 7-1.1 8-1.1.2.1.1.1 9-1.1.2 10-1.1.2.2 12-1.1.2.2.1.1 15-1 16-1.2.1 17-1.2.1.1.r 18-1.2.1.1.1.1 19-1.2.4 19-1.2.4.r 20-1.2 21-1.1.2.1.1.1 24-1.2.3.r 26-1.2.3 27-1.2.3.1.r 28-1.2.3.1.1 29-1.2.3.1 33-1.3.1.1
# ::id bel_pmid_1106_2502_20880
(c / contrast-01~e.15
      :ARG1 (b / block-01~e.7
            :ARG0 (i / introduce-02~e.0
                  :ARG1~e.1 (m / molecular-physical-entity
                        :name (n / name :op1 "N17Rac1"~e.2))
                  :ARG2~e.3 (c2 / cell~e.5
                        :name (n2 / name :op1 "NK92"~e.4)))
            :ARG1 (a / activate-01~e.9
                  :ARG1 (e / enzyme
                        :name (n3 / name :op1 "PAK1"~e.8,21))
                  :ARG1-of (t / trigger-01~e.10
                        :ARG0 (l / ligate-01
                              :ARG1 (t2 / target-01~e.12))))
            :degree (t3 / total~e.6))
      :ARG2 (s / stimulate-01~e.20
            :ARG0 (i2 / introduce-02~e.16
                  :ARG1~e.17 (m2 / molecular-physical-entity
                        :name (n4 / name :op1 "V12Rac1"~e.18))
                  :ARG2 c2)
            :ARG1 (a2 / act-01
                  :ARG1 e)
            :concession~e.24 (a3 / absent-01~e.26
                  :ARG1~e.27 (c3 / cell~e.29
                        :ARG1-of (t4 / target-01~e.28))
                  :ARG2 s)
            :manner~e.19 (s2 / strong~e.19))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "7d"~e.33)))

# ::tok Examination of whole cell lysates from the same NK92 cells showed that kinase @-@ deficient ( KD ) PAK1 , unlike control CD56 , also effectively suppressed MEK and ERK activation by target ligation ( Fig . 7b ) . Thus , PAK1 is upstream of both MEK and ERK in the NK lytic process .
# ::alignments 0-1.1.1 2-1.1.1.1.3 3-1.1.1.1.1 5-1.1.1.1.2.r 7-1.1.1.1.2.2 8-1.1.1.1.2.1.1 9-1.1.1.1.1 10-1.1 12-1.1.2.1.1.2 18-1.1.2.1.1.1.1 20-1.1.2.2.1 21-1.1.2.2.2 21-1.1.2.2.2.2 21-1.1.2.2.2.2.r 22-1.1.2.2.2.1.1 24-1.1.2.1.3 25-1.1.2.1.4 25-1.1.2.1.4.r 26-1.1.2.1 26-1.1.2.2 27-1.1.2.1.2.2.1.1.1 28-1.1.2.1.2.2 29-1.1.2.1.2.2.2.1.1 30-1.1.2.1.2 32-1.1.2.1.2.1.1 37-1.1.3.1.1 40-1.2 42-1.2.1.1.1.1 43-1.2.1 44-1.2.1.2.2 47-1.2.1.2.1.1.1.1 48-1.2.1.2.1 49-1.2.1.2.1.2.1.1 52-1.2.1.3.1.1.1.1 54-1.2.1.3
# ::id bel_pmid_1106_2502_21386
(m / multi-sentence
      :snt1 (s / show-01~e.10
            :ARG0 (e / examine-01~e.0
                  :ARG1 (l / lysate
                        :mod (c / cell~e.3,9)
                        :source~e.5 (c2 / cell
                              :name (n / name :op1 "NK92"~e.8)
                              :mod (s2 / same~e.7))
                        :mod (w / whole~e.2)))
            :ARG1 (c3 / contrast-01
                  :ARG1 (s3 / suppress-01~e.26
                        :ARG0 (e2 / enzyme
                              :name (n2 / name :op1 "PAK1"~e.18)
                              :mod (k / kinase~e.12
                                    :ARG2-of (m2 / mutate-01 :mod "-/-")))
                        :ARG1 (a / activate-01~e.30
                              :ARG0 (l2 / ligate-01
                                    :ARG1 (t / target-01~e.32))
                              :ARG1 (a2 / and~e.28
                                    :op1 (e3 / enzyme
                                          :name (n3 / name :op1 "MEK"~e.27))
                                    :op2 (e4 / enzyme
                                          :name (n4 / name :op1 "ERK"~e.29))))
                        :mod (a3 / also~e.24)
                        :manner~e.25 (e5 / effective~e.25))
                  :ARG2 (s4 / suppress-01~e.26
                        :polarity "-"~e.20
                        :ARG0 (p / protein~e.21
                              :name (n5 / name :op1 "CD56"~e.22)
                              :ARG2-of~e.21 (c4 / control-01~e.21))
                        :ARG1 a))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "7b"~e.37)))
      :snt2 (c5 / cause-01~e.40
            :ARG1 (b / be-located-at-91~e.43
                  :ARG1 (e6 / enzyme
                        :name (n6 / name :op1 "PAK1"~e.42))
                  :ARG2 (r / relative-position
                        :op1 (a4 / and~e.48
                              :op1 (e7 / enzyme
                                    :name (n7 / name :op1 "MEK"~e.47))
                              :op2 (e8 / enzyme
                                    :name (n8 / name :op1 "ERK"~e.49)))
                        :direction (u / upstream~e.44))
                  :time (p2 / process-01~e.54
                        :mod (l3 / lyse-00
                              :ARG1 (c6 / cell
                                    :name (n9 / name :op1 "NK"~e.52)))))))

# ::tok PRL enhanced tyrosine phosphorylation of NKCC1 , and this effect was attenuated by the JAK2 inhibitor AG490 .
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2.1.1.1 3-1.1.2 5-1.1.2.1.2.1.1 7-1 8-1.2.2.1 9-1.2.2 11-1.2 12-1.2.1.r 14-1.2.1.2.1.1.1 15-1.2.1 15-1.2.1.2 15-1.2.1.2.r 16-1.2.1.1.1
# ::id bel_pmid_1111_7534_6206
(a / and~e.7
      :op1 (e / enhance-01~e.1
            :ARG0 (m / molecular-physical-entity
                  :name (n / name :op1 "PRL"~e.0))
            :ARG1 (p / phosphorylate-01~e.3
                  :ARG1 (a2 / amino-acid
                        :name (n2 / name :op1 "tyrosine"~e.2)
                        :part-of (p2 / protein
                              :name (n3 / name :op1 "NKCC1"~e.5)))))
      :op2 (a3 / attenuate-01~e.11
            :ARG0~e.12 (m2 / molecular-physical-entity~e.15
                  :name (n4 / name :op1 "AG490"~e.16)
                  :ARG0-of~e.15 (i / inhibit-01~e.15
                        :ARG1 (e2 / enzyme
                              :name (n5 / name :op1 "JAK2"~e.14))))
            :ARG1 (e3 / effect-01~e.9
                  :mod (t / this~e.8))))

# ::tok PRL treatment of HC11 cells increased phosphorylation of STAT5. The JAK2 inhibitor AG490 blocked phosphorylation of STAT5 and PRL @-@ induced , but not PGE1 @-@ induced , Cl @- transport
# ::alignments 0-1.1.1.2.1.1 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1 4-1.1.1.1 5-1.1 6-1.1.2 10-1.2.1.2.1.1.1 11-1.2.1 11-1.2.1.2 11-1.2.1.2.r 12-1.2.1.1.1 13-1.2 13-1.2.2.2.3.1 14-1.2.2.1 16-1.1.2.1.1.1 16-1.2.2.1.1.1.1 17-1.2.2 18-1.2.2.2.2.1.1.1 20-1.2.2.2.2 22-1.2.2.2.3 23-1.2.2.2.3.1.1 23-1.2.2.2.3.1.1.r 24-1.2.2.2.3.1.2.2.1.1.1 26-1.2.2.2.2 26-1.2.2.2.3.1.2.2 28-1.2.2.2.1.1.1 30-1.2.2.2 30-1.2.2.2.3.1.2
# ::id bel_pmid_1111_7534_6208
(m / multi-sentence
      :snt1 (i / increase-01~e.5
            :ARG0 (t / treat-04~e.1
                  :ARG1~e.2 (c / cell~e.4
                        :name (n / name :op1 "HC11"~e.3))
                  :ARG2 (m2 / molecular-physical-entity
                        :name (n2 / name :op1 "PRL"~e.0)))
            :ARG1 (p / phosphorylate-01~e.6
                  :ARG1 (p2 / protein
                        :name (n3 / name :op1 "STAT5"~e.16))))
      :snt2 (b / block-01~e.13
            :ARG0 (m3 / molecular-physical-entity~e.11
                  :name (n4 / name :op1 "AG490"~e.12)
                  :ARG0-of~e.11 (i2 / inhibit-01~e.11
                        :ARG1 (e / enzyme
                              :name (n5 / name :op1 "JAK2"~e.10))))
            :ARG1 (a / and~e.17
                  :op1 (p3 / phosphorylate-01~e.14
                        :ARG1 (p4 / protein
                              :name (n6 / name :op1 "STAT5"~e.16)))
                  :op2 (t2 / transport-01~e.30
                        :ARG1 (m4 / molecular-physical-entity
                              :name (n7 / name :op1 "Cl"~e.28))
                        :ARG1-of (i3 / induce-01~e.20,26
                              :ARG0 (m5 / molecular-physical-entity
                                    :name (n8 / name :op1 "PRL"~e.18)))
                        :ARG1-of (c2 / contrast-01~e.22
                              :ARG2 (b2 / block-01~e.13
                                    :polarity~e.23 "-"~e.23
                                    :ARG1 (t3 / transport-01~e.30
                                          :ARG1 m4
                                          :ARG1-of (i4 / induce-01~e.26
                                                :ARG0 (m7 / molecular-physical-entity
                                                      :name (n10 / name :op1 "PGE1"~e.24))))))))))

# ::tok These results suggest that ERK2 has a regulatory role in activating CREB in vivo in lung neutrophils after hemorrhage or endotoxemia .
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1.2.r 4-1.2.1.1.1.1 7-1.2.1 8-1.2 9-1.2.1.2.2 10-1.2.1.2 11-1.2.1.2.1.1.1 12-1.2.1.2.2 13-1.2.1.2.2 14-1.2.1.2.2 14-1.2.1.2.3.r 15-1.2.1.2.3.2 16-1.2.1.2.3.1.1 17-1.2.1.2.4 18-1.2.1.2.4.1.1 19-1.2.1.2.4.1 20-1.2.1.2.4.1.2
# ::id bel_pmid_1112_3332_21962
(s / suggest-01~e.2
      :ARG0 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t2 / this~e.0))
      :ARG1~e.3 (r2 / role~e.8
            :topic (r3 / regulate-01~e.7
                  :ARG0 (e / enzyme
                        :name (n3 / name :op1 "ERK2"~e.4))
                  :ARG1 (a / activate-01~e.10
                        :ARG1 (p / protein
                              :name (n / name :op1 "CREB"~e.11))
                        :manner (i / in-vivo~e.9,12,13,14)
                        :location~e.14 (c / cell
                              :name (n2 / name :op1 "neutrophil"~e.16)
                              :part-of (l / lung~e.15))
                        :time (a2 / after~e.17
                              :mod (o / or~e.19
                                    :op1 (h / hemorrhage-01~e.18)
                                    :op2 (e2 / endotoxemia~e.20)))))
            :poss e))

# ::tok These results suggest that ERK2 has a regulatory role in activating CREB in vivo in lung neutrophils after hemorrhage or endotoxemia .
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1.2.r 4-1.2.1.1.1.1 7-1.2.1 8-1.2 9-1.2.1.2.2 10-1.2.1.2 11-1.2.1.2.1.1.1 12-1.2.1.2.2 13-1.2.1.2.2 14-1.2.1.2.2 14-1.2.1.2.3.r 15-1.2.1.2.3.2 16-1.2.1.2.3.1.1 17-1.2.1.2.4 18-1.2.1.2.4.1.1 19-1.2.1.2.4.1 20-1.2.1.2.4.1.2
# ::id bel_pmid_1112_3332_37042
(s / suggest-01~e.2
      :ARG0 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t2 / this~e.0))
      :ARG1~e.3 (r2 / role~e.8
            :topic (r3 / regulate-01~e.7
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "ERK2"~e.4))
                  :ARG1 (a / activate-01~e.10
                        :ARG1 (p / protein
                              :name (n2 / name :op1 "CREB"~e.11))
                        :manner (i / in-vivo~e.9,12,13,14)
                        :location~e.14 (c / cell
                              :name (n3 / name :op1 "neutrophil"~e.16)
                              :part-of (l / lung~e.15))
                        :time (a2 / after~e.17
                              :mod (o / or~e.19
                                    :op1 (h / hemorrhage-01~e.18)
                                    :op2 (e2 / endotoxemia~e.20)))))
            :poss e))

# ::tok Tyrosine phosphorylation of JAK1 was detected at a very low concentration of IL @-@ 4 ( 1 ng/ml ) , while IL @-@ 13 induced phosphorylation only at concentrations of 50 ng @/@ ml and above , both in normal ( Figure 2a , b, upper blots ) and tumor lung myo®broblasts ( Figure 2c , d, upper blots ) .
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 3-1.1.1.1.2.1.1 5-1.1 5-1.2 6-1.1.2.r 7-1.1.2.2.1 8-1.1.2.2.3.1 9-1.1.2.2.3 10-1.1.2.2 12-1.1.2.1.1 14-1.1.2.1.1 16-1.1.2.2.1 20-1 21-1.2.1.1.1 22-1.2.1.1.1 23-1.2.1.1.1 24-1.2.1.1 25-1.2.1 26-1.2.2.2.3 28-1.2.2.2.1 30-1.2.2.2.1.1 34-1.2.2.2 35-1.2.2.2.2 39-1.3.1.2 41-1.3.1.3.1.1 42-1.3.1.3.1.1.1 45-1.3.1.3.1.3.1 46-1.3.1.3.1.3 48-1.3.1.3.1 49-1.3.2.2 50-1.3.1.1 53-1.3.1.3.1.2 53-1.3.2.3.1.1 53-1.3.2.3.1.2 54-1.3.2.3.1.1.1 57-1.3.2.3.1.3 58-1.3.2.3.1.3
# ::id bel_pmid_1112_7821_23468
(c / contrast-01~e.20
      :ARG1 (d / detect-01~e.5
            :ARG1 (p / phosphorylate-01~e.1
                  :ARG1 (a / amino-acid
                        :name (n / name :op1 "tyrosine"~e.0)
                        :part-of (e / enzyme
                              :name (n2 / name :op1 "JAK1"~e.3))))
            :condition~e.6 (p2 / protein
                  :name (n3 / name :op1 "IL-4"~e.12,14)
                  :quant (c2 / concentration-quantity~e.10
                        :quant "1"~e.7,16
                        :unit (n4 / nanogram-per-milliliter)
                        :mod (l / low~e.9
                              :degree (v / very~e.8)))))
      :ARG2 (d2 / detect-01~e.5
            :ARG1 (p3 / phosphorylate-01~e.25
                  :ARG1-of (i / induce-01~e.24
                        :ARG0 p4~e.21,22,23))
            :condition (p4 / protein
                  :name (n5 / name :op1 "IL-13")
                  :quant (a2 / and~e.34
                        :op1 (c3 / concentration-quantity~e.28
                              :quant "50"~e.30
                              :unit n4)
                        :op2 (a3 / above~e.35
                              :op1 c3)
                        :mod (o / only~e.26))))
      :location (a4 / and
            :op1 (m / myofibroblast
                  :part-of (l2 / lung~e.50)
                  :mod (n6 / normal~e.39)
                  :ARG1-of (d3 / describe-01
                        :ARG0 (a5 / and~e.48
                              :op1 (f / figure~e.41 :mod "2a"~e.42)
                              :op2 (f2 / figure~e.53 :mod "2b")
                              :op3 (b / blot~e.46
                                    :mod (u / upper~e.45)))))
            :op2 (m2 / myofibroblast
                  :part-of l2
                  :mod (t / tumor~e.49)
                  :ARG1-of (d4 / describe-01
                        :ARG0 (a6 / and
                              :op1 (f3 / figure~e.53 :mod "2c"~e.54)
                              :op2 (f4 / figure~e.53 :mod "2d")
                              :op3 b~e.57,58)))))

# ::tok the constitutive phosphorylation of STAT3 was observed repeatedly in tumor myo®bro @- blasts ( Figure 6f ) , but only occasionally in normal ®broblasts ( Figure 6e ) . In the latter cells , IL @-@ 4 and IL @- 13 induced ( Figure 6d ) or increased ( Figure 6e ) the tyrosine phosphorylation of STAT3 , whereas in tumor myo®broblasts the two cytokines only caused an increase in the phosphorylation of STAT3 ( Figure 6f ) .
# ::alignments 2-1.1.1.1 3-1.1.1.1.1.r 4-1.1.1.1.1.1.1 6-1.1.1 6-1.1.2 7-1.1.1.2 9-1.1.1.3.1 14-1.1.1.4.1 15-1.1.1.4.1.1 18-1.1 19-1.1.2.2.1 20-1.1.2.2 22-1.1.2.3.1 25-1.1.2.4.1 26-1.1.2.4.1.1 31-1.2.1.3.1 32-1.2.1.3 34-1.2.1.1.1.1.1.1 34-1.2.1.1.1.2.1.1 36-1.2.1.1.1.1.1.1 37-1.2.1.1.1 38-1.2.1.1.1.1.1.1 38-1.2.1.1.1.2.1.1 40-1.2.1.1.1.2.1.1 41-1.2.1.1 43-1.2.1.1.3.1 44-1.2.1.1.3.1.1 46-1.2.1 47-1.2.1.2 49-1.2.1.2.3.1 50-1.2.1.2.3.1.1 53-1.2.1.2.2 54-1.2.1.2.2 55-1.2.1.2.2 56-1.2.1.2.2 58-1.2 59-1.2.2.r 60-1.2.2.4.1 65-1.2.2.3 66-1.2.2 68-1.2.2.2 69-1.2.2.2.2.r 71-1.2.2.2.2 72-1.2.2.2.2 73-1.2.2.2.2 75-1.2.2.5.1 76-1.2.2.5.1.1
# ::id bel_pmid_1112_7821_23470
(m / multi-sentence
      :snt1 (c / contrast-01~e.18
            :ARG1 (o / observe-01~e.6
                  :ARG1 (p / phosphorylate-01~e.2
                        :ARG1~e.3 (p2 / protein
                              :name (n / name :op1 "STAT3"~e.4))
                        :mod (c2 / constitute-01))
                  :ARG1-of (r / repeat-01~e.7)
                  :location (m2 / myofibroblast
                        :mod (t / tumor~e.9))
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure~e.14 :mod "6f"~e.15)))
            :ARG2 (o2 / observe-01~e.6
                  :ARG1 p
                  :frequency (o3 / occasional~e.20
                        :mod (o4 / only~e.19))
                  :location (f2 / fibroblast
                        :mod (n2 / normal~e.22))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f3 / figure~e.25 :mod "6e"~e.26))))
      :snt2 (c3 / contrast-01~e.58
            :ARG1 (o5 / or~e.46
                  :op1 (i / induce-01~e.41
                        :ARG0 (a / and~e.37
                              :op1 (c4 / cytokine
                                    :name (n3 / name :op1 "IL-4"~e.34,36,38))
                              :op2 (c5 / cytokine
                                    :name (n4 / name :op1 "IL-13"~e.34,38,40)))
                        :ARG1 (p3 / phosphorylate-01
                              :ARG0 (a2 / amino-acid
                                    :name (n6 / name :op1 "tyrosine")
                                    :part-of (p4 / protein
                                          :name (n5 / name :op1 "STAT3"))))
                        :ARG1-of (d3 / describe-01
                              :ARG0 (f4 / figure~e.43 :mod "6d"~e.44)))
                  :op2 (i2 / increase-01~e.47
                        :ARG0 a
                        :ARG1 p3~e.53,54,55,56
                        :ARG1-of (d4 / describe-01
                              :ARG0 (f5 / figure~e.49 :mod "6e"~e.50)))
                  :location (c6 / cell~e.32
                        :mod (l / latter~e.31)))
            :ARG2~e.59 (c7 / cause-01~e.66
                  :ARG0 a
                  :ARG1 (i3 / increase-01~e.68
                        :ARG0 a
                        :ARG1~e.69 p3~e.71,72,73)
                  :mod (o6 / only~e.65)
                  :location (m3 / myofibroblast
                        :mod (t2 / tumor~e.60))
                  :ARG1-of (d5 / describe-01
                        :ARG0 (f6 / figure~e.75 :mod "6f"~e.76)))))

# ::tok In normal lung ®broblasts and in tumor myo®broblasts , STAT6 was indeed phosphorylated on tyrosine residues in response to IL @-@ 4 and IL @-@ 13 ( Figure 4a , b, upper blots ) .
# ::alignments 1-1.1.3.1.1 2-1.1.3.1.2 4-1.1.3 6-1.1.3.2.1 9-1.1.2.1.1 11-1.3 12-1 14-1.1.1.1.1 15-1.1 16-1.2.r 17-1.2 18-1.2.1.r 19-1.2.1.1.1.1 19-1.2.1.2.1.1 21-1.2.1.1.1.1 22-1.2.1 23-1.2.1.1.1.1 23-1.2.1.2.1.1 25-1.2.1.2.1.1 27-1.4.1.1 27-1.4.1.2 28-1.4.1.1.1 31-1.4.1.3.1 32-1.4.1.3
# ::id bel_pmid_1112_7821_23472
(p / phosphorylate-01~e.12
      :ARG1 (r / residue~e.15
            :mod (a / amino-acid
                  :name (n / name :op1 "tyrosine"~e.14))
            :part-of (p2 / protein
                  :name (n2 / name :op1 "STAT6"~e.9))
            :location (a2 / and~e.4
                  :op1 (f / fibroblast
                        :mod (n3 / normal~e.1)
                        :part-of (l / lung~e.2))
                  :op2 (m / myofibroblast
                        :mod (t / tumor~e.6))))
      :ARG2-of~e.16 (r2 / respond-01~e.17
            :ARG1~e.18 (a3 / and~e.22
                  :op1 (p3 / protein
                        :name (n4 / name :op1 "IL-4"~e.19,21,23))
                  :op2 (p4 / protein
                        :name (n5 / name :op1 "IL-13"~e.19,23,25))))
      :mod (i / indeed~e.11)
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and
                  :op1 (f2 / figure~e.27 :mod "4a"~e.28)
                  :op2 (f3 / figure~e.27 :mod "4b")
                  :op3 (b / blot~e.32
                        :mod (u / upper~e.31)))))

# ::tok Finally , Tyk2 , the fourth member of the JAK family , was found to be constitutively tyrosine @-@ phosphorylated in these cells . However , IL @-@ 4 and IL @-@ 13 increased its phosphorylation level in lung myo®broblasts ( Figure 2j ) , but not in normal cells , where both cytokines appear to slightly decrease its extent of phosphoryla @- tion ( Figure 2i ) .
# ::alignments 0-1.1.2 2-1.1.1.1.2.1.1 5-1.1.1.1.2.2.1.1 5-1.1.1.1.2.2.1.1.1 5-1.1.1.1.2.2.1.1.1.r 6-1.1.1.1.2.2.1 9-1.1.1.1.2.2.1.2.1.1.1 10-1.1.1.1.2.2.1.2.1.2 13-1.1 16-1.1.1.2 16-1.1.1.2.r 17-1.1.1.1.1.1 17-1.2.1.2.1.1.1.1 19-1.1.1 20-1.1.1.3.r 21-1.1.1.3.1 22-1.1.1.3 24-1.2 26-1.2.1.1.1.1.1 26-1.2.1.1.2.1.1 28-1.2.1.1.1.1.1 29-1.2.1.1 30-1.2.1.1.1.1.1 30-1.2.1.1.2.1.1 32-1.2.1.1.2.1.1 33-1.2.1 33-1.2.2 35-1.2.1.2.1 36-1.2.1.2 38-1.2.1.3.1 41-1.2.1.4.1 42-1.2.1.4.1.1 45-1.2 46-1.2.2.1 46-1.2.2.1.r 47-1.2.2.4.r 48-1.2.2.4.1 49-1.2.2.4 51-1.2.2.4.2.r 54-1.2.2.4.2.3 56-1.2.2.4.2.4 57-1.2.2.4.2 59-1.2.2.4.2.2 65-1.2.2.5.1 66-1.2.2.5.1.1
# ::id bel_pmid_1112_7821_23474
(m / multi-sentence
      :snt1 (f / find-01~e.13
            :ARG1 (p / phosphorylate-01~e.19
                  :ARG1 (a / amino-acid
                        :name (n / name :op1 "tyrosine"~e.17)
                        :part-of (e / enzyme
                              :name (n2 / name :op1 "Tyk2"~e.2)
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (m3 / member~e.6
                                          :ord (o / ordinal-entity~e.5 :value~e.5 "4"~e.5)
                                          :ARG1-of (i / include-91
                                                :ARG2 (e2 / enzyme
                                                      :name (n3 / name :op1 "JAK"~e.9)
                                                      :mod (f2 / family~e.10)))))))
                  :manner~e.16 (c / constitutive~e.16)
                  :location~e.20 (c2 / cell~e.22
                        :mod (t / this~e.21)))
            :mod (f3 / final~e.0))
      :snt2 (c3 / contrast-01~e.24,45
            :ARG1 (i2 / increase-01~e.33
                  :ARG0 (a2 / and~e.29
                        :op1 (c4 / cytokine
                              :name (n4 / name :op1 "IL-4"~e.26,28,30))
                        :op2 (c5 / cytokine
                              :name (n5 / name :op1 "IL-13"~e.26,30,32)))
                  :ARG1 (l / level~e.36
                        :degree-of (p2 / phosphorylate-01~e.35
                              :ARG1 (a3 / amino-acid
                                    :name (n6 / name :op1 "tyrosine"~e.17))))
                  :location (m4 / myofibroblast
                        :part-of (l2 / lung~e.38))
                  :ARG1-of (d / describe-01
                        :ARG0 (f4 / figure~e.41 :mod "2j"~e.42)))
            :ARG2 (i3 / increase-01~e.33
                  :polarity~e.46 "-"~e.46
                  :ARG0 a2
                  :ARG1 l
                  :location~e.47 (c6 / cell~e.49
                        :mod (n7 / normal~e.48)
                        :location-of~e.51 (d2 / decrease-01~e.57
                              :ARG0 a2
                              :ARG1 (e3 / extent~e.59
                                    :degree-of p2)
                              :ARG1-of (a4 / appear-02~e.54)
                              :degree (s / slight~e.56)))
                  :ARG1-of (d3 / describe-01
                        :ARG0 (f5 / figure~e.65 :mod "2i"~e.66)))))

# ::tok IL @-@ 4 and IL @-@ 13 induced tyrosine phosphorylation of STAT6 ( green cytoplasmic staining ) but probably also nuclear translocation of some phosphorylated STAT6 mole @- cules , accounting for the yellow signal detected . Similar results were obtained with normal lung ®broblasts .
# ::alignments 0-1.1.1.1.1.1 0-1.1.1.2.1.1 2-1.1.1.1.1.1 3-1.1.1 4-1.1.1.1.1.1 4-1.1.1.2.1.1 6-1.1.1.2.1.1 7-1.1 8-1.1.2.1.1.1.1 9-1.1.2.1 11-1.1.2.1.1.2.1.1 13-1.1.2.1.2.1.2 14-1.1.2.1.2.1.1 15-1.1.2.1.2.1 18-1.1.2.2.2 19-1.1.2.2.4 20-1.1.2.2.3 21-1.1.2.2 23-1.1.2.2.1.3 24-1.1.2.2.1.2 25-1.1.2.2.1.2 30-1.1.2.2.5 31-1.1.2.2.5.1.r 33-1.1.2.2.5.1.2 34-1.1.2.2.5.1 35-1.1.2.2.5.1.1 37-1.2.1.2 38-1.2.1 38-1.2.1.1 38-1.2.1.1.r 40-1.2 42-1.2.2.2 43-1.2.2.1
# ::id bel_pmid_1112_7821_23486
(m / multi-sentence
      :snt1 (i / induce-01~e.7
            :ARG0 (a / and~e.3
                  :op1 (p / protein
                        :name (n / name :op1 "IL-4"~e.0,2,4))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "IL-13"~e.0,4,6)))
            :ARG1 (a2 / and
                  :op1 (p3 / phosphorylate-01~e.9
                        :ARG1 (a3 / amino-acid
                              :name (n3 / name :op1 "tyrosine"~e.8)
                              :part-of (p4 / protein
                                    :name (n4 / name :op1 "STAT6"~e.11)))
                        :ARG1-of (d / describe-01
                              :ARG0 (s / stain-01~e.15
                                    :ARG2 (c / cytoplasm~e.14)
                                    :mod (g / green~e.13))))
                  :op2 (t / translocate-00~e.21
                        :ARG1 (m2 / molecule
                              :mod p4
                              :ARG1-of p3~e.24,25
                              :quant (s2 / some~e.23))
                        :mod (p5 / probable~e.18)
                        :location (n5 / nucleus~e.20)
                        :mod (a4 / also~e.19)
                        :ARG2-of (a5 / account-01~e.30
                              :ARG1~e.31 (s3 / signal-01~e.34
                                    :ARG1-of (d2 / detect-01~e.35)
                                    :mod (y / yellow~e.33))))))
      :snt2 (o / obtain-01~e.40
            :ARG1 (t2 / thing~e.38
                  :ARG2-of~e.38 (r / result-01~e.38)
                  :ARG1-of (r2 / resemble-01~e.37))
            :ARG2 (f / fibroblast
                  :part-of (l / lung~e.43)
                  :mod (n6 / normal~e.42))))

# ::tok Using purified wild @-@ type and mutant c @-@ Raf @-@ 1 proteins , we demonstrate that Thr( 269 ) is the major c @-@ Raf @-@ 1 site phosphorylated by KSR in vitro and that phosphorylation of this site is essential for c @-@ Raf @-@ 1 activation by KSR .
# ::alignments 0-1.3 1-1.3.2.1.2 2-1.3.2.1.1 4-1.3.2.1.1 5-1.3.2 6-1.3.2.2 6-1.3.2.2.2 6-1.3.2.2.2.r 7-1.2.1.1.1.1 7-1.3.2.2.1.1 9-1.2.1.1.1.1 9-1.3.2.2.1.1 11-1.2.1.1.1.1 11-1.3.2.2.1.1 12-1.2.1 12-1.3.2.1 14-1.1 15-1 18-1.2.1.2.1 20-1.2.1.2.r 22-1.2.1.3 23-1.2.1.1.1.1 25-1.2.1.1.1.1 27-1.2.1.1.1.1 28-1.2.1 29-1.2.1.4 31-1.2.1.4.1.1.1 32-1.2.1.4.2 33-1.2.1.4.2 36-1.2.1.4 36-1.2.2.1 39-1.2.1 40-1.2.1.2.r 41-1.2.2 41-1.2.2.1.2 42-1.2.2.1.3.r 43-1.2.2.1.3.2 44-1.2.2.1.3.2 45-1.2.2.1.3.2 46-1.2.2.1.3.2 47-1.2.2.1.3.2 48-1.2.2.1.3 49-1.2.2.1.3.1.r 50-1.2.2.1.3.1
# ::id bel_pmid_1113_4016_21280
(d / demonstrate-01~e.15
      :ARG0 (w / we~e.14)
      :ARG1 (a / and
            :op1 (p2 / protein-segment~e.12,28,39
                  :part-of (p3 / protein
                        :name (n2 / name :op1 "c-Raf-1"~e.7,9,11,23,25,27))
                  :domain~e.20,40 (a2 / amino-acid
                        :mod "269"~e.18
                        :name (n / name :op1 "threonine"))
                  :mod (m / major~e.22)
                  :ARG1-of (p / phosphorylate-01~e.29,36
                        :ARG2 (e2 / enzyme
                              :name (n3 / name :op1 "KSR"~e.31))
                        :manner (i / in-vitro~e.32,33)))
            :op1 (e3 / essential~e.41
                  :domain (p5 / phosphorylate-01~e.36
                        :ARG1 a2
                        :mod (e / essential~e.41)
                        :purpose~e.42 (a3 / activate-01~e.48
                              :ARG0~e.49 e2~e.50
                              :ARG1 p3~e.43,44,45,46,47)
                        :mod a2)))
      :manner (u / use-01~e.0
            :ARG0 w
            :ARG1 (a4 / and~e.5
                  :op1 (p6 / protein~e.12
                        :mod (w2 / wild-type~e.2,4)
                        :ARG1-of (p8 / purify-01~e.1))
                  :op2 (e4 / enzyme~e.6
                        :name (n4 / name :op1 "c-Raf-1"~e.7,9,11)
                        :ARG2-of~e.6 (m2 / mutate-01~e.6)))))

# ::tok In vivo , low physiologic doses of EGF ( 0.001 @-@ 0.1 ng/ml ) stimulated KSR activation and induced Thr( 269 ) phosphorylation and activation of c @-@ Raf @-@ 1 .
# ::alignments 0-1.3 1-1.3 3-1.1.1.2.1 5-1.1.1.2 6-1.1.1.2.r 7-1.1.1.1.1 9-1.1.1.3.1 11-1.1.1.3.2 14-1.1 15-1.1.2.1.1.1 16-1.1.2 17-1 18-1.2 20-1.2.2.1.1.1 22-1.2.2.1 23-1.2.2 24-1.2.2.2 25-1.2.2.1.2.r 26-1.2.2.1.2.1.1 28-1.2.2.1.2.1.1 30-1.2.2.1.2.1.1
# ::id bel_pmid_1113_4016_22950
(a / and~e.17
      :op1 (s / stimulate-01~e.14
            :ARG0 (p / protein
                  :name (n / name :op1 "EGF"~e.7)
                  :quant~e.6 (d / dose~e.5
                        :degree (l / low~e.3)
                        :mod (p2 / physiology))
                  :quant (v / value-interval
                        :op1 "0.001"~e.9
                        :op1 "0.1"~e.11
                        :unit (n3 / nanogram-per-milliliter)))
            :ARG1 (a2 / activate-01~e.16
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "KSR"~e.15))))
      :op2 (i / induce-01~e.18
            :ARG0 p
            :ARG1 (a3 / and~e.23
                  :op1 (p4 / phosphorylate-01~e.22
                        :ARG1 (a4 / amino-acid
                              :mod "269"~e.20
                              :name (n5 / name :op1 "threonine"))
                        :part-of~e.25 (p6 / protein
                              :name (n4 / name :op1 "c-Raf-1"~e.26,28,30)))
                  :op2 (a5 / activate-01~e.24
                        :ARG1 p6)))
      :manner (i2 / in-vivo~e.0,1))

# ::tok In conclusion , our results show that IL @-@ 6 stimulates hepatic IGFBP @-@ 4 gene expression and production in vitro and in vivo , thereby suggesting another mechanism by which cytokines could control IGF @-@ I action .
# ::alignments 0-1.2.2.2.3.1 1-1 3-1.2.1.1.1 3-1.2.1.1.1.r 4-1.2.1 4-1.2.1.1 4-1.2.1.1.r 5-1.2 7-1.2.2.1.1.1 9-1.2.2.1.1.1 10-1.2.2 11-1.2.2.2.1.1.2 12-1.2.2.2.1.1.1.1 14-1.2.2.2.1.1.1.1 15-1.2.2.2.1.1 16-1.2.2.2.1 17-1.2.2.2 18-1.2.2.2.2 19-1.2.2.2.3.1 20-1.2.2.2.3.1 21-1.2.2.2.3 22-1.2.2.2.3.1 22-1.2.2.2.3.2 23-1.2.2.2.3.2 25-1.2.2.2.3.r 26-1.2.3 27-1.2.3.1.1.3.1 28-1.2.3.1.1.3 32-1.2.3.1 33-1.2.3.1.1 34-1.2.3.1.1.2.1.1.1 36-1.2.3.1.1.2.1.1.1 37-1.2.3.1.1.2
# ::id bel_pmid_1114_5587_7292
(c / conclude-02~e.1
      :ARG0 (w / we~e.3)
      :ARG1 (s / show-01~e.5
            :ARG0 (t / thing~e.4
                  :ARG1-of~e.4 (r / result-01~e.4
                        :poss~e.3 w))
            :ARG1 (s2 / stimulate-01~e.10
                  :ARG0 (p / protein
                        :name (n / name :op1 "IL-6"~e.7,9))
                  :ARG1 (a / and~e.17
                        :op1 (e / express-03~e.16
                              :ARG1 (g / gene~e.15
                                    :name (n2 / name :op1 "IGFBP-4"~e.12,14)
                                    :mod (h / hepatic~e.11)))
                        :op2 (p2 / produce-01~e.18
                              :ARG1 g)
                        :manner~e.25 (a2 / and~e.21
                              :op1 (i / in-vitro~e.0,19,20,22)
                              :op2 (i2 / in-vivo~e.22,23))))
            :ARG0-of (s3 / suggest-01~e.26
                  :ARG1 (p5 / possible~e.32
                        :domain (c2 / control-01~e.33
                              :ARG0 (c3 / cytokine)
                              :ARG1 (a3 / act-02~e.37
                                    :ARG0 (p4 / protein
                                          :name (n4 / name :op1 "IGF-I"~e.34,36)))
                              :manner (m / mechanism~e.28
                                    :mod (a4 / another~e.27)))))))

# ::tok GAGA box of the rat serine protease inhibitor 2 ( spi 2 ) genes not only acts as a basal promoter element , but also mediates transcriptional activation by growth hormone and interleukin @-@ 6 .
# ::alignments 0-1.1.1.1.1 1-1.1.1.1.2 4-1.1.1.2.4 5-1.1.1.2.2.1 6-1.1.1.2.2.2 7-1.1.1.2.3 8-1.1.1.2.1 8-1.1.1.3.1.1 10-1.1.1.3.1.1 11-1.1.1.2.1 11-1.1.1.3.1.1 13-1.1.1.2 13-1.1.1.3 16-1.1 17-1.1.2.r 19-1.1.2.1.1 21-1.1.2 24-1.2.3 25-1.2 27-1.2.2 28-1.2.2.1.r 29-1.2.2.1.1.1 30-1.2.2.1.1 31-1.2.2.1 32-1.2.2.1.2.1.1 34-1.2.2.1.2.1.1
# ::id bel_pmid_1115_4060_8844
(a / and
      :op1 (a2 / act-02~e.16
            :ARG0 (d2 / dna-sequence
                  :name (n3 / name :op1 "GAGA"~e.0 :op2 "box"~e.1)
                  :poss (g2 / gene~e.13
                        :mod "2"~e.8,11
                        :name (n / name :op1 "serine"~e.5 :op2 "protease"~e.6)
                        :ARG1-of (i / inhibit-01~e.7)
                        :mod (r / rat~e.4))
                  :part-of (g3 / gene~e.13
                        :name (n4 / name :op1 "spi-2"~e.8,10,11)))
            :ARG1~e.17 (e2 / element~e.21
                  :ARG0-of (p / promote-01
                        :mod (b2 / basal~e.19))))
      :op2 (m / mediate-01~e.25
            :ARG0 d2
            :ARG1 (a3 / activate-01~e.27
                  :ARG0~e.28 (a4 / and~e.31
                        :op1 (h / hormone~e.30
                              :ARG0-of (g / grow-01~e.29))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "interleukin-6"~e.32,34)))
                  :mod (t / transcribe-01))
            :mod (a5 / also~e.24)))

# ::tok Stimulation of cells with the ligand for CXCR4 , stromal cell @-@ derived factor @-@ 1 alpha ( SDF @-@ 1 alpha ) , resulted in an elevation in intracellular Ca( 2+) concentration
# ::alignments 0-1.1 1-1.1.2.r 2-1.1.2 3-1.1.1.r 5-1.1.1 6-1.1.1.2.r 7-1.1.1.2.1.1 9-1.1.1.1.1 10-1.1.1.1.2 12-1.1.1.1.2 13-1.1.1.1.3 24-1 25-1.2.r 27-1.2 28-1.2.1.r 29-1.2.1.1.2 32-1.2.1
# ::id bel_pmid_1116_0334_22876
(r / result-01~e.24
      :ARG1 (s / stimulate-01~e.0
            :ARG0~e.3 (l / ligand~e.5
                  :name (n / name
                        :op1 "stromal"~e.9
                        :op2 "cell-derived"~e.10,12
                        :op3 "factor-1alpha"~e.13)
                  :beneficiary~e.6 (p / protein
                        :name (n2 / name :op1 "CXCR4"~e.7)))
            :ARG1~e.1 (c / cell~e.2))
      :ARG2~e.25 (e / elevate-01~e.27
            :ARG1~e.28 (c2 / concentrate-02~e.32
                  :ARG1 (c3 / calcium
                        :mod "2+"
                        :mod (i / intracellular~e.29)))))

# ::tok resulted in an elevation in intracellular Ca( 2+) concentration and activation of the mitogen @-@ activated protein kinase cascade , specifically , extracellular signal @-@ regulated kinase 2 ( ERK2 ) mitogen @-@ activated protein kinase .
# ::alignments 0-1 1-1.1.r 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1.2 8-1.1.1.1 9-1.1 10-1.1.2 11-1.1.2.1.r 13-1.1.2.1.1.1.1 15-1.1.2.1.1.1.1 16-1.1.2.1.1.1.2 17-1.1.2.1.1.1.3 18-1.1.2.1 20-1.1.2.1.1.2.2 22-1.1.2.1.1.2.1.1.1 23-1.1.2.1.1.2.1.1.2 25-1.1.2.1.1.2.1.1.2 26-1.1.2.1.1.2.1.1.3 26-1.1.2.1.1.2.1.1.7 27-1.1.2.1.1.2.1.1.4 31-1.1.2.1.1.1.1 31-1.1.2.1.1.2.1.1.5 33-1.1.2.1.1.1.1 33-1.1.2.1.1.2.1.1.5 34-1.1.2.1.1.1.2 34-1.1.2.1.1.2.1.1.6 35-1.1.2.1.1.1.3 35-1.1.2.1.1.2.1.1.3 35-1.1.2.1.1.2.1.1.7
# ::id bel_pmid_1116_0334_22880
(r / result-01~e.0
      :ARG1~e.1 (a3 / and~e.9
            :op1 (e / elevate-01~e.3
                  :ARG1~e.4 (c2 / concentrate-02~e.8
                        :ARG1 (c / calcium
                              :mod "2+"
                              :mod (i / intracellular~e.5))))
            :op2 (a2 / activate-01~e.10
                  :ARG1~e.11 (c3 / cascade~e.18
                        :mod (p / pathway
                              :name (n / name
                                    :op1 "mitogen-activated"~e.13,15,31,33
                                    :op2 "protein"~e.16,34
                                    :op3 "kinase"~e.17,35)
                              :ARG1-of (m / mean-01
                                    :ARG2 (p2 / pathway
                                          :name (n2 / name
                                                :op1 "extracellular"~e.22
                                                :op2 "signal-regulated"~e.23,25
                                                :op3 "kinase"~e.26,35
                                                :op4 "2"~e.27
                                                :op5 "mitogen-activated"~e.31,33
                                                :op6 "protein"~e.34
                                                :op7 "kinase"~e.26,35))
                                    :manner (s / specific~e.20)))))))

# ::tok IL @-@ 1 beta stimulation also enhanced CXCR4 expression ( 28.8 % for CRT @-@ J and 41.6 % for U87 @-@ MG cells ) .
# ::alignments 0-1.1.1.1 4-1 5-1.2.2 6-1.2 7-1.2.1.1.1.1 8-1.2.1 10-1.2.1.1.2.1.1.2.1.1 11-1.2.1.1.2.1.1.2 13-1.2.1.1.2.1.1.1.1 15-1.2.1.1.2.1.1.1.1 16-1.2.1.1.2.1 17-1.2.1.1.2.1.2.2.1.1 18-1.2.1.1.2.1.2.2 20-1.2.1.1.2.1.2.1.1 22-1.2.1.1.2.1.2.1.1 23-1.2.1.1.2.1.1 23-1.2.1.1.2.1.2
# ::id bel_pmid_1116_0334_23556
(s / stimulate-01~e.4
      :ARG0 (p / protein
            :name (n / name :op1 "IL-1beta"~e.0))
      :ARG0-of (e / enhance-01~e.6
            :ARG1 (e2 / express-03~e.8
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "CXCR4"~e.7)
                        :ARG0-of (m / mean-01
                              :ARG1 (a / and~e.16
                                    :op1 (c / cell~e.23
                                          :name (n3 / name :op1 "CRT-J"~e.13,15)
                                          :mod (p3 / percentage-entity~e.11
                                                :name (n4 / name :op1 "28.8"~e.10)))
                                    :op2 (c2 / cell~e.23
                                          :name (n5 / name :op1 "U87-MG"~e.20,22)
                                          :mod (p4 / percentage-entity~e.18
                                                :name (n6 / name :op1 "41.6"~e.17)))))))
            :mod (a2 / also~e.5)))

# ::tok SDF @-@ 1 alpha @-@ induced chemokine expression was abrogated upon inclusion of U0126 , a pharmacological inhibitor of ERK1 @/@ 2 , indicating that the ERK signaling cascade is involved in this response .
# ::alignments 0-1.1.2.1.1.1 2-1.1.2.1.1.1 3-1.1.2.1.1.2 5-1.1.2 6-1.1.1 7-1.1 9-1 11-1.2 12-1.2.1.r 13-1.2.1.1.1 16-1.2.1.2.2 17-1.2.1 17-1.2.1.2 17-1.2.1.2.r 19-1.2.1.2.1.1.1.1 23-1.3 24-1.3.1.r 26-1.3.1.1.1.1 27-1.3.1.1.2 30-1.3.1 31-1.3.1.2.r 32-1.3.1.2.1 33-1.3.1.2
# ::id bel_pmid_1116_0334_37038
(a / abrogate-01~e.9
      :ARG1 (e / express-03~e.7
            :ARG2 (c / chemokine~e.6)
            :ARG1-of (i / induce-01~e.5
                  :ARG0 (p / protein
                        :name (n / name :op1 "SDF-1"~e.0,2 :op2 "alpha"~e.3))))
      :time (i2 / include-01~e.11
            :ARG1~e.12 (m / molecular-physical-entity~e.17
                  :name (n5 / name :op1 "U0126"~e.13)
                  :ARG0-of~e.17 (i3 / inhibit-01~e.17
                        :ARG1 (s / slash
                              :op1 (e2 / enzyme
                                    :name (n2 / name :op1 "ERK1"~e.19))
                              :op2 (e3 / enzyme
                                    :name (n3 / name :op1 "ERK2")))
                        :mod (p2 / pharmacology~e.16))))
      :ARG0-of (i4 / indicate-01~e.23
            :ARG1~e.24 (i5 / involve-01~e.30
                  :ARG1 (p3 / pathway
                        :name (n4 / name :op1 "ERK"~e.26)
                        :ARG0-of (s2 / signal-01~e.27))
                  :ARG2~e.31 (r / respond-01~e.33
                        :mod (t / this~e.32)))))

# ::tok SDF @-@ 1 alpha treatment induced expression of the chemokines monocyte chemoattractant protein @-@ 1 , IL @-@ 8 , and IFN @-@ gamma @-@ inducible protein @-@ 10 .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 3-1.1.1.1.2 4-1.1 5-1 6-1.2 10-1.2.1.1.1.1 11-1.2.1.1.1.2 12-1.2.1.1.1.3 14-1.2.1.1.1.3 16-1.2.1.2.1.1 18-1.2.1.2.1.1 20-1.2.1 21-1.2.1.3.1.1 23-1.2.1.3.1.1 25-1.2.1.3.1.1 26-1.2.1.3.1.2 28-1.2.1.3.1.2
# ::id bel_pmid_1116_0334_6798
(i / induce-01~e.5
      :ARG0 (t / treat-04~e.4
            :ARG2 (p / protein
                  :name (n / name :op1 "SDF-1"~e.0,2 :op2 "alpha"~e.3)))
      :ARG1 (e / express-03~e.6
            :ARG2 (a / and~e.20
                  :op1 (c / chemokine
                        :name (n2 / name
                              :op1 "monocyte"~e.10
                              :op2 "chemoattractant"~e.11
                              :op3 "protein-1"~e.12,14))
                  :op2 (c2 / chemokine
                        :name (n4 / name :op1 "IL-8"~e.16,18))
                  :op3 (c3 / chemokine
                        :name (n3 / name :op1 "IFN-gamma-inducible"~e.21,23,25 :op2 "protein-10"~e.26,28)))))

# ::tok CXCR4 protein expression was also enhanced upon treatment with TNF @-@ alpha and IL @-@ 1 beta ( 2 @- to 3 @-@ fold ) .
# ::alignments 0-1.1.1.1.1 1-1.1.1 1-1.3.1.1 1-1.3.1.2 2-1.1 4-1.2 5-1 7-1.3 8-1.3.1.r 9-1.3.1.1.1.1 11-1.3.1.1.1.1 12-1.3.1 13-1.3.1.2.1.1 18-1.3.1.2.2.1.1.1 21-1.3.1.2.2.1.1.2 23-1.3.1.2.2
# ::id bel_pmid_1116_0334_7176
(e / enhance-01~e.5
      :ARG1 (e2 / express-03~e.2
            :ARG2 (p / protein~e.1
                  :name (n / name :op1 "CXCR4"~e.0)))
      :mod (a / also~e.4)
      :condition (t / treat-04~e.7
            :ARG2~e.8 (a2 / and~e.12
                  :op1 (p2 / protein~e.1
                        :name (n2 / name :op1 "TNF-alpha"~e.9,11))
                  :op2 (p3 / protein~e.1
                        :name (n3 / name :op1 "IL-1beta"~e.13)
                        :ARG1-of (f / fold-00~e.23
                              :quant (p4 / product-of
                                    :op1 (v / value-interval :op1 "2"~e.18 :op2 "3"~e.21)))))))

# ::tok Enhancement of CXC chemokine receptor 4 ( CXCR4 ) mRNA expression was observed upon treatment with the cytokines TNF @-@ alpha and IL @-@ 1 beta .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.2.1.1 3-1.1.1.2.1.2 4-1.1.1.2.1.3 5-1.1.1.2.1.4 7-1.1.1.2.2.1.1.1 9-1.1.1.1.1.1 10-1.1.1 12-1 14-1.2 18-1.2.1.1.1.1 20-1.2.1.1.1.1 21-1.2.1 22-1.2.1.2.1.1
# ::id bel_pmid_1116_0334_7194
(o / observe-01~e.12
      :ARG1 (e / enhance-01~e.0
            :ARG1~e.1 (e2 / express-03~e.10
                  :ARG1 (r / rna
                        :name (n5 / name :op1 "mRNA"~e.9))
                  :ARG2 (p / protein
                        :name (n / name
                              :op1 "CXC"~e.2
                              :op2 "chemokine"~e.3
                              :op3 "receptor"~e.4
                              :op4 "4"~e.5)
                        :ARG1-of (d / describe-01
                              :ARG2 (p2 / protein
                                    :name (n4 / name :op1 "CXCR4"~e.7))))))
      :condition (t / treat-04~e.14
            :ARG2 (a / and~e.21
                  :op1 (c / cytokine
                        :name (n2 / name :op1 "TNF-alpha"~e.18,20))
                  :op2 (c2 / cytokine
                        :name (n3 / name :op1 "IL-1beta"~e.22)))))

# ::tok The IL @-@ 6 @-@ type cytokines , IL @-@ 6 and oncostatin M , simultaneously inhibited cell proliferation and increased cell migration
# ::alignments 1-1.1.1.1 1-1.1.2.1.1 3-1.1.1.1 3-1.1.2.1.1 5-1.1.1.1 8-1.1.1.1 8-1.1.2.1.1 10-1.1.1.1 10-1.1.2.1.1 11-1.1 12-1.1.3 13-1.1.3.1.1 15-1.3 15-1.3.r 16-1 17-1.2.1.1 18-1.2.1 19-1.2 20-1.2.2 21-1.2.2.1.1 22-1.2.2.1
# ::id bel_pmid_1119_6191_23672
(i / inhibit-01~e.16
      :ARG0 (a / and~e.11
            :op1 (c / cytokine :mod "IL-6-type"~e.1,3,5,8,10)
            :op2 (c2 / cytokine
                  :name (n / name :op1 "IL-6"~e.1,3,8,10))
            :op3 (o / oncostatin~e.12
                  :name (n2 / name :op1 "M"~e.13)))
      :ARG1 (a2 / and~e.19
            :op1 (p / proliferate-01~e.18
                  :ARG0 (c3 / cell~e.17))
            :op2 (i2 / increase-01~e.20
                  :ARG1 (m / migrate-01~e.22
                        :ARG0 (c4 / cell~e.21))))
      :manner~e.15 (s / simultaneous~e.15))

# ::tok In T47D cells , IL @-@ 6 stimulated the activation of Janus @-@ activated kinase 1 tyrosine kinase and signal transducers and activators of transcription ( STAT ) 1 and STAT3 transcription factors . Expression of dominant negative STAT3 in the cells strongly reduced IL @-@ 6 @-@ mediated growth inhibition but did not prevent IL @-@ 6 @-@ induced cell migration .
# ::alignments 1-1.1.3.1.1 2-1.1.3 4-1.1.1.1.1 6-1.1.1.1.1 7-1.1 9-1.1.2 10-1.1.2.1.r 11-1.1.2.1.1.1.1 13-1.1.2.1.1.1.1 14-1.1.2.1.1.1.2 14-1.1.2.1.1.1.5 15-1.1.2.1.1.1.3 16-1.1.2.1.1.1.4 17-1.1.2.1.1.1.2 17-1.1.2.1.1.1.5 18-1.1.2.1 19-1.1.2.1.2.1.1 20-1.1.2.1.2.1.2 21-1.1.2.1 22-1.1.2.1.2.1.3 24-1.1.2.1.2.1.4 28-1.1.2.1.1.1.3 29-1.1.2.1 30-1.1.2.1.3.1.1 31-1.1.2.1.3.1.2 32-1.1.2.1.3.1.3 34-1.2.1.1 37-1.2.1.1.1.2 37-1.2.1.1.1.2.1 37-1.2.1.1.1.2.1.r 38-1.2.1.1.1.1.1 39-1.2.1.1.2.r 41-1.2.1.1.2 42-1.2.1.3 43-1.2.1 44-1.2.1.2.2.1 45-1.2.1.2.2.1 46-1.2.1.2.2.1 48-1.2.1.2.2 49-1.2.1.2.1 50-1.2.1.2 51-1.2 53-1.2.2.1 53-1.2.2.1.r 54-1.2.2 55-1.2.2.3.2.1 56-1.2.2.3.2.1 57-1.2.2.3.2.1 59-1.2.2.3.2 60-1.2.2.3.1 61-1.2.2.3
# ::id bel_pmid_1119_6191_2576
(m / multi-sentence
      :snt1 (s / stimulate-01~e.7
            :ARG0 (p / protein
                  :name (n / name :op1 "il-6"~e.4,6))
            :ARG1 (a / activate-01~e.9
                  :ARG1~e.10 (a2 / and~e.18,21,29
                        :op1 (e / enzyme
                              :name (n2 / name
                                    :op1 "Janus-activated"~e.11,13
                                    :op2 "kinase"~e.14,17
                                    :op3 "1"~e.15,28
                                    :op4 "tyrosine"~e.16
                                    :op5 "kinase"~e.14,17))
                        :op2 (p2 / protein
                              :name (n3 / name
                                    :op1 "signal"~e.19
                                    :op2 "transducers"~e.20
                                    :op3 "activator"~e.22
                                    :op4 "transcription"~e.24))
                        :op3 (e2 / enzyme
                              :name (n4 / name
                                    :op1 "STAT3"~e.30
                                    :op2 "transcription"~e.31
                                    :op3 "factors"~e.32))))
            :location (c4 / cell~e.2
                  :name (n8 / name :op1 "T47D"~e.1)))
      :snt2 (c / contrast-01~e.51
            :ARG1 (r / reduce-01~e.43
                  :ARG0 (e3 / express-03~e.34
                        :ARG2 (p3 / protein
                              :name (n5 / name :op1 "STAT3"~e.38)
                              :mod (n6 / negative~e.37
                                    :mod~e.37 (n7 / negative~e.37)))
                        :location~e.39 (c2 / cell~e.41))
                  :ARG1 (i / inhibit-01~e.50
                        :ARG1 (g / grow-01~e.49)
                        :ARG1-of (m2 / mediate-01~e.48
                              :ARG0 p~e.44,45,46))
                  :mod (s2 / strong~e.42))
            :ARG2 (p4 / prevent-01~e.54
                  :polarity~e.53 "-"~e.53
                  :ARG0 e3
                  :ARG1 (m3 / migrate-01~e.61
                        :ARG0 (c3 / cell~e.60)
                        :ARG1-of (i2 / induce-01~e.59
                              :ARG0 p~e.55,56,57)))))

# ::tok Pretreatment of cells with EGF receptor specific inhibitor CGP59326 or with the bispecific EGF receptor @/@ ERBB2 inhibitor PD153035 , diminished IL6 induced MAPK activation . Even the PKB phosphorylation was also affected by these two inhibitors .
# ::alignments 2-1.1.1.1.2 2-1.1.1.2.2 4-1.1.1.1.1.3.1.1.1.1 5-1.1.1.1.1.3.1 6-1.1.1.1.1.3 7-1.1.1.1.1 7-1.1.1.1.1.2 7-1.1.1.1.1.2.r 8-1.1.1.1.1.1.1 9-1.1.1 12-1.1.1.2.1.3 13-1.1.1.2.1.3.1.2 14-1.1.1.2.1.3.1.2 16-1.1.1.2.1.3.1.1 17-1.1.1.2.1 17-1.1.1.2.1.2 17-1.1.1.2.1.2.r 18-1.1.1.2.1.1.1 20-1.1 21-1.1.2.2.1.1.1 22-1.1.2.2 23-1.1.2.1.1.1 24-1.1.2 28-1.2.1.1.1.1 29-1.2.1 32-1.2 33-1.2.2.r 34-1.2.2.3 35-1.2.2.1 36-1.2.2 36-1.2.2.2 36-1.2.2.2.r
# ::id bel_pmid_1119_6191_38528
(m / multi-sentence
      :snt1 (d / diminish-01~e.20
            :ARG0 (o / or~e.9
                  :op1 (p / pretreat-00
                        :ARG0 (m3 / molecular-physical-entity~e.7
                              :name (n / name :op1 "CGP59326"~e.8)
                              :ARG0-of~e.7 (i / inhibit-01~e.7)
                              :mod (s / specific~e.6
                                    :prep-to (r / receptor~e.5
                                          :mod (p2 / protein
                                                :name (n2 / name :op1 "EGF"~e.4)))))
                        :ARG1 (c / cell~e.2))
                  :op2 (p3 / pretreat-00
                        :ARG0 (m2 / molecular-physical-entity~e.17
                              :name (n3 / name :op1 "PD153035"~e.18)
                              :ARG0-of~e.17 (i2 / inhibit-01~e.17)
                              :mod (b / bispecific~e.12
                                    :prep-to (s2 / slash
                                          :op2 "ERBB2"~e.16
                                          :op1 r~e.13,14)))
                        :ARG1 (c2 / cell~e.2)))
            :ARG1 (a / activate-01~e.24
                  :ARG1 (p4 / pathway
                        :name (n4 / name :op1 "MAPK"~e.23))
                  :ARG1-of (i3 / induce-01~e.22
                        :ARG0 (p5 / protein
                              :name (n5 / name :op1 "il6"~e.21)))))
      :snt2 (a2 / affect-01~e.32
            :ARG1 (p6 / phosphorylate-01~e.29
                  :ARG1 (p7 / protein
                        :name (n6 / name :op1 "PKB"~e.28)))
            :ARG2~e.33 (t / thing~e.36
                  :quant "2"~e.35
                  :ARG0-of~e.36 (i4 / inhibit-01~e.36)
                  :mod (t2 / this~e.34))))

# ::tok Tissue factor ( TF ) can be induced in monocytes by external signals such as growth factors , inflammatory cytokines ( interleukin [IL]-1b and tumor necrosis factor [TNF]-a ) , oxidized LDLs , and endotoxin . 2
# ::alignments 0-1.1.1 1-1.1 3-1.1.2.1 7-1 8-1.2.r 9-1.2 10-1.3.r 11-1.3.1 12-1.3 13-1.3.2.r 14-1.3.2.r 15-1.3.2.1.1.1 16-1.3.2.1.1.2 18-1.3.2.2.1 21-1.3.2.2.2.1.1.1.1 23-1.3.2.2.2.1 24-1.3.2.2.2.1.2.1.1 25-1.3.2.2.2.1.2.1.2 26-1.3.2.2.2.1.2.1.3 30-1.3.2.3.2 33-1.3.2 33-1.3.2.2.2.1 34-1.3.2.4.1.1 36-1.4.1.1.1
# ::id bel_pmid_1120_8678_16854
(i / induce-01~e.7
      :ARG1 (f / factor~e.1
            :location (t / tissue~e.0)
            :ARG1-of (d / describe-01 :ARG2 "TF"~e.3))
      :location~e.8 (m / monocyte~e.9)
      :manner~e.10 (s / signal-01~e.12
            :mod (e / external~e.11)
            :example~e.13,14 (a / and~e.33
                  :op1 (e2 / enzyme
                        :name (n / name :op1 "growth"~e.15 :op2 "factor"~e.16))
                  :op2 (c / cytokine
                        :ARG1-of (i2 / inflame-01~e.18)
                        :ARG0-of (m2 / mean-01
                              :ARG1 (a2 / and~e.23,33
                                    :op1 (p / protein
                                          :name (n2 / name :op1 "interleukin"~e.21 :op2 "IL-1b"))
                                    :op2 (p4 / protein
                                          :name (n3 / name
                                                :op1 "tumor"~e.24
                                                :op2 "necrosis"~e.25
                                                :op3 "factor"~e.26)
                                          :ARG1-of (d3 / describe-01 :ARG2 "TNF-a")))))
                  :op3 (p2 / protein
                        :name (n4 / name :op1 "LDL")
                        :ARG1-of (o / oxidize-01~e.30))
                  :op4 (m3 / molecule
                        :name (n5 / name :op1 "endotoxin"~e.34))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "2"~e.36))))

# ::tok Incubation of monocytes with LPS or IL @-@ 1b resulted in a 10 @- and 5 @-@ fold increase of TF activity , respectively .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1 3-1.1.2.r 4-1.1.2.1.1.1 5-1.1.2 6-1.1.2.2.1.1 8-1.1.2.2.1.1 9-1 10-1.2.r 12-1.2.2.1 15-1.2.2.2 18-1.2 19-1.2.1.r 19-1.2.2 20-1.2.1.1 21-1.2.1
# ::id bel_pmid_1120_8678_23564
(r / result-01~e.9
      :ARG1 (i / incubate-01~e.0
            :ARG1~e.1 (m / monocyte~e.2)
            :ARG2~e.3 (o / or~e.5
                  :op1 (m2 / molecule
                        :name (n / name :op1 "LPS"~e.4))
                  :op2 (p / protein
                        :name (n2 / name :op1 "IL-1b"~e.6,8))))
      :ARG2~e.10 (i2 / increase-01~e.18
            :ARG1~e.19 (a / act-02~e.21 :ARG1 "TF"~e.20)
            :ARG2 (p2 / product-of~e.19 :op1 "10"~e.12 :op2 "5"~e.15)))

# ::tok In human aortic smooth muscle cells , fibrates inhibit the IL @-@ 1b ? induced expression of cyclooxygenase ( COX )-2 and IL @-@ 6 by inhibiting the NF @-@ kB and AP @-@ 1 signaling pathway.9,10
# ::alignments 1-1.4.2.1 2-1.4.2 3-1.4.1.1 4-1.4.1 5-1.4 8-1 8-1.3 10-1.2.2.1.1.1 12-1.2.2.1.1.1 14-1.2.2 15-1.2 16-1.2.1.r 17-1.2.1.1.1.1 21-1.2.1 22-1.2.1.2.1.1 24-1.2.1.2.1.1 25-1.3.r 26-1.3 28-1.3.1.1.1.1 30-1.3.1.1.1.1 31-1.3.1 32-1.3.1.2.1.1 34-1.3.1.2.1.1 35-1.3.1.2.2
# ::id bel_pmid_1120_8678_24148
(i / inhibit-01~e.8
      :ARG0 (f / fibrate)
      :ARG1 (e / express-03~e.15
            :ARG2~e.16 (a / and~e.21
                  :op1 (e2 / enzyme
                        :name (n / name :op1 "cyclooxygenase"~e.17 :op2 "2"))
                  :op2 (p2 / protein
                        :name (n3 / name :op1 "il-6"~e.22,24)))
            :ARG1-of (i2 / induce-01~e.14
                  :ARG0 (p / protein
                        :name (n2 / name :op1 "IL-1b"~e.10,12))))
      :manner~e.25 (i3 / inhibit-01~e.8,26
            :ARG1 (a2 / and~e.31
                  :op1 (p3 / protein
                        :name (n4 / name :op1 "NF-kB"~e.28,30))
                  :op2 (p4 / pathway
                        :name (n5 / name :op1 "AP-1"~e.32,34)
                        :ARG0-of (s / signal-01~e.35))))
      :location (c / cell~e.5
            :mod (m / muscle~e.4
                  :mod (s2 / smooth~e.3))
            :mod (a3 / aortic~e.2
                  :mod (h / human~e.1)))
      :ARG1-of (d / describe-01
            :ARG0 (p5 / publication
                  :ARG0-of (c2 / cite-01
                        :ARG2 (a4 / and :op1 "9" :op2 "10")))))

# ::tok PPARa activators prevent TNF @-@ a ? induced VCAM @-@ 1 expression in human saphenous vein endothelial cells , partly via inhibition of the NF @-@ kB pathway.14
# ::alignments 0-1.1.1.1.1 1-1.1 2-1 3-1.2.2.1.1.1 5-1.2.2.1.1.1 7-1.2.2 8-1.2.1.1.1 10-1.2.1.1.1 11-1.2 12-1.3.r 13-1.3.1.1 14-1.3.1.2 15-1.3.1.3 16-1.3.1.4 17-1.3 21-1.5 22-1.5.1.r 24-1.5.1.1.1 26-1.5.1.1.1
# ::id bel_pmid_1120_8678_24150
(p / prevent-01~e.2
      :ARG0 (a / activate-01~e.1
            :ARG1 (p2 / protein
                  :name (n / name :op1 "PPARa"~e.0)))
      :ARG1 (e / express-03~e.11
            :ARG2 (p3 / protein
                  :name (n2 / name :op1 "VCAM-1"~e.8,10))
            :ARG1-of (i / induce-01~e.7
                  :ARG0 (p4 / protein
                        :name (n3 / name :op1 "TNF-a"~e.3,5))))
      :location~e.12 (c / cell~e.17
            :name (n4 / name
                  :op1 "human"~e.13
                  :op2 "saphenous"~e.14
                  :op3 "vein"~e.15
                  :op4 "endothelial"~e.16))
      :extent (p5 / part)
      :manner (i2 / inhibit-01~e.21
            :ARG1~e.22 (p6 / pathway
                  :name (n5 / name :op1 "NF-kB"~e.24,26)))
      :ARG1-of (d / describe-01
            :ARG0 (p7 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "14"))))

# ::tok In human vascular endothelial cells , PPARa inhibits the thrombin @-@ mediated activation of endothelin @-@ 1 via negative interference with the AP @-@ 1 signaling pathway.13
# ::alignments 1-1.4.1.1 2-1.4.1.2 3-1.4.1.3 4-1.4 6-1.1.1.1 7-1 9-1.2.2.1.1.1 11-1.2.2 12-1.2 13-1.2.1.r 14-1.2.1.1.1 16-1.2.1.1.1 18-1.3.3 19-1.3 20-1.3.2.r 22-1.3.2.1.1 24-1.3.2.1.1 25-1.3.2.2
# ::id bel_pmid_1120_8678_24166
(i / inhibit-01~e.7
      :ARG0 (p / protein
            :name (n / name :op1 "PPARa"~e.6))
      :ARG1 (a / activate-01~e.12
            :ARG1~e.13 (p2 / protein
                  :name (n2 / name :op1 "endothelin-1"~e.14,16))
            :ARG1-of (m / mediate-01~e.11
                  :ARG0 (e / enzyme
                        :name (n3 / name :op1 "thrombin"~e.9))))
      :manner (i2 / interfere-01~e.19
            :ARG0 p
            :ARG1~e.20 (p3 / pathway
                  :name (n5 / name :op1 "AP-1"~e.22,24)
                  :ARG0-of (s / signal-01~e.25))
            :mod (n4 / negative~e.18))
      :location (c / cell~e.4
            :name (n6 / name
                  :op1 "human"~e.1
                  :op2 "vascular"~e.2
                  :op3 "endothelial"~e.3))
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "13"))))

# ::tok Incubation of THP @-@ 1 cells with PPARa activators 1 hour before LPS stimulation for 2 hours resulted in a decreased level of TF mRNA compared with cells incubated with only LPS ( Figure 2A ) .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1 4-1.1.1.1.1 5-1.1.1 6-1.1.2.r 7-1.1.2.1.1.1 8-1.1.2 9-1.1.1.1.1 10-1.1.3.1.2.2 10-1.1.3.2.2 11-1.1.3 12-1.1.3.1.1.1.1 13-1.1.3.1 15-1.1.3.1.2.1 15-1.1.3.2.1 16-1.1.3.1.2.2 16-1.1.3.2.2 17-1 18-1.2.r 20-1.2 21-1.2.1 22-1.2.1.1.r 23-1.2.1.1.1.1 24-1.2.1.1.1.2 25-1.2.2.r 27-1.2.2 28-1.2.2.1 29-1.2.2.1.2.r 30-1.2.2.1.2 31-1.2.2.1.1 33-1.3.1 34-1.3.1.1
# ::id bel_pmid_1120_8678_24170
(r / result-01~e.17
      :ARG1 (i / incubate-01~e.0
            :ARG1~e.1 (c / cell~e.5
                  :name (n / name :op1 "THP-1"~e.2,4,9))
            :ARG2~e.6 (a / activate-01~e.8
                  :ARG1 (p / protein
                        :name (n2 / name :op1 "PPARa"~e.7)))
            :time (b / before~e.11
                  :op1 (s / stimulate-01~e.13
                        :ARG1 (m / molecule
                              :name (n3 / name :op1 "LPS"~e.12))
                        :duration (t2 / temporal-quantity
                              :quant "2"~e.15
                              :unit (h2 / hour~e.10,16)))
                  :duration (t / temporal-quantity
                        :quant "2"~e.15
                        :unit (h / hour~e.10,16))))
      :ARG2~e.18 (d / decrease-01~e.20
            :ARG1 (l / level~e.21
                  :quant-of~e.22 (p2 / protein
                        :name (n4 / name :op1 "TF"~e.23 :op2 "mRNA"~e.24)))
            :compared-to~e.25 (c2 / cell~e.27
                  :ARG1-of (i2 / incubate-01~e.28
                        :ARG2 m~e.31
                        :mod~e.29 (o / only~e.30))))
      :ARG1-of (d2 / describe-01
            :ARG2 (f / figure~e.33 :mod "2A"~e.34)))

# ::tok Bag1 , a co @-@ chaperone for heat @-@ shock protein 70 ( Hsp70 ) , coordinates signals for cell growth in response to cell stress , by downregulating the activity of Raf @-@ 1 kinase . Raf @-@ 1 and Hsp70 compete for binding to Bag1 , such that Bag1 binds to and activates Raf @-@ 1 , subsequently activating the downstream extracellular signal @-@ related kinases
# ::alignments 0-1.1.1.1.1 3-1.1.1.2.1.1.1 5-1.1.1.2.1.1.1 7-1.1.1.2.1.2.1.1 9-1.1.1.2.1.2.1.1 10-1.1.1 10-1.1.1.2.1 10-1.1.1.2.1.2 10-1.1.1.2.1.2.r 10-1.2.1.2 10-1.2.2.1 11-1.1.1.2.1.2.2.1 13-1.2.1.2.1.1 16-1.1 17-1.1.2 18-1.1.2.1.r 19-1.1.2.1.1 20-1.1.2.1 21-1.1.2.2.r 22-1.1.2.2 24-1.1.2.2.1.1 25-1.1.2.2.1 30-1.1.3.1 32-1.1.3.1.1.1.1 32-1.2.1.1.1.1 34-1.1.3.1.1.1.1 34-1.2.1.1.1.1 35-1.1.3.1.1 37-1.1.3.1.1.1.1 37-1.2.1.1.1.1 39-1.1.3.1.1.1.1 39-1.2.1.1.1.1 40-1.2.1 41-1.2.1.2.1.1 42-1.2 43-1.2.2.r 44-1.2.2 45-1.2.3 46-1.2.2.1.1.1 50-1.2.2.1.1.1 51-1.2.3.1.1 53-1.2.3.1 54-1.2.3.1.2 55-1.2.1.1.1.1 57-1.2.1.1.1.1 59-1.2.4 59-1.2.4.r 60-1.2.4.1 62-1.2.4.1.1.2 63-1.2.4.1.1.1.1 64-1.2.4.1.1.1.2 66-1.2.4.1.1.1.2 67-1.1.3.1.1 67-1.2.4.1.1.1.3
# ::id bel_pmid_1123_1577_20122
(m / multi-sentence
      :snt1 (c / coordinate-01~e.16
            :ARG1 (p / protein~e.10
                  :name (n / name :op1 "Bag1"~e.0)
                  :ARG0-of (m2 / mean-01
                        :ARG1 (p2 / protein~e.10
                              :name (n2 / name :op1 "co-chaperone"~e.3,5)
                              :beneficiary~e.10 (p3 / protein~e.10
                                    :name (n3 / name :op1 "heat-shock"~e.7,9)
                                    :mod (m3 / molecular-mass :mod "70"~e.11)))))
            :ARG2 (s / signal-01~e.17
                  :beneficiary~e.18 (g / grow-01~e.20
                        :ARG1 (c2 / cell~e.19))
                  :ARG0-of~e.21 (r / respond-01~e.22
                        :ARG1 (s2 / stress-01~e.25
                              :ARG1 (c3 / cell~e.24))))
            :manner (d / downregulate-01
                  :ARG1 (a / act-02~e.30
                        :ARG0 (k / kinase~e.35,67
                              :name (n4 / name :op1 "Raf-1"~e.32,34,37,39)))))
      :snt2 (c4 / compete-01~e.42
            :ARG0 (a2 / and~e.40
                  :op1 (e / enzyme
                        :name (n5 / name :op1 "Raf-1"~e.32,34,37,39,55,57))
                  :op2 (p4 / protein~e.10
                        :name (n6 / name :op1 "Hsp70"~e.13,41)))
            :ARG2~e.43 (b / bind-01~e.44
                  :ARG1 (p5 / protein~e.10
                        :name (n7 / name :op1 "Bag1"~e.46,50)))
            :ARG1-of (c5 / cause-01~e.45
                  :ARG0 (a3 / and~e.53
                        :op1 (b2 / bind-01~e.51
                              :ARG0 p5
                              :ARG1 e)
                        :op2 (a4 / activate-01~e.54
                              :ARG0 p5
                              :ARG1 e)))
            :time~e.59 (s3 / subsequent~e.59
                  :op1 (a5 / activate-01~e.60
                        :ARG1 (e2 / enzyme
                              :name (n8 / name
                                    :op1 "extracellular"~e.63
                                    :op2 "signal-related"~e.64,66
                                    :op3 "kinase"~e.67)
                              :mod (d2 / downstream~e.62))))))

# ::tok Phosphorylation of Shc produces its binding to the adaptor protein Grb2 , causing activation of the protooncogene ras , which is also upstream of the MAP kinase pathway .
# ::alignments 0-1.1.1 2-1.1.1.1.1.1 3-1.1 4-1.1.2.1 4-1.1.2.1.r 5-1.1.2 6-1.1.2.2.r 8-1.1.2.2.2 9-1.1.1.1 9-1.1.2.2 10-1.1.2.2.1.1 12-1 13-1.2 14-1.2.1.r 16-1.2.1 17-1.2.1.1.1 20-1.2.1.2 21-1.2.1.2.3 22-1.2.1.2.2 25-1.2.1.2.1.1.1 26-1.2.1.2.1.1.2 27-1.2.1.2.1
# ::id bel_pmid_1123_9409_20136
(c / cause-01~e.12
      :ARG0 (p / produce-01~e.3
            :ARG0 (p2 / phosphorylate-01~e.0
                  :ARG1 (p3 / protein~e.9
                        :name (n / name :op1 "shc"~e.2)))
            :ARG1 (b / bind-01~e.5
                  :ARG1~e.4 p3~e.4
                  :ARG2~e.6 (p4 / protein~e.9
                        :name (n2 / name :op1 "grb2"~e.10)
                        :mod (a / adaptor~e.8))))
      :ARG1 (a2 / activate-01~e.13
            :ARG1~e.14 (p5 / protooncogene~e.16
                  :name (n3 / name :op1 "ras"~e.17)
                  :ARG1-of (b2 / be-located-at-91~e.20
                        :ARG2 (p6 / pathway~e.27
                              :name (n4 / name :op1 "MAP"~e.25 :op2 "kinase"~e.26))
                        :direction (u / upstream~e.22)
                        :mod (a3 / also~e.21)))))

# ::tok insulin receptor phosphorylates a number of intracellular substrates on tyrosine including members of the insulin receptor substrate family ( IRS1 @/@ 2/3 @/@ 4 ) , the Shc adaptor...
# ::alignments 0-1.2.1 1-1.2 2-1 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1.1 7-1.1.1.1 8-1.3.r 9-1.3.1.1 10-1.1.2 11-1.1.2.1 12-1.1.2.2.r 14-1.1.2.2.1.1 15-1.1.2.2.1.2 16-1.1.2.2.1.3 17-1.1.2.2.2 19-1.1.2.2.3.1.1 27-1.1.3.1.1
# ::id bel_pmid_1123_9409_21258
(p / phosphorylate-01~e.2
      :ARG1 (a2 / and
            :op1 (n / number~e.4
                  :quant-of~e.5 (s / substrate~e.7
                        :mod (i2 / intracellular~e.6)))
            :op2 (i4 / include-01~e.10
                  :ARG1 (m / member~e.11)
                  :ARG2~e.12 (p2 / protein
                        :name (n3 / name
                              :op1 "insulin"~e.14
                              :op2 "receptor"~e.15
                              :op3 "substrate"~e.16)
                        :mod (f / family~e.17)
                        :ARG0-of (m2 / mean-01
                              :ARG1 (s2 / slash
                                    :op1 "IRS1"~e.19
                                    :op2 "IRS2"
                                    :op3 "IRS3"
                                    :op4 "IRS4"))))
            :op3 (p3 / protein
                  :name (n4 / name :op1 "Shc"~e.27 :op2 "adaptor")))
      :ARG2 (r / receptor~e.1
            :mod (i / insulin~e.0))
      :location~e.8 (a / amino-acid
            :name (n2 / name :op1 "tyrosine"~e.9)))

# ::tok Insulin stimulates the tyrosine kinase activity of its receptor , leading to the phosphorylation of a number of cellular substrates , including Gab1 , Shc , IRS 1 - 4 , and Cbl . Gab1 appears to interact with the SH2 containing tyrosine phosphatase SHP2 , leading to the activation of the MAP kinase pathway .
# ::alignments 0-1.1.1 1-1.1 3-1.1.2.2.1.1 4-1.1.2.2.1.2 5-1.1.2 8-1.1.2.1 10-1.1.3 11-1.1.3.1.r 13-1.1.3.1 14-1.1.3.1.1.r 16-1.1.3.1.1 17-1.1.3.1.1.1.r 18-1.1.3.1.1.1.1 19-1.1.3.1.1.1 21-1.1.3.1.1.1.2 22-1.1.3.1.1.1.2.1.1.1.1 24-1.1.3.1.1.1.2.1.2.1.1 26-1.1.3.1.1.1.2.1.3.1.1 27-1.1.3.1.1.1.2.1.3.2.1 29-1.1.3.1.1.1.2.1.3.2.2 31-1.1.3.1.1.1.2.1 32-1.1.3.1.1.1.2.1.4.1.1 34-1.1.3.1.1.1.2.1.1.1.1 34-1.2.1.1.1 35-1.2 37-1.2.2 38-1.2.2.2.r 40-1.2.2.2.2.1.1.1 41-1.2.2.2.2 42-1.2.2.2.1.1 43-1.2.2.2.1.2 44-1.2.2.2.1.3 46-1.2.2.3 47-1.2.2.3.1.r 49-1.2.2.3.1 50-1.2.2.3.1.1.r 52-1.2.2.3.1.1.1.1 53-1.2.2.3.1.1.1.2 54-1.2.2.3.1.1
# ::id bel_pmid_1123_9409_23154
(m / multi-sentence
      :snt1 (s / stimulate-01~e.1
            :ARG0 (i / insulin~e.0)
            :ARG1 (a / act-02~e.5
                  :ARG0 (r / receptor~e.8)
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "tyrosine"~e.3 :op2 "kinase"~e.4)))
            :ARG0-of (l / lead-03~e.10
                  :ARG2~e.11 (p / phosphorylate-01~e.13
                        :ARG1~e.14 (n2 / number~e.16
                              :quant-of~e.17 (s2 / substrate~e.19
                                    :mod (c / cell~e.18)
                                    :ARG2-of (i2 / include-01~e.21
                                          :ARG1 (a2 / and~e.31
                                                :op1 (p2 / protein
                                                      :name (n3 / name :op1 "Gab1"~e.22,34))
                                                :op2 (p3 / protein
                                                      :name (n4 / name :op1 "Shc"~e.24))
                                                :op3 (p4 / protein
                                                      :name (n5 / name :op1 "IRS"~e.26)
                                                      :mod (v / value-interval :op1 "1"~e.27 :op2 "4"~e.29))
                                                :op4 (p5 / protein
                                                      :name (n6 / name :op1 "Cbl"~e.32)))))))))
      :snt2 (a3 / appear-02~e.35
            :ARG1 (p6 / protein
                  :name (n7 / name :op1 "Gab1"~e.34))
            :ARG2 (i3 / interact-01~e.37
                  :ARG0 p6
                  :ARG1~e.38 (p7 / protein
                        :name (n8 / name
                              :op1 "tyrosine"~e.42
                              :op2 "phosphatase"~e.43
                              :op3 "SHP2"~e.44)
                        :ARG1-of (c2 / contain-01~e.41
                              :ARG0 (p8 / protein
                                    :name (n9 / name :op1 "Sh2"~e.40))))
                  :ARG0-of (l2 / lead-03~e.46
                        :ARG2~e.47 (a4 / activate-01~e.49
                              :ARG1~e.50 (p9 / pathway~e.54
                                    :name (n10 / name :op1 "MAP"~e.52 :op2 "kinase"~e.53)))))))

# ::tok Overexpression of these enzymes [LAR and PTP1B] in cultured cells prevents insulin receptor kinase activation .
# ::alignments 3-1.1.1.1 3-1.1.1.2 3-1.2.1 5-1.1.1 8-1.1.2.1 9-1.1.2 10-1 11-1.2.1.1.1 12-1.2.1.1.2 13-1.2.1.1.3 14-1.2
# ::id bel_pmid_1123_9409_24744
(p / prevent-01~e.10
      :ARG0 (o / overexpress-00
            :ARG1 (a / and~e.5
                  :op1 (e / enzyme~e.3
                        :name (n / name :op1 "LAR"))
                  :op2 (e2 / enzyme~e.3
                        :name (n2 / name :op1 "PTP1B")))
            :location (c / cell~e.9
                  :ARG1-of (c2 / culture-01~e.8)))
      :ARG1 (a2 / activate-01~e.14
            :ARG1 (p2 / protein~e.3
                  :name (n3 / name
                        :op1 "insulin"~e.11
                        :op2 "receptor"~e.12
                        :op3 "kinase"~e.13))))

# ::tok The translocation of phosphorylated cbl recruits additional signaling proteins to the lipid raft , resulting in the activation of the G protein TC10 .
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.2 4-1.1.1.1.1 5-1 6-1.2.2 7-1.2.1 8-1.2 9-1.3.r 11-1.3.1 12-1.3 14-1.4 15-1.4.1.r 17-1.4.1 18-1.4.1.1.r 20-1.4.1.1.1.1 21-1.4.1.1 22-1.4.1.1.1.2
# ::id bel_pmid_1123_9409_32116
(r / recruit-01~e.5
      :ARG0 (t / translocate-00~e.1
            :ARG1~e.2 (p / protein
                  :name (n / name :op1 "cbl"~e.4)
                  :ARG1-of (p2 / phosphorylate-01~e.3)))
      :ARG1 (p3 / protein~e.8
            :ARG0-of (s / signal-01~e.7)
            :mod (a / additional~e.6))
      :ARG2~e.9 (r2 / raft~e.12
            :mod (l / lipid~e.11))
      :ARG2-of (r3 / result-01~e.14
            :ARG1~e.15 (a2 / activate-01~e.17
                  :ARG1~e.18 (p4 / protein~e.21
                        :name (n2 / name :op1 "G"~e.20 :op2 "TC10"~e.22)))))

# ::tok Contrary to the hypothesis , both IL @-@ 1 beta and IL @-@ 6 treatment resulted in a significant decrease in OT receptor messenger RNA measured by ribonuclease protection analysis .
# ::alignments 3-1.3.1 5-1.1.2 6-1.1.1.1.1.1 6-1.1.1.2.1.1 10-1.1.1 11-1.1.1.1.1.1 11-1.1.1.2.1.1 13-1.1.1.2.1.1 14-1.1 15-1 16-1.2.r 18-1.2.2 19-1.2 20-1.2.1.r 21-1.2.1.1 22-1.2.1 25-1.2.3 26-1.2.3.1.r 27-1.2.3.1.1.1 28-1.2.3.1.1 29-1.2.3.1
# ::id bel_pmid_1125_0916_23582
(r / result-01~e.15
      :ARG1 (t / treat-04~e.14
            :ARG0 (a / and~e.10
                  :op1 (p / protein
                        :name (n / name :op1 "IL-1beta"~e.6,11))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "IL-6"~e.6,11,13)))
            :mod (b / both~e.5))
      :ARG2~e.16 (d / decrease-01~e.19
            :ARG1~e.20 (r2 / receptor~e.22 :mod "OT"~e.21 :mod "mRNA")
            :degree (s / significant~e.18)
            :ARG1-of (m / measure-01~e.25
                  :ARG2~e.26 (a2 / analyze-01~e.29
                        :ARG1 (p3 / protection~e.28
                              :mod (r3 / ribonuclease~e.27)))))
      :ARG0-of (c / counter-01
            :ARG1 (h / hypothesis~e.3)))

# ::tok We demonstrated that ROR alpha is expressed in human primary smooth @-@ muscle cells and that ectopic expression of ROR alpha1 inhibits TNFalpha @-@ induced IL @-@ 6 , IL @-@ 8 and COX @-@ 2 expression in these cells .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1.1 4-1.2.1.1.1.2 6-1.2.1 8-1.2.1.2.2 9-1.2.1.2.1.1.1 10-1.2.1.2.1.1 12-1.2.1.2.1 13-1.2.1.2 14-1.2 15-1.2.r 16-1.2.2.1.2 17-1.2.2.1 17-1.2.2.2.3 19-1.2.2.1.1.1.1 20-1.2.2.1.1.1.2 21-1.2.2 22-1.2.2.2.1.2.1.1.1 24-1.2.2.2.1.2 25-1.2.2.2.1.1.1 27-1.2.2.2.1.1.1 29-1.2.2.2.1.1.1 29-1.2.2.2.2.1.1 31-1.2.2.2.2.1.1 33-1.2.2.2.3.1.1.1 35-1.2.2.2.3.1.1.1 36-1.2.1 37-1.2.2.3.r 38-1.2.2.3.1 39-1.2.2.3
# ::id bel_pmid_1125_2722_32494
(d / demonstrate-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2,15 (a / and~e.14
            :op1 (e / express-03~e.6,36
                  :ARG2 (r / receptor
                        :name (n / name :op1 "ROR"~e.3 :op2 "alpha"~e.4))
                  :location (c / cell~e.13
                        :mod (m / muscle~e.12
                              :mod (s / smooth~e.10
                                    :mod (p / primary~e.9)))
                        :mod (h / human~e.8)))
            :op2 (i / inhibit-01~e.21
                  :ARG0 (e2 / express-03~e.17
                        :ARG2 (r2 / receptor
                              :name (n2 / name :op1 "ROR"~e.19 :op2 "alpha1"~e.20))
                        :manner (e3 / ectopic~e.16))
                  :ARG1 (a2 / and
                        :op1 (c2 / cytokine
                              :name (n3 / name :op1 "IL-6"~e.25,27,29)
                              :ARG1-of (i2 / induce-01~e.24
                                    :ARG0 (p3 / protein
                                          :name (n4 / name :op1 "TNFalpha"~e.22))))
                        :op2 (c3 / cytokine
                              :name (n5 / name :op1 "IL-8"~e.29,31))
                        :op3 (e4 / express-03~e.17
                              :ARG2 (e5 / enzyme
                                    :name (n6 / name :op1 "COX-2"~e.33,35))))
                  :location~e.37 (c4 / cell~e.39
                        :mod (t / this~e.38)))))

# ::tok Constitutively active MKK6 @/@ 3 mutants up @-@ regulated GLUT1 expression and down @-@ regulated GLUT4 expression , thereby significantly increasing basal glucose transport but diminishing transport induced by insulin .
# ::alignments 0-1.1.1.2.1.2.1 2-1.1.1.2.1.1.1 5-1.1.1.2.3 6-1.2.1 9-1.1.1.1.1.1.1 10-1.1.1.1 10-1.1.2.1 11-1.1 15-1.1.2.1.1.1.1 16-1.1.1.1 16-1.1.2.1 19-1.2.1.2 20-1.2.1 21-1.2.1.1.1.1 22-1.2.1.1.1 23-1.2.1.1 24-1.2 25-1.2.2 26-1.2.2.1 27-1.2.2.1.1 28-1.2.2.1.1.1.r 29-1.2.2.1.1.1.1.1
# ::id bel_pmid_1127_9172_21850
(c / cause-01
      :ARG0 (a / and~e.11
            :op1 (u / upregulate-01
                  :ARG1 (e2 / express-03~e.10,16
                        :ARG2 (p / protein
                              :name (n2 / name :op1 "GLUT1"~e.9)))
                  :ARG2 (s2 / slash
                        :op1 (e4 / enzyme
                              :name (n5 / name :op1 "MKK6"~e.2)
                              :ARG1-of (a2 / activate-01
                                    :mod (c2 / constitutive~e.0)))
                        :op2 (e5 / enzyme
                              :name (n6 / name :op1 "MKK3")
                              :ARG1-of a2)
                        :ARG2-of (m / mutate-01~e.5)))
            :op2 (d / downregulate-01
                  :ARG1 (e3 / express-03~e.10,16
                        :ARG2 (p2 / protein
                              :name (n3 / name :op1 "GLUT4"~e.15)))
                  :ARG2 m))
      :ARG1 (c3 / contrast-01~e.24
            :ARG1 (i / increase-01~e.6,20
                  :ARG1 (t / transport-01~e.23
                        :ARG1 (g / glucose~e.22
                              :mod (b / basal~e.21)))
                  :degree (s / significant~e.19))
            :ARG2 (d2 / diminish-01~e.25
                  :ARG1 (t2 / transport-01~e.26
                        :ARG1-of (i2 / induce-01~e.27
                              :ARG0~e.28 (m2 / molecular-physical-entity
                                    :name (n4 / name :op1 "insulin"~e.29)))))))

# ::tok SB203580 , a specific p38 MAPK inhibitor , attenuated these effects , further confirming that both MMK6 and MMK3 act via p38 MAPK , whereas they had no effect on the increase in glucose transport induced by a constitutively active MAPK kinase 1 ( MEK1 ) mutant or by myristoylated Akt .
# ::alignments 0-1.1.1.1 3-1.1.2.2 4-1.1.2.1.1.1 5-1.1.2.1.1.2 6-1.1 6-1.1.2 6-1.1.2.r 8-1 9-1.2.1 10-1.2 12-1.3.2 13-1.3 16-1.3.1.1.1.1.1 17-1.3.1.1 18-1.3.1.1.2.1.1 19-1.3.1 21-1.3.1.2 22-1.3.1.2 24-1.3.1.3 25-1.3.1.3.1.2 26-1.3.1.3.1 27-1.3.1.3.1.1 27-1.3.1.3.1.1.r 28-1.3.1.3.1 29-1.3.1.3.1.3.r 31-1.3.1.3.1.3 32-1.3.1.3.1.3.1.r 33-1.3.1.3.1.3.1.1 34-1.3.1.3.1.3.1 35-1.3.1.3.1.3.2 36-1.3.1.3.1.3.2.1.r 38-1.3.1.3.1.3.2.1.1.3.1 39-1.3.1 40-1.3.1.3.1.3.2.1.1.1.1 41-1.3.1.3.1.3.2.1.1.1.2 42-1.3.1.3.1.3.2.1.1.1.3 44-1.3.1.3.1.3.2.1.1.4.1 46-1.3.1.3.1.3.2.1.1 46-1.3.1.3.1.3.2.1.1.2 46-1.3.1.3.1.3.2.1.1.2.r 47-1.3.1.3.1.3.2.1 50-1.3.1.3.1.3.2.1.2.1.1
# ::id bel_pmid_1127_9172_6266
(a6 / attenuate-01~e.8
      :ARG0 (s2 / small-molecule~e.6
            :name (n / name :op1 "SB203580"~e.0)
            :ARG0-of~e.6 (i2 / inhibit-01~e.6
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "p38"~e.4 :op2 "MAPK"~e.5))
                  :mod (s / specific~e.3)))
      :ARG1 (e2 / effect-01~e.10
            :mod (t / this~e.9))
      :ARG0-of (c / confirm-01~e.13
            :ARG1 (a4 / act-02~e.19,39
                  :ARG0 (a7 / and~e.17
                        :op1 (m / molecular-physical-entity
                              :name (n3 / name :op1 "MMK6"~e.16))
                        :op2 (m2 / molecular-physical-entity
                              :name (n4 / name :op1 "MMK3"~e.18)))
                  :manner e~e.21,22
                  :ARG1-of (c2 / contrast-01~e.24
                        :ARG2 (e3 / effect-01~e.26,28
                              :polarity~e.27 "-"~e.27
                              :ARG0 a7~e.25
                              :ARG1~e.29 (i3 / increase-01~e.31
                                    :ARG1~e.32 (t2 / transport-01~e.34
                                          :ARG1 (g / glucose~e.33))
                                    :ARG1-of (i4 / induce-01~e.35
                                          :ARG0~e.36 (o / or~e.47
                                                :op1 (e4 / enzyme~e.46
                                                      :name (n5 / name
                                                            :op1 "MAPK"~e.40
                                                            :op2 "kinase"~e.41
                                                            :op3 "1"~e.42)
                                                      :ARG2-of~e.46 (m3 / mutate-01~e.46)
                                                      :ARG1-of (a / activate-01
                                                            :mod (c3 / constitutive~e.38))
                                                      :ARG1-of (d / describe-01
                                                            :ARG2 (m4 / MEK1~e.44)))
                                                :op2 (e5 / enzyme
                                                      :name (n6 / name :op1 "Akt"~e.50)
                                                      :ARG1-of (m5 / myristoylate-00))))))))
            :degree (f / further~e.12)))

# ::tok A similar 24P3 induction was observed in other T cell lymphomas ( EL4 and TH201 ) in response to IL @-@ 9 , as well as in EL4 cells stimulated with IL @-@ 6 or IL @-@ 1 .
# ::alignments 1-1.1.2 2-1.1.1.1.1 3-1.1 5-1 6-1.2.r 7-1.2.1.2 8-1.2.1.4.1.1 9-1.2.1.1.1 9-1.2.1.1.2 9-1.2.1.4 10-1.2.1 12-1.2.1.1.1.1.1 13-1.2.1.1 14-1.2.1.1.2.1.1 16-1.2.1.3.r 17-1.2.1.3 18-1.2.1.3.1.r 19-1.2.1.3.1.1.1 21-1.2.1.3.1.1.1 27-1.2.2.1.1 28-1.2.2 29-1.2.2.2 30-1.2.2.2.1.r 31-1.2.2.2.1.1.1.1 33-1.2.2.2.1.1.1.1 34-1.2.2.2.1 35-1.2.2.2.1.1.1.1 35-1.2.2.2.1.2.1.1 37-1.2.2.2.1.2.1.1
# ::id bel_pmid_1128_2560_28384
(o / observe-01~e.5
      :ARG1 (i / induce-01~e.3
            :ARG1 (p / protein
                  :name (n / name :op1 "24P3"~e.2))
            :ARG1-of (r / resemble-01~e.1))
      :location~e.6 (a2 / and
            :op1 (l / lymphomas~e.10
                  :example (a / and~e.13
                        :op1 (c2 / cell~e.9
                              :name (n3 / name :op1 "EL4"~e.12))
                        :op2 (c3 / cell~e.9
                              :name (n4 / name :op1 "TH201"~e.14)))
                  :mod (o2 / other~e.7)
                  :ARG2-of~e.16 (r2 / respond-01~e.17
                        :ARG1~e.18 (p2 / protein
                              :name (n5 / name :op1 "IL-9"~e.19,21)))
                  :mod (c5 / cell~e.9
                        :name (n9 / name :op1 "T"~e.8)))
            :op2 (c4 / cell~e.28
                  :name (n6 / name :op1 "EL4"~e.27)
                  :ARG1-of (s / stimulate-01~e.29
                        :ARG0~e.30 (o3 / or~e.34
                              :op1 (p3 / protein
                                    :name (n7 / name :op1 "IL-6"~e.31,33,35))
                              :op2 (p4 / protein
                                    :name (n8 / name :op1 "IL-1"~e.35,37)))))))

# ::tok Searching for genes specifically modulated by IL @-@ 9 , we observed that the 24P3 mRNA is strongly upregulated in BW5147 T lymphoma cells upon IL @-@ 9 stimulation .
# ::alignments 0-1.3 1-1.3.2.r 2-1.3.2 3-1.3.2.1.2 4-1.3.2.1 5-1.3.2.1.1.r 6-1.3.2.1.1 7-1.3.2.1.1 8-1.3.2.1.1 10-1.1 11-1 14-1.2.1.1.2.1.1.1 15-1.2.1.1.1.1 17-1.2.1.3 17-1.2.1.3.r 20-1.2.1.2.1.1 21-1.2.1.2.1.2 22-1.2.1.2.2 23-1.2.1.2 25-1.2.2.1.1.1 27-1.2.2.1.1.1 28-1.2.2
# ::id bel_pmid_1128_2560_28446
(o / observe-01~e.11
      :ARG0 (w / we~e.10)
      :ARG1 (h / have-condition-91
            :ARG1 (u / upregulate-01
                  :ARG1 (r / rna
                        :name (n5 / name :op1 "mRNA"~e.15)
                        :ARG0-of (e / encode-01
                              :ARG1 (p / protein
                                    :name (n / name :op1 "24P3"~e.14))))
                  :location (c / cell~e.23
                        :name (n2 / name :op1 "BW5147"~e.20 :op2 "T"~e.21)
                        :mod (l / lymphoma~e.22))
                  :manner~e.17 (s2 / strong~e.17))
            :ARG2 (s / stimulate-01~e.28
                  :ARG0 (p2 / protein
                        :name (n3 / name :op1 "IL-9"~e.25,27))))
      :time (s3 / search-01~e.0
            :ARG0 w
            :ARG1~e.1 (g / gene~e.2
                  :ARG1-of (m2 / modulate-01~e.4
                        :ARG0~e.5 p2~e.6,7,8
                        :manner (s4 / specific~e.3)))))

# ::tok ResnetDB sentence : Gadd45 gamma expression is induced by several cytokines , including IL @-@ 3 , IL @-@ 6 , and GM @-@ CSF ( 20 ) .
# ::alignments 0-1.1.1 1-1.1 3-1.2.2.1.1.1 4-1.2.2.1.1.2 5-1.2.2 7-1.2 9-1.2.1.2 12-1.2.1.1 13-1.2.1.1.1.1.1.1 13-1.2.1.1.1.2.1.1 15-1.2.1.1.1.1.1.1 17-1.2.1.1.1.1.1.1 17-1.2.1.1.1.2.1.1 19-1.2.1.1.1.2.1.1 21-1.2.1.1.1 22-1.2.1.1.1.3.1.1 24-1.2.1.1.1.3.1.1 26-1.3.1.1.1
# ::id bel_pmid_1128_7618_22858
(d / describe-01
      :ARG0 (s / sentence~e.1
            :mod (r / ResnetDB~e.0))
      :ARG1 (i / induce-01~e.7
            :ARG0 (c / cytokine
                  :ARG2-of (i2 / include-91~e.12
                        :ARG1 (a / and~e.21
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "IL-3"~e.13,15,17))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "IL-6"~e.13,17,19))
                              :op3 (p4 / protein
                                    :name (n4 / name :op1 "GM-CSF"~e.22,24))))
                  :quant (s2 / several~e.9))
            :ARG1 (e / express-03~e.5
                  :ARG2 (p7 / protein
                        :name (n6 / name :op1 "Gadd45"~e.3 :op2 "gamma"~e.4))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "20"~e.26))))

# ::tok Gadd45 gamma , a family member of the growth arrest and DNA damage @-@ inducible gene family 45 ( Gadd45 ) , is strongly induced by interleukin @-@ 2 ( IL @-@ 2 ) in peripheral T cells .
# ::alignments 4-1.2.2.1.2 8-1.2.2.1.1.1 9-1.2.2.1.1.2 10-1.2.2.1.1.3 11-1.2.2.1.1.4 12-1.2.2.1.1.5 14-1.2.2.1.1.5 15-1.2.2.1.1.6 16-1.2.2.1.2 17-1.2.2.1.1.7 23-1.4 23-1.4.r 24-1 25-1.1.r 26-1.1.1.1 28-1.1.1.1 32-1.1.1.1 34-1.3.r 35-1.3.2 36-1.3.1.1 37-1.3
# ::id bel_pmid_1128_7618_23626
(i / induce-01~e.24
      :ARG0~e.25 (p2 / protein
            :name (n3 / name :op1 "interleukin-2"~e.26,28,32))
      :ARG1 (g / gene
            :name (n / name :op1 "Gadd45 gamma")
            :ARG1-of (i3 / include-91
                  :ARG2 (g2 / gene
                        :name (n2 / name
                              :op1 "growth"~e.8
                              :op2 "arrest"~e.9
                              :op3 "and"~e.10
                              :op4 "DNA"~e.11
                              :op5 "damage-inducible"~e.12,14
                              :op6 "gene"~e.15
                              :op7 "45"~e.17)
                        :mod (f / family~e.4,16))))
      :location~e.34 (c / cell~e.37
            :name (n4 / name :op1 "T"~e.36)
            :mod (p3 / peripheral~e.35))
      :manner~e.23 (s / strong~e.23))

# ::tok K @-@ Ras @-@ mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1 .
# ::alignments 0-1.2.2.1.1.1 2-1.2.2.1.1.1 4-1.2.2 5-1.2 6-1.2.1.r 7-1.2.1.1.2.1.1.1 8-1.2.1.1.2.1.1.2 9-1.2.1.1.1.1 10-1.2.1 11-1 12-1.1 13-1.1.1.r 15-1.1.1.1.1 16-1.1.1.1.2 17-1.1.1.1.3
# ::id bel_pmid_1128_9146_5754
(i2 / involve-01~e.11
      :ARG1 (a / activate-01~e.12
            :ARG1~e.13 (e4 / enzyme
                  :name (n3 / name
                        :op1 "protein"~e.15
                        :op2 "kinase"~e.16
                        :op3 "B1"~e.17)))
      :ARG2 (i / increase-01~e.5
            :ARG1~e.6 (s / stability~e.10
                  :mod (r / rna
                        :name (n4 / name :op1 "mRNA"~e.9)
                        :ARG0-of (e2 / encode-01
                              :ARG1 (e3 / enzyme
                                    :name (n2 / name :op1 "cyclooxygenase"~e.7 :op2 "2"~e.8)))))
            :ARG1-of (m / mediate-01~e.4
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "K-Ras"~e.0,2)))))

# ::tok Thus , Akt @/@ PKB activity is involved in K @-@ Ras @-@ induced expression of COX @-@ 2 and stabilization of COX @-@ 2 mRNA largely depends on the activation of Akt/PKB .
# ::alignments 0-1 2-1.1.1.1.1.1.1 4-1.1.1.1.1.1.1 5-1.1.1.1 7-1.1.1 8-1.1.1.2.r 9-1.1.1.2.2.1.1.1 11-1.1.1.2.2.1.1.1 13-1.1.1.2.2 14-1.1.1.2 15-1.1.1.2.1.r 16-1.1.1.2.1.1.1 18-1.1.1.2.1.1.1 19-1.1 20-1.1.2.1 22-1.1.1.2.1.1.1 24-1.1.1.2.1.1.1 25-1.1.2.1.1.1.1 26-1.1.2.3 27-1.1.2 28-1.1.2.2.r 30-1.1.2.2 31-1.1.2.2.1.r 32-1.1.2.2.1
# ::id bel_pmid_1128_9146_7350
(c / cause-01~e.0
      :ARG1 (a / and~e.19
            :op1 (i / involve-01~e.7
                  :ARG1 (a2 / act-02~e.5
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "Akt/PKB"~e.2,4)))
                  :ARG2~e.8 (e3 / express-03~e.14
                        :ARG2~e.15 (e4 / enzyme
                              :name (n3 / name :op1 "COX-2"~e.16,18,22,24))
                        :ARG1-of (i2 / induce-01~e.13
                              :ARG0 (e2 / enzyme
                                    :name (n2 / name :op1 "K-Ras"~e.9,11)))))
            :op2 (d / depend-01~e.27
                  :ARG0 (s / stabilize-01~e.20
                        :ARG2 (r / rna
                              :name (n4 / name :op1 "mRNA"~e.25)
                              :ARG0-of (e5 / encode-01
                                    :ARG1 e4)))
                  :ARG1~e.28 (a3 / activate-01~e.30
                        :ARG1~e.31 e~e.32)
                  :degree (l / large~e.26))))

# ::tok Addition of a single tyrosine residue , Y724 , restored its [Fgfr3] ability to stimulate cellular transformation , phosphatidylinositol 3 @-@ kinase activation , and phosphorylation of Shp2 , MAPK , Stat1 , and Stat3 .
# ::alignments 0-1.1 1-1.1.1.r 3-1.1.1.2 4-1.1.1.1.2.1 5-1.1.1 9-1 12-1.2 14-1.2.2 15-1.2.2.2.1.1 16-1.2.2.2.1 18-1.2.2.2.2.1.1.1 19-1.2.2.2.2.1.1.2 21-1.2.2.2.2.1.1.2 22-1.2.2.2.2 24-1.2.2.2 25-1.2.2.2.3 26-1.2.2.2.3.1.r 27-1.2.2.2.3.1.1.1.1 29-1.2.2.2.3.1.2.1.1 31-1.2.2.2.3.1.3.1.1 34-1.2.2.2.3.1.4.1.1
# ::id bel_pmid_1129_4897_21214
(r3 / restore-01~e.9
      :ARG0 (a / add-02~e.0
            :ARG1~e.1 (r / residue~e.5
                  :mod (a2 / amino-acid
                        :mod "724"
                        :name (n / name :op1 "tyrosine"~e.4))
                  :mod (s / single~e.3)))
      :ARG1 (c / capable-01~e.12
            :ARG1 (p / protein
                  :name (n3 / name :op1 "Fgfr3"))
            :ARG2 (s2 / stimulate-01~e.14
                  :ARG0 p
                  :ARG1 (a4 / and~e.24
                        :op1 (t / transform-01~e.16
                              :mod (c2 / cell~e.15))
                        :op2 (a5 / activate-01~e.22
                              :ARG1 (e / enzyme
                                    :name (n4 / name :op1 "phosphatidylinositol"~e.18 :op2 "3-kinase"~e.19,21)))
                        :op3 (p2 / phosphorylate-01~e.25
                              :ARG1~e.26 (a6 / and
                                    :op1 (e2 / enzyme
                                          :name (n5 / name :op1 "Shp2"~e.27))
                                    :op2 (e3 / enzyme
                                          :name (n6 / name :op1 "MAPK"~e.29))
                                    :op3 (p3 / protein
                                          :name (n7 / name :op1 "Stat1"~e.31))
                                    :op4 (p4 / protein
                                          :name (n8 / name :op1 "Stat3"~e.34))))))))

# ::tok We also found that Y770 may function as a negative regulatory site for FGFR3 @-@ stimulated transformation and PI 3 @-@ kinase activation .
# ::alignments 0-1.1 1-1.3 2-1 5-1.2 6-1.2.1 11-1.2.1.2 13-1.2.1.2.1.1.1.1.1.1.1 15-1.2.1.2.1.1.1.1 16-1.2.1.2.1.1.1 17-1.2.1.2.1.1 18-1.2.1.2.1.1.2.1.1.1 19-1.2.1.2.1.1.2.1.1.2 21-1.2.1.2.1.1.2.1.1.2 22-1.2.1.2.1.1.2
# ::id bel_pmid_1129_4897_23128
(f / find-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (p / possible~e.5
            :domain (f2 / function-01~e.6
                  :ARG0 (a / amino-acid
                        :mod "770"
                        :name (n / name :op1 "tyrosine"))
                  :ARG1 (p3 / protein-segment~e.11
                        :ARG2-of (d / downregulate-01
                              :ARG1 (a2 / and~e.17
                                    :op1 (t / transform-01~e.16
                                          :ARG1-of (s2 / stimulate-01~e.15
                                                :ARG0 (p2 / protein
                                                      :name (n2 / name :op1 "FGFR3"~e.13))))
                                    :op2 (a3 / activate-01~e.22
                                          :ARG1 (e / enzyme
                                                :name (n3 / name :op1 "PI"~e.18 :op2 "3-kinase"~e.19,21))))))))
      :mod (a4 / also~e.1))

# ::tok We present pharmacological and genetic evidence that p90( RSK ) mediated this phosphorylation in response to agonists that activate ERK1 @/@ 2 and that cAMP @-@ dependent protein kinase mediated this phosphorylation in response to agonists that activate adenylate cyclase
# ::alignments 0-1.1 1-1 2-1.2.3 3-1.2.1 4-1.2.2 5-1.2 8-1.2.1.1.1.1.2 10-1.2.1.1 11-1.2.1.1.2.1 12-1.2.1.1.2 14-1.2.1.1.3 17-1.2.1.1.3.1.r 18-1.2.1.1.3.1 18-1.2.1.1.3.1.2 18-1.2.1.1.3.1.2.r 19-1.2.1.1.3.1.2.1.1.1 21-1.2.1.1.3.1.2.1.1.1 22-1.2.1 23-1.2.1.r 24-1.2.1.2.1.1.1 26-1.2.1.2.1.1.1 27-1.2.1.2.1.1.2 28-1.2.1.2.1.1.3 29-1.2.1.1 29-1.2.1.2 30-1.2.1.2.2 31-1.2.1.2.2 32-1.2.1.2.3.r 33-1.2.1.2.3 37-1.2.1.2.3.1.1 38-1.2.1.2.3.1.1.1.1.1 39-1.2.1.2.3.1.1.1.1.2
# ::id bel_pmid_1129_7520_22158
(p / present-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (e / evidence-01~e.5
            :ARG1~e.23 (a / and~e.3,22
                  :op1 (m / mediate-01~e.10,29
                        :ARG0 (p7 / protein
                              :name (n8 / name :op1 "p90" :op2 "RSK"~e.8))
                        :ARG1 (p4 / phosphorylate-01~e.12
                              :mod (t / this~e.11))
                        :ARG2-of (r / respond-01~e.14
                              :ARG1~e.17 (m2 / molecular-physical-entity~e.18
                                    :name (n2 / name :op1 "agonist")
                                    :ARG0-of~e.18 (a2 / activate-01~e.18
                                          :ARG1 (e2 / enzyme
                                                :name (n3 / name :op1 "ERK1/2"~e.19,21))))))
                  :op2 (m3 / mediate-01~e.29
                        :ARG0 (e3 / enzyme
                              :name (n4 / name
                                    :op1 "cAMP-dependent"~e.24,26
                                    :op2 "protein"~e.27
                                    :op3 "kinase"~e.28))
                        :ARG1 p4~e.30,31
                        :ARG2-of~e.32 (r2 / respond-01~e.33
                              :ARG1 (a4 / agonist
                                    :ARG0-of (a3 / activate-01~e.37
                                          :ARG1 (e4 / enzyme
                                                :name (n6 / name :op1 "adenylate"~e.38 :op2 "cyclase"~e.39)))))))
            :mod (g / genetics~e.4)
            :mod (p2 / pharmacology~e.2)))

# ::tok The reintroduction of wild @-@ type LKB1 into a cancer cell line that lacks LKB1 suppressed growth , but mutants of LKB1 in which Ser( 431 ) was mutated to Ala to prevent phosphorylation of LKB1 were ineffective in inhibiting growth .
# ::alignments 3-1.1.1.1.2 5-1.1.1.1.2 6-1.1.1.1.1.1 9-1.1.1.2.1 10-1.1.1.2 11-1.1.1.2 13-1.1.1.2.2 14-1.1.1.2.2.1.1.1 15-1.1 16-1.1.2 18-1 19-1.2.3 19-1.2.3.3 19-1.2.3.3.r 21-1.2.3.1.1 25-1.2.3.2.1 28-1.2.3.2.3 29-1.2.3.2.3.1.r 30-1.2.3.2.3.1.1.1 32-1.2.3.2.3.2 33-1.2.3.2.3.2.1 35-1.2.3.1.1 36-1.2.3.r 37-1.2 37-1.2.1 37-1.2.1.r 38-1.2.2.r 39-1.2.2 40-1.2.2.2
# ::id bel_pmid_1129_7520_6398
(c / contrast-01~e.18
      :ARG1 (s / suppress-01~e.15
            :ARG0 (r / reintroduce-01
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "LKB1"~e.6)
                        :mod (w / wild-type~e.3,5))
                  :ARG2 (c4 / cell-line~e.10,11
                        :mod (c2 / cancer~e.9)
                        :ARG0-of (l2 / lack-01~e.13
                              :ARG1 (e3 / enzyme
                                    :name (n4 / name :op1 "LKB1"~e.14)))))
            :ARG1 (g / grow-01~e.16))
      :ARG2 (e2 / effective~e.37
            :polarity~e.37 "-"~e.37
            :purpose~e.38 (i / inhibit-01~e.39
                  :ARG0 (e4 / enzyme~e.19
                        :name (n5 / name :op1 "LKB1"~e.21,35)
                        :part (a / amino-acid
                              :mod "431"~e.25
                              :name (n2 / name :op1 "serine")
                              :ARG1-of (m2 / mutate-01~e.28
                                    :ARG2~e.29 (a2 / amino-acid
                                          :name (n3 / name :op1 "Ala"~e.30))
                                    :ARG0-of (p / prevent-01~e.32
                                          :ARG1 (p2 / phosphorylate-01~e.33
                                                :ARG1 e))))
                        :ARG1-of~e.19 (m / mutate-01~e.19))
                  :ARG1 g~e.40)
            :domain~e.36 e4))

# ::tok Immunoblot analysis of extracts from control and HT15 cells showed an increase in the activated forms of ERK1 @/@ 2 in the Sod2 @-@ overexpressing cells that was reversed upon coexpression of catalase ( Fig . 5A ) .
# ::alignments 0-1.1.1.2 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1 3-1.1.1.1.1 3-1.1.1.1.1.r 4-1.1.1.1.1.1.r 5-1.1.1.1.1.1 6-1.1 7-1.1.2.1.1 8-1.1.2 9-1 11-1.2 12-1.2.1.r 14-1.2.1.2 17-1.2.1.1.1 19-1.2.1.1.1 20-1.2.2.r 22-1.2.2.1.1.1.1 25-1.2.2 28-1.2.3 32-1.2.3.1.1.1.1 36-1.3.1.1
# ::id bel_pmid_1129_7530_22688
(s / show-01~e.9
      :ARG0 (a / and~e.6
            :op1 (a2 / analyze-01~e.1
                  :ARG1~e.2 (t / thing~e.3
                        :ARG1-of~e.3 (e / extract-01~e.3
                              :ARG2~e.4 (c / control~e.5)))
                  :mod (i / immunoblot-00~e.0))
            :op2 (c2 / cell~e.8
                  :name (n / name :op1 "HT15"~e.7)))
      :ARG1 (i2 / increase-01~e.11
            :ARG1~e.12 (e2 / enzyme
                  :name (n2 / name :op1 "ERK1/2"~e.17,19)
                  :ARG1-of (a3 / activate-01~e.14))
            :location~e.20 (c3 / cell~e.25
                  :ARG3-of (o / overexpress-00
                        :ARG2 (e3 / enzyme
                              :name (n3 / name :op1 "Sod2"~e.22))))
            :ARG1-of (r / reverse-01~e.28
                  :ARG0 (c4 / coexpress-00
                        :ARG2 (e4 / enzyme
                              :name (n4 / name :op1 "catalase"~e.32)))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "5A"~e.36)))

# ::tok Analysis of IL @-@ 1a levels in Sod2 @-@ overexpressing cells showed a 3 @-@ fold increase in basal IL @-@ 1a levels that was reversed when catalase was coexpressed in these cell lines ( Fig . 2A ) .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1 4-1.1.1.1.1.1 5-1.1.1 6-1.1.2.r 7-1.1.2.1.1.1.1 10-1.1.2 11-1 13-1.2.2.1 16-1.2 17-1.2.1.r 18-1.2.1.1 19-1.2.1.2 20-1.2.1.2 21-1.2.1.2 22-1.2.1 25-1.2.3 26-1.2.3.1.r 27-1.2.3.1.1.1.1 31-1.2.3.1.2.1 32-1.2.3.1.2 33-1.2.3.1.2 37-1.3.1.1
# ::id bel_pmid_1129_7530_22690
(s / show-01~e.11
      :ARG0 (a / analyze-01~e.0
            :ARG1~e.1 (l / level~e.5
                  :quant-of (p / protein
                        :name (n / name :op1 "IL-1a"~e.2,4)))
            :location~e.6 (c / cell~e.10
                  :ARG3-of (o / overexpress-00
                        :ARG2 (e2 / enzyme
                              :name (n5 / name :op1 "Sod2"~e.7)))))
      :ARG1 (i / increase-01~e.16
            :ARG1~e.17 (l2 / level~e.22
                  :mod (b / basal~e.18)
                  :quant-of p~e.19,20,21)
            :ARG2 (p3 / product-of :op1 "3"~e.13)
            :ARG1-of (r / reverse-01~e.25
                  :time~e.26 (c2 / coexpress-00
                        :ARG2 (e / enzyme
                              :name (n4 / name :op1 "catalase"~e.27))
                        :ARG3 (c4 / cell-line~e.32,33
                              :mod (t / this~e.31)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2A"~e.37)))

# ::tok Thus , a 15 @-@ fold increase in Sod2 levels , which is well within the range of activity observed in response to cytokines and growth factors , can enhance MMP @-@ 1 expression in an H2O2 @-@ dependent fashion .
# ::alignments 0-1 3-1.1.1.1.2.1 6-1.1.1.1 7-1.1.1.1.1.r 8-1.1.1.1.1.1.1.1 9-1.1.1.1.1 13-1.1.1.1.3.3 16-1.1.1.1.3 17-1.1.1.1.3.1.r 18-1.1.1.1.3.1 19-1.1.1.1.3.2 20-1.1.1.1.3.2.1.r 21-1.1.1.1.3.2.1 24-1.1.1.1.3.2.1.1 25-1.1.1.1.3.2.1.1.2.1.1 26-1.1.1.1.3.2.1.1.2.1.2 28-1.1 29-1.1.1 30-1.1.1.2.1.1.1 32-1.1.1.2.1.1.1 33-1.1.1.2 34-1.1.1.3.r 36-1.1.1.3.2.1.1 38-1.1.1.3
# ::id bel_pmid_1129_7530_24362
(c / cause-01~e.0
      :ARG1 (p / possible~e.28
            :domain (e / enhance-01~e.29
                  :ARG0 (i / increase-01~e.6
                        :ARG1~e.7 (l / level~e.9
                              :quant-of (e2 / enzyme
                                    :name (n / name :op1 "Sod2"~e.8)))
                        :ARG2 (p2 / product-of :op1 "15"~e.3)
                        :part-of (r / range-01~e.16
                              :ARG1~e.17 (a / activity~e.18)
                              :ARG1-of (o / observe-01~e.19
                                    :ARG2-of~e.20 (r2 / respond-01~e.21
                                          :ARG1 (a2 / and~e.24
                                                :op1 (c2 / cytokine)
                                                :op2 (s / small-mollecule
                                                      :name (n2 / name :op1 "growth"~e.25 :op2 "factor"~e.26)))))
                              :degree (w / well~e.13)))
                  :ARG1 (e3 / express-03~e.33
                        :ARG2 (e4 / enzyme
                              :name (n3 / name :op1 "MMP-1"~e.30,32)))
                  :manner~e.34 (d / depend-01~e.38
                        :ARG0 e3
                        :ARG1 (m / molecular-physical-entity
                              :name (n4 / name :op1 "H2O2"~e.36))))))

# ::tok In support of this hypothesis , the gelatinolytic activity of MMP @-@ 2 and the mRNA levels of MMP @-@ 3 and MMP @-@ 7 were increased in the Sod2 overexpressors compared with control cell lines ( Fig . 5C , left panel ) .
# ::alignments 1-1 2-1.2.r 3-1.2.1 4-1.2 7-1.1.1.1.2 10-1.1.1.1.1.1.1 12-1.1.1.1.1.1.1 13-1.1.1 15-1.1.1.2.1.1.1 16-1.1.1.2 18-1.1.1.2.1.2.1.1.1.1 20-1.1.1.2.1.2.1.1.1.1 21-1.1.1.2.1.2.1 22-1.1.1.2.1.2.1.1.1.1 22-1.1.1.2.1.2.1.2.1.1 24-1.1.1.2.1.2.1.2.1.1 26-1.1 27-1.1.2.r 29-1.1.2.1.1.1.1 31-1.1.2.2.r 33-1.1.2.2.1 34-1.1.2 34-1.1.2.2 35-1.1.2.2 39-1.3.1.1 41-1.3.1.2.1 42-1.3.1.2
# ::id bel_pmid_1129_7530_24364
(s / support-01~e.1
      :ARG0 (i / increase-01~e.26
            :ARG1 (a / and~e.13
                  :op1 (a2 / act-01
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "MMP-2"~e.10,12))
                        :mod (g / gelatinolytic~e.7))
                  :op2 (l / level~e.16
                        :quant-of (r / rna
                              :name (n5 / name :op1 "mRNA"~e.15)
                              :ARG0-of (e4 / encode-01
                                    :ARG1 (a3 / and~e.21
                                          :op1 (e2 / enzyme
                                                :name (n2 / name :op1 "MMP-3"~e.18,20,22))
                                          :op2 (e3 / enzyme
                                                :name (n3 / name :op1 "MMP-7"~e.22,24)))))))
            :location~e.27 (c3 / cell-line~e.34
                  :ARG3-of (o / overexpress-00
                        :ARG1 (e5 / enzyme
                              :name (n4 / name :op1 "Sod2"~e.29)))
                  :compared-to~e.31 (c4 / cell-line~e.34,35
                        :ARG2-of (c2 / control-01~e.33))))
      :ARG1~e.2 (h / hypothesize-01~e.4
            :mod (t / this~e.3))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod "5C"~e.39
                  :location (p / panel~e.42
                        :direction (l3 / left~e.41)))))

# ::tok The observed decline in MMP @-@ 9 activity in the HT15 cell line may represent a negative regulatory aspect of Sod2 in MMP expression .
# ::alignments 1-1.1.1.2 2-1.1.1 4-1.1.1.1.1.1.1 6-1.1.1.1.1.1.1 10-1.1.1.1.2.1.1 11-1.1.1.1.2 12-1.1.1.1.2 13-1 14-1.1 18-1.1.2 20-1.1.2.1.1.1.1 22-1.1.2.1.2.1.1.1 23-1.1.2.1.2
# ::id bel_pmid_1129_7530_24366
(p / possible~e.13
      :domain (r / represent-01~e.14
            :ARG0 (d / decline-01~e.2
                  :ARG1 (a / act-01
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "MMP-9"~e.4,6))
                        :location (c2 / cell-line~e.11,12
                              :name (n5 / name :op1 "HT15"~e.10)))
                  :ARG1-of (o / observe-01~e.1))
            :ARG1 (a2 / aspect~e.18
                  :ARG0-of (d2 / downregulate-01
                        :ARG2 (e2 / enzyme
                              :name (n3 / name :op1 "Sod2"~e.20))
                        :topic (e3 / express-03~e.23
                              :ARG2 (e4 / enzyme
                                    :name (n4 / name :op1 "MMP"~e.22)))))))

# ::tok The induction of MMP @-@ 13 by IL @-@ 1a and phorbol myristate acetate was severely impaired in the Sod2-/+ fibroblasts compared with the Sod2+/+ fibroblasts ( Fig . 3 , A and B ) .
# ::alignments 1-1.1 2-1.1.2.r 3-1.1.2.1.1 5-1.1.2.1.1 6-1.1.1.r 7-1.1.1.1.1.1 9-1.1.1.1.1.1 10-1.1.1 11-1.1.1.2.1.1 12-1.1.1.2.1.2 13-1.1.1.2.1.3 15-1.4 16-1 20-1.2 20-1.5 21-1.5.r 25-1.2 32-1.1.1 32-1.3.1
# ::id bel_pmid_1129_7530_28094
(i / impair-01~e.16
      :ARG1 (i2 / induce-01~e.1
            :ARG0~e.6 (a / and~e.10,32
                  :op1 (p / protein
                        :name (n2 / name :op1 "IL-1a"~e.7,9))
                  :op2 (m / molecular-physical-entity
                        :name (n3 / name
                              :op1 "phorbol"~e.11
                              :op2 "myristate"~e.12
                              :op3 "acetate"~e.13)))
            :ARG1~e.2 (e / enzyme
                  :name (n / name :op1 "MMP-13"~e.3,5)))
      :location (f / fibroblast~e.20,25
            :mod (e2 / enzyme
                  :name (n4 / name :op1 "Sod2")
                  :ARG2-of (m2 / mutate-01 :mod "-/+")))
      :ARG1-of (d / describe-01
            :ARG0 (a3 / and~e.32
                  :op1 (f3 / figure :mod "3A")
                  :op2 (f4 / figure :mod "3B")))
      :degree (s / severe~e.15)
      :compared-to~e.21 (f2 / fibroblast~e.20
            :mod (e3 / enzyme
                  :name (n5 / name :op1 "Sod2")
                  :mod (w / wild-type))))

# ::tok the wild @-@ type MEFs responded to the induction of MMP @-@ 13 by TNF , whereas the heterozygotes did not .
# ::alignments 1-1.1.1.2 3-1.1.1.2 5-1.1 5-1.2 6-1.1.2.r 8-1.1.2 9-1.1.2.2.r 10-1.1.2.2.1.1 12-1.1.2.2.1.1 13-1.1.2.1.r 14-1.1.2.1.1.1 16-1 20-1.2.1 20-1.2.1.r
# ::id bel_pmid_1129_7530_30812
(c / contrast-01~e.16
      :ARG1 (r / respond-01~e.5
            :ARG0 (p / protein
                  :name (n / name :op1 "MEF")
                  :mod (w / wild-type~e.1,3))
            :ARG1~e.6 (i / induce-01~e.8
                  :ARG0~e.13 (p2 / protein
                        :name (n3 / name :op1 "TNF"~e.14))
                  :ARG1~e.9 (e / enzyme
                        :name (n2 / name :op1 "MMP-13"~e.10,12))))
      :ARG2 (r2 / respond-01~e.5
            :polarity~e.20 "-"~e.20
            :ARG0 (h / heterozygote)
            :ARG1 i))

# ::tok Although the growth factors epidermal growth factor ( EGF ) and neuregulin ( NRG ) 1 similarly stimulated Erk1 @/@ 2 in MDA @-@ MB @-@ 361 cells , EGF acting through an EGF receptor @/@ ErbB2 heterodimer preferentially stimulated protein kinase C , and NRG1 beta acting through an ErbB2 @/@ ErbB3 heterodimer preferentially stimulated Akt .
# ::alignments 0-1 4-1.2.1.2.1.1.1 5-1.2.1.1.1 5-1.2.1.2.1.1.2 6-1.2.1.1.2 6-1.2.1.2.1.1.3 8-1.1.1.1.1.1 10-1.1 11-1.2.1.2.2.1.1 15-1.2.1.2.2.1.2 16-1.2.3 17-1.2 18-1.2.2.1.1 20-1.2.2.1.1 21-1.2.4.r 22-1.2.4.1.1 24-1.2.4.1.1 26-1.2.4.1.1 27-1.2.4 29-1.1.1.1.1.1 30-1.1.1.1.2 33-1.1.1.1.2.1.1.1.1 34-1.1.1.1.2.1.1 36-1.1.1.1.2.1.2.1.1 37-1.1.1.1.2.1 38-1.1.1.3 39-1.1.1 39-1.1.2 40-1.1.1.2.1.1 41-1.1.1.2.1.2 42-1.1.1.2.1.3 47-1.1.1.1.2 47-1.1.2.1.2 50-1.1.2.1.2.1.3 52-1.1.2.1.2.1.2.1.1 53-1.1.2.1.2.1.1.1 54-1.1.1.3 55-1.1.1 56-1.1.2.2.1.1
# ::id bel_pmid_1129_7548_19988
(h / have-concession-91~e.0
      :ARG1 (a2 / and~e.10
            :op1 (s2 / stimulate-01~e.39,55
                  :ARG0 (p3 / protein
                        :name (n5 / name :op1 "EGF"~e.8,29)
                        :ARG0-of (a3 / act-01~e.30,47
                              :instrument (h2 / heterodimer~e.37
                                    :part (r2 / receptor~e.34
                                          :name (n6 / name :op1 "EGF"~e.33))
                                    :part (p4 / protein
                                          :name (n7 / name :op1 "ErbB2"~e.36)))))
                  :ARG1 (e2 / enzyme
                        :name (n8 / name
                              :op1 "protein"~e.40
                              :op2 "kinase"~e.41
                              :op3 "C"~e.42))
                  :ARG1-of (p5 / prefer-01~e.38,54))
            :op2 (s3 / stimulate-01~e.39
                  :ARG0 (p6 / protein
                        :name (n9 / name :op1 "NRG1beta")
                        :ARG0-of (a4 / act-01~e.47
                              :instrument (m / macro-molecular-complex
                                    :name (n13 / name :op1 "heterodimer"~e.53)
                                    :part (p8 / protein
                                          :name (n11 / name :op1 "ErbB3"~e.52))
                                    :part p4~e.50)))
                  :ARG1 (e3 / enzyme
                        :name (n14 / name :op1 "Akt"~e.56))
                  :ARG1-of p5))
      :ARG2 (s / stimulate-01~e.17
            :ARG0 (p9 / protein
                  :name (n12 / name :op1 "growth"~e.5 :op2 "factor"~e.6)
                  :example (a / and
                        :op1 (p / protein
                              :name (n / name
                                    :op1 "epidermal"~e.4
                                    :op2 "growth"~e.5
                                    :op3 "factor"~e.6))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "neuregulin"~e.11 :op2 "1"~e.15))))
            :ARG1 (e / enzyme
                  :name (n3 / name :op1 "Erk1/2"~e.18,20))
            :manner (r / resemble-01~e.16)
            :location~e.21 (c / cell~e.27
                  :name (n4 / name :op1 "MDA-MB-361"~e.22,24,26))))

# ::tok In MDA @-@ MB @-@ 453 cells , NRG1 beta acting through an ErbB2 @/@ ErbB3 heterodimer stimulated prolonged signaling of all pathways examined relative to NRG2 beta acting through the same heterodimeric receptor species . Surprisingly , NRG1 beta and NRG2 beta also regulated partially overlapping but distinct sets of genes in these cells .
# ::alignments 1-1.1.4.1.1 3-1.1.4.1.1 5-1.1.4.1.1 6-1.1.4 10-1.1.1.2 13-1.1.1.2.1.1.1.1 15-1.1.1.2.1.2.1.1 16-1.1.1.2.1 16-1.1.3.1.2.1.1.2 17-1.1 18-1.1.2.2 19-1.1.2 20-1.1.2.1.r 21-1.1.2.1.1 22-1.1.2.1 23-1.1.2.1.2 24-1.1.3 28-1.1.3.1.2 31-1.1.3.1.2.1.1.1 33-1.1.3.1.2.1.1 34-1.1.3.1.2.1 36-1.2.4 40-1.2.1 43-1.2.5 44-1.2 45-1.2.2.2.1 46-1.2.2.2 47-1.2.2.2.2 48-1.2.2.2.2.1 49-1.2.2 50-1.2.2.1.r 51-1.2.2.1 52-1.2.3.r 53-1.2.3.1 54-1.2.3
# ::id bel_pmid_1129_7548_24054
(m / multi-sentence
      :snt1 (s / stimulate-01~e.17
            :ARG0 (p / protein
                  :name (n / name :op1 "NRG1beta")
                  :ARG0-of (a / act-01~e.10
                        :instrument (h / heterodimer~e.16
                              :part (p2 / protein
                                    :name (n3 / name :op1 "ErbB2"~e.13))
                              :part (p3 / protein
                                    :name (n4 / name :op1 "ErbB3"~e.15)))))
            :ARG1 (s2 / signal-01~e.19
                  :ARG0~e.20 (p5 / pathway~e.22
                        :mod (a2 / all~e.21)
                        :ARG1-of (e / examine-01~e.23))
                  :ARG1-of (p4 / prolong-01~e.18))
            :ARG1-of (r / relative-05~e.24
                  :ARG3 (p6 / protein
                        :name (n5 / name :op1 "NRG2beta")
                        :ARG0-of (a3 / act-01~e.28
                              :instrument (s3 / specie~e.34
                                    :mod (r2 / receptor~e.33
                                          :ARG1-of (s5 / same-01~e.31)
                                          :mod (h2 / heterodimer~e.16))))))
            :location (c / cell~e.6
                  :name (n7 / name :op1 "MDA-MB-453"~e.1,3,5)))
      :snt2 (r3 / regulate-01~e.44
            :ARG0 (a4 / and~e.40
                  :op1 (p7 / protein
                        :name (n8 / name :op1 "NRG1beta"))
                  :op2 (p8 / protein
                        :name (n9 / name :op1 "NRG2beta")))
            :ARG1 (s4 / set~e.49
                  :mod~e.50 (g / gene~e.51)
                  :ARG0-of (o / overlap-01~e.46
                        :degree (p9 / partial~e.45)
                        :ARG1-of (c3 / contrast-01~e.47
                              :ARG2 (d / distinct~e.48
                                    :domain s4))))
            :location~e.52 (c2 / cell~e.54
                  :mod (t / this~e.53))
            :ARG0-of (s6 / surprise-01~e.36)
            :mod (a5 / also~e.43)))

# ::tok As expected , EGF preferentially stimulated the recruitment of the adaptor protein Grb2 to EGF receptor whereas NRG1 beta preferentially stimulated the recruitment of this protein to ErbB3. NRG1 beta also preferentially stimulated the association of p85 , the 85 @-@ kDa subunit of PI3K , with ErbB3 , as demonstrated previously ( 40 ) .
# ::alignments 0-1.2.5.1.r 1-1.1.3 3-1.1.1.1.1.1 4-1.1.1.3 5-1.1.1 7-1.1.1.2 8-1.1.1.2.1.r 10-1.1.1.2.1.2 11-1.1.1.1 11-1.1.1.2.1 12-1.1.1.2.1.1.1 13-1.1.1.2.2.r 14-1.1.1.2.2.1.1 15-1.1.1.2.2 16-1.1 19-1.1.2.3 20-1.1.2 22-1.1.2.2 25-1.1.2.1 25-1.1.2.2.2 25-1.2.1 25-1.2.2.1 25-1.2.2.1.2.1 25-1.2.2.1.2.1.2 25-1.2.2.1.2.1.2.r 25-1.2.2.2 30-1.2.3 31-1.2.4 32-1.2 34-1.2.2 36-1.2.2.1.1.1 39-1.2.2.1.2.1.1.1 41-1.2.2.1.2.1.1.1 44-1.2.2.1.2.1.2.1.1 47-1.1.2.2.2.1.1 47-1.2.2.2.1.1 49-1.2.5.1.r 50-1.2.5 51-1.2.5.1 53-1.2.6.1.1.1
# ::id bel_pmid_1129_7548_24056
(m / multi-sentence
      :snt1 (c / contrast-01~e.16
            :ARG1 (s / stimulate-01~e.5
                  :ARG0 (p / protein~e.11
                        :name (n / name :op1 "EGF"~e.3))
                  :ARG1 (r / recruit-01~e.7
                        :ARG1~e.8 (p4 / protein~e.11
                              :name (n2 / name :op1 "Grb2"~e.12)
                              :mod (a / adaptor~e.10))
                        :ARG2~e.13 (r2 / receptor~e.15
                              :name (n3 / name :op1 "EGF"~e.14)))
                  :ARG1-of (p2 / prefer-01~e.4))
            :ARG2 (s2 / stimulate-01~e.20
                  :ARG0 (p3 / protein~e.25
                        :name (n4 / name :op1 "NRG1beta"))
                  :ARG1 (r3 / recruit-01~e.22
                        :ARG1 p4
                        :ARG2 (p5 / protein~e.25
                              :name (n5 / name :op1 "ErbB3"~e.47)))
                  :ARG1-of p2~e.19)
            :ARG1-of (e / expect-01~e.1))
      :snt2 (s3 / stimulate-01~e.32
            :ARG0 (p7 / protein~e.25
                  :name (n6 / name :op1 "NRG1beta"))
            :ARG1 (a3 / associate-01~e.34
                  :ARG1 (p8 / protein~e.25
                        :name (n7 / name :op1 "p85"~e.36)
                        :ARG1-of (m2 / mean-01
                              :ARG2 (p9 / protein-segment~e.25
                                    :name (n8 / name :op1 "85-kDa"~e.39,41)
                                    :part-of~e.25 (p10 / protein~e.25
                                          :name (n9 / name :op1 "PI3K"~e.44)))))
                  :ARG2 (p11 / protein~e.25
                        :name (n10 / name :op1 "ErbB3"~e.47)))
            :mod (a2 / also~e.30)
            :ARG1-of (p6 / prefer-01~e.31)
            :ARG1-of (d / demonstrate-01~e.50
                  :time~e.0,49 (p12 / previous~e.51))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p13 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "40"~e.53)))))

# ::tok Although the growth factors epidermal growth factor ( EGF ) and neuregulin ( NRG ) 1 similarly stimulated Erk1 @/@ 2 in MDA @-@ MB @-@ 361 cells , EGF acting through an EGF receptor @/@ ErbB2 heterodimer preferentially stimulated protein kinase C , and NRG1 beta acting through an ErbB2 @/@ ErbB3 heterodimer preferentially stimulated Akt .
# ::alignments 0-1 4-1.2.1.2.1.1.1 5-1.2.1.1.1 5-1.2.1.2.1.1.2 6-1.2.1.1.2 6-1.2.1.2.1.1.3 8-1.1.1.1.1.1 10-1.1 11-1.2.1.2.2.1.1 15-1.2.1.2.2.1.2 16-1.2.3 17-1.2 18-1.2.2.1.1 20-1.2.2.1.1 21-1.2.4.r 22-1.2.4.1.1 24-1.2.4.1.1 26-1.2.4.1.1 27-1.2.4 29-1.1.1.1.1.1 30-1.1.1.1.2 33-1.1.1.1.2.1.1.1.1 34-1.1.1.1.2.1.1 36-1.1.1.1.2.1.2.1.1 37-1.1.1.1.2.1 38-1.1.1.3 39-1.1.1 39-1.1.2 40-1.1.1.2.1.1 41-1.1.1.2.1.2 42-1.1.1.2.1.3 47-1.1.1.1.2 47-1.1.2.1.2 50-1.1.2.1.2.1.2 52-1.1.2.1.2.1.1.1.1 53-1.1.2.1.2.1 54-1.1.1.3 55-1.1.1 56-1.1.2.2.1.1
# ::id bel_pmid_1129_7548_38074
(h / have-concession-91~e.0
      :ARG1 (a / and~e.10
            :op1 (s / stimulate-01~e.39,55
                  :ARG0 (p / protein
                        :name (n / name :op1 "EGF"~e.8,29)
                        :ARG0-of (a2 / act-01~e.30,47
                              :instrument (h2 / heterodimer~e.37
                                    :part (r / receptor~e.34
                                          :name (n3 / name :op1 "EGF"~e.33))
                                    :part (p2 / protein
                                          :name (n4 / name :op1 "ErbB2"~e.36)))))
                  :ARG1 (e / enzyme
                        :name (n5 / name
                              :op1 "protein"~e.40
                              :op2 "kinase"~e.41
                              :op3 "C"~e.42))
                  :ARG1-of (p3 / prefer-01~e.38,54))
            :op2 (s2 / stimulate-01~e.39
                  :ARG0 (p4 / protein
                        :name (n6 / name :op1 "NRG1beta")
                        :ARG0-of (a3 / act-01~e.47
                              :instrument (h3 / heterodimer~e.53
                                    :part (p6 / protein
                                          :name (n9 / name :op1 "ErbB3"~e.52))
                                    :part p2~e.50)))
                  :ARG1 (e2 / enzyme
                        :name (n10 / name :op1 "Akt"~e.56))
                  :ARG1-of p3))
      :ARG2 (s3 / stimulate-01~e.17
            :ARG0 (p5 / protein
                  :name (n2 / name :op1 "growth"~e.5 :op2 "factor"~e.6)
                  :example (a4 / and
                        :op1 (p8 / protein
                              :name (n11 / name
                                    :op1 "epidermal"~e.4
                                    :op2 "growth"~e.5
                                    :op3 "factor"~e.6))
                        :op2 (p9 / protein
                              :name (n12 / name :op1 "neuregulin"~e.11 :op2 "1"~e.15))))
            :ARG1 (e3 / enzyme
                  :name (n13 / name :op1 "Erk1/2"~e.18,20))
            :manner (r2 / resemble-01~e.16)
            :location~e.21 (c / cell~e.27
                  :name (n14 / name :op1 "MDA-MB-361"~e.22,24,26))))

# ::tok We find that Cdk10 binds full length Ets2 in vitro and in vivo and inhibits Ets2 transactivation in mammalian cells .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1.1 4-1.2.1 5-1.2.1.2.2 6-1.2.1.2 7-1.2.1.2.1.1.1 8-1.2.1.3.1 9-1.2.1.3.1 10-1.2.1.3 11-1.2.1.3.1 11-1.2.1.3.2 12-1.2.1.3.2 13-1.2 13-1.2.1.3 14-1.2.2 15-1.2.2.2.1 16-1.2.2.2 17-1.2.1.3.1 19-1.2.2.2.2
# ::id bel_pmid_1131_3931_5286
(f3 / find-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (a3 / and~e.13
            :op1 (b / bind-01~e.4
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "Cdk10"~e.3))
                  :ARG1 (l / length~e.6
                        :poss (p / protein
                              :name (n2 / name :op1 "Ets2"~e.7))
                        :degree (f2 / full~e.5))
                  :manner (a2 / and~e.10,13
                        :op1 (i / in-vitro~e.8,9,11,17)
                        :op2 (i2 / in-vivo~e.11,12)))
            :op2 (i3 / inhibit-01~e.14
                  :ARG0 e
                  :ARG1 (t / transactivate-00~e.16
                        :ARG1 p~e.15
                        :location (c / cell~e.19
                              :mod (m / mammal))))))

# ::tok Consistently , substrate @-@ trapping experiments with a SHP2 catalytic inactive mutant suggested that Gab1 was a SHP2 PTPase substrate in the cells . Therefore , Gab1 not only is a SHP2 activator but also is a target of its PTPase .
# ::alignments 0-1.1.3 0-1.1.3.r 2-1.1.1.1.1 4-1.1.1.1.1.1 5-1.1.1.1 8-1.1.1.1.1.1.1.1.1 8-1.2.1.1.2.1.1 9-1.1.1.1.1.1.1.3.2 10-1.1.1.1.1.1.1.3.1 11-1.1.1.1.1.1.1 11-1.1.1.1.1.1.1.2 11-1.1.1.1.1.1.1.2.r 12-1.1 13-1.1.2.r 14-1.1.2.1.1.1 15-1.1.2.1.r 17-1.1.2.2.1.1 18-1.1.2.2.1.2 19-1.1.2 20-1.1.2.3.r 22-1.1.2.3 24-1.2 26-1.1.2.1.1.1 26-1.2.1.1.1.1.1 27-1.1.1.1.1.1.1.3.1 27-1.1.1.1.1.1.1.3.1.r 29-1.1.2.1.r 31-1.1.1.1.1.1.1.1.1 32-1.1.1.1.1.1.1.3 32-1.2.1.1 35-1.1.2.1.r 37-1.2.1.2 38-1.2.1.2.2.r 39-1.2.1.2.2 40-1.2.1.2.1.1.1
# ::id bel_pmid_1132_3411_1008
(m / multi-sentence
      :snt1 (s / suggest-01~e.12
            :ARG0 (a / and
                  :op1 (e / experiment-01~e.5
                        :ARG1 (s2 / substrate~e.2
                              :ARG1-of (t / trap-01~e.4
                                    :ARG0 (e2 / enzyme~e.11
                                          :name (n / name :op1 "SHP2"~e.8,31)
                                          :ARG2-of~e.11 (m2 / mutate-01~e.11)
                                          :ARG1-of (a2 / activate-01~e.32
                                                :polarity~e.27 "-"~e.10,27
                                                :mod (c / catalysis~e.9)))))))
            :ARG1~e.13 (s3 / substrate~e.19
                  :domain~e.15,29,35 (p / protein
                        :name (n2 / name :op1 "Gab1"~e.14,26))
                  :mod (e3 / enzyme
                        :name (n3 / name :op1 "SHP2"~e.17 :op2 "PTPase"~e.18))
                  :location~e.20 (c2 / cell~e.22))
            :manner~e.0 (c4 / consistent~e.0))
      :snt2 (c3 / cause-01~e.24
            :ARG1 (a3 / and
                  :op1 (a4 / activate-01~e.32
                        :ARG0 (p2 / protein
                              :name (n5 / name :op1 "Gab1"~e.26))
                        :ARG1 (e4 / enzyme
                              :name (n4 / name :op1 "SHP2"~e.8)))
                  :op2 (t2 / target-01~e.37
                        :ARG0 (e5 / enzyme
                              :name (n6 / name :op1 "PTPase"~e.40)
                              :part-of e4)
                        :ARG1~e.38 p2~e.39))))

# ::tok We found that both Tyr @-@ 627 and Tyr @-@ 659 of Gab1 were required for SHP2 binding to Gab1 and for ERK2 activation by EGF .
# ::alignments 0-1.1 1-1 6-1.2.2.1.1 10-1.2.2.2.1 12-1.2.2.2.3 14-1.2 15-1.2.1.r 16-1.2.1.1.1.1.1 17-1.2.1.1 18-1.2.1.1.2.r 19-1.2.1.1.2.1.1 20-1.2.1 22-1.2.1.2.2.1.1 23-1.2.1.2 24-1.2.1.2.1.r 25-1.2.1.2.1.1.1
# ::id bel_pmid_1132_3411_6960
(f / find-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (r / require-01~e.14
            :ARG0~e.15 (a4 / and~e.20
                  :op1 (b / bind-01~e.17
                        :ARG1 (e / enzyme
                              :name (n4 / name :op1 "SHP2"~e.16))
                        :ARG2~e.18 (p2 / protein
                              :name (n5 / name :op1 "Gab1"~e.19)))
                  :op2 (a5 / activate-01~e.23
                        :ARG0~e.24 (p3 / protein
                              :name (n6 / name :op1 "EGF"~e.25))
                        :ARG1 (p4 / protein
                              :name (n7 / name :op1 "ERK2"~e.22))))
            :ARG1 (a / and
                  :op1 (a2 / amino-acid
                        :mod "627"~e.6
                        :name (n / name :op1 "tyrosine")
                        :part-of p2)
                  :op2 (a3 / amino-acid
                        :mod "659"~e.10
                        :name (n3 / name :op1 "tyrosine")
                        :part-of p2~e.12))))

# ::tok We demonstrated that lung myofibroblasts , incubated in the presence of E2 , showed a rapid phosphorylation on serine @-@ 259 of Raf1 and tyrosine @-@ 204 of ERK1 @/@ 2 MAP kinase at 15 min , by approximately 3 @- and 5 @-@ fold , respectively
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1 6-1.2.1.2 9-1.2.1.2.1.1 10-1.2.1.2.1.1.1.r 11-1.2.1.2.1.1.1.1.1 13-1.2 16-1.2.2.1 16-1.2.2.2 17-1.2.2.1.1.r 18-1.2.2.1.1.2.1 20-1.2.2.1.1.1 21-1.2.2.1.2.r 21-1.2.2.1.4.1 22-1.2.2.1.2.1.1 23-1.2.2 24-1.2.2.2.1.2.1 26-1.2.2.2.1.1 27-1.2.2.2.2.r 27-1.2.2.2.3.1 28-1.2.2.2.2.1.1 30-1.2.2.2.2.1.1 31-1.2.2.2.2.1.2 32-1.2.2.2.2.1.3 33-1.2.2.r 34-1.2.2.3.1 38-1.2.2.1.4 38-1.2.2.2.3 39-1.2.2.1.4.1.1 41-1.2.2 42-1.2.2.2.3.1.1 46-1.2.2.4
# ::id bel_pmid_1134_1776_3378
(d / demonstrate-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (s / show-01~e.13
            :ARG0 (m2 / myofibroblast
                  :mod (l / lung~e.3)
                  :ARG1-of (i / incubate-01~e.6
                        :ARG1-of (h / have-condition-91
                              :ARG2 (p / present~e.9
                                    :domain~e.10 (e / enzyme
                                          :name (n3 / name :op1 "E2"~e.11))))))
            :ARG1~e.33 (a / and~e.23,41
                  :op1 (p2 / phosphorylate-01~e.16
                        :ARG0~e.17 (a2 / amino-acid
                              :mod "259"~e.20
                              :name (n4 / name :op1 "serine"~e.18))
                        :ARG1~e.21 (e2 / enzyme
                              :name (n5 / name :op1 "Raf1"~e.22))
                        :mod (r2 / rapide)
                        :quant (a4 / approximately~e.38
                              :op1 (p4 / product-of~e.21 :op1 "3"~e.39)))
                  :op2 (p3 / phosphorylate-01~e.16
                        :ARG0 (a3 / amino-acid
                              :mod "204"~e.26
                              :name (n6 / name :op1 "tyrosine"~e.24))
                        :ARG1~e.27 (e3 / enzyme
                              :name (n7 / name
                                    :op1 "ERK1/2"~e.28,30
                                    :op2 "MAP"~e.31
                                    :op3 "kinase"~e.32))
                        :quant (a5 / approximately~e.38
                              :op1 (p5 / product-of~e.27 :op1 "5"~e.42)))
                  :duration (t / temporal-quantity
                        :quant "15"~e.34
                        :unit (m / minute))
                  :mod (r / respective~e.46))))

# ::tok since in PKR @-@ null MEFs there is a marked defect in Erk1 and Erk2 activation by PDGF ( Figure1D ) , it appears that PKR is involved in serine phosphorylation of Stat3 through the activation of Erks .
# ::alignments 0-1.2 1-1.2.1.1.r 2-1.2.1.4.2.1.1.1 9-1.2.1.2 10-1.2.1 11-1.2.1.1.r 12-1.2.1.1.2.1.1.1 13-1.2.1.1.2 14-1.2.1.1.2.2.1.1 15-1.2.1.1 16-1.2.1.1.1.r 17-1.2.1.1.1.1.1 23-1 25-1.1.1.1.1 25-1.2.1.4.2.1.1.1 27-1.1 28-1.1.2.r 28-1.2.1.1.r 29-1.1.2.1.1.1 30-1.1.2 32-1.1.2.1.2.1.1 35-1.1.2.2
# ::id bel_pmid_1135_0938_21662
(a / appear-02~e.23
      :ARG1 (i / involve-01~e.27
            :ARG0 (e / enzyme
                  :name (n / name :op1 "PKR"~e.25))
            :ARG2~e.28 (p / phosphorylate-01~e.30
                  :ARG1 (a3 / amino-acid
                        :name (n4 / name :op1 "serine"~e.29)
                        :part-of (p2 / protein
                              :name (n2 / name :op1 "Stat3"~e.32)))
                  :ARG2 (a2 / activate-01~e.35
                        :ARG1 (e2 / enzyme
                              :name (n3 / name :op1 "Erk")))))
      :ARG1-of (c / cause-01~e.0
            :ARG0 (d / defect~e.10
                  :prep-in~e.1,11,28 (a4 / activate-01~e.15
                        :ARG0~e.16 (p3 / protein
                              :name (n5 / name :op1 "PDGF"~e.17))
                        :ARG1 (a5 / and~e.13
                              :op1 (e3 / enzyme
                                    :name (n6 / name :op1 "Erk1"~e.12))
                              :op2 (e4 / enzyme
                                    :name (n7 / name :op1 "Erk2"~e.14))))
                  :mod (m2 / marked~e.9)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f2 / figure :mod "1D"))
                  :location (m3 / molecular-physical-entity
                        :name (n8 / name :op1 "MEF")
                        :ARG3-of (e6 / express-03
                              :ARG2 (e5 / enzyme
                                    :name (n9 / name :op1 "PKR"~e.2,25)
                                    :ARG2-of (m / mutate-01 :mod "-/-")))))))

# ::tok Whereas PKR+/+ cells exhibited a clear induction in phospho @-@ Ser727 Stat3 , PKR @-@ null cells were defective in this process ( Figure1B )
# ::alignments 0-1 2-1.1.2 2-1.2.1 3-1.1 3-1.2 5-1.2.2.2 6-1.1.3 6-1.2.2 11-1.2.2.1.1.3.1.1 13-1.1.2.1.1.1.1 13-1.2.1.1.1.1.1 16-1.1.2
# ::id bel_pmid_1135_0938_21664
(c / contrast-01~e.0
      :ARG1 (e3 / exhibit-01~e.3
            :polarity "-"
            :ARG0 (c4 / cell~e.2,16
                  :ARG3-of (e5 / express-03
                        :ARG2 (e4 / enzyme
                              :name (n4 / name :op1 "PKR"~e.13)
                              :ARG2-of (m / mutate-01 :mod "-/-"))))
            :ARG1 (i2 / induce-01~e.6
                  :ARG1 (p3 / phosphorylate-01
                        :ARG1 (a / amino-acid
                              :mod "727"
                              :name (n2 / name :op1 "serine")
                              :part-of (p2 / protein
                                    :name (n3 / name :op1 "Stat3"~e.11))))))
      :ARG2 (e / exhibit-01~e.3
            :ARG0 (c2 / cell~e.2
                  :ARG3-of (e6 / express-03
                        :ARG2 (e2 / enzyme
                              :name (n / name :op1 "PKR"~e.13)
                              :mod (w / wild-type))))
            :ARG1 (i / induce-01~e.6
                  :ARG1 (p / phosphorylate-01
                        :ARG1 a)
                  :mod (c3 / clear~e.5)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "1B")))

# ::tok Accordingly , nuclear extracts prepared from PDGF @-@ treated PKR @- null cells were severely deficient in Stat3 containing DNA @-@ binding complexes compared with wild @-@ type MEFs ( data not shown ) . Taken together , we conclude that PDGF @-@ induced activation of Stat3 DNA binding is PKR dependent .
# ::alignments 0-1.1.5 2-1.1.1.1 3-1.1.1 4-1.1.1.2 5-1.1.1.2.1.r 6-1.1.1.2.1.1.1.1.1 8-1.1.1.2.1.1 9-1.1.1.2.1.2.1.1.1 12-1.1.1.2.1 14-1.1.4 17-1.1.2.2.1.1.1 18-1.1.2.2 19-1.1.2.1.1 21-1.1.2.1 22-1.1.2 23-1.1.6.r 25-1.1.6.2 27-1.1.6.2 31-1.1.3.1 31-1.1.3.1.r 32-1.1.3 35-1.2.3 36-1.2.3.1 38-1.2.1 39-1.2 40-1.2.2.r 41-1.2.2.1.1.1.1 44-1.2.2.1 45-1.2.2.1.2.r 46-1.2.2.1.2.1.1.1.1 47-1.2.2.1.2.1 48-1.2.2.1.2 50-1.2.2.2.1.1 51-1.2.2
# ::id bel_pmid_1135_0938_21666
(m / multi-sentence
      :snt1 (l / lack-01
            :ARG0 (e / extract~e.3
                  :mod (n / nucleus~e.2)
                  :ARG1-of (p / prepare-01~e.4
                        :ARG2~e.5 (c / cell~e.12
                              :ARG1-of (t / treat-04~e.8
                                    :ARG2 (p2 / protein
                                          :name (n2 / name :op1 "PDGF"~e.6)))
                              :ARG2-of (e5 / express-03
                                    :ARG1 (e2 / enzyme
                                          :name (n3 / name :op1 "PKR"~e.9)
                                          :ARG2-of (m4 / mutate-01 :mod "-/-"))))))
            :ARG1 (m3 / macro-molecular-complex~e.22
                  :ARG0-of (b / bind-01~e.21
                        :ARG1 (d / dna~e.19))
                  :ARG0-of (c3 / contain-01~e.18
                        :ARG1 (p3 / protein
                              :name (n4 / name :op1 "Stat3"~e.17))))
            :ARG1-of (s / show-01~e.32 :polarity~e.31 "-"~e.31)
            :degree (s2 / severe~e.14)
            :manner (a2 / accordingly~e.0)
            :compared-to~e.23 (m5 / molecular-physical-entity
                  :name (n8 / name :op1 "MEF")
                  :mod (w2 / wild-type~e.25,27)))
      :snt2 (c4 / conclude-01~e.39
            :ARG0 (w / we~e.38)
            :ARG1~e.40 (d2 / depend-01~e.51
                  :ARG0 (a / activate-01~e.44
                        :ARG0 (p4 / protein
                              :name (n6 / name :op1 "PDGF"~e.41))
                        :ARG1~e.45 (b2 / bind-01~e.48
                              :ARG1 (d3 / dna~e.47
                                    :mod (p5 / protein
                                          :name (n7 / name :op1 "Stat3"~e.46)))))
                  :ARG1 (e3 / enzyme
                        :name (n5 / name :op1 "PKR"~e.50)))
            :ARG1-of (t2 / take-01~e.35
                  :mod (t3 / together~e.36))))

# ::tok PDGF treatment induced two Tyr705 @-@ phosphorylated forms of Stat3 in PKR+/+ cells , a faster migrating species termed Stat3 fm and a slower migrating species termed Stat3 sm ( Figure1A ) .....Importantly , PDGF treatment did not induce either form of tyrosine @-@ phosphorylated Stat3 in PKR @-@ null cells ( Figure1A ) , implicating a requirement for PKR in both tyrosine and serine phosphorylation of Stat3 .
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 2-1.1 2-1.2 6-1.1.2.1.4.3 6-1.2.3.1.2.2 7-1.2.3 9-1.1.2.1.1.1 9-1.2.3.1.1.1 12-1.1.3 12-1.2.4 15-1.1.2.1.2.1 15-1.1.2.1.2.1.1 15-1.1.2.1.2.1.1.r 16-1.1.2.1.2 18-1.1.2.1.3 18-1.1.2.2.3 19-1.1.2.1.1.1 19-1.1.2.2.1.1 21-1.1.2 23-1.1.2.2.2.1 24-1.1.2.2.2 26-1.1.2.1.3 26-1.1.2.2.3 27-1.2.3.1.1.1 34-1.1.1.1.1.1 34-1.2.2.1.1.1 35-1.2.2 37-1.2.1 37-1.2.1.r 38-1.2 39-1.2.3.2 40-1.2.3 42-1.2.3.1.2.1.1 44-1.2.3.1.2.2 45-1.2.3.1.1.1 47-1.2.4.1.1.1.1 50-1.2.4 57-1.2.6.1 59-1.1.3.1.1.1.1 59-1.2.4.1.1.1.1 62-1.1.2.1.4.2.1 62-1.2.3.1.2.1.1 62-1.2.6.1.1.1.1.1.1 63-1.2.6.1.1.1 64-1.2.6.1.1.1.2.1.1 65-1.2.6.1.1 66-1.2.6.1.1.1.r 67-1.2.6.1.1.1.1.2.1.1
# ::id bel_pmid_1135_0938_26648
(m2 / multi-sentence
      :snt1 (i / induce-01~e.2
            :ARG0 (t / treat-04~e.1
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "PDGF"~e.0,34)))
            :ARG1 (a2 / and~e.21
                  :op1 (p4 / protein
                        :name (n5 / name :op1 "Stat3"~e.9,19)
                        :ARG0-of (m3 / migrate-01~e.16
                              :mod (f2 / fast~e.15
                                    :degree~e.15 (m4 / more~e.15)))
                        :ARG1-of (t2 / term-01~e.18,26
                              :ARG3 (s2 / Stat3fm))
                        :part (a3 / amino-acid
                              :mod "705"
                              :name (n4 / name :op1 "tyrosine"~e.62)
                              :ARG1-of (p3 / phosphorylate-01~e.6)))
                  :op2 (p5 / protein
                        :name (n6 / name :op1 "Stat3"~e.19)
                        :ARG0-of (m5 / migrate-01~e.24
                              :mod (s3 / slow~e.23
                                    :degree (l / less)))
                        :ARG1-of (t3 / term-01~e.18,26
                              :ARG3 (s / Stat3sm))
                        :part a3))
            :location (c / cell~e.12
                  :ARG2-of (e4 / express-03
                        :ARG1 (e / enzyme
                              :name (n3 / name :op1 "PKR"~e.59)
                              :mod (w / wild-type))))
            :ARG1-of (d / describe-01
                  :ARG0 (f3 / figure :mod "1A")))
      :snt2 (i2 / induce-01~e.2,38
            :polarity~e.37 "-"~e.37
            :ARG0 (t4 / treat-04~e.35
                  :ARG1 (p6 / protein
                        :name (n7 / name :op1 "PDGF"~e.34)))
            :ARG1 (f / form~e.7,40
                  :mod (p7 / protein
                        :name (n8 / name :op1 "Stat3"~e.9,27,45)
                        :part (a4 / amino-acid
                              :name (n9 / name :op1 "tyrosine"~e.42,62)
                              :ARG1-of (p8 / phosphorylate-01~e.6,44)))
                  :mod (e2 / either~e.39))
            :location (c2 / cell~e.12,50
                  :ARG2-of (e5 / express-03
                        :ARG1 (e3 / enzyme
                              :name (n10 / name :op1 "PKR"~e.47,59)
                              :ARG2-of (m / mutate-01 :mod "-/-"))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f4 / figure :mod "1A"))
            :ARG0-of (i3 / imply-01
                  :ARG1 (r / require-01~e.57
                        :ARG0 (p9 / phosphorylate-01~e.65
                              :ARG1~e.66 (a / and~e.63
                                    :op1 (a5 / amino-acid
                                          :name (n11 / name :op1 "tyrosine"~e.62)
                                          :part-of (p10 / protein
                                                :name (n13 / name :op1 "Stat3"~e.67)))
                                    :op2 (a6 / amino-acid
                                          :name (n12 / name :op1 "serine"~e.64)
                                          :part-of p10)))
                        :ARG1 e3))
            :mod (i4 / important)))

# ::tok The results ( Figure4A and B ) showed a 16 @-@ fold induction in PKR wild @-@ type cells in contrast to a 0.8 @-@ fold induction in c @-@ fos message in PKR @-@ null cells at 15 min of PDGF treatment
# ::alignments 1-1.1 1-1.1.1 1-1.1.1.r 4-1.1.1.1.1 7-1 9-1.2.1.2.1 12-1.2.1 13-1.2.1.1.r 14-1.2.1.1.1.1.1.1 15-1.2.1.1.1.1.2 17-1.2.1.1.1.1.2 18-1.2.1.1 18-1.2.2.2 20-1.2 21-1.2.2.r 23-1.2.2.3.1 26-1.2.2 28-1.2.2.1.1.1.1 30-1.2.2.1.1.1.1 33-1.2.1.1.1.1.1.1 33-1.2.2.2.1.1.1.1 36-1.2.1.1 38-1.2.3.2.1 41-1.2.3.1.1.1.1 42-1.2.3.1
# ::id bel_pmid_1135_0938_26650
(s / show-01~e.7
      :ARG0 (t / thing~e.1
            :ARG1-of~e.1 (r / result-01~e.1
                  :ARG1-of (d / describe-01
                        :ARG0 (a2 / and~e.4
                              :op1 (f / figure :mod "4A")
                              :op2 (f2 / figure :mod "4B")))))
      :ARG1 (c / contrast-01~e.20
            :ARG1 (i / induce-01~e.12
                  :location~e.13 (c2 / cell~e.18,36
                        :ARG3-of (e5 / express-03
                              :ARG2 (e / enzyme
                                    :name (n / name :op1 "PKR"~e.14,33)
                                    :mod (w / wild-type~e.15,17))))
                  :mod (p2 / product-of :op1 "16"~e.9))
            :ARG2~e.21 (i2 / induce-01~e.26
                  :ARG1 (e4 / express-03
                        :ARG1 (g / gene
                              :name (n4 / name :op1 "c-fos"~e.28,30)))
                  :location (c3 / cell~e.18
                        :ARG2-of (e3 / express-03
                              :ARG1 (e2 / enzyme
                                    :name (n2 / name :op1 "PKR"~e.33)
                                    :ARG2-of (m4 / mutate-01 :mod "-/-"))))
                  :mod (p3 / product-of :op1 "0.8"~e.23))
            :time (a / after
                  :op1 (t2 / treat-04~e.42
                        :ARG2 (p / protein
                              :name (n3 / name :op1 "PDGF"~e.41)))
                  :quant (t3 / temporal-quantity
                        :quant "15"~e.38
                        :unit (m2 / minute)))))

# ::tok Immunoblotting with anti @-@ Stat3 as well as anti @-@ PKR anti bodies ( Figure2E ) showed an increase in interaction within 5 @-@ 15 min of treatment with the growth factor , followed by a decrease to below basal level at later time points .
# ::alignments 2-1.1.1.1.1 2-1.1.1.2.1 4-1.1.1.1.1.1.1.1 5-1.2.2.r 7-1.2.2.r 8-1.1.1.1.1 8-1.1.1.2.1 10-1.1.1.2.1.1.1.1 11-1.1.1.1.1 11-1.1.1.2.1 16-1 18-1.2 19-1.2.1.r 20-1.2.1 22-1.2.2.2.1.1 24-1.2.2.2.1.2 27-1.2.2.1 28-1.2.2.1.1.r 30-1.2.2.1.1.1.1 31-1.2.2.1.1.1.2 33-1.2.3 34-1.2.3.1.r 36-1.2.3.1 37-1.2.3.1.1.r 38-1.2.3.1.1 39-1.2.3.1.1.1.1 40-1.2.3.1.1.1 41-1.2.3.1.2.r 42-1.2.3.1.2 42-1.2.3.1.2.1 42-1.2.3.1.2.1.r 43-1.2.2.2
# ::id bel_pmid_1135_0938_29866
(s2 / show-01~e.16
      :ARG0 (i / immunoblot-00
            :ARG2 (a / and
                  :op1 (a2 / antibody
                        :ARG0-of (c / counter-01~e.2,8,11
                              :ARG1 (p / protein
                                    :name (n2 / name :op1 "Stat3"~e.4))))
                  :op2 (a3 / antibody
                        :ARG0-of (c2 / counter-01~e.2,8,11
                              :ARG1 (e / enzyme
                                    :name (n3 / name :op1 "PKR"~e.10)))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "2E")))
      :ARG1 (i2 / increase-01~e.18
            :ARG1~e.19 (i3 / interact-01~e.20)
            :time~e.5,7 (a4 / after
                  :op1 (t / treat-04~e.27
                        :ARG2~e.28 (s / small-molecule
                              :name (n / name :op1 "growth"~e.30 :op2 "factor"~e.31)))
                  :quant (t2 / temporal-quantity~e.43
                        :quant (b / between :op1 "5"~e.22 :op2 "15"~e.24)
                        :unit (m2 / minute)))
            :ARG2-of (f2 / follow-01~e.33
                  :ARG1~e.34 (d2 / decrease-01~e.36
                        :ARG4~e.37 (b3 / below~e.38
                              :op1 (l2 / level~e.40
                                    :mod (b2 / basal~e.39)))
                        :time~e.41 (l / late~e.42
                              :degree~e.42 (m / more~e.42))))))

# ::tok To examine the role of TrkA in NGF 's effects , we used K252a , which inhibits the tyrosine kinase activity of this receptor . Pretreatment of the cells with K252a ( 50 ng/mL ) inhibited the production of TNF @-@ a by NGF
# ::alignments 1-1.1.3 3-1.1.3.2 4-1.1.3.2.1.r 5-1.1.3.2.1.1.1 6-1.1.3.2.2.r 7-1.1.3.2.2.1.1.1.1 8-1.1.3.2.2 8-1.1.3.2.2.1 8-1.1.3.2.2.1.r 9-1.1.3.2.2 9-1.1.3.2.2.1 9-1.1.3.2.2.1.r 11-1.1.1 12-1.1 13-1.1.2.1.1 16-1.1.2 16-1.1.2.2 16-1.1.2.2.r 18-1.1.2.2.1.2.1.1 19-1.1.2.2.1.2 28-1.2.1.1 30-1.2.1.2.1.1 32-1.2.1.2.2.1 35-1.2 37-1.2.2 38-1.2.2.2.r 39-1.2.2.2.1.1 41-1.2.2.2.1.1 42-1.2.2.1.r 43-1.2.2.1.1.1
# ::id bel_pmid_1140_4390_22028
(m / multi-sentence
      :snt1 (u / use-01~e.12
            :ARG0 (w / we~e.11)
            :ARG1 (s / small-molecule~e.16
                  :name (n / name :op1 "K252a"~e.13)
                  :ARG0-of~e.16 (i / inhibit-01~e.16
                        :ARG1 (a / act-01
                              :ARG0 (p / protein
                                    :name (n2 / name :op1 "TrkA"~e.5))
                              :ARG1 (k / kinase~e.19
                                    :name (n4 / name :op1 "tyrosine"~e.18)))))
            :ARG2 (e / examine-01~e.1
                  :ARG0 w
                  :ARG1 (r / role~e.3
                        :poss~e.4 p
                        :prep-in~e.6 (t / thing~e.8,9
                              :ARG1-of~e.8,9 (e2 / effect-01~e.8,9
                                    :ARG0 (p2 / protein
                                          :name (n3 / name :op1 "NGF"~e.7)))))))
      :snt2 (i2 / inhibit-01~e.35
            :ARG0 (p6 / pretreat-00
                  :ARG1 (c / cell~e.28)
                  :ARG2 (s2 / small-molecule
                        :name (n5 / name :op1 "K252a"~e.30)
                        :quant (m2 / mass-quantity
                              :quant "50"~e.32
                              :unit (n8 / nanogram-per-milliliter))))
            :ARG1 (p3 / produce-01~e.37
                  :ARG0~e.42 (p4 / protein
                        :name (n6 / name :op1 "NGF"~e.43))
                  :ARG1~e.38 (p5 / protein
                        :name (n7 / name :op1 "TNF-a"~e.39,41)))))

# ::tok NGF activates Erk1 @/@ Erk2 and JNK but not p38MAPK in J774 cells... NGF also induced phosphorylation of JNK
# ::alignments 0-1.2.1.1.1 1-1.1.1 1-1.1.2 2-1.1.1.2.1.1.1 4-1.1.1.2.2.1.1 5-1.1.1.2 6-1.1.1.2.3.1.1 7-1.1 8-1.1.2.1 8-1.1.2.1.r 9-1.1.2.3.1.1 10-1.1.1.3.r 11-1.1.1.3.1.1 13-1.1.1.1.1.1 13-1.2.1.1.1 14-1.2.3 15-1.2 16-1.2.2 17-1.2.2.1.r 18-1.2.2.1.1.1
# ::id bel_pmid_1140_4390_29562
(m / multi-sentence
      :snt1 (c / contrast-01~e.7
            :ARG1 (a / activate-01~e.1
                  :ARG0 (p2 / protein
                        :name (n / name :op1 "NGF"~e.13))
                  :ARG1 (a3 / and~e.5
                        :op1 (e / enzyme
                              :name (n2 / name :op1 "Erk1"~e.2))
                        :op2 (e2 / enzyme
                              :name (n3 / name :op1 "Erk2"~e.4))
                        :op3 (e3 / enzyme
                              :name (n4 / name :op1 "JNK"~e.6)))
                  :location~e.10 (c2 / cell-line
                        :name (n6 / name :op1 "J774"~e.11)))
            :ARG2 (a2 / activate-01~e.1
                  :polarity~e.8 "-"~e.8
                  :ARG0 p2
                  :ARG1 (e4 / enzyme
                        :name (n5 / name :op1 "p38MAPK"~e.9))
                  :location c2))
      :snt2 (i / induce-01~e.15
            :ARG0 (p3 / protein
                  :name (n7 / name :op1 "NGF"~e.0,13))
            :ARG1 (p4 / phosphorylate-01~e.16
                  :ARG1~e.17 (e5 / enzyme
                        :name (n8 / name :op1 "JNK"~e.18)))
            :mod (a4 / also~e.14)))

# ::tok The MAP kinase @-@ Erk kinase ( MEK ) inhibitor PD 098059 inhibits the production of TNF @-@ alpha induced by NGF
# ::alignments 1-1.1.2.1.1.1.1 2-1.1.2.1.1 2-1.1.2.1.2 4-1.1.2.1.2.1.1 5-1.1.2.1.1 5-1.1.2.1.2 9-1 9-1.1 9-1.1.2 9-1.1.2.r 9-1.1.r 12-1 12-1.1 12-1.1.2 12-1.1.2.r 12-1.1.r 14-1.2 15-1.2.1.r 16-1.2.1.1.1 18-1.2.1.1.1 19-1.2.2
# ::id bel_pmid_1140_4390_29566
(i2 / inhibit-01~e.9,12
      :ARG0~e.9,12 (s / small-molecule~e.9,12
            :name (n4 / name :op1 "PD098059")
            :ARG0-of~e.9,12 (i / inhibit-01~e.9,12
                  :ARG1 (a / and
                        :op1 (k / kinase~e.2,5
                              :name (n2 / name :op1 "MAP"~e.1))
                        :op2 (k2 / kinase~e.2,5
                              :name (n3 / name :op1 "Erk"~e.4)))))
      :ARG1 (p / produce-01~e.14
            :ARG1~e.15 (p2 / protein
                  :name (n5 / name :op1 "TNF-alpha"~e.16,18))
            :ARG1-of (i3 / induce-01~e.19)))

# ::tok The induction of TNF @-@ alpha production by NGF was blocked by K252a , an inhibitor of the TrkA receptor .
# ::alignments 1-1.2 2-1.2.2.r 3-1.2.2.1.1.1 5-1.2.2.1.1.1 6-1.2.2 7-1.2.1.r 8-1.2.1.1.1 10-1 11-1.1.r 12-1.1.1.1 15-1.1 15-1.1.2 15-1.1.2.r 16-1.1.2.1.r 18-1.1.2.1.1.1 19-1.1.2.1
# ::id bel_pmid_1140_4390_9676
(b / block-01~e.10
      :ARG0~e.11 (s / small-molecule~e.15
            :name (n3 / name :op1 "K252a"~e.12)
            :ARG0-of~e.15 (i / inhibit-01~e.15
                  :ARG1~e.16 (r / receptor~e.19
                        :name (n4 / name :op1 "TrkA"~e.18))))
      :ARG1 (i2 / induce-01~e.1
            :ARG0~e.7 (p / protein
                  :name (n / name :op1 "NGF"~e.8))
            :ARG1~e.2 (p2 / produce-01~e.6
                  :ARG1 (p3 / protein
                        :name (n2 / name :op1 "TNF-alpha"~e.3,5)))))

# ::tok Both early passage and immortalized MEF cells from GSTpi(-/-) animals expressed significantly elevated activity of extracellular signal @-@ regulated kinases ERK1/ERK2 , kinases linked to cell proliferation pathways
# ::alignments 1-1.1.1.1.1 2-1.1.1.1 3-1.1 4-1.1.2.1 5-1.1.1.2.1.1 6-1.1.1 6-1.1.2 7-1.1.1.2.r 10-1.1.1.2.2 12-1.2.2 13-1.2 14-1.2.1.r 15-1.2.1.1 16-1.2.1.1 18-1.2.1.1 19-1.2.1.1 22-1.2.1.1 22-1.2.1.2 23-1.2.1.1.2 24-1.2.1.1.2.1.r 25-1.2.1.1.2.1.1.1 26-1.2.1.1.2.1.1 27-1.2.1.1.2.1
# ::id bel_pmid_1140_8560_1760
(e / exhibit-01
      :ARG0 (a / and~e.3
            :op1 (c / cell~e.6
                  :mod (p / passage~e.2
                        :mod (e2 / early~e.1))
                  :source~e.7 (m3 / molecular-physical-entity
                        :name (n4 / name :op1 "MEF"~e.5)
                        :ARG3-of (e4 / express-03~e.10
                              :ARG2 (p2 / protein
                                    :name (n3 / name :op1 "GSTpi")
                                    :ARG2-of (m2 / mutate-01 :mod "-/-")))))
            :op2 (c2 / cell~e.6
                  :ARG1-of (i / immortalize-00~e.4)
                  :source m3))
      :ARG1 (a2 / act-02~e.13
            :ARG0~e.14 (a3 / and
                  :op1 (e6 / extracellular-signal-regulated-kinase~e.15,16,18,19,22
                        :name (n / name :op1 "ERK1")
                        :ARG1-of (l / link-01~e.23
                              :ARG1~e.24 (p3 / pathway~e.27
                                    :mod (p4 / proliferate-01~e.26
                                          :ARG0 (c3 / cell~e.25)))))
                  :op2 (e7 / extracellular-signal-regulated-kinase~e.22
                        :name (n2 / name :op1 "ERK2")
                        :ARG1-of l))
            :ARG1-of (e5 / elevate-01~e.12)))

# ::tok A tetrameric Stat3 complex was found to be essential in transfection experiments for maximal interleukin @-@ 6 @-@ inducible activation of alpha2 @-@ macroglobulin gene promoter .
# ::alignments 1-1.1.1.1 2-1.1.1.2.1.1 3-1.1.1 4-1.1.1.r 5-1 7-1.1.1.r 8-1.1 9-1.1.3.r 10-1.1.3.1 11-1.1.3 12-1.1.2.r 13-1.1.2.2 14-1.1.2.3.1.1.1 16-1.1.2.3.1.1.1 18-1.1.2.3 19-1.1.2 20-1.1.2.1.r 21-1.1.2.1.1.1.1.1.1.1 23-1.1.2.1.1.1.1.1.1.1 24-1.1.2.1.1.1
# ::id bel_pmid_1143_8543_2568
(f / find-01~e.5
      :ARG1 (e / essential~e.8
            :domain~e.4,7 (m3 / macro-molecular-complex~e.3
                  :mod (t / tetrameric~e.1)
                  :mod (p / protein
                        :name (n / name :op1 "Stat3"~e.2)))
            :purpose~e.12 (a / activate-01~e.19
                  :ARG1~e.20 (m2 / molecular-physical-entity
                        :ARG0-of (p4 / promote-01
                              :ARG1 (g / gene~e.24
                                    :ARG0-of (e3 / encode-01
                                          :ARG1 (p5 / protein
                                                :name (n3 / name :op1 "alpha2-macroglobulin"~e.21,23))))))
                  :degree (m / maximum~e.13)
                  :ARG1-of (i / induce-01~e.18
                        :ARG0 (p3 / protein
                              :name (n2 / name :op1 "interleukin-6"~e.14,16))
                        :mod (p2 / possible)))
            :prep-in~e.9 (e2 / experiment-01~e.11
                  :ARG2 (t3 / transfect-00~e.10))))

# ::tok We have previously demonstrated that complex formation between the SH2 domain of Grb2 and FRS2a is mediated via Y196-, Y306-, Y349-, and Y392 @-@ designated Grb2 binding sites ( 4 , 5 ) .
# ::alignments 0-1.1 3-1 4-1.2.r 5-1.2.2.2 6-1.2.2 11-1.2.2.1.r 12-1.2.2.1.1.2.1.1 13-1.2.2.1 14-1.2.2.1.2.1.1 16-1.2 21-1.2.1.1 21-1.2.2.1 25-1.2.2.1.1.2.1.1 26-1.2.1 27-1.2.2.1.1 29-1.4.1.1.1.1 31-1.4.1.1.1.2
# ::id bel_pmid_1144_7289_27070
(d / demonstrate-01~e.3
      :ARG0 (w2 / we~e.0)
      :ARG1~e.4 (m / mediate-01~e.16
            :ARG0 (b / bind-01~e.26
                  :ARG2 (a2 / and~e.21
                        :op1 (a4 / amino-acid
                              :mod "196"
                              :name (n8 / name :op1 "tyrosine")
                              :part-of (p2 / protein
                                    :name (n2 / name :op1 "Grb2"~e.12,25)))
                        :op2 (a5 / amino-acid
                              :mod "306"
                              :name (n9 / name :op1 "tyrosine")
                              :part-of p2)
                        :op3 (a6 / amino-acid
                              :mod "349"
                              :name (n10 / name :op1 "tyrosine")
                              :part-of p2)))
            :ARG1 (f / form-01~e.6
                  :ARG0~e.11 (a / and~e.13,21
                        :op1 (p / protein-segment~e.27
                              :name (n / name :op1 "SH2 domain")
                              :part-of p2)
                        :op2 (p3 / protein
                              :name (n3 / name :op1 "FRS2a"~e.14)))
                  :ARG1 (m2 / macro-molecular-complex~e.5)))
      :time (b2 / before)
      :ARG1-of (d2 / describe-01
            :ARG0 (p8 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (a3 / and :op1 "4"~e.29 :op2 "5"~e.31)))))

# ::tok In addition , FRS2a recruits Grb2 indirectly by means of two binding sites for the SH2 domains of the protein tyrosine phosphatase Shp2 at Y436 @- and Y471 @-@ designated Shp2 binding sites ( 5 ) .
# ::alignments 0-1 1-1 1-1.1.6 3-1.1.1.1.1 4-1.1 5-1.1.2.1.1 6-1.1.3 6-1.1.3.1 6-1.1.3.1.r 6-1.1.3.r 11-1.1.4 12-1.1.6.1.3 19-1.1.1 19-1.1.2 19-1.1.6.1.3 19-1.1.6.1.3.2 19-1.1.6.1.3.2.r 20-1.1.6.1.2.1 20-1.1.6.2.2.1 21-1.1.6.1.3.2 22-1.1.6.1.3.2.1.1 30-1.1.6.1.3.2.1.1 31-1.1.6.1.3.3 32-1.1.6.1.3 34-1.1.5.1.1.1
# ::id bel_pmid_1144_7289_27072
(a / and~e.0,1
      :op2 (r / recruit-01~e.4
            :ARG0 (p / protein~e.19
                  :name (n / name :op1 "FRS2a"~e.3))
            :ARG1 (p2 / protein~e.19
                  :name (n2 / name :op1 "Grb2"~e.5))
            :manner~e.6 (d / direct~e.6 :polarity~e.6 "-"~e.6)
            :manner (b / bind-01~e.11)
            :ARG1-of (d3 / describe-01
                  :ARG0 (p7 / publication
                        :ARG1-of (c / cite-01 :ARG2 "5"~e.34)))
            :instrument (a3 / and~e.1
                  :op1 (a4 / amino-acid
                        :mod "436"
                        :name (n7 / name :op1 "tyrosine"~e.20)
                        :part-of (p3 / protein-segment~e.12,19,32
                              :name (n3 / name :op1 "SH2 domain")
                              :part-of~e.19 (p4 / protein-tyrosine-phosphatase~e.19,21
                                    :name (n4 / name :op1 "Shp2"~e.22,30))
                              :ARG1-of (b2 / bind-01~e.31)))
                  :op2 (a5 / amino-acid
                        :mod "471"
                        :name (n8 / name :op1 "tyrosine"~e.20)
                        :part-of p3))))

# ::tok We further show that SAF @-@ 1 is phosphorylated in vitro by PKA @-@ Calpha and that addition of cAMP markedly induces in vivo phosphorylation of SAF @-@ 1 and transcription of SAF @-@ regulated reporter genes .
# ::alignments 0-1.1.1 2-1.1 3-1.1.2.r 4-1.1.2.1.1.1.1 6-1.1.2.1.1.1.1 8-1.1.2.1 9-1.1.2.1.3 10-1.1.2.1.3 11-1.1.2.1.2.r 12-1.1.2.1.2.1.1 14-1.1.2.1.2.1.1 15-1.1.2 16-1.1.2.r 17-1.1.2.2.1 18-1.1.2.2.1.1.r 19-1.1.2.2.1.1.1.1 20-1.1.2.2.3 20-1.1.2.2.3.r 21-1.1.2.2 22-1.1.2.2.2.1.2 23-1.1.2.2.2.1.2 24-1.1.2.2.2.1 25-1.1.2.2.2.1.1.r 26-1.1.2.2.2.1.1 27-1.1.2.2.2.1.1 28-1.1.2.2.2.1.1 29-1.1.2.2.2 30-1.1.2.2.2.2 31-1.1.2.2.2.2.1.r 32-1.1.2.2.2.2.1.1.1 34-1.1.2.2.2.2.1.1 35-1.1.2.2.2.2.1.2 36-1.1.2.2.2.2.1
# ::id bel_pmid_1149_0023_22070
(a / and
      :op2 (s / show-01~e.2
            :ARG0 (w / we~e.0)
            :ARG1~e.3,16 (a2 / and~e.15
                  :op1 (p3 / phosphorylate-01~e.8
                        :ARG1 (p4 / protein
                              :name (n / name :op1 "SAF-1"~e.4,6))
                        :ARG2~e.11 (e / enzyme
                              :name (n2 / name :op1 "PKA-Calpha"~e.12,14))
                        :manner (i2 / in-vitro~e.9,10))
                  :op2 (i / induce-01~e.21
                        :ARG0 (a3 / add-02~e.17
                              :ARG1~e.18 (e2 / enzyme
                                    :name (n3 / name :op1 "cAMP"~e.19)))
                        :ARG1 (a4 / and~e.29
                              :op1 (p5 / phosphorylate-01~e.24
                                    :ARG1~e.25 p4~e.26,27,28
                                    :manner (i3 / in-vivo~e.22,23))
                              :op2 (t / transcribe-01~e.30
                                    :ARG1~e.31 (g / gene~e.36
                                          :ARG1-of (r2 / regulate-01~e.34
                                                :ARG0 p4~e.32)
                                          :ARG0-of (r3 / report-01~e.35))
                                    :manner i3))
                        :manner~e.20 (m / marked~e.20)))))

# ::tok Serum amyloid A @-@ activating factor @-@ 1 ( SAF @-@ 1 ) is a zinc finger transcription factor that is activated by many mediators of inflammation including IL @-@ 1 , IL @-@ 6 , and bacterial LPS .
# ::alignments 0-1.2.1.1 1-1.2.1.2 2-1.2.1.3 4-1.2.1.3 5-1.2 5-1.2.1.4 7-1.2.1.4 11-1.2.1.4 15-1.2 16-1.2 17-1.2 18-1.2 18-1.2.1.4 21-1 22-1.1.r 23-1.1.2 24-1.1 24-1.1.1 24-1.1.1.r 25-1.1.1.1.r 26-1.1.1.1 27-1.1.3 28-1.1.3.1.1.1.1 28-1.1.3.1.2.1.1 30-1.1.3.1.1.1.1 32-1.1.3.1.1.1.1 32-1.1.3.1.2.1.1 34-1.1.3.1.2.1.1 36-1.1.3.1 37-1.1.3.1.3.2 38-1.1.3.1.3.1.1
# ::id bel_pmid_1149_0023_3486
(a / activate-01~e.21
      :ARG0~e.22 (m2 / molecular-physical-entity~e.24
            :ARG0-of~e.24 (m3 / mediate-01~e.24
                  :ARG1~e.25 (i / inflammation~e.26))
            :quant (m4 / many~e.23)
            :ARG2-of (i2 / include-01~e.27
                  :ARG1 (a2 / and~e.36
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "IL-1"~e.28,30,32))
                        :op2 (p3 / protein
                              :name (n3 / name :op1 "IL-6"~e.28,32,34))
                        :op3 (m5 / macro-molecular-complex
                              :name (n4 / name :op1 "LPS"~e.38)
                              :mod (b / bacteria~e.37)))))
      :ARG1 (z / zinc-finger-transcription-factor~e.5,15,16,17,18
            :name (n / name
                  :op1 "serum"~e.0
                  :op2 "amyloid"~e.1
                  :op3 "A-activating"~e.2,4
                  :op4 "factor-1"~e.5,7,11,18)))

# ::tok Either constitutive expression or inducible activation of MyoD in 10T( 1 @/@ 2 ) fibroblasts promotes SHPS @-@ 1 tyrosyl phosphorylation and its association with SHP @-@ 2 .
# ::alignments 1-1.1.1.3 2-1.1.1 4-1.1.2.2 5-1.1.2 6-1.1.2.1.r 7-1.1.2.1.1.1 10-1.2.2.1 12-1.2.2.2.1.1 14-1.1.1.2 15-1 16-1.2.1.1.2.1.1 18-1.2.1.1.2.1.1 19-1.2.1.1.1.1 20-1.2.1 21-1.2 23-1.2.2 25-1.2.2.2.1.1 27-1.2.2.2.1.1
# ::id bel_pmid_1149_3654_11578
(p2 / promote-00~e.15
      :ARG0 (a / and
            :op1 (e / express-03~e.2
                  :ARG2 (p / protein
                        :name (n / name :op1 "MyoD"~e.7))
                  :ARG3 (f / fibroblast~e.14
                        :part-of (c2 / cell-line
                              :name (n2 / name :op1 "10T(1/2)")))
                  :mod (c / constitutive~e.1))
            :op2 (a2 / activate-01~e.5
                  :ARG1~e.6 p
                  :ARG1-of (i / induce-01~e.4
                        :mod (p3 / possible))
                  :location f))
      :ARG1 (a3 / and~e.21
            :op1 (p5 / phosphorylate-01~e.20
                  :ARG1 (a4 / amino-acid
                        :name (n3 / name :op1 "tyrosyl"~e.19)
                        :part-of (p6 / protein
                              :name (n4 / name :op1 "SHPS-1"~e.16,18))))
            :op2 (a5 / associate-01~e.23
                  :ARG1 p6~e.10
                  :ARG2 (p7 / protein
                        :name (n5 / name :op1 "SHP-2"~e.12,25,27)))))

# ::tok We have identified that the 120 kDa complex consists of the SHP @-@ 2 substrate @-@ 1 ( SHPS @-@ 1 ) and the Grb2 @-@ associated binder @-@ 1 ( Gab @-@ 1 ) . SHPS @-@ 1 , but not Gab @-@ 1 , undergoes tyrosyl phosphorylation and association with SHP @-@ 2 during myogenesis ,
# ::alignments 0-1.1.1 5-1.1.2.1.1.1.1 7-1.1.2.1 8-1.1.2 9-1.1.2.2.r 11-1.1.2.2.1.1.1 13-1.1.2.2.1.1.1 14-1.1.2.2.1.1.2 16-1.1.2.2.1.1.2 16-1.1.2.2.2.1.2 20-1.1.2.2.1.1.2 20-1.1.2.2.2.1.2 22-1.1.2.2 24-1.1.2.2.2.1.1 26-1.1.2.2.2.1.1 26-1.2.2.1.2.2.1.1 27-1.1.2.2.2.1.2 29-1.1.2.2.1.1.2 29-1.1.2.2.2.1.2 33-1.1.2.2.1.1.2 33-1.1.2.2.2.1.2 38-1.1.2.2.1.1.2 38-1.1.2.2.2.1.2 40-1.2 41-1.2.2.1.1 41-1.2.2.1.1.r 44-1.2.1.1.1.2.1.2 44-1.2.2.1.2.2.1.2 47-1.2.1.1.1.1.1 47-1.2.2.1.2.1.1 48-1.2.1.1 48-1.2.2.1 49-1.2.1 49-1.2.2 50-1.2.1.2 50-1.2.2.2 52-1.2.1.1.1.2.1.1 52-1.2.1.2.2.1.1 54-1.2.1.1.1.2.1.1 54-1.2.1.2.2.1.1 55-1.2.1.1.2.r 55-1.2.1.2.3.r 55-1.2.2.1.3.r 55-1.2.2.2.3.r 56-1.2.1.1.2
# ::id bel_pmid_1149_3654_30640
(m / multi-sentence
      :snt1 (f / find-01
            :ARG0 (w2 / we~e.0)
            :ARG1 (c / consist-01~e.8
                  :ARG1 (m4 / macro-molecular-complex~e.7
                        :ARG1-of (e / equal-01
                              :ARG2 (m2 / mass-quantity
                                    :quant "120"~e.5
                                    :unit (k / kilodalton))))
                  :ARG2~e.9 (a / and~e.22
                        :op1 (p2 / protein
                              :name (n / name :op1 "SHP-2"~e.11,13 :op2 "substrate-1"~e.14,16,20,29,33,38))
                        :op2 (p3 / protein
                              :name (n2 / name :op1 "Grb2-associated"~e.24,26 :op2 "binder-1"~e.16,20,27,29,33,38)))))
      :snt2 (c3 / contrast-01~e.40
            :ARG1 (a3 / and~e.49
                  :op1 (p4 / phosphorylate-01~e.48
                        :ARG1 (a2 / amino-acid
                              :name (n3 / name :op1 "tyrosyl"~e.47)
                              :part-of (p / protein
                                    :name (n6 / name :op1 "SHP-2"~e.52,54 :op2 "substrate-1"~e.44)))
                        :time~e.55 (m3 / myogenesis~e.56))
                  :op2 (a4 / associate-01~e.50
                        :ARG1 p
                        :ARG2 (p5 / protein
                              :name (n4 / name :op1 "SHP-2"~e.52,54))
                        :time~e.55 m3))
            :ARG2 (a5 / and~e.49
                  :op1 (p6 / phosphorylate-01~e.48
                        :polarity~e.41 "-"~e.41
                        :ARG1 (a6 / amino-acid
                              :name (n5 / name :op1 "tyrosyl"~e.47)
                              :part-of (p7 / protein
                                    :name (n7 / name :op1 "Grb2-associated"~e.26 :op2 "binder-1"~e.44)))
                        :time~e.55 m3)
                  :op2 (a7 / associate-01~e.50
                        :ARG1 p7
                        :ARG2 p5
                        :time~e.55 m3))))

# ::tok Inhibition of p38 MAPK by SB203580 in differentiating C2C12 myoblasts blocks MyoD expression , SHPS @-@ 1 tyrosyl phosphorylation and the association of SHPS @-@ 1 with SHP @-@ 2 .
# ::alignments 0-1.1 4-1.1.1.r 5-1.1.1.1.1 7-1.1.3.1.2 8-1.1.3.1.1.1 10-1 11-1.2.1.1.1.1 12-1.2.1 14-1.2.2.1.2.1.1 16-1.2.2.1.2.1.1 17-1.2.2.1.1.1 18-1.2.2 19-1.2 21-1.2.3 22-1.2.3.1.r 23-1.2.3.1 24-1.2.3.1 25-1.2.3.1 26-1.2.3.2.r 27-1.2.3.2.1.1 29-1.2.3.2.1.1
# ::id bel_pmid_1149_3654_6262
(b / block-01~e.10
      :ARG0 (i / inhibit-01~e.0
            :ARG0~e.4 (s / small-molecule
                  :name (n2 / name :op1 "SB203580"~e.5))
            :ARG1 (e / enzyme
                  :name (n3 / name :op1 "p38MAPK"))
            :location (m / myoblast
                  :part-of (c / cell-line
                        :name (n4 / name :op1 "C2C12"~e.8)
                        :ARG1-of (d / differentiate-101~e.7))))
      :ARG1 (a / and~e.19
            :op1 (e2 / express-03~e.12
                  :ARG2 (p4 / protein
                        :name (n5 / name :op1 "MyoD"~e.11)))
            :op2 (p3 / phosphorylate-01~e.18
                  :ARG1 (a3 / amino-acid
                        :name (n6 / name :op1 "tyrosyl"~e.17)
                        :part-of (p5 / protein
                              :name (n7 / name :op1 "SHPS-1"~e.14,16))))
            :op3 (a2 / associate-01~e.21
                  :ARG1~e.22 p5~e.23,24,25
                  :ARG2~e.26 (p6 / protein
                        :name (n8 / name :op1 "SHP-2"~e.27,29)))))

# ::tok The expression and activity of the protein @-@ tyrosine phosphatase 1B ( PTP1B ) , but not protein @-@ tyrosine phosphatases SHP @-@ 1 , SHP @-@ 2 , and LAR , were constitutively decreased in tissues expressing the Q205L Galpha( i2 ) .
# ::alignments 1-1.1.1.1 1-1.2.2.1 2-1.1.1 3-1.1.1.2 3-1.2.2.2 6-1.1.1.1.1 6-1.2.2.1.1.1 6-1.2.2.1.1.2 6-1.2.2.1.1.3 8-1.1.1.1.1 9-1.1.1.1.1 10-1.1.1.1.1.1.1 15-1 16-1.2.1 16-1.2.1.r 17-1.1.1.1.1 17-1.1.1.1.2.1.1 19-1.1.1.1.1 20-1.1.1.1.1 21-1.2.2.1.1.1.1.1 21-1.2.2.1.1.2.1.1 23-1.2.2.1.1.1.1.1 25-1.2.2.1.1.1.1.1 25-1.2.2.1.1.2.1.1 27-1.2.2.1.1.2.1.1 30-1.2.2.1.1.3.1.1 33-1.1.2 34-1.1 34-1.2 35-1.1.1.1.2.r 36-1.1.1.1.2 37-1.1.1.1.2.1 39-1.1.1.1.2.1.1.2.1
# ::id bel_pmid_1150_0506_8864
(c2 / contrast-01~e.15
      :ARG1 (d / decrease-01~e.34
            :ARG1 (a / and~e.2
                  :op1 (e / express-03~e.1
                        :ARG2 (p / protein-tyrosine-phosphatase~e.6,8,9,17,19,20
                              :name (n / name :op1 "1B"~e.10))
                        :ARG3~e.35 (t / tissue~e.36
                              :ARG3-of (e2 / express-03~e.37
                                    :ARG2 (p2 / protein~e.17
                                          :name (n2 / name :op1 "Galpha(i2)")
                                          :ARG1-of (m / mutate-01 :mod "Q205L"~e.39)))))
                  :op2 (a2 / act-02~e.3
                        :ARG0 p
                        :location t))
            :mod (c / constitutive~e.33))
      :ARG2 (d2 / decrease-01~e.34
            :polarity~e.16 "-"~e.16
            :ARG1 (a3 / and
                  :op1 (e3 / express-03~e.1
                        :ARG2 (a4 / and
                              :op1 (p3 / protein-tyrosine-phophatase~e.6
                                    :name (n3 / name :op1 "SHP-1"~e.21,23,25))
                              :op2 (p4 / protein-tyrosine-phosphatase~e.6
                                    :name (n4 / name :op1 "SHP-2"~e.21,25,27))
                              :op3 (p5 / protein-tyrosine-phosphatase~e.6
                                    :name (n5 / name :op1 "LAR"~e.30)))
                        :ARG3 t)
                  :op2 (a5 / act-02~e.3
                        :ARG0 a4
                        :location t))))

# ::tok IL @-@ 6 induced STAT3 transactivation was reduced from sixfold to 2.5 @-@ fold when cells were pre @-@ treated with the JAK2 inhibitor ( Figure 2b ) .
# ::alignments 0-1.1.2.1.1.1 2-1.1.2.1.1.1 2-1.2.1 3-1.1.2 4-1.1.1.1.1 5-1.1 7-1 11-1.3.1 14-1.4.3.r 15-1.4.1 22-1.4.2.1.1.1.1 23-1.4.2 23-1.4.2.1 23-1.4.2.1.r 25-1.5.1 26-1.5.1.1
# ::id bel_pmid_1153_6047_16526
(r / reduce-01~e.7
      :ARG1 (t2 / transactivate-00~e.5
            :ARG1 (p / protein
                  :name (n / name :op1 "STAT3"~e.4))
            :ARG1-of (i2 / induce-01~e.3
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "IL-6"~e.0,2))))
      :ARG3 (p4 / product-of :op1 "6"~e.2)
      :ARG4 (p5 / product-of :op1 "2.5"~e.11)
      :condition (p3 / pretreat-00
            :ARG1 (c / cell~e.15)
            :ARG2 (m3 / molecular-physical-entity~e.23
                  :ARG0-of~e.23 (i / inhibit-01~e.23
                        :ARG1 (e / enzyme
                              :name (n4 / name :op1 "JAK2"~e.22))))
            :time~e.14 (b / before))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.25 :mod "2b"~e.26)))

# ::tok Overexpression of both MEN2A @-@ RET and STAT3 strongly enhanced reporter activation , indicating that MEN2A @-@ RET induces cyclin @-@ D1 gene expression via STAT3 ( Figure 4a ) .
# ::alignments 0-1.4.1.2 2-1.1.1.3 3-1.1.1.1.1.1 5-1.1.1.1.1.1 6-1.1.1 7-1.1.1.2.1.1 8-1.3 8-1.3.r 9-1 10-1.2.1.1 11-1.2 13-1.4 15-1.1.1.1.1.1 17-1.1.1.1.1.1 18-1.4.1 19-1.4.1.2.1.1.1 22-1.2.1 23-1.4.1.2 25-1.4.1.3 27-1.5.1 28-1.5.1.1
# ::id bel_pmid_1153_6047_22124
(e / enhance-01~e.9
      :ARG0 (o / overexpress-00
            :ARG2 (a / and~e.6
                  :op1 (p2 / protein
                        :name (n / name :op1 "MEN2A-RET"~e.3,5,15,17))
                  :op2 (p3 / protein
                        :name (n2 / name :op1 "STAT3"~e.7))
                  :mod (b / both~e.2)))
      :ARG1 (a2 / activate-01~e.11
            :ARG1 (g / gene~e.22
                  :ARG0-of (r2 / report-01~e.10)))
      :manner~e.8 (s / strong~e.8)
      :ARG0-of (i / indicate-01~e.13
            :ARG1 (i2 / induce-01~e.18
                  :ARG0 p2
                  :ARG1 (e2 / express-03~e.0,23
                        :ARG1 (g2 / gene
                              :name (n3 / name :op1 "cyclin-D"~e.19)))
                  :instrument p3~e.25))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.27 :mod "4a"~e.28)))

# ::tok These data indicate that MEN2A @-@ RET enhances proliferation via STAT3 , and that a full length STAT3 is required to mediate the MEN2A @-@ RET induced proliferation .
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.r 4-1.2.1.1.1.1 6-1.2.1.1.1.1 7-1.2.1 8-1.2.1.2 10-1.2.1.3.1.1 10-1.2.2.2.1.1 12-1.2 13-1.2.r 15-1.2.2.2.2.1 16-1.2.2.2.2 17-1.2.2.2.1.1 19-1.2.2 21-1.2.2.1 23-1.2.2.1.2.1.1 24-1.2.2.1.2.1.1 25-1.2.2.1.2.1.1 26-1.2.2.1.2.1 27-1.2.2.1.2
# ::id bel_pmid_1153_6047_22126
(i / indicate-01~e.2
      :ARG0 (d / data~e.1
            :mod (t / this~e.0))
      :ARG1~e.3,13 (a / and~e.12
            :op1 (e / enhance-01~e.7
                  :ARG0 (p / protein
                        :name (n / name :op1 "MEN2A-RET"~e.4,6))
                  :ARG1 (p2 / proliferate-01~e.8)
                  :ARG2 (p3 / protein
                        :name (n2 / name :op1 "STAT3"~e.10)))
            :op2 (r / require-01~e.19
                  :ARG0 (m / mediate-01~e.21
                        :ARG0 (p4 / protein
                              :name (n3 / name :op1 "STAT3"~e.10,17)
                              :mod (l / long~e.16
                                    :degree (f / full~e.15)))
                        :ARG1 (p5 / proliferate-01~e.27
                              :ARG1-of (i2 / induce-01~e.26
                                    :ARG0 p~e.23,24,25)))
                  :ARG1 p4)))

# ::tok Over @-@ expression of MEN2A @-@ RET mutants reduced STAT3 ser727 phosphorylation to basal levels , suggesting that STAT3 tyr705 phosphorylation is a prerequisite for maximal MEN2A @-@ RET induced STAT3 ser727 phosphorylation ( Figure 3b ) .
# ::alignments 4-1.1.1.1.1 6-1.1.1.1.1 7-1.1.1 7-1.1.1.2 7-1.1.1.2.r 8-1 11-1.2 12-1.3.r 13-1.3.1 14-1.3 16-1.4 20-1.4.1.1 20-1.4.1.2 25-1.4.1.1.2 26-1.4.1.1.3.1.1.1 28-1.4.1.1.3.1.1.1 29-1.4.1.1.3 32-1.4.1.1 32-1.4.1.2 34-1.5.1 35-1.5.1.1
# ::id bel_pmid_1153_6047_30396
(r / reduce-01~e.8
      :ARG0 (o / overexpress-00
            :ARG2 (p3 / protein~e.7
                  :name (n / name :op1 "MEN2A-RET"~e.4,6)
                  :ARG1-of~e.7 (m / mutate-01~e.7)))
      :ARG1 (p2 / phosphorylate-01~e.11
            :ARG1 (a / amino-acid
                  :mod "727"
                  :name (n2 / name :op1 "serine")
                  :part-of (p4 / protein
                        :name (n3 / name :op1 "STAT-3"))))
      :ARG4~e.12 (l / level~e.14
            :mod (b / basal~e.13))
      :ARG0-of (s / suggest-01~e.16
            :ARG1 (r2 / require-01
                  :ARG0 (p5 / phosphorylate-01~e.20,32
                        :ARG1 (a2 / amino-acid
                              :mod "727"
                              :name (n4 / name :op1 "serine")
                              :part-of p4)
                        :degree (m2 / maximum~e.25)
                        :ARG1-of (i / induce-01~e.29
                              :ARG0 (p6 / protein
                                    :name (n5 / name :op1 "MEN2A-RET"~e.26,28))))
                  :ARG1 (p / phosphorylate-01~e.20,32
                        :ARG1 (a3 / amino-acid
                              :mod "705"
                              :name (n6 / name :op1 "tyrosine")
                              :part-of p4))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.34 :mod "3b"~e.35)))

# ::tok STAT3 tyr705 phosphorylation was reduced when the MEN2A @-@ RET single mutants tyr752 phe or tyr928 phe were overexpressed , while no STAT3 tyr705 phosphorylation was observed in the presence of the MEN2A @-@ RET double mutant ( Figure 3b ) .
# ::alignments 0-1.1.1.1.3.1.1 2-1.1.1 4-1.1 7-1.1.2.1.1.1.1 7-1.1.2.1.2.1.1 9-1.1.2.1.1.1.1 9-1.1.2.1.2.1.1 10-1.1.2.1.1.3 10-1.1.2.1.2.3 11-1.1.2.1.1 11-1.1.2.1.1.2 11-1.1.2.1.1.2.r 11-1.1.2.1.2 11-1.1.2.1.2.2 11-1.1.2.1.2.2.r 14-1.1.2.1 20-1 21-1.2.1 21-1.2.1.r 22-1.2.2 23-1.2.2 24-1.2.2 26-1.2 27-1.2.3.r 29-1.2.3 30-1.2.3.1.r 32-1.2.3.1.1.1 34-1.2.3.1.1.1 35-1.2.3.1.2.1 36-1.2.3.1 36-1.2.3.1.2 36-1.2.3.1.2.r 38-1.3.1 39-1.3.1.1
# ::id bel_pmid_1153_6047_30398
(c / contrast-01~e.20
      :ARG1 (r / reduce-01~e.4
            :ARG1 (p2 / phosphorylate-01~e.2
                  :ARG1 (a / amino-acid
                        :mod "705"
                        :name (n / name :op1 "tyrosine")
                        :part-of (p3 / protein
                              :name (n2 / name :op1 "STAT3"~e.0))))
            :condition (o / overexpress-00
                  :ARG2 (o2 / or~e.14
                        :op1 (p / protein~e.11
                              :name (n4 / name :op1 "MEN2A-RET"~e.7,9)
                              :ARG2-of~e.11 (m2 / mutate-01~e.11 :value "tyr752phe")
                              :mod (s / single~e.10))
                        :op2 (p5 / protein~e.11
                              :name (n9 / name :op1 "MEN2A-RET"~e.7,9)
                              :ARG2-of~e.11 (m5 / mutate-01~e.11 :value "tyr928phe")
                              :mod (s2 / single~e.10)))))
      :ARG2 (o3 / observe-01~e.26
            :polarity~e.21 "-"~e.21
            :ARG1 p2~e.22,23,24
            :condition~e.27 (p6 / present~e.29
                  :mod~e.30 (p7 / protein~e.36
                        :name (n5 / name :op1 "MEN2A-RET"~e.32,34)
                        :ARG1-of~e.36 (m3 / mutate-01~e.36
                              :mod (d / double~e.35)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.38 :mod "3b"~e.39)))

# ::tok As depicted in Figure 3a , mutation of tyr928 ( RET ) reduced STAT3 transactivation approximately 1.5 @-@ fold , indicating that other STAT3 docking sites must be present in MEN2A @-@ RET as well .
# ::alignments 0-1.4.1.1.3 1-1.5 2-1.5.1.r 3-1.5.1 4-1.5.1.1 6-1.1 7-1.3 10-1.1.1.3.1.1 12-1 13-1.2.1.1.1 14-1.2 15-1.3.2 16-1.3.1 20-1.4 22-1.4.1.1.1.2 23-1.4.1.1.1.1.1 24-1.4.1.1.1.1 25-1.4.1.1.1 26-1.4.1 27-1.4.1.1 30-1.4.1.1.2.1.1 32-1.4.1.1.2.1.1 33-1.4.1.1.3 34-1.4.1.1.3
# ::id bel_pmid_1153_6047_30400
(r / reduce-01~e.12
      :ARG0 (m / mutate-01~e.6
            :ARG1 (a / amino-acid
                  :mod "928"
                  :name (n / name :op1 "tyrosine")
                  :part-of (p / protein
                        :name (n2 / name :op1 "RET"~e.10))))
      :ARG1 (t / transactivate-00~e.14
            :ARG1 (p2 / protein
                  :name (n3 / name :op1 "STAT3"~e.13)))
      :ARG2 (p5 / product-of~e.7
            :op1 "1.5"~e.16
            :mod (a3 / approximate~e.15))
      :ARG0-of (i / indicate-01~e.20
            :ARG1 (o / obligate-01~e.26
                  :ARG2 (b / be-located-at-91~e.27
                        :ARG1 (p4 / protein-segment~e.25
                              :ARG2-of (d / dock-01~e.24
                                    :ARG1 p2~e.23)
                              :mod (o2 / other~e.22))
                        :ARG2 (p3 / protein
                              :name (n4 / name :op1 "MEN2A-RET"~e.30,32))
                        :mod (a2 / as-well~e.0,33,34))))
      :ARG1-of (d2 / depict-01~e.1
            :ARG0~e.2 (f / figure~e.3 :mod "3a"~e.4)))

# ::tok As depicted in Figure 1a , b, over @-@ expression of both MEN2A @-@ RET and STAT3 strongly enhanced IRE transactivation , while overexpression of STAT3 alone did not affect reporter activation .
# ::alignments 1-1.3 3-1.3.1.1 3-1.3.1.2 4-1.3.1.1.1 12-1.1.1.1.1.1.1 14-1.1.1.1.1.1.1 15-1.1.1.1 16-1.1.1.1.2.1.1 17-1.1.3 17-1.1.3.r 18-1.1 19-1.1.2.1.1.1 20-1.1.2 22-1 24-1.2.r 25-1.2.2.1.1.1 26-1.2.2.1.2 28-1.2.1 28-1.2.1.r 29-1.2 30-1.2.3.1 30-1.2.3.1.1 30-1.2.3.1.1.r 31-1.2.3
# ::id bel_pmid_1153_6047_30402
(c / contrast-01~e.22
      :ARG1 (e / enhance-01~e.18
            :ARG0 (o / overexpress-00
                  :ARG2 (a / and~e.15
                        :op1 (p2 / protein
                              :name (n / name :op1 "MEN2A-RET"~e.12,14))
                        :op2 (p3 / protein
                              :name (n2 / name :op1 "STAT3"~e.16))))
            :ARG1 (t / transactivate-00~e.20
                  :ARG1 (p4 / protein-segment
                        :name (n3 / name :op1 "IRE"~e.19)))
            :manner~e.17 (s / strong~e.17))
      :ARG2~e.24 (a2 / affect-01~e.29
            :polarity~e.28 "-"~e.28
            :ARG0 (o2 / overexpress-00
                  :ARG2 (p5 / protein
                        :name (n4 / name :op1 "STAT3"~e.25)
                        :mod (a3 / alone~e.26)))
            :ARG1 (a4 / activate-01~e.31
                  :ARG1 (g / gene~e.30
                        :ARG0-of~e.30 (r2 / report-01~e.30))))
      :ARG1-of (d / depict-01~e.1
            :ARG0 (a5 / and
                  :op1 (f / figure~e.3 :mod "1a"~e.4)
                  :op2 (f2 / figure~e.3 :mod "1b"))))

# ::tok After bFGF was added to pulmonary fibroblasts , the kinase activities of p44 @/@ p42 ERK1 @/@ 2 were determined by an in @-@ gel assay at various times after exposure ( Fig . 1 ) . The data demonstrate that the addition of bFGF results in activation of ERK1 @/@ 2 within 5 min , with the highest activity at 30 min , followed by a lower level of activity that persists for 8 @-@ 12 h .
# ::alignments 0-1.1.3 0-1.2.2.2.2 1-1.1.3.1.1.1.1 3-1.1.3.1 6-1.1.3.1.2 9-1.1.1.1.2 10-1.2.2.2.1.3.1.1 12-1.1.1.1.1.1.1 14-1.1.1.2.1.1.1 15-1.2.2.2.1.1.1.1 19-1.1 20-1.1.2.r 22-1.1.2.1 24-1.1.2.1 25-1.1.2 26-1.1.5.r 27-1.1.5 28-1.1.5.1.r 28-1.2.2.2.1.3.1.1.3.1 28-1.2.2.2.1.3.2.2.2 28-1.2.2.2.2.2.1 29-1.1.5.1 29-1.2.2.2.1.3.2.2 30-1.1.5.1.1 34-1.1.4.1.1 38-1.2.1 39-1.2 42-1.2.2.1 43-1.2.2.1.1.r 44-1.2.2.1.1.1.1 45-1.2.2 46-1.1.2.1 47-1.2.2.2 49-1.2.2.2.1.1.1.1 53-1.2.2.2.2.2.1.1 58-1.2.2.2.1.3.2 58-1.2.2.2.1.3.2.1 58-1.2.2.2.1.3.2.1.r 59-1.2.2.2.1.3 61-1.2.2.2.1.3.2.2.2.1 64-1.2.2.2.1.3.1 67-1.2.2.2.1.3.1.1.2 67-1.2.2.2.1.3.1.1.2.1 67-1.2.2.2.1.3.1.1.2.1.r 70-1.2.2.2.1.3.1.1 72-1.2.2.2.1.3.1.1.3 74-1.2.2.2.1.3.1.1.3.1.1.1 76-1.2.2.2.1.3.1.1.3.1.1.2
# ::id bel_pmid_1155_7580_38186
(m3 / multi-sentence
      :snt1 (d / determine-01~e.19
            :ARG1 (a14 / and
                  :op1 (a / act-01
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "p44"~e.12 :op2 "ERK1"))
                        :ARG1 (k / kinase~e.9))
                  :op2 (a15 / act-01
                        :ARG0 (e3 / enzyme
                              :name (n3 / name :op1 "p42"~e.14 :op2 "ERK2"))
                        :ARG1 k))
            :manner~e.20 (a3 / assay-00~e.25
                  :manner (i / in-gel~e.22,24,46))
            :time (a5 / after~e.0
                  :op1 (a6 / add-02~e.3
                        :ARG1 (s / small-molecule
                              :name (n2 / name :op1 "bFGF"~e.1))
                        :ARG2 (f3 / fibroblast~e.6
                              :part-of (l3 / lung))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "1"~e.34))
            :frequency~e.26 (v / various~e.27
                  :time~e.28 (a4 / after~e.29
                        :op1 (e2 / expose-01~e.30))))
      :snt2 (d3 / demonstrate-01~e.39
            :ARG0 (d4 / data~e.38)
            :ARG1 (r / result-01~e.45
                  :ARG1 (a7 / add-02~e.42
                        :ARG1~e.43 (s2 / small-molecule
                              :name (n5 / name :op1 "bFGF"~e.44)))
                  :ARG2 (a8 / activate-01~e.47
                        :ARG1 (a9 / and
                              :op1 (e4 / enzyme
                                    :name (n6 / name :op1 "ERK1"~e.15,49))
                              :op2 (e5 / enzyme
                                    :name (n7 / name :op1 "ERK2"))
                              :ARG0-of (a2 / act-02~e.59
                                    :ARG2-of (f2 / follow-01~e.64
                                          :ARG1 (a12 / act-02~e.10,70
                                                :ARG0 a9
                                                :mod (l / low~e.67
                                                      :degree~e.67 (m2 / more~e.67))
                                                :ARG1-of (p2 / persist-01~e.72
                                                      :duration (t3 / temporal-quantity~e.28
                                                            :quant (b / between :op1 "8"~e.74 :op2 "12"~e.76)
                                                            :unit (h2 / hour)))))
                                    :mod (h / high~e.58
                                          :degree~e.58 (m / most~e.58)
                                          :time (a11 / after~e.29
                                                :op1 a7
                                                :quant (t2 / temporal-quantity~e.28
                                                      :quant "30"~e.61
                                                      :unit (m4 / minute))))))
                        :time (a10 / after~e.0
                              :op1 a7
                              :quant (u / up-to
                                    :op1 (t / temporal-quantity~e.28
                                          :quant "5"~e.53
                                          :unit m4)))))))

# ::tok PPARalpha ( NR1C1 ) controls lipid oxidation and clearance in hepatocytes and PPARgamma ( NR1C3 ) promotes preadipocyte differentiation and lipogenesis .
# ::alignments 0-1.1.1.1.1 2-1.1.1.2.1.1.1 4-1.1 5-1.1.2.1.1 7-1.1.2 8-1.1.2.2 11-1.1.2 12-1.2.1.1.1 14-1.2.1.2.1.1.1 16-1.2 17-1.2.2.1.1 18-1.2.2.1 19-1.2.2 20-1.2.2.2
# ::id bel_pmid_1155_7774_11824
(a / and
      :op1 (c / control-01~e.4
            :ARG0 (p / protein
                  :name (n / name :op1 "PPARalpha"~e.0)
                  :ARG1-of (d2 / describe-01
                        :ARG2 (p4 / protein
                              :name (n5 / name :op1 "NR1C1"~e.2))))
            :ARG1 (a2 / and~e.7,11
                  :op1 (o / oxidize-01
                        :ARG1 (l / lipid~e.5))
                  :op2 (c2 / clear-01~e.8
                        :ARG2 l))
            :location (h / hepatocyte))
      :op2 (p2 / promote-02~e.16
            :ARG0 (p3 / protein
                  :name (n3 / name :op1 "PPARgamma"~e.12)
                  :ARG1-of (d3 / describe-01
                        :ARG2 (p5 / protein
                              :name (n6 / name :op1 "NR1C3"~e.14))))
            :ARG1 (a3 / and~e.19
                  :op1 (d / differentiate-01~e.18
                        :ARG1 (p6 / preadipocyte~e.17))
                  :op2 (l2 / lipogenesis~e.20
                        :location p6))))

# ::tok Furthermore , it has been shown that activation of PPARg by the thiozolidinedione , rosiglitazaone , decreased scavenger receptor class A expresion .
# ::alignments 5-1.1 6-1.1.1.r 7-1.1.1.1 16-1.1.1 17-1.1.1.2.1.1.1 18-1.1.1.2.1.1.2 19-1.1.1.2.1.1.3 20-1.1.1.2.1.1.4
# ::id bel_pmid_1155_7774_16262
(a / and
      :op2 (s / show-01~e.5
            :ARG1~e.6 (d / decrease-01~e.16
                  :ARG0 (a2 / activate-01~e.7
                        :ARG0 (s3 / small-molecule
                              :name (n3 / name :op1 "rosiglitazone")
                              :ARG1-of (i / include-91
                                    :ARG2 (s2 / small-molecule
                                          :name (n2 / name :op1 "thiazolidinedione"))))
                        :ARG1 (p / protein
                              :name (n / name :op1 "PPARgamma")))
                  :ARG1 (e / express-03
                        :ARG2 (p2 / protein
                              :name (n4 / name
                                    :op1 "scavenger"~e.17
                                    :op2 "receptor"~e.18
                                    :op3 "class"~e.19
                                    :op4 "A"~e.20))))))

# ::tok Pparg , which is activated by 15 @-@ deoxy @-@ D12,14 @-@ prostaglandin J2 and the thiazolidione class of insulin @-@ sensitizing drugs , ...Among its known target genes are adipocyte factty @-@ acid binidng protein and fatty acid synthase , which are efeeectors of lipid accumulaiton during adipogeesis .
# ::alignments 4-1.1 5-1.1.1.r 6-1.1.1.1.1.1 8-1.1.1.1.1.1 12-1.1.1.1.1.2 13-1.1.1.1.1.3 14-1.1.1 16-1.1.1.2.1.1.1 17-1.1.1.2 19-1.1.1.2.2.1.1.1.1.1 21-1.1.1.2.2.1.1 22-1.1.1.2.2.1 26-1.2.2.2 27-1.2.2.1 28-1.2.1.1 28-1.2.1.2 28-1.2.2 30-1.2.1.1.1.1.1.1 30-1.2.1.4 33-1.2.1.1.1.1.1.2 35-1.2.1.1.1.1.1.4 36-1.2.1 37-1.2.1.2.1.1.1.1 38-1.2.1.2.1.1.1.2 39-1.2.1.2.1.1.1.3 45-1.2.1.3.1.1.1 47-1.2.1.3.1.2.r
# ::id bel_pmid_1155_7774_16418
(m / multi-sentence
      :snt1 (a / activate-01~e.4
            :ARG0~e.5 (a2 / and~e.14
                  :op1 (s / small-molecule
                        :name (n2 / name
                              :op1 "15-deoxy-D12"~e.6,8
                              :op2 "14-prostaglandin"~e.12
                              :op3 "J2"~e.13))
                  :op2 (c / class~e.17
                        :mod (s2 / small-molecule
                              :name (n3 / name :op1 "thiazolidione"~e.16))
                        :ARG1-of (i / include-91
                              :ARG2 (d / drug~e.22
                                    :ARG0-of (s3 / sensitize-01~e.21
                                          :ARG2 (p4 / protein
                                                :name (n4 / name :op1 "insulin"~e.19)))))))
            :ARG1 (p / protein
                  :name (n / name :op1 "PPAR-gamma")))
      :snt2 (i2 / include-91
            :ARG1 (a3 / and~e.36
                  :op1 (g2 / gene~e.28
                        :ARG0-of (e3 / encode-01
                              :ARG1 (p5 / protein
                                    :name (n8 / name
                                          :op1 "adipocyte"~e.30
                                          :op2 "fatty-acid"~e.33
                                          :op3 "biniding"
                                          :op4 "protein"~e.35))))
                  :op2 (g3 / gene~e.28
                        :ARG0-of (e4 / encode-01
                              :ARG1 (e / enzyme
                                    :name (n7 / name
                                          :op1 "fatty"~e.37
                                          :op2 "acid"~e.38
                                          :op3 "synthase"~e.39))))
                  :mod (e2 / effector
                        :ARG0-of (c2 / cause-01
                              :ARG1 (a4 / accumulate-01
                                    :ARG1 (l / lipid~e.45))
                              :time~e.47 (a5 / adipogenesis)))
                  :part-of (a6 / adipocyte~e.30))
            :ARG2 (g / gene~e.28
                  :ARG1-of (t / target-01~e.27
                        :ARG2 (p2 / protein
                              :name (n5 / name :op1 "PPARgamma")))
                  :ARG1-of (k / know-01~e.26))))

# ::tok Therefore the profound repression of CYP27 and apoE expressoin by activatoin or overexpression of PPARd might contribute to the lipid accumulation observed in these cells in culture
# ::alignments 0-1 2-1.1.1.1.3 3-1.1.1.1 4-1.1.1.1.2.r 5-1.1.1.1.2.1.1.1.1 6-1.1.1.1.2.1 7-1.1.1.1.2.1.2.1.1 11-1.1.1.1.1 12-1.1.1.1.2 15-1.1 16-1.1.1 17-1.1.1.2.r 19-1.1.1.2.1 20-1.1.1.2 21-1.1.1.2.2 22-1.1.1.2.2.1.r 22-1.1.1.2.2.2 23-1.1.1.2.2.1.1 24-1.1.1.2.2.1 25-1.1.1.2.2.2 26-1.1.1.2.2.2
# ::id bel_pmid_1155_7774_30036
(i / infer-01~e.0
      :ARG1 (p / possible~e.15
            :domain (c / contribute-01~e.16
                  :ARG0 (r / repress-01~e.3
                        :ARG0 (o / or~e.11
                              :op1 (a3 / activate-01
                                    :ARG1 (p2 / protein
                                          :name (n3 / name :op1 "PPARdelta")))
                              :op2 (o2 / overexpress-00
                                    :ARG2 p2))
                        :ARG1~e.4 (e / express-03~e.12
                              :ARG1 (a2 / and~e.6
                                    :op1 (g / gene
                                          :name (n / name :op1 "CYP27"~e.5))
                                    :op2 (g2 / gene
                                          :name (n2 / name :op1 "apoE"~e.7))))
                        :mod (p3 / profound~e.2))
                  :ARG2~e.17 (a / accumulate-01~e.20
                        :ARG1 (l / lipid~e.19)
                        :ARG1-of (o3 / observe-01~e.21
                              :location~e.22 (c2 / cell~e.24
                                    :mod (t / this~e.23))
                              :manner (i2 / in-culture~e.22,25,26))))))

# ::tok However , plaque formation is also appreciated to be an inflammoratory response and it has been shown that activators of Pparg inhibit the production of inflammoratory cytokines such as TNFa , Il6 and Il1b .
# ::alignments 0-1 2-1.1.1.1.1 3-1.1.1.1 5-1.1.1.3 7-1.1.1 11-1.1.1.2 12-1.1 16-1.1.2 17-1.1.2.1.r 18-1.1.2.1.1 18-1.1.2.1.1.1 18-1.1.2.1.1.1.r 21-1.1.2.1 23-1.1.2.1.2 27-1.1.2.1.2.1.1.r 28-1.1.2.1.2.1.1.r 32-1.1 32-1.1.2.1.2.1.1
# ::id bel_pmid_1155_7774_33822
(c2 / contrast-01~e.0
      :ARG2 (a2 / and~e.12,32
            :op1 (u / understand-01~e.7
                  :ARG1 (f / form-01~e.3
                        :ARG1 (p / plaque~e.2))
                  :ARG2 (r / respond-01~e.11
                        :ARG2 (i / inflame-01))
                  :mod (a4 / also~e.5))
            :op2 (s / show-01~e.16
                  :ARG1~e.17 (i2 / inhibit-01~e.21
                        :ARG0 (t / thing~e.18
                              :ARG0-of~e.18 (a / activate-01~e.18
                                    :ARG1 (p2 / protein
                                          :name (n / name :op1 "PPARgamma"))))
                        :ARG1 (p3 / produce-01~e.23
                              :ARG1 (c / cytokine
                                    :example~e.27,28 (a3 / and~e.32
                                          :op1 (p5 / protein
                                                :name (n3 / name :op1 "TNF-alpha"))
                                          :op2 (p6 / protein
                                                :name (n4 / name :op1 "IL-6"))
                                          :op3 (p7 / protein
                                                :name (n5 / name :op1 "IL-1b")))
                                    :ARG0-of i))))))

# ::tok These studies started with the observation that Pparg up @-@ regulates CD36 ( savenger receptor calss @-@ B ) expression in macrophages .
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.r 5-1.2 11-1.2.1.1.1.1.1 13-1.2.1.1.1.2.1.1.1 14-1.2.1.1.1.2.1.1.2 17-1.2.1.1.1.2.1.1.4 19-1.2.1.1 20-1.2.1.1.2.r 21-1.2.1.1.2
# ::id bel_pmid_1155_7774_33878
(s / start-01~e.2
      :ARG1 (s2 / study-01~e.1
            :mod (t / this~e.0))
      :ARG2~e.3 (o / observe-02~e.5
            :ARG1 (u / upregulate-01
                  :ARG1 (e / express-03~e.19
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "CD36"~e.11)
                              :ARG1-of (d / describe-01
                                    :ARG2 (p3 / protein
                                          :name (n3 / name
                                                :op1 "savenger"~e.13
                                                :op2 "receptor"~e.14
                                                :op3 "class"
                                                :op4 "B"~e.17))))
                        :ARG3~e.20 (m / macrophage~e.21))
                  :ARG2 (p / protein
                        :name (n / name :op1 "PPARgamma")))))

# ::tok Exogenous ANXA1 but not ANXA5 , administered to IL @-@ 6 KO mice before LPS challenge inhibited TNF @-@ alpha release .
# ::alignments 0-1.1.2 1-1.1.1.1 2-1.1 2-1.1.3 2-1.1.3.r 4-1.1.3.1.1.1 6-1.1.4 7-1.1.4.1.r 8-1.1.4.1.1.1.1 10-1.1.4.1.1.1.1 12-1.1.4.1 13-1.1.4.2 14-1.1.4.2.1.1.1.1 15-1.1.4.2.1 16-1 17-1.2.1.1.1 19-1.2.1.1.1 20-1.2
# ::id bel_pmid_1158_3971_7986
(i / inhibit-01~e.16
      :ARG0 (p / protein~e.2
            :name (n / name :op1 "ANXA1"~e.1)
            :mod (e / exogenous~e.0)
            :ARG1-of~e.2 (c / contrast-01~e.2
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "ANXA5"~e.4)))
            :ARG1-of (a / administer-01~e.6
                  :ARG2~e.7 (m / mouse~e.12
                        :mod (p3 / protein
                              :name (n3 / name :op1 "IL-6"~e.8,10)
                              :ARG2-of (m2 / mutate-01 :mod "-/+")))
                  :time (b / before~e.13
                        :op1 (c2 / challenge-01~e.15
                              :ARG2 (m3 / molecular-physical-entity
                                    :name (n4 / name :op1 "LPS"~e.14))))))
      :ARG1 (r / release-01~e.20
            :ARG1 (p4 / protein
                  :name (n5 / name :op1 "TNF-alpha"~e.17,19))))

# ::tok recombinant IL @-@ 6 to IL @-@ 6 KO animals before LPS or TNF @-@ alpha challenge , replenished ANXA1 liver synthesis to that of WT animals .
# ::alignments 1-1.1.1.1 1-1.1.3.1.1.1.1 3-1.1.1.1 3-1.1.3.1.1.1.1 5-1.1.1.1 5-1.1.3.1.1.1.1 7-1.1.1.1 7-1.1.3.1.1.1.1 9-1.1.3.1 10-1.1.3.2 11-1.1.3.2.1.1.1.1.1 12-1.1.3.2.1.1 13-1.1.3.2.1.1.2.1.1 15-1.1.3.2.1.1.2.1.1 16-1.1.3.2.1 18-1 19-1.2.2.1.1 20-1.2.1 20-1.3.1 25-1.3.1.1.1 26-1.1.3.1 26-1.3.1.1
# ::id bel_pmid_1158_3971_9278
(r / replenish-01~e.18
      :ARG0 (p / protein
            :name (n / name :op1 "IL-6"~e.1,3,5,7)
            :ARG1-of (r2 / recombine-01)
            :ARG1-of (a / administer-01
                  :ARG2 (a2 / animal~e.9,26
                        :mod (p4 / protein
                              :name (n5 / name :op1 "IL-6"~e.1,3,5,7)
                              :ARG2-of (m / mutate-01 :mod "-/+")))
                  :time (b / before~e.10
                        :op1 (c / challenge-01~e.16
                              :ARG2 (o / or~e.12
                                    :op1 (m2 / molecular-physical-entity
                                          :name (n2 / name :op1 "LPS"~e.11))
                                    :op2 (p2 / protein
                                          :name (n3 / name :op1 "TNF-alpha"~e.13,15)))))))
      :ARG1 (s2 / synthesize-01
            :ARG0 (l / liver~e.20)
            :ARG1 (p3 / protein
                  :name (n4 / name :op1 "ANXA1"~e.19)))
      :extent (s3 / synthesize-01
            :ARG0 (l2 / liver~e.20
                  :part-of (a3 / animal~e.26
                        :mod (w / wild-type~e.25)))
            :ARG1 p3))

# ::tok Here we show that IL @-@ 10 directly affects progenitor myeloid cells by protecting them from death following the removal of growth factors .
# ::alignments 0-1.3 1-1.1 2-1 3-1.2.r 4-1.2.1.1.1 6-1.2.1.1.1 7-1.2.4 7-1.2.4.r 8-1.2 9-1.2.2.1 10-1.2.2.2 11-1.2.2 12-1.2.3.r 13-1.2.3 15-1.2.3.3.r 16-1.2.3.3 17-1.2.3.3.1 19-1.2.3.3.1.1 20-1.2.3.3.1.1.1.r 21-1.2.3.3.1.1.1.1.1 22-1.2.3.3.1.1.1.1.2
# ::id bel_pmid_1159_1769_19228
(s / show-01~e.2
      :ARG0 (w / we~e.1)
      :ARG1~e.3 (a / affect-01~e.8
            :ARG0 (p2 / protein
                  :name (n / name :op1 "IL-10"~e.4,6))
            :ARG1 (c / cell~e.11
                  :mod (p3 / progenitor~e.9)
                  :mod (m / myeloid~e.10))
            :ARG2~e.12 (p4 / protect-01~e.13
                  :ARG0 p2
                  :ARG1 c
                  :ARG2~e.15 (d / die-01~e.16
                        :ARG1-of (f / follow-01~e.17
                              :ARG2 (r / remove-01~e.19
                                    :ARG1~e.20 (s2 / small-molecule
                                          :name (n2 / name :op1 "growth"~e.21 :op2 "factor"~e.22))))))
            :manner~e.7 (d2 / direct~e.7))
      :medium (h / here~e.0))

# ::tok Following ligand binding to the IL @-@ 10R , Jak1 and Tyk2 , which are constitutively associated with IL @-@ 10R1 and IL @-@ 10R2 , respectively ( 3 , 14 ) , are phosphorylated on tyrosine The phosphorylated IL @-@ 10R/Jak1/Tyk2 complex serves as a docking site for the transcription factors Stat @-@ 1 and Stat @-@ 3 Jak1 , which is required for the biological activity of IL @-@ 10 ( 20 ) , also tyrosine phosphorylates the insulin receptor substrate @-@ 1 ( IRS @-@ 1 )
# ::alignments 0-1.1.2 1-1.1.2.1.1 2-1.1.2.1 5-1.1.2.1.2.1.1 7-1.1.2.1.2.1.1 9-1.3.2.1.1 11-1.1.1.2.2.1.1 11-1.2.1.3.1.1 15-1.1.1.1.2.2.2 15-1.1.1.1.2.2.2.r 16-1.1.1.1.2.2 16-1.1.1.2.2.2 18-1.1.1.1.2.2.1.1.1 20-1.1.1.1.2.2.1.1.1 21-1.1.1 21-1.1.1.1.2.2.4.1.1.1 22-1.1.1.1.2.2.1.1.1 22-1.1.1.2.2.2.1.1.1 24-1.1.1.2.2.2.1.1.1 26-1.1.1.1.2.2.3 26-1.1.1.1.2.2.3.r 28-1.1.1.1.2.2.4.1.1.1.1 30-1.1.1.1.2.2.4.1.1.1.2 34-1.1 34-1.2.1.4 36-1.1.1.1.1.1 38-1.2.1.4 39-1.2.1.1.1.1 42-1.2.1 43-1.2 44-1.2.2.r 46-1.2.2.1 47-1.2.2 48-1.2.2.1.1.r 50-1.2.2.1.1.3.1 51-1.2.2.1.1.3 52-1.2.2.1.1.1.1.1 52-1.2.2.1.1.2.1.1 54-1.2.2.1.1.1.1.1 55-1.2.2.1.1 56-1.2.2.1.1.1.1.1 56-1.2.2.1.1.2.1.1 58-1.1.1.1.2.2.4.1.1.1.1 58-1.2.2.1.1.2.1.1 59-1.1.1.1.2.1.1 59-1.2.1.2.1.1 59-1.3.2.1.1 63-1.3.2.2 66-1.3.2.2.1.2 69-1.3.2.2.1.1.1.1 71-1.3.2.2.1.1.1.1 73-1.3.2.2.2.1.1.1 76-1.3.3 77-1.1.1.2.1.1 77-1.3.1.1.1 78-1.3 80-1.3.1.2.1.1 81-1.1.1.1.2.2.1 81-1.1.1.2.2.2.1 81-1.1.2.1.2 81-1.2.1.1 81-1.3.1.2.1.2 82-1.3.1.2.1.3 84-1.3.1.2.1.4 84-1.3.1.2.2.1.1.1 86-1.3.1.2.2.1.1.1 88-1.2.2.1.1.1.1.1 88-1.3.1.2.2.1.1.1
# ::id bel_pmid_1159_1769_21788
(m / multi-sentence
      :snt1 (p / phosphorylate-01~e.34
            :ARG1 (a / and~e.21
                  :op1 (a2 / amino-acid
                        :name (n3 / name :op1 "tyrosine"~e.36)
                        :part-of (e / enzyme
                              :name (n / name :op1 "Jak1"~e.59)
                              :ARG1-of (a4 / associate-01~e.16
                                    :ARG2 (r2 / receptor~e.81
                                          :name (n6 / name :op1 "IL-10R1"~e.18,20,22))
                                    :manner~e.15 (c / constitutive~e.15)
                                    :manner~e.26 (r4 / respective~e.26)
                                    :ARG1-of (d / describe-01
                                          :ARG0 (p2 / publication
                                                :ARG1-of (c2 / cite-01
                                                      :ARG2 (a6 / and~e.21 :op1 "3"~e.28,58 :op2 "14"~e.30)))))))
                  :op2 (a3 / amino-acid
                        :name (n4 / name :op1 "tyrosine"~e.77)
                        :part-of (e2 / enzyme
                              :name (n2 / name :op1 "Tyk2"~e.11)
                              :ARG1-of (a5 / associate-01~e.16
                                    :ARG2 (r3 / receptor~e.81
                                          :name (n7 / name :op1 "IL-10R2"~e.22,24))
                                    :manner c
                                    :ARG1-of d
                                    :manner r4))))
            :ARG1-of (f / follow-01~e.0
                  :ARG2 (b / bind-01~e.2
                        :ARG1 (l / ligand~e.1)
                        :ARG2 (r / receptor~e.81
                              :name (n5 / name :op1 "IL-10R"~e.5,7)))))
      :snt2 (s / serve-01~e.43
            :ARG0 (m2 / macro-molecular-complex~e.42
                  :part (r5 / receptor~e.81
                        :name (n8 / name :op1 "IL-10R"~e.39))
                  :part (e3 / enzyme
                        :name (n9 / name :op1 "Jak1"~e.59))
                  :part (e4 / enzyme
                        :name (n10 / name :op1 "Tyk2"~e.11))
                  :ARG1-of (p3 / phosphorylate-01~e.34,38))
            :ARG1~e.44 (s2 / site~e.47
                  :ARG2-of (d2 / dock-01~e.46
                        :ARG1~e.48 (a7 / and~e.55
                              :op1 (p4 / protein
                                    :name (n11 / name :op1 "Stat-1"~e.52,54,56,88))
                              :op2 (p5 / protein
                                    :name (n12 / name :op1 "Stat-3"~e.52,56,58))
                              :mod (f2 / factor~e.51
                                    :ARG0-of (t / transcribe-01~e.50))))))
      :snt3 (p6 / phosphorylate-01~e.78
            :ARG1 (a9 / amino-acid
                  :name (n14 / name :op1 "tyrosine"~e.77)
                  :part-of (p7 / protein
                        :name (n15 / name
                              :op1 "insulin"~e.80
                              :op2 "receptor"~e.81
                              :op3 "substrate"~e.82
                              :op4 "1"~e.84)
                        :ARG1-of (d3 / describe-01
                              :ARG2 (p8 / protein
                                    :name (n16 / name :op1 "IRS-1"~e.84,86,88)))))
            :ARG2 (e5 / enzyme
                  :name (n13 / name :op1 "Jak1"~e.9,59)
                  :ARG1-of (r6 / require-01~e.63
                        :ARG0 (a10 / act-01
                              :ARG0 (p9 / protein
                                    :name (n17 / name :op1 "IL-10"~e.69,71))
                              :mod (b2 / biology~e.66))
                        :ARG1-of (d4 / describe-01
                              :ARG0 (p10 / publication
                                    :ARG1-of (c3 / cite-01 :ARG2 "20"~e.73)))))
            :mod (a8 / also~e.76)))

# ::tok We and others have shown that activation of IL @-@ 4 ( 23 ) and IFN-{alpha} receptors stimulates tyrosyl phosphorylation of IRS docking proteins , which depends upon Jak ,
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.1 4-1 5-1.2.r 6-1.2.1 7-1.2.1.1.r 8-1.2.1.1.1.1.1 10-1.2.1.1.1.1.1 12-1.2.1.1.1.2.1.1.1 14-1.2.1.1 16-1.2.1.1.2 17-1.2 19-1.2.2 20-1.2.2.1.r 21-1.2.2.1.2.1.1 22-1.2.2.1.2.2 23-1.2.1.1.1 23-1.2.2.1.2 26-1.2.2.2 28-1.2.2.2.1.1.1
# ::id bel_pmid_1159_1769_27658
(s / show-01~e.4
      :ARG0 (a / and~e.1
            :op1 (w / we~e.0)
            :op2 (p2 / person
                  :mod (o / other~e.2)))
      :ARG1~e.5 (s2 / stimulate-01~e.17
            :ARG0 (a2 / activate-01~e.6
                  :ARG1~e.7 (a3 / and~e.14
                        :op1 (p3 / protein~e.23
                              :name (n / name :op1 "IL-4"~e.8,10)
                              :ARG1-of (d / describe-01
                                    :ARG0 (p4 / publication
                                          :ARG1-of (c / cite-01 :ARG2 "23"~e.12))))
                        :op2 (r / receptor~e.16
                              :name (n2 / name :op1 "IFN-alpha"))))
            :ARG1 (p / phosphorylate-01~e.19
                  :ARG1~e.20 (a4 / amino-acid
                        :name (n3 / name :op1 "tyrosine")
                        :part-of (p5 / protein~e.23
                              :name (n4 / name :op1 "IRS"~e.21)
                              :ARG1-of (d2 / dock-01~e.22)))
                  :ARG0-of (d3 / depend-01~e.26
                        :ARG1 (e / enzyme
                              :name (n5 / name :op1 "Jak"~e.28))))))

# ::tok IL @-@ 10 can directly promote the death of inflammatory cells , including activated macrophages ( 4 ) , neutrophils ( 5 ) , and T cells
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 3-1 4-1.1.3 4-1.1.3.r 5-1.1 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1.1 10-1.1.2.1 12-1.1.2.1.2 13-1.1.2.1.2.1.1.1 14-1.1.2.1.2.1.1 16-1.1.2.1.2.1.1.2.1.1.1 19-1.1.2.1.2.1.2 21-1.1.2.1.2.1.2.1.1.1.1 24-1.1.2.1.2.1 25-1.1.2.1.2.1.3.1.1 26-1.1.2.1.2.1.3
# ::id bel_pmid_1159_1769_27854
(p / possible~e.3
      :domain (p2 / promote-02~e.5
            :ARG0 (p3 / protein
                  :name (n / name :op1 "IL-10"~e.0,2))
            :ARG1 (d2 / die-01~e.7
                  :ARG1~e.8 (c / cell~e.10
                        :ARG0-of (i / inflame-01~e.9)
                        :ARG2-of (i2 / include-01~e.12
                              :ARG1 (a / and~e.24
                                    :op1 (m / macrophage~e.14
                                          :ARG1-of (a2 / activate-01~e.13)
                                          :ARG1-of (d3 / describe-01
                                                :ARG0 (p4 / publication
                                                      :ARG1-of (c2 / cite-01 :ARG2 "4"~e.16))))
                                    :op2 (n2 / neutrophil~e.19
                                          :ARG1-of (d4 / describe-01
                                                :ARG0 (p5 / publication
                                                      :ARG1-of (c3 / cite-01 :ARG2 "5"~e.21))))
                                    :op3 (c4 / cell~e.26
                                          :name (n3 / name :op1 "T"~e.25))))))
            :manner~e.4 (d / direct~e.4)))

# ::tok In contrast , IL @-@ 10 increases the survival of some types of human cancer cells , such as Burkitt lymphoma ( 7 ) . Non @-@ Hodgkin s lymphoma cells secrete IL @-@ 10 , and inhibition of this autocrine IL @-@ 10 has recently been shown to promote cell death and reduce expression of the anti @-@ apoptotic protein Bcl @-@ 2
# ::alignments 1-1.1 3-1.1.1.1.1.1 5-1.1.1.1.1.1 6-1.1.1 8-1.1.1.2 9-1.1.1.2.1.r 10-1.1.1.2.1.2.1 11-1.1.1.2.1.2 12-1.1.1.2.1.2.r 13-1.1.1.2.1.1.1 14-1.1.1.2.1.1 15-1.1.1.2.1 17-1.1.1.2.1.1.2.r 18-1.1.1.2.1.1.2.r 19-1.1.1.2.1.1.2.1.1 20-1.1.1.2.1.1.2.1.2 22-1.1.2.1.1.1 25-1.2.1.1.1.1.1 27-1.2.1.1.1.1.1 29-1.2.1.1.1.1.2 30-1.2.1.1 31-1.2.1 32-1.2.1.2.1.1 34-1.2.1.2.1.1 36-1.2 37-1.2.2.1.1.1 40-1.2.2.1.1.1.1 41-1.2.2.1.1.1.1 42-1.2.2.1.1.1.1 43-1.2.2.1.1.1.1 45-1.2.2.2 47-1.2.2 49-1.2.2.1.1 50-1.2.2.1.1.2.1 51-1.2.2.1.1.2 52-1.2.2.1 53-1.2.2.1.2 54-1.2.2.1.2.2 55-1.2.2.1.2.2.1.r 57-1.2.2.1.2.2.1.2 59-1.2.2.1.2.2.1.2.1 60-1.1.1.1 60-1.2.1.2 60-1.2.2.1.2.2.1 61-1.2.2.1.2.2.1.1.1 63-1.2.2.1.2.2.1.1.1
# ::id bel_pmid_1159_1769_27880
(m / multi-sentence
      :snt1 (c / contrast-01~e.1
            :ARG2 (i / increase-01~e.6
                  :ARG0 (p / protein~e.60
                        :name (n2 / name :op1 "IL-10"~e.3,5))
                  :ARG1 (s / survive-01~e.8
                        :ARG0~e.9 (c2 / cell~e.15
                              :mod (c3 / cancer~e.14
                                    :mod (h / human~e.13)
                                    :example~e.17,18 (d / disease
                                          :name (n / name :op1 "Burkitt"~e.19 :op2 "lymphoma"~e.20)))
                              :mod~e.12 (t / type~e.11
                                    :quant (s2 / some~e.10)))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p2 / publication
                        :ARG1-of (c4 / cite-01 :ARG2 "7"~e.22))))
      :snt2 (a / and~e.36
            :op1 (s3 / secrete-01~e.31
                  :ARG0 (c5 / cell~e.30
                        :mod (d4 / disease
                              :name (n4 / name :op1 "non-Hodgkin"~e.25,27 :op2 "lymphoma"~e.29)))
                  :ARG1 (p3 / protein~e.60
                        :name (n3 / name :op1 "IL-10"~e.32,34)
                        :mod (a3 / autocrine)))
            :op2 (s4 / show-01~e.47
                  :ARG1 (a2 / and~e.52
                        :op1 (p4 / promote-01~e.49
                              :ARG0 (i2 / inhibit-01~e.37
                                    :ARG1 p3~e.40,41,42,43)
                              :ARG1 (d3 / die-01~e.51
                                    :ARG1 (c6 / cell~e.50)))
                        :op2 (r / reduce-01~e.53
                              :ARG0 i2
                              :ARG1 (e / express-03~e.54
                                    :ARG2~e.55 (p5 / protein~e.60
                                          :name (n5 / name :op1 "Bcl-2"~e.61,63)
                                          :ARG0-of (c7 / counter-01~e.57
                                                :ARG1 (a4 / apoptosis~e.59))))))
                  :time (r2 / recent~e.45))))

# ::tok Similarly , IL @-@ 10 increases the expression of Bcl @-@ xL in thyrocytes from patients with Graves disease
# ::alignments 0-1.3 2-1.1.1.1 4-1.1.1.1 5-1 7-1.2 8-1.2.1.r 9-1.2.1.1.1 11-1.2.1.1.1 14-1.2.2.1.r 15-1.2.2.1.2.1 17-1.2.2.1.1.1.1.1 18-1.2.2.1.1.1
# ::id bel_pmid_1159_1769_27882
(i / increase-01~e.5
      :ARG0 (p / protein
            :name (n / name :op1 "IL-10"~e.2,4))
      :ARG1 (e / express-03~e.7
            :ARG2~e.8 (p2 / protein
                  :name (n2 / name :op1 "Bcl-xL"~e.9,11))
            :ARG3 (t / thyrocyte
                  :source~e.14 (p3 / person
                        :ARG0-of (s / suffer-01
                              :ARG1 (d / disease~e.18
                                    :name (n5 / name :op1 "Graves"~e.17)))
                        :ARG0-of (h / have-rel-role-91
                              :ARG2 (p4 / patient~e.15)))))
      :ARG1-of (r / resemble-01~e.0))

# ::tok LDL , in pathophysiological concentrations , affect the IGF @-@ I signaling pathway at multiple levels : 1 ) they induce phosphorylation of IGF @-@ I receptor beta and IRS @-@ 1 in a time @- and dose @-@ dependent manner ; 2 ) they up @-@ regulate IRS @-@ 1 @-@ associated PI3 kinase @/@ Akt activation in response to IGF @-@ I at early times ; and 3 ) they show additive effects with IGF @-@ I on extracellular signal @-@ regulated MAPK 1 @/@ 2 phosphorylation .
# ::alignments 0-1.1.1.1 4-1.1.2 6-1 8-1.2.1.1 10-1.2.1.1 11-1.2.2 12-1.2 12-1.3.2.1.2.2.1 13-1.3.r 14-1.3.1 15-1.3 17-1.3.2.1.1.1 19-1.3.2.1.1.2 20-1.3.2.1.1 21-1.3.2.1.1.3 22-1.3.2.1.1.3.1.r 23-1.3.2.1.1.3.1.1.1.1 25-1.3.2.1.1.3.1.1.1.1 26-1.3.2.1.1.3.1.1.1.2 27-1.3.2.1.1.3.1.1.1.3 28-1.3.2.1.1.3.1 29-1.3.2.1.1.3.1.2.1.1 31-1.3.2.1.1.1 31-1.3.2.1.1.3.1.2.1.1 34-1.3.2.1.1.4.2.1 36-1.3.2.1.1.4.2 37-1.3.2.1.1.4.2.2 39-1.3.2.1.1.4 40-1.3.2.1.1.4.r 42-1.3.2.1.2.1 47-1.3.2.1.3.3.2.2 48-1.3.2.1.1.3.1.2.1.1 50-1.3.2.1.1.1 50-1.3.2.1.1.3.1.2.1.1 52-1.3.2.1.2.2.2 53-1.3.2.1.2.2.1.1.1 54-1.3.2.1.2.2.1.1.1 56-1.3.2.1.2.2.1.1.1 57-1.3.2.1.2.2 59-1.3.2.1.2.4 61-1.3.2.1.1.3.1.1.1.1 63-1.3.2.1.1.1 63-1.3.2.1.1.3.1.2.1.1 65-1.3.2.1.2.5 66-1.3.2.1.2.5.r 68-1.3.2.1 68-1.3.2.1.3.3.2.1 69-1.3.2.1.3.1 72-1.3.2.1.3 74-1.3.2.1.3.3 76-1.3.2.1.1.3.1.1.1.1 78-1.3.2.1.1.1 78-1.3.2.1.1.3.1.2.1.1 80-1.3.2.1.3.3.2.2.1.1 81-1.3.2.1.3.3.2.2.1 83-1.3.2.1.3.3.2.2 85-1.3.2.1.1.1 85-1.3.2.1.1.3.1.2.1.1 87-1.3.2.1.2.1 88-1.3.2.1.3.3.2
# ::id bel_pmid_1160_6453_38354
(a / affect-01~e.6
      :ARG0 (m3 / molecular-physical-entity
            :name (n2 / name :op1 "LDL"~e.0)
            :quant (c / concentration~e.4
                  :mod (p2 / pathophysiology)))
      :ARG1 (p4 / pathway~e.12
            :name (n3 / name :op1 "IGF-I"~e.8,10)
            :ARG0-of (s2 / signal-01~e.11))
      :manner~e.13 (l / level~e.15
            :quant (m / multiple~e.14)
            :ARG1-of (m2 / mean-01
                  :ARG2 (a2 / and~e.68
                        :op1 (i / induce-01~e.20
                              :li "1"~e.17,31,50,63,78,85
                              :ARG0 m3~e.19
                              :ARG1 (p / phosphorylate-01~e.21
                                    :ARG2~e.22 (a3 / and~e.28
                                          :op1 (p6 / protein-segment
                                                :name (n4 / name
                                                      :op1 "IGF-I"~e.23,25,61,76
                                                      :op2 "receptor"~e.26
                                                      :op3 "beta"~e.27))
                                          :op2 (p7 / protein
                                                :name (n5 / name :op1 "IRS-1"~e.29,31,48,50,63,78,85))))
                              :manner~e.40 (d / depend-01~e.39
                                    :ARG0 p
                                    :ARG1 (a4 / and~e.36
                                          :op1 (t / time~e.34)
                                          :op2 (d2 / dose~e.37))))
                        :op2 (u / upregulate-01
                              :li "2"~e.42,87
                              :ARG1 (a5 / activate-01~e.57
                                    :ARG1 (p8 / pathway~e.12
                                          :name (n6 / name :op1 "PI3-kinase/Akt"~e.53,54,56))
                                    :ARG1-of (a6 / associate-01~e.52
                                          :ARG2 p7))
                              :ARG2 m3
                              :ARG2-of (r / respond-01~e.59
                                    :ARG1 (p5 / protein))
                              :time~e.66 (e / early~e.65))
                        :op3 (s3 / show-01~e.72
                              :li "3"~e.69
                              :ARG0 m3
                              :ARG1 (a7 / affect-01~e.74
                                    :ARG0 m3
                                    :ARG1 (p9 / phosphorylate-01~e.88
                                          :ARG1 (a9 / and~e.68
                                                :op1 (e3 / enzyme
                                                      :name (n / name :op1 "MAPK1"))
                                                :op2 (e4 / enzyme
                                                      :name (n7 / name :op1 "MAPK2")))
                                          :ARG1-of (r2 / regulate-01~e.47,83
                                                :ARG0 (s4 / signal-01~e.81
                                                      :mod (e2 / extracellular~e.80))))
                                    :ARG1-of (a8 / add-02
                                          :ARG2 p5)))))))

# ::tok identification of an acidic domain of gp130 as a binding region for Hck , which mediates proliferative signaling the deletion of this region of gp130 resulted in a significant reduction of Hck kinase activity and cell proliferation upon stimulation of gp130 compared to wild @-@ type gp130
# ::alignments 0-1.1 1-1.1.1.r 3-1.1.1.1 6-1.1.1.2.1.1 7-1.1.2.r 9-1.1.2.1 10-1.1.2 12-1.1.2.1.1.1.1 15-1.1.2.2 17-1.1.2.2.1 19-1.2.1 20-1.2.1.1.r 21-1.2.1.1.1 22-1.1.2 24-1.2.1.1.2.1.1 25-1.2 26-1.2.2.r 28-1.2.2.2 29-1.2.2 30-1.2.2.1.r 31-1.2.2.1.1.1.1.1 32-1.1.2.1.1 32-1.2.2.1.1.1 34-1.2.2.1 35-1.2.2.1.2.1 36-1.1.2.2.1.1 36-1.2.2.1.2 38-1.2.2.4 40-1.2.2.3.1.1 41-1.2.2.3.r 43-1.2.2.3.2 45-1.2.2.3.2 46-1.2.2.3.1.1
# ::id bel_pmid_1168_9697_19254
(m / multi-sentence
      :snt1 (i / identify-01~e.0
            :ARG1~e.1 (p / protein-segment
                  :mod (a / acid~e.3)
                  :part-of (p2 / protein
                        :name (n / name :op1 "gp130"~e.6)))
            :ARG2~e.7 (r / region~e.10,22
                  :ARG2-of (b / bind-01~e.9
                        :ARG1 (k2 / kinase~e.32
                              :name (n2 / name :op1 "Hck"~e.12)))
                  :ARG0-of (m2 / mediate-01~e.15
                        :ARG1 (s / signal-01~e.17
                              :mod (p3 / proliferate-01~e.36)))))
      :snt2 (r2 / result-01~e.25
            :ARG1 (d / delete-01~e.19
                  :ARG1~e.20 (p4 / protein-segment
                        :mod (t / this~e.21)
                        :part-of (p5 / protein
                              :name (n3 / name :op1 "gp130"~e.24))))
            :ARG2~e.26 (r3 / reduce-01~e.29
                  :ARG1~e.30 (a4 / and~e.34
                        :op1 (a3 / act-01
                              :ARG0 (k3 / kinase~e.32
                                    :name (n4 / name :op1 "Hck"~e.31)))
                        :op2 (p6 / proliferate-01~e.36
                              :ARG0 (c / cell~e.35)))
                  :ARG2 (s2 / significant~e.28)
                  :compared-to~e.41 (p7 / protein
                        :name (n5 / name :op1 "gp130"~e.40,46)
                        :mod (w / wild-type~e.43,45))
                  :condition (s3 / stimulate-01~e.38
                        :ARG1 p5))))

# ::tok Il6 induces the activation of the Src family kinase Hck , which is associated with the Il6 receptor beta @-@ chain , gp130
# ::alignments 1-1 3-1.2 4-1.2.1.r 6-1.2.1.2.1.1.1.1 7-1.2.1.2.1 8-1.2.1 8-1.2.1.2.1.1 9-1.2.1.1.1 13-1.2.1.3 17-1.2.1.3.1.1.2 18-1.2.1.3.1.1.3 20-1.2.1.3.1.1.3 22-1.2.1.3.1.2.1.1.1
# ::id bel_pmid_1168_9697_28350
(i / induce-01~e.1
      :ARG0 (p / protein
            :name (n / name :op1 "IL-6"))
      :ARG1 (a / activate-01~e.3
            :ARG1~e.4 (k2 / kinase~e.8
                  :name (n2 / name :op1 "Hck"~e.9)
                  :ARG1-of (i2 / include-01
                        :ARG2 (f / family~e.7
                              :mod (k / kinase~e.8
                                    :name (n3 / name :op1 "Src"~e.6))))
                  :ARG1-of (a2 / associate-01~e.13
                        :ARG2 (p3 / protein
                              :name (n4 / name
                                    :op1 "IL-6"
                                    :op2 "receptor"~e.17
                                    :op3 "beta-chain"~e.18,20)
                              :ARG1-of (m / mean-01
                                    :ARG2 (p2 / protein
                                          :name (n5 / name :op1 "gp130"~e.22))))))))

# ::tok this acidic domain of gp130 is responsible for the activation of Hck , Erk , Pyk2 and signals cell proliferation upon growth factor stimulation
# ::alignments 0-1.1.1.3 1-1.1.1.1 4-1.1.1.2.1.1 6-1.1 7-1.1.2.r 9-1.1.2 10-1.1.2.1.r 11-1.1.2.1.1.1.1 13-1.1.2.1.2.1.1 15-1.1.2.1.3.1.1 16-1 16-1.1.2.1 17-1.2 18-1.2.2.1 19-1.2.2 21-1.2.3.1.1.1 22-1.2.3.1.1.2 23-1.2.3
# ::id bel_pmid_1168_9697_28396
(a / and~e.16
      :op1 (r / responsible-01~e.6
            :ARG0 (p / protein-segment
                  :mod (a3 / acid~e.1)
                  :part-of (p2 / protein
                        :name (n3 / name :op1 "gp130"~e.4))
                  :mod (t / this~e.0))
            :ARG1~e.7 (a2 / activate-01~e.9
                  :ARG1~e.10 (a4 / and~e.16
                        :op1 (e2 / enzyme
                              :name (n4 / name :op1 "Hck"~e.11))
                        :op2 (e3 / enzyme
                              :name (n5 / name :op1 "Erk"~e.13))
                        :op3 (e4 / enzyme
                              :name (n6 / name :op1 "Pyk2"~e.15)))))
      :op2 (s2 / signal-01~e.17
            :ARG0 p
            :ARG1 (p3 / proliferate-01~e.19
                  :ARG0 (c / cell~e.18))
            :condition (s3 / stimulate-01~e.23
                  :ARG2 (s / small-molecule
                        :name (n2 / name :op1 "growth"~e.21 :op2 "factor"~e.22)))))

# ::tok It hasrecently been reported that a cytosolic isoform of PTPepsilon ( PTPepsilonC ) whenover @-@ expressed in murine M1 myeloid cells inhibits interleukin @-@ 6 ( IL @-@ 6 )- and leukemia inhibitory factor @-@ induced activation of Janus kinases ( JAKs ) , thereby suppressing STAT3 tyrosine phosphorylation and STAT3 signaling .
# ::alignments 3-1 4-1.1.r 6-1.1.1.1 7-1.1.1 8-1.1.1.2.r 9-1.1.1.2.1.1 11-1.1.1.3.1.1.1 18-1.1.3.2.1.1 19-1.1.3.2.2 20-1.1.3.2 21-1.1 22-1.1.2.2.1.1.1.1 24-1.1.2.2.1.1.1.1 24-1.1.2.2.1.1.2.1.1.1 26-1.1.2.2.1.1.2.1.1.1 28-1.1.2.2.1.1.1.1 28-1.1.2.2.1.1.2.1.1.1 30-1.1.2.2.1 31-1.1.2.2.1.2.1.1 32-1.1.2.2.1.2.1.2 33-1.1.2.2.1.2.1.3 35-1.1.2.2 36-1.1.2 37-1.1.2.1.r 38-1.1.2.1.1.1 39-1.1.2.1 39-1.1.2.1.2.1 45-1.1.4.1 46-1.1.4.1.2.1.1.2.1.1 47-1.1.4.1.2.1.1.1.1 48-1.1.4.1.2.1 50-1.1.4.1.2.2.1 51-1.1.4.1.2.2
# ::id bel_pmid_1169_8287_20332
(r / report-01~e.3
      :ARG1~e.4 (i / inhibit-01~e.21
            :ARG0 (i2 / isoform~e.7
                  :part-of (c / cytosol~e.6)
                  :mod~e.8 (e / enzyme
                        :name (n2 / name :op1 "PTPepsilon"~e.9))
                  :ARG1-of (d2 / describe-01
                        :ARG2 (e2 / enzyme
                              :name (n3 / name :op1 "PTPepsilonC"~e.11))))
            :ARG1 (a / activate-01~e.36
                  :ARG1~e.37 (k / kinase~e.39
                        :name (n5 / name :op1 "Janus"~e.38)
                        :ARG1-of (d3 / describe-01
                              :ARG2 (k2 / kinase~e.39
                                    :name (n6 / name :op1 "JAK"))))
                  :ARG1-of (i3 / induce-01~e.35
                        :ARG0 (a3 / and~e.30
                              :op1 (p2 / protein
                                    :name (n7 / name :op1 "interleukin-6"~e.22,24,28)
                                    :ARG1-of (d4 / describe-01
                                          :ARG2 (p3 / protein
                                                :name (n8 / name :op1 "IL-6"~e.24,26,28))))
                              :op2 (p5 / protein
                                    :name (n / name
                                          :op1 "leukemia"~e.31
                                          :op2 "inhibitory"~e.32
                                          :op3 "factor"~e.33)))))
            :condition (o / overexpress-00
                  :ARG2 i2
                  :ARG3 (c2 / cell-line~e.20
                        :name (n4 / name :op1 "M1"~e.18)
                        :mod (m / myeloid~e.19)
                        :part-of (m2 / mouse)))
            :ARG0-of (c3 / cause-01
                  :ARG1 (s / suppress-01~e.45
                        :ARG0 i2
                        :ARG1 (a5 / and
                              :op1 (p / phosphorylate-01~e.48
                                    :ARG1 (a2 / amino-acid
                                          :name (n11 / name :op1 "tyrosine"~e.47)
                                          :part-of (p4 / protein
                                                :name (n10 / name :op1 "STAT3"~e.46))))
                              :op2 (s2 / signal-01~e.51
                                    :ARG2 p4~e.50)))))
      :time (r2 / recent))

# ::tok Others are themselves enzymes , including the phosphotyrosine phosphatase SHP2 and the cytoplasmic tyrosine kinase Fyn .
# ::alignments 0-1.1.1 1-1.1.r 3-1 5-1.1.2 7-1.1.2.1.1.1.1 8-1.1.2.1.1.1.2 9-1.1.2.1.1.2.1.1.1 10-1.1.2.1 12-1.1.2.1.2.2 13-1.1.2.1.2.3 14-1.1.2.1.2 15-1.1.2.1.2.1.1
# ::id bel_pmid_1174_2412_20342
(e / enzyme~e.3
      :domain~e.1 (m / molecular-physical-entity
            :mod (o / other~e.0)
            :ARG2-of (i / include-01~e.5
                  :ARG1 (a / and~e.10
                        :op1 (e5 / enzyme
                              :name (n / name :op1 "phosphotyrosine"~e.7 :op2 "phosphatase"~e.8)
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (e3 / enzyme
                                          :name (n2 / name :op1 "SHP2"~e.9))))
                        :op2 (k / kinase~e.14
                              :name (n4 / name :op1 "Fyn"~e.15)
                              :part-of (c / cytoplasm~e.12)
                              :mod (t / tyrosine~e.13))))))

# ::tok Blockade of the pathway with dominant negative mutants or pharmacological inhibitors prevents the stimulation of cell growth by insulin , but has no effect on the metabolic actions of the hormone deletion of Akt2 produces hepatic insulin resistance in mice
# ::alignments 3-1.1.1.1.1 5-1.1.1.1.2.1.2 6-1.1.1.1.2.1.3 7-1.1.1.1.2.1 7-1.1.1.1.2.1.1 7-1.1.1.1.2.1.1.r 8-1.1.1.1.2 9-1.1.1.1.2.2.2 10-1.1.1.1.2.2 10-1.1.1.1.2.2.1 10-1.1.1.1.2.2.1.r 11-1.1.1 13-1.1.1.2 14-1.1.1.2.1.r 15-1.1.1.2.1.1 16-1.1.1.2.1 17-1.1.1.2.2.r 18-1.1.1.2.2.1.1 20-1.1 22-1.1.2.1 22-1.1.2.1.r 23-1.1.2 27-1.1.2.3 28-1.1.2.3.1.r 30-1.1.2.3.1 31-1.2.1 32-1.2.1.1.r 33-1.2.1.1.1.1 34-1.2 35-1.2.2.1 36-1.1.1.2.2.1.1 37-1.2.2 38-1.2.3.r 39-1.2.3
# ::id bel_pmid_1174_2412_25070
(m2 / multi-sentence
      :snt1 (c / contrast-01~e.20
            :ARG1 (p / prevent-01~e.11
                  :ARG0 (b / block-01
                        :ARG1 (p2 / pathway~e.3)
                        :ARG3 (o / or~e.8
                              :op1 (g2 / gene~e.7
                                    :ARG2-of~e.7 (m / mutate-01~e.7)
                                    :ARG0-of (d / dominate-01~e.5)
                                    :mod (n4 / negative~e.6))
                              :op2 (m5 / molecular-physical-entity~e.10
                                    :ARG0-of~e.10 (i / inhibit-01~e.10)
                                    :mod (p3 / pharmacological~e.9))))
                  :ARG1 (s / stimulate-01~e.13
                        :ARG1~e.14 (g / grow-01~e.16
                              :ARG1 (c2 / cell~e.15))
                        :ARG2~e.17 (p6 / protein
                              :name (n / name :op1 "insulin"~e.18,36))))
            :ARG2 (a / affect-01~e.23
                  :polarity~e.22 "-"~e.22
                  :ARG0 b
                  :ARG1 (a2 / act-01~e.27
                        :ARG0~e.28 (h / hormone~e.30
                              :ARG1-of (m6 / mean-01
                                    :ARG2 p6))
                        :ARG1 (m3 / metabolize-01))))
      :snt2 (p4 / produce-01~e.34
            :ARG0 (d2 / delete-01~e.31
                  :ARG1~e.32 (e / enzyme
                        :name (n2 / name :op1 "Akt2"~e.33)))
            :ARG1 (r / resist-01~e.37
                  :ARG0 (l / liver~e.35)
                  :ARG1 (p5 / protein
                        :name (n3 / name :op1 "insuline")))
            :location~e.38 (m4 / mouse~e.39)))

# ::tok Upon its activation downstream of PI( 3 ) K , Akt phosphorylates and inactivates GSK @-@ 3 , decreasing the rate of phosphorylation of glycogen synthase , thus increasing its activity state59 .
# ::alignments 1-1.4.1 1-1.4.1.r 2-1.4 3-1.4.2.2 6-1.1.1.1.1 10-1.1.2.1.1 11-1.1 12-1 13-1.2 14-1.2.2 15-1.2.2 16-1.2.2 18-1.3.1 20-1.3.1.1 21-1.3.1.1.1.r 22-1.3.1.1.1 23-1.3.1.1.1.1.r 24-1.3.1.1.1.1.1.1 25-1.3.1.1.1.1.1.2 27-1.3 27-1.3.1.2 28-1.3.1.2.1
# ::id bel_pmid_1174_2412_38246
(a / and~e.12
      :op1 (p / phosphorylate-01~e.11
            :ARG1 (k / kinase
                  :name (n2 / name :op1 "GSK-3"~e.6))
            :ARG2 (e / enzyme
                  :name (n / name :op1 "Akt"~e.10)))
      :op2 (i / inactivate-00~e.13
            :ARG0 e
            :ARG1 k~e.14,15,16)
      :ARG0-of (c / cause-01~e.27
            :ARG1 (d / decrease-01~e.18
                  :ARG1 (r / rate~e.20
                        :degree-of~e.21 (p2 / phosphorylate-01~e.22
                              :ARG1~e.23 (e2 / enzyme
                                    :name (n3 / name :op1 "glycogen"~e.24 :op2 "synthase"~e.25))))
                  :ARG0-of (c2 / cause-01~e.27
                        :ARG1 (i2 / increase-01~e.28
                              :ARG1 (s / state
                                    :mod (a2 / act-01
                                          :ARG0 e2))))))
      :condition (a3 / activate-01~e.2
            :ARG1~e.1 e~e.1
            :location (r2 / relative-position
                  :op1 (e3 / enzyme
                        :name (n4 / name :op1 "PI(3)K"))
                  :direction (d2 / downstream~e.3)))
      :ARG1-of (d3 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "59"))))

# ::tok interleukin @-@ 6 ( IL @-@ 6 ) or leukemia inhibitory factor ( LIF )-induced differentiation of the myeloid cell line M1 was associated with a rapid increase in the level of mRNA encoding the signaling adaptor protein , SKAP55R
# ::alignments 0-1.1.2.1.1.1.1 2-1.1.2.1.1.1.1 2-1.1.2.1.1.2.1.1.1 4-1.1.2.1.1.2.1.1.1 6-1.1.2.1.1.1.1 6-1.1.2.1.1.2.1.1.1 8-1.1.2.1 9-1.1.2.1.2.1.1 10-1.1.2.1.2.1.2 11-1.1.2.1.2.1.3 13-1.1.2.1.2.2.1.1.1 15-1.1 16-1.1.1.r 18-1.1.1.2 19-1.1.1 20-1.1.1 21-1.1.1.1.1 23-1 24-1.2.r 26-1.2.2 27-1.2 28-1.2.1.r 30-1.2.1 32-1.2.1.1.1.1 33-1.2.1.1.2 35-1.2.1.1.2.1.3 36-1.2.1.1.2.1.2 37-1.1.2.1.1 37-1.1.2.1.1.2.1 37-1.1.2.1.2 37-1.2.1.1.2.1 39-1.2.1.1.2.1.1.1
# ::id bel_pmid_1175_3615_28390
(a / associate-01~e.23
      :ARG1 (d2 / differentiate-01~e.15
            :ARG1~e.16 (c / cell-line~e.19,20
                  :name (n2 / name :op1 "M1"~e.21)
                  :mod (m / myeloid~e.18))
            :ARG1-of (i / induce-01
                  :ARG0 (o / or~e.8
                        :op1 (p / protein~e.37
                              :name (n3 / name :op1 "interleukin-6"~e.0,2,6)
                              :ARG1-of (d3 / describe-01
                                    :ARG2 (p2 / protein~e.37
                                          :name (n4 / name :op1 "IL-6"~e.2,4,6))))
                        :op2 (p5 / protein~e.37
                              :name (n5 / name
                                    :op1 "leukemia"~e.9
                                    :op2 "inhibitory"~e.10
                                    :op3 "factor"~e.11)
                              :ARG1-of (d4 / describe-01
                                    :ARG2 (s2 / small-molecule
                                          :name (n6 / name :op1 "LIF"~e.13)))))))
      :ARG2~e.24 (i2 / increase-01~e.27
            :ARG1~e.28 (l / level~e.30
                  :quant-of (r2 / rna
                        :name (n7 / name :op1 "mRNA"~e.32)
                        :ARG0-of (e / encode-01~e.33
                              :ARG1 (p4 / protein~e.37
                                    :name (n9 / name :op1 "SKAP55R"~e.39)
                                    :mod (a2 / adaptor~e.36)
                                    :ARG0-of (s3 / signal-01~e.35)))))
            :mod (r / rapid~e.26)))

# ::tok inflammatory cytokines , notably Tnf @-@ alpha , and Il6 , induce the expression of Cox2 and the secretion of Pge2 in human prostate cancer cell lines
# ::alignments 0-1.1.2 3-1.1.1.1.3 4-1.1.1.1.1.1.1 6-1.1.1.1.1.1.1 8-1.1.1.1 9-1.1.1.1.2.1.1 11-1 13-1.2.1 14-1.2.1.1.r 15-1.2.1.1.1.1 16-1.2 18-1.2.2 19-1.2.2.1.r 20-1.2.2.1.1.1 21-1.2.r 22-1.2.3.2 23-1.2.3.1.1 24-1.2.3.1 25-1.2.3 26-1.2.3
# ::id bel_pmid_1177_9161_28386
(i / induce-01~e.11
      :ARG0 (c3 / cytokine
            :ARG2-of (i2 / include-91
                  :ARG1 (a2 / and~e.8
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "Tnf-alpha"~e.4,6))
                        :op2 (p3 / protein
                              :name (n4 / name :op1 "Il6"~e.9))
                        :mod (n3 / notable~e.3)))
            :ARG0-of (i3 / inflame-01~e.0))
      :ARG1~e.21 (a / and~e.16
            :op1 (e / express-03~e.13
                  :ARG2~e.14 (e2 / enzyme
                        :name (n5 / name :op1 "Cox2"~e.15)))
            :op2 (s / secrete-01~e.18
                  :ARG1~e.19 (m / molecular-physical-entity
                        :name (n6 / name :op1 "Pge2"~e.20)))
            :location (c / cell-line~e.25,26
                  :mod (c2 / cancer~e.24
                        :mod (p4 / prostate~e.23))
                  :mod (h / human~e.22))))

# ::tok the human COx2 gene contains a putative NF @-@ IL @-@ 6 element in the 5 ' @-@ flanking promoter region which can be activated by Il6
# ::alignments 1-1.1.2 2-1.1.1.1 3-1.1 4-1 6-1.2.2 7-1.2.1.1.1 9-1.2.1.1.1 11-1.2.1.1.1 12-1.2 18-1.3.1.1.1 20-1.3 22-1.2.3 22-1.2.4.2 24-1.2.4 25-1.2.4.1.r 26-1.2.4.1.1.1
# ::id bel_pmid_1177_9161_28388
(c / contain-01~e.4
      :ARG0 (g / gene~e.3
            :name (n / name :op1 "COx2"~e.2)
            :mod (h / human~e.1))
      :ARG1 (e2 / element~e.12
            :mod (p / protein
                  :name (n2 / name :op1 "NF-IL-6"~e.7,9,11))
            :ARG1-of (t / think-01~e.6)
            :mod (p3 / possible~e.22)
            :ARG1-of (a2 / activate-01~e.24
                  :ARG0~e.25 (p5 / protein
                        :name (n4 / name :op1 "Il6"~e.26))
                  :mod (p4 / possible~e.22)))
      :location (r / region~e.20
            :mod (d / dna-sequence
                  :name (n3 / name :op1 "5'-flanking"~e.18))
            :ARG0-of (p2 / promote-01)))

# ::tok events lead to activation of Stat signaling and result in the induction of proteins , such as bcl @-@ 2 and cMyc , both of which are critical regulators of cell cycle progression and apoptosis
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.r 3-1.1.2 4-1.1.2.1.r 5-1.1.2.1.1.1 6-1.1.2.1.2 7-1 8-1.2 13-1.2.2.1 15-1.2.2.1.1.r 16-1.2.2.1.1.r 17-1.2.2.1.1.1.1.1 19-1.2.2.1.1.1.1.1 20-1.2.2.1.1 21-1.2.2.1.1.2.1.1 23-1.2.2.1.1.3.3 27-1.2.2.1.1.3.2 28-1.2.2.1.1.3 29-1.2.2.1.1.3.1.r 30-1.2.2.1.1.3.1.1.1.1 31-1.2.2.1.1.3.1.1.1 32-1.2.2.1.1.3.1.1 33-1.2.2.1.1.3.1 34-1.2.2.1.1.3.1.2
# ::id bel_pmid_1177_9161_34138
(a / and~e.7
      :op1 (l / lead-03~e.1
            :ARG0 (e / event~e.0)
            :ARG2~e.2 (a2 / activate-01~e.3
                  :ARG1~e.4 (p / protein
                        :name (n / name :op1 "Stat"~e.5)
                        :ARG1-of (s / signal-01~e.6))))
      :op2 (r / result-01~e.8
            :ARG1 e
            :ARG2 (i / induct-01
                  :ARG1 (p2 / protein~e.13
                        :example~e.15,16 (a3 / and~e.20
                              :op1 (p3 / protein
                                    :name (n2 / name :op1 "bcl-2"~e.17,19))
                              :op2 (p4 / protein
                                    :name (n3 / name :op1 "cMyc"~e.21))
                              :ARG0-of (r2 / regulate-01~e.28
                                    :ARG1~e.29 (a4 / and~e.33
                                          :op1 (p5 / progress-01~e.32
                                                :ARG1 (c2 / cycle~e.31
                                                      :mod (c3 / cell~e.30)))
                                          :op2 (a5 / apoptosis~e.34
                                                :mod c2))
                                    :mod (c / critical~e.27)
                                    :mod (b / both~e.23)))))))

# ::tok Further work revealed that TGF @-@ R signaling ( Massague and Wotton , 2000 ) was required for EMT , invasion in vitro , and metastasis in vivo ,
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.r 4-1.2.2.1.1.1 6-1.2.2.1.1.1 7-1.2.2 9-1.3.1.1.1.1.1 10-1.3.1.1 11-1.3.1.1.2.1.1 13-1.3.1.2.1 16-1.2 17-1.2.1.r 18-1.2.1.1.1.1 20-1.2.1.2 21-1.2.1.2.1 22-1.2.1.2.1 24-1.2.1 25-1.2.1.3 26-1.2.1.3.1 27-1.2.1.3.1
# ::id bel_pmid_1179_0801_20476
(r / reveal-01~e.2
      :ARG0 (w / work-01~e.1
            :degree (f / further~e.0))
      :ARG1~e.3 (r2 / require-01~e.16
            :ARG0~e.17 (a2 / and~e.24
                  :op1 (t / thing
                        :name (n4 / name :op1 "EMT"~e.18))
                  :op2 (i / invade-01~e.20
                        :manner (i2 / in-vitro~e.21,22))
                  :op3 (m / metastasis~e.25
                        :manner (i3 / in-vivo~e.26,27)))
            :ARG1 (s / signal-01~e.7
                  :ARG1 (p / pathway
                        :name (n / name :op1 "TGF-R"~e.4,6))))
      :ARG1-of (d / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a / and~e.10
                        :op1 (p3 / person
                              :name (n2 / name :op1 "Massague"~e.9))
                        :op2 (p4 / person
                              :name (n3 / name :op1 "Wotton"~e.11)))
                  :time (d2 / date-entity :year "2000"~e.13))))

# ::tok Raf @/@ mitogen @-@ activated protein kinase ( MAPK ) is required for EMT , whereas activation of phosphatidylinositol 3 @-@ kinase ( PI3K ) causes scattering and protects from TGFbeta @-@ induced apoptosis .
# ::alignments 0-1.2.1.1 4-1.3.1.2.1 5-1.3.1.2.2.1.1 6-1.3.1.1.1.1.1.2 8-1.2.1.1 11-1 13-1.1.1.1 15-1.3 16-1.3.1.1.1 18-1.3.1.1.1.1.1.1 19-1.3.1.1.1.1.1.2 21-1.3.1.1.1.1.1.2 25-1.3.1.1 26-1.3.1.1.2 27-1.3.1 28-1.3.1.2 29-1.3.1.2.2.r 30-1.3.1.2.2.1.1.1.1 32-1.3.1.2.2.1 33-1.3.1.2.2
# ::id bel_pmid_1179_0801_21076
(r / require-01~e.11
      :ARG0 (p4 / process
            :name (n3 / name :op1 "EMT"~e.13))
      :ARG1 (p3 / pathway
            :name (n6 / name :op1 "Raf/MAPK"~e.0,8))
      :ARG1-of (c / contrast-01~e.15
            :ARG2 (a2 / and~e.27
                  :op1 (c2 / cause-01~e.25
                        :ARG0 (a3 / activate-01~e.16
                              :ARG1 (e / enzyme
                                    :name (n4 / name :op1 "phosphatidylinositol"~e.18 :op2 "3-kinase"~e.6,19,21)))
                        :ARG1 (s / scatter-01~e.26))
                  :op2 (p5 / protect-01~e.28
                        :ARG0 a3~e.4
                        :ARG2~e.29 (a4 / apoptosis~e.33
                              :ARG1-of (i / induce-01~e.32
                                    :ARG0 (p6 / protein~e.5
                                          :name (n5 / name :op1 "TGFbeta"~e.30))))))))

# ::tok In addition to oncogenic Ras ( Oft et al. , 1996 ) , hepatocyte growth factor ( HGF )/scatter factor ( SF ) , fibroblast growth factor ( FGF ) , and TGF alone induce mesenchymal features in diverse epithelial cell systems ( Brinkmann et al. , 1995; Piek et al. , 1999; Thiery and Chopin , 1999 ) .
# ::alignments 0-1.1 0-1.4.1 0-1.4.1.1.1 1-1.1 1-1.4.1 1-1.4.1.1.1 2-1.1.1 2-1.1.1.2 2-1.1.1.2.r 3-1.1.1 3-1.1.1.2 3-1.1.1.2.1 3-1.1.1.2.1.r 3-1.1.1.2.r 4-1.1.1.1.1 6-1.1.1.3.1.1.1.1.1 7-1.1.1.3.1.1 8-1.1.1.3.1.1.2.1 10-1.1.1.3.1.2.1 13-1.1.2.1.1.1 14-1.1.2.1.1.2 15-1.1.2.1.1.3 19-1.1.3.1.2 24-1.1.4.1.1 25-1.1.4.1.2 26-1.1.4.1.3 31-1.1 32-1.1.5.1.1 33-1.1.5.2 34-1 36-1.2 39-1.3.1.1 40-1.3.1 41-1.3 43-1.4.1.1.1.1.1.1 44-1.4.1 44-1.4.1.1.1 44-1.4.1.2.1 44-1.4.1.3.1 45-1.4.1.1.1.2.1 45-1.4.1.2.1.2.1 45-1.4.1.3.1.2.1 48-1.4.1.2.1.1.1.1 49-1.4.1 49-1.4.1.1.1 49-1.4.1.2.1 49-1.4.1.3.1 50-1.4.1.1.1.2.1 50-1.4.1.2.1.2.1 50-1.4.1.3.1.2.1 53-1.4.1.3.1.1.1.1 54-1.4.1 54-1.4.1.1.1 54-1.4.1.2.1 54-1.4.1.3.1 57-1.4.1.2.1.3.1
# ::id bel_pmid_1179_0801_26880
(i / induce-01~e.34
      :ARG0 (a / and~e.0,1,31
            :op1 (p / protein~e.2,3
                  :name (n / name :op1 "Ras"~e.4)
                  :ARG0-of~e.2,3 (c / cause-01~e.2,3
                        :ARG1~e.3 (c2 / cancer~e.3))
                  :ARG1-of (d / describe-01
                        :ARG0 (p2 / publication-91
                              :ARG0 (a2 / and~e.7
                                    :op1 (p3 / person
                                          :name (n3 / name :op1 "Oft"~e.6))
                                    :op2 (p4 / person
                                          :mod (o / other~e.8)))
                              :time (d2 / date-entity :year "1996"~e.10))))
            :op2 (s / slash
                  :op1 (s4 / small-molecule
                        :name (n2 / name
                              :op1 "hepatocyte"~e.13
                              :op2 "growth"~e.14
                              :op3 "factor"~e.15)))
            :op3 (s2 / small-molecule
                  :name (n5 / name :op1 "scatter" :op2 "factor"~e.19)
                  :mod (n4 / name)
                  :ARG1-of (d3 / describe-01
                        :ARG0 (a4 / and~e.0,1,44,49,54
                              :op1 (p5 / publication-91
                                    :ARG0 (a5 / and~e.0,1,44,49,54
                                          :op1 (p6 / person
                                                :name (n9 / name :op1 "Brinkmann"~e.43))
                                          :op2 (p14 / person
                                                :mod (o2 / other~e.45,50))
                                          :time (d4 / date-entity :year "1995")))
                              :op2 (p7 / publication-91
                                    :ARG0 (a6 / and~e.44,49,54
                                          :op1 (p8 / person
                                                :name (n11 / name :op1 "Piek"~e.48))
                                          :op2 (p15 / person
                                                :mod (o3 / other~e.45,50))
                                          :time (d5 / date-entity :year "1999"~e.57)))
                              :op3 (p9 / publication-91
                                    :ARG0 (a7 / and~e.44,49,54
                                          :op1 (p10 / person
                                                :name (n13 / name :op1 "Thiery"~e.53))
                                          :op2 (p11 / person
                                                :mod (o4 / other~e.45,50))
                                          :time (d6 / date-entity :year "1990"))))))
            :op4 (s6 / small-molecule
                  :name (n8 / name
                        :op1 "fibroblast"~e.24
                        :op2 "growth"~e.25
                        :op3 "factor"~e.26))
            :op5 (p12 / protein
                  :name (n6 / name :op1 "TGF"~e.32)
                  :mod (a3 / alone~e.33)))
      :ARG1 (f / feature~e.36
            :mod (m4 / mesenchyme))
      :location (s5 / system~e.41
            :consist-of (c6 / cell~e.40
                  :mod (e / epithelium~e.39)))
      :ARG1-of d3)

# ::tok Ha @-@ Ras cooperates with transforming growth factor beta ( TGFbeta ) to cause epithelial mesenchymal transition ( EMT ) characterized by spindle @-@ like cell morphology , loss of epithelial markers , and induction of mesenchymal markers .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1 4-1.2.r 5-1.2.1.1 6-1.2.1.2 7-1.2.1.3 8-1.2.1.4 12-1.3 13-1.3 14-1.3.1.1.1 15-1.3.1.1.2 16-1.3.1.1.3 20-1.3.1.2 21-1.3.1.2.1.r 22-1.3.1.2.1.1.2.1 24-1.3.1.2.1.1.2 25-1.3.1.2.1.1.1 26-1.3.1.2.1.1 28-1.3.1.2.1.2 30-1.3.1.2.1.2.1.1 31-1.3.1.2.1.2.1 31-1.3.1.2.1.3.1 33-1.3.1.2.1 37-1.3.1.2.1.2.1 37-1.3.1.2.1.3.1
# ::id bel_pmid_1179_0801_27514
(c / cooperate-01~e.3
      :ARG0 (p / protein
            :name (n / name :op1 "Ha-Ras"~e.0,2))
      :ARG1~e.4 (s2 / small-molecule
            :name (n3 / name
                  :op1 "transforming"~e.5
                  :op2 "growth"~e.6
                  :op3 "factor"~e.7
                  :op4 "beta"~e.8))
      :ARG2 (c2 / cause-01~e.12,13
            :ARG1 (t / thing
                  :name (n2 / name
                        :op1 "epithelial"~e.14
                        :op2 "mesenchymal"~e.15
                        :op3 "transition"~e.16)
                  :ARG1-of (c3 / characterize-01~e.20
                        :ARG2~e.21 (a / and~e.33
                              :op1 (m / morphology~e.26
                                    :mod (c4 / cell~e.25)
                                    :ARG1-of (r / resemble-01~e.24
                                          :ARG2 (s / spindle~e.22)))
                              :op2 (l / lose-02~e.28
                                    :ARG1 (m2 / marker~e.31,37
                                          :mod (e / epithelial~e.30)))
                              :op3 (i / induct-01
                                    :ARG1 (m3 / marker~e.31,37
                                          :mod (m4 / mesenchyme))))))))

# ::tok the spindle @-@ like phenotype induced by TGF treatment ( Fig . 1 A , inset ) persisted after factor removal ( Fig . 1 B , inset ) and involved loss of E @-@ cadherin/4 @-@ integrin , whereas vimentin was strongly induced
# ::alignments 1-1.1.1.1.1 3-1.1.1.1 4-1.1.1 5-1.1.1.2 6-1.1.1.2.1.r 7-1.1.1.2.1.1.1.1 8-1.1.1.2.1 15-1.1.1.2.2.1.2 17-1.1 18-1.1.2 20-1.1.2.1 27-1.1.1.2.2.1.2 29-1 30-1.2 31-1.2.2 33-1.2.2.1.1.1.1 37-1.2.2.1.2.1.1 39-1.3 40-1.3.1.1.1.1 42-1.3.1.2 42-1.3.1.2.r 43-1.3.1
# ::id bel_pmid_1179_0801_31150
(a / and~e.29
      :op1 (p / persist-01~e.17
            :ARG1 (p2 / phenotype~e.4
                  :ARG1-of (r / resemble-01~e.3
                        :ARG2 (s / spindle~e.1))
                  :ARG1-of (i2 / induce-01~e.5
                        :ARG0~e.6 (t / treat-04~e.8
                              :ARG2 (p5 / protein
                                    :name (n3 / name :op1 "TGF"~e.7)))
                        :ARG1-of (d / describe-01
                              :ARG0 (f2 / figure
                                    :mod "1A"
                                    :location (i3 / inset~e.15,27)))))
            :time (a2 / after~e.18
                  :op1 (r2 / remove-01~e.20
                        :ARG1 p5
                        :ARG1-of (d2 / describe-01
                              :ARG0 (f3 / figure
                                    :mod "1B"
                                    :location i3)))))
      :op2 (i / involve-01~e.30
            :ARG0 p2
            :ARG1 (l / lose-02~e.31
                  :ARG1 (s2 / slash
                        :op1 (p3 / protein
                              :name (n / name :op1 "E-cadherin"~e.33))
                        :op2 (p4 / protein
                              :name (n2 / name :op1 "4-integrin"~e.37)))))
      :ARG1-of (c / contrast-01~e.39
            :ARG2 (i4 / induce-01~e.43
                  :ARG1 (p6 / protein
                        :name (n4 / name :op1 "vimentin"~e.40))
                  :manner~e.42 (s3 / strong~e.42))))

# ::tok Two peroxisome proliferator @-@ activated receptor a agonsists : Wy @-@ 14643 and a marketed fribrate drug , fenofibrate
# ::alignments 0-1.3.1 1-1.3.2.1.1 2-1.3.2.1.2 4-1.3.2.1.2 5-1.3.2.1.3 9-1.1.1.1 11-1.1.1.1 12-1 14-1.2.2.1 16-1.2.2 18-1.2.1.1
# ::id bel_pmid_1179_8191_15678
(a / and~e.12
      :op1 (s / small-molecule
            :name (n / name :op1 "Wy-14643"~e.9,11))
      :op3 (s2 / small-molecule
            :name (n2 / name :op1 "fenofibrate"~e.18)
            :domain (d / drug~e.16
                  :ARG1-of (m / market-01~e.14)
                  :mod (f / fibrate)))
      :domain (a2 / agonist
            :quant "2"~e.0
            :mod (p / protein
                  :name (n3 / name
                        :op1 "peroxisome"~e.1
                        :op2 "proliferator-activated"~e.2,4
                        :op3 "receptor"~e.5
                        :op4 "alpha"))))

# ::tok Several pro @-@ inflammatory mediators up @-@ regulate SAA transcription , including Il1 , Il6 , TNFalpha , and Lif .
# ::alignments 0-1.1.1.1 0-1.1.4 1-1.1.2 3-1.1.2.1 4-1.1 4-1.1.1 4-1.1.1.r 8-1.2.1.1.1 9-1.2 11-1.1.3 12-1.1.3.1.1.1.1 14-1.1.3.1.2.1.1 16-1.1.3.1.3.1.1 18-1.1.3.1 19-1.1.3.1.4.1.1
# ::id bel_pmid_1179_8191_28334
(u / upregulate-01
      :ARG0 (m2 / molecular-physical-entity~e.4
            :ARG0-of~e.4 (m / mediate-01~e.4
                  :quant (s / several~e.0))
            :ARG0-of (f / favor-01~e.1
                  :ARG1 (i / inflame-01~e.3))
            :ARG2-of (i2 / include-91~e.11
                  :ARG1 (a / and~e.18
                        :op1 (p / protein
                              :name (n2 / name :op1 "Il1"~e.12))
                        :op2 (p2 / protein
                              :name (n3 / name :op1 "Il6"~e.14))
                        :op3 (p3 / protein
                              :name (n4 / name :op1 "TNFalpha"~e.16))
                        :op4 (p4 / protein
                              :name (n5 / name :op1 "Lif"~e.19))))
            :quant (s2 / several~e.0))
      :ARG1 (t / transcribe-01~e.9
            :ARG1 (g / gene
                  :name (n / name :op1 "SAA"~e.8))))

# ::tok Fibrates induce the peroxisomal b @-@ oxidation system of fatty acids in rodents , resulting in proliferation of peroxisomes , hepatomegaly and eventually hepatocarcinoma .
# ::alignments 1-1 7-1.2 10-1.2.1.1 11-1.4.r 12-1.4 14-1.3 15-1.3.1.r 16-1.3.1.1 20-1.3.1.2 21-1.3.1 22-1.3.1.3.1 23-1.3.1.3
# ::id bel_pmid_1179_8191_33678
(i / induce-01~e.1
      :ARG0 (f / fibrate)
      :ARG1 (s / system~e.7
            :mod (o / oxidize-01
                  :ARG1 (a / acid~e.10
                        :mod (f2 / fat))
                  :mod (b / beta)
                  :mod (m2 / molecular-physical-entity
                        :name (n3 / name :op1 "peroxisome"))))
      :ARG1-of (r / result-01~e.14
            :ARG2~e.15 (a2 / and~e.21
                  :op1 (p2 / proliferate-01~e.16
                        :ARG0 m2)
                  :op2 (h / hepatomegaly~e.20)
                  :op3 (h2 / hepatocarcinoma~e.23
                        :time (e / eventual~e.22))))
      :location~e.11 (r2 / rodent~e.12))

# ::tok We note a marked and differential increase in Itih @-@ 4 labeling in proliferating hepatocytes , compared with bile duct cells in liver explant cultures treated with interleukin @-@ 6 ( IL @-@ 6 )
# ::alignments 0-1.1 1-1 3-1.2.4 5-1.2.5 6-1.2 7-1.2.1.r 8-1.2.1.1.1.1 10-1.2.1.1.1.1 11-1.2.1 13-1.2.2.1 16-1.2.3.r 18-1.2.3.1.1 19-1.2.3.1 20-1.2.3 21-1.2.3.2.r 22-1.2.3.2.2 23-1.2.3.2.1 24-1.2.3.2 25-1.2.3.2.3 26-1.2.3.2.3.1.r 27-1.2.3.2.3.1.1.1 29-1.2.3.2.3.1.1.1 33-1.2.3.2.3.1.1.1
# ::id bel_pmid_1180_3570_9290
(n / note-01~e.1
      :ARG1 (w / we~e.0)
      :ARG2 (i / increase-01~e.6
            :ARG1~e.7 (l / label-01~e.11
                  :ARG1 (p / protein
                        :name (n2 / name :op1 "Itih-4"~e.8,10)))
            :location (h / hepatocyte
                  :ARG0-of (p2 / proliferate-01~e.13))
            :compared-to~e.16 (c2 / cell~e.20
                  :mod (d2 / duct~e.19
                        :mod (b / bile~e.18))
                  :location~e.21 (c3 / culture~e.24
                        :mod (e / explant~e.23)
                        :mod (l2 / liver~e.22)
                        :ARG1-of (t / treat-04~e.25
                              :ARG2~e.26 (p3 / protein
                                    :name (n4 / name :op1 "interleukin-6"~e.27,29,33)))))
            :ARG2-of (m / mark-02~e.3)
            :ARG1-of (d / differ-02~e.5)))

# ::tok Inter @-@ alpha @-@ trypsin inhibitor @-@ 4 ( Itih @-@ 4 ) is a liver @-@ restricted member of the serine protease inhibitor family with diverse functions as an anti @-@ apoptotic and matrix stabilizing molecule that are important throughout development .
# ::alignments 0-1.1.1.1 2-1.1.1.1 4-1.1.1.1 5-1.1.1.2 7-1.1.1.2 11-1.1.1.2 15-1.1.2.1 17-1.1.2 21-1.2.1.1.2.1.1 22-1.2.1.1.1.1 23-1.2 23-1.2.1 23-1.2.1.r 24-1.2.2 26-1.1.3.3 27-1.1 27-1.1.3 27-1.1.3.r 28-1.1.3.1.r 30-1.1.3.1.1 32-1.1.3.1.1.1 33-1.1.3.1 34-1.1.3.1.2.2 35-1.1.3.1.2 36-1.1.3.1.2.1 39-1.1.3.2 41-1.1.3.2.1
# ::id bel_pmid_1180_3570_9376
(i / include-91
      :ARG1 (p2 / protein~e.27
            :name (n4 / name :op1 "Inter-alpha-trypsin"~e.0,2,4 :op2 "inhibitor-4"~e.5,7,11)
            :ARG1-of (r / restrict-01~e.17
                  :ARG2 (l / liver~e.15))
            :ARG0-of~e.27 (f2 / function-01~e.27
                  :ARG1~e.28 (a2 / and~e.33
                        :op1 (c / counter-01~e.30
                              :ARG1 (a3 / apoptosis~e.32))
                        :op2 (s / stabilize-01~e.35
                              :ARG0 (m / molecule~e.36)
                              :ARG1 (m2 / matrix~e.34)))
                  :mod (i3 / important~e.39
                        :duration (d / develop-01~e.41))
                  :mod (d2 / diverse~e.26)))
      :ARG2 (p / protein~e.23
            :ARG0-of~e.23 (i2 / inhibit-01~e.23
                  :mod (e / enzyme
                        :name (n / name :op1 "protease"~e.22)
                        :mod (a / amino-acid
                              :name (n2 / name :op1 "serine"~e.21))))
            :mod (f / family~e.24)))

# ::tok tryosine phosphorylation of gp130 was observed in fibroblasts after stimulation with all the cytokines
# ::alignments 0-1.1.1.1.1 1-1.1 3-1.1.1.2.1.1 5-1 6-1.2.r 7-1.2 8-1.3 9-1.3.1 11-1.3.1.1.1
# ::id bel_pmid_1182_0727_27898
(o / observe-01~e.5
      :ARG1 (p / phosphorylate-01~e.1
            :ARG1 (a / amino-acid
                  :name (n2 / name :op1 "tryosine"~e.0)
                  :part-of (p2 / protein
                        :name (n / name :op1 "gp130"~e.3))))
      :location~e.6 (f / fibroblast~e.7)
      :time (a2 / after~e.8
            :op1 (s / stimulate-01~e.9
                  :ARG2 (c / cytokine
                        :mod (a3 / all~e.11)))))

# ::tok We have previously shown that B cell lymphoma @/@ leukemia @-@ 2 ( bcl @-@ 2 ) -/- mice develop cystic kidneys and exhibit sustained phosphorylation of FAK and paxillin .
# ::alignments 0-1.1 2-1.3 3-1 11-1.2.1.1.1.1.1 13-1.2.1.1.1.1.1 15-1.2.1.1.1.1.1 17-1.2.1.1.1.2.1 18-1.2.1.1 19-1.2.1 20-1.2.1.2.1 21-1.2.1.2 22-1.2 23-1.2.2 24-1.2.2.2.2 25-1.2.2.2 26-1.2.2.2.1.r 27-1.2.2.2.1.1.1.1 28-1.2.2.2.1 29-1.2.2.2.1.2.1.1
# ::id bel_pmid_1183_2424_8080
(s / show-01~e.3
      :ARG0 (w / we~e.0)
      :ARG1 (a / and~e.22
            :op1 (d / develop-01~e.19
                  :ARG1 (m / mouse~e.18
                        :mod (p5 / protein
                              :name (n3 / name :op1 "bcl-2"~e.11,13,15)
                              :ARG2-of (m3 / mutate-01 :mod "-/-"~e.17)))
                  :ARG2 (k2 / kidney~e.21
                        :mod (c / cyst~e.20)))
            :op2 (e / exhibit-01~e.23
                  :ARG0 m
                  :ARG1 (p / phosphorylate-01~e.25
                        :ARG1~e.26 (a2 / and~e.28
                              :op1 (p2 / protein
                                    :name (n / name :op1 "FAK"~e.27))
                              :op2 (p3 / protein
                                    :name (n2 / name :op1 "paxillin"~e.29)))
                        :ARG1-of (s2 / sustain-01~e.24))))
      :time (p4 / previous~e.2))

# ::tok Cystic kidneys from postnatal day 20 bcl @-@ 2 -/- mice demonstrate a reduced expression , sixfold decrease in activity , and altered distribution of SHP @-@ 2 and PTP 1B
# ::alignments 0-1.1.1 1-1.1 2-1.1.3.r 4-1.1.2 5-1.1.2.1 6-1.1.3.1.1.1 8-1.1.3.1.1.1 9-1.1.3.1.2.1 10-1.1.3 11-1 13-1.2.1 14-1.2.1.1 17-1.2.2 18-1.2.2.1.r 19-1.2.2.1 21-1.2 22-1.2.3.2 23-1.2.3 24-1.2.3.1.r 25-1.2.3.1.1.1.1 27-1.2.3.1.1.1.1 29-1.2.3.1.2.1.1 30-1.2.3.1.2.1.2
# ::id bel_pmid_1183_2424_8082
(d / demonstrate-01~e.11
      :ARG0 (k / kidney~e.1
            :mod (c / cyst~e.0)
            :time (d2 / day~e.4 :value "20"~e.5)
            :source~e.2 (m / mouse~e.10
                  :mod (p2 / protein
                        :name (n / name :op1 "bcl-2"~e.6,8)
                        :ARG2-of (m2 / mutate-01 :mod "-/-"~e.9)))
            :time (a5 / after
                  :op1 (b / birth)))
      :ARG1 (a / and~e.21
            :op1 (r2 / reduce-01~e.13
                  :ARG1-of (e / express-03~e.14))
            :op2 (d3 / decrease-01~e.17
                  :ARG1~e.18 (a2 / activity~e.19)
                  :ARG2 (p / product-of :op1 "6"))
            :op3 (d4 / distribute-01~e.23
                  :ARG1~e.24 (a3 / and
                        :op1 (p3 / protein
                              :name (n2 / name :op1 "SHP-2"~e.25,27))
                        :op2 (e2 / enzyme
                              :name (n3 / name :op1 "PTP"~e.29 :op2 "1B"~e.30)))
                  :ARG1-of (a4 / alter-01~e.22))))

# ::tok Cystic kidneys from postnatal day 20 bcl @-@ 2 -/- mice demonstrate a reduced expression , sixfold decrease in activity , and altered distribution of SHP @-@ 2 and PTP 1B .
# ::alignments 0-1.1.1 1-1.1 2-1.1.3.r 4-1.1.2 5-1.1.2.1 6-1.1.3.1.1.1 8-1.1.3.1.1.1 9-1.1.3.1.2.1 10-1.1.3 11-1 13-1.2.1 14-1.2.1.1 17-1.2.2 18-1.2.2.1.r 19-1.2.2.1 21-1.2 22-1.2.3.2 23-1.2.3 24-1.2.3.1.r 25-1.2.3.1.1.1.1 27-1.2.3.1.1.1.1 29-1.2.3.1.2.1.1 30-1.2.3.1.2.1.2
# ::id bel_pmid_1183_2424_8084
(d / demonstrate-01~e.11
      :ARG0 (k / kidney~e.1
            :mod (c / cyst~e.0)
            :time (d2 / day~e.4 :value "20"~e.5)
            :source~e.2 (m / mouse~e.10
                  :mod (p2 / protein
                        :name (n / name :op1 "bcl-2"~e.6,8)
                        :ARG0-of (m2 / mutate-01 :mod "-/-"~e.9)))
            :time (a5 / after
                  :op1 (b / birth)))
      :ARG1 (a / and~e.21
            :op1 (r / reduce-01~e.13
                  :ARG1 (e / express-03~e.14))
            :op2 (d3 / decrease-01~e.17
                  :ARG1~e.18 (a2 / activity~e.19)
                  :ARG2 (p / product-of :op1 "6"))
            :op3 (d4 / distribute-01~e.23
                  :ARG1~e.24 (a3 / and
                        :op1 (p3 / protein
                              :name (n3 / name :op1 "SHP-2"~e.25,27))
                        :op2 (e2 / enzyme
                              :name (n2 / name :op1 "PTP"~e.29 :op2 "1B"~e.30)))
                  :ARG1-of (a4 / alter-01~e.22))))

# ::tok The primary substrates of CDK4 @/@ 6 and CDK2 in G1 progression are the members of the retinoblastoma protein family RB , p107 and p130 The activity of the RB proteins is modulated by sequential phosphorylation by CDK4 @/@ 6 cyclinD and CDK2 cyclinE complexes
# ::alignments 2-1.1.1 3-1.1.1.1.r 4-1.1.1.1.1.1.1 6-1.1.1.1.1.1.1 7-1.1.1.1 8-1.1.1.1.2.1.1 9-1.1.1.2.r 10-1.1.1.2.1.1.1 11-1.1.1.2 17-1.1.2.1.1.1 18-1.1.2.1 18-1.1.2.2.1.1 18-1.1.2.2.1.2 18-1.1.2.2.1.3 19-1.1.2 20-1.1.2.2.1.1.1.1 22-1.1.2.2.1.2.1.1 23-1.1.2.2.1 24-1.1.2.2.1.3.1.1 26-1.2.2 29-1.2.2.1.1.1 30-1.2.1.1.1.2 30-1.2.1.1.2.2 30-1.2.2.1 32-1.2 33-1.2.1.r 34-1.2.1.2 35-1.2.1 36-1.2.1.1.r 37-1.2.1.1.1.1.1.1 39-1.2.1.1.1.1.1.1 40-1.2.1.1.1.2.1.1 41-1.2.1.1 42-1.2.1.1.2.1.1.1 43-1.2.1.1.2.2.1.1 44-1.2.1.1.1 44-1.2.1.1.2
# ::id bel_pmid_1190_2577_36732
(m / multi-sentence
      :snt1 (i / include-91
            :ARG1 (s5 / substrate~e.2
                  :poss~e.3 (a5 / and~e.7
                        :op1 (e3 / enzyme
                              :name (n9 / name :op1 "CDK4/6"~e.4,6))
                        :op2 (e4 / enzyme
                              :name (n10 / name :op1 "CDK2"~e.8)))
                  :time~e.9 (p9 / progress-01~e.11
                        :ARG1 (e5 / event
                              :name (n12 / name :op1 "G1"~e.10))))
            :ARG2 (f / family~e.19
                  :mod (p / protein~e.18
                        :name (n / name :op1 "retinoblastoma"~e.17))
                  :ARG1-of (m2 / mean-01
                        :ARG2 (a / and~e.23
                              :op1 (p2 / protein~e.18
                                    :name (n2 / name :op1 "RB"~e.20))
                              :op2 (p3 / protein~e.18
                                    :name (n3 / name :op1 "p107"~e.22))
                              :op2 (p4 / protein~e.18
                                    :name (n4 / name :op1 "p130"~e.24))))))
      :snt2 (m3 / modulate-01~e.32
            :ARG0~e.33 (p5 / phosphorylate-01~e.35
                  :ARG2~e.36 (a2 / and~e.41
                        :op1 (m4 / macro-molecular-complex~e.44
                              :op1 (e / enzyme
                                    :name (n5 / name :op1 "CDK4/6"~e.37,39))
                              :op2 (p7 / protein~e.30
                                    :name (n7 / name :op1 "cyclinD"~e.40)))
                        :op2 (m5 / macro-molecular-complex~e.44
                              :op1 (e2 / enzyme
                                    :name (n11 / name :op1 "CDK2"~e.42))
                              :op2 (p8 / protein~e.30
                                    :name (n8 / name :op1 "cyclinE"~e.43))))
                  :mod (s3 / sequence~e.34))
            :ARG1 (a3 / act-02~e.26
                  :ARG0 (p6 / protein~e.30
                        :name (n6 / name :op1 "RB"~e.29)))))

# ::tok Inhibitory phosphorylation of adjacent threonine and tyrosine residues ( T14/Y15 in CDK1 ) is mediated by dualspecificity kinases ( such as WEE1 and MYT1 ) . This inhibition is relieved when the CDC25 phosphatases ( CDC25A , CDC25B and CDC25C ) dephosphorylate these residues , which triggers entry into mitosis
# ::alignments 1-1.1.2 2-1.1.2.1.r 3-1.1.2.1.3 4-1.1.2.1.1.1.1.1 5-1.1.2.1 6-1.1.2.1.2.1.1.1 7-1.1.2.1.1 7-1.1.2.1.2 11-1.1.2.1.1.1.2.1.1 14-1.1 15-1.1.1.r 16-1.1.1.1 17-1.1.1 17-1.1.1.2.1 17-1.1.1.2.2 19-1.1.1.2.r 20-1.1.1.2.r 21-1.1.1.2.1.1.1 22-1.1.1.2 23-1.1.1.2.2.1.1 26-1.2.1.1 27-1.1.2.2 27-1.2.1 29-1.2 30-1.2.2.r 32-1.2.2.2.1.1 33-1.2.2.2 35-1.2.2.2.2.1.1.1.1 37-1.2.2.2.2.1.2.1.1 38-1.2.2.2.2.1 39-1.2.2.2.2.1.3.1.1 41-1.2.2 42-1.2.2.1.1 43-1.2.2.1 46-1.2.2.3 47-1.2.2.3.1 48-1.2.2.3.1.1.r 49-1.2.2.3.1.1
# ::id bel_pmid_1190_2577_37122
(m / multi-sentence
      :snt1 (m2 / mediate-01~e.14
            :ARG0~e.15 (k / kinase~e.17
                  :mod (d / dualspecificity~e.16)
                  :example~e.19,20 (a5 / and~e.22
                        :op1 (k2 / kinase~e.17
                              :name (n4 / name :op1 "WEE1"~e.21))
                        :op2 (k3 / kinase~e.17
                              :name (n5 / name :op1 "MYT1"~e.23))))
            :ARG1 (p / phosphorylate-01~e.1
                  :ARG1~e.2 (a7 / and~e.5
                        :op1 (r / residue~e.7
                              :mod (a / amino-acid
                                    :name (n / name :op1 "threonine"~e.4)
                                    :part-of (p2 / protein
                                          :name (n3 / name :op1 "CDK1"~e.11))))
                        :op2 (r3 / residue~e.7
                              :mod (a2 / amino-acid
                                    :name (n2 / name :op1 "tyrosine"~e.6)
                                    :part-of p2))
                        :mod (a4 / adjacent~e.3))
                  :ARG0-of (i / inhibit-01~e.27)))
      :snt2 (r2 / relieve-01~e.29
            :ARG1 (i2 / inhibit-01~e.27
                  :mod (t / this~e.26))
            :time~e.30 (d2 / dephosphorylate-01~e.41
                  :ARG1 (r4 / residue~e.43
                        :mod (t2 / this~e.42))
                  :ARG2 (p3 / phosphatase~e.33
                        :name (n6 / name :op1 "CDC25"~e.32)
                        :ARG2-of (i3 / include-91
                              :ARG1 (a3 / and~e.38
                                    :op1 (e / enzyme
                                          :name (n7 / name :op1 "CDC25A"~e.35))
                                    :op2 (e2 / enzyme
                                          :name (n8 / name :op1 "CDC25B"~e.37))
                                    :op3 (e3 / enzyme
                                          :name (n9 / name :op1 "CDC25C"~e.39)))))
                  :ARG0-of (t4 / trigger-01~e.46
                        :ARG1 (e4 / enter-01~e.47
                              :ARG1~e.48 (m4 / mitosis~e.49))))))

# ::tok CDK2 is sequentially activated by the E @-@ type cyclins cyclin E1 and E2 during the G1/S transition , and the A @-@ type cyclins cyclin A1 and A2 during S phase
# ::alignments 0-1.2.1.1 2-1.3 3-1 8-1.1.1.3 8-1.1.2.2 10-1.1.1.4.1.1.1.1 11-1.1.1.4.1.1.1.2 12-1.1.1.4.1 13-1.1.1.4.1.2.1.2 14-1.1.1.2.r 17-1.1.1.2 19-1.1 19-1.1.1.4.1 19-1.1.2.3.1 23-1.1.1.3 23-1.1.2.2 24-1.1.1.4.1.2.1.1 25-1.1.2.3.1.1.1.1 26-1.1.2.3.1.1.1.2 27-1.1.2.3.1 28-1.1.2.3.1.2.1.2 29-1.1.1.2.r 29-1.1.2.4.r 30-1.1.1.2.1.1.1
# ::id bel_pmid_1190_2577_37858
(a / activate-01~e.3
      :ARG0 (a2 / and~e.19
            :op1 (p / protein
                  :name (n2 / name :op1 "cyclin E")
                  :time~e.14,29 (t / transition-01~e.17
                        :ARG2 (e3 / event
                              :name (n9 / name :op1 "S"~e.30))
                        :ARG3 (e / event
                              :name (n7 / name :op1 "G1")))
                  :mod (t2 / type~e.8,23)
                  :ARG1-of (m / mean-01
                        :ARG2 (a3 / and~e.12,19
                              :op1 (p7 / protein
                                    :name (n11 / name :op1 "cyclin"~e.10 :op2 "E1"~e.11))
                              :op2 (p8 / protein
                                    :name (n12 / name :op1 "cyclin"~e.24 :op2 "E2"~e.13)))))
            :op2 (p4 / protein
                  :name (n5 / name :op1 "cyclin A")
                  :mod (t3 / type~e.8,23)
                  :ARG1-of (m2 / mean-01
                        :ARG2 (a4 / and~e.19,27
                              :op1 (p2 / protein
                                    :name (n / name :op1 "cyclin"~e.25 :op2 "A1"~e.26))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "cyclin" :op2 "A2"~e.28))))
                  :time~e.29 e3))
      :ARG1 (e2 / enzyme
            :name (n8 / name :op1 "CDK2"~e.0))
      :manner (s / sequence~e.2))

# ::tok CKIs are of two types( reviewed in REF . 17 ) . The four members of the INK4 family INK4A ( also known as p16 ) ,INK4B( also known as p15 ) ,INK4C ( also known as p18 ) and INK4D ( also known as p19 ) exert their inhibitory activity by binding to the CDK4 and CDK6 kinases and preventing their association with D @-@ type cyclins
# ::alignments 3-1.1.2.1 5-1.1.3 6-1.1.3.1.r 7-1.1.3.1 9-1.1.3.1.1 13-1.2.1.5.2 17-1.2.1.5.1.1.1.1 18-1.2.1.5.1 19-1.2.1.1.1.1 21-1.2.1.1.2.2 22-1.2.1.1 22-1.2.1.1.2 22-1.2.1.1.2.1.1.r 22-1.2.1.1.2.r 23-1.2.1.1.2.1.1.r 24-1.2.1.1.2.1.1.1 27-1.2.1.1.2.2 28-1.2.1.1 28-1.2.1.1.1.r 28-1.2.1.1.2 28-1.2.1.1.2.1.1.r 28-1.2.1.1.2.r 28-1.2.1.2 28-1.2.1.2.1.r 28-1.2.1.2.2 28-1.2.1.2.2.1.1.r 28-1.2.1.2.2.r 28-1.2.1.3 28-1.2.1.3.1.r 28-1.2.1.3.2 28-1.2.1.3.2.1.1.r 28-1.2.1.3.2.r 28-1.2.1.4.1.r 29-1.2.1.1.1.r 29-1.2.1.1.2.1.1.r 29-1.2.1.2.1.r 29-1.2.1.2.2.1.1.r 29-1.2.1.3.1.r 29-1.2.1.3.2.1.1.r 29-1.2.1.4.1.r 30-1.2.1.2.2.1.1.1 34-1.2.1.2.2.2 35-1.2.1.1 35-1.2.1.1.1.r 35-1.2.1.1.2 35-1.2.1.1.2.1.1.r 35-1.2.1.1.2.r 35-1.2.1.2 35-1.2.1.2.1.r 35-1.2.1.2.2 35-1.2.1.2.2.1.1.r 35-1.2.1.2.2.r 35-1.2.1.3 35-1.2.1.3.1.r 35-1.2.1.3.2 35-1.2.1.3.2.1.1.r 35-1.2.1.3.2.r 35-1.2.1.4.1.r 36-1.2.1.1.1.r 36-1.2.1.1.2.1.1.r 36-1.2.1.2.1.r 36-1.2.1.2.2.1.1.r 36-1.2.1.3.1.r 36-1.2.1.3.2.1.1.r 36-1.2.1.4.1.r 37-1.2.1.3.2.1.1.1 39-1.2.1 40-1.2.1.4.1.1 42-1.2.1.1.2.2 43-1.2.1.1 43-1.2.1.1.2 43-1.2.1.1.2.r 43-1.2.1.2 43-1.2.1.2.1.r 43-1.2.1.2.2 43-1.2.1.2.2.1.1.r 43-1.2.1.2.2.r 43-1.2.1.3 43-1.2.1.3.1.r 43-1.2.1.3.2 43-1.2.1.3.2.1.1.r 43-1.2.1.3.2.r 43-1.2.1.4 43-1.2.1.4.1.r 43-1.2.1.4.2 43-1.2.1.4.2.1.1.r 43-1.2.1.4.2.r 44-1.2.1.2.1.r 44-1.2.1.2.2.1.1.r 44-1.2.1.3.1.r 44-1.2.1.3.2.1.1.r 44-1.2.1.4.1.r 44-1.2.1.4.2.1.1.r 44-1.2.1.4.2.1.r 45-1.2.1.4.2.1.1.1 47-1.2 51-1.2.3.r 52-1.2.3.1 55-1.2.3.1.1.1.1.1 56-1.2.3.1.1 57-1.2.3.1.1.2.1.1 58-1.2.3.1.1.1 58-1.2.3.1.1.2 59-1.2.3 59-1.2.3.1.1 60-1.2.3.2 61-1.2.3.2.1.1 61-1.2.3.2.1.1.r 62-1.2.3.2.1 63-1.2.3.2.1.2.r 64-1.2.3.2.1.2.1.2 66-1.1.2 67-1.2.3.2.1.2.1.1
# ::id bel_pmid_1190_2577_37928
(m / multi-sentence
      :snt1 (e / enzyme
            :name (n / name :op1 "CKI")
            :mod (t / type~e.66 :quant "2"~e.3)
            :ARG1-of (r / review-01~e.5
                  :medium~e.6 (r2 / ref~e.7 :mod "17"~e.9)))
      :snt2 (e2 / exert-01~e.47
            :ARG0 (a / and~e.39
                  :op1 (p / protein~e.22,28,35,43
                        :name~e.28,29,35,36 (n2 / name :op1 "INK4A"~e.19)
                        :ARG1-of~e.22,28,35,43 (k / know-02~e.22,28,35,43
                              :ARG2 (p5 / protein
                                    :name~e.22,23,28,29,35,36 (n6 / name :op1 "p16"~e.24))
                              :mod (a5 / also~e.21,27,42)))
                  :op2 (p2 / protein~e.28,35,43
                        :name~e.28,29,35,36,43,44 (n3 / name :op1 "INK4B")
                        :ARG1-of~e.28,35,43 (k2 / know-02~e.28,35,43
                              :ARG2 (p6 / protein
                                    :name~e.28,29,35,36,43,44 (n7 / name :op1 "p15"~e.30))
                              :mod a5~e.34))
                  :op3 (p3 / protein~e.28,35,43
                        :name~e.28,29,35,36,43,44 (n4 / name :op1 "INK4C")
                        :ARG1-of~e.28,35,43 (k3 / know-02~e.28,35,43
                              :ARG2 (p7 / protein
                                    :name~e.28,29,35,36,43,44 (n8 / name :op1 "p18"~e.37))
                              :mod a5))
                  :op4 (p4 / protein~e.43
                        :name~e.28,29,35,36,43,44 (n5 / name :op1 "INK4D"~e.40)
                        :ARG1-of~e.43 (k4 / know-02~e.43
                              :ARG2~e.44 (p8 / protein
                                    :name~e.43,44 (n9 / name :op1 "p19"~e.45))
                              :mod a5))
                  :ARG1-of (i2 / include-91
                        :ARG2 (f / family~e.18
                              :mod (p10 / protein
                                    :name (n12 / name :op1 "INK4"~e.17)))
                        :ARG3 (f2 / four~e.13)))
            :ARG1 (a3 / act-01
                  :ARG0 a
                  :ARG1 (i / inhibit-01
                        :ARG0 a))
            :manner~e.51 (a4 / and~e.59
                  :op1 (b / bind-01~e.52
                        :ARG1 (a2 / and~e.56,59
                              :op1 (k5 / kinase~e.58
                                    :name (n10 / name :op1 "CDK4"~e.55))
                              :op2 (k6 / kinase~e.58
                                    :name (n11 / name :op1 "CDK6"~e.57))))
                  :op2 (p9 / prevent-01~e.60
                        :ARG1 (a6 / associate-01~e.62
                              :ARG1~e.61 a2~e.61
                              :ARG2~e.63 (p13 / protein
                                    :name (n13 / name :op1 "cyclin"~e.67 :op2 "D"~e.64)))))))

# ::tok Cotransfection of JAK1 or JAK3 with TCPTP @-@ WT resulted in substantial dephosphorylation of the kinases
# ::alignments 2-1.1.1.1.1.1 3-1.1.1 4-1.1.1.2.1.1 6-1.1.2.1.1 8-1.1.2.2 9-1 10-1.2.r 11-1.2.2 12-1.2 13-1.2.1.r 15-1.2.1
# ::id bel_pmid_1190_9529_24784
(r / result-01~e.9
      :ARG1 (c / cotransfect-00
            :ARG1 (o / or~e.3
                  :op1 (k2 / kinase
                        :name (n / name :op1 "JAK1"~e.2))
                  :op2 (k3 / kinase
                        :name (n2 / name :op1 "JAK3"~e.4)))
            :ARG2 (p3 / protein
                  :name (n3 / name :op1 "TCPTP"~e.6)
                  :mod (w / wild-type~e.8)))
      :ARG2~e.10 (d / dephosphorylate-01~e.12
            :ARG1~e.13 o~e.15
            :degree (s / substantial~e.11)))

# ::tok Immunoblotting with a phospho @-@ STAT1 antibody revealed an increase in STAT1 phosphorylation in TCPTP @-@ deficient thymocytes
# ::alignments 5-1.1.1.1.1.1.1 6-1.1.1 7-1 9-1.2 11-1.1.1.1.1.1.1 12-1.1.1.1.1.2 12-1.2.1 13-1.2.2.r 14-1.2.2.2.1.1.1
# ::id bel_pmid_1190_9529_30256
(r / reveal-01~e.7
      :ARG0 (i / immunoblot-00
            :ARG0 (a / antibody~e.6
                  :ARG0-of (c / counter-01
                        :ARG1 (p / protein
                              :name (n / name :op1 "STAT1"~e.5,11)
                              :ARG3-of (p5 / phosphorylate-01~e.12)))))
      :ARG1 (i2 / increase-01~e.9
            :ARG1 (p2 / phosphorylate-01~e.12
                  :ARG1 p)
            :location~e.13 (c2 / cell
                  :name (n4 / name :op1 "thymocyte")
                  :ARG0-of (l2 / lack-01
                        :ARG1 (p4 / protein
                              :name (n3 / name :op1 "TCPTP"~e.14))))))

# ::tok PKA also decreased Raf @-@ 1 serine 338 phosphorylation of Raf @-@ 1 , previously shown to be required for Raf @-@ 1 activation .
# ::alignments 0-1.1.1.1 1-1.3 2-1 3-1.2.1.3.1.1 5-1.2.1.3.1.1 6-1.2.1.2.1 7-1.2.1.1 8-1.2 10-1.2.1.3.1.1 12-1.2.1.3.1.1 14-1.2.3.2.1 15-1.2.3.2 18-1.2.3 19-1.2.3.1.r 20-1.2.3.1.1 21-1.2.3.1.1 22-1.2.3.1.1 23-1.2.3.1
# ::id bel_pmid_1197_1957_1966
(d / decrease-01~e.2
      :ARG0 (e2 / enzyme
            :name (n2 / name :op1 "PKA"~e.0))
      :ARG1 (p / phosphorylate-01~e.8
            :ARG1 (a / amino-acid
                  :mod "338"~e.7
                  :name (n3 / name :op1 "serine"~e.6)
                  :part-of (e / enzyme
                        :name (n / name :op1 "Raf-1"~e.3,5,10,12)))
            :ARG2 e
            :ARG1-of (r / require-01~e.18
                  :purpose~e.19 (a4 / activate-01~e.23
                        :ARG1 e~e.20,21,22)
                  :ARG1-of (s2 / show-01~e.15
                        :time (p2 / previous~e.14))))
      :mod (a2 / also~e.1))

# ::tok The cyclic AMP ( cAMP )-dependent protein kinase ( PKA ) can inhibit Raf @-@ 1 by direct phosphorylation . We have mapped all cAMP @-@ induced phosphorylation sites in Raf @-@ 1 , showing that serines 43 , 259 , and 621 are phosphorylated by PKA in vitro and induced by cAMP in vivo .
# ::alignments 1-1.1.1.1.1.1 2-1.1.1.1.1.2 4-1.2.2.3.1.1.1 6-1.1.1.1.1.3 6-1.2.2 7-1.1.1.1.1.4 9-1.2.3.1.2.1.2.1.1 11-1.1 12-1.1.1 13-1.1.1.2.1.1 15-1.1.1.2.1.1 16-1.1.1.3.r 17-1.1.1.3.1 18-1.1.1.3 20-1.2.1 22-1.2 23-1.2.2.4 24-1.2.2.3.1.1.1 26-1.2.2.3 27-1.2.2.2 28-1.2.2 29-1.2.3.1.2.1.3 30-1.2.2.1.1.1.1 32-1.2.2.1.1.1.1 34-1.2.3.1 36-1.2.3.1.2.1.1.1.2.1 36-1.2.3.1.2.1.1.2.2.1 36-1.2.3.1.2.1.1.3.2.1 37-1.2.3.1.2.1.1.1.1 39-1.2.3.1.2.1.1.2.1 42-1.2.3.1.2.1.1.3.1 44-1.2.3.1.2.1 46-1.2.3.1.2.1.2.1.1 47-1.2.3.1.2.1.3 48-1.2.3.1.2.1.3 49-1.2.3.1.2 50-1.2.3.1.2.2 51-1.2.3.1.2.2.1.r 52-1.2.3.1.2.2.1 53-1.2.3.1.2.2.3 54-1.2.3.1.2.2.3
# ::id bel_pmid_1197_1957_37446
(m / multi-sentence
      :snt1 (p2 / possible~e.11
            :domain (i / inhibit-01~e.12
                  :ARG0 (e5 / enzyme
                        :name (n5 / name
                              :op1 "cyclic"~e.1
                              :op2 "AMP-dependent"~e.2
                              :op3 "protein"~e.6
                              :op4 "kinase"~e.7))
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Raf-1"~e.13,15))
                  :manner~e.16 (p4 / phosphorylate-01~e.18
                        :mod (d2 / direct~e.17))))
      :snt2 (m3 / map-01~e.22
            :ARG0 (w / we~e.20)
            :ARG1 (p3 / protein-segment~e.6,28
                  :ARG1-of (b / be-located-at-91
                        :ARG2 (e2 / enzyme
                              :name (n4 / name :op1 "Raf-1"~e.30,32)))
                  :ARG1-of (p / phosphorylate-01~e.27)
                  :ARG1-of (i2 / induce-01~e.26
                        :ARG0 (s / small-molecule
                              :name (n10 / name :op1 "cAMP"~e.4,24)))
                  :mod (a / all~e.23))
            :ARG0-of (c2 / cause-01
                  :ARG1 (s2 / show-01~e.34
                        :ARG0 w
                        :ARG1 (a7 / and~e.49
                              :op1 (p6 / phosphorylate-01~e.44
                                    :ARG1 (a2 / and
                                          :op1 (a3 / amino-acid
                                                :mod "43"~e.37
                                                :name (n6 / name :op1 "serine"~e.36))
                                          :op2 (a4 / amino-acid
                                                :mod "259"~e.39
                                                :name (n7 / name :op1 "serine"~e.36))
                                          :op3 (a5 / amino-acid
                                                :mod "621"~e.42
                                                :name (n8 / name :op1 "serine"~e.36)))
                                    :ARG2 (e3 / enzyme
                                          :name (n9 / name :op1 "PKA"~e.9,46))
                                    :manner (i3 / in-vitro~e.29,47,48))
                              :op2 (i4 / induce-01~e.50
                                    :ARG0~e.51 s~e.52
                                    :ARG1 a2
                                    :manner (i5 / in-vivo~e.53,54)))))))

# ::tok In contrast , LPS from Escherichia coli stimulated mast cells in a TLR4 @-@ dependent manner to produce TNF @-@ alpha , IL @-@ 1 beta , IL @-@ 6 , and IL @-@ 13 , but not IL @-@ 4 nor IL @-@ 5 .
# ::alignments 1-1 4-1.1.1.2.r 5-1.1.1.2.1.1 6-1.1.1.2.1.2 7-1.1 8-1.1.2.1 9-1.1.2 12-1.1.3.1.1.1 14-1.1.3 15-1.1.3.r 16-1.1.4.r 17-1.1.4.1 17-1.1.4.2 18-1.1.4.1.2.1.1.1 20-1.1.4.1.2.1.1.1 22-1.1.4.1.2.2.1.1 22-1.1.4.1.2.3.1.1 22-1.1.4.1.2.4.1.1 27-1.1.4.1.2.2.1.1 27-1.1.4.1.2.3.1.1 27-1.1.4.1.2.4.1.1 29-1.1.4.1.2.3.1.1 31-1.1.4.1.2 32-1.1.4.1.2.2.1.1 32-1.1.4.1.2.3.1.1 32-1.1.4.1.2.4.1.1 34-1.1.4.1.2.4.1.1 36-1.1.4 37-1.1.4.2.1 37-1.1.4.2.1.r 38-1.1.4.2.3.1.1.1 40-1.1.4.2.3.1.1.1 41-1.1.4.2.1.r 42-1.1.4.2.3.1.1.1 42-1.1.4.2.3.2.1.1 44-1.1.4.2.3.2.1.1
# ::id bel_pmid_1202_1251_10412
(c / contrast-01~e.1
      :ARG2 (s / stimulate-01~e.7
            :ARG0 (m / molecular-physical-entity
                  :name (n / name :op1 "Lipopolysaccharide")
                  :source~e.4 (t / thing
                        :name (n2 / name :op1 "Escherichia"~e.5 :op2 "coli"~e.6)))
            :ARG1 (c3 / cell~e.9
                  :mod (m2 / mast~e.8))
            :manner~e.15 (d / depend-01~e.14
                  :ARG1 (p / protein
                        :name (n3 / name :op1 "TLR4"~e.12)))
            :purpose~e.16 (c4 / contrast-01~e.36
                  :ARG1 (p8 / produce-01~e.17
                        :ARG0 c3
                        :ARG1 (a / and~e.31
                              :op1 (p2 / protein
                                    :name (n4 / name :op1 "TNF-alpha"~e.18,20))
                              :op2 (p3 / protein
                                    :name (n5 / name :op1 "IL-1beta"~e.22,27,32))
                              :op3 (p4 / protein
                                    :name (n6 / name :op1 "IL-6"~e.22,27,29,32))
                              :op4 (p5 / protein
                                    :name (n7 / name :op1 "IL-13"~e.22,27,32,34))))
                  :ARG2 (p9 / produce-01~e.17
                        :polarity~e.37,41 "-"~e.37
                        :ARG0 c3
                        :ARG1 (a2 / and
                              :op1 (p6 / protein
                                    :name (n8 / name :op1 "IL-4"~e.38,40,42))
                              :op2 (p7 / protein
                                    :name (n9 / name :op1 "IL-5"~e.42,44)))))))

# ::tok Like IL @-@ 12 , IL @-@ 23 binds to the IL @-@ 12R subunit IL @-@ 12Rbeta1 .
# ::alignments 0-1.1 0-1.1.2 0-1.1.2.r 1-1.1.2.1.1.1 3-1.1.2.1.1.1 5-1.1.1.1 5-1.1.2.1.1.1 7-1.1.1.1 8-1 11-1.1.1.1 11-1.2.2.1.1.1 13-1.2.2.1.1.1 15-1.2.1.1 15-1.2.2.1.1.1 17-1.2.1.1
# ::id bel_pmid_1202_3369_1246
(b / bind-01~e.8
      :ARG1 (p / protein~e.0
            :name (n2 / name :op1 "IL-23"~e.5,7,11)
            :ARG1-of~e.0 (r / resemble-01~e.0
                  :ARG2 (p2 / protein
                        :name (n / name :op1 "IL-12"~e.1,3,5))))
      :ARG2 (p4 / protein
            :name (n3 / name :op1 "IL-12Rbeta1"~e.15,17)
            :ARG1-of (i / include-91
                  :ARG2 (p3 / protein
                        :name (n4 / name :op1 "IL-12R"~e.11,13,15)))))

# ::tok IL @-@ 23 activates the same Jak @-@ stat signaling molecules as IL @-@ 12: Jak2 , Tyk2 , and stat1 , -@ 3 , -@ 4 , and -@ 5 , but stat4 activation is substantially weaker and different DNA @-@ binding stat complexes form in response to IL @-@ 23 compared with IL @-@ 12. IL @-@ 23R associates constitutively with Jak2 and in a ligand @-@ dependent manner with stat3 .
# ::alignments 0-1.1.1.2.2.1.1.1 0-1.2.1.1.1.1 2-1.1.2.1 3-1.1.2 3-1.1.2.2.3.1.1 6-1.1.2.2.1.1.1.1 8-1.1.2.2.1.1.1.1 9-1.1.2.2.1 10-1.1.2.2 10-1.1.2.2.3.1 12-1.1.1.2.2.1.1.1 12-1.1.1.2.3.1.1 15-1.1.2.2.2.1.1.1.1 17-1.1.2.2.2.1.2.1.1 19-1.1.2.2.2.1 20-1.1.2.2.2.1.3.1.1 28-1.1.1 28-1.1.2.2.2.1 32-1.1 33-1.1.2.2.2.1.5.1.1 34-1.1.1.1.2 34-1.1.2 35-1.1.1.1.2.r 36-1.1.1.1.3 37-1.1.1.1 37-1.1.1.1.1 37-1.1.1.1.1.r 38-1.1.1 39-1.1.1.2.1.3 39-1.1.2.2.3 40-1.1.1.2.1.1.1 42-1.1.1.2.1.1 43-1.1.1.2.1.2.1.1 44-1.1.1.2.1 45-1.1.1.2 46-1.1.1.2.2.r 47-1.1.1.2.2 48-1.1.1.2.2.1.r 49-1.1.1.2.2.1.1.1 51-1.1.1.2.2.1.1.1 52-1.1.1.2.3.r 54-1.1.1.2.3.1.1 54-1.2.1.1.1.1 57-1.1.1.2.3.1.1 57-1.2.1.1.1.1 59-1.2.1.1.1.1 60-1.2.1 60-1.2.2 61-1.2.1.3 62-1.2.1.2.r 63-1.2.1.2.1.1 64-1.2 65-1.2.2.3.r 67-1.2.2.3.1 69-1.2.2.3 70-1.2.1.3.r 72-1.1.2.2.2.1.4.1.1 72-1.2.2.2.1.1
# ::id bel_pmid_1202_3369_35656
(m / multi-sentence
      :snt1 (h / have-concession-91~e.32
            :ARG1 (a3 / and~e.28,38
                  :op1 (w / weak~e.37
                        :degree~e.37 (m2 / more~e.37)
                        :domain~e.35 (a4 / activate-01~e.34
                              :ARG1 (p12 / protein
                                    :name (n10 / name :op1 "stat4"~e.33)))
                        :degree (s / substantial~e.36))
                  :op2 (f / form-01~e.45
                        :ARG1 (m3 / macro-molecular-complex~e.44
                              :ARG1-of (b / bind-01~e.42
                                    :ARG2 (d2 / DNA~e.40))
                              :mod (p7 / protein
                                    :name (n13 / name :op1 "stat"~e.43))
                              :ARG1-of (d3 / differ-02~e.39))
                        :ARG2-of~e.46 (r2 / respond-01~e.47
                              :ARG1~e.48 (p5 / protein
                                    :name (n5 / name :op1 "IL-23"~e.0,12,49,51)))
                        :compared-to~e.52 (p6 / protein
                              :name (n6 / name :op1 "IL-12"~e.12,54,57))))
            :ARG2 (a2 / activate-01~e.3,34
                  :ARG0 p5~e.2
                  :ARG1 (m4 / molecule~e.10
                        :ARG0-of (s3 / signal-01~e.9
                              :ARG1 (p4 / pathway
                                    :name (n7 / name :op1 "Jak-stat"~e.6,8)))
                        :ARG1-of (m5 / mean-01
                              :ARG2 (a5 / and~e.19,28
                                    :op1 (p9 / protein
                                          :name (n4 / name :op1 "Jak2"~e.15))
                                    :op2 (p8 / protein
                                          :name (n12 / name :op1 "Tyk2"~e.17))
                                    :op3 (p10 / protein
                                          :name (n8 / name :op1 "stat1"~e.20))
                                    :op4 (p11 / protein
                                          :name (n9 / name :op1 "stat3"~e.72))
                                    :op5 p12
                                    :op6 (p13 / protein
                                          :name (n11 / name :op1 "stat5"))))
                        :ARG1-of (r3 / resemble-01~e.39
                              :ARG2 (m6 / molecule~e.10
                                    :ARG1-of (a8 / activate-01~e.3
                                          :ARG0 p6))))))
      :snt2 (a / and~e.64
            :op1 (a6 / associate-01~e.60
                  :ARG1 (p / protein
                        :name (n / name :op1 "IL-23R"~e.0,54,57,59))
                  :ARG2~e.62 (p2 / protein
                        :name (n2 / name :op1 "Jak2"~e.63))
                  :manner~e.70 (c / constitutive~e.61))
            :op2 (a7 / associate-01~e.60
                  :ARG1 p
                  :ARG2 (p3 / protein
                        :name (n3 / name :op1 "stat3"~e.72))
                  :manner~e.65 (d / depend-01~e.69
                        :ARG0 (l / ligand~e.67)))))

# ::tok At day 7 following infection , lung tissue from mice given hIL @-@ 17F Ad showed substantial increases in the mRNA for inflammatory cytokines and chemokines , including IL @-@ 6 , IFN @-@ g , inflammatory protein 10 , and monokine induced by IFN @-@ g ( Fig . 3 ) .
# ::alignments 1-1.4.2.2 2-1.4.2.1 4-1.4.1 6-1.1.1 7-1.1 8-1.1.2.r 9-1.1.2 10-1.1.2.1 11-1.1.2.1.1.2.1.1.1 13-1.1.2.1.1.2.1.1.1 14-1.1.2.1.1.1.1 15-1 16-1.2.2 17-1.2 20-1.2.1.1.1.1 22-1.2.1.1.2.3 24-1.2.1.1.2 27-1.2.1.1.2.4 28-1.2.1.1.2.4.1.1.1.1 30-1.2.1.1.2.4.1.1.1.1 32-1.2.1.1.2.4.1.2.1.1 34-1.2.1.1.2.4.1.2.1.1 36-1.2.1.1.2.4.1.3.1.1 37-1.2.1.1.2.4.1.3.1.2 38-1.2.1.1.2.4.1.3.1.3 40-1.2.1.1.2.4.1 41-1.2.1.1.2.4.1.4 42-1.2.1.1.2.4.1.4.1 43-1.2.1.1.2.4.1.4.1.1.r 44-1.2.1.1.2.4.1.4.1.1 45-1.2.1.1.2.4.1.4.1.1 46-1.2.1.1.2.4.1.4.1.1 50-1.3.1.1
# ::id bel_pmid_1207_7275_28056
(s / show-01~e.15
      :ARG0 (t / tissue~e.7
            :location (l / lung~e.6)
            :source~e.8 (m / mouse~e.9
                  :ARG2-of (g / give-01~e.10
                        :ARG1 (g2 / gene
                              :name (n / name :op1 "Ad"~e.14)
                              :ARG3-of (e / express-03
                                    :ARG2 (p6 / protein
                                          :name (n8 / name :op1 "hil-17F"~e.11,13)))))))
      :ARG1 (i2 / increase-01~e.17
            :ARG1 (a2 / and
                  :op1 (r / rna
                        :name (n2 / name :op1 "mRNA"~e.20)
                        :purpose (a3 / and~e.24
                              :op1 (c / cytokine)
                              :op2 (c2 / chemokine)
                              :ARG0-of (i3 / inflame-01~e.22)
                              :ARG2-of (i4 / include-91~e.27
                                    :ARG1 (a4 / and~e.40
                                          :op1 (p3 / protein
                                                :name (n5 / name :op1 "IL-6"~e.28,30))
                                          :op2 (p4 / protein
                                                :name (n6 / name :op1 "IFN-g"~e.32,34))
                                          :op3 (p5 / protein
                                                :name (n7 / name
                                                      :op1 "inflammatory"~e.36
                                                      :op2 "protein"~e.37
                                                      :op3 "10"~e.38))
                                          :op4 (m2 / monokine~e.41
                                                :ARG1-of (i5 / induce-01~e.42
                                                      :ARG0~e.43 p4~e.44,45,46)))))))
            :degree (s2 / substantial~e.16))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure :mod "3"~e.50))
      :time (a / after
            :op1 (i / infect-01~e.4
                  :ARG1 t)
            :quant (t2 / temporal-quantity
                  :quant "7"~e.2
                  :unit (d / day~e.1))))

# ::tok We cultured sorted mast cells and basophils with IL @-@ 25 , IL @-@ 18 , or IL @-@ 25 IL @-@ 18 and detected both IL @-@ 5 and IL @-@ 13 from IL @-@ 18 cultured cell supernatants
# ::alignments 0-1.1.1 1-1.1 2-1.1.3.1.2 3-1.1.3.1.1 4-1.1.3.1 5-1.1.3 6-1.1.3.2.1.1 7-1.1.2.r 8-1.1.2.1.1.1.1 10-1.1.2.1.1.1.1 12-1.1.2.1.1.1.1 12-1.1.2.1.2.1.1 14-1.1.2.1.2.1.1 16-1.1.2 17-1.1.2.1.1.1.1 17-1.1.2.1.2.1.1 19-1.1.2.1.1.1.1 20-1.1.2.1.1.1.1 20-1.1.2.1.2.1.1 22-1.1.2.1.2.1.1 23-1 23-1.1.2.1 23-1.1.2.2 24-1.2 26-1.2.2.1.1.1 28-1.2.2.1.1.1 29-1.2.2 30-1.2.2.1.1.1 30-1.2.2.2.1.1 32-1.2.2.2.1.1 33-1.2.2.3.r 34-1.1.2.1.1.1.1 34-1.1.2.1.2.1.1 34-1.2.2.1.1.1 34-1.2.2.2.1.1 36-1.2.2.3.2.2 37-1.2.2.3.2 38-1.2.2.3.1 39-1.2.2.3
# ::id bel_pmid_1207_7275_28070
(a / and~e.23
      :op1 (c / culture-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1~e.7 (o / or~e.16
                  :op1 (a3 / and~e.23
                        :op1 (p / protein
                              :name (n / name :op1 "IL-25"~e.8,10,12,17,19,20,34))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "IL-18"~e.12,14,17,20,22,34)))
                  :op2 (a4 / and~e.23
                        :op1 p
                        :op2 p2))
            :location (a2 / and~e.5
                  :op1 (c2 / cell~e.4
                        :mod (m / mast~e.3)
                        :ARG1-of (s2 / sort-01~e.2))
                  :op2 (c5 / cell
                        :name (n3 / name :op1 "basophil"~e.6))))
      :op2 (d / detect-01~e.24
            :ARG0 w
            :ARG1 (a5 / and~e.29
                  :op1 (p3 / protein
                        :name (n4 / name :op1 "IL-5"~e.26,28,30,34))
                  :op2 (p4 / protein
                        :name (n5 / name :op1 "IL-13"~e.30,32,34))
                  :source~e.33 (s / supernatant~e.39
                        :mod (c3 / cell~e.38)
                        :location-of (c4 / culture-01~e.37
                              :ARG0 w
                              :ARG1 p2~e.36)))))

# ::tok The dual phosphorylation of Thr @-@ 183 and Tyr @-@ 185 in ERK2 is catalyzed by MAPK @/@ ERK kinase 1 ( MEK1 ) .
# ::alignments 1-1.2.2 2-1.2 6-1.2.1.1.1 7-1.2.1 10-1.2.1.2.1 12-1.2.1.1.3.1.1 14-1 15-1.1.r 16-1.1.1.1 18-1.1.1.1 19-1.1 19-1.1.1.2 20-1.1.1.3
# ::id bel_pmid_1208_2107_1700
(c / catalyze-01~e.14
      :ARG0~e.15 (k / kinase~e.19
            :name (n / name
                  :op1 "MAPK/ERK"~e.16,18
                  :op2 "kinase"~e.19
                  :op3 "1"~e.20))
      :ARG1 (p2 / phosphorylate-01~e.2
            :ARG1 (a / and~e.7
                  :op1 (a2 / amino-acid
                        :mod "183"~e.6
                        :name (n2 / name :op1 "threonine")
                        :part-of (e / enzyme
                              :name (n4 / name :op1 "ERK2"~e.12)))
                  :op2 (a3 / amino-acid
                        :mod "185"~e.10
                        :name (n3 / name :op1 "tyrosine")
                        :part-of e))
            :mod (d / dual~e.1)))

# ::tok the phosphorylation of Raf @-@ 1 on Ser @-@ 259 induced by paclitaxel he region surrounding Ser @-@ 259 in Raf @-@ 1 conforms to a consensus sequence for phosphorylation by Akt
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.3.1.1 5-1.1.1.3.1.1 9-1.1.1.1 10-1.1.2 11-1.1.2.1.r 12-1.1.2.1 14-1.1.2.1.1 15-1.1.2.1.1.1 18-1.1.2.1.1.1.1 19-1.1.2.1.1.1.1 20-1.1.2.1.1.1.1 21-1.1.2.1.1.1.1 22-1.1.2.1.1.1.1 23-1 24-1.2.r 26-1.2.1 27-1.2 28-1.2.2.r 29-1.2.2 30-1.2.2.1.r 31-1.2.2.1.1.1
# ::id bel_pmid_1208_7097_38812
(c / conform-01~e.23
      :ARG1 (p / phosphorylate-01~e.1
            :ARG2~e.2 (a / amino-acid
                  :mod "259"~e.9
                  :name (n2 / name :op1 "serine")
                  :part-of (e2 / enzyme
                        :name (n3 / name :op1 "Raf-1"~e.3,5)))
            :ARG1-of (i / induce-01~e.10
                  :ARG0~e.11 (p3 / paclitaxel~e.12
                        :location (r / region~e.14
                              :ARG0-of (s2 / surround-01~e.15
                                    :ARG1 a~e.18,19,20,21,22)))))
      :ARG2~e.24 (s / sequence~e.27
            :mod (c2 / consensus~e.26)
            :purpose~e.28 (p2 / phosphorylate-01~e.29
                  :ARG2~e.30 (e / enzyme
                        :name (n / name :op1 "Akt"~e.31)))))

# ::tok calcium @-@ independent pathways are accounted for in part by MAPK activation ( Rap1/B @-@ Raf @/@ MAPK @-@ ERK kinase @/@ ERK1 @/@ 2 ) AtT @-@ 20 corticotrophs express B @-@ Raf , as do other cells in which cAMP stimulates MAPK . CRH @/@ cAMP stimulated ERK2 ( Mapk1 ) activity and increased transcriptional activity of a Gal4 @-@ Elk1 protein , which was blocked by overexpression of dominant negative mutants and kinase inhibitors and stimulated by expression of B @-@ Raf .
# ::alignments 0-1.1.2.1.2 2-1.1.2.1 2-1.1.2.1.1 2-1.1.2.1.1.r 3-1.1.2 5-1.1 6-1.1.3.r 7-1.1.3 8-1.1.3 9-1.1.1.r 10-1.1.1.1.1.1 11-1.1.1 15-1.1.1.2.2.1.1 17-1.1.1.1.1.1 19-1.1.1.2.3.1.1 20-1.1.1.2.3.1.2 22-1.1.1.2.4.1.1 26-1.2.1.1.1 28-1.2.1.1.1 30-1.2 30-1.2.3.1 31-1.2.2.1.1 33-1.2.2.1.1 37-1.2.3.1.1.1 38-1.2.3.1.1 39-1.1.3 41-1.2.3.1.1.2.1.1.1.1 42-1.3.1 43-1.2.3.1.1.2.1.2.1.1 45-1.3.1.1.1.1.1 47-1.3.1.1.2.1.1 48-1.3.1 49-1.1.1.2.5.1.1 49-1.3.1.2.1.1.1 53-1.3.1.2 54-1.3 55-1.3.2 57-1.3.1.2 60-1.3.2.2.1.1.1 62-1.3.2.2.1.1.1 63-1.3.2.2.1.2.1.1.1 67-1.3.2.2.1.2 69-1.3.2.2.1.3.1 73-1.3.2.2.1.2.1.1.1.1 74-1.3.2.2.1.2.1 75-1.3.2.2.1.2.1.2.1.1 76-1.3.2.2.1.2.1.2 76-1.3.2.2.1.2.1.2.1 76-1.3.2.2.1.2.1.2.1.r 77-1.3 78-1.2.3.1.1.2.1 78-1.3.2.2.1.3 80-1.2 82-1.2.2.1.1 84-1.2.2.1.1 84-1.3.2.2.1.3.1.1.1.1
# ::id bel_pmid_1208_9357_19824
(m / multi-sentence
      :snt1 (a5 / account-01~e.5
            :ARG0~e.9 (a6 / activate-01~e.11
                  :ARG0 (p7 / pathway
                        :name (n3 / name :op1 "MAPK"~e.10,17))
                  :ARG1 (s7 / slash
                        :op1 (e4 / enzyme
                              :name (n15 / name :op1 "Rap1"))
                        :op2 (e10 / enzyme
                              :name (n7 / name :op1 "B-Raf"~e.15))
                        :op3 (e7 / enzyme
                              :name (n13 / name :op1 "MAPK-ERK"~e.19 :op2 "kinase"~e.20))
                        :op4 (e8 / enzyme
                              :name (n12 / name :op1 "ERK1"~e.22))
                        :op5 (e9 / enzyme
                              :name (n11 / name :op1 "ERK2"~e.49))))
            :ARG1 (p / pathway~e.3
                  :ARG0-of (d2 / depend-01~e.2
                        :polarity~e.2 "-"~e.2
                        :ARG1 (c / calcium~e.0)))
            :degree~e.6 (i / in-part~e.7,8,39))
      :snt2 (e / express-03~e.30,80
            :ARG1 (c2 / corticotroph
                  :name (n / name :op1 "AtT-20"~e.26,28))
            :ARG2 (e2 / enzyme
                  :name (n2 / name :op1 "B-Raf"~e.31,33,82,84))
            :ARG1-of (r / resemble-01
                  :ARG2 (e11 / express-03~e.30
                        :ARG1 (c3 / cell~e.38
                              :mod (o2 / other~e.37)
                              :ARG2-of (b2 / be-located-at-91
                                    :ARG1 (s4 / stimulate-01~e.78
                                          :ARG0 (s6 / small-molecule
                                                :name (n10 / name :op1 "cAMP"~e.41))
                                          :ARG1 (p2 / pathway
                                                :name (n14 / name :op1 "MAPK"~e.43))))))))
      :snt3 (a / and~e.54,77
            :op1 (s / stimulate-01~e.42,48
                  :ARG0 (s2 / slash
                        :op1 (m5 / molecular-physical-entity
                              :name (n4 / name :op1 "CRH"~e.45))
                        :op2 (s5 / small-molecule
                              :name (n5 / name :op1 "cAMP"~e.47)))
                  :ARG1 (a2 / act-02~e.53,57
                        :ARG0 (e3 / enzyme
                              :name (n6 / name :op1 "ERK2"~e.49))))
            :op2 (i2 / increase-01~e.55
                  :ARG0 s2
                  :ARG1 (a3 / act-01
                        :ARG0 (p5 / protein
                              :name (n8 / name :op1 "Gal4-Elk1"~e.60,62)
                              :ARG1-of (b / block-01~e.67
                                    :ARG0 (a4 / and~e.74
                                          :op1 (o3 / overexpress-00
                                                :ARG2 (p6 / protein~e.63
                                                      :ARG2-of (m3 / mutate-01~e.73 :mod "-/-")))
                                          :op2 (m2 / molecular-physical-entity~e.76
                                                :ARG0-of~e.76 (i3 / inhibit-01~e.76
                                                      :ARG1 (k / kinase~e.75)))))
                              :ARG1-of (s3 / stimulate-01~e.78
                                    :ARG0 (e5 / express-03~e.69
                                          :ARG2 (e6 / enzyme
                                                :name (n9 / name :op1 "B-Raf"~e.84)))))
                        :ARG1 (t2 / transcribe-01)))))

# ::tok CRH and cAMP induce Nur77 and Nurr1 expression and transcription at the NurRE site by protein kinase A ( PKA ) and calcium @-@ dependent and -@ independent mechanisms .
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2.1.1 3-1 4-1.2.1.1.1.1.1 6-1.2.1.1.2.1.1 7-1.2.1 8-1.2 9-1.2.2 10-1.2.2.3.r 12-1.2.2.3.1.1 13-1.2.2.3 14-1.2.2.1.r 15-1.2.2.1.1.1.1 16-1.2.2.1.1.1.2 17-1.2.2.1.1.1.3 22-1.2.2.1.2.1.1 22-1.2.2.1.3.1.2 24-1.2.2.1.3.1 25-1.2.2.1 27-1.2.2.1.2.1 27-1.2.2.1.3.1 27-1.2.2.1.3.1.1 27-1.2.2.1.3.1.1.r 28-1.2.2.1.2 28-1.2.2.1.3
# ::id bel_pmid_1208_9357_26116
(i / induce-01~e.3
      :ARG0 (a / and~e.1
            :op1 (m3 / molecular-physical-entity
                  :name (n / name :op1 "CRH"~e.0))
            :op2 (s2 / small-molecule
                  :name (n2 / name :op1 "cAMP"~e.2)))
      :ARG1 (a4 / and~e.8
            :op1 (e / express-03~e.7
                  :ARG2 (a2 / and
                        :op1 (p3 / protein
                              :name (n3 / name :op1 "Nur77"~e.4))
                        :op2 (p4 / protein
                              :name (n4 / name :op1 "Nurr1"~e.6))))
            :op2 (t / transcribe-01~e.9
                  :ARG0~e.14 (a3 / and~e.25
                        :op1 (e2 / enzyme
                              :name (n6 / name
                                    :op1 "protein"~e.15
                                    :op2 "kinase"~e.16
                                    :op3 "A"~e.17))
                        :op2 (m / mechanism~e.28
                              :ARG0-of (d / depend-01~e.27
                                    :ARG1 (c / calcium~e.22)))
                        :op3 (m2 / mechanism~e.28
                              :ARG0-of (d2 / depend-01~e.24,27
                                    :polarity~e.27 "-"~e.27
                                    :ARG1 (c2 / calcium~e.22))))
                  :ARG1 a2
                  :location~e.10 (p / protein-segment~e.13
                        :name (n5 / name :op1 "NurRE"~e.12)))))

# ::tok The MAPK kinase inhibitors did not affect Nur77 and Nurr1 mRNA induction but blocked CRH or cAMP @-@ stimulated Nur transcriptional activity .
# ::alignments 1-1.1.2.1.1.1.1 2-1.1.2.1.1 3-1.1.2 3-1.1.2.1 3-1.1.2.1.r 5-1.1.1 5-1.1.1.r 6-1.1 7-1.1.3.1.1.2.1.1 8-1.1.3.1 9-1.1.3.1.2.2.1.1 10-1.1.3.1.1.1.1 10-1.1.3.1.2.1.1 12-1 13-1.2 14-1.2.2.3.1.1.1.1 15-1.2.2.3.1 16-1.2.2.3.1.2.1.1 18-1.2.2.3 19-1.2.2.1.1.1
# ::id bel_pmid_1208_9357_6280
(c / contrast-01~e.12
      :ARG1 (a / affect-01~e.6
            :polarity~e.5 "-"~e.5
            :ARG0 (m / molecular-physical-entity~e.3
                  :ARG0-of~e.3 (i3 / inhibit-01~e.3
                        :ARG1 (k / kinase~e.2
                              :name (n8 / name :op1 "MAPK"~e.1))))
            :ARG1 (i / induct-01
                  :ARG1 (a2 / and~e.8
                        :op1 (r / rna
                              :name (n6 / name :op1 "mRNA"~e.10)
                              :mod (p / protein
                                    :name (n / name :op1 "Nur77"~e.7)))
                        :op2 (r2 / rna
                              :name (n7 / name :op1 "mRNA"~e.10)
                              :mod (p2 / protein
                                    :name (n2 / name :op1 "Nurr1"~e.9))))))
      :ARG2 (b / block-01~e.13
            :ARG0 m
            :ARG1 (a4 / act-01
                  :ARG0 (p6 / protein
                        :name (n5 / name :op1 "Nur"~e.19))
                  :ARG1 (t2 / transcribe-01)
                  :ARG1-of (s / stimulate-01~e.18
                        :ARG0 (o / or~e.15
                              :op1 (m2 / molecular-physical-entity
                                    :name (n3 / name :op1 "CRH"~e.14))
                              :op2 (s3 / small-molecule
                                    :name (n4 / name :op1 "cAMP"~e.16)))))))

# ::tok The levels of collagen alpha1 ( I ) , alpha1 ( III ) , and fibronectin mRNAs were reduced in 1 @-@ day wounds of Nrf2 knockout mice compared to control littermates .
# ::alignments 1-1.1.1 1-1.1.2 1-1.1.3 2-1.1.1.1.r 3-1.1.1.1.1.1 6-1.2.3.1.1 14-1.1 15-1.1.3.1.2 16-1.1.3.1.1.1 18-1 20-1.2.3.1.1 22-1.2.3.1.2 23-1.2 24-1.2.2.r 25-1.2.2.1.1 27-1.2.1 28-1.2.4.r 30-1.2.4.1
# ::id bel_pmid_1210_1242_29522
(r / reduce-01~e.18
      :ARG1 (a / and~e.14
            :op1 (l2 / level~e.1
                  :quant-of~e.2 (p2 / protein
                        :name (n3 / name :op1 "collagen"~e.3 :op2 "alpha1 I")))
            :op2 (l3 / level~e.1
                  :quant-of (p3 / protein
                        :name (n / name :op1 "alpha1 III")))
            :op3 (l4 / level~e.1
                  :quant-of (r2 / rna
                        :name (n4 / name :op1 "mRNA"~e.16)
                        :mod (f / fibronectin~e.15))))
      :location (w / wound-01~e.23
            :ARG1 (m / mouse~e.27)
            :mod~e.24 (p / protein
                  :name (n2 / name :op1 "Nrf2"~e.25)
                  :ARG2-of (m2 / mutate-01 :mod "+/-"))
            :ARG1-of (a2 / age-01
                  :ARG2 (t / temporal-quantity
                        :quant "1"~e.6,20
                        :unit (d / day~e.22)))
            :compared-to~e.28 (l / littermate
                  :ARG1-of (c / control-01~e.30))))

# ::tok Interestingly , the normally observed induction of IL @-@ 1 beta and TNF @-@ alpha expression ( 22 ) was delayed in the knockout mice . The levels of IL @-@ 1 beta mRNA were 50 % lower in the 1 @-@ day wounds of Nrf2-/- mice than for control littermates .
# ::alignments 3-1.1.1.2.1 3-1.1.1.2.1.r 4-1.1.1.2 7-1.1.1.1.1.1.1.1 9-1.2.4.2.1.1 11-1.1.1.1.1 12-1.1.1.1.1.2.1.1 14-1.1.1.1.1.2.1.1 15-1.1.1.1 17-1.1.1.3.1.1.1 20-1.1 24-1.1.3 27-1.2.3 29-1.2.3.1.2.1.1 31-1.2.4.2.1.1 33-1.2.3.1.1.1 34-1.2.3.r 35-1.2.2.1 36-1.2.2 37-1.2 37-1.2.1 37-1.2.1.r 40-1.2.4.2.1.1 42-1.2.4.2.1.2 43-1.2.4 46-1.2.4.1 47-1.2.5.r 49-1.2.5.1
# ::id bel_pmid_1210_1242_29526
(m2 / multi-sentence
      :snt1 (d2 / delay-01~e.20
            :ARG1 (i / induct-01
                  :ARG1 (e / express-03~e.15
                        :ARG2 (a / and~e.11
                              :op1 (p4 / protein
                                    :name (n5 / name :op1 "IL-1beta"~e.7))
                              :op2 (p5 / protein
                                    :name (n6 / name :op1 "TNF-alpha"~e.12,14))))
                  :ARG1-of (o / observe-01~e.4
                        :manner~e.3 (n4 / normal~e.3))
                  :ARG1-of (d3 / describe-01
                        :ARG0 (p6 / publication
                              :ARG1-of (c2 / cite-01 :ARG2 "22"~e.17))))
            :ARG2-of (i2 / interest-01)
            :location (m5 / mouse~e.24
                  :ARG2-of (m6 / mutate-01 :mod "+/-")))
      :snt2 (l2 / low~e.37
            :degree~e.37 (m / more~e.37)
            :quant (p / percentage-entity~e.36 :value "50"~e.35)
            :domain~e.34 (l / level~e.27
                  :quant-of (r / rna
                        :name (n / name :op1 "mRNA"~e.33)
                        :mod (p2 / protein
                              :name (n2 / name :op1 "IL-1beta"~e.29))))
            :location (w / wound-01~e.43
                  :ARG1 (m3 / mouse~e.46
                        :mod (p3 / protein
                              :name (n3 / name :op1 "Nrf2")
                              :ARG2-of (m4 / mutate-01 :mod "-/-")))
                  :ARG1-of (a2 / age-01
                        :ARG2 (t / temporal-quantity
                              :quant "1"~e.9,31,40
                              :unit (d / day~e.42))))
            :compared-to~e.47 (l3 / littermate
                  :ARG1-of (c / control-01~e.49))))

# ::tok Expression of IL @-@ 6 was also lower in 1 @-@ day wounds of Nrf2 null mice , but in contrast to IL @-@ 1 beta the mRNA of this cytokine was no longer detectable at later stages of repair .
# ::alignments 0-1.2.2 1-1.2.2.1.r 2-1.2.2.1.1.1 4-1.2.2.1.1.1 5-1.2.2.r 6-1.2.3 7-1.2 7-1.2.1 7-1.2.1.r 8-1.2.4.r 9-1.2.4.2.1.1 11-1.2.4.2.1.2 12-1.2.4 13-1.2.4.1.r 14-1.2.4.1.1.1.1 16-1.2.4.1 18-1 18-1.1 18-1.1.r 20-1.1 22-1.2.2.1.1.1 24-1.2.4.2.1.1 25-1.1.1.1.1 27-1.1.2.1.1.1.1 31-1.1.2.1.r 32-1.1.2.1.2 33-1.1.2.1.2 36-1.1.2.1.3.1 36-1.1.2.1.3.1.1 36-1.1.2.1.3.1.1.r 37-1.1.2.1.3 38-1.1.2.1.3.2.r 39-1.1.2.1.3.2
# ::id bel_pmid_1210_1242_29528
(h / have-concession-91~e.18
      :ARG1~e.18 (c2 / contrast-01~e.18,20
            :ARG1 (p3 / protein
                  :name (n3 / name :op1 "IL1-beta"~e.25))
            :ARG2 (p4 / possible
                  :domain~e.31 (d2 / detect-01
                        :ARG1 (r / rna
                              :name (n4 / name :op1 "mRNA"~e.27)
                              :poss (p / protein
                                    :name (n / name :op1 "IL-6"~e.2,4,22)))
                        :time (n6 / no-longer~e.32,33)
                        :time (s / stage~e.37
                              :time (l / late~e.36
                                    :degree~e.36 (m3 / more~e.36))
                              :subevent-of~e.38 (r2 / repair-01~e.39)))))
      :ARG2 (l3 / low~e.7
            :degree~e.7 (m / more~e.7)
            :domain~e.5 (e / express-03~e.0
                  :ARG2~e.1 p)
            :mod (a / also~e.6)
            :location~e.8 (w / wound-01~e.12
                  :ARG1~e.13 (m2 / mouse~e.16
                        :mod (p2 / protein
                              :name (n2 / name :op1 "Nrf2"~e.14)
                              :ARG2-of (m4 / mutate-01 :mod "-/-")))
                  :ARG1-of (a2 / age-01
                        :ARG2 (t / temporal-quantity
                              :quant "1"~e.9,24
                              :unit (d / day~e.11))))))

# ::tok Indeed , TGF @-@ beta1 mRNA was present at lower levels in unwounded back skin and in 1 @-@ day wounds of Nrf2-/- mice ( Fig.7 ) .
# ::alignments 0-1.4 2-1.1.2.1.1 4-1.1.2.1.1 5-1.1.1.1 6-1 8-1 9-1.1.3.1 9-1.1.3.1.1 9-1.1.3.1.1.r 10-1.1.3 12-1.2.1.2.1 13-1.2.1.1 14-1.2.1 15-1.2 17-1.2.2.1.2.1.1 19-1.2.2.1.2.1.2 20-1.2.1.2 20-1.2.2 23-1.2.2.1
# ::id bel_pmid_1210_1242_29532
(b / be-located-at-91~e.6,8
      :ARG1 (r / rna
            :name (n2 / name :op1 "mRNA"~e.5)
            :mod (p / protein
                  :name (n3 / name :op1 "TGF-beta1"~e.2,4))
            :quant (l / level~e.10
                  :mod (l2 / low~e.9
                        :degree~e.9 (m / more~e.9))))
      :ARG2 (a2 / and~e.15
            :op1 (s / skin~e.14
                  :location (b2 / back~e.13)
                  :ARG1-of (w / wound-01~e.20 :polarity "-"~e.12))
            :op2 (w2 / wound-01~e.20
                  :ARG1 (m2 / mouse~e.23
                        :mod (p2 / protein
                              :name (n / name :op1 "Nrf2")
                              :ARG2-of (m3 / mutate-01 :mod "-/-"))
                        :ARG1-of (a / age-01
                              :ARG2 (t / temporal-quantity
                                    :quant "1"~e.17
                                    :unit (d / day~e.19))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "7"))
      :mod (i / indeed~e.0))

# ::tok Expression of VEGF , a major regulator of angiogenesis , was also reduced in nonwounded skin and in 1 @-@ day wounds of Nrf2 null mice ( Fig.7 ) .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1 5-1.1.1.2.2 6-1.1.1 6-1.1.1.2 6-1.1.1.2.r 7-1.1.1.2.1.r 8-1.1.1.2.1 11-1.2 12-1 15-1.3.1 16-1.3 17-1.3.r 18-1.3.2.2.1.1 20-1.3.2.2.1.2 21-1.3.1.1 23-1.3.2.1.1.1 25-1.3.2
# ::id bel_pmid_1210_1242_29534
(r2 / reduce-01~e.12
      :ARG1 (e / express-03~e.0
            :ARG2~e.1 (p / protein~e.6
                  :name (n2 / name :op1 "VEGF"~e.2)
                  :ARG0-of~e.6 (r / regulate-01~e.6
                        :ARG1~e.7 (a4 / angiogenesis~e.8)
                        :mod (m3 / major~e.5))))
      :mod (a2 / also~e.11)
      :location~e.17 (a3 / and~e.16
            :op1 (s / skin~e.15
                  :ARG1-of (w / wound-01~e.21 :polarity "-"))
            :op2 (m / mouse~e.25
                  :mod (p2 / protein
                        :name (n3 / name :op1 "Nrf2"~e.23)
                        :ARG2-of (m2 / mutate-01 :mod "-/-"))
                  :ARG1-of (a / age-01
                        :ARG2 (t / temporal-quantity
                              :quant "1"~e.18
                              :unit (d / day~e.20)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "7")))

# ::tok in Il6 signal cascade , the SHP2 interaction site of gp130 has also been shown to be a Socs3 contact site so that Socs3 may compete for the SHP2 @-@ gp130 interaction site
# ::alignments 2-1.2.1 3-1.2 6-1.1.1.1.1.1 7-1.1.1 8-1.1 10-1.1.3.1.1 12-1.3 13-1.1.2.r 14-1 16-1.1.2.r 18-1.1.2.1.1.1.1 19-1.1.2.1 20-1.1 20-1.1.2 21-1.1.4.r 22-1.1.4.r 23-1.1.2.1.1.1.1 24-1.1.4 25-1.1.4.1 28-1.1.1.1.1.1 30-1.1.3.1.1 31-1.1.1 32-1.1
# ::id bel_pmid_1211_0143_20340
(s / show-01~e.14
      :ARG1 (p5 / protein-segment~e.8,20,32
            :mod (i / interact-01~e.7,31
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "SHP2"~e.6,28)))
            :domain~e.13,16 (p6 / protein-segment~e.20
                  :ARG0-of (c / contact-01~e.19
                        :ARG1 (p2 / protein
                              :name (n3 / name :op1 "Socs3"~e.18,23))))
            :part-of (p / protein
                  :name (n2 / name :op1 "gp130"~e.10,30))
            :purpose~e.21,22 (p3 / possible~e.24
                  :domain (c2 / compete-01~e.25
                        :ARG0 p2
                        :ARG1 p5)))
      :location (c3 / cascade~e.3
            :mod (s2 / signal-01~e.2
                  :ARG0 (p4 / protein
                        :name (n4 / name :op1 "IL-6"))))
      :mod (a / also~e.12))

# ::tok binding of Il6 to Il6R induces homodimerization ofgp130 , activating JAK associated with gp130 at Box1 .
# ::alignments 0-1.1 5-1 9-1.3 10-1.3.1.1.1 11-1.3.1.2 13-1.2.1.1.1 14-1.3.1.2.2.r 15-1.3.1.2.2.1.1
# ::id bel_pmid_1211_0143_268
(i / induce-01~e.5
      :ARG0 (b / bind-01~e.0
            :ARG1 (p / protein
                  :name (n / name :op1 "IL-6"))
            :ARG2 (p2 / protein
                  :name (n2 / name :op1 "IL-6R")))
      :ARG1 (d / dimerize-00
            :ARG1 (p3 / protein
                  :name (n3 / name :op1 "gp130"~e.13))
            :mod (h / hetero))
      :ARG0-of (a / activate-01~e.9
            :ARG1 (p4 / protein
                  :name (n4 / name :op1 "JAK"~e.10)
                  :ARG1-of (a2 / associate-01~e.11
                        :ARG2 p3
                        :location~e.14 (p5 / protein-segment
                              :name (n5 / name :op1 "Box1"~e.15)
                              :part-of p3)))))

# ::tok nonreceptor tyrosine kinases , such as Btk , Tec , Fes , and Hck are activated through the Il6R receptor
# ::alignments 0-1.2.1.1 1-1.2.1.2 2-1.2.1.3 4-1.2.2.r 5-1.2.2.r 6-1.2.2.1.1.1 8-1.2.2.2.1.1 10-1.2.2.3.1.1 12-1.2.2 13-1.2.2.4.1.1 15-1 19-1.1
# ::id bel_pmid_1211_0143_28372
(a / activate-01~e.15
      :ARG0 (r / receptor~e.19
            :name (n / name :op1 "IL-6R"))
      :ARG1 (e5 / enzyme
            :name (n2 / name
                  :op1 "nonreceptor"~e.0
                  :op2 "tyrosine"~e.1
                  :op3 "kinase"~e.2)
            :example~e.4,5 (a3 / and~e.12
                  :op1 (e / enzyme
                        :name (n3 / name :op1 "Btk"~e.6))
                  :op2 (e2 / enzyme
                        :name (n4 / name :op1 "Tec"~e.8))
                  :op3 (e3 / enzyme
                        :name (n5 / name :op1 "Fes"~e.10))
                  :op4 (e4 / enzyme
                        :name (n6 / name :op1 "Hck"~e.13)))))

# ::tok tyrosine phosphorylation of SHP2 , a phosphotyrosine phosphatase , and that of STAT3 depend on the second tyrosine residue Y2 from the membrane in gp130
# ::alignments 0-1.2.2.1.1 1-1.1.1 1-1.1.2 2-1.1.1.1.r 3-1.1.1.1.2.1.1 6-1.1.1.1.2.2.1.1 7-1.1.1.1.2.2.1 9-1.1 11-1.1.2.1.r 12-1.1.2.1.2.1.1 13-1 16-1.2.3 16-1.2.3.1 16-1.2.3.1.r 17-1.1.1.1.1.1 17-1.1.2.1.1.1 17-1.2.2.1.1 18-1.2 19-1.2.1.1 20-1.2.4.r 22-1.2.4 23-1.2.4.1.r 24-1.2.4.1.1.1
# ::id bel_pmid_1211_0143_28412
(d / depend-01~e.13
      :ARG0 (a / and~e.9
            :op1 (p / phosphorylate-01~e.1
                  :ARG1~e.2 (a3 / amino-acid
                        :name (n6 / name :op1 "tyrosine"~e.17)
                        :part-of (e / enzyme
                              :name (n4 / name :op1 "SHP2"~e.3)
                              :ARG1-of (m / mean-01
                                    :ARG2 (p3 / phosphatase~e.7
                                          :mod (p5 / phosphotyrosine~e.6))))))
            :op2 (p4 / phosphorylate-01~e.1
                  :ARG1~e.11 (a4 / amino-acid
                        :name (n7 / name :op1 "tyrosine"~e.17)
                        :part-of (p6 / protein
                              :name (n5 / name :op1 "STAT3"~e.12)))))
      :ARG1 (r / residue~e.18
            :name (n2 / name :op1 "Y2"~e.19)
            :mod (a2 / amino-acid
                  :name (n / name :op1 "tyrosine"~e.0,17))
            :mod (o / ordinal-entity~e.16 :value~e.16 "2"~e.16)
            :location~e.20 (m2 / membrane~e.22
                  :part-of~e.23 (p2 / protein
                        :name (n3 / name :op1 "gp130"~e.24)))))

# ::tok presence of type 1 Il6R , which is a binding site for NF @-@ IL @-@ 6 , IL @-@ 6DBP , and CEBPbeta has been confirmed in the genes for CRP , hemoplexin A and haptoglobin binding activity of NF @-@ IL @-@ 6 is probably induced by Il6 through the increased expression of the NF @-@ IL @-@ 6 gene
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.2 3-1.1.1.1.2.1 7-1.1.1.1.3.r 9-1.2.2.2 10-1.1.1.1.3 11-1.1.1.1.3.1.r 12-1.1.1.1.3.1.1.1.1.1 14-1.1.1.1.3.1.1.1.1.1 14-1.1.1.1.3.1.1.2.1.1 16-1.1.1.1.3.1.1.1.1.1 18-1.1.1.1.3.1.1.1.1.1 18-1.1.1.1.3.1.1.2.1.1 20-1.1.1.1.3.1.1.2.1.1 23-1.1.1.1.3.1.1.3.1.1 25-1.1.1.1.3.r 26-1.1 27-1.1.3.r 29-1.1.3 30-1.1.2.r 31-1.1.2.1.1.1 33-1.1.2.2.1.1 34-1.1.2.2.1.2 36-1.1.2.3.1.1 37-1.1.1.1.3.1 40-1.2.2.1.1.1 42-1.1.1.1.1.1 44-1.2.2.1.1.1 45-1.1.1.1.3.r 46-1.2.3 47-1.2 48-1.2.1.r 49-1.2.1.1.1 52-1.2.4.2 53-1.2.4 54-1.2.4.1.r 56-1.2.4.1.1.1 57-1.2.4.1.1.1 58-1.2.4.1.1.1 59-1.2.4.1.1.1 60-1.2.4.1.1.1 61-1.2.4.1
# ::id bel_pmid_1211_0143_32746
(m / multi-sentence
      :snt1 (c / confirm-01~e.26
            :ARG1 (p3 / present~e.0
                  :mod~e.1 (p4 / protein
                        :name (n3 / name :op1 "IL-6R"~e.42)
                        :mod (t / type~e.2 :mod "1"~e.3)
                        :domain~e.7,25,45 (p8 / protein-segment~e.10
                              :ARG1-of~e.11 (b2 / bind-01~e.37
                                    :ARG2 (a3 / and
                                          :op1 (p5 / protein
                                                :name (n / name :op1 "NF-IL-6"~e.12,14,16,18))
                                          :op2 (p6 / protein
                                                :name (n4 / name :op1 "IL-6DBP"~e.14,18,20))
                                          :op3 (p7 / protein
                                                :name (n5 / name :op1 "CEBPbeta"~e.23)))))))
            :ARG2~e.30 (a / and
                  :op1 (p9 / protein
                        :name (n6 / name :op1 "CRP"~e.31))
                  :op2 (p10 / protein
                        :name (n7 / name :op1 "hemoplexin"~e.33 :op2 "A"~e.34))
                  :op3 (p11 / protein
                        :name (n9 / name :op1 "haptoglobin"~e.36)))
            :location~e.27 (g2 / gene~e.29))
      :snt2 (i / induce-01~e.47
            :ARG0~e.48 (p2 / protein
                  :name (n10 / name :op1 "Il6"~e.49))
            :ARG1 (a2 / act-01
                  :ARG0 (p12 / protein
                        :name (n8 / name :op1 "NF-IL-6"~e.40,44))
                  :ARG1 (b / bind-01~e.9))
            :mod (p / probable~e.46)
            :manner (e / express-03~e.53
                  :ARG2~e.54 (g / gene~e.61
                        :ARG0-of (e2 / encode-01
                              :ARG1 p12~e.56,57,58,59,60))
                  :ARG1-of (i2 / increase-01~e.52))))

# ::tok binding of Il6 to Il6R induces homodimerization ofgp130 , activating JAK associated with gp130 at Box1.......Our group and others found that JAK1 , JAK2 , and Tky @-@ 2 are activated and are tyrosine @-@ phosphorylated in response to IL @-@ 6 , CNTF , LIF , and OSM [14]
# ::alignments 0-1.1.1 5-1.1 9-1.1.3 10-1.1.3.1.1.1 11-1.1.3.1.2 13-1.1.2.1.1.1 16-1.2.1.1 16-1.2.1.2 17-1.2.1 18-1.2.1.2.1 19-1.2 20-1.2.2.r 21-1.2.2.1.1.1.1.1 23-1.2.2.1.1.2.1.1 25-1.2.2 26-1.2.2.2.1.3.2.1.1 28-1.2.2.2.1.3.2.1.1 30-1.2.2.1 31-1.2.2 31-1.2.2.2.1 33-1.2.2.2.1.1.1.1 33-1.2.2.2.1.2.1.1 33-1.2.2.2.1.3.1.1 35-1.2.2.2 36-1.2.2.2.2.r 37-1.2.2.2.2 39-1.1.1.2.1.1 39-1.2.2.2.2.1.1.1.1 41-1.1.1.1.1.1 41-1.2.2.2.2.1.1.1.1 43-1.2.2.2.2.1.2.1.1 45-1.2.2.2.2.1.3.1.1 48-1.2.2.2.2.1.4.1.1
# ::id bel_pmid_1211_0143_35664
(m / multi-sentence
      :snt1 (i / induce-01~e.5
            :ARG0 (b / bind-01~e.0
                  :ARG1 (p / protein
                        :name (n / name :op1 "IL-6"~e.41))
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "IL-6R"~e.39)))
            :ARG1 (d / dimerize-00
                  :ARG1 (p3 / protein
                        :name (n3 / name :op1 "gp130"~e.13))
                  :mod (h / homo))
            :ARG0-of (a / activate-01~e.9
                  :ARG1 (p4 / protein
                        :name (n4 / name :op1 "JAK"~e.10)
                        :ARG1-of (a2 / associate-01~e.11
                              :ARG2 p3
                              :location (p5 / protein-segment
                                    :name (n5 / name :op1 "Box1"))))))
      :snt2 (f / find-01~e.19
            :ARG0 (a3 / and~e.17
                  :op1 (g / group~e.16
                        :poss (w / we))
                  :op2 (g2 / group~e.16
                        :mod (o / other~e.18)))
            :ARG1~e.20 (a4 / and~e.25,31
                  :op1 (a5 / activate-01~e.30
                        :ARG1 (a6 / and
                              :op1 (p7 / protein
                                    :name (n6 / name :op1 "JAK1"~e.21))
                              :op2 (p8 / protein
                                    :name (n7 / name :op1 "JAK2"~e.23))
                              :op3 (p9 / protein
                                    :name (n8 / name :op1 "Tky2"))))
                  :op2 (p6 / phosphorylate-01~e.35
                        :ARG1 (a9 / and~e.31
                              :op1 (a7 / amino-acid
                                    :name (n9 / name :op1 "tyrosine"~e.33)
                                    :part-of p7)
                              :op2 (a10 / amino-acid
                                    :name (n14 / name :op1 "tyrosine"~e.33)
                                    :part-of p8)
                              :op3 (a11 / amino-acid
                                    :name (n15 / name :op1 "tyrosine"~e.33)
                                    :part-of (e / enzyme
                                          :name (n16 / name :op1 "Tky-2"~e.26,28))))
                        :ARG2-of~e.36 (r / respond-01~e.37
                              :ARG1 (a8 / and
                                    :op1 (p10 / protein
                                          :name (n10 / name :op1 "IL-6"~e.39,41))
                                    :op2 (p11 / protein
                                          :name (n11 / name :op1 "CNTF"~e.43))
                                    :op3 (p12 / protein
                                          :name (n12 / name :op1 "LIF"~e.45))
                                    :op4 (e2 / enzyme
                                          :name (n13 / name :op1 "OSM"~e.48))))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p14 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "14")))))

# ::tok Socs1 is essential for inhibition of IFN @-@ gamma @-@ induced inhibition of STAT6
# ::alignments 0-1.1.1.1 1-1.1.r 2-1 3-1.2.r 4-1.2 5-1.2.1.r 6-1.2.1.2.1.1.1 8-1.2.1.2.1.1.1 10-1.2.1.2 11-1.2.1 12-1.2.1.1.r 13-1.2.1.1.1.1
# ::id bel_pmid_1211_0143_38318
(e / essential~e.2
      :domain~e.1 (p / protein
            :name (n / name :op1 "Socs1"~e.0))
      :purpose~e.3 (i / inhibit-01~e.4
            :ARG1~e.5 (i2 / inhibit-01~e.11
                  :ARG1~e.12 (p3 / protein
                        :name (n3 / name :op1 "STAT6"~e.13))
                  :ARG1-of (i3 / induce-01~e.10
                        :ARG0 (p2 / protein
                              :name (n2 / name :op1 "IFN-gamma"~e.6,8))))))

# ::tok Socs1 inhibits activation of STAT6 by Il4 stimulation
# ::alignments 0-1.1.1.1 1-1 2-1.2 3-1.2.2.r 4-1.2.2.1.1 7-1.2.1
# ::id bel_pmid_1211_0143_38516
(i / inhibit-01~e.1
      :ARG0 (p3 / protein
            :name (n / name :op1 "Socs1"~e.0))
      :ARG1 (a / activate-01~e.2
            :ARG0 (s / stimulate-01~e.7
                  :ARG1 (p2 / protein
                        :name (n3 / name :op1 "IL-4")))
            :ARG1~e.3 (p / protein
                  :name (n2 / name :op1 "STAT6"~e.4))))

# ::tok Il6 activates STAT1 and STAT5 in addition to STAT3
# ::alignments 1-1 2-1.2.1.1.1 3-1.2 4-1.2.2.1.1 5-1.2 6-1.2 7-1.2.r 8-1.2.3.1.1
# ::id bel_pmid_1211_0143_38548
(a / activate-01~e.1
      :ARG0 (p / protein
            :name (n5 / name :op1 "IL-6"))
      :ARG1~e.7 (a2 / and~e.3,5,6
            :op1 (p2 / protein
                  :name (n2 / name :op1 "STAT1"~e.2))
            :op2 (p3 / protein
                  :name (n3 / name :op1 "STAT5"~e.4))
            :op3 (p4 / protein
                  :name (n4 / name :op1 "STAT3"~e.8))))

# ::tok the down @-@ regulation of D1 and D2 cyclins by OSM was mediated by STAT3 but not by SHP2 @/@ Ras STAT3 activation is necessary and sufficient for down @-@ regulation of D1 and D2 cyclins in fetal hepatocytes
# ::alignments 5-1.1.1.2.1.1.1.1 6-1.1.1.2.1 6-1.2 7-1.1.1.2.1.2.1.1 8-1.1.1.2.1.1.1.2 8-1.1.1.2.1.2.1.2 10-1.1.1.2.2.1.1 12-1.1.1 12-1.1.2 13-1.1.1.1.r 14-1.1.1.1.1.1 15-1.1 16-1.1.2.1 16-1.1.2.1.r 17-1.1.2.2.r 18-1.1.2.2.1.1 20-1.1.2.2.1.1 21-1.2.1.2.1.1.1 22-1.2.1.2 24-1.2.1 25-1.2 25-1.2.1.1.1 26-1.2.2 32-1.2.1.1.1.1.1.1 33-1.2 34-1.2.1.1.1.2.1.1 35-1.2.1.1.1.1.1.2 35-1.2.1.1.1.2.1.2 37-1.2.1.1.1.3.1
# ::id bel_pmid_1214_7685_34134
(m3 / multi-sentence
      :snt1 (c4 / contrast-01~e.15
            :ARG1 (m / mediate-01~e.12
                  :ARG0~e.13 (p7 / protein
                        :name (n10 / name :op1 "STAT3"~e.14))
                  :ARG1 (d2 / downregulate-01
                        :ARG1 (a5 / and~e.6
                              :op1 (p5 / protein
                                    :name (n8 / name :op1 "D1"~e.5 :op2 "cyclin"~e.8))
                              :op2 (p6 / protein
                                    :name (n9 / name :op1 "D2"~e.7 :op2 "cyclin"~e.8)))
                        :ARG2 (e / enzyme
                              :name (n4 / name :op1 "OSM"~e.10))))
            :ARG2 (m2 / mediate-01~e.12
                  :polarity~e.16 "-"~e.16
                  :ARG0~e.17 (p4 / pathway
                        :name (n7 / name :op1 "SHP2/Ras"~e.18,20))
                  :ARG1 d2))
      :snt2 (a / and~e.6,25,33
            :op1 (n / need-01~e.24
                  :ARG0 (d / downregulate-01
                        :ARG1 (a2 / and~e.25
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "D1"~e.32 :op2 "cyclin"~e.35))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "D2"~e.34 :op2 "cyclin"~e.35))
                              :location (h / hepatocyte
                                    :mod (f / fetus~e.37))))
                  :ARG1 (a4 / activate-01~e.22
                        :ARG1 (p / protein
                              :name (n6 / name :op1 "STAT3"~e.21))))
            :op2 (s / suffice-01~e.26
                  :ARG0 a2
                  :ARG1 d)))

# ::tok Substitution of Arg @-@ 238 , equivalent to conserved Arg in the 14 @-@ 3 @-@ 3 binding motif , with Glu ( R238E ) decreased 14 @-@ 3 @-@ 3 theta binding to PDK1 ( Fig . 3 C , upper panel , lane 4 ) . In contrast , substitution of Val @-@ 243 with Pro ( V243P ) , a residue conserved in many 14 @-@ 3 @-@ 3 targets , such as Raf @-@ 1 and Bad ( Fig.3 A ) , dramatically increased the amount of 14 @-@ 3 @-@ 3 theta bound to PDK1
# ::alignments 0-1.1.1 4-1.1.1.3.1 8-1.1.1.3.3.1.2 10-1.1.1.3.3.1.2.1.r 12-1.1.1.3.3.1.2.1.1.1.1.1 14-1.1.1.3.3.1.2.1.1.1.1.1 16-1.1.1.3.3.1.2.1.1.1.1.1 17-1.1.1.3.3.1.2.1.1 18-1.1.1.3.3.1.2.1 23-1.1.1.1 25-1.1 26-1.1.2.1.1.1 28-1.1.2.1.1.1 30-1.1.2.1.1.1 32-1.1.2 34-1.1.2.2.1.1 38-1.1.2.1.1.1 41-1.1.3.2.2.1 42-1.1.3.2.2 44-1.1.3.2 45-1.1.3.2.1 49-1.2 51-1.2.1.1 55-1.2.1.1.3.1 59-1.2.1.1.1 63-1.2.1.1.3.3.1 64-1.2.1.1.3.3.1.1 65-1.2.1.1.3.3.1.1.1.r 66-1.2.1.1.3.3.1.1.1.3 67-1.2.1.1.3.3.1.1.1.1.1.1.1 69-1.2.1.1.3.3.1.1.1.1.1.1.1 71-1.2.1.1.3.3.1.1.1.1.1.1.1 72-1.2.1.1.3.3.1.1.1 72-1.2.1.1.3.3.1.1.1.1 72-1.2.1.1.3.3.1.1.1.1.r 74-1.2.1.1.3.3.1.1.1.2.r 75-1.2.1.1.3.3.1.1.1.2.r 76-1.2.1.1.3.3.1.1.1.2.1.1.1 78-1.2.1.1.3.3.1.1.1.2.1.1.1 79-1.2.1.1.3.3.1.1.1.2 80-1.2.1.1.3.3.1.1.1.2.2.1.1 86-1.2.1.3 87-1.2.1 89-1.2.1.2 91-1.1.2.1.1.1 91-1.2.1.2.1.1.1 93-1.1.2.1.1.1 93-1.2.1.2.1.1.1 95-1.1.2.1.1.1 95-1.2.1.2.1.1.1 97-1.1.2 97-1.2.1.2.1 97-1.2.1.2.1.2 97-1.2.1.2.1.2.r 99-1.1.2.2.1.1 99-1.2.1.2.1.2.1.1.1
# ::id bel_pmid_1217_7059_29876
(m / multi-sentence
      :snt1 (d / decrease-01~e.25
            :ARG0 (s / substitute-01~e.0
                  :value "R238E"~e.23
                  :ARG1 (a3 / amino-acid
                        :name (n4 / name :op1 "glutamic acid"))
                  :ARG3 (a / amino-acid
                        :mod "238"~e.4
                        :name (n2 / name :op1 "arginine")
                        :ARG1-of (e / equal-01
                              :ARG2 (a2 / amino-acid
                                    :name (n3 / name :op1 "arginine")
                                    :ARG1-of (c / conserve-01~e.8
                                          :location~e.10 (p9 / protein-segment~e.18
                                                :ARG1-of (b2 / bind-01~e.17
                                                      :ARG2 (p / protein
                                                            :name (n / name :op1 "14-3-3"~e.12,14,16)))))))))
            :ARG1 (b3 / bind-01~e.32,97
                  :ARG1 (p2 / protein
                        :name (n5 / name :op1 "14-3-3theta"~e.26,28,30,38,91,93,95))
                  :ARG2 (p3 / protein
                        :name (n6 / name :op1 "PDK1"~e.34,99)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "3C")
                  :location (l / lane~e.44
                        :mod "4"~e.45
                        :location (p8 / panel~e.42
                              :mod (u2 / upper~e.41)))))
      :snt2 (c2 / contrast-01~e.49
            :ARG2 (i / increase-01~e.87
                  :ARG0 (s2 / substitute-01~e.51
                        :value "V243P"~e.59
                        :ARG1 (a4 / amino-acid
                              :name (n7 / name :op1 "proline"))
                        :ARG3 (a5 / amino-acid
                              :mod "243"~e.55
                              :name (n8 / name :op1 "valine")
                              :ARG1-of (m3 / mean-01
                                    :ARG2 (r / residue~e.63
                                          :ARG1-of (c3 / conserve-01~e.64
                                                :location~e.65 (m2 / molecular-physical-entity~e.72
                                                      :ARG1-of~e.72 (t / target-01~e.72
                                                            :ARG0 (p4 / protein
                                                                  :name (n9 / name :op1 "14-3-3"~e.67,69,71)))
                                                      :example~e.74,75 (a6 / and~e.79
                                                            :op1 (e2 / enzyme
                                                                  :name (n10 / name :op1 "Raf-1"~e.76,78))
                                                            :op2 (p5 / protein
                                                                  :name (n11 / name :op1 "Bad"~e.80)))
                                                      :quant (m4 / many~e.66)))
                                          :ARG1-of (d3 / describe-01
                                                :ARG0 (f2 / figure :mod "3A"))))))
                  :ARG1 (a7 / amount~e.89
                        :quant-of (p6 / protein~e.97
                              :name (n12 / name :op1 "14-3-3theta"~e.91,93,95)
                              :ARG1-of~e.97 (b4 / bind-01~e.97
                                    :ARG2 (p7 / protein
                                          :name (n13 / name :op1 "PDK1"~e.99)))))
                  :manner (d4 / dramatic~e.86))))

# ::tok Co @-@ immunoprecipitation analysis indicated that mutation at Ser @-@ 241 impairs the PDK1 binding ability for 14 @-@ 3 @-@ 3 theta and 14 @-@ 3 @-@ 3 eta ( Fig . 3 B , upper panel , lane 3 , and data not shown ) .
# ::alignments 0-1.1.1 3-1.1 4-1 5-1.2.r 6-1.2.1 10-1.2.1.1.1 11-1.2 13-1.2.2.1.1.1 14-1.2.2.2 15-1.2.2 16-1.2.2.2.2.r 17-1.2.2.2.2.1.1.1 17-1.2.2.2.2.2.1.1 19-1.2.2.2.2.1.1.1 19-1.2.2.2.2.2.1.1 21-1.2.2.2.2.1.1.1 21-1.2.2.2.2.2.1.1 23-1.2.2.2.2 24-1.2.2.2.2.1.1.1 24-1.2.2.2.2.2.1.1 26-1.2.2.2.2.1.1.1 26-1.2.2.2.2.2.1.1 26-1.3.1.1.2.1 28-1.2.2.2.2.1.1.1 28-1.2.2.2.2.2.1.1 28-1.3.1.1.2.1 33-1.2.2.2.2.1.1.1 33-1.2.2.2.2.2.1.1 33-1.3.1.1.2.1 36-1.3.1.1.2.2.1 37-1.3.1.1.2.2 39-1.3.1.1.2 40-1.3.1.1.2.1 42-1.3.1 43-1.3.1.2 44-1.3.1.2.1.1 44-1.3.1.2.1.1.r 45-1.3.1.2.1
# ::id bel_pmid_1217_7059_29878
(i / indicate-01~e.4
      :ARG0 (a / analyze-01~e.3
            :instrument (c / co-immunoprecipitate-00~e.0))
      :ARG1~e.5 (i2 / impair-01~e.11
            :ARG0 (m / mutate-01~e.6
                  :ARG1 (a2 / amino-acid
                        :mod "241"~e.10
                        :name (n2 / name :op1 "serine")))
            :ARG1 (c2 / capable-01~e.15
                  :ARG1 (p2 / protein
                        :name (n3 / name :op1 "PDK1"~e.13))
                  :ARG2 (b2 / bind-01~e.14
                        :ARG1 p2
                        :ARG2~e.16 (a3 / and~e.23
                              :op1 (p3 / protein
                                    :name (n4 / name :op1 "14-3-3theta"~e.17,19,21,24,26,28,33))
                              :op2 (p4 / protein
                                    :name (n5 / name :op1 "14-3-3eta"~e.17,19,21,24,26,28,33))))))
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and~e.42
                  :op1 (f / figure
                        :mod "3B"
                        :location (l / lane~e.39
                              :mod "3"~e.26,28,33,40
                              :location (p5 / panel~e.37
                                    :mod (u2 / upper~e.36))))
                  :op2 (d2 / data~e.43
                        :ARG1-of (s / show-01~e.45 :polarity~e.44 "-"~e.44)))))

# ::tok Hepatic expression of Ccnd1 , cMyc , IL @-@ 1r1 , and IL @-@ 6r was induced in wild @-@ type mice , but not Pparalpha @-@ null mice , after acute exposure to the potent Pparalpha agonist Wy @-@ 14,643 , indicating a role for Pparalpha in regulating the expression of these genes .
# ::alignments 0-1.1.2 1-1.1 1-1.2.2.1.2 2-1.1.1.r 3-1.1.1.1.1.1 5-1.1.1.2.1.1 7-1.1.1.3.1.1 7-1.1.1.4.1.1 9-1.1.1.3.1.1 11-1.1.1 12-1.1.1.3.1.1 12-1.1.1.4.1.1 14-1.1.1.4.1.1 16-1 17-1.2.r 18-1.2.1 20-1.2.1 21-1.2 23-1.2.2 24-1.2.2.1.1 24-1.2.2.1.1.r 25-1.2.2.1.2.1.1.1 28-1.2.2.1 30-1.3 31-1.3.1.2 32-1.3.1 33-1.3.1.1.r 35-1.3.1.1.2 36-1.3.1.1.3.1.1 37-1.3.1.1 38-1.3.1.1.1.1 40-1.3.1.1.1.1 42-1.3.1.3 44-1.3.1.3.1 45-1.3.1.3.1.1.r 46-1.3.1.3.1.1.1 48-1.3.1.3.1.1 50-1.3.1.3.1.1.2 53-1.3.1.3.1.1.2.1
# ::id bel_pmid_1219_8646_11798
(i / induce-01~e.16
      :ARG0 (e / express-03~e.1
            :ARG2~e.2 (a / and~e.11
                  :op1 (g / gene
                        :name (n / name :op1 "Ccnd1"~e.3))
                  :op2 (g2 / gene
                        :name (n2 / name :op1 "cMyc"~e.5))
                  :op3 (g3 / gene
                        :name (n3 / name :op1 "IL-1r1"~e.7,9,12))
                  :op4 (g4 / gene
                        :name (n4 / name :op1 "IL-6r"~e.7,12,14)))
            :mod (h / hepatic~e.0))
      :location~e.17 (m / mouse~e.21
            :mod (w / wild-type~e.18,20)
            :ARG1-of (c / contrast-01~e.23
                  :ARG2 (m2 / mouse~e.28
                        :polarity~e.24 "-"~e.24
                        :ARG3-of (e4 / express-03~e.1
                              :ARG2 (p5 / protein
                                    :name (n6 / name :op1 "Pparalpha"~e.25)
                                    :ARG2-of (m3 / mutate-01 :mod "-/-"))))))
      :time (a2 / after~e.30
            :op1 (e2 / expose-01~e.32
                  :ARG2~e.33 (a4 / agonist~e.37
                        :name (n7 / name :op1 "Wy-14,643"~e.38,40)
                        :mod (p6 / potent~e.35)
                        :mod (p7 / protein
                              :name (n8 / name :op1 "Pparalpha"~e.36)))
                  :mod (a3 / acute~e.31)
                  :ARG0-of (i2 / indicate-01~e.42
                        :ARG1 (r / role~e.44
                              :topic~e.45 (r2 / regulate-01~e.48
                                    :ARG0 p7~e.46
                                    :ARG1 (e3 / express-03~e.50
                                          :ARG2 a~e.53)))))))

# ::tok Jak1 phosphorylation was reduced in wildtype indivduals after Il13 treatement , implying that SHP @-@ 2 is responsible for this effect .
# ::alignments 0-1.1.1.1.1 1-1.1 3-1 7-1.3 8-1.3.1.1.1.1 11-1.4 12-1.4.1.r 13-1.4.1.1.1.1 15-1.4.1.1.1.1 17-1.4.1 20-1.4.1.2
# ::id bel_pmid_1220_4103_24772
(r / reduce-01~e.3
      :ARG1 (p / phosphorylate-01~e.1
            :ARG1 (e3 / enzyme
                  :name (n / name :op1 "Jak1"~e.0)))
      :location (i / individual
            :mod (w / wild-type))
      :time (a / after~e.7
            :op1 (t / treat-04
                  :ARG2 (p3 / protein
                        :name (n2 / name :op1 "Il13"~e.8))))
      :ARG0-of (i2 / imply-01~e.11
            :ARG1~e.12 (r2 / responsible-01~e.17
                  :ARG0 (e / enzyme
                        :name (n3 / name :op1 "SHP-2"~e.13,15))
                  :ARG1 (e2 / effect-01~e.20
                        :ARG1 r))))

# ::tok as for Jak1 , the phosphoryaltions of Tyk2 and IRS @-@ 2 were reduced after IL13 stimulaiton in wildtype cells .
# ::alignments 0-1.3.r 2-1.2.1.1 7-1.1.1.1.1.1 8-1.1.1 9-1.1.1.2.1.1 11-1.1.1.2.1.1 13-1 14-1.3 15-1.3.1.1.1.1 19-1.3.1.2
# ::id bel_pmid_1220_4103_27950
(r / reduce-01~e.13
      :ARG1 (p / phosphorylate-01
            :ARG1 (a / and~e.8
                  :op1 (e / enzyme
                        :name (n / name :op1 "Tyk2"~e.7))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "IRS-2"~e.9,11))))
      :topic (e2 / enzyme
            :name (n3 / name :op1 "Jak1"~e.2))
      :time~e.0 (a2 / after~e.14
            :op1 (s / stimulate-01
                  :ARG1 (p4 / protein
                        :name (n4 / name :op1 "IL13"~e.15))
                  :location (c / cell~e.19
                        :mod (w / wild-type)))))

# ::tok Results In cytoplasmic extracts , phosphoryalation of the p85 alpha subunit of PI3 @-@ kinase was markedly increased after stimulation with Il13 in both groups of probands .
# ::alignments 0-1.4 2-1.5.1.1 3-1.5 3-1.5.1 3-1.5.1.r 12-1.1.1.2.1.1 14-1.1.1.2.1.1 16-1.2 16-1.2.r 17-1 18-1.3 19-1.3.1 20-1.3.1.1.r 21-1.3.1.1.1.1 22-1.3.1.2.r 23-1.3.1.2.1 24-1.3.1.2
# ::id bel_pmid_1220_4103_27958
(i / increase-01~e.17
      :ARG1 (p / phosphorylate-01
            :ARG1 (p2 / protein-segment
                  :name (n / name :op1 "p85alpha")
                  :part-of (e / enzyme
                        :name (n2 / name :op1 "PI3-kinase"~e.12,14))))
      :manner~e.16 (m / marked~e.16)
      :time (a / after~e.18
            :op1 (s / stimulate-01~e.19
                  :ARG2~e.20 (p3 / protein
                        :name (n3 / name :op1 "Il13"~e.21))
                  :location~e.22 (g / group~e.24
                        :mod (b / both~e.23)
                        :ARG2-of (i2 / include-91
                              :ARG1 (p4 / proband)))))
      :ARG2-of (r / result-01~e.0)
      :location (m2 / molecular-physical-entity~e.3
            :ARG1-of~e.3 (e2 / extract-01~e.3
                  :ARG2 (c / cytoplasm~e.2))))

# ::tok when Il6 and Il6R were combined , significant stimulation of both mineral and matrix release from bone explants was noted
# ::alignments 0-1.2.r 1-1.2.1.1.1 3-1.2.2.1.1 5-1.2 7-1.1.2 8-1.1 11-1.1.1.1.1 12-1.1.1.1 13-1.1.1.1.2 14-1.1.1 16-1.1.1.2.1 19-1
# ::id bel_pmid_1221_8157_20330
(n / note-02~e.19
      :ARG1 (s / stimulate-01~e.8
            :ARG1 (r / release-01~e.14
                  :ARG1 (a / and~e.12
                        :op1 (m / mineral~e.11)
                        :op2 (m2 / matrix~e.13))
                  :ARG2 (e / explant
                        :mod (b / bone~e.16)))
            :degree (s2 / significant~e.7))
      :time~e.0 (c / combine-01~e.5
            :ARG1 (p / protein
                  :name (n2 / name :op1 "Il6"~e.1))
            :ARG2 (p2 / protein
                  :name (n3 / name :op1 "Il6R"~e.3))))

# ::tok Il6 plus Il6R enhanced the expression of RANKL and OPG in calvarial bones , but decreased RANK expression
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.2.1.1 3-1.1 5-1.1.2 6-1.1.2.1.r 7-1.1.2.1.1.1.1 8-1.1.2.1 9-1.1.2.1.2.1.1 10-1.1.3.r 11-1.1.3.1 12-1.1.3 14-1 15-1.2 16-1.2.2.1.1.1 17-1.2.2
# ::id bel_pmid_1221_8157_20336
(c / contrast-01~e.14
      :ARG1 (e / enhance-01~e.3
            :ARG0 (a / and
                  :op1 (p / protein
                        :name (n / name :op1 "Il6"~e.0))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "Il6R"~e.2)))
            :ARG1 (e2 / express-03~e.5
                  :ARG2~e.6 (a2 / and~e.8
                        :op1 (p3 / protein
                              :name (n3 / name :op1 "RANKL"~e.7))
                        :op2 (p4 / protein
                              :name (n4 / name :op1 "OPG"~e.9))))
            :location~e.10 (b / bone~e.12
                  :mod (c2 / calvarial~e.11)))
      :ARG2 (d / decrease-01~e.15
            :ARG0 a
            :ARG1 (e3 / express-03~e.17
                  :ARG2 (p5 / protein
                        :name (n5 / name :op1 "RANK"~e.16)))))

# ::tok Il6 , leukemia inhibitory factor [LIF}, and oncostatin M [OSM] are Il6 @-@ type cytokines that stimulate osteoclast formation and function
# ::alignments 0-1.1.1.1.1 0-1.2.1.1.1 2-1.2.2.1.1 3-1.2.2.1.2 4-1.2.2.1.3 6-1.2 7-1.2.3.1.1 8-1.2.3.1.2 10-1.2.r 11-1.1.1.1.1 11-1.2.1.1.1 13-1.1 16-1.3 17-1.3.1.1.1 18-1.3.1.1 19-1.3.1 20-1.3.1.2
# ::id bel_pmid_1221_8157_28344
(c / cytokine
      :mod (t / type~e.13
            :mod (p4 / protein
                  :name (n5 / name :op1 "Il6"~e.0,11)))
      :domain~e.10 (a3 / and~e.6
            :op1 (p / protein
                  :name (n2 / name :op1 "Il6"~e.0,11))
            :op2 (p2 / protein
                  :name (n3 / name
                        :op1 "leukemia"~e.2
                        :op2 "inhibitory"~e.3
                        :op3 "factor"~e.4))
            :op3 (p3 / protein
                  :name (n4 / name :op1 "oncostatin"~e.7 :op2 "M"~e.8)))
      :ARG0-of (s / stimulate-01~e.16
            :ARG1 (a2 / and~e.19
                  :op1 (f / form-01~e.18
                        :ARG1 (o / osteoclast~e.17))
                  :op2 (f2 / function-01~e.20
                        :ARG0 o))))

# ::tok OSM also stimulated Ca release and enhanced the mRNA expression of RANKL and OPG in mouse calcaria , but have no effect on the expression of RANK
# ::alignments 0-1.1.1.1.1.1 1-1.1.1.3 2-1.1.1 4-1.1.1.2 5-1.1 6-1.1.2 8-1.1.2.2.1.1.1 9-1.1.2.2 10-1.1.2.2.2.r 11-1.1.2.2.2.1.1.1 12-1.1.2.2.2 13-1.1.2.2.2.2.1.1 14-1.1.2.2.3.r 15-1.1.2.2.3.1 16-1.1.2.2.3 18-1 20-1.2.1 20-1.2.1.r 21-1.2 22-1.2.3.r 24-1.2.3 25-1.2.3.1.r 26-1.2.3.1.1.1
# ::id bel_pmid_1221_8157_29756
(c / contrast-01~e.18
      :ARG1 (a / and~e.5
            :op1 (s2 / stimulate-01~e.2
                  :ARG0 (p / protein
                        :name (n2 / name :op1 "OSM"~e.0))
                  :ARG1 (r / release-01~e.4
                        :ARG1 (c3 / calcium))
                  :mod (a2 / also~e.1))
            :op2 (e / enhance-01~e.6
                  :ARG0 p
                  :ARG1 (e2 / express-03~e.9
                        :ARG1 (r2 / rna
                              :name (n / name :op1 "mRNA"~e.8))
                        :ARG2~e.10 (a3 / and~e.12
                              :op1 (p2 / protein
                                    :name (n4 / name :op1 "RANKL"~e.11))
                              :op2 (p3 / protein
                                    :name (n5 / name :op1 "OPG"~e.13)))
                        :ARG3~e.14 (c2 / calcaria~e.16
                              :mod (m2 / mouse~e.15)))))
      :ARG2 (a4 / affect-01~e.21
            :polarity~e.20 "-"~e.20
            :ARG0 p
            :ARG1~e.22 (e3 / express-03~e.24
                  :ARG2~e.25 (p4 / protein
                        :name (n6 / name :op1 "RANK"~e.26)))))

# ::tok functions of the 2 major signaling pathways , the signal transducers and activators of transcription 1 and 3 [STAT1 @/@ 3] and the Src @-@ homology tyrosine phosphatase 2 [SHP2]-Ras @-@ ERK [Ptpn11], emanating from the common signal transducer , gp130 , in the gastrointestinal tract
# ::alignments 0-1 1-1.1.r 3-1.1.1 4-1.1.3 5-1.1.2 6-1.1 9-1.1.2 10-1.1.4.1.1.1.2 10-1.1.4.1.2.1.2 11-1.1.4.1 11-1.1.4.1.1.1.3 11-1.1.4.1.2.1.3 12-1.1.4.1.1.1.4 12-1.1.4.1.2.1.4 13-1.1.4.1.1.1.5 13-1.1.4.1.2.1.5 14-1.1.4.1.1.1.6 14-1.1.4.1.2.1.6 15-1.1.4.1.1.1.7 16-1.1.4.1.1.1.3 16-1.1.4.1.2.1.3 17-1.1.4.1.2.1.7 21-1.1.4 21-1.1.4.1.1.1.3 21-1.1.4.1.2.1.3 23-1.1.4.2.1.1 25-1.1.4.2.1.1 26-1.1.4.2.1.2 27-1.1.4.2.1.3 28-1.1.1 31-1.1.4.2.1.4 33-1.2 34-1.2.1.r 36-1.2.1.2 37-1.1.2 37-1.1.4.1.1.1.1 37-1.1.4.1.2.1.1 37-1.2.1.1.1 38-1.1.4.1.1.1.2 38-1.1.4.1.2.1.2 40-1.2.1.1.2.1.1.1 42-1.2.2.r 44-1.2.2.1 45-1.2.2
# ::id bel_pmid_1221_9085_28406
(f2 / function-01~e.0
      :ARG0~e.1 (p / pathway~e.6
            :quant "2"~e.3,28
            :ARG0-of (s / signal-01~e.5,9,37)
            :mod (m / major~e.4)
            :example (a2 / and~e.21
                  :op1 (a / and~e.11
                        :op1 (p3 / pathway
                              :name (n2 / name
                                    :op1 "signal"~e.37
                                    :op2 "transducer"~e.10,38
                                    :op3 "and"~e.11,16,21
                                    :op4 "activator"~e.12
                                    :op5 "of"~e.13
                                    :op6 "transcription"~e.14
                                    :op7 "1"~e.15))
                        :op2 (p6 / pathway
                              :name (n5 / name
                                    :op1 "signal"~e.37
                                    :op2 "transducer"~e.10,38
                                    :op3 "and"~e.11,16,21
                                    :op4 "activator"~e.12
                                    :op5 "of"~e.13
                                    :op6 "transcription"~e.14
                                    :op7 "3"~e.17)))
                  :op2 (p4 / pathway
                        :name (n3 / name
                              :op1 "Src-homology"~e.23,25
                              :op2 "tyrosine"~e.26
                              :op3 "phosphatase"~e.27
                              :op4 "2 Ras-ERK"~e.31))))
      :ARG1-of (e / emanate-01~e.33
            :ARG2~e.34 (m3 / molecular-physical-entity
                  :ARG0-of (t / transduct-00
                        :ARG1 (s2 / signal-01~e.37)
                        :ARG1-of (m2 / mean-01
                              :ARG2 (p2 / protein-segment
                                    :name (n / name :op1 "gp130"~e.40))))
                  :mod (c / common~e.36))
            :location~e.42 (t3 / tract~e.45
                  :mod (g / gastrointestinal~e.44))))

# ::tok increased Erk2 protein level under BMP2 inducement comes from BMP2 @-@ up @-@ regulated Erk2 mRNA expression .
# ::alignments 0-1.1.2 1-1.1.1.1.1 2-1.1.1 2-1.1.3.1 3-1.1 5-1.1.3.1.1.1 6-1.1.3 7-1 8-1.2.r 9-1.1.3.1.1.1 11-1.1.2 14-1.1.1.1.1 15-1.2.1.1.1 16-1.2
# ::id bel_pmid_1222_0517_25504
(c / come-01~e.7
      :ARG1 (l / level~e.3
            :quant-of (p / protein~e.2
                  :name (n / name :op1 "Erk2"~e.1,14))
            :ARG1-of (i / increase-01~e.0,11)
            :ARG1-of (i2 / induce-01~e.6
                  :ARG0 (p2 / protein~e.2
                        :name (n2 / name :op1 "BMP2"~e.5,9))))
      :ARG3~e.8 (e / express-03~e.16
            :ARG2 (r / rna
                  :name (n5 / name :op1 "mRNA"~e.15)
                  :ARG1-of (u / upregulate-01
                        :ARG2 p2)
                  :ARG0-of (e2 / encode-01
                        :ARG1 p))))

# ::tok Sp1 @-@ mediated transcription is one of the mechanisms , which is responsible for BMP2 @-@ induced up @-@ regulation of Erk2 expression .
# ::alignments 0-1.1.1.1.1 2-1.1 3-1 8-1.2.1 12-1.3 13-1.3.1.r 14-1.3.1.1.2.1.1.1 16-1.3.1.1.2 21-1.3.1.1.1.1.1 22-1.3.1
# ::id bel_pmid_1222_0517_8134
(t2 / transcribe-01~e.3
      :ARG1-of (m / mediate-01~e.2
            :ARG0 (p / protein
                  :name (n / name :op1 "Sp1"~e.0)))
      :ARG1-of (i / include-91
            :ARG2 (m2 / mechanism~e.8))
      :ARG0-of (r / responsible-01~e.12
            :ARG1~e.13 (e / express-03~e.22
                  :ARG2 (u / upregulate-01
                        :ARG1 (e2 / enzyme
                              :name (n3 / name :op1 "Erk2"~e.21))
                        :ARG1-of (i2 / induce-01~e.16
                              :ARG0 (p2 / protein
                                    :name (n2 / name :op1 "BMP2"~e.14)))))))

# ::tok NIH3T3 cells expressing either Raf :ER @-@ DD or Raf : ER @-@ YY synthesized RALT upon stimulation with Tamoxifen for 4 ± 8 h in serum @-@ deprived medium ( Figure 4b ) . The effect of tamoxifen was as strong as serum stimulation and was reverted by the administra @- tion of U0126 ( Figure 4b )
# ::alignments 0-1.1.1.1.1 1-1.1.1 2-1.1.1.2 4-1.1.1.2.1.1.1.1 4-1.1.1.2.1.2.1.1 7-1.1.1.2.1.1.1.1 8-1.1.1.2.1 9-1.1.1.2.1.1.1.1 9-1.1.1.2.1.2.1.1 11-1.1.1.2.1.1.1.1 11-1.1.1.2.1.2.1.1 13-1.1.1.2.1.2.1.1 14-1.1 15-1.1.2.1.1 17-1.1.3 18-1.2.2.2.r 19-1.1.3.1.1.1 19-1.2.1.1.1.1.1 20-1.1.3.2.r 21-1.1.3.2.1.1 23-1.1.3.2.2.1 25-1.1.3.3.r 26-1.1.3.3.1.1 28-1.1.3.3.1 29-1.1.3.3 31-1.1.4.1 31-1.2.3.1 32-1.1.4.1.1 32-1.2.3.1.1 36-1.2.1.1 37-1.2.1.1.1.r 38-1.2.1.1.1.1.1 39-1.2.1.1.r 40-1.1.3.r 41-1.2.1 42-1.1.3.r 42-1.2.1.3.r 43-1.2.1.3.1 44-1.2.1.3 46-1.2.1.1.r 47-1.2.2 54-1.2.2.2.1.1.1 56-1.1.4.1 56-1.2.3.1 57-1.1.4.1.1 57-1.2.3.1.1
# ::id bel_pmid_1222_6756_17890
(m / multi-sentence
      :snt1 (s2 / synthesize-01~e.14
            :ARG0 (c / cell~e.1
                  :name (n3 / name :op1 "NIH3T3"~e.0)
                  :ARG3-of (e2 / express-03~e.2
                        :ARG2 (o / or~e.8
                              :op1 (p2 / protein
                                    :name (n / name :op1 "Raf:ER-DD"~e.4,7,9,11))
                              :op2 (p3 / protein
                                    :name (n4 / name :op1 "Raf:ER-YY"~e.4,9,11,13)))))
            :ARG1 (p / protein
                  :name (n8 / name :op1 "RALT"~e.15))
            :time~e.40,42 (s3 / stimulate-01~e.17
                  :ARG2 (m4 / molecular-physical-entity
                        :name (n9 / name :op1 "tamoxifen"~e.19))
                  :duration~e.20 (v / value-interval
                        :op1 (t / temporal-quantity
                              :quant "4"~e.21
                              :unit (h / hour))
                        :op2 (t2 / temporal-quantity
                              :quant "8"~e.23
                              :unit (h2 / hour)))
                  :location~e.25 (m5 / medium~e.29
                        :ARG1-of (d / deprive-01~e.28
                              :ARG2 (s4 / serum~e.26))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure~e.31,56 :mod "4b"~e.32,57)))
      :snt2 (a / and
            :op1 (s5 / strong~e.41
                  :domain~e.39,46 (e / effect-01~e.36
                        :ARG0~e.37 (m6 / molecular-physical-entity
                              :name (n10 / name :op1 "tamoxifen"~e.19,38)))
                  :degree (e3 / equal)
                  :compared-to~e.42 (s6 / stimulate-01~e.44
                        :ARG0 (s8 / serum~e.43)))
            :op2 (r / revert-01~e.47
                  :ARG1 e
                  :instrument~e.18 (a3 / administrate-01
                        :ARG1 (s / small-molecule
                              :name (n2 / name :op1 "U0126"~e.54))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (f2 / figure~e.31,56 :mod "4b"~e.32,57))))

# ::tok Ablation of RALT expression by MEK @- 1 inhibitors is caused by suppression of RALT transcription , as indicated by the Northern blot analysis presented in Figure 3 .
# ::alignments 0-1.2 1-1.2.2.r 2-1.2.2.1.1.1 3-1.2.2 4-1.2.1.r 5-1.2.1.1.1.1.1 7-1.2.1.1.1.1.1 8-1.2.1 8-1.2.1.1 8-1.2.1.1.r 10-1 11-1.1.r 12-1.1 13-1.1.1.r 14-1.1.1.1 15-1.1.1 17-1.3.r 18-1.3 19-1.3.1.r 21-1.3.1.1.1.1 22-1.3.1.1.1.2 23-1.3.1 24-1.3.1.2 25-1.3.1.2.1.r 26-1.3.1.2.1 27-1.3.1.2.1.1
# ::id bel_pmid_1222_6756_17894
(c2 / cause-01~e.10
      :ARG0~e.11 (s / suppress-01~e.12
            :ARG1~e.13 (t2 / transcribe-01~e.15
                  :ARG1 p~e.14))
      :ARG1 (a / ablate-00~e.0
            :ARG0~e.4 (m / molecular-physical-entity~e.8
                  :ARG0-of~e.8 (i2 / inhibit-01~e.8
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "MEK-1"~e.5,7))))
            :ARG1~e.1 (e3 / express-03~e.3
                  :ARG2 (p / protein
                        :name (n3 / name :op1 "RALT"~e.2))))
      :ARG1-of~e.17 (i3 / indicate-01~e.18
            :ARG0~e.19 (a2 / analyze-01~e.23
                  :instrument (t3 / thing
                        :name (n4 / name :op1 "Northern"~e.21 :op2 "blot"~e.22))
                  :ARG1-of (p2 / present-01~e.24
                        :location~e.25 (f / figure~e.26 :mod "3"~e.27)))))

# ::tok Upon stimulation with EGF ( 0.3 ng/ml ) or bFGF ( 0.3 ng/ml ) about 20 % of uninjected EGFR @/@ ErbB @-@ 2 cells entered S phase ( data not shown ) . We observed a similar rate of entrance into S phase when counting cells microinjected with a control antiserum ( RAM , Figure 1e ) . Cells micro @- injected with anti @-@ RALT antibodies and stimulated with EGF progressed to S phase at a frequency which was 2.8 @-@ fold higher than control cells .
# ::alignments 1-1.1.3 2-1.1.3.1.r 3-1.1.3.1.1.1.1 5-1.1.3.1.1.2.1 5-1.1.3.1.2.2.1 8-1.1.3.1 9-1.1.3.1.2.1.1 11-1.1.3.1.1.2.1 11-1.1.3.1.2.2.1 14-1.1.1 15-1.1.1.1.1 16-1.1.1.1 19-1.1.1.1.2.2.1.1.1 21-1.1.1.1.2.2.2.1.1 23-1.1.1.1.2.2.2.1.1 24-1.1.1.1.2 25-1.1 26-1.1.2.1.1 27-1.1.2.1.2 29-1.1.4.1 30-1.1.1.1.2.1.1 30-1.1.4.1.1.1 30-1.1.4.1.1.1.r 31-1.1.4.1.1 34-1.2.1 35-1.2 37-1.2.2.2 38-1.2.2 39-1.2.2.1.r 40-1.2.2.1 41-1.2.2.1.1.r 42-1.2.2.1.1.1.1 43-1.2.2.1.1.1.2 44-1.2.3.r 45-1.2.3 46-1.2.3.1 46-1.3.1.1.2 47-1.2.3.1.1 47-1.3.1.1 48-1.2.3.1.1.1.r 50-1.2.3.1.1.1.1 51-1.2.3.1.1.1 53-1.2.4.1.1 55-1.2.4.1.2 56-1.2.4.1.2.1 59-1.1.1.1.2 62-1.1.1.1.2.1 63-1.3.1.1.1.r 64-1.3.1.1.1.1 66-1.3.1.1.1.1.1.1.1 67-1.3.1.1.1 68-1.3.1 69-1.3.1.2 70-1.3.1.2.2.r 71-1.3.1.2.2.1.1 72-1.3 73-1.3.2.r 74-1.3.2.1.1 75-1.3.2.1.2 78-1.3.3 81-1.3.3.1.1 84-1.3.3.2 85-1.3.3.3.r 86-1.3.3.3.1 87-1.3.3.3
# ::id bel_pmid_1222_6756_26554
(m / multi-sentence
      :snt1 (e / enter-01~e.25
            :ARG0 (a / about~e.14
                  :op1 (p2 / percentage-entity~e.16
                        :value "20"~e.15
                        :quant-of (c3 / cell~e.24,59
                              :ARG2-of (i / inject-01~e.62 :polarity "-"~e.30)
                              :mod (s4 / slash
                                    :op1 (p7 / protein
                                          :name (n8 / name :op1 "EGFR"~e.19))
                                    :op2 (p8 / protein
                                          :name (n9 / name :op1 "ErbB-2"~e.21,23))))))
            :ARG1 (e4 / event
                  :name (n10 / name :op1 "S"~e.26 :op2 "phase"~e.27))
            :time (s / stimulate-01~e.1
                  :ARG2~e.2 (o / or~e.8
                        :op1 (m2 / molecular-physical-entity
                              :name (n / name :op1 "EGF"~e.3)
                              :quant (c / concentration-quantity
                                    :quant "0.3"~e.5,11
                                    :unit (n2 / nanogram-per-milliliter)))
                        :op2 (m3 / molecular-physical-entity
                              :name (n3 / name :op1 "bFGF"~e.9)
                              :quant (c2 / concentration-quantity
                                    :quant "0.3"~e.5,11
                                    :unit (n4 / nanogram-per-milliliter)))))
            :ARG1-of (d / describe-01
                  :ARG0 (d2 / data~e.29
                        :ARG1-of (s2 / show-01~e.31 :polarity~e.30 "-"~e.30))))
      :snt2 (o2 / observe-01~e.35
            :ARG0 (w / we~e.34)
            :ARG1 (r / rate-01~e.38
                  :ARG1~e.39 (e2 / enter-01~e.40
                        :ARG1~e.41 (e5 / event
                              :name (n11 / name :op1 "S"~e.42 :op2 "phase"~e.43)))
                  :ARG1-of (r2 / resemble-01~e.37))
            :time~e.44 (c4 / count-01~e.45
                  :ARG1 (c5 / cell~e.46
                        :ARG2-of (m4 / microinject-00~e.47
                              :ARG1~e.48 (a2 / antiserum~e.51
                                    :mod (c6 / control-01~e.50)))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (a3 / and
                        :op1 (r3 / RAM~e.53)
                        :op2 (f / figure~e.55 :mod "1e"~e.56))))
      :snt3 (p4 / progress-01~e.72
            :ARG1 (a4 / and~e.68
                  :op1 (m5 / microinject-00~e.47
                        :ARG1~e.63 (a5 / antibody~e.67
                              :ARG0-of (c10 / counter-01~e.64
                                    :ARG1 (p9 / protein
                                          :name (n5 / name :op1 "RALT"~e.66))))
                        :ARG2 (c7 / cell~e.46))
                  :op2 (s3 / stimulate-01~e.69
                        :ARG1 c7
                        :ARG2~e.70 (m6 / molecular-physical-entity
                              :name (n7 / name :op1 "EGF"~e.71))))
            :ARG4~e.73 (e3 / event
                  :name (n6 / name :op1 "S"~e.74 :op2 "phase"~e.75))
            :ARG1-of (h2 / have-frequency-91~e.78
                  :ARG2 (p6 / product-of :op1 "2.8"~e.81)
                  :degree (h / high~e.84)
                  :compared-to~e.85 (c8 / cell~e.87
                        :mod (c9 / control-01~e.86)))))

# ::tok We conclude that endogenous RALT protein behaves as a bonafide feedback inhibitor of the ErbB @-@ 2 kinase .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.2 4-1.2.1.1.1 5-1.2.1 5-1.2.2.1.1 6-1.2 7-1.2.2.r 9-1.2.2.1.2.1 10-1.2.2.1.2 11-1.2.2 11-1.2.2.1 11-1.2.2.1.r 14-1.2.2.1.1.1.1 16-1.2.2.1.1.1.1 17-1.2.2.1.1.1.2
# ::id bel_pmid_1222_6756_26768
(c / conclude-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (b / behave-01~e.6
            :ARG0 (p / protein~e.5
                  :name (n / name :op1 "RALT"~e.4)
                  :mod (m / monocot~e.3))
            :ARG1~e.7 (m2 / molecular-physical-entity~e.11
                  :ARG0-of~e.11 (i / inhibit-01~e.11
                        :ARG1 (p2 / protein~e.5
                              :name (n2 / name :op1 "ErbB-2"~e.14,16 :op2 "kinase"~e.17))
                        :mod (f / feedback~e.10
                              :mod (b2 / bonafide~e.9))))))

# ::tok These observations were extended to HC @-@ 11 cells , a murine cell line derived from breast epithelium . In these cells TGF @-@ a , an activator of EGFR , and HRG @- 1b , which triggers ErbB @-@ 2/ErbB @-@ 3 dimers ( Marte et al. , 1995a , b ) , are able to induce RALT expression ( Fiorentino et al. , 2000 ) .
# ::alignments 0-1.1.1.2 1-1.1.1 1-1.1.1.1 1-1.1.1.1.r 3-1.1 4-1.1.2.r 5-1.1.2.1.1 7-1.1.2.1.1 8-1.1.2 10-1.2.1.1.1.1.1 11-1.1.2.2.1.1.1.1 12-1.1.2.2.1 13-1.1.2.2.1 14-1.1.2.2.1.2 15-1.1.2.2.1.2.1.r 16-1.1.2.2.1.2.1.1 17-1.1.2.2.1.2.1 20-1.2.1.4.1 21-1.2.1.4 22-1.2.1.1.1.1.1 24-1.2.1.1.1.1.1 24-1.2.1.1.3.2.1.1.1 27-1.2.1.1.1 27-1.2.1.1.1.2 27-1.2.1.1.1.2.r 28-1.2.1.1.1.2.1.r 29-1.2.1.1.1.2.1.1.1 32-1.2.1.1.2.1.1 34-1.2.1.1.2.1.1 37-1.2.1.1.3 38-1.2.1.1.3.1.1.1.1 38-1.2.1.1.3.1.2.1.1 42-1.2.1.1.3.1.2.1.1 43-1.2.1.1.3.1.1 43-1.2.1.1.3.1.2 45-1.2.1.1.3.2.1.1.2.1.1.1 46-1.2.1.1.3.1 46-1.2.1.1.3.2.1 46-1.2.1.1.3.2.1.1.2 47-1.2.1.1.3.2.1.1.2.2.1 51-1.2.1.1.3.2.1.2.1 54-1.2.1.r 55-1.2 57-1.2.1 58-1.2.1.2.1.1.1 59-1.2.1.2 61-1.2.1.3.1.1.1.1.1 62-1.2.1.1 62-1.2.1.3.1.1 63-1.2.1.3.1.1.2.1 65-1.2.1.3.1.2.1
# ::id bel_pmid_1222_6756_29724
(m / multi-sentence
      :snt1 (e2 / extend-01~e.3
            :ARG1 (t / thing~e.1
                  :ARG1-of~e.1 (o / observe-01~e.1)
                  :mod (t2 / this~e.0))
            :ARG4~e.4 (c / cell~e.8
                  :name (n2 / name :op1 "HC-11"~e.5,7)
                  :ARG1-of (m2 / mean-01
                        :ARG2 (c3 / cell-line~e.12,13
                              :mod (a / animal
                                    :name (n / name :op1 "Muridae"~e.11))
                              :ARG1-of (d3 / derive-01~e.14
                                    :ARG2~e.15 (e3 / epithelium~e.17
                                          :mod (b / breast~e.16)))))))
      :snt2 (p / possible~e.55
            :domain~e.54 (i / induce-01~e.57
                  :ARG0 (a2 / and~e.62
                        :op1 (p2 / protein~e.27
                              :name (n3 / name :op1 "TGF-a"~e.10,22,24)
                              :ARG0-of~e.27 (a3 / activate-01~e.27
                                    :ARG1~e.28 (e4 / enzyme
                                          :name (n4 / name :op1 "EGFR"~e.29))))
                        :op2 (p3 / protein
                              :name (n5 / name :op1 "HRG-1b"~e.32,34))
                        :ARG0-of (t3 / trigger-01~e.37
                              :ARG1 (a6 / and~e.46
                                    :op1 (d7 / dimer~e.43
                                          :name (n10 / name :op1 "ErbB-2"~e.38))
                                    :op2 (d8 / dimer~e.43
                                          :name (n11 / name :op1 "ErbB-3"~e.38,42)))
                              :ARG1-of (d5 / describe-01
                                    :ARG0 (a7 / and~e.46
                                          :op1 (p4 / publication-91
                                                :mod "a"~e.24
                                                :ARG0 (a4 / and~e.46
                                                      :op1 (p5 / person
                                                            :name (n7 / name :op1 "Marte"~e.45))
                                                      :op2 (p6 / person
                                                            :mod (o2 / other~e.47))))
                                          :op2 (p12 / publication-91
                                                :mod "b"~e.51
                                                :ARG0 a4)
                                          :time (d / date-entity :year "1995")))))
                  :ARG1 (e5 / express-03~e.59
                        :ARG2 (p7 / protein
                              :name (n8 / name :op1 "RALT"~e.58)))
                  :ARG1-of (d6 / describe-01
                        :ARG0 (p8 / publication-91
                              :ARG0 (a5 / and~e.62
                                    :op1 (p9 / person
                                          :name (n9 / name :op1 "Fiorentino"~e.61))
                                    :op2 (p10 / person
                                          :mod (o3 / other~e.63)))
                              :time (d2 / date-entity :year "2000"~e.65)))
                  :location (c2 / cell~e.21
                        :mod (t4 / this~e.20)))))

# ::tok We tested if human coronary artery endothelial cells ( HCAEC ) may become a source of cytokine and adhesion molecule expression when stimulated with bacterial lipopolysaccharide ( LPS ) . Analysis of HCAEC supernatants by ELISA identified enhanced secretion of IL @-@ 6 , IL @-@ 8 , and MCP @-@ 1 while
# ::alignments 0-1.1.1 1-1.1 3-1.1.2.1.2.1.1 4-1.1.2.1.2.1.2 5-1.1.2.1.2.1.3 6-1.1.2.1.2.1.4 7-1.1.2.1.2 7-1.2.1.1.1 9-1.2.1.1.1.1.1 11-1.1.2 12-1.1.2.1 14-1.1.2.1.3 15-1.1.2.1.3.1.r 16-1.1.2.1.3.1.1.1 17-1.1.2.1.3.1.1 18-1.1.2.1.3.1.1.2.1.1 19-1.1.2.1.3.1.1.2.1.2 20-1.1.2.1.3.1 21-1.1.2.1.4.r 22-1.1.2.1.4 23-1.1.2.1.4.2.r 23-1.2.1.2.r 24-1.1.2.1.4.2.2 25-1.1.2.1.4.2.1.1 30-1.2.1 32-1.2.1.1.1.1.1 33-1.2.1.1 35-1.2.1.2.1.1 36-1.2 37-1.2.2.2 38-1.2.2 39-1.2.2.1.r 40-1.2.2.1.1.1.1 40-1.2.2.1.2.1.1 42-1.2.2.1.1.1.1 44-1.2.2.1.1.1.1 44-1.2.2.1.2.1.1 46-1.2.2.1.2.1.1 48-1.2.2.1 49-1.2.2.1.3.1.1 51-1.2.2.1.3.1.1 52-1.1.2.1.4.r
# ::id bel_pmid_1223_7173_1150
(m / multi-sentence
      :snt1 (t / test-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (p / possible~e.11
                  :domain (b / become-01~e.12
                        :mode "interrogative"
                        :ARG1 (c / cell~e.7
                              :name (n / name
                                    :op1 "human"~e.3
                                    :op2 "corona"~e.4
                                    :op3 "artery"~e.5
                                    :op4 "endothelium"~e.6))
                        :ARG2 (s / source-02~e.14
                              :ARG1~e.15 (e / express-03~e.20
                                    :ARG2 (a5 / and~e.17
                                          :op1 (c2 / cytokine~e.16)
                                          :op2 (p5 / protein
                                                :name (n8 / name :op1 "adhesion"~e.18 :op2 "molecule"~e.19)))))
                        :time~e.21,52 (s2 / stimulate-01~e.22
                              :ARG1 c
                              :ARG2~e.23 (m3 / molecular-physical-entity
                                    :name (n2 / name :op1 "lipopolysaccharide"~e.25)
                                    :mod (b2 / bacteria~e.24))))))
      :snt2 (i / identify-01~e.36
            :ARG1 (a3 / analyze-01~e.30
                  :ARG1 (s3 / supernatant~e.33
                        :mod (c3 / cell~e.7
                              :name (n3 / name :op1 "HCAEC"~e.9,32)))
                  :instrument~e.23 (t2 / thing
                        :name (n4 / name :op1 "ELISA"~e.35)))
            :ARG2 (s4 / secrete-01~e.38
                  :ARG1~e.39 (a4 / and~e.48
                        :op1 (p2 / protein
                              :name (n5 / name :op1 "IL-6"~e.40,42,44))
                        :op2 (p3 / protein
                              :name (n6 / name :op1 "IL-8"~e.40,44,46))
                        :op3 (p4 / protein
                              :name (n7 / name :op1 "MCP-1"~e.49,51)))
                  :ARG1-of (e2 / enhance-01~e.37))))

# ::tok IL @-@ 1 beta and TNF @-@ alpha but not IL @-@ 10. FACS analysis showed an LPS @-@ induced upregulation of ICAM @-@ 1 , VCAM , and ELAM @-@ 1 .
# ::alignments 0-1.1.1.1.1.1 0-1.1.2.2.1 2-1.2.2.1.1.1.1 2-1.2.2.1.3.1.1 4-1.1.1 5-1.1.1.2.1.1 7-1.1.1.2.1.1 8-1.1 9-1.1.2.1 9-1.1.2.1.r 10-1.1.1.1.1.1 10-1.1.2.2.1 13-1.2.1.1.1.1 14-1.2.1 15-1.2 17-1.2.2.2.1.1.1 19-1.2.2.2 20-1.2.2 21-1.2.2.1.r 22-1.2.2.1.1.1.1 24-1.2.2.1.1.1.1 24-1.2.2.1.3.1.1 26-1.2.2.1.2.1.1 28-1.2.2.1 29-1.2.2.1.3.1.1 31-1.2.2.1.1.1.1 31-1.2.2.1.3.1.1
# ::id bel_pmid_1223_7173_1152
(m / multi-sentence
      :snt1 (c / contrast-01~e.8
            :ARG1 (a / and~e.4
                  :op1 (p / protein
                        :name (n / name :op1 "IL-1beta"~e.0,10))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "TNF-alpha"~e.5,7)))
            :ARG2 (p3 / protein
                  :polarity~e.9 "-"~e.9
                  :name (n3 / name :op1 "IL-10"~e.0,10)))
      :snt2 (s / show-01~e.15
            :ARG0 (a2 / analyze-01~e.14
                  :instrument (t / thing
                        :name (n4 / name :op1 "FACS"~e.13)))
            :ARG1 (u / upregulate-01~e.20
                  :ARG1~e.21 (a3 / and~e.28
                        :op1 (p4 / protein
                              :name (n6 / name :op1 "ICAM-1"~e.2,22,24,31))
                        :op2 (p5 / protein
                              :name (n7 / name :op1 "VCAM"~e.26))
                        :op3 (p6 / protein
                              :name (n8 / name :op1 "ELAM-1"~e.2,24,29,31)))
                  :ARG1-of (i / induce-01~e.19
                        :ARG0 (m2 / molecular-physical-entity
                              :name (n5 / name :op1 "LPS"~e.17))))))

# ::tok Consistently , purified GST @-@ SHP @-@ 2 dephosphorylated Stat1 at both tyrosine and serine residues when immunoprecipitated phospho @-@ Stat1 or a peptide corresponding to the sequence surrounding Tyr( P )( 701 ) or Ser( P )( 727 ) of Stat1 was used as the substrate .
# ::alignments 0-1.4 2-1.2.2 3-1.2.1.1 5-1.2.1.1 7-1.2.1.1 8-1 9-1.1.3.1.1 12-1.1.1.1.1.1 12-1.3.1.2.1.1.1.1.1.2.1 13-1.1 14-1.1.2.1.1.1 14-1.3.1.2.1.1.1.1.2.2.1 15-1.1.1 15-1.1.2 16-1.3.r 20-1.3.1.1.1.1 21-1.3.1 23-1.3.1.2 24-1.3.1.2.1 25-1.3.1.2.1.1.r 27-1.3.1.2.1.1 28-1.3.1.2.1.1.1 32-1.3.1.2.1.1.1.1.1.1 34-1.3.1.2.1.1.1.1 38-1.3.1.2.1.1.1.1.2.1 41-1.3.1.1.1.1 43-1.3 44-1.3.2.r 44-1.3.r 46-1.3.2
# ::id bel_pmid_1227_0932_39476
(d / dephosphorylate-01~e.8
      :ARG1 (a2 / and~e.13
            :op1 (r / residue~e.15
                  :mod (a3 / amino-acid
                        :name (n3 / name :op1 "tyrosine"~e.12)))
            :op2 (r2 / residue~e.15
                  :mod (a4 / amino-acid
                        :name (n4 / name :op1 "serine"~e.14)))
            :part-of (p2 / protein
                  :name (n5 / name :op1 "Stat1"~e.9)))
      :ARG2 (e / enzyme
            :name (n2 / name :op1 "GST-SHP-2"~e.3,5,7)
            :ARG1-of (p / purify-01~e.2))
      :time~e.16,44 (u / use-01~e.43
            :ARG1 (o / or~e.21
                  :op1 (p3 / protein
                        :name (n6 / name :op1 "Stat1"~e.20,41)
                        :ARG1-of (i / immunoprecipitate-00)
                        :ARG3-of (p4 / phosphorylate-01))
                  :op2 (p5 / peptide~e.23
                        :ARG0-of (c / correspond-01~e.24
                              :ARG1~e.25 (s / sequence~e.27
                                    :ARG1-of (s2 / surround-01~e.28
                                          :ARG2 (o2 / or~e.34
                                                :op1 (a5 / amino-acid
                                                      :mod "701"~e.32
                                                      :name (n7 / name :op1 "tyrosine"~e.12)
                                                      :ARG1-of (p6 / phosphorylate-01)
                                                      :part-of p2)
                                                :op2 (a6 / amino-acid
                                                      :mod "727"~e.38
                                                      :name (n8 / name :op1 "serine"~e.14)
                                                      :ARG1-of (p7 / phosphorylate-01)
                                                      :part-of p2)))))))
            :ARG2~e.44 (s3 / substrate~e.46))
      :ARG1-of (c2 / consistent-01~e.0))

# ::tok SHP @-@ 2 is a dual @-@ specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1.1.r 5-1.3.1 8-1 9-1.2 10-1.2.1.r 11-1.2.1.1.3.1.1 12-1.2.1 15-1.2.1.1.1.1.1.1 16-1.2.1.1 17-1.2.1.1.2.1.1.1 18-1.2.1.1.1 18-1.2.1.1.2 19-1.2.1.2.r 20-1.2.1.2
# ::id bel_pmid_1227_0932_7862
(p3 / phosphatase~e.8
      :domain~e.3 (e / enzyme
            :name (n2 / name :op1 "SHP-2"~e.0,2))
      :ARG1-of (i / involve-01~e.9
            :ARG2~e.10 (d2 / dephosphorylate-01~e.12
                  :ARG1 (a2 / and~e.16
                        :op1 (r2 / residue~e.18
                              :mod (a3 / amino-acid
                                    :name (n4 / name :op1 "tyrosine"~e.15)))
                        :op2 (r3 / residue~e.18
                              :mod (a / amino-acid
                                    :name (n / name :op1 "serine"~e.17)))
                        :part-of (p2 / protein
                              :name (n3 / name :op1 "Stat1"~e.11)))
                  :location~e.19 (n5 / nucleus~e.20)))
      :mod (s / specific
            :mod (d / dual~e.5)))

# ::tok In SHP @-@ 2-/- mouse fibroblast cells , Stat1 phosphorylation at both the tyrosine residue Tyr( 701 ) and the serine residue Ser( 727 ) by IFNgamma was enhanced and prolonged .
# ::alignments 1-1.3.3.1.1 4-1.3.2 5-1.3.1.1 6-1.3 8-1.1.1.1.3.1.1 9-1.1.1 13-1.1.1.1.1.1.2.1 14-1.1.1.1.1 16-1.1.1.1.1.1.1 18-1.1.1.1 20-1.1.1.1.2.1.2.1 21-1.1.1.1.2 23-1.1.1.1.2.1.1 25-1.1.1.2.r 26-1.1.1.2.1.1 28-1.1 29-1 30-1.2
# ::id bel_pmid_1227_0932_9942
(a2 / and~e.29
      :op1 (e / enhance-01~e.28
            :ARG1 (p / phosphorylate-01~e.9
                  :ARG1 (a3 / and~e.18
                        :op1 (r / residue~e.14
                              :mod (a4 / amino-acid
                                    :mod "701"~e.16
                                    :name (n3 / name :op1 "tyrosine"~e.13)))
                        :op2 (r2 / residue~e.21
                              :mod (a / amino-acid
                                    :mod "727"~e.23
                                    :name (n / name :op1 "serine"~e.20)))
                        :part-of (p2 / protein
                              :name (n2 / name :op1 "Stat1"~e.8)))
                  :ARG2~e.25 (p3 / protein
                        :name (n4 / name :op1 "IFNgamma"~e.26))))
      :op2 (p4 / prolong-01~e.30
            :ARG1 p)
      :location (c2 / cell~e.6
            :name (n5 / name :op1 "fibroblast"~e.5)
            :mod (m / mouse~e.4)
            :mod (e2 / enzyme
                  :name (n6 / name :op1 "SHP-2"~e.1)
                  :ARG2-of (m2 / mutate-01 :mod "-/-"))))

# ::tok Next , they bind to the adaptor protein Grb2 and inhibit the recruitment of the Grb2 @-@ Sos complex either to the fibroblast growth factor receptor ( FGFR ) docking adaptor protein FRS2 or to Shp2. Membrane translocation of Spry is necessary for its phosphorylation , which is essential for its inhibitor activity .
# ::alignments 0-1.1.3 2-1.1.1.1 3-1.1.1 4-1.1.1.2.r 6-1.1.1.2.1.1 7-1.1.1.2.1.2 8-1.1.1.2.1.3 9-1.1 10-1.1.2 12-1.1.2.2 13-1.1.2.2.1.r 15-1.1.2.2.1.1.1.1 17-1.1.2.2.1.2.1.1 18-1.1.2.2.1 22-1.1.2.3.1.1.1 23-1.1.2.3.1.1.2 24-1.1.2.3.1.1.3 25-1.1.2.3.1.1.4 29-1.1.2.3.1.2 30-1.1.2.3.1.2.1.1.1 31-1.1.2.3.1.2.1.1.2 32-1.1.2.3.1.2.1.1.3 33-1.1.2.3 36-1.2.1.2 37-1.2.1 38-1.2.1.1.r 39-1.2.1.1.1.1 41-1.2 42-1.2.2.r 43-1.2.2.1 43-1.2.2.1.r 44-1.2.2 48-1.2.2.2 51-1.1.2 51-1.2.2.3.2
# ::id bel_pmid_1240_2043_10224
(m / multi-sentence
      :snt1 (a / and~e.9
            :op1 (b / bind-01~e.3
                  :ARG1 (t2 / they~e.2)
                  :ARG2~e.4 (p2 / protein
                        :name (n3 / name
                              :op1 "adaptor"~e.6
                              :op2 "protein"~e.7
                              :op3 "Grb2"~e.8)))
            :op2 (i2 / inhibit-01~e.10,51
                  :ARG0 t2
                  :ARG1 (r / recruit-01~e.12
                        :ARG1~e.13 (m2 / macro-molecular-complex~e.18
                              :part (p3 / protein
                                    :name (n4 / name :op1 "Grb2"~e.15))
                              :part (p4 / protein
                                    :name (n5 / name :op1 "Sos"~e.17))))
                  :location (o / or~e.33
                        :op1 (p5 / protein
                              :name (n6 / name
                                    :op1 "fibroblast"~e.22
                                    :op2 "growth"~e.23
                                    :op3 "factor"~e.24
                                    :op4 "receptor"~e.25)
                              :ARG0-of (d / dock-01~e.29
                                    :ARG1 (p6 / protein
                                          :name (n7 / name
                                                :op1 "adaptor"~e.30
                                                :op2 "protein"~e.31
                                                :op3 "FRS2"~e.32))))
                        :op2 (p7 / protein
                              :name (n8 / name :op1 "Shp2"))))
            :time (n / next~e.0))
      :snt2 (n2 / need-01~e.41
            :ARG0 (t3 / translocate-00~e.37
                  :ARG1~e.38 (p8 / protein
                        :name (n9 / name :op1 "Spry"~e.39))
                  :location (m3 / membrane~e.36))
            :ARG1~e.42 (p9 / phosphorylate-01~e.44
                  :ARG1~e.43 p8~e.43
                  :mod (e / essential~e.48)
                  :purpose (a2 / act-01
                        :ARG0 p8
                        :ARG1 (i3 / inhibit-01~e.51)))))

# ::tok Using an antibody against Spry2 , we showed that endogenous Spry2 becomes phosphorylated on tyrosine in response to EGF or FGF stimulation in C2C12 cells ( Fig . 4b , left ) and in COS7 cells ( Fig . 4b , right ) .
# ::alignments 0-1.3 2-1.3.1 3-1.3.1.1 4-1.2.1.1.1 4-1.3.1.1.1.1.1 6-1.1 7-1 8-1.2.r 9-1.2.1.2 10-1.2.1.1.1 11-1.2 12-1.2.2 13-1.2.2.1.r 14-1.2.2.1.1.1 15-1.2.2.2.r 16-1.2.2.2 17-1.2.2.2.1.r 18-1.2.2.2.1.2.1.1.1 19-1.2.2.2.1.2 20-1.2.2.2.1.2.2.1.1 21-1.2.2.2.1 22-1.2.2.2.1.3.r 23-1.2.2.2.1.3.1.1.1 24-1.2.2.2.1.3.1 28-1.2.2.2.1.3.1.2.1.1 30-1.2.2.2.1.3.1.2.1.2 32-1.2.2.2.1.3 34-1.2.2.2.1.3.2.1.1 35-1.2.2.2.1.3.2 39-1.2.2.2.1.3.2.2.1.1 41-1.2.2.2.1.3.2.2.1.2
# ::id bel_pmid_1240_2043_26582
(s / show-01~e.7
      :ARG0 (w / we~e.6)
      :ARG1~e.8 (b / become-01~e.11
            :ARG1 (p / protein
                  :name (n / name :op1 "Spry2"~e.4,10)
                  :mod (m / monocot~e.9))
            :ARG2 (p2 / phosphorylate-01~e.12
                  :ARG1~e.13 (a / amino-acid
                        :name (n2 / name :op1 "tyrosine"~e.14)
                        :part-of p)
                  :ARG2-of~e.15 (r / respond-01~e.16
                        :ARG1~e.17 (s2 / stimulate-01~e.21
                              :ARG1 p
                              :ARG2 (o / or~e.19
                                    :op1 (p3 / protein
                                          :name (n3 / name :op1 "EGF"~e.18))
                                    :op2 (p4 / protein
                                          :name (n4 / name :op1 "FGF"~e.20)))
                              :location~e.22 (a2 / and~e.32
                                    :op1 (c / cell~e.24
                                          :name (n5 / name :op1 "C2C12"~e.23)
                                          :ARG1-of (d / describe-01
                                                :ARG0 (f / figure
                                                      :mod "4b"~e.28
                                                      :mod (l / left~e.30))))
                                    :op2 (c2 / cell~e.35
                                          :name (n6 / name :op1 "COS7"~e.34)
                                          :ARG1-of (d2 / describe-01
                                                :ARG0 (f2 / figure
                                                      :mod "4b"~e.39
                                                      :ARG1-of (r2 / right-04~e.41)))))))))
      :manner (u / use-01~e.0
            :ARG1 (a3 / antibody~e.2
                  :ARG0-of (c3 / counter-01~e.3
                        :ARG1 (p5 / protein
                              :name (n7 / name :op1 "Spry2"~e.4))))))

# ::tok In addition , neither xSpry1Y53F nor mSpry2Y55F was tyrosine phosphorylated in cells stimulated with EGF ( data not shown ) .
# ::alignments 0-1 1-1 1-1.1.2 3-1.1.1.r 4-1.1.2.1.2.1.1 5-1.1.1 5-1.1.1.r 6-1.1.2.2.2.1.1 8-1.1.2.1.1.1 8-1.1.2.2.1.1 9-1.1 10-1.1.3.r 11-1.1.3 12-1.1.3.1 13-1.1.3.1.1.r 14-1.1.3.1.1.1.1 16-1.2.1 17-1.2.1.1.1 17-1.2.1.1.1.r 18-1.2.1.1
# ::id bel_pmid_1240_2043_26584
(a / and~e.0,1
      :op2 (p / phosphorylate-01~e.9
            :polarity~e.3,5 "-"~e.5
            :ARG1 (a6 / and~e.1
                  :op1 (a5 / amino-acid
                        :name (n5 / name :op1 "tyrosine"~e.8)
                        :part-of (p4 / protein
                              :name (n7 / name :op1 "xSpry1Y53F"~e.4)))
                  :op2 (a7 / amino-acid
                        :name (n8 / name :op1 "tyrosine"~e.8)
                        :part-of (p5 / protein
                              :name (n9 / name :op1 "mSpry2Y55F"~e.6))))
            :location~e.10 (c / cell~e.11
                  :ARG1-of (s / stimulate-01~e.12
                        :ARG0~e.13 (p2 / protein
                              :name (n6 / name :op1 "EGF"~e.14)))))
      :ARG1-of (d / describe-01
            :ARG0 (d2 / data~e.16
                  :ARG1-of (s3 / show-01~e.18 :polarity~e.17 "-"~e.17))))

# ::tok When Myc @-@ tagged mSpry2 and haemagluttinin A ( HA )- tagged Grb2 were expressed in cultured cells , both molecules translocated to the ruffling membrane region in response to stimulation with FGF or EGF and colocalized there ( Fig . 1c ) .
# ::alignments 0-1.3.r 1-1.3.1.1.2.1.1.1 3-1.3.1.1.2 4-1.3.1.1.1.1 5-1.3.1 6-1.3.1.2.2.1.1.1 7-1.3.1.2.2.1.1.2 11-1.3.1.2.2 12-1.3.1.2.1.1 14-1.3 15-1.3.2.r 16-1.3.2.1 17-1.3.2 24-1.1.2.2 25-1.1.2.1 26-1.1.2 28-1.1.3 29-1.1.3.1.r 30-1.1.3.1 31-1.1.3.1.1.r 32-1.1.3.1.1.1.1.1 33-1.1.3.1.1 34-1.1.3.1.1.2.1.1 35-1 36-1.2 41-1.4.1.1
# ::id bel_pmid_1240_2043_26602
(a5 / and~e.35
      :op1 (t4 / translocate-00
            :ARG1 (a2 / and~e.5
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "mSpry2"~e.4)
                        :ARG1-of (t / tag-01~e.3
                              :ARG0 (p / protein
                                    :name (n / name :op1 "Myc"~e.1))))
                  :op2 (p4 / protein
                        :name (n4 / name :op1 "Grb2"~e.12)
                        :ARG1-of (t2 / tag-01~e.11
                              :ARG0 (p3 / protein
                                    :name (n3 / name :op1 "haemagluttinin"~e.6 :op2 "A"~e.7)))))
            :location (r / region~e.26
                  :part-of (m / membrane~e.25)
                  :ARG0-of (r2 / ruffle-02~e.24))
            :ARG2-of (r3 / respond-01~e.28
                  :ARG1~e.29 (s / stimulate-01~e.30
                        :ARG0~e.31 (o / or~e.33
                              :op1 (p5 / protein
                                    :name (n5 / name :op1 "FGF"~e.32))
                              :op2 (p6 / protein
                                    :name (n6 / name :op1 "EGF"~e.34))))))
      :op2 (c3 / colocalize-00~e.36
            :ARG1 a2
            :ARG2 r)
      :time~e.0 (e / express-03~e.14
            :ARG2 a2
            :ARG3~e.15 (c / cell~e.17
                  :ARG1-of (c2 / culture-01~e.16)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "1c"~e.41)))

# ::tok both xSpry1Y53F and mSpry2Y55F were unable to inhibit the binding of Grb2 to FRS2 or Shp2 in response to FGF stimulation ( Fig . 2a , b ) or the recruitment of Grb2–Sos complex to FRS2 ( Fig . 2c ) .
# ::alignments 1-1.2.1.1.2.1.1 2-1.2.1 3-1.2.1.2.2.1.1 4-1.2.r 5-1 5-1.1 5-1.1.r 7-1.2 9-1.2.2.1 10-1.2.2.1.1.r 11-1.2.2.1.1.1.1 12-1.2.2.1.2.r 13-1.2.2.1.2.1.1.1 14-1.2.2.1.2 15-1.2.2.1.2.2.1.1 16-1.2.2.1.3.r 17-1.2.2.1.3 18-1.2.2.1.3.1.r 19-1.2.2.1.3.1.1.1.1.1 20-1.2.2.1.3.1.1 24-1.2.2.1.3.1.1.2.1.1.1 28-1.2.2.1.3.1 30-1.2.2.2 33-1.2.2.2.1 34-1.2.2.2.2.r 35-1.2.2.2.2 39-1.2.2.2.3.1.1
# ::id bel_pmid_1240_2043_30896
(p / possible~e.5
      :polarity~e.5 "-"~e.5
      :domain~e.4 (i / inhibit-01~e.7
            :ARG0 (a / and~e.2
                  :op1 (a6 / amino-acid
                        :name (n12 / name :op1 "phenylalanine")
                        :part-of (p11 / protein
                              :name (n13 / name :op1 "xSpry1Y53F"~e.1)))
                  :op2 (a2 / amino-acid
                        :name (n / name :op1 "phenylalanine")
                        :part-of (p2 / protein
                              :name (n2 / name :op1 "mSpry2Y55F"~e.3))))
            :ARG1 (a5 / and
                  :op1 (b / bind-01~e.9
                        :ARG1~e.10 (p4 / protein
                              :name (n5 / name :op1 "Grb2"~e.11))
                        :ARG2~e.12 (o / or~e.14
                              :op1 (p5 / protein
                                    :name (n6 / name :op1 "FRS2"~e.13))
                              :op2 (p6 / protein
                                    :name (n7 / name :op1 "Shp2"~e.15)))
                        :ARG2-of~e.16 (r / respond-01~e.17
                              :ARG1~e.18 (o2 / or~e.28
                                    :op1 (s / stimulate-01~e.20
                                          :ARG0 (p7 / protein
                                                :name (n8 / name :op1 "FGF"~e.19))
                                          :ARG1-of (d / describe-01
                                                :ARG0 (a4 / and
                                                      :op1 (f / figure :mod "2a"~e.24)
                                                      :op2 (f2 / figure :mod "2b")))))))
                  :op2 (r2 / recruit-01~e.30
                        :ARG1 (m / macro-molecular-complex~e.33
                              :part p4
                              :part (p9 / protein
                                    :name (n10 / name :op1 "Sos")))
                        :ARG2~e.34 p5~e.35
                        :ARG1-of (d2 / describe-01
                              :ARG0 (f3 / figure :mod "2c"~e.39))))))

# ::tok We investigated the ability of the Spry mutants to bind to Grb2. Both xSpry1Y53F and mSpry2Y55F failed to bind to Grb2 in response to FGF stimulation ( Fig . 5c ) .
# ::alignments 0-1.1.1 1-1.1 3-1.1.2 4-1.1.2.1.r 6-1.1.2.1.1.1 7-1.1.2.1 7-1.1.2.1.2 7-1.1.2.1.2.r 9-1.1.2.2 13-1.2.1.1.2.1.1 14-1.2.1 15-1.2.1.2.2.1.1 16-1.2 18-1.2.2 20-1.1.2.2.2.1.1 20-1.2.2.2.1.1 21-1.2.2.3.r 22-1.2.2.3 23-1.2.2.3.1.r 24-1.2.2.3.1.1.1.1 25-1.2.2.3.1 29-1.2.3.1.1
# ::id bel_pmid_1240_2043_30898
(m / multi-sentence
      :snt1 (i / investigate-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (c / capable-01~e.3
                  :ARG1~e.4 (p / protein~e.7
                        :name (n / name :op1 "Spry"~e.6)
                        :ARG2-of~e.7 (m2 / mutate-01~e.7))
                  :ARG2 (b / bind-01~e.9
                        :ARG1 m2
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "Grb2"~e.20)))))
      :snt2 (f / fail-01~e.16
            :ARG1 (a / and~e.14
                  :op1 (a4 / amino-acid
                        :name (n9 / name :op1 "phenylalanine")
                        :part-of (p7 / protein
                              :name (n10 / name :op1 "xSpry1Y53F"~e.13)))
                  :op2 (a2 / amino-acid
                        :name (n3 / name :op1 "phenylalanine")
                        :part-of (p3 / protein
                              :name (n4 / name :op1 "mSpry2Y55F"~e.15))))
            :ARG2 (b2 / bind-01~e.18
                  :ARG1 a
                  :ARG2 (p5 / protein
                        :name (n7 / name :op1 "Grb2"~e.20))
                  :ARG2-of~e.21 (r / respond-01~e.22
                        :ARG1~e.23 (s / stimulate-01~e.25
                              :ARG0 (p6 / protein
                                    :name (n8 / name :op1 "FGF"~e.24)))))
            :ARG1-of (d / describe-01
                  :ARG0 (f2 / figure :mod "5c"~e.29))))

# ::tok We also found that the tyrosine @- phosphorylated , endogenous Spry2 binds to endogenous Grb2 in a manner dependent on FGF stimulation ( Fig . 4c ) .
# ::alignments 0-1.1 1-1.4 2-1 3-1.2.r 5-1.2.1.1.1 7-1.2.1.2 9-1.2.1.3.2 10-1.2.1.3.1.1 11-1.2 12-1.2.2.r 13-1.2.2.2 14-1.2.2.1.1 17-1.2.3.r 18-1.2.3 19-1.2.3.1.r 20-1.2.3.1.1.1.1 21-1.2.3.1 25-1.3.1.1
# ::id bel_pmid_1240_2043_30900
(f / find-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1~e.3 (b / bind-01~e.11
            :ARG1 (a / amino-acid
                  :name (n / name :op1 "tyrosine"~e.5)
                  :ARG1-of (p / phosphorylate-01~e.7)
                  :part-of (p2 / protein
                        :name (n2 / name :op1 "Spry2"~e.10)
                        :mod (m / monocot~e.9)))
            :ARG2~e.12 (p3 / protein
                  :name (n3 / name :op1 "Grb2"~e.14)
                  :mod m~e.13)
            :manner~e.17 (d / depend-01~e.18
                  :ARG1~e.19 (s / stimulate-01~e.21
                        :ARG0 (p4 / protein
                              :name (n4 / name :op1 "FGF"~e.20)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure :mod "4c"~e.25))
      :mod (a2 / also~e.1))

# ::tok Here we show that after stimulation by growth factors Spry1 and Spry2 translocate to the plasma membrane and become phosphorylated on a conserved tyrosine .
# ::alignments 0-1.3 1-1.1 2-1 3-1.2.r 4-1.2.3 5-1.2.3.1 6-1.2.3.1.1.r 7-1.2.3.1.1.1.1 8-1.2.3.1.1.1.2 9-1.2.1.1.1.1.1 11-1.2.1.1.2.1.1 12-1.2.1 13-1.2.1.2.r 15-1.2.1.2.1 16-1.2.1.2 17-1.2 18-1.2.2 19-1.2.2.2 20-1.2.2.2.1.r 22-1.2.2.2.1.2 23-1.2.2.2.1.1.1
# ::id bel_pmid_1240_2043_4190
(s / show-01~e.2
      :ARG0 (w / we~e.1)
      :ARG1~e.3 (a / and~e.17
            :op1 (t / translocate-00~e.12
                  :ARG1 (a2 / and
                        :op1 (p / protein
                              :name (n / name :op1 "Spry1"~e.9))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "Spry2"~e.11)))
                  :location~e.13 (m / membrane~e.16
                        :mod (p3 / plasma~e.15)))
            :op2 (b / become-01~e.18
                  :ARG1 a2
                  :ARG2 (p4 / phosphorylate-01~e.19
                        :ARG1~e.20 (a3 / amino-acid
                              :name (n3 / name :op1 "tyrosine"~e.23)
                              :ARG1-of (c / conserve-01~e.22)
                              :part-of a2)))
            :time (a4 / after~e.4
                  :op1 (s2 / stimulate-01~e.5
                        :ARG0~e.6 (s3 / small-molecule
                              :name (n4 / name :op1 "growth"~e.7 :op2 "factor"~e.8))
                        :ARG1 a2)))
      :location (h / here~e.0))

# ::tok gp130 @-@ mediated Stat1 @/@ 3 activation is required to maintain the normal balance of hematopoietic progenitors during fetal and adult hematopoiesis
# ::alignments 0-1.1.2.1.1.1 2-1.1.2 3-1.1.1.1.1.1 6-1.1 8-1 10-1.2 13-1.2.1 16-1.2.1.1 17-1.2.2.r 18-1.2.2.1 19-1.2.2 20-1.2.2.2 21-1.2.1.1.1
# ::id bel_pmid_1242_3677_2596
(r / require-01~e.8
      :ARG1 (a / activate-01~e.6
            :ARG1 (s / slash
                  :op1 (p / protein
                        :name (n / name :op1 "Stat1"~e.3))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "Stat3")))
            :ARG1-of (m / mediate-01~e.2
                  :ARG0 (p3 / protein
                        :name (n3 / name :op1 "gp130"~e.0))))
      :purpose (m2 / maintain-01~e.10
            :ARG1 (b / balance-01~e.13
                  :ARG1 (p4 / progenitor~e.16
                        :mod (h / hematopoiesis~e.21)))
            :time~e.17 (a2 / and~e.19
                  :op1 (f / fetal~e.18
                        :mod h)
                  :op2 (a3 / adult~e.20
                        :mod h))))

# ::tok Immunoblots using antibodies to BATF detected an increase in BATF protein in response to LIF @/@ IL @-@ 6 stimulation .
# ::alignments 2-1.1.2 4-1.1.2.1.1.1.1 5-1 7-1.1.1 9-1.1.2.1.1.1.1 10-1.1.2.1.1 11-1.1.1.2.r 12-1.1.1.2 13-1.1.1.2.1.r 14-1.1.1.2.1.1.1.1.1 16-1.1.1.2.1.1.2.1.1 18-1.1.1.2.1.1.2.1.1 19-1.1.1.2.1
# ::id bel_pmid_1244_4555_28358
(d / detect-01~e.5
      :ARG0 (i / immunoblot-00
            :ARG1 (i2 / increase-01~e.7
                  :ARG1 (q / quant-of
                        :name (n2 / name :op1 "p"))
                  :ARG0-of~e.11 (r / respond-01~e.12
                        :ARG1~e.13 (s2 / stimulate-01~e.19
                              :ARG1 (s / slash
                                    :op1 (c2 / cytokine
                                          :name (n3 / name :op1 "LIF"~e.14))
                                    :op2 (c3 / cytokine
                                          :name (n4 / name :op1 "IL-6"~e.16,18))))))
            :ARG2 (a / antibody~e.2
                  :ARG0-of (c / counter-01
                        :ARG1 (p / protein~e.10
                              :name (n / name :op1 "BATF"~e.4,9))))))

# ::tok These data demonstrate that OSM induces up @-@ regulation of C/EBPdelta via a Stat3 @-@ dependent pathway in mammary epithelial cells and that the growth inhibition induced by OSM depends on the presence of C/EBPdelta .
# ::alignments 0-1.1.1 1-1.1 2-1 3-1.2.r 4-1.2.2.1.1 5-1.2.2.1 9-1.2.r 10-1.2.1.2.1.1.1 13-1.2.1.2.2.1.1.1.1 15-1.2.1.2.2.1 16-1.2.1.2.2 18-1.2.1.2.3.1.1 20-1.2.1.2.3 21-1.2 24-1.2.2.1.2.1 25-1.2.2.1.2 26-1.2.1 26-1.2.2.1 27-1.2.1.1.r 28-1.2.1.1.1.1 29-1.2.2 33-1.2.2.2.r 34-1.2.2.2
# ::id bel_pmid_1247_9220_29758
(d / demonstrate-01~e.2
      :ARG0 (d2 / data~e.1
            :mod (t / this~e.0))
      :ARG1~e.3,9 (a / and~e.21
            :op1 (i / induce-01~e.26
                  :ARG0~e.27 (p / protein
                        :name (n / name :op1 "OSM"~e.28))
                  :ARG1 (u / upregulate-01
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "C/EBPdelta"~e.10))
                        :ARG2 (p3 / pathway~e.16
                              :ARG0-of (d3 / depend-01~e.15
                                    :ARG1 (p4 / protein
                                          :name (n3 / name :op1 "Stat3"~e.13))))
                        :location (c / cell~e.20
                              :mod (e / epithalium
                                    :mod (m / mammary~e.18)))))
            :op2 (d4 / depend-01~e.29
                  :ARG0 (i2 / induce-01~e.5,26
                        :ARG0 p~e.4
                        :ARG1 (i3 / inhibit-01~e.25
                              :ARG1 (g / grow-01~e.24)))
                  :condition~e.33 p2~e.34)))

# ::tok The treatment of NCI @-@ N87 cells with EGF resulted in increases in phosphorylation of Erk1 @/@ 2 , Akt , and P38. Blockade of the Erk , phosphatidylinositol @-@ 3 kinase/Akt , or P38 pathways in this cell line
# ::alignments 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1 5-1.1.1.1.1.1 6-1.1.1.1 7-1.1.1.2.r 8-1.1.1.2.1.1 9-1.1 10-1.1.2.r 11-1.1.2 12-1.1.2.2.r 13-1.1.2.2 14-1.1.2.2.1.r 15-1.1.2.2.1.1.1.1 17-1.1.2.2.1.1.1.1 19-1.1.2.2.1.2.1.1 21-1.1.2.2.1 23-1.2 24-1.2.1.r 26-1.2.1.1.1.1 28-1.2.1.2.1.1 30-1.2.1.2.1.1 33-1.2.1 34-1.1.2.2.1.3.1.1 34-1.2.1.3.1.1 35-1.2.1.1 35-1.2.1.2 35-1.2.1.3 36-1.2.2.r 37-1.2.2.1 38-1.2.2 39-1.2.2
# ::id bel_pmid_1261_8892_1630
(m / multi-sentence
      :snt1 (r / result-01~e.9
            :ARG1 (t / treat-04~e.1
                  :ARG1~e.2 (c / cell~e.6
                        :name (n / name :op1 "NCI-N87"~e.3,5))
                  :ARG2~e.7 (p / protein
                        :name (n2 / name :op1 "EGF"~e.8)))
            :ARG2~e.10 (i / increase-01~e.11
                  :ARG0 t
                  :ARG1~e.12 (p2 / phosphorylate-01~e.13
                        :ARG1~e.14 (a / and~e.21
                              :op1 (e / enzyme
                                    :name (n3 / name :op1 "Erk1/2"~e.15,17))
                              :op2 (e2 / enzyme
                                    :name (n4 / name :op1 "Akt"~e.19))
                              :op3 (e3 / enzyme
                                    :name (n5 / name :op1 "P38"~e.34))))))
      :snt2 (b / blockade-01~e.23
            :ARG1~e.24 (o / or~e.33
                  :op1 (p3 / pathway~e.35
                        :name (n6 / name :op1 "Erk"~e.26))
                  :op2 (p4 / pathway~e.35
                        :name (n7 / name :op1 "phosphatidylinositol-3-kinase/Akt"~e.28,30))
                  :op3 (p5 / pathway~e.35
                        :name (n8 / name :op1 "P38"~e.34)))
            :location~e.36 (c2 / cell-line~e.38,39
                  :mod (t2 / this~e.37))))

# ::tok infusion of EGF and CNTF into adult forebrain lateral ventricles increased periventricular NOTCH1 compared with EGF alone
# ::alignments 0-1.1 0-1.3 1-1.1.1.r 2-1.1.1.1.1.1 3-1.1.1 4-1.1.1.2.1.1 5-1.1.2.r 6-1.1.2.2.1 7-1.1.2.2 8-1.1.2.1 9-1.1.2 10-1 11-1.2.2 12-1.2.1.1 13-1.3.r 14-1.3.1.r 15-1.3.1.1.1 16-1.3.1.2
# ::id bel_pmid_1262_9177_26086
(i / increase-01~e.10
      :ARG0 (i2 / infuse-01~e.0
            :ARG1~e.1 (a / and~e.3
                  :op1 (p / protein
                        :name (n / name :op1 "EGF"~e.2))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "CNTF"~e.4)))
            :ARG2~e.5 (v / ventricle~e.9
                  :location (l / lateral~e.8)
                  :part-of (f / forebrain~e.7
                        :mod (a2 / adult~e.6))))
      :ARG1 (p3 / protein
            :name (n3 / name :op1 "NOTCH1"~e.12)
            :location (p4 / periventricular~e.11))
      :compared-to~e.13 (i3 / infuse-01~e.0
            :ARG1~e.14 (p5 / protein
                  :name (n4 / name :op1 "EGF"~e.15)
                  :mod (a3 / alone~e.16))
            :ARG2 v))

# ::tok NOTCH1 activation , indicated by tumor necrosis factor alpha @-@ converting enzyme , TACE [Adam17], and presenilin @-@ mediated processing , also increased
# ::alignments 0-1.1.1.1.1 1-1.1 3-1.1.2 4-1.1.2.1.r 5-1.1.2.1.1.1.1 6-1.1.2.1.1.1.2 7-1.1.2.1.1.1.3 8-1.1.2.1.1.1.4 10-1.1.2.1.1.1.4 11-1.1.2.1.1.1.5 15-1.1.2.1 16-1.1.2.1.2.1.1.1.1 18-1.1.2.1.2.1 19-1.1.2.1.2 21-1.2 22-1
# ::id bel_pmid_1262_9177_28408
(i / increase-01~e.22
      :ARG1 (a / activate-01~e.1
            :ARG1 (p / protein
                  :name (n / name :op1 "NOTCH1"~e.0))
            :ARG1-of (i2 / indicate-01~e.3
                  :ARG0~e.4 (a2 / and~e.15
                        :op1 (e / enzyme
                              :name (n2 / name
                                    :op1 "tumor"~e.5
                                    :op2 "necrosis"~e.6
                                    :op3 "factor"~e.7
                                    :op4 "alpha-converting"~e.8,10
                                    :op5 "enzyme"~e.11))
                        :op2 (p2 / process-01~e.19
                              :ARG1-of (m / mediate-01~e.18
                                    :ARG0 (p3 / protein
                                          :name (n3 / name :op1 "presenilin"~e.16)))))))
      :mod (a4 / also~e.21))

# ::tok ciliary neurotrophic factor , CNTF , activation of gp130 in NSCs rapidly increased Notch1 expression
# ::alignments 0-1.1.1.1.1 1-1.1.1.1.2 2-1.1.1.1.3 6-1.1 7-1.1.2.r 8-1.1.2.1.1 11-1.3 11-1.3.r 12-1 13-1.2.1.1.1 14-1.2
# ::id bel_pmid_1262_9177_8352
(i / increase-01~e.12
      :ARG0 (a / activate-01~e.6
            :ARG0 (p / protein
                  :name (n / name
                        :op1 "ciliary"~e.0
                        :op2 "neurotrophic"~e.1
                        :op3 "factor"~e.2))
            :ARG1~e.7 (p2 / protein
                  :name (n2 / name :op1 "gp130"~e.8))
            :location (c / cell
                  :name (n3 / name :op1 "NSC")))
      :ARG1 (e / express-03~e.14
            :ARG2 (p3 / protein
                  :name (n4 / name :op1 "Notch1"~e.13)))
      :manner~e.11 (r / rapid~e.11))

# ::tok We used a murine macrophage @-@ like cell line , RAW264.7 , to demonstrate that Janus kinase ( JAK ) 2 is tyrosine phosphorylated immediately after LPS stimulation . Anti @-@ Toll @-@ like receptor ( TLR ) 4 neutralization antibody inhibits the phosphorylation of JAK2 and the c @-@ Jun NH2 @-@ terminal protein kinase ( JNK ) .
# ::alignments 0-1.1.1 1-1.1 3-1.1.2.3.1.1 4-1.1.2.2.1.1.1 6-1.1.2.2 7-1.1.2 7-1.1.2.2.1 8-1.1.2 10-1.1.2.1.1 13-1.1.3 14-1.1.3.2.r 15-1.1.3.2.1.2.1.1 16-1.1.3.2.1.2.1.2 20-1.1.3.2.1.2.1.3 22-1.1.3.2.1.1.1 23-1.1.3.2 24-1.1.3.2.2.2 25-1.1.3.2.2 26-1.1.3.2.2.1.1.1.1 27-1.1.3.2.2.1 31-1.2.1.1.1.1.1 33-1.2.1.1.1.1.1 34-1.2.1.1.1.1.2 38-1.2.1.1.1.1.3 39-1.2.1.1 40-1.2.1 41-1.2 43-1.2.2 44-1.2.2.1.r 45-1.2.2.1.1.1.1 46-1.2.2.1 48-1.2.2.1.2.1.1 50-1.2.2.1.2.1.1 51-1.2.2.1.2.1.2 53-1.2.2.1.2.1.2 54-1.2.2.1.2.1.3 55-1.2.2.1.2.1.4
# ::id bel_pmid_1268_6512_15962
(m / multi-sentence
      :snt1 (u / use-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (c / cell-line~e.7,8
                  :name (n / name :op1 "RAW264.7"~e.10)
                  :ARG1-of (r / resemble-01~e.6
                        :ARG2 (c2 / cell~e.7
                              :name (n2 / name :op1 "macrophage"~e.4)))
                  :part-of (o / organism
                        :name (n3 / name :op1 "Muridae"~e.3)))
            :ARG2 (d / demonstrate-01~e.13
                  :ARG0 w
                  :ARG1~e.14 (p / phosphorylate-01~e.23
                        :ARG1 (a / amino-acid
                              :name (n4 / name :op1 "tyrosine"~e.22)
                              :part-of (e / enzyme
                                    :name (n5 / name
                                          :op1 "Janus"~e.15
                                          :op2 "kinase"~e.16
                                          :op3 "2"~e.20)))
                        :time (a2 / after~e.25
                              :op1 (s / stimulate-01~e.27
                                    :ARG0 (m2 / molecular-physical-entity
                                          :name (n6 / name :op1 "LPS"~e.26))
                                    :ARG1 e)
                              :mod (i / immediate~e.24)))))
      :snt2 (i2 / inhibit-01~e.41
            :ARG0 (a3 / antibody~e.40
                  :ARG0-of (n7 / neutralize-01~e.39
                        :ARG1 (p2 / protein
                              :name (n8 / name
                                    :op1 "Toll-like"~e.31,33
                                    :op2 "receptor"~e.34
                                    :op3 "4"~e.38))))
            :ARG1 (p3 / phosphorylate-01~e.43
                  :ARG1~e.44 (a4 / and~e.46
                        :op1 (e2 / enzyme
                              :name (n9 / name :op1 "JAK2"~e.45))
                        :op2 (e3 / enzyme
                              :name (n10 / name
                                    :op1 "c-Jun"~e.48,50
                                    :op2 "NH2-terminal"~e.51,53
                                    :op3 "protein"~e.54
                                    :op4 "kinase"~e.55))))))

# ::tok Il6 can elicit proinflammatory or anti @-@ inflammatory effects , depending on the in vivo environmental circumstances
# ::alignments 0-1.1.1.1.1 1-1 2-1.1 5-1.1.2.2.1 7-1.1.2.1.1.1 8-1.1.2.1 8-1.1.2.2 10-1.2 11-1.2.1.r 13-1.2.1.1 14-1.2.1.1 15-1.2.1.2 16-1.2.1
# ::id bel_pmid_1268_7404_28336
(p / possible~e.1
      :domain (e / elicit-01~e.2
            :ARG0 (p2 / protein
                  :name (n / name :op1 "Il6"~e.0))
            :ARG1 (a / and
                  :op1 (e2 / effect-01~e.8
                        :ARG0-of (f / favor-01
                              :ARG1 (i / inflame-01~e.7)))
                  :op2 (e3 / effect-01~e.8
                        :ARG0-of (c / counter-01~e.5
                              :ARG1 i))))
      :ARG0-of (d / depend-01~e.10
            :ARG1~e.11 (c2 / circumstance~e.16
                  :manner (i2 / in-vivo~e.13,14)
                  :mod (e4 / environment~e.15))))

# ::tok Il6 promotes the growth arrest and differentiation of M1 cells through gp130 @-@ mediated Stat3 activation , whereas the Y759 @/@ SHP @-@ 2 @-@ mediated cascade by gp130 stimulation has growth @-@ enhancing effects
# ::alignments 0-1.1.1.1.1 1-1.1 3-1.1.2.1.1 4-1.1.2.1 5-1.1.2 6-1.1.2.2 7-1.1.2.1.1.1.r 8-1.1.2.1.1.1.1.1 9-1.1.2.1.1.1 11-1.1.3.2.1.1.1 13-1.1.3.2 14-1.1.3.1.1.1 15-1.1.3 17-1 21-1.2.1.1.1.3.1.1 23-1.2.1.1.1.3.1.1 25-1.2.1.1 26-1.2.1 28-1.2.1.2.1 29-1.2.2.1 30-1.2 31-1.2.2.2 33-1.2.2 34-1.2
# ::id bel_pmid_1268_7404_38564
(c / contrast-01~e.17
      :ARG1 (p / promote-01~e.1
            :ARG0 (p2 / protein
                  :name (n / name :op1 "Il6"~e.0))
            :ARG1 (a / and~e.5
                  :op1 (a2 / arrest-02~e.4
                        :ARG1 (g / grow-01~e.3
                              :ARG1~e.7 (c2 / cell~e.9
                                    :name (n2 / name :op1 "M1"~e.8))))
                  :op2 (d / differentiate-01~e.6
                        :ARG1 c2))
            :manner (a3 / activate-01~e.15
                  :ARG1 (p3 / protein
                        :name (n3 / name :op1 "Stat3"~e.14))
                  :ARG1-of (m / mediate-01~e.13
                        :ARG0 (p4 / protein
                              :name (n4 / name :op1 "gp130"~e.11)))))
      :ARG2 (e / effect-01~e.30,34
            :ARG0 (c3 / cascade~e.26
                  :ARG1-of (m2 / mediate-01~e.25
                        :ARG0 (a4 / amino-acid
                              :mod "759"
                              :name (n5 / name :op1 "tyrosine")
                              :part-of (e2 / enzyme
                                    :name (n6 / name :op1 "SHP-2"~e.21,23))))
                  :ARG1-of (s / stimulate-01
                        :ARG0 p4~e.28))
            :ARG1 (e3 / enhance-01~e.33
                  :ARG0 c3~e.29
                  :ARG1 (g2 / grow-01~e.31))))

# ::tok Mutational inactivation of the MYCantagonist Mxi @-@ 1 in prostate carcinoma may be another mechanism of MYC activation [54]. Mxi @-@ 1 inactivation would presumably shift the equilibrium between Mxi @-@ 1/MAX and c @-@ MYC @/@ MAX in prostate cells towards c @- MYC @/@ MAX hetero @-@ dimers , and therefore lead to elevated expression of c @-@ MYC @-@ target genes .
# ::alignments 0-1.1.3.3 1-1.1.3 1-1.1.3.1 1-1.1.3.1.r 5-1.1.3.2.1.1 7-1.1.3.2.1.1 9-1.1.3.4.2 10-1.1.3.4.1.1 11-1.1.1 12-1.1.3.r 13-1.1.4 14-1.1 16-1.1.2.1.1.1 17-1.1.2 17-1.1.3 19-1.2.1.1.2.1.1 21-1.2.1.1.2.1.1 22-1.2.1.1 22-1.2.1.1.1 22-1.2.1.1.1.r 24-1.2.1.5 25-1.2.1 27-1.2.1.2 28-1.2.1.2.1 29-1.2.1.1.2.1.1 32-1.2.1.2.1 33-1.2.1.2.1.2.1.1.1 35-1.2.1.2.1.2.1.1.1 37-1.2.1.2.1.1.2.1.1 38-1.2.1.4.r 39-1.2.1.4.1 40-1.2.1.4 42-1.2.1.2.1.2.1.1.1 44-1.2.1.2.1.2.1.1.1 46-1.2.1.2.1.2.2 47-1.2.1.3 49-1.2.1.3 51-1.2 52-1.2.2 53-1.2.2.2 54-1.2.2.2.1.r 55-1.2.2.2.1.2 56-1.2.2.2.1 57-1.2.2.2.1.1.r 58-1.2.2.2.1.1.1.1 60-1.2.2.2.1.1.1.1 62-1.2.2.2.1.1 62-1.2.2.2.1.1.2 62-1.2.2.2.1.1.2.r
# ::id bel_pmid_1276_9686_36092
(m / multi-sentence
      :snt1 (m2 / mechanism~e.14
            :mod (p / possible~e.11)
            :ARG0-of (a / activate-01~e.17
                  :ARG1 (p10 / protein
                        :name (n / name :op1 "MYC"~e.16)))
            :domain~e.12 (a2 / activate-01~e.1,17
                  :polarity~e.1 "-"~e.1
                  :ARG1 (p11 / protein
                        :name (n2 / name :op1 "Mxi-1"~e.5,7)
                        :ARG0-of (a3 / antagonize-01
                              :ARG1 p10))
                  :ARG1-of (m3 / mutate-01~e.0)
                  :location (d / disease
                        :name (n3 / name :op1 "carcinoma"~e.10)
                        :location (p2 / prostate~e.9)))
            :mod (a4 / another~e.13)
            :ARG1-of (d2 / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c / cite-01 :ARG2 "54"))))
      :snt2 (a5 / and~e.51
            :op1 (s / shift-01~e.25
                  :ARG0 (a6 / activate-01~e.22
                        :polarity~e.22 "-"~e.22
                        :ARG1 (p9 / protein
                              :name (n4 / name :op1 "Mxi-1"~e.19,21,29)))
                  :ARG1 (e / equilibrium~e.27
                        :mod (b / between~e.28,32
                              :op1 (m4 / macro-molecular-complex
                                    :part p9
                                    :part (p4 / protein
                                          :name (n5 / name :op1 "MAX"~e.37)))
                              :op2 (m5 / macro-molecular-complex
                                    :part (p8 / protein
                                          :name (n6 / name :op1 "c-MYC"~e.33,35,42,44))
                                    :part p4~e.46)))
                  :ARG2 (h / hetero-dimer~e.47,49
                        :mod m5)
                  :location~e.38 (c2 / cell~e.40
                        :part-of (p5 / prostate~e.39))
                  :ARG1-of (p6 / presume-01~e.24))
            :op2 (c3 / cause-01~e.52
                  :ARG0 s
                  :ARG1 (l / lead-03~e.53
                        :ARG2~e.54 (e2 / express-03~e.56
                              :ARG1~e.57 (p7 / protein~e.62
                                    :name (n7 / name :op1 "c-MYC"~e.58,60)
                                    :ARG1-of~e.62 (t / target-01~e.62))
                              :ARG1-of (e3 / elevate-01~e.55))))))

# ::tok The encoded protein ( CDKN1A ) binds to and inhibits the activity of cyclin @-@ CDK2 or -@ CDK4 complexes
# ::alignments 1-1.1.1.1 2-1.1.1 4-1.1.1.1.1.1.1 6-1.1 8-1 9-1.2 11-1.2.2 12-1.1.2.r 13-1.1.2.1.1.1.1 15-1.1.2.1.2.1.1 16-1.1.2 18-1.1.2.2.2.1.1 19-1.1.2.1 19-1.1.2.2
# ::id bel_pmid_1276_9686_37908
(a / and~e.8
      :op1 (b / bind-01~e.6
            :ARG1 (p / protein~e.2
                  :ARG1-of (e / encode-01~e.1
                        :ARG0 (g / gene
                              :name (n / name :op1 "CDKN1A"~e.4))))
            :ARG2~e.12 (o / or~e.16
                  :op1 (m / macro-molecular-complex~e.19
                        :part (p2 / protein
                              :name (n2 / name :op1 "cyclin"~e.13))
                        :part (e2 / enzyme
                              :name (n3 / name :op1 "CDK2"~e.15)))
                  :op2 (m2 / macro-molecular-complex~e.19
                        :part p2
                        :part (e3 / enzyme
                              :name (n4 / name :op1 "CDK4"~e.18)))))
      :op2 (i / inhibit-01~e.9
            :ARG0 p
            :ARG1 (a2 / act-02~e.11
                  :ARG0 o)))

# ::tok The encoded protein binds to and prevents the activation of cyclin E @-@ CDK2 or cyclin D @-@ CDK4 complexes
# ::alignments 1-1.1.1.1 2-1.1.1 3-1.1 5-1 6-1.2 8-1.2.2 9-1.1.2.r 10-1.1.2.1.1.1.1 11-1.1.2.1.1.1.2 13-1.1.2.1.2.1.1 14-1.1.2 15-1.1.2.2.1.1.1 16-1.1.2.2.1.1.2 18-1.1.2.2.2.1.1 19-1.1.2.1 19-1.1.2.2
# ::id bel_pmid_1276_9686_37918
(a / and~e.5
      :op1 (b / bind-01~e.3
            :ARG1 (p / protein~e.2
                  :ARG1-of (e / encode-01~e.1))
            :ARG2~e.9 (o / or~e.14
                  :op1 (m / macro-molecular-complex~e.19
                        :part (p2 / protein
                              :name (n / name :op1 "cyclin"~e.10 :op2 "E"~e.11))
                        :part (e2 / enzyme
                              :name (n2 / name :op1 "CDK2"~e.13)))
                  :op2 (m2 / macro-molecular-complex~e.19
                        :part (p3 / protein
                              :name (n3 / name :op1 "cyclin"~e.15 :op2 "D"~e.16))
                        :part (e3 / enzyme
                              :name (n4 / name :op1 "CDK4"~e.18)))))
      :op2 (p4 / prevent-01~e.6
            :ARG0 p
            :ARG1 (a2 / activate-01~e.8
                  :ARG1 o)))

# ::tok In many cells PKA inhibits the extracellular receptor kinase ( ERK1 @/@ 2 ) cascade of the mitogen @-@ activated protein kinase ( MAPK ) pathway leading to inhibition of cell proliferation .
# ::alignments 1-1.3.1 2-1.3 3-1.1.1.1 4-1 6-1.2.1.1.1 7-1.2.1.1.2 8-1.2.1.1.3 14-1.2 15-1.2.2.r 17-1.2.2.1.1 19-1.2.2.1.1 20-1.2.2.1.2 21-1.2.2.1.3 25-1.2.2 26-1.4 27-1.4.1.r 28-1.4.1 29-1.4.1.1.r 30-1.4.1.1.1 31-1.4.1.1
# ::id bel_pmid_1281_2976_37028
(i / inhibit-01~e.4
      :ARG0 (e / enzyme
            :name (n / name :op1 "PKA"~e.3))
      :ARG1 (c / cascade~e.14
            :mod (e2 / enzyme
                  :name (n2 / name
                        :op1 "extracellular"~e.6
                        :op2 "receptor"~e.7
                        :op3 "kinase"~e.8))
            :poss~e.15 (p / pathway~e.25
                  :name (n3 / name
                        :op1 "mitogen-activated"~e.17,19
                        :op2 "protein"~e.20
                        :op3 "kinase"~e.21)))
      :location (c2 / cell~e.2
            :quant (m / many~e.1))
      :ARG0-of (l / lead-03~e.26
            :ARG2~e.27 (i2 / inhibit-01~e.28
                  :ARG1~e.29 (p2 / proliferate-01~e.31
                        :ARG0 (c3 / cell~e.30)))))

# ::tok Here we demonstrate that Ser311 accounts for zetaPKC phosphorylation of RelA and that this site is phosphorylated in vivo in response to TNF @-@ alpha .
# ::alignments 0-1.3 1-1.1 2-1 5-1.2.1 6-1.2.1.2.r 7-1.2.1.2.2.1.1 8-1.2.1.2 9-1.2.1.2.1.r 10-1.2.1.2.1.1.1 11-1.2 12-1.2.r 13-1.2.2.1.1 14-1.2.2.1 16-1.2.2 17-1.2.2.2 18-1.2.2.2 19-1.2.2.2 19-1.2.2.3.r 20-1.2.2.3 21-1.2.2.3.1.r 22-1.2.2.3.1.1.1 24-1.2.2.3.1.1.1
# ::id bel_pmid_1288_1425_6346
(d / demonstrate-01~e.2
      :ARG0 (w / we~e.1)
      :ARG1~e.12 (a / and~e.11
            :op1 (a2 / account-01~e.5
                  :ARG0 (a3 / amino-acid
                        :mod "311"
                        :name (n / name :op1 "serine"))
                  :ARG1~e.6 (p / phosphorylate-01~e.8
                        :ARG1~e.9 (p2 / protein
                              :name (n2 / name :op1 "RelA"~e.10))
                        :ARG2 (e / enzyme
                              :name (n3 / name :op1 "zetaPKC"~e.7))))
            :op2 (p3 / phosphorylate-01~e.16
                  :ARG1 (p4 / protein-segment~e.14
                        :mod (t / this~e.13))
                  :manner (i / in-vivo~e.17,18,19)
                  :ARG2-of~e.19 (r / respond-01~e.20
                        :ARG1~e.21 (p5 / protein
                              :name (n4 / name :op1 "TNF-alpha"~e.22,24)))))
      :location (h / here~e.0))

# ::tok Also , an inactivating mutation of that residue severely impairs RelA transcriptional activity , blocks its anti @-@ apoptotic function and abrogates the interaction of RelA with the co @-@ activator CBP as well as its recruitment , and that of RNA polymerase II ( Pol II ) with the interleukin @-@ 6 ( IL @-@ 6 ) promoter .
# ::alignments 3-1.1.1.1.2.1 4-1.1.1.1 5-1.1.1.1.1.r 6-1.1.1.1.1.1 7-1.1.1.1.1 8-1.1.4 8-1.1.4.r 9-1.1.1 10-1.1.1.2.1.1.1 14-1.1.2 16-1.1.2.2.2 18-1.1.2.2.2.1 19-1.1.2.2 20-1.1 21-1.1.3 23-1.1.3.2.1 23-1.1.3.2.2 24-1.1.3.2.1.1.r 25-1.1.3.2.1.1 26-1.1.3.2.1.2.r 28-1.1.3.2.1.2.1 28-1.1.3.2.1.2.1.2 28-1.1.3.2.1.2.1.2.r 30-1.1.1.1.2 31-1.1.3.2.1.2.1.1.1 35-1.1.3.2.1.2.2.1 35-1.1.3.2.1.2.2.1.r 36-1.1.3.2.1.2.2 38-1.1 38-1.1.3.2.1.2 39-1.1.1.1.1.1 40-1.1.3.2.2.1.r 41-1.1.3.2.2.1.1.1 42-1.1.3.2.2.1.1.2 43-1.1.3.2.2.1.1.3 48-1.1.3.2.2.2.r 50-1.1.3.2.2.2.1.1.1.1 52-1.1.3.2.2.2.1.1.1.1 56-1.1.3.2.2.2.1.1.1.1
# ::id bel_pmid_1288_1425_9992
(a / and
      :op2 (a2 / and~e.20,38
            :op1 (i / impair-01~e.9
                  :ARG0 (m / mutate-01~e.4
                        :ARG1~e.5 (r / residue~e.7
                              :mod (t / that~e.6,39))
                        :ARG1-of (a3 / activate-01~e.30 :polarity "-"~e.3))
                  :ARG1 (a4 / act-01
                        :ARG0 (p / protein
                              :name (n / name :op1 "RelA"~e.10))
                        :ARG1 (t2 / transcribe-01)))
            :op2 (b / block-01~e.14
                  :ARG0 m
                  :ARG1 (f / function-01~e.19
                        :ARG0 r
                        :ARG1 (o / oppose-01~e.16
                              :ARG1 (a5 / apoptosis~e.18))))
            :op3 (a6 / abrogate-01~e.21
                  :ARG0 m
                  :ARG1 (a7 / and
                        :op1 (i2 / interact-01~e.23
                              :ARG0~e.24 p~e.25
                              :ARG1~e.26 (a8 / and~e.38
                                    :op1 (p2 / protein~e.28
                                          :name (n2 / name :op1 "CBP"~e.31)
                                          :ARG0-of~e.28 (c / co-activate-00~e.28))
                                    :op2 (r2 / recruit-01~e.36
                                          :ARG0~e.35 p2~e.35)))
                        :op2 (i3 / interact-01~e.23
                              :ARG0~e.40 (e / enzyme
                                    :name (n3 / name
                                          :op1 "RNA"~e.41
                                          :op2 "polymerase"~e.42
                                          :op3 "II"~e.43))
                              :ARG1~e.48 (m2 / molecular-physical-entity
                                    :ARG0-of (p3 / promote-01
                                          :ARG1 (p4 / protein
                                                :name (n4 / name :op1 "interleukin-6"~e.50,52,56)))))))
            :manner~e.8 (s / severe~e.8)))

# ::tok Y542F @-@ expressing cells exhibited an ?50 % decrease in Tyr @-@ 580 phosphorylation ( Fig . 3C , right panel ) .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1 3-1.1 4-1 7-1.2.2.1 8-1.2 12-1.2.1.1.1 13-1.2.1 17-1.3.1.1.1 19-1.3.1.1.2.1 20-1.3.1.1.2
# ::id bel_pmid_1292_3167_29880
(e / exhibit-01~e.4
      :ARG0 (c / cell~e.3
            :ARG3-of (e2 / express-03~e.2
                  :ARG2 (a / amino-acid
                        :ARG2-of (m / mutate-01 :value "Y542F"~e.0))))
      :ARG1 (d / decrease-01~e.8
            :ARG1 (p / phosphorylate-01~e.13
                  :ARG1 (a2 / amino-acid
                        :mod "580"~e.12
                        :name (n / name :op1 "tyrosine")))
            :quant (a3 / approximately
                  :op1 (p2 / percentage-entity~e.7 :value "50")))
      :ARG1-of (d2 / describe-01
            :ARG0 (a4 / and
                  :op1 (f / figure
                        :mod "3C"~e.17
                        :part (p3 / panel~e.20
                              :ARG1-of (r / right-04~e.19))))))

# ::tok Immunoblot analyses confirm that Tyr @-@ 542 and Tyr @-@ 580 are the major sites of Shp2 tyrosyl phosphorylation and that Tyr @-@ 542 is the major Grb2 binding site .
# ::alignments 0-1.1.1 1-1.1 2-1 6-1.2.1.1.1.1 10-1.2.1.1.2.1 11-1.2.1.1.r 13-1.2.1.2 14-1.2.1 15-1.2.1.3.r 16-1.2.1.3.1.2.1.1 18-1.2.1.3 19-1.2.1.1 23-1.2.1.1.1.1 24-1.2.1.1.r 26-1.2.1.2 27-1.2.2.4.1.1 28-1.2.2.3 29-1.2.2
# ::id bel_pmid_1292_3167_9944
(c / confirm-01~e.2
      :ARG0 (a / analyze-01~e.1
            :manner (i / immunoblot-00~e.0))
      :ARG1 (a2 / and
            :op1 (p / protein-segment~e.14
                  :domain~e.11,24 (a3 / and~e.19
                        :op1 (a4 / amino-acid
                              :mod "542"~e.6,23
                              :name (n / name :op1 "tyrosine"))
                        :op2 (a5 / amino-acid
                              :mod "580"~e.10
                              :name (n2 / name :op1 "tyrosine")))
                  :mod (m / major~e.13,26)
                  :location-of~e.15 (p2 / phosphorylate-01~e.18
                        :ARG1 (a6 / amino-acid
                              :name (n3 / name :op1 "tyrosine")
                              :part-of (e / enzyme
                                    :name (n4 / name :op1 "Shp2"~e.16)))))
            :op2 (p3 / protein-segment~e.29
                  :domain a4
                  :mod m
                  :ARG1-of (b / bind-01~e.28)
                  :part-of (p4 / protein
                        :name (n5 / name :op1 "Grb2"~e.27)))))

# ::tok from full text - Three E @-@ box elements were found within 1.2 kb of the mouse wee1 gene 5 @-@ upstream region ( Fig . 3B ) . CLOCK and BMAL1 together , but neither of them alone , produced a major increase in transcriptional activity through this fragment in transfected NIH3T3 cells
# ::alignments 0-1.3.r 1-1.3.1 2-1.3 4-1.1.1.1 5-1.1.1.2.1.1 7-1.1.1.2.1.1 8-1.1.1 10-1.1 12-1.1.2.2.3.1 16-1.1.2.2.2 17-1.1.2.2.1.1 18-1.1.2.2 18-1.2.1.1.1 18-1.2.1.1.2 19-1.1.2.1.1 21-1.1.2.1 22-1.1.2 26-1.1.3.1.1 29-1.2.1.1.1.1.1 30-1.2.1.1 31-1.2.1.1.2.1.1 32-1.2.1.1.3 34-1.2.1 36-1.2.1.2.r 37-1.2.1.2.1 38-1.2.1.2 40-1.2 42-1.2.2.4 43-1.2.2 48-1.2.2.2.1 49-1.2.2.2 50-1.2.2.3.r 51-1.2.2.3.2 52-1.2.2.3.1.1 53-1.2.2.3
# ::id bel_pmid_1293_4012_20242
(m / multi-sentence
      :snt1 (f / find-01~e.10
            :ARG1 (e / element~e.8
                  :quant "3"~e.4
                  :mod (d / dna-sequence
                        :name (n / name :op1 "E-box"~e.5,7)))
            :location (r / region~e.22
                  :direction (u / upstream~e.21 :mod "5"~e.19)
                  :location (g / gene~e.18
                        :name (n2 / name :op1 "wee1"~e.17)
                        :part-of (m2 / mouse~e.16)
                        :quant (d2 / distance-quantity
                              :quant "1.2"~e.12
                              :unit (k / kilo-base-pair))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (f2 / figure :mod "3B"~e.26)))
      :snt2 (p / produce-01~e.40
            :ARG0 (c / contrast-01~e.34
                  :ARG1 (a / and~e.30
                        :op1 (g2 / gene~e.18
                              :name (n3 / name :op1 "CLOCK"~e.29))
                        :op2 (g3 / gene~e.18
                              :name (n4 / name :op1 "BMAL1"~e.31))
                        :mod (t / together~e.32))
                  :ARG2~e.36 (a2 / alone~e.38
                        :mod a~e.37))
            :ARG1 (i / increase-01~e.43
                  :ARG1 (a3 / act-01
                        :ARG0 a
                        :ARG1 (t2 / transcribe-01))
                  :medium (f3 / fragment~e.49
                        :mod (t3 / this~e.48))
                  :location~e.50 (c2 / cell~e.53
                        :name (n5 / name :op1 "NIH3T3"~e.52)
                        :ARG1-of (t4 / transfect-00~e.51))
                  :mod (m3 / major~e.42)))
      :source~e.0 (t5 / text~e.2
            :mod (f4 / full~e.1)))

# ::tok from full text - The wee1 gene product phosphorylates Cdc2 on Tyr @-@ 15 [p @-@ Cdc2( Tyr 15 )] and keeps it in an inactive form
# ::alignments 0-1.3.r 1-1.3.1 2-1.3 5-1.1.2.1.1.1 6-1.1.2.1 7-1.1.2 8-1.1 8-1.2.2.4 9-1.1.1.3.1.1 13-1.1.1.1 18-1.1.1.1 18-1.2.2.1 20-1 21-1.2 23-1.2.2.r 25-1.2.2.5.1.1 26-1.2.2.5
# ::id bel_pmid_1293_4012_22244
(a / and~e.20
      :op1 (p / phosphorylate-01~e.8
            :ARG1 (a2 / amino-acid
                  :mod "15"~e.13,18
                  :name (n / name :op1 "tyrosine")
                  :part-of (e / enzyme
                        :name (n2 / name :op1 "Cdc2"~e.9)))
            :ARG2 (p2 / product~e.7
                  :poss (g / gene~e.6
                        :name (n3 / name :op1 "wee1"~e.5))))
      :op2 (k / keep-10~e.21
            :ARG0 p2
            :ARG1~e.23 (a4 / amino-acid
                  :mod "15"~e.18
                  :name (n5 / name :op1 "tyrosine")
                  :part-of e
                  :ARG3-of (p3 / phosphorylate-01~e.8)
                  :mod (f / form~e.26
                        :ARG1-of (a3 / activate-01 :polarity "-"~e.25))))
      :source~e.0 (t / text~e.2
            :mod (f2 / full~e.1)))

# ::tok from full text - Furthermore , Cdc2 kinase activity was reduced ( Figs . 2B and 1C ) . Therefore , the cell cycle progression from S to M phase was impaired during liver regeneration in Cry @-@ deficient mice
# ::alignments 0-1.3.r 1-1.3.1 2-1.3 6-1.1.1.1.1.1.1 7-1.1.1.1.1 10-1.1.1 14-1.1.2.1.1.1 15-1.1.2.1 16-1.1.2.1.2.1 19-1.2 22-1.2.1.1.1.1 23-1.2.1.1.1 24-1.2.1.1 25-1.2.1.1.2.r 25-1.3.r 26-1.2.1.1.2.1.1 27-1.2.1.1.3.r 28-1.2.1.1.3.1.1 29-1.2.1.1.3.1.2 31-1.2.1 32-1.2.1.2.r 33-1.2.1.2.1 34-1.2.1.2 35-1.2.1.2.2.r 36-1.2.1.2.2.1.1.1 39-1.2.1.2.2
# ::id bel_pmid_1293_4012_26132
(m / multi-sentence
      :snt1 (a / and
            :op2 (r / reduce-01~e.10
                  :ARG1 (a2 / act-01
                        :ARG1 (k / kinase~e.7
                              :name (n / name :op1 "Cdc2"~e.6))))
            :ARG1-of (d / describe-01
                  :ARG0 (a3 / and~e.15
                        :op1 (f / figure :mod "2B"~e.14)
                        :op2 (f2 / figure :mod "1C"~e.16))))
      :snt2 (c / cause-01~e.19
            :ARG1 (i / impair-01~e.31
                  :ARG1 (p / progress-01~e.24
                        :ARG1 (c2 / cycle~e.23
                              :mod (c3 / cell~e.22))
                        :ARG3~e.25 (t / thing
                              :name (n2 / name :op1 "S"~e.26 :op2 "phase"))
                        :ARG4~e.27 (t2 / thing
                              :name (n3 / name :op1 "M"~e.28 :op2 "phase"~e.29)))
                  :time~e.32 (r2 / regenerate-01~e.34
                        :ARG1 (l / liver~e.33)
                        :location~e.35 (m2 / mouse~e.39
                              :mod (p2 / protein
                                    :name (n4 / name :op1 "Cry"~e.36)
                                    :ARG2-of (m3 / mutate-01 :mod "-/-"))))))
      :source~e.0,25 (t3 / text~e.2
            :mod (f3 / full~e.1)))

# ::tok from full text - The expression profiles of cyclin D1 and wee1 transcripts were markedly different between Cry @-@ deficient and wildtype mice throughout the liver regeneration process : cyclin D1 expression decreased up to 86 % and wee1 expression increased up to 4.6 @-@ fold
# ::alignments 0-1.8.r 1-1.8.1 2-1.8 5-1.3 6-1.1 6-1.2 7-1.1.1.r 8-1.1.1.1.1 9-1.1.1.1.2 10-1.5 11-1.2.1.1.1 14-1.4 15-1 16-1.5 17-1.5.1.1.1.1 20-1.5 22-1.5.1 22-1.5.2 25-1.6.1.1 26-1.6.1 27-1.6 29-1.7.1.1.1.1 30-1.7.1.1.1.1 31-1.7.1.1.1 32-1.7.1.1 33-1.7.1.1.2 34-1.7.1.1.2 35-1.7.1.1.2.1.1 36-1.7.1.1.2.1 37-1.3.1 37-1.7.1 38-1.2.1.1.1 39-1.3 39-1.7.1.2.1 40-1.7.1.2 41-1.7.1.2 41-1.7.1.2.2 41-1.7.1.2.2.r 42-1.7.1.2.2 43-1.7.1.2.2.1.1
# ::id bel_pmid_1293_4012_26134
(d / differ-02~e.15
      :ARG1 (p / profile-01~e.6
            :ARG1~e.7 (p2 / protein
                  :name (n / name :op1 "cyclin"~e.8 :op2 "D1"~e.9)
                  :ARG1-of (t / transcribe-01)))
      :ARG2 (p3 / profile-01~e.6
            :ARG1 (p4 / protein
                  :name (n2 / name :op1 "wee1"~e.11,38)
                  :ARG1-of t))
      :degree (e / express-03~e.5,39
            :ARG2 (a / and~e.37
                  :op1 p2
                  :op2 p4))
      :degree (m / marked~e.14)
      :location (b / between~e.10,16,20
            :op1 (m2 / mouse~e.22
                  :mod (p5 / protein
                        :name (n3 / name :op1 "Cry"~e.17)
                        :ARG2-of (m3 / mutate-01 :mod "-/-")))
            :op2 (m4 / mouse~e.22
                  :mod (w / wild-type)))
      :time (p6 / process~e.27
            :mod (r / regenerate-01~e.26
                  :ARG1 (l / liver~e.25)))
      :ARG1-of (m5 / mean-01
            :ARG2 (a2 / and~e.37
                  :op1 (d2 / decrease-01~e.32
                        :ARG1 (e2 / express-03~e.31
                              :ARG1 p2~e.29,30)
                        :ARG2 (u / up-to~e.33,34
                              :op1 (p7 / percentage-entity~e.36 :value "86"~e.35)))
                  :op2 (i / increase-01~e.40,41
                        :ARG1 (e3 / express-03~e.39
                              :ARG1 p4)
                        :ARG2~e.41 (u2 / up-to~e.41,42
                              :op1 (p8 / product-of :op1 "4.6"~e.43)))))
      :source~e.0 (t2 / text~e.2
            :mod (f / full~e.1)))

# ::tok Therefore , the cell cycle progression from S to M phase was impaired during liver regeneration in Cry @-@ deficient mice
# ::alignments 0-1 3-1.1.1.1.1 4-1.1.1.1 5-1.1.1 6-1.1.1.2.r 7-1.1.1.2.1.1 8-1.1.1.3.r 9-1.1.1.3.1.1 10-1.1.1.3.1.2 12-1.1 13-1.1.2.r 14-1.1.2.1 15-1.1.2 16-1.1.2.2.r 17-1.1.2.2.1.1.1 20-1.1.2.2
# ::id bel_pmid_1293_4012_314
(c / cause-01~e.0
      :ARG1 (i / impair-01~e.12
            :ARG1 (p / progress-01~e.5
                  :ARG1 (c2 / cycle~e.4
                        :mod (c3 / cell~e.3))
                  :ARG3~e.6 (t / thing
                        :name (n / name :op1 "S"~e.7 :op2 "phase"))
                  :ARG4~e.8 (t2 / thing
                        :name (n2 / name :op1 "M"~e.9 :op2 "phase"~e.10)))
            :time~e.13 (r / regenerate-01~e.15
                  :ARG1 (l / liver~e.14)
                  :location~e.16 (m / mouse~e.20
                        :mod (p2 / protein
                              :name (n3 / name :op1 "Cry"~e.17)
                              :ARG2-of (m2 / mutate-01 :mod "-/-"))))))

# ::tok from full text - However , in Clock mutant ( Clock/Clock ) mice ( 26 ) , which carry dominantnegative Clock mutations ( 27 ) , wee1 expression was low at both ZTs
# ::alignments 0-1.2.r 1-1.2.1 2-1.2 4-1 7-1.1.3.1.1.1 7-1.1.3.3.1.1.1 8-1.1.3.1 8-1.1.3.1.2 8-1.1.3.1.2.r 8-1.1.3.3.1 8-1.1.3.3.1.2 8-1.1.3.3.1.2.r 12-1.1.3 14-1.1.3.2.1.1.1 18-1.1.3.3 20-1.1.3.3.1.1.1 21-1.1.3.3.1 21-1.1.3.3.1.2 21-1.1.3.3.1.2.r 23-1.1.3.3.2.1.1.1 26-1.1.1.1.1.1 27-1.1.1 28-1.1.1.r 29-1.1 31-1.1.2.1
# ::id bel_pmid_1293_4012_32782
(h / have-concession-91~e.4
      :ARG1 (l / low~e.29
            :domain~e.28 (e / express-03~e.27
                  :ARG2 (p / protein
                        :name (n / name :op1 "wee1"~e.26)))
            :time (z / zeitgeber-time
                  :mod (b / both~e.31))
            :location (m / mouse~e.12
                  :mod (g / gene~e.8
                        :name (n2 / name :op1 "Clock"~e.7)
                        :ARG2-of~e.8 (m2 / mutate-01~e.8
                              :mod (w / wild-type)))
                  :ARG1-of (d / describe-01
                        :ARG0 (p2 / publication
                              :ARG1-of (c / cite-01 :ARG2 "26"~e.14)))
                  :ARG0-of (c2 / carry-01~e.18
                        :ARG1 (g2 / gene~e.8,21
                              :name (n3 / name :op1 "Clock"~e.7,20)
                              :ARG2-of~e.8,21 (m3 / mutate-01~e.8,21 :mod "-/-"))
                        :ARG1-of (d2 / describe-01
                              :ARG0 (p3 / publication
                                    :ARG1-of (c3 / cite-01 :ARG2 "27"~e.23))))))
      :source~e.0 (t / text~e.2
            :mod (f / full~e.1)))

# ::tok Studies crossing PPAR-–deficient mice with apolipoprotein E atherosclerosis @-@ prone mice and placing them on high @-@ fat diets found less atherosclerosis , despite the PPAR @- null mice having higher atherogenic lipids.101
# ::alignments 0-1.1 1-1.1.1 3-1.1.1.1.2 4-1.1.2.2.1.r 5-1.1.1.1.2.2.1.1 6-1.1.1.1.2.2.1.2 7-1.1.1.1.2.1.1.1.1 9-1.1.1.1.2.1 10-1.1.1.1.2 11-1.1.1.1 12-1.1.2 15-1.1.2.2.1.1 17-1.1.2.2.1 18-1.1.2.2 19-1 20-1.2.2 21-1.2.1.1 23-1.3 25-1.1.1.1.1.1.1.1 28-1.1.1.1.1 29-1.3 29-1.3.1 29-1.3.1.r 30-1.3.1.2.2 30-1.3.1.2.2.1 30-1.3.1.2.2.1.r 31-1.3.1.2.1
# ::id bel_pmid_1295_7325_25184
(f / find-01~e.19
      :ARG0 (s / study-01~e.0
            :ARG0-of (c / cross-01~e.1
                  :ARG1 (a / and~e.11
                        :op1 (m / mouse~e.28
                              :mod (p / protein
                                    :name (n / name :op1 "PPAR"~e.25)
                                    :ARG2-of (m2 / mutate-01 :mod "-/-")))
                        :op2 (m3 / mouse~e.3,10
                              :ARG1-of (p2 / prone-01~e.9
                                    :ARG2 (d / disease
                                          :name (n2 / name :op1 "atherosclerosis"~e.7)))
                              :mod (p3 / protein
                                    :name (n3 / name :op1 "apolipoprotein"~e.5 :op2 "E"~e.6)))))
            :ARG0-of (p4 / place-01~e.12
                  :ARG1 a
                  :ARG2 (d2 / diet~e.18
                        :instrument~e.4 (f2 / fat~e.17
                              :quant (h / high~e.15)))))
      :ARG1 (d3 / disease
            :name (n4 / name :op1 "atherosclerosis"~e.21)
            :quant (l / less~e.20))
      :ARG1-of (h2 / have-concession-91~e.23,29
            :ARG2~e.29 (h3 / have-03~e.29
                  :ARG0 m
                  :ARG1 (l2 / lipid
                        :mod (a2 / atherogenic~e.31)
                        :quant (h4 / high~e.30
                              :degree~e.30 (m4 / more~e.30)))))
      :ARG1-of (d4 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "101"))))

# ::tok These investigators went on to demonstrate that interleukin @-@ 6 production is increased in aortic explants of PPAR-–deficient mice.95
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1 5-1.2 6-1.2.2.r 7-1.2.2.1.1.1.1 9-1.2.2.1.1.1.1 10-1.2.2.1 12-1.2.2
# ::id bel_pmid_1295_7325_30032
(g / go-15~e.2,3
      :ARG1 (p / person~e.1
            :ARG0-of~e.1 (i / investigate-01~e.1)
            :mod (t / this~e.0))
      :purpose (d / demonstrate-01~e.5
            :ARG0 p
            :ARG1~e.6 (i2 / increase-01~e.12
                  :ARG1 (p2 / produce-01~e.10
                        :ARG1 (p3 / protein
                              :name (n / name :op1 "interleukin-6"~e.7,9)))
                  :location (e / explant
                        :part-of (a / aorta
                              :part-of (m / mouse
                                    :mod (p4 / protein
                                          :name (n2 / name :op1 "PPAR")
                                          :ARG2-of (m2 / mutate-01 :mod "-/-")))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c / cite-01 :ARG2 "95"))))

# ::tok As demonstrated in Fig. 3A , blockade of the OX40 @/@ OX40L interaction significantly reduced the Th1 @-@ specific transcription factor T @-@ bet to 30.8 % compared with controls ( p=0.007 ) . On the other hand , expression of IL @-@ 10 , a cytokine that was shown to be protective in chronic DSS @-@ induced colitis [29], increased 3.6 @-@ fold ( p=0.008 ) .
# ::alignments 1-1.1.6 4-1.1.6.1.1 6-1.1.1 7-1.1.1.1.r 9-1.1.1.1.1.1.1 11-1.1.1.1.2.1.1 12-1.1.1.1 13-1.1.4 13-1.1.4.r 14-1.1 16-1.1.2.3.1.1.1 18-1.1.2.3 19-1.1.2.2 20-1.1.2 21-1.1.2.1.1 23-1.1.2.1.1 24-1.1.3.r 25-1.1.3.1 26-1.1.3 27-1.1.5 28-1.1.5.1.r 29-1.1.5.1 39-1.2.1.1 40-1.2.1.1.1.r 41-1.2.1.1.1.1.1 43-1.2.1.1.1.1.1 46-1.2.1.1.1.2.1 49-1.2.1.1.1.2.1.1.1 52-1.2.1.1.1.2.1.1 53-1.2.1.1.1.2.1.1.2.r 54-1.2.1.1.1.2.1.1.2.2 55-1.2.1.1.1.2.1.1.2.3.1.1.1 57-1.2.1.1.1.2.1.1.2.3 58-1.2.1.1.1.2.1.1.2.1.1 60-1.2.1 61-1.2.1.2.1
# ::id bel_pmid_1463_5034_19774
(m / multi-sentence
      :snt1 (r / reduce-01~e.14
            :ARG0 (b / blockade-01~e.6
                  :ARG1~e.7 (i / interact-01~e.12
                        :ARG0 (m2 / molecular-physical-entity
                              :name (n / name :op1 "OX40"~e.9))
                        :ARG1 (m3 / molecular-physical-entity
                              :name (n2 / name :op1 "OX40L"~e.11))))
            :ARG1 (f / factor~e.20
                  :name (n3 / name :op1 "T-bet"~e.21,23)
                  :ARG0-of (t / transcribe-01~e.19)
                  :mod (s / specific~e.18
                        :topic (c / cell
                              :name (n4 / name :op1 "Th1"~e.16))))
            :ARG4~e.24 (p / percentage-entity~e.26 :value "30.8"~e.25)
            :manner~e.13 (s2 / significant~e.13)
            :ARG1-of (c2 / compare-01~e.27
                  :ARG2~e.28 (c3 / control-01~e.29))
            :ARG1-of (d / demonstrate-01~e.1
                  :ARG0 (f2 / figure :mod "3A"~e.4))
            :value (p2 / probability :quant "0.007"))
      :snt2 (c4 / contrast-01
            :ARG2 (i2 / increase-01~e.60
                  :ARG1 (e / express-03~e.39
                        :ARG2~e.40 (p3 / protein
                              :name (n5 / name :op1 "IL-10"~e.41,43)
                              :ARG1-of (m4 / mean-01
                                    :ARG2 (c5 / cytokine~e.46
                                          :ARG0-of (p4 / protect-01~e.52
                                                :ARG1-of (s3 / show-01~e.49)
                                                :location~e.53 (d2 / disease
                                                      :name (n6 / name :op1 "colitis"~e.58)
                                                      :mod (c6 / chronic~e.54)
                                                      :ARG1-of (i3 / induce-01~e.57
                                                            :ARG0 (m5 / molecular-physical-entity
                                                                  :name (n7 / name :op1 "DSS"~e.55))))))
                                    :ARG1-of (d3 / describe-01
                                          :ARG0 (p5 / publication
                                                :ARG1-of (c7 / cite-01 :ARG2 "29"))))))
                  :ARG2 (p6 / product-of :op1 "3.6"~e.61)
                  :value (p7 / probability :quant "0.008"))))

# ::tok IL @- 10 secretion increased 20 @-@ fold ( p X 0.0001 ) . This was accompanied by a significant , 18 @-@ fold , increase of IL @-@ 5 secretion . IFNG levels were not altered , but IL @-@ 6 secretion was reduced to 60 % compared with controls .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.2.1.1 4-1.2.1 5-1.1.2.1 10-1.1.1.1.1.1 11-1.1.3.1.1 14-1.2.2 16-1.2 19-1.2.1.3 21-1.2.1.2.1 25-1.1 25-1.2.1 26-1.2.1.1.1.r 26-1.2.1.2 27-1.2.1.1.1.1.1 29-1.2.1.1.1.1.1 30-1.1.1 33-1.3.2.2 35-1.3.2.1 35-1.3.2.1.r 36-1.3.2 38-1.3 39-1.3.1.1.1.1.1 41-1.3.1.1.1.1.1 42-1.3.1.1 44-1.3.1 45-1.3.1.2.r 46-1.3.1.2.1 47-1.3.1.2 48-1.3.1.3 49-1.3.1.3.1.r 50-1.3.1.3.1
# ::id bel_pmid_1463_5034_19776
(m / multi-sentence
      :snt1 (i / increase-01~e.25
            :ARG1 (s / secrete-01~e.30
                  :ARG1 (p / protein
                        :name (n / name :op1 "IL-10"~e.0,2,10)))
            :ARG2 (p2 / product-of :op1 "20"~e.5)
            :value (p3 / probability
                  :degree (l / less-than :quant "0.0001"~e.11)))
      :snt2 (a / accompany-01~e.16
            :ARG0 (i2 / increase-01~e.4,25
                  :ARG1 (s2 / secrete-01~e.3
                        :ARG1~e.26 (p4 / protein
                              :name (n2 / name :op1 "IL-5"~e.27,29)))
                  :ARG2 (p5 / product-of~e.26 :op1 "18"~e.21)
                  :mod (s3 / significant~e.19))
            :ARG1 (t / this~e.14))
      :snt3 (c / contrast-01~e.38
            :ARG1 (r / reduce-01~e.44
                  :ARG1 (s4 / secrete-01~e.42
                        :ARG1 (p6 / protein
                              :name (n3 / name :op1 "IL-6"~e.39,41)))
                  :ARG4~e.45 (p7 / percentage-entity~e.47 :value "60"~e.46)
                  :ARG1-of (c2 / compare-01~e.48
                        :ARG2~e.49 (c3 / control-01~e.50)))
            :ARG2 (a2 / alter-01~e.36
                  :polarity~e.35 "-"~e.35
                  :ARG1 (l2 / level~e.33
                        :quant-of (p8 / protein
                              :name (n4 / name :op1 "IFN-γ"))))))

# ::tok In neutrophils challenged with LPS , IkB @-@ a underwent time @-@ dependent degradation ( Fig . 8C ) . However , in neutrophils incubated with both LPS and H2O2 , no degradation of IkB @-@ a was apparent .
# ::alignments 1-1.1.3.1.1 2-1.1.3.2 3-1.1.3.2.1.r 4-1.1.3.2.1.1.1 9-1.1 10-1.1.2.2.1 12-1.1.2.2 13-1.1.2 17-1.1.4.1.1 20-1.2 23-1.2.1.3.1.1 24-1.2.1.3.2 27-1.2.1.3.2.1.1.1.1 28-1.2.1.3.2.1 29-1.2.1.3.2.1.2.1.1 31-1.2.1.1 31-1.2.1.1.r 32-1.2.1.2 38-1.2.1
# ::id bel_pmid_1465_6721_15754
(m / multi-sentence
      :snt1 (u / undergo-01~e.9
            :ARG1 (p / protein
                  :name (n / name :op1 "IκB-α"))
            :ARG2 (d / degrade-01~e.13
                  :ARG1 p
                  :ARG0-of (d2 / depend-01~e.12
                        :ARG1 (t / time~e.10)))
            :location (c / cell
                  :name (n2 / name :op1 "neutrophil"~e.1)
                  :ARG1-of (c2 / challenge-01~e.2
                        :ARG0~e.3 (m2 / molecular-physical-entity
                              :name (n3 / name :op1 "LPS"~e.4))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (f / figure :mod "8C"~e.17)))
      :snt2 (h / have-concession-91~e.20
            :ARG1 (a / appear-02~e.38
                  :polarity~e.31 "-"~e.31
                  :ARG1 (d4 / degrade-01~e.32
                        :ARG1 (p2 / protein
                              :name (n4 / name :op1 "IκB-α")))
                  :location (c3 / cell
                        :name (n5 / name :op1 "neutrophil"~e.23)
                        :ARG1-of (i / incubate-01~e.24
                              :ARG2 (a2 / and~e.28
                                    :op1 (m3 / molecular-physical-entity
                                          :name (n6 / name :op1 "LPS"~e.27))
                                    :op2 (m4 / molecular-physical-entity
                                          :name (n7 / name :op1 "H2O2"~e.29))))))))

# ::tok neutrophils stimulated with LPS demonstrated increased TNF @-@ a secretion ( Fig . 6A ) . The response was significantly attenuated by concurrent incubation of neutrophils with H2O2 .
# ::alignments 0-1.1.1.1.1 1-1.1.1.2 2-1.1.1.2.1.r 3-1.1.1.2.1.1.1 4-1.1 5-1.1.2.2 6-1.1.2.1.1.1 9-1.1.2 13-1.1.3.1.1 17-1.2.2 17-1.2.2.1 17-1.2.2.1.r 19-1.2.3 20-1.2 23-1.2.1 24-1.2.1.1.r 25-1.2.1.1.1.1 26-1.2.1.2.r 27-1.2.1.2.1.1
# ::id bel_pmid_1465_6721_15758
(m / multi-sentence
      :snt1 (d / demonstrate-01~e.4
            :ARG0 (c / cell
                  :name (n / name :op1 "neutrophil"~e.0)
                  :ARG1-of (s / stimulate-01~e.1
                        :ARG2~e.2 (m2 / molecular-physical-entity
                              :name (n2 / name :op1 "LPS"~e.3))))
            :ARG1 (s2 / secrete-01~e.9
                  :ARG1 (p / protein
                        :name (n3 / name :op1 "TNF-α"~e.6))
                  :ARG1-of (i / increase-01~e.5))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "6A"~e.13)))
      :snt2 (a / attenuate-01~e.20
            :ARG0 (i2 / incubate-01~e.23
                  :ARG1~e.24 (c2 / cell
                        :name (n4 / name :op1 "neutrophil"~e.25))
                  :ARG2~e.26 (m3 / molecular-physical-entity
                        :name (n5 / name :op1 "H2O2"~e.27)
                        :ARG1-of (c3 / concur-01)))
            :ARG1 (t / thing~e.17
                  :ARG2-of~e.17 (r / respond-01~e.17))
            :degree (s3 / significant~e.19)))

# ::tok As was the case for p38 , ERK1 @/@ 2 was both rapidly and persistently activated in neutrophils exposed to H2O2 ( Fig . 2A ) .
# ::alignments 5-1.4.1.1.1 7-1.1.1.1 9-1.1.1.1 12-1.3.1 13-1.3 14-1.3.2 15-1 16-1.2.r 17-1.2.1.1 18-1.2.2 19-1.2.2.1.r 20-1.2.2.1.1.1 24-1.5.1.1
# ::id bel_pmid_1465_6721_15794
(a / activate-01~e.15
      :ARG1 (e / enzyme
            :name (n / name :op1 "ERK1/2"~e.7,9))
      :location~e.16 (c / cell
            :name (n2 / name :op1 "neutrophil"~e.17)
            :ARG1-of (e2 / expose-01~e.18
                  :ARG2~e.19 (m / molecular-physical-entity
                        :name (n3 / name :op1 "H2O2"~e.20))))
      :manner (a2 / and~e.13
            :op1 (r / rapid~e.12)
            :op2 (p / persistent~e.14))
      :ARG1-of (r2 / resemble-01
            :ARG2 (e3 / enzyme
                  :name (n4 / name :op1 "p38"~e.5)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2A"~e.24)))

# ::tok Similar to the patterns seen with ERK1 @/@ 2 and p38 , JNK activation in neutrophils exposed to H2O2 was both rapid and persistent ( Fig . 2B ) .
# ::alignments 0-1.4 1-1.4.1.r 3-1.4.1 4-1.4.1.1 5-1.4.1.2.r 6-1.4.1.2.1.1.1 8-1.4.1.2.1.1.1 9-1.4.1.2 10-1.4.1.2.2.1.1 12-1.3.1.1.1 13-1.3 14-1.3.2.r 15-1.3.2.1.1 16-1.3.2.2 17-1.3.2.2.1.r 18-1.3.2.2.1.1.1 19-1.3.r 21-1.1 22-1 23-1.2 27-1.5.1.1
# ::id bel_pmid_1465_6721_15796
(a / and~e.22
      :op1 (r / rapid~e.21)
      :op2 (p / persistent~e.23)
      :domain~e.19 (a2 / activate-01~e.13
            :ARG1 (e / enzyme
                  :name (n / name :op1 "JNK"~e.12))
            :location~e.14 (c / cell
                  :name (n2 / name :op1 "neutrophil"~e.15)
                  :ARG1-of (e2 / expose-01~e.16
                        :ARG2~e.17 (m / molecular-physical-entity
                              :name (n3 / name :op1 "H2O2"~e.18)))))
      :ARG1-of (r2 / resemble-01~e.0
            :ARG2~e.1 (p2 / pattern~e.3
                  :ARG1-of (s / see-01~e.4)
                  :poss~e.5 (a3 / and~e.9
                        :op1 (e3 / enzyme
                              :name (n4 / name :op1 "ERK1/2"~e.6,8))
                        :op2 (e4 / enzyme
                              :name (n5 / name :op1 "p38"~e.10)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2B"~e.27)))

# ::tok whereas exposure of neutrophils to LPS or TNF @-@ a resulted in increased levels of the transcriptionally active serine 133 @-@ phosphorylated form of CREB
# ::alignments 0-1 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1 4-1.1.1.2.r 5-1.1.1.2.1.1.1 6-1.1.1.2 7-1.1.1.2.2.1.1 10-1.1 11-1.1.2.r 12-1.1.2.1 13-1.1.2 18-1.1.2.2.2.2.1 19-1.1.2.2.2.1 21-1.1.2.2.3 24-1.1.2.2.1.1
# ::id bel_pmid_1465_6721_15930
(c / contrast-01~e.0
      :ARG2 (r / result-01~e.10
            :ARG1 (e / expose-01~e.1
                  :ARG1~e.2 (c2 / cell
                        :name (n / name :op1 "neutrophil"~e.3))
                  :ARG2~e.4 (o / or~e.6
                        :op1 (m / molecular-physical-entity
                              :name (n2 / name :op1 "LPS"~e.5))
                        :op2 (p / protein
                              :name (n3 / name :op1 "TNF-α"~e.7))))
            :ARG2~e.11 (l / level~e.13
                  :ARG1-of (i / increase-01~e.12)
                  :quant-of (p2 / protein
                        :name (n4 / name :op1 "CREB"~e.24)
                        :part (a / amino-acid
                              :mod "133"~e.19
                              :name (n5 / name :op1 "serine"~e.18))
                        :ARG1-of (p3 / phosphorylate-01~e.21)
                        :ARG1-of (a2 / activate-01
                              :manner (t / transcribe-01))))))

# ::tok Exposure of neutrophils to LPS resulted in persistence of p38 activation that was similar to that produced by H2O2 , but the increase in phosphorylated p38 was less rapid , rising above baseline values more than 5 min after LPS was added to the neutrophils .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1 3-1.1.1.2.r 4-1.1.1.2.1.1 5-1.1 6-1.1.2.r 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1.1.1.1 10-1.1.2.1 13-1.1.2.2 16-1.1.2.2.1 17-1.1.2.2.1.1.r 18-1.1.2.2.1.1.1.1 20-1 22-1.2.2 23-1.2.2.1.r 24-1.2.2.1.3 25-1.2.2.1.1.1 26-1.2.2.r 27-1.2.1 28-1.2 30-1.2.2.1.2 31-1.2.2.1.2.1 32-1.2.2.1.2.1.1.1 33-1.2.2.1.2.1.1 34-1.2.2.1.2.2.2.3 36-1.2.2.1.2.2.2.1 38-1.2.2.1.2.2 39-1.2.2.1.2.2.1.1 40-1.2.2.r 41-1.2.2.1.2.2.1 42-1.2.2.1.2.2.1.2.r 44-1.2.2.1.2.2.1.2
# ::id bel_pmid_1465_6721_15966
(c / contrast-01~e.20
      :ARG1 (r / result-01~e.5
            :ARG1 (e / expose-01~e.0
                  :ARG1~e.1 (c2 / cell
                        :name (n / name :op1 "neutrophil"~e.2))
                  :ARG2~e.3 (m / molecular-physical-entity
                        :name (n2 / name :op1 "LPS"~e.4)))
            :ARG2~e.6 (p / persist-01~e.7
                  :ARG1~e.8 (a / activate-01~e.10
                        :ARG1 (e2 / enzyme
                              :name (n3 / name :op1 "p38"~e.9)))
                  :ARG1-of (r2 / resemble-01~e.13
                        :ARG2 (p2 / produce-01~e.16
                              :ARG0~e.17 (m2 / molecular-physical-entity
                                    :name (n4 / name :op1 "H2O2"~e.18))
                              :ARG1 p))))
      :ARG2 (r3 / rapid~e.28
            :degree (l / less~e.27)
            :domain~e.26,40 (i / increase-01~e.22
                  :ARG1~e.23 (e3 / enzyme
                        :name (n5 / name :op1 "p38"~e.25)
                        :ARG1-of (r4 / rise-01~e.30
                              :ARG4 (a2 / above~e.31
                                    :op1 (v / value~e.33
                                          :mod (b / baseline~e.32)))
                              :time (a3 / after~e.38
                                    :op1 (a4 / add-02~e.41
                                          :ARG1 m~e.39
                                          :ARG2~e.42 c2~e.44)
                                    :quant (t / temporal-quantity
                                          :quant "5"~e.36
                                          :unit (m3 / minute)
                                          :mod (m4 / more~e.34))))
                        :ARG3-of (p3 / phosphorylate-01~e.24)))))

# ::tok Phosphorylation of ERK1 @/@ 2 after exposure of neutrophils with LPS was only apparent after 20 @-@ min incubation and was less intense than that produced by stimulation of neutrophils with H2O2 .
# ::alignments 0-1.1.1 0-1.2.3 1-1.1.1.1.r 2-1.1.1.1.1.1 4-1.1.1.1.1.1 5-1.1.1.2 6-1.1.1.2.1 7-1.1.1.2.1.1.r 8-1.1.1.2.1.1.1.1 9-1.1.1.2.1.2.r 10-1.1.1.2.1.2.1.1 12-1.1.2 13-1.1 14-1.1.3 15-1.1.3.1.1.1 18-1.1.3.1 19-1 20-1.2.2.r 21-1.2.1 22-1.2 23-1.2.3.r 25-1.2.3.2 26-1.2.3.2.1.r 27-1.2.3.2.1 28-1.2.3.2.1.1.r 29-1.2.3.2.1.1 30-1.2.3.2.1.2.r 31-1.2.3.2.1.2.1.1
# ::id bel_pmid_1465_6721_15968
(a / and~e.19
      :op1 (a2 / appear-02~e.13
            :ARG1 (p / phosphorylate-01~e.0
                  :ARG1~e.1 (e / enzyme
                        :name (n / name :op1 "ERK1/2"~e.2,4))
                  :time (a3 / after~e.5
                        :op1 (e2 / expose-01~e.6
                              :ARG1~e.7 (c / cell
                                    :name (n2 / name :op1 "neutrophil"~e.8))
                              :ARG2~e.9 (m / molecular-physical-entity
                                    :name (n3 / name :op1 "LPS"~e.10)))))
            :mod (o / only~e.12)
            :time (a4 / after~e.14
                  :op1 (i / incubate-01~e.18
                        :duration (t / temporal-quantity
                              :quant "20"~e.15
                              :unit (m2 / minute)))))
      :op2 (i2 / intense~e.22
            :degree (l / less~e.21)
            :domain~e.20 p
            :compared-to~e.23 (p2 / phosphorylate-01~e.0
                  :ARG1 e
                  :ARG1-of (p3 / produce-01~e.25
                        :ARG0~e.26 (s / stimulate-01~e.27
                              :ARG1~e.28 c~e.29
                              :ARG2~e.30 (m3 / molecular-physical-entity
                                    :name (n4 / name :op1 "H2O2"~e.31)))))))

# ::tok JNK activation induced by LPS only became apparent 20 min after LPS was added to the cells and was of a lesser degree than that induced by H2O2 at all time points .
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 1-1.2.3 2-1.1.1.2 2-1.2.3.2 3-1.1.1.2.r 4-1.1.1.2.1.1.1 5-1.1.3 6-1.1 7-1.1.2 8-1.1.4.2.1 10-1.1.4 11-1.1.4.1.1 13-1.1.4.1 14-1.1.4.1.2.r 16-1.1.4.1.2 17-1 21-1.2 21-1.2.1 21-1.2.1.r 22-1.2.1.r 22-1.2.2.r 23-1.2.3.r 25-1.1.1.2 26-1.2.3.2.1.r 27-1.2.3.2.1.1.1 28-1.2.4.r 29-1.2.4 30-1.1.4.2 31-1.2.4
# ::id bel_pmid_1465_6721_15970
(a / and~e.17
      :op1 (b / become-01~e.6
            :ARG1 (a2 / activate-01~e.1
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "JNK"~e.0))
                  :ARG1-of~e.3 (i / induce-01~e.2,25
                        :ARG0 (m / molecular-physical-entity
                              :name (n2 / name :op1 "LPS"~e.4))))
            :ARG2 (a3 / appear-02~e.7
                  :ARG1 a2)
            :mod (o / only~e.5)
            :time (a4 / after~e.10
                  :op1 (a5 / add-02~e.13
                        :ARG1 m~e.11
                        :ARG2~e.14 (c / cell~e.16))
                  :quant (t / temporal-quantity~e.30
                        :quant "20"~e.8
                        :unit (m2 / minute))))
      :op2 (l / less~e.21
            :degree~e.21,22 (m3 / more~e.21)
            :degree-of~e.22 a2
            :compared-to~e.23 (a6 / activate-01~e.1
                  :ARG1 e
                  :ARG1-of (i2 / induce-01~e.2
                        :ARG0~e.26 (m4 / molecular-physical-entity
                              :name (n3 / name :op1 "H2O2"~e.27))))
            :time~e.28 (a7 / all-time-points~e.29,31)))

# ::tok Further , evidence is presented for TGF @-@ beta @-@ stimulated p160ROCK translocation to the nucleus and inhibitory phosphorylation of the cyclin @-@ dependent kinase @-@ activating phosphatase , Cdc25A .
# ::alignments 0-1.2 2-1.1 4-1 5-1.1.1.r 6-1.1.1.1.1.2.1.1.1 8-1.1.1.1.1.2.1.1.1 10-1.1.1.1.1.2 11-1.1.1.1.1.1.1 12-1.1.1.1 13-1.1.1.1.2.r 15-1.1.1.1.2 16-1.1.1 18-1.1.1.2 19-1.1.1.2.2.r 21-1.1.1.2.2.1 23-1.1.1.2.2 24-1.1.1.2.2.1.1.1 26-1.1.1.2.2.1.1 27-1.1.1.2.1 29-1.1.1.2.1.1.1
# ::id bel_pmid_1465_7354_10332
(p / present-01~e.4
      :ARG1 (e / evidence-01~e.2
            :ARG1~e.5 (a / and~e.16
                  :op1 (t / translocate-00~e.12
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "p160ROCK"~e.11)
                              :ARG1-of (s / stimulate-01~e.10
                                    :ARG0 (p4 / protein
                                          :name (n2 / name :op1 "TGF-beta"~e.6,8))))
                        :ARG2~e.13 (n3 / nucleus~e.15))
                  :op2 (p3 / phosphorylate-01~e.18
                        :ARG1 (p6 / phosphatase~e.27
                              :name (n4 / name :op1 "Cdc25A"~e.29))
                        :ARG0-of~e.19 (d / depend-01~e.23
                              :ARG1 (c / cyclin~e.21
                                    :ARG0-of (a2 / activate-01~e.26
                                          :ARG1 (k / kinase~e.24)))))))
      :mod (f / further~e.0))

# ::tok p57Kip2 ( Cdkn1c ) is expressed in postmitotic differentiating midbrain dopamine cells . Induction of p57Kip2 expression depends on Nurr1,
# ::alignments 0-1.1.1.1.1 0-1.2.1.1.1.1.1 2-1.1.1.2.1.1.1 5-1.1 6-1.1.2.r 7-1.1.2.3 8-1.1.2.4 9-1.1.2.2 10-1.1.2.1 11-1.1.2 13-1.2.1 14-1.2.1.1.r 15-1.2.1.1.1.1.1 16-1.2.1.1 17-1.2
# ::id bel_pmid_1467_1317_33588
(m3 / multi-sentence
      :snt1 (e / express-03~e.5
            :ARG2 (p / protein
                  :name (n / name :op1 "p57Kip2"~e.0)
                  :ARG1-of (m / mean-01
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "Cdkn1c"~e.2))))
            :ARG3~e.6 (c / cell~e.11
                  :mod (d / dopamine~e.10)
                  :mod (m2 / midbrain~e.9)
                  :mod (p3 / postmitotic~e.7)
                  :ARG0-of (d2 / differentiate-01~e.8)))
      :snt2 (d3 / depend-01~e.17
            :ARG0 (i / induce-01~e.13
                  :ARG1~e.14 (e2 / express-03~e.16
                        :ARG2 (p5 / protein
                              :name (n4 / name :op1 "p57Kip2"~e.0,15))))
            :ARG1 (p4 / protein
                  :name (n3 / name :op1 "Nurr1"))))

# ::tok The expression of MUP2 is known to be stimulated by growth hormone ( GH ) , through the GH receptor ( GHR ) , Janus kinase 2 ( JAK2 ) and signal transducer and activator of transcription 5 ( STAT5 ) signal transduction pathway .
# ::alignments 1-1.1.2 2-1.1.2.1.r 3-1.1.2.1.1.1 5-1 8-1.1 9-1.1.1.r 10-1.1.1.1.1 11-1.1.1.1.2 13-1.1.3.1.1.1 18-1.1.3.1.1.1 19-1.1.3.1 24-1.1.3.2.1.1 25-1.1.3.2.1.2 26-1.1.3.2.1.3 30-1.1.3 31-1.1.3.3.1.1 32-1.1.3.3.1.2 33-1.1.3.3.1.3 34-1.1.3.3.1.4 35-1.1.3.3.1.5 36-1.1.3.3.1.6 37-1.1.3.3.1.7 41-1.1.3.3.2 43-1.1.3.3
# ::id bel_pmid_1475_9523_36890
(k / know-01~e.5
      :ARG1 (s / stimulate-01~e.8
            :ARG0~e.9 (s2 / small-molecule
                  :name (n3 / name :op1 "growth"~e.10 :op2 "hormone"~e.11))
            :ARG1 (e / express-03~e.1
                  :ARG2~e.2 (p / protein
                        :name (n / name :op1 "MUP2"~e.3)))
            :ARG2 (a / and~e.30
                  :op1 (r / receptor~e.19
                        :name (n2 / name :op1 "GH"~e.13,18))
                  :op2 (k2 / kinase
                        :name (n4 / name
                              :op1 "Janus"~e.24
                              :op2 "kinase"~e.25
                              :op3 "2"~e.26))
                  :op3 (p2 / pathway~e.43
                        :name (n5 / name
                              :op1 "signal"~e.31
                              :op2 "transducer"~e.32
                              :op3 "and"~e.33
                              :op4 "activator"~e.34
                              :op5 "of"~e.35
                              :op6 "transcription"~e.36
                              :op7 "5"~e.37)
                        :ARG0-of (s3 / signal-07~e.41
                              :ARG1-of (t / transduct-00))))))

# ::tok Phosphorylation at Ser727 in signal transducer and activator of transcription 1 ( STAT1 ) is essential for its activation and signal transduction .
# ::alignments 0-1.1 3-1.1.1.r 4-1.1.1.3.1.1 5-1.1.1.3.1.2 6-1.1.1.3.1.3 7-1.1.1.3.1.4 8-1.1.1.3.1.5 9-1.1.1.3.1.6 10-1.1.1.3.1.7 14-1.1.r 15-1 16-1.2.r 17-1.2.1.1 17-1.2.1.1.r 18-1.2.1 19-1.2 20-1.2.2
# ::id bel_pmid_1496_3018_30938
(e / essential~e.15
      :domain~e.14 (p / phosphorylate-01~e.0
            :ARG1~e.3 (a / amino-acid
                  :mod "727"
                  :name (n / name :op1 "serine")
                  :part-of (p2 / protein
                        :name (n2 / name
                              :op1 "signal"~e.4
                              :op2 "transducer"~e.5
                              :op3 "and"~e.6
                              :op4 "activator"~e.7
                              :op5 "of"~e.8
                              :op6 "transcription"~e.9
                              :op7 "1"~e.10))))
      :purpose~e.16 (a2 / and~e.19
            :op1 (a3 / activate-01~e.18
                  :ARG1~e.17 p2~e.17)
            :op2 (s / signal-07~e.20
                  :ARG0 p2
                  :ARG1 (t / transduct-00))))

# ::tok In vitro kinase assays using the combined STAT1 proteins as substrates from immunoprecipitation and glutathione S @-@ transferase pull down show that active ERK1 , JNK1 , p38 kinase , MEK1 and MSK1 stimulated phosphorylation of STAT1 ( Ser727 ) indirectly through an unidentified factor or a downstream kinase .
# ::alignments 0-1.1.2 1-1.1.2 2-1.1.1 3-1.1 4-1.1.3 6-1.1.3.1.2 7-1.1.3.1.1.1 8-1.1.3.1 9-1.1.3.2.r 10-1.1.3.2 11-1.1.3.2.1.r 13-1.1.3.2.1 14-1.1.3.2.1.2.1.1.1 15-1.1.3.2.1.2.1.1.2 17-1.1.3.2.1.2.1.1.2 18-1.1.3.2.1.2 20-1 23-1.2.1.1.1.1 25-1.2.1.2.1.1 27-1.2.1.3.1.1 28-1.2.1.3 30-1.2.1.4.1.1 31-1.2.1 32-1.2.1.5.1.1 33-1.2 34-1.2.2 36-1.1.3.1.1.1 40-1.2.3 40-1.2.3.1 40-1.2.3.r 43-1.2.2.2.1.1 43-1.2.2.2.1.1.1 43-1.2.2.2.1.1.1.r 43-1.2.3.1.r 44-1.2.2.2.1 45-1.2.2.2 47-1.2.2.2.2.1 48-1.2.2.2.2
# ::id bel_pmid_1496_3018_37018
(s / show-01~e.20
      :ARG0 (a / assay-00~e.3
            :ARG1 (k / kinase~e.2)
            :manner (i / in-vitro~e.0,1)
            :ARG0-of (u / use-01~e.4
                  :ARG1 (p / protein~e.8
                        :name (n / name :op1 "STAT1"~e.7,36)
                        :ARG3-of (c / combine-01~e.6))
                  :ARG2~e.9 (s2 / substrate~e.10
                        :source~e.11 (a2 / and~e.13
                              :op1 (i2 / immunoprecipitate-00)
                              :op2 (p4 / pull-00~e.18
                                    :ARG1 (e / enzyme
                                          :name (n2 / name :op1 "glutathione"~e.14 :op2 "S-transferase"~e.15,17)))))))
      :ARG1 (s3 / stimulate-01~e.33
            :ARG0 (a3 / and~e.31
                  :op1 (e2 / enzyme
                        :name (n3 / name :op1 "ERK1"~e.23))
                  :op2 (e3 / enzyme
                        :name (n4 / name :op1 "JNK1"~e.25))
                  :op3 (k2 / kinase~e.28
                        :name (n5 / name :op1 "p38"~e.27))
                  :op4 (e4 / enzyme
                        :name (n6 / name :op1 "MEK1"~e.30))
                  :op5 (e5 / enzyme
                        :name (n7 / name :op1 "MSK1"~e.32)))
            :ARG1 (p3 / phosphorylate-01~e.34
                  :ARG1 (a4 / amino-acid
                        :mod "727"
                        :name (n8 / name :op1 "serine")
                        :part-of p)
                  :ARG2 (o / or~e.45
                        :op1 (f / factor~e.44
                              :ARG1-of (i4 / identify-01~e.43 :polarity~e.43 "-"~e.43))
                        :op2 (k3 / kinase~e.48
                              :mod (d / downstream~e.47))))
            :manner~e.40 (d2 / direct~e.40 :polarity~e.43 "-"~e.40)
            :ARG1-of (a6 / activate-01)))

# ::tok Inactivation of Icmt inhibited cell growth and K @-@ Ras @-@ induced oncogenic transformation , both in soft agar assays and in a nude mice model .
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 1-1.1.2.r 2-1.1.2.1.1 3-1.1.3 4-1.1.3.1.1 5-1.1.3.1 6-1 6-1.1.3.2 7-1.2.2.1.1.1 9-1.2.2.1.1.1 11-1.2.2 12-1.2.3 12-1.2.3.1 12-1.2.3.1.r 13-1.2 16-1.1.3.2.r 17-1.1.3.2.1.1.1 18-1.1.3.2.1.1 19-1.1.3.2.1 20-1.1.3.2 23-1.1.3.2.2.2 24-1.1.3.2.2.1 25-1.1.3.2.2
# ::id bel_pmid_1496_6563_336
(a2 / and~e.6
      :op1 (a / activate-01~e.0
            :polarity~e.0 "-"~e.0
            :ARG1~e.1 (e / enzyme
                  :name (n / name :op1 "Icmt"~e.2))
            :ARG0-of (i / inhibit-01~e.3
                  :ARG1 (g / grow-01~e.5
                        :ARG1 (c / cell~e.4))
                  :location~e.16 (a5 / and~e.6,20
                        :op1 (a3 / assay-00~e.19
                              :ARG1 (a4 / agar~e.18
                                    :mod (s / soft~e.17)))
                        :op2 (m / model~e.25
                              :topic (m2 / mouse~e.24)
                              :mod (n3 / nude~e.23)))))
      :op2 (t / transform-01~e.13
            :ARG1 c
            :ARG1-of (i2 / induce-01~e.11
                  :ARG0 (e2 / enzyme
                        :name (n2 / name :op1 "K-Ras"~e.7,9)))
            :ARG0-of (c2 / cause-01~e.12
                  :ARG1~e.12 (c3 / cancer~e.12))))

# ::tok The effect of inactivating Icmt was not limited to the inhibition of K @-@ Ras @-@ induced transformation : inactivation of Icmt blocked transformation by an oncogenic form of B @-@ Raf
# ::alignments 1-1.1.2 3-1.1.1 4-1.1.2.1.2.1.1 6-1.1.1 6-1.1.1.r 6-1.1.2.1.1.r 7-1.1 8-1.1.3.r 10-1.1.3 11-1.1.3.1.r 12-1.1.3.1.1.1.1.1 14-1.1.3.1.1.1.1.1 16-1.1.3.1.1 17-1.1.3.1 19-1.2.1 20-1.2.1 21-1.2.1 22-1.2 23-1.2.2 24-1.2.3.r 26-1.2.3.1 26-1.2.3.1.1 26-1.2.3.1.1.r 27-1.2.3 28-1.2.3.2.r 29-1.2.3.2.1.1 31-1.2.3.2.1.1
# ::id bel_pmid_1496_6563_338
(a3 / and
      :op1 (l / limit-01~e.7
            :polarity~e.6 "-"~e.3,6
            :ARG1 (a / affect-01~e.1
                  :ARG0 (a2 / activate-01
                        :polarity~e.6 "-"
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "Icmt"~e.4))))
            :ARG2~e.8 (i / inhibit-01~e.10
                  :ARG1~e.11 (t / transform-01~e.17
                        :ARG1-of (i2 / induce-01~e.16
                              :ARG0 (e2 / enzyme
                                    :name (n2 / name :op1 "K-Ras"~e.12,14))))))
      :op2 (b / block-01~e.22
            :ARG0 a2~e.19,20,21
            :ARG1 (t2 / transform-01~e.23)
            :ARG3~e.24 (f / form~e.27
                  :ARG0-of (c2 / cause-01~e.26
                        :ARG1~e.26 (c3 / cancer~e.26))
                  :mod~e.28 (e3 / enzyme
                        :name (n3 / name :op1 "B-Raf"~e.29,31)))))

# ::tok In the case of the Ras proteins , carboxyl methylation is important for targeting of the proteins to the plasma membrane .
# ::alignments 5-1.1.2.1.1 6-1.1.1 8-1.1.1.1.1 9-1.1.1.1.2 11-1 13-1.1 16-1.1.1 17-1.1.3.r 19-1.1.3.1 20-1.1.3
# ::id bel_pmid_1496_6563_4878
(i / important~e.11
      :purpose (t / target-01~e.13
            :ARG0 (p / protein~e.6,16
                  :name (n / name :op1 "carboxyl"~e.8 :op2 "methylation"~e.9))
            :ARG1 (e / enzyme
                  :name (n2 / name :op1 "Ras"~e.5))
            :direction~e.17 (m / membrane~e.20
                  :part-of (p2 / plasma~e.19))))

# ::tok levels of RhoA were greatly reduced as a consequence of accelerated protein turnover . In addition , there was a large Ras @/@ Erk1 @/@ 2 @-@ dependent increase in p21( Cip1 ) , which was probably a consequence of the reduced levels of RhoA . Deletion of p21( Cip1 ) restored the ability of K @-@ Ras @-@ Icmt( Delta/Delta ) fibroblasts to grow in soft agar .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1 4-1.1.2 5-1.1 6-1.1.3 7-1.1.3 8-1.1.3 9-1.1.3.1.r 10-1.1.3.1.2 11-1.1.3.1.1 12-1.1.3.1 14-1.3 15-1.3 20-1.3.1.2 21-1.3.1.3.1.1.1 23-1.3.1.3.1.1.1 25-1.3.1.3.1.1.1 27-1.3.1.3 28-1.3.1 36-1.3.1.4.2 38-1.3.1.4 39-1.3.1.4.1.r 41-1.3.1.4.1 42-1.3.1.4.1.1 43-1.3.1.4.1.1.1.r 44-1.3.1.4.1.1.1.1.1 46-1.2.1 51-1.2 53-1.2.2 54-1.2.2.1.r 55-1.2.2.1.1.1.1.1 57-1.2.2.1.1.1.1.1 62-1.2.2.1 64-1.2.2.2 65-1.2.2.2.2.r 66-1.2.2.2.2.1 67-1.2.2.2.2
# ::id bel_pmid_1496_6563_4882
(m / multi-sentence
      :snt1 (r / reduce-01~e.5
            :ARG1 (l / level~e.0
                  :degree-of~e.1 (p / protein
                        :name (n / name :op1 "RhoA"~e.2)))
            :ARG2 (g / great~e.4)
            :ARG1-of (c / cause-01~e.6,7,8
                  :ARG0~e.9 (t / turnover~e.12
                        :mod (p2 / protein~e.11)
                        :ARG1-of (a / accelerate-01~e.10))))
      :snt3 (r2 / restore-01~e.51
            :ARG0 (d2 / delete-01~e.46
                  :ARG1 (p6 / protein
                        :name (n5 / name :op1 "p21(Cip1)")))
            :ARG1 (c3 / capable-01~e.53
                  :ARG1~e.54 (f / fibroblast~e.62
                        :ARG0-of (c4 / contain-01
                              :ARG1 (e2 / enzyme
                                    :name (n6 / name :op1 "K-Ras-Icmt(Delta/Delta)"~e.55,57))))
                  :ARG2 (g2 / grow-01~e.64
                        :ARG1 f
                        :location~e.65 (a3 / agar~e.67
                              :mod (s / soft~e.66)))))
      :snt2 (a2 / and~e.14,15
            :op2 (i / increase-01~e.28
                  :ARG1 (p3 / protein
                        :name (n2 / name :op1 "p21(Cip1)"))
                  :ARG2 (l2 / large~e.20)
                  :ARG0-of (d / depend-01~e.27
                        :ARG1 (e / enzyme
                              :name (n3 / name :op1 "Ras/Erk1/2"~e.21,23,25)))
                  :ARG1-of (c2 / cause-01~e.38
                        :ARG0~e.39 (r3 / reduce-01~e.41
                              :ARG1 (l3 / level~e.42
                                    :quant-of~e.43 (p5 / protein
                                          :name (n4 / name :op1 "RhoA"~e.44))))
                        :mod (p4 / probable~e.36)))))

# ::tok The increase in IL @-@ 6 in septic DPPI(-/-) mice , which appears to protect these mice from death , may be related to reduced DPPI @-@ mediated activation of mast cell tryptase and other peptidases , which we show cleave IL @-@ 6 in vitro .
# ::alignments 1-1.1.1 2-1.1.1.1.r 2-1.1.2.1.3.2 3-1.1.1.1.1.1 5-1.1.1.1.1.1 6-1.1.2.1.3.2 7-1.1.1.1.2.1 8-1.1.1.1.2.1 9-1.1.1.1.2.1 12-1.1.1.1.2.3 14-1.1.1.1 14-1.1.1.1.2 14-1.1.1.1.2.r 16-1.1.1.1.2.2.1 17-1.1.1.1.2.2.r 18-1.1.1.1.2.2 20-1 21-1.1.r 22-1.1 24-1.1.2.3 25-1.1.1.2.2.1.1 27-1.1.2.2 28-1.1.2 29-1.1.2.1.r 30-1.1.2.1.1.3 31-1.1.2.1.1.2 32-1.1.2.1.1.1.1 33-1.1.2.1 34-1.1.2.1.2.1 35-1.1.2.1.2 38-1.1.2.1.3.3.1 39-1.1.2.1.3.3 40-1.1.2.1.3 41-1.1.1.1.1.1 43-1.1.1.1.1.1 44-1.1.2.1.3.2 45-1.1.2.1.3.2
# ::id bel_pmid_1496_6572_18984
(p / possible~e.20
      :domain~e.21 (r / relate-01~e.22
            :ARG1 (i / increase-01~e.1
                  :ARG1~e.2 (p2 / protein~e.14
                        :name (n / name :op1 "IL-6"~e.3,5,41,43)
                        :ARG0-of~e.14 (p3 / protect-01~e.14
                              :ARG1 m~e.7,8,9
                              :ARG2~e.17 (d / die-01~e.18
                                    :ARG1 m~e.16)
                              :ARG1-of (a2 / appear-02~e.12)))
                  :location (m / mouse
                        :mod (s / septic)
                        :mod (e / enzyme
                              :name (n2 / name :op1 "DPPI"~e.25)
                              :ARG2-of (m2 / mutate-01 :mod "-/-"))))
            :ARG2 (a / activate-01~e.28
                  :ARG1~e.29 (a3 / and~e.33
                        :op1 (e3 / enzyme
                              :name (n4 / name :op1 "tryptase"~e.32)
                              :mod (c2 / cell~e.31)
                              :mod (m4 / mast~e.30))
                        :op2 (p4 / peptidase~e.35
                              :mod (o / other~e.34))
                        :ARG0-of (c / cleave-01~e.40
                              :ARG1 p2
                              :manner (i2 / in-vitro~e.2,6,44,45)
                              :ARG1-of (s2 / show-01~e.39
                                    :ARG0 (w / we~e.38))))
                  :ARG1-of (m3 / mediate-01~e.27
                        :ARG0 e)
                  :ARG1-of (r2 / reduce-01~e.24))))

# ::tok Importantly , over @-@ expression of c @-@ Jun rescued the defects in proliferation and premature senescence observed in mkk7-/- MEFs ( Fig . 7b @-@ d ) .
# ::alignments 0-1.3 4-1.1 5-1.1.1.r 6-1.1.1.1.1 8-1.1.1.1.1 9-1 11-1.2 12-1.2.1.r 13-1.2.1.1 14-1.2.1 15-1.2.1.2.1 16-1.2.1.2 17-1.2.1.3 24-1.4.1.1.1
# ::id bel_pmid_1503_9780_28646
(r / rescue-01~e.9
      :ARG0 (e / express-03~e.4
            :ARG2~e.5 (p / protein
                  :name (n / name :op1 "c-Jun"~e.6,8))
            :degree (t / too))
      :ARG1 (d / defect~e.11
            :topic~e.12 (a / and~e.14
                  :op1 (p2 / proliferate-01~e.13)
                  :op2 (s / senescence~e.16
                        :mod (p3 / premature~e.15))
                  :ARG1-of (o / observe-01~e.17
                        :location (c / cell
                              :name (n2 / name :op1 "MEF")
                              :part (e2 / enzyme
                                    :name (n3 / name :op1 "mkk7")
                                    :ARG2-of (m / mutate-01 :mod "-/-"))))))
      :mod (i / important~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (v / value-interval
                  :op1 (f / figure :mod "7b"~e.24)
                  :op2 (f2 / figure :mod "7d"))))

# ::tok Moreover , genetic inactivation of MKK4 in MEFs resulted in reduced proliferation doubling times and premature senescence , indicating that both MKK4 and MKK7 are essential for these cellular processes ( data not shown ) .
# ::alignments 2-1.1.1.3 3-1.1.1 3-1.1.1.1 3-1.1.1.1.r 4-1.1.1.2.r 5-1.1.1.2.1.1 8-1.1 9-1.1.2.r 10-1.1.2.1.1 11-1.1.2.1.2.1 12-1.1.2.1.2 13-1.1.2.1 14-1.1.2 15-1.1.2.2.1 16-1.1.2.2 18-1.1.3 21-1.1.3.1.2.1 22-1.1.3.1.2 23-1.1.3.1.2.2.1.1 24-1.1.3.1.2.r 25-1.1.3.1 26-1.1.3.1.1.r 27-1.1.3.1.1.2 28-1.1.3.1.1.1 29-1.1.3.1.1 32-1.1.3.1.3.1 32-1.1.3.1.3.1.r 33-1.1.3.1.3
# ::id bel_pmid_1503_9780_29004
(a4 / and
      :op2 (r / result-01~e.8
            :ARG1 (a / activate-01~e.3
                  :polarity~e.3 "-"~e.3
                  :ARG1~e.4 (e / enzyme
                        :name (n / name :op1 "MKK4"~e.5)
                        :location (c / cell
                              :name (n2 / name :op1 "MEF")))
                  :mod (g / genetic~e.2)
                  :location c)
            :ARG2~e.9 (a2 / and~e.14
                  :op1 (t2 / time~e.13
                        :ARG1-of (r2 / reduce-01~e.10)
                        :duration-of (d / double-01~e.12
                              :ARG1 (p / proliferate-01~e.11
                                    :ARG0 c)))
                  :op2 (s / senescence~e.16
                        :mod (p3 / premature~e.15)))
            :ARG0-of (i / indicate-01~e.18
                  :ARG1 (e2 / essential~e.25
                        :purpose~e.26 (p4 / process~e.29
                              :location (c2 / cell~e.28)
                              :mod (t / this~e.27))
                        :domain~e.24 (a3 / and~e.22
                              :op1 e~e.21
                              :op2 (e3 / enzyme
                                    :name (n3 / name :op1 "MKK7"~e.23)))
                        :ARG1-of (s2 / show-01~e.33 :polarity~e.32 "-"~e.32)))))

# ::tok In contrast , proliferation of hepatocytes was markedly impaired in E11.5 mkk7-/- embryos , as determined by BrdU in vivo labelling ( data not shown ) .
# ::alignments 0-1.1.4.1.2 1-1 3-1.1.1 7-1.1.2 7-1.1.2.r 8-1.1 9-1.1.4.1.2 12-1.1.3 15-1.1.4 17-1.1.4.1.1.1.1 18-1.1.4.1.2 19-1.1.4.1.2 20-1.1.4.1 23-1.1.5.1 23-1.1.5.1.r 24-1.1.5
# ::id bel_pmid_1503_9780_29010
(c2 / contrast-01~e.1
      :ARG2 (i / impair-01~e.8
            :ARG1 (p / proliferate-01~e.3
                  :ARG0 (c / cell
                        :name (n / name :op1 "hepatocyte")))
            :manner~e.7 (m / marked~e.7)
            :location (e / embryo~e.12
                  :mod (e2 / enzyme
                        :name (n2 / name :op1 "mkk7")
                        :ARG2-of (m2 / mutate-01 :mod "-/-"))
                  :age (t2 / temporal-quantity
                        :quant "11.5"
                        :unit (d2 / day)))
            :ARG1-of (d / determine-01~e.15
                  :ARG0 (l / label-01~e.20
                        :instrument (p2 / protein
                              :name (n4 / name :op1 "BrdU"~e.17))
                        :manner (i2 / in-vivo~e.0,9,18,19)))
            :ARG1-of (s / show-01~e.24 :polarity~e.23 "-"~e.23)))

# ::tok Re @-@ expression of wild @-@ type MKK7 ( Fig . 2c ) restored the reduced proliferation of mkk7 @- /- MEFs to levels observed in wild @-@ type MEFs .
# ::alignments 2-1.1 3-1.1.1.r 4-1.1.1.2 6-1.1.1.2 7-1.1.1.1.1 11-1.1.3.1.1 13-1 15-1.2.2 16-1.2 18-1.1.1.1.1 18-1.2.1.2.1.1 22-1.3.r 23-1.3 24-1.3.1 26-1.1.1.2 28-1.1.1.2
# ::id bel_pmid_1503_9780_29012
(r / restore-01~e.13
      :ARG0 (e / express-03~e.2
            :ARG2~e.3 (e2 / enzyme
                  :name (n / name :op1 "MKK7"~e.7,18)
                  :mod (w / wild-type~e.4,6,26,28))
            :mod (a / again)
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "2c"~e.11)))
      :ARG1 (p / proliferate-01~e.16
            :ARG0 (c / cell
                  :name (n2 / name :op1 "MEF")
                  :part (e3 / enzyme
                        :name (n3 / name :op1 "mkk7"~e.18)
                        :ARG2-of (m / mutate-01 :mod "-/-")))
            :ARG1-of (r2 / reduce-01~e.15))
      :ARG2~e.22 (l / level~e.23
            :ARG1-of (o / observe-01~e.24
                  :location c)))

# ::tok loss of MKK7 expression resulted in impaired JNK activation in MEFs at the basal level and after stimulation with tumour necrosis factor alpha ( TNF @-@ alpha ) or UV irradiation ( Fig . 2a ) .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1 3-1.1.1 4-1 5-1.2.r 6-1.2.2 7-1.2.1.1.1 8-1.2 11-1.2.4.r 13-1.2.4.1 14-1.2.4 16-1.2.5 17-1.2.5.1 18-1.2.5.1.2.r 19-1.2.5.1.2.1.1.1 20-1.2.5.1.2.1.1.2 21-1.2.5.1.2.1.1.3 22-1.2.5.1.2.1.1.4 28-1.2.5.1.2 29-1.2.5.1.2.2.1 30-1.2.5.1.2.2 34-1.3.1.1
# ::id bel_pmid_1503_9780_29014
(r / result-01~e.4
      :ARG1 (l / lose-02~e.0
            :ARG1~e.1 (e / express-03~e.3
                  :ARG2 (e2 / enzyme
                        :name (n / name :op1 "MKK7"~e.2))))
      :ARG2~e.5 (a / activate-01~e.8
            :ARG1 (e3 / enzyme
                  :name (n2 / name :op1 "JNK"~e.7))
            :ARG1-of (i / impair-01~e.6)
            :location (c / cell
                  :name (n3 / name :op1 "MEF"))
            :location~e.11 (l2 / level~e.14
                  :mod (b / basal~e.13))
            :time (a2 / after~e.16
                  :op1 (s / stimulate-01~e.17
                        :ARG1 e3
                        :ARG2~e.18 (o / or~e.28
                              :op1 (e4 / enzyme
                                    :name (n4 / name
                                          :op1 "tumour"~e.19
                                          :op2 "necrosis"~e.20
                                          :op3 "factor"~e.21
                                          :op4 "alpha"~e.22))
                              :op2 (i2 / irradiate-01~e.30
                                    :mod (u / UV~e.29))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2a"~e.34)))

# ::tok Importantly , cyclin B1 @-@ associated CDC2 kinase activity was markedly reduced in mkk7-/- MEFs ( Fig . 4d ) , indicating that reduced CDC2 expression correlates with impaired cyclin B1 @/@ CDC2 activity .
# ::alignments 0-1.2 2-1.1.1.2.1.1.1 3-1.1.1.2.1.1.2 5-1.1.1.2 6-1.1.1.1.1 7-1.1.1 10-1.3 10-1.3.r 11-1 18-1.5.1.1 21-1.6 23-1 23-1.6.1.1.2 24-1.6.1.1.1 25-1.6.1.1 26-1.6.1 28-1.6.1.2.2 29-1.1.1.2.1.1.1 30-1.1.1.2.1.1.2 32-1.1.1.1.1
# ::id bel_pmid_1503_9780_29016
(r / reduce-01~e.11,23
      :ARG1 (a / act-01
            :ARG0 (k / kinase~e.7
                  :name (n / name :op1 "CDC2"~e.6,32)
                  :ARG1-of (a2 / associate-01~e.5
                        :ARG2 (p / protein
                              :name (n2 / name :op1 "cyclin"~e.2,29 :op2 "B1"~e.3,30)))))
      :mod (i / important~e.0)
      :manner~e.10 (m / marked~e.10)
      :location (c / cell
            :name (n3 / name :op1 "MEF")
            :part (e / enzyme
                  :name (n4 / name :op1 "mkk7")
                  :ARG2-of (m2 / mutate-01 :mod "-/-")))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4d"~e.18))
      :ARG0-of (i2 / indicate-01~e.21
            :ARG1 (c2 / correlate-01~e.26
                  :ARG1 (e2 / express-03~e.25
                        :ARG2 k~e.24
                        :ARG1-of (r2 / reduce-01~e.23))
                  :ARG2 (a3 / act-01
                        :ARG0 (s / slash
                              :op1 p
                              :op2 k)
                        :ARG1-of (i3 / impair-01~e.28)))))

# ::tok Similarly to mkk7-/- MEFs , cdc2 mRNA expression was downregulated in primary mkk7-/- hepatocytes ( Fig . 4g ) .
# ::alignments 0-1.3 5-1.1.1.2.1.1.1 7-1.1 7-1.3.1 11-1.2.2 17-1.4.1.1
# ::id bel_pmid_1503_9780_29022
(d / downregulate-01
      :ARG1 (e / express-03~e.7
            :ARG1 (r / rna
                  :name (n / name :op1 "messenger" :op2 "RNA")
                  :ARG0-of (e2 / encode-01
                        :ARG1 (p / protein
                              :name (n2 / name :op1 "cdc2"~e.5)))))
      :location (c / cell
            :name (n3 / name :op1 "hepatocyte")
            :mod (p2 / primary~e.11)
            :mod (e3 / enzyme
                  :name (n4 / name :op1 "mkk7")
                  :ARG2-of (m / mutate-01 :mod "-/-")))
      :ARG1-of (r2 / resemble-01~e.0
            :ARG2 (e4 / express-03~e.7
                  :ARG3 (c2 / cell
                        :name (n5 / name :op1 "MEF")
                        :part e3)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4g"~e.17)))

# ::tok These results are consistent with previous data showing that loss of JNK1 @/@ JNK2 in MEFs results in reduced proliferation17 and that inactivation of c @-@ Jun in MEFs results in premature senescence and impaired proliferation19 .
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 3-1 4-1.2.r 5-1.2.1 6-1.2 7-1.2.2 9-1.2.2.1.1.1 11-1.2.2.1.1.1.1.1.1.1 13-1.2.2.1.1.1.1.2.1.1 16-1.2.2.1.1 18-1.2.2.1.1.1.2.1 20-1.2.2.1 22-1.2.2.1.2.1 22-1.2.2.1.2.1.1 22-1.2.2.1.2.1.1.r 23-1.2.2.1.2.1.2.r 24-1.2.2.1.2.1.2.1.1 26-1.2.2.1.2.1.2.1.1 29-1.2.2.1.2 30-1.2.2.1.2.2.r 31-1.2.2.1.2.2.1.1 32-1.2.2.1.2.2.1 33-1.2.2.1.2.2 34-1.2.2.1.2.2.2.1
# ::id bel_pmid_1503_9780_29098
(c / consistent-01~e.3
      :ARG1 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t2 / this~e.0))
      :ARG2~e.4 (d / data~e.6
            :time (p / previous~e.5)
            :ARG0-of (s / show-01~e.7
                  :ARG2 (a / and~e.20
                        :op1 (r2 / result-01~e.16
                              :ARG1 (l / lose-02~e.9
                                    :ARG1 (s2 / slash
                                          :op1 (e / enzyme
                                                :name (n / name :op1 "JNK1"~e.11))
                                          :op2 (e2 / enzyme
                                                :name (n2 / name :op1 "JNK2"~e.13))
                                          :location (c2 / cell
                                                :name (n3 / name :op1 "MEF")))
                                    :ARG2 (p2 / proliferate-01
                                          :ARG1-of (r4 / reduce-01~e.18)))
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p4 / publication-91
                                          :ARG1-of (c3 / cite-01 :ARG2 "17"))))
                        :op2 (r3 / result-01~e.29
                              :ARG1 (a2 / activate-01~e.22
                                    :polarity~e.22 "-"~e.22
                                    :ARG1~e.23 (e3 / enzyme
                                          :name (n4 / name :op1 "c-Jun"~e.24,26)
                                          :location c2))
                              :ARG2~e.30 (a3 / and~e.33
                                    :op1 (s3 / senescence~e.32
                                          :mod (p3 / premature~e.31))
                                    :op2 (p5 / proliferate-01
                                          :ARG1-of (i2 / impair-01~e.34)))
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (p6 / publication-91
                                          :ARG1-of (c4 / cite-01 :ARG2 "19"))))))))

# ::tok Over @-@ expression of c @-@ Jun in mkk7-/- MEFs restored CDC2 expression ( Fig . 6c ) and transactivation of the cdc2 AP @-@ 1 promoter construct to levels observed in wild @-@ type MEFs ( Fig . 6d ) .
# ::alignments 2-1.1 3-1.1.1.r 4-1.1.1.1.1 6-1.1.1.1.1 10-1 11-1.2.1.1.1.1 12-1.2.1 16-1.2.1.2.1.1 18-1.2 19-1.2.2 20-1.2.2.1.r 22-1.2.2.1.1.1.1.1 23-1.2.2.1.1.1.1.2 25-1.2.2.1.1.1.1.2 27-1.2.2.1.1.1 27-1.2.2.1.1.1.2 27-1.2.2.1.1.1.2.r 28-1.3.r 29-1.3 30-1.3.1 31-1.3.1.1.r 32-1.3.1.1.2 34-1.3.1.1.2 39-1.2.2.2.1.1
# ::id bel_pmid_1503_9780_33214
(r / restore-01~e.10
      :ARG0 (e / express-03~e.2
            :ARG2~e.3 (p / protein
                  :name (n / name :op1 "c-Jun"~e.4,6))
            :degree (t / too)
            :location (c / cell
                  :name (n2 / name :op1 "MEF")
                  :part (e2 / enzyme
                        :name (n3 / name :op1 "mkk7")
                        :ARG2-of (m / mutate-01 :mod "-/-"))))
      :ARG1 (a / and~e.18
            :op1 (e3 / express-03~e.12
                  :ARG2 (p2 / protein
                        :name (n4 / name :op1 "CDC2"~e.11))
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure :mod "6c"~e.16)))
            :op2 (t2 / transactivate-00~e.19
                  :ARG1~e.20 (m2 / molecular-physical-entity
                        :ARG0-of (p3 / promote-01
                              :ARG1 (p4 / protein~e.27
                                    :name (n5 / name :op1 "cdc2"~e.22 :op2 "AP-1"~e.23,25)
                                    :ARG1-of~e.27 (c2 / construct-01~e.27))))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f2 / figure :mod "6d"~e.39))))
      :ARG2~e.28 (l / level~e.29
            :ARG1-of (o / observe-01~e.30
                  :location~e.31 (c3 / cell
                        :name (n6 / name :op1 "MEF")
                        :mod (w / wild-type~e.32,34)))))

# ::tok In this study , we found that H @-@ Ras interacted with ASK1 to cause the inhibition of both ASK1 activity and ASK1 @-@ induced apoptosis in vivo
# ::alignments 0-1.2.3.2.1.2.1.2 1-1.3.1 2-1.3 4-1.1 5-1 7-1.2.1.1.1 9-1.2.1.1.1 10-1.2 11-1.2.2.r 12-1.2.2.1.1 13-1.2.3 14-1.2.3 16-1.2.3.2 19-1.2.2.1.1 22-1.2.2.1.1 24-1.2.3.2.1.2.1 25-1.2.3.2.1.2 26-1.2.3.2.1.2.1.2 27-1.2.3.2.1.2.1.2
# ::id bel_pmid_1511_5616_1726
(f / find-01~e.5
      :ARG0 (w / we~e.4)
      :ARG1 (i / interact-01~e.10
            :ARG0 (e / enzyme
                  :name (n / name :op1 "H-Ras"~e.7,9))
            :ARG1~e.11 (e2 / enzyme
                  :name (n2 / name :op1 "ASK1"~e.12,19,22))
            :purpose (c / cause-01~e.13,14
                  :ARG0 e
                  :ARG1 (i2 / inhibit-01~e.16
                        :ARG1 (a2 / and
                              :op1 (a / act-01
                                    :ARG0 e2)
                              :op2 (a3 / apoptosis~e.25
                                    :ARG1-of (i3 / induce-01~e.24
                                          :ARG0 e2
                                          :manner (i4 / in-vivo~e.0,26,27)))))))
      :medium (s / study~e.2
            :mod (t / this~e.1)))

# ::tok In this report , we demonstrate that the CDC25B phosphatase , an activator of cyclin dependent kinases at mitosis , is phosphorylated both in vitro and in vivo by Aurora @-@ A on serine 353 and that this phosphorylated form of CDC25B is located at the centrosome during mitosis .
# ::alignments 0-1.2.1.3.1 1-1.3.1 2-1.3 4-1.1 5-1 8-1.2.1.1.3.1.1 9-1.2.1.1.3 12-1.2.1.1.3.2 13-1.2.1.1.3.2.1.r 14-1.2.1.1.3.2.1.1.1 15-1.2.1.1.3.2.1.1 16-1.2.1.1.3.2.1 17-1.2.2 18-1.2.2.3 21-1.2.1 23-1.2.1.3.1 24-1.2.1.3.1 25-1.2.1.3 26-1.2.1.3.1 26-1.2.1.3.2 27-1.2.1.3.2 29-1.2.1.2.1.1 31-1.2.1.2.1.1 33-1.2.1.1.2.1 34-1.2.1.1.1 35-1.2 35-1.2.1.3 37-1.3.1 38-1.2.1 41-1.2.1.1.3.1.1 42-1.2.2 43-1.2.2 44-1.2.2 46-1.2.2.2 47-1.2.1.1.3.2.2.r 47-1.2.2.3.r 48-1.2.1.1.3.2.2
# ::id bel_pmid_1512_8871_1604
(d / demonstrate-01~e.5
      :ARG0 (w / we~e.4)
      :ARG1 (a4 / and~e.35
            :op1 (p / phosphorylate-01~e.21,38
                  :ARG1 (a2 / amino-acid
                        :mod "353"~e.34
                        :name (n2 / name :op1 "serine"~e.33)
                        :part-of (p3 / phosphatase~e.9
                              :name (n4 / name :op1 "CDC25B"~e.8,41)
                              :ARG0-of (a / activate-01~e.12
                                    :ARG1~e.13 (k / kinase~e.16
                                          :ARG0-of (d2 / depend-01~e.15
                                                :ARG1 (c / cyclin~e.14)))
                                    :time~e.47 (m / mitosis~e.48))))
                  :ARG2 (e / enzyme
                        :name (n3 / name :op1 "Aurora-A"~e.29,31))
                  :manner (a3 / and~e.25,35
                        :op1 (i / in-vitro~e.0,23,24,26)
                        :op2 (i2 / in-vivo~e.26,27)))
            :op2 (b2 / be-located-at-91~e.17,42,43,44
                  :ARG1 (p2 / protein)
                  :ARG2 (c2 / centrosome~e.46)
                  :time~e.47 m~e.18))
      :medium (r / report~e.2
            :mod (t / this~e.1,37)))

# ::tok PTPD1 activates src tyrosine kinase and increases the magnitude and duration of epidermal growth factor ( EGF ) signaling . EGF receptor phosphorylation and downstream activation of ERK 1 @/@ 2 and Elk1 @-@ dependent gene transcription are enhanced by PTPD1 .
# ::alignments 0-1.1.1.1.1.1 0-1.2.1.1.1 1-1.1.1 2-1.1.1.2.1.1 3-1.1.1.2.1.2 4-1.1.1.2.1.3 5-1.1 6-1.1.2 8-1.1.2.2.1 9-1.1.2.2 10-1.1.2.2.2 11-1.1.2.2.2.1.r 12-1.1.2.2.2.1 13-1.1.2.2.2.1 14-1.1.2.2.2.1 16-1.2.2.1.1.1.1 18-1.1.2.2.1.1 20-1.2.2.1.1.1.1 21-1.2.2.1.1 22-1.2.2.1 23-1.2.2 24-1.2.2.2.2 25-1.2.2.2 26-1.2.2.2.1.r 27-1.2.2.2.1.2.1.1.1.1 28-1.2.2.2.1.2.1.1.1.2 30-1.2.2.2.1.2.1.1.1.2 31-1.2.2.2.1.2.1 32-1.2.2.2.1.2.1.2.1.1 34-1.2.2.2.1.2 35-1.2.2.2.1.1 36-1.2.2.2.1 38-1.2 39-1.2.1.r 40-1.2.1.1.1
# ::id bel_pmid_1514_3158_1864
(m / multi-sentence
      :snt1 (a / and~e.5
            :op1 (a2 / activate-01~e.1
                  :ARG0 (p / protein
                        :name (n / name :op1 "PTPD1"~e.0))
                  :ARG1 (p2 / protein
                        :name (n3 / name
                              :op1 "src"~e.2
                              :op2 "tyrosine"~e.3
                              :op3 "kinase"~e.4)))
            :op2 (i / increase-01~e.6
                  :ARG0 p
                  :ARG1 (a3 / and~e.9
                        :op1 (m2 / magnitude~e.8
                              :poss (s / signal-07~e.18
                                    :ARG0 (p3 / protein
                                          :name (n2 / name
                                                :op1 "epidermal"
                                                :op2 "growth"
                                                :op3 "factor"))))
                        :op2 (d / duration~e.10
                              :duration-of~e.11 s~e.12,13,14))))
      :snt2 (e / enhance-01~e.38
            :ARG0~e.39 (p4 / protein
                  :name (n4 / name :op1 "PTPD1"~e.0,40))
            :ARG1 (a4 / and~e.23
                  :op1 (p5 / phosphorylate-01~e.22
                        :ARG1 (r / receptor~e.21
                              :name (n5 / name :op1 "EGF"~e.16,20)))
                  :op2 (a5 / activate-01~e.25
                        :ARG1~e.26 (t / transcribe-01~e.36
                              :ARG1 (g / gene~e.35)
                              :ARG0-of (d3 / depend-01~e.34
                                    :ARG1 (a6 / and~e.31
                                          :op1 (e2 / enzyme
                                                :name (n6 / name :op1 "ERK"~e.27 :op2 "1/2"~e.28,30))
                                          :op2 (p6 / protein
                                                :name (n7 / name :op1 "Elk1"~e.32)))))
                        :mod (d2 / downstream~e.24)))))

# ::tok Importantly , expression of Myc–Hes1 greatly increased the amount of endogenous JAK2 coprecipitated with endogenous STAT3 ( Fig . 4e ) , suggesting that Hes1 facilitates the interaction between JAK2 and its substrate STAT3
# ::alignments 0-1.4 2-1.1 5-1.3 6-1 8-1.2 9-1.2.1.r 10-1.2.1.2 11-1.2.1.1.1 14-1.2.1.3.1.2 15-1.2.1.3.1.1.1 19-1.5.1.1 22-1.6 24-1.1.1.2.1.1 24-1.6.1.1.1.1 25-1.6.1 27-1.6.1.2 29-1.6.1.2.1 30-1.6.1.2.1 31-1.6.1.2.1 32-1.6.1.2.1 33-1.6.1.2.1
# ::id bel_pmid_1515_6153_27354
(i / increase-01~e.6
      :ARG0 (e / express-03~e.2
            :ARG2 (m / macro-molecular-complex
                  :part (p / protein
                        :name (n / name :op1 "Myc"))
                  :part (p4 / protein
                        :name (n5 / name :op1 "Hes1"~e.24))))
      :ARG1 (a / amount~e.8
            :quant-of~e.9 (e2 / enzyme
                  :name (n2 / name :op1 "JAK2"~e.11)
                  :mod (e3 / endogenous~e.10)
                  :ARG1-of (c / coprecipitate-00
                        :ARG2 (p2 / protein
                              :name (n3 / name :op1 "STAT3"~e.15)
                              :mod e3~e.14))))
      :ARG2 (g / great~e.5)
      :mod (i2 / important~e.0)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4e"~e.19))
      :ARG0-of (s / suggest-01~e.22
            :ARG1 (f2 / facilitate-01~e.25
                  :ARG0 (p3 / protein
                        :name (n4 / name :op1 "Hes1"~e.24))
                  :ARG1 (i3 / interact-01~e.27
                        :ARG0 e2~e.29,30,31,32,33
                        :ARG1 p2))))

# ::tok Expression of either Hes1 or Hes5 significantly activated the STAT reporter gene construct in both E13 neuroepithelial cells and MNS @-@ 70 cells ,
# ::alignments 0-1.1 3-1.1.1.1.1.1 4-1.1.1 5-1.1.1.2.1.1 6-1.3 6-1.3.r 7-1 9-1.2.1.1 10-1.2.2 11-1.2 12-1.2.3 15-1.4.1.1.1 17-1.4.1 17-1.4.2 18-1.4 19-1.4.2.1.1 21-1.4.2.1.1 22-1.4.1
# ::id bel_pmid_1515_6153_27358
(a / activate-01~e.7
      :ARG0 (e / express-03~e.0
            :ARG2 (o / or~e.4
                  :op1 (p / protein
                        :name (n / name :op1 "Hes1"~e.3))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "Hes5"~e.5))))
      :ARG1 (g / gene~e.11
            :name (n3 / name :op1 "STAT"~e.9)
            :ARG0-of (r / report-01~e.10)
            :ARG1-of (c / construct-01~e.12))
      :manner~e.6 (s / significant~e.6)
      :location (a2 / and~e.18
            :op1 (c3 / cell~e.17,22
                  :name (n5 / name :op1 "E13"~e.15)
                  :part-of (n4 / neuroepithelium))
            :op2 (c2 / cell~e.17
                  :name (n6 / name :op1 "MNS-70"~e.19,21))))

# ::tok Expression of an active form of Notch ( Notch ? E; the transmembrane and intracellular domains of mouse Notch1 , comprising residues 1,704–2,531 ) 15 , significantly induced activation of a STAT @-@ dependent reporter gene ( APRE @-@ Luc ) 16 in mouse cortical neuroepithelial cells derived on embryonic day ( E ) 13 or in the rat neural precursor MNS @-@ 70 cells17
# ::alignments 0-1.1 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1.1.1 8-1.1.1.1.1.1 12-1.1.1.1.2.1.2.1.1.1 17-1.1.1.1.2.1.2.1.1.2.2 18-1.1.1.1.2.1.2.1.1.2.1.1 20-1.1.1.1.2.1.2.1.3 21-1.1.1.1.2.1.2.1.3.1 24-1.1.2.1.1.1 26-1.3 26-1.3.r 27-1 28-1.1.1.2 28-1.2 28-1.2.1.2.1 28-1.2.1.2.1.2 28-1.2.1.2.1.2.r 29-1.2.1.r 31-1.2.1.2.1.1.1 33-1.2.1.2 34-1.2.1.3 35-1.2.1 37-1.2.1.1.1 39-1.2.1.1.1 41-1.4.1.1.1 43-1.1.1.1.2.1.2.1.1.2.2 44-1.2.2.1.2 46-1.1.1.1.2.1.2.1.2.1 46-1.2.2.1 47-1.2.2.1.3 50-1.2.2.1.3.1.2 52-1.1.1.1.2.1.1.3 54-1.2.2.1.3.1.1 55-1.2.2 56-1.2.2.r 58-1.2.2.2.3 59-1.2.2.2.4 60-1.2.2.2.2 61-1.2.2.2.1.1 63-1.2.2.2.1.1
# ::id bel_pmid_1515_6153_29634
(i / induce-01~e.27
      :ARG0 (e / express-03~e.0
            :ARG2 (f / form~e.4
                  :mod~e.5 (p2 / protein
                        :name (n3 / name :op1 "Notch"~e.6,8)
                        :ARG1-of (m3 / mean-01
                              :ARG2 (p9 / protein
                                    :name (n4 / name
                                          :op1 "Notch"
                                          :op2 "Delta"
                                          :op3 "E"~e.52)
                                    :ARG1-of (m / mean-01
                                          :ARG2 (a4 / and
                                                :op1 (p3 / protein-segment
                                                      :mod (t / transmembrane~e.12)
                                                      :part-of (p5 / protein
                                                            :name (n6 / name :op1 "Notch1"~e.18)
                                                            :mod (m2 / mouse~e.17,43)))
                                                :op2 (p10 / protein-segment
                                                      :mod (c2 / cell~e.46
                                                            :part-of p5))
                                                :ARG1-of (c / comprise-01~e.20
                                                      :ARG2 (r2 / residue~e.21
                                                            :mod (v / value-interval :op1 "1,704" :op2 "2,531"))))))))
                  :ARG1-of (a3 / activate-01~e.28))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p4 / publication-91
                        :ARG1-of (c6 / cite-01 :ARG2 "15"~e.24))))
      :ARG1 (a / activate-01~e.28
            :ARG1~e.29 (g / gene~e.35
                  :name (n / name :op1 "APRE-Luc"~e.37,39)
                  :ARG0-of (d / depend-01~e.33
                        :ARG1 (p / protein~e.28
                              :name (n2 / name :op1 "STAT"~e.31)
                              :ARG1-of~e.28 (a2 / activate-01~e.28)))
                  :ARG0-of (r / report-01~e.34))
            :location~e.56 (o / or~e.55
                  :op1 (c3 / cell~e.46
                        :part-of (n7 / neuroepithelium)
                        :mod (c4 / cortex~e.44)
                        :ARG1-of (d2 / derive-01~e.47
                              :duration (t2 / temporal-quantity
                                    :quant "13"~e.54
                                    :unit (d3 / day~e.50
                                          :age-of (e2 / embryo)))
                              :ARG1-of (d6 / describe-01
                                    :ARG0 (p8 / publication-91
                                          :ARG1-of (c8 / cite-01 :ARG2 "17")))))
                  :op2 (c5 / cell
                        :name (n8 / name :op1 "MNS-70"~e.61,63)
                        :mod (p6 / precursor~e.60)
                        :mod (r3 / rat~e.58)
                        :mod (n9 / neural~e.59))))
      :manner~e.26 (s / significant~e.26)
      :ARG1-of (d5 / describe-01
            :ARG0 (p7 / publication-91
                  :ARG1-of (c7 / cite-01 :ARG2 "16"~e.41))))

# ::tok Following depletion of both serum and Epo for 2 hours , p44 @/@ 42 ERK ( Phospho ERK1 ( Thr202/Tyr204 ) ; phospho @-@ ERK2 ( Thr185/Tyr187 )) remained active in H @-@ ras.V12 @-@ transduced cells but not in the control cells . No difference was seen in the expression of total p44 @/@ 42 ERK in the 2 populations of cells
# ::alignments 1-1.1.3.1 4-1.1.3.1.1.1 5-1.1.3.1.1 6-1.1.3.1.1.2.1.1 7-1.1.3.1.2.r 8-1.1.3.1.2.1 9-1.1.3.1.2.2 17-1.1.1.3.1.1.2.3.1.1 24-1.1.1.3.1.2.2.2.1.1 28-1.1 30-1.1.2.r 31-1.1.2.1.2.2.1.1.1 36-1.1.2.1.2 37-1.1.2 38-1.1.2.2.1 38-1.1.2.2.1.r 41-1.1.2.2.3.1 42-1.1.2.1.2 42-1.1.2.2.3 45-1.2.1 45-1.2.1.1 45-1.2.1.1.r 47-1.2 48-1.2.1.2.r 50-1.2.1.2 52-1.2.1.2.1.3 57-1.2.1.2.2.r 59-1.2.1.2.2.1 60-1.2.1.2.2 61-1.2.1.2.2.2.r 62-1.2.1.2.2.2
# ::id bel_pmid_1516_6036_20904
(m3 / multi-sentence
      :snt1 (r / remain-01~e.28
            :ARG1 (s2 / slash
                  :op1 (e6 / enzyme
                        :name (n10 / name :op1 "p44ERK"))
                  :op2 (e7 / enzyme
                        :name (n11 / name :op1 "p42ERK"))
                  :ARG1-of (m / mean-01
                        :ARG2 (a5 / and
                              :op1 (s3 / slash
                                    :op1 (a6 / amino-acid
                                          :mod "202"
                                          :name (n / name :op1 "threonine")
                                          :part-of (e / enzyme
                                                :name (n6 / name :op1 "ERK1"~e.17))
                                          :ARG1-of (p / phosphorylate-01))
                                    :op2 (a7 / amino-acid
                                          :mod "204"
                                          :name (n2 / name :op1 "tyrosine")
                                          :part-of e
                                          :ARG1-of p))
                              :op2 (s4 / slash
                                    :op1 (a8 / amino-acid
                                          :mod "185"
                                          :name (n7 / name :op1 "threonine")
                                          :part-of (e4 / enzyme
                                                :name (n9 / name :op1 "ERK2"~e.24))
                                          :ARG1-of p)
                                    :op2 (a9 / amino-acid
                                          :name (n8 / name :op1 "tyrosine")
                                          :part-of e4
                                          :ARG1-of p)))))
            :ARG3~e.30 (c / contrast-01~e.37
                  :ARG1 (a3 / activate-01
                        :ARG1 s2
                        :location (c5 / cell~e.36,42
                              :ARG2-of (m2 / mutate-01 :value "V12")
                              :ARG1-of (t / transduct-00
                                    :ARG0 (e2 / enzyme
                                          :name (n5 / name :op1 "H-Ras"~e.31)))))
                  :ARG2 (a4 / activate-01
                        :polarity~e.38 "-"~e.38
                        :ARG1 s2
                        :location (c2 / cell~e.42
                              :ARG0-of (c3 / control-01~e.41))))
            :time (a / after
                  :op1 (d / deplete-01~e.1
                        :ARG1 (a2 / and~e.5
                              :op1 (s / serum~e.4)
                              :op2 (t4 / thing
                                    :name (n3 / name :op1 "Epo"~e.6)))
                        :duration~e.7 (t2 / temporal-quantity
                              :quant "2"~e.8
                              :unit (h2 / hour~e.9)))))
      :snt2 (s5 / see-01~e.47
            :ARG0 (d2 / differ-02~e.45
                  :polarity~e.45 "-"~e.45
                  :ARG1~e.48 (e5 / express-03~e.50
                        :ARG2 (s6 / slash
                              :op1 (e3 / enzyme
                                    :name (n12 / name :op1 "p44ERK"))
                              :op2 (e8 / enzyme
                                    :name (n13 / name :op1 "p42ERK"))
                              :mod (t3 / total~e.52))
                        :ARG3~e.57 (p2 / population~e.60
                              :quant "2"~e.59
                              :consist-of~e.61 (c4 / cell~e.62))))))

# ::tok Furthermore , GH induced rapid , time @- and dose @-@ dependent signaling events in LNCaP cells , including phosphorylation of JAK2 tyrosine kinase , of GHR itself and of STAT5A ( JAK2 @-@ STAT5A pathway ) , of p42 @/@ p44 MAPK and of Akt/PKB .
# ::alignments 2-1.1.1.1.1 3-1.1 4-1.1.2.1.2 6-1.1.2.1.1.1.1 8-1.1.2.1.1.1 9-1.1.2.1.1.1.2 11-1.1.2.1.1 12-1.1.2.1 13-1.1.2 14-1.1.2.2.r 15-1.1.2.2.1.1 16-1.1.2.2 18-1.1.2.3 19-1.1.2.3.1 20-1.1.2.3.1.1.r 21-1.1.2.3.1.1.1.1.1 22-1.1.2.3.1.1.1 23-1.1.2.3.1.1.1 26-1.1.2.3.1.1.2.1.1 28-1.1.2.3.1.1 30-1.1.2.3.1.1.3.1.1 32-1.1.2.3.1.1.1.1.1 34-1.1.2.3.1.1.3.1.1 43-1.1.2.3.1.1 45-1.1.2.3.1.1.5.1.1
# ::id bel_pmid_1519_6705_1680
(a2 / and
      :op2 (i / induce-01~e.3
            :ARG0 (m / molecular-physical-entity
                  :name (n2 / name :op1 "GH"~e.2))
            :ARG1 (e / event~e.13
                  :mod (s / signal-01~e.12
                        :ARG0-of (d / depend-01~e.11
                              :ARG1 (a / and~e.8
                                    :op1 (t / time~e.6)
                                    :op2 (d2 / dose~e.9)))
                        :mod (r / rapid~e.4))
                  :location~e.14 (c / cell~e.16
                        :name (n3 / name :op1 "LNCaP"~e.15))
                  :ARG2-of (i2 / include-01~e.18
                        :ARG1 (p3 / phosphorylate-01~e.19
                              :ARG1~e.20 (a3 / and~e.28,43
                                    :op1 (t2 / tyrosine-kinase~e.22,23
                                          :name (n / name :op1 "JAK2"~e.21,32))
                                    :op2 (m2 / molecular-physical-entity
                                          :name (n5 / name :op1 "GHR"~e.26))
                                    :op3 (p4 / protein
                                          :name (n6 / name :op1 "STAT5A"~e.30,34))
                                    :op4 (s2 / slash
                                          :op1 (e2 / enzyme
                                                :name (n4 / name :op1 "p42MAPK"))
                                          :op2 (e3 / enzyme
                                                :name (n9 / name :op1 "p44MAPK")))
                                    :op5 (e4 / enzyme
                                          :name (n8 / name :op1 "Akt/PKB"~e.45))))))))

# ::tok COX @-@ 2 protein and activity measured as prostaglandin E( 2 ) level were up @-@ regulated in cells expressing mutant K @-@ ras( V12 ) ;
# ::alignments 0-1.1.2.1 1-1.1.2.1 2-1.1.2.1 3-1.1.2.1 4-1.1 5-1.1.2 6-1.1.2.2 7-1.1.2.2.1.r 8-1.1.2.2.1.1.1.1 10-1.1.1.1.1 12-1.1.2.2.1 18-1.2 19-1.2.1 20-1.2.1.1 20-1.2.1.1.2 20-1.2.1.1.2.r 21-1.2.1.1.1.1 24-1.2.1.1.2.1
# ::id bel_pmid_1528_4181_1506
(u / upregulate-01
      :ARG1 (a / and~e.4
            :op1 (p / protein
                  :name (n / name :op1 "COX-2"~e.10))
            :op2 (a2 / act-02~e.5
                  :ARG0 p~e.0,1,2,3
                  :ARG1-of (m / measure-01~e.6
                        :ARG3~e.7 (l / level~e.12
                              :quant-of (m2 / macro-molecular-complex
                                    :name (n2 / name :op1 "prostaglandin"~e.8 :op2 "E2"))))))
      :location (c / cell~e.18
            :ARG1-of (e / express-03~e.19
                  :ARG2 (e2 / enzyme~e.20
                        :name (n3 / name :op1 "K-ras"~e.21)
                        :ARG2-of~e.20 (m3 / mutate-01~e.20 :value "V12"~e.24)))))

# ::tok In conclusion , the results suggest that ROS generation , through COX @-@ 2 up @-@ regulation , may contribute to the active oncogenicity of mutant K @-@ ras in the lung as a result of DNA damage
# ::alignments 1-1 4-1.1 4-1.1.1 4-1.1.1.r 5-1.1.2 6-1.1.2.1.r 7-1.1.2.1.1.1.1.1.1 8-1.1.2.1.1.1 11-1.1.2.1.1.1.2.1.1.1 13-1.1.2.1.1.1.2.1.1.1 18-1.1.2.1 19-1.1.2.1.1 23-1.1.2.1.1.2 24-1.1.2.1.1.2.2.r 25-1.1.2.1.1.2.2 25-1.1.2.1.1.2.2.2 25-1.1.2.1.1.2.2.2.r 26-1.1.2.1.1.2.2.1.1 28-1.1.2.1.1.2.2.1.1 29-1.1.2.1.1.2.3.r 31-1.1.2.1.1.2.3 32-1.1.2.1.1.2.4.r 34-1.1.2.1.1.2.4 35-1.1.2.1.1.2.4.1.r 36-1.1.2.1.1.2.4.1.1 37-1.1.2.1.1.2.4.1
# ::id bel_pmid_1528_4181_19506
(c / conclude-02~e.1
      :ARG1 (t / thing~e.4
            :ARG2-of~e.4 (r / result-01~e.4)
            :ARG0-of (s / suggest-01~e.5
                  :ARG1~e.6 (p / possible~e.18
                        :domain (c2 / contribute-01~e.19
                              :ARG0 (g / generate-01~e.8
                                    :ARG1 (m / molecular-physical-entity
                                          :name (n2 / name :op1 "ROS"~e.7))
                                    :instrument (u / upregulate-01
                                          :ARG1 (e2 / enzyme
                                                :name (n3 / name :op1 "COX-2"~e.11,13))))
                              :ARG2 (o / oncogenicity~e.23
                                    :ARG1-of (a / activate-01)
                                    :poss~e.24 (e3 / enzyme~e.25
                                          :name (n4 / name :op1 "K-ras"~e.26,28)
                                          :ARG2-of~e.25 (m2 / mutate-01~e.25))
                                    :location~e.29 (l / lung~e.31)
                                    :ARG2-of~e.32 (r2 / result-01~e.34
                                          :ARG1~e.35 (d2 / damage-01~e.37
                                                :ARG1 (d / DNA~e.36)))))))))

# ::tok Constitutively active mutant K @-@ ras( V12 ) in E10 cells led to a highly significant ( P < 0.001 ) increased level of peroxides , and a corresponding increase in the amount of DNA strand @-@ break damage , compared with the parental line E10 and the vector control
# ::alignments 0-1.1.2.1 2-1.1 2-1.1.3 2-1.1.3.r 3-1.1.1.1 6-1.1.3.1 9-1.2.1.1 10-1.2 11-1 12-1.3.r 14-1.3.1.2.1 15-1.3.1.2 19-1.3.1.3.1.1 21-1.3.1 22-1.3.1.1 23-1.3.1.1.1.r 24-1.3.1.1.1 26-1.3 28-1.3.2.2 29-1.3.2 30-1.3.2.1.r 32-1.3.2.1 33-1.3.2.1.1.r 34-1.3.2.1.1.1.1.1 35-1.3.2.1.1.2 37-1.3.2.1.1.2 38-1.3.2.1.1 40-1.4 41-1.4.1.r 43-1.4.1.1.2 44-1.4.1.1 45-1.4.1.1.1.1 46-1.4.1 48-1.4.1.2.1 49-1.4.1.2
# ::id bel_pmid_1528_4181_28764
(l / lead-03~e.11
      :ARG0 (e / enzyme~e.2
            :name (n / name :op1 "K-ras"~e.3)
            :ARG1-of (a / activate-01
                  :mod (c / constitutive~e.0))
            :ARG2-of~e.2 (m / mutate-01~e.2 :value "V12"~e.6))
      :ARG1 (c2 / cell-line~e.10
            :name (n2 / name :op1 "E10"~e.9))
      :ARG2~e.12 (a2 / and~e.26
            :op1 (i / increase-01~e.21
                  :ARG1 (l2 / level~e.22
                        :quant-of~e.23 (p / peroxide~e.24))
                  :ARG2 (s2 / significant~e.15
                        :degree (h / high~e.14))
                  :mod (p3 / probability
                        :quant (l3 / less-than :op1 "0.001"~e.19)))
            :op2 (i2 / increase-01~e.29
                  :ARG1~e.30 (a3 / amount~e.32
                        :degree-of~e.33 (d / damage-01~e.38
                              :ARG1 (d2 / dna-sequence
                                    :name (n3 / name :op1 "DNA"~e.34))
                              :mod (s / strand-break~e.35,37)))
                  :ARG2-of (c4 / correspond-02~e.28
                        :ARG1 i)))
      :ARG1-of (c5 / compare-01~e.40
            :ARG2~e.41 (a4 / and~e.46
                  :op1 (c6 / cell-line~e.44
                        :name (n4 / name :op1 "E10"~e.45)
                        :mod (p2 / parent~e.43))
                  :op2 (c7 / control-01~e.49
                        :ARG0 (v / vector~e.48)))))

# ::tok STAT3 activation is much stronger and more prolonged in STAT1 @-@ null mouse embryo fibroblasts than in wild @-@ type cells .
# ::alignments 0-1.1.2.1.1.1 1-1.1.2 2-1.1.2.r 3-1.1.1 4-1.1 5-1 6-1.1.1.1 6-1.2.2 7-1.2 8-1.1.3.r 9-1.1.3.1.1.1 12-1.1.3.2.1 13-1.1.3.2 14-1.1.3 17-1.3.1.1 19-1.3.1.1 20-1.3.1
# ::id bel_pmid_1528_4232_30936
(a3 / and~e.5
      :op1 (s / strong~e.4
            :mod (m5 / much~e.3
                  :degree (m6 / more~e.6))
            :domain~e.2 (a2 / activate-01~e.1
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "STAT3"~e.0)))
            :location~e.8 (f / fibroblast~e.14
                  :mod (p3 / protein
                        :name (n2 / name :op1 "STAT1"~e.9)
                        :ARG2-of (m3 / mutate-01 :mod "-/-"))
                  :part-of (e / embryo~e.13
                        :mod (m4 / mouse~e.12))))
      :op2 (p / prolong-01~e.7
            :ARG1 a2
            :degree (m2 / more~e.6)
            :location f)
      :ARG1-of (c / compare-01
            :ARG2 (c2 / cell~e.20
                  :mod (w / wild-type~e.17,19))))

# ::tok In response to IFNgamma , SRC @-@ family kinases are required to activate STAT3 ( but not STAT1 ) through tyrosine phosphorylation , whereas the receptor @-@ bound kinases JAK1 and JAK2 are required to activate both STATs .
# ::alignments 1-1.3 2-1.3.1.r 3-1.3.1.1.1 5-1.1.1.1.2.1.1 7-1.1.1.1.1.1 8-1.1.1.1 10-1 10-1.2.1 12-1.1.1 12-1.1.2 12-1.2.1.1 13-1.1.1.2.1.1 15-1.1 15-1.2 16-1.1.2.1 16-1.1.2.1.r 17-1.1.2.3.1.1 20-1.1.1.3.1.1.1 21-1.1.1.3 23-1.1 25-1.2.1.1.1.1.2.1 27-1.2.1.1.1.1.2 28-1.2.1.1.1.1 28-1.2.1.1.1.2 29-1.2.1.1.1.1.1.1 30-1.2.1.1.1 31-1.2.1.1.1.2.1.1 33-1.2.1 35-1.2.1.1
# ::id bel_pmid_1528_4232_36882
(r2 / require-01~e.10
      :ARG1 (c / contrast-01~e.15,23
            :ARG1 (a / activate-01~e.12
                  :ARG0 (k / kinase~e.8
                        :ARG1-of (i / include-91
                              :ARG2 (f / family~e.7))
                        :mod (p / protein
                              :name (n7 / name :op1 "SRC"~e.5)))
                  :ARG1 (p5 / protein
                        :name (n2 / name :op1 "STAT3"~e.13))
                  :instrument (p3 / phosphorylate-01~e.21
                        :ARG1 (a6 / amino-acid
                              :name (n4 / name :op1 "tyrosine"~e.20))))
            :ARG2 (a2 / activate-01~e.12
                  :polarity~e.16 "-"~e.16
                  :ARG0 k
                  :ARG1 (p6 / protein
                        :name (n3 / name :op1 "STAT1"~e.17))
                  :instrument p3))
      :ARG1-of (c2 / contrast-01~e.15
            :ARG2 (r3 / require-01~e.10,33
                  :ARG1 (a3 / activate-01~e.12,35
                        :ARG0 (a4 / and~e.30
                              :op1 (k4 / kinase~e.28
                                    :name (n6 / name :op1 "JAK1"~e.29)
                                    :ARG1-of (b / bind-01~e.27
                                          :ARG2 (r4 / receptor~e.25)))
                              :op2 (k3 / kinase~e.28
                                    :name (n5 / name :op1 "JAK2"~e.31)
                                    :ARG1-of b))
                        :ARG1 (a5 / and
                              :op1 p5
                              :op2 p6))))
      :ARG2-of (r / respond-01~e.1
            :ARG1~e.2 (p2 / protein
                  :name (n / name :op1 "IFNgamma"~e.3))))

# ::tok Taken together , these observations strongly support a role for NADPH oxidase @-@ generated ROS in mediating hyperoxia @-@ induced Nrf2 activation in pulmonary epithelial cells .
# ::alignments 0-1.3 1-1.3.2 3-1.1.3 4-1.1 4-1.1.1 4-1.1.1.r 5-1.1.2.1 5-1.1.2.1.r 6-1 6-1.1.2 8-1.2 9-1.2.2.r 10-1.2.2.2.1.2.1.1 11-1.2.2.2.1.1 13-1.2.2.2 14-1.2.2.1.1 15-1.2.1.r 16-1.2.1 17-1.2.1.1.2.1 19-1.2.1.1.2 20-1.2.1.1.1.1.1 21-1.2.1.1 24-1.2.1.1.3.1 25-1.2.1.1.3
# ::id bel_pmid_1529_2179_16234
(s4 / support-01~e.6
      :ARG0 (t3 / thing~e.4
            :ARG1-of~e.4 (o / observe-02~e.4)
            :ARG0-of (s / support-01~e.6
                  :manner~e.5 (s2 / strong~e.5))
            :mod (t4 / this~e.3))
      :ARG1 (r / role~e.8
            :topic~e.15 (m4 / mediate-01~e.16
                  :ARG1 (a / activate-01~e.21
                        :ARG1 (p / protein
                              :name (n3 / name :op1 "Nrf2"~e.20))
                        :ARG1-of (i / induce-01~e.19
                              :ARG0 (h2 / hyperoxia~e.17))
                        :location (c / cell~e.25
                              :part-of (e2 / epithelium~e.24
                                    :part-of (l / lung)))))
            :beneficiary~e.9 (s3 / small-molecule
                  :name (n / name :op1 "ROS"~e.14)
                  :ARG1-of (g / generate-01~e.13
                        :ARG0 (m2 / macro-molecular-complex
                              :part (o2 / oxidase~e.11)
                              :part (m3 / molecular-physical-entity
                                    :name (n4 / name :op1 "NADPH"~e.10))))))
      :condition (t6 / take-01~e.0
            :ARG1 t3
            :mod (t2 / together~e.1)))

# ::tok hyperoxia stimulated ERK @-@ 1 and ERK @-@ 2 phosphorylation {SE : Canonical ERK phosphorylation leading directly to activation}
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.1.1.1.1 4-1.1.2.1.1.1.1 5-1.1.2.1 6-1.1.2.1.1.1.1 6-1.1.2.1.2.1.1 8-1.1.2.1.2.1.1 9-1.1.2 13-1.2.1.1.1 14-1.2 15-1.2.3 16-1.2.3.2 16-1.2.3.2.r
# ::id bel_pmid_1529_2179_22402
(m / multi-sentence
      :snt1 (s / stimulate-01~e.1
            :ARG0 (h / hyperoxia~e.0)
            :ARG1 (p2 / phosphorylate-01~e.9
                  :ARG1 (a / and~e.5
                        :op1 (e2 / enzyme
                              :name (n2 / name :op1 "ERK-1"~e.2,4,6))
                        :op2 (e3 / enzyme
                              :name (n3 / name :op1 "ERK-2"~e.6,8)))))
      :snt2 (p / phosphorylate-01~e.14
            :ARG1 (e / enzyme
                  :name (n / name :op1 "ERK"~e.13))
            :mod (c2 / canon)
            :ARG0-of (l / lead-03~e.15
                  :ARG2 (a2 / activate-01)
                  :manner~e.16 (d / direct~e.16))))

# ::tok Overexpression of the ERK @-@ 1 mutant , but not the ERK @-@ 2 mutant , significantly inhibited hyperoxia @-@ induced ARE transcription , suggesting that ERK @-@ 1 at least in part mediates Nrf2 translocation and its downstream target expression ( Fig . 7B ) .
# ::alignments 0-1.2.2 3-1.1.1.1.1.1 3-1.2.2.1.1.1 5-1.1.1.1.1.1 6-1.1.1.1 6-1.1.1.1.2 6-1.1.1.1.2.r 6-1.2.2.1 6-1.2.2.1.2 6-1.2.2.1.2.r 8-1 9-1.2.1 9-1.2.1.r 11-1.2.2.1.1.1 13-1.2.2.1.1.1 14-1.1.1.1 14-1.1.1.1.2 14-1.1.1.1.2.r 14-1.2.2.1 14-1.2.2.1.2 14-1.2.2.1.2.r 16-1.1.3 16-1.1.3.r 17-1.1 17-1.2 18-1.1.2.2.1 20-1.1.2.2 21-1.1.2.1.1.1 22-1.1.2 24-1.3 26-1.1.1.1.1.1 26-1.2.2.1.1.1 28-1.3.1.1 29-1.3.1.3 30-1.3.1.3 31-1.3.1.4 32-1.3.1.4 33-1.3.1 34-1.3.1.2.1.1.1.1 35-1.3.1.2.1 36-1.3.1.2 37-1.3.1.2.2.1 37-1.3.1.2.2.1.r 38-1.3.1.2.2.2 39-1.3.1.2.2.3 40-1.3.1.2.2 44-1.4.1.1
# ::id bel_pmid_1529_2179_37048
(c / contrast-01~e.8
      :ARG1 (i / inhibit-01~e.17
            :ARG0 (o / overexpress-00
                  :ARG2 (e2 / enzyme~e.6,14
                        :name (n / name :op1 "ERK-1"~e.3,5,26)
                        :ARG2-of~e.6,14 (m / mutate-01~e.6,14)))
            :ARG1 (t3 / transcribe-01~e.22
                  :ARG1 (m4 / molecular-physical-entity
                        :name (n3 / name :op1 "ARE"~e.21))
                  :ARG1-of (i3 / induce-01~e.20
                        :ARG0 (h / hyperoxia~e.18)))
            :manner~e.16 (s2 / significant~e.16))
      :ARG2 (i2 / inhibit-01~e.17
            :polarity~e.9 "-"~e.9
            :ARG0 (e3 / express-03~e.0
                  :ARG2 (e4 / enzyme~e.6,14
                        :name (n2 / name :op1 "ERK-2"~e.3,11,13,26)
                        :ARG1-of~e.6,14 (m2 / mutate-01~e.6,14)))
            :ARG1 t3)
      :ARG0-of (s / suggest-01~e.24
            :ARG1 (m3 / mediate-01~e.33
                  :ARG0 e2~e.28
                  :ARG1 (a2 / and~e.36
                        :op1 (t4 / translocate-00~e.35
                              :ARG1 (p / protein
                                    :name (n4 / name :op1 "Nrf2"~e.34)))
                        :op2 (e5 / express-03~e.40
                              :ARG2~e.37 p~e.37
                              :location (d / downstream~e.38)
                              :mod (t / target-01~e.39)))
                  :mod (a / at-least~e.29,30)
                  :degree (i4 / in-part~e.31,32)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "7B"~e.44)))

# ::tok hyperoxia stimulated ERK @-@ 1 and ERK @-@ 2 phosphorylation
# ::alignments 0-1.1 1-1 2-1.2.1.1.1.1 2-1.2.1.2.1.1 4-1.2.1.1.1.1 5-1.2.1 6-1.2.1.1.1.1 6-1.2.1.2.1.1 8-1.2.1.2.1.1 9-1.2
# ::id bel_pmid_1529_2179_378
(s / stimulate-01~e.1
      :ARG0 (h / hyperoxia~e.0)
      :ARG1 (p2 / phosphorylate-01~e.9
            :ARG1 (a / and~e.5
                  :op1 (e / enzyme
                        :name (n / name :op1 "ERK-1"~e.2,4,6))
                  :op2 (e2 / enzyme
                        :name (n2 / name :op1 "ERK-2"~e.2,6,8)))))

# ::tok Collectively , these results indicate that ERK @-@ 1 regulates hyperoxia @-@ stimulated Nrf2 phosphorylation and the subsequent ARE @-@ driven transcriptional response .
# ::alignments 0-1.3 2-1.1.2 3-1.1 3-1.1.1 3-1.1.1.r 4-1 5-1.2.r 6-1.2.1.1.1 8-1.2.1.1.1 9-1.2 10-1.2.2.1.1.2.1 12-1.2.2.1.1.2 13-1.2.2.1.1.1.1 14-1.2.2.1 15-1.2.2 17-1.2.2.2.1 18-1.2.2.2.3.1.1.1 20-1.2.2.2.3 22-1.2.2.2
# ::id bel_pmid_1529_2179_380
(i / indicate-01~e.4
      :ARG0 (t / thing~e.3
            :ARG2-of~e.3 (r / result-01~e.3)
            :mod (t3 / this~e.2))
      :ARG1~e.5 (r2 / regulate-01~e.9
            :ARG0 (e / enzyme
                  :name (n3 / name :op1 "ERK-1"~e.6,8))
            :ARG1 (a / and~e.15
                  :op1 (p2 / phosphorylate-01~e.14
                        :ARG1 (p / protein
                              :name (n / name :op1 "Nrf2"~e.13)
                              :ARG1-of (s / stimulate-01~e.12
                                    :ARG0 (h / hyperoxia~e.10))))
                  :op2 (r3 / respond-01~e.22
                        :mod (s2 / subsequent~e.17)
                        :mod (t2 / transcribe-01)
                        :ARG1-of (d / drive-02~e.20
                              :ARG0 (m / molecular-physical-entity
                                    :name (n2 / name :op1 "ARE"~e.18))))))
      :mod (c / collective~e.0))

# ::tok As was seen for wild @-@ type MEFs , hyperoxia enhanced the phosphorylation of endogenous Nrf2 ( lane 6 ) when compared with room air @-@ exposed controls ( lane 5 ) .
# ::alignments 2-1.4.1 2-1.4.1.1 2-1.4.1.1.r 4-1.4.1.1.1.2 6-1.4.1.1.1.2 9-1.1 10-1 12-1.2 15-1.2.1.1.1 17-1.2.1.3.1 18-1.2.1.3.1.1.1 21-1.3 22-1.3.2.r 23-1.3.2.1.1.1 24-1.3.2.1.1 26-1.3.2.1 27-1.3.2 29-1.3.2.2.1 30-1.3.2.2.1.1.1
# ::id bel_pmid_1529_2179_382
(e5 / enhance-01~e.10
      :ARG0 (h / hyperoxia~e.9)
      :ARG1 (p2 / phosphorylate-01~e.12
            :ARG1 (p / protein
                  :name (n / name :op1 "Nrf2"~e.15)
                  :mod (e2 / endogene)
                  :ARG1-of (d / describe-01
                        :ARG0 (l / lane~e.17
                              :ARG1-of (l2 / label-01 :ARG2 "6"~e.18)))))
      :condition (c3 / compare-01~e.21
            :ARG1 h
            :ARG2~e.22 (c2 / control~e.27
                  :ARG1-of (e3 / expose-01~e.26
                        :ARG2 (a / air~e.24
                              :mod (r / room~e.23)))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (l3 / lane~e.29
                              :ARG1-of (l4 / label-01 :ARG2 "5"~e.30)))))
      :ARG1-of (r2 / resemble-01
            :ARG2 (t / thing~e.2
                  :ARG1-of~e.2 (s2 / see-01~e.2
                        :location (f / fibroblast
                              :part-of (e4 / embryo
                                    :mod (m / mouse))
                              :mod (w / wild-type~e.4,6))))))

# ::tok In ERK @-@ 1+/+ MEFs , hyperoxia stimulated phosphorylation of Nrf2 ( lane 4 ) , when compared with room air @-@ exposed controls ( lane 3 ) .
# ::alignments 1-1.5.2.1.1 6-1.1 7-1 8-1.2 9-1.2.1.r 10-1.2.1.1.1 12-1.3.1 13-1.3.1.1.1 17-1.4 18-1.4.2.r 19-1.4.2.1.1.1 20-1.4.2.1.1 22-1.4.2.1 23-1.4.2 25-1.4.2.2.1 26-1.4.2.2.1.1.1
# ::id bel_pmid_1529_2179_384
(s2 / stimulate-01~e.7
      :ARG0 (h / hyperoxia~e.6)
      :ARG1 (p2 / phosphorylate-01~e.8
            :ARG1~e.9 (p / protein
                  :name (n / name :op1 "Nrf2"~e.10)))
      :ARG1-of (d / describe-01
            :ARG0 (l / lane~e.12
                  :ARG1-of (l2 / label-01 :ARG2 "4"~e.13)))
      :condition (c / compare-01~e.17
            :ARG1 s2
            :ARG2~e.18 (c2 / control~e.23
                  :ARG1-of (e2 / expose-01~e.22
                        :ARG2 (a / air~e.20
                              :mod (r / room~e.19)))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (l3 / lane~e.25
                              :ARG1-of (l4 / label-01 :ARG2 "3"~e.26)))))
      :location (f2 / fibroblast
            :part-of (e / embryo
                  :mod (m / mouse))
            :mod (e3 / enzyme
                  :name (n2 / name :op1 "ERK-1"~e.1)
                  :mod (w / wild-type))))

# ::tok However , a high proportion of Nrf2 accumulated in the nucleus of both cell types following the exposure of cells to hyperoxia ( Fig . 1A , right panels ) .
# ::alignments 0-1 3-1.1.1.1 4-1.1.1 5-1.1.1.2.r 6-1.1.1.2.1.1 7-1.1 8-1.1.2.r 10-1.1.2 11-1.1.2.1.r 12-1.1.2.1.2 13-1.1.2.1.1 14-1.1.2.1 17-1.1.3.1 18-1.1.3.1.1.r 19-1.1.3.1.1 20-1.1.3.1.2.r 21-1.1.3.1.2 25-1.2.1.1 27-1.2.1.2.1 28-1.2.1.2
# ::id bel_pmid_1529_2179_386
(h3 / have-concession-91~e.0
      :ARG1 (a / accumulate-01~e.7
            :ARG1 (p / proportion~e.4
                  :mod (h / high~e.3)
                  :quant-of~e.5 (p3 / protein
                        :name (n / name :op1 "Nrf2"~e.6)))
            :location~e.8 (n2 / nucleus~e.10
                  :part-of~e.11 (t / type~e.14
                        :mod (c2 / cell~e.13)
                        :mod (b / both~e.12)))
            :time (a2 / after
                  :op1 (e / expose-01~e.17
                        :ARG1~e.18 c2~e.19
                        :ARG2~e.20 (h2 / hyperoxia~e.21))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure
                  :mod "1A"~e.25
                  :location (p2 / panel~e.28
                        :ARG1-of (r / right-04~e.27)))))

# ::tok hyperoxia caused the translocation of Nrf2 from the cytoplasm to the nucleus within 30 @-@ 60 min of exposure
# ::alignments 0-1.1 1-1 3-1.2 4-1.2.1.r 5-1.2.1.1.1 6-1.2.2.r 8-1.2.2 9-1.2.3.r 9-1.2.4.2 11-1.2.3 13-1.2.4.2.1.1.1 15-1.2.4.2.1.2.1 18-1.2.4.1
# ::id bel_pmid_1529_2179_388
(c / cause-01~e.1
      :ARG0 (h / hyperoxia~e.0)
      :ARG1 (t / translocate-00~e.3
            :ARG1~e.4 (p / protein
                  :name (n / name :op1 "Nrf2"~e.5))
            :ARG2~e.6 (c2 / cytoplasm~e.8)
            :ARG3~e.9 (n2 / nucleus~e.11)
            :time (a / after
                  :op1 (e / expose-01~e.18)
                  :quant (u / up-to~e.9
                        :op1 (v / value-interval
                              :op1 (t2 / temporal-quantity
                                    :quant "30"~e.13
                                    :unit (m2 / minute))
                              :op2 (t3 / temporal-quantity
                                    :quant "60"~e.15
                                    :unit (m3 / minute)))))))

# ::tok The interleukin @-@ 6 ( IL6 ) family of cytokines signals through the common receptor subunit gp130 , and subsequently activates Stat3 , MAPK , and PI3K .
# ::alignments 1-1.1.1.1.1.1 3-1.1.1.1.1.1 7-1.1.1 10-1.1 13-1.1.2.2.1.1 14-1.1.2.2.1 15-1.1.2.2 16-1.1.2.1.1 18-1 19-1.2.2 19-1.2.2.r 20-1.2 21-1.2.1.1.1.1 23-1.2.1.2.1.1 26-1.2.1.3.1.1
# ::id bel_pmid_1529_2206_19252
(a / and~e.18
      :op1 (s / signal-01~e.10
            :ARG0 (f / family~e.7
                  :mod (p / protein
                        :name (n2 / name :op1 "interleukin-6"~e.1,3))
                  :ARG1-of (i / include-91
                        :ARG2 (c / cytokine)))
            :instrument (p4 / protein
                  :name (n3 / name :op1 "gp130"~e.16)
                  :mod (s2 / subunit~e.15
                        :part-of (r2 / receptor~e.14
                              :mod (c2 / common~e.13)))))
      :op2 (a2 / activate-01~e.20
            :ARG1 (a3 / and
                  :op1 (p3 / protein
                        :name (n4 / name :op1 "Stat3"~e.21))
                  :op2 (e / enzyme
                        :name (n / name :op1 "MAPK"~e.23))
                  :op3 (e2 / enzyme
                        :name (n5 / name :op1 "PI3K"~e.26)))
            :manner~e.19 (s4 / subsequent~e.19)))

# ::tok Experiments in primary mammary epithelial cells and transfected COS @-@ 7 cells revealed a p44 @/@ 42 MAPK and EGFR @-@ dependent Stat3 activation .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.2 3-1.1.1.1.3 4-1.1.1.1.1 5-1.1.1.1 6-1.1.1 7-1.1.1.2.2 8-1.1.1.2.1.1 10-1.1.1.2.1.1 11-1.1.1.2 12-1 18-1.2.2.1 19-1.2.2.1.1.1.1 21-1.2.2 22-1.2.1.1.1 23-1.2
# ::id bel_pmid_1529_2206_21658
(r / reveal-01~e.12
      :ARG0 (e / experiment-01~e.0
            :ARG1~e.1 (a / and~e.6
                  :op1 (c / cell~e.5
                        :part-of (e2 / epithelium~e.4)
                        :mod (p2 / primary~e.2)
                        :mod (m / mammary~e.3))
                  :op2 (c2 / cell-line~e.11
                        :name (n2 / name :op1 "COS-7"~e.8,10)
                        :ARG1-of (t / transfect-00~e.7))))
      :ARG1 (a2 / activate-01~e.23
            :ARG1 (p / protein
                  :name (n3 / name :op1 "Stat3"~e.22))
            :ARG0-of (d / depend-01~e.21
                  :ARG1 (a3 / and~e.18
                        :op1 (e5 / enzyme
                              :name (n4 / name :op1 "EGFR"~e.19))
                        :op2 (s / slash
                              :op1 (e3 / enzyme
                                    :name (n / name :op1 "p44MAPK"))
                              :op2 (e4 / enzyme
                                    :name (n5 / name :op1 "p42MAPK")))))))

# ::tok Stat3 controls cell death and tissue remodeling in the mouse mammary gland during involution , which is partially induced by IL6 and LIF .
# ::alignments 0-1.1.1.1 1-1 2-1.2.1.1 3-1.2.1 4-1.2 5-1.2.2.1 6-1.2.2 7-1.3.r 9-1.3.2 10-1.3.1 11-1.3 12-1.4.r 13-1.4 17-1.4.1.2 18-1.4.1 19-1.4.1.1.r 20-1.4.1.1.1.1.1 21-1.4.1.1 22-1.4.1.1.2.1.1
# ::id bel_pmid_1529_2206_28426
(c / control-01~e.1
      :ARG0 (p2 / protein
            :name (n / name :op1 "Stat3"~e.0))
      :ARG1 (a / and~e.4
            :op1 (d / die-01~e.3
                  :ARG1 (c2 / cell~e.2))
            :op2 (r / remodel-01~e.6
                  :ARG1 (t / tissue~e.5)))
      :location~e.7 (g2 / gland~e.11
            :mod (m / mammary~e.10)
            :part-of (m2 / mouse~e.9))
      :time~e.12 (i / involution~e.13
            :ARG1-of (i2 / induce-01~e.18
                  :ARG0~e.19 (a2 / and~e.21
                        :op1 (p3 / protein
                              :name (n2 / name :op1 "IL6"~e.20))
                        :op2 (p4 / protein
                              :name (n3 / name :op1 "LIF"~e.22)))
                  :degree (p / partial~e.17))))

# ::tok We found that the Tyr701 phosphorylation kinetics of Stat1 mediated by IFN stimulation was higher when cells were incubated with IFN @-@ alpha5 than when using IFN @-@ alpha2. Similarly , Tyr( 1054 @/@ 1055 ) phosphorylation kinetics of Tyk2 were more intense after exposure to IFN @-@ alpha5 than when using IFN @-@ alpha2. Concomitantly , Tyr705 phosphorylation of Stat3 was higher after stimulation with IFN @-@ alpha5 than with IFN @-@ alpha2 .
# ::alignments 0-1.1.1 1-1.1 5-1.1.2.4.1 6-1.1.2.4 7-1.1.2.4.1.1.r 8-1.1.2.4.1.1.3.1.1 9-1.1.2.4.2 10-1.1.2.4.2.1.r 11-1.1.2.4.2.1.1.1.1 12-1.1.2.4.2.1 13-1.1.2.4.r 14-1.1.2 14-1.1.2.1 14-1.1.2.1.r 14-1.3 14-1.3.1 14-1.3.1.r 15-1.3.3.r 16-1.1.2.2.1 18-1.1.2.2 20-1.1.2.2.2.1.1 20-1.1.2.3.1.1.1 22-1.1.2.2.2.1.1 23-1.1.2.3.r 24-1.3.3.r 25-1.1.2.3 26-1.1.2.3.1.1.1 26-1.3.3.1.1.1.1 26-1.3.4.1.1.1 29-1.2.5 32-1.2.3.1.1.1.1 34-1.2.3.1.1.2.1 36-1.2.3.1 37-1.2.3 39-1.2.3.1.1.1.3.1.1 40-1.2.3.r 41-1.1.2.1 41-1.2.1 41-1.3.1 42-1.2 43-1.2.4 44-1.2.4.1 46-1.2.2.1.1.1 46-1.2.4.1.1.1.1 48-1.2.4.1.1.1.1 49-1.2.2.r 50-1.2.4.r 51-1.2.2 52-1.1.2.3.1.1.1 52-1.2.2.1.1.1 52-1.3.3.1.1.1.1 52-1.3.4.1.1.1 55-1.3.5 58-1.3.2 59-1.3.2.1.r 60-1.3.2.1.3.1.1 61-1.3.2.r 62-1.3 62-1.3.1 62-1.3.1.r 63-1.3.3 64-1.3.3.1 64-1.3.4 66-1.3.3.1.1.1.1 66-1.3.4.1.1.1 68-1.3.3.1.1.1.1 69-1.3.4.r 71-1.1.2.3.1.1.1 71-1.2.2.1.1.1 71-1.3.4.1.1.1 73-1.1.2.3.1.1.1 73-1.2.2.1.1.1 73-1.3.4.1.1.1
# ::id bel_pmid_1532_0963_2798
(m / multi-sentence
      :snt1 (f / find-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (h2 / high~e.14
                  :degree~e.14 (m3 / more~e.14,41)
                  :condition (i / incubate-01~e.18
                        :ARG1 (c / cell~e.16)
                        :ARG2 (p4 / protein
                              :name (n4 / name :op1 "IFN-alpha5"~e.20,22)))
                  :compared-to~e.23 (u / use-01~e.25
                        :ARG1 (p5 / protein
                              :name (n7 / name :op1 "IFN-alpha2"~e.20,26,52,71,73)))
                  :domain~e.13 (k / kinetics~e.6
                        :mod (p2 / phosphorylate-01~e.5
                              :ARG1~e.7 (a / amino-acid
                                    :mod "701"
                                    :name (n / name :op1 "tyrosine")
                                    :part-of (p / protein
                                          :name (n12 / name :op1 "Stat1"~e.8))))
                        :ARG1-of (m2 / mediate-01~e.9
                              :ARG0~e.10 (s / stimulate-01~e.12
                                    :ARG0 (p3 / protein
                                          :name (n3 / name :op1 "IFN"~e.11)))))))
      :snt2 (i2 / intense~e.42
            :degree (m4 / more~e.41)
            :compared-to~e.49 (u2 / use-01~e.51
                  :ARG1 (p7 / protein
                        :name (n8 / name :op1 "IFN-alpha2"~e.46,52,71,73)))
            :domain~e.40 (k3 / kinetics~e.37
                  :mod (p6 / phosphorylate-01~e.36
                        :ARG1 (s2 / slash
                              :op1 (a4 / amino-acid
                                    :mod "1054"~e.32
                                    :name (n2 / name :op1 "tyrosine")
                                    :part-of (e2 / enzyme
                                          :name (n6 / name :op1 "Tyk2"~e.39)))
                              :op2 (a5 / amino-acid
                                    :mod "1055"~e.34
                                    :name (n5 / name :op1 "tyrosine")
                                    :part-of e2))))
            :time~e.50 (a3 / after~e.43
                  :op1 (e / expose-01~e.44
                        :ARG1 (p8 / protein
                              :name (n9 / name :op1 "IFN-alpha5"~e.46,48))))
            :ARG1-of (r / resemble-01~e.29))
      :snt3 (h / high~e.14,62
            :degree~e.14,62 (m5 / more~e.14,41,62)
            :domain~e.61 (p9 / phosphorylate-01~e.58
                  :ARG1~e.59 (a6 / amino-acid
                        :mod "705"
                        :name (n13 / name :op1 "tyrosine")
                        :part-of (p10 / protein
                              :name (n14 / name :op1 "Stat3"~e.60))))
            :time~e.15,24 (a7 / after~e.63
                  :op1 (s3 / stimulate-01~e.64
                        :ARG0 (p11 / protein
                              :name (n15 / name :op1 "IFN-alpha5"~e.26,52,66,68))))
            :compared-to~e.69 (s4 / stimulate-01~e.64
                  :ARG0 (p12 / protein
                        :name (n16 / name :op1 "IFN-alpha2"~e.26,52,66,71,73)))
            :mod (c2 / concomitant~e.55)))

# ::tok Results obtained with H @-@ RasV12 partial loss of function mutants H @-@ RasV12S35 ( Raf signal only ) , H @-@ RasV12C40 ( PI3 @-@ kinase signal only ) and H @-@ RasV12G37 ( RalGEFs signal only ) suggest that the H @-@ Ras induction of the mouse ST6Gal I gene ( Siat1 ) transcription is primarily routed through RalGEFs .
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 1-1.1.2 2-1.1.2.1.r 3-1.1.2.1.1.1.1 3-1.1.2.1.1.3.1.1.1 3-1.1.2.1.2.1.1 3-1.1.2.1.3.1.1 6-1.1.2.1.1.3.1.3.2 7-1.1.2.1.1.3.1.3 8-1.1.2.1.1.3.1.3.1.r 9-1.1.2.1.1.3.1.3.1 10-1.1.2.1.1 10-1.1.2.1.1.2 10-1.1.2.1.1.2.r 10-1.1.2.1.1.3.1 10-1.1.2.1.1.3.1.2 10-1.1.2.1.1.3.1.2.r 10-1.1.2.1.2 10-1.1.2.1.2.2 10-1.1.2.1.2.2.r 10-1.1.2.1.3 10-1.1.2.1.3.2 10-1.1.2.1.3.2.r 11-1.1.2.1.1.1.1 11-1.1.2.1.1.3.1.1.1 15-1.1.2.1.1.4.1.1.1 16-1.1.2.1.1.4 16-1.1.2.1.2.3 16-1.1.2.1.3.3 20-1.1.2.1.1.1.1 20-1.1.2.1.2.1.1 20-1.1.2.1.3.1.1 26-1.1.2.1.2.3.1 27-1.1.2.1.1.4 27-1.1.2.1.2.3 27-1.1.2.1.3.3 30-1.1.2.1 31-1.1.2.1.1.1.1 31-1.1.2.1.2.1.1 31-1.1.2.1.3.1.1 36-1.1.2.1.1.4 36-1.1.2.1.2.3 36-1.1.2.1.3.3 39-1 42-1.1.2.1.3.1.1 42-1.2.2.1.1.1 44-1.1.2.1.3.1.1 44-1.2.2.1.1.1 45-1.2.2 49-1.2.2.2.1.1.1 50-1.2.2.2.1.1.2 51-1.2.2.2.1 55-1.2.2.2 57-1.2.3 58-1.2
# ::id bel_pmid_1535_5339_19518
(s / suggest-01~e.39
      :ARG0 (t / thing~e.0
            :ARG2-of~e.0 (r / result-01~e.0)
            :ARG1-of (o / obtain-01~e.1
                  :instrument~e.2 (a / and~e.30
                        :op1 (e / enzyme~e.10
                              :name (n3 / name :op1 "H-Ras"~e.3,11,20,31)
                              :ARG2-of~e.10 (m / mutate-01~e.10 :value "V12S35")
                              :ARG1-of (m5 / mean-01
                                    :ARG2 (e2 / enzyme~e.10
                                          :name (n / name :op1 "H-Ras"~e.3,11)
                                          :ARG2-of~e.10 (m6 / mutate-01~e.10 :value "V12")
                                          :ARG0-of (l2 / lose-02~e.7
                                                :ARG1~e.8 (f2 / function~e.9)
                                                :degree (p / partial~e.6))))
                              :ARG1-of (s2 / signal-01~e.16,27,36
                                    :ARG0 (e5 / enzyme
                                          :name (n2 / name :op1 "Raf"~e.15))))
                        :op2 (e3 / enzyme~e.10
                              :name (n4 / name :op1 "H-Ras"~e.3,20,31)
                              :ARG2-of~e.10 (m2 / mutate-01~e.10 :value "V12C40")
                              :ARG1-of (s3 / signal-01~e.16,27,36
                                    :ARG0 (k / kinase~e.26
                                          :name (n6 / name :op1 "P13"))))
                        :op3 (e4 / enzyme~e.10
                              :name (n5 / name :op1 "H-Ras"~e.3,20,31,42,44)
                              :ARG2-of~e.10 (m3 / mutate-01~e.10 :value "V12G37")
                              :ARG1-of (s4 / signal-01~e.16,27,36
                                    :ARG0 (p2 / pathway
                                          :name (n9 / name :op1 "RalGEF")))))))
      :ARG1 (r2 / route-01~e.58
            :ARG0 p2
            :ARG1 (i / induce-01~e.45
                  :ARG0 (e6 / enzyme
                        :name (n7 / name :op1 "H-Ras"~e.42,44))
                  :ARG1 (t2 / transcribe-01~e.55
                        :ARG1 (g / gene~e.51
                              :name (n8 / name :op1 "ST6Gal"~e.49 :op2 "I"~e.50))))
            :mod (p3 / primary~e.57)))

# ::tok Transformation by human K @-@ Ras or H @-@ Ras ( S12 and V12 point mutations , respectively ) results in a 10 @-@ fold increase in ST6Gal I mRNA , but no alteration in the expression of related sialyltransferases .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.3 3-1.1.1.1.1.1 5-1.1.1.1.1.1 5-1.1.1.2.1.1 6-1.1.1 7-1.1.1.2.1.1 9-1.1.1.2.1.1 13-1.1.1.2.2.1 15-1.1.1.1 15-1.1.1.1.2 15-1.1.1.1.2.r 15-1.1.1.2 15-1.1.1.2.2 15-1.1.1.2.2.r 19-1 20-1.2.r 22-1.2.1.2.1 25-1.2.1 27-1.2.1.1.2.1.1.1 28-1.2.1.1.2.1.1.2 29-1.2.1.1.1.1 31-1.2 32-1.2.2.1 32-1.2.2.1.r 33-1.2.2 34-1.2.2.2.r 36-1.2.2.2 37-1.2.2.2.1.r 38-1.2.2.2.1.2
# ::id bel_pmid_1535_5339_20914
(r / result-01~e.19
      :ARG1 (t / transform-01~e.0
            :ARG0~e.1 (o / or~e.6
                  :op1 (e / enzyme~e.15
                        :name (n / name :op1 "K-Ras"~e.3,5)
                        :ARG2-of~e.15 (m / mutate-01~e.15 :value "S2")
                        :mod (h / human~e.2))
                  :op2 (e2 / enzyme~e.15
                        :name (n2 / name :op1 "H-Ras"~e.5,7,9)
                        :ARG2-of~e.15 (m2 / mutate-01~e.15 :value "V12"~e.13)
                        :mod h)))
      :ARG2~e.20 (c / contrast-01~e.31
            :ARG1 (i / increase-01~e.25
                  :ARG1 (r2 / rna
                        :name (n4 / name :op1 "mRNA"~e.29)
                        :ARG0-of (e5 / encode-01
                              :ARG1 (e6 / enzyme
                                    :name (n3 / name :op1 "ST6Gal"~e.27 :op2 "I"~e.28))))
                  :ARG2 (p / product-of :op1 "10"~e.22))
            :ARG2 (a / alter-01~e.33
                  :polarity~e.32 "-"~e.32
                  :ARG1~e.34 (e3 / express-03~e.36
                        :ARG2~e.37 (e4 / enzyme
                              :name (n5 / name :op1 "sialyltransferase")
                              :ARG1-of (r3 / relate-01~e.38))))))

# ::tok The accumulation of the ST6Gal I transcript in response to activated Ras was accompanied by an increase of alpha2,6 @-@ sialyltransferase activity and of Neu5Acalpha2,6Gal at the cell surface .
# ::alignments 1-1.2 2-1.2.1.r 4-1.2.1.1.1.1.1 5-1.2.1.1.1.1.1 7-1.2.2.r 8-1.2.2 9-1.2.2.1.r 10-1.2.2.1.2 11-1.2.2.1.1.1 13-1 14-1.1.r 16-1.1 17-1.1.1.r 18-1.1.1.1.1.1.1 20-1.1.1.1.1.1.1 21-1.1.1 22-1.1.1.1 23-1.1.1.1.r 24-1.1.1.1.2.1.1 25-1.1.1.2.r 27-1.1.1.2.1 28-1.1.1.2
# ::id bel_pmid_1535_5339_5770
(a6 / accompany-01~e.13
      :ARG0~e.14 (i / increase-01~e.16
            :ARG1~e.17 (a4 / act-02~e.21
                  :ARG0~e.23 (a5 / and~e.22
                        :op1 (e3 / enzyme
                              :name (n4 / name :op1 "alpha2,6-sialyltransferase"~e.18,20))
                        :op2 (e4 / enzyme
                              :name (n5 / name :op1 "Neu5Acalpha2,6Gal"~e.24)))
                  :location~e.25 (s / surface~e.28
                        :part-of (c / cell~e.27))))
      :ARG1 (a / accumulate-01~e.1
            :ARG1~e.2 (m / molecular-physical-entity
                  :ARG0-of (t / transcribe-01
                        :ARG1 (e / enzyme
                              :name (n2 / name :op1 "ST6Gal-I"~e.4,5))))
            :ARG2-of~e.7 (r / respond-01~e.8
                  :ARG1~e.9 (e2 / enzyme
                        :name (n3 / name :op1 "Ras"~e.11)
                        :ARG1-of (a3 / activate-01~e.10)))))

# ::tok Over @-@ expression of constitutively activated H @-@ Ras ( CA @-@ Ras ) in Ba @/@ F3 cells blocked down @-@ modulation of Survivin expression , G0 @/@ G1 arrest , and apoptosis induced by IL @-@ 3 withdrawal , while dominant @-@ negative ( DN ) H @-@ Ras down @-@ regulated Survivin .
# ::alignments 2-1.1.2.1.1 4-1.1.1.1.2.1 4-1.1.1.1.2.1.r 5-1.1.1.1.2 6-1.1.1.1.1.1 8-1.1.1.1.1.1 12-1.1.1.1.1.1 15-1.1.1.2.1.1 17-1.1.1.2.1.1 18-1.1.1.2 18-1.1.2.2.1 19-1.1 24-1.1.2.1.1.1.1.1 25-1.1.2.1.1 27-1.1.2.2.1.1.1 29-1.1.2.2.1.1.1 30-1.1.2.2 32-1.1.2 33-1.1.2.3 34-1.1.2.3.1 35-1.1.2.3.1.1.r 36-1.1.2.3.1.1.1.1.1 38-1.1.2.3.1.1.1.1.1 39-1.1.2.3.1.1 41-1 48-1.2.1.2.1 50-1.2.1.2.1 54-1.2.2
# ::id bel_pmid_1536_9798_27516
(c4 / contrast-01~e.41
      :ARG1 (b / block-01~e.19
            :ARG0 (o / overexpress-00
                  :ARG2 (e / enzyme
                        :name (n / name :op1 "H-Ras"~e.6,8,12)
                        :ARG1-of (a / activate-01~e.5
                              :manner~e.4 (c / constitutive~e.4)))
                  :ARG3 (c5 / cell-line~e.18
                        :name (n7 / name :op1 "Ba/F3"~e.15,17)))
            :ARG1 (a2 / and~e.32
                  :op1 (d4 / downmodulate-00
                        :ARG1 (e3 / express-03~e.2,25
                              :ARG2 (p / protein
                                    :name (n3 / name :op1 "Survivin"~e.24))))
                  :op2 (a3 / arrest-02~e.30
                        :ARG1 (c3 / cell-line~e.18
                              :name (n4 / name :op1 "G0/G1"~e.27,29)))
                  :op3 (a4 / apoptosis~e.33
                        :ARG1-of (i / induce-01~e.34
                              :ARG0~e.35 (w / withdraw-01~e.39
                                    :ARG1 (p2 / protein
                                          :name (n5 / name :op1 "IL-3"~e.36,38)))))))
      :ARG2 (d / downregulate-01
            :ARG0 (e4 / enzyme
                  :mod "-/-"
                  :name (n6 / name :op1 "H-Ras"~e.48,50))
            :ARG1 p~e.54))

# ::tok Survivin disruption by DN T34A Survivin blocked CA @-@ Ras @-@ induced IL @-@ 3 @-@ independent cell survival and proliferation ; however , it did not affect CA @-@ Ras @-@ mediated enhancement of S @-@ phase , indicating that the anti @-@ apoptotic activity of CA @-@ Ras is Survivin dependent while its S @-@ phase enhancing effect is not .
# ::alignments 0-1.2.1.1.1.1 0-1.2.1.2.1.1 1-1.2.1 4-1.2.1.1.2.1 5-1.2.1.1.1.1 5-1.2.1.2.1.1 6-1.2 7-1.2.2.1.2.1.1.1 9-1.2.2.1.2.1.1.1 11-1.2.2.1.2 12-1.2.2.1.3.1.1.1 14-1.2.2.1.3.1.1.1 16-1.1.4.1.2.1 16-1.2.2.1.3 17-1.2.2.1.1 18-1.2.2.1 19-1.2.2 20-1.2.2.2 22-1 24-1.1.2 26-1.1.1 26-1.1.1.r 27-1.1 28-1.1.3.2.1 29-1.1.3.2.1 30-1.1.3.2.1 32-1.1.3.2 33-1.1.3 34-1.1.3.1.r 35-1.1.3.1.1.1 37-1.1.3.1.1.1 39-1.1.4 40-1.1.4.1.r 42-1.1.4.1.1.2 44-1.1.4.1.1.2.1 45-1.1.4.1.1 46-1.1.4.1.1.1.r 47-1.1.4.1.1.1 48-1.1.4.1.1.1 49-1.1.4.1.1.1 51-1.2.1.1.1.1 51-1.2.1.2.1.1 52-1.1.4.1.1.3 52-1.1.4.1.2 53-1.1.4.1 55-1.1.4.1.2.2.1.1 56-1.1.4.1.2.2.1.1 57-1.1.4.1.2.2.1.1 58-1.1.4.1.2.2.1 59-1.1.4.1.2.2 61-1.1.4.1.2.1.r
# ::id bel_pmid_1536_9798_8104
(h / have-concession-91~e.22
      :ARG1 (a2 / affect-01~e.27
            :polarity~e.26 "-"~e.26
            :ARG0 d~e.24
            :ARG1 (e2 / enhance-01~e.33
                  :ARG1~e.34 (e5 / event
                        :name (n / name :op1 "S-phase"~e.35,37))
                  :ARG1-of (m / mediate-01~e.32
                        :ARG0 e~e.28,29,30))
            :ARG0-of (i2 / indicate-01~e.39
                  :ARG1~e.40 (c3 / contrast-01~e.53
                        :ARG1 (a3 / act-02~e.45
                              :ARG0~e.46 e~e.47,48,49
                              :ARG0-of (o / oppose-01~e.42
                                    :ARG1 (a4 / apoptosis~e.44))
                              :ARG0-of (d4 / depend-01~e.52
                                    :ARG1 (p / protein
                                          :name (n5 / name :op1 "Survivin"~e.0,5,51))))
                        :ARG2 (d5 / depend-01~e.52
                              :polarity~e.61 "-"~e.16
                              :ARG0 (e3 / effect~e.59
                                    :mod (e4 / enhance-01~e.58
                                          :ARG0 e5~e.55,56,57))
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "Survivin"~e.0,5,51)
                                    :ARG2-of (m2 / mutate-01 :value "T34A"~e.4 :mod "-/-"))))))
      :ARG2 (b / block-01~e.6
            :ARG0 (d / disrupt-01~e.1
                  :ARG0 p2
                  :ARG1 p)
            :ARG1 (a / and~e.19
                  :op1 (s / survive-01~e.18
                        :ARG0 (c / cell~e.17)
                        :ARG1-of (i / induce-01~e.11
                              :ARG0 (e / enzyme
                                    :name (n3 / name :op1 "CA-Ras"~e.7,9)))
                        :ARG0-of (d3 / depend-01~e.16
                              :ARG1 (p5 / protein
                                    :name (n4 / name :op1 "IL-3"~e.12,14))))
                  :op2 (p3 / proliferate-01~e.20
                        :ARG0 c
                        :ARG1-of i
                        :ARG0-of d3))))

# ::tok Survivin expression is up @-@ regulated by IL @-@ 3 in Ba @/@ F3 and CD34+ cells and inhibited by the Ras inhibitor , farnesylthiosalicylic acid .
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 1-1.1.3.2.1 7-1.1.2.1.1 9-1.1.2.1.1 11-1.1.3.1.1.1 13-1.1.3.1.1.1 14-1.1.3 15-1.1.3.2.1.1.1.1 16-1.1.3.2 17-1 17-1.1.3 18-1.2 18-1.2.1.2 21-1.2.1.2.1.1.1 22-1.2 22-1.2.1.2
# ::id bel_pmid_1536_9798_9254
(a2 / and~e.17
      :op1 (u / upregulate-01
            :ARG1 (e2 / express-03~e.1
                  :ARG2 (p / protein
                        :name (n2 / name :op1 "Survivin"~e.0)))
            :ARG2 (p2 / protein
                  :name (n3 / name :op1 "IL-3"~e.7,9))
            :location (a / and~e.14,17
                  :op1 (c2 / cell-line
                        :name (n4 / name :op1 "Ba/F3"~e.11,13))
                  :op2 (c3 / cell~e.16
                        :ARG3-of (e / express-03~e.1
                              :ARG2 (p3 / protein
                                    :name (n / name :op1 "CD34+"~e.15))))))
      :op2 (i2 / inhibit-01~e.18,22
            :ARG0 (m / molecular-physical-entity
                  :name (n5 / name :op1 "farnesylthiosalicylic acid")
                  :ARG0-of (i / inhibit-01~e.18,22
                        :ARG1 (e3 / enzyme
                              :name (n6 / name :op1 "Ras"~e.21))))
            :ARG1 e2))

# ::tok By contrast , serum @- and glucocorticoid @-@ inducible kinase 1 ( SGK1 ) was significantly induced in a p53 @-@ dependent manner after DNA damage , and this induction was through extracellular signal @-@ regulated kinase 1 @/@ 2 @-@ mediated posttranslational regulation .
# ::alignments 1-1 8-1.1 9-1.1.5.3.1.1.1.1 10-1.1.5.3.1.1.1.2 12-1.1.1.1.1 15-1.1.4 16-1.1 17-1.1.2.r 19-1.1.2.1.1.1 21-1.1.2 22-1.1.4.r 23-1.1.3 23-1.1.5.4 24-1.1.3.1.1 25-1.1.3.1 29-1.1 32-1.1.5.1 33-1.1.5.2.1 35-1.1.5 35-1.1.5.2 35-1.1.5.2.r 36-1.1.5.3.1.1.1.1 37-1.1.5.3.1.1.1.2 39-1.1.5.3.1.2.1.2 41-1.1.5.3 43-1.1.5
# ::id bel_pmid_1538_3658_21950
(c / contrast-01~e.1
      :ARG2 (i / induce-01~e.8,16,29
            :ARG1 (e3 / enzyme
                  :name (n3 / name :op1 "SGK1"~e.12))
            :manner~e.17 (d / depend-01~e.21
                  :ARG1 (p / protein
                        :name (n / name :op1 "p53"~e.19)))
            :time (a2 / after~e.23
                  :op1 (d2 / damage-01~e.25
                        :ARG1 (d3 / DNA~e.24)))
            :manner~e.22 (s3 / significant~e.15)
            :instrument (r2 / regulate-01~e.35,43
                  :mod (e / extracellular~e.32)
                  :ARG1-of~e.35 (r / regulate-01~e.35
                        :ARG0 (s / signal-01~e.33))
                  :ARG1-of (m / mediate-01~e.41
                        :ARG0 (s2 / slash
                              :op1 (e2 / enzyme
                                    :name (n2 / name :op1 "kinase"~e.9,36 :op2 "1"~e.10,37))
                              :op2 (e4 / enzyme
                                    :name (n4 / name :op1 "kinase" :op2 "2"~e.39))))
                  :time (a4 / after~e.23
                        :op1 (t2 / translate-01)))))

# ::tok IL @-@ 6 family cytokines ( Interleukin @-@ 6 and Oncostatin M ( OSM ))-increase STAT3 phosphorylation ( pSTAT3 ) , increase CCAAT enhancer binding protein delta ( C/EBPdelta ) gene expression
# ::alignments 0-1.1.1.1.1.1.1 2-1.1.1.1.1.1.1 3-1.1.1.1 6-1.1.2.1.1.1.1 8-1.1.2.1.1.1.1 9-1.1.2.1 10-1.1.2.1.2.1.1 11-1.1.2.1.2.1.1 15-1.2.1.1.1.1 16-1.2.1 21-1 25-1.1.1.1.1 25-1.1.2.1.1 25-1.1.2.1.2 25-1.2.1.1 28-1.2.2.1.1.1 30-1.2.2.1 31-1.2.2
# ::id bel_pmid_1538_9879_2572
(i / increase-01~e.21
      :ARG0 (c / cytokine
            :ARG1-of (i2 / include-91
                  :ARG2 (f2 / family~e.3
                        :mod (p4 / protein~e.25
                              :name (n7 / name :op1 "IL-6"~e.0,2))))
            :ARG1-of (m2 / mean-01
                  :ARG2 (a3 / and~e.9
                        :op1 (p5 / protein~e.25
                              :name (n8 / name :op1 "Interleukin-6"~e.6,8))
                        :op2 (p6 / protein~e.25
                              :name (n9 / name :op1 "Oncostatin-M"~e.10,11)))))
      :ARG1 (a2 / and
            :op1 (p / phosphorylate-01~e.16
                  :ARG1 (p2 / protein~e.25
                        :name (n5 / name :op1 "STAT3"~e.15)))
            :op2 (e / express-03~e.31
                  :ARG2 (g3 / gene~e.30
                        :name (n6 / name :op1 "C/EBPdelta"~e.28)))))

# ::tok results indicate that BCL @-@ 6 negatively regulates proliferation of the monocytic @/@ macrophage lineage by suppressing an autocrine IL @-@ 6/STAT3 @-@ mediated gene expression program .
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 1-1 3-1.2.1.1.1 5-1.2.1.1.1 8-1.2.2 13-1.2.2.1.2.1 14-1.2.2.1.1 14-1.2.2.1.2 16-1.2.3 18-1.2.3.1.3 19-1.2.3.1.2.1.1.1.1 23-1.2.3.1.2 24-1.2.3.1.1.1 25-1.2.3.1.1 26-1.2.3.1
# ::id bel_pmid_1550_7530_2578
(i / indicate-01~e.1
      :ARG0 (t / thing~e.0
            :ARG2-of~e.0 (r / result-01~e.0))
      :ARG1 (d / downregulate-01
            :ARG0 (p3 / protein
                  :name (n / name :op1 "BCL-6"~e.3,5))
            :ARG1 (p / proliferate-01~e.8
                  :ARG0 (s2 / slash
                        :op1 (l2 / lineage~e.14
                              :mod (m2 / monocyte))
                        :op2 (l3 / lineage~e.14
                              :mod (m3 / macrophage~e.13))))
            :manner (s / suppress-01~e.16
                  :ARG1 (p2 / program~e.26
                        :mod (e / express-03~e.25
                              :ARG2 (g2 / gene~e.24))
                        :ARG1-of (m / mediate-01~e.23
                              :ARG0 (s3 / slash
                                    :op1 (p4 / protein
                                          :name (n3 / name :op1 "IL-6"~e.19))
                                    :op2 (p5 / protein
                                          :name (n4 / name :op1 "STAT3"))))
                        :mod (a / autocrine~e.18)))))

# ::tok Crucial to this enhanced proliferation is spontaneous interleukin 6 ( IL @-@ 6 ) production and signal transducer and activator of transcription 3 ( STAT3 ) activation in BCL @-@ 6(-/-) macrophages . Gene expression studies demonstrate that BCL @-@ 6 binds to several sequence motifs scattered in the IL @-@ 6 locus and can repress IL @-@ 6 transcription both in 293T cells and in macrophages .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.2 3-1.1.1.1 4-1.1.1 5-1.1.2.r 6-1.1.2.1.2 7-1.1.2.1.1.1.1 8-1.1.2.1.1.1.1 8-1.2.2.1.1.1.1 8-1.2.2.1.2.3.1.1.1.1 10-1.2.2.1.2.3.1.1.1.1 12-1.1.2.1.1.1.1 12-1.2.2.1.1.1.1 12-1.2.2.1.2.3.1.1.1.1 14-1.1.2.1 15-1.1.2 16-1.1.2.2.1.1.1 17-1.1.2.2.1.1.2 18-1.1.2.2.1.1.3 19-1.1.2.2.1.1.4 20-1.1.2.2.1.1.5 21-1.1.2.2.1.1.6 22-1.1.2.2.1.1.7 26-1.1.2.2 27-1.1.2.2.2.r 28-1.1.2.2.2.1.1.1 31-1.1.2.2.2 33-1.2.1.1.1 34-1.2.1.1 35-1.2.1 36-1.2 38-1.2.2.1.1.1.1 40-1.2.2.1.1.1.1 40-1.2.2.1.2.3.1.1.1.1 41-1.2.2.1 43-1.2.2.1.2.2 44-1.2.2.1.2.1 45-1.2.2.1.2 46-1.2.2.1.2.3 49-1.2.2.1.2.3.1.1.1.1 51-1.2.2.1.2.3.1.1.1.1 52-1.2.2.1.2.3.1 53-1.2.2 54-1.2.2.2 55-1.2.2.2.1 56-1.2.2.1.2.3.1.1.1.1 58-1.2.2.1.1.1.1 58-1.2.2.1.2.3.1.1.1.1 59-1.2.2.2.1.2 61-1.2.2.2.1.3.r 62-1.2.2.2.1.3.1.1.1 63-1.2.2.2.1.3.1 64-1.2.2.2.1.3 66-1.2.2.2.1.3.2
# ::id bel_pmid_1550_7530_32694
(m3 / multi-sentence
      :snt1 (c / crucial~e.0
            :prep-to~e.1 (p3 / proliferate-01~e.4
                  :ARG1-of (e / enhance-01~e.3)
                  :mod (t2 / this~e.2))
            :domain~e.5 (a2 / and~e.15
                  :op1 (p / produce-01~e.14
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "interleukin-6"~e.7,8,12))
                        :mod (s / spontaneous~e.6))
                  :op2 (a3 / activate-01~e.26
                        :ARG1 (p8 / protein
                              :name (n9 / name
                                    :op1 "signal"~e.16
                                    :op2 "transducer"~e.17
                                    :op3 "and"~e.18
                                    :op4 "activator"~e.19
                                    :op5 "of"~e.20
                                    :op6 "transcription"~e.21
                                    :op7 "3"~e.22))
                        :location~e.27 (m4 / macrophage~e.31
                              :mod (p4 / protein
                                    :name (n4 / name :op1 "BCL-6"~e.28)
                                    :ARG2-of (m / mutate-01 :mod "-/-"))))))
      :snt2 (d / demonstrate-01~e.36
            :ARG0 (s2 / study-01~e.35
                  :ARG1 (e2 / express-03~e.34
                        :ARG2 (g2 / gene~e.33)))
            :ARG1 (a4 / and~e.53
                  :op1 (b / bind-01~e.41
                        :ARG0 (p7 / protein
                              :name (n8 / name :op1 "BCL-6"~e.8,12,38,40,58))
                        :ARG1 (m2 / motif~e.45
                              :mod (s4 / sequence~e.44)
                              :quant (s5 / several~e.43)
                              :ARG1-of (s6 / scatter-01~e.46
                                    :ARG2 (l / locus~e.52
                                          :location-of (g3 / gene
                                                :name (n5 / name :op1 "IL-6"~e.8,10,12,40,49,51,56,58))))))
                  :op2 (p5 / possible~e.54
                        :domain (r / repress-01~e.55
                              :ARG0 p7
                              :ARG1 (t4 / transcribe-01~e.59
                                    :ARG1 g3)
                              :location~e.61 (a5 / and~e.64
                                    :op1 (c2 / cell~e.63
                                          :name (n2 / name :op1 "293T"~e.62))
                                    :op2 (m5 / macrophage~e.66)))))))

# ::tok ERK1 @/@ 2 and JNK inactivation was associated with Ets @-@ like transcription factor @-@ 1 ( ELK @-@ 1 ) dephosphorylation .
# ::alignments 0-1.1.2.1.1.1 3-1.1.2 4-1.1.2.3.1.1 5-1.1 5-1.1.1 5-1.1.1.r 7-1 8-1.2.r 9-1.2.1.1.1 11-1.2.1.1.1 12-1.2.1.1.2 13-1.2.1.1.3 15-1.2.1.1.3 15-1.2.1.2.1.1.1 17-1.2.1.2.1.1.1 19-1.2.1.1.3 19-1.2.1.2.1.1.1 21-1.2
# ::id bel_pmid_1559_0693_2660
(a / associate-01~e.7
      :ARG1 (a3 / activate-01~e.5
            :polarity~e.5 "-"~e.5
            :ARG1 (a2 / and~e.3
                  :op1 (e / enzyme
                        :name (n / name :op1 "ERK1"~e.0))
                  :op2 (e2 / enzyme
                        :name (n2 / name :op1 "ERK2"))
                  :op3 (e3 / enzyme
                        :name (n3 / name :op1 "JNK"~e.4))))
      :ARG2~e.8 (d / dephosphorylate-01~e.21
            :ARG1 (p2 / protein
                  :name (n6 / name
                        :op1 "Ets-like"~e.9,11
                        :op2 "transcription"~e.12
                        :op3 "factor-1"~e.13,15,19)
                  :ARG1-of (d2 / describe-01
                        :ARG2 (p / protein
                              :name (n5 / name :op1 "ELK-1"~e.15,17,19))))))

# ::tok Rev @-@ erbbeta is an orphan nuclear receptor that selectively blocks trans @-@ activation mediated by the retinoic acid @-@ related orphan receptor @-@ alpha ( RORalpha )
# ::alignments 0-1.3.1.1 2-1.3.1.1 3-1.3.r 5-1.1 6-1.2 7-1 7-1.4.1.1.1.2.1 9-1.4.2 9-1.4.2.r 10-1.4 14-1.4.1.1 15-1.4.1.1.1.r 17-1.4.1.1.1.1.1 18-1.4.1.1.1.1.2 20-1.4.1.1.1.1.2 21-1.4.1.1.1.1.3 22-1.4.1.1.1.1.4 24-1.4.1.1.1.1.4 26-1.4.1.1.1.2.1.1.1
# ::id bel_pmid_1562_3503_11656
(r / receptor~e.7
      :mod (o / orphan~e.5)
      :mod (n / nucleus~e.6)
      :domain~e.3 (p / protein
            :name (n2 / name :op1 "Rev-erbbeta"~e.0,2))
      :ARG0-of (b / block-01~e.10
            :ARG1 (t / transactivate-00
                  :ARG1-of (m / mediate-01~e.14
                        :ARG0~e.15 (p2 / protein
                              :name (n3 / name
                                    :op1 "retinoic"~e.17
                                    :op2 "acid-related"~e.18,20
                                    :op3 "orphan"~e.21
                                    :op4 "receptor-alpha"~e.22,24)
                              :ARG1-of (d / describe-01
                                    :ARG2 (r2 / receptor~e.7
                                          :name (n4 / name :op1 "RORalpha"~e.26))))))
            :manner~e.9 (s / selective~e.9)))

# ::tok Exogenous expression of a dominant negative version of mouse Rev @-@ erbbeta decreases the expression of many genes involved in fatty acid @/@ lipid absorption ( including Cd36 , and Fabp @-@ 3 and -@ 4 ) . Interestingly , we observed a robust induction ( 15 @-@ fold ) in mRNA expression of interleukin @-@ 6
# ::alignments 0-1.1.1.2 1-1.1.1 2-1.1.1.1.r 4-1.1.1.1.1 5-1.1.1.1.2 6-1.1.1.1 7-1.1.1.1.3.r 8-1.1.1.1.3.2 9-1.1.1.1.3.1.1 11-1.1.1.1.3.1.1 12-1.1 14-1.1.2 15-1.1.2.1.r 16-1.1.2.1.1 17-1.1.2.1 18-1.1.2.1.2 19-1.1.2.1.2.1.r 20-1.1.2.1.2.1.1.1 21-1.1.2.1.2.1.1.1 23-1.1.2.1.2.1.1.2 24-1.1.2.1.2.1 26-1.1.2.1.3 27-1.1.2.1.3.1.1.1.1 29-1.1.2.1.3.1 30-1.1.2.1.3.1.2.1.1 30-1.1.2.1.3.1.3.1.1 32-1.1.2.1.3.1.2.1.1 33-1.1.2.1.3.1 35-1.1.2.1.3.1.3.1.1 40-1.2.1 41-1.2 43-1.2.2.2 44-1.2.2 46-1.2.2.2.1.1.1 50-1.2.2.1.r 51-1.2.2.1.1.1.1 52-1.2.2.1 54-1.2.2.1.1.2.1.1.1 56-1.2.2.1.1.2.1.1.1
# ::id bel_pmid_1562_3503_33508
(m / multi-sentence
      :snt1 (d / decrease-01~e.12
            :ARG0 (e / express-03~e.1
                  :ARG2~e.2 (v / version~e.6
                        :ARG0-of (d2 / dominate-01~e.4)
                        :mod (n2 / negative~e.5)
                        :mod~e.7 (p / protein
                              :name (n / name :op1 "Rev-erbbeta"~e.9,11)
                              :source (m2 / mouse~e.8)))
                  :mod (e2 / exogenous~e.0))
            :ARG1 (e3 / express-03~e.14
                  :ARG1~e.15 (g / gene~e.17
                        :quant (m3 / many~e.16)
                        :ARG1-of (i / involve-01~e.18
                              :ARG2~e.19 (a / absorb-01~e.24
                                    :ARG1 (s / slash
                                          :op1 (f / fatty-acid~e.20,21)
                                          :op2 (l / lipid~e.23))))
                        :ARG2-of (i2 / include-01~e.26
                              :ARG1 (a4 / and~e.29,33
                                    :op1 (g2 / gene
                                          :name (n3 / name :op1 "Cd36"~e.27))
                                    :op2 (g3 / gene
                                          :name (n4 / name :op1 "Fabp-3"~e.30,32))
                                    :op3 (g4 / gene
                                          :name (n5 / name :op1 "Fabp-4"~e.30,35)))))))
      :snt2 (o / observe-01~e.41
            :ARG0 (w / we~e.40)
            :ARG1 (i3 / induce-01~e.44
                  :ARG1~e.50 (e4 / express-03~e.52
                        :ARG2 (r2 / rna
                              :name (n6 / name :op1 "mRNA"~e.51)
                              :ARG0-of (e5 / encode-01
                                    :ARG1 (p3 / protein
                                          :name (n7 / name :op1 "interleukin-6"~e.54,56)))))
                  :mod (r / robust~e.43
                        :ARG1-of (m4 / mean-01
                              :ARG2 (p2 / product-of :op1 "15"~e.46))))
            :ARG2-of (i4 / interest-01)))

# ::tok We report here that loss of Lsh specifically alters expression of the Cdkn1c gene The reactivation of the silenced paternal Cdkn1c allele correlates closely with a loss of CpG methylation at the 5 ' DMR at the Cdkn1c promoter Chromatin immunoprecipitations demonstrate a direct association of Lsh with the 5 ' DMR at the Cdkn1c promoter
# ::alignments 0-1.1.1 1-1.1 2-1.1.3 3-1.1.2.r 4-1.1.2.1 5-1.1.2.1.1.r 6-1.1.2.1.1.1.1 7-1.1.2.3 8-1.1.2 9-1.1.2.2 10-1.1.2.2.1.r 12-1.1.2.2.1.1.1 13-1.1.2.2.1 13-1.2.1.1.1 13-1.3.2.2.3.1.1 15-1.2.1 16-1.2.1.1.r 18-1.2.1.1.3 19-1.2.1.1.2 20-1.2.1.1.1.1.1 21-1.2.1.1 22-1.2 23-1.2.3 23-1.2.3.r 24-1.2.2.r 26-1.2.2 27-1.2.2.1.r 28-1.2.2.1.1.1.1 29-1.2.2.1 32-1.3.2.2.1 33-1.3.2.2.1 34-1.3.2.2.2.1 37-1.1.2.2.1.1.1 39-1.3.1.1.1.1 41-1.3 43-1.3.2.3 44-1.3.2 45-1.3.2.1.r 46-1.3.2.1.1.1 49-1.3.2.2.1 50-1.2.2.1.1.2.1 50-1.3.2.2.1 51-1.2.2.1.1.2.2.1 51-1.3.2.2.2.1 54-1.1.2.2.1.1.1 54-1.3.2.2.3.1.1.1.1
# ::id bel_pmid_1564_7320_19184
(m / multi-sentence
      :snt1 (r / report-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1~e.3 (a / alter-01~e.8
                  :ARG0 (l / lose-01~e.4
                        :ARG1~e.5 (p2 / protein
                              :name (n / name :op1 "Lsh"~e.6)))
                  :ARG1 (e / express-03~e.9
                        :ARG1~e.10 (g / gene~e.13
                              :name (n2 / name :op1 "Cdkn1c"~e.12,37,54)))
                  :manner (s / specific~e.7))
            :medium (h / here~e.2))
      :snt2 (c / correlate-01~e.22
            :ARG1 (r2 / reactivate-01~e.15
                  :ARG1~e.16 (a2 / allele~e.21
                        :mod (g2 / gene~e.13
                              :name (n3 / name :op1 "Cdkn1c"~e.20))
                        :mod (p3 / paternal~e.19)
                        :ARG1-of (s2 / silence-01~e.18)))
            :ARG2~e.24 (l2 / lose-01~e.26
                  :ARG1~e.27 (m2 / methylate-01~e.29
                        :ARG1 (d / dna-sequence
                              :name (n4 / name :op1 "CpG"~e.28)
                              :part-of (d2 / dna-sequence
                                    :mod "5'"~e.50
                                    :name (n5 / name :op1 "DMR"~e.51)
                                    :part-of (m4 / molecular-physical-entity
                                          :ARG0-of (p4 / promote-02
                                                :ARG1 g2))))))
            :manner~e.23 (c2 / close~e.23))
      :snt3 (d3 / demonstrate-01~e.41
            :ARG0 (i / immunoprecipitate-00
                  :ARG1 (m3 / macro-molecular-complex
                        :name (n6 / name :op1 "chromatin"~e.39)))
            :ARG1 (a4 / associate-01~e.44
                  :ARG1~e.45 (p6 / protein
                        :name (n7 / name :op1 "Lsh"~e.46))
                  :ARG2 (d5 / dna-sequence
                        :mod "5'"~e.32,33,49,50
                        :name (n8 / name :op1 "DMR"~e.34,51)
                        :part-of (m5 / molecular-physical-entity
                              :ARG0-of (p7 / promote-02
                                    :ARG1 (g3 / gene~e.13
                                          :name (n9 / name :op1 "Cdkn1c"~e.54)))))
                  :mod (d4 / direct~e.43))))

# ::tok Entrez gene : Cyclin @-@ dependent kinase inhibitor 1C is a tight @-@ binding inhibitor of several G1 cyclin @/@ Cdk complexes and a negative regulator of cell proliferation .
# ::alignments 0-1.3.1.1.1 1-1.3.1.1.2 3-1.1.2.2.1.1 5-1.1.1.1.1 6-1.1.1.1.2 7-1.1.1.1.3 8-1.1.1.1.4 11-1.1.1.2.1 13-1.1.1.2 14-1.1 16-1.1.2.4 17-1.1.2.1 18-1.1.2.2.1.1 20-1.1.2.3.1.1 21-1.1.2 22-1 27-1.2.1.1 28-1.2.1
# ::id bel_pmid_1564_7320_25946
(a / and~e.22
      :op1 (i2 / inhibit-01~e.14
            :ARG0 (p / protein
                  :name (n / name
                        :op1 "cyclin-dependent"~e.5
                        :op2 "kinase"~e.6
                        :op3 "inhibitor"~e.7
                        :op4 "1C"~e.8)
                  :ARG1-of (b / bind-01~e.13
                        :mod (t2 / tight~e.11)))
            :ARG1 (m / macro-molecular-complex~e.21
                  :time "G1"~e.17
                  :part (p2 / protein
                        :name (n2 / name :op1 "cyclin"~e.3,18))
                  :part (e / enzyme
                        :name (n3 / name :op1 "Cdk"~e.20))
                  :quant (s / several~e.16)))
      :op2 (d / downregulate-01
            :ARG1 (p3 / proliferate-01~e.28
                  :ARG0 (c / cell~e.27))
            :ARG2 p)
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG8 (n4 / name :op1 "Entrez"~e.0 :op2 "gene"~e.1))))

# ::tok CDK2 @-@ cyclin A1 @/@ E1 and CDK1 @-@ cyclin B1 phosphorylate BARD1 on its NH( 2 ) terminus in vivo and in vitro .
# ::alignments 0-1.2.1.1.1.1 2-1.2.1.2.1.1 3-1.2.1.2.1.2 5-1.2.2.1.1.2 6-1.2 7-1.2.3.1.1.1 9-1.2.3.2.1.1 10-1.2.3.2.1.2 11-1 12-1.1.2.1.1 18-1.1.1.1 19-1.3.1 20-1.3.1 21-1.3 22-1.3.1 22-1.3.2 23-1.3.2
# ::id bel_pmid_1566_5273_5396
(p / phosphorylate-01~e.11
      :ARG1 (p5 / protein-segment
            :name (n7 / name :op1 "NH2-terminus"~e.18)
            :part-of (p6 / protein
                  :name (n8 / name :op1 "BARD1"~e.12)))
      :ARG2 (a / and~e.6
            :op1 (m / macro-molecular-complex
                  :part (e / enzyme
                        :name (n / name :op1 "CDK2"~e.0))
                  :part (p2 / protein
                        :name (n3 / name :op1 "cyclin"~e.2 :op2 "A1"~e.3)))
            :op2 (m2 / macro-molecular-complex
                  :part (p3 / protein
                        :name (n4 / name :op1 "cyclin" :op2 "E1"~e.5))
                  :part e)
            :op3 (m3 / macro-molecular-complex
                  :part (e3 / enzyme
                        :name (n5 / name :op1 "CDK1"~e.7))
                  :part (p4 / protein
                        :name (n6 / name :op1 "cyclin"~e.9 :op2 "B1"~e.10))))
      :manner (a2 / and~e.21
            :op1 (i / in-vivo~e.19,20,22)
            :op2 (i2 / in-vitro~e.22,23)))

# ::tok We also provide evidence that IRF @-@ 5 interacts with and is activated by MyD88 and TRAF6
# ::alignments 0-1.1 1-1.3 2-1 3-1.2 5-1.2.1.1.1.1.1 7-1.2.1.1.1.1.1 8-1.2.1.1 10-1.2.1 10-1.2.1.1.2 12-1.2.1.2 13-1.2.1.1.2.r 14-1.2.1.1.2.1.1.1 16-1.2.1.1.2.2.1.1
# ::id bel_pmid_1566_5823_1056
(p / provide-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (e / evidence~e.3
            :topic (a2 / and~e.10
                  :op1 (i / interact-01~e.8
                        :ARG0 (p2 / protein
                              :name (n / name :op1 "IRF-5"~e.5,7))
                        :ARG1~e.13 (a3 / and~e.10
                              :op1 (p3 / protein
                                    :name (n2 / name :op1 "MyD88"~e.14))
                              :op2 (p4 / protein
                                    :name (n3 / name :op1 "TRAF6"~e.16))))
                  :op2 (a4 / activate-01~e.12
                        :ARG0 a3
                        :ARG1 p2)))
      :mod (a / also~e.1))

# ::tok Here , we demonstrate that the transcription factor IRF @-@ 5 is generally involved downstream of the TLR @-@ MyD88 signalling pathway for gene induction of proinflammatory cytokines , such as interleukin @-@ 6 ( IL @-@ 6 ) , IL @-@ 12 and tumour @-@ necrosis factor @-@ alpha . In haematopoietic cells from mice deficient in the Irf5 gene ( Irf5-/- mice ) , the induction of these cytokines by various TLR ligands is severely impaired
# ::alignments 0-1.1.3 2-1.1.1 3-1.1 4-1.1.2.r 6-1.1.2.1.2.1 7-1.1.2.1.2 8-1.1.2.1.1.1 10-1.1.2.1.1.1 12-1.1.2.2 12-1.1.2.2.r 13-1.1.2 14-1.1.2.3.2 17-1.1.2.3.1.1.1 19-1.1.2.3.1.1.1 20-1.1.2.3.1.2 21-1.1.2.3.1 22-1.1.2.3.1.2.1.r 23-1.1.2.3.1.2.1.1 24-1.1.2.3.1.2.1 29-1.1.2.3.1.2.1.1.1.1.2.r 30-1.1.2.3.1.2.1.1.1.1.2.r 31-1.1.2.3.1.2.1.1.1.1.2.1.1.1 33-1.1.2.3.1.2.1.1.1.1.2.1.1.1 33-1.1.2.3.1.2.1.1.1.1.2.1.2.1.1.1 35-1.1.2.3.1.2.1.1.1.1.2.1.2.1.1.1 37-1.1.2.3.1.2.1.1.1.1.2.1.1.1 37-1.1.2.3.1.2.1.1.1.1.2.1.2.1.1.1 40-1.1.2.3.1.2.1.1.1.1.2.1.2.1.1.1 40-1.1.2.3.1.2.1.1.1.1.2.2.1.1 42-1.1.2.3.1.2.1.1.1.1.2.2.1.1 43-1.1.2.3.1.2.1.1.1.1.2 44-1.1.2.3.1.2.1.1.1.1.2.3.1.1 46-1.1.2.3.1.2.1.1.1.1.2.3.1.1 47-1.1.2.3.1.2.1.1.1.1.2.3.1.2 49-1.1.2.3.1.2.1.1.1.1.2.3.1.2 52-1.2.3.1 53-1.2.3 54-1.2.3.2.r 55-1.2.3.2 59-1.2.3.2.1.1.1.1 59-1.2.3.2.2.1.1.1.1 60-1.2.3.2.1.1 60-1.2.3.2.2.1.1 63-1.2.3.2.2.1 67-1.2.1 69-1.2.1.2.1 71-1.2.1.1.r 72-1.2.1.1.2 73-1.2.1.1.1.1.1 74-1.2.1.1 76-1.2.2 76-1.2.2.r 77-1.2
# ::id bel_pmid_1566_5823_33196
(m / multi-sentence
      :snt1 (d / demonstrate-01~e.3
            :ARG0 (w / we~e.2)
            :ARG1~e.4 (i / involve-01~e.13
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "IRF-5"~e.8,10)
                        :mod (f / factor~e.7
                              :ARG0-of (t2 / transcribe-01~e.6)))
                  :manner~e.12 (g / general~e.12)
                  :location (r / relative-position
                        :op1 (p3 / pathway~e.21
                              :name (n2 / name :op1 "TLR-MyD88"~e.17,19)
                              :ARG0-of (s / signal-01~e.20
                                    :ARG1~e.22 (i2 / induce-01~e.24
                                          :ARG1 (g2 / gene~e.23
                                                :ARG0-of (e / encode-01
                                                      :ARG1 (c2 / cytokine
                                                            :ARG0-of (f2 / favor-01
                                                                  :ARG1 (i3 / inflame-01))
                                                            :example~e.29,30 (a / and~e.43
                                                                  :op1 (p5 / protein
                                                                        :name (n4 / name :op1 "interleukin-6"~e.31,33,37)
                                                                        :ARG1-of (d3 / describe-01
                                                                              :ARG2 (p8 / protein
                                                                                    :name (n7 / name :op1 "IL-6"~e.33,35,37,40))))
                                                                  :op2 (p6 / protein
                                                                        :name (n5 / name :op1 "IL-12"~e.40,42))
                                                                  :op3 (p7 / protein
                                                                        :name (n6 / name :op1 "tumour-necrosis"~e.44,46 :op2 "factor-alpha"~e.47,49)))))))))
                        :direction (d2 / downstream~e.14)))
            :medium (h2 / here~e.0))
      :snt2 (i4 / impair-01~e.77
            :ARG1 (i5 / induce-01~e.67
                  :ARG0~e.71 (l / ligand~e.74
                        :mod (p10 / protein
                              :name (n9 / name :op1 "TLR"~e.73))
                        :mod (v / various~e.72))
                  :ARG1 (c3 / cytokine
                        :mod (t3 / this~e.69)))
            :manner~e.76 (s2 / severe~e.76)
            :location (c / cell~e.53
                  :mod (h / haematopoietic~e.52)
                  :source~e.54 (m2 / mouse~e.55
                        :ARG0-of (l2 / lack-01
                              :ARG1 (g4 / gene~e.60
                                    :name (n3 / name :op1 "IRF5"~e.59)))
                        :ARG1-of (d4 / describe-01
                              :ARG2 (m3 / mouse~e.63
                                    :mod (g3 / gene~e.60
                                          :name (n10 / name :op1 "IRF5"~e.59)
                                          :ARG2-of (m4 / mutate-01 :mod "-/-"))))))))

# ::tok Stable knockdown of mutant KRAS( D12 ) in murine C26 CRC cells by RNA interference lead to a dramatic reduction of COX @-@ 2 synthesis and prostaglandin E2 production .
# ::alignments 0-1.1.2 3-1.1.1 3-1.1.1.2 3-1.1.1.2.r 5-1.1.1.2.1 9-1.1.4.1.1 10-1.1.4.1.2 11-1.1.4 13-1.1.3.1.1 14-1.1.3.1 15-1 16-1.1.3 16-1.2.r 18-1.2.2 19-1.2 20-1.2.1.r 21-1.2.1.1.1.1.1 23-1.2.1.1.1.1.1 25-1.2.1 26-1.2.1.2.1.1.1 27-1.2.1.2.1.1.2 28-1.2.1.2
# ::id bel_pmid_1567_1526_28746
(l / lead-03~e.15
      :ARG0 (k / knock-02
            :ARG1 (e2 / enzyme~e.3
                  :name (n / name :op1 "KRAS")
                  :ARG1-of~e.3 (m / mutate-01~e.3 :value "D12"~e.5))
            :mod (s / stable~e.0)
            :ARG1-of (c4 / cause-01~e.16
                  :ARG0 (i / interfere-01~e.14
                        :ARG0 (r / rna~e.13)))
            :location (c / cell-line~e.11
                  :name (n4 / name :op1 "C26"~e.9 :op2 "CRC"~e.10)
                  :source (m2 / mouse)))
      :ARG2~e.16 (r2 / reduce-01~e.19
            :ARG1~e.20 (a2 / and~e.25
                  :op1 (s2 / synthesize-01
                        :ARG1 (e / enzyme
                              :name (n2 / name :op1 "COX-2"~e.21,23)))
                  :op2 (p2 / produce-01~e.28
                        :ARG1 (s3 / small-molecule
                              :name (n3 / name :op1 "prostaglandin"~e.26 :op2 "E2"~e.27))))
            :degree (d / dramatic~e.18)))

# ::tok These findings indicate that lipid accumulation in the liver leads to subacute hepatic ' inflammation ' through NF @-@ kappaB activation and downstream cytokine production . This causes insulin resistance both locally in liver and systemically .
# ::alignments 0-1.1.1.1 0-1.2.1 1-1.1.1 1-1.1.1.2 1-1.1.1.2.r 2-1.1 3-1.1.2.r 4-1.1.2.1.2 5-1.1.2.1 6-1.1.2.1.1.r 8-1.1.2.1.1 9-1.1.2 11-1.1.2.2.3 12-1.1.2.2.2 17-1.1.2.2.1.1.1.1.1 19-1.1.2.2.1.1.1.1.1 20-1.1.2.2.1.1 21-1.1.2.2.1 22-1.1.2.2.1.2.2 23-1.1.2.2.1.2.1 24-1.1.2.2.1.2 26-1.2.1 27-1.2 28-1.2.2.1.1.1 29-1.2.2 31-1.2.3.1 32-1.2.3.1.1.r 33-1.2.3.1.1 34-1.2.3
# ::id bel_pmid_1568_5173_4092
(m / multi-sentence
      :snt1 (i / indicate-01~e.2
            :ARG0 (t / thing~e.1
                  :mod (t2 / this~e.0)
                  :ARG1-of~e.1 (f / find-01~e.1))
            :ARG1~e.3 (l / lead-03~e.9
                  :ARG0 (a / accumulate-01~e.5
                        :ARG0~e.6 (l3 / liver~e.8)
                        :ARG1 (l2 / lipid~e.4))
                  :ARG1 (i2 / inflame-01
                        :ARG0 (a2 / and~e.21
                              :op1 (a3 / activate-01~e.20
                                    :ARG1 (m2 / macro-molecular-complex
                                          :name (n / name :op1 "NF-kappaB"~e.17,19)))
                              :op2 (p / produce-01~e.24
                                    :ARG1 (c2 / cytokine~e.23)
                                    :location (d / downstream~e.22)))
                        :ARG1 l3~e.12
                        :mod (s / subacute~e.11))))
      :snt2 (c / cause-01~e.27
            :ARG0 (t3 / this~e.0,26)
            :ARG1 (r / resist-01~e.29
                  :ARG1 (p2 / protein
                        :name (n3 / name :op1 "insulin"~e.28)))
            :manner (a4 / and~e.34
                  :op1 (l4 / local~e.31
                        :location~e.32 (l5 / liver~e.33))
                  :op2 (s2 / system))))

# ::tok Insulin resistance was improved by systemic neutralization of IL @-@ 6 or salicylate inhibition of IKK @-@ beta .
# ::alignments 0-1.2.1.1.1 1-1.2 3-1 6-1.1.1 7-1.1.1.1.r 8-1.1.1.1.1.1 10-1.1.1.1.1.1 11-1.1 12-1.1.2.1.1.1 13-1.1.2 14-1.1.2.2.r 15-1.1.2.2.1.1 17-1.1.2.2.1.1
# ::id bel_pmid_1568_5173_6180
(i / improve-01~e.3
      :ARG0 (o / or~e.11
            :op1 (n2 / neutralize-01~e.6
                  :ARG1~e.7 (p / protein
                        :name (n3 / name :op1 "IL-6"~e.8,10))
                  :mod (s2 / system))
            :op2 (i2 / inhibit-01~e.13
                  :ARG0 (s3 / small-molecule
                        :name (n5 / name :op1 "salicylate"~e.12))
                  :ARG1~e.14 (p2 / protein
                        :name (n4 / name :op1 "IKK-beta"~e.15,17))))
      :ARG1 (r / resist-01~e.1
            :ARG1 (p3 / protein
                  :name (n / name :op1 "insulin"~e.0))))

# ::tok We here report that the NFkappaB and C/EBP beta controlled gene IL6 is upregulated in DDIT3 @- and FUS @-@ DDIT3 @-@ expressing fibrosarcoma cell lines
# ::alignments 0-1.1 1-1.3 2-1 6-1.2.1.2.1 6-1.2.2.2.1 7-1.2.1.2.1.2.1.1 8-1.2.1.2.1.2.1.2 9-1.2.1.2 10-1.2.1 10-1.2.2.2.1.1 10-1.2.2.2.1.2 11-1.2.1.1.1 15-1.2.2.2.1.1.1.1 17-1.2.2.2.1 18-1.2.2.2.1.2.1.1 20-1.2.2.2.1.1.1.1 22-1.2.2.2 23-1.2.2.1 24-1.2.2 25-1.2.2
# ::id bel_pmid_1568_8424_11152
(r / report-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (u / upregulate-01
            :ARG1 (g / gene~e.10
                  :name (n / name :op1 "IL6"~e.11)
                  :ARG1-of (c / control-01~e.9
                        :ARG0 (a / and~e.6
                              :op1 (m / macro-molecular-complex
                                    :name (n2 / name :op1 "NF-kappaB"))
                              :op2 (p2 / protein
                                    :name (n3 / name :op1 "C/EBP"~e.7 :op2 "beta"~e.8)))))
            :location (c2 / cell-line~e.24,25
                  :part-of (f / fibrosarcoma~e.23)
                  :ARG3-of (e / express-03~e.22
                        :ARG1 (a2 / and~e.6,17
                              :op1 (g2 / gene~e.10
                                    :name (n4 / name :op1 "DDIT3"~e.15,20))
                              :op2 (g3 / gene~e.10
                                    :name (n5 / name :op1 "FUS-DDIT3"~e.18))))))
      :medium (h / here~e.1))

# ::tok Knockdown experiments using siRNA against CEBPB transcripts showed that the effect of FUS @-@ DDIT3 on IL6 expression is C/EBP beta dependent
# ::alignments 1-1.1 2-1.1.2 3-1.1.2.1.1.1 4-1.1.2.1.2 5-1.1.2.1.2.1.1.1.1 7-1 8-1.2.r 10-1.2.1 11-1.2.1.1.r 12-1.2.1.1.1.1 14-1.2.1.1.1.1 15-1.2.1.2.r 16-1.2.1.2.1.1.1 17-1.2.1.2 19-1.2.2.1.1 20-1.2.2.1.2 21-1.2
# ::id bel_pmid_1568_8424_11196
(s / show-01~e.7
      :ARG0 (e / experiment~e.1
            :topic (k / knock-02)
            :ARG0-of (u / use-01~e.2
                  :ARG1 (r / rna
                        :name (n / name :op1 "siRNA"~e.3)
                        :ARG0-of (c / counter-01~e.4
                              :ARG1 (t / transcribe-01
                                    :ARG1 (g / gene
                                          :name (n3 / name :op1 "CEBPB"~e.5)))))))
      :ARG1~e.8 (d / depend-01~e.21
            :ARG0 (a / affect-01~e.10
                  :ARG0~e.11 (p2 / protein
                        :name (n6 / name :op1 "FUS-DDIT3"~e.12,14))
                  :ARG1~e.15 (e2 / express-03~e.17
                        :ARG1 (g2 / gene
                              :name (n5 / name :op1 "IL6"~e.16))))
            :ARG1 (p / protein
                  :name (n4 / name :op1 "C/EBP"~e.19 :op2 "beta"~e.20))))

# ::tok Our results suggest that Chk1 associates with BAD and phosphorylates the BAD protein at serine @-@ 155
# ::alignments 0-1.1.2 0-1.1.2.r 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1.2.r 4-1.2.1.1.1.1 5-1.2.1 6-1.2.1.2.r 7-1.2.1.2.1.1 8-1.2 9-1.2.2 11-1.2.2.1.3 12-1.2.2.1.3 14-1.2.2.1.2.1 16-1.2.2.1.1
# ::id bel_pmid_1573_6430_6098
(s / suggest-01~e.2
      :ARG0 (t / thing~e.1
            :ARG1-of~e.1 (r / result-01~e.1)
            :poss~e.0 (w / we~e.0))
      :ARG1~e.3 (a / and~e.8
            :op1 (a2 / associate-01~e.5
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Chk1"~e.4))
                  :ARG2~e.6 (p / protein
                        :name (n2 / name :op1 "BAD"~e.7)))
            :op2 (p2 / phosphorylate-01~e.9
                  :ARG1 (a3 / amino-acid
                        :mod "155"~e.16
                        :name (n3 / name :op1 "serine"~e.14)
                        :part-of p~e.11,12)
                  :ARG2 e)))

# ::tok Furthermore , Chk1 also phosphorylates Cdc25A on serine 123 which accelerates its degradation through the ubiquitin @-@ proteasome pathway and arrests cells in late G2 @-@ phase after DNA damage .
# ::alignments 2-1.1.2.1.1 3-1.1.5 4-1.1 5-1.1.1.3.1.1 7-1.1.1.2.1 8-1.1.1.1 10-1.1.3 11-1.1.3.1.1 11-1.1.3.1.1.r 12-1.1.3.1 15-1.1.3.1.2.1.1 17-1.1.3.1.2.1.1 18-1.1.3.1.2 20-1.1.4 21-1.1.4.1 22-1.1.4.2.r 23-1.1.4.2.2 24-1.1.4.2.1 26-1.1.4.2 27-1.1.4.3 28-1.1.4.3.1.1 29-1.1.4.3.1
# ::id bel_pmid_1573_6430_6100
(a2 / and
      :op2 (p / phosphorylate-01~e.4
            :ARG1 (a / amino-acid
                  :mod "123"~e.8
                  :name (n / name :op1 "serine"~e.7)
                  :part-of (e / enzyme
                        :name (n3 / name :op1 "Cdc25A"~e.5)))
            :ARG2 (e2 / enzyme
                  :name (n2 / name :op1 "Chk1"~e.2))
            :ARG0-of (a3 / accelerate-01~e.10
                  :ARG1 (d / degrade-01~e.12
                        :ARG1~e.11 e~e.11
                        :ARG2 (p2 / pathway~e.18
                              :name (n4 / name :op1 "ubiquitin-proteasome"~e.15,17))))
            :ARG0-of (a4 / arrest-02~e.20
                  :ARG1 (c / cell~e.21)
                  :time~e.22 (p3 / phase~e.26
                        :mod "G2"~e.24
                        :mod (l / late~e.23))
                  :time (a5 / after~e.27
                        :op1 (d2 / damage-01~e.29
                              :ARG1 (d3 / DNA~e.28))))
            :mod (a6 / also~e.3)))

# ::tok IkappaBNS was recruited to the IL @-@ 6 promoter , but not to the TNF @-@ alpha promoter , together with p50 .
# ::alignments 0-1.1.1.1 2-1 2-1.3.1 3-1.2.r 5-1.2.1.1.1.1 7-1.2.1.1.1.1 10-1.3 11-1.3.1.1 11-1.3.1.1.r 12-1.3.1.3.r 14-1.3.1.3.1.1.1.1 16-1.3.1.3.1.1.1.1 20-1.3.1.2 21-1.3.1.2
# ::id bel_pmid_1574_9903_11636
(r / recruit-01~e.2
      :ARG1 (p / protein
            :name (n / name :op1 "IkappaBNS"~e.0)
            :accompanier (p6 / protein
                  :name (n4 / name :op1 "p50")))
      :ARG2~e.3 (m / molecular-physical-entity
            :ARG0-of (p2 / promote-01
                  :ARG1 (p3 / protein
                        :name (n2 / name :op1 "IL-6"~e.5,7))))
      :ARG1-of (c / contrast-01~e.10
            :ARG2 (r2 / recruit-01~e.2
                  :polarity~e.11 "-"~e.11
                  :ARG1 p~e.20,21
                  :ARG2~e.12 (m2 / molecular-physical-entity
                        :ARG0-of (p4 / promote-01
                              :ARG1 (p5 / protein
                                    :name (n3 / name :op1 "TNF-alpha"~e.14,16)))))))

# ::tok IkappaBNS resulted in impaired LPS @-@ induced IL @-@ 6 production , but not TNF @-@ alpha production in the murine macrophage cell line RAW264.7 .
# ::alignments 0-1.1.1.1 1-1 1-1.3.1 2-1.2.r 3-1.2.2 4-1.2.3.1.1.1 6-1.2.3 7-1.2.1.1.1 9-1.2.1.1.1 10-1.2 12-1.3 13-1.3.1.1 13-1.3.1.1.r 14-1.3.1.3.1.1.1 16-1.3.1.3.1.1.1 17-1.2 17-1.3.1.3 21-1.2.4.2 22-1.2.4 23-1.2.4 24-1.2.4.1.1
# ::id bel_pmid_1574_9903_11638
(r / result-01~e.1
      :ARG1 (p / protein
            :name (n / name :op1 "IkappaBNS"~e.0))
      :ARG2~e.2 (p2 / produce-01~e.10,17
            :ARG1 (p3 / protein
                  :name (n2 / name :op1 "IL-6"~e.7,9))
            :ARG1-of (i / impair-01~e.3)
            :ARG1-of (i2 / induce-01~e.6
                  :ARG0 (m3 / molecular-physical-entity
                        :name (n3 / name :op1 "LPS"~e.4)))
            :location (c / cell-line~e.22,23
                  :name (n5 / name :op1 "RAW264.7"~e.24)
                  :consist-of (m / macrophage~e.21
                        :mod (m2 / mouse))))
      :ARG1-of (c2 / contrast-01~e.12
            :ARG2 (r2 / result-01~e.1
                  :polarity~e.13 "-"~e.13
                  :ARG1 p
                  :ARG2 (p4 / produce-01~e.17
                        :ARG1 (p5 / protein
                              :name (n4 / name :op1 "TNF-alpha"~e.14,16))
                        :location c))))

# ::tok We compared CLPMphi gene expression profiles of wild @-@ type mice with IL @-@ 10 @-@ deficient mice , and identified genes that are selectively expressed in wild @-@ type CLPMphi . These genes included nuclear IkappaB proteins such as Bcl @-@ 3 and IkappaBNS .
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1.1.2.1.1.1.1 3-1.1.1.2.1.1 4-1.1.1.2.1 5-1.1.1.2 6-1.1.1.2.2.r 7-1.1.1.2.2.1 9-1.1.1.2.2.1 10-1.1.1.2.2 10-1.1.1.3 12-1.1.1.3.1.1.1.1 14-1.1.1.3.1.1.1.1 17-1.1.2.2.1.1 20-1.1.2 21-1.1.2.2 24-1.1.2.2.1.2 24-1.1.2.2.1.2.r 25-1.1.2.2.1 27-1.1.1.2.2.1 29-1.1.1.2.2.1 30-1.1.1.2.1.1.1.1 32-1.2.2.1 33-1.2.2 34-1.2 35-1.2.1.2 36-1.2.1.1.1 37-1.1.1.3.1.1 37-1.2.1 37-1.2.1.3.1 37-1.2.1.3.2 38-1.2.1.3.r 39-1.2.1.3.r 40-1.2.1.3.1.1.1 42-1.2.1.3.1.1.1 43-1.2.1.3 44-1.2.1.3.2.1.1
# ::id bel_pmid_1574_9903_27884
(m / multi-sentence
      :snt1 (a / and
            :op1 (c / compare-01~e.1
                  :ARG0 (w / we~e.0)
                  :ARG1 (p / profile~e.5
                        :mod (e / express-03~e.4
                              :ARG1 (g / gene~e.3
                                    :name (n / name :op1 "CLPMphi"~e.2,30)))
                        :poss~e.6 (m2 / mouse~e.10
                              :mod (w2 / wild-type~e.7,9,27,29)))
                  :ARG2 (m3 / mouse~e.10
                        :ARG0-of (l / lack-01
                              :ARG1 (p2 / protein~e.37
                                    :name (n2 / name :op1 "IL-10"~e.12,14)))))
            :op2 (i / identify-01~e.20
                  :ARG0 w
                  :ARG1 (g2 / gene~e.21
                        :ARG1-of (e2 / express-03~e.25
                              :ARG3 (m4 / mouse~e.17
                                    :mod w2
                                    :mod g)
                              :manner~e.24 (s / selective~e.24)))))
      :snt2 (i2 / include-01~e.34
            :ARG1 (p3 / protein~e.37
                  :name (n3 / name :op1 "IkappaB"~e.36)
                  :mod (n4 / nucleus~e.35)
                  :example~e.38,39 (a2 / and~e.43
                        :op1 (p4 / protein~e.37
                              :name (n5 / name :op1 "Bcl-3"~e.40,42))
                        :op2 (p5 / protein~e.37
                              :name (n6 / name :op1 "IkappaBNS"~e.44))))
            :ARG2 (g3 / gene~e.33
                  :mod (t / this~e.32))))

# ::tok One of the phenotypes of mice with targeted disruption of the uncoupling protein @-@ 2 gene ( Ucp2-/-) is greater macrophage phagocytic activity and free radical production , resulting in a striking resistance to infectious microorganisms .
# ::alignments 3-1.1.4 3-1.2 4-1.2.1.r 5-1.2.1 6-1.2.1.1.r 7-1.2.1.1.2 8-1.2.1.1 9-1.2.1.1.1.r 11-1.2.1.1.1.1.1 12-1.2.1.1.1.1.2 14-1.2.1.1.1.1.2 14-1.2.1.1.1.2.1.1.1 15-1.2.1.1.1 15-1.2.1.1.1.2.1 18-1.1.4.r 19-1.1.1.3 19-1.1.1.3.1 19-1.1.1.3.1.r 20-1.1.1.1 21-1.1.1.2 23-1.1 24-1.1.2.1.1 25-1.1.2.1 26-1.1.2 28-1.1.3 29-1.1.3.1.r 31-1.1.3.1.2 32-1.1.3.1 33-1.1.3.1.1.r 34-1.1.3.1.1.1 35-1.1.3.1.1
# ::id bel_pmid_1575_7894_10588
(i / include-91
      :ARG1 (a / and~e.23
            :op1 (a2 / act-01
                  :ARG0 (m2 / macrophage~e.20)
                  :ARG1 (p / phagocyte~e.21)
                  :mod (g / great~e.19
                        :degree~e.19 (m / more~e.19)))
            :op2 (p2 / produce-01~e.26
                  :ARG1 (r3 / radical~e.25
                        :ARG3-of (f / free-04~e.24)))
            :ARG1-of (r / result-01~e.28
                  :ARG2~e.29 (r2 / resist-01~e.32
                        :ARG1~e.33 (m5 / microorganism~e.35
                              :ARG0-of (i2 / infect-01~e.34))
                        :ARG0-of (s2 / strike-01~e.31)))
            :domain~e.18 (p4 / phenotype~e.3))
      :ARG2 (p3 / phenotype~e.3
            :poss~e.4 (m3 / mouse~e.5
                  :mod~e.6 (d / disrupt-01~e.8
                        :ARG1~e.9 (g2 / gene~e.15
                              :name (n2 / name :op1 "uncoupling"~e.11 :op2 "protein-2"~e.12,14)
                              :ARG1-of (d2 / describe-01
                                    :ARG2 (g3 / gene~e.15
                                          :name (n3 / name :op1 "Ucp-2"~e.14)
                                          :ARG2-of (m4 / mutate-01 :mod "-/-"))))
                        :ARG1-of (t / target-01~e.7)))))

# ::tok We found that levels of nitric oxide measured in either plasma or isolated macrophages from Ucp2-/- mice are significantly elevated in response to bacterial lipopolysaccharide challenge compared with similarly treated Ucp2+/+ mice .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1 4-1.2.1.1.r 5-1.2.1.1.1.1 6-1.2.1.1.1.2 7-1.2.1.2 10-1.2.1.2.1.1 11-1.2.1.2.1 12-1.2.1.2.1.2.1 13-1.2.1.2.1.2 14-1.2.1.2.1.3.r 16-1.2.1.2.1.3 16-1.2.4 18-1.2.2 19-1.2 20-1.2.3.r 21-1.2.3 24-1.2.3.1.1.1.1 25-1.2.3.1 26-1.2.4.r 28-1.2.4.1.1 29-1.2.4.1 31-1.2.4
# ::id bel_pmid_1575_7894_31794
(f / find-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (e / elevate-01~e.19
            :ARG1 (l / level~e.3
                  :quant-of~e.4 (s2 / small-molecule
                        :name (n / name :op1 "nitric"~e.5 :op2 "oxide"~e.6))
                  :ARG1-of (m / measure-01~e.7
                        :location (o / or~e.11
                              :op1 (p / plasma~e.10)
                              :op2 (m2 / macrophage~e.13
                                    :ARG1-of (i / isolate-01~e.12))
                              :source~e.14 (m3 / mouse~e.16
                                    :mod (g / gene
                                          :name (n2 / name :op1 "Ucp2")
                                          :ARG2-of (m4 / mutate-01 :mod "-/-"))))))
            :degree (s / significant~e.18)
            :ARG2-of~e.20 (r / respond-01~e.21
                  :ARG1 (c2 / challenge-01~e.25
                        :ARG2 (m6 / molecular-physical-entity
                              :name (n3 / name :op1 "lipopolysaccharide"~e.24)
                              :mod (b / bacterium))))
            :compared-to~e.26 (m5 / mouse~e.16,31
                  :ARG1-of (t / treat-03~e.29
                        :manner (r2 / resemble-01~e.28))
                  :mod (g2 / gene
                        :name (n4 / name :op1 "Ucp2")
                        :mod (w2 / wild-type)))))

# ::tok Protein levels of iNOS and {beta}-actin were measured by Western blotting . ( increased Nos2 expression )
# ::alignments 0-1.1.2.1 1-1.1.1 1-1.1.2 2-1.1.1.1.r 3-1.1.1.1.1.1 4-1.1 7-1 8-1.2.r 9-1.2.1.1 10-1.2.1.2 13-1.3.2 14-1.3.1.1.1 15-1.3
# ::id bel_pmid_1575_7894_31802
(m / measure-01~e.7
      :ARG1 (a2 / and~e.4
            :op1 (l / level~e.1
                  :quant-of~e.2 (e3 / enzyme
                        :name (n2 / name :op1 "iNOS"~e.3)))
            :op2 (l2 / level~e.1
                  :quant-of (p2 / protein~e.0
                        :name (n3 / name :op1 "beta-actin"))))
      :ARG2~e.8 (t / thing
            :name (n4 / name :op1 "Western"~e.9 :op2 "blotting"~e.10))
      :ARG3 (e / express-03~e.15
            :ARG2 (e2 / enzyme
                  :name (n / name :op1 "Nos2"~e.14))
            :ARG1-of (i / increase-01~e.13)))

# ::tok nduction of inflammatory cytokines by LPS is increased in Ucp2-/- mice . A , Northern blotting . Spleen total RNA was isolated from mice treated with 4 µg/g bw LPS or PBS . RNA for IFNg , IL1b , TNF and IL6 were elevated in Ucp2-/- mice in response to LPS .
# ::alignments 2-1.1.1.2.1 5-1.1.1.1.1.1 7-1.1 10-1.1.2 12-1.2.2.1.1 14-1.2.1.1 15-1.2.1.2 17-1.3.1.2 18-1.3.1.1 19-1.3.1 21-1.3 22-1.3.2.r 23-1.3.2 24-1.3.2.1 25-1.3.2.1.1.r 26-1.3.2.1.1.1.2.1 29-1.3.2.1.1.1.1.1 30-1.3.2.1.1 31-1.3.2.1.1.2.1.1 33-1.4.1.1 33-1.4.1.2 33-1.4.1.3 33-1.4.1.4 35-1.4.1.1.1.1.1.1 39-1.4.1.3.1.1.1.1 40-1.4.1 43-1.4 46-1.4.2 47-1.4.3.r 48-1.4.3 49-1.4.3.1.r 50-1.4.3.1.1.1
# ::id bel_pmid_1575_7894_31804
(m / multi-sentence
      :snt1 (i / increase-01~e.7
            :ARG1 (i2 / induce-01
                  :ARG0 (m8 / molecular-physical-entity
                        :name (n2 / name :op1 "LPS"~e.5))
                  :ARG1 (c4 / cytokine
                        :ARG0-of (i3 / inflame-01~e.2)))
            :location (m2 / mouse~e.10
                  :mod (g / gene
                        :name (n3 / name :op1 "Ucp2")
                        :ARG2-of (m3 / mutate-01 :mod "-/-"))))
      :snt2 (t / thing
            :name (n4 / name :op1 "Northern"~e.14 :op2 "blotting"~e.15)
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "A"~e.12)))
      :snt3 (i4 / isolate-01~e.21
            :ARG1 (r / rna~e.19
                  :quant (t2 / total~e.18)
                  :mod (s2 / spleen~e.17))
            :ARG2~e.22 (m4 / mouse~e.23
                  :ARG1-of (t3 / treat-03~e.24
                        :ARG3~e.25 (o / or~e.30
                              :op1 (m9 / molecular-physical-entity
                                    :name (n5 / name :op1 "LPS"~e.29)
                                    :quant (c2 / concentration-quantity
                                          :quant "4"~e.26
                                          :unit (m5 / microgram-per-gram-basis-weight)))
                              :op2 (m10 / molecular-physical-entity
                                    :name (n6 / name :op1 "PBS"~e.31)
                                    :quant c2)))))
      :snt4 (e / elevate-01~e.43
            :ARG1 (a / and~e.40
                  :op1 (r2 / rna~e.33
                        :ARG0-of (e2 / encode-01
                              :ARG1 (p2 / protein
                                    :name (n8 / name :op1 "IFNg"~e.35))))
                  :op2 (r3 / rna~e.33
                        :ARG0-of (e3 / encode-01
                              :ARG1 (p3 / protein
                                    :name (n9 / name :op1 "IL-1b"))))
                  :op3 (r4 / rna~e.33
                        :ARG0-of (e4 / encode-01
                              :ARG1 (p4 / protein
                                    :name (n10 / name :op1 "TNF"~e.39))))
                  :op4 (r5 / rna~e.33
                        :ARG0-of (e5 / encode-01
                              :ARG1 (p5 / protein
                                    :name (n11 / name :op1 "IL-6")))))
            :location (m6 / mouse~e.46
                  :mod (g2 / gene
                        :name (n12 / name :op1 "Ucp2")
                        :ARG2-of (m7 / mutate-01 :mod "-/-")))
            :ARG2-of~e.47 (r6 / respond-01~e.48
                  :ARG1~e.49 (m11 / molecular-physical-entity
                        :name (n13 / name :op1 "LPS"~e.50)))))

# ::tok Signal transducer and activator of transcription 3 ( STAT3 ) is activated by the IL @-@ 6 family of cytokines and growth factors . STAT3 requires phosphorylation on Ser @-@ 727 , in addition to tyrosine phosphorylation on Tyr @-@ 705 , to be transcriptionally active .
# ::alignments 0-1.1.2.1.1 1-1.1.2.1.2 2-1.1.2.1.3 3-1.1.2.1.4 4-1.1.2.1.5 5-1.1.2.1.6 6-1.1.2.1.7 11-1.2.2 14-1.1.1.1.1.1.1.1 16-1.1.1.1.1.1.1.1 17-1.1.1.1.1 20-1.1.1 21-1.1.1.2.1.1 22-1.1.1.2.1.2 25-1.2 26-1.2.1 30-1.2.1.1.1 32-1.1.1 32-1.2.1.2.r 33-1.2.1.2 34-1.2.1.2.1.r 35-1.2.1.2.1.1.2.1 36-1.2.1.2.1 40-1.2.1.2.1.1.1
# ::id bel_pmid_1576_4709_2580
(m / multi-sentence
      :snt1 (a2 / activate-01
            :ARG0 (a3 / and~e.20,32
                  :op1 (c / cytokine
                        :part-of (f / family~e.17
                              :mod (p5 / protein
                                    :name (n4 / name :op1 "IL-6"~e.14,16))))
                  :op2 (p6 / protein
                        :name (n5 / name :op1 "growth"~e.21 :op2 "factor"~e.22)))
            :ARG1 (p2 / protein
                  :name (n / name
                        :op1 "signal"~e.0
                        :op2 "transducer"~e.1
                        :op3 "and"~e.2
                        :op4 "activator"~e.3
                        :op5 "of"~e.4
                        :op6 "transcription"~e.5
                        :op7 "3"~e.6)
                  :ARG1-of (d / describe-01
                        :ARG2 (p3 / protein
                              :name (n2 / name :op1 "STAT-3")))))
      :snt2 (r / require-01~e.25
            :ARG1 (p / phosphorylate-01~e.26
                  :ARG1 (a4 / amino-acid
                        :mod "727"~e.30
                        :name (n7 / name :op1 "serine")
                        :part-of (p7 / protein
                              :name (n6 / name :op1 "STAT-3")))
                  :ARG1-of~e.32 (a5 / add-02~e.33
                        :ARG2~e.34 (p8 / phosphorylate-01~e.36
                              :ARG1 (a6 / amino-acid
                                    :mod "705"~e.40
                                    :name (n8 / name :op1 "tyrosine"~e.35)
                                    :part-of p7))))
            :purpose (a / activate-01~e.11
                  :ARG1 p7
                  :mod (t2 / transcribe-01))))

# ::tok Interference with Rho or Pyk2 inhibited cofilin inactivation and the migratory speed of DCs , but did not affect chemotaxis .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1.1 3-1.1.1.1 4-1.1.1.1.2.1.1 5-1.1 6-1.1.2.1.2.1.1 7-1.1.2.1 7-1.1.2.1.1 7-1.1.2.1.1.r 8-1.1.2 10-1.1.2.2.1 11-1.1.2.2 15-1 17-1.2.1 17-1.2.1.r 18-1.2 19-1.2.3
# ::id bel_pmid_1577_8365_1824
(c / contrast-01~e.15
      :ARG1 (i / inhibit-01~e.5
            :ARG0 (i2 / interfere-01~e.0
                  :ARG1~e.1 (o / or~e.3
                        :op1 (p / protein
                              :name (n / name :op1 "Rho"~e.2))
                        :op2 (e / enzyme
                              :name (n2 / name :op1 "Pyk2"~e.4))))
            :ARG1 (a3 / and~e.8
                  :op1 (a2 / activate-01~e.7
                        :polarity~e.7 "-"~e.7
                        :ARG1 (p2 / protein
                              :name (n3 / name :op1 "cofilin"~e.6)))
                  :op2 (s / speed~e.11
                        :mod (m / migrate-01~e.10
                              :ARG0 (c2 / cell
                                    :name (n4 / name :op1 "DC"))))))
      :ARG2 (a4 / affect-01~e.18
            :polarity~e.17 "-"~e.17
            :ARG0 i2
            :ARG1 (c3 / chemotaxis~e.19)))

# ::tok We found that CCR7 induced a Gi @-@ dependent activation of MAPK members ERK1 @/@ 2 , JNK , and p38 , with ERK1 @/@ 2 and p38 controlling JNK . MAPK members regulated chemotaxis , but not the migratory speed , of DCs .
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.r 3-1.1.2.1.1.1 4-1.1.2 6-1.1.2.2.2.1.1.1 8-1.1.2.2.2 9-1.1.2.2 11-1.1.2.2.1.5.1.1.1 11-1.2.1.1.1.1.1 12-1.2.1 13-1.1.2.2.1.1.1.1 17-1.1.2.2.1.3.1.1 19-1.1.2.2.1 20-1.1.2.2.1.4.1.1 23-1.1.2.2.1.1.1.1 27-1.1.2.2.1.4.1.1 28-1.1.2.2.3 29-1.1.2.2.3.2 31-1.1.2.2.1.5.1.1.1 31-1.2.1.1.1.1.1 32-1.2.1 33-1.2 33-1.2.3.1 34-1.2.2 36-1.2.3 37-1.2.3.1.1 37-1.2.3.1.1.r 39-1.2.3.1.3.1 40-1.2.3.1.3
# ::id bel_pmid_1577_8365_952
(m3 / multi-sentence
      :snt1 (f / find-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1~e.2 (i / induce-01~e.4
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "CCR7"~e.3))
                  :ARG1 (a / activate-01~e.9
                        :ARG1 (a2 / and~e.19
                              :op1 (e / enzyme
                                    :name (n4 / name :op1 "ERK1"~e.13,23))
                              :op2 (e2 / enzyme
                                    :name (n5 / name :op1 "ERK2"))
                              :op3 (e3 / enzyme
                                    :name (n6 / name :op1 "JNK"~e.17))
                              :op4 (k / kinase
                                    :name (n7 / name :op1 "p38"~e.20,27))
                              :ARG1-of (i2 / include-91
                                    :ARG2 (e5 / enzyme
                                          :name (n / name :op1 "MAPK"~e.11,31))))
                        :ARG0-of (d / depend-01~e.8
                              :ARG1 (p3 / protein
                                    :name (n3 / name :op1 "Gi"~e.6)))
                        :manner (c / control-01~e.28
                              :ARG0 (a3 / and
                                    :op1 e
                                    :op2 e2
                                    :op3 k)
                              :ARG1 e3~e.29))))
      :snt2 (r / regulate-01~e.33
            :ARG0 (m4 / member~e.12,32
                  :ARG1-of (i3 / include-91
                        :ARG2 (e4 / enzyme
                              :name (n8 / name :op1 "MAPK"~e.11,31))))
            :ARG1 (c2 / chemotaxis~e.34
                  :mod (c3 / cell
                        :name (n9 / name :op1 "DC")))
            :ARG1-of (c4 / contrast-01~e.36
                  :ARG2 (r2 / regulate-01~e.33
                        :polarity~e.37 "-"~e.37
                        :ARG0 m4
                        :ARG1 (s / speed~e.40
                              :mod (m6 / migrate-01~e.39
                                    :ARG0 c3))))))

# ::tok AdipoQ ( 23 ) , has been suggested to serve as an insulin @-@ sensitizing factor ( 24 ) . The mRNA level in mesenteric fat from Tg mice was markedly decreased
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.2.1.1.1 7-1.1 9-1.1.1 10-1.1.1.2.r 12-1.1.1.2.1.1.1.1 14-1.1.1.2.1 15-1.1.1.2 17-1.1.2.1.1.1 21-1.2.1.1.1.1 22-1.2.1 23-1.2.1.2.r 24-1.2.1.2.1 25-1.2.1.2 26-1.2.1.2.2.r 28-1.2.1.2.2 30-1.2.2 30-1.2.2.r 31-1.2
# ::id bel_pmid_1579_3228_19202
(m / multi-sentence
      :snt1 (s / suggest-01~e.7
            :ARG1 (s2 / serve-01~e.9
                  :ARG0 (p / protein
                        :name (n / name :op1 "AdipoQ"~e.0)
                        :ARG1-of (d2 / describe-01
                              :ARG0 (p3 / publication
                                    :ARG1-of (c / cite-01 :ARG2 "23"~e.2))))
                  :ARG1~e.10 (f / factor~e.15
                        :ARG0-of (s3 / sensitize-01~e.14
                              :ARG2 (p2 / protein
                                    :name (n2 / name :op1 "insulin"~e.12)))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p4 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "24"~e.17))))
      :snt2 (d / decrease-01~e.31
            :ARG1 (l / level~e.22
                  :quant-of (r / rna
                        :name (n3 / name :op1 "mRNA"~e.21))
                  :location~e.23 (f2 / fat~e.25
                        :mod (m3 / mesentery~e.24)
                        :source~e.26 (m4 / mouse~e.28
                              :mod (t / transgenic))))
            :manner~e.30 (m2 / marked~e.30)))

# ::tok Angiotensinogen mRNA , which is up @-@ regulated by glucocorticoids ( 26 ) , was substantially increased in Tg mice .
# ::alignments 0-1.1.2.1.1.1 1-1.1.1.1 5-1 9-1.1.3.1.1.1 11-1.1.3.2.1.1.1 15-1.2 16-1 19-1.3
# ::id bel_pmid_1579_3228_19204
(i / increase-01~e.5,16
      :ARG1 (r / rna
            :name (n / name :op1 "mRNA"~e.1)
            :ARG0-of (e / encode-01
                  :ARG1 (p / protein
                        :name (n2 / name :op1 "angiotensinogen"~e.0)))
            :ARG1-of (u / upregulate-01
                  :ARG2 (s2 / small-molecule
                        :name (n3 / name :op1 "glucocorticoid"~e.9))
                  :ARG1-of (d / describe-01
                        :ARG0 (p3 / publication
                              :ARG1-of (c / cite-01 :ARG2 "26"~e.11)))))
      :degree (s / substantial~e.15)
      :location (m / mouse~e.19
            :mod (t / transgenic)))

# ::tok The mRNA for resistin , which has been suggested to be involved in glucose homeostasis ( 25 ) , was significantly decreased in Tg mice .
# ::alignments 1-1.1.1.1 3-1.1.2.1.1.1 8-1.1.3.2 11-1.1.3 12-1.1.3.1.r 13-1.1.3.1.1 14-1.1.3.1 16-1.1.3.3.1.1.1 20-1.2 21-1 24-1.3
# ::id bel_pmid_1579_3228_19208
(d / decrease-01~e.21
      :ARG1 (r / rna
            :name (n / name :op1 "mRNA"~e.1)
            :ARG0-of (e / encode-01
                  :ARG1 (p / protein
                        :name (n2 / name :op1 "resistin"~e.3)))
            :ARG1-of (i / involve-01~e.11
                  :ARG2~e.12 (h / homeostasis~e.14
                        :mod (g / glucose~e.13))
                  :ARG1-of (s / suggest-01~e.8)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p2 / publication
                              :ARG1-of (c / cite-01 :ARG2 "25"~e.16)))))
      :degree (s2 / significant~e.20)
      :location (m / mouse~e.24
            :mod (t / transgenic)))

# ::tok model . Tumor necrosis factor @- alpha ( TNF @-@ a ) , a fat cell @- derived cytokine that can cause insulin resistance ( 3 , 22 ) , was significantly elevated in serum of Tg mice
# ::alignments 0-1.1 2-1.2.1.1.1 3-1.2.1.1.2 4-1.2.1.1.3 6-1.2.1.1.4 8-1.2.1.2.1.1.1 10-1.2.1.2.1.1.1 13-1.2.1.2.1.1.1 14-1.2.1.3.1.1.1 15-1.2.1.3.1.1 17-1.2.1.3.1 18-1.2.1 18-1.2.1.2.1 18-1.2.1.3 18-1.2.1.3.r 20-1.2.1.3.2.2 21-1.2.1.3.2 22-1.2.1.3.2.1.1.1.1 23-1.2.1.3.2.1 25-1.2.1.3.3.1.1.1.1 27-1.2.1.3.3.1.1.1.2 31-1.2.2 32-1.2 33-1.2.3.r 34-1.2.3 37-1.2.3.1
# ::id bel_pmid_1579_3228_19210
(m / multi-sentence
      :snt1 (m2 / model~e.0)
      :snt2 (e / elevate-01~e.32
            :ARG1 (c5 / cytokine~e.18
                  :name (n / name
                        :op1 "tumor"~e.2
                        :op2 "necrosis"~e.3
                        :op3 "factor"~e.4
                        :op4 "alpha"~e.6)
                  :ARG1-of (d / describe-01
                        :ARG2 (c6 / cytokine~e.18
                              :name (n2 / name :op1 "TNF-a"~e.8,10,13)))
                  :mod~e.18 (c / cytokine~e.18
                        :ARG1-of (d2 / derive-01~e.17
                              :ARG2 (c2 / cell~e.15
                                    :mod (f / fat~e.14)))
                        :ARG0-of (c3 / cause-01~e.21
                              :ARG1 (r / resist-01~e.23
                                    :ARG1 (p4 / protein
                                          :name (n3 / name :op1 "insulin"~e.22)))
                              :mod (p3 / possible~e.20))
                        :ARG1-of (d3 / describe-01
                              :ARG0 (p5 / publication
                                    :ARG1-of (c4 / cite-01
                                          :ARG2 (a / and :op1 "3"~e.25 :op2 "22"~e.27))))))
            :degree (s / significant~e.31)
            :location~e.33 (s2 / serum~e.34
                  :source (m3 / mouse~e.37
                        :mod (t / transgenic)))))

# ::tok Genetic disruption of these pathways improves insulin resistance ( 86,87 ) . Heterozygous IKKbeta+/- mice , fed with a high @-@ fat diet or crossed with obese ob @/@ ob mice , showed a significant decrease in blood glucose levels and improved insulin resistance ( 87 ) .
# ::alignments 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1 4-1.1.1.1 5-1.1 6-1.1.2.1.1.1 7-1.1.2 12-1.2.1.3 14-1.2.1 16-1.2.1.2 17-1.2.1.2.1.r 19-1.2.1.2.1.1.1.1 21-1.2.1.2.1.1.1 22-1.2.1.2.1 23-1.2.1.2.2 24-1.2.1.2.2.1 25-1.2.1.2.2.1.1.r 26-1.2.1.2.2.1.1.2.1 27-1.2.1.2.2.1.1.2.2 29-1.2.1.2.2.1.1.2.2 30-1.2.1.2.2.1.1.2 32-1.2 34-1.2.2.1.2 35-1.2.2.1 36-1.2.2.1.1.r 37-1.2.2.1.1.2 38-1.2.2.1.1.1 39-1.2.2.1.1 40-1.1.3.1.1.1 40-1.2.2 41-1.1 41-1.2.2.2.2 42-1.1.2.1.1.1 42-1.2.2.2.1.1.1 43-1.1.2 43-1.2.2.2 45-1.1.3.1.1.1.2 45-1.2.3.1.1.1
# ::id bel_pmid_1579_3228_21750
(m / multi-sentence
      :snt1 (i / improve-01~e.5,41
            :ARG0 (d / disrupt-01~e.1
                  :ARG1~e.2 (p / pathway~e.4
                        :mod (t / this~e.3))
                  :mod (g / gene))
            :ARG1 (r / resist-01~e.7,43
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "insulin"~e.6,42)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c / cite-01
                              :ARG2 (a / and~e.40 :op1 "86" :op2 "87"~e.45)))))
      :snt2 (s / show-01~e.32
            :ARG0 (m2 / mouse~e.14
                  :mod (p6 / protein
                        :name (n2 / name :op1 "IKKbeta")
                        :ARG2-of (m3 / mutate-01 :mod "+/-"))
                  :ARG2-of (f / feed-01~e.16
                        :ARG1~e.17 (d5 / diet~e.22
                              :ARG0-of (c3 / contain-01
                                    :ARG1 (f2 / fat~e.21
                                          :quant (h2 / high~e.19))))
                        :op1-of (o / or~e.23
                              :op2 (c4 / cross-01~e.24
                                    :ARG1~e.25 (a3 / and
                                          :op1 m2
                                          :op2 (m4 / mouse~e.30
                                                :mod (o2 / obese~e.26)
                                                :mod (o3 / ob-ob~e.27,29))))))
                  :mod (h / heterozygous~e.12))
            :ARG1 (a2 / and~e.40
                  :op1 (d3 / decrease-01~e.35
                        :ARG1~e.36 (l / level~e.39
                              :quant-of (g3 / glucose~e.38)
                              :location (b / blood~e.37))
                        :degree (s2 / significant~e.34))
                  :op2 (r2 / resist-01~e.43
                        :ARG1 (p4 / protein
                              :name (n3 / name :op1 "insulin"~e.42))
                        :ARG1-of (i2 / improve-01~e.41)))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p5 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "87"~e.45)))))

# ::tok JNK1 knockout mice gain less weight and are protected against diet @-@ induced insulin resistance or insulin resistance associated with a genetic model of obesity ( ob/ob ) ( 86 ) .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1 3-1.1 4-1.1.2.1 5-1.1.2 6-1 8-1.2 9-1.2.2.r 10-1.2.2.1.2.1 12-1.2.2.1.2 13-1.2.2.1.1.1.1 14-1.2.2.1 15-1.2.2 16-1.2.2.2.1 17-1.2.2.2 18-1.2.2.2.2 19-1.2.2.2.2.1.r 21-1.2.2.2.2.1.1 22-1.2.2.2.2.1 23-1.2.2.2.2.1.2.r 24-1.2.2.2.2.1.2 29-1.3.1.1.1
# ::id bel_pmid_1579_3228_21980
(a / and~e.6
      :op1 (g / gain-02~e.3
            :ARG0 (m / mouse~e.2
                  :mod (e / enzyme
                        :name (n / name :op1 "JNK1"~e.0)
                        :ARG2-of (m2 / mutate-01 :mod "-/-")))
            :ARG1 (w / weight~e.5
                  :quant (l / less~e.4)))
      :op2 (p / protect-01~e.8
            :ARG1 m
            :ARG2~e.9 (o / or~e.15
                  :op1 (r / resist-01~e.14
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "insulin"~e.13))
                        :ARG1-of (i / induce-01~e.12
                              :ARG0 (d / diet~e.10)))
                  :op2 (r2 / resist-01~e.17
                        :ARG1 p2~e.16
                        :ARG1-of (a2 / associate-01~e.18
                              :ARG2~e.19 (m3 / model~e.22
                                    :mod (g2 / genetic~e.21)
                                    :mod~e.23 (o2 / obesity~e.24)
                                    :ARG1-of (d2 / describe-01
                                          :ARG2 (o3 / ob-ob)))))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c / cite-01 :ARG2 "86"~e.29))))

# ::tok and in mice , IL @-@ 6 treatment causes insulin resistance in skeletal muscle and in liver most likely due to defects in IRS @-@ 1 ( and IRS @-@ 2 , respectively )-associated PI 3 @-@ kinase activity ( 56 ) .
# ::alignments 2-1.1.1.1 4-1.1.1.2.1.1 6-1.1.1.2.1.1 7-1.1.1 8-1.1 9-1.1.2.1.1.1 10-1.1.2 13-1.1.2.3.1 14-1.1.2.3 15-1.1.2.3.r 16-1.1.2.3.2 17-1.1.2.2.2.1 18-1.1.2.2.2 19-1.1.2.2 20-1.1.2.2 21-1.1.2.2.1 22-1.1.2.2.1.1.r 23-1.1.2.2.1.1.2.1.1.1.1 23-1.1.2.2.1.1.2.1.2.1.1 25-1.1.2.2.1.1.2.1.1.1.1 27-1.1.2.2.1.1.2.1 28-1.1.2.2.1.1.2.1.1.1.1 28-1.1.2.2.1.1.2.1.2.1.1 30-1.1.2.2.1.1.2.1.2.1.1 32-1.1.2.2.1.1.2.1.3 32-1.1.2.2.1.1.2.1.3.r 34-1.1.2.2.1.1.1.1.1 35-1.1.2.2.1.1.1.1.2 37-1.1.2.2.1.1.1 37-1.1.2.2.1.1.1.1.2 38-1.1.2.2.1.1 40-1.2.1.1.1
# ::id bel_pmid_1579_3228_28348
(a / and
      :op2 (c / cause-01~e.8
            :ARG0 (t / treat-03~e.7
                  :ARG1 (m2 / mouse~e.2)
                  :ARG3 (p / protein
                        :name (n / name :op1 "IL-6"~e.4,6)))
            :ARG1 (r / resist-01~e.10
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "insulin"~e.9))
                  :ARG1-of (c2 / cause-01~e.19,20
                        :ARG0 (d / defect-01~e.21
                              :ARG0~e.22 (a3 / act-02~e.38
                                    :ARG0 (k / kinase~e.37
                                          :name (n3 / name :op1 "PI"~e.34 :op2 "3-kinase"~e.35,37))
                                    :ARG1-of (a4 / associate-01
                                          :ARG2 (a5 / and~e.27
                                                :op1 (p3 / protein
                                                      :name (n4 / name :op1 "IRS-1"~e.23,25,28))
                                                :op2 (p4 / protein
                                                      :name (n5 / name :op1 "IRS-2"~e.23,28,30))
                                                :manner~e.32 (r2 / respective~e.32)))))
                        :mod (l / likely~e.18
                              :degree (m / most~e.17)))
                  :location~e.15 (a2 / and~e.14
                        :op1 (m3 / muscle~e.13
                              :mod (s / skeleton))
                        :op2 (l2 / liver~e.16))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "56"~e.40))))

# ::tok As previously reported , expression of Dok @-@ R in EGF @-@ stimulated cells resulted in a dramatic decrease in the induction of Erk @-@ 2 activation as well as a delay in the activation kinetics ( Fig . 1 ) , while Dok @-@ R {Delta}PRR completely lost this Erk @-@ 2 attenuating capacity , which demonstrates that the key residues for mediating this attenuation are found within the PRR .
# ::alignments 0-1.3.1.r 1-1.3.1 2-1.3 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1.1.1 8-1.1.1.1.1.1 9-1.1.1.2.r 10-1.1.1.2.1.1.1.1 12-1.1.1.2.1 13-1.1.1.2 14-1.1 15-1.1.2.r 17-1.1.2.1.2 18-1.1.2.1 19-1.1.2.1.1.r 21-1.1.2.1.1 22-1.1.2.1.1.1.r 23-1.1.2.1.1.1.1.1.1 25-1.1.2.1.1.1.1.1.1 26-1.1.2.1.1.1 27-1.3.1.r 29-1.3.1.r 31-1.1.2.2 32-1.1.2.2.1.r 34-1.1.2.2.1.1 35-1.1.2.2.1 39-1.1.3.1.1 42-1 43-1.1.1.1.1.1 43-1.2.1.1.1 45-1.1.1.1.1.1 45-1.2.1.1.1 47-1.2.3 48-1.2 50-1.2.2.1.1 51-1.2.2.1.1 52-1.2.2.1.1 53-1.2.2.1 54-1.2.2 57-1.2.4 58-1.2.4.1.r 60-1.2.4.1.1.1 61-1.2.4.1.1 62-1.2.4.1.1.2.r 63-1.2.4.1.1.2 65-1.2.4.1.1.2.1 67-1.2.4.1 70-1.2.4.1.2.1.1
# ::id bel_pmid_1583_1486_36764
(c / contrast-01~e.42
      :ARG1 (r / result-01~e.14
            :ARG1 (e / express-03~e.4
                  :ARG2~e.5 (p / protein
                        :name (n / name :op1 "Dok-R"~e.6,8,43,45))
                  :ARG3~e.9 (c2 / cell~e.13
                        :ARG1-of (s / stimulate-01~e.12
                              :ARG2 (s2 / small-molecule
                                    :name (n2 / name :op1 "EGF"~e.10)))))
            :ARG2~e.15 (a2 / and
                  :op1 (d / decrease-01~e.18
                        :ARG1~e.19 (i / induce-01~e.21
                              :ARG1~e.22 (a / activate-01~e.26
                                    :ARG1 (e2 / enzyme
                                          :name (n3 / name :op1 "Erk-2"~e.23,25))))
                        :degree (d2 / dramatic~e.17))
                  :op2 (d3 / delay-01~e.31
                        :ARG1~e.32 (k / kinetics~e.35
                              :mod (a3 / activate-01~e.34))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (f / figure :mod "1"~e.39)))
      :ARG2 (l / lose-02~e.48
            :ARG0 (p2 / protein
                  :name (n4 / name
                        :op1 "Dok-R"~e.43,45
                        :op2 "delta"
                        :op3 "PRR"))
            :ARG1 (c5 / capable-01~e.54
                  :ARG2 (a4 / attenuate-01~e.53
                        :ARG1 e2~e.50,51,52))
            :degree (c4 / complete~e.47)
            :ARG0-of (d5 / demonstrate-01~e.57
                  :ARG1~e.58 (f2 / find-01~e.67
                        :ARG1 (r2 / residue~e.61
                              :mod (k2 / key~e.60)
                              :ARG0-of~e.62 (m / mediate-01~e.63
                                    :ARG1 a4~e.65))
                        :location (p3 / protein
                              :name (n5 / name :op1 "PRR"~e.70)))))
      :ARG1-of (r3 / report-01~e.2
            :time~e.0,27,29 (p4 / previous~e.1)))

# ::tok The isoform SH2 @-@ Bbeta modulates JAK2 activity by binding to the phosphorylated enzyme , further increasing its activity . in an animal model of GH excess in which JAK2 is not phosphorylated , although it is increased in the membrane @-@ fraction , both the level of SH2 @-@ Bbeta , and especially its association to membranes , are augmented .
# ::alignments 1-1.1.1.2 2-1.1.1.1.1 4-1.1.1.1.1 5-1.1 6-1.1.3.2.1.1 7-1.1.2 9-1.1.3 12-1.1.3.2.2 13-1.1.1 13-1.1.3.2 13-1.2.1.1.1 13-1.2.2.2.1 13-1.2.2.3.2 15-1.1.3.3.2 16-1.1.3.3 17-1.1.3.3.1 18-1.1.3.3.1 22-1.2.2.1 23-1.2.2 24-1.2.2.2.r 25-1.2.2.2.1.1.1 26-1.2.2.2 29-1.2.2.3.2.1.1 31-1.2.2.3.1 31-1.2.2.3.1.r 32-1.2.2.3 34-1.2.2.3.3.r 35-1.2.2.3.3.1 37-1.2.2.3.3 38-1.2.2.3.3.2.r 40-1.2.2.3.3.2.1 42-1.2.2.3.3.2 46-1.2.1.1 48-1.2.1.1.1.1.1 50-1.2.1.1.1.1.1 52-1.2.1 53-1.2.1.2.3 55-1.2.1.2 56-1.2.1.2.2.r 57-1.2.1.2.2 60-1.2
# ::id bel_pmid_1584_5922_27198
(m / multi-sentence
      :snt1 (m2 / modulate-01~e.5
            :ARG0 (p / protein~e.13
                  :name (n / name :op1 "SH2-Bbeta"~e.2,4)
                  :mod (i / isoform~e.1))
            :ARG1 (a / act-02~e.7
                  :ARG0 (e / enzyme~e.13
                        :name (n2 / name :op1 "JAK2"~e.6)
                        :ARG1-of (p2 / phosphorylate-01~e.12)))
            :manner (b / bind-01~e.9
                  :ARG1 p
                  :ARG2 e
                  :ARG0-of (i2 / increase-01~e.16
                        :ARG1 a~e.17,18
                        :degree (f / further~e.15))))
      :snt2 (a2 / augment-01~e.60
            :ARG1 (a3 / and~e.52
                  :op1 (l / level~e.46
                        :quant-of (p3 / protein~e.13
                              :name (n3 / name :op1 "SH2-Bbeta"~e.48,50)))
                  :op2 (a4 / associate-01~e.55
                        :ARG1 p3
                        :ARG2~e.56 (m3 / membrane~e.57)
                        :mod (e3 / especially~e.53)))
            :location (m4 / model~e.23
                  :mod (a5 / animal~e.22)
                  :mod~e.24 (e4 / exceed-01~e.26
                        :ARG0 (p4 / protein~e.13
                              :name (n4 / name :op1 "GH"~e.25)))
                  :location-of (p5 / phosphorylate-01~e.32
                        :polarity~e.31 "-"~e.31
                        :ARG1 (e5 / enzyme~e.13
                              :name (n5 / name :op1 "JAK2"~e.29))
                        :concession~e.34 (i3 / increase-01~e.37
                              :ARG1 e5~e.35
                              :location~e.38 (f2 / fraction~e.42
                                    :mod m3~e.40))))))

# ::tok In response to IFN @-@ gamma , C/EBP @-@ beta undergoes phosphorylation at a critical ERK1 @/@ 2 phosphorylation motif .
# ::alignments 1-1.3 2-1.3.1.r 3-1.3.1.1.1 5-1.3.1.1.1 9-1.1.1.1 10-1 11-1.2 14-1.2.1.2 15-1.2.2.1.1.1 18-1.2 19-1.2.1
# ::id bel_pmid_1587_9117_18042
(u / undergo-01~e.10
      :ARG1 (p2 / protein
            :name (n / name :op1 "C/EBP-beta"~e.9))
      :ARG2 (p / phosphorylate-01~e.11,18
            :ARG1 (p4 / protein-segment~e.19
                  :part-of p2
                  :mod (c / critical~e.14))
            :ARG2 (a / and
                  :op1 (e / enzyme
                        :name (n3 / name :op1 "ERK1"~e.15))
                  :op2 (e2 / enzyme
                        :name (n4 / name :op1 "ERK2"))))
      :ARG2-of (r / respond-01~e.1
            :ARG1~e.2 (p3 / protein
                  :name (n2 / name :op1 "IFN-gamma"~e.3,5))))

# ::tok Serine @-@ 642 was identified as an Akt @-@ dependent phosphorylation site . WEE1Hu kinase activity was not affected by serine @-@ 642 phosphorylation . We revealed that serine @-@ 642 phosphorylation promoted cytoplasmic localization of WEE1Hu . The nuclear @-@ to @-@ cytoplasmic translocation was mediated by phosphorylation @-@ dependent WEE1Hu binding to 14 @-@ 3 @-@ 3 theta but not 14 @-@ 3 @-@ 3 beta or -@ sigma preventing Y15 phosphorylation of Cdc2 by WEE1 .
# ::alignments 0-1.1.1.2.1 2-1.1.1.1 3-1.3.2.2 4-1.1 5-1.1.2.r 7-1.1.2.2.1.1.1 9-1.1.2.2 10-1.1.2.1 11-1.1.2 13-1.2.3.1.1.1 13-1.3.2.2.1.1.1 14-1.2.3.1 14-1.3.2.2.1 14-1.4.1.1 14-1.4.3.1.2 15-1.2.3 17-1.2.1 17-1.2.1.r 18-1.2 19-1.2.2.r 20-1.2.2.1.2.1 22-1.2.2.1.1 23-1.2.2 25-1.3.1 26-1.3 27-1.3.2.r 28-1.3.2.1.1.2.1 30-1.3.2.1.1.1 31-1.3.2.1 32-1.3.2 33-1.4.2.2 36-1.4.1.1.1.1 39-1.4.2.1 43-1.3.2.2.2 43-1.4.2.2 44-1.4.2 46-1.4 46-1.4.4.1 48-1.4.1.3.1 50-1.4.1.3 51-1.4.1.1.1.1 52-1.4.1 52-1.4.4.1.2 53-1.4.1.2.r 54-1.4.1.2.1.1 56-1.4.1.2.1.1 58-1.4.1.2.1.1 59-1.4.1.2.1.2 60-1.4.4 61-1.4.4.1.1 61-1.4.4.1.1.r 62-1.4.4.1.2.2.1.1.1 64-1.4.4.1.2.2.1.1.1 66-1.4.4.1.2.2.1.1.1 66-1.4.4.1.2.2.2.1.1 67-1.4.4.1.2.2.1.1.2 68-1.4.4.1.2.2 70-1.4.4.1.2.2.2.1.2 71-1.4.3 73-1.4.3.1 74-1.4.3.1.1.r 75-1.4.3.1.1.3.1.1 77-1.4.3.1.2.1.1
# ::id bel_pmid_1596_4826_36122
(m / multi-sentence
      :snt1 (i / identify-01~e.4
            :ARG1 (a / amino-acid
                  :mod "642"~e.2
                  :name (n2 / name :op1 "serine"~e.0))
            :ARG2~e.5 (s / site~e.11
                  :ARG1-of (p / phosphorylate-01~e.10)
                  :ARG0-of (d / depend-01~e.9
                        :ARG1 (e / enzyme
                              :name (n3 / name :op1 "Akt"~e.7)))))
      :snt2 (a2 / affect-01~e.18
            :polarity~e.17 "-"~e.17
            :ARG0~e.19 (p3 / phosphorylate-01~e.23
                  :ARG1 (a4 / amino-acid
                        :mod "642"~e.22
                        :name (n5 / name :op1 "serine"~e.20)))
            :ARG1 (a3 / act-02~e.15
                  :ARG0 (k / kinase~e.14
                        :name (n4 / name :op1 "WEE1Hu"~e.13))))
      :snt3 (r / reveal-01~e.26
            :ARG0 (w / we~e.25)
            :ARG1~e.27 (p4 / promote-02~e.32
                  :ARG0 (p5 / phosphorylate-01~e.31
                        :ARG1 (a5 / amino-acid
                              :mod "642"~e.30
                              :name (n6 / name :op1 "serine"~e.28)))
                  :ARG1 (b2 / be-located-at-91~e.3
                        :ARG1 (k2 / kinase~e.14
                              :name (n7 / name :op1 "WEE1Hu"~e.13))
                        :ARG2 (c / cytoplasm~e.43))))
      :snt4 (m2 / mediate-01~e.46
            :ARG0 (b / bind-01~e.52
                  :ARG1 (k3 / kinase~e.14
                        :name (n8 / name :op1 "WEE1Hu"~e.36,51))
                  :ARG2~e.53 (p6 / protein
                        :name (n9 / name :op1 "14-3-3"~e.54,56,58 :op2 "theta"~e.59))
                  :ARG0-of (d2 / depend-01~e.50
                        :ARG1 (p2 / phosphorylate-01~e.48)))
            :ARG1 (t / translocate-00~e.44
                  :source (n / nucleus~e.39)
                  :location (c2 / cytoplasm~e.33,43))
            :ARG0-of (p9 / prevent-01~e.71
                  :ARG1 (p10 / phosphorylate-01~e.73
                        :ARG1~e.74 (a6 / amino-acid
                              :mod "15"
                              :name (n12 / name :op1 "tyrosine")
                              :part-of (e2 / enzyme
                                    :name (n13 / name :op1 "Cdc2"~e.75)))
                        :ARG2 (k4 / kinase~e.14
                              :name (n14 / name :op1 "WEE1"~e.77))))
            :ARG1-of (c3 / contrast-01~e.60
                  :ARG2 (m3 / mediate-01~e.46
                        :polarity~e.61 "-"~e.61
                        :ARG0 (b3 / bind-01~e.52
                              :ARG1 k3
                              :ARG2 (o / or~e.68
                                    :op1 (p7 / protein
                                          :name (n10 / name :op1 "14-3-3"~e.62,64,66 :op2 "beta"~e.67))
                                    :op2 (p8 / protein
                                          :name (n11 / name :op1 "14-3-3"~e.66 :op2 "sigma"~e.70))))
                        :ARG1 t))))

# ::tok KLF5 accelerates mitotic entry in H @-@ Ras @-@ transformed cells by transcriptionally activating cyclin B1 and Cdc2 , which leads to an increase in cyclin B1 @/@ Cdc2 kinase activity
# ::alignments 0-1.1.1.1 1-1 2-1.2.1 3-1.2 4-1.2.2.r 5-1.2.2.1.1.1.1 7-1.2.2.1.1.1.1 9-1.2.2.1 10-1.2.2 13-1.3 14-1.3.2.1.1.1 15-1.3.2.1.1.2 16-1.3.2 17-1.3.2.2.1.1 20-1.3.4 23-1.3.4.1 25-1.3.4.1.1.1 26-1.3.4.1.1.1 27-1.3.4.1.1.1 28-1.3.4.1.1.1 29-1.3.4.1.1.1
# ::id bel_pmid_1610_2754_11486
(a / accelerate-01~e.1
      :ARG0 (p / protein
            :name (n / name :op1 "KLF5"~e.0))
      :ARG1 (e / enter-01~e.3
            :ARG0 (m / mitosis~e.2)
            :ARG1~e.4 (c / cell~e.10
                  :ARG1-of (t / transform-01~e.9
                        :ARG0 (e2 / enzyme
                              :name (n2 / name :op1 "H-Ras"~e.5,7)))))
      :manner (a2 / activate-01~e.13
            :ARG0 p
            :ARG1 (a3 / and~e.16
                  :op1 (p2 / protein
                        :name (n3 / name :op1 "cyclin"~e.14 :op2 "B1"~e.15))
                  :op2 (k / kinase
                        :name (n4 / name :op1 "Cdc2"~e.17)))
            :mod (t2 / transcribe-01)
            :ARG0-of (l / lead-03~e.20
                  :ARG2 (i / increase-01~e.23
                        :ARG1 (a4 / act-01
                              :ARG0 a3~e.25,26,27,28,29)))))

# ::tok We report that phosphorylation @-@ induced turnover of endogenous N @-@ myc protein in CGNPs increases during mitosis , due to increased priming phosphorylation of N @-@ myc for GSK @-@ 3 beta . The priming phosphorylation requires the Cdk1 complex , whose cyclin subunits are indirect Sonic hedgehog targets
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.r 3-1.1.2.1.1.1 5-1.1.2.1.1 6-1.1.2.1 8-1.1.2.1.2.2 9-1.1.2.1.2.1.1 11-1.1.2.1.2.1.1 12-1.1.2.1.2 12-1.2.2.2 12-1.2.2.2.2.1 15-1.1.2 16-1.1.2.2.r 17-1.1.2.2 19-1.1.2.3 20-1.1.2.3 21-1.1.2.3.1.4 22-1.1.2.3.1.3 23-1.1.2.3.1 24-1.1.2.3.1.1.r 25-1.1.2.3.1.1 26-1.1.2.3.1.1 27-1.1.2.3.1.1 28-1.1.2.3.1.2.r 29-1.1.2.3.1.2.1.1 35-1.2.1.1 36-1.2.1 37-1.2 39-1.2.2.1.1 40-1.2.2 43-1.2.2.2.1.1 46-1.2.2.2.2.2 47-1.2.2.2.2.1.1.1 48-1.2.2.2.2.1.1.2 49-1.2.2.2.2
# ::id bel_pmid_1613_9224_21092
(m / multi-sentence
      :snt1 (r / report-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1~e.2 (i / increase-01~e.15
                  :ARG1 (t / turnover~e.6
                        :ARG1-of (i2 / induce-01~e.5
                              :ARG0 (p / phosphorylate-01~e.3))
                        :mod (p2 / protein~e.12
                              :name (n / name :op1 "N-myc"~e.9,11)
                              :mod (e / endogenous~e.8))
                        :location (c2 / cell
                              :name (n6 / name :op1 "CGNP")))
                  :time~e.16 (m2 / mitosis~e.17)
                  :ARG1-of (c / cause-01~e.19,20
                        :ARG0 (p3 / phosphorylate-01~e.23
                              :ARG1~e.24 p2~e.25,26,27
                              :ARG2~e.28 (e2 / enzyme
                                    :name (n2 / name :op1 "GSK-3beta"~e.29))
                              :mod (p4 / priming~e.22)
                              :ARG1-of (i3 / increase-01~e.21)))))
      :snt2 (r2 / require-01~e.37
            :ARG0 (p5 / phosphorylate-01~e.36
                  :mod (p6 / priming~e.35))
            :ARG1 (m3 / macro-molecular-complex~e.40
                  :name (n3 / name :op1 "Cdk1"~e.39)
                  :part (p7 / protein-segment~e.12
                        :name (n4 / name :op1 "cyclin"~e.43)
                        :ARG1-of (t2 / target-01~e.49
                              :ARG2 (p8 / protein~e.12
                                    :name (n5 / name :op1 "Sonic"~e.47 :op2 "hedgehog"~e.48))
                              :mod (i4 / indirect~e.46))))))

# ::tok TNFalpha , but not IGF @-@ I , induced tissue inhibitor of metalloproteinase @-@ 1 ( TIMP @-@ 1 ) expression and reduced matrix metalloproteinases @-@ 2 activity and collagen degradation . TNFalpha also activated ERK1 @/@ 2 .
# ::alignments 2-1.1.1.1 2-1.1.1.1.2 2-1.1.1.1.2.r 4-1.1.1.1.2.1.1.1 6-1.1.1.1.2.1.1.1 6-1.1.1.2.1.1.4 8-1.1.1 9-1.1.1.2.1.1.1 10-1.1.1.2.1.1.2 11-1.1.1.2.1.1.3 12-1.1.1.2.1.1.4 14-1.1.1.2.1.1.4 14-1.1.1.2.1.2.1.1.1 16-1.1.1.2.1.2.1.1.1 18-1.1.1.2.1.1.4 18-1.1.1.2.1.2.1.1.1 20-1.1.1.2 21-1.1 22-1.1.2 23-1.1.2.2.1.1.1.1 26-1.1.2.2.1.1.1.2 27-1.1.2.2.1 28-1.1.2.2 29-1.1.2.2.2.1.1.1 30-1.1.2.2.2 33-1.2.3 34-1.2 35-1.2.2.1.1.1 37-1.1.2.2.1.1.1.2
# ::id bel_pmid_1614_1211_10448
(m / multi-sentence
      :snt1 (a / and~e.21
            :op1 (i2 / induce-01~e.8
                  :ARG0 (p / protein~e.2
                        :name (n / name :op1 "TNF-alpha")
                        :ARG1-of~e.2 (c / contrast-01~e.2
                              :ARG2 (p2 / protein
                                    :name (n2 / name :op1 "IGF-I"~e.4,6))))
                  :ARG1 (e / express-03~e.20
                        :ARG2 (p3 / protein
                              :name (n3 / name
                                    :op1 "tissue"~e.9
                                    :op2 "inhibitor"~e.10
                                    :op3 "of"~e.11
                                    :op4 "metalloproteinase-1"~e.6,12,14,18)
                              :ARG1-of (d / describe-01
                                    :ARG2 (p4 / protein
                                          :name (n4 / name :op1 "TIMP-1"~e.14,16,18))))))
            :op2 (r / reduce-01~e.22
                  :ARG0 p
                  :ARG1 (a2 / and~e.28
                        :op1 (a3 / act-02~e.27
                              :ARG0 (e2 / enzyme
                                    :name (n5 / name :op1 "matrix"~e.23 :op2 "metalloproteinase-2"~e.26,37)))
                        :op2 (d2 / degrade-01~e.30
                              :ARG1 (p5 / protein
                                    :name (n6 / name :op1 "collagen"~e.29))))))
      :snt2 (a4 / activate-01~e.34
            :ARG0 (p6 / protein
                  :name (n7 / name :op1 "TNF-alpha"))
            :ARG1 (a6 / and
                  :op1 (e3 / enzyme
                        :name (n8 / name :op1 "ERK1"~e.35))
                  :op2 (e4 / enzyme
                        :name (n9 / name :op1 "ERK2")))
            :mod (a5 / also~e.33)))

# ::tok We conclude that TNFalpha and IGF @-@ I may additively contribute to fibrosis during intestinal inflammation . TNFR2 is a primary mediator of fibrogenic actions of TNFalpha acting through ERK1 @/@ 2 to stimulate proliferation and through STAT3 to stimulate TIMP @-@ 1 and inhibit collagen degradation .
# ::alignments 0-1.1.1 1-1.1 4-1.1.2.1.1 5-1.1.2.1.1.2.1.1 7-1.1.2.1.1.2.1.1 8-1.1.2 10-1.1.2.1 11-1.1.2.1.2.r 12-1.1.2.1.2 13-1.1.2.1.4.r 14-1.1.2.1.4.1 17-1.2.1.1.1 20-1.2.3 21-1.2 24-1.2.2 27-1.2.4.1 27-1.2.4.2 28-1.2.4.1.2.r 28-1.2.4.2.2.r 29-1.2.4.1.2.1.1.1 33-1.2.4.1.3 34-1.2.4.1.3.2 35-1.2.4.1.2 36-1.2.4.1.2.r 38-1.2.4.2.3.r 39-1.2.4.2.3.1 40-1.2.4.2.3.1.2.1.1 42-1.2.4.2.3.1.2.1.1 43-1.2.4.2.3 44-1.2.4.2.3.2 45-1.2.4.2.3.2.2.1.1.1 46-1.2.4.2.3.2.2
# ::id bel_pmid_1614_1211_1764
(m2 / multi-sentence
      :snt1 (c / conclude-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (p2 / possible~e.8
                  :domain (c2 / contribute-01~e.10
                        :ARG0 (a / and~e.4
                              :op1 (p3 / protein
                                    :name (n / name :op1 "TNF-alpha"))
                              :op2 (p4 / protein
                                    :name (n2 / name :op1 "IGF-I"~e.5,7)))
                        :ARG2~e.11 (f / fibrosis~e.12)
                        :manner (a2 / add-02)
                        :time~e.13 (i / inflame-01
                              :ARG1 (i2 / intestine~e.14)))))
      :snt2 (m3 / mediate-01~e.21
            :ARG0 (p5 / protein
                  :name (n3 / name :op1 "TNFR2"~e.17))
            :ARG1 (a3 / act-01~e.24
                  :ARG0 (p7 / protein
                        :name (n4 / name :op1 "TNF-alpha"))
                  :ARG1 (f2 / fibrogenesis))
            :mod (p6 / primary~e.20)
            :manner (a8 / and
                  :op1 (a4 / act-02~e.27
                        :ARG0 p5
                        :path~e.28,36 (a5 / and~e.35
                              :op1 (e / enzyme
                                    :name (n5 / name :op1 "ERK1"~e.29))
                              :op2 (e2 / enzyme
                                    :name (n6 / name :op1 "ERK2")))
                        :purpose (s / stimulate-01~e.33
                              :ARG0 p5
                              :ARG1 (p8 / proliferate-01~e.34)))
                  :op2 (a6 / act-02~e.27
                        :ARG0 p5
                        :path~e.28 (p9 / protein
                              :name (n7 / name :op1 "STAT-3"))
                        :purpose~e.38 (a7 / and~e.43
                              :op1 (s2 / stimulate-01~e.39
                                    :ARG0 p5
                                    :ARG1 (p10 / protein
                                          :name (n8 / name :op1 "TIMP-1"~e.40,42)))
                              :op2 (i3 / inhibit-01~e.44
                                    :ARG0 p5
                                    :ARG1 (d2 / degrade-01~e.46
                                          :ARG1 (p11 / protein
                                                :name (n9 / name :op1 "collagen"~e.45)))))))))

# ::tok These responses to TNFalpha were absent in TNFR2-/- and TNFR1 @/@ 2-/- myofibroblasts , whereas TNFR1-/- cells showed similar responses to WT .
# ::alignments 0-1.1.1.2 1-1.1.1 1-1.1.1.1 1-1.1.1.1.r 5-1.1 8-1.1.2 9-1.1.2.2.1.1.1 14-1 16-1.2.1 16-1.2.2.2.1 17-1.2 18-1.2.2.2 19-1.2.2 19-1.2.2.1 19-1.2.2.1.r 20-1.2.2.2.1.1.r 21-1.2.2.2.1.1
# ::id bel_pmid_1614_1211_19760
(c / contrast-01~e.14
      :ARG1 (a3 / absent-01~e.5
            :ARG1 (t / thing~e.1
                  :ARG2-of~e.1 (r2 / respond-01~e.1
                        :ARG1 (p / protein
                              :name (n / name :op1 "TNF-alpha")))
                  :mod (t3 / this~e.0))
            :ARG2 (a / and~e.8
                  :op1 (m2 / myofibroblast
                        :mod (p2 / protein
                              :name (n2 / name :op1 "TNFR2")
                              :ARG2-of (m / mutate-01 :mod "-/-")))
                  :op2 (m3 / myofibroblast
                        :mod (p3 / protein
                              :name (n3 / name :op1 "TNFR1"~e.9)
                              :ARG2-of m)
                        :mod p2)))
      :ARG2 (s / show-01~e.17
            :ARG0 (c2 / cell~e.16
                  :mod p3)
            :ARG1 (t2 / thing~e.19
                  :ARG2-of~e.19 (r3 / respond-01~e.19)
                  :ARG1-of (r / resemble-01~e.18
                        :ARG2 (c3 / cell~e.16
                              :mod~e.20 (w / wild-type~e.21))))))

# ::tok Tumor necrosis factor ( TNF ) alpha has defined proinflammatory
# ::alignments 0-1.1.1.1 1-1.1.1.2 2-1.1.1.3 4-1.1.2.1.1.1 6-1.1.1.4 8-1
# ::id bel_pmid_1614_1211_2914
(d / define-01~e.8
      :ARG1 (p3 / protein
            :name (n3 / name
                  :op1 "tumor"~e.0
                  :op2 "necrosis"~e.1
                  :op3 "factor"~e.2
                  :op4 "alpha"~e.6)
            :ARG1-of (d2 / describe-01
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "TNF"~e.4))))
      :ARG2 (f / favor-01
            :ARG0 (p / protein)
            :ARG1 (i / inflame-01)))

# ::tok Additionally , genistein enhanced RA @-@ induced neuronal differentiation by increasing the activation of extracellular signal @-@ related kinase 1 @/@ 2 ( ERK1 @/@ 2 ) via phosphorylation at Thr183 and Tyr185 in 3 @-@ 7 days .
# ::alignments 2-1.1.1.1 3-1 4-1.2.2.1.1.1 6-1.2.2 8-1.2 9-1.3.r 10-1.3 12-1.3.1 14-1.3.1.1.1.1.1 14-1.3.1.1.2.1.1 15-1.3.1.1.1.1.2 15-1.3.1.1.2.1.2 17-1.3.1.1.1.1.2 17-1.3.1.1.2.1.2 18-1.3.1.1.1.1.3 18-1.3.1.1.2.1.3 19-1.3.1.1.1.1.4 21-1.3.1.1.2.1.4 23-1.3.1.1.1.2.1.1.1 25-1.3.1.1.2.1.4 28-1.3.2 31-1.3.2.1 31-1.5.1 33-1.5.r 34-1.5.1.1 36-1.5.1.2 37-1.5.2
# ::id bel_pmid_1614_9052_2664
(e / enhance-01~e.3
      :ARG0 (s / small-molecule
            :name (n / name :op1 "genistein"~e.2))
      :ARG1 (d3 / differentiate-01~e.8
            :ARG1 (n2 / neuron)
            :ARG1-of (i / induce-01~e.6
                  :ARG0 (m2 / molecular-physical-entity
                        :name (n3 / name :op1 "RA"~e.4))))
      :manner~e.9 (i2 / increase-01~e.10
            :ARG1 (a / activate-01~e.12
                  :ARG1 (a2 / and
                        :op1 (e2 / enzyme
                              :name (n4 / name
                                    :op1 "extracellular"~e.14
                                    :op2 "signal-related"~e.15,17
                                    :op3 "kinase"~e.18
                                    :op4 "1"~e.19)
                              :ARG1-of (d4 / describe-01
                                    :ARG2 (e4 / enzyme
                                          :name (n6 / name :op1 "ERK1"~e.23))))
                        :op2 (e3 / enzyme
                              :name (n5 / name
                                    :op1 "extracellular"~e.14
                                    :op2 "signal-related"~e.15,17
                                    :op3 "kinase"~e.18
                                    :op4 "2"~e.21,25)
                              :ARG1-of (d5 / describe-01
                                    :ARG2 (e5 / enzyme
                                          :name (n7 / name :op1 "ERK2"))))))
            :manner (p / phosphorylate-01~e.28
                  :ARG1 (a3 / and~e.31
                        :op1 (a4 / amino-acid
                              :mod "183"
                              :name (n8 / name :op1 "tyrosine"))
                        :op2 (a5 / amino-acid
                              :mod "185"
                              :name (n9 / name :op1 "tyrosine")))))
      :ARG1-of (a6 / add-02)
      :duration~e.33 (t3 / temporal-quantity
            :quant (b / between~e.31 :op1 "3"~e.34 :op2 "7"~e.36)
            :unit (d / day~e.37)))

# ::tok Ag stimulation of Lyn unique domain transfectants was accompanied by enhanced phosphorylation of MEK and ERK @-@ 2 , which are required for leukotriene C4 ( LTC4 ) release , and production of LTC4 was increased 3 @- to 5 @-@ fold , compared with cells transfected with vector alone .
# ::alignments 1-1.1.2 2-1.1.2.2.r 3-1.1.2.2.1.1.2.1.1 4-1.1.2.2.1.1.1 5-1.1.2.2.1.1 8-1.1 9-1.1.1.r 10-1.1.1.2 11-1.1.1 12-1.1.1.1.r 13-1.1.1.1.1.1.1 14-1.1.1.1 15-1.1.1.1.2.1.1 17-1.1.1.1.2.1.1 21-1.1.1.1.3 22-1.1.1.1.3.1.r 23-1.1.1.1.3.1.1.1.1 24-1.1.1.1.3.1.1.1.2 28-1.1.1.1.3.1 30-1 31-1.2.1 32-1.2.2.1 35-1.2 36-1.2.2.1.1 39-1.2.2.2.1 43-1.2.3.r 45-1.2.3 46-1.1.2.2.1 46-1.2.3.1 47-1.2.3.1.1.r 48-1.2.3.1.1 49-1.2.3.1.1.1
# ::id bel_pmid_1617_7098_35020
(a / and~e.30
      :op1 (a2 / accompany-01~e.8
            :ARG0~e.9 (p / phosphorylate-01~e.11
                  :ARG1~e.12 (a3 / and~e.14
                        :op1 (e / enzyme
                              :name (n / name :op1 "MEK"~e.13))
                        :op2 (e2 / enzyme
                              :name (n2 / name :op1 "ERK-2"~e.15,17))
                        :ARG1-of (r / require-01~e.21
                              :ARG0~e.22 (r2 / release-01~e.28
                                    :ARG1 (s2 / small-molecule
                                          :name (n4 / name :op1 "leukotriene"~e.23 :op2 "C4"~e.24)))))
                  :ARG1-of (e4 / enhance-01~e.10))
            :ARG1 (s / stimulate-01~e.1
                  :ARG0 (a4 / antigen)
                  :ARG1~e.2 (m / molecular-physical-entity
                        :ARG2-of (t / transfect-00~e.46
                              :ARG1 (d / domain~e.5
                                    :mod (u / unique~e.4)
                                    :part-of (e3 / enzyme
                                          :name (n3 / name :op1 "Lyn"~e.3)))))))
      :op2 (i / increase-01~e.35
            :ARG1 (p2 / produce-01~e.31
                  :ARG1 s2)
            :ARG2 (v / value-interval
                  :op1 (p3 / product-of~e.32 :op1 "3"~e.36)
                  :op2 (p4 / product-of :op1 "5"~e.39))
            :compared-to~e.43 (c / cell~e.45
                  :ARG1-of (t2 / transfect-00~e.46
                        :ARG2~e.47 (v2 / vector~e.48
                              :mod (a5 / alone~e.49))))))

# ::tok rmEP reduced IL @-@ 18 expression in WT @- and EP –/–-derived keratinocytes at 8 h after stimulation , and there was no obvious difference between WT and EP –/– ( Fig . 3D ) .
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2.1.1.1 4-1.1.2.1.1.1 5-1.1.2 5-1.1.2.2.2.1 7-1.1.2.2.1.1 9-1.1.2.2 10-1.1.2.2.2.1.1.1.1 13-1.1.3.r 14-1.1.3.2.1 16-1.1.3 17-1.1.3.1 19-1.1.2.2 22-1.2.2.1 22-1.2.2.1.r 23-1.2.2 24-1.2 26-1.2.1 27-1.2.1 28-1.2.1 33-1.3.1.1
# ::id bel_pmid_1618_2244_26736
(a / and
      :op1 (r / reduce-01~e.1
            :ARG0 (p / protein
                  :name (n / name :op1 "rmEP"~e.0))
            :ARG1 (e / express-03~e.5
                  :ARG2 (p2 / protein
                        :name (n2 / name :op1 "IL-18"~e.2,4))
                  :ARG3 (a2 / and~e.9,19
                        :op1 (k / keratinocyte
                              :mod (w / wild-type~e.7))
                        :op2 (k2 / keratinocyte
                              :ARG3-of (e2 / express-03~e.5
                                    :ARG2 (p3 / protein
                                          :name (n3 / name :op1 "EP"~e.10)
                                          :ARG2-of (m / mutate-01 :mod "-/-"))))))
            :time~e.13 (a3 / after~e.16
                  :op1 (s / stimulate-01~e.17)
                  :quant (t / temporal-quantity
                        :quant "8"~e.14
                        :unit (h / hour))))
      :op2 (d / differ-02~e.24
            :ARG1 a2~e.26,27,28
            :ARG1-of (o2 / obvious-01~e.23 :polarity~e.22 "-"~e.22))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "3D"~e.33)))

# ::tok Our analyses using epiregulin @-@ deficient mice with mixed and inbred genetic backgrounds revealed that epiregulin deficiency results in the reduction of IL @-@ 6 production levels in both cell types upon peptidoglycan stimulation , and that the extent of this reduction is more evident under the BALB/c background compared with the C57BL @/@ 6J background .
# ::alignments 0-1.1.1.1 0-1.1.1.1.r 1-1.1 1-1.1.1 1-1.1.1.r 3-1.1.1.2.1.1.1.1 6-1.1.1.2 7-1.1.1.2.r 8-1.1.1.2.2.1.1.1 11-1.1.1.2.2.1.1.2 12-1.1.1.2.2.1.1 12-1.1.1.2.2.1.2 13-1 14-1.2.r 15-1.2.1.1 17-1.2.1 18-1.2.1.2.2.r 20-1.2.1.2 21-1.2.1.2.1.r 22-1.2.1.2.1.1.1.1.1 24-1.2.1.2.1.1.1.1.1 25-1.2.1.2.1.1 26-1.2.1.2.1 27-1.2.1.2.2.r 29-1.2.2.3.1 29-1.2.2.4.1 32-1.2.2.1.1 33-1.2.2.1.1 38-1.2.2.1 41-1.2.2.1.1 42-1.2.2.1.r 43-1.2.2.2 44-1.2.2 45-1.2.2.3.r 47-1.2.2.3.1.1.1 48-1.2.2.3 48-1.2.2.4 49-1.2.2.4.r 50-1.1.1.2.r 52-1.2.2.4.1.1.1 54-1.2.2.4.1.1.1 55-1.2.2.3
# ::id bel_pmid_1618_2244_3476
(r / reveal-01~e.13
      :ARG0 (t / thing~e.1
            :ARG1-of~e.1 (a / analyze-01~e.1
                  :ARG0~e.0 (w2 / we~e.0)
                  :instrument~e.7,50 (m / mouse~e.6
                        :ARG0-of (l / lack-01
                              :ARG1 (p / protein
                                    :name (n / name :op1 "epiregulin"~e.3)))
                        :ARG0-of (h / have-03
                              :ARG1 (a2 / and
                                    :op1 (b / background~e.12
                                          :ARG3-of (m2 / mix-01~e.8)
                                          :mod (g / genetic~e.11))
                                    :op2 (b2 / background~e.12
                                          :ARG1-of (i / inbreed-00)
                                          :mod g))))))
      :ARG1~e.14 (a3 / and
            :op1 (r2 / result-01~e.17
                  :ARG1 l~e.15
                  :ARG2 (r3 / reduce-01~e.20
                        :ARG1~e.21 (l2 / level~e.26
                              :degree-of (p2 / produce-01~e.25
                                    :ARG1 (p3 / protein
                                          :name (n2 / name :op1 "IL-6"~e.22,24))))
                        :prep-in~e.18,27 a2
                        :condition (s / stimulate-01
                              :ARG1 (m3 / macro-molecular-complex
                                    :name (n3 / name :op1 "peptidoglycan")))))
            :op2 (e / evident~e.44
                  :domain~e.42 (e2 / extent~e.38
                        :degree-of r3~e.32,33,41)
                  :degree (m4 / more~e.43)
                  :prep-under~e.45 (b3 / background~e.48,55
                        :mod (c / cell-line~e.29
                              :name (n4 / name :op1 "BALB/c"~e.47)))
                  :compared-to~e.49 (b4 / background~e.48
                        :mod (c2 / cell-line~e.29
                              :name (n5 / name :op1 "C57BL/6J"~e.52,54))))))

# ::tok Here , we show that ras @-@ transformed cancer cells can also induce TSP @-@ 1 down @-@ regulation in their adjacent nontransformed stromal fibroblasts , but not in endothelial cells , in a paracrine and distance @-@ dependent manner .
# ::alignments 0-1.3 2-1.1 3-1 4-1.2.r 5-1.2.1.1.1.2.1.1.1 7-1.2.1.1.1.2 7-1.2.1.1.2.2.2 8-1.2.1.1.1.1 9-1.2.1.1.1 10-1.2.1 10-1.2.2 11-1.2.1.1.3 12-1.2.1.1 12-1.2.2.2 13-1.2.1.1.2.1.1.1 15-1.2.1.1.2.1.1.1 24-1.2.1.1.2.2 26-1.2 27-1.2.1.1.2.2.2.1 27-1.2.1.1.2.2.2.1.r 27-1.2.2.1 27-1.2.2.1.r 29-1.2.2.2.2.2.1 30-1.2.2.2.2.2 34-1.2.1.1.4 36-1.2.1.1.5.1 38-1.2.1.1.5 39-1.2.1.1.4.r
# ::id bel_pmid_1620_4059_41796
(s / show-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1~e.4 (c3 / contrast-01~e.26
            :ARG1 (p / possible~e.10
                  :domain (i / induce-01~e.12
                        :ARG0 (c / cell~e.9
                              :mod (c2 / cancer~e.8)
                              :ARG1-of (t / transform-01~e.7
                                    :ARG0 (e / enzyme
                                          :name (n / name :op1 "ras"~e.5))))
                        :ARG1 (d / downregulate-01
                              :ARG1 (p3 / protein
                                    :name (n2 / name :op1 "TSP-1"~e.13,15))
                              :location (f / fibroblast~e.24
                                    :mod (s2 / stroma)
                                    :ARG1-of (t2 / transform-01~e.7 :polarity~e.27 "-"~e.27)
                                    :ARG2-of (b / border-01)))
                        :mod (a / also~e.11)
                        :manner~e.39 (p5 / paracrine~e.34)
                        :ARG0-of (d3 / depend-01~e.38
                              :ARG1 (d4 / distance~e.36))))
            :ARG2 (p4 / possible~e.10
                  :polarity~e.27 "-"~e.27
                  :domain (i2 / induce-01~e.12
                        :ARG0 c
                        :ARG1 (d2 / downregulate-01
                              :ARG1 p3
                              :location (c4 / cell~e.30
                                    :mod (e2 / endothelium~e.29))))))
      :location (h / here~e.0))

# ::tok Indeed , MDF528 nontransformed dermal fibroblasts , like many other types of normal nonangiogenic cells ( 12 ) , express copious amounts of TSP @-@ 1 ( Fig . 1B , lane 1 ) , which becomes undetectable in their H @-@ ras -@ expressing counterparts ( 528 ras1 cells ; Fig. 1B , lane 2; refs .
# ::alignments 0-1.3 2-1.2.3.1.1 4-1.2.1 7-1.5 8-1.5.1.1.3.1 9-1.5.1.1.3.2 10-1.5.1.1.3 11-1.5.1.1.3.r 12-1.5.1.1.2 14-1.5.1.1 16-1.5.2.1.1.1 19-1 19-1.5.1 20-1.1.1 21-1.1 22-1.1.2.r 23-1.1.2.1.1 25-1.1.2.1.1 29-1.4.1.1 31-1.4.1.2 32-1.1.2.1.1 32-1.4.1.2.1 36-1.1.2 36-1.1.2.2 36-1.1.2.2.r 37-1.1.2.2.1.2.1 37-1.2.2.1 37-1.5.1.1.1.1 38-1.1.2.2.2.r 39-1.1.2.2.2.2 39-1.1.2.2.2.2.r 40-1.1.2.2.2.1.1.1.1 42-1.1.2.2.2.1.1.1.1 44-1.1.2.2.2.1 45-1.1.2.2.2 49-1.1.2.2.2.3.2.2 52-1.1.2.2.2.3.1.1 52-1.4.1.1 54-1.1.2.2.2.3.1.2 54-1.4.1.2
# ::id bel_pmid_1620_4059_41800
(e / express-03~e.19
      :ARG2 (a / amount~e.21
            :mod (c3 / copious~e.20)
            :quant-of~e.22 (p / protein~e.36
                  :name (n3 / name :op1 "TSP-1"~e.23,25,32)
                  :ARG1-of~e.36 (b / become-01~e.36
                        :ARG2 (d3 / detect-01
                              :ARG1 p
                              :mod (p4 / possible :polarity "-"~e.37))
                        :location~e.38 (c4 / counterpart~e.45
                              :ARG3-of (e2 / express-03~e.44
                                    :ARG2 (e4 / enzyme
                                          :name (n4 / name :op1 "H-ras"~e.40,42)))
                              :poss~e.39 f~e.39
                              :ARG1-of (d4 / describe-01
                                    :ARG0 (f3 / figure
                                          :mod "1B"~e.52
                                          :mod (l2 / lane~e.54 :mod "2"))
                                    :ARG2 (n7 / name :op1 "528ras1" :op2 "cells"~e.49))
                              :ARG1-of (d6 / describe-01
                                    :ARG0 (p2 / publication
                                          :ARG1-of (c5 / cite-01)))))))
      :ARG3 (f / fibrolast
            :mod (d / dermis~e.4)
            :ARG1-of (t / transform-01 :polarity "-"~e.37)
            :mod (c / cell-line
                  :name (n5 / name :op1 "MDF528"~e.2)))
      :mod (i / indeed~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure
                  :mod "1B"~e.29,52
                  :mod (l / lane~e.31,54 :mod "1"~e.32)))
      :ARG1-of (r / resemble-01~e.7
            :ARG2 (e3 / express-03~e.19
                  :ARG3 (c2 / cell~e.14
                        :mod (a2 / angiogenic :polarity "-"~e.37)
                        :mod (n2 / normal~e.12)
                        :mod~e.11 (t2 / type~e.10
                              :quant (m / many~e.8)
                              :mod (o / other~e.9))))
            :ARG1-of (d5 / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c7 / cite-01 :ARG2 "12"~e.16)))))

# ::tok Down @-@ regulation of thrombospondin @-@ 1 promoter activity in nontumorigenic dermal fibroblasts exposed to tumor cell @-@ derived soluble mediator( s ) .
# ::alignments 4-1.1.1.1.1.1.1.1 6-1.1.1.1.1.1.1.1 8-1.1.1 11-1.1.1.2.1 12-1.1.1.2 13-1 14-1.1.1.2.2 15-1.1.1.2.2.2 16-1.2.2.1 18-1.2.2 19-1.2.3
# ::id bel_pmid_1620_4059_41802
(e / expose-01~e.13
      :ARG1 (d / downregulate-01
            :ARG1 (a / act-02~e.8
                  :ARG0 (m / molecular-physical-entity
                        :ARG0-of (p / promote-01
                              :ARG1 (p2 / protein
                                    :name (n / name :op1 "thrombospondin-1"~e.4,6))))
                  :location (f / fibroblast~e.12
                        :mod (d2 / dermis~e.11)
                        :ARG0-of (c2 / cause-01~e.14
                              :polarity "-"
                              :ARG1 (t / tumor~e.15)))))
      :ARG2 (m2 / molecular-physical-entity
            :ARG0-of (m3 / mediate-01)
            :ARG1-of (d3 / derive-01~e.18
                  :ARG2 (c / cell~e.16
                        :source t))
            :mod (s / soluble~e.19)))

# ::tok Interestingly , exposure of MDF @-@ EGFP @/@ TSP @-@ 1 fibroblasts to conditioned medium derived rom H @-@ ras @-@ expressing 528 ras1 cancer cells ( 528 ras1 conditioned medium ) induced a near complete inhibition of GFP fluorescence as indicated by both confocal microscopy and flow cytometry ( Fig . 2C , left ) .
# ::alignments 0-1.3 2-1.1 3-1.1.1.r 4-1.1.1.1.1.1 6-1.1.1.1.1.1 8-1.1.1.1.1.1 10-1.1.1.1.1.1 11-1.1.1 12-1.1.2.r 13-1.1.2.1 13-1.1.2.3.1.2 14-1.1.2 14-1.1.2.3.1.3 15-1.1.2.2 17-1.1.2.2.1.2.1.1.1 19-1.1.2.2.1.2.1.1.1 21-1.1.2.2.1.2 24-1.1.2.2.1.1 25-1.1.2.2.1 29-1.1.2.1 29-1.1.2.3.1.2 30-1.1.2 30-1.1.2.3.1.3 32-1 34-1.2.2.1 35-1.2.2 36-1.2 38-1.2.1.1.1.1 40-1.4.r 41-1.4 44-1.4.1.1.1.1 45-1.4.1.1.1.2 46-1.4.1 47-1.4.1.2.1.1 48-1.4.1.2.1.2 52-1.4.2.1.1 54-1.4.2.1.2
# ::id bel_pmid_1620_4059_41804
(i / induce-01~e.32
      :ARG0 (e / expose-01~e.2
            :ARG1~e.3 (f / fibroblast~e.11
                  :mod (c2 / cell-line
                        :name (n2 / name :op1 "MDF-EGFP/TSP-1"~e.4,6,8,10)))
            :ARG2~e.12 (m / medium~e.14,30
                  :ARG1-of (c / condition-01~e.13,29)
                  :ARG1-of (d2 / derive-01~e.15
                        :ARG2 (c3 / cell~e.25
                              :mod (c4 / cancer~e.24)
                              :ARG3-of (e2 / express-03~e.21
                                    :ARG2 (e3 / enzyme
                                          :name (n3 / name :op1 "H-ras"~e.17,19)))
                              :mod (c5 / cell-line
                                    :name (n4 / name :op1 "528ras1"))))
                  :ARG1-of (d / describe-01
                        :ARG2 (n9 / name
                              :op1 "528ras1"
                              :op2 "conditioned"~e.13,29
                              :op3 "medium"~e.14,30))))
      :ARG1 (i3 / inhibit-01~e.36
            :ARG1 (f2 / fluoresce-01
                  :ARG1 (p2 / protein
                        :name (n6 / name :op1 "GFP"~e.38)))
            :mod (c6 / complete~e.35
                  :degree (n5 / near~e.34)))
      :mod (i2 / interesting~e.0)
      :ARG1-of~e.40 (i4 / indicate-01~e.41
            :instrument (a / and~e.46
                  :op1 (t / thing
                        :name (n7 / name :op1 "confocal"~e.44 :op2 "microscopy"~e.45))
                  :op2 (t2 / thing
                        :name (n8 / name :op1 "flow"~e.47 :op2 "cytometry"~e.48)))
            :ARG1-of (d3 / describe-01
                  :ARG0 (f3 / figure
                        :mod "2C"~e.52
                        :mod (l / left~e.54)))))

# ::tok Again , this effect was paralleled by comparable decreases in TSP @-@ 1 mRNA and protein expression in these cells exposed to 528 ras1 conditioned medium ( Fig . 2C ) .
# ::alignments 0-1.3 2-1.1.1 3-1.1 5-1 8-1.2 9-1.2.1.r 10-1.2.1.1.2.1.1 12-1.2.1.1.2.1.1 13-1.2.1.1.1.1.1 14-1.2.1.1 15-1.2.1.1.2 16-1.2.1 17-1.2.1.2.r 18-1.2.1.2.1 19-1.2.1.2 20-1.2.1.2.2 24-1.2.1.2.2.1.1 25-1.2.1.2.2.1 29-1.4.1.1
# ::id bel_pmid_1620_4059_41806
(p / parallel-01~e.5
      :ARG0 (e / effect~e.3
            :mod (t / this~e.2))
      :ARG1 (d / decrease-01~e.8
            :ARG1~e.9 (e2 / express-03~e.16
                  :ARG2 (a / and~e.14
                        :op1 (r / rna
                              :name (n / name :op1 "mRNA"~e.13)
                              :ARG0-of (e4 / encode-01
                                    :ARG1 (p3 / protein~e.15
                                          :name (n3 / name :op1 "TSP-1"~e.10,12))))
                        :op2 p3)
                  :ARG3~e.17 (c2 / cell~e.19
                        :mod (t2 / this~e.18)
                        :ARG1-of (e3 / expose-01~e.20
                              :ARG2 (m / medium~e.25
                                    :ARG1-of (c3 / condition-01~e.24)
                                    :mod (c4 / cell-line
                                          :name (n2 / name :op1 "528ras1"))))))
            :ARG1-of (c / compare-01
                  :mod (p2 / possible)))
      :mod (a2 / again~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "2C"~e.29)))

# ::tok In addition to the aforementioned paracrine properties of 528 ras1 cells , we observed that also conditioned medium of human colorectal cancer cells harboring a mutant K @-@ ras oncogene ( DLD @-@ 1 ) , but not that of a DLD @-@ 1 variant with genetically disrupted K @-@ ras allele ( DKO @-@ 3 cells ) , efficiently suppressed the activity of the TSP @-@ 1 reporter gene in MDF @-@ EGFP/ TSP @-@ 1 cells ( Fig . 4A ) .
# ::alignments 0-1.2 1-1.2 5-1.2.1.1 6-1.2.1 10-1.2.1.3 12-1.1 13-1 14-1.2.r 15-1.2.2.1.1.3 16-1.2.2.1.1.1 16-1.2.2.2.2.1 17-1.2.2.1.1 17-1.2.2.2.2 18-1.2.2.1.1.2.r 19-1.2.2.1.1.2.2 20-1.2.2.1.1.2.1.1 21-1.2.2.1.1.2.1 22-1.2.2.1.1.2 23-1.2.2.1.1.2.3 25-1.2.2.1.1.2.3.1.2 26-1.2.2.1.1.2.3.1.1.1 28-1.2.2.1.1.2.3.1.1.1 29-1.2.2.1.1.2.3.1 31-1.2.2.1.1.2.4.1.1 33-1.2.2.1.1.2.4.1.1 33-1.2.2.1.3.1.1 36-1.2.2 37-1.2.2.2.1 37-1.2.2.2.1.r 39-1.2.2.2.2.2.r 41-1.2.2.2.2.2.1.1.1 43-1.2.2.2.2.2.1.1.1 44-1.2.2.2.2.2 45-1.2.2.2.2.2.2.r 46-1.2.2.2.2.2.2.2.1 47-1.2.2.2.2.2.2.2 48-1.2.2.2.2.2.2.1.1 50-1.2.2.2.2.2.2.1.1 51-1.2.2.2.2.2.2 53-1.2.2.2.2.2.3.1.1 55-1.2.2.2.2.2.3.1.1 56-1.2.2.2.2.2.3.1.2 59-1.2.2.1.4 59-1.2.2.1.4.r 60-1.2.2.1 60-1.2.2.2 62-1.2.2.1.2 63-1.2.2.1.2.1.r 65-1.2.2.1.2.1.1.1.1.1 67-1.2.2.1.2.1.1.1.1.1 68-1.2.2.1.2.1.1 69-1.2.2.1.2.1 70-1.2.2.1.3.r 71-1.2.2.1.3.1.1 74-1.2.2.1.3.1.1 76-1.2.2.2.2.2.1.1.1 77-1.2.2.2.2.2.3.1.2 81-1.3.1.1
# ::id bel_pmid_1620_4059_41808
(o / observe-01~e.13
      :ARG0 (w / we~e.12)
      :ARG1~e.14 (a / and~e.0,1
            :op1 (p2 / property~e.6
                  :mod (p3 / paracrine~e.5)
                  :ARG1-of (m / mention-01
                        :time (b / before))
                  :poss (c2 / cell-line~e.10
                        :name (n3 / name :op1 "528ras1")))
            :op1 (c10 / contrast-01~e.36
                  :ARG1 (s / suppress-01~e.60
                        :ARG0 (m2 / medium~e.17
                              :ARG1-of (c / condition-01~e.16)
                              :mod~e.18 (c5 / cell~e.22
                                    :mod (c6 / cancer~e.21
                                          :mod (c7 / colon~e.20))
                                    :source (h / human~e.19)
                                    :ARG0-of (h2 / harbor-01~e.23
                                          :ARG1 (o2 / oncogene~e.29
                                                :name (n6 / name :op1 "K-ras"~e.26,28)
                                                :ARG2-of (m3 / mutate-01~e.25)))
                                    :ARG1-of (d4 / describe-01
                                          :ARG2 (n12 / name :op1 "DLD-1"~e.31,33)))
                              :mod (a4 / also~e.15))
                        :ARG1 (a2 / act-02~e.62
                              :ARG0~e.63 (g / gene~e.69
                                    :ARG0-of (r2 / report-01~e.68
                                          :ARG1 (p4 / protein
                                                :name (n4 / name :op1 "TSP-1"~e.65,67)))))
                        :location~e.70 (c3 / cell-line
                              :name (n5 / name :op1 "MDF-EGFP/TSP-1"~e.33,71,74))
                        :manner~e.59 (e2 / efficient~e.59))
                  :ARG2 (s2 / suppress-01~e.60
                        :polarity~e.37 "-"~e.37
                        :ARG0 (m4 / medium~e.17
                              :ARG1-of (c4 / condition-01~e.16)
                              :mod~e.39 (v / variant~e.44
                                    :poss (c9 / cell-line
                                          :name (n7 / name :op1 "DLD-1"~e.41,43,76))
                                    :part~e.45 (a3 / allele~e.51
                                          :name (n8 / name :op1 "K-ras"~e.48,50)
                                          :ARG1-of (d3 / disrupt-01~e.47
                                                :mod (g2 / genetic~e.46)))
                                    :ARG1-of (d5 / describe-01
                                          :ARG2 (n10 / name :op1 "DKO-3"~e.53,55 :op2 "cells"~e.56,77))))
                        :ARG1 a2
                        :location c3)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4A"~e.81)))

# ::tok Once again , we observed that expression of TSP @-@ 1 by the nontransformed MDFB6 fibroblasts was precipitously down @-@ regulated when these cells were incubated with B6 ras conditioned medium ( Fig . 5A ) .
# ::alignments 0-1.3.1 1-1.3 3-1.1 4-1 6-1.2.1 7-1.2.1.1.r 8-1.2.1.1.1.1 10-1.2.1.1.1.1 14-1.2.1.2.1.1.1 15-1.2.1.2 17-1.2.2 17-1.2.2.r 23-1.2.1.2.1 23-1.2.3.2.2 25-1.2.3 29-1.2.3.2.1 29-1.2.3.r 30-1.2.3.2 34-1.4.1.1
# ::id bel_pmid_1620_4059_41810
(o2 / observe-01~e.4
      :ARG0 (w / we~e.3)
      :ARG1 (d / downregulate-01
            :ARG1 (e2 / express-03~e.6
                  :ARG2~e.7 (p / protein
                        :name (n2 / name :op1 "TSP-1"~e.8,10))
                  :ARG3 (f / fibroblast~e.15
                        :mod (c / cell-line~e.23
                              :name (n3 / name :op1 "MDFB6"~e.14))
                        :ARG1-of (t / transform-01 :polarity "-")))
            :manner~e.17 (p2 / precipitous~e.17)
            :condition~e.29 (i / incubate-01~e.25
                  :ARG1 f
                  :ARG2 (m / medium~e.30
                        :ARG1-of (c2 / condition-01~e.29)
                        :mod (c3 / cell-line~e.23
                              :name (n4 / name :op1 "B6ras")))))
      :mod (a / again~e.1
            :mod (o / once~e.0))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure :mod "5A"~e.34)))

# ::tok A , immortalized dermal fibroblasts ( MDFB6 ) down @-@ regulate TSP @-@ 1 protein expression in the presence of conditioned medium from their H @-@ ras @-@ transformed counterparts ( B6 ras CM ) ; quantification of representative Western blot .
# ::alignments 0-1.2.1.1 2-1.1.2.2 3-1.1.2.1 4-1.1.2 6-1.1.2.3.1.1 11-1.1.1.1.1.1 13-1.1.1.1.1.1 14-1.1.1.1 15-1.1.1 20-1.1.3.1 20-1.1.3.r 21-1.1.3 22-1.1.3.2.r 23-1.1.3.2.1 23-1.1.3.2.1.r 24-1.1.3.2.2.1.1.1 26-1.1.3.2.2.1.1.1 28-1.1.3.2.2 29-1.1.3.2 32-1.1.3.2.2.1.1.1 33-1.1.3.3.1.2 36-1.3 37-1.3.1.r 38-1.3.1 38-1.3.1.2 38-1.3.1.2.r 39-1.3.1.1.1 40-1.3.1.1.2
# ::id bel_pmid_1620_4059_41812
(m / multi-sentence
      :snt1 (d / downregulate-01
            :ARG1 (e2 / express-03~e.15
                  :ARG2 (p2 / protein~e.14
                        :name (n3 / name :op1 "TSP-1"~e.11,13)))
            :location (f / fibroblast~e.4
                  :mod (d2 / dermis~e.3)
                  :ARG1-of (i / immortalize-00~e.2)
                  :ARG1-of (d3 / describe-01
                        :ARG2 (n5 / name :op1 "MDFB6"~e.6)))
            :condition~e.20 (m2 / medium~e.21
                  :ARG1-of (c / condition-01~e.20)
                  :mod~e.22 (c2 / counterpart~e.29
                        :poss~e.23 f~e.23
                        :ARG1-of (t / transform-01~e.28
                              :ARG0 (e / enzyme
                                    :name (n6 / name :op1 "H-ras"~e.24,26,32))))
                  :ARG1-of (d5 / describe-01
                        :ARG2 (n8 / name :op1 "B6ras" :op2 "CM"~e.33))))
      :ARG1-of (d4 / describe-01
            :ARG0 (f2 / figure :mod "A"~e.0))
      :snt2 (q / quantify-01~e.36
            :ARG1~e.37 (t2 / thing~e.38
                  :name (n9 / name :op1 "Western"~e.39 :op2 "blot"~e.40)
                  :ARG0-of~e.38 (r2 / represent-01~e.38))))

# ::tok B , absence of TSP @-@ 1 down @-@ regulation in Id1 @-@ deficient dermal fibroblasts exposed to conditioned medium of ras @-@ transformed ( 528 ras1 CM and B6 ras CM ) and neu @-@ transformed ( 528 neu CM ) tumor cells .
# ::alignments 0-1.2.1.1 2-1 4-1.1.1.1.1 6-1.1.1.1.1 11-1.1.2.2.1.1.1 14-1.1.2.1 15-1.1.2 16-1.1.2.3 17-1.1.2.3.1.r 18-1.1.2.3.1.1 19-1.1.2.3.1 20-1.1.2.3.1.2.r 21-1.1.2.3.1.2.2.1.1.1 23-1.1.2.3.1.2.2 30-1.1.2.3.1.2.2.1.1.1 34-1.1.2.3.1.2.3.1.1.1 36-1.1.2.3.1.2.3 39-1.1.2.3.1.2.3.1.1.1 42-1.1.2.3.1.2.1 43-1.1.2.3.1.2
# ::id bel_pmid_1620_4059_41814
(a / absent-01~e.2
      :ARG1 (d2 / downregulate-01
            :ARG1 (p / protein
                  :name (n2 / name :op1 "TSP-1"~e.4,6))
            :location (f2 / fibroblast~e.15
                  :mod (d3 / dermis~e.14)
                  :ARG0-of (l / lack-01
                        :ARG1 (p2 / protein
                              :name (n3 / name :op1 "Id1"~e.11)))
                  :ARG1-of (e2 / expose-01~e.16
                        :ARG2~e.17 (m / medium~e.19
                              :ARG1-of (c / condition-01~e.18)
                              :mod~e.20 (c2 / cell~e.43
                                    :source (t / tumor~e.42)
                                    :ARG1-of (t2 / transform-01~e.23
                                          :ARG0 (e / enzyme
                                                :name (n / name :op1 "ras"~e.21,30)))
                                    :ARG1-of (t3 / transform-01~e.36
                                          :ARG0 (p3 / protein
                                                :name (n4 / name :op1 "neu"~e.34,39))))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "B"~e.0)))

# ::tok Paracrine effects of various ras @-@ driven cancer cells were detected at the level of TSP @-@ 1 protein , mRNA , and promoter activity ( Fig . 2C ) .
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.r 3-1.1.2.1 4-1.1.2.3.1.1.1 6-1.1.2.3 7-1.1.2.2 8-1.1.2 10-1 14-1.2.r 15-1.2.1.1.1 17-1.2.1.1.1 18-1.2.1 20-1.2.2.1.1 22-1.2 28-1.3.1.1
# ::id bel_pmid_1620_4059_41816
(d2 / detect-01~e.10
      :ARG1 (e / effect~e.1
            :mod (p / paracrine~e.0)
            :poss~e.2 (c / cell~e.8
                  :mod (v / various~e.3)
                  :mod (c2 / cancer~e.7)
                  :ARG1-of (d3 / drive-02~e.6
                        :ARG0 (e2 / enzyme
                              :name (n2 / name :op1 "ras"~e.4)))))
      :location~e.14 (a / and~e.22
            :op1 (p3 / protein~e.18
                  :name (n3 / name :op1 "TSP-1"~e.15,17))
            :op2 (r / rna
                  :name (n4 / name :op1 "mRNA"~e.20)
                  :ARG0-of (e3 / encode-01
                        :ARG1 p3))
            :op3 (m / molecular-physical-entity
                  :ARG0-of (p4 / promote-01
                        :ARG1 p3)))
      :ARG1-of (d4 / describe-01
            :ARG0 (f / figure :mod "2C"~e.28)))

# ::tok In contrast , abrogation of TSP @-@ 1 suppression was observed ( Fig . 6C ) when MDF528 cells were incubated with dimethylsphingosine , a specific inhibitor of sphingosine kinase .
# ::alignments 1-1 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1.1.1 7-1.1.1.1.1.1.1 8-1.1.1.1 10-1.1 14-1.1.2.1.1 17-1.1.1.2.1.1.1 18-1.1.1.2.1 20-1.1.1.2 21-1.1.1.2.2.r 22-1.1.1.2.2.1.1 25-1.1.1.2.2.2.2 26-1.1.1.2.2 26-1.1.1.2.2.2 26-1.1.1.2.2.2.r 27-1.1.1.2.2.2.1.r 28-1.1.1.2.2.2.1.1.1 29-1.1.1.2.2.2.1
# ::id bel_pmid_1620_4059_41820
(c / contrast-01~e.1
      :ARG2 (o / observe-01~e.10
            :ARG1 (a / abrogate-01~e.3
                  :ARG1~e.4 (s / suppress-01~e.8
                        :ARG1 (p / protein
                              :name (n / name :op1 "TSP-1"~e.5,7)))
                  :condition (i2 / incubate-01~e.20
                        :ARG1 (c2 / cell-line~e.18
                              :name (n2 / name :op1 "MDF528"~e.17))
                        :ARG2~e.21 (s2 / small-molecule~e.26
                              :name (n3 / name :op1 "dimethylsphingosine"~e.22)
                              :ARG0-of~e.26 (i3 / inhibit-01~e.26
                                    :ARG1~e.27 (k / kinase~e.29
                                          :name (n4 / name :op1 "sphingosine"~e.28))
                                    :manner (s3 / specific~e.25)))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "6C"~e.14))))

# ::tok Thus , suppression of TSP @-@ 1 promoter activity by fraction 2 of 528 ras1 conditioned medium was moderately sensitive to pertussis toxin but was completely abolished by dimethylsphingosine .
# ::alignments 2-1.1.1.1 3-1.1.1.1.2.r 4-1.1.1.1.2.1.1.1.1 6-1.1.1.1.2.1.1.1.1 9-1.1.1.1.1.r 10-1.1.1.1.1 11-1.1.1.1.1.1 15-1.1.1.1.1.2.1.1 16-1.1.1.1.1.2.1 18-1.1.1.3 19-1.1.1 20-1.1.1.2.r 21-1.1.1.2.1.1 22-1.1.1.2.1.2 23-1.1 25-1.1.2.3 26-1.1.2 27-1.1.2.1.r 28-1.1.2.1.1.1
# ::id bel_pmid_1620_4059_41822
(i / infer-01
      :ARG1 (c / contrast-01~e.23
            :ARG1 (s / sensitive-03~e.19
                  :ARG0 (s2 / suppress-01~e.2
                        :ARG0~e.9 (f / fraction~e.10
                              :mod "2"~e.11
                              :ARG1-of (i2 / include-91
                                    :ARG2 (m2 / medium~e.16
                                          :ARG1-of (c2 / condition-01~e.15)
                                          :mod (c3 / cell-line
                                                :name (n2 / name :op1 "528ras1")))))
                        :ARG1~e.3 (m / molecular-physical-entity
                              :ARG0-of (p / promote-01
                                    :ARG1 (p2 / protein
                                          :name (n / name :op1 "TSP-1"~e.4,6)))))
                  :ARG1~e.20 (s3 / small-molecule
                        :name (n3 / name :op1 "pertussis"~e.21 :op2 "toxin"~e.22))
                  :degree (m3 / moderate~e.18))
            :ARG2 (a / abolish-01~e.26
                  :ARG0~e.27 (s4 / small-molecule
                        :name (n4 / name :op1 "dimethylsphingosine"~e.28))
                  :ARG1 s2
                  :degree (c4 / complete~e.25))))

# ::tok Table 3. Alteration of Gene Expression Specially Associated with p53 and H @-@ ras Status in Skin Tumorigenesis upregulated
# ::alignments 0-1.3.1 2-1 3-1.1.r 4-1.1.1 5-1.1 6-1.1.2.2 6-1.1.2.2.r 7-1.1.2 8-1.1.2.1.r 9-1.1.2.1.1.1.1.1 10-1.1.2.1 11-1.1.2.1.2.1.1.1 13-1.1.2.1.2.1.1.1 14-1.1.2.1.1 14-1.1.2.1.2 15-1.2.r 16-1.2.1 17-1.2
# ::id bel_pmid_1625_4190_34278
(a / alter-01~e.2
      :ARG1~e.3 (e2 / express-03~e.5
            :ARG1 (g / gene~e.4)
            :ARG1-of (a2 / associate-01~e.7
                  :ARG2~e.8 (a3 / and~e.10
                        :op1 (s / status~e.14
                              :mod (p / protein
                                    :name (n2 / name :op1 "p53"~e.9)))
                        :op2 (s2 / status~e.14
                              :mod (e / enzyme
                                    :name (n3 / name :op1 "H-ras"~e.11,13))))
                  :manner~e.6 (s4 / special~e.6)))
      :prep-in~e.15 (t / tumorigenesis~e.17
            :mod (s3 / skin~e.16))
      :ARG1-of (d / describe-01
            :ARG0 (t2 / table~e.0 :mod "3")))

# ::tok It is known that there are two isoforms of ERK , ERK1 and ERK2 , and they phosphorylate and activate various transcription factors , such as Elk @-@ 1 and Elk @-@ 2. These transcription factors regulate expression of diverse genes that relates to the proliferation and growth of the cells .
# ::alignments 2-1.1 6-1.1.1.1.3.1.2.2.1.1 9-1.1.1.1.2.1.1.1 11-1.1.1.1.1.1 12-1.1.1 13-1.1.1.2.1.1 15-1.1.1.1.3.1.2 17-1.1.1.1 17-1.1.1.1.3 17-1.1.1.1.3.r 18-1.1.1.1.3.1.2 19-1.1.1.1.4 20-1.1.1.1.4.1 21-1.1.1.1.4.1 22-1.1.1.1.4.1 23-1.1.1.1.4.1 24-1.1.1.1.4.1 25-1.1.1.1.4.1 26-1.1.1.1.4.1 27-1.1.1.1.4.1 28-1.1.1.1.4.1 29-1.1.1.1.4.1 30-1.1.1.1.4.1 33-1.2.1.2 34-1.2.1.1 35-1.2.1 36-1.2 37-1.2.2 38-1.2.2.1.r 39-1.2.2.1.1 40-1.2.2.1 42-1.2.2.2 43-1.2.2.2.1.r 45-1.2.2.2.1.1 46-1.2.2.2.1 47-1.2.2.2.1.2 48-1.2.2.2.1.1.1.r 50-1.2.2.2.1.1.1
# ::id bel_pmid_1628_7813_37026
(m / multi-sentence
      :snt1 (k / know-02~e.2
            :ARG1 (a4 / and~e.12
                  :op1 (e2 / enzyme~e.17
                        :name (n2 / name :op1 "ERK1"~e.11)
                        :mod (i / isoform
                              :mod (e4 / enzyme
                                    :name (n4 / name :op1 "ERK"~e.9)))
                        :ARG0-of~e.17 (p / phosphorylate-01~e.17
                              :ARG1 (f / factor
                                    :mod (t / transcribe-01)
                                    :example (a / and~e.15,18
                                          :op1 (p2 / protein
                                                :name (n5 / name :op1 "Elk-1"))
                                          :op2 (p3 / protein
                                                :name (n6 / name :op1 "Elk-2"~e.6)))
                                    :mod (v / various)))
                        :ARG0-of (a3 / activate-01~e.19
                              :ARG1 f~e.20,21,22,23,24,25,26,27,28,29,30))
                  :op2 (e3 / enzyme
                        :name (n3 / name :op1 "ERK2"~e.13)
                        :mod i
                        :ARG0-of p
                        :ARG0-of a3)))
      :snt2 (r / regulate-01~e.36
            :ARG0 (f2 / factor~e.35
                  :mod (t2 / transcribe-01~e.34)
                  :mod (t3 / this~e.33))
            :ARG1 (e5 / express-03~e.37
                  :ARG1~e.38 (g / gene~e.40
                        :mod (d / diverse~e.39))
                  :ARG1-of (r2 / relate-01~e.42
                        :ARG2~e.43 (a2 / and~e.46
                              :op1 (p4 / proliferate-01~e.45
                                    :ARG0~e.48 (c / cell~e.50))
                              :op2 (g2 / grow-01~e.47
                                    :ARG1 c))))))

# ::tok IL @-@ 12 activates the Janus family tyrosine kinases JAK2 and Tyk2 , which in turn phosphorylate STAT4 on tyrosine 693 .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1 5-1.2.3.1.1.1 6-1.2.3 7-1.2.1 8-1.2.1 8-1.2.2 9-1.2.1.1.1 10-1.2 11-1.2.2.1.1 14-1.2.4.2 15-1.2.4.2 16-1.2.4 17-1.2.4.1.3.1.1 19-1.2.4.1.2.1 20-1.2.4.1.1
# ::id bel_pmid_1632_4152_36878
(a / activate-01~e.3
      :ARG0 (p / protein
            :name (n / name :op1 "IL-12"~e.0,2))
      :ARG1 (a2 / and~e.10
            :op1 (t / tyrosine-kinase~e.7,8
                  :name (n2 / name :op1 "JAK2"~e.9))
            :op2 (t2 / tyrosine-kinase~e.8
                  :name (n3 / name :op1 "Tyk2"~e.11))
            :part-of (f / family~e.6
                  :mod (m / molecular-physical-entity
                        :name (n6 / name :op1 "Janus"~e.5)))
            :ARG2-of (p2 / phosphorylate-01~e.16
                  :ARG1 (a3 / amino-acid
                        :mod "693"~e.20
                        :name (n4 / name :op1 "tyrosine"~e.19)
                        :part-of (p3 / protein
                              :name (n5 / name :op1 "STAT4"~e.17)))
                  :mod (i / in-turn~e.14,15))))

# ::tok Among the cytokines expressed after 4 h of Ag stimulation in BMMCs , our data show that levels of mRNA and protein for IL @-@ 4 , IL @-@ 6 , and for IL @-@ 13 are all significantly higher in Lyn-/- than in WT BMMCs .
# ::alignments 0-1.2.4.7 3-1.2.2.2 3-1.2.4.7.1.1 4-1.2.4.7.1.1.1 5-1.2.4.7.1.1.1.2.1 9-1.2.4.7.1.1.1.1 13-1.1.1 13-1.1.1.r 14-1.1 15-1 17-1.2.4.1 17-1.2.4.2 17-1.2.4.3 17-1.2.4.4 17-1.2.4.5 17-1.2.4.6 19-1.2.4.4.1.1.1 19-1.2.4.5.1.1.1 19-1.2.4.6.1.1.1 20-1.2.4 21-1.2.4.1.1 21-1.2.4.2.1 21-1.2.4.3.1 23-1.2.4.1.1.1.1 23-1.2.4.2.1.1.1 23-1.2.4.3.1.1.1 25-1.2.4.1.1.1.1 25-1.2.4.7.1.1.1.2.1 27-1.2.4.1.1.1.1 27-1.2.4.2.1.1.1 27-1.2.4.3.1.1.1 29-1.2.4.2.1.1.1 31-1.2.4 33-1.2.4.1.1.1.1 33-1.2.4.2.1.1.1 33-1.2.4.3.1.1.1 35-1.2.4.3.1.1.1 36-1.2.4.r 38-1.2.1.1 39-1.2 39-1.2.1 39-1.2.1.r 42-1.2.3.r 44-1.2.3.2
# ::id bel_pmid_1633_9523_28962
(s / show-01~e.15
      :ARG0 (d / data~e.14
            :poss~e.13 (w / we~e.13))
      :ARG1 (h / high~e.39
            :degree~e.39 (m / more~e.39
                  :mod (s3 / significant~e.38))
            :location (c3 / cell-line
                  :name (n8 / name :op1 "BMMC")
                  :ARG3-of (e2 / express-03~e.3
                        :ARG2 (e3 / enzyme
                              :name (n9 / name :op1 "Lyn")
                              :ARG2-of (m2 / mutate-01 :mod "-/-"))))
            :compared-to~e.42 (c4 / cell-line
                  :name (n10 / name :op1 "BMMC")
                  :mod (w2 / wild-type~e.44))
            :domain~e.36 (a4 / and~e.20,31
                  :op1 (l2 / level~e.17
                        :quant-of (p / protein~e.21
                              :name (n / name :op1 "IL-4"~e.23,25,27,33)))
                  :op2 (l3 / level~e.17
                        :quant-of (p2 / protein~e.21
                              :name (n2 / name :op1 "IL-6"~e.23,27,29,33)))
                  :op3 (l4 / level~e.17
                        :quant-of (p3 / protein~e.21
                              :name (n3 / name :op1 "IL-13"~e.23,27,33,35)))
                  :op4 (l5 / level~e.17
                        :quant-of (r / rna
                              :name (n4 / name :op1 "mRNA"~e.19)
                              :ARG0-of (e4 / encode-01
                                    :ARG1 p)))
                  :op5 (l6 / level~e.17
                        :quant-of (r2 / rna
                              :name (n5 / name :op1 "mRNA"~e.19)
                              :ARG0-of (e5 / encode-01
                                    :ARG1 p2)))
                  :op6 (l7 / level~e.17
                        :quant-of (r3 / rna
                              :name (n6 / name :op1 "mRNA"~e.19)
                              :ARG0-of (e6 / encode-01
                                    :ARG1 p3)))
                  :ARG1-of (i / include-91~e.0
                        :ARG2 (c / cytokine
                              :ARG2-of (e / express-03~e.3
                                    :time (a2 / after~e.4
                                          :op1 (s2 / stimulate-01~e.9
                                                :ARG0 (a3 / antigen)
                                                :location (c2 / cell-line
                                                      :name (n7 / name :op1 "BMMC")))
                                          :quant (t / temporal-quantity
                                                :quant "4"~e.5,25
                                                :unit (h2 / hour)))))))))

# ::tok Our data show that mRNA coding for at least one transcription factor , the cytoplasmic NF @-@ AT ( NF @-@ ATC , also known as NFATC1 and NFAT2 ) is induced 3 @-@ fold more in Lyn–/– BMMCs than in WT BMMCs ( Table II ) .
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1 2-1 3-1.2.r 4-1.2.1.2.1.1 5-1.2.1 6-1.2.1.1.r 7-1.2.1.1.2 8-1.2.1.1.2 9-1.2.1.1.2.1 10-1.2.1.1.1 11-1.2.1.1 14-1.2.1.1.3.1.2 15-1.2.1.1.3.1.1.1 17-1.2.1.1.3.1.1.1 19-1.2.1.1.3.1.1.1 23-1.2.1.1.3.1.3.2 24-1.2.1.1.3.1 24-1.2.1.1.3.1.3 24-1.2.1.1.3.1.3.1.1.1.r 24-1.2.1.1.3.1.3.r 25-1.2.1.1.3.1.3.1.1.1.r 26-1.2.1.1.3.1.3.1.1.1.1 27-1.2.1.1.3.1.3.1 28-1.2.1.1.3.1.3.1.2.1.1 31-1.2 32-1.2.2.1 39-1.2.4.r 41-1.2.4.2 44-1.3.1 45-1.3.1.1
# ::id bel_pmid_1633_9523_28966
(s / show-01~e.2
      :ARG0 (d / data~e.1
            :poss~e.0 (w / we~e.0))
      :ARG1~e.3 (i / induce-01~e.31
            :ARG1 (c / code-01~e.5
                  :ARG1~e.6 (f / factor~e.11
                        :mod (t / transcribe-01~e.10)
                        :quant (a / at-least~e.7,8 :op1 "1"~e.9)
                        :ARG1-of (m / mean-01
                              :ARG2 (p4 / protein~e.24
                                    :name (n2 / name :op1 "NF-AT"~e.15,17,19)
                                    :mod (c2 / cytoplasm~e.14)
                                    :ARG1-of~e.24 (k / know-02~e.24
                                          :ARG2 (a4 / and~e.27
                                                :op1 (p2 / protein
                                                      :name~e.24,25 (n3 / name :op1 "NFATC1"~e.26))
                                                :op2 (p3 / protein
                                                      :name (n4 / name :op1 "NFAT2"~e.28)))
                                          :mod (a3 / also~e.23)))))
                  :instrument (r / rna
                        :name (n / name :op1 "mRNA"~e.4)))
            :degree (p / product-of :op1 "3"~e.32)
            :location (c3 / cell-line
                  :name (n5 / name :op1 "BMMC")
                  :ARG3-of (e / express-03
                        :ARG2 (e2 / enzyme
                              :name (n6 / name :op1 "Lyn")
                              :ARG2-of (m2 / mutate-01 :mod "-/-"))))
            :compared-to~e.39 (c4 / cell-line
                  :name (n7 / name :op1 "BMMC")
                  :mod (w2 / wild-type~e.41)))
      :ARG1-of (d2 / describe-01
            :ARG0 (t2 / table~e.44 :mod "II"~e.45)))

# ::tok The 33 @-@ fold up @-@ regulation of sphingosine kinase 1 in Ag @-@ stimulated Lyn–/– BMMCs may also contribute to increased chemokine production
# ::alignments 1-1.1.1.2.1 4-1.1.2.2 7-1.1.1.2 8-1.1.1.1.1.1 9-1.1.1.1.1.2 10-1.1.1.1.1.3 14-1.1.1.3.3 17-1 18-1.1.3 19-1.1 21-1.1.2.2 22-1.1.2.1 23-1.1.2
# ::id bel_pmid_1633_9523_28968
(p / possible~e.17
      :domain (c / contribute-01~e.19
            :ARG0 (u / upregulate-01
                  :ARG1 (k / kinase
                        :name (n / name
                              :op1 "sphingosine"~e.8
                              :op2 "kinase"~e.9
                              :op3 "1"~e.10))
                  :degree (p2 / product-of~e.7 :op1 "33"~e.1)
                  :location (c2 / cell-line
                        :name (n2 / name :op1 "BMMC")
                        :ARG3-of (e / express-03
                              :ARG2 (e2 / enzyme
                                    :name (n3 / name :op1 "Lyn")
                                    :ARG2-of (m / mutate-01 :mod "-/-")))
                        :ARG1-of (s / stimulate-01~e.14
                              :ARG0 (a / antigen))))
            :ARG2 (p3 / produce-01~e.23
                  :ARG1 (c3 / chemokine~e.22)
                  :ARG1-of (i / increase-01~e.4,21))
            :mod (a2 / also~e.18)))

# ::tok After 24 hours of IL @-@ 13 induction , phosphorylation of ERK1 ( p44 ) and ERK2 ( p42 ) but not JNK1 @/@ 2 or p38 MAPK was observed ( Figure 1 ) .
# ::alignments 0-1.3 1-1.3.2.1 2-1.3.2.2 3-1.3.1.r 4-1.3.1.1.1.1 6-1.3.1.1.1.1 7-1.3.1 9-1.1.1 9-1.2.2 15-1.1.1.1 20-1 21-1.2.1 21-1.2.1.r 22-1.2.2.1.1.1.1 25-1.2.2.1 29-1.1 29-1.2 31-1.4.1 32-1.4.1.1
# ::id bel_pmid_1637_4521_27952
(c / contrast-01~e.20
      :ARG1 (o / observe-01~e.29
            :ARG1 (p / phosphorylate-01~e.9
                  :ARG1 (a2 / and~e.15
                        :op1 (e / enzyme
                              :name (n3 / name :op1 "p44ERK1"))
                        :op2 (e2 / enzyme
                              :name (n4 / name :op1 "p42ERK2")))))
      :ARG2 (o2 / observe-01~e.29
            :polarity~e.21 "-"~e.21
            :ARG1 (p4 / phosphorylate-01~e.9
                  :ARG1 (o3 / or~e.25
                        :op1 (e3 / enzyme
                              :name (n5 / name :op1 "JNK1"~e.22))
                        :op2 (e4 / enzyme
                              :name (n6 / name :op1 "JNK2"))
                        :op3 (e5 / enzyme
                              :name (n7 / name :op1 "p38MAPK")))))
      :time (a / after~e.0
            :op1~e.3 (i / induce-01~e.7
                  :ARG1 (p3 / protein
                        :name (n2 / name :op1 "IL-13"~e.4,6)))
            :quant (t / temporal-quantity
                  :quant "24"~e.1
                  :unit (h / hour~e.2)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.31 :mod "1"~e.32)))

# ::tok Our previous studies demonstrated that IL @-@ 13 causes MMP @- and cathepsin @-@ dependent lung remodeling and inhibits the expression of a1–AT ( 4 ) .
# ::alignments 0-1.1.1 0-1.1.1.r 1-1.1.2 2-1.1 3-1 4-1.2.r 5-1.2.1.1.1.1 7-1.2.1.1.1.1 8-1.2.1 9-1.2.1.2.2.1.1.1.1 11-1.2.1.2.2.1 12-1.2.1.2.2.1.2.1.1 14-1.2.1.2.2 15-1.2.1.2.1 16-1.2.1.2 17-1.2 18-1.2.2 20-1.2.2.1 21-1.2.2.1.1.r 22-1.2.2.1.1.1.1 24-1.3.1.1.1
# ::id bel_pmid_1637_4521_27960
(d / demonstrate-01~e.3
      :ARG0 (s / study-01~e.2
            :ARG0~e.0 (w / we~e.0)
            :time (p / previous~e.1))
      :ARG1~e.4 (a / and~e.17
            :op1 (c / cause-01~e.8
                  :ARG0 (p2 / protein
                        :name (n / name :op1 "IL-13"~e.5,7))
                  :ARG1 (r / remodel-01~e.16
                        :ARG1 (l / lung~e.15)
                        :ARG0-of (d2 / depend-01~e.14
                              :ARG1 (a2 / and~e.11
                                    :op1 (e / enzyme
                                          :name (n2 / name :op1 "MMP"~e.9))
                                    :op2 (e2 / enzyme
                                          :name (n3 / name :op1 "cathepsin"~e.12))))))
            :op2 (i / inhibit-01~e.18
                  :ARG1 (e3 / express-03~e.20
                        :ARG2~e.21 (p3 / protein
                              :name (n4 / name :op1 "a1–AT"~e.22)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "4"~e.24))))

# ::tok IL @-@ 13 Tg can be inducibly expressed in the adult murine lung by the administration of doxycycline @-@ containing ( dox @-@ containing ) water . As expected , increased levels of phospho @-@ STAT6 were readily detected by Western blot analysis after Tg activation ( Figure 1 ) .
# ::alignments 0-1.1.1.1.1.1 0-1.2.5.1.1.1.1 2-1.1.1.1.1.1 4-1.1 4-1.1.1.3.1 5-1.1.1.r 7-1.1.1 8-1.1.1.2.r 10-1.1.1.2.1.2 11-1.1.1.2.1.1.1 12-1.1.1.2 13-1.1.1.4.r 15-1.1.1.4 16-1.1.1.4.1.r 17-1.1.1.4.1.1.1.1.1 19-1.1.1.4.1.1 23-1.1.1.4.1.1 25-1.1.1.4.1 27-1.2.5.r 28-1.2.2 30-1.2.1.1 31-1.2.1 35-1.2.1.2.1.1 37-1.2.3 37-1.2.3.r 38-1.2 39-1.2.4.r 40-1.2.4.1.1 41-1.2.4.1.2 42-1.2.4 43-1.2.5 45-1.2.5.1 47-1.2.6.1 48-1.2.6.1.1
# ::id bel_pmid_1637_4521_27968
(m / multi-sentence
      :snt1 (p / possible~e.4
            :domain~e.5 (e / express-03~e.7
                  :ARG2 (p3 / protein
                        :name (n2 / name :op1 "IL-13"~e.0,2)
                        :mod (t / transgenic))
                  :ARG3~e.8 (l / lung~e.12
                        :part-of (a / animal
                              :name (n / name :op1 "Muridae"~e.11)
                              :mod (a2 / adult~e.10)))
                  :manner (i / induce-01
                        :mod (p2 / possible~e.4))
                  :instrument~e.13 (a3 / administer-01~e.15
                        :ARG1~e.16 (w2 / water~e.25
                              :ARG0-of (c / contain-01~e.19,23
                                    :ARG1 (s / small-molecule
                                          :name (n3 / name :op1 "doxycycline"~e.17)))))))
      :snt2 (d / detect-01~e.38
            :ARG1 (l2 / level~e.31
                  :ARG1-of (i2 / increase-01~e.30)
                  :quant-of (p4 / protein
                        :name (n4 / name :op1 "STAT6"~e.35)
                        :ARG3-of (p5 / phosphorylate-01)))
            :ARG1-of (e2 / expect-01~e.28)
            :manner~e.37 (r / ready~e.37)
            :instrument~e.39 (a4 / analysis~e.42
                  :name (n5 / name :op1 "Western"~e.40 :op2 "blot"~e.41))
            :time~e.27 (a5 / after~e.43
                  :op1 (a6 / activate-01~e.45
                        :ARG0 (p6 / protein
                              :name (n6 / name :op1 "IL-6"~e.0)
                              :mod (t2 / transgenic))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure~e.47 :mod "1"~e.48))))

# ::tok Tg IL @-@ 13 caused increases in lung volume , alveolar size , goblet cell number , and Gob @-@ 5 , Muc @-@ 5 ac , and Muc @-@ 1 gene expression in Tg+ ERK1 @/@ 2 MAPK @-@ sufficient animals ( Figure 8 , A–H ) .
# ::alignments 1-1.1.1.1 3-1.1.1.1 4-1 5-1.2 6-1.2.1.r 7-1.2.1.1.1 8-1.2.1.1 10-1.2.1.2.1 11-1.2.1.2 13-1.2.1.3.1.1 14-1.2.1.3.1 15-1.2.1.3 17-1.2.1 18-1.2.1.4.1.1.1.1 20-1.2.1.4.1.1.1.1 22-1.2.1.4.1.2.1.1 22-1.2.1.4.1.3.1.1 24-1.2.1.4.1.1.1.1 27-1.2.1.4.1 28-1.2.1.4.1.2.1.1 28-1.2.1.4.1.3.1.1 30-1.2.1.4.1.3.1.1 31-1.2.1.4.1.1 31-1.2.1.4.1.2 31-1.2.1.4.1.3 32-1.2.1.4 35-1.2.2.1.1.1.1 37-1.2.2.1.1.1.1 38-1.2.2.1.1.1.2 40-1.2.2.1 41-1.2.2 43-1.3.1 44-1.3.1.1
# ::id bel_pmid_1637_4521_27988
(c / cause-01~e.4
      :ARG0 (p / protein
            :name (n / name :op1 "IL-13"~e.1,3)
            :mod (t / transgenic))
      :ARG1 (i / increase-01~e.5
            :ARG1~e.6 (a / and~e.17
                  :op1 (v / volume~e.8
                        :mod (l / lung~e.7))
                  :op2 (s / size~e.11
                        :mod (a2 / alveolus~e.10))
                  :op3 (n2 / number~e.15
                        :quant-of (c2 / cell~e.14
                              :mod (g / goblet~e.13)))
                  :op3 (e / express-03~e.32
                        :ARG1 (a3 / and~e.27
                              :op1 (g2 / gene~e.31
                                    :name (n3 / name :op1 "Gob-5"~e.18,20,24))
                              :op2 (g3 / gene~e.31
                                    :name (n4 / name :op1 "Muc-5ac"~e.22,28))
                              :op3 (g4 / gene~e.31
                                    :name (n5 / name :op1 "Muc-1"~e.22,28,30)))))
            :location (a4 / animal~e.41
                  :ARG1-of (s2 / suffice-01~e.40
                        :ARG0 (p2 / pathway
                              :name (n6 / name :op1 "ERK1/2"~e.35,37 :op2 "MAPK"~e.38)))
                  :mod (t2 / transgenic :mod "+")))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.43
                  :mod "8"~e.44
                  :mod (v2 / value-interval :op1 "A" :op2 "H"))))

# ::tok BMMCs from mice lacking Map3k2 showed reduced production ( 50 @-@ 60 %) of IL @-@ 6 , IL @-@ 13 , and TNF @-@ alpha after stimulation
# ::alignments 1-1.1.2.r 2-1.1.2 3-1.1.2.1 4-1.1.2.1.1.1.1 5-1 6-1.2.2 7-1.2 9-1.2.2.1.1.1.1 11-1.2.2.1.1.2.1 13-1.2.1.r 14-1.2.1.1.1.1 14-1.2.1.2.1.1 16-1.2.1.1.1.1 18-1.2.1.1.1.1 18-1.2.1.2.1.1 20-1.2.1.2.1.1 22-1.2.1 23-1.2.1.3.1.1 25-1.2.1.3.1.1 26-1.3 27-1.3.1
# ::id bel_pmid_1643_0878_29026
(s / show-01~e.5
      :ARG0 (c / cell-line
            :name (n / name :op1 "BMMC")
            :source~e.1 (m / mouse~e.2
                  :ARG0-of (l / lack-01~e.3
                        :ARG1 (g / gene
                              :name (n2 / name :op1 "Map3k2"~e.4)))))
      :ARG1 (p2 / produce-01~e.7
            :ARG1~e.13 (a / and~e.22
                  :op1 (p4 / protein
                        :name (n3 / name :op1 "IL-6"~e.14,16,18))
                  :op2 (p5 / protein
                        :name (n4 / name :op1 "IL-13"~e.14,18,20))
                  :op3 (p6 / protein
                        :name (n5 / name :op1 "TNF-alpha"~e.23,25)))
            :ARG1-of (r / reduce-01~e.6
                  :ARG1-of (m2 / mean-01
                        :ARG2 (v / value-interval
                              :op1 (p / percentage-entity :value "50"~e.9)
                              :op2 (p3 / percentage-entity :value "60"~e.11)))))
      :time (a2 / after~e.26
            :op1 (s2 / stimulate-01~e.27)))

# ::tok In asbestos @-@ associated transformation of rodent mesothelial cells , the use of dominant negative ERK1 or Fra @-@ 1 constructs reverses the phenotype of mesothelioma cells to that of normal mesothelial cells ( 12 ) . Moreover , Fra @-@ 1 expression is increased in human mesotheliomas and in other tumor types .
# ::alignments 0-1.1.4.r 1-1.1.4.2.1 3-1.1.4.2 4-1.1.4 6-1.1.2.1.2 8-1.1.2.1 11-1.1.1 12-1.1.1.1.r 13-1.1.1.1.1.2.1 14-1.1.1.1.1.2 15-1.1.1.1.1.1.1.1.1 16-1.1.1.1 17-1.1.1.1.2.1.1.1.1 19-1.1.1.1.2.1.1.1.1 20-1.1.1.1.1 20-1.1.1.1.1.1 20-1.1.1.1.1.1.r 20-1.1.1.1.2 20-1.1.1.1.2.1 20-1.1.1.1.2.1.r 21-1.1 23-1.1.2 23-1.1.3 25-1.2.1.1.2.1 26-1.1.3.1 30-1.1.3.1.2 32-1.1.3.1 34-1.1.5.1.1.1 39-1.1.1.1.2.1.1.1.1 39-1.2.1.1.1.1.1 41-1.1.1.1.2.1.1.1.1 41-1.2.1.1.1.1.1 42-1.2.1.1 44-1.2.1 45-1.1.4.r 45-1.2.1.1.2.1.1.r 46-1.2.1.1.2.1.1 48-1.2 48-1.2.1.1.2 49-1.1.4.r 49-1.2.1.1.2.r 50-1.2.1.1.2.2.1 51-1.2.1.1.2.2
# ::id bel_pmid_1648_4683_21972
(m / multi-sentence
      :snt1 (r / reverse-01~e.21
            :ARG0 (u / use-01~e.11
                  :ARG1~e.12 (o / or~e.16
                        :op1 (m2 / molecular-physical-entity~e.20
                              :ARG1-of~e.20 (c / construct-01~e.20
                                    :mod (e / enzyme
                                          :name (n / name :op1 "ERK1"~e.15)))
                              :mod (n3 / negative~e.14
                                    :mod (d / dominate-01~e.13)))
                        :op2 (m6 / molecular-physical-entity~e.20
                              :ARG1-of~e.20 (c5 / construct-01~e.20
                                    :mod (e2 / enzyme
                                          :name (n2 / name :op1 "Fra-1"~e.17,19,39,41)))
                              :mod n3)))
            :ARG1 (p / phenotype~e.23
                  :poss (c2 / cell~e.8
                        :mod (m3 / mesothelium)
                        :source (r2 / rodent~e.6)))
            :prep-to (p2 / phenotype~e.23
                  :poss (c3 / cell~e.26,32
                        :mod (m4 / mesothelium)
                        :mod (n4 / normal~e.30)))
            :prep-in~e.0,45,49 (t / transform-01~e.4
                  :ARG1 c2
                  :ARG1-of (a / associate-01~e.3
                        :ARG2 (a2 / asbestos~e.1)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c4 / cite-01 :ARG2 "12"~e.34))))
      :snt2 (a3 / and~e.48
            :op2 (i / increase-01~e.44
                  :ARG1 (e3 / express-03~e.42
                        :ARG2 (e4 / enzyme
                              :name (n5 / name :op1 "Fra-1"~e.39,41))
                        :ARG3~e.49 (a4 / and~e.48
                              :op1 (m5 / mesothelioma~e.25
                                    :source~e.45 (h / human~e.46))
                              :op2 (t2 / tumor~e.51
                                    :mod (o2 / other~e.50)))))))

# ::tok We have used siRNA approaches to show that Fra @-@ 1 expression is critical to the expression of genes , such as cd44 and c @-@ met , that are critical to migration and autocrine growth factor production in transformation and invasion of mesotheliomas ( 13 ) .
# ::alignments 0-1.1 2-1 2-1.3.r 3-1.2.1.1.1 4-1.2 6-1.3 7-1.3.2.r 8-1.3.2.1.1.1.1 10-1.3.2.1.1.1.1 11-1.3.2.1 12-1.3.2.1.r 13-1.3.2 14-1.3.2.2.r 16-1.3.2.2 17-1.3.2.2.1.r 18-1.3.2.2.1 22-1.3.2.2.1.1.1.1.1.1 23-1.3.2.2.1.1.1 24-1.3.2.2.1.1.1.2.1.1 26-1.3.2.2.1.1.1.2.1.1 30-1.3.2.2.1.2 31-1.3.2.2.1.2.1.r 32-1.3.2.2.1.2.1.1 33-1.3.2.2.1.2.1 34-1.3.2.2.1.2.1.2.1.2 35-1.3.2.2.1.2.1.2.1.1.1 36-1.3.2.2.1.2.1.2.1.1.2 37-1.3.2.2.1.2.1.2 38-1.3.2.2.1.2.1.3.r 39-1.3.2.2.1.2.1.3.1 40-1.3.2.2.1.2.1.3 41-1.3.2.2.1.2.1.3.2 45-1.4.1.1.1
# ::id bel_pmid_1648_4683_26962
(u / use-01~e.2
      :ARG0 (w2 / we~e.0)
      :ARG1 (a / approach-02~e.4
            :instrument (r / rna
                  :name (n2 / name :op1 "siRNA"~e.3)))
      :purpose~e.2 (s2 / show-01~e.6
            :ARG0 w2
            :ARG1~e.7 (c / critical~e.13
                  :domain~e.12 (e / express-03~e.11
                        :ARG2 (p / protein
                              :name (n3 / name :op1 "Fra-1"~e.8,10)))
                  :topic~e.14 (e2 / express-03~e.16
                        :ARG1~e.17 (g / gene~e.18
                              :ARG1-of (e3 / exemplify-01
                                    :ARG0 (a2 / and~e.23
                                          :op1 (g2 / gene
                                                :name (n4 / name :op1 "cd44"~e.22))
                                          :op2 (g3 / gene
                                                :name (n5 / name :op1 "c-met"~e.24,26))))
                              :mod (c2 / critical~e.30
                                    :topic~e.31 (a3 / and~e.33
                                          :op1 (m2 / migrate-01~e.32)
                                          :op2 (p2 / produce-01~e.37
                                                :ARG1 (s / small-molecule
                                                      :name (n / name :op1 "growth"~e.35 :op2 "factor"~e.36)
                                                      :mod (a4 / autocrine~e.34)))
                                          :prep-in~e.38 (a5 / and~e.40
                                                :op1 (t / transform-01~e.39
                                                      :ARG1 (m3 / mesothelioma))
                                                :op2 (i / invade-01~e.41
                                                      :ARG1 m3))))))))
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "13"~e.45))))

# ::tok In contrast , EGFR activation by gram @-@ positive bacteria occurred through cleavage of the transmembrane ligand HBEGF by ADAM 10 .
# ::alignments 1-1 3-1.1.2.1.1 4-1.1 5-1.1.1.r 6-1.1.1.1 8-1.1.1.1 9-1.1.1 15-1.1.3.2.2 16-1.1.3.2 17-1.1.3.2.1.1 19-1.1.3.1.1.1 20-1.1.3.1.1.2
# ::id bel_pmid_1648_4683_37584
(c / contrast-01~e.1
      :ARG2 (a / activate-01~e.4
            :ARG0~e.5 (b / bacteria~e.9
                  :mod (g / gram-positive~e.6,8))
            :ARG1 (e / enzyme
                  :name (n / name :op1 "EGFR"~e.3))
            :manner (c2 / cleave-01
                  :ARG0 (p / protein
                        :name (n3 / name :op1 "ADAM"~e.19 :op2 "10"~e.20))
                  :ARG1 (l / ligand~e.16
                        :name (n2 / name :op1 "HBEGF"~e.17)
                        :mod (t / transmembrane~e.15)))))

# ::tok from full text - Furthermore , the decreased expression of either b @-@ arrestin 1 or b @-@ arrestin 2 ( via siRNA ) resulted in a decrease in ERK1 @/@ 2 activity
# ::alignments 1-1.2.1.1 2-1.2.1 7-1.1.1.2 8-1.1.1 11-1.1.1.1.1.1.1 11-1.1.1.1.2.1.1 13-1.1.1.1.1.1.1 13-1.1.1.1.2.1.1 14-1.1.1.1.1.1.2 15-1.1.1.1 16-1.1.1.1.1.1.1 16-1.1.1.1.2.1.1 18-1.1.1.1.1.1.1 18-1.1.1.1.2.1.1 19-1.1.1.1.2.1.2 22-1.1.1.3.1.1 24-1.1 25-1.1.2.r 27-1.1.2 28-1.1.2.1.r 29-1.1.2.1.1.1.1 31-1.1.2.1.1.1.1 32-1.1.2.1
# ::id bel_pmid_1649_2667_37650
(a / and
      :op2 (r / result-01~e.24
            :ARG1 (e / express-03~e.8
                  :ARG2 (o / or~e.15
                        :op1 (p / protein
                              :name (n / name :op1 "b-arrestin"~e.11,13,16,18 :op2 "1"~e.14))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "b-arrestin"~e.11,13,16,18 :op2 "2"~e.19)))
                  :ARG1-of (d / decrease-01~e.7)
                  :instrument (r2 / rna
                        :name (n3 / name :op1 "siRNA"~e.22)))
            :ARG2~e.25 (d2 / decrease-01~e.27
                  :ARG1~e.28 (a2 / act-02~e.32
                        :ARG0 (e2 / enzyme
                              :name (n4 / name :op1 "ERK1/2"~e.29,31)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (t / text~e.2
                  :mod (f / full~e.1))))

# ::tok FBLN @-@ 3 expression in MB114 cells also prevented their activation of p38 MAPK , but not that of extracellular signal @-@ regulated kinase 1 @/@ 2 ( ERK1 @/@ 2 ) , stimulated by VEGF ( Fig . 2E ) .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.1.1 4-1.1.1.2.r 5-1.1.1.2.1.1 6-1.1.1.2 7-1.1.3 8-1.1 8-1.2 10-1.1.2 10-1.2.2 15-1 16-1.2.1 16-1.2.1.r 18-1.2.2.1.r 19-1.2.2.1.1.1 20-1.2.2.1.1.2 22-1.2.2.1.1.2 23-1.2.2.1.1.3 24-1.2.2.1.1.4 26-1.2.2.1.1.4 30-1.2.2.1.1.4 33-1.2.2.2 34-1.2.2.2.1.r 35-1.2.2.2.1.1.1 39-1.3.1.1
# ::id bel_pmid_1651_0581_41864
(c / contrast-01~e.15
      :ARG1 (p2 / prevent-01~e.8
            :ARG0 (e / express-03~e.3
                  :ARG2 (p3 / protein
                        :name (n2 / name :op1 "FBLN-3"~e.0,2))
                  :ARG3~e.4 (c2 / cell-line~e.6
                        :name (n3 / name :op1 "MB114"~e.5)))
            :ARG1 (a / activate-01~e.10
                  :ARG0 c2
                  :ARG1 (e2 / enzyme
                        :name (n4 / name :op1 "p38MAPK")))
            :mod (a2 / also~e.7))
      :ARG2 (p4 / prevent-01~e.8
            :polarity~e.16 "-"~e.16
            :ARG1 (a3 / activate-01~e.10
                  :ARG1~e.18 (e3 / enzyme
                        :name (n5 / name
                              :op1 "extracellular"~e.19
                              :op2 "signal-regulated"~e.20,22
                              :op3 "kinase"~e.23
                              :op4 "1/2"~e.24,26,30))
                  :ARG1-of (s / stimulate-01~e.33
                        :ARG0~e.34 (p5 / protein
                              :name (n6 / name :op1 "VEGF"~e.35)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2E"~e.39)))

# ::tok Figure 3A shows that relative to control cells , FBLN @-@ 3 and FBLN @-@ 5 both decreased MB114 cell expression of MMP @-@ 2 and MMP @-@ 3 while simultaneously increasing that of the MMP antagonists , TIMP @-@ 1 and TIMP @-@ 3 .
# ::alignments 0-1.1 1-1.1.1 2-1 5-1.2.r 6-1.2.3.1 7-1.2.3 9-1.2.1.1.1.1.1 9-1.2.1.1.2.1.1 11-1.2.1.1.1.1.1 13-1.2.1.1.1.1.1 13-1.2.1.1.2.1.1 15-1.2.1.1.2.1.1 17-1.2.1 18-1.2.1.2.2.1.1 19-1.2.1.2.2 20-1.2.1.2 21-1.2.1.2.1.r 22-1.2.1.2.1.1.1.1 22-1.2.1.2.1.2.1.1 24-1.2.1.2.1.1.1.1 25-1.2 25-1.2.1.2.1 26-1.2.1.2.1.1.1.1 26-1.2.1.2.1.2.1.1 28-1.2.1.2.1.2.1.1 30-1.2.2.3 30-1.2.2.3.r 31-1.2.2 33-1.2.2.2.r 35-1.2.2.2.1.2.1.1.1 38-1.2.2.2.1.1.1 38-1.2.2.2.2.1.1 40-1.2.2.2.1.1.1 42-1.2.2.2.1.1.1 42-1.2.2.2.2.1.1 44-1.2.1.2.1.2.1.1 44-1.2.2.2.2.1.1
# ::id bel_pmid_1651_0581_41866
(s / show-01~e.2
      :ARG0 (f / figure~e.0 :mod "3A"~e.1)
      :ARG1~e.5 (a / and~e.25
            :op1 (d / decrease-01~e.17
                  :ARG0 (a2 / and
                        :op1 (p / protein
                              :name (n / name :op1 "FBLN-3"~e.9,11,13))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "FBLN-5"~e.9,13,15)))
                  :ARG1 (e / express-03~e.20
                        :ARG2~e.21 (a3 / and~e.25
                              :op1 (p3 / protein
                                    :name (n4 / name :op1 "MMP-2"~e.22,24,26))
                              :op2 (p4 / protein
                                    :name (n5 / name :op1 "MMP-3"~e.22,26,28,44)))
                        :ARG3 (c3 / cell-line~e.19
                              :name (n3 / name :op1 "MB114"~e.18))))
            :op2 (i / increase-01~e.31
                  :ARG0 a2
                  :ARG2~e.33 (a4 / and
                        :op1 (p5 / protein
                              :name (n6 / name :op1 "TIMP-1"~e.38,40,42)
                              :ARG1-of (a5 / antagonize-02
                                    :ARG2 (p6 / protein
                                          :name (n7 / name :op1 "MMP"~e.35))))
                        :op2 (p7 / protein
                              :name (n8 / name :op1 "TIMP-3"~e.38,42,44)
                              :ARG0-of a5))
                  :manner~e.30 (s2 / simultaneous~e.30))
            :compared-to (c / cell~e.7
                  :mod (c2 / control-01~e.6))))

# ::tok Although MB114 cell expression of TIMP @-@ 2 was unaffected by either FBLN @-@ 3 or FBLN @-@ 5 , both FBLNs induced MB114 cell expression of the angiostatic molecule , TSP @-@ 1 ( Fig . 3A ) .
# ::alignments 0-1 1-1.2.3.2 2-1.2.3.2 3-1.2.3 4-1.2.3.1.r 5-1.2.3.1.1.1 7-1.2.3.1.1.1 9-1.2 9-1.2.1 9-1.2.1.r 12-1.1.1.1.1.1 12-1.1.1.2.1.1 14-1.1.1.1.1.1 16-1.1.1.1.1.1 16-1.1.1.2.1.1 18-1.1.1.2.1.1 22-1.1 23-1.1.2.2.1.1 24-1.1.2.2 25-1.1.2 26-1.1.2.1.r 28-1.1.2.1.2 31-1.1.2.1.1.1 33-1.1.2.1.1.1 37-1.3.1.1
# ::id bel_pmid_1651_0581_41868
(h / have-concession-91~e.0
      :ARG1 (i / induce-01~e.22
            :ARG0 (a / and
                  :op1 (p / protein
                        :name (n / name :op1 "FBLN-3"~e.12,14,16))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "FBLN-5"~e.12,16,18)))
            :ARG1 (e / express-03~e.25
                  :ARG2~e.26 (p3 / protein
                        :name (n4 / name :op1 "TSP-1"~e.31,33)
                        :mod (a2 / angiostatic~e.28))
                  :ARG3 (c2 / cell-line~e.24
                        :name (n3 / name :op1 "MB114"~e.23))))
      :ARG2 (a3 / affect-01~e.9
            :polarity~e.9 "-"~e.9
            :ARG0 a
            :ARG1 (e2 / express-03~e.3
                  :ARG2~e.4 (p4 / protein
                        :name (n5 / name :op1 "TIMP-2"~e.5,7))
                  :ARG3 c2~e.1,2))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "3A"~e.37)))

# ::tok Interestingly , although TIMP @-@ 3 expression was elevated basally in FBLN @-@ 5 @-@ expressing MB114 cells , only FBLN @-@ 3 stimulated TIMP @-@ 3 expression in tubulating MB114 cells ( Fig . 3B ) .
# ::alignments 0-1.3 2-1 3-1.1.2.1.1.1 5-1.1.1.1.1 5-1.1.2.1.1.1 6-1.2.1 8-1.2 11-1.2.1.2.2.1.1.1 13-1.2.1.2.2.1.1.1 15-1.1.2 15-1.2.1 15-1.2.1.2.2 16-1.1.2.2.1.1 16-1.2.1.2.1.1 17-1.1.2.2 17-1.2.1.2 19-1.1.1.2 20-1.1.1.1.1 22-1.1.1.1.1 22-1.1.2.1.1.1 23-1.1 24-1.1.2.1.1.1 26-1.1.2.1.1.1 27-1.1.2 30-1.1.2.2.1.1 30-1.2.1.2.1.1 31-1.2.1.2
# ::id bel_pmid_1651_0581_41870
(h / have-concession-91~e.2
      :ARG1 (s / stimulate-01~e.23
            :ARG0 (p / protein
                  :name (n / name :op1 "FBLN-3"~e.5,20,22)
                  :mod (o / only~e.19))
            :ARG1 (e / express-03~e.15,27
                  :ARG2 (p2 / protein
                        :name (n3 / name :op1 "TIMP-3"~e.3,5,22,24,26))
                  :ARG3 (c2 / cell-line~e.17
                        :name (n2 / name :op1 "MB114"~e.16,30)
                        :ARG1-of (t / tubulate-00))))
      :ARG2 (e2 / elevate-01~e.8
            :ARG1 (e3 / express-03~e.6,15
                  :ARG2 p2
                  :ARG3 (c3 / cell-line~e.17,31
                        :name (n4 / name :op1 "MB114"~e.16,30)
                        :ARG3-of (e4 / express-03~e.15
                              :ARG2 (p3 / protein
                                    :name (n5 / name :op1 "FBLN-5"~e.11,13)))))
            :manner (b / basal))
      :mod (i / interesting~e.0))

# ::tok Gelatin zymography of MB114 cell conditioned medium confirmed that expression of either FBLN @-@ 3 or FBLN @-@ 5 significantly reduced MMP @-@ 2 protease activity in tubulating MB114 cells ( Fig . 3C ) .
# ::alignments 0-1.1.1.1 1-1.1.1.2 3-1.1.2.2.1.1 4-1.1.2.2 5-1.1.2.1 6-1.1.2 7-1 8-1.2.r 9-1.2.1 12-1.2.1.1.1.1.1 12-1.2.1.1.2.1.1 14-1.2.1.1.1.1.1 15-1.2.1.1 16-1.2.1.1.1.1.1 16-1.2.1.1.2.1.1 18-1.2.1.1.2.1.1 19-1.2.3 20-1.2 21-1.2.2.1.1.1 23-1.2.2.1.1.1 24-1.2.2.1 25-1.2.2 28-1.2.2.2.1.1 29-1.2.2.2 33-1.3.1.1
# ::id bel_pmid_1651_0581_41872
(c / confirm-01~e.7
      :ARG0 (t2 / thing
            :name (n / name :op1 "gelatin"~e.0 :op2 "zymography"~e.1)
            :topic (m / medium~e.6
                  :ARG1-of (c2 / condition-01~e.5)
                  :mod (c3 / cell-line~e.4
                        :name (n2 / name :op1 "MB114"~e.3))))
      :ARG1~e.8 (r / reduce-01~e.20
            :ARG0 (e / express-03~e.9
                  :ARG2 (o / or~e.15
                        :op1 (p / protein
                              :name (n3 / name :op1 "FBLN-3"~e.12,14,16))
                        :op2 (p2 / protein
                              :name (n4 / name :op1 "FBLN-5"~e.12,16,18))))
            :ARG1 (a2 / act-02~e.25
                  :ARG0 (p3 / protease~e.24
                        :name (n5 / name :op1 "MMP-2"~e.21,23))
                  :location (c4 / cell-line~e.29
                        :name (n6 / name :op1 "MB114"~e.28)
                        :ARG1-of (t / tubulate-00)))
            :degree (s / significant~e.19))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "3C"~e.33)))

# ::tok FBLN @-@ 3 and FBLN @-@ 5 antagonize angiogenesis in vivo .
# ::alignments 0-1.1.1.1.1 0-1.1.2.1.1 2-1.1.1.1.1 3-1.1 4-1.1.1.1.1 4-1.1.2.1.1 6-1.1.2.1.1 7-1 8-1.2 9-1.3 10-1.3
# ::id bel_pmid_1651_0581_41874
(a / antagonize-02~e.7
      :ARG1 (a2 / and~e.3
            :op1 (p / protein
                  :name (n / name :op1 "FBLN-3"~e.0,2,4))
            :op2 (p2 / protein
                  :name (n2 / name :op1 "FBLN-5"~e.0,4,6)))
      :ARG2 (a3 / angiogenesis~e.8)
      :manner (i / in-vivo~e.9,10))

# ::tok Moreover , recombinant FBLN @-@ 3 and FBLN @-@ 5 ( Fig . 4B ) both inhibited human HMEC @-@ 1 endothelial cell migration to fibronectin ( Fig . 4C ) , whereas FBLN @-@ 5 , but not FBLN @-@ 3 , mediated their adhesion in an RGD @-@ dependent manner ( Fig . 4D ; refs .
# ::alignments 3-1.1.1.1.1.1.1 3-1.1.1.1.2.1.1 5-1.1.1.1.1.1.1 6-1.1.1.1 7-1.1.1.1.1.1.1 7-1.1.1.1.2.1.1 9-1.1.1.1.2.1.1 13-1.1.1.1.4.1.1 16-1.1.1 18-1.1.1.2.1.1.1 20-1.1.1.2.1.1.1 22-1.1.1.2.1 23-1.1.1.2 24-1.1.1.2.2.r 25-1.1.1.2.2.1.1 29-1.1.1.3.1.1 32-1.1 32-1.1.2 32-1.1.2.r 33-1.1.1.1.1.1.1 33-1.1.1.1.2.1.1 35-1.1.1.1.2.1.1 37-1.1.2 38-1.1.2.2.1 38-1.1.2.2.1.r 39-1.1.1.1.1.1.1 39-1.1.1.1.2.1.1 41-1.1.1.1.1.1.1 43-1.1.2.1 43-1.1.2.2 48-1.1.2.1.2.2.2.1.1 50-1.1.2.1.2.2 51-1.1.2.1.2.2.r 55-1.1.2.3.1.1
# ::id bel_pmid_1651_0581_41878
(a3 / and
      :op2 (c / contrast-01~e.32
            :ARG1 (i / inhibit-01~e.16
                  :ARG0 (a / and~e.6
                        :op1 (p / protein
                              :name (n / name :op1 "FBLN-3"~e.3,5,7,33,39,41))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "FBLN-5"~e.3,7,9,33,35,39))
                        :ARG3-of (r / recombine-01)
                        :ARG1-of (d / describe-01
                              :ARG0 (f / figure :mod "4B"~e.13)))
                  :ARG1 (m / migrate-01~e.23
                        :ARG0 (c2 / cell-line~e.22
                              :name (n3 / name :op1 "HMEC-1"~e.18,20))
                        :ARG1~e.24 (p3 / protein
                              :name (n4 / name :op1 "fibronectin"~e.25)))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f2 / figure :mod "4C"~e.29)))
            :ARG2~e.32 (c3 / contrast-01~e.32,37
                  :ARG1 (m2 / mediate-01~e.43
                        :ARG0 p2
                        :ARG1 (a2 / adhere-01
                              :ARG1 c2
                              :manner~e.51 (d3 / depend-01~e.50
                                    :ARG0 c2
                                    :ARG1 (s / small-molecule
                                          :name (n5 / name :op1 "RGD"~e.48)))))
                  :ARG2 (m3 / mediate-01~e.43
                        :polarity~e.38 "-"~e.38
                        :ARG0 p
                        :ARG1 a2)
                  :ARG1-of (d4 / describe-01
                        :ARG0 (f3 / figure :mod "4D"~e.55))
                  :ARG1-of (d5 / describe-01
                        :ARG0 (p4 / publication
                              :ARG1-of (c4 / cite-01))))))

# ::tok Figure 5A shows that bFGF stimulated significant vascularization of implanted Matrigel plugs , which was quantified by measuring plug hemoglobin contents ( Fig . 5A ) and microvessel densities ( Fig . 5B ) .
# ::alignments 0-1.1 0-1.2.2.3.1.1.2.2.1 1-1.1.1 2-1 3-1.2.r 4-1.2.1.1.1 5-1.2 6-1.2.2.2 9-1.2.2.1.1 10-1.2.2.1.2.1.1 11-1.2.2.1 15-1.2.2.3 16-1.2.2.3.1.r 17-1.2.2.3.1 18-1.2.2.3.1.1.1.3 19-1.2.2.3.1.1.1.1 20-1.2.2.3.1.1.1 24-1.1.1 26-1.2.2.3.1.1 27-1.2.2.3.1.1.2.1 28-1.2.2.3.1.1.2 32-1.2.2.3.1.1.2.2.1.1
# ::id bel_pmid_1651_0581_41880
(s / show-01~e.2
      :ARG0 (f / figure~e.0 :mod "5A"~e.1,24)
      :ARG1~e.3 (s2 / stimulate-01~e.5
            :ARG0 (p / protein
                  :name (n / name :op1 "bFGF"~e.4))
            :ARG1 (v / vascularize-00
                  :ARG1 (p2 / plug~e.11
                        :ARG1-of (i / implant-01~e.9)
                        :mod (m3 / macro-molecular-complex
                              :name (n2 / name :op1 "Matrigel"~e.10)))
                  :mod (s3 / significant~e.6)
                  :ARG1-of (q / quantify-01~e.15
                        :manner~e.16 (m / measure-01~e.17
                              :ARG1 (a / and~e.26
                                    :op1 (c / content~e.20
                                          :mod (h / hemoglobin~e.19)
                                          :ARG1-of (d2 / describe-01
                                                :ARG0 f)
                                          :location (p3 / plug~e.18))
                                    :op2 (d / density~e.28
                                          :mod (m2 / microvessel~e.27)
                                          :ARG1-of (d3 / describe-01
                                                :ARG0 (f2 / figure~e.0 :mod "5B"~e.32)))))))))

# ::tok More importantly , tumors derived from FBLN @-@ expressing MCA102 fibrosarcoma cells also exhibited significantly reduced blood vessel densities compared with tumors derived from control cells ( Fig . 6D ) .
# ::alignments 0-1.3.1 1-1.3 3-1.1 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1.2.1.1.1 8-1.1.1.1.2 9-1.1.1.1.1.1 11-1.1.1.1 12-1.5 13-1 14-1.2.2.1 15-1.2.2 16-1.2.1.1 17-1.2.1 18-1.2 19-1.2.2.2.r 21-1.2.2.2 22-1.2.2.2.1 23-1.2.2.2.1.1.r 24-1.2.2.2.1.1.1 25-1.2.2.2.1.1 29-1.4.1.1
# ::id bel_pmid_1651_0581_41890
(e / exhibit-01~e.13
      :ARG0 (t / tumor~e.3
            :ARG1-of (d / derive-01~e.4
                  :ARG2~e.5 (c / cell-line~e.11
                        :name (n / name :op1 "MCA102"~e.9)
                        :ARG3-of (e2 / express-03~e.8
                              :ARG2 (p / protein
                                    :name (n2 / name :op1 "FBLN"~e.6))))))
      :ARG1 (d2 / density~e.18
            :mod (v / vessel~e.17
                  :mod (b / blood~e.16))
            :ARG1-of (r / reduce-01~e.15
                  :degree (s / significant~e.14)
                  :compared-to~e.19 (t2 / tumor~e.21
                        :ARG1-of (d4 / derive-01~e.22
                              :ARG2~e.23 (c2 / cell~e.25
                                    :mod (c3 / control-01~e.24))))))
      :mod (i / important~e.1
            :degree (m / more~e.0))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "6D"~e.29))
      :mod (a / also~e.12))

# ::tok In addition , FBLN @-@ 3 @-@ expressing MCA102 tumors contained significantly enlarged regions of central and peripheral necrosis that were typically absent in their control counterparts .
# ::alignments 0-1.1.2.3 1-1.1.2.3 3-1.1.1.2.1.1.1 5-1.1.1.2.1.1.1 7-1.1.1.2 8-1.1.1.1.1.1 9-1.1.1 10-1.1 11-1.1.2.1.1 12-1.1.2.1 13-1.1.2 15-1.1.2.3.1.1 16-1.1.2.3 18-1.1.2.3.1 18-1.1.2.3.2 21-1.1.2.2.2 21-1.1.2.2.2.r 22-1.1.2.2 23-1.1.2.2.1.r 24-1.1.2.2.1.1 24-1.1.2.2.1.1.r 25-1.1.2.2.1.2 26-1.1.2.2.1
# ::id bel_pmid_1651_0581_41892
(a / and
      :op2 (c / contain-01~e.10
            :ARG0 (t / tumor~e.9
                  :source (c2 / cell-line
                        :name (n / name :op1 "MCA102"~e.8))
                  :ARG3-of (e / express-03~e.7
                        :ARG2 (p / protein
                              :name (n2 / name :op1 "FBLN-3"~e.3,5))))
            :ARG1 (r / region~e.13
                  :ARG1-of (e2 / enlarge-01~e.12
                        :degree (s / significant~e.11))
                  :ARG1-of (a3 / absent-01~e.22
                        :ARG2~e.23 (c4 / counterpart~e.26
                              :poss~e.24 r~e.24
                              :mod (c5 / control-01~e.25))
                        :manner~e.21 (t2 / typical~e.21))
                  :location-of (a2 / and~e.0,1,16
                        :op1 (n3 / necrosis~e.18
                              :mod (c3 / center~e.15))
                        :op2 (n4 / necrosis~e.18
                              :mod (p2 / periphery))))))

# ::tok The TLR3 agonist poly ( I : C ) significantly increased bidirectional secretion of CCL2 , IL6 , TNFA and CSF2 and basolateral secretion of CSF3 .
# ::alignments 1-1.1.2.1.1 2-1.1 3-1.1.1.1 9-1.3 10-1 11-1.2.1.2 12-1.2.1 13-1.2.1.1.r 14-1.2.1.1.1.1.1 16-1.2.1.1.2.1.1 18-1.2.1.1.3.1.1 19-1.2.1.1 20-1.2.1.1.4.1.1 21-1.2 22-1.2.2.2 23-1.2.2 24-1.2.2.1.r 25-1.2.2.1.1.1
# ::id bel_pmid_1651_0838_19670
(i / increase-01~e.10
      :ARG0 (a / agonist~e.2
            :name (n / name :op1 "poly"~e.3 :op2 "(I:C)")
            :mod (p / protein
                  :name (n2 / name :op1 "TLR3"~e.1)))
      :ARG1 (a3 / and~e.21
            :op1 (s2 / secrete-01~e.12
                  :ARG1~e.13 (a2 / and~e.19
                        :op1 (p3 / protein
                              :name (n4 / name :op1 "CCL2"~e.14))
                        :op2 (p2 / protein
                              :name (n3 / name :op1 "IL6"~e.16))
                        :op3 (p4 / protein
                              :name (n5 / name :op1 "TNFA"~e.18))
                        :op4 (p5 / protein
                              :name (n6 / name :op1 "CSF2"~e.20)))
                  :mod (b2 / bidirectional~e.11))
            :op2 (s3 / secrete-01~e.23
                  :ARG1~e.24 (p6 / protein
                        :name (n7 / name :op1 "CSF3"~e.25))
                  :mod (b / basolateral~e.22)))
      :degree (s / significant~e.9))

# ::tok To verify the absence of the STAT6 @-@ signaling cascade in STAT6-/- MLF , we assessed mOSM and mIL @-@ 4 induced responses with respect to STAT3 and STAT6 activation . Fig. 6 confirms the absence of STAT6 protein and STAT6 induction in STAT6-/- MLF but equivalent activation of STAT3 in both wt and STAT6-/- MLF .
# ::alignments 1-1.1.3 3-1.1.3.2 6-1.1.3.2.1.1.1 6-1.1.3.2.2.2.1.1 8-1.1.3.2.1.2.1 9-1.1.3.2.1.2 14-1.1.1 15-1.1 20-1.1.2.2.1.2.1.1 21-1.2.2.1.2 22-1.1.2 22-1.1.2.1 22-1.1.2.1.r 26-1.1.4.1.1.1.1 26-1.2.2.2.1.1.1 27-1.1.4.1 28-1.1.4.1.2.1.1 28-1.2.2.1.1.1.1.1 28-1.2.2.1.2.2.2.1.1 29-1.1.4 29-1.2.2.2 32-1.2.1.1 33-1.2 35-1.2.2.1.1 36-1.2.2.1.1.1.r 37-1.2.2.1.1.1.1.1 38-1.1.2.2.1.1 38-1.1.2.2.1.2 38-1.1.3.2.1 38-1.1.3.2.2.2 38-1.1.4.1.1 38-1.1.4.1.2 38-1.2.2.1.1.1 38-1.2.2.1.2.2.2 38-1.2.2.2.1 39-1.2.2.1 40-1.2.2.1.1.1.1.1 41-1.1.2.2 45-1.2.2 47-1.2.2.2 49-1.2.2.2.1.1.1 53-1.2.2.2.3
# ::id bel_pmid_1654_7273_28276
(m / multi-sentence
      :snt1 (a / assess-01~e.15
            :ARG0 (w / we~e.14)
            :ARG1 (t / thing~e.22
                  :ARG2-of~e.22 (r / respond-01~e.22)
                  :ARG1-of (i2 / induce-01~e.41
                        :ARG0 (a2 / and
                              :op1 (p11 / protein~e.38
                                    :name (n8 / name :op1 "OSM")
                                    :mod (m2 / mouse))
                              :op2 (p / protein~e.38
                                    :name (n / name :op1 "IL-4"~e.20)
                                    :mod m2))))
            :purpose (v / verify-01~e.1
                  :ARG0 w
                  :ARG1 (a5 / absent-01~e.3
                        :ARG1 (p5 / protein~e.38
                              :name (n7 / name :op1 "STAT6"~e.6)
                              :mod (c / cascade-01~e.9
                                    :subevent (s / signal-07~e.8)))
                        :ARG2 (f2 / fibroblast
                              :mod (l / lung
                                    :mod m2)
                              :mod (p6 / protein~e.38
                                    :name (n9 / name :op1 "STAT6"~e.6)
                                    :ARG2-of (m3 / mutate-01 :mod "-/-")))))
            :topic (a3 / activate-01~e.29
                  :ARG1 (a4 / and~e.27
                        :op1 (p3 / protein~e.38
                              :name (n5 / name :op1 "STAT3"~e.26))
                        :op2 (p4 / protein~e.38
                              :name (n6 / name :op1 "STAT6"~e.28)))))
      :snt2 (c2 / confirm-01~e.33
            :ARG0 (f / figure :mod "6"~e.32)
            :ARG1 (c3 / contrast-01~e.45
                  :ARG1 (a6 / and~e.39
                        :op1 (a7 / absent-01~e.35
                              :ARG1~e.36 (p7 / protein~e.38
                                    :name (n10 / name :op1 "STAT6"~e.28,37,40))
                              :ARG2 (f3 / fibroblast
                                    :mod (l2 / lung
                                          :mod (m11 / mouse))
                                    :mod (p8 / protein~e.38
                                          :name (n12 / name :op1 "STAT6"~e.28)
                                          :ARG2-of (m5 / mutate-01 :mod "-/-"))))
                        :op2 (i / induce-01~e.21
                              :ARG1 p7
                              :location f3))
                  :ARG2 (a8 / activate-01~e.29,47
                        :ARG1 (p9 / protein~e.38
                              :name (n13 / name :op1 "STAT3"~e.26,49))
                        :ARG2-of (e3 / equal-01)
                        :location (a9 / and~e.53
                              :op1 f3
                              :op2 (f5 / fibroblast
                                    :mod (w2 / wild-type)
                                    :mod l2))))))

# ::tok Twenty @-@ four hour stimulation with 25.0 ng @/@ ml mOSM induced detectable increases in eotaxin @-@ 1 expression at the mRNA and protein level in both wt and STAT6-/- MLF ( Fig . 5 , A and C ) . Stimulation of wt MLF using 10.0 ng @/@ ml mIL @-@ 4 induced eotaxin mRNA expression and protein production that was nondetectable in STAT6-/- MLF ( Fig . 5 , A and C )
# ::alignments 2-1.2.1.2.1.1.1 3-1.1.1.2.2 4-1.1.1 11-1.1 13-1.1.2 14-1.1.2.1.r 15-1.1.2.1.1.1.1 17-1.1.2.1.1.1.1 18-1.1.2.1 21-1.1.2.1.2.1.1.1.1 22-1.1.2.1.2 23-1.1.2.1.2.2.1 24-1.1.2.1.2.1 24-1.1.2.1.2.2 28-1.1.2.1.2 28-1.1.3.1 28-1.2.3.1 37-1.1.2.1.2 37-1.1.3.1 37-1.2.3.1 41-1.2.1 45-1.2.1.2 52-1.2.1.2.1.1.1 53-1.2 54-1.2.2.1.1.2.1.1.1 55-1.2.2.1.1.1.1 56-1.2.2.1 57-1.2.2 57-1.2.3.1 58-1.2.2.2.1 59-1.2.2.2 72-1.1.3.1 72-1.2.2 72-1.2.3.1
# ::id bel_pmid_1654_7273_28294
(m / multi-sentence
      :snt1 (i / induce-01~e.11
            :ARG0 (s / stimulate-01~e.4
                  :ARG2 (p / protein
                        :name (n2 / name :op1 "OSM")
                        :mod (m5 / mouse)
                        :quant (c / concentration-quantity
                              :quant "25"
                              :unit (n3 / nanogram-per-milliliter)))
                  :duration (t3 / temporal-quantity
                        :quant "24"
                        :unit (h3 / hour~e.3)))
            :ARG1 (i2 / increase-01~e.13
                  :ARG1~e.14 (e2 / express-03~e.18
                        :ARG2 (p11 / protein
                              :name (n / name :op1 "eotaxin-1"~e.15,17))
                        :manner (a4 / and~e.22,28,37
                              :op1 (l6 / level~e.24
                                    :mod (r2 / rna
                                          :name (n5 / name :op1 "mRNA"~e.21)))
                              :op2 (l / level~e.24
                                    :mod (p2 / protein~e.23))))
                  :ARG3 (a2 / and
                        :op1 (f5 / fibroblast
                              :mod (l2 / lung
                                    :mod m5)
                              :mod (p3 / protein
                                    :name (n7 / name :op1 "STAT6")
                                    :ARG2-of (m3 / mutate-01 :mod "-/-")))
                        :op2 (f6 / fibroblast
                              :mod (w / wild-type)
                              :mod l2))
                  :ARG1-of (d / detect-01
                        :mod (p4 / possible)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a3 / and~e.28,37,72
                        :op1 (f / figure :mod "5A")
                        :op2 (f2 / figure :mod "5C"))))
      :snt2 (i3 / induce-01~e.53
            :ARG0 (s2 / stimulate-01~e.41
                  :ARG1 (f7 / fibroblast
                        :mod (l4 / lung
                              :mod (m4 / mouse))
                        :mod (w2 / wild-type))
                  :ARG2-of (u / use-01~e.45
                        :ARG1 (p5 / protein
                              :name (n12 / name :op1 "IL-4"~e.2,52)
                              :quant (c2 / concentration-quantity
                                    :quant "10"
                                    :unit (n13 / nanogram-per-milliliter))
                              :mod m4)))
            :ARG1 (a / and~e.57,72
                  :op1 (e5 / express-03~e.56
                        :ARG1 (r4 / rna
                              :name (n14 / name :op1 "mRNA"~e.55)
                              :ARG0-of (e6 / encode-01
                                    :ARG1 (p6 / protein
                                          :name (n15 / name :op1 "eotaxin"~e.54)))))
                  :op2 (p7 / produce-01~e.59
                        :ARG1 (p8 / protein~e.58))
                  :ARG1-of (d3 / detect-01
                        :polarity "-"
                        :location (f8 / fibroblast
                              :mod (p10 / protein
                                    :name (n17 / name :op1 "STAT6")
                                    :ARG2-of (m8 / mutate-01 :mod "-/-"))
                              :mod l4)
                        :mod (p9 / possible)))
            :ARG1-of (d4 / describe-01
                  :ARG0 (a5 / and~e.28,37,57,72
                        :op1 (f3 / figure :mod "5A")
                        :op2 (f4 / figure :mod "5C")))))

# ::tok We and others have shown that OSM can induce eotaxin @-@ 1 in mouse lung fibroblasts ( MLF ) ( 28 ) and lung smooth muscle cells ( 29 ) .
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.1 4-1 5-1.2.r 6-1.2.1.1.1.1 7-1.2 8-1.2.1 9-1.2.1.2.1.1 11-1.2.1.2.1.1 12-1.2.1.3.r 13-1.2.1.3.1.1.1 14-1.2.1.3.1.1 15-1.2.1.3.1 17-1.2.1.3.1.3.1 20-1.2.1.3.1.2.1.1.1 22-1.2.1.3 23-1.2.1.3.2.1.2 24-1.2.1.3.2.1.1 25-1.2.1.3.2.1 26-1.2.1.3.2 28-1.2.1.3.2.2.1.1.1
# ::id bel_pmid_1654_7273_29762
(s / show-01~e.4
      :ARG0 (a / and~e.1
            :op1 (w / we~e.0)
            :op2 (p / person
                  :mod (o / other~e.2)))
      :ARG1~e.5 (p2 / possible~e.7
            :domain (i / induce-01~e.8
                  :ARG0 (p3 / protein
                        :name (n / name :op1 "OSM"~e.6))
                  :ARG1 (p6 / protein
                        :name (n2 / name :op1 "eotaxin-1"~e.9,11))
                  :location~e.12 (a2 / and~e.22
                        :op1 (f / fibroblast~e.15
                              :mod (l / lung~e.14
                                    :mod (m / mouse~e.13))
                              :ARG1-of (d / describe-01
                                    :ARG0 (p4 / publication
                                          :ARG1-of (c / cite-01 :ARG2 "28"~e.20)))
                              :ARG1-of (m3 / mean-01
                                    :ARG2 (m4 / MLF~e.17)))
                        :op2 (c2 / cell~e.26
                              :mod (m2 / muscle~e.25
                                    :mod (s2 / smooth~e.24)
                                    :mod (l2 / lung~e.23))
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p5 / publication
                                          :ARG1-of (c3 / cite-01 :ARG2 "29"~e.28))))))))

# ::tok We also compared the effects of mOSM on IL @-@ 6 expression in both wt and STAT6-/- MLF ( Fig . 5 , B and D ) and show that STAT6-/- MLF respond similarly to wt MLF in IL @-@ 6 expression at both the mRNA and protein levels .
# ::alignments 0-1.1.1 1-1.1.3 2-1.1 4-1.1.2 7-1.1.2.2.r 8-1.1.2.2.1.1.1 10-1.1.2.2.1.1.1 11-1.1.2.2 15-1.1.2.2.2 15-1.1.4.1 24-1 24-1.1.4.1 27-1 27-1.1.4.1 28-1.2 32-1.2.2 33-1.2.2.2 38-1.2.2.3.1.1 39-1.2.2.3.1.1 40-1.2.2.3.1.1 41-1.2.2.3.1 45-1.2.2.3.1.2.1.1.1.1 46-1.2.2.3.1.2 47-1.2.2.3.1.2.2.1 48-1.2.2.3.1.2.1 48-1.2.2.3.1.2.2
# ::id bel_pmid_1654_7273_29766
(a / and~e.24,27
      :op1 (c / compare-01~e.2
            :ARG0 (w / we~e.0)
            :ARG1 (a3 / affect-01~e.4
                  :ARG0 (p / protein
                        :name (n2 / name :op1 "OSM")
                        :mod (m4 / mouse))
                  :ARG1~e.7 (e2 / express-03~e.11
                        :ARG2 (p2 / protein
                              :name (n3 / name :op1 "IL-6"~e.8,10))
                        :ARG3 (a4 / and~e.15
                              :op1 (f3 / fibroblast
                                    :mod (l2 / lung
                                          :mod m4)
                                    :mod (w2 / wild-type))
                              :op2 (f4 / fibroblast
                                    :mod (p3 / protein
                                          :name (n6 / name :op1 "STAT6")
                                          :ARG2-of (m3 / mutate-01 :mod "-/-"))
                                    :mod l2))))
            :mod (a2 / also~e.1)
            :ARG1-of (d / describe-01
                  :ARG0 (a5 / and~e.15,24,27
                        :op1 (f / figure :mod "5B")
                        :op2 (f2 / figure :mod "5D"))))
      :op2 (s / show-01~e.28
            :ARG0 w
            :ARG1 (r2 / respond-01~e.32
                  :ARG0 f4
                  :ARG1-of (r3 / resemble-01~e.33
                        :ARG2 f3)
                  :ARG1-of (h / have-condition-91
                        :ARG2 (e3 / express-01~e.41
                              :ARG2 p2~e.38,39,40
                              :manner (a7 / and~e.46
                                    :op1 (l3 / level~e.48
                                          :mod (r4 / rna
                                                :name (n7 / name :op1 "mRNA"~e.45)))
                                    :op2 (l / level~e.48
                                          :mod (p5 / protein~e.47))))))))

# ::tok mOSM induced STAT1 ( Y701 ) , STAT3 ( Y705 ) , and STAT5 ( Y694 ) phosphorylation as reported by others ( 57 , 58 , 59 ) .
# ::alignments 1-1 2-1.2.1.1.3.1.1 7-1.2.1.2.3.1.1 12-1.2.1 13-1.2.1.3.3.1.1 17-1.2 18-1.3.r 19-1.3 20-1.3.1.r 21-1.3.1.1 23-1.4.1.1.1.1 25-1.4.1.1.1.2 27-1.4.1.1.1.3
# ::id bel_pmid_1654_7273_29768
(i / induce-01~e.1
      :ARG0 (p2 / protein
            :name (n2 / name :op1 "OSM")
            :mod (m / mouse))
      :ARG1 (p / phosphorylate-01~e.17
            :ARG1 (a / and~e.12
                  :op1 (a2 / amino-acid
                        :mod "701"
                        :name (n3 / name :op1 "tyrosine")
                        :part-of (p3 / protein
                              :name (n4 / name :op1 "STAT1"~e.2)))
                  :op2 (a3 / amino-acid
                        :mod "705"
                        :name (n5 / name :op1 "tyrosine")
                        :part-of (p4 / protein
                              :name (n6 / name :op1 "STAT3"~e.7)))
                  :op3 (a4 / amino-acid
                        :mod "694"
                        :name (n7 / name :op1 "tyrosine")
                        :part-of (p5 / protein
                              :name (n8 / name :op1 "STAT5"~e.13)))))
      :ARG1-of~e.18 (r2 / report-01~e.19
            :ARG0~e.20 (p6 / person
                  :mod (o / other~e.21)))
      :ARG1-of (d / describe-01
            :ARG0 (p7 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 (a5 / and
                              :op1 "57"~e.23
                              :op2 "58"~e.25
                              :op3 "59"~e.27)))))

# ::tok Levels of VCAM @-@ 1 in STAT @-@ 6 @-@ deficient MLF were somewhat reduced compared with those observed in wt MLF , however , the ability of mOSM or mTNF-{alpha} to induce VCAM @-@ 1 was maintained ( Fig . 7B ) .
# ::alignments 0-1.1.1 0-1.1.1.3.1 1-1.1.1.1.r 2-1.1.1.1.1.1 4-1.1.1.1.1.1 13-1.1.2 14-1.1 15-1.1.1.3 18-1.1.1.3.1.1 23-1 26-1.2.1 29-1.2.1.1 32-1.2.1.2 33-1.2.1.2.2 34-1.2.1.2.2 35-1.2.1.2.2 37-1.2 41-1.3.1.1
# ::id bel_pmid_1654_7273_29770
(h / have-concession-91~e.23
      :ARG1 (r / reduce-01~e.14
            :ARG1 (l / level~e.0
                  :quant-of~e.1 (p / protein
                        :name (n / name :op1 "VCAM-1"~e.2,4))
                  :location (f / fibroblast
                        :mod (l2 / lung
                              :mod (m4 / mouse))
                        :mod (p2 / protein
                              :name (n2 / name :op1 "STAT6")
                              :ARG2-of (m6 / mutate-01 :mod "-/-")))
                  :ARG1-of (c / compare-01~e.15
                        :ARG2 (l3 / level~e.0
                              :ARG1-of (o / observe-01~e.18
                                    :location (f2 / fibroblast
                                          :mod (w / wild-type)
                                          :mod l2))
                              :quant-of p)))
            :ARG2 (s / somewhat~e.13))
      :ARG2 (m3 / maintain-01~e.37
            :ARG1 (c2 / capable-01~e.26
                  :ARG1 (o2 / or~e.29
                        :op1 (p4 / protein
                              :name (n4 / name :op1 "OSM")
                              :mod m4)
                        :op2 (p5 / protein
                              :name (n5 / name :op1 "TNF-{alpha}")
                              :mod m4))
                  :ARG2 (i / induce-01~e.32
                        :ARG0 o2
                        :ARG1 p~e.33,34,35)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f3 / figure :mod "7B"~e.41)))

# ::tok IL @-@ 4 has been documented to regulate the expression of eotaxin @-@ 1 ( 41 ) , eotaxin @-@ 2 ( 42 ) , and eotaxin @-@ 3 ( 34 ) in endothelial cells and fibroblasts in a STAT6 @-@ dependent manner ( 42 , 43 , 44 , 45 ) . IL @-@ 4 signal transduction includes activation of STAT6 ( 46 , 47 , 48 , 49 , 50 ) .
# ::alignments 0-1.2.2.1.1.1.1 2-1.2.2.1.1.1.1 5-1.1 6-1.1.1.r 7-1.1.1 7-1.1.1.2 7-1.1.1.2.r 9-1.1.1.2.1 10-1.1.1.2.1.1.r 11-1.1.1.2.1.1.1.1.1 11-1.1.1.2.1.1.2.1.1 11-1.1.1.2.1.1.3.1.1 13-1.1.1.2.1.1.1.1.1 15-1.1.1.2.1.1.1.2.1.1.1 18-1.1.1.2.1.1.2.1.1 18-1.1.1.2.1.1.3.1.1 20-1.1.1.2.1.1.2.1.1 22-1.1.1.2.1.1.2.2.1.1.1 25-1.1.1.2.1.1 26-1.1.1.2.1.1.2.1.1 26-1.1.1.2.1.1.3.1.1 28-1.1.1.2.1.1.3.1.1 30-1.1.1.2.1.1.3.2.1.1.1 32-1.1.1.2.1.2.r 33-1.1.1.2.1.2.1.1 34-1.1.1.2.1.2.1 35-1.1.1.2.1.2 36-1.1.1.2.1.2.2 39-1.1.1.2.2.2.1.1 41-1.1.1.2.2 42-1.1.1.2.2.r 44-1.1.2.1.1.1.1 46-1.1.2.1.1.1.2 48-1.1.2.1.1.1.3 50-1.1.2.1.1.1.4 53-1.2.2.1.1.1.1 55-1.1.1.1.1 55-1.2.2.1.1.1.1 56-1.2.2.1 58-1.2 59-1.2.1 60-1.2.1.1.r 61-1.2.1.1.1.1 63-1.2.3.1.1.1.1 65-1.2.3.1.1.1.2 67-1.2.3.1.1.1.3 69-1.2.3.1.1.1.4 71-1.2.3.1.1.1.5
# ::id bel_pmid_1654_7273_38510
(m / multi-sentence
      :snt1 (d / document-01~e.5
            :ARG1~e.6 (p / protein~e.7
                  :name (n / name :op1 "IL-4"~e.55)
                  :ARG0-of~e.7 (r / regulate-01~e.7
                        :ARG1 (e / express-03~e.9
                              :ARG2~e.10 (a / and~e.25
                                    :op1 (p2 / protein
                                          :name (n2 / name :op1 "eotaxin-1"~e.11,13)
                                          :ARG1-of (d2 / describe-01
                                                :ARG0 (p3 / publication
                                                      :ARG1-of (c / cite-01 :ARG2 "41"~e.15))))
                                    :op2 (p4 / protein
                                          :name (n3 / name :op1 "eotaxin-2"~e.11,18,20,26)
                                          :ARG1-of (d3 / describe-01
                                                :ARG0 (p5 / publication
                                                      :ARG1-of (c2 / cite-01 :ARG2 "42"~e.22))))
                                    :op3 (p6 / protein
                                          :name (n4 / name :op1 "eotaxin-3"~e.11,18,26,28)
                                          :ARG1-of (d4 / describe-01
                                                :ARG0 (p7 / publication
                                                      :ARG1-of (c3 / cite-01 :ARG2 "34"~e.30)))))
                              :ARG3~e.32 (a2 / and~e.35
                                    :op1 (c4 / cell~e.34
                                          :mod (e2 / endothelium~e.33))
                                    :op2 (f / fibroblast~e.36)))
                        :manner~e.42 (d5 / depend-01~e.41
                              :ARG0 r
                              :ARG1 (p8 / protein
                                    :name (n5 / name :op1 "STAT6"~e.39)))))
            :ARG1-of (d6 / describe-01
                  :ARG0 (p9 / publication
                        :ARG1-of (c5 / cite-01
                              :ARG2 (a3 / and
                                    :op1 "42"~e.44
                                    :op2 "43"~e.46
                                    :op3 "44"~e.48
                                    :op4 "45"~e.50)))))
      :snt2 (i / include-01~e.58
            :ARG1 (a4 / activate-01~e.59
                  :ARG1~e.60 (p11 / protein
                        :name (n7 / name :op1 "STAT6"~e.61)))
            :ARG2 (t / transduct-00
                  :ARG1 (s / signal-07~e.56
                        :ARG0 (p10 / protein
                              :name (n6 / name :op1 "IL-4"~e.0,2,53,55))))
            :ARG1-of (d7 / describe-01
                  :ARG0 (p12 / publication
                        :ARG1-of (c6 / cite-01
                              :ARG2 (a5 / and
                                    :op1 "46"~e.63
                                    :op2 "47"~e.65
                                    :op3 "48"~e.67
                                    :op4 "49"~e.69
                                    :op5 "50"~e.71))))))

# ::tok To verify the absence of the STAT6 @-@ signaling cascade in STAT6-/- MLF , we assessed mOSM and mIL @-@ 4 induced responses with respect to STAT3 and STAT6 activation . Fig. 6 confirms the absence of STAT6 protein and STAT6 induction in STAT6-/- MLF but equivalent activation of STAT3 in both wt and STAT6-/- MLF .
# ::alignments 1-1.1.3 3-1.1.3.2 6-1.1.3.2.1.1.1 6-1.1.3.2.2.2.1.1 8-1.1.3.2.1.2.1 9-1.1.3.2.1.2 14-1.1.1 15-1.1 20-1.1.2.2.1.2.1.1 21-1.2.2.1.2 22-1.1.2 22-1.1.2.1 22-1.1.2.1.r 26-1.1.4.1.1.1.1 26-1.2.2.2.1.1.1 27-1.1.4.1 28-1.1.4.1.2.1.1 28-1.2.2.1.1.1.1.1 28-1.2.2.1.2.2.2.1.1 29-1.1.4 29-1.2.2.2 32-1.2.1.1 33-1.2 35-1.2.2.1.1 36-1.2.2.1.1.1.r 37-1.2.2.1.1.1.1.1 38-1.1.2.2.1.1 38-1.1.2.2.1.2 38-1.1.3.2.1 38-1.1.3.2.2.2 38-1.1.4.1.1 38-1.1.4.1.2 38-1.2.2.1.1.1 38-1.2.2.1.2.2.2 38-1.2.2.2.1 39-1.2.2.1 40-1.2.2.1.1.1.1.1 41-1.1.2.2 45-1.2.2 47-1.2.2.2 49-1.2.2.2.1.1.1 53-1.2.2.2.3
# ::id bel_pmid_1654_7273_38520
(m / multi-sentence
      :snt1 (a / assess-01~e.15
            :ARG0 (w / we~e.14)
            :ARG1 (t / thing~e.22
                  :ARG1-of~e.22 (r / respond-01~e.22)
                  :ARG1-of (i2 / induce-01~e.41
                        :ARG0 (a2 / and
                              :op1 (p / protein~e.38
                                    :name (n / name :op1 "OSM")
                                    :mod (m2 / mouse))
                              :op2 (p2 / protein~e.38
                                    :name (n2 / name :op1 "IL-4"~e.20)
                                    :mod m2))))
            :purpose (v / verify-01~e.1
                  :ARG0 w
                  :ARG1 (a5 / absent-01~e.3
                        :ARG1 (p5 / protein~e.38
                              :name (n5 / name :op1 "STAT6"~e.6)
                              :mod (c / cascade-01~e.9
                                    :subevent (s / signal-07~e.8)))
                        :ARG2 (f / fibroblast
                              :mod (l / lung
                                    :mod m2)
                              :mod (p6 / protein~e.38
                                    :name (n6 / name :op1 "STAT6"~e.6)
                                    :ARG2-of (m5 / mutate-01 :mod "-/-")))))
            :topic (a3 / activate-01~e.29
                  :ARG1 (a4 / and~e.27
                        :op1 (p3 / protein~e.38
                              :name (n3 / name :op1 "STAT3"~e.26))
                        :op2 (p4 / protein~e.38
                              :name (n4 / name :op1 "STAT6"~e.28)))))
      :snt2 (c2 / confirm-01~e.33
            :ARG0 (f2 / figure :mod "6"~e.32)
            :ARG1 (c3 / contrast-01~e.45
                  :ARG1 (a6 / and~e.39
                        :op1 (a7 / absent-01~e.35
                              :ARG1~e.36 (p7 / protein~e.38
                                    :name (n7 / name :op1 "STAT6"~e.28,37,40))
                              :ARG2 (f3 / fibroblast
                                    :mod (l2 / lung
                                          :mod (m6 / mouse))
                                    :mod (p8 / protein~e.38
                                          :name (n8 / name :op1 "STAT6"~e.28)
                                          :ARG2-of (m7 / mutate-01 :mod "-/-"))))
                        :op2 (i / induce-01~e.21
                              :ARG1 p7
                              :location f3))
                  :ARG2 (a8 / activate-01~e.29,47
                        :ARG1 (p9 / protein~e.38
                              :name (n9 / name :op1 "STAT3"~e.26,49))
                        :ARG2-of (e / equal-01)
                        :location (a9 / and~e.53
                              :op1 (f4 / fibroblast
                                    :mod (w2 / wild-type)
                                    :mod l2)
                              :op2 f3)))))

# ::tok Levels of VCAM @-@ 1 in STAT @-@ 6 @-@ deficient MLF were somewhat reduced compared with those observed in wt MLF , however , the ability of mOSM or mTNF-{alpha} to induce VCAM @-@ 1 was maintained ( Fig . 7B ) .
# ::alignments 0-1.1.1 0-1.1.1.3.1 1-1.1.1.1.r 2-1.1.1.1.1.1 4-1.1.1.1.1.1 6-1.1.1.2.2.1.1 8-1.1.1.2.2.1.1 13-1.1.2 14-1.1 15-1.1.1.3 18-1.1.1.3.1.1 23-1 26-1.2.1 29-1.2.1.1 32-1.2.1.2 33-1.2.1.2.2 34-1.2.1.2.2 35-1.2.1.2.2 37-1.2 41-1.3.1.1
# ::id bel_pmid_1654_7273_39184
(h / have-concession-91~e.23
      :ARG1 (r / reduce-01~e.14
            :ARG1 (l / level~e.0
                  :quant-of~e.1 (p / protein
                        :name (n / name :op1 "VCAM-1"~e.2,4))
                  :location (f / fibroblast
                        :mod (l2 / lung
                              :mod (m4 / mouse))
                        :mod (p2 / protein
                              :name (n2 / name :op1 "STAT-6"~e.6,8)
                              :ARG2-of (m6 / mutate-01 :mod "-/-")))
                  :ARG1-of (c / compare-01~e.15
                        :ARG2 (l3 / level~e.0
                              :ARG1-of (o / observe-01~e.18
                                    :location (f2 / fibroblast
                                          :mod (w / wild-type)
                                          :mod l2))
                              :quant-of p)))
            :ARG2 (s / somewhat~e.13))
      :ARG2 (m3 / maintain-01~e.37
            :ARG1 (c2 / capable-01~e.26
                  :ARG1 (o2 / or~e.29
                        :op1 (p4 / protein
                              :name (n4 / name :op1 "OSM")
                              :mod m4)
                        :op2 (p5 / protein
                              :name (n5 / name :op1 "TNF-{alpha}")
                              :mod m4))
                  :ARG2 (i / induce-01~e.32
                        :ARG0 o2
                        :ARG1 p~e.33,34,35)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f3 / figure :mod "7B"~e.41)))

# ::tok Focus formation was consistently observed with both mutants . However , C @-@ RAF mutant proteins caused the formation of much smaller cell aggregates ( Fig . 5A ) as compared with v @-@ Raf .
# ::alignments 0-1.1.1.1 1-1.1.1 3-1.1.2 3-1.1.2.r 4-1.1 5-1.1.3.r 6-1.1.3.2 7-1.1.3 7-1.1.3.1 7-1.1.3.1.r 9-1.2 11-1.2.1.1.1.1 13-1.2.1.1.1.1 14-1.2.1.1 14-1.2.1.1.2 14-1.2.1.1.2.r 16-1.2.1 18-1.2.1.2 19-1.2.1.2.1.r 20-1.2.1.2.1.2.1 21-1.2.1.2.1.2 22-1.2.1.2.1.1 23-1.2.1.2.1 27-1.2.1.2.2.1.1 30-1.2.1.2.1.2.2.r 31-1.1.3.r 34-1.2.1.2.1.2.2.1.1
# ::id bel_pmid_1658_5161_22112
(m / multi-sentence
      :snt1 (o / observe-01~e.4
            :ARG1 (f / form-01~e.1
                  :ARG1 (f2 / focus~e.0))
            :manner~e.3 (c / consistent~e.3)
            :instrument~e.5,31 (m5 / molecular-physical-entity~e.7
                  :ARG2-of~e.7 (m2 / mutate-01~e.7)
                  :mod (b / both~e.6)))
      :snt2 (c5 / contrast-01~e.9
            :ARG2 (c2 / cause-01~e.16
                  :ARG0 (e / enzyme~e.14
                        :name (n / name :op1 "C-RAF"~e.11,13)
                        :ARG2-of~e.14 (m3 / mutate-01~e.14))
                  :ARG1 (f3 / form-01~e.18
                        :ARG1~e.19 (a / aggregate-01~e.23
                              :ARG1 (c3 / cell~e.22)
                              :mod (s2 / small~e.21
                                    :degree (m4 / much~e.20)
                                    :compared-to~e.30 (e2 / enzyme
                                          :name (n2 / name :op1 "C-Raf"~e.34))))
                        :ARG1-of (d / describe-01
                              :ARG0 (f4 / figure :mod "5A"~e.27))))))

# ::tok Wild @-@ type MEFs induced Ifnb , Tnfa , and Il @-@ 6 in response to poly( I : C ) {an viral mimetic activator of FADD signaling @-@ SE}, whereas the induction was severely impaired in FADD @-@ deficient MEFs as examined by RT @-@ PCR analyses ( Fig . 1A ) .
# ::alignments 0-1.1.1.2 2-1.1.1.2 4-1.1 5-1.1.2.1.1.1 7-1.1.2.2.1.1 9-1.1.2 10-1.1.2.3.1.1 12-1.1.2.3.1.1 14-1.1.3 22-1.1.3.1.2.1.2.1 24-1.1.3.1.2.1 24-1.1.3.1.2.1.1 24-1.1.3.1.2.1.1.r 25-1.1.3.1.2.1.1.1.r 26-1.1.3.1.2.1.1.1.1.1.1 27-1.1.3.1.2.1.1.1 30-1 32-1.1 32-1.2.1 34-1.2.2 35-1.2 37-1.2.3.2.1.1 41-1.2.4.r 42-1.2.4 43-1.2.4.1.r 44-1.2.4.1.1.1.1 46-1.2.4.1.1.1.1 47-1.2.4.1 51-1.3.1.1
# ::id bel_pmid_1658_5540_18258
(c / contrast-01~e.30
      :ARG1 (i / induce-01~e.4,32
            :ARG0 (f / fibroblast
                  :mod (e / embryo
                        :mod (m / mouse))
                  :mod (w / wild-type~e.0,2))
            :ARG1 (a2 / and~e.9
                  :op1 (p / protein
                        :name (n / name :op1 "Ifnb"~e.5))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "Tnfa"~e.7))
                  :op3 (p3 / protein
                        :name (n3 / name :op1 "IL-6"~e.10,12)))
            :ARG2-of (r / respond-01~e.14
                  :ARG1 (s3 / small-molecule
                        :name (n4 / name :op1 "poly(I:C)")
                        :ARG1-of (m2 / mean-01
                              :ARG2 (m6 / molecular-physical-entity~e.24
                                    :ARG0-of~e.24 (a3 / activate-01~e.24
                                          :ARG1~e.25 (s / signal-07~e.27
                                                :ARG0 (p4 / protein
                                                      :name (n5 / name :op1 "FADD"~e.26))
                                                :ARG1 (t3 / thing
                                                      :name (n6 / name :op1 "SE"))))
                                    :ARG0-of (m3 / mimic-01
                                          :ARG1 (v / virus~e.22)))))))
      :ARG2 (i2 / impair-01~e.35
            :ARG1 (i3 / induce-01~e.32)
            :degree (s2 / severe~e.34)
            :location (f2 / fibroblast
                  :mod (e2 / embryo
                        :mod (m4 / mouse))
                  :mod (p5 / protein
                        :name (n7 / name :op1 "FADD"~e.37)
                        :ARG2-of (m5 / mutate-01 :mod "-/-")))
            :ARG1-of~e.41 (e3 / examine-01~e.42
                  :ARG0~e.43 (a4 / analyze-01~e.47
                        :mod (t / thing
                              :name (n8 / name :op1 "RT-PCR"~e.44,46)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f3 / figure :mod "1A"~e.51)))

# ::tok the induction of Tnfa and Il @-@ 6 was severely impaired after 2 h of poly( I : C ) stimulation and reduced after 6 h of stimulation in caspase @-@ 8 @-@ deficient cells ( Fig . 4B ) .
# ::alignments 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1.1 4-1.1.1.1 5-1.1.1.1.2.1.1 7-1.1.1.1.2.1.1 9-1.1.2 10-1.1 11-1.1.3 12-1.1.3.1.2.1 20-1.1.3.1 21-1 22-1.2 23-1.2.2 24-1.2.2.1.1.1 27-1.2.2.1 28-1.2.2.1.2.r 29-1.2.2.1.2.1.1.1 31-1.2.2.1.2.1.1.1 34-1.2.2.1.2 38-1.3.1.1
# ::id bel_pmid_1658_5540_25628
(a / and~e.21
      :op1 (i / impair-01~e.10
            :ARG1 (i2 / induce-01~e.1
                  :ARG1~e.2 (a2 / and~e.4
                        :op1 (p / protein
                              :name (n / name :op1 "Tnfa"~e.3))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "IL-6"~e.5,7))))
            :degree (s / severe~e.9)
            :time (a3 / after~e.11
                  :op1 (s2 / stimulate-01~e.20
                        :ARG0 (s4 / small-molecule
                              :name (n3 / name :op1 "poly(I:C)"))
                        :duration (t / temporal-quantity
                              :quant "2"~e.12
                              :unit (h / hour)))))
      :op2 (r / reduce-01~e.22
            :ARG1 i2
            :time (a4 / after~e.23
                  :op1 (s3 / stimulate-01~e.27
                        :duration (t2 / temporal-quantity
                              :quant "6"~e.24
                              :unit (h2 / hour))
                        :location~e.28 (c / cell~e.34
                              :mod (p4 / protein
                                    :name (n4 / name :op1 "caspase-8"~e.29,31)
                                    :ARG2-of (m / mutate-01 :mod "-/-"))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4B"~e.38)))

# ::tok nuclear translocation of p65 , a component of NF-{kappa}B , was reduced in caspase @-@ 8 @-@ deficient cells ( Fig . 4C )
# ::alignments 0-1.1.2 1-1.1 2-1.1.1.r 3-1.1.1.1.1 8-1.1.1.2.1.1 11-1 12-1.2.r 13-1.2.1.1.1 15-1.2.1.1.1 18-1.2 22-1.3.1.1
# ::id bel_pmid_1658_5540_25630
(r / reduce-01~e.11
      :ARG1 (t / translocate-00~e.1
            :ARG1~e.2 (p / protein-segment
                  :name (n / name :op1 "p65"~e.3)
                  :part-of (p2 / protein
                        :name (n3 / name :op1 "NF-{kappa}B"~e.8)))
            :location (n2 / nucleus~e.0))
      :location~e.12 (c / cell~e.18
            :mod (p3 / protein
                  :name (n4 / name :op1 "caspase-8"~e.13,15)
                  :ARG2-of (m / mutate-01 :mod "-/-")))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4C"~e.22)))

# ::tok In contrast , small @-@ interfering RNA @-@ mediated reduction of LMW @-@ DSP2 expression enhanced IL @-@ 6 @-@ induced STAT3 @-@ dependent transcription .
# ::alignments 1-1 3-1.1.1.2.1.1.1 5-1.1.1.2.1.1.1 6-1.1.1.2.1 6-1.1.1.2.1.1.2 8-1.1.1.2 9-1.1.1 10-1.1.1.1.r 11-1.1.1.1.1.1.1 13-1.1.1.1.1.1.1 14-1.1.1.1 15-1.1 16-1.1.2.1.1.1.1 18-1.1.2.1.1.1.1 20-1.1.2.1 21-1.1.2.2.1.1.1 23-1.1.2.2 24-1.1.2
# ::id bel_pmid_1663_6663_24748
(c / contrast-01~e.1
      :ARG2 (e / enhance-01~e.15
            :ARG0 (r2 / reduce-01~e.9
                  :ARG1~e.10 (e2 / express-03~e.14
                        :ARG2 (e3 / enzyme
                              :name (n2 / name :op1 "LMW-DSP2"~e.11,13)))
                  :ARG1-of (m / mediate-01~e.8
                        :ARG0 (r3 / rna~e.6
                              :name (n5 / name :op1 "small-interfering"~e.3,5 :op2 "RNA"~e.6))))
            :ARG1 (t / transcribe-01~e.24
                  :ARG1-of (i / induce-01~e.20
                        :ARG0 (p / protein
                              :name (n3 / name :op1 "IL-6"~e.16,18)))
                  :ARG0-of (d / depend-01~e.23
                        :ARG1 (p2 / protein
                              :name (n4 / name :op1 "STAT3"~e.21))))))

# ::tok LMW @-@ DSP2 overexpression in 293T cells suppressed IL @-@ 6 @-@ induced phosphorylation and activation of STAT3 .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 5-1.1.2.1.1 6-1.1.2 7-1 8-1.2.3.1.1.1 10-1.2.3.1.1.1 12-1.2.3 13-1.2.1 14-1.2 15-1.2.2 16-1.2.2.1.r 17-1.2.2.1.1.1
# ::id bel_pmid_1663_6663_7850
(s / suppress-01~e.7
      :ARG0 (o / overexpress-00
            :ARG2 (e / enzyme
                  :name (n / name :op1 "LMW-DSP2"~e.0,2))
            :ARG3 (c / cell-line~e.6
                  :name (n2 / name :op1 "293T"~e.5)))
      :ARG1 (a / and~e.14
            :op1 (p / phosphorylate-01~e.13
                  :ARG1 (p3 / protein
                        :name (n4 / name :op1 "STAT3"~e.17)))
            :op2 (a2 / activate-01~e.15
                  :ARG1~e.16 p3)
            :ARG1-of (i / induce-01~e.12
                  :ARG0 (p2 / protein
                        :name (n3 / name :op1 "IL-6"~e.8,10)))))

# ::tok Expression of wild @-@ type ( wt ) Cbp remarkably suppressed EGF @-@ induced activation of Src , ERK1 @/@ 2 , and Akt @-@ 1 enzymes , and NIH3T3 cell transformation , as well as colony formation of a breast cancer cell line ( MDA @-@ MB @-@ 468 ) in soft agar .
# ::alignments 0-1.1 2-1.1.1.2 4-1.1.1.2 8-1.1.1.1.1 9-1.3 9-1.3.r 10-1 11-1.2.1.2.1.1.1 13-1.2.1.2 14-1.2.1 16-1.2.1.1.1.1.1 18-1.2.1.1.2.1.1.1 22-1.2.1.1 23-1.2.1.1.3.1.1 25-1.2.1.1.3.1.1 26-1.1.1 26-1.2.1.1.1 26-1.2.1.1.2.1 26-1.2.1.1.2.2 26-1.2.1.1.3 26-1.2.1.2.1 28-1.2 28-1.2.1.1 29-1.2.2.1.1.1 30-1.2.2.1 31-1.2.2 35-1.2.r 36-1.2.3.2 37-1.2.3 38-1.2.3.1.r 40-1.2.3.1.2.1 41-1.2.3.1.2 42-1.2.3.1 43-1.2.3.1 45-1.2.3.1.1.1 47-1.2.3.1.1.1 49-1.2.3.1.1.1 51-1.2.3.3.r 52-1.2.3.3.1 53-1.2.3.3
# ::id bel_pmid_1663_6672_36768
(s / suppress-01~e.10
      :ARG0 (e / express-03~e.0
            :ARG2 (p / protein~e.26
                  :name (n2 / name :op1 "Cbp"~e.8)
                  :mod (w / wild-type~e.2,4)))
      :ARG1~e.35 (a2 / and~e.28
            :op1 (a4 / activate-01~e.14
                  :ARG1 (a / and~e.22,28
                        :op1 (e3 / enzyme~e.26
                              :name (n4 / name :op1 "Src"~e.16))
                        :op2 (s2 / slash
                              :op1 (e4 / enzyme~e.26
                                    :name (n5 / name :op1 "ERK1"~e.18))
                              :op2 (e5 / enzyme~e.26
                                    :name (n6 / name :op1 "ERK2")))
                        :op3 (e2 / enzyme~e.26
                              :name (n7 / name :op1 "Akt-1"~e.23,25)))
                  :ARG1-of (i2 / induce-01~e.13
                        :ARG0 (p2 / protein~e.26
                              :name (n3 / name :op1 "EGF"~e.11))))
            :op2 (t / transform-01~e.31
                  :ARG1 (c / cell-line~e.30
                        :name (n8 / name :op1 "NIH3T3"~e.29)))
            :op3 (f / form-01~e.37
                  :ARG1~e.38 (c3 / cell-line~e.42,43
                        :name (n9 / name :op1 "MDA-MB-468"~e.45,47,49)
                        :mod (c4 / cancer~e.41
                              :mod (b / breast~e.40)))
                  :mod (c2 / colony~e.36)
                  :location~e.51 (a3 / agar~e.53
                        :mod (s3 / soft~e.52))))
      :manner~e.9 (r / remarkable~e.9))

# ::tok Interestingly , 500 ng @/@ ml GH and 30 ng @/@ ml IL @-@ 6 increased PAI @-@ 1 secretion five @-@ fold and 3.6 @-@ fold , respectively . Furthermore , GH and IL @-@ 6 induced PAI @-@ 1 mRNA by up to 7.3 @-@ fold , and 3.6 @-@ fold , respectively , in a time @-@ dependent fashion with significant stimulation seen at concentrations as low as 5 ng @/@ ml GH and 10 ng @/@ ml IL @-@ 6 .
# ::alignments 0-1.1.4 2-1.1.1.1.2.1 6-1.1.1.1.1.1 8-1.1.2.1.2.1 12-1.1.2.1.1.1 14-1.1.2.1.1.1 15-1.1.1 15-1.1.2 16-1.1.1.2.1.1.1 18-1.1.1.2.1.1.1 19-1.1.1.2 20-1.1.1.3.1 23-1.1 23-1.2 24-1.2.1.2.2.3.1.1 28-1.1.3 32-1.2.1.5.2.1.1.1.1.1 33-1.2 33-1.2.1 33-1.2.1.r 34-1.2.1.2.1.1.1 36-1.2.1.2.1.1.1 37-1.2.1.1 37-1.2.1.2 38-1.2.1.1.2.2.1.1.1 40-1.2.1.1.2.2.1.1.1 41-1.2.1.1.2.1.1 41-1.2.1.2.2.1.1 43-1.2.1.1.2.3 43-1.2.1.2.2.3 44-1.2.1.1.2.3 44-1.2.1.2.2.3 45-1.2.1.1.2.3.1.1 49-1.2.1 49-1.2.1.5 50-1.1.2.3.1 50-1.2.1.2.2.3.1.1 54-1.2.1.3 56-1.2.1.5.r 58-1.2.1.5.1.1 60-1.2.1.5.1 62-1.2.1.4.r 63-1.2.1.4.1 64-1.2.1.4 65-1.2.1.5.2 67-1.1.1.1.2 67-1.1.2.1.2 67-1.2.1.5.2.1 67-1.2.1.5.2.1.1.1.2 67-1.2.1.5.2.1.1.2.2 68-1.2.1.5.2.1.2.r 68-1.2.1.5.2.1.r 69-1.2.1.5.2.1.2 70-1.2.1.5.2.1.r 71-1.2.1.5.2.1.1.1.2.1 75-1.2.1.1.1.1.1 75-1.2.1.5.2.1.1.1.1.1 76-1.2.1.5.2.1.1 77-1.2.1.5.2.1.1.2.2.1 81-1.2.1.2.1.1.1 81-1.2.1.5.2.1.1.2.1.1 83-1.2.1.2.1.1.1 83-1.2.1.5.2.1.1.2.1.1
# ::id bel_pmid_1671_3670_8846
(m / multi-sentence
      :snt1 (a2 / and~e.23
            :op1 (i / increase-01~e.15
                  :ARG0 (p / protein
                        :name (n / name :op1 "GH"~e.6)
                        :quant (c / concentration-quantity~e.67
                              :quant "500"~e.2
                              :unit (n2 / nanogram-per-milliliter)))
                  :ARG1 (s / secrete-01~e.19
                        :ARG1 (p3 / protein
                              :name (n5 / name :op1 "PAI-1"~e.16,18)))
                  :ARG2 (p4 / product-of :op1 "5"~e.20))
            :op2 (i2 / increase-01~e.15
                  :ARG0 (p2 / protein
                        :name (n3 / name :op1 "IL-6"~e.12,14)
                        :quant (c2 / concentration-quantity~e.67
                              :quant "30"~e.8
                              :unit (n4 / nanogram-per-milliliter)))
                  :ARG1 s
                  :ARG2 (p6 / product-of :op1 "3.6"~e.50))
            :mod (r / respective~e.28)
            :mod (i5 / interesting~e.0))
      :snt2 (a / and~e.23,33
            :op2~e.33 (a3 / and~e.33,49
                  :op1 (i3 / induce-01~e.37
                        :ARG0 (p5 / protein
                              :name (n6 / name :op1 "GH"~e.75))
                        :ARG1 (r2 / rna
                              :name (n7 / name :op1 "mRNA"~e.41)
                              :ARG0-of (e / encode-01
                                    :ARG1 (p7 / protein
                                          :name (n8 / name :op1 "PAI-1"~e.38,40)))
                              :quant (u / up-to~e.43,44
                                    :op1 (p8 / product-of :op1 "7.3"~e.45))))
                  :op2 (i4 / induce-01~e.37
                        :ARG0 (p9 / protein
                              :name (n9 / name :op1 "IL-6"~e.34,36,81,83))
                        :ARG1 (r3 / rna
                              :name (n10 / name :op1 "mRNA"~e.41)
                              :ARG0-of (e2 / encode-01
                                    :ARG1 p7)
                              :quant (u2 / up-to~e.43,44
                                    :op1 (p10 / product-of :op1 "3.6"~e.24,50))))
                  :mod (r4 / respective~e.54)
                  :instrument~e.62 (s3 / stimulate-01~e.64
                        :mod (s4 / significant~e.63))
                  :manner~e.56 (a5 / and~e.49
                        :op1 (d / depend-01~e.60
                              :ARG1 (t / time~e.58))
                        :op2 (s5 / see-01~e.65
                              :time~e.68,70 (c3 / concentrate-02~e.67
                                    :ARG1 (a4 / and~e.76
                                          :op1 (p11 / protein
                                                :name (n11 / name :op1 "GH"~e.32,75)
                                                :quant (c4 / concentration-quantity~e.67
                                                      :quant "5"~e.71
                                                      :unit (n12 / nanogram-per-milliliter)))
                                          :op2 (p12 / protein
                                                :name (n13 / name :op1 "IL-6"~e.81,83)
                                                :quant (c5 / concentration-quantity~e.67
                                                      :quant "10"~e.77
                                                      :unit (n14 / nanogram-per-milliliter))))
                                    :mod~e.68 (l / low~e.69)))))))

# ::tok When compared with an equimolar concentration of palmitate , fibroblast @-@ stimulating lipopeptide @-@ 1 , a known TLR2 ligand , was a slightly more potent activator of signal transduction and interleukin ( IL )-6 production .
# ::alignments 1-1.1.3.2.r 4-1.1.3.2.2 5-1.1.3.2 6-1.1.3.2.1.r 7-1.1.3.2.1.1.1 9-1.1.1.1 11-1.1.1.1 12-1.1.1.2 14-1.1.1.2 17-1.1 17-1.1.2 17-1.1.2.r 18-1.1.2.1.1.1 19-1.1.2.1 23-1.1.3.1.1 24-1.1.3.1 25-1.1.3 26-1 27-1.2.r 28-1.2.1.1 30-1.2 31-1.2.2.1.1.1 35-1.2.2
# ::id bel_pmid_1679_8732_19654
(a2 / activate-01~e.26
      :ARG0 (p / protein~e.17
            :name (n / name :op1 "fibroblast-stimulating"~e.9,11 :op2 "lipopeptide-1"~e.12,14)
            :ARG1-of~e.17 (k / know-02~e.17
                  :ARG2 (l / ligand~e.19
                        :name (n2 / name :op1 "TLR2"~e.18)))
            :mod (p2 / potent~e.25
                  :degree (m / more~e.24
                        :degree (s / slight~e.23))
                  :compared-to~e.1 (c2 / concentrate-02~e.5
                        :ARG1~e.6 (m2 / molecular-physical-entity
                              :name (n4 / name :op1 "palmitate"~e.7))
                        :mod (e / equimolar~e.4))))
      :ARG1~e.27 (a3 / and~e.30
            :op1 (t2 / transduct-00
                  :ARG1 (s2 / signal-07~e.28))
            :op2 (p3 / produce-01~e.35
                  :ARG1 (p4 / protein
                        :name (n3 / name :op1 "interleukin-6"~e.31)))))

# ::tok RNA interference @-@ mediated inhibition of TLR2 and MyD88 expression in C2C12 muscle cells resulted in a near complete inhibition of palmitate @-@ induced insulin resistance and IL @-@ 6 production .
# ::alignments 0-1.1.2.1.1 1-1.1.2.1 3-1.1.2 4-1.1 5-1.1.1.r 6-1.1.1.1.1.1.1 7-1.1.1.1 8-1.1.1.1.2.1.1 9-1.1.1 10-1.1.1.2.r 11-1.1.1.2.1.1 12-1.1.1.2.2 13-1.1.1.2 14-1 15-1.2.r 17-1.2.1.2.1 18-1.2.1.2 19-1.2.1 20-1.2.1.1.r 21-1.2.1.1.2.1.1.1 23-1.2.1.1.2 24-1.2.1.1.1.1.1 25-1.2.1.1 26-1.2 27-1.2.2.1.1.1 29-1.2.2.1.1.1 30-1.2.2
# ::id bel_pmid_1679_8732_4954
(r / result-01~e.14
      :ARG1 (i2 / inhibit-01~e.4
            :ARG1~e.5 (e / express-03~e.9
                  :ARG2 (a3 / and~e.7
                        :op1 (p / protein
                              :name (n / name :op1 "TLR2"~e.6))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "MyD88"~e.8)))
                  :ARG3~e.10 (c / cell~e.13
                        :name (n3 / name :op1 "C2C12"~e.11)
                        :mod (m2 / muscle~e.12)))
            :ARG1-of (m / mediate-01~e.3
                  :ARG0 (i / interfere-01~e.1
                        :ARG0 (r2 / RNA~e.0))))
      :ARG2~e.15 (a / and~e.26
            :op1 (i3 / inhibit-01~e.19
                  :ARG1~e.20 (r3 / resist-01~e.25
                        :ARG1 (m3 / molecular-physical-entity
                              :name (n5 / name :op1 "insulin"~e.24))
                        :ARG1-of (i4 / induce-01~e.23
                              :ARG0 (m4 / molecular-physical-entity
                                    :name (n6 / name :op1 "palmitate"~e.21))))
                  :mod (c2 / complete~e.18
                        :degree (n4 / near~e.17)))
            :op2 (p3 / produce-01~e.30
                  :ARG1 (p4 / protein
                        :name (n7 / name :op1 "IL-6"~e.27,29)))))

# ::tok When c @-@ H @-@ ras expression was induced with heavy metal ions there was a marked reduction in the expression of two glycosylphosphatidylinositol ( GPI ) anchored proteins , TAP @/@ Ly @-@ 6A.2 and Thy @-@ 1 , on the plasma membrane of the transformed cells .
# ::alignments 0-1.3.r 1-1.3.1.1.1.1 3-1.3.1.1.1.1 5-1.3.1.1.1.1 6-1.3.1 8-1.3 9-1.3.2.r 10-1.3.2.1.1 11-1.3.2.1 12-1.3.2 16-1.2 17-1 18-1.1.r 20-1.1 21-1.1.1.r 22-1.1.1.1 23-1.1.1.2.1 27-1.1.1.2.2 28-1.1.1.2.3 30-1.1.1.3.1.1.1.1 32-1.1.1.3.1.1.1.1 34-1.1.1.3.1.1.1.1 35-1.1.1.3.1 36-1.1.1.3.1.2.1.1 38-1.1.1.3.1.2.1.1 40-1.1.2.r 42-1.1.2.1 43-1.1.2 44-1.1.2.2.r 46-1.1.2.2.1 47-1.1.2.2
# ::id bel_pmid_167_9532_20916
(r2 / reduce-01~e.17
      :ARG1~e.18 (e / express-03~e.20
            :ARG2~e.21 (p5 / protein
                  :quant "2"~e.22
                  :name (n5 / name
                        :op1 "glycosylphosphatidylinositol"~e.23
                        :op2 "anchored"~e.27
                        :op3 "protein"~e.28)
                  :ARG2-of (i / include-91
                        :ARG1 (a2 / and~e.35
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "TAP/Ly-6A.2"~e.30,32,34))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "Thy-1"~e.36,38)))))
            :ARG3~e.40 (m2 / membrane~e.43
                  :mod (p / plasma~e.42)
                  :part-of~e.44 (c / cell~e.47
                        :ARG1-of (t / transform-01~e.46))))
      :ARG1-of (m / mark-01~e.16)
      :time~e.0 (i2 / induce-01~e.8
            :ARG1 (e2 / express-03~e.6
                  :ARG2 (e3 / enzyme
                        :name (n / name :op1 "c-H-ras"~e.1,3,5)))
            :instrument~e.9 (i3 / ion~e.12
                  :mod (m3 / metal~e.11
                        :mod (h / heavy~e.10)))))

# ::tok We demonstrate that siRNA targeting ULK2 in mouse P19 cells results in elevated FGFR1 mediated FRS3 and SHP2 tyrosyl phosphorylation .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1.1 4-1.2.1 5-1.2.1.2.1.1 6-1.2.1.3.r 7-1.2.1.3.2 8-1.2.1.3.1.1 9-1.2.1.3 10-1.2 11-1.2.2.r 12-1.2.2.3 13-1.2.2.2.1.1.1 14-1.2.2.2 15-1.2.2.1.2.2.1.1 16-1.2.2.1 17-1.2.2.1.1.2.1.1 19-1.2.2
# ::id bel_pmid_1688_7332_6142
(d / demonstrate-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (r2 / result-01~e.10
            :ARG1 (t / target-01~e.4
                  :ARG0 (r / rna
                        :name (n / name :op1 "siRNA"~e.3))
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "ULK2"~e.5))
                  :location~e.6 (c / cell~e.9
                        :name (n3 / name :op1 "P19"~e.8)
                        :mod (m / mouse~e.7)))
            :ARG2~e.11 (p / phosphorylate-01~e.19
                  :ARG1 (a3 / and~e.16
                        :op1 (a2 / amino-acid
                              :name (n6 / name :op1 "tyrosine")
                              :part-of (e3 / enzyme
                                    :name (n7 / name :op1 "SHP2"~e.17)))
                        :op2 (a4 / amino-acid
                              :name (n8 / name :op1 "tyrosine")
                              :part-of (p2 / protein
                                    :name (n4 / name :op1 "FRS3"~e.15))))
                  :ARG1-of (m2 / mediate-01~e.14
                        :ARG0 (e2 / enzyme
                              :name (n5 / name :op1 "FGFR1"~e.13)))
                  :ARG1-of (e4 / elevate-01~e.12
                        :ARG0 e2))))

# ::tok In contrast , PGD( 2 ) induced a marked stimulation of IL @-@ 6 and MCP @-@ 1 expression ; with IL @-@ 6 , this was rapid , the mRNA level increasing by >50 @-@ fold by 1 h . The rise in mRNA was accompanied by an increase in IL @-@ 6 and MCP @-@ 1 release ( up to 100 @- and 6.5 @-@ fold , respectively ) .
# ::alignments 1-1.2.1 6-1.2.1.1 8-1.2.1.1.2.2 9-1.2.1.1.2 9-1.2.2.3.1 10-1.2.1.1.2.1.r 11-1.2.1.1.2.1.1.1.1.1 13-1.2.1.1.2.1.1.1.1.1 14-1.2.1.1.2.1 15-1.2.1.1.2.1.2.1.1.1 17-1.2.1.1.2.1.2.1.1.1 18-1.2.1.1.2.1.1 18-1.2.1.1.2.1.2 21-1.2.1.1.2.1.1.1.1.1 23-1.2.1.1.2.1.1.1.1.1 27-1.2.1.1.2.1.1.2 30-1.2.2.1.1.1.1 31-1.2.2.1 32-1.2.2 38-1.2.2.3.2.1.1 42-1.1.2 44-1.1.2.1.1.1 46-1.1 47-1.1.1.r 49-1.1.1.1 51-1.1.1.1.1.1.1.1 53-1.1.1.1.1.1.1.1 54-1.1.1 55-1.1.1.2.1.1.1.1 57-1.1.1.2.1.1.1.1 58-1.1.1.1.1 58-1.1.1.2.1 60-1.1.1.1 60-1.1.1.2 62-1.1.1.1.2.1 64-1.1.1 65-1.1.1.2.2.1 69-1.1.1.3
# ::id bel_pmid_1692_4534_16206
(m / multi-sentence
      :snt2 (a2 / accompany-01~e.46
            :ARG0~e.47 (a4 / and~e.54,64
                  :op1 (i3 / increase-01~e.49,60
                        :ARG1 (r6 / release-01~e.58
                              :ARG1 (p4 / protein
                                    :name (n6 / name :op1 "IL-6"~e.51,53)))
                        :ARG2 (p6 / product-of :op1 "100"~e.62))
                  :op2 (i4 / increase-01~e.60
                        :ARG1 (r7 / release-01~e.58
                              :ARG1 (p5 / protein
                                    :name (n7 / name :op1 "MCP-1"~e.55,57)))
                        :ARG2 (p7 / product-of :op1 "6.5"~e.65))
                  :mod (r8 / respective~e.69))
            :ARG1 (r4 / rise-01~e.42
                  :ARG1 (r5 / rna
                        :name (n5 / name :op1 "mRNA"~e.44))))
      :snt1 (a3 / and
            :op1 (c / contrast-01~e.1
                  :ARG2 (i / induce-01~e.6
                        :ARG0 (m2 / molecular-physical-entity
                              :name (n / name :op1 "PGD2"))
                        :ARG1 (s / stimulate-01~e.9
                              :ARG1~e.10 (a5 / and~e.14
                                    :op1 (e3 / express-03~e.18
                                          :ARG2 (p / protein
                                                :name (n2 / name :op1 "IL-6"~e.11,13,21,23))
                                          :mod (r / rapid~e.27))
                                    :op2 (e / express-03~e.18
                                          :ARG2 (p2 / protein
                                                :name (n3 / name :op1 "MCP-1"~e.15,17))))
                              :ARG1-of (m3 / mark-01~e.8))))
            :op2 (i2 / increase-01~e.32
                  :ARG1 (l / level~e.31
                        :quant-of (r2 / rna
                              :name (n4 / name :op1 "mRNA"~e.30)
                              :ARG0-of (e2 / encode-01
                                    :ARG1 p)))
                  :ARG2 (m4 / more-than
                        :op1 (p3 / product-of :quant "50"))
                  :time (a / after
                        :op1 (s2 / stimulate-01~e.9
                              :ARG1 e3)
                        :quant (u / up-to
                              :op1 (t / temporal-quantity
                                    :quant "1"~e.38
                                    :unit (h / hour)))))))

# ::tok PGD( 2 ) induced a reduction in adiponectin and leptin mRNA , and the secretion of these adipokines was also inhibited , the effect being greater with leptin ( up to 10 @-@ fold ) than with adiponectin ( twofold ) .
# ::alignments 1-1.3.4.2.1 3-1.1 5-1.1.2 6-1.1.2.1.r 7-1.1.2.1.1.2.1.1.1 8-1.1.2.1 9-1.1.2.1.2.2.1.1.1 10-1.1.2.1.1.1.1 10-1.1.2.1.2.1.1 12-1.2.1.1 14-1.2.1 19-1.2.2 20-1.2 23-1.3 23-1.3.4 25-1.3.2 25-1.3.2.1 25-1.3.2.1.r 27-1.1.2.1.2.2.1.1.1 29-1.3.3 30-1.3.3 31-1.3.3.1.1 35-1.3.4.r 36-1.3.4.1.r 37-1.3.4.1
# ::id bel_pmid_1692_4534_3554
(a / and
      :op1 (i / induce-01~e.3
            :ARG0 (m2 / molecular-physical-entity
                  :name (n / name :op1 "PGD2"))
            :ARG1 (r / reduce-01~e.5
                  :ARG1~e.6 (a2 / and~e.8
                        :op1 (r2 / rna
                              :name (n2 / name :op1 "mRNA"~e.10)
                              :ARG0-of (e / encode-01
                                    :ARG1 (a5 / adipokine
                                          :name (n3 / name :op1 "adiponectin"~e.7))))
                        :op2 (r3 / rna
                              :name (n4 / name :op1 "mRNA"~e.10)
                              :ARG0-of (e2 / encode-01
                                    :ARG1 (a6 / adipokine
                                          :name (n5 / name :op1 "leptin"~e.9,27)))))))
      :op2 (i2 / inhibit-01~e.20
            :ARG1 (s / secrete-01~e.14
                  :ARG1 (a7 / and~e.12
                        :op1 a5
                        :op2 a6))
            :mod (a4 / also~e.19))
      :ARG1-of (e3 / effect-01~e.23
            :topic a6
            :mod (g / great~e.25
                  :degree~e.25 (m / more~e.25))
            :quant (u / up-to~e.29,30
                  :op1 (p3 / product-of :op1 "10"~e.31))
            :compared-to~e.35 (e4 / effect-01~e.23
                  :topic~e.36 a5~e.37
                  :quant (p4 / product-of :quant "2"~e.1))))

# ::tok IL @-@ 13 increased Egr @-@ 1 mRNA levels in a biphasic manner in Stat6/ fibroblasts ; early induction of Egr @-@ 1 mRNA was observed 30 min following exposure to IL @-@ 13 and declined after 3–6 h ( Fig . 6A ) . Egr @-@ 1 protein was increased in Stat6/ fibroblasts as compared with Stat6/ fibroblasts from 30 min to 3 h after IL @-@ 13 treatment ( Fig . 6 , B and C ) .
# ::alignments 0-1.2.1.1.1.1 2-1.2.1.1.1.1 3-1.2.1 4-1.2.1.2.1 5-1.2.1.2.1 6-1.2.1.2.1 7-1.2.1.2.1 8-1.2.1.2 11-1.2.1.3 12-1.2.1.3.r 15-1.1.2 17-1.2.2.1.1.2 18-1.2.2.1.1 20-1.2.2.1.1.1.2.1.1.1 22-1.2.2.1.1.1.2.1.1.1 23-1.2.2.1.1.1.1.1 25-1.2.2.1 26-1.2.2.1.2.1 28-1.2.2.1.1.3 29-1.2.2.1.1.3.1 30-1.2.2.1.1.3.1.2.r 31-1.2.2.1.1.3.1.2 32-1.2.2.1.1.3.1.2 33-1.2.2.1.1.3.1.2 34-1.2 34-1.2.2 34-1.2.2.r 35-1.2.2.2 36-1.2.2.2.2 42-1.2.2.3.1.1 45-1.2.2.1.1.1.2.1.1.1 47-1.1.1.1.1 47-1.2.2.1.1.1.2.1.1.1 48-1.1.1 48-1.1.2.1 48-1.1.2.2.1 48-1.1.3.1.2 48-1.2.1.1 48-1.2.1.4.1 48-1.2.2.1.1.1.2.1 50-1.1 50-1.2.1 53-1.1.2 53-1.1.2.2 53-1.2.1.4 54-1.2.2.2.2.r 55-1.1.2.2.r 58-1.1.2 59-1.1.3.r 60-1.1.3.2.1.1 63-1.1.3.2.2.1 63-1.2.2.2.2.2.1.1 65-1.1.3 66-1.1.3.1.2.1.1 68-1.1.3.1.2.1.1 69-1.1.3.1 73-1.2.2.2.2.2.2.1 76-1.1.3.2 76-1.1.4.1
# ::id bel_pmid_1695_1379_27948
(m / multi-sentence
      :snt2 (i3 / increase-01~e.50
            :ARG1 (p6 / protein~e.48
                  :name (n8 / name :op1 "Erg-1"~e.47))
            :location (f4 / fibroblast~e.15,53,58
                  :mod (p7 / protein~e.48
                        :name (n9 / name :op1 "Stat6"))
                  :compared-to~e.55 (f5 / fibroblast~e.53
                        :mod (p8 / protein~e.48
                              :name (n10 / name :op1 "Stat6")
                              :ARG2-of (m3 / mutate-01 :mod "-/-")))
                  :mod (w2 / wild-type))
            :time~e.59 (a3 / after~e.65
                  :op1 (t6 / treat-04~e.69
                        :ARG1 f4
                        :ARG2 (p9 / protein~e.48
                              :name (n11 / name :op1 "IL-13"~e.66,68)))
                  :quant (b2 / between~e.76
                        :op1 (t4 / temporal-quantity
                              :quant "30"~e.60
                              :unit (m4 / minute))
                        :op2 (t5 / temporal-quantity
                              :quant "3"~e.63
                              :unit (h3 / hour))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (a4 / and~e.76
                        :op1 (f6 / figure :mod "6B")
                        :op2 (f7 / figure :mod "6C"))))
      :snt1 (a5 / and~e.34
            :op1 (i / increase-01~e.3,50
                  :ARG0 (p / protein~e.48
                        :name (n / name :op1 "IL-13"~e.0,2))
                  :ARG1 (l / level~e.8
                        :quant-of r2~e.4,5,6,7)
                  :manner~e.12 (b / biphasic~e.11)
                  :location (f / fibroblast~e.53
                        :mod (p3 / protein~e.48
                              :name (n4 / name :op1 "Stat6"))
                        :mod (w / wild-type)))
            :op2~e.34 (a / and~e.34
                  :op1 (o / observe-01~e.25
                        :ARG1 (i2 / induce-01~e.18
                              :ARG1 (r2 / rna
                                    :name (n5 / name :op1 "mRNA"~e.23)
                                    :ARG0-of (e2 / encode-01
                                          :ARG1 (p4 / protein~e.48
                                                :name (n6 / name :op1 "Egr-1"~e.20,22,45,47))))
                              :time (e3 / early~e.17)
                              :ARG1-of (f2 / follow-01~e.28
                                    :ARG2 (e4 / expose-01~e.29
                                          :ARG1 f
                                          :ARG2~e.30 p~e.31,32,33)))
                        :duration (t / temporal-quantity
                              :quant "30"~e.26
                              :unit (m2 / minute)))
                  :op2 (d / decline-01~e.35
                        :ARG1 i2
                        :time~e.54 (a2 / after~e.36
                              :op1 e4
                              :quant (b3 / between
                                    :op1 (t2 / temporal-quantity
                                          :quant "3"~e.63
                                          :unit (h / hour))
                                    :op2 (t3 / temporal-quantity
                                          :quant "6"~e.73
                                          :unit (h2 / hour)))))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f3 / figure :mod "6A"~e.42)))))

# ::tok PDGF @-@ AA immunostaining was strongly expressed in the lungs of IL @-@ 13 transgene @-@ positive mice and localized to the airway epithelium , airway smooth muscle , and interstitial cells ( Fig . 1 , B–E ) .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 5-1.1.3 5-1.1.3.r 6-1.1 7-1.1.2.r 9-1.1.2 10-1.1.2.1.r 11-1.1.2.1.1.1.1 13-1.1.2.1.1.1.1 14-1.1.2.1.1 16-1.1.2.1.2 17-1.1.2.1 18-1 18-1.2.2 22-1.2.2.1.1 23-1.2.2.1 25-1.2.2.1.1 26-1.2.2.2.1 27-1.2.2.2 29-1.2.2 30-1.2.2.3.1 31-1.2.2.3
# ::id bel_pmid_1695_1379_27954
(a / and~e.18
      :op1 (e / express-03~e.6
            :ARG2 (p / protein
                  :name (n / name :op1 "PDGF-AA"~e.0,2)
                  :ARG0-of (i / immunostain-00))
            :ARG3~e.7 (l / lung~e.9
                  :mod~e.10 (m / mouse~e.17
                        :mod (t / transgene~e.14
                              :name (n3 / name :op1 "IL-13"~e.11,13))
                        :mod (p2 / positive~e.16)))
            :manner~e.5 (s / strong~e.5))
      :op2 (b / be-located-at-91
            :ARG1 p
            :ARG2 (a2 / and~e.18,29
                  :op1 (e2 / epithelium~e.23
                        :mod (a3 / airway~e.22,25))
                  :op2 (m2 / muscle~e.27
                        :mod (s2 / smooth~e.26)
                        :mod a3)
                  :op3 (c / cell~e.31
                        :mod (i2 / interstice~e.30))))
      :ARG1-of (d / describe-01
            :ARG0 (v / value-interval
                  :op1 (f / figure :mod "1B")
                  :op2 (f2 / figure :mod "1E"))))

# ::tok PDGF @-@ CC immunostaining was strongly expressed in the lungs of IL @-@ 13 transgene @-@ positive mice and localized to airway epithelium , type II pneumocytes , alveolar macrophages , and fibroblasts ( Fig . 1G ) .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 5-1.1.3 5-1.1.3.r 6-1.1 7-1.1.2.r 9-1.1.2 10-1.1.2.1.r 11-1.1.2.1.1.1.1 13-1.1.2.1.1.1.1 14-1.1.2.1.1 16-1.1.2.1.2 17-1.1.2.1 18-1 18-1.2.2 21-1.2.2.1.1 22-1.2.2.1 24-1.2.2.2.1.1 25-1.2.2.2.1.2 26-1.2.2.2.1.3 28-1.2.2.3.2 29-1.2.2.3.1.1 31-1.2.2 32-1.2.2.4 36-1.3.1.1
# ::id bel_pmid_1695_1379_27956
(a / and~e.18
      :op1 (e / express-03~e.6
            :ARG2 (p / protein
                  :name (n / name :op1 "PDGF-CC"~e.0,2)
                  :ARG0-of (i / immunostain-00))
            :ARG3~e.7 (l / lung~e.9
                  :poss-of~e.10 (m / mouse~e.17
                        :mod (t / transgene~e.14
                              :name (n2 / name :op1 "IL-13"~e.11,13))
                        :mod (p2 / positive~e.16)))
            :manner~e.5 (s / strong~e.5))
      :op2 (b / be-located-at-91
            :ARG1 p
            :ARG2 (a2 / and~e.18,31
                  :op1 (e2 / epithelium~e.22
                        :mod (a3 / airway~e.21))
                  :op2 (c / cell
                        :name (n3 / name
                              :op1 "type"~e.24
                              :op2 "II"~e.25
                              :op3 "pneumocytes"~e.26))
                  :op3 (c2 / cell
                        :name (n4 / name :op1 "macrophage"~e.29)
                        :mod (a4 / alveolus~e.28))
                  :op4 (f / fibroblast~e.32)))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "1G"~e.36)))

# ::tok we observed that IL @-@ 13 caused tyrosine phosphorylation of Stat1 in Stat6/ and Stat6/ fibroblasts ( Fig . 3 , A and C ) .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1 5-1.2.1.1.1 6-1.2 7-1.2.2.1.1.1 8-1.2.2 10-1.2.2.1.2.1.1 13-1.2.2.2 15-1.2.2.2.1 15-1.2.2.2.2 22-1.2.2.2 22-1.3.1
# ::id bel_pmid_1695_1379_27964
(o / observe-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (c / cause-01~e.6
            :ARG0 (p2 / protein
                  :name (n / name :op1 "IL-13"~e.3,5))
            :ARG1 (p / phosphorylate-01~e.8
                  :ARG1 (a / amino-acid
                        :name (n2 / name :op1 "tyrosine"~e.7)
                        :part-of (p3 / protein
                              :name (n3 / name :op1 "Stat1"~e.10)))
                  :location (a2 / and~e.13,22
                        :op1 (f / fibroblast~e.15
                              :mod (p4 / protein
                                    :name (n4 / name :op1 "Stat6")
                                    :ARG2-of (m / mutate-01 :mod "-/-")))
                        :op2 (f2 / fibroblast~e.15
                              :mod (p5 / protein
                                    :name (n5 / name :op1 "Stat6"))
                              :mod (w2 / wild-type)))))
      :ARG1-of (d / describe-01
            :ARG0 (a3 / and~e.22
                  :op1 (f3 / figure :mod "3A")
                  :op2 (f4 / figure :mod "3C"))))

# ::tok Next , we observed that Stat6 was tyrosine phosphorylated in Stat1/ and Stat1/ fibroblasts ( Fig . 3 , B and D ) .
# ::alignments 0-1.3 2-1.1 3-1 4-1.2.r 5-1.2.1.1.1 7-1.2.1.2.1.1 8-1.2 11-1.2.2 13-1.2.2.1 13-1.2.2.2 20-1.2.2 20-1.4.1
# ::id bel_pmid_1695_1379_27966
(o / observe-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1~e.4 (p2 / phosphorylate-01~e.8
            :ARG1 (p / protein
                  :name (n / name :op1 "Stat6"~e.5)
                  :part (a / amino-acid
                        :name (n2 / name :op1 "tyrosine"~e.7)))
            :location (a2 / and~e.11,20
                  :op1 (f / fibroblast~e.13
                        :mod (p3 / protein
                              :name (n3 / name :op1 "Stat1")
                              :ARG2-of (m / mutate-01 :mod "-/-")))
                  :op2 (f2 / fibroblast~e.13
                        :mod (p4 / protein
                              :name (n4 / name :op1 "Stat1"))
                        :mod (w2 / wild-type))))
      :time (n5 / next~e.0)
      :ARG1-of (d / describe-01
            :ARG0 (a3 / and~e.20
                  :op1 (f3 / figure :mod "3B")
                  :op2 (f4 / figure :mod "3D"))))

# ::tok A late peak of Egr @-@ 1 mRNA occurred 12–24 h after IL @-@ 13 treatment but was not accompanied by an increase in Egr @-@ 1 protein .
# ::alignments 1-1.1.1 2-1.1 4-1.1.2.2.1.1.1 6-1.1.2.2.1.1.1 7-1.1.2.1.1 11-1.1.3 12-1.1.3.1.1.1.1 14-1.1.3.1.1.1.1 15-1.1.3.1 16-1 18-1.2.1 18-1.2.1.r 19-1.2 20-1.2.2.r 22-1.2.2 23-1.2.2.1.r 24-1.2.2.1 25-1.2.2.1 26-1.2.2.1 27-1.2.3
# ::id bel_pmid_1695_1379_27992
(c / contrast-01~e.16
      :ARG1 (p / peak~e.2
            :mod (l / late~e.1)
            :mod (r / rna
                  :name (n / name :op1 "mRNA"~e.7)
                  :ARG0-of (e / encode-01
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "Egr-1"~e.4,6))))
            :time (a / after~e.11
                  :op1 (t / treat-04~e.15
                        :ARG2 (p3 / protein
                              :name (n3 / name :op1 "IL-13"~e.12,14))
                        :duration (b / between
                              :op1 (t2 / temporal-quantity
                                    :quant "12"
                                    :unit (h / hour))
                              :op2 (t3 / temporal-quantity
                                    :quant "24"
                                    :unit (h2 / hour))))))
      :ARG2 (a2 / accompany-01~e.19
            :polarity~e.18 "-"~e.18
            :ARG0~e.20 (i / increase-01~e.22
                  :ARG1~e.23 p2~e.24,25,26)
            :ARG1 p~e.27))

# ::tok IL @-@ 13 @-@ induced PDGF @-@ A and PDGF @-@ C mRNA levels were significantly reduced in fibroblasts isolated from the lungs of Stat6/ mice compared with fibroblasts isolated from the lungs of the wild @-@ type Stat6/ mice ( Fig . 2 , A and B ) .
# ::alignments 0-1.1.3.1.1.1 2-1.1.3.1.1.1 4-1.1.3 5-1.1.1.1.2.1.1.1 5-1.1.2.1.2.1.1.1 7-1.1.1.1.2.1.1.1 8-1.1 9-1.1.1.1.2.1.1.1 9-1.1.2.1.2.1.1.1 11-1.1.2.1.2.1.1.1 12-1.1.1.1.1.1 12-1.1.2.1.1.1 13-1.1.1 13-1.1.2 15-1.2 15-1.2.r 16-1 17-1.3.r 18-1.3 18-1.3.2 19-1.3.1 20-1.3.1.1.r 22-1.3.1.1 25-1.3.1.1.1 26-1.3.2.r 28-1.3.2 29-1.3.2.1 30-1.3.2.1.1.r 32-1.3.2.1.1 33-1.3.2.2.r 35-1.3.2.2 37-1.3.2.2 39-1.3.2.1.1.1 45-1.1.1.1.2.1.1.1 46-1.1 46-1.4.1
# ::id bel_pmid_1695_1379_28002
(r / reduce-01~e.16
      :ARG1 (a / and~e.8,46
            :op1 (l / level~e.13
                  :quant-of (r2 / rna
                        :name (n2 / name :op1 "mRNA"~e.12)
                        :ARG0-of (e / encode-01
                              :ARG1 (p / protein
                                    :name (n / name :op1 "PDGF-A"~e.5,7,9,45)))))
            :op2 (l2 / level~e.13
                  :quant-of (r3 / rna
                        :name (n4 / name :op1 "mRNA"~e.12)
                        :ARG0-of (e2 / encode-01
                              :ARG1 (p3 / protein
                                    :name (n5 / name :op1 "PDGF-C"~e.5,9,11)))))
            :ARG1-of (i / induce-01~e.4
                  :ARG0 (p2 / protein
                        :name (n3 / name :op1 "IL-13"~e.0,2))))
      :manner~e.15 (s / significant~e.15)
      :location~e.17 (f / fibroblast~e.18
            :ARG1-of (i2 / isolate-01~e.19
                  :ARG2~e.20 (l3 / lung~e.22
                        :mod (m / mouse~e.25
                              :mod (p4 / protein
                                    :name (n6 / name :op1 "Stat6")
                                    :ARG2-of (m2 / mutate-01 :mod "-/-")))))
            :compared-to~e.26 (f2 / fibroblast~e.18,28
                  :ARG1-of (i3 / isolate-01~e.29
                        :ARG2~e.30 (l4 / lung~e.32
                              :mod (m3 / mouse~e.39
                                    :mod (p5 / protein
                                          :name (n7 / name :op1 "Stat6")))))
                  :mod~e.33 (w / wild-type~e.35,37)))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.46
                  :op1 (f3 / figure :mod "2A")
                  :op2 (f4 / figure :mod "2B"))))

# ::tok Egr @-@ 1 has been characterized as a transcriptional regulator of both PDGF @-@ A and PDGF @-@ C gene expression ( 18 , 19 ) .
# ::alignments 2-1.1.1.1 5-1 9-1.2 12-1.2.1.1.1.1.1 12-1.2.1.1.2.1.1 14-1.2.1.1.1.1.1 15-1.2.1.1 16-1.2.1.1.1.1.1 16-1.2.1.1.2.1.1 18-1.2.1.1.2.1.1 19-1.2.1.1.1 19-1.2.1.1.2 20-1.2.1 22-1.3.1.1.1.1 24-1.3.1.1.1.2
# ::id bel_pmid_1695_1379_32888
(c / characterize-01~e.5
      :ARG1 (p / protein
            :name (n / name :op1 "Erg-1"~e.2))
      :ARG2 (r / regulate-01~e.9
            :ARG1 (e / express-03~e.20
                  :ARG1 (a / and~e.15
                        :op1 (g / gene~e.19
                              :name (n2 / name :op1 "PDGF-A"~e.12,14,16))
                        :op2 (g2 / gene~e.19
                              :name (n3 / name :op1 "PDGF-C"~e.12,16,18))))
            :mod (t / transcribe-01))
      :ARG1-of (d / describe-01
            :ARG0 (p2 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (a2 / and :op1 "18"~e.22 :op2 "19"~e.24)))))

# ::tok Western blot analysis demonstrated that PD98059 blocked IL @-@ 13 @-@ induced phosphorylation of ERK1 @/@ 2 ( Fig . 8A ) yet enhanced the phosphorylation of Stat6 and increased protein expression of Egr @-@ 1 in a time @-@ dependent manner after IL @-@ 13 treatment ( Fig . 8 , B and C ) .
# ::alignments 0-1.1.1.1 1-1.1.1.2 2-1.1 3-1 5-1.2.1.1.1.1 6-1.2.1 7-1.2.1.2.2.1.1.1 9-1.2.1.2.2.1.1.1 11-1.2.1.2.2 12-1.2.1.2 13-1.2.1.2.1.r 14-1.2.1.2.1.1.1 16-1.2.1.2.1.1.1 20-1.2.1.3.1.1 23-1.2.2.1 25-1.2.2.1.2 27-1.2.2.1.2.1.1.1 28-1.2.2 28-1.2.2.3.1 29-1.2.2.2 30-1.2.1.2.2.1 30-1.2.2.1.2.1 30-1.2.2.2.2.1 31-1.2.2.2.2 35-1.2.2.2.2.1.1.1 38-1.2.2.2.3.r 38-1.2.2.2.4.2 40-1.2.2.2.4 41-1.2.2.2.4.r 42-1.2.2.2.3 43-1.2.2.2.3.1.1 44-1.2.2.2.3.1.1 45-1.2.2.2.3.1.1 46-1.2.2.2.3.1 53-1.2.2 53-1.2.2.3.1
# ::id bel_pmid_1695_1379_38388
(d / demonstrate-01~e.3
      :ARG0 (a / analyze-01~e.2
            :name (n / name :op1 "Western"~e.0 :op2 "blot"~e.1))
      :ARG1 (c / contrast-01
            :ARG1 (b / block-01~e.6
                  :ARG0 (m / molecular-physical-entity
                        :name (n3 / name :op1 "PD98059"~e.5))
                  :ARG1 (p / phosphorylate-01~e.12
                        :ARG1~e.13 (e3 / enzyme
                              :name (n2 / name :op1 "ERK1/2"~e.14,16))
                        :ARG1-of (i / induce-01~e.11
                              :ARG0 (p4 / protein~e.30
                                    :name (n6 / name :op1 "IL-13"~e.7,9))))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f / figure :mod "8A"~e.20)))
            :ARG2 (a2 / and~e.28,53
                  :op1 (e / enhance-01~e.23
                        :ARG0 m
                        :ARG1 (p5 / phosphorylate-01~e.25
                              :ARG1 (p6 / protein~e.30
                                    :name (n7 / name :op1 "Stat6"~e.27))))
                  :op2 (i2 / increase-01~e.29
                        :ARG0 m
                        :ARG1 (e2 / express-03~e.31
                              :ARG2 (p7 / protein~e.30
                                    :name (n8 / name :op1 "Erg-1"~e.35)))
                        :time~e.38 (a3 / after~e.42
                              :op1 (t / treat-04~e.46
                                    :ARG2 p4~e.43,44,45))
                        :manner~e.41 (d3 / depend-01~e.40
                              :ARG0 i2
                              :ARG1 (t2 / time~e.38)))
                  :ARG1-of (d4 / describe-01
                        :ARG0 (a4 / and~e.28,53
                              :op1 (f2 / figure :mod "8B")
                              :op2 (f3 / figure :mod "8C"))))))

# ::tok In cycling cells , the effects of Nox1 were dose dependent : levels of Nox1 that induced 3 @- to 10 @-@ fold increases in ROS promoted phosphorylation of ERK1 @/@ 2 and expression of cyclin D1,
# ::alignments 1-1.3.1 2-1.3 5-1.1 6-1.1.1.r 7-1.1.1.1.1 9-1.2 10-1 12-1.4.1.1 13-1.4.1.1.1.r 14-1.4.1.1.1 16-1.4.1.1.2 17-1.4.1.1.2.1.2.1.1 20-1.4.1.1.2.1.2.2.1 23-1.4.1.1.2.1 24-1.4.1.1.2.1.1.r 25-1.4.1.1.2.1.1.1.1 26-1.4.1 27-1.4.1.2.1 28-1.4.1.2.1.1.r 29-1.4.1.2.1.1.1.1 31-1.4.1.2.1.1.1.1 32-1.4.1.2 33-1.4.1.2.2 34-1.4.1.2.2.1.r 35-1.4.1.2.2.1.1.1
# ::id bel_pmid_1698_7002_500
(d / depend-01~e.10
      :ARG0 (a / affect-01~e.5
            :ARG0~e.6 (e / enzyme
                  :name (n / name :op1 "Nox1"~e.7)))
      :ARG1 (d2 / dose~e.9)
      :location (c / cell~e.2
            :mod (c2 / cycle~e.1))
      :ARG1-of (m / mean-01
            :ARG2 (p / promote-01~e.26
                  :ARG0 (l / level~e.12
                        :quant-of~e.13 e~e.14
                        :ARG0-of (i / induce-01~e.16
                              :ARG1 (i2 / increase-01~e.23
                                    :ARG1~e.24 (s / small-molecule
                                          :name (n4 / name :op1 "ROS"~e.25))
                                    :ARG2 (b / between
                                          :op1 (p4 / product-of :op1 "3"~e.17)
                                          :op2 (p5 / produt-of :op1 "10"~e.20)))))
                  :ARG1 (a2 / and~e.32
                        :op1 (p2 / phosphorylate-01~e.27
                              :ARG1~e.28 (e3 / enzyme
                                    :name (n2 / name :op1 "ERK1/2"~e.29,31)))
                        :op2 (e2 / express-03~e.33
                              :ARG2~e.34 (p3 / protein
                                    :name (n3 / name :op1 "cyclin"~e.35 :op2 "D1")))))))

# ::tok Induction of STAT3 Tyr705 and Ser727 phosphorylations by Galpha( s ) QL was suppressed by inhibition of protein kinase A , Janus kinase 2 @/@ 3 , Rac1 , c @-@ Jun N @-@ terminal kinase ( JNK ) , or phosphatidylinositol 3 @-@ kinase , and a similar profile was observed in response to beta2 @-@ adrenergic receptor stimulation
# ::alignments 2-1.1.2.1.1.3.1.1 4-1.1.2.1.1 6-1.1.2.1 13-1.1 14-1.1.1.r 15-1.1.1 16-1.1.1.1.r 17-1.1.1.1.1.1.1 18-1.1.1.1.1.1.2 19-1.1.1.1.1.1.3 21-1.1.1.1.2.1.1 22-1.1.1.1.2.1.2 23-1.1.1.1.2.1.3 25-1.1.1.1.2.1.3 25-1.1.1.1.5.1.2 27-1.1.1.1.3.1.1 29-1.1.1.1.4.1.1 31-1.1.1.1.4.1.1 32-1.1.1.1.4.1.2 34-1.1.1.1.4.1.2 35-1.1.1.1.2.1.2 35-1.1.1.1.4 35-1.1.1.1.4.1.3 35-1.1.1.1.5.1.2 40-1.1.1.1 41-1.1.1.1.5.1.1 42-1.1.1.1.2.1.3 42-1.1.1.1.5.1.2 44-1.1.1.1.2.1.2 44-1.1.1.1.4 44-1.1.1.1.4.1.3 44-1.1.1.1.5 44-1.1.1.1.5.1.2 48-1.2.1.1 49-1.2.1 51-1.2 52-1.2.1.2.r 53-1.2.1.2 54-1.2.1.2.1.r 55-1.2.1.2.1.1.1.1 57-1.2.1.2.1.1.1.1 58-1.2.1.2.1.1.1.2 59-1.2.1.2.1
# ::id bel_pmid_1700_8315_1518
(a / and
      :op1 (s / suppress-01~e.13
            :ARG0~e.14 (i2 / inhibit-01~e.15
                  :ARG1~e.16 (o2 / or~e.40
                        :op1 (e / enzyme
                              :name (n5 / name
                                    :op1 "protein"~e.17
                                    :op2 "kinase"~e.18
                                    :op3 "A"~e.19))
                        :op2 (e2 / enzyme
                              :name (n6 / name
                                    :op1 "Janus"~e.21
                                    :op2 "kinase"~e.22,35,44
                                    :op3 "2/3"~e.23,25,42))
                        :op3 (p4 / protein
                              :name (n7 / name :op1 "Rac1"~e.27))
                        :op4 (k / kinase~e.35,44
                              :name (n8 / name
                                    :op1 "c-Jun"~e.29,31
                                    :op2 "N-terminal"~e.32,34
                                    :op3 "kinase"~e.35,44))
                        :op5 (k2 / kinase~e.44
                              :name (n9 / name :op1 "phosphatidylinositol"~e.41 :op2 "3-kinase"~e.25,35,42,44))))
            :ARG1 (i / induct-01
                  :ARG1 (p / phosphorylate-01~e.6
                        :ARG1 (a2 / and~e.4
                              :op1 (a3 / amino-acid
                                    :mod "705"
                                    :name (n2 / name :op1 "tyrosine"))
                              :op2 (a4 / amino-acid
                                    :mod "727"
                                    :name (n3 / name :op1 "serine"))
                              :part-of (p2 / protein
                                    :name (n / name :op1 "STAT3"~e.2)))
                        :ARG2 (p3 / protein
                              :name (n4 / name :op1 "Galpha(s)QL")))))
      :op2 (o / observe-01~e.51
            :ARG1 (p5 / profile~e.49
                  :ARG1-of (r2 / resemble-01~e.48)
                  :ARG2-of~e.52 (r / respond-01~e.53
                        :ARG1~e.54 (s3 / stimulate-01~e.59
                              :ARG1 (p6 / protein
                                    :name (n10 / name :op1 "beta2-adrenergic"~e.55,57 :op2 "receptor"~e.58)))))))

# ::tok Activated KRAS is known to induce tyrosine phosphorylation of beta @-@ catenin , leading to its release from E @-@ cadherin at the adherens junction
# ::alignments 0-1.1.2 1-1.1.1.1 3-1.4 5-1 6-1.2.1.1.1 7-1.2 9-1.2.1.2.1.1 11-1.2.1.2.1.1 13-1.3 15-1.3.1.1 15-1.3.1.1.r 16-1.3.1 17-1.3.1.2.r 18-1.3.1.2.1.1 20-1.3.1.2.1.1 21-1.3.1.3.r 23-1.3.1.3.1.1 24-1.3.1.3.1.2
# ::id bel_pmid_1703_0180_5428
(i / induce-01~e.5
      :ARG0 (e / enzyme
            :name (n / name :op1 "KRAS"~e.1)
            :ARG1-of (a / activate-01~e.0))
      :ARG1 (p2 / phosphorylate-01~e.7
            :ARG1 (a2 / amino-acid
                  :name (n4 / name :op1 "tyrosine"~e.6)
                  :part-of (p3 / protein
                        :name (n2 / name :op1 "beta-catenin"~e.9,11))))
      :ARG1-of (l / lead-03~e.13
            :ARG2 (r / release-01~e.16
                  :ARG1~e.15 p3~e.15
                  :ARG2~e.17 (p4 / protein
                        :name (n3 / name :op1 "E-cadherin"~e.18,20))
                  :location~e.21 (m / macro-molecular-complex
                        :name (n5 / name :op1 "adherens"~e.23 :op2 "junction"~e.24))))
      :ARG1-of (k / know-01~e.3))

# ::tok TNF @-@ a strongly stimulated FRA @-@ 1 promoter activity in WT MEFs as compared with the erk1-/- MEFs ( Fig . 9B ) .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1.3 4-1 5-1.2.1.1.1.1.1 7-1.2.1.1.1.1.1 11-1.2.2.2 14-1.2.2.3 22-1.4.1.1
# ::id bel_pmid_1708_2637_21974
(s / stimulate-01~e.4
      :ARG0 (p / protein
            :name (n / name :op1 "TNF-a"~e.0,2))
      :ARG1 (a / act-01
            :ARG0 (m2 / molecular-physical-entity
                  :ARG0-of (p2 / promote-01
                        :ARG1 (p3 / protein
                              :name (n2 / name :op1 "FRA-1"~e.5,7))))
            :location (f2 / fibroblast
                  :source (e / embryo
                        :mod (m3 / mouse))
                  :mod (w / wild-type~e.11)
                  :ARG2-of (c / compare-01~e.14
                        :ARG1 (f3 / fibroblast
                              :source (e2 / embryo
                                    :mod (m / mouse))
                              :mod (p4 / protein
                                    :name (n3 / name :op1 "erk1")
                                    :ARG2-of (m4 / mutate-01 :mod "-/-"))))))
      :degree (s2 / strong~e.3)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "9B"~e.22)))

# ::tok the recruitment of c @-@ Jun was strongly enhanced following TNF @-@ a treatment ( Fig . 10B , lanes 3 and 4 ) . In contrast , the binding of c @-@ Jun to the fra @-@ 1 promoter was significantly diminished in MEFS lacking the erk1-/- signaling ( cf lanes 7 and 8 with lanes 3 and 4 ) .
# ::alignments 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1 5-1.1.1.1.1.1 7-1.1.4 8-1.1 9-1.1.3 10-1.1.3.1.1.1.1 12-1.1.3.1.1.1.1 13-1.1.3.1 17-1.1.2.1.3.1 19-1.1.2.1.1 19-1.1.2.1.2 19-1.2.2.1.2.1 19-1.2.2.1.2.2 20-1.1.2.1.1.1 20-1.2.2.1.2.1.1 21-1.1.2.1 21-1.2.2.1.2 22-1.2.2.1.2.2.1 26-1.2 29-1.2.1.1 30-1.2.1.1.1.r 31-1.2.1.1.1.1.1 33-1.2.1.1.1.1.1 34-1.2.1.1.2.r 36-1.2.1.1.2.2.1.1 38-1.2.1.1.2.2.1.1 41-1.2.1.2 42-1.2.1 45-1.2.1.3.2 48-1.2.1.3.2.1 51-1.2.2.1.1.1 51-1.2.2.1.1.2 52-1.2.2.1.1.1.1 53-1.2.2.1.1 54-1.2.2.1.1.2.1 56-1.2.2.1.1.2 56-1.2.2.1.2.1 56-1.2.2.1.2.2 57-1.2.2.1.2.1.1 58-1.2.2.1.2 59-1.2.2.1.2.2.1
# ::id bel_pmid_1708_2637_21978
(m / multi-sentence
      :snt1 (e2 / enhance-01~e.8
            :ARG1 (r / recruit-01~e.1
                  :ARG1~e.2 (e / enzyme
                        :name (n / name :op1 "c-Jun"~e.3,5)))
            :ARG1-of (d / describe-01
                  :ARG0 (a / and~e.21
                        :op1 (l / lane~e.19 :mod "3"~e.20)
                        :op2 (l5 / lane~e.19 :mod "5")
                        :part-of (f / figure :mod "10B"~e.17)))
            :ARG1-of (f2 / follow-01~e.9
                  :ARG2 (t / treat-04~e.13
                        :ARG2 (p / protein
                              :name (n2 / name :op1 "TNF-a"~e.10,12))))
            :degree (s / strong~e.7))
      :snt2 (c / contrast-01~e.26
            :ARG2 (d2 / diminish-01~e.42
                  :ARG1 (b / bind-01~e.29
                        :ARG1~e.30 (e3 / enzyme
                              :name (n4 / name :op1 "c-Jun"~e.31,33))
                        :ARG2~e.34 (m2 / molecular-physical-entity
                              :ARG0-of (p2 / promote-01)
                              :mod (p3 / protein
                                    :name (n3 / name :op1 "fra-1"~e.36,38))))
                  :degree (s2 / significant~e.41)
                  :location (f3 / fibroblast
                        :source (e4 / embryo
                              :mod (m3 / mouse))
                        :ARG0-of (l2 / lack-01~e.45
                              :ARG1 (s3 / signal-07~e.48
                                    :ARG0 (e5 / enzyme
                                          :name (n5 / name :op1 "erk1")
                                          :ARG2-of (m4 / mutate-01 :mod "-/-"))))))
            :ARG1-of (c2 / conform-01
                  :ARG0 (c3 / compare-01
                        :ARG1 (a2 / and~e.53
                              :op1 (l3 / lane~e.51 :mod "7"~e.52)
                              :op2 (l4 / lane~e.51,56 :mod "8"~e.54))
                        :ARG2 (a3 / and~e.21,58
                              :op1 (l6 / lane~e.19,56 :mod "3"~e.20,57)
                              :op2 (l7 / lane~e.19,56 :mod "4"~e.22,59))))))

# ::tok As shown in Fig. 9A , TNF @-@ a strongly stimulated both ERK1 and ERK2 phosphorylation in WT cells ( cf lanes 1 and 2 ) .
# ::alignments 1-1.4 4-1.4.1.1 6-1.1.1.1 8-1.1.1.1 9-1.5 9-1.5.r 10-1 11-1.2.1.3 12-1.2.1.1.1.1 13-1.2.1 14-1.2.1.2.1.1 15-1.2 16-1.2.2.r 17-1.2.2.1 18-1.2.2 21-1.3.1.1 21-1.3.1.2 22-1.3.1.1.1 24-1.3.1.2.1
# ::id bel_pmid_1708_2637_31490
(s / stimulate-01~e.10
      :ARG0 (p / protein
            :name (n / name :op1 "TNF-a"~e.6,8))
      :ARG1 (p2 / phosphorylate-01~e.15
            :ARG1 (a / and~e.13
                  :op1 (e / enzyme
                        :name (n2 / name :op1 "ERK1"~e.12))
                  :op2 (e2 / enzyme
                        :name (n3 / name :op1 "ERK2"~e.14))
                  :mod (b / both~e.11))
            :location~e.16 (c / cell~e.18
                  :mod (w / wild-type~e.17)))
      :ARG1-of (c3 / conform-01
            :ARG0 (c2 / compare-01
                  :ARG1 (l / lane~e.21 :mod "1"~e.22)
                  :ARG2 (l2 / lane~e.21 :mod "2"~e.24)))
      :ARG1-of (s2 / show-01~e.1
            :location (f / figure :mod "9A"~e.4))
      :manner~e.9 (s3 / strong~e.9))

# ::tok The -@ 318 TRE mediates c @-@ Jun @-@ dependent , TNF @-@ alpha @-@ inducible FRA @-@ 1 promoter activity.....Consistent with this result , ectopic expression of a c @-@ Jun mutant lacking the transactivation domain greatly reduced (~80 %) TNF @-@ alpha @-@ stimulated promoter activity ( Fig . 2B ) ....However , TNF @-@ a induced the binding of c @-@ Jun to the promoter as early as 30 min ( Fig . 3A , lane 2 ) , and it remained high through 60 min ( Fig . 3A , lane 3 ) .
# ::alignments 2-1.1.1.1 3-1.1.1.2.1 4-1.1 5-1.1.2.2.1.1.1 7-1.1.2.2.1.1.1 9-1.1.2.2 11-1.1.2.3.1.1.1 13-1.1.2.3.1.1.1 15-1.3.1.1 16-1.1.2.1.1.1.1.1 18-1.1.2.1.1.1.1.1 22-1.2.5.1.1 23-1.2.5.1 23-1.2.5.1.2 23-1.2.5.1.2.r 25-1.2.1.2 26-1.2.1 28-1.3.1.1.1.1.1 29-1.2.1.1.1.1 29-1.3.1.1.2.1.1.1 31-1.2.1.1.1.1 31-1.3.1.1.2.1.1.1 32-1.2.1.1 32-1.2.1.1.2 32-1.2.1.1.2.r 33-1.2.1.1.3 35-1.2.1.1.3.1.1 36-1.2.1.1.3.1 37-1.2.4 38-1.2 41-1.2.2.2.1.1.1 43-1.2.2.2.1.1.1 45-1.2.2.2 51-1.2.6.1.1 55-1.1.2.3.1.1.1 55-1.3.1.1.1.1.1 57-1.3.1.1.1.1.1 58-1.3.1.1 60-1.3.1.1.2 61-1.3.1.1.2.1.r 62-1.3.1.1.2.1.1.1 64-1.3.1.1.2.1.1.1 68-1.3.1.1.3.r 69-1.3.1.1.3.1 70-1.3.1.1.3.r 71-1.3.1.1.3.2.1 76-1.3.1.1.4.1.2.1 78-1.3.1.1.4.1 79-1.3.1.1.4.1.1 82-1.3.1 83-1.3.1.2.1 84-1.3.1.2 85-1.3.1.2.2 87-1.3.1.2.3.1 92-1.3.1.2.4.1.2 94-1.3.1.2.4.1 95-1.3.1.2.4.1.1
# ::id bel_pmid_1708_2637_39256
(m / multi-sentence
      :snt1 (m2 / mediate-01~e.4
            :ARG0 (d / dna-sequence
                  :mod "-318"~e.2
                  :name (n / name :op1 "TRE"~e.3))
            :ARG1 (a / act-01
                  :ARG0 (m8 / molecular-physical-entity
                        :ARG0-of (p / promote-01
                              :mod (p2 / protein
                                    :name (n2 / name :op1 "FRA-1"~e.16,18))))
                  :ARG0-of (d2 / depend-01~e.9
                        :ARG1 (e5 / enzyme
                              :name (n3 / name :op1 "c-Jun"~e.5,7)))
                  :ARG1-of (i / induct-01
                        :ARG0 (p4 / protein
                              :name (n4 / name :op1 "TNF-alpha"~e.11,13,55))
                        :mod (p12 / possible))))
      :snt2 (r / reduce-01~e.38
            :ARG0 (e / express-03~e.26
                  :ARG2 (e4 / enzyme~e.32
                        :name (n5 / name :op1 "c-Jun"~e.29,31)
                        :ARG2-of~e.32 (m3 / mutate-01~e.32)
                        :ARG0-of (l / lack-01~e.33
                              :ARG1 (d3 / domain~e.36
                                    :ARG1-of (t / transactivate-00~e.35))))
                  :mod (e2 / ectopic~e.25))
            :ARG1 (a3 / act-01
                  :ARG0 (m6 / molecular-physical-entity
                        :ARG0-of (p3 / promote-01))
                  :ARG1-of (s / stimulate-01~e.45
                        :ARG0 (p8 / protein
                              :name (n6 / name :op1 "TNF-alpha"~e.41,43))))
            :ARG2 (a2 / approximate
                  :op1 (p6 / percentage-entity :value "80"))
            :degree (g / great~e.37)
            :ARG1-of (c / consistent-01
                  :ARG2 (t5 / thing~e.23
                        :mod (t2 / this~e.22)
                        :ARG2-of~e.23 (r2 / result-01~e.23)))
            :ARG1-of (d4 / describe-01
                  :ARG0 (f / figure :mod "2B"~e.51)))
      :snt3 (c2 / contrast-01
            :ARG2 (a4 / and~e.82
                  :op1 (i2 / induce-01~e.15,58
                        :ARG0 (p9 / protein
                              :name (n7 / name :op1 "TNF-a"~e.28,55,57))
                        :ARG1 (b / bind-01~e.60
                              :ARG1~e.61 (e6 / enzyme
                                    :name (n8 / name :op1 "c-Jun"~e.29,31,62,64))
                              :ARG2 (m7 / molecular-physical-entity
                                    :ARG0-of (p5 / promote-01)))
                        :time~e.68,70 (a5 / after
                              :mod (e3 / early~e.69)
                              :quant (t3 / temporal-quantity
                                    :quant "30"~e.71
                                    :unit (m4 / minute)))
                        :ARG1-of (d5 / describe-01
                              :ARG0 (l2 / lane~e.78
                                    :mod "2"~e.79
                                    :part-of (f2 / figure :mod "3A"~e.76))))
                  :op2 (r3 / remain-01~e.84
                        :ARG1 b~e.83
                        :ARG3 (h / high~e.85)
                        :duration (t4 / temporal-quantity
                              :quant "60"~e.87
                              :unit (m5 / minute))
                        :ARG1-of (d6 / describe-01
                              :ARG0 (l3 / lane~e.94
                                    :mod "3"~e.95
                                    :part-of f2~e.92))))))

# ::tok Real @-@ time RT @-@ PCR revealed that IL @-@ 1 beta induced SYN expression at the transcriptional level , because the mRNA level of SYN was upregulated by IL @-@ 1?. TNF-? had a weaker effect on SYN transcription , whereas IL @-@ 6 had no effect
# ::alignments 0-1.1.1.2 2-1.1.1.2 3-1.1.1.1.1 5-1.1.1.1.1 6-1.1 7-1.1.2.r 8-1.1.2.1.1.1 12-1.1.2 13-1.1.2.2.1.1.1 14-1.1.2.2 18-1.1.2.3 20-1.1.3 22-1.1.3.1.1.1.1 23-1.1.2.3 23-1.1.3.1.1.2 25-1.2.2.3 29-1.2.2.2.1.1 35-1.2.1.3 35-1.2.1.3.1 35-1.2.1.3.1.r 36-1.2.1 38-1.2.1.2.1.1.1 39-1.1.2.3.1 39-1.2.1.2 41-1.2 42-1.2.2.2.1.1 44-1.2.2.2.1.1 46-1.2.2.1 46-1.2.2.1.r 47-1.2.2
# ::id bel_pmid_1710_5652_28156
(m / multi-sentence
      :snt1 (r / reveal-01~e.6
            :ARG0 (e / event
                  :name (n / name :op1 "RT-PCR"~e.3,5)
                  :mod (r2 / real-time~e.0,2))
            :ARG1~e.7 (i / induce-01~e.12
                  :ARG0 (p / protein
                        :name (n2 / name :op1 "IL-1beta"~e.8))
                  :ARG1 (e2 / express-03~e.14
                        :ARG2 (e3 / enzyme
                              :name (n3 / name :op1 "SYN"~e.13)))
                  :mod (l / level~e.18,23
                        :mod (t / transcribe-01~e.39)))
            :ARG1-of (c / cause-01~e.20
                  :ARG0 (u / upregulate-01
                        :ARG1 (r3 / rna
                              :name (n4 / name :op1 "mRNA"~e.22)
                              :mod (l2 / level~e.23)
                              :ARG0-of (e5 / encode-01
                                    :ARG1 e3))
                        :ARG2 (p2 / protein
                              :name (n5 / name :op1 "IL1B")))))
      :snt2 (c2 / contrast-01~e.41
            :ARG1 (a / affect-01~e.36
                  :ARG0 (p3 / protein
                        :name (n6 / name :op1 "TNF-α"))
                  :ARG1 (t2 / transcribe-01~e.39
                        :ARG1 (e4 / enzyme
                              :name (n7 / name :op1 "SYN"~e.38)))
                  :mod (w / weak~e.35
                        :degree~e.35 (m2 / more~e.35)))
            :ARG2 (a2 / affect-01~e.47
                  :polarity~e.46 "-"~e.46
                  :ARG0 (p4 / protein
                        :name (n8 / name :op1 "IL-6"~e.29,42,44))
                  :ARG1 t2~e.25)))

# ::tok STAT3 is also able to prevent cell death through inhibition of the extrinsic apoptotic pathway . This pathway is activated upon binding of extracellular ligands such as FAS ligand ( FAS @-@ L ) to cell @-@ surface death receptors . Upon interaction with FAS @-@ L , the FAS death receptor induces cell death through caspase @-@ 8 activation and truncation of the death agonist BID .
# ::alignments 0-1.1.1.1.1.1 1-1.1.1.r 2-1.1.1.4 3-1.1 5-1.1.1 6-1.1.1.2.1 7-1.1.1.2 9-1.1.1.3 10-1.1.1.3.1.r 12-1.1.1.3.1.1 13-1.1.1.3.1.2 14-1.1.1.3.1 16-1.2.1.1 17-1.2.1 19-1.2 21-1.2.2 22-1.2.2.1.r 23-1.2.2.1.1 24-1.2.2.1 24-1.2.2.1.2 25-1.2.2.1.2.r 26-1.2.2.1.2.r 27-1.2.2.1.2.1.1 28-1.2.2.1 28-1.2.2.1.2 30-1.3.4.1.1.1 32-1.3.4.1.1.1 34-1.2.2.2.r 35-1.2.2.2.1.1 37-1.2.2.2.1 38-1.2.2.2.2 39-1.2.2.2 42-1.3.4 44-1.3.4.1.1.1 46-1.3.4.1.1.1 49-1.3.1.1.1 50-1.3.1.1.2 51-1.3.1.1.3 52-1.3 53-1.3.2.1 54-1.3.2 56-1.3.3.1.1.1.1 58-1.3.3.1.1.1.1 59-1.3.3.1 60-1.3.3 61-1.3.3.2 62-1.3.3.2.1.r 64-1.3.3.2.1.1.1 65-1.3.3.2.1.1.2 66-1.3.3.2.1.1.3
# ::id bel_pmid_1711_8707_35424
(m / multi-sentence
      :snt1 (p / possible~e.3
            :domain~e.1 (p2 / prevent-01~e.5
                  :ARG0 (p3 / protein
                        :name (n / name :op1 "STAT3"~e.0))
                  :ARG1 (d / die-01~e.7
                        :ARG1 (c / cell~e.6))
                  :ARG3 (i / inhibit-01~e.9
                        :ARG1~e.10 (p4 / pathway~e.14
                              :mod (e2 / extrinsic~e.12)
                              :mod (a5 / apoptosis~e.13)))
                  :mod (a / also~e.2)))
      :snt2 (a2 / activate-01~e.19
            :ARG1 (p5 / pathway~e.17
                  :mod (t / this~e.16))
            :time (b / bind-01~e.21
                  :ARG1~e.22 (l / ligand~e.24,28
                        :mod (e / extracellular~e.23)
                        :example~e.25,26 (l2 / ligand~e.24,28
                              :name (n3 / name :op1 "FAS"~e.27)))
                  :ARG2~e.34 (r / receptor~e.39
                        :location (s / surface~e.37
                              :part-of (c2 / cell~e.35))
                        :ARG1-of (d2 / die-01~e.38))))
      :snt3 (i2 / induce-01~e.52
            :ARG0 (p6 / protein
                  :name (n4 / name
                        :op1 "FAS"~e.49
                        :op2 "death"~e.50
                        :op3 "receptor"~e.51))
            :ARG1 (d3 / die-01~e.54
                  :ARG1 (c3 / cell~e.53))
            :manner (a3 / and~e.60
                  :op1 (a4 / activate-01~e.59
                        :ARG1 (p7 / protein
                              :name (n5 / name :op1 "caspase-8"~e.56,58)))
                  :op2 (t2 / truncate-01~e.61
                        :ARG1~e.62 (p8 / protein
                              :name (n6 / name
                                    :op1 "death"~e.64
                                    :op2 "agonist"~e.65
                                    :op3 "BID"~e.66))))
            :time (i3 / interact-01~e.42
                  :ARG1 (p9 / protein
                        :name (n7 / name :op1 "FAS-L"~e.30,32,44,46)))))

# ::tok These genes can be divided in three classes : one that controls cell @-@ cycle arrest and senescence , one that controls apoptosis and one that regulates glucose metabolism and autophagy [42]. p53 is essentially known as a pro @-@ apoptotic transcription factor that upregulates the expression of proteins such as BCL2 @-@ associated X protein ( BAX ) , p53 upregulated modulator of apoptosis ( PUMA ) or NOXA .
# ::alignments 0-1.2.1.1.1 1-1.2.1.1 2-1.2 3-1.2.1.r 4-1.2.1 5-1.2.1.2.r 6-1.2.1.2.1 7-1.2.1.2 7-1.2.1.2.2.1.1 7-1.2.1.2.2.1.2 7-1.2.1.2.2.1.3 11-1.2.1.2.2.1.1.1 12-1.2.1.2.2.1.1.1.1.1.1.1 14-1.2.1.2.2.1.1.1.1.1.1 15-1.2.1.2.2.1.1.1.1.1 16-1.2.1.2.2.1.1.1.1 17-1.2.1.2.2.1.1.1.1.2 21-1.2.1.2.2.1.1.1 21-1.2.1.2.2.1.2.1 22-1.2.1.2.2.1.2.1.1 23-1.2.1.2.2.1.1.1.1 26-1.2.1.2.2.1.3.1 27-1.2.1.2.2.1.3.1.1.1.1 29-1.2.1.2.2.1.3.1.1 30-1.2.1.2.2.1.3.1.1.2 32-1.1.1.1.1 34-1.1.3 34-1.1.3.r 35-1.1 36-1.1.1.1.r 36-1.1.2.r 38-1.1.2 38-1.1.2.2 38-1.1.2.2.r 40-1.1.2.2.1 41-1.1.2.1.1 42-1.1.2.1.2 46-1.1.2.3.1 47-1.1.2.3.1.1.r 48-1.1.2.3.1.1 49-1.1.2.3.1.1.1.r 50-1.1.2.3.1.1.1.r 53-1.1.2.3.1.1.1.1.1.1 54-1.1.2.3.1.1.1.1.1.2 55-1.1.2.3.1.1.1.1 55-1.1.2.3.1.1.1.2 55-1.1.2.3.1.1.1.3 60-1.1.2.3.1.1.1.2.1.1 61-1.1.2.3.1.1.1.2.1.2 62-1.1.2.3.1.1.1.2.1.3 63-1.1.2.3.1.1.1.2.1.4 64-1.1.2.3.1.1.1.2.1.5 68-1.1.2.3.1.1.1 69-1.1.2.3.1.1.1.3.1.1
# ::id bel_pmid_1711_8707_37686
(m / multi-sentence
      :snt2 (k / know-02~e.35
            :ARG1 (p2 / protein
                  :name~e.36 (n / name :op1 "p53"~e.32))
            :ARG2~e.36 (p3 / protein~e.38
                  :name (n2 / name :op1 "transcription"~e.41 :op2 "factor"~e.42)
                  :ARG0-of~e.38 (f / favor-01~e.38
                        :ARG1 (a7 / apoptosis~e.40))
                  :ARG0-of (u / upregulate-01
                        :ARG1 (e / express-03~e.46
                              :ARG2~e.47 (p4 / protein~e.48
                                    :example~e.49,50 (o2 / or~e.68
                                          :op1 (p5 / protein~e.55
                                                :name (n3 / name :op1 "Bcl-2-associated"~e.53 :op2 "X"~e.54))
                                          :op2 (p6 / protein~e.55
                                                :name (n4 / name
                                                      :op1 "p53"~e.60
                                                      :op2 "upregulated"~e.61
                                                      :op3 "modulator"~e.62
                                                      :op4 "of"~e.63
                                                      :op5 "apoptosis"~e.64))
                                          :op3 (p7 / protein~e.55
                                                :name (n5 / name :op1 "NOXA"~e.69)))))))
            :manner~e.34 (e2 / essential~e.34))
      :snt1 (p8 / possible~e.2
            :domain~e.3 (d / divide-02~e.4
                  :ARG1 (g / gene~e.1
                        :mod (t / this~e.0))
                  :ARG2~e.5 (c / class~e.7
                        :quant "3"~e.6
                        :ARG1-of (m2 / mean-01
                              :ARG2 (a / and
                                    :op1 (c3 / class~e.7
                                          :ARG0-of (c2 / control-01~e.11,21
                                                :ARG1 (a2 / and~e.16,23
                                                      :op1 (a3 / arrest-02~e.15
                                                            :ARG1 (c6 / cycle~e.14
                                                                  :mod (c7 / cell~e.12)))
                                                      :op2 (s / senescence~e.17))))
                                    :op2 (c8 / class~e.7
                                          :ARG0-of (c9 / control-01~e.21
                                                :ARG1 (a4 / apoptosis~e.22)))
                                    :op3 (c10 / class~e.7
                                          :ARG0-of (r / regulate-01~e.26
                                                :ARG1 (a5 / and~e.29
                                                      :op1 (m3 / metabolize-01
                                                            :ARG1 (g2 / glucose~e.27))
                                                      :op2 (a6 / autophagy~e.30)))))))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p / publication
                              :ARG1-of (c5 / cite-01 :ARG2 "42"))))))

# ::tok that IL @-@ 6 and IL @-@ 10 , two cytokines that are known to activate STAT3 , confer a drug @-@ resistant phenotype in renal carcinomas , which was subsequently confirmed in different cancer cell lines such as multiple myeloma [72,73].
# ::alignments 1-1.1.1.1.1 1-1.1.2.1.1 3-1.1.1.1.1 4-1.1 5-1.1.1.1.1 5-1.1.2.1.1 7-1.1.2.1.1 13-1.1.3 15-1.1.3.1 16-1.1.3.1.1.1.1 18-1 20-1.2.1.1 22-1.2.1 23-1.2 24-1.3.r 25-1.3.1 26-1.3 30-1.2.2.2 30-1.2.2.2.r 31-1.2.2 32-1.2.2.1.r 33-1.2.2.1.1 34-1.2.2.1.2 35-1.2.2.1 36-1.2.2.1 37-1.2.2.1.2.1.r 38-1.2.2.1.2.1.r 39-1.2.2.1.2.1.1.1 40-1.2.2.1.2.1.1.2
# ::id bel_pmid_1711_8707_38556
(c / confer-02~e.18
      :ARG0 (a / and~e.4
            :op1 (c9 / cytokine
                  :name (n / name :op1 "IL-6"~e.1,3,5))
            :op2 (c10 / cytokine
                  :name (n2 / name :op1 "IL-10"~e.1,5,7))
            :ARG1-of (k / know-02~e.13
                  :ARG2 (a2 / activate-01~e.15
                        :ARG1 (p / protein
                              :name (n3 / name :op1 "STAT3"~e.16)))))
      :ARG1 (p4 / phenotype~e.23
            :ARG0-of (r / resist-01~e.22
                  :ARG1 (d / drug~e.20))
            :ARG1-of (c3 / confirm-01~e.31
                  :location~e.32 (c6 / cell-line~e.35,36
                        :ARG1-of (d3 / differ-02~e.33)
                        :mod (c4 / cancer~e.34
                              :example~e.37,38 (d4 / disease
                                    :name (n5 / name :op1 "multiple"~e.39 :op2 "myeloma"~e.40))))
                  :time~e.30 (s / subsequent~e.30)))
      :location~e.24 (c2 / carcinoma~e.26
            :mod (k2 / kidney~e.25))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c8 / cite-01
                        :ARG2 (a3 / and :op1 "72" :op2 "73")))))

# ::tok Importantly , the expression of survivin correlates with STAT3 activation in breast tumors , and the inhibition of this signaling pathway induces apoptosis [47,48]. Finally , it has also been shown that AKT is a direct target gene of STAT3 , which binds directly to its promoter to enhance its expression [49].
# ::alignments 0-1.1.3 0-1.1.3.r 3-1.1.1.1 4-1.1.1.1.1.r 5-1.1.1.1.1.1.1 6-1.1.1 7-1.1.1.2.r 8-1.1.1.2.1.1.1 9-1.1.1.2 10-1.1.1.3.r 11-1.1.1.3.1 12-1.1.1.3 14-1.1 14-1.1.4.1.1.1 16-1.1.2.1 19-1.1.2.1.1 20-1.1.2.1.1 21-1.1.2 22-1.1.2.2 24-1.2.3 28-1.2.2 30-1.2 31-1.2.1.r 32-1.2.1.2.1.1 35-1.2.1.3 36-1.2.1 37-1.2.1.2 38-1.2.1.1.r 39-1.2.1.1.1.1 42-1.2.1.1 42-1.2.1.1.2 42-1.2.1.1.2.r 43-1.2.1.3 45-1.2.1.1.2.2.1 45-1.2.1.1.2.2.1.r 48-1.2.1.1.2.2 49-1.2.1.1.2.2.2.1 49-1.2.1.1.2.2.2.1.r 50-1.2.1.1.2.2.2
# ::id bel_pmid_1711_8707_39772
(m / multi-sentence
      :snt1 (a / and~e.14
            :op1 (c / correlate-01~e.6
                  :ARG1 (e / express-03~e.3
                        :ARG2~e.4 (p7 / pathway
                              :name (n4 / name :op1 "survivin"~e.5)
                              :ARG0-of (s / signal-07)))
                  :ARG2~e.7 (a2 / activate-01~e.9
                        :ARG1 (p / protein
                              :name (n / name :op1 "STAT3"~e.8)))
                  :location~e.10 (t / tumor~e.12
                        :mod (b / breast~e.11)))
            :op2 (i / induce-01~e.21
                  :ARG0 (i2 / inhibit-01~e.16
                        :ARG1 p7~e.19,20)
                  :ARG1 (a3 / apoptosis~e.22))
            :manner~e.0 (i3 / important~e.0)
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c2 / cite-01
                              :ARG2 (a4 / and~e.14 :op1 "47" :op2 "48")))))
      :snt2 (s3 / show-01~e.30
            :ARG1~e.31 (t3 / target-01~e.36
                  :ARG0~e.38 (p4 / protein~e.42
                        :name (n2 / name :op1 "STAT3"~e.39)
                        :ARG1-of~e.42 (b2 / bind-01~e.42
                              :ARG2 (m2 / molecular-physical-entity
                                    :ARG0-of (p2 / promote-01
                                          :ARG1 (g / gene~e.37
                                                :name (n3 / name :op1 "AKT"~e.32))))
                              :purpose (e2 / enhance-01~e.48
                                    :ARG0~e.45 p4~e.45
                                    :ARG1 (e3 / express-03~e.50
                                          :ARG1~e.49 g~e.49))))
                  :ARG1 g
                  :mod (d2 / direct~e.35,43))
            :mod (a5 / also~e.28)
            :time (f / final~e.24)
            :ARG1-of (d3 / describe-01
                  :ARG0 (p6 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "49")))))

# ::tok Tyk2 , along with JAK2 , does appear to regulate TPO receptor localization at the plasma membrane by stimulating recycling and enhancing the stability of the receptor in Ba @/@ F3 cells
# ::alignments 0-1.1.1.1.1.1 4-1.1.1.2.1.1 7-1 9-1.1 10-1.1.2.1.1.1 11-1.1.2.1.1.2 13-1.1.2 15-1.1.2.2.1 16-1.1.2.2 17-1.1.3.r 18-1.1.3.1 19-1.1.3.1.2 20-1.1.3 21-1.1.3.2 23-1.1.3.2.2 24-1.1.3.2.2.1.r 26-1.1.3.2.2.1 27-1.1.3.2.2.2.r 28-1.1.3.2.2.2.1.1 30-1.1.3.2.2.2.1.1 31-1.1.3.2.2.2
# ::id bel_pmid_1712_7443_21794
(a / appear-02~e.7
      :ARG1 (r / regulate-01~e.9
            :ARG0 (a3 / and
                  :op1 (e / enzyme
                        :name (n / name :op1 "Tyk2"~e.0))
                  :op2 (e4 / enzyme
                        :name (n5 / name :op1 "JAK2"~e.4)))
            :ARG1 (b / be-located-at-91~e.13
                  :ARG1 (p / protein
                        :name (n3 / name :op1 "TPO"~e.10 :op2 "receptor"~e.11))
                  :ARG2 (m / membrane~e.16
                        :mod (p2 / plasma~e.15)))
            :manner~e.17 (a2 / and~e.20
                  :op1 (s / stimulate-01~e.18
                        :ARG0 a3
                        :ARG1 (r2 / recycle-01~e.19))
                  :op2 (e3 / enhance-01~e.21
                        :ARG0 a3
                        :ARG1 (s2 / stability~e.23
                              :poss~e.24 p~e.26
                              :location~e.27 (c / cell~e.31
                                    :name (n4 / name :op1 "Ba/F3"~e.28,30)))))))

# ::tok Other notable genes downregulated with GATA @-@ 1 knockdown are the p45 subunit of nuclear factor erythroid @-@ derived 2 ( NF @- E2 ) , JAK2 , and beta1 @-@ tubulin .
# ::alignments 0-1.2.1 1-1.2.2 2-1.2 5-1.2.3.1.1.1 7-1.2.3.1.1.1 11-1.1.1.2.1.1 12-1.1.1 13-1.1.1.1.r 14-1.1.1.1.1.1 15-1.1.1.1.1.2 16-1.1.1.1.1.3 18-1.1.1.1.1.3 19-1.1.1.1.1.4 26-1.1.2.1.1 28-1.1 29-1.1.3.1.1 31-1.1.3.1.1
# ::id bel_pmid_1712_7443_27130
(i / include-91
      :ARG1 (a / and~e.28
            :op1 (s / subunit~e.12
                  :part-of~e.13 (g4 / gene
                        :name (n4 / name
                              :op1 "nuclear"~e.14
                              :op2 "factor"~e.15
                              :op3 "erythroid-derived"~e.16,18
                              :op4 "2"~e.19))
                  :mod (p2 / protein
                        :name (n6 / name :op1 "p45"~e.11)))
            :op2 (g2 / gene
                  :name (n2 / name :op1 "JAK2"~e.26))
            :op3 (g3 / gene
                  :name (n3 / name :op1 "beta1-tubulin"~e.29,31)))
      :ARG2 (g / gene~e.2
            :mod (o / other~e.0)
            :mod (n / notable~e.1)
            :ARG1-of (d / downregulate-01
                  :ARG2 (p / protein
                        :name (n5 / name :op1 "GATA-1"~e.5,7)
                        :ARG1-of (k / knock-02)))))

# ::tok There are two isoforms of 3 beta @- HSD expressed in wild @-@ type megakaryocytes ( I and VI ) , but neither are expressed in NF @-@ E2 null megakaryocytes .
# ::alignments 2-1.2.2 3-1.2.2 4-1.2.2 5-1.2.2 6-1.2.2 7-1.2.2 8-1.2.2 9-1.2 11-1.1.2.1 13-1.1.2.1 14-1.1.2 14-1.2.3 16-1.1.1.3.1.1.1.3 17-1.1.1.3.1 21-1 22-1.2.1 22-1.2.1.r 24-1.1 24-1.2 25-1.2.3.1.r 26-1.2.3.1.1.1 28-1.2.3.1.1.1 30-1.1.2
# ::id bel_pmid_1712_7443_29536
(c / contrast-01~e.21
      :ARG1 (e / express-03~e.24
            :ARG2 (i / isoform
                  :quant "2"
                  :mod (e2 / enzyme
                        :name (n / name :op1 "3beta-" :op2 "HSD"))
                  :ARG1-of (m / mean-01
                        :ARG2 (a / and~e.17
                              :op1 (e4 / enzyme
                                    :name (n2 / name
                                          :op1 "3beta-"
                                          :op2 "HSD"
                                          :op3 "I"~e.16))
                              :op2 (e5 / enzyme
                                    :name (n3 / name
                                          :op1 "3beta-"
                                          :op2 "HSD"
                                          :op3 "IV")))))
            :ARG3 (m4 / megakaryocyte~e.14,30
                  :mod (w / wild-type~e.11,13)))
      :ARG2 (e3 / express-03~e.9,24
            :polarity~e.22 "-"~e.22
            :ARG2 i~e.2,3,4,5,6,7,8
            :ARG3 (m3 / megakaryocyte~e.14
                  :mod~e.25 (p / protein
                        :name (n5 / name :op1 "NF-E2"~e.26,28)
                        :ARG1-of (m2 / mutate-01 :mod "-/-")))))

# ::tok TPO is necessary for megakaryocyte maturation in that TPO deficient mice display greatly reduced megakaryocyte production as well as reduced numbers of mature megakaryocytes
# ::alignments 0-1.2.1.1 2-1 4-1.1.1 8-1.3.1.1.1.1 10-1.3.1.1 11-1.3.1 12-1.3.1.2.1.2.1 13-1.3.1.2.1.2 14-1.3.1.2.1.1 15-1.3.1.2.1 18-1.3.1.2.r 19-1.3.1.2.2.1 20-1.3.1.2.2 22-1.1 22-1.3.1.2.2.2.1 23-1.1.1 23-1.3.1.2.2.2
# ::id bel_pmid_1712_7443_31646
(n / need-01~e.2
      :ARG0 (m / mature-01~e.22
            :ARG1 (m4 / megakaryocyte~e.4,23))
      :ARG1 (e / enzyme
            :name (n2 / name :op1 "TPO"~e.0))
      :ARG1-of (c2 / cause-01
            :ARG0 (d / display-01~e.11
                  :ARG0 (m2 / mouse~e.10
                        :ARG0-of (l / lack-01
                              :ARG1 e~e.8))
                  :ARG1~e.18 (a / and
                        :op1 (p / produce-01~e.15
                              :ARG1 m4~e.14
                              :ARG1-of (r / reduce-01~e.13
                                    :degree (g / great~e.12)))
                        :op2 (n3 / number~e.20
                              :ARG1-of (r2 / reduce-01~e.19)
                              :quant-of (m5 / megakaryocyte~e.23
                                    :mod (m3 / mature~e.22)))))))

# ::tok Several transcription factors have also been implicated in megakaryopoiesis including , GATA @-@ 1 , friend of GATA @-@ 1 ( FOG @-@ 1 ) , nuclear factor @-@ erythroid 2 ( NF @-@ E2 ) , and Fli @-@ 1 .
# ::alignments 0-1.1.2 1-1.1.1.1 2-1.1.1.2 4-1.3 6-1 7-1.2.r 8-1.2 9-1.1.3 11-1.1.3.1.1.1.1 11-1.1.3.1.2.1.3 13-1.1.3.1.1.1.1 13-1.1.3.1.2.1.3 13-1.1.3.1.4.1.1 15-1.1.3.1.2.1.1 16-1.1.3.1.2.1.2 17-1.1.3.1.1.1.1 17-1.1.3.1.2.1.3 19-1.1.3.1.1.1.1 19-1.1.3.1.2.1.3 19-1.1.3.1.4.1.1 23-1.1.3.1.1.1.1 23-1.1.3.1.2.1.3 23-1.1.3.1.4.1.1 26-1.1.3.1.3.1.1 27-1.1.3.1.3.1.2 29-1.1.3.1.3.1.2 30-1.1.3.1.3.1.3 37-1.1.3.1 38-1.1.3.1.4.1.1 40-1.1.3.1.1.1.1 40-1.1.3.1.2.1.3 40-1.1.3.1.4.1.1
# ::id bel_pmid_1712_7443_3208
(i / implicate-01~e.6
      :ARG1 (p / protein
            :name (n / name :op1 "transcription"~e.1 :op2 "factor"~e.2)
            :quant (s / several~e.0)
            :ARG2-of (i2 / include-91~e.9
                  :ARG1 (a2 / and~e.37
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "GATA-1"~e.11,13,17,19,23,40))
                        :op2 (p3 / protein
                              :name (n5 / name
                                    :op1 "friend"~e.15
                                    :op2 "of"~e.16
                                    :op3 "GATA-1"~e.11,13,17,19,23,40))
                        :op3 (p4 / protein
                              :name (n3 / name
                                    :op1 "nuclear"~e.26
                                    :op2 "factor-erythroid"~e.27,29
                                    :op3 "2"~e.30))
                        :op4 (p5 / protein
                              :name (n4 / name :op1 "Fli-1"~e.13,19,23,38,40)))))
      :ARG2~e.7 (m / megakaryopoiesis~e.8)
      :mod (a / also~e.4))

# ::tok TPO to c @-@ Mpl ( a receptor tyrosine kinase ) activates both Janus Kinase 2 ( JAK2 ) and Tyk2
# ::alignments 0-1.1.1.1.1 2-1.1.2.1.1 4-1.1.2.1.1 7-1.1.2.2.1.1.1 8-1.1.2.2.1.1.2 9-1.1.2.2.1.1.3 11-1 12-1.3 13-1.2.1.1.1 14-1.2.1.1.2 15-1.2.1.1.3 19-1.2 20-1.2.2.1.1
# ::id bel_pmid_1712_7443_35706
(a / activate-01~e.11
      :ARG0 (a3 / and
            :op1 (e / enzyme
                  :name (n3 / name :op1 "TPO"~e.0))
            :op2 (p3 / protein
                  :name (n4 / name :op1 "c-Mpl"~e.2,4)
                  :ARG1-of (m / mean-01
                        :ARG2 (k / kinase
                              :name (n5 / name
                                    :op1 "receptor"~e.7
                                    :op2 "tyrosine"~e.8
                                    :op3 "kinase"~e.9)))))
      :ARG1 (a2 / and~e.19
            :op1 (e2 / enzyme
                  :name (n / name
                        :op1 "Janus"~e.13
                        :op2 "Kinase"~e.14
                        :op3 "2"~e.15))
            :op2 (e3 / enzyme
                  :name (n2 / name :op1 "Tyk2"~e.20)))
      :mod (b / both~e.12))

# ::tok . Furthermore , the bFGF @-@ induced activation of ERK1 @/@ 2 seems to enhance the transcriptional activity of STAT3. Co @-@ stimulation of KMS @-@ 11 with bFGF and IL @-@ 6 leads to marked expression of STAT3 target genes , such as c @-@ myc and bcl @-@ 2 , further suggesting the relevance of STAT3 phosphorylated at both Tyr705 and Ser727 for the full activation as a transcription factor ( Fig . 5 ) . In addition , the
# ::alignments 4-1.1.1.1.1.2.1.1.1 6-1.1.1.1.1.2 7-1.1.1.1.1 8-1.1.1.1.1.1.r 9-1.1.1.1.1.1.1.1 11-1.1.1.1.1.1.1.1 12-1.1.1 14-1.1.1.1 22-1.2.1 23-1.2.1.1.r 24-1.2.1.1.1.1 26-1.2.1.1.1.1 27-1.2.1.2.r 28-1.2.1.2.1.1.1 29-1.2.1.2 30-1.2.1.2.2.1.1 32-1.2.1.2.2.1.1 33-1.2 34-1.2.2.r 35-1.2.2.2 36-1.2.2 37-1.2.2.1.r 38-1.2.2.1.2.1.1.1 39-1.2.2.1.2 40-1.2.2.1 44-1.2.2.1.1.1.1.1.1 46-1.2.2.1.1.1.1.1.1 47-1.2.2.1.1.1 48-1.2.2.1.1.1.2.1.1 50-1.2.2.1.1.1.2.1.1 52-1.2.3.2 53-1.2.3 55-1.2.3.1 57-1.1.1.1.2.1.1.1 57-1.2.3.1.1.1.1 58-1.2.3.1.1.2.2 64-1.2.3.1.2.r 66-1.2.3.1.2.2 67-1.2.3.1.2 70-1.1.1.1.2.2 70-1.2.3.1.2.1.1 71-1.2.3.1.2.1 75-1.2.4.1.1 78-1.3 79-1.3
# ::id bel_pmid_1714_2955_38942
(m / multi-sentence
      :snt1 (a / and
            :op2 (s / seem-01~e.12
                  :ARG1 (e / enhance-01~e.14
                        :ARG0 (a3 / activate-01~e.7
                              :ARG1~e.8 (e3 / enzyme
                                    :name (n2 / name :op1 "ERK1/2"~e.9,11))
                              :ARG1-of (i / induce-01~e.6
                                    :ARG0 (p3 / protein
                                          :name (n3 / name :op1 "bFGF"~e.4))))
                        :ARG1 (a2 / act-01
                              :ARG0 (p / protein
                                    :name (n / name :op1 "STAT3"~e.57))
                              :ARG1 (t / transcribe-01~e.70)))))
      :snt2 (l / lead-03~e.33
            :ARG0 (s2 / stimulate-01~e.22
                  :ARG1~e.23 (c / cell-line
                        :name (n4 / name :op1 "KMS-11"~e.24,26))
                  :ARG2~e.27 (a4 / and~e.29
                        :op1 (p4 / protein
                              :name (n5 / name :op1 "bFGF"~e.28))
                        :op2 (p5 / protein
                              :name (n6 / name :op1 "IL-6"~e.30,32)))
                  :manner (j / joint))
            :ARG1~e.34 (e2 / express-03~e.36
                  :ARG1~e.37 (g4 / gene~e.40
                        :ARG2-of (i2 / include-91
                              :ARG1 (a5 / and~e.47
                                    :op1 (g2 / gene
                                          :name (n8 / name :op1 "c-myc"~e.44,46))
                                    :op2 (g3 / gene
                                          :name (n9 / name :op1 "bcl-2"~e.48,50))))
                        :ARG1-of (t2 / target-01~e.39
                              :ARG0 (p2 / protein
                                    :name (n7 / name :op1 "STAT3"~e.38))))
                  :ARG1-of (m2 / mark-01~e.35))
            :ARG0-of (s3 / suggest-01~e.53
                  :ARG1 (r / relevant-01~e.55
                        :ARG1 (p6 / protein
                              :name (n10 / name :op1 "STAT3"~e.57)
                              :part (a6 / amino-acid
                                    :name (n11 / name :op1 "tyrosine")
                                    :ARG1-of (p7 / phosphorylate-01~e.58))
                              :part (a7 / amino-acid
                                    :name (n12 / name :op1 "serine")
                                    :ARG1-of p7))
                        :ARG2~e.64 (a9 / activate-01~e.67
                              :ARG1 (f3 / factor~e.71
                                    :ARG0-of (t3 / transcribe-01~e.70))
                              :mod (f2 / full~e.66)))
                  :mod (f / further~e.52))
            :ARG1-of (d / describe-01
                  :ARG0 (f4 / figure :mod "5"~e.75)))
      :snt3 (a10 / and~e.78,79))

# ::tok Expression of PGC @-@ 1?, PEPCK , and glucose @-@ 6 @-@ phosphatase mRNAs were also significantly increased in fasted KO compared with fasted WT livers ( Table 2 ) , consistent with enhanced glucose production in KO livers .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1 5-1.1.1.2.1.1 7-1.1.1 8-1.1.1.3.2.1.1.1 10-1.1.1.3.2.1.1.1 12-1.1.1.3.2.1.1.1 15-1.5 16-1.2 17-1 18-1.3.r 19-1.3.1 21-1.3.2 23-1.3.2.1.1 24-1.3.2.1.2 25-1.3 25-1.3.2.1 27-1.3.3.1 28-1.3.3.1.1 31-1.4 32-1.4.1.r 33-1.4.1.2 34-1.4.1.1 35-1.4.1 38-1.4.1.3
# ::id bel_pmid_1714_3332_29844
(i / increase-01~e.17
      :ARG1 (e / express-03~e.0
            :ARG2~e.1 (a / and~e.7
                  :op1 (p / protein
                        :name (n / name :op1 "PGC-1a"~e.2))
                  :op2 (e2 / enzyme
                        :name (n2 / name :op1 "PEPCK"~e.5))
                  :op3 (r / rna
                        :name (n3 / name :op1 "mrna")
                        :ARG0-of (e3 / encode-01
                              :ARG1 (e5 / enzyme
                                    :name (n4 / name :op1 "glucose-6-phosphatase"~e.8,10,12))))))
      :degree (s / significant~e.16)
      :location~e.18 (l2 / liver~e.25
            :ARG1-of (f / fast-00~e.19)
            :ARG1-of (c / compare-01~e.21
                  :ARG2 (l / liver~e.25
                        :ARG1-of f~e.23
                        :mod (w / wild-type~e.24)))
            :ARG1-of (d / describe-01
                  :ARG0 (t / table~e.27 :mod "2"~e.28))
            :ARG2-of (m / mutate-01 :mod "-/-"))
      :ARG1-of (c2 / consistent-01~e.31
            :ARG2~e.32 (p2 / produce-01~e.35
                  :ARG1 (g / glucose~e.34)
                  :ARG1-of (e4 / enhance-01~e.33)
                  :location l2~e.38))
      :mod (a2 / also~e.15))

# ::tok As analyzed by real @-@ time RT @-@ PCR , levels of SOCS @-@ 3 mRNA and mRNAs of proinflammatory cytokines IL @-@ 1 , IL @-@ 6 , TNF-?, and plasminogen activator inhibitor–1 ( PAI @-@ 1 ) were increased in fasted KO liver ( Table 2 ) .
# ::alignments 1-1.4 2-1.4.1.r 3-1.4.1.2 5-1.4.1.2 6-1.4.1.1.1 8-1.4.1.1.1 10-1.1.1 10-1.1.2 12-1.1.1.1.2.1.1.1 14-1.1.1.1.2.1.1.1 15-1.1.1.1.1.1 15-1.1.2.1.1.1 16-1.1 16-1.1.2.1.2.1 16-1.1.2.1.2.1.1.1.1 21-1.1.2.1.2.1.1.1.1.1.1.1 21-1.1.2.1.2.1.1.1.1.2.1.1 23-1.1.2.1.2.1.1.1.1.1.1.1 25-1.1.2.1.2.1.1.1.1.1.1.1 25-1.1.2.1.2.1.1.1.1.2.1.1 27-1.1.2.1.2.1.1.1.1.2.1.1 30-1.1.2.1.2.1 30-1.1.2.1.2.1.1.1.1 31-1.1.2.1.2.1.2.1.1 32-1.1.2.1.2.1.2.1.2 33-1.1.2.1.2.1.2.1.3 37-1.1.2.1.2.1.1.1.1.1.1.1 40-1 41-1.2.r 42-1.2.1 44-1.2 46-1.3.1 47-1.3.1.1
# ::id bel_pmid_1714_3332_29846
(i / increase-01~e.40
      :ARG1 (a / and~e.16
            :op1 (l2 / level~e.10
                  :quant-of (r2 / rna
                        :name (n / name :op1 "mrna"~e.15)
                        :ARG0-of (e2 / encode-01
                              :ARG1 (p / protein
                                    :name (n2 / name :op1 "SOCS-3"~e.12,14)))))
            :op2 (l3 / level~e.10
                  :quant-of (r3 / rna
                        :name (n3 / name :op1 "mrna"~e.15)
                        :ARG0-of (e3 / encode-01
                              :ARG1 (a2 / and~e.16,30
                                    :op1 (c / cytokine
                                          :ARG2-of (i2 / include-91
                                                :ARG1 (a3 / and~e.16,30
                                                      :op1 (c2 / cytokine
                                                            :name (n4 / name :op1 "IL-1"~e.21,23,25,37))
                                                      :op2 (c3 / cytokine
                                                            :name (n5 / name :op1 "IL-6"~e.21,25,27))
                                                      :op3 (c4 / cytokine
                                                            :name (n7 / name :op1 "TNF-a"))))
                                          :ARG0-of (f2 / favor-01
                                                :ARG1 (i3 / inflame-01)))
                                    :op2 (p2 / protein
                                          :name (n8 / name
                                                :op1 "plasminogen"~e.31
                                                :op2 "activator"~e.32
                                                :op3 "inhibitor–1"~e.33)))))))
      :location~e.41 (l / liver~e.44
            :ARG1-of (f / fast-00~e.42)
            :ARG2-of (m / mutate-01 :mod "-/-"))
      :ARG1-of (d / describe-01
            :ARG0 (t / table~e.46 :mod "2"~e.47))
      :ARG1-of (a4 / analyze-01~e.1
            :ARG0~e.2 (e / event
                  :name (n6 / name :op1 "RT-PCR"~e.6,8)
                  :mod (r / real-time~e.3,5))))

# ::tok In addition , expression of tribbles 3 ( TRB3 ) protein ( Figure 8C ) and mRNA ( Table 2 ) was increased in fasted KO livers .
# ::alignments 0-1.1.1.1 1-1.1.1.1 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1.1.1 6-1.1.1.1.1.1.2 10-1.1.1.1.1 12-1.1.1.1.1.2.1 13-1.1.1.1.1.2.1.1 15-1.1.1.1 16-1.1.1.1.2.1.1 18-1.1.1.1.2.2.1 19-1.1.1.1.2.2.1.1 22-1.1 23-1.1.2.r 24-1.1.2.1 26-1.1.2
# ::id bel_pmid_1714_3332_29848
(a / and
      :op2 (i / increase-01~e.22
            :ARG1 (e / express-03~e.3
                  :ARG2~e.4 (a2 / and~e.0,1,15
                        :op1 (p / protein~e.10
                              :name (n / name :op1 "tribbles"~e.5 :op2 "3"~e.6)
                              :ARG1-of (d / describe-01
                                    :ARG0 (f / figure~e.12 :mod "8C"~e.13)))
                        :op2 (r / rna
                              :name (n2 / name :op1 "mrna"~e.16)
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (t / table~e.18 :mod "2"~e.19)))))
            :location~e.23 (l / liver~e.26
                  :ARG1-of (f2 / fast-00~e.24)
                  :ARG2-of (m / mutate-01 :mod "-/-"))))

# ::tok mTORC2 can be activated by PI3K directly and phosphorylates Akt at S473 , which together with phosphorylation at T308 results in the full activation of Akt [12,13].
# ::alignments 0-1.1.1.2.1.1.1 1-1.1 2-1.1.1.r 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1.1 6-1.1.1.3 6-1.1.1.3.r 7-1 7-1.3.1.1.1 8-1.2 8-1.2.3 9-1.2.3.1.3 15-1.2.3.r 16-1.2 16-1.2.3 19-1.2.4 20-1.2.4.1.r 22-1.2.4.1.2 23-1.2.4.1 24-1.2.4.1.1.r 25-1.2.4.1.1
# ::id bel_pmid_1720_0144_37610
(a / and~e.7
      :op1 (p / possible~e.1
            :domain~e.2 (a2 / activate-01~e.3
                  :ARG0~e.4 (e / enzyme
                        :name (n / name :op1 "PI3K"~e.5))
                  :ARG1 (m / macro-molecular-complex
                        :part (m2 / macro-molecular-complex
                              :name (n2 / name :op1 "mTORC2"~e.0)))
                  :manner~e.6 (d / direct~e.6)))
      :op2 (p3 / phosphorylate-01~e.8,16
            :ARG1 (a3 / amino-acid
                  :mod "473"
                  :name (n4 / name :op1 "serine")
                  :part-of (e2 / enzyme
                        :name (n3 / name :op1 "Akt")))
            :ARG2 m2
            :accompanier~e.15 (p5 / phosphorylate-01~e.8,16
                  :ARG1 (a4 / amino-acid
                        :mod "308"
                        :name (n5 / name :op1 "tyrosine")
                        :part-of e2~e.9))
            :ARG1-of (r / result-01~e.19
                  :ARG2~e.20 (a5 / activate-01~e.23
                        :ARG1~e.24 e2~e.25
                        :mod (f / full~e.22))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 (a6 / and~e.7 :op1 "12" :op2 "13")))))

# ::tok The intracellular signaling induced by IL @-@ 4/IL @-@ 4R interactions on CD4 T cells has been characterized in great detail . The binding of IL @-@ 4 to the Type I receptor in CD4 T cells induces the activation of the nonreceptor tyrosine kinase Jak1 , which promotes the phosphorylation of STAT6 .
# ::alignments 1-1.1.1.1 2-1.1.1 3-1.1.1.2 4-1.1.1.2.1.r 5-1.1.1.2.1.1.1.1 5-1.1.1.2.1.2.1.1 9-1.1.1.2.1.2.1.1 10-1.1.1.2.1 12-1.2.1.3.1.1 13-1.2.1.3.1.2 14-1.1.1.2.1.3 14-1.2.1.3 17-1.1 18-1.1.2.r 19-1.1.2.1 20-1.1.2 23-1.2.1 24-1.2.1.1.r 25-1.2.1.1.1.1 27-1.2.1.1.1.1 28-1.2.1.2.r 30-1.2.1.2.1.1 31-1.2.1.2.1.2 32-1.2.1.2.1.3 34-1.2.1.3.1.1 35-1.2.1.3.1.2 36-1.2.1.3 37-1.2 39-1.2.2 42-1.2.2.1.1.1 43-1.2.2.1.1.2 44-1.2.2.1.1.3 45-1.2.2.1.1.4 48-1.2.2.1.2 50-1.2.2.1.2.1 51-1.2.2.1.2.1.1.r 52-1.2.2.1.2.1.1.1.1
# ::id bel_pmid_1720_0144_38486
(m / multi-sentence
      :snt1 (c / characterize-01~e.17
            :ARG1 (s / signal-07~e.2
                  :mod (i / intracellular~e.1)
                  :ARG1-of (i2 / induce-01~e.3
                        :ARG0~e.4 (i3 / interact-01~e.10
                              :ARG0 (p / protein
                                    :name (n / name :op1 "IL-4"~e.5))
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "IL-4R"~e.5,9))
                              :location (c2 / cell~e.14
                                    :name (n3 / name :op1 "CD4T")))))
            :manner~e.18 (d / detail-01~e.20
                  :degree (g / great~e.19)))
      :snt2 (i4 / induce-01~e.37
            :ARG0 (b / bind-01~e.23
                  :ARG1~e.24 (p3 / protein
                        :name (n4 / name :op1 "IL-4"~e.25,27))
                  :ARG2~e.28 (p4 / protein
                        :name (n5 / name
                              :op1 "Type"~e.30
                              :op2 "I"~e.31
                              :op3 "receptor"~e.32))
                  :location (c3 / cell~e.14,36
                        :name (n6 / name :op1 "CD4"~e.12,34 :op2 "T"~e.13,35)))
            :ARG1 (a / activate-01~e.39
                  :ARG1 (k / kinase
                        :name (n7 / name
                              :op1 "nonreceptor"~e.42
                              :op2 "tyrosine"~e.43
                              :op3 "kinase"~e.44
                              :op4 "Jak1"~e.45)
                        :ARG0-of (p5 / promote-01~e.48
                              :ARG1 (p6 / phosphorylate-01~e.50
                                    :ARG1~e.51 (p7 / protein
                                          :name (n8 / name :op1 "STAT6"~e.52))))))))

# ::tok Marimastat ( 100 mg/kg ) , dexamethasone ( 10 mg/kg ) and rolipram ( 0.3 mg/kg ) reduced significantly IL @-@ 6 , KC/CXCL1 , MIP @-@ 1 alpha @/@ CCL3 and MMP @-@ 9 levels in bronchoalveolar lavage fluid .
# ::alignments 0-1.1.1.1.1 2-1.1.1.2.1 6-1.1.2.1.1 8-1.1.2.2.1 11-1.1 12-1.1.3.1.1 14-1.1.3.2.1 17-1 18-1.3 18-1.3.r 19-1.2.1.1.1.1 21-1.2.1.1.1.1 23-1.2.2.1.1.1 25-1.2.3.1.1.1 30-1.2.3.1.1.1 31-1.2 32-1.2.4.1.1.1 34-1.2.4.1.1.1 35-1.2.1 35-1.2.2 35-1.2.3 35-1.2.4 36-1.4.r 37-1.4.2 38-1.4.1 39-1.4
# ::id bel_pmid_1723_4180_3578
(r / reduce-01~e.17
      :ARG0 (a / and~e.11
            :op1 (s2 / small-molecule
                  :name (n5 / name :op1 "marimastat"~e.0)
                  :quant (c2 / concentration-quantity
                        :quant "100"~e.2
                        :unit (m / milligram-per-kilogram)))
            :op2 (s3 / small-molecule
                  :name (n6 / name :op1 "dexamethasone"~e.6)
                  :quant (c / concentration-quantity
                        :quant "10"~e.8
                        :unit (m2 / milligram-per-kilogram)))
            :op3 (s4 / small-molecule
                  :name (n7 / name :op1 "rolipram"~e.12)
                  :quant (c3 / concentration-quantity
                        :quant "0.3"~e.14
                        :unit (m3 / milligram-per-kilogram))))
      :ARG1 (a2 / and~e.31
            :op1 (l / level~e.35
                  :quant-of (p / protein
                        :name (n / name :op1 "IL-6"~e.19,21)))
            :op2 (l3 / level~e.35
                  :quant-of (p2 / protein
                        :name (n2 / name :op1 "KC/CXCL1"~e.23)))
            :op3 (l4 / level~e.35
                  :quant-of (p3 / protein
                        :name (n3 / name :op1 "MIP-1alpha/CCL3"~e.25,30)))
            :op4 (l5 / level~e.35
                  :quant-of (e2 / enzyme
                        :name (n4 / name :op1 "MMP-9"~e.32,34))))
      :manner~e.18 (s / significant~e.18)
      :location~e.36 (f / fluid~e.39
            :mod (l2 / lavage~e.38)
            :mod (b / bronchoalveolar~e.37)))

# ::tok Nox1 and Nox4 mRNAs were upregulated in H @-@ RasV12 @-@ transformed p38??/? MEFs , suggesting that these two NOX family members may be involved in H @-@ RasV12 @-@ induced ROS production in fibroblasts ( Figure S5B ) .
# ::alignments 0-1.1.1.2.1.1 1-1.1 2-1.1.2.2.1.1 3-1.1.1.1.1 3-1.1.2.1.1 4-1.2.1.1.r 7-1.4.3.1 11-1.4.3 15-1.2 18-1.2.1.1.1.1 19-1.2.1.1.1.2.1.1.1 20-1.2.1.1.1.2 21-1.2.1.1.1 22-1.2.1 23-1.2.1.1.r 24-1.2.1.1 25-1.2.1.1.2.r 26-1.2.1.1.2.2.1.1.1 30-1.2.1.1.2.2 31-1.2.1.1.2.1.1.1 32-1.2.1.1.2 36-1.3.1 37-1.3.1.1
# ::id bel_pmid_1729_2829_29076
(u / upregulate-01
      :ARG1 (a / and~e.1
            :op1 (r / rna
                  :name (n4 / name :op1 "mRNA"~e.3)
                  :part-of (e / enzyme
                        :name (n6 / name :op1 "Nox1"~e.0)))
            :op2 (r2 / rna
                  :name (n5 / name :op1 "mRNA"~e.3)
                  :part-of (e2 / enzyme
                        :name (n7 / name :op1 "Nox4"~e.2))))
      :ARG0-of (s / suggest-01~e.15
            :ARG1 (p / possible~e.22
                  :domain~e.4,23 (i / involve-01~e.24
                        :ARG1 (m / member~e.21
                              :quant "2"~e.18
                              :part-of (f / family~e.20
                                    :mod (e3 / enzyme
                                          :name (n / name :op1 "NOX"~e.19)))
                              :ARG1-of (m4 / mean-01
                                    :ARG2 a))
                        :ARG2~e.25 (p2 / produce-01~e.32
                              :ARG1 (m2 / molecular-physical-entity
                                    :name (n2 / name :op1 "ROS"~e.31))
                              :ARG1-of (i2 / induce-01~e.30
                                    :ARG0 (e4 / enzyme
                                          :name (n3 / name :op1 "H-Ras"~e.26)
                                          :ARG2-of (m3 / mutate-01 :value "V12")))))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.36 :mod "S5B"~e.37))
      :location (c / cell
            :name (n8 / name :op1 "MEF")
            :mod (p3 / protein
                  :name (n9 / name :op1 "p38"))
            :ARG1-of (t2 / transform-01~e.11
                  :ARG0 e4~e.7)))

# ::tok Papillary adenomas ( 1.2.1.2.2 ) were detected 6–8 wk after BRafVE expression and appeared to increase in number and size . These lesions were bronchiolocentric , but did not appear to involve the terminal bronchioles . Rather , the lesions appeared to arise in alveolar ducts and expand outward and around bronchioles ( Fig . 4B ) .
# ::alignments 0-1.1.1.1.1 1-1.1.1.1 3-1.1.1.1.2.1 6-1.1.1 9-1.1.1.2 11-1.1.1.2.1 12-1.1 12-1.1.1.2.2 13-1.1.2 15-1.1.2.1 16-1.1.2.1.1.r 17-1.1.2.1.1.1 18-1.1.2.1.1 19-1.1.2.1.1.2 21-1.3.1.1.1 22-1.3.1.1 23-1.3.1.1.r 24-1.3.1 26-1.3 28-1.3.2.1 28-1.3.2.1.r 29-1.3.2 31-1.3.2.2 33-1.3.2.2.1.1 34-1.3.2.2.1 36-1.4.2 39-1.4.1.1.1 40-1.4 42-1.4.1.1 43-1.4.1.1.2.r 44-1.4.1.1.2.1 45-1.4.1.1.2 46-1.4.1 47-1.4.1.2 48-1.4.1.2.2.1 49-1.4.1.2.2 50-1.4.1.2.2.2 51-1.4.1.2.2.1.1 55-1.2.1.1 55-1.5.1.1
# ::id bel_pmid_1729_9132_25542
(m / multi-sentence
      :snt1 (a / and~e.12
            :op1 (d / detect-01~e.6
                  :ARG1 (a3 / adenoma~e.1
                        :mod (p / papilla~e.0)
                        :ARG1-of (l2 / label-01 :ARG2 "1.2.1.2.2"~e.3))
                  :time (a4 / after~e.9
                        :op1 (e / express-03~e.11
                              :ARG2 (e2 / enzyme
                                    :name (n / name :op1 "BRaf")
                                    :ARG2-of (m2 / mutate-01 :value "VE")))
                        :quant (b5 / between~e.12
                              :op1 (t / temporal-quantity
                                    :quant "6"
                                    :unit (w / week))
                              :op2 (t3 / temporal-quantity
                                    :quant "8"
                                    :unit (w2 / week)))))
            :op2 (a2 / appear-02~e.13
                  :ARG1 (i / increase-01~e.15
                        :ARG1~e.16 (a12 / and~e.18
                              :op1 (n2 / number~e.17
                                    :quant-of a3)
                              :op2 (s / size~e.19
                                    :poss-of a3)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4B"~e.55))
      :snt2 (c / contrast-01~e.26
            :ARG1 (b / bronchiolocentric~e.24
                  :domain~e.23 (l / lesion~e.22
                        :mod (t5 / this~e.21)))
            :ARG2 (a5 / appear-02~e.29
                  :polarity~e.28 "-"~e.28
                  :ARG1 (i2 / involve-01~e.31
                        :ARG1 (b3 / bronchiole~e.34
                              :mod (t2 / terminus~e.33))
                        :ARG2 l)))
      :snt3 (a6 / appear-02~e.40
            :ARG1 (a8 / and~e.46
                  :op1 (a7 / arise-01~e.42
                        :ARG1 (l3 / lesion~e.39)
                        :location~e.43 (d3 / duct~e.45
                              :part-of (a9 / alveolus~e.44)))
                  :op2 (e3 / expand-01~e.47
                        :ARG1 l3
                        :location (a10 / and~e.49
                              :op1 (o / outward~e.48
                                    :op1 (b4 / bronchiole~e.51))
                              :op2 (a11 / around~e.50
                                    :op1 b4))))
            :mod (r / rather~e.36))
      :ARG1-of (d4 / describe-01
            :ARG0 (f2 / figure :mod "4B"~e.55)))

# ::tok At early times after induced BRafVE expression , we detected evidence of epithelial hyperplasia ( classified as 1.1.1.1 ) arising within the terminal bronchioles and within the central lung parenchyma .
# ::alignments 1-1.3.1 2-1.3 2-1.3.2.r 2-1.3.r 3-1.3.2 4-1.3.2.1.2 5-1.3.2.1.1.1.1 6-1.3.2.1 8-1.1 9-1 10-1.2 11-1.2.1.r 12-1.2.1.1 13-1.2.1 15-1.2.1.3 16-1.3.r 17-1.2.1.3.1 19-1.2.1.2 22-1.2.1.2.1.1.1 23-1.2.1.2.1.1 24-1.2.1.2.1 27-1.2.1.2.1.2.1.1 28-1.2.1.2.1.2.1 29-1.2.1.2.1.2
# ::id bel_pmid_1729_9132_25544
(d / detect-01~e.9
      :ARG0 (w / we~e.8)
      :ARG1 (e / evidence-01~e.10
            :ARG1~e.11 (h / hyperplasia~e.13
                  :mod (e2 / epithelium~e.12)
                  :ARG1-of (a / arise-01~e.19
                        :ARG2 (a2 / and~e.24
                              :op1 (b / bronchiole~e.23
                                    :mod (t / terminal~e.22))
                              :op2 (p / parenchyma~e.29
                                    :mod (l / lung~e.28
                                          :mod (c / central~e.27)))))
                  :ARG1-of (c2 / classify-01~e.15 :ARG2 "1.1.1.1"~e.17)))
      :time~e.2,16 (t2 / time~e.2
            :mod (e3 / early~e.1)
            :time~e.2 (a3 / after~e.3
                  :op1 (e4 / express-03~e.6
                        :ARG2 (e5 / enzyme
                              :name (n / name :op1 "BRafVE"~e.5)
                              :ARG2-of (m / mutate-01 :value "VE"))
                        :ARG1-of (i / induce-01~e.4)))))

# ::tok the majority of cells within BRafVE @-@ induced tumors expressed SP @-@ C , suggesting that they have properties of ATII pneumocytes ( Fig . 2K , L ) .
# ::alignments 1-1.2.1 2-1.2.1.r 3-1.2 3-1.2.2.1 7-1.2.2.1.1.1 8-1.2.2.1.1 9-1 10-1.1.1.1 12-1.1.1.1 14-1.3 15-1.3.1.r 16-1.3.1.1 17-1.3.1 18-1.3.1.2 19-1.3.1.2.1.r 20-1.3.1.2.1.1 21-1.3.1.2.1 25-1.4.1.1.1
# ::id bel_pmid_1729_9132_25548
(e / express-03~e.9
      :ARG2 (p5 / protein
            :name (n4 / name :op1 "SP-C"~e.10,12))
      :ARG3 (c2 / cell~e.3
            :quant~e.2 (m / majority~e.1)
            :ARG1-of (i / include-91
                  :ARG2 (c3 / cell~e.3
                        :location (t / tumor~e.8
                              :ARG1-of (i2 / induce-01~e.7
                                    :ARG0 (e2 / enzyme
                                          :name (n2 / name :op1 "Braf")
                                          :ARG2-of (m2 / mutate-01 :value "VE")))))))
      :ARG0-of (s / suggest-01~e.14
            :ARG1~e.15 (h / have-03~e.17
                  :ARG0 c2~e.16
                  :ARG1 (p / property~e.18
                        :poss~e.19 (p2 / pneumocytes~e.21
                              :mod (a2 / ATII~e.20)))))
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (f / figure :mod "2K"~e.25)
                  :op2 (f2 / figure :mod "2L"))))

# ::tok It is reported that KRasG12D @-@ induced lung tumors do not routinely display elevated pERK1 @/@ 2 but display stress @-@ activated MAP kinase ( SAPK/JNK ) activation ( Lee et al. 2002 ) ... Interestingly , the major difference appears to be that expression of KRasG12D in the lung leads to more rapid and consistent progression to adenocarcinoma than that elicited by BRafVE .
# ::alignments 2-1.2 6-1.2.1.1.2.1.1 7-1.2.1.1.2.1 8-1.2.1.1.2 10-1.2.1.1.1 10-1.2.1.1.1.r 11-1.2.1.1.4 11-1.2.1.1.4.r 12-1.2.1.1 13-1.2.1.1.3.2 16-1.2.1.1.3.1.1 17-1.2.1 18-1.2.1.2 19-1.2.1.2.1.1.2.1 21-1.2.1.2.1 21-1.2.1.2.1.1.2 22-1.2.1.2.1.1.1.1 23-1.2.1.2.1.1.1.2 25-1.2.1.2.1.1.3.1.1.1 27-1.2.1.2.1.1.2 29-1.2.2.1.1.1.1.1 30-1.2.2.1.1 31-1.2.2.1.1.2.1 32-1.2.2.2.1 38-1.1.1.3 39-1.1.1 40-1.1 43-1.1.1.1.r 44-1.1.1.1.1 47-1.1.1.1.1.2.r 49-1.1.1.1.1.2 50-1.1.1.1 51-1.1.1.1.2.r 52-1.1.1.1.2.2.1 53-1.1.1.1.2.2 55-1.1.1.1.2.3 56-1.1.1.1.2 56-1.1.1.2 57-1.1.1.1.2.1.r 58-1.1.1.1.2.1 61-1.1.1.2.2
# ::id bel_pmid_1729_9132_28748
(m / multi-sentence
      :snt2 (a / appear-01~e.40
            :ARG1 (d / differ-02~e.39
                  :ARG1~e.43 (l2 / lead-03~e.50
                        :ARG0 (e2 / express-03~e.44
                              :ARG2 (e6 / enzyme
                                    :name (n2 / name :op1 "KRAS")
                                    :ARG2-of (m3 / mutate-01 :value "G12D"))
                              :ARG3~e.47 (l / lung~e.49))
                        :ARG2~e.51 (p / progress-01~e.56
                              :ARG4~e.57 (a3 / adenocarcinoma~e.58)
                              :mod (r / rapid~e.53
                                    :degree (m5 / more~e.52))
                              :mod (c / consistent~e.55
                                    :degree m5)))
                  :ARG2 (p6 / progress-01~e.56
                        :ARG4 a3
                        :ARG1-of (e3 / elicit-01~e.61
                              :ARG0 (e4 / enzyme
                                    :name (n / name :op1 "Braf")
                                    :ARG2-of (m6 / mutate-01 :value "VE"))))
                  :mod (m2 / major~e.38))
            :ARG2-of (i / interest-01))
      :snt1 (r2 / report-01~e.2
            :ARG1 (c3 / contrast-01~e.17
                  :ARG1 (d4 / display-01~e.12
                        :polarity~e.10 "-"~e.10
                        :ARG0 (t / tumor~e.8
                              :location (l4 / lung~e.7
                                    :ARG1-of (i2 / induce-01~e.6
                                          :ARG0 (e7 / enzyme
                                                :name (n4 / name :op1 "KRAS")
                                                :ARG1-of (m4 / mutate-01 :value "G12D")))))
                        :ARG1 (p4 / pathway
                              :name (n5 / name :op1 "ERK1/2"~e.16)
                              :ARG1-of (e5 / elevate-01~e.13))
                        :manner~e.11 (r3 / routine~e.11))
                  :ARG2 (d5 / display-01~e.18
                        :ARG1 (a5 / activate-01~e.21
                              :ARG1 (p9 / pathway
                                    :name (n8 / name :op1 "MAP"~e.22 :op2 "kinase"~e.23)
                                    :ARG1-of (a6 / activate-01~e.21,27
                                          :ARG0 (s / stress~e.19))
                                    :ARG1-of (m7 / mean-01
                                          :ARG2 (p7 / pathway
                                                :name (n7 / name :op1 "SAPK/JNK"~e.25)))))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p5 / publication-91
                        :ARG0 (a2 / and~e.30
                              :op1 (p2 / person
                                    :name (n3 / name :op1 "Lee"~e.29))
                              :op2 (p3 / person
                                    :mod (o / other~e.31))))
                  :time (d3 / date-entity :year "2002"~e.32))))

# ::tok from full text - As shown in Fig. 1A , ERK1 @/@ 2 in wild @-@ type MEFs is phosphorylated after IGF @-@ 1 stimulation with a peak at 5–10 min , after which pERK declined substantially . In b @-@ arrestin1 KO MEFs , on the other hand , ERK1 @/@ 2 remained essentially inactivated upon IGF @-@ 1 stimulation ( Fig . 1A ) .
# ::alignments 0-1.2.r 1-1.2.1 2-1.2 5-1.3.1.2 8-1.3.1.2.1.1 10-1.3.1.1.1.1 12-1.3.1.1.1.1 14-1.3.1.3.2 16-1.3.1.3.2 19-1.3.1 19-1.3.2.1.2 20-1.3.1.4 21-1.3.1.4.1.1.1.1 23-1.3.1.4.1.1.1.1 24-1.3.1.4.1 25-1.3.1.5.r 27-1.3.1.5 32-1.3.2.3 35-1.3.2 36-1.3.2.2 39-1.1.1.4.2.1.1 41-1.1.1.4.2.1.1 50-1.1.1.1.2.1.1 52-1.1.1.1.2.1.1 53-1.1.1 54-1.1.1.2 54-1.1.1.2.r 55-1.1.1.1.1 57-1.1.1.1.3.1.1.1 59-1.1.1.1.3.1.1.1 60-1.1.1.1.3 64-1.1.1.3.1.1
# ::id bel_pmid_1730_3558_25228
(m / multi-sentence
      :snt2 (c3 / contrast-01
            :ARG2 (r / remain-01~e.53
                  :ARG1 (a / activate-01
                        :polarity "-"~e.55
                        :ARG1 (e2 / enzyme
                              :name (n / name :op1 "ERK1/2"~e.50,52))
                        :time (s / stimulate-01~e.60
                              :ARG0 (p3 / protein
                                    :name (n2 / name :op1 "IGF-1"~e.57,59))))
                  :manner~e.54 (e / essential~e.54)
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure :mod "1A"~e.64))
                  :location (c / cell-line
                        :name (n8 / name :op1 "MEF")
                        :mod (p4 / protein
                              :name (n3 / name :op1 "b-arrestin1"~e.39,41)
                              :ARG2-of (m4 / mutate-01 :value "-/-")))))
      :source~e.0 (t2 / text~e.2
            :mod (f3 / full~e.1))
      :snt1 (a3 / and
            :op1 (p / phosphorylate-01~e.19
                  :ARG1 (e3 / enzyme
                        :name (n7 / name :op1 "ERK1/2"~e.10,12))
                  :ARG1-of (s2 / show-01~e.5
                        :ARG0 (f2 / figure :mod "1A"~e.8))
                  :location (c2 / cell-line
                        :name (n4 / name :op1 "MEF")
                        :mod (w / wild-type~e.14,16))
                  :time (a2 / after~e.20
                        :op1 (s3 / stimulate-01~e.24
                              :ARG0 (p5 / protein
                                    :name (n5 / name :op1 "IGF-1"~e.21,23))))
                  :ARG1-of~e.25 (p6 / peak-01~e.27
                        :time (b / between
                              :op1 (t / temporal-quantity
                                    :quant "5"
                                    :unit (m2 / minute))
                              :op2 (t3 / temporal-quantity
                                    :quant "10"
                                    :unit (m3 / minute)))))
            :op2 (d2 / decline-01~e.35
                  :ARG1 (e4 / enzyme
                        :name (n6 / name :op1 "ERK")
                        :ARG1-of (p2 / phosphorylate-01~e.19))
                  :degree (s4 / substantial~e.36)
                  :time (a4 / after~e.32
                        :op1 p6))))

# ::tok from full text - Similarly , we find that both b @-@ arrestin1 and 2 are ubiquitinated in IGF @-@ 1 @-@ stimulated WT MEF cells .
# ::alignments 0-1.4.r 1-1.4.1 2-1.4 4-1.3 6-1.1 7-1 10-1.2.1.1.1.1 10-1.2.1.2.1.1 12-1.2.1.1.1.1 13-1.2.1 16-1.2 17-1.2.2.r 18-1.2.2.3.1.1.1 20-1.2.2.3.1.1.1 22-1.2.2.3 23-1.2.2.2 24-1.2.2.1.1 25-1.2.2
# ::id bel_pmid_1730_3558_27774
(f / find-01~e.7
      :ARG0 (w / we~e.6)
      :ARG1 (u / ubiquitinate-01~e.16
            :ARG1 (a / and~e.13
                  :op1 (p / protein
                        :name (n / name :op1 "b-arrestin1"~e.10,12))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "b-arrestin2"~e.10)))
            :location~e.17 (c / cell~e.25
                  :name (n3 / name :op1 "MEF"~e.24)
                  :mod (w2 / wild-type~e.23)
                  :ARG1-of (s / stimulate-01~e.22
                        :ARG0 (p3 / protein
                              :name (n4 / name :op1 "IGF-1"~e.18,20)))))
      :ARG1-of (r / resemble-01~e.4)
      :source~e.0 (t / text~e.2
            :mod (f2 / full~e.1)))

# ::tok the preincubation of RAW264.7 cells with a specific PPARalpha agonist , K @-@ 111 ( 2,2 @-@ dichloro @-@ 12-( 4 @-@ chlorophenyl ) dodecanoic acid ) . K @-@ 111 reduced both the IL @-@ 6 production and mRNA expression in RAW264.7 cells
# ::alignments 3-1.1.1.1.1 4-1.1.1 7-1.1.2.3 8-1.1.2.2.1.1 9-1.1.2 9-1.2.1 11-1.1.2.1.1 11-1.2.1.1.1 13-1.1.2.1.1 13-1.2.1.1.1 15-1.2.1.2.1.1.1 17-1.2.1.2.1.1.1 25-1.2.1.2.1.1.2 28-1.2.1.1.1 30-1.2.1.1.1 31-1.2 34-1.2.2.1.1.1.1 36-1.2.2.1.1.1.1 37-1.2.2.1 38-1.2.2 39-1.2.2.2.1.1.1 40-1.2.2.2 42-1.1.1.1.1 42-1.2.2.2.2.1.1 43-1.1.1 43-1.2.2.2.2
# ::id bel_pmid_1732_0860_11808
(m / multi-sentence
      :snt1 (p4 / preincubate-00
            :ARG1 (c / cell-line~e.4,43
                  :name (n / name :op1 "RAW264.7"~e.3,42))
            :ARG2 (a / agonist~e.9
                  :name (n3 / name :op1 "K-111"~e.11,13)
                  :mod (p / protein
                        :name (n2 / name :op1 "PPARalpha"~e.8))
                  :mod (s / specific~e.7)))
      :snt2 (r / reduce-01~e.31
            :ARG0 (a2 / agonist~e.9
                  :name (n4 / name :op1 "K-111"~e.11,13,28,30)
                  :ARG1-of (m2 / mean-01
                        :ARG2 (m3 / molecular-physical-entity
                              :name (n8 / name :op1 "2,2-dichloro-12-(4-chlorophenyl)dodecanoic"~e.15,17 :op2 "acid"~e.25))))
            :ARG1 (a3 / and~e.38
                  :op1 (p2 / produce-01~e.37
                        :ARG1 (p3 / protein
                              :name (n5 / name :op1 "IL-6"~e.34,36)))
                  :op2 (e / express-03~e.40
                        :ARG1 (r2 / rna
                              :name (n6 / name :op1 "mRNA"~e.39))
                        :ARG3 (c2 / cell-line~e.43
                              :name (n7 / name :op1 "RAW264.7"~e.42))))))

# ::tok Since activation of NF @-@ B in A549 cells is dependent on IKK2 , which phosphorylates serines 32 and 36 of IB as a prelude to IB degradation and activation of NF @-@ B ( Catley et al. , 2005
# ::alignments 0-1.2.2.2.r 1-1.1 2-1.1.1.r 3-1.1.1.1.1 5-1.1.1.1.1 7-1.1.1.2.1.1 8-1.1.1.2 10-1 12-1.2.1.1 15-1.2 15-1.2.2 15-1.2.2.r 16-1.2.2.1.1.2.1 16-1.2.2.1.2.2.1 17-1.2.2.1.1.1 18-1.2.2.1 19-1.2.2.1.2.1 20-1.2.2.1.r 21-1.2.2.1.3.1.1 22-1.3.2.r 24-1.2.2.2 25-1.2.2.2.1.r 26-1.2.2.2.1.1.1 27-1.2.2.2.1.1 28-1.2.2.2.1 29-1.2.2.2.1.2 30-1.2.2.2.1.2.1.r 31-1.2.2.2.1.2.1 32-1.2.2.2.1.2.1 33-1.2.2.2.1.2.1 35-1.3.1.1.1.1.1 36-1.3.1.1 37-1.3.1.1.2.1 39-1.3.2.1
# ::id bel_pmid_1732_2026_36370
(d / depend-01~e.10
      :ARG0 (a / activate-01~e.1
            :ARG1~e.2 (p / protein
                  :name (n / name :op1 "NF-B"~e.3,5)
                  :location (c / cell~e.8
                        :name (n2 / name :op1 "A549"~e.7))))
      :ARG1 (e / enzyme~e.15
            :name (n3 / name :op1 "IKK2"~e.12)
            :ARG2-of~e.15 (p3 / phosphorylate-01~e.15
                  :ARG1~e.20 (a2 / and~e.18
                        :op1 (a6 / amino-acid
                              :mod "32"~e.17
                              :name (n6 / name :op1 "serine"~e.16))
                        :op2 (a7 / amino-acid
                              :mod "36"~e.19
                              :name (n7 / name :op1 "serine"~e.16))
                        :part-of (e2 / enzyme
                              :name (n4 / name :op1 "IB"~e.21)))
                  :purpose~e.0 (p4 / prelude~e.24
                        :prep-to~e.25 (a3 / and~e.28
                              :op1 (d2 / degrade-01~e.27
                                    :ARG1 e2~e.26)
                              :op2 (a4 / activate-01~e.29
                                    :ARG1~e.30 p~e.31,32,33)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a5 / and~e.36
                        :op1 (p5 / person
                              :name (n5 / name :op1 "Catley"~e.35))
                        :op2 (p6 / person
                              :mod (o / other~e.37))))
            :time~e.22 (d4 / date-entity :year "2005"~e.39)))

# ::tok Thus , IL @-@ 6 release was substantially increased by both IL @-@ 1 and to a lesser extent by TNF . In each case , prior infection with the null adenovirus showed no significant effect , whereas dominant IBN reduced IL @-@ 6 release to near @-@ background levels . Likewise , the dominant @-@ negative IKK2 adenovirus prevented IL @-@ 6 release
# ::alignments 0-1.3 2-1.3.1.1.2.1.1.1 4-1.3.1.1.2.1.1.1 5-1.3.1.1.2 7-1.3.1.1.3 8-1.3.1.1 8-1.3.1.2 11-1.3.1.1.1.1.1 11-1.3.1.1.2.1.1.1 13-1.3.1.1.1.1.1 14-1.3.1 15-1.3.1.2.3.r 17-1.3.1.2.3 17-1.3.1.2.3.1 17-1.3.1.2.3.1.r 19-1.3.1.2.1.r 20-1.3.1.2.1.1.1 22-1.2.1.3.r 23-1.2.1.3.1 24-1.2.1.3 26-1.2.1.1.2 27-1.2.1.1 31-1.2.1.1.1 32-1.2.1 33-1.2.1.2.1 33-1.2.1.2.1.r 34-1.2.1.2.2 35-1.2.1.2 37-1.2 38-1.2.2.1 38-1.2.2.1.2 38-1.2.2.1.2.r 39-1.2.2.1.1.1 40-1.2.2 41-1.2.2.2.1.1.1 43-1.2.2.2.1.1.1 44-1.2.2.2 45-1.2.2.3.r 46-1.2.2.3 48-1.2.2.3.1.1 49-1.2.2.3.1 51-1.1.3 54-1.1.1.1 54-1.1.1.1.2 54-1.1.1.1.2.r 56-1.1.1.1.3 57-1.1.1.1.1.1 58-1.1.1 59-1.1 60-1.1.2.1.1.1 62-1.1.2.1.1.1 63-1.1.2
# ::id bel_pmid_1732_2026_38418
(m / multi-sentence
      :snt3 (p / prevent-01~e.59
            :ARG0 (a / adenovirus~e.58
                  :mod (e2 / enzyme~e.54
                        :name (n / name :op1 "IKK2"~e.57)
                        :ARG0-of~e.54 (d2 / dominate-01~e.54)
                        :mod (n9 / negative~e.56)))
            :ARG1 (r / release-01~e.63
                  :ARG1 (p2 / protein
                        :name (n10 / name :op1 "IL-6"~e.60,62)))
            :manner (l3 / likewise~e.51))
      :snt2 (c2 / contrast-01~e.37
            :ARG1 (s / show-01~e.32
                  :ARG0 (i2 / infect-01~e.27
                        :ARG0 (a2 / adenovirus~e.31
                              :ARG2-of (m3 / mutate-01 :mod "-/-"))
                        :time (p3 / prior~e.26))
                  :ARG1 (a3 / affect-01~e.35
                        :polarity~e.33 "-"~e.33
                        :mod (s3 / significant~e.34))
                  :prep-in~e.22 (c / case~e.24
                        :mod (e / each~e.23)))
            :ARG2 (r3 / reduce-01~e.40
                  :ARG0 (m5 / molecular-physical-entity~e.38
                        :name (n2 / name :op1 "IBN"~e.39)
                        :ARG0-of~e.38 (d / dominate-01~e.38))
                  :ARG1 (r4 / release-01~e.44
                        :ARG1 (p4 / protein
                              :name (n3 / name :op1 "IL-6"~e.41,43)))
                  :ARG4~e.45 (n4 / near~e.46
                        :op1 (l / level~e.49
                              :mod (b / background~e.48)))))
      :snt1 (c3 / cause-01~e.0
            :ARG1 (a4 / and~e.14
                  :op1 (i / increase-01~e.8
                        :ARG0 (p6 / protein
                              :name (n6 / name :op1 "IL-1"~e.11,13))
                        :ARG1 (r5 / release-01~e.5
                              :ARG1 (p5 / protein
                                    :name (n5 / name :op1 "IL-6"~e.2,4,11)))
                        :ARG2 (s2 / substantial~e.7))
                  :op2 (i3 / increase-01~e.8
                        :ARG0~e.19 (p7 / protein
                              :name (n7 / name :op1 "TNF"~e.20))
                        :ARG1 r5
                        :ARG2~e.15 (l2 / less~e.17
                              :degree~e.17 (m4 / more~e.17))))))

# ::tok Similar levels of RANTES and MCP @-@ 1 release were induced by IL @-@ 1 and TNF treatments . However , the induction of IL @-@ 6 , IL @-@ 8 , and GMCSF by TNF was 50 to 80 % lower than for IL @-@ 1 , whereas TNF @-@ induced GRO was some 35 @- to 40 @-@ fold lower than that for IL @-@ 1. In all instances , preincubation with PS @-@ 1145 or ML120B resulted in a significant attenuation of cytokine release ( Fig . 6 ) .
# ::alignments 0-1.1.2.1.2 1-1.1.2.1 1-1.1.2.1.2.1 2-1.1.2.1.1.r 3-1.1.2.1.1.1.1 5-1.1.2.1.2.1.1.1.1 7-1.1.1.2.1.1.1 7-1.1.2.1.2.1.1.1.1 8-1.1.2.1.2.1.1 8-1.1.2.1.2.1.1.2 8-1.1.2.1.2.1.1.2.r 10-1.1 11-1.1.1.r 12-1.1.1.2.1.1.1 14-1.1.1.2.1.1.1 14-1.1.2.1.2.1.1.1.1 15-1.1.1 16-1.1.1.1.1.1.1 17-1.1.1.1 17-1.1.1.2 19-1.2 19-1.2.3 19-1.2.3.r 22-1.2.2.1.2 24-1.2.1.1.2.1.1.1 24-1.2.1.1.2.2.1.1 26-1.2.1.1.2.1.1.1 28-1.2.1.1.2.1.1.1 28-1.2.1.1.2.2.1.1 30-1.2.1.1.2.2.1.1 32-1.2.1.1.2 33-1.2.1.1.2.3.1.1 35-1.2.1.1.1.1.1 37-1.2.1.2.1.1 39-1.2.1.2.2.1 40-1.2.1.2.1 40-1.2.1.2.2 40-1.2.2.2.1 40-1.2.2.2.2 41-1.2.1 41-1.2.2 42-1.2.1.3.r 42-1.2.2.3.r 44-1.2.1.1.2.1.1.1 44-1.2.1.3.2.1.1 46-1.2.1.3.2.1.1 48-1.2 48-1.2.3 48-1.2.3.r 49-1.2.2.1.2.1 51-1.2.2.1.2 52-1.2.2.1.1.1 55-1.2.2.2.1.1 58-1.2.2.2.2.1 61-1.2.1 62-1.2.1.3.r 65-1.1.1.2.1.1.1 65-1.2.1.3.2.1.1 68-1.3.3.r 69-1.3.3.1 70-1.3.3 74-1.3.1.1.1.1.1 76-1.3.1.1.1.1.1 77-1.3.1.1 78-1.3.1.1.2.1.1 79-1.3 80-1.3.2.r 80-1.3.3.r 82-1.3.2.2 83-1.3.2 84-1.3.2.1.r 85-1.3.2.1.1 86-1.3.2.1 90-1.4.1.1
# ::id bel_pmid_1732_2026_39144
(m2 / multi-sentence
      :snt1 (i / induce-01~e.10
            :ARG0~e.11 (a / and~e.15
                  :op1 (t / treat-04~e.17
                        :ARG2 (p2 / protein
                              :name (n / name :op1 "TNF"~e.16)))
                  :op2 (t2 / treat-04~e.17
                        :ARG2 (p3 / protein
                              :name (n2 / name :op1 "IL-1"~e.7,12,14,65))))
            :ARG1 (a2 / and
                  :op1 (l2 / level~e.1
                        :quant-of~e.2 (e / enzyme
                              :name (n3 / name :op1 "RANTES"~e.3)
                              :ARG1-of (r2 / release-01~e.8))
                        :ARG1-of (r3 / resemble-01~e.0
                              :ARG2 (l3 / level~e.1
                                    :quant-of (p4 / protein~e.8
                                          :name (n4 / name :op1 "MCP-1"~e.5,7,14)
                                          :ARG1-of~e.8 r2))))))
      :snt2 (c / contrast-01~e.19,48
            :ARG1 (l / lower-05~e.41,61
                  :ARG1 (i2 / induct-01
                        :ARG0 (p9 / protein
                              :name (n8 / name :op1 "TNF"~e.35))
                        :ARG1 (a3 / and~e.32
                              :op1 (p6 / protein
                                    :name (n5 / name :op1 "IL-6"~e.24,26,28,44))
                              :op2 (p7 / protein
                                    :name (n6 / name :op1 "IL-8"~e.24,28,30))
                              :op3 (p8 / protein
                                    :name (n7 / name :op1 "GMCSF"~e.33))))
                  :ARG2 (b / between
                        :op1 (p5 / percentage-entity~e.40 :value "50"~e.37)
                        :op2 (p / percentage-entity~e.40 :value "80"~e.39))
                  :compared-to~e.42,62 (i5 / induct-01
                        :ARG0 p9
                        :ARG1 (p10 / protein
                              :name (n9 / name :op1 "IL-1"~e.44,46,65))))
            :ARG2 (l4 / lower-05~e.41
                  :ARG1 (e2 / enzyme
                        :name (n10 / name :op1 "GRO"~e.52)
                        :ARG1-of (i3 / induce-01~e.22,51
                              :ARG0 p9~e.49))
                  :ARG2 (b2 / between
                        :op1 (p11 / percentage-entity~e.40 :value "35"~e.55)
                        :op2 (p12 / percentage-entity~e.40 :value "40"~e.58))
                  :compared-to~e.42 i5)
            :ARG2-of~e.19,48 (c2 / contrast-01~e.19,48))
      :snt3 (r / result-01~e.79
            :ARG1 (p15 / preincubate-00
                  :ARG2 (o / or~e.77
                        :op1 (m / molecular-physical-entity
                              :name (n11 / name :op1 "PS-1145"~e.74,76))
                        :op2 (s2 / small-molecule
                              :name (n12 / name :op1 "ML120B"~e.78))))
            :ARG2~e.80 (a5 / attenuate-01~e.83
                  :ARG1~e.84 (r4 / release-01~e.86
                        :ARG1 (c3 / cytokine~e.85))
                  :mod (s / significant~e.82))
            :prep-in~e.68,80 (i6 / instance~e.70
                  :mod (a4 / all~e.69)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6"~e.90)))

# ::tok Exposure of CD40L enhanced the constitutive production of IL @-@ 6 and MCP @-@ 1 protein ( Figure 4A and 4B ) .
# ::alignments 0-1.1 2-1.1.1.1.1 3-1 5-1.2.2 6-1.2 7-1.2.1.r 8-1.2.1.1.1.1 10-1.2.1.1.1.1 11-1.2.1 12-1.2.1.2.1.1 14-1.2.1.2.1.1 15-1.1.1 15-1.2.1.1 15-1.2.1.2 17-1.3.1.1 17-1.3.1.2 18-1.3.1.1.1.1 19-1.3.1 20-1.3.1.2.1.1
# ::id bel_pmid_1733_2487_25838
(e / enhance-01~e.3
      :ARG0 (e2 / expose-01~e.0
            :ARG1 (p / protein~e.15
                  :name (n / name :op1 "CD40L"~e.2)))
      :ARG1 (p2 / produce-01~e.6
            :ARG1~e.7 (a / and~e.11
                  :op1 (p3 / protein~e.15
                        :name (n2 / name :op1 "IL-6"~e.8,10))
                  :op2 (p4 / protein~e.15
                        :name (n3 / name :op1 "MCP-1"~e.12,14)))
            :mod (c / constitutive~e.5))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.19
                  :op1 (f / figure~e.17
                        :name (n4 / name :op1 "4A"~e.18))
                  :op2 (f2 / figure~e.17
                        :name (n5 / name :op1 "4B"~e.20)))))

# ::tok Figure 1 TRF2 ( myc @-@ tagged ) induces telomere dysfunction and cellular senescence in p53 P/P primary mouse embryonic fibroblasts .
# ::alignments 0-1.4.1 1-1.4.1.1 2-1.1.1.1 4-1.1.2.1.1.1 6-1.1.2 8-1 9-1.2.1.2 11-1.2 12-1.2.2.1 13-1.2.2 16-1.3.1.1.2.2.1 17-1.3.1.1.1 18-1.3.1.1 20-1.3
# ::id bel_pmid_1739_6137_31084
(i / induce-01~e.8
      :ARG0 (p / protein
            :name (n / name :op1 "TRF2"~e.2)
            :ARG1-of (t2 / tag-01~e.6
                  :ARG0 (p4 / protein
                        :name (n2 / name :op1 "myc"~e.4))))
      :ARG1 (a / and~e.11
            :op1 (f2 / function-01
                  :polarity "-"
                  :ARG0 (t / telomere~e.9))
            :op2 (s / senescence~e.13
                  :mod (c2 / cell~e.12)))
      :location (f3 / fibroblast~e.20
            :mod (e / embryo
                  :source (m / mouse~e.18
                        :mod (p2 / primary~e.17)
                        :mod (p3 / protein
                              :name (n3 / name :op1 "p35")
                              :ARG2-of (m2 / mutate-01 :mod "p/p"~e.16)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f4 / figure~e.0 :mod "1"~e.1)))

# ::tok overexpression of TRF2 in p53 P/P MEFs resulted in upregulation of p21 ( Fig 1D ) . In addition , reduction of BrdU incorporation , induction of p21 level and increased number of SA @-@ beta @-@ gal @-@ positive senescent cells were also observed when oncogenic H @-@ Ras was overexpressed in p53 P/P MEFs ( Fig 1A ? C ) .
# ::alignments 2-1.1.1.1.1.1 4-1.1.1.2.2.1.1 5-1.1.1.2.2.2.1 7-1.1 8-1.1.2.r 9-1.1.2 10-1.1.2.1.r 11-1.1.2.1.1.1 14-1.1.3.1.1 17-1.2.1.1 18-1.2.1.1 20-1.2.1.1.1 21-1.2.1.1.1.1.r 22-1.2.1.1.1.1.1.1.1 23-1.2.1.1.1.1 27-1.2.1.1.2.1.1.1.1 28-1.2.1.1.2.1 29-1.2.1.1 30-1.2.1.1.3.2 31-1.2.1.1.3 32-1.2.1.1.3.1.r 33-1.2.1.1.3.1.2.1.1.1 35-1.2.1.1.3.1.2.1.1.1 37-1.2.1.1.3.1.2.1.1.1 39-1.2.1.1.3.1.2 40-1.2.1.1.3.1.1 41-1.2.1.1.3.1 43-1.2.1.3 44-1.2.1 45-1.2.1.2.r 46-1.2.1.2.1.2 47-1.2.1.2.1.1.1 49-1.2.1.2.1.1.1 53-1.1.1.2.2.1.1 53-1.2.1.2.2.2.1.1 54-1.1.1.2.2.2.1
# ::id bel_pmid_1739_6137_31086
(m / multi-sentence
      :snt1 (r / result-01~e.7
            :ARG1 (o / overexpress-00
                  :ARG2 (p / protein
                        :name (n2 / name :op1 "TRF2"~e.2))
                  :ARG3 (c / cell
                        :name (n3 / name :op1 "MEF")
                        :mod (p2 / protein
                              :name (n4 / name :op1 "p53"~e.4,53)
                              :ARG2-of (m3 / mutate-01 :mod "p/p"~e.5,54))))
            :ARG2~e.8 (u / upregulate-01~e.9
                  :ARG1~e.10 (p3 / protein
                        :name (n5 / name :op1 "p21"~e.11)))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "1D"~e.14)))
      :snt2 (a / and
            :op2 (o2 / observe-01~e.44
                  :ARG1 (a2 / and~e.17,18,29
                        :op1 (r2 / reduce-01~e.20
                              :ARG1~e.21 (i / incorporate-01~e.23
                                    :ARG1 (p5 / protein
                                          :name (n / name :op1 "BrdU"~e.22))))
                        :op2 (i2 / induct-01
                              :ARG1 (l / level~e.28
                                    :degree-of (p6 / protein
                                          :name (n9 / name :op1 "p21"~e.27))))
                        :op3 (n10 / number~e.31
                              :quant-of~e.32 (c3 / cell~e.41
                                    :mod (s / senescent~e.40)
                                    :mod (p7 / positive~e.39
                                          :mod (e / enzyme
                                                :name (n11 / name :op1 "SA-beta-gal"~e.33,35,37))))
                              :ARG1-of (i3 / increase-01~e.30)))
                  :time~e.45 (o3 / overexpress-00
                        :ARG2 (e2 / enzyme
                              :name (n6 / name :op1 "H-Ras"~e.47,49)
                              :mod (o4 / oncogenic~e.46))
                        :ARG3 (c2 / cell
                              :name (n8 / name :op1 "MEF")
                              :mod (p4 / protein
                                    :name (n7 / name :op1 "p53"~e.53))))
                  :mod (a3 / also~e.43)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure :mod "1AC")))

# ::tok As shown in Fig. 3 , A and B , IL @-@ 1B mRNA and proIL @-@ 1B protein were detected in a constitutive manner at low levels in nontreated pMphi . Those treated with 4 microM UA for 3 and 6 h were markedly up @-@ regulated , whereas , intriguingly , the levels diminished after 12 h .
# ::alignments 0-1.2.2.2.r 1-1.1.2 4-1.2.1.1.1.2.1.1 7-1.1.2.1 10-1.1.1.1.2.1.1 12-1.1.1.2.1.1 13-1.1.1.1.1.1 14-1.1.1 15-1.1.1.2.1.1 17-1.1.1.2.1.1 18-1.1.1.1.2 18-1.1.1.2 20-1.1 23-1.1.3 24-1.1.3.r 25-1.1.1.r 26-1.1.1.3.1 27-1.1.1.3 30-1.1.4.1.1 33-1.1.4.2 33-1.2.1.1.1 34-1.2.1.1.1.1.r 35-1.2.1.1.1.1.2.1 37-1.2.1.1.1.1.1.1 39-1.2.1.1.1.2.1.1 40-1.2.1.1.1.2 41-1.2.1.1.1.2.2.1 44-1.2.1.2 44-1.2.1.2.r 49-1.2 54-1.2.2.1 55-1.2.2 56-1.2.2.2 57-1.2.2.2.1.1
# ::id bel_pmid_1740_4266_16378
(m / multi-sentence
      :snt1 (d / detect-01~e.20
            :ARG1~e.25 (a4 / and~e.14
                  :op1 (r / rna
                        :name (n3 / name :op1 "mRNA"~e.13)
                        :part (p3 / protein~e.18
                              :name (n4 / name :op1 "IL-B1"~e.10)))
                  :op2 (p2 / protein~e.18
                        :name (n2 / name :op1 "proIL-1B"~e.12,15,17))
                  :quant (l2 / level~e.27
                        :degree (l3 / low~e.26)))
            :ARG1-of (s / show-01~e.1
                  :ARG0 (a3 / and~e.7
                        :op1 (f / figure :mod "3A")
                        :op2 (f2 / figure :mod "3B")))
            :manner~e.24 (c3 / constitutive~e.23)
            :location (c4 / cell
                  :name (n5 / name :op1 "pMphi"~e.30)
                  :ARG1-of (t5 / treat-04~e.33 :polarity "-")))
      :snt2 (c / contrast-01~e.49
            :ARG1 (u / upregulate-01
                  :ARG1 (c5 / cell
                        :ARG1-of (t / treat-04~e.33
                              :ARG2~e.34 (m2 / molecular-physical-entity
                                    :name (n / name :op1 "UA"~e.37)
                                    :quant (c2 / concentration-quantity
                                          :quant "4"~e.35
                                          :unit (m3 / micromolar)))
                              :duration (a / and~e.40
                                    :op1 (t2 / temporal-quantity
                                          :quant "3"~e.4,39
                                          :unit (h / hour))
                                    :op2 (t3 / temporal-quantity
                                          :quant "6"~e.41
                                          :unit (h2 / hour)))))
                  :manner~e.44 (m4 / marked~e.44))
            :ARG2 (d2 / diminish-01~e.55
                  :ARG1 (l / level~e.54)
                  :time~e.0 (a2 / after~e.56
                        :op1 (t4 / temporal-quantity
                              :quant "12"~e.57
                              :unit (h3 / hour)))
                  :ARG0-of (i / intrigue-01))))

# ::tok In addition , i.p . administration of UA increased the levels of IL @-@ 1 beta secretion and MPO activity in colonic mucosa of ICR mice .
# ::alignments 0-1.1.2 1-1 1-1.1.2 5-1.1.1 6-1.1.1.1.r 7-1.1.1.1.1.1 8-1.1 10-1.1.2.1 10-1.1.2.2 11-1.1.2.1.1.r 12-1.1.2.1.1.1.1.1 16-1.1.2.1.1 17-1.1.2 18-1.1.2.2.1.1.1.1 19-1.1.2.2.1 20-1.1.2.2.1.2.r 21-1.1.2.2.1.2.1 22-1.1.2.2.1.2 23-1.1.2.2.1.2.2.r 24-1.1.2.2.1.2.2.1 25-1.1.2.2.1.2.2
# ::id bel_pmid_1740_4266_3636
(a2 / and~e.1
      :op2 (i / increase-01~e.8
            :ARG0 (a / administrate-01~e.5
                  :ARG1~e.6 (m / molecular-physical-entity
                        :name (n / name :op1 "UA"~e.7))
                  :mod (i2 / injection
                        :mod (i3 / intraperitoneal)))
            :ARG1 (a3 / and~e.0,1,17
                  :op1 (l / level~e.10
                        :degree-of~e.11 (s / secrete-01~e.16
                              :ARG1 (p / protein
                                    :name (n3 / name :op1 "IL-1beta"~e.12))))
                  :op2 (l2 / level~e.10
                        :degree-of (a4 / act-02~e.19
                              :ARG0 (e / enzyme
                                    :name (n4 / name :op1 "MPO"~e.18))
                              :location~e.20 (m2 / mucosa~e.22
                                    :part-of (c / colon~e.21)
                                    :source~e.23 (m3 / mouse~e.25
                                          :mod (i4 / ICR~e.24))))))))

# ::tok UA increased the protein release of IL @-@ 1 beta , IL @-@ 6 , and MIF , but not of TNF @-@ alpha , in dose @- and time @-@ dependent manners .
# ::alignments 0-1.1.1.1.1 1-1.1 1-1.2 3-1.1.2.1.1 3-1.1.2.1.2 3-1.1.2.1.3 3-1.2.3.1 4-1.1.2 4-1.2.3 5-1.1.2.1.r 6-1.1.2.1.1.1.1 6-1.1.2.1.2.1.1 11-1.1.2.1.1.1.1 11-1.1.2.1.2.1.1 13-1.1.2.1.2.1.1 15-1.1.2.1 16-1.1.2.1.3.1.1 18-1 19-1.2.1 19-1.2.1.r 21-1.2.3.1.1.1 23-1.2.3.1.1.1 26-1.3.1.2 28-1.3 29-1.3.2.2 31-1.3.1 31-1.3.2 32-1.3.r
# ::id bel_pmid_1740_4266_3638
(c / contrast-01~e.18
      :ARG1 (i2 / increase-01~e.1
            :ARG0 (m / molecular-physical-entity
                  :name (n / name :op1 "UA"~e.0))
            :ARG1 (r / release-01~e.4
                  :ARG1~e.5 (a / and~e.15
                        :op1 (p2 / protein~e.3
                              :name (n2 / name :op1 "IL-1beta"~e.6,11))
                        :op2 (p3 / protein~e.3
                              :name (n3 / name :op1 "IL-6"~e.6,11,13))
                        :op3 (p4 / protein~e.3
                              :name (n4 / name :op1 "MIF"~e.16)))))
      :ARG2 (i3 / increase-01~e.1
            :polarity~e.19 "-"~e.19
            :ARG0 m
            :ARG1 (r2 / release-01~e.4
                  :ARG1 (p5 / protein~e.3
                        :name (n5 / name :op1 "TNF-alpha"~e.21,23))))
      :manner~e.32 (a2 / and~e.28
            :op1 (d / depend-01~e.31
                  :ARG0 i2
                  :ARG1 (d3 / dose~e.26))
            :op2 (d2 / depend-01~e.31
                  :ARG0 i2
                  :ARG1 (t / time~e.29))))

# ::tok JAK @-@ 2 activation and phosphorylation have been demonstrated in response to exogenous H2O2 in fibroblasts and VSMCs , respectively ( 27,63 ) .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.1.1 4-1.1 5-1.1.2 8-1 9-1.2.r 10-1.2 11-1.2.1.r 12-1.2.1.2 13-1.2.1.1.1 15-1.2.1.3.1 16-1.2.1.3 16-1.3.1
# ::id bel_pmid_1740_6055_15774
(d2 / demonstrate-01~e.8
      :ARG1 (a / and~e.4
            :op1 (a2 / activate-01~e.3
                  :ARG1 (e2 / enzyme
                        :name (n / name :op1 "JAK-2"~e.0,2)))
            :op2 (p / phosphorylate-01~e.5
                  :ARG1 e2))
      :ARG2-of~e.9 (r / respond-01~e.10
            :ARG1~e.11 (m / molecular-physical-entity
                  :name (n2 / name :op1 "H2O2"~e.13)
                  :mod (e / exogenous~e.12)
                  :location (a3 / and~e.16
                        :op1 (f / fibroblast~e.15)
                        :op2 (c / cell
                              :name (n3 / name :op1 "VSMC")))))
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and~e.16
                  :op1 (p3 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "27"))
                  :op2 (p4 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "63")))))

# ::tok in view of the ability of H2O2 to inhibit protein tyrosine phosphatases ( PTPases ) , such as PTP @-@ 1B ( 68 ) , and SH @-@ 2 domain @-@ containing tyrosine phosphatase ( SHP )-2 ( 69 ) ,
# ::alignments 4-1.1 5-1.1.1.r 6-1.1.1.1.1 8-1.1.2 9-1.1.2.2.1.1.1 10-1.1.2.2.1.1.2 11-1.1.2.2.1.1.3 16-1.1.2.2.1.2.r 17-1.1.2.2.1.2.r 18-1.1.2.2.1.2.1.1 20-1.1.2.2.1.2.1.1 22-1.1.2.2.1.3.1.1.1 25-1.1.2.2 26-1.1.2.2.2.2.1.1.1 28-1.1.2.2.2.2.1.1.1 29-1.1.2.2.2.2.1 31-1.1.2.2.2.2 32-1.1.2.2.2.1.1 33-1.1.2.2.2.1.2 38-1.1.2.2.2.3.1.1.1
# ::id bel_pmid_1740_6055_15784
(h / have-purpose-91
      :ARG2 (c / capable-01~e.4
            :ARG1~e.5 (m / molecular-physical-entity
                  :name (n / name :op1 "H2O2"~e.6))
            :ARG2 (i / inhibit-01~e.8
                  :ARG0 m
                  :ARG1 (a / and~e.25
                        :op1 (e / enzyme
                              :name (n2 / name
                                    :op1 "protein"~e.9
                                    :op2 "tyrosine"~e.10
                                    :op3 "phosphatase"~e.11)
                              :example~e.16,17 (e2 / enzyme
                                    :name (n3 / name :op1 "PTP-1B"~e.18,20))
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p2 / publication
                                          :ARG1-of (c3 / cite-01 :ARG2 "68"~e.22))))
                        :op2 (e3 / enzyme
                              :name (n5 / name :op1 "tyrosine"~e.32 :op2 "phosphatase"~e.33)
                              :ARG0-of (c4 / contain-01~e.31
                                    :ARG1 (d3 / domain~e.29
                                          :name (n4 / name :op1 "SH-2"~e.26,28)))
                              :ARG1-of (d / describe-01
                                    :ARG0 (p / publication
                                          :ARG1-of (c2 / cite-01 :ARG2 "69"~e.38))))))))

# ::tok c @-@ Src has also been shown to be activated in response to ROS , including H2O2 , in different cell types ( 19,20 , 33,37,50 ) .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 4-1.3 6-1 9-1.1 10-1.1.2.r 11-1.1.2 12-1.1.2.1.r 13-1.1.2.1.1.1 15-1.1.2.1.3 16-1.1.2.1.3.1.1.1 19-1.1.2.1.2.2 20-1.1.2.1.2.1 21-1.1.2.1.2
# ::id bel_pmid_1740_6055_34632
(s / show-01~e.6
      :ARG1 (a2 / activate-01~e.9
            :ARG1 (e / enzyme
                  :name (n3 / name :op1 "c-Src"~e.0,2))
            :ARG2-of~e.10 (r / respond-01~e.11
                  :ARG1~e.12 (m / molecular-physical-entity
                        :name (n / name :op1 "ROS"~e.13)
                        :location (t / type~e.21
                              :mod (c6 / cell~e.20)
                              :ARG1-of (d2 / differ-02~e.19))
                        :ARG2-of (i / include-91~e.15
                              :ARG1 (m2 / molecular-physical-entity
                                    :name (n2 / name :op1 "H2O2"~e.16))))))
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (p / publication
                        :ARG1-of (c / cite-01 :ARG2 "19"))
                  :op2 (p3 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "20"))
                  :op3 (p2 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "33"))
                  :op4 (p4 / publication
                        :ARG1-of (c4 / cite-01 :ARG2 "37"))
                  :op5 (p5 / publication
                        :ARG1-of (c5 / cite-01 :ARG2 "50"))))
      :mod (a3 / also~e.4))

# ::tok deletion of p38 alpha mitogen @-@ activated protein ( MAP ) kinase in adult mice results in increased proliferation
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1 3-1.1.1.1.2 4-1.1.1.1.3 6-1.1.1.1.3 7-1.1.1.1.4 11-1.1.1.1.5 12-1.1.2.r 13-1.1.2.1 14-1.1.2 15-1 16-1.2.r 17-1.2.1 18-1.2
# ::id bel_pmid_1746_8755_1748
(r / result-01~e.15
      :ARG1 (d / delete-01~e.0
            :ARG1~e.1 (e / enzyme
                  :name (n / name
                        :op1 "p38"~e.2
                        :op2 "alpha"~e.3
                        :op3 "mitogen-activated"~e.4,6
                        :op4 "protein"~e.7
                        :op5 "kinase"~e.11))
            :location~e.12 (m / mouse~e.14
                  :mod (a / adult~e.13)))
      :ARG2~e.16 (p / proliferate-01~e.18
            :ARG1-of (i / increase-01~e.17)))

# ::tok In addition , p38 alpha controls self @-@ renewal of the lung stem and progenitor cell population by inhibiting proliferation @-@ inducing signals , most notably epidermal growth factor receptor
# ::alignments 0-1 1-1 3-1.1.1.1.1 4-1.1.1.1.2 5-1.1 8-1.1.2 9-1.1.2.1.r 11-1.1.2.1.1.1.1.1 12-1.1.2.1.1.1.1 13-1.1.2.1 14-1.1.2.1.2.1.1 15-1.1.2.1.1.1 15-1.1.2.1.2.1 16-1.1.2.1.1 16-1.1.2.1.2 17-1.1.3.r 18-1.1.3 19-1.1.3.2.1.1 21-1.1.3.2.1 22-1.1.3.2 24-1.1.3.3.1 25-1.1.3.3 26-1.1.3.2.2.1.1.1 27-1.1.3.2.2.1.1.2 28-1.1.3.2.2.1.1.3 29-1.1.3.2.2.1.1.4
# ::id bel_pmid_1746_8755_1750
(a / and~e.0,1
      :op2 (c / control-01~e.5
            :ARG0 (e / enzyme
                  :name (n2 / name :op1 "P38"~e.3 :op2 "Alpha"~e.4))
            :ARG1 (r / renew-01~e.8
                  :ARG0~e.9 (a2 / and~e.13
                        :op1 (p2 / population~e.16
                              :consist-of (c2 / cell~e.15
                                    :mod (s2 / stem~e.12
                                          :source (l / lung~e.11))))
                        :op2 (p / population~e.16
                              :consist-of (c3 / cell~e.15
                                    :mod (p4 / progenitor~e.14))))
                  :ARG1 a2)
            :ARG2~e.17 (i / inhibit-01~e.18
                  :ARG0 e
                  :ARG1 (s3 / signal~e.22
                        :ARG0-of (i2 / induce-01~e.21
                              :ARG1 (p5 / proliferate-01~e.19))
                        :ARG2-of (i3 / include-91
                              :ARG1 (e2 / enzyme
                                    :name (n / name
                                          :op1 "epidermal"~e.26
                                          :op2 "growth"~e.27
                                          :op3 "factor"~e.28
                                          :op4 "receptor"~e.29))))
                  :mod (n3 / notable~e.25
                        :degree (m / most~e.24)))))

# ::tok We found that p38 alpha positively regulates factors such as CCAAT @/@ enhancer @-@ binding protein that are required for lung cell differentiation .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1 4-1.2.1.1.2 5-1.2.3 5-1.2.3.r 6-1.2 7-1.2.2 8-1.2.2.1.r 9-1.2.2.1.r 10-1.2.2.1.1.1 12-1.2.2.1.1.1 14-1.2.2.1.1.1 15-1.2.2.1.1.2 18-1.2.2.1.2 19-1.2.2.1.2.1.r 20-1.2.2.1.2.1.1.1 21-1.2.2.1.2.1.1 22-1.2.2.1.2.1
# ::id bel_pmid_1746_8755_1754
(f / find-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (r / regulate-01~e.6
            :ARG0 (e2 / enzyme
                  :name (n / name :op1 "p38"~e.3 :op2 "alpha"~e.4))
            :ARG1 (f2 / factor~e.7
                  :example~e.8,9 (p / protein
                        :name (n3 / name :op1 "CCAAT/enhancer-binding"~e.10,12,14 :op2 "protein"~e.15)
                        :ARG1-of (r2 / require-01~e.18
                              :ARG0~e.19 (d / differentiate-01~e.22
                                    :ARG1 (c / cell~e.21
                                          :mod (l / lung~e.20))))))
            :manner~e.5 (p2 / positive~e.5)))

# ::tok The reduction in C/EBPa could be accounted for by lower levels of phospho @-@ C/EBPb ( Fig . 3a ) , a known target for p38a ( refs . 12,20 ) , which in turn regulates the expression of C/EBPa ( ref . 21 ) .
# ::alignments 1-1.1.1 2-1.1.2.2.3.1.2.2 3-1.1.1.1.1.1 3-1.1.2.2.1.1 4-1 5-1.1.r 6-1.1 9-1.1.2.1 9-1.1.2.1.1 9-1.1.2.1.1.r 10-1.1.2 18-1.1.3.1.1 22-1.1.2.2.3.3 23-1.1.2.2 23-1.1.2.2.3 23-1.1.2.2.3.r 25-1.1.2.2.3.1.1.1 33-1.1.2.2.3.1.2.2 34-1.1.2.2.3.1.2.2 35-1.1.2.2.3.1 35-1.1.2.2.3.1.2 35-1.1.2.2.3.1.2.r 37-1.1.2.2.3.1.2.1 39-1.1.2.2.1.1 43-1.1.2.2.3.1.2.3.1.1.1
# ::id bel_pmid_1746_8755_21936
(p / possible~e.4
      :domain~e.5 (a / account-01~e.6
            :ARG1 (r / reduce-01~e.1
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "C/EBPa"~e.3)))
            :ARG2 (l / level~e.10
                  :mod (l2 / low~e.9
                        :degree~e.9 (m / more~e.9))
                  :quant-of (p8 / protein~e.23
                        :name (n3 / name :op1 "C/EBPa"~e.3,39)
                        :ARG1-of (p3 / phosphorylate-01)
                        :ARG1-of~e.23 (t / target-01~e.23
                              :ARG0 (e2 / enzyme~e.35
                                    :name (n2 / name :op1 "p38a"~e.25)
                                    :ARG0-of~e.35 (r2 / regulate-01~e.35
                                          :ARG1 (e / express-03~e.37
                                                :ARG2 p2)
                                          :manner (i / in-turn~e.2,33,34)
                                          :ARG1-of (d3 / describe-01
                                                :ARG0 (p7 / publication
                                                      :ARG1-of (c3 / cite-01 :ARG2 "21"~e.43)))))
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (a2 / and
                                          :op1 (p5 / publication
                                                :ARG1-of (c / cite-01 :ARG2 "12"))
                                          :op2 (p6 / publication
                                                :ARG1-of (c2 / cite-01 :ARG2 "20"))))
                              :ARG1-of (k / know-01~e.22))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "3a"~e.18))))

# ::tok Mnk1 was also activated at lower levels in Mapk14 @-@ null mice ( Fig . 3b ) . This p38a @-@ activated protein kinase phosphorylates and stabilizes Sprouty2 ( ref . 26 ) , which in turn can negatively regulate tyrosine kinase receptor signaling in lung cells27 .
# ::alignments 0-1.1.1.1.1 2-1.1.3 3-1.1 4-1.1.4.r 5-1.1.4.1 5-1.1.4.1.1 5-1.1.4.1.1.r 6-1.1.4 7-1.1.5.r 7-1.2.2.2.2.2 8-1.1.5.1.1.1 11-1.1.5 15-1.1.2.1.1 15-1.1.6.1.1 19-1.2.2.1.2.1.1.1 21-1.2.2.1.2 22-1.2.2.1.1 23-1.2.2.1 24-1.2.1 25-1.2 26-1.2.2 27-1.2.2.2.1.1 31-1.2.2.3.1.1.1 35-1.2.2.2.2.2 36-1.2.2.2.2.2 37-1.2.2.2.2.3 40-1.2.2.2.2.1.1.1.1 41-1.2.2.2.2.1.1.1.2 42-1.2.2.2.2.1.1.1.3 43-1.2.2.2.2.1 44-1.2.2.2.2.1.2.r 44-1.2.2.2.2.2 45-1.2.2.2.2.1.2.1
# ::id bel_pmid_1746_8755_22008
(m2 / multi-sentence
      :snt1 (a / activate-01~e.3
            :ARG1 (e3 / enzyme
                  :name (n3 / name :op1 "Mnk1"~e.0))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "3b"~e.15))
            :mod (a5 / also~e.2)
            :degree~e.4 (l3 / level~e.6
                  :mod (l / low~e.5
                        :degree~e.5 (m / more~e.5)))
            :location~e.7 (m3 / mouse~e.11
                  :mod (e2 / enzyme
                        :name (n5 / name :op1 "Mapk14"~e.8)
                        :ARG2-of (m4 / mutate-01 :mod "-/-")))
            :ARG1-of (d5 / describe-01
                  :ARG0 (f2 / figure :mod "3b"~e.15)))
      :snt2 (a2 / and~e.25
            :op1 (p / phosphorylate-01~e.24
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Sprouty2"~e.27)
                        :ARG2-of (d2 / downregulate-01
                              :ARG1 (s2 / signal-07~e.43
                                    :ARG0 (p4 / protein
                                          :name (n2 / name
                                                :op1 "tyrosine"~e.40
                                                :op2 "kinase"~e.41
                                                :op3 "receptor"~e.42))
                                    :location~e.44 (c2 / cell
                                          :source (l2 / lung~e.45)))
                              :manner (i / in-turn~e.7,35,36,44)
                              :mod (p3 / possible~e.37)
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (p5 / publication
                                          :ARG1-of (c3 / cite-01 :ARG2 "27")))))
                  :ARG2 (k / kinase~e.23
                        :mod (p6 / protein~e.22)
                        :ARG1-of (a4 / activate-01~e.21
                              :ARG0 (p7 / protein
                                    :name (n4 / name :op1 "p38a"~e.19)))))
            :op2 (s / stabilize-01~e.26
                  :ARG0 k
                  :ARG1 e
                  :ARG1-of (d4 / describe-01
                        :ARG0 (p2 / publication
                              :ARG1-of (c / cite-01 :ARG2 "26"~e.31))))))

# ::tok Our results indicated that the p38a @-@ deficient lungs had hyperproliferative alveolar tissue with loss of differentiation markers . A similar but more marked lung phenotype , with hyperproliferation and defective cell maturation , has been described previously in CCAAT/ enhancer @-@ binding protein ( C/EBP ) a knockout mice , which die shortly after birth because of respiratory failure16–18 .
# ::alignments 0-1.1.1.1 0-1.1.1.1.r 1-1.1.1 1-1.1.1.2 1-1.1.1.2.r 2-1.1 3-1.1.2.r 5-1.1.2.1.1.1.1.1 8-1.1.2.1 9-1.1.2 11-1.1.2.2.2 12-1.1.2.2 13-1.1.2.2.3.r 14-1.1.2.2.3 15-1.1.2.2.3.1.r 16-1.1.2.2.3.1.1 17-1.1.2.2.3.1 20-1.3.1.4 21-1.3.1.4.1 22-1.3.1.4.1.1.1 23-1.3.1.4.1.1 24-1.3.1.1 25-1.3.1 30-1.3.1.3.2 31-1.3.1.3.1 32-1.3.1.3 35-1.3.1.4.1.1.2.r 36-1.2 36-1.3 37-1.3.2 38-1.3.3.r 39-1.3.3.2.1.1 40-1.3.3.2.1.2 42-1.3.3.2.1.2 43-1.3.3.2.1.3 45-1.3.3.2.3.1.1.1 49-1.3.3 52-1.3.3.1 53-1.3.3.1.1.2 54-1.3.3.1.1 55-1.3.3.1.1.1 56-1.3.3.1.2 58-1.3.3.1.2.1.2
# ::id bel_pmid_1746_8755_25974
(m / multi-sentence
      :snt1 (i / indicate-01~e.2
            :ARG0 (t3 / thing~e.1
                  :poss~e.0 (w / we~e.0)
                  :ARG2-of~e.1 (r / result-01~e.1))
            :ARG1~e.3 (h / have-03~e.9
                  :ARG0 (l / lung~e.8
                        :ARG0-of (l2 / lack-01
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "p38a"~e.5))))
                  :ARG1 (t / tissue~e.12
                        :ARG1-of (h4 / hyperproliferate-00)
                        :mod (a / alveolus~e.11)
                        :mod~e.13 (l3 / lose-02~e.14
                              :ARG1~e.15 (m8 / marker~e.17
                                    :ARG1-of (d / differentiate-01~e.16))))))
      :ARG1-of (d5 / describe-01~e.36
            :ARG0 (p7 / publication
                  :ARG1-of (c4 / cite-01
                        :ARG2 (v / value-interval :op1 "16" :op2 "18"))))
      :snt2 (d2 / describe-01~e.36
            :ARG1 (p4 / phenotype~e.25
                  :mod (l4 / lung~e.24)
                  :mod (p5 / proliferate-01
                        :ARG0 (c2 / cell~e.31)
                        :degree (h3 / hyper))
                  :ARG0-of (m5 / maturate-01~e.32
                        :ARG1 c2
                        :mod (d3 / defective~e.30))
                  :ARG1-of (r2 / resemble-01~e.20
                        :ARG1-of (c6 / contrast-01~e.21
                              :ARG2 (m3 / marked~e.23
                                    :degree (m4 / more~e.22)
                                    :domain~e.35 p4))))
            :time (p3 / previous~e.37)
            :location~e.38 (m6 / mouse~e.49
                  :ARG1-of (d4 / die-01~e.52
                        :time (a2 / after~e.54
                              :op1 (b / birth-01~e.55
                                    :ARG1 m6)
                              :quant (s / short~e.53))
                        :ARG1-of (c3 / cause-01~e.56
                              :ARG0 (f / fail-01
                                    :ARG1 m6
                                    :ARG2 (r3 / respiration~e.58))))
                  :mod (p2 / protein
                        :name (n4 / name
                              :op1 "CCAAT/"~e.39
                              :op2 "enhancer-binding"~e.40,42
                              :op3 "protein"~e.43)
                        :ARG2-of (m7 / mutate-01 :mod "+/-")
                        :ARG1-of (m2 / mean-01
                              :ARG2 (p / protein
                                    :name (n3 / name :op1 "C/EBP"~e.45)))))))

# ::tok the amount of Tgfb1 ( TGFb ) mRNA was higher in p38a @-@ deficient lungs compared with Mapk14D/+ lungs ( Fig . 3e ) . TGFb has been found to be overexpressed in C/EBPa knockout lungs17 , so the reduced C/EBPa levels in the Mapk14 @-@ null lungs could account for the higher TGFb expression .
# ::alignments 1-1.1.3 3-1.1.3.1.2.1.1 5-1.2.1.1.1.1.1 7-1.1.3.1.1.1 8-1.1.3.r 9-1.1 9-1.1.1 9-1.1.1.r 10-1.1.2.r 11-1.1.2.1.1.1.1 14-1.1.2 14-1.1.2.2.1 15-1.1.2.2 18-1.1.2 22-1.1.4.1.1 25-1.2.1.1.1.1.1 28-1.2.1 33-1.2.1.1.2.1.1.1 37-1.2 39-1.2.2.1.1.1 40-1.2.2.1.1.2 41-1.2.2.1.1 44-1.2.2.1.1.3.1.1.1 47-1.2.1.1.2 47-1.2.2.1.1.3 48-1.1.2.2.1.1.2.1 48-1.2.2 49-1.2.2.1 50-1.2.2.1.2.r 52-1.2.2.1.2.2 52-1.2.2.1.2.2.1 52-1.2.2.1.2.2.1.r 53-1.2.2.1.2.1 54-1.2.2.1.2
# ::id bel_pmid_1746_8755_25986
(m2 / multi-sentence
      :snt1 (h / high~e.9
            :degree~e.9 (m / more~e.9)
            :location~e.10 (l / lung~e.14,18
                  :ARG0-of (l2 / lack-01
                        :ARG1 (p / protein
                              :name (n / name :op1 "p38a"~e.11)))
                  :ARG1-of (c / compare-01~e.15
                        :ARG2 (l3 / lung~e.14
                              :mod (e / enzyme
                                    :name (n2 / name :op1 "Mapk14D")
                                    :ARG2-of (m3 / mutate-01 :mod "-/+"~e.48)))))
            :domain~e.8 (a / amount~e.1
                  :quant-of (r / rna
                        :name (n4 / name :op1 "mRNA"~e.7)
                        :part-of (p2 / protein
                              :name (n3 / name :op1 "Tgfb1"~e.3))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "3e"~e.22)))
      :snt2 (c2 / cause-01~e.37
            :ARG0 (f2 / find-01~e.28
                  :ARG1 (o / overexpress-00
                        :ARG2 (p3 / protein
                              :name (n5 / name :op1 "Tgfb"~e.5,25))
                        :ARG3 (l4 / lung~e.47
                              :mod (p5 / protein
                                    :name (n6 / name :op1 "C/EBPa"~e.33)
                                    :ARG2-of (m6 / mutate-01 :mod "-/-")))
                        :ARG1-of (d2 / describe-01
                              :ARG0 (p4 / publication :mod "17"))))
            :ARG1 (p6 / possible~e.48
                  :domain (a2 / account-01~e.49
                        :ARG0 (l6 / level~e.41
                              :ARG1-of (r2 / reduce-01~e.39)
                              :quant-of p5~e.40
                              :location (l5 / lung~e.47
                                    :mod (e2 / enzyme
                                          :name (n7 / name :op1 "Mapk14"~e.44)
                                          :ARG2-of (m4 / mutate-01 :mod "-/-"))))
                        :ARG1~e.50 (e3 / express-03~e.54
                              :ARG2 p3~e.53
                              :mod (h2 / high~e.52
                                    :degree~e.52 (m5 / more~e.52)))))))

# ::tok Expression of KrasG12V induced also a loss of epithelial markers ( as assessed by E @-@ cadherin staining , which was similar in Mapk14D/+ and Mapk14D/D alveoli ; Fig. 6c ) and an increase in SP @-@ C+ cells ( Fig . 6d ) .
# ::alignments 0-1.1 3-1 4-1.3 6-1.2.1 7-1.2.1.1.r 8-1.2.1.1.1 9-1.2.1.1 11-1.2.1.2.r 12-1.2.1.2 13-1.2.1.2.1.r 14-1.2.1.2.1.1.1.1 16-1.2.1.2.1.1.1.1 17-1.2.1.2.1 21-1.2.1.2.1.2.3 25-1.2.1.2.1.2.3.1.1.1.1 26-1.2.1.2.1.2 26-1.2.1.2.1.2.3.1 29-1.2.1.2.2.1.1 31-1.2 33-1.2.2 38-1.2.2.1 42-1.4.1.1
# ::id bel_pmid_1746_8755_28766
(i / induce-01~e.3
      :ARG0 (e / express-03~e.0
            :ARG2 (e5 / enzyme
                  :name (n / name :op1 "KRAS")
                  :ARG2-of (m / mutate-01 :value "G12V")))
      :ARG1 (a2 / and~e.31
            :op1 (l / lose-02~e.6
                  :ARG1~e.7 (m4 / marker~e.9
                        :mod (e2 / epithelium~e.8))
                  :ARG1-of~e.11 (a3 / assess-01~e.12
                        :ARG0~e.13 (s / stain-00~e.17
                              :ARG2 (p / protein
                                    :name (n3 / name :op1 "E-cadherin"~e.14,16))
                              :location (a5 / alveoli~e.26
                                    :mod (e3 / enzyme
                                          :name (n5 / name :op1 "Mapk14D"))
                                    :ARG2-of (m3 / mutate-01 :mod "+/-")
                                    :ARG1-of (r / resemble-01~e.21
                                          :ARG2 (a6 / alveoli~e.26
                                                :mod (e4 / enzyme
                                                      :name (n4 / name :op1 "Mapk14D/D"~e.25))))))
                        :ARG1-of (d2 / describe-01
                              :ARG0 (f2 / figure :mod "6c"~e.29))))
            :op2 (i2 / increase-01~e.33
                  :location (c / cell~e.38
                        :mod (p2 / protein
                              :name (n2 / name :op1 "SPC+")))))
      :mod (a / also~e.4)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6d"~e.42)))

# ::tok However , the SP @-@ C+ cells were more numerous in the Mapk14-/- lungs ( with almost twice as many as in Mapk14-/+ lungs ; Fig. 2c ) . Notably , immunohistological staining showed reduced levels of the epithelial marker E @-@ cadherin in the alveolar cells ( Fig . 2c ) , indicating defective differentiation of these cells .
# ::alignments 0-1.1 6-1.1.1.2 6-1.1.2.1 7-1.1.1.2.r 8-1.1.1.1 9-1.1.1 9-1.1.2.1.1 13-1.1.1.3 17-1.1.2.1.1.1.1 23-1.1.1.3 23-1.1.2.1.1.1.2.1 26-1.2.5.1.1 29-1.2.4 32-1.2.1 33-1.2 34-1.2.2.1 35-1.2.2 36-1.2.2.2.r 38-1.2.2.2.1 39-1.2.2.2 40-1.2.2.2.2.1.1 42-1.2.2.2.2.1.1 46-1.2.3.1.1 50-1.2.5.1.1 53-1.2.3 54-1.2.3.1.2 55-1.2.3.1 58-1.1.2.1.1.1.2
# ::id bel_pmid_1746_8755_29060
(m / multi-sentence
      :snt1 (c / contrast-01~e.0
            :ARG2 (n / numerous~e.9
                  :degree (m2 / more~e.8)
                  :domain~e.7 (c2 / cell~e.6
                        :mod (p2 / protein
                              :name (n2 / name :op1 "SPC+")))
                  :location (l / lung~e.13,23
                        :mod (e / enzyme
                              :name (n3 / name :op1 "Mapk14")
                              :ARG2-of (m3 / mutate-01 :mod "-/-"))))
            :ARG1-of (m5 / mean-01
                  :ARG2 (c4 / cell~e.6
                        :quant (n6 / numerous~e.9
                              :quant (p3 / product-of
                                    :op1 "2"~e.17
                                    :op2 (c5 / cell~e.58
                                          :location (l3 / lung~e.23
                                                :mod (e3 / enzyme
                                                      :name (n7 / name :op1 "Mapk14")
                                                      :ARG2-of (m6 / mutate-01 :mod "-/+")))))))))
      :snt2 (s / show-01~e.33
            :ARG0 (s2 / stain-01~e.32
                  :mod (i2 / immunohistology))
            :ARG1 (l2 / level~e.35
                  :ARG1-of (r / reduce-01~e.34)
                  :quant-of~e.36 (m7 / marker~e.39
                        :mod (e2 / epithelium~e.38)
                        :mod (p / protein
                              :name (n5 / name :op1 "E-cadherin"~e.40,42)
                              :location (c3 / cell~e.46
                                    :mod (a / aveolus)))))
            :ARG0-of (i / indicate-01~e.53
                  :ARG1 (d / differentiate-01~e.55
                        :ARG1 c3
                        :mod (d2 / defective~e.54)))
            :mod (n4 / notable~e.29)
            :ARG1-of (d3 / describe-01
                  :ARG0 (f / figure :mod "2c"~e.26,50))))

# ::tok Notably , we found that p38a @-@ deficient lungs contained lower levels of C/EBPa and HNF3b , another transcription factor involved in lung differentiation whose expression is controlled by C/EBPa ( ref . 19 ) ( Fig . 3a and Supplementary Fig. 1a online ) .
# ::alignments 0-1.3 2-1.1 3-1 4-1.2.r 5-1.2.1.1.1.1.1 8-1.2.1 9-1.2 10-1.2.2.3 10-1.2.2.3.1 10-1.2.2.3.1.r 11-1.2.2.1 11-1.2.2.2 12-1.2.2.1.1.r 13-1.2.2.1.1.1.1 14-1.2.2 15-1.2.2.2.1.1.1 17-1.2.2.2.1.2.4 18-1.2.2.2.1.2.1.1 19-1.2.2.2.1.2.1.2 20-1.2.2.2.1.2.2 21-1.2.2.2.1.2.2.1.r 22-1.2.2.2.1.2.2.1.1 23-1.2.2.2.1.2.2.1 25-1.2.2.2.1.2 25-1.2.2.2.1.2.3 25-1.2.2.2.1.2.3.r 27-1.2.2.2.1.2.3.1 28-1.2.2.2.1.2.3.1.1.r 29-1.2.2.2.1.2.3.1.1 33-1.4.1.1.1 38-1.5.1.1.1 39-1.5.1 42-1.5.1.2.1 43-1.5.1.2.3
# ::id bel_pmid_1746_8755_29062
(f / find-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1~e.4 (c / contain-01~e.9
            :ARG0 (l2 / lung~e.8
                  :ARG0-of (l3 / lack-01
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "p38a"~e.5))))
            :ARG1 (a / and~e.14
                  :op1 (l4 / level~e.11
                        :quant-of~e.12 (p2 / protein
                              :name (n3 / name :op1 "C/EBPa"~e.13)))
                  :op2 (l5 / level~e.11
                        :quant-of (p3 / protein
                              :name (n4 / name :op1 "HNF3b"~e.15)
                              :domain (p4 / protein~e.25
                                    :name (n5 / name :op1 "transcription"~e.18 :op2 "factor"~e.19)
                                    :ARG1-of (i / involve-01~e.20
                                          :ARG2~e.21 (d / differentiate-01~e.23
                                                :ARG1 (l6 / lung~e.22)))
                                    :ARG2-of~e.25 (e / express-03~e.25
                                          :ARG1-of (c2 / control-01~e.27
                                                :ARG0~e.28 p2~e.29))
                                    :mod (a2 / another~e.17))))
                  :mod (l / low~e.10
                        :degree~e.10 (m / more~e.10))))
      :mod (n / notable~e.0)
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "19"~e.33)))
      :ARG1-of (d3 / describe-01
            :ARG0 (a3 / and~e.39
                  :op1 (f2 / figure :mod "3a"~e.38)
                  :op2 (f3 / figure
                        :mod "1a"~e.42
                        :ARG2-of (s / supplement-01)
                        :medium (o / online~e.43)))))

# ::tok Furthermore , the higher number of AT2 cells correlated with an almost fivefold increase in Ki67+ cells in Mapk14-/- lungs compared with the number of Ki67+ cells in their heterozygous Mapk14D/+ counterparts ( Fig . 2d ) .
# ::alignments 3-1.1.1.2 3-1.1.1.2.1 3-1.1.1.2.1.r 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1.1.1 7-1.1.1.1 8-1.1 9-1.1.2.r 11-1.1.2.2 13-1.1.2 16-1.1.2.1 19-1.1.2.1.3 20-1.1.2.3 21-1.1.2.3.1.r 23-1.1.2.3.1 26-1.1.2.3.1.1 29-1.1.2.3.1.1.2.2 31-1.1.2.3.1.1.2 35-1.2.1.1
# ::id bel_pmid_1746_8755_29066
(a / and
      :op2 (c / correlate-01~e.8
            :ARG1 (n / number~e.4
                  :quant-of~e.5 (c3 / cell~e.7
                        :name (n3 / name :op1 "AT2"~e.6))
                  :mod (h / high~e.3
                        :degree~e.3 (m / more~e.3)))
            :ARG2~e.9 (i / increase-01~e.13
                  :ARG1 (c4 / cell~e.16
                        :name (n4 / name :op1 "Ki67")
                        :ARG2-of (m2 / mutate-01 :mod "+/-")
                        :location (l / lung~e.19
                              :mod (e / enzyme
                                    :name (n5 / name :op1 "Mapk14")
                                    :ARG2-of (m3 / mutate-01 :mod "-/-"))))
                  :ARG2 (a2 / almost~e.11
                        :op1 (p / product-of :op1 "5"))
                  :ARG1-of (c2 / compare-01~e.20
                        :ARG2~e.21 (n2 / number~e.23
                              :quant-of (c5 / cell~e.26
                                    :name (n6 / name :op1 "Ki67")
                                    :location (c7 / counterpart~e.31
                                          :mod (e2 / enzyme
                                                :name (n7 / name :op1 "Mapk14D"))
                                          :mod (h2 / heterozygous~e.29)
                                          :ARG2-of (m4 / mutate-01 :mod "-/+")))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2d"~e.35)))

# ::tok We also detected a reduction in STAT3 protein in Mapk14D/D lungs ( Fig . 3a ) that correlated with the reduction in Il6 mRNA ( Fig . 3 ) .
# ::alignments 0-1.1 1-1.3 2-1 4-1.2 6-1.2.1.1.1 7-1.2.1 7-1.2.3.1.1.2 8-1.2.2.r 9-1.2.2.1.1.1 10-1.2.2 14-1.2.4.1.1 17-1.2.3 18-1.2.3.1.r 20-1.2.3.1 23-1.2.3.1.1.1.1 27-1.4.1.1
# ::id bel_pmid_1746_8755_29068
(d / detect-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (r / reduce-01~e.4
            :ARG1 (p / protein~e.7
                  :name (n / name :op1 "STAT3"~e.6))
            :location~e.8 (l / lung~e.10
                  :mod (p2 / pathway
                        :name (n2 / name :op1 "Mapk14D/D"~e.9)))
            :ARG1-of (c / correlate-01~e.17
                  :ARG2~e.18 (r2 / reduce-01~e.20
                        :ARG1 (r3 / rna
                              :name (n3 / name :op1 "mRNA"~e.23)
                              :part (p3 / protein~e.7
                                    :name (n4 / name :op1 "IL-6")))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "3a"~e.14)))
      :mod (a / also~e.1)
      :ARG1-of (d3 / describe-01
            :ARG0 (f2 / figure :mod "3"~e.27)))

# ::tok three times as much Egfr mRNA was present in Mapk14D/D lungs ( Fig . 3d ) compared with Mapk14D/+ lungs , suggesting that EGFR expression was transcriptionally enhanced in the absence of p38a .
# ::alignments 0-1.1.1.1 1-1.1.1 4-1.1.2.1.1 6-1.1.r 7-1 8-1.4.r 9-1.4.1.1.1 10-1.4 14-1.6.1.1 16-1.2 19-1.2.1 21-1.3 22-1.3.1.r 23-1.3.1.1.1.1.1 24-1.3.1.1 27-1.3.1 28-1.3.1.3.r 30-1.3.1.3 31-1.3.1.3.1.r 32-1.3.1.3.1.1.1
# ::id bel_pmid_1746_8755_29072
(p / present~e.7
      :domain~e.6 (r / rna
            :quant (p3 / product-of~e.1 :quant "3"~e.0)
            :part (e5 / enzyme
                  :name (n4 / name :op1 "Egfr"~e.4)))
      :ARG1-of (c / compare-01~e.16
            :ARG2 (l2 / lung~e.19
                  :mod (p4 / pathway
                        :name (n5 / name :op1 "Mapk14D")
                        :ARG2-of (m / mutate-01 :mod "+/+"))))
      :ARG0-of (s / suggest-01~e.21
            :ARG1~e.22 (e / enhance-01~e.27
                  :ARG1 (e2 / express-03~e.24
                        :ARG2 (e3 / enzyme
                              :name (n / name :op1 "EGFR"~e.23)))
                  :manner (t / transcribe-01)
                  :condition~e.28 (a / absent-01~e.30
                        :ARG1~e.31 (e4 / enzyme
                              :name (n2 / name :op1 "p38a"~e.32)))))
      :location~e.8 (l / lung~e.10
            :mod (p2 / pathway
                  :name (n3 / name :op1 "Mapk14D/D"~e.9)))
      :mod e3
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "3d"~e.14)))

# ::tok Notably , EGFR transcription is regulated by AP @-@ 1 ( ref . 28 ) , and we observed higher levels of phospho @-@ c @-@ Jun , one of the AP @-@ 1 components , in the p38a @-@ deficient lungs ( Fig . 3c ) , suggesting that p38a downregulation might activate AP @-@ 1 .
# ::alignments 0-1.1.4 2-1.1.2.1.1.1 3-1.1.2 5-1.1 6-1.1.1.r 7-1.1.1.1.1 9-1.1.1.1.1 13-1.1.3.1.1.1 16-1 17-1.2.1 18-1.2 19-1.2.2.1 19-1.2.2.1.1 19-1.2.2.1.1.r 20-1.2.2 24-1.2.2.2.1.1 26-1.2.2.2.1.1 28-1.2.2.2.2.1.1 29-1.2.2.2.2.1.1 30-1.2.2.2.2.1.1 31-1.2.2.2.2.1.1 32-1.2.2.2.2.1.1 33-1.2.2.2.2.1.1 34-1.2.2.2.2.1 36-1.2.2.3.r 38-1.2.2.3.1.1.1.1 41-1.2.2.3 45-1.2.3.1.1 48-1.3 49-1.3.1.r 50-1.3.1.1.1.1 51-1.3.1.1.1 52-1.3.1 53-1.3.1.1 54-1.3.1.1.2 55-1.3.1.1.2 56-1.3.1.1.2
# ::id bel_pmid_1746_8755_29082
(a / and~e.16
      :op1 (r / regulate-01~e.5
            :ARG0~e.6 (p3 / protein
                  :name (n3 / name :op1 "AP-1"~e.7,9))
            :ARG1 (t / transcribe-01~e.3
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "EGFR"~e.2)))
            :ARG1-of (d / describe-01
                  :ARG0 (p2 / publication
                        :ARG1-of (c / cite-01 :ARG2 "28"~e.13)))
            :mod (n2 / notable~e.0))
      :op2 (o / observe-01~e.18
            :ARG0 (w / we~e.17)
            :ARG1 (l / level~e.20
                  :mod (h / high~e.19
                        :degree~e.19 (m / more~e.19))
                  :quant-of (p / protein
                        :name (n4 / name :op1 "c-Jun"~e.24,26)
                        :ARG1-of (i / include-91
                              :ARG2 (c2 / component~e.34
                                    :poss p3~e.28,29,30,31,32,33))
                        :ARG1-of (p4 / phosphorylate-01))
                  :location~e.36 (l2 / lung~e.41
                        :ARG0-of (l3 / lack-01
                              :ARG1 (e2 / enzyme
                                    :name (n5 / name :op1 "p38a"~e.38)))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "3c"~e.45)))
      :ARG0-of (s / suggest-01~e.48
            :ARG1~e.49 (p5 / possible~e.52
                  :domain (a2 / activate-01~e.53
                        :ARG0 (d3 / downregulate-01~e.51
                              :ARG1 e2~e.50)
                        :ARG1 p3~e.54,55,56))))

# ::tok Furthermore , inactivation of JNK or c @-@ Jun suppressed the increased proliferation of Mapk14 @-@ deficient hepatocytes and tumor cells .
# ::alignments 2-1.1.1 2-1.1.1.1 2-1.1.1.1.r 3-1.1.1.2.r 4-1.1.1.2.1.1.1 5-1.1.1.2 6-1.1.1.2.2.1.1 8-1.1.1.2.2.1.1 9-1.1 11-1.1.2.2 12-1.1.2 13-1.1.2.1.r 14-1.1.2.1.1.2.1.1.1 18-1.1.2.1 19-1.1.2.1.2.1 20-1.1.2.1.2
# ::id bel_pmid_1746_8757_6426
(a / and
      :op2 (s / suppress-01~e.9
            :ARG0 (a2 / activate-01~e.2
                  :polarity~e.2 "-"~e.2
                  :ARG1~e.3 (o / or~e.5
                        :op1 (e / enzyme
                              :name (n / name :op1 "JNK"~e.4))
                        :op2 (p / protein
                              :name (n2 / name :op1 "c-Jun"~e.6,8))))
            :ARG1 (p2 / proliferate-01~e.12
                  :ARG0~e.13 (a3 / and~e.18
                        :op1 (c / cell
                              :name (n3 / name :op1 "hepatocyte")
                              :ARG0-of (l / lack-01
                                    :ARG1 (e2 / enzyme
                                          :name (n4 / name :op1 "Mapk14"~e.14))))
                        :op2 (c2 / cell~e.20
                              :mod (t / tumor~e.19)))
                  :ARG1-of (i / increase-01~e.11))))

# ::tok Upon stimulation with TLR ligands , p105 is phosphorylated by I kappa B kinase ( IKK ) complex and partially degraded , which releases TPL2. The free TPL2 is active and stimulates the ERK pathway via MEK1 @/@ 2 .
# ::alignments 1-1.1.4 2-1.1.4.1.r 3-1.1.4.1.1.1 4-1.1.4.1 6-1.1.1.1.1.1 8-1.1.1 13-1.1.1.2.1.2 17-1.1.1.2 18-1.1 19-1.1.2.2 20-1.1.2 23-1.1.3 26-1.2.1.1 26-1.2.1.1.2 26-1.2.1.1.2.r 27-1.1.3.1.1.1 27-1.2.1.1.1.1 30-1.2 31-1.2.2 33-1.2.2.2.1.1 34-1.2.2.2 36-1.2.2.3.1.1 38-1.2.2.3.1.1
# ::id bel_pmid_1750_7094_5814
(m / multi-sentence
      :snt1 (a / and~e.18
            :op1 (p / phosphorylate-01~e.8
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "p105"~e.6))
                  :ARG2 (m2 / macro-molecular-complex~e.17
                        :name (n2 / name :op1 "IκB" :op2 "kinase"~e.13)))
            :op2 (d / degrade-01~e.20
                  :ARG1 p2
                  :degree (p3 / partial~e.19))
            :ARG0-of (r / release-01~e.23
                  :ARG1 (e / enzyme
                        :name (n3 / name :op1 "TPL2"~e.27)))
            :time (s / stimulate-01~e.1
                  :ARG2~e.2 (l / ligand~e.4
                        :name (n4 / name :op1 "TLR"~e.3))))
      :snt2 (a2 / and~e.30
            :op1 (a3 / activate-01
                  :ARG1 (e2 / enzyme~e.26
                        :name (n5 / name :op1 "TPL2"~e.27)
                        :ARG1-of~e.26 (f / free-04~e.26)))
            :op2 (s2 / stimulate-01~e.31
                  :ARG0 e2
                  :ARG1 (p4 / pathway~e.34
                        :name (n6 / name :op1 "ERK"~e.33))
                  :ARG2 (e3 / enzyme
                        :name (n7 / name :op1 "MEK1/2"~e.36,38)))))

# ::tok Angiopoietin @-@ 1 stimulates association of SHP @-@ 2 to the phosphorylated Tie @-@ 2 receptor ( 47 ) , which in turn inhibits PI3 kinase @-@ dependent signaling pathways leading to EC migration .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1 4-1.2 5-1.2.2.r 6-1.2.2.1.1 8-1.2.2.1.1 9-1.2.3.r 11-1.2.3.2 12-1.2.3.1.1 14-1.2.3.1.1 15-1.2.3 17-1.3.1.1.1 21-1.2.4.3 22-1.2.4.3 23-1.2.4 24-1.2.4.1.2.1.1.1 25-1.2.4.1.2.1 27-1.2.4.1.2 28-1.2.4.1.1 29-1.2.4.1 30-1.2.4.2 31-1.2.4.2.1.r 32-1.2.4.2.1.1.1.1 33-1.2.4.2.1
# ::id bel_pmid_1751_1588_20428
(s / stimulate-01~e.3
      :ARG0 (p / protein
            :name (n / name :op1 "angiopoietin-1"~e.0,2))
      :ARG1 (a / associate-01~e.4
            :ARG0 p
            :ARG1~e.5 (e / enzyme
                  :name (n2 / name :op1 "SHP-2"~e.6,8))
            :ARG2~e.9 (r / receptor~e.15
                  :name (n3 / name :op1 "Tie-2"~e.12,14)
                  :ARG1-of (p2 / phosphorylate-01~e.11))
            :ARG0-of (i / inhibit-01~e.23
                  :ARG1 (p3 / pathway~e.29
                        :ARG0-of (s2 / signal-07~e.28)
                        :ARG0-of (d / depend-01~e.27
                              :ARG1 (k / kinase~e.25
                                    :name (n4 / name :op1 "PI3"~e.24))))
                  :ARG0-of (l / lead-03~e.30
                        :ARG2~e.31 (m / migrate-01~e.33
                              :ARG0 (c / cell
                                    :name (n5 / name :op1 "EC"~e.32))))
                  :mod (i2 / in-turn~e.21,22)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "47"~e.17))))

# ::tok Overexpression of dominant negative N17Rac1 significantly inhibits VEGF @-@ induced ROS production that is involved in VEGFR2 activation , EC migration , and proliferation ( 100 ) .
# ::alignments 2-1.1.1 2-1.1.1.3 2-1.1.1.3.r 3-1.1.1.2 4-1.1.1.1.1 5-1.3 6-1 7-1.2.2.1.1.1 9-1.2.2 10-1.2.1.1.1 11-1.2 14-1.2.3 15-1.2.3.1.r 16-1.2.3.1.1.1.1.1 17-1.2.3.1.1 19-1.2.3.1.2.1.1.1.1 20-1.2.3.1.2.1 22-1.2.3.1.2 23-1.2.3.1.2.2 25-1.4.1.1.1
# ::id bel_pmid_1751_1588_36510
(i / inhibit-01~e.6
      :ARG0 (o / overexpress-00
            :ARG1 (e / enzyme~e.2
                  :name (n / name :op1 "N17Rac1"~e.4)
                  :mod (n2 / negative~e.3)
                  :ARG0-of~e.2 (d / dominate-01~e.2)))
      :ARG1 (p / produce-01~e.11
            :ARG1 (m / molecular-physical-entity
                  :name (n3 / name :op1 "ROS"~e.10))
            :ARG1-of (i2 / induce-01~e.9
                  :ARG0 (p2 / protein
                        :name (n4 / name :op1 "VEGF"~e.7)))
            :ARG1-of (i3 / involve-01~e.14
                  :ARG2~e.15 (a / and
                        :op1 (a2 / activate-01~e.17
                              :ARG1 (p3 / protein
                                    :name (n5 / name :op1 "VEGFR2"~e.16)))
                        :op2 (a3 / and~e.22
                              :op1 (m2 / migrate-01~e.20
                                    :ARG0 (c / cell
                                          :name (n6 / name :op1 "EC"~e.19)))
                              :op2 (p4 / proliferate-01~e.23
                                    :ARG0 c)))))
      :degree (s / significant~e.5)
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "100"~e.25))))

# ::tok VEGFR2 forms a complex with VE @-@ cadherin , -@ catenin , and PI3 kinase that is required for phosphorylation of Akt , which plays an important role in EC survival ( 15 ) and migration ( 27 , 28 , 80 ) .
# ::alignments 0-1.1.1.1 1-1 3-1.2 5-1.2.2.1.1 5-1.2.3.1.1 7-1.2.2.1.1 10-1.2.3.1.1 13-1.2.4.1.1 14-1.2.4 17-1.2.5 18-1.2.5.1.r 19-1.2.5.1 20-1.2.5.1.1.r 21-1.2.5.1.1.1.1 24-1.2.5.1.2 26-1.2.5.1.2.1.3 28-1.2.5.1.2.1.r 29-1.2.5.1.2.1.1.1.1.1 30-1.2.5.1.2.1.1 32-1.2.5.1.2.1.1.2.1.1.1 34-1.2.5.1.2.1 35-1.2.5.1.2.1.2 37-1.2.5.1.2.1.2.2.1.1.1.1 39-1.2.5.1.2.1.2.2.1.1.1.2 41-1.2.5.1.2.1.2.2.1.1.1.3
# ::id bel_pmid_1751_1588_36636
(f / form-01~e.1
      :ARG0 (p / protein
            :name (n / name :op1 "VEGFR2"~e.0))
      :ARG1 (m / macro-molecular-complex~e.3
            :part p
            :part (p2 / protein
                  :name (n2 / name :op1 "VE-cadherin"~e.5,7))
            :part (p3 / protein
                  :name (n3 / name :op1 "VE-catenin"~e.5,10))
            :part (k / kinase~e.14
                  :name (n4 / name :op1 "PI3"~e.13))
            :ARG1-of (r / require-01~e.17
                  :ARG0~e.18 (p4 / phosphorylate-01~e.19
                        :ARG2~e.20 (e / enzyme
                              :name (n5 / name :op1 "Akt"~e.21))
                        :ARG0-of (p5 / play-02~e.24
                              :ARG1~e.28 (a / and~e.34
                                    :op1 (s / survive-02~e.30
                                          :ARG0 (c / cell
                                                :name (n6 / name :op1 "EC"~e.29))
                                          :ARG1-of (d / describe-01
                                                :ARG0 (p6 / publication
                                                      :ARG1-of (c2 / cite-01 :ARG2 "15"~e.32))))
                                    :op2 (m2 / migrate-01~e.35
                                          :ARG0 c
                                          :ARG1-of (d2 / describe-01
                                                :ARG0 (p7 / publication
                                                      :ARG1-of (c3 / cite-01
                                                            :ARG2 (a2 / and
                                                                  :op1 "27"~e.37
                                                                  :op2 "28"~e.39
                                                                  :op3 "80"~e.41)))))
                                    :mod (i / important~e.26)))))))

# ::tok FIGURE 9. TGF @-@ beta1 induces snail @-@ 1 in hepatocytes in EMT state and lack of evidence for Akt @/@ Erk1 @/@ 2 activation
# ::alignments 0-1.1 2-1.2.1.1.1 5-1.2 6-1.2.2.1.1 8-1.2.2.1.1 11-1.2.3.r 12-1.2.3.2.1.1.1 13-1.2.3.2.1 14-1.2.3.2 15-1.2.3.2.2 16-1.2.3.2.2.1.r 17-1.2.3.2.2.1 18-1.2.3.2.2.1.1.r 19-1.2.3.2.2.1.1.1.1.1 21-1.2.3.2.2.1.1.1.1.1 23-1.2.3.2.2.1.1.1.1.1 24-1.2.3.2.2.1.1
# ::id bel_pmid_1751_3865_31240
(d / describe-01
      :ARG0 (f / figure~e.0 :mod "9")
      :ARG1 (i / induce-01~e.5
            :ARG0 (p / protein
                  :name (n / name :op1 "TGF-β1"~e.2))
            :ARG1 (p2 / protein
                  :name (n2 / name :op1 "snail-1"~e.6,8))
            :location~e.11 (c / cell
                  :name (n3 / name :op1 "hepatocyte")
                  :condition (a / and~e.14
                        :op1 (s / state~e.13
                              :name (n4 / name :op1 "EMT"~e.12))
                        :op2 (l / lack-01~e.15
                              :ARG1~e.16 (e / evidence-01~e.17
                                    :ARG1~e.18 (a2 / activate-01~e.24
                                          :ARG1 (p3 / pathway
                                                :name (n5 / name :op1 "Akt/Erk1/2"~e.19,21,23)))))))))

# ::tok FIGURE 11. TGF @-@ beta1 induces activation of Smad2 @/@ 3 pathway in AML12 cell line
# ::alignments 0-1.1 2-1.2.1.1.1 5-1.2 6-1.2.2 7-1.2.2.2.r 8-1.2.2.2.1.1 10-1.2.2.2.1.1 11-1.2.2.2 12-1.2.2.3.r 13-1.2.2.3.1.1 14-1.2.2.3 15-1.2.2.3
# ::id bel_pmid_1751_3865_39040
(d / describe-01
      :ARG0 (f / figure~e.0 :mod "11")
      :ARG1 (i / induce-01~e.5
            :ARG0 (p / protein
                  :name (n / name :op1 "TGF-β1"~e.2))
            :ARG1 (a / activate-01~e.6
                  :ARG0 p
                  :ARG1~e.7 (p2 / pathway~e.11
                        :name (n2 / name :op1 "Smad2/3"~e.8,10))
                  :location~e.12 (c / cell-line~e.14,15
                        :name (n3 / name :op1 "AML12"~e.13)))))

# ::tok Aortas from COX @-@ 2?/? mice on atherogenic diet after 3 weeks had significantly larger areas of neutral lipid content as measured by Oil Red O staining ( Fig . 1A ) .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1 5-1.1.1 6-1.1.1.2.r 7-1.1.1.2.1 8-1.1.1.2 9-1.3 10-1.3.1.1 11-1.3.1.2 12-1 13-1.2.1.2 14-1.2.1 14-1.2.1.1 14-1.2.1.1.r 15-1.2 16-1.2.2.r 17-1.2.2.1.1 18-1.2.2.1 19-1.2.2 20-1.2.3.r 20-1.3.r 21-1.2.3 22-1.2.3.1.r 23-1.2.3.1.1.1.1 24-1.2.3.1.1.1.2 25-1.2.3.1.1.1.3 26-1.2.3.1 30-1.4.1.1
# ::id bel_pmid_1764_3885_30204
(h / have-03~e.12
      :ARG0 (a / aorta~e.0
            :source~e.1 (m / mouse~e.5
                  :mod (e / enzyme
                        :name (n / name :op1 "COX-2"~e.2)
                        :ARG2-of (m2 / mutate-01 :mod "-/-"))
                  :condition~e.6 (d / diet~e.8
                        :mod (a2 / atherogenic~e.7))))
      :ARG1 (a3 / area~e.15
            :quant (l / large~e.14
                  :degree~e.14 (m3 / more~e.14)
                  :degree (s / significant~e.13))
            :ARG0-of~e.16 (c / contain-01~e.19
                  :ARG1 (l2 / lipid~e.18
                        :mod (n2 / neutral~e.17)))
            :ARG1-of~e.20 (m4 / measure-01~e.21
                  :ARG2~e.22 (s2 / stain-00~e.26
                        :ARG2 (m5 / molecular-physical-entity
                              :name (n3 / name
                                    :op1 "Oil"~e.23
                                    :op2 "Red"~e.24
                                    :op3 "O"~e.25)))))
      :time~e.20 (a4 / after~e.9
            :op1 (t / temporal-quantity
                  :quant "3"~e.10
                  :unit (w / week~e.11)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "1A"~e.30)))

# ::tok Serum TXB2 is significantly increased in COX @-@ 2?/? mice on chow compared to wild @-@ type littermates ( Fig . 4A ) .
# ::alignments 0-1.1.2 1-1.1.1.1 3-1.3 4-1 5-1.2.r 6-1.2.1.1.1 9-1.2 11-1.2.2.1 12-1.4.r 14-1.4.1 16-1.4.1 21-1.5.1.1
# ::id bel_pmid_1764_3885_30206
(i / increase-01~e.4
      :ARG1 (m / molecular-physical-entity
            :name (n / name :op1 "TXB2"~e.1)
            :location (s / serum~e.0))
      :location~e.5 (m2 / mouse~e.9
            :mod (e / enzyme
                  :name (n2 / name :op1 "COX-2"~e.6)
                  :ARG2-of (m3 / mutate-01 :mod "-/-"))
            :mod (d / diet
                  :mod (c / chow~e.11)))
      :degree (s2 / significant~e.3)
      :compared-to~e.12 (l / littermate
            :mod (w / wild-type~e.14,16))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4A"~e.21)))

# ::tok Interestingly , COX @-@ 2?/? mice on atherogenic diet showed more systemic inflammation with higher levels of TNF ( Fig . 5B ) and IL @-@ 6 ( Fig . 5D ) than wild @-@ type controls . Furthermore , IL @-@ 12 was significantly increased by atherogenic diet in wild @-@ type controls , while COX @-@ 2 depletion completely abolished this induction ( Fig . 5E ) .
# ::alignments 0-1.1.3 0-1.1.3.r 2-1.1.1.1.1.1 5-1.1.1 6-1.1.1.2.r 7-1.1.1.2.1 8-1.1.1.2 9-1.1 10-1.1.2.1.1 10-1.1.2.2.2.1 11-1.1.2.1 14-1.1.2.2.2 14-1.1.2.2.2.1 14-1.1.2.2.2.1.r 15-1.1.2.2 16-1.1.2.2.1.r 17-1.1.2.2.1.1.1.1 21-1.1.2.2.1.1.2.1.1 23-1.1.2.2.1 24-1.1.2.2.1.2.1.1 26-1.1.2.2.1.2.1.1 30-1.1.2.2.1.2.2.1.1 32-1.1.2.2.2.2.r 33-1.1.2.2.2.2.1 35-1.1.2.2.2.2.1 36-1.1.2.2.2.2 40-1.2.1.1.2.1.1 42-1.2.1.1.2.1.1 44-1.2.1.1.3 45-1.2.1.1 46-1.2.1.1.1.r 47-1.2.1.1.1.1 48-1.2.1.1.1 50-1.1.2.2.2.2.1 52-1.2.1.1.4.1 53-1.2.1.1.4 55-1.2.1 56-1.2.1.2.1.1.1.1 58-1.2.1.2.1.1.1.1 59-1.2.1.2.1 60-1.2.1.2.3 61-1.2.1.2 62-1.2.1.2.2.1 67-1.2.2.1.1
# ::id bel_pmid_1764_3885_30216
(m / multi-sentence
      :snt1 (s / show-01~e.9
            :ARG0 (m2 / mouse~e.5
                  :mod (e / enzyme
                        :name (n / name :op1 "COX-2"~e.2)
                        :ARG2-of (m3 / mutate-01 :mod "-/-"))
                  :condition~e.6 (d / diet~e.8
                        :mod (a / atherogenic~e.7)))
            :ARG1 (i / inflame-01
                  :mod (s2 / systemic~e.11
                        :degree (m4 / more~e.10))
                  :mod (l / level~e.15
                        :quant-of~e.16 (a2 / and~e.23
                              :op1 (p / protein
                                    :name (n2 / name :op1 "TNF"~e.17)
                                    :ARG1-of (d2 / describe-01
                                          :ARG0 (f / figure :mod "5B"~e.21)))
                              :op2 (p2 / protein
                                    :name (n3 / name :op1 "IL-6"~e.24,26)
                                    :ARG1-of (d3 / describe-01
                                          :ARG0 (f2 / figure :mod "5D"~e.30))))
                        :mod (h / high~e.14
                              :degree~e.14 (m5 / more~e.10,14)
                              :compared-to~e.32 (c / control-01~e.36
                                    :mod (w / wild-type~e.33,35,50)))))
            :manner~e.0 (i2 / interesting~e.0))
      :snt2 (a3 / and
            :op2 (c2 / contrast-01~e.55
                  :ARG1 (i3 / increase-01~e.45
                        :ARG0~e.46 (d4 / diet~e.48
                              :mod (a4 / atherogenic~e.47))
                        :ARG1 (p3 / protein
                              :name (n4 / name :op1 "IL-12"~e.40,42))
                        :degree (s3 / significant~e.44)
                        :location (c3 / control-01~e.53
                              :mod (w2 / wild-type~e.52)))
                  :ARG2 (a5 / abolish-01~e.61
                        :ARG0 (d5 / deplete-01~e.59
                              :ARG1 (e2 / enzyme
                                    :name (n5 / name :op1 "COX-2"~e.56,58)))
                        :ARG1 (i4 / induct-01
                              :mod (t / this~e.62))
                        :degree (c4 / complete~e.60)))
            :ARG1-of (d6 / describe-01
                  :ARG0 (f3 / figure :mod "5E"~e.67))))

# ::tok Table 1. Production of pro @- and anti @-@ angiogenic mediators by DCs Pro @-@ angiogenic mediators : VEGF , FGF2 , TNF @-@ a , IL @-@ 6 , TGF @-@ b , CXCL8 , CXCL5 , CXCL1 , 2, 3 , CCL2 , GM @-@ CSF , ET @-@ 1 , OPN , Anti @-@ angiogenic mediators : IL @-@ 12 , IL @-@ 18 , IL @-@ 10 , TSP @-@ 1 , PTX3 , IFN @-@ a/b , CXCL9 , CXCL10 , CXCL13 , CCL21
# ::alignments 0-1.1 2-1.2 3-1.2.2.r 4-1.2.2.1.2 6-1.2.2 6-1.2.2.1.3.1 7-1.2.2.2 7-1.2.2.2.2 7-1.2.2.2.2.r 10-1.2.2.1 10-1.2.2.1.1 10-1.2.2.1.1.r 13-1.2.2.1.2 16-1.2.2.1 16-1.2.2.1.1 16-1.2.2.1.1.r 18-1.2.2.1.3.1.1.1.1 20-1.2.2.1.3.1.2.1.1 22-1.2.2.1.3.1.3.1.1 26-1.2.2.1.3.1.4.1.1 28-1.2.2.1.3.1.4.1.1 30-1.2.2.1.3.1.5.1.1 34-1.2.2.1.3.1.6.1.1 36-1.2.2.1.3.1.7.1.1 38-1.2.2.1.3.1.8.1.1 43-1.2.2.1.3.1.11.1.1 45-1.2.2.1.3.1.12.1.1 47-1.2.2.1.3.1.12.1.1 49-1.2.2.1.3.1 49-1.2.2.1.3.1.13.1.1 51-1.2.2.1.3.1.13.1.1 53-1.2.2.1.3.1.14.1.1 55-1.2.2.2 55-1.2.2.2.2 55-1.2.2.2.2.r 58-1.2.2.2.1 60-1.2.2.2.3.1.1.1.1 62-1.2.2.2.3.1.1.1.1 64-1.2.2.2.3.1.1.1.1 64-1.2.2.2.3.1.2.1.1 64-1.2.2.2.3.1.3.1.1 66-1.2.2.2.3.1.2.1.1 68-1.2.2.2.3.1.1.1.1 68-1.2.2.2.3.1.2.1.1 68-1.2.2.2.3.1.3.1.1 70-1.2.2.2.3.1.3.1.1 72-1.2.2.2.3.1.4.1.1 74-1.1.1 74-1.2.2.2.3.1.4.1.1 76-1.2.2.2.3.1.5.1.1 78-1.2.2.2.3.1.6.1.1 82-1.2.2.2.3.1.7.1.1 84-1.2.2.2.3.1.8.1.1 86-1.2.2.2.3.1.9.1.1 88-1.2.2.2.3.1.10.1.1
# ::id bel_pmid_1769_2569_37970
(d / describe-01
      :ARG0 (t / table~e.0 :mod "1"~e.74)
      :ARG1 (p / produce-01~e.2
            :ARG0 (c / cell
                  :name (n / name :op1 "DC"))
            :ARG1~e.3 (a / and~e.6
                  :op1 (m / molecular-physical-entity~e.10,16
                        :ARG0-of~e.10,16 (m2 / mediate-01~e.10,16)
                        :ARG0-of (f / favor-01~e.4,13
                              :ARG1 (a2 / angiogenesis))
                        :ARG1-of (m3 / mean-01
                              :ARG2 (a3 / and~e.6,49
                                    :op1 (p2 / protein
                                          :name (n2 / name :op1 "VEGF"~e.18))
                                    :op2 (p3 / protein
                                          :name (n3 / name :op1 "FGF2"~e.20))
                                    :op3 (p4 / protein
                                          :name (n4 / name :op1 "TNF-α"~e.22))
                                    :op4 (p5 / protein
                                          :name (n5 / name :op1 "IL-6"~e.26,28))
                                    :op5 (p6 / protein
                                          :name (n6 / name :op1 "TGF-β"~e.30))
                                    :op6 (p7 / protein
                                          :name (n7 / name :op1 "CXCL8"~e.34))
                                    :op7 (p8 / protein
                                          :name (n8 / name :op1 "CXCL5"~e.36))
                                    :op8 (p9 / protein
                                          :name (n9 / name :op1 "CXCL1"~e.38))
                                    :op9 (p10 / protein
                                          :name (n10 / name :op1 "CXCL2"))
                                    :op10 (p11 / protein
                                          :name (n11 / name :op1 "CXCL3"))
                                    :op11 (p12 / protein
                                          :name (n12 / name :op1 "CCL2"~e.43))
                                    :op12 (p13 / protein
                                          :name (n13 / name :op1 "GM-CSF"~e.45,47))
                                    :op13 (p14 / protein
                                          :name (n14 / name :op1 "ET-1"~e.49,51))
                                    :op14 (p15 / protein
                                          :name (n15 / name :op1 "OPN"~e.53)))))
                  :op2 (m4 / molecular-physical-entity~e.7,55
                        :ARG0-of m2~e.58
                        :ARG0-of~e.7,55 (c2 / counter-01~e.7,55
                              :ARG1 a2)
                        :ARG1-of (m5 / mean-01
                              :ARG2 (a4 / and
                                    :op1 (p16 / protein
                                          :name (n16 / name :op1 "IL-12"~e.60,62,64,68))
                                    :op2 (p17 / protein
                                          :name (n17 / name :op1 "IL-18"~e.64,66,68))
                                    :op3 (p18 / protein
                                          :name (n18 / name :op1 "IL-10"~e.64,68,70))
                                    :op4 (p19 / protein
                                          :name (n19 / name :op1 "TSP-1"~e.72,74))
                                    :op5 (p20 / protein
                                          :name (n20 / name :op1 "PTX3"~e.76))
                                    :op6 (p21 / protein
                                          :name (n21 / name :op1 "IFN-α/β"~e.78))
                                    :op7 (p22 / protein
                                          :name (n22 / name :op1 "CXCL9"~e.82))
                                    :op8 (p23 / protein
                                          :name (n23 / name :op1 "CXCL10"~e.84))
                                    :op9 (p24 / protein
                                          :name (n24 / name :op1 "CXCL13"~e.86))
                                    :op10 (p25 / protein
                                          :name (n25 / name :op1 "CCL21"~e.88))))))))

# ::tok Flow cytometry confirmed that follicular B cells present in Itpkb ?/? and Itpkb ?/? E ? -2–22 BCL @-@ 2 mice expressed a higher level of Bim protein .
# ::alignments 0-1.1.1.1 1-1.1.1.2 2-1 3-1.2.r 4-1.2.2.3 5-1.2.2.1.1 6-1.2.2 9-1.2.2.2.1.1.1.1.1 12-1.2.2.2.1.1.1.1.1 17-1.2.2.2.1.2.1.1.1 19-1.2.2.2.1.2.1.1.1 20-1.2.2.2.1.1 20-1.2.2.2.1.2 21-1.2 23-1.2.1.2 23-1.2.1.2.1 23-1.2.1.2.1.r 24-1.2.1 26-1.2.1.1.1.1 27-1.2.1.1 27-1.2.2.2.1.2.1
# ::id bel_pmid_1770_9751_28596
(c / confirm-01~e.2
      :ARG0 (t / thing
            :name (n / name :op1 "flow"~e.0 :op2 "cytometry"~e.1))
      :ARG1~e.3 (e / express-03~e.21
            :ARG2 (l / level~e.24
                  :quant-of (p / protein~e.27
                        :name (n2 / name :op1 "Bim"~e.26))
                  :quant (h / high~e.23
                        :degree~e.23 (m / more~e.23)))
            :ARG3 (c2 / cell~e.6
                  :name (n3 / name :op1 "B"~e.5)
                  :ARG1-of (b / be-located-at-91
                        :ARG2 (a / and
                              :op1 (m2 / mouse~e.20
                                    :mod (e2 / enzyme
                                          :name (n4 / name :op1 "Itpkb"~e.9,12)
                                          :ARG2-of (m3 / mutate-01 :mod "-/-")))
                              :op2 (m4 / mouse~e.20
                                    :mod (p2 / protein~e.27
                                          :name (n5 / name :op1 "BCL-2"~e.17,19)
                                          :mod (d / dna-sequence
                                                :name (n6 / name :op1 "Eμ-2–22")
                                                :mod e2)))))
                  :location (f / follicle~e.4))))

# ::tok Erk1 and Erk2 were found to be much less phosphorylated in Itpkb ?/? E ? -2?22 @-@ BCL @-@ 2 B cells than in control B cells after BCR activation ( Fig . 3 b ) .
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 2-1.1.1.2.1.1 4-1 7-1.1.2.1 8-1.1.2 9-1.1 10-1.1.3.r 11-1.1.3.2.2.2.1.1 17-1.1.3.2.1.1 19-1.1.3.2.1.1 20-1.1.3.1.1 20-1.1.3.3.1.1 21-1.1.3 21-1.1.3.3 22-1.1.3.3.r 24-1.1.3.3.2 25-1.1.3.3.1.1 26-1.1.3.3 27-1.2 28-1.2.1.1.1.1 29-1.2.1 34-1.1.3.1.1 34-1.1.3.3.1.1
# ::id bel_pmid_1770_9751_28598
(f / find-01~e.4
      :ARG1 (p / phosphorylate-01~e.9
            :ARG1 (a / and~e.1
                  :op1 (e / enzyme
                        :name (n / name :op1 "Erk1"~e.0))
                  :op2 (e2 / enzyme
                        :name (n2 / name :op1 "Erk2"~e.2)))
            :quant (l / less~e.8
                  :degree (m / much~e.7))
            :location~e.10 (c / cell~e.21
                  :name (n3 / name :op1 "B"~e.20,34)
                  :mod (p2 / protein
                        :name (n6 / name :op1 "BCL-2"~e.17,19)
                        :mod (d / dna-sequence
                              :name (n4 / name :op1 "Eμ-2–22")
                              :mod (e3 / enzyme
                                    :name (n5 / name :op1 "Itpkb"~e.11)
                                    :ARG2-of (m2 / mutate-01 :mod "-/-"))))
                  :compared-to~e.22 (c2 / cell~e.21,26
                        :name (n7 / name :op1 "B"~e.20,25,34)
                        :ARG0-of (c3 / control-01~e.24))))
      :time (a2 / after~e.27
            :op1 (a3 / activate-01~e.29
                  :ARG1 (p3 / protein
                        :name (n8 / name :op1 "BCR"~e.28))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure :mod "3b")))

# ::tok Quantitative real @-@ time RT @-@ PCR analysis revealed a slight , but very significant , increase in Bim messenger RNA level in splenic resting follicular B cells persisting in Itpkb ?/? mice .
# ::alignments 0-1.1.3 1-1.1.2 3-1.1.2 4-1.1.1.1.1 6-1.1.1.1.1 7-1.1 8-1 10-1.2.2 12-1.2.2.1 13-1.2.2.1.1.1 14-1.2.2.1.1 16-1.2 17-1.2.1.r 18-1.2.1.1.2.1.1.1 19-1.2.1.1.1.1 20-1.2.1.1.1.2 21-1.2.1 22-1.2.3.r 23-1.2.3.3.1 24-1.2.3.3 25-1.2.3.2 26-1.2.3.1.1 27-1.2.3 28-1.2.3.4 29-1.2.3.4.1.r 30-1.2.3.4.1.1.1.1 32-1.2.3.4.1
# ::id bel_pmid_1770_9751_28600
(r / reveal-01~e.8
      :ARG0 (a / analyze-01~e.7
            :mod (t / thing
                  :name (n / name :op1 "RT-PCR"~e.4,6))
            :mod (r2 / real-time~e.1,3)
            :mod (q / quantitative~e.0))
      :ARG1 (i / increase-01~e.16
            :ARG1~e.17 (l / level~e.21
                  :quant-of (r3 / rna
                        :name (n2 / name :op1 "messenger"~e.19 :op2 "RNA"~e.20)
                        :ARG1-of (e / express-03
                              :ARG2 (p / protein
                                    :name (n3 / name :op1 "Bim"~e.18)))))
            :ARG2 (s / slight~e.10
                  :ARG1-of (c / contrast-01~e.12
                        :ARG2 (s2 / significant-02~e.14
                              :degree (v / very~e.13))))
            :location~e.22 (c2 / cell~e.27
                  :name (n4 / name :op1 "B"~e.26)
                  :location (f / follicle~e.25)
                  :ARG1-of (r4 / rest-01~e.24
                        :location (s3 / spleen~e.23))
                  :ARG1-of (p2 / persist-01~e.28
                        :location~e.29 (m / mouse~e.32
                              :mod (e2 / enzyme
                                    :name (n5 / name :op1 "Itpkb"~e.30)
                                    :ARG2-of (m2 / mutate-01 :mod "-/-")))))))

# ::tok The forkhead transcription factor Foxp3 is highly expressed in CD4+CD25+ regulatory T cells ( Treg ) and was recently identified as a key player in mediating their inhibitory functions .
# ::alignments 1-1.1.1.1.1 2-1.1.1.1.2 3-1.1.1.1.3 4-1.1.1.2.1.1.1 6-1.1.3 7-1.1 10-1.1.2.4 11-1.1.2.1.1 12-1.1.2 16-1 18-1.2.3 19-1.2 20-1.2.2.r 20-1.2.3.r 22-1.2.2.2 25-1.2.2.1.1 28-1.2.2.1.1.2
# ::id bel_pmid_1780_4750_41494
(a / and~e.16
      :op1 (e / express-03~e.7
            :ARG2 (p / protein
                  :name (n / name
                        :op1 "forkhead"~e.1
                        :op2 "transcription"~e.2
                        :op3 "factor"~e.3)
                  :ARG1-of (m / mean-01
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "Foxp3"~e.4))))
            :ARG3 (c / cell~e.12
                  :name (n3 / name :op1 "T"~e.11)
                  :mod (p3 / protein
                        :name (n4 / name :op1 "CD4"))
                  :mod (p4 / protein
                        :name (n5 / name :op1 "CD25"))
                  :ARG0-of (r / regulate-01~e.10))
            :degree (h / high~e.6))
      :op2 (i / identify-01~e.19
            :ARG1 p
            :ARG2~e.20 (m2 / molecular-physical-entity
                  :ARG0-of (p5 / play-02
                        :ARG1 (m3 / mediate-01~e.25
                              :ARG0 p
                              :ARG1 (f / function-01~e.28
                                    :ARG0 c
                                    :ARG1 (i2 / inhibit-01))))
                  :mod (k / key~e.22))
            :time~e.20 (r2 / recent~e.18)))

# ::tok Foxp3 expression was induced by transforming growth factor-( 32 ( TGF-( 32 ) , but not TGF-( 31 stimulation in these cells , and was partially suppressed following antibody @-@ mediated neutralization of TGF-( 32 .
# ::alignments 0-1.1.1.2.1.1.1 1-1.1.1.2 3-1.1.1 3-1.1.2 5-1.1.1.1.1.1.1 6-1.1.1.1.1.1.2 14-1.1 15-1.1.2.1 15-1.1.2.1.r 18-1.1.1.1 18-1.1.2.2 19-1.1.3.r 20-1.1.3.1 21-1.1.3 23-1 25-1.2.2 26-1.2 27-1.2.3 28-1.2.3.1.2.1 30-1.2.3.1.2 31-1.2.3.1
# ::id bel_pmid_1780_4750_41496
(a / and~e.23
      :op1 (c / contrast-01~e.14
            :ARG1 (i / induce-01~e.3
                  :ARG0 (s / stimulate-01~e.18
                        :ARG1 (p / protein
                              :name (n / name
                                    :op1 "transforming"~e.5
                                    :op2 "growth"~e.6
                                    :op3 "factor-(32")))
                  :ARG1 (e / express-03~e.1
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "Foxp3"~e.0))))
            :ARG2 (i2 / induce-01~e.3
                  :polarity~e.15 "-"~e.15
                  :ARG0 (s2 / stimulate-01~e.18
                        :ARG1 (p3 / protein
                              :name (n3 / name :op1 "TGF-(31"))))
            :location~e.19 (c2 / cell~e.21
                  :mod (t / this~e.20)))
      :op2 (s3 / suppress-01~e.26
            :ARG1 e
            :degree (p4 / partial~e.25)
            :ARG1-of (f / follow-01~e.27
                  :ARG2 (n4 / neutralize-01~e.31
                        :ARG1 p
                        :ARG1-of (m / mediate-01~e.30
                              :ARG0 (a2 / antibody~e.28))))))

# ::tok Down @-@ regulation of Foxp3 with small interfering RNA ( siRNA ) in pancreatic carcinoma cells resulted in the up @-@ regulation of interleukin 6 ( IL @-@ 6 ) and IL @-@ 8 expression , providing evidence for a negative transcriptional activity of Foxp3 also in these epithelial cells .
# ::alignments 4-1.1.1.1.1 6-1.1.2.1.1 7-1.1.2.1.2 8-1.1.2.1.3 13-1.1.3.1.1 14-1.1.3.1 15-1.1.3 16-1 23-1.2.1.1.1.1.1 24-1.2.1.1.1.1.2 26-1.2.1.1.2.1.1 30-1.2.1.1 31-1.2.1.1.2.1.1 33-1.2.1.1.2.1.1 34-1.2.1 36-1.3 37-1.3.1 40-1.3.1.2.3 44-1.3.1.2.1 45-1.3.1.2.4.3 47-1.3.1.2.4.2 48-1.3.1.2.4.1 49-1.3.1.2.4
# ::id bel_pmid_1780_4750_41498
(r / result-01~e.16
      :ARG1 (d / downregulate-01
            :ARG1 (p / protein
                  :name (n / name :op1 "Foxp3"~e.4))
            :ARG2 (r2 / rna
                  :name (n2 / name
                        :op1 "small"~e.6
                        :op2 "interfering"~e.7
                        :op3 "RNA"~e.8))
            :location (c / cell~e.15
                  :mod (c2 / carcinoma~e.14
                        :mod (p2 / pancreas~e.13))))
      :ARG2 (u / upregulate-01
            :ARG1 (e / express-03~e.34
                  :ARG2 (a / and~e.30
                        :op1 (p3 / protein
                              :name (n3 / name :op1 "interleukin"~e.23 :op2 "6"~e.24))
                        :op2 (p4 / protein
                              :name (n4 / name :op1 "IL-8"~e.26,31,33)))))
      :ARG0-of (p5 / provide-01~e.36
            :ARG1 (e2 / evidence-01~e.37
                  :ARG0 u
                  :ARG1 (a2 / act-01
                        :ARG0 p~e.44
                        :ARG1 (t / transcribe-01)
                        :mod (n5 / negative~e.40)
                        :location (c3 / cell~e.49
                              :mod (e3 / epithelium~e.48)
                              :mod (t2 / this~e.47)
                              :mod (a3 / also~e.45))))))

# ::tok Coculture of Foxp3 @-@ expressing tumor cells with naive T cells completely inhibited T @-@ cell proliferation , but not activation , and this antiproliferative effect was partially abrogated following specific inhibition of Foxp3 expression .
# ::alignments 0-1.1.1.1 1-1.1.1.1.1.r 2-1.1.1.1.1.2.1.1.1 4-1.1.1.1.1.2 5-1.1.1.1.1.1 6-1.1.1.1.1 7-1.1.1.1.1.3.r 8-1.1.1.1.1.3.2 9-1.1.1.1.1.3.1.1 10-1.1.1.1.1.3 11-1.1.1.3 12-1.1.1 12-1.1.2 13-1.1.1.1.1.3.1.1 13-1.1.1.2.1.1.1 15-1.1.1.2.1 16-1.1.1.2 16-1.2.1.1.1 18-1.1 19-1.1.2.1 19-1.1.2.1.r 20-1.1.2.3 22-1 23-1.2.1.2 25-1.2.1 27-1.2.2 28-1.2 29-1.2.3 30-1.2.3.1.2 31-1.2.3.1 32-1.2.3.1.1.r 33-1.2.3.1.1.1 34-1.2.3.1.1
# ::id bel_pmid_1780_4750_41500
(a / and~e.22
      :op1 (c / contrast-01~e.18
            :ARG1 (i / inhibit-01~e.12
                  :ARG0 (c2 / coculture-00~e.0
                        :ARG1~e.1 (c3 / cell~e.6
                              :mod (t / tumor~e.5)
                              :ARG3-of (e / express-03~e.4
                                    :ARG2 (p / protein
                                          :name (n / name :op1 "Foxp3"~e.2)))
                              :accompanier~e.7 (c4 / cell~e.10
                                    :name (n2 / name :op1 "T"~e.9,13)
                                    :mod (n3 / naive~e.8))))
                  :ARG1 (p2 / proliferate-01~e.16
                        :ARG0 (c5 / cell~e.15
                              :name (n4 / name :op1 "T"~e.13)))
                  :degree (c6 / complete~e.11))
            :ARG2 (i2 / inhibit-01~e.12
                  :polarity~e.19 "-"~e.19
                  :ARG0 c2
                  :ARG1 (a2 / activate-01~e.20
                        :ARG0 c5)))
      :op2 (a3 / abrogate-01~e.28
            :ARG1 (e2 / effect-01~e.25
                  :ARG1 (c7 / counter-01
                        :ARG1 (p3 / proliferate-01~e.16))
                  :mod (t2 / this~e.23))
            :degree (p4 / partial~e.27)
            :ARG1-of (f / follow-01~e.29
                  :ARG2 (i3 / inhibit-01~e.31
                        :ARG1~e.32 (e3 / express-03~e.34
                              :ARG2 p~e.33)
                        :mod (s / specific~e.30)))))

# ::tok In an initial analysis of microdissected pancreatic carcinoma tissue using Affymetrix chip technology , Foxp3 was among the up @-@ regulated genes in some tumor samples ( 26 ) ; ( Fig . 1A ) .
# ::alignments 2-1.4.3 3-1.4 6-1.4.1.1.1 7-1.4.1.1 8-1.4.1 9-1.4.2 10-1.4.2.1.1.1 11-1.4.2.1.1.2 12-1.4.2.1 14-1.1.1.1 16-1 21-1.2 23-1.3.2 24-1.3 25-1.3.1 27-1.5.1.1.1 33-1.6.1.1
# ::id bel_pmid_1780_4750_41502
(i / include-91~e.16
      :ARG1 (g / gene
            :name (n / name :op1 "Foxp3"~e.14))
      :ARG2 (g2 / gene~e.21
            :ARG1-of (u / upregulate-01))
      :location (t / tumor~e.24
            :ARG1-of (s / sample-01~e.25)
            :quant (s2 / some~e.23))
      :time (a / analyze-01~e.3
            :ARG1 (t2 / tissue~e.8
                  :mod (c / carcinoma~e.7
                        :mod (p / pancreas~e.6))
                  :ARG1-of (m / microdissect-00))
            :ARG0-of (u2 / use-01~e.9
                  :ARG1 (t3 / technology~e.12
                        :name (n2 / name :op1 "Affymetrix"~e.10 :op2 "chip"~e.11)))
            :mod (i2 / initial~e.2))
      :ARG1-of (d / describe-01
            :ARG0 (p2 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "26"~e.27)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "1A"~e.33)))

# ::tok In accordance with the immunohistochemistry data pointing to FoxP3 expression in tumor cells ( see above ) , Foxp3 expression was clearly detectable in several pancreatic carcinoma cell lines at both mRNA ( Fig . 2A ) and protein levels ( Fig . 2B ) .
# ::alignments 0-1.2 1-1.2 2-1.2 4-1.2.1.1 5-1.2.1 6-1.2.1.2 7-1.2.1.2.1.r 8-1.2.1.2.1.1 9-1.2.1.2.1 10-1.2.1.2.1.2.r 11-1.2.1.2.1.2.1 12-1.2.1.2.1.2 14-1.2.2 15-1.2.2.3 18-1.1.1.1.1.1 19-1.1.1 20-1.1.r 21-1.1.2 21-1.1.2.r 24-1.1.3.2 25-1.1.3.1.1 26-1.1.3.1 27-1.1.3 28-1.1.3 31-1.1.3.3.1.1.1.1 35-1.1.3.3.1.2.1.1 37-1.1.3.3 38-1.1.3.3.2.1 39-1.1.3.3.1 39-1.1.3.3.2 43-1.1.3.3.2.2.1.1
# ::id bel_pmid_1780_4750_41504
(p / possible
      :domain~e.20 (d / detect-01
            :ARG1 (e / express-03~e.19
                  :ARG2 (p2 / protein
                        :name (n / name :op1 "Foxp3"~e.18)))
            :manner~e.21 (c / clear~e.21)
            :location (c2 / cell-line~e.27,28
                  :mod (c3 / carcinoma~e.26
                        :mod (p3 / pancreas~e.25))
                  :quant (s / several~e.24)
                  :location-of (a / and~e.37
                        :op1 (l / level~e.39
                              :mod (r / rna
                                    :name (n2 / name :op1 "mRNA"~e.31))
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (f / figure :mod "2A"~e.35)))
                        :op2 (l2 / level~e.39
                              :mod (p4 / protein~e.38)
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (f2 / figure :mod "2B"~e.43))))))
      :ARG1-of (c4 / conform-01~e.0,1,2
            :ARG2 (d4 / data~e.5
                  :mod (i / immunohistochemistry~e.4)
                  :ARG0-of (p5 / point-01~e.6
                        :ARG2~e.7 (e2 / express-03~e.9
                              :ARG2 p2~e.8
                              :ARG3~e.10 (c5 / cell~e.12
                                    :mod (t / tumor~e.11)))))
            :ARG1-of (s2 / see-01~e.14
                  :mode "imperative"
                  :ARG0 (y / you)
                  :location (a2 / above~e.15))))

# ::tok Treatment of PANC @-@ 89 , Capan1 , and Panc1 cells with TGF @-@ h2 led to an up @-@ regulation of the Foxp3 protein , which was moderate for PANC @-@ 89 and Capan1 and strong for Panc1 ( Fig . 3A and D ) .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1 4-1.1.1.1.1.1 6-1.1.1.2.1.1 8-1.1.1 9-1.1.1.3.1.1 10-1.1.1.1 10-1.1.1.2 10-1.1.1.3 12-1.1.2.1.1 14-1.1.2.1.1 15-1 23-1.2.1.1.1 24-1.1.2 24-1.2.1 28-1.2.2.1 30-1.1.1.1.1.1 32-1.1.1.1.1.1 34-1.1.1.2.1.1 35-1.2.2 36-1.2.2.2 37-1.2.2.2.1.r 38-1.2.2.2.1 42-1.2.2.1.2.1.1 43-1.2.2
# ::id bel_pmid_1780_4750_41506
(l / lead-03~e.15
      :ARG0 (t / treat-04~e.0
            :ARG1~e.1 (a / and~e.8
                  :op1 (c / cell-line~e.10
                        :name (n / name :op1 "PANC-89"~e.2,4,30,32))
                  :op2 (c2 / cell-line~e.10
                        :name (n2 / name :op1 "Capan1"~e.6,34))
                  :op3 (c3 / cell-line~e.10
                        :name (n3 / name :op1 "Panc1"~e.9)))
            :ARG2 (p / protein~e.24
                  :name (n4 / name :op1 "TGF-h2"~e.12,14)))
      :ARG2 (u / upregulate-01
            :ARG1 (p2 / protein~e.24
                  :name (n5 / name :op1 "Foxp3"~e.23))
            :degree (a2 / and~e.35,43
                  :op1 (m / moderate~e.28
                        :poss (a3 / and
                              :op1 c
                              :op2 c2)
                        :ARG1-of (d / describe-01
                              :ARG0 (f / figure :mod "3A"~e.42)))
                  :op2 (s / strong~e.36
                        :poss~e.37 c3~e.38
                        :ARG1-of (d2 / describe-01
                              :ARG0 (f2 / figure :mod "3D"))))))

# ::tok RT @-@ PCR analysis detected a 13 @-@ fold ( mean value of four independent experiments ) increase of Foxp3 mRNA expression in PANC @-@ 89 cells after a 48 @-@ h stimulation with TGF @-@ h2 , whereas no such effect was evident after stimulation with TGF @-@ h1 ( Fig . 3B ) .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 3-1.1.1 4-1.1 6-1.1.2.2.1 10-1.1.2.2.2.1.1 11-1.1.2.2.2.1 12-1.1.2.2.2.1.2.r 13-1.1.2.2.2.1.2.1 14-1.1.2.2.2.1.2.2 14-1.1.2.2.2.1.2.2.1 14-1.1.2.2.2.1.2.2.1.r 15-1.1.2.2.2.1.2 17-1.1.2 18-1.1.2.1.r 18-1.1.2.2 19-1.1.2.1.1.2.1.1 20-1.1.2.1.1.1.1 21-1.1.2.1 22-1.1.2.1.2.r 23-1.1.2.1.2.1.1 25-1.1.2.1.2.1.1 26-1.1.2.1.2 27-1.1.2.3 29-1.1.2.3.1.2.1 32-1.1.2.3.1 33-1.1.2.3.1.1.r 34-1.1.2.3.1.1.1.1 36-1.1.2.3.1.1.1.1 38-1 39-1.2.1.1 39-1.2.1.1.r 40-1.2.1.2 41-1.2.1 42-1.2.1.r 43-1.2 44-1.2.2 45-1.2.2.1 46-1.2.2.1.1.r 47-1.2.2.1.1.1.1 49-1.2.2.1.1.1.1 53-1.3.1.1
# ::id bel_pmid_1780_4750_41508
(c / contrast-01~e.38
      :ARG1 (d / detect-01~e.4
            :ARG0 (a / analyze-01~e.3
                  :name (n3 / name :op1 "RT-PCR"~e.0,2))
            :ARG1 (i / increase-01~e.17
                  :ARG1~e.18 (e / express-03~e.21
                        :ARG1 (r / rna
                              :name (n2 / name :op1 "mRNA"~e.20)
                              :part (p / protein
                                    :name (n / name :op1 "Foxp3"~e.19)))
                        :ARG3~e.22 (c2 / cell~e.26
                              :name (n4 / name :op1 "PANC-89"~e.23,25)))
                  :ARG2 (p2 / product-of~e.18
                        :op1 "13"~e.6
                        :ARG1-of (d2 / describe-01
                              :ARG0 (v / value~e.11
                                    :mod (m / mean~e.10)
                                    :quant-of~e.12 (e2 / experiment-01~e.15
                                          :quant "4"~e.13
                                          :ARG0-of (d3 / depend-01~e.14 :polarity~e.14 "-"~e.14)))))
                  :time (a2 / after~e.27
                        :op1 (s / stimulate-01~e.32
                              :ARG2~e.33 (p3 / protein
                                    :name (n5 / name :op1 "TGF-h2"~e.34,36))
                              :duration (t / temporal-quantity
                                    :quant "48"~e.29
                                    :unit (h / hour))))))
      :ARG2 (e3 / evident~e.43
            :domain~e.42 (e4 / effect-01~e.41
                  :polarity~e.39 "-"~e.39
                  :mod (s2 / such~e.40))
            :time (a3 / after~e.44
                  :op1 (s3 / stimulate-01~e.45
                        :ARG2~e.46 (p4 / protein
                              :name (n6 / name :op1 "TGF-h1"~e.47,49)))))
      :ARG1-of (d4 / describe-01
            :ARG0 (f / figure :mod "3B"~e.53)))

# ::tok Moreover , the incubation of PANC @-@ 89 and Capan1 cells with anti @-@ TGF @-@ h2 antibody for 48 h clearly suppressed the Foxp3 signal ( Fig . 3A ) , suggesting that endogenously produced TGF @-@ h2 maintains Foxp3 expression in pancreatic cancer cell cultures .
# ::alignments 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1.1.1 7-1.1.1.1.1.1.1 8-1.1.1.1 9-1.1.1.1.2.1.1 10-1.1.1.1.1 10-1.1.1.1.2 11-1.1.1.2.r 12-1.1.1.2.1.1 14-1.1.1.2.1.1 16-1.1.1.2.1.1 17-1.1.1.2 18-1.1.1.3.r 19-1.1.1.3.1 21-1.1.3 21-1.1.3.r 22-1.1 24-1.1.2.1.1.1 25-1.1.2 29-1.1.4.1.1 32-1.1.5 33-1.1.5.1.r 34-1.1.5.1.1.2.1 34-1.1.5.1.1.2.1.r 35-1.1.5.1.1.2 36-1.1.5.1.1.1.1 38-1.1.5.1.1.1.1 39-1.1.5.1 40-1.1.5.1.2.1 41-1.1.5.1.2 42-1.1.5.1.2.2.r 43-1.1.5.1.2.2.1.1.1 44-1.1.5.1.2.2.1.1 45-1.1.5.1.2.2.1 46-1.1.5.1.2.2
# ::id bel_pmid_1780_4750_41510
(a / and
      :op2 (s / suppress-01~e.22
            :ARG0 (i / incubate-01~e.3
                  :ARG1~e.4 (a2 / and~e.8
                        :op1 (c / cell~e.10
                              :name (n / name :op1 "PANC-89"~e.5,7))
                        :op2 (c2 / cell~e.10
                              :name (n2 / name :op1 "Capan1"~e.9)))
                  :ARG2~e.11 (a3 / antibody~e.17
                        :name (n3 / name :op1 "anti-TGF-h2"~e.12,14,16))
                  :duration~e.18 (t / temporal-quantity
                        :quant "48"~e.19
                        :unit (h / hour)))
            :ARG1 (s2 / signal-07~e.25
                  :ARG0 (p / protein
                        :name (n4 / name :op1 "Foxp3"~e.24)))
            :manner~e.21 (c3 / clear~e.21)
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "3A"~e.29))
            :ARG0-of (s3 / suggest-01~e.32
                  :ARG1~e.33 (m / maintain-01~e.39
                        :ARG0 (p2 / protein
                              :name (n5 / name :op1 "TGF-h2"~e.36,38)
                              :ARG1-of (p3 / produce-01~e.35
                                    :manner~e.34 (e / endogenous~e.34)))
                        :ARG1 (e2 / express-03~e.41
                              :ARG2 p~e.40
                              :ARG3~e.42 (c4 / culture~e.46
                                    :mod (c5 / cell~e.45
                                          :mod (c6 / cancer~e.44
                                                :mod (p4 / pancreas~e.43)))))))))

# ::tok Specific down @-@ regulation of Foxp3 in pancreatic carcinoma cells results in up @-@ regulation of IL @-@ 6 and IL @-@ 8 .
# ::alignments 0-1.1.3 5-1.1.1.1.1 7-1.1.2.1.1 8-1.1.2.1 9-1.1.2 10-1 16-1.2.1.1.1.1 16-1.2.1.2.1.1 18-1.2.1.1.1.1 19-1.2.1 20-1.2.1.1.1.1 20-1.2.1.2.1.1 22-1.2.1.2.1.1
# ::id bel_pmid_1780_4750_41512
(r / result-01~e.10
      :ARG1 (d / downregulate-01
            :ARG1 (p / protein
                  :name (n / name :op1 "Foxp3"~e.5))
            :location (c / cell~e.9
                  :mod (c2 / carcinoma~e.8
                        :mod (p2 / pancreas~e.7)))
            :mod (s / specific~e.0))
      :ARG2 (u / upregulate-01
            :ARG1 (a / and~e.19
                  :op1 (p3 / protein
                        :name (n3 / name :op1 "IL-6"~e.16,18,20))
                  :op2 (p4 / protein
                        :name (n4 / name :op1 "IL-8"~e.16,20,22)))))

# ::tok A screen for changes in cytokine secretion in these cells using the Raybiotec Cytokine Array ( Hoelzel Diagnostica ) revealed an increase of IL @-@ 6 and IL @-@ 8 in the culture supernatant , whereas other cytokines remained unchanged ( data not shown ) .
# ::alignments 1-1.1.1 3-1.1.1.1 3-1.2.2 4-1.1.1.1.1.r 5-1.1.1.1.1.1 6-1.1.1.1.1 7-1.1.1.1.1.2.r 8-1.1.1.1.1.2.1 9-1.1.1.1.1.2 10-1.1.1.2 13-1.1.1.2.1.1.2 13-1.2.1 14-1.1.1.2.1.1.3 16-1.1.1.2.1.2.1.1 19-1.1 21-1.1.2 22-1.1.2.1.r 23-1.1.2.1.1.1.1 23-1.1.2.1.2.1.1 25-1.1.2.1.1.1.1 26-1.1.2.1 27-1.1.2.1.1.1.1 27-1.1.2.1.2.1.1 29-1.1.2.1.2.1.1 30-1.1.2.2.r 32-1.1.2.2.1 33-1.1.2.2 35-1 36-1.2.1.1 38-1.2 39-1.2.2.1 41-1.2.3.1 42-1.2.3.1.1.1 42-1.2.3.1.1.1.r 43-1.2.3.1.1
# ::id bel_pmid_1780_4750_41514
(c / contrast-01~e.35
      :ARG1 (r / reveal-01~e.19
            :ARG0 (s / screen-01~e.1
                  :ARG2 (c2 / change-01~e.3
                        :ARG1~e.4 (s2 / secrete-01~e.6
                              :ARG1 (c3 / cytokine~e.5)
                              :location~e.7 (c4 / cell~e.9
                                    :mod (t / this~e.8))))
                  :ARG2-of (u / use-01~e.10
                        :ARG1 (p / product
                              :name (n / name
                                    :op1 "Raybiotech"
                                    :op2 "Cytokine"~e.13
                                    :op3 "Array"~e.14)
                              :source (c5 / company
                                    :name (n2 / name :op1 "Hoelzel"~e.16 :op2 "Diagnostika")))))
            :ARG1 (i / increase-01~e.21
                  :ARG1~e.22 (a / and~e.26
                        :op1 (p2 / protein
                              :name (n3 / name :op1 "IL-6"~e.23,25,27))
                        :op2 (p3 / protein
                              :name (n4 / name :op1 "IL-8"~e.23,27,29)))
                  :location~e.30 (s3 / supernatant~e.33
                        :ARG1-of (c6 / culture-01~e.32))))
      :ARG2 (r2 / remain-01~e.38
            :ARG1 (c7 / cytokine~e.13
                  :mod (o / other~e.36))
            :ARG3 (c8 / change-01~e.3 :polarity "-"~e.39)
            :ARG1-of (d / describe-01
                  :ARG0 (d2 / data~e.41
                        :ARG1-of (s4 / show-01~e.43 :polarity~e.42 "-"~e.42)))))

# ::tok In the cocultures , Colo357 , PANC @-@ 89 , and PancTu1 tumor cells strongly inhibited the proliferation of anti @-@ CD3 @/@ anti @-@ CD28 @-@ stimulated T cells ( Fig . 4D ) .
# ::alignments 4-1.1.1.1.1 6-1.1.2.1.1 8-1.1.2.1.1 10-1.1 11-1.1.3.1.1 12-1.1.4 13-1.1.1 13-1.1.2 13-1.1.3 14-1.3 15-1 17-1.2 18-1.2.1.r 19-1.2.1.2.1.1 19-1.2.1.2.1.1.1 19-1.2.1.2.1.1.1.r 19-1.2.1.2.1.2 19-1.2.1.2.1.2.1 19-1.2.1.2.1.2.1.r 21-1.2.1.2.1.1.1.1.1.1 23-1.2.1.2.1.1 23-1.2.1.2.1.1.1 23-1.2.1.2.1.1.1.r 23-1.2.1.2.1.2 23-1.2.1.2.1.2.1 23-1.2.1.2.1.2.1.r 25-1.2.1.2.1.2.1.1.1.1 27-1.2.1.2 28-1.2.1.1.1 29-1.2.1 33-1.5.1.1
# ::id bel_pmid_1780_4750_41518
(i / inhibit-01~e.15
      :ARG0 (a / and~e.10
            :op1 (c / cell~e.13
                  :name (n / name :op1 "Colo357"~e.4))
            :op2 (c2 / cell~e.13
                  :name (n2 / name :op1 "PANC-89"~e.6,8))
            :op3 (c3 / cell~e.13
                  :name (n3 / name :op1 "PancTu1"~e.11))
            :mod (t / tumor~e.12))
      :ARG1 (p / proliferate-01~e.17
            :ARG0~e.18 (c4 / cell~e.29
                  :name (n4 / name :op1 "T"~e.28)
                  :ARG1-of (s / stimulate-01~e.27
                        :ARG0 (a2 / and
                              :op1 (m / molecular-physical-entity~e.19,23
                                    :ARG0-of~e.19,23 (c5 / counter-01~e.19,23
                                          :ARG1 (p2 / protein
                                                :name (n5 / name :op1 "CD3"~e.21))))
                              :op2 (m2 / molecular-physical-entity~e.19,23
                                    :ARG0-of~e.19,23 (c6 / counter-01~e.19,23
                                          :ARG1 (p3 / protein
                                                :name (n6 / name :op1 "CD28"~e.25))))))))
      :degree (s2 / strong~e.14)
      :location (c7 / coculture-00)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4D"~e.33)))

# ::tok As shown in Fig. 5B , CD25 GITR and CD69 were up @-@ regulated after anti @-@ CD3 @/@ anti @-@ CD28 stimulation , irrespective of the presence or absence of tumor cells .
# ::alignments 0-1.2.r 1-1.4 4-1.4.1.1 6-1.1.1.1.1 7-1.1.2.1.1 8-1.1 9-1.1.3.1.1 14-1.2 15-1.2.1.1.1 15-1.2.1.1.1.1 15-1.2.1.1.1.1.r 15-1.2.1.1.2 15-1.2.1.1.2.1 15-1.2.1.1.2.1.r 17-1.2.1.1.1.1.1.1.1 19-1.2.1.1.1 19-1.2.1.1.1.1 19-1.2.1.1.1.1.r 19-1.2.1.1.2 19-1.2.1.1.2.1 19-1.2.1.1.2.1.r 21-1.2.1.1.2.1.1.1.1 22-1.2.1 28-1.3 29-1.3.2 31-1.3.1.1.1 32-1.3.1.1
# ::id bel_pmid_1780_4750_41520
(u / upregulate-01
      :ARG1 (a / and~e.8
            :op1 (p / protein
                  :name (n / name :op1 "CD25"~e.6))
            :op2 (p2 / protein
                  :name (n2 / name :op1 "GITR"~e.7))
            :op3 (p3 / protein
                  :name (n3 / name :op1 "CD69"~e.9)))
      :time~e.0 (a2 / after~e.14
            :op1 (s / stimulate-01~e.22
                  :ARG0 (a3 / and
                        :op1 (m / molecular-physical-entity~e.15,19
                              :ARG0-of~e.15,19 (c / counter-01~e.15,19
                                    :ARG1 (p4 / protein
                                          :name (n4 / name :op1 "CD3"~e.17))))
                        :op2 (m2 / molecular-physical-entity~e.15,19
                              :ARG0-of~e.15,19 (c2 / counter-01~e.15,19
                                    :ARG1 (p5 / protein
                                          :name (n5 / name :op1 "CD28"~e.21)))))))
      :concession (o / or~e.28
            :op1 (b / be-located-at-91
                  :ARG1 (c3 / cell~e.32
                        :mod (t / tumor~e.31)))
            :op2 (a4 / absent-01~e.29
                  :ARG1 c3))
      :ARG1-of (s2 / show-01~e.1
            :ARG0 (f / figure :mod "5B"~e.4)))

# ::tok When using these cells , we observed an ~ 45 % recovery of T @-@ cell proliferation in the coculture system ( Fig . 5A ) .
# ::alignments 0-1.4.r 1-1.4 2-1.4.2.1 3-1.4.2 5-1.1 6-1 9-1.2.2.1.1 10-1.2.2.1 11-1.2 12-1.2.1.r 13-1.2.1.1.1.1 15-1.2.1.1 16-1.2.1 17-1.3.r 19-1.3.1 20-1.3 24-1.5.1.1
# ::id bel_pmid_1780_4750_41522
(o / observe-01~e.6
      :ARG0 (w / we~e.5)
      :ARG1 (r / recover-02~e.11
            :ARG1~e.12 (p / proliferate-01~e.16
                  :ARG0 (c / cell~e.15
                        :name (n / name :op1 "T"~e.13)))
            :quant (a / approximately
                  :op1 (p2 / percentage-entity~e.10 :value "45"~e.9)))
      :location~e.17 (s / system~e.20
            :mod (c2 / coculture-00~e.19))
      :time~e.0 (u / use-01~e.1
            :ARG0 w
            :ARG1 (c3 / cell~e.3
                  :mod (t / this~e.2)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "5A"~e.24)))

# ::tok Results Tumor @-@ associated inflammation is reduced in IL @-@ 1R—/— mice .
# ::alignments 0-1.3 1-1.1.1.1 3-1.1.1 6-1 7-1.2.r 8-1.2.1.1.1 11-1.2
# ::id bel_pmid_1794_2936_40216
(r / reduce-01~e.6
      :ARG1 (i / inflame-01
            :ARG1-of (a / associate-01~e.3
                  :ARG2 (t / tumor~e.1)))
      :location~e.7 (m2 / mouse~e.11
            :mod (p / protein
                  :name (n2 / name :op1 "IL-1R"~e.8)
                  :ARG2-of (m3 / mutate-01 :mod "-/-")))
      :ARG2-of (r2 / result-01~e.0))

# ::tok Canonical proinflammatory cytokines , such as IL @-@ 6 , MCP @-@ 1 , TGFh , and IL @-@ 1h were significantly elevated in 4T1 tumor tissue .
# ::alignments 6-1.1.1.1.1 6-1.1.4.1.1 8-1.1.1.1.1 10-1.1.2.1.1 12-1.1.2.1.1 14-1.1.3.1.1 16-1.1 17-1.1.1.1.1 17-1.1.4.1.1 19-1.1.4.1.1 21-1.2 21-1.2.r 22-1 23-1.3.r 24-1.3.1.1.1.1 25-1.3.1 26-1.3
# ::id bel_pmid_1794_2936_40218
(e / elevate-01~e.22
      :ARG1 (a / and~e.16
            :op1 (c3 / cytokine
                  :name (n / name :op1 "IL-6"~e.6,8,17))
            :op2 (c4 / cytokine
                  :name (n2 / name :op1 "MCP-1"~e.10,12))
            :op3 (c5 / cytokine
                  :name (n3 / name :op1 "TGFh"~e.14))
            :op4 (c6 / cytokine
                  :name (n4 / name :op1 "IL-1h"~e.6,17,19))
            :mod (c2 / canon)
            :ARG0-of (p / promote-01
                  :ARG1 (i / inflame-01)))
      :manner~e.21 (s / significant~e.21)
      :location~e.23 (t / tissue~e.26
            :mod (t2 / tumor~e.25
                  :mod (c / cell-line
                        :name (n5 / name :op1 "4T1"~e.24)))))

# ::tok Additionally , IL @-@ 1R—/— tumor tissue had less IL @-@ 12p70 and more TGFh and IFNg than tumor tissue from wild @-@ type BALB/c mice .
# ::alignments 2-1.1.1.2.1.1 2-1.1.2.1.1.1 5-1.1.1.1 6-1.1.1 7-1.1 8-1.1.2.1.3 9-1.1.2.1.1.1 12-1.1.2 13-1.1.2.2.2 14-1.1.2.2.1.1 15-1.1.2 16-1.1.2.3.1.1 17-1.1.2.4.r 18-1.1.2.4.1 19-1.1.2.4 20-1.1.2.4.2.r 21-1.1.2.4.2.2 23-1.1.2.4.2.2 24-1.1.2.4.2.1.1 25-1.1.2.4.2
# ::id bel_pmid_1794_2936_40222
(a / and
      :op2 (h / have-03~e.7
            :ARG0 (t / tissue~e.6
                  :part-of (t2 / tumor~e.5)
                  :mod (p / protein
                        :name (n / name :op1 "IL-1R"~e.2)
                        :ARG2-of (m / mutate-01 :mod "-/-")))
            :ARG1 (a2 / and~e.12,15
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "IL-12"~e.2,9)
                        :ARG2-of (m2 / mutate-01 :value "p70")
                        :degree (l / less~e.8))
                  :op2 (p3 / protein
                        :name (n3 / name :op1 "TGFh"~e.14)
                        :degree (m3 / more~e.13))
                  :op3 (p4 / protein
                        :name (n4 / name :op1 "IFNg"~e.16)
                        :degree m3)
                  :compared-to~e.17 (t3 / tissue~e.19
                        :mod (t4 / tumor~e.18)
                        :source~e.20 (m4 / mouse~e.25
                              :name (n5 / name :op1 "BALB/c"~e.24)
                              :mod (w / wild-type~e.21,23))))))

# ::tok A potential downstream candidate is the proinflammatory cytokine , IL @-@ 6 , the production of which is reduced in IL @-@ 1R—/— tumor tissue ( Fig . 1B ) .
# ::alignments 1-1.2.1 2-1.2.2 3-1.2 4-1.2.r 7-1 9-1.1.1 11-1.1.1 14-1.3 18-1.3.1 19-1.3.1.1.r 20-1.3.1.1.2.1.1 23-1.3.1.1.1 24-1.3.1.1 28-1.5.1.1
# ::id bel_pmid_1794_2936_40248
(c / cytokine~e.7
      :name (n / name :op1 "IL-6"~e.9,11)
      :domain~e.4 (c2 / candidate~e.3
            :mod (p3 / potential~e.1)
            :location (d / downstream~e.2))
      :ARG1-of (p / produce-01~e.14
            :ARG1-of (r / reduce-01~e.18
                  :location~e.19 (t / tissue~e.24
                        :part-of (t2 / tumor~e.23)
                        :mod (p4 / protein
                              :name (n2 / name :op1 "IL-1R"~e.20)
                              :ARG2-of (m / mutate-01 :mod "-/-")))))
      :ARG0-of (p2 / promote-01
            :ARG1 (i / inflame-01))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "1B"~e.28)))

# ::tok These data demonstrate that it is the hemin @-@ induced surge in cellular ROS levels , in particular the superoxide generated most likely from NADPH oxidase activity , and consequent oxidative stress which mediates Egr @-@ 1 upregulation via ERK @-@ 1 @/@ 2 activation .
# ::alignments 0-1.1.1 1-1.1 2-1 7-1.2.1.2.1.1.1 9-1.2.1.2 10-1.2.1 11-1.2.1.1.r 12-1.2.1.1.1.2 13-1.2.1.1.1.1.1 14-1.2.1.1 16-1.2.r 17-1.2.2.2 19-1.2.2.1.1 20-1.2.2.3 21-1.2.2.3.2.1 22-1.2.2.3.2 23-1.2.2.3.1.r 24-1.2.2.3.1.1.2.1.1 25-1.2.2.3.1.1.1 26-1.2.2.3.1 28-1.2 31-1.2.3 33-1.2.4 34-1.2.4.1.1.1.1 36-1.2.4.1.1.1.1 36-1.2.4.1.2.1.1.1.1 37-1.2.4.1 39-1.2.4.1.2.1.1.1.1 39-1.2.4.1.2.1.2.1.1 41-1.2.4.1.2.1.1.1.1 43-1.2.4.1.2.1.2.1.1 44-1.2.4.1.2
# ::id bel_pmid_1796_7787_34624
(d3 / demonstrate-01~e.2
      :ARG0 (d2 / data~e.1
            :mod (t2 / this~e.0))
      :ARG1~e.16 (a / and~e.28
            :op1 (s / surge-01~e.10
                  :ARG1~e.11 (l2 / level~e.14
                        :quant-of (m3 / molecular-physical-entity
                              :name (n / name :op1 "ROS"~e.13)
                              :part-of (c / cell~e.12)))
                  :ARG1-of (i / induce-01~e.9
                        :ARG0 (t / thing
                              :name (n2 / name :op1 "hemin"~e.7))))
            :op2 (m4 / macro-molecular-complex
                  :name (n3 / name :op1 "superoxide"~e.19)
                  :mod (p / particular~e.17)
                  :ARG1-of (g / generate-01~e.20
                        :ARG2~e.23 (a2 / act-02~e.26
                              :ARG0 (m5 / macro-molecular-complex
                                    :part (o / oxidase~e.25)
                                    :part (m6 / molecular-physical-entity
                                          :name (n4 / name :op1 "NADPH"~e.24))))
                        :mod (l / likely~e.22
                              :degree (m / most~e.21))))
            :op3 (s2 / stress~e.31
                  :ARG2-of (r / result-01
                        :ARG1 o))
            :ARG0-of (m2 / mediate-01~e.33
                  :ARG1 (u / upregulate-01~e.37
                        :ARG1 (p2 / protein
                              :name (n5 / name :op1 "Egr-1"~e.34,36))
                        :ARG2 (a3 / activate-01~e.44
                              :ARG1 (s3 / slash
                                    :op1 (e / enzyme
                                          :name (n6 / name :op1 "ERK-1"~e.36,39,41))
                                    :op2 (e2 / enzyme
                                          :name (n7 / name :op1 "ERK-2"~e.39,43))))))))

# ::tok However , RELMbeta stimulated naive bone marrow @-@ derived macrophages to secrete significant amounts of TNF @-@ alpha , IL @-@ 6 , and RANTES
# ::alignments 0-1 2-1.1.1.1.1 3-1.1 4-1.1.2.1.1.1.1.1 5-1.1.2.1.1.1.1 6-1.1.2.1.1.1 8-1.1.2.1.1 9-1.1.2.1 11-1.1.2 12-1.1.2.2.2 13-1.1.2.2 14-1.1.2.2.1.r 15-1.1.2.2.1.1.1.1 17-1.1.2.2.1.1.1.1 19-1.1.2.2.1.2.1.1 21-1.1.2.2.1.2.1.1 23-1.1.2.2.1 24-1.1.2.2.1.3.1.1
# ::id bel_pmid_1798_2092_10006
(h / have-concession-91~e.0
      :ARG1 (s / stimulate-01~e.3
            :ARG0 (s2 / small-molecule
                  :name (n / name :op1 "RELMbeta"~e.2))
            :ARG1 (s3 / secrete-01~e.11
                  :ARG0 (m2 / macrophage~e.9
                        :ARG1-of (d / derive-01~e.8
                              :ARG2 (m / marrow~e.6
                                    :source (b / bone~e.5
                                          :mod (n3 / naive~e.4)))))
                  :ARG1 (a / amount~e.13
                        :quant-of~e.14 (a2 / and~e.23
                              :op1 (p / protein
                                    :name (n4 / name :op1 "TNF-alpha"~e.15,17))
                              :op2 (p2 / protein
                                    :name (n5 / name :op1 "IL-6"~e.19,21))
                              :op3 (p3 / protein
                                    :name (n6 / name :op1 "RANTES"~e.24)))
                        :degree (s4 / significant~e.12)))))

# ::tok MMP @-@ 2 ( 76 kDa ) activity was elevated only at day 11 in C57BL/6 mice but not in MyD88–/– and IL @-@ 1R1–/– mice ( Figure 4B ) .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 7-1.1.1 7-1.2.2 9-1.1 9-1.2 10-1.1.3 12-1.1.2.1.2 13-1.1.2.1.1 14-1.1.4.r 15-1.1.4.1.1 16-1.1.4 17-1 18-1.2.1 18-1.2.1.r 21-1.2.4 22-1.2.4.2.1.1.1 25-1.2.4.1 25-1.2.4.2 27-1.3.1 28-1.3.1.1
# ::id bel_pmid_1799_2263_15480
(c / contrast-01~e.17
      :ARG1 (e / elevate-01~e.9
            :ARG1 (a / act-02~e.7
                  :ARG0 (e2 / enzyme
                        :name (n / name :op1 "MMP-2"~e.0,2)))
            :time (a2 / after
                  :op1 (t / temporal-quantity
                        :quant "11"~e.13
                        :unit (d / day~e.12)))
            :mod (o / only~e.10)
            :location~e.14 (m6 / mouse~e.16
                  :name (n4 / name :op1 "C57BL/6"~e.15)))
      :ARG2 (e3 / elevate-01~e.9
            :polarity~e.18 "-"~e.18
            :ARG1 (a3 / act-02~e.7
                  :ARG0 e2)
            :time a2
            :location (a4 / and~e.21
                  :op1 (m2 / mouse~e.25
                        :mod (p / protein
                              :name (n2 / name :op1 "MyD88")
                              :ARG2-of (m3 / mutate-01 :mod "-/-")))
                  :op2 (m4 / mouse~e.25
                        :mod (p2 / protein
                              :name (n3 / name :op1 "IL-1R1"~e.22)
                              :ARG2-of (m5 / mutate-01 :mod "-/-")))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.27 :mod "4B"~e.28)))

# ::tok MMP @-@ 9 activity was significantly upregulated in BALF at day 1 in C57BL/6 mice but not in MyD88–/– mice , and only partially in IL @-@ 1R1–/– mice ( Figure 4A ) .
# ::alignments 0-1.1.1.1.1.1.1 2-1.1.1.1.1.1.1 3-1.1.1.1 5-1.1.1.2 8-1.1.1.3.1.1 10-1.1.1.4.1.1.2 11-1.1.1.4.1.1.1 13-1.1.1.5.1.1 14-1.1.1.5 14-1.2.3 15-1 16-1.2.1 16-1.2.1.r 19-1.1.1.5 19-1.2.3 21-1.1 22-1.1.2.2.1 23-1.1.2.2 25-1.1.2.3.1.1.1 28-1.1.2.3 28-1.2.3 30-1.3.1 31-1.3.1.1
# ::id bel_pmid_1799_2263_15482
(c / contrast-01~e.15
      :ARG1 (a3 / and~e.21
            :op1 (u / upregulate-01
                  :ARG1 (a / act-02~e.3
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "MMP-9"~e.0,2)))
                  :degree (s / significant~e.5)
                  :location (t / thing
                        :name (n2 / name :op1 "BALF"~e.8))
                  :time (a2 / after
                        :quant (u2 / up-to
                              :op1 (t2 / temporal-quantity
                                    :quant "1"~e.11
                                    :unit (d / day~e.10))))
                  :location (m6 / mouse~e.14,19
                        :name (n5 / name :op1 "C57BL/6"~e.13)))
            :op2 (u3 / upregulate-01
                  :ARG1 a
                  :degree (p / partial~e.23
                        :mod (o / only~e.22))
                  :location (m2 / mouse~e.28
                        :mod (p3 / protein
                              :name (n3 / name :op1 "IL-1R1"~e.25)
                              :ARG2-of (m3 / mutate-01 :mod "-/-")))))
      :ARG2 (u4 / upregulate-01
            :polarity~e.16 "-"~e.16
            :ARG1 a
            :location (m4 / mouse~e.14,19,28
                  :mod (p2 / protein
                        :name (n4 / name :op1 "MyD88")
                        :ARG2-of (m5 / mutate-01 :mod "-/-"))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.30 :mod "4A"~e.31)))

# ::tok Latent TGF-?1 was detected after activation in BALF from WT mice 7 days after BLM administration , but was not detected in BALF from MyD88 @- or IL @-@ 1R1–deficient mice ( Figure 5G )
# ::alignments 0-1.1.1.2 3-1.1 4-1.1.2 4-1.1.3 5-1.1.2.1 7-1.1.2.1.1.1.1 7-1.2.3.2.1.1 8-1.1.2.1.1.2.r 9-1.1.2.1.1.2.1 10-1.1.2.1.1.2 11-1.1.3.2.1 12-1.1.3.2.2 13-1.1.3 14-1.1.3.1.1.1.1 15-1.1.3.1 17-1 19-1.2.1 19-1.2.1.r 20-1.2 22-1.1.2.1.1.1.1 22-1.2.3.1.1.1 23-1.1.2.1.1.2.r 23-1.2.3.r 24-1.2.3.1.2.1.1.1.1 26-1.2.3 27-1.2.3.2.2.1.1.1.1 30-1.1.2.1.1.2 30-1.2.3.1.2 30-1.2.3.2.2 32-1.3.1 33-1.3.1.1
# ::id bel_pmid_1799_2263_15488
(c / contrast-01~e.17
      :ARG1 (d2 / detect-01~e.3
            :ARG1 (p / protein
                  :name (n / name :op1 "TGFβ-1")
                  :mod (l / latent~e.0))
            :time (a2 / after~e.4
                  :op1 (a3 / activate-01~e.5
                        :location (t2 / thing
                              :name (n2 / name :op1 "BALF"~e.7,22)
                              :source~e.8,23 (m / mouse~e.10,30
                                    :mod (w / wild-type~e.9)))))
            :time (a4 / after~e.4,13
                  :op1 (a5 / administer-01~e.15
                        :ARG1 (s / small-molecule
                              :name (n3 / name :op1 "BLM"~e.14)))
                  :quant (t3 / temporal-quantity
                        :quant "7"~e.11
                        :unit (d3 / day~e.12))))
      :ARG2 (d4 / detect-01~e.20
            :polarity~e.19 "-"~e.19
            :ARG1 (p2 / protein
                  :name (n4 / name :op1 "TGFβ-1"))
            :location~e.23 (o / or~e.26
                  :op1 (t / thing
                        :name (n7 / name :op1 "BALF"~e.22)
                        :source (m3 / mouse~e.30
                              :ARG0-of (l3 / lack-01
                                    :ARG1 (p3 / protein
                                          :name (n5 / name :op1 "MyD88"~e.24)))))
                  :op2 (t4 / thing
                        :name (n8 / name :op1 "BALF"~e.7)
                        :source (m4 / mouse~e.30
                              :ARG0-of (l4 / lack-01
                                    :ARG1 (p4 / protein
                                          :name (n9 / name :op1 "IL-1R1"~e.27)))))))
      :ARG1-of (d5 / describe-01
            :ARG0 (f / figure~e.32 :mod "5G"~e.33)))

# ::tok 7 days of administration IL @-@ 1? caused tissue injury with marked tissue destruction , disruption of alveolar architecture , inflammation , and fibrosis ( although less pronounced than that obtained after BLM treatment ; Figure 7 , D and E ) that was absent in saline controls ( Figure 7C )
# ::alignments 0-1.1.2.1 0-1.1.2.2 3-1.1 4-1.1.1.1.1 7-1 8-1.2.1 8-1.2.4.2.1 9-1.2 9-1.2.4.2 10-1.2.2.r 11-1.2.2.1.2 12-1.2.1 13-1.2.2.1 15-1.2.2.2 16-1.2.2.2.1.r 17-1.2.2.2.1.1 18-1.2.2.2.1 22-1.2.2 23-1.2.2.4 25-1.2.3 26-1.2.4.1 27-1.2.4 28-1.2.4.2.r 30-1.2.4.2.2 32-1.2.4.2.2.1.1.1.1 33-1.2.4.2.2.1 35-1.2.4.2.2.2.1.1 35-1.2.4.2.2.2.1.2 36-1.1.2.1 36-1.1.2.2 39-1.2.4.2.2.2.1 44-1.2.5 45-1.2.5.1.r 46-1.2.5.1.1 47-1.2.5.1 49-1.3.1 50-1.3.1.1
# ::id bel_pmid_1799_2263_28110
(c / cause-01~e.7
      :ARG0 (a2 / administer-01~e.3
            :ARG1 (p / protein
                  :name (n / name :op1 "IL-1β"~e.4))
            :duration (t2 / temporal-quantity :quant "7"~e.0,36 :unit "7"~e.0,36))
      :ARG1 (i2 / injure-01~e.9
            :ARG1 (t3 / tissue~e.8,12)
            :accompanier~e.10 (a / and~e.22
                  :op1 (d2 / destroy-01~e.13
                        :ARG1 t3
                        :ARG1-of (m / mark-01~e.11))
                  :op2 (d4 / disrupt-01~e.15
                        :ARG1~e.16 (a7 / architecture~e.18
                              :poss (a8 / alveolus~e.17)))
                  :op3 (i / inflame-01)
                  :op4 (f2 / fibrosis~e.23))
            :ARG2-of (h / have-concession-91~e.25)
            :ARG1-of (p2 / pronounce-01~e.27
                  :degree (l / less~e.26)
                  :compared-to~e.28 (i4 / injure-01~e.9
                        :ARG1 (t4 / tissue~e.8)
                        :ARG1-of (o / obtain-01~e.30
                              :ARG2 (t5 / treat-04~e.33
                                    :ARG2 (t6 / thing
                                          :name (n2 / name :op1 "BLM"~e.32)))
                              :ARG1-of (d5 / describe-01
                                    :ARG0 (a9 / and~e.39
                                          :op1 (f3 / figure~e.35 :mod "7D")
                                          :op2 (f4 / figure~e.35 :mod "7E"))))))
            :ARG1-of (a10 / absent-01~e.44
                  :ARG2~e.45 (c2 / control-01~e.47
                        :ARG0 (s / saline~e.46))))
      :ARG1-of (d6 / describe-01
            :ARG0 (f5 / figure~e.49 :mod "7C"~e.50)))

# ::tok IL @-@ 1? production into the lung was attenuated in ASC–/– in comparison with ASC+/+ control littermates 24 hours after BLM administration ( Figure 9D ) .
# ::alignments 0-1.1.1.1.1 3-1.1 3-1.5 4-1.1.2.r 6-1.1.2 8-1 12-1.5.r 15-1.2.2 15-1.2.2.3 15-1.2.2.3.r 15-1.5.2.2 15-1.5.2.2.3 15-1.5.2.2.3.r 17-1.3.2.1 18-1.3.2.2 19-1.3 20-1.3.1.1.1.1 21-1.3.1 23-1.4.1 24-1.4.1.1
# ::id bel_pmid_1799_2263_30264
(a2 / attenuate-01~e.8
      :ARG1 (p / produce-01~e.3
            :ARG1 (p2 / protein
                  :name (n / name :op1 "IL-1β"~e.0))
            :location~e.4 (l / lung~e.6))
      :location (m / mouse
            :mod (l2 / littermate)
            :mod (p3 / protein~e.15
                  :name (n2 / name :op1 "ASC")
                  :ARG2-of (m2 / mutate-01 :mod "-/-")
                  :ARG0-of~e.15 (c / control-01~e.15)))
      :time (a4 / after~e.19
            :op1 (a5 / administer-01~e.21
                  :ARG1 (s / small-molecule
                        :name (n4 / name :op1 "BLM"~e.20)))
            :quant (t3 / temporal-quantity
                  :quant "24"~e.17
                  :unit (h2 / hour~e.18)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.23 :mod "9D"~e.24))
      :compared-to~e.12 (p4 / produce-01~e.3
            :ARG1 p2
            :location (m3 / mouse
                  :mod (l3 / littermate)
                  :mod (p5 / protein~e.15
                        :name (n3 / name :op1 "ASC")
                        :mod (w / wild-type)
                        :ARG0-of~e.15 (c2 / control-01~e.15)))))

# ::tok IL @-@ 6 production into the lung 24 hours after BLM treatment was attenuated in ASC–/– in comparison with ASC+/+ control littermates ( Figure 9E ) . Comparable reductions of IL @-@ 1? and IL @-@ 6 were obtained in the BALF
# ::alignments 0-1.2.1.1.2.1.1 2-1.2.1.1.2.1.1 3-1.1.1 3-1.1.4 4-1.1.1.2.r 6-1.1.1.2 7-1.1.2.2.1 7-1.1.2.2.2 9-1.1.2 10-1.1.2.1.1.1.1 11-1.1.2.1 13-1.1 17-1.1.4.r 17-1.2.1.2 20-1.1.3.2 20-1.1.3.2.3 20-1.1.3.2.3.r 20-1.1.4.2.2 20-1.1.4.2.2.3 20-1.1.4.2.2.3.r 23-1.1.5.1 24-1.1.5.1.1 28-1.2.1 30-1.2.1.1.1.1.1 30-1.2.1.1.2.1.1 33-1.2.1.1 34-1.2.1.1.1.1.1 34-1.2.1.1.2.1.1 36-1.1.1.1.1.1 36-1.2.1.1.2.1.1 38-1.2 39-1.2.2.r 41-1.2.2.1.1
# ::id bel_pmid_1799_2263_30266
(m4 / multi-sentence
      :snt1 (a / attenuate-01~e.13
            :ARG1 (p / produce-01~e.3
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "IL-6"~e.36))
                  :location~e.4 (l / lung~e.6))
            :time (a2 / after~e.9
                  :op1 (t2 / treat-04~e.11
                        :ARG2 (s / small-molecule
                              :name (n2 / name :op1 "BLM"~e.10)))
                  :quant (t4 / temporal-quantity :quant "24"~e.7 :unit "24"~e.7))
            :location (m / mouse
                  :mod (l2 / littermate)
                  :mod (p3 / protein~e.20
                        :name (n3 / name :op1 "ASC")
                        :ARG2-of (m2 / mutate-01 :mod "-/-")
                        :ARG0-of~e.20 (c / control-01~e.20)))
            :compared-to~e.17 (p4 / produce-01~e.3
                  :ARG1 p2
                  :location (m3 / mouse
                        :mod (l3 / littermate)
                        :mod (p5 / protein~e.20
                              :name (n4 / name :op1 "ASC")
                              :mod (w / wild-type)
                              :ARG0-of~e.20 (c2 / control-01~e.20))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure~e.23 :mod "9E"~e.24)))
      :snt2 (o / obtain-01~e.38
            :ARG1 (r / reduce-01~e.28
                  :ARG1 (a3 / and~e.33
                        :op1 (p6 / protein
                              :name (n5 / name :op1 "IL-1β"~e.30,34))
                        :op2 (p7 / protein
                              :name (n6 / name :op1 "IL-6"~e.0,2,30,34,36)))
                  :ARG1-of (c3 / compare-01~e.17
                        :mod (p8 / possible)))
            :location~e.39 (t5 / thing
                  :name (n7 / name :op1 "BALF"~e.41))))

# ::tok Studies using bone marrow @-@ derived macrophages ( BMDM ) isolated from a spontaneous mouse model of Crohn 's disease @-@ like ileitis ( SAMP1/YitFc strain ) revealed significant inhibition by CGP57380 of the proinflammatory cytokines TNF , IL @-@ 6 , and monocyte chemoattractant protein @-@ 1 at 4 and 24 h after LPS stimulation
# ::alignments 0-1.1 1-1.1.1 2-1.1.1.1.1.1.1 3-1.1.1.1.1.1 5-1.1.1.1.1 6-1.1.1.1 10-1.1.1.1.2 11-1.1.1.1.2.1.r 13-1.1.1.1.2.1.2 14-1.1.1.1.2.1.1 15-1.1.1.1.2.1 18-1.1.1.1.2.1.3.2.1.1.1 19-1.1.1.1.2.1.3 19-1.1.1.1.2.1.3.2.1 21-1.1.1.1.2.1.3.2 22-1.1.1.1.2.1.3.1.1 24-1.1.1.1.2.1.4.1.1.1 25-1.1.1.1.2.1.4.1 27-1 28-1.2.3 29-1.2 30-1.2.1.r 31-1.2.1.1.1 36-1.2.2.1.1.1 38-1.2.2.2.1.1 40-1.2.2.2.1.1 42-1.2.2 43-1.2.2.3.1.1 43-1.2.2.4.1.1 44-1.2.2.3.1.1 44-1.2.2.4.1.1 45-1.2.2.3.1.1 45-1.2.2.4.1.1 47-1.2.2.3.1.1 48-1.2.2.r 49-1.2.2.4.1.1 50-1.2.2 51-1.3.2.1 53-1.3 54-1.3.1.1.1.1 55-1.3.1
# ::id bel_pmid_1803_2482_6302
(r / reveal-01~e.27
      :ARG0 (s2 / study-01~e.0
            :ARG0-of (u / use-01~e.1
                  :ARG1 (m5 / macrophage~e.6
                        :ARG1-of (d / derive-01~e.5
                              :ARG2 (m / marrow~e.3
                                    :poss (b / bone~e.2)))
                        :ARG1-of (i / isolate-01~e.10
                              :ARG2~e.11 (m2 / model~e.15
                                    :mod (m3 / mouse~e.14)
                                    :mod (s / spontaneity~e.13)
                                    :topic (d2 / disease~e.19
                                          :name (n2 / name :op1 "ileitis"~e.22)
                                          :ARG1-of (r2 / resemble-01~e.21
                                                :ARG2 (d4 / disease~e.19
                                                      :name (n / name :op1 "Chron's"~e.18))))
                                    :ARG1-of (m6 / mean-01
                                          :ARG2 (s5 / strain~e.25
                                                :name (n3 / name :op1 "SAMP1/YitFc"~e.24))))))))
      :ARG1 (i2 / inhibit-01~e.29
            :ARG0~e.30 (s6 / small-molecule
                  :name (n4 / name :op1 "CGP57380"~e.31))
            :ARG1~e.48 (a / and~e.42,50
                  :op1 (c2 / cytokine
                        :name (n5 / name :op1 "TNF"~e.36)
                        :ARG0-of (p2 / promote-01
                              :ARG1 (i3 / inflame-01)))
                  :op2 (c3 / cytokine
                        :name (n6 / name :op1 "IL-6"~e.38,40)
                        :ARG0-of p2)
                  :op3 (p / protein
                        :name (n7 / name :op1 "monocyte-chemoattractant-protein-1"~e.43,44,45,47))
                  :op4 (p3 / protein
                        :name (n8 / name :op1 "monocyte-chemoattractant-protein-4"~e.43,44,45,49)))
            :manner (s3 / significant~e.28))
      :time (a2 / after~e.53
            :op1 (s4 / stimulate-01~e.55
                  :ARG0 (m4 / molecular-physical-entity
                        :name (n9 / name :op1 "LPS"~e.54)))
            :quant (t2 / temporal-quantity
                  :quant "24"~e.51
                  :unit (h / hour))))

# ::tok Co @-@ immunoprecipitation studies with H @-@ Ras @-@ transformed cells revealed that Spry2 and H @-@ Ras interact and that H @-@ Ras interacts with Spry2 @-@ binding partners , c @-@ Cbl and CIN85 , in a Spry2 @-@ dependent manner .
# ::alignments 3-1.1 4-1.1.2.r 5-1.1.2.1.1.1.1 7-1.1.2.1.1.1.1 9-1.1.2.1 10-1.1.2 11-1 12-1.2.r 13-1.2.1.1.1.1 14-1.2 15-1.1.2.1.1.1.1 17-1.1.2.1.1.1.1 18-1.2.1 18-1.2.2 19-1.2 21-1.2.2.1 22-1.2.2.1 23-1.2.2.1 24-1.2.2 25-1.1.2.r 25-1.2.2.2.r 26-1.2.2.2.1.1.1 28-1.2.2.2.1.1 29-1.2.2.2.1 31-1.2.2.2.1.2.1.1.1.1 33-1.2.2.2.1.2.1.1.1.1 34-1.2.2.2.1.2.1 35-1.2.2.2.1.2.1.2.1.1 37-1.2.2.3.r 39-1.2.2.3.1 41-1.2.2.3
# ::id bel_pmid_1804_8363_10226
(r / reveal-01~e.11
      :ARG0 (s / study-01~e.3
            :mod (c / coimmunoprecipitate-00)
            :instrument~e.4,25 (c2 / cell~e.10
                  :ARG1-of (t / transform-01~e.9
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "H-Ras"~e.5,7,15,17)))))
      :ARG1~e.12 (a / and~e.14,19
            :op1 (i / interact-01~e.18
                  :ARG0 (p / protein
                        :name (n2 / name :op1 "Spry2"~e.13))
                  :ARG1 e)
            :op2 (i2 / interact-01~e.18,24
                  :ARG0 e~e.21,22,23
                  :ARG1~e.25 (a2 / and
                        :op1 (p2 / partner~e.29
                              :ARG2-of (b / bind-01~e.28
                                    :ARG1 p~e.26)
                              :ARG1-of (m / mean-01
                                    :ARG2 (a3 / and~e.34
                                          :op1 (p4 / protein
                                                :name (n3 / name :op1 "c-Cbl"~e.31,33))
                                          :op2 (p3 / protein
                                                :name (n4 / name :op1 "CIN85"~e.35))))))
                  :ARG0-of~e.37 (d / depend-01~e.41
                        :ARG1 p~e.39))))

# ::tok We compared human fibroblasts malignantly transformed by overexpression of H @-@ Ras( V12 ) oncogene to their nontransformed parental cells and found that the malignant cells express a high level of Spry2 .
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.1 3-1.1.2 4-1.1.2.2.2 4-1.1.2.2.2.r 5-1.1.2.2 5-1.1.3.2 7-1.2.1 9-1.1.2.2.1.1.1.1 12-1.1.2.2.1.1.2.1 14-1.1.2.2.1.1 15-1.1.3.r 16-1.1.3.3 16-1.1.3.3.r 18-1.1.3.1 19-1.1.3 20-1 21-1.2 24-1.2.1.1.1 25-1.2.1.1 26-1.2.1 28-1.2.1.2.1 29-1.2.1.2 30-1.2.1.2.2.r 31-1.2.1.2.2.1.1
# ::id bel_pmid_1804_8363_20908
(a / and~e.20
      :op1 (c / compare-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (f / fibroblast~e.3
                  :mod (h2 / human~e.2)
                  :ARG1-of (t / transform-01~e.5
                        :ARG0 (o / overexpress-00
                              :ARG1 (o2 / oncogene~e.14
                                    :name (n / name :op1 "H-Ras"~e.9)
                                    :ARG2-of (m2 / mutate-01 :value "V12"~e.12)))
                        :manner~e.4 (m / malignant~e.4)))
            :ARG2~e.15 (c2 / cell~e.19
                  :mod (p / parent~e.18)
                  :ARG1-of (t2 / transform-01~e.5 :polarity "-")
                  :poss~e.16 f~e.16))
      :op2 (f2 / find-01~e.21
            :ARG1 (e / express-03~e.7,26
                  :ARG1 (c3 / cell~e.25
                        :mod (m3 / malignant~e.24))
                  :ARG2 (l / level~e.29
                        :mod (h / high~e.28)
                        :quant-of~e.30 (g / gene
                              :name (n2 / name :op1 "Spry2"~e.31))))))

# ::tok When we decreased expression of Spry2 , using a Spry2 @-@ specific shRNA , the H @-@ Ras( V12 )-transformed fibroblasts could no longer form large colonies in agarose , grow in reduced levels of serum , or form tumors in athymic mice . The level of active H @-@ Ras in these cells remained unaltered .
# ::alignments 0-1.1.4.r 0-1.1.5.r 1-1.1.4.1 2-1.1.4 3-1.1.4.2 4-1.1.4.2.1.r 5-1.1.4.2.1.1.1 9-1.1.4.2.1.1.1 11-1.1.4.3.2 12-1.1.4.3.1.1 15-1.1.1.1.1.1.1.1.1 18-1.1.1.1.1.1.1.2.1 20-1.1.1.1.1 21-1.1.1 21-1.1.2 21-1.1.3 22-1.1.5 23-1.1.5 24-1.1.1.1 25-1.1.1.1.2.1 26-1.1.1.1.2 27-1.1.1.1.3.r 28-1.1.1.1.3 30-1.1.2.1 31-1.1.2.1.2.r 32-1.1.2.1.2.2 33-1.1.2.1.2 34-1.1.2.1.2.1.r 35-1.1.2.1.2.1 37-1.1 38-1.1.3.1 39-1.1.3.1.2 40-1.1.3.1.3.r 41-1.1.3.1.3.1 42-1.1.3.1.3 45-1.2.1 48-1.2.1.1.1.1 50-1.2.1.1.1.1 52-1.2.3.1 53-1.2.3 54-1.2 55-1.2.2 55-1.2.2.1 55-1.2.2.1.r
# ::id bel_pmid_1804_8363_30892
(m4 / multi-sentence
      :snt1 (o / or~e.37
            :op1 (p2 / possible~e.21
                  :domain (f / form-01~e.24
                        :ARG0 (f2 / fibroblast~e.20
                              :ARG1-of (t / transform-01
                                    :ARG0 (e / enzyme
                                          :name (n2 / name :op1 "H-Ras"~e.15)
                                          :ARG2-of (m / mutate-01 :value "V12"~e.18))))
                        :ARG1 (c / colony~e.26
                              :mod (l / large~e.25))
                        :location~e.27 (a4 / agarose~e.28)))
            :op2 (p / possible~e.21
                  :domain (g / grow-01~e.30
                        :ARG0 f2
                        :location~e.31 (l2 / level~e.33
                              :quant-of~e.34 (s / serum~e.35)
                              :ARG1-of (r / reduce-01~e.32))))
            :op3 (p3 / possible~e.21
                  :domain (f3 / form-01~e.38
                        :ARG0 f2
                        :ARG1 (t2 / tumor~e.39)
                        :location~e.40 (m3 / mouse~e.42
                              :mod (a / athymic~e.41))))
            :time~e.0 (d / decrease-01~e.2
                  :ARG0 (w / we~e.1)
                  :ARG1 (e2 / express-03~e.3
                        :ARG2~e.4 (g2 / gene
                              :name (n5 / name :op1 "Spry2"~e.5,9)))
                  :instrument (r2 / rna
                        :name (n6 / name :op1 "shRNA"~e.12)
                        :mod (s2 / specific~e.11
                              :topic g2)))
            :time~e.0 (n / no-longer~e.22,23))
      :snt2 (r3 / remain-01~e.54
            :ARG1 (l3 / level~e.45
                  :quant-of (e3 / enzyme
                        :name (n7 / name :op1 "H-Ras"~e.48,50)
                        :ARG1-of (a2 / activate-01)))
            :ARG3 (a3 / alter-01~e.55
                  :polarity~e.55 "-"~e.55
                  :ARG1 l3)
            :location (c2 / cell~e.53
                  :mod (t3 / this~e.52))))

# ::tok We next determined whether the ?EGFR @-@ expressing MCF @-@ 10A cells produced high levels of IL @-@ 6 , leading to activation of STAT3 , as was observed in lung adenocarcinoma–derived cell lines harboring mutant EGFR . The ?EGFR–MCF @-@ 10A cells were treated with P6 , gp130 , and IL @-@ 6 blocking antibodies , which inhibited STAT3 activation .
# ::alignments 0-1.1.1 1-1.1.4 2-1.1 3-1.1.2.1 3-1.1.2.1.r 7-1.1.2.2.2 7-1.2.1.2 8-1.1.2.2.1.1 10-1.1.2.2.1.1 11-1.1.2.2 12-1.1.2 13-1.1.2.3.1 14-1.1.2.3 15-1.1.2.3.2.r 16-1.1.2.3.2.1.1 18-1.1.2.3.2.1.1 20-1.1.2.4 21-1.1.2.4.1.r 22-1.1.2.4.1 23-1.1.2.4.1.1.r 24-1.1.2.4.1.1.1.1 26-1.1.4.r 28-1.1.3.1 29-1.1.3.1.1.r 30-1.1.3.1.1.1.1.2 32-1.1.3.1.1 33-1.1.3.1.1 34-1.1.3.1.1.2 35-1.1.3.1.1.2.1 35-1.1.3.1.1.2.1.2 35-1.1.3.1.1.2.1.2.r 36-1.1.3.1.1.2.1.1.1 41-1.2.1.1.1 42-1.2.1 44-1.2 45-1.2.2.r 46-1.2.2.1.1.1 48-1.2.2.2.1.1 50-1.2.2 51-1.2.2.3.1.1.1.1 53-1.2.2.3.1.1.1.1 54-1.2.2.3.1 55-1.2.2.3 58-1.2.2.4 59-1.2.2.4.1.1.1.1 60-1.2.2.4.1
# ::id bel_pmid_1806_0032_38560
(m2 / multi-sentence
      :snt1 (d / determine-01~e.2
            :ARG0 (w / we~e.0)
            :ARG1 (p / produce-01~e.12
                  :mode~e.3 "interrogative"~e.3
                  :ARG0 (c2 / cell-line~e.11
                        :name (n3 / name :op1 "MCF-10A"~e.8,10)
                        :ARG1-of (e2 / express-03~e.7
                              :ARG2 (e / enzyme
                                    :name (n2 / name :op1 "ΔEGFR"))))
                  :ARG1 (l / level~e.14
                        :mod (h / high~e.13)
                        :quant-of~e.15 (p2 / protein
                              :name (n4 / name :op1 "IL-6"~e.16,18)))
                  :ARG0-of (l2 / lead-03~e.20
                        :ARG1~e.21 (a / activate-01~e.22
                              :ARG1~e.23 (p3 / protein
                                    :name (n5 / name :op1 "STAT3"~e.24)))))
            :ARG2-of (r / resemble-01
                  :ARG1 (o / observe-01~e.28
                        :location~e.29 (c / cell-line~e.32,33
                              :ARG1-of (d2 / derive-01
                                    :ARG2 (d3 / disease
                                          :name (n6 / name :op1 "adenocarcinoma")
                                          :mod (l3 / lung~e.30)))
                              :ARG0-of (h2 / harbor-01~e.34
                                    :ARG1 (e4 / enzyme~e.35
                                          :name (n7 / name :op1 "EGFR"~e.36)
                                          :ARG2-of~e.35 (m / mutate-01~e.35))))))
            :time~e.26 (n / next~e.1))
      :snt2 (t / treat-04~e.44
            :ARG1 (c3 / cell~e.42
                  :name (n8 / name :op1 "MCF-10A"~e.41)
                  :ARG1-of (e5 / express-03~e.7
                        :ARG2 (e3 / enzyme
                              :name (n9 / name :op1 "ΔEGFR"))))
            :ARG2~e.45 (a2 / and~e.50
                  :op1 (p4 / protein
                        :name (n10 / name :op1 "P6"~e.46))
                  :op2 (p5 / protein
                        :name (n11 / name :op1 "gp130"~e.48))
                  :op3 (a3 / antibody~e.55
                        :ARG0-of (b / block-01~e.54
                              :ARG1 (p7 / protein
                                    :name (n13 / name :op1 "IL-6"~e.51,53))))
                  :ARG0-of (i / inhibit-01~e.58
                        :ARG1 (a4 / activate-01~e.60
                              :ARG1 (p6 / protein
                                    :name (n12 / name :op1 "STAT3"~e.59)))))))

# ::tok In contrast , enhanced thrombopoietin signaling , conferred by enforced expression of constitutively active JAK2 or c @-@ MPL , induced phosphorylation of STAT3 and STAT5 , but not STAT1 , and failed to rescue megakaryocyte maturation .
# ::alignments 1-1.1.1.2.2 3-1.1.1.1.2 4-1.1.1.1.1.1.1 5-1.1.1.1 7-1.1.1.1.3 8-1.1.1.1.3.1.r 9-1.1.1.1.3.1.2 10-1.1.1.1.3.1 11-1.1.1.1.3.1.1.r 12-1.1.1.1.3.1.1.1.2.1 14-1.1.1.1.3.1.1.1.1.1 15-1.1.1.1.3.1.1 16-1.1.1.1.3.1.1.2.1.1 18-1.1.1.1.3.1.1.2.1.1 20-1.1.1 20-1.1.1.2.2.1 21-1.1.1.2 21-1.1.1.2.2.1.3 22-1.1.1.2.1.r 23-1.1.1.2.1.1.1.1 24-1.1.1.2.1 25-1.1.1.2.1.2.1.1 27-1 27-1.1.1.2.2 28-1.1.1.2.2.1.1 28-1.1.1.2.2.1.1.r 29-1.1.1.2.2.1.3.1.1.1 31-1.1 32-1.1.2 34-1.1.2.2 35-1.1.2.2.2.1 36-1.1.2.2.2
# ::id bel_pmid_1806_0035_1688
(c / contrast-01~e.27
      :ARG2 (a2 / and~e.31
            :op1 (i / induce-01~e.20
                  :ARG0 (s / signal-07~e.5
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "thrombopoietin"~e.4))
                        :ARG1-of (e / enhance-01~e.3)
                        :ARG1-of (c2 / confer-02~e.7
                              :ARG0~e.8 (e2 / express-03~e.10
                                    :ARG2~e.11 (o / or~e.15
                                          :op1 (p7 / protein
                                                :name (n2 / name :op1 "JAK2"~e.14)
                                                :ARG1-of (a3 / activate-01
                                                      :mod (c5 / constitutive~e.12)))
                                          :op2 (p8 / protein
                                                :name (n3 / name :op1 "c-MPL"~e.16,18)))
                                    :ARG1-of (e3 / enforce-01~e.9))))
                  :ARG1 (p / phosphorylate-01~e.21
                        :ARG1~e.22 (a / and~e.24
                              :op1 (p3 / protein
                                    :name (n4 / name :op1 "STAT3"~e.23))
                              :op2 (p4 / protein
                                    :name (n5 / name :op1 "STAT5"~e.25)))
                        :ARG1-of (c3 / contrast-01~e.1,27
                              :ARG2 (i2 / induce-01~e.20
                                    :polarity~e.28 "-"~e.28
                                    :ARG0 s
                                    :ARG1 (p5 / phosphorylate-01~e.21
                                          :ARG1 (p6 / protein
                                                :name (n6 / name :op1 "STAT1"~e.29)))))))
            :op2 (f / fail-01~e.32
                  :ARG0 s
                  :ARG1 (r / rescue-01~e.34
                        :ARG0 s
                        :ARG1 (m / maturate-01~e.36
                              :ARG1 (m2 / megakaryocyte~e.35))))))

# ::tok We show that ectopic expression of STAT1 or its downstream transcriptional target IRF @-@ 1 promotes features of megakaryocytic differentiation of G1ME cells , a Gata1 @-@ null erythromegakaryocytic cell line ( 25 ) ,
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.2 4-1.2.1.1 4-1.2.2.1.2.2.1.1 5-1.2.1.1.1.r 6-1.2.1.1.1.1.1 7-1.2.1 8-1.2.1.2.2 8-1.2.1.2.2.r 9-1.2.1.2.3 11-1.2.1.2 11-1.2.1.2.5 11-1.2.1.2.5.r 12-1.2.1.2.1.1 14-1.2.1.2.1.1 15-1.2 16-1.2.2 17-1.2.2.1.r 18-1.2.2.1.1 18-1.2.2.1.2.2.1.2 19-1.2.2.1 20-1.2.2.1.2.r 21-1.2.2.1.2.1.1 22-1.2.2.1.2.2.1 25-1.2.2.1.2.2.1.1.1.1.1 29-1.2.2.1.2 30-1.2.2.1.2.2.1 32-1.2.3.1.1.1
# ::id bel_pmid_1806_0035_28492
(s2 / show-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (p / promote-01~e.15
            :ARG0 (o / or~e.7
                  :op1 (e / express-03~e.4
                        :ARG2~e.5 (p2 / protein
                              :name (n / name :op1 "STAT1"~e.6))
                        :mod (e2 / ectopic~e.3))
                  :op2 (p4 / protein~e.11
                        :name (n2 / name :op1 "IRF-1"~e.12,14)
                        :poss~e.8 p2~e.8
                        :location (d / downstream~e.9)
                        :ARG0-of (t / transcribe-01)
                        :ARG1-of~e.11 (t2 / target-01~e.11)))
            :ARG1 (f / feature~e.16
                  :topic~e.17 (d2 / differentiate-01~e.19
                        :ARG0 (m5 / megakaryocyte~e.18)
                        :ARG1~e.20 (c2 / cell~e.29
                              :name (n4 / name :op1 "G1ME"~e.21)
                              :ARG1-of (m4 / mean-01
                                    :ARG2 (c3 / cell-line~e.22,30
                                          :ARG3-of (e3 / express-03~e.4
                                                :ARG2 (p5 / protein
                                                      :name (n5 / name :op1 "Gata1"~e.25)
                                                      :ARG2-of (m / mutate-01 :mod "-/-")))
                                          :mod (m2 / megakaryocyte~e.18)
                                          :mod (e4 / erythroid))))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c5 / cite-01 :ARG2 "25"~e.32)))))

# ::tok In most cell types , STAT1 is primarily triggered by interferon signaling ( 21 ) . However , TPO signaling phosphorylates STAT1 in WT megakaryocytes ( 10 ) .
# ::alignments 1-1.1.4.2 2-1.1.4.1 3-1.1.4 5-1.1.2.1.1 7-1.1.3 7-1.1.3.r 8-1.1 9-1.1.1.r 10-1.1.1.1.1.1 11-1.1.1 13-1.1.5.1.1.1 16-1.2 18-1.2.1.2.1.1.1 19-1.2.1.2 20-1.2.1 21-1.2.1.1.1.1 22-1.2.1.3.r 23-1.2.1.3.1 24-1.2.1.3 26-1.2.1.4.1.1.1
# ::id bel_pmid_1806_0035_31648
(m2 / multi-sentence
      :snt1 (t / trigger-01~e.8
            :ARG0~e.9 (s / signal-07~e.11
                  :ARG1 (p3 / protein
                        :name (n2 / name :op1 "interferon"~e.10)))
            :ARG1 (p / protein
                  :name (n / name :op1 "STAT1"~e.5))
            :manner~e.7 (p2 / primary~e.7)
            :location (t2 / type~e.3
                  :mod (c / cell~e.2)
                  :quant (m / most~e.1))
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "21"~e.13))))
      :snt2 (h / have-concession-91~e.16
            :ARG1 (p5 / phosphorylate-01~e.20
                  :ARG1 (p6 / protein
                        :name (n4 / name :op1 "STAT1"~e.21))
                  :ARG2 (s2 / signal-07~e.19
                        :ARG1 (p8 / protein
                              :name (n3 / name :op1 "TPO"~e.18)))
                  :location~e.22 (m3 / megakaryocyte~e.24
                        :mod (w / wild-type~e.23))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p7 / publication
                              :ARG1-of (c4 / cite-01 :ARG2 "10"~e.26))))))

# ::tok Moreover , GATA @-@ 1 transactivated the Stat1 promoter in luciferase reporter assays ( Supplemental Figure 1 ) . STAT1 and IRF @-@ 1 reciprocally activated each other’s transcription , as previously reported ( Figure ?( Figure1D1D and Supplemental Table 1; also reviewed in ref . 26 ) .
# ::alignments 2-1.1.1.1.1.1 4-1.1.1.1.1.1 4-1.1.1.4.1.1 5-1.1.1 7-1.1.1.2.1.1.1.1 9-1.1.1.3.r 10-1.1.1.3.1.1.1.1 11-1.1.1.3.1 12-1.1.1.3 14-1.1.1.4.1.2 15-1.1.1.4.1 16-1.1.1.4.1.1 16-1.2.1.2.1.1.1 19-1.1.1.2.1.1.1.1 19-1.2.1.1.1.1 20-1.1 20-1.2 21-1.2.1.2.1.1.1 23-1.2.1.2.1.1.1 23-1.2.4.1.2.1 25-1.2.1 25-1.2.2 28-1.2.1.2 28-1.2.2.2 30-1.2.3.1.r 31-1.2.3.1 32-1.2.3 34-1.2.4.1.1 37-1.2.4.1 38-1.2.4.1.2.2 39-1.2.4.1.2 42-1.2.5 46-1.2.5.1.1.1
# ::id bel_pmid_1806_0035_33056
(m / multi-sentence
      :snt1 (a / and~e.20
            :op2 (t / transactivate-00~e.5
                  :ARG0 (p / protein
                        :name (n / name :op1 "GATA-1"~e.2,4))
                  :ARG1 (m2 / molecular-physical-entity
                        :ARG0-of (p2 / promote-01
                              :ARG1 (p3 / protein
                                    :name (n2 / name :op1 "Stat1"~e.7,19))))
                  :location~e.9 (a2 / assay-00~e.12
                        :ARG0-of (r2 / report-01~e.11
                              :ARG1 (e / enzyme
                                    :name (n3 / name :op1 "luciferase"~e.10))))
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure~e.15
                              :mod "1"~e.4,16
                              :ARG2-of (s / supplement-01~e.14)))))
      :snt2 (a5 / and~e.20
            :op1 (a3 / activate-01~e.25
                  :ARG0 (p4 / protein
                        :name (n4 / name :op1 "STAT1"~e.19))
                  :ARG1 (t3 / transcribe-01~e.28
                        :ARG1 (p7 / protein
                              :name (n5 / name :op1 "IRF-1"~e.16,21,23))))
            :op2 (a4 / activate-01~e.25
                  :ARG0 p7
                  :ARG1 (t4 / transcribe-01~e.28
                        :ARG1 p4))
            :ARG1-of (r3 / report-01~e.32
                  :time~e.30 (p5 / previous~e.31))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a6 / and~e.37
                        :op1 (f2 / figure~e.34 :mod "1D")
                        :op2 (t5 / table~e.39
                              :mod "1"~e.23
                              :ARG2-of (s2 / supplement-01~e.38))))
            :ARG1-of (r4 / review-01~e.42
                  :location (p6 / publication
                        :ARG1-of (c / cite-01 :ARG2 "26"~e.46)))))

# ::tok In addition , STAT1 or IRF @-@ 1 induced the expression of CD42 , a late marker of megakaryocyte maturation , albeit to a much lesser extent than GATA @-@ 1 ( Figure ?( Figure1C ) .1C ) .
# ::alignments 0-1 1-1 3-1.1.1.1.1.1 4-1.1.1 5-1.1.1.2.1.1 7-1.1.1.2.1.1 8-1.1 8-1.2.1 10-1.1.2 10-1.2.1.4 11-1.1.2.1.r 12-1.1.2.1.1.1 15-1.1.2.1.3 18-1.1.2.1.2.1.1 19-1.1.2.1.2.1 24-1.2.1.3.1.1 25-1.2.1.3 25-1.2.1.3.1 25-1.2.1.3.1.r 26-1.2.1.3.r 27-1.2.1.4.r 28-1.2.1.4.1.1.1 30-1.2.1.4.1.1.1 32-1.3.1
# ::id bel_pmid_1806_0035_33182
(a / and~e.0,1
      :op2 (i / induce-01~e.8
            :ARG0 (o / or~e.4
                  :op1 (p / protein
                        :name (n / name :op1 "STAT1"~e.3))
                  :op2 (p3 / protein
                        :name (n2 / name :op1 "IRF-1"~e.5,7)))
            :ARG1 (e / express-03~e.10
                  :ARG2~e.11 (p2 / protein
                        :name (n3 / name :op1 "CD42"~e.12)
                        :ARG0-of (m / mark-02
                              :ARG1 (m2 / maturate-01~e.19
                                    :ARG1 (m4 / megakaryocyte~e.18)))
                        :mod (l3 / late~e.15))))
      :ARG1-of (h / have-concession-91
            :ARG2 (i2 / induce-01~e.8
                  :ARG0 o
                  :ARG1 e
                  :extent~e.26 (l / less~e.25
                        :degree~e.25 (m3 / more~e.25
                              :degree (m5 / much~e.24)))
                  :compared-to~e.27 (e2 / express-03~e.10
                        :ARG2 (p4 / protein
                              :name (n5 / name :op1 "GATA-1"~e.28,30)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.32 :mod "1C")))

# ::tok enforced STAT1 expression promoted several features of megakaryocytic differentiation of G1ME cells , as evidenced by increased cell size ( forward scatter ) and increased DNA content , reflecting polyploidization ( Figure ?( Figure1,1 , A and B ) . Similar effects were produced by enforced expression of IRF @-@ 1 , a major STAT1 effector ( reviewed in ref . 26 ) .
# ::alignments 0-1.1.1.2 1-1.1.1.1.1.1 2-1.1.1 3-1.1 4-1.1.2.1 5-1.1.2 6-1.1.2.2.r 7-1.1.2.2.1 8-1.1.2.2 9-1.1.2.2.2.r 10-1.1.2.2.2.1.1 11-1.1.2.2.2 13-1.1.3.r 14-1.1.3 15-1.1.3.1.r 16-1.1.3.1.1.2 17-1.1.3.1.1.1 18-1.1.3.1.1 20-1.1.3.1.1.3.1.1 21-1.1.3.1.1.3.1 23-1.1.3.1 24-1.1.3.1.2.1.1 25-1.1.3.1.2.1 26-1.1.3.1.2 28-1.1.4 31-1.1.5.1.1 31-1.1.5.1.2 36-1.1.5.1 40-1.2.2.1 41-1.2.1.1 41-1.2.1.1.2 41-1.2.1.1.2.r 41-1.2.2 43-1.2 44-1.2.1.r 45-1.2.1.2 46-1.2.1 48-1.2.1.1.1.1 50-1.2.1.1.1.1 53-1.2.1.1.2.2 54-1.2.1.1.2.1.1.1 61-1.2.3.1.1.1
# ::id bel_pmid_1806_0035_34122
(m / multi-sentence
      :snt1 (p / promote-01~e.3
            :ARG0 (e / express-03~e.2
                  :ARG2 (p2 / protein
                        :name (n / name :op1 "STAT1"~e.1))
                  :ARG1-of (e2 / enforce-01~e.0))
            :ARG1 (f / feature~e.5
                  :quant (s / several~e.4)
                  :topic~e.6 (d / differentiate-01~e.8
                        :ARG0 (m3 / megakaryocyte~e.7)
                        :ARG1~e.9 (c2 / cell-line~e.11
                              :name (n3 / name :op1 "G1ME"~e.10))))
            :ARG1-of~e.13 (e3 / evidence-01~e.14
                  :ARG0~e.15 (a2 / and~e.23
                        :op1 (s2 / size~e.18
                              :poss (c3 / cell~e.17)
                              :ARG1-of (i / increase-01~e.16)
                              :ARG1-of (s3 / show-01
                                    :ARG0 (s4 / scatter-01~e.21
                                          :direction (f4 / forward~e.20))))
                        :op2 (c4 / contain-01~e.26
                              :ARG1 (d2 / DNA~e.25
                                    :ARG1-of (i2 / increase-01~e.24)))))
            :ARG1-of (r2 / reflect-01~e.28
                  :ARG2 (p3 / polyploidizate-00))
            :ARG1-of (d3 / describe-01
                  :ARG0 (a / and~e.36
                        :op1 (f2 / figure~e.31 :mod "1.1.A")
                        :op2 (f3 / figure~e.31 :mod "1.1.B"))))
      :snt2 (p4 / produce-01~e.43
            :ARG0~e.44 (e5 / express-03~e.46
                  :ARG2 (p6 / protein~e.41
                        :name (n4 / name :op1 "IRF-1"~e.48,50)
                        :ARG0-of~e.41 (a4 / affect-01~e.41
                              :ARG1 (p5 / protein
                                    :name (n5 / name :op1 "STAT1"~e.54))
                              :mod (m2 / major~e.53)))
                  :ARG1-of (e6 / enforce-01~e.45))
            :ARG1 (a3 / affect-01~e.41
                  :ARG1-of (r3 / resemble-01~e.40))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p7 / publication
                        :ARG1-of (c / cite-01 :ARG2 "26"~e.61)))))

# ::tok Second , mice deficient for both STAT5A and STAT5B are thrombocytopenic , likely due to a reduction in functional hematopoietic progenitors ( 18 ) .
# ::alignments 0-1.3 0-1.3.1 0-1.3.1.r 2-1.1 7-1.1.1.1 9-1.1.r 10-1 12-1.2.2 13-1.2 14-1.2 16-1.2.1 17-1.2.1.1.r 18-1.2.1.1.2 19-1.2.1.1.1 20-1.2.1.1 22-1.4.1.1.1
# ::id bel_pmid_1806_0035_34154
(t / thrombocytopenic~e.10
      :domain~e.9 (m / mouse~e.2
            :ARG0-of (l / lack-01
                  :ARG1 (a / and~e.7
                        :op1 (g / gene
                              :name (n / name :op1 "STAT1A"))
                        :op2 (g2 / gene
                              :name (n2 / name :op1 "STAT1B")))))
      :ARG1-of (c / cause-01~e.13,14
            :ARG0 (r / reduce-01~e.16
                  :ARG1~e.17 (p / progenitor~e.20
                        :mod (h / hematopoietic~e.19)
                        :ARG0-of (f / function-01~e.18)))
            :mod (l2 / likely~e.12))
      :mod (o / ordinal-entity~e.0 :value~e.0 "2"~e.0)
      :ARG1-of (d / describe-01
            :ARG0 (p2 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "18"~e.22))))

# ::tok TPO functions through binding its receptor , c @-@ Mpl , to activate JAK2 , STAT1 , STAT3 , and STAT5 in megakaryocytes and other hematopoietic cells ( 10–12 ) .
# ::alignments 0-1.1.1.1 1-1 3-1.2 4-1.2.1.2 4-1.2.1.2.r 5-1.2.1 7-1.2.1.1.1 9-1.2.1.1.1 12-1.2.3 13-1.2.3.2.1.1.1 15-1.2.3.2.2.1.1 17-1.2.3.2.3.1.1 19-1.2.3.2 20-1.2.3.2.4.1.1 21-1.2.3.3.r 22-1.2.3.3.1 23-1.2.3.3 24-1.2.3.3.2.2 25-1.2.3.3.2.1 26-1.2.3.3.2
# ::id bel_pmid_1806_0035_39068
(f / function-01~e.1
      :ARG0 (p5 / protein
            :name (n / name :op1 "TPO"~e.0))
      :instrument (b / bind-01~e.3
            :ARG1 (r2 / receptor~e.5
                  :name (n2 / name :op1 "c-Mpl"~e.7,9)
                  :poss~e.4 p5~e.4)
            :ARG2 p5
            :purpose (a / activate-01~e.12
                  :ARG0 p5
                  :ARG1 (a2 / and~e.19
                        :op1 (p6 / protein
                              :name (n3 / name :op1 "JAK2"~e.13))
                        :op2 (p / protein
                              :name (n4 / name :op1 "STAT1"~e.15))
                        :op3 (p2 / protein
                              :name (n5 / name :op1 "STAT3"~e.17))
                        :op4 (p3 / protein
                              :name (n6 / name :op1 "STAT5"~e.20)))
                  :location~e.21 (a3 / and~e.23
                        :op1 (m / megakaryocyte~e.22)
                        :op2 (c2 / cell~e.26
                              :mod (h / hematopoietic~e.25)
                              :mod (o / other~e.24)))))
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (v / value-interval :op1 "10" :op2 "12")))))

# ::tok enforced STAT1 expression promoted several features of megakaryocytic differentiation of G1ME cells , as evidenced by increased cell size ( forward scatter ) and increased DNA content , reflecting polyploidization ( Figure ?( Figure1,1 , A and B ) . Similar effects were produced by enforced expression of IRF @-@ 1 , a major STAT1 effector ( reviewed in ref . 26 ) .
# ::alignments 0-1.1.1.2 1-1.1.1.1.1.1 2-1.1.1 3-1.1 4-1.1.2.1 5-1.1.2 6-1.1.2.2.r 7-1.1.2.2.1 8-1.1.2.2 9-1.1.2.2.2.r 10-1.1.2.2.2.1.1 11-1.1.2.2.2 13-1.1.3.r 14-1.1.3 15-1.1.3.1.r 16-1.1.3.1.1.2 17-1.1.3.1.1.1 18-1.1.3.1.1 20-1.1.3.1.1.3.1.1 21-1.1.3.1.1.3.1 23-1.1.3.1 24-1.1.3.1.2.1.1 25-1.1.3.1.2.1 26-1.1.3.1.2 28-1.1.4 31-1.1.5.1.1 31-1.1.5.1.2 36-1.1.5.1 40-1.2.2.1 41-1.2.1.1 41-1.2.1.1.2 41-1.2.1.1.2.r 41-1.2.2 43-1.2 44-1.2.1.r 45-1.2.1.2 46-1.2.1 48-1.2.1.1.1.1 50-1.2.1.1.1.1 53-1.2.1.1.2.2 54-1.2.1.1.2.1.1.1 61-1.2.3.1.1.1
# ::id bel_pmid_1806_0035_39758
(m / multi-sentence
      :snt1 (p / promote-01~e.3
            :ARG0 (e / express-03~e.2
                  :ARG2 (p2 / protein
                        :name (n / name :op1 "STAT1"~e.1))
                  :ARG1-of (e2 / enforce-01~e.0))
            :ARG1 (f / feature~e.5
                  :quant (s / several~e.4)
                  :topic~e.6 (d / differentiate-01~e.8
                        :ARG0 (m3 / megakaryocyte~e.7)
                        :ARG1~e.9 (c2 / cell-line~e.11
                              :name (n3 / name :op1 "G1ME"~e.10))))
            :ARG1-of~e.13 (e3 / evidence-01~e.14
                  :ARG0~e.15 (a / and~e.23
                        :op1 (s2 / size~e.18
                              :poss (c3 / cell~e.17)
                              :ARG1-of (i / increase-01~e.16)
                              :ARG1-of (s3 / show-01
                                    :ARG0 (s4 / scatter-01~e.21
                                          :direction (f4 / forward~e.20))))
                        :op2 (c4 / contain-01~e.26
                              :ARG1 (d2 / DNA~e.25
                                    :ARG1-of (i2 / increase-01~e.24)))))
            :ARG1-of (r2 / reflect-01~e.28
                  :ARG2 (p3 / polyploidizate-00))
            :ARG1-of (d3 / describe-01
                  :ARG0 (a2 / and~e.36
                        :op1 (f2 / figure~e.31 :mod "1.1.A")
                        :op2 (f3 / figure~e.31 :mod "1.1.B"))))
      :snt2 (p4 / produce-01~e.43
            :ARG0~e.44 (e4 / express-03~e.46
                  :ARG2 (p6 / protein~e.41
                        :name (n4 / name :op1 "IRF-1"~e.48,50)
                        :ARG0-of~e.41 (a4 / affect-01~e.41
                              :ARG1 (p5 / protein
                                    :name (n5 / name :op1 "STAT1"~e.54))
                              :mod (m2 / major~e.53)))
                  :ARG1-of (e6 / enforce-01~e.45))
            :ARG1 (a3 / affect-01~e.41
                  :ARG1-of (r3 / resemble-01~e.40))
            :ARG1-of (d4 / describe-01
                  :ARG0 (p7 / publication
                        :ARG1-of (c / cite-01 :ARG2 "26"~e.61)))))

# ::tok Functional assessment of NCC by using thiazide @-@ sensitive ( 22 ) Na(+) uptakes revealed that TPA completely suppresses NCC function . Biotinylation experiments demonstrated that this result was primarily because of decreased surface expression of NCC .
# ::alignments 0-1.1.1.2 1-1.1.1 3-1.2.2.1.1.1.1.1 4-1.1.1.3.r 5-1.1.1.3 6-1.1.1.3.1.2.1.1.1 13-1.1.1.3.1 14-1.1 15-1.1.2.r 16-1.1.2.1.1.1 17-1.1.2.3 18-1.1.2 19-1.1.2.2.1.1.1 20-1.1.2.2 23-1.2.1 24-1.2 26-1.2.2.2.2 27-1.2.2.2 27-1.2.2.2.1 27-1.2.2.2.1.r 29-1.2.2.3 30-1.2.2 32-1.2.2.1 33-1.2.2.1.1.2 34-1.2.2.1.1 36-1.1.2.2.1.1.1 36-1.2.2.1.1.1.1.1
# ::id bel_pmid_1807_7438_32114
(m / multi-sentence
      :snt1 (r / reveal-01~e.14
            :ARG0 (a / assess-01~e.1
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "NCC"~e.19,36))
                  :mod (f2 / function-01~e.0)
                  :manner~e.4 (u / use-01~e.5
                        :ARG1 (u2 / uptake~e.13
                              :mod (s5 / small-molecule
                                    :name (n3 / name :op1 "22Na+"))
                              :ARG1-of (s2 / sensitize-01
                                    :ARG2 (s3 / small-molecule
                                          :name (n4 / name :op1 "thiazide"~e.6))))))
            :ARG1~e.15 (s / suppress-01~e.18
                  :ARG0 (s6 / small-molecule
                        :name (n / name :op1 "TPA"~e.16))
                  :ARG1 (f / function-01~e.20
                        :ARG0 p2)
                  :degree (c / complete~e.17)))
      :snt2 (d / demonstrate-01~e.24
            :ARG0 (e / experiment-01~e.23
                  :ARG1 (b / biotinylate-00))
            :ARG1 (c2 / cause-01~e.30
                  :ARG0 (d2 / decrease-01~e.32
                        :ARG1 (e2 / express-03~e.34
                              :ARG2 (p5 / protein
                                    :name (n5 / name :op1 "NCC"~e.3,36))
                              :ARG3 (s4 / surface~e.33)))
                  :ARG1 (t / thing~e.27
                        :ARG2-of~e.27 (r2 / result-01~e.27)
                        :mod (t2 / this~e.26))
                  :mod (p4 / primary~e.29))))

# ::tok Although inhibitors of PKC had no effect on this suppression , MAPK inhibitors completely prevented the TPA effect . RasGRP1 activates the MAPK pathway through activation of the small G protein H @-@ Ras .
# ::alignments 0-1.1.4.r 1-1.1.4.2 1-1.1.4.2.1 1-1.1.4.2.1.r 2-1.1.4.2.1.1.r 3-1.1.4.2.1.1.1.1 5-1.1.4.1 5-1.1.4.1.r 6-1.1.4 9-1.1.4.3 11-1.1.1.1.1.1.1 12-1.1.1 12-1.1.1.1 12-1.1.1.1.r 13-1.1.3 14-1.1 16-1.1.2.1.1.1 17-1.1.2 19-1.2.1.1.1 20-1.2 22-1.2.2.1.1 23-1.2.2 25-1.2 25-1.2.3 25-1.2.3.r 26-1.2.3.2.r 28-1.2.3.2.2.1.1 29-1.2.3.2.2.1.2 30-1.2.3.2.2.1.3 31-1.2.3.2.1.1 33-1.2.3.2.1.1
# ::id bel_pmid_1807_7438_4108
(m / multi-sentence
      :snt1 (p / prevent-01~e.14
            :ARG0 (m2 / molecular-physical-entity~e.12
                  :ARG0-of~e.12 (i / inhibit-01~e.12
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "MAPK"~e.11))))
            :ARG1 (a / affect-01~e.17
                  :ARG0 (s / small-molecule
                        :name (n2 / name :op1 "TPA"~e.16)))
            :degree (c / complete~e.13)
            :concession~e.0 (a2 / affect-01~e.6
                  :polarity~e.5 "-"~e.5
                  :ARG0 (m3 / molecular-physical-entity~e.1
                        :ARG0-of~e.1 (i2 / inhibit-01~e.1
                              :ARG1~e.2 (e2 / enzyme
                                    :name (n3 / name :op1 "PKC"~e.3))))
                  :ARG1 (s3 / suppress-01~e.9
                        :ARG1 a)))
      :snt2 (a3 / activate-01~e.20,25
            :ARG0 (p3 / protein
                  :name (n4 / name :op1 "RasGRP1"~e.19))
            :ARG1 (p4 / pathway~e.23
                  :name (n5 / name :op1 "MAPK"~e.22))
            :manner~e.25 (a4 / activate-01~e.25
                  :ARG0 p3
                  :ARG1~e.26 (e3 / enzyme
                        :name (n7 / name :op1 "H-Ras"~e.31,33)
                        :mod (e4 / enzyme
                              :name (n6 / name
                                    :op1 "small"~e.28
                                    :op2 "G"~e.29
                                    :op3 "protein"~e.30))))))

# ::tok Expression of all proinflammatory @/@ profibrotic mediators as assessed by reverse transcriptase @-@ PCR and densitometry was less in Lenti @-@ IL @-@ 10 @-@ injected wounds compared with Lenti @-@ GFP @-@ injected wounds , with the difference in the expression of IL @-@ 6 , MCP @-@ 1 , and HSP47 reaching statistical significance ( Figure 5 ) .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.3 6-1.1.1.1 6-1.1.1.1.2 6-1.1.1.1.2.r 8-1.4 10-1.4.1.1.1.1 11-1.4.1.1.1.2 13-1.4.1.1.1.2 14-1.4.1 15-1.4.1.2.1.1 16-1.1.r 17-1 19-1.1.2.1.1.1.1 21-1.1.2.1.1.1.1 23-1.1.2.1.1.1.1 25-1.1.2.1 26-1.1.2 27-1.5.r 28-1.4.1.r 29-1.5.2.1.1.1.1 31-1.5.2.1.1.1.1 33-1.5.2.1 34-1.1.2 34-1.5.2 36-1.2.r 36-1.4.1.r 38-1.2.1 41-1.2.1.1.1 41-1.2.1.1.2 41-1.2.1.1.3 41-1.5 42-1.2.1.1.1.1.r 42-1.2.1.1.r 43-1.2.1.1.1.1.1.1 45-1.2.1.1.1.1.1.1 47-1.2.1.1.2.1.1.1 49-1.2.1.1.2.1.1.1 51-1.2.1.1 52-1.2.1.1.3.1.1.1 53-1.2 57-1.3.1 58-1.3.1.1
# ::id bel_pmid_1820_0061_27886
(l / less~e.17
      :domain~e.16 (e / express-03~e.0
            :ARG2~e.1 (a / and
                  :op1 (m2 / molecular-physical-entity~e.6
                        :ARG0-of (f / favor-01
                              :ARG1 (i / inflame-01))
                        :ARG0-of~e.6 (m / mediate-01~e.6))
                  :op2 (m3 / molecular-physical-entity
                        :ARG0-of m
                        :ARG0-of (f2 / favor-01
                              :ARG1 (f3 / fibrosis)))
                  :mod (a2 / all~e.2))
            :ARG3 (w / wound-01~e.26,34
                  :ARG2-of (i2 / inject-01~e.25
                        :ARG1 (p / protein
                              :name (n / name :op1 "Lenti-IL-10"~e.19,21,23)))))
      :manner~e.36 (r / reach-01~e.53
            :ARG0 (d / differ-02~e.38
                  :ARG1~e.42 (a3 / and~e.51
                        :op1 (e2 / express-03~e.41
                              :ARG2~e.42 (p3 / protein
                                    :name (n3 / name :op1 "IL-6"~e.43,45)))
                        :op2 (e3 / express-03~e.41
                              :ARG2 (p4 / protein
                                    :name (n4 / name :op1 "MCP-1"~e.47,49)))
                        :op3 (e4 / express-03~e.41
                              :ARG2 (p5 / protein
                                    :name (n5 / name :op1 "HSP47"~e.52)))))
            :ARG1 (s3 / signify-01
                  :mod (s4 / statistic)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f4 / figure~e.57 :mod "5"~e.58))
      :ARG2-of (a4 / assess-01~e.8
            :instrument~e.28,36 (a5 / and~e.14
                  :op1 (t / thing
                        :name (n6 / name :op1 "reverse"~e.10 :op2 "transcriptase-PCR"~e.11,13))
                  :op2 (t2 / thing
                        :name (n7 / name :op1 "densitometry"~e.15))))
      :compared-to~e.27 (e5 / express-03~e.41
            :ARG2 a
            :ARG3 (w2 / wound-01~e.34
                  :ARG2-of (i3 / inject-01~e.33
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "Lenti-GFP"~e.29,31))))))

# ::tok observations that inhibition of PI3K or EGF @-@ R is sufficient to prevent terminal differentiation in keratinocytes in suspension ( Rodeck et al. , 1997; Nikolopoulos et al. , 2005 ) , and that function disrupting antibodies to E @-@ cadherin abrogate Akt phosphorylation inducing growth arrest and terminal differentiation in conventional submerged mouse keratinocyte cultures at confluency ( Calautti et al. , 2005 ) .
# ::alignments 0-1 1-1.1.r 2-1.1.1.1 3-1.1.1.1.1.r 4-1.1.1.1.1.1.1.1 5-1.1.1.1.1 6-1.1.1.1.1.2.1.1 8-1.1.1.1.1.2.1.1 10-1.1.1 12-1.1.1.2 13-1.1.1.2.1.2 14-1.1.1.2.1 17-1.1.1.2.1.1.r 18-1.1.1.2.1.1 18-1.1.1.2.1.1.2 18-1.1.1.2.1.1.2.r 20-1.1.1.3.1.1.1.1.1.1 21-1.1.1.3.1 21-1.1.1.3.1.1.1 21-1.1.1.3.1.2.1 22-1.1.1.3.1.1.1.2.1 22-1.1.1.3.1.2.1.2.1 25-1.1.1.3.1.2.1.1.1.1 26-1.1 26-1.1.1.3.1 26-1.1.1.3.1.2.1 27-1.1.1.3.1.2.1.2.1 29-1.1.1.3.1.2.2 32-1.1.2.4.1.1 34-1.1.2.1.1.1 35-1.1.2.1.1 36-1.1.2.1 38-1.1.2.1.2.1.1.1 40-1.1.2.1.2.1.1.1 41-1.1.2 42-1.1.2.2.1.1.1 43-1.1.2.2 44-1.1.2.3 45-1.1.2.3.1.1.1 46-1.1.2.3.1.1 47-1.1 47-1.1.1.3.1 47-1.1.1.3.1.2.1 47-1.1.2.3.1 47-1.1.2.4.1.1 48-1.1.2.3.1.2.2 49-1.1.2.3.1.2 50-1.1.2.3.1.2.1.r 51-1.1.2.3.1.2.1.3.1 52-1.1.2.3.1.2.1.3 53-1.1.2.3.1.2.1.1 54-1.1.2.3.1.2.1.2 55-1.1.2.3.1.2.1 56-1.1.2.3.2.r 57-1.1.2.3.2 59-1.1.2.4.1.1.1.1.1 60-1.1.2.4.1.1 61-1.1.2.4.1.1.2.1 63-1.1.2.4.1.2.1
# ::id bel_pmid_1826_8536_21638
(o / observe-02~e.0
      :ARG1~e.1 (a / and~e.26,47
            :op1 (s / suffice-01~e.10
                  :ARG0 (i / inhibit-01~e.2
                        :ARG1~e.3 (o2 / or~e.5
                              :op1 (e2 / enzyme
                                    :name (n2 / name :op1 "PI3K"~e.4))
                              :op2 (e / enzyme
                                    :name (n / name :op1 "EGF-R"~e.6,8))))
                  :ARG1 (p / prevent-01~e.12
                        :ARG1 (d / differentiate-01~e.14
                              :ARG1~e.17 (c / cell~e.18
                                    :name (n3 / name :op1 "keratinocyte")
                                    :ARG1-of~e.18 (s2 / suspend-02~e.18))
                              :mod (t / terminal~e.13)))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (a2 / and~e.21,26,47
                              :op1 (p2 / publication-91
                                    :ARG0 (a3 / and~e.21
                                          :op1 (p3 / person
                                                :name (n4 / name :op1 "Rodeck"~e.20))
                                          :op2 (p4 / person
                                                :mod (o3 / other~e.22)))
                                    :time (d7 / date-entity :year "1997"))
                              :op2 (p5 / publication-91
                                    :ARG0 (a4 / and~e.21,26,47
                                          :op1 (p6 / person
                                                :name (n5 / name :op1 "Nikolopoulos"~e.25))
                                          :op2 (p7 / person
                                                :mod (o4 / other~e.22,27)))
                                    :time d6~e.29))))
            :op2 (a5 / abrogate-01~e.41
                  :ARG0 (a6 / antibody~e.36
                        :ARG0-of (d3 / disrupt-01~e.35
                              :ARG1 (f / function-01~e.34))
                        :ARG0-of (c2 / counter-01
                              :ARG1 (p8 / protein
                                    :name (n6 / name :op1 "E-cadherin"~e.38,40))))
                  :ARG1 (p9 / phosphorylate-01~e.43
                        :ARG1 (e3 / enzyme
                              :name (n7 / name :op1 "Akt"~e.42)))
                  :ARG0-of (i2 / induce-01~e.44
                        :ARG1 (a7 / and~e.47
                              :op1 (a8 / arrest-02~e.46
                                    :ARG1 (g / grow-01~e.45
                                          :ARG1 (c3 / culture~e.55
                                                :source (m / mouse~e.53)
                                                :mod c~e.54
                                                :ARG1-of (s3 / submerge-01~e.52
                                                      :manner (c4 / conventional~e.51)))))
                              :op2 (d4 / differentiate-01~e.49
                                    :ARG1~e.50 c3
                                    :mod t~e.48))
                        :manner~e.56 (c5 / confluency~e.57))
                  :ARG1-of (d5 / describe-01
                        :ARG0 (p10 / publication-91
                              :ARG0 (a9 / and~e.32,47,60
                                    :op1 (p11 / person
                                          :name (n8 / name :op1 "Calautti"~e.59))
                                    :op2 (p12 / person
                                          :mod (o5 / other~e.61)))
                              :time (d6 / date-entity :year "2005"~e.63))))))

# ::tok In vivo , b4 @-@ integrin amplifies proproliferative signals in basal epidermal keratinocytes ( Nikolopoulos et al. , 2005 ) , where STAT3 is expressed and can be activated by EGF @/@ EGF @-@ R ( Nishio et al. , 2001; Chan et al. , 2004; Li et al. , 2007 )
# ::alignments 0-1.4 1-1.4 3-1.1.1.1 5-1.1.1.1 6-1 8-1.2 9-1.3.r 9-1.4 10-1.3.2 14-1.5.1.1.1.1.1 15-1.5.1.1 16-1.5.1.1.2.1 18-1.5.1.2.1 21-1.3.5.r 22-1.3.4.1.1.1 24-1.3.4 26-1.3.5 27-1.3.5.1.r 28-1.3.5.1 30-1.3.5.1.1.1.1.1 32-1.3.5.1.1.1.1.1 34-1.3.5.1.1.2.1.1 36-1.3.5.2.1.1.1.1.1.1 37-1.3.5.2.1 37-1.3.5.2.1.1.1 37-1.3.5.2.1.2.1 37-1.3.5.2.1.3.1 38-1.3.5.2.1.1.1.2.1 38-1.3.5.2.1.2.1.2.1 38-1.3.5.2.1.3.1.2.1 41-1.3.5.2.1.2.1.1.1.1 42-1.3.5.2.1 42-1.3.5.2.1.1.1 42-1.3.5.2.1.2.1 42-1.3.5.2.1.3.1 43-1.3.5.2.1.1.1.2.1 43-1.3.5.2.1.2.1.2.1 43-1.3.5.2.1.3.1.2.1 46-1.3.5.2.1.3.1.1.1.1 47-1.3.5.2.1.3.1 48-1.3.5.2.1.3.1.2.1 50-1.3.5.2.1.3.2.1
# ::id bel_pmid_1826_8536_21660
(a / amplify-01~e.6
      :ARG0 (p / protein
            :name (n / name :op1 "b4-integrin"~e.3,5))
      :ARG1 (s / signal-07~e.8
            :mod (p2 / proliferate-01))
      :location~e.9 (c / cell
            :name (n2 / name :op1 "keratinocyte")
            :mod (b / basal~e.10)
            :part-of (e / epidermis)
            :ARG3-of (e2 / express-03~e.24
                  :ARG2 (p6 / protein
                        :name (n4 / name :op1 "STAT3"~e.22)))
            :location-of~e.21 (p7 / possible~e.26
                  :domain~e.27 (a3 / activate-01~e.28
                        :ARG0 (s3 / slash
                              :op1 (s2 / small-molecule
                                    :name (n5 / name :op1 "EGF"~e.30,32))
                              :op2 (e4 / enzyme
                                    :name (n6 / name :op1 "EGF-R"~e.34)))
                        :ARG1 p6)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (a5 / and~e.37,42
                              :op1 (p8 / publication-91
                                    :ARG0 (a6 / and~e.37,42
                                          :op1 (p9 / person
                                                :name (n7 / name :op1 "Nishio"~e.36))
                                          :op2 (p10 / person
                                                :mod (o2 / other~e.38,43)))
                                    :time (d3 / date-entity :year "2001"))
                              :op2 (p11 / publication-91
                                    :ARG0 (a7 / and~e.37,42
                                          :op1 (p12 / person
                                                :name (n8 / name :op1 "Chan"~e.41))
                                          :op2 (p13 / person
                                                :mod (o3 / other~e.38,43)))
                                    :time (d4 / date-entity :year "2004"))
                              :op3 (p14 / publication-91
                                    :ARG0 (a8 / and~e.37,42,47
                                          :op1 (p15 / person
                                                :name (n9 / name :op1 "Li"~e.46))
                                          :op2 (p16 / person
                                                :mod (o4 / other~e.38,43,48)))
                                    :time (d5 / date-entity :year "2007"~e.50))))))
      :manner (i / in-vivo~e.0,1,9)
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a2 / and~e.15
                        :op1 (p4 / person
                              :name (n3 / name :op1 "Nikolopoulos"~e.14))
                        :op2 (p5 / person
                              :mod (o / other~e.16)))
                  :time (d6 / date-entity :year "2005"~e.18))))

# ::tok Src @-@ family kinases then phosphorylate the plaque proteins b @-@ catenin , plakoglobin , p120 cnt , and acatenin , which is required for their association with the E @-@ cadherin tail ( Calautti et al. , 1998 , 2005 ) .
# ::alignments 0-1.2.1.1.1.1.1 2-1.2.1.1 3-1.2 3-1.2.1.1.1 4-1.3 5-1 7-1.1.5 8-1.5.1.2 9-1.1.1.1.1 11-1.1.1.1.1 13-1.1.2.1.1 18-1.1 19-1.1.4.1.1 23-1.5 25-1.5.1.1 25-1.5.1.1.r 26-1.5.1 27-1.5.1.2.1.r 29-1.5.1.2.1.1.1 31-1.5.1.2.1.1.1 34-1.4.1.1.1.1.1.1 35-1.4.1 35-1.4.1.1.1 36-1.4.1.1.1.2.1 38-1.4.1.1.2.1 40-1.4.1.2.2.1
# ::id bel_pmid_1826_8536_22176
(p / phosphorylate-01~e.5
      :ARG1 (a / and~e.18
            :op1 (p2 / protein
                  :name (n2 / name :op1 "b-catenin"~e.9,11))
            :op2 (p3 / protein
                  :name (n3 / name :op1 "plakoglobin"~e.13))
            :op3 (p4 / protein
                  :name (n4 / name :op1 "p120cnt"))
            :op4 (p5 / protein
                  :name (n5 / name :op1 "acatenin"~e.19))
            :part-of (p6 / plaque~e.7))
      :ARG2 (k / kinase~e.3
            :ARG1-of (i / include-91
                  :ARG2 (f / family~e.2
                        :mod (k2 / kinase~e.3
                              :name (n / name :op1 "Src"~e.0)))))
      :time (t / then~e.4)
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and~e.35
                  :op1 (p9 / publication-91
                        :ARG0 (a3 / and~e.35
                              :op1 (p10 / person
                                    :name (n7 / name :op1 "Calautti"~e.34))
                              :op2 (p11 / person
                                    :mod (o / other~e.36)))
                        :time (d2 / date-entity :year "1998"~e.38))
                  :op2 (p12 / publication-91
                        :ARG0 a3
                        :time (d3 / date-entity :year "2005"~e.40))))
      :ARG1-of (r / require-01~e.23
            :purpose (a2 / associate-01~e.26
                  :ARG1~e.25 a~e.25
                  :ARG2 (p7 / protein-segment~e.8
                        :part-of~e.27 (p8 / protein
                              :name (n6 / name :op1 "E-cadherin"~e.29,31))))))

# ::tok JNK2 might potentially be activated via Src kinasemediated phosphorylation of EGF @-@ R on Tyr920 ( Calautti et al. , 2005 ) ,
# ::alignments 0-1.1.2.1.1 1-1 2-1.2 2-1.2.r 3-1.1.r 4-1.1 6-1.1.1.2.1.1.1 8-1.1.1 9-1.1.1.1.r 10-1.1.1.1.3.1.1 12-1.1.1.1.3.1.1 16-1.3.1.1.1.1.1 17-1.3.1.1 18-1.3.1.1.2.1 20-1.3.1.2.1
# ::id bel_pmid_1826_8536_22182
(p / possible~e.1
      :domain~e.3 (a / activate-01~e.4
            :ARG0 (p2 / phosphorylate-01~e.8
                  :ARG1~e.9 (a3 / amino-acid
                        :mod "920"
                        :name (n3 / name :op1 "tyrosine")
                        :part-of (e2 / enzyme
                              :name (n4 / name :op1 "EGF-R"~e.10,12)))
                  :ARG1-of (m / mediate-01
                        :ARG0 (k / kinase
                              :name (n2 / name :op1 "Src"~e.6))))
            :ARG1 (e / enzyme
                  :name (n / name :op1 "JNK2"~e.0)))
      :manner~e.2 (p3 / potential~e.2)
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a2 / and~e.17
                        :op1 (p6 / person
                              :name (n5 / name :op1 "Calautti"~e.16))
                        :op2 (p7 / person
                              :mod (o / other~e.18)))
                  :time (d / date-entity :year "2005"~e.20))))

# ::tok b1 @-@ integrin phosphorylation by Src results in EGF @-@ R activation ( Miranti and Brugge , 2002 ) , and b1 @-@ integrin expression is required for the initiation of mouse mammary tumors expressing the polyoma virus middle T antigen ( White et al. , 2004 ) .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.1.1 4-1.1.1.2.r 5-1.1.1.2.1.1 6-1.1 7-1.1.2.r 8-1.1.2.1.1.1 10-1.1.2.1.1.1 11-1.1.2 13-1.1.3.1.1.1.1.1 14-1.1.3.1.1 15-1.1.3.1.1.2.1.1 17-1.1.3.1.2.1 21-1.2.2.1 22-1.2.2.1 23-1.2.2.1 24-1.2.2 26-1.2 27-1.2.1.r 29-1.2.1 30-1.2.1.1.r 31-1.2.1.1.2 32-1.2.1.1.1 33-1.2.1.1 34-1.2.1.1.3 36-1.2.1.1.3.1.1.1 37-1.2.1.1.3.1.1.2 38-1.2.1.1.3.1.1.3 39-1.2.1.1.3.1.1.4 40-1.2.1.1.3.1.1.5 42-1.2.3.1.1.1.1.1 43-1 43-1.2.3.1.1 44-1.2.3.1.1.2.1 46-1.2.3.1.2.1
# ::id bel_pmid_1826_8536_22186
(a / and~e.43
      :op1 (r / result-01~e.6
            :ARG1 (p / phosphorylate-01~e.3
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "b1-integrin"~e.0,2))
                  :ARG2~e.4 (p10 / protein
                        :name (n2 / name :op1 "Src"~e.5)))
            :ARG2~e.7 (a2 / activate-01~e.11
                  :ARG1 (e / enzyme
                        :name (n3 / name :op1 "EGF-R"~e.8,10)))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p3 / publication-91
                        :ARG0 (a3 / and~e.14
                              :op1 (p4 / person
                                    :name (n4 / name :op1 "Miranti"~e.13))
                              :op2 (p5 / person
                                    :name (n5 / name :op1 "Brugge"~e.15)))
                        :time (d / date-entity :year "2002"~e.17))))
      :op2 (r2 / require-01~e.26
            :ARG0~e.27 (i / initiate-01~e.29
                  :ARG1~e.30 (t / tumor~e.33
                        :mod (m / mammary~e.32)
                        :location (m2 / mouse~e.31)
                        :ARG3-of (e3 / express-03~e.34
                              :ARG2 (p6 / protein
                                    :name (n6 / name
                                          :op1 "polyoma"~e.36
                                          :op2 "virus"~e.37
                                          :op3 "middle"~e.38
                                          :op4 "T"~e.39
                                          :op5 "antigen"~e.40)))))
            :ARG1 (e2 / express-03~e.24
                  :ARG2 p2~e.21,22,23)
            :ARG1-of (d4 / describe-01
                  :ARG0 (p7 / publication-91
                        :ARG0 (a4 / and~e.43
                              :op1 (p8 / person
                                    :name (n7 / name :op1 "White"~e.42))
                              :op2 (p9 / person
                                    :mod (o / other~e.44)))
                        :time (d2 / date-entity :year "2004"~e.46)))))

# ::tok E @-@ cadherin gene deletion , which results in some hyperproliferation in the epidermis ( Young et al. , 2003; Tinkle et al. , 2004; Tunggal et al. , 2005 ) .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.1 4-1 7-1.2 9-1.2.1.2 13-1.2.1.1 15-1.3.1.1.1.1.1.1 16-1.3.1 16-1.3.1.1.1 16-1.3.1.2.1 16-1.3.1.3.1 17-1.3.1.1.1.2.1 17-1.3.1.2.1.2.1 17-1.3.1.3.1.2.1 20-1.3.1.2.1.1.1.1 21-1.3.1 21-1.3.1.1.1 21-1.3.1.2.1 21-1.3.1.3.1 22-1.3.1.1.1.2.1 22-1.3.1.2.1.2.1 22-1.3.1.3.1.2.1 25-1.3.1.3.1.1.1.1 26-1.3.1.3.1 27-1.3.1.3.1.2.1 29-1.3.1.3.2.1
# ::id bel_pmid_1826_8536_25888
(d6 / delete-01~e.4
      :ARG1 (g / gene~e.3
            :ARG0-of (e / encode-01
                  :ARG1 (p / protein
                        :name (n / name :op1 "E-cadherin"~e.0,2))))
      :ARG1-of (r / result-01~e.7
            :ARG2 (h / hyperproliferate-00
                  :location (e2 / epidermis~e.13)
                  :degree (s / some~e.9)))
      :ARG1-of (d5 / describe-01
            :ARG0 (a / and~e.16,21
                  :op1 (p2 / publication-91
                        :ARG0 (a2 / and~e.16,21
                              :op1 (p3 / person
                                    :name (n2 / name :op1 "Young"~e.15))
                              :op2 (p4 / person
                                    :mod (o / other~e.17,22)))
                        :time (d / date-entity :year "2003"))
                  :op2 (p5 / publication-91
                        :ARG0 (a3 / and~e.16,21
                              :op1 (p6 / person
                                    :name (n3 / name :op1 "Tinkle"~e.20))
                              :op2 (p7 / person
                                    :mod (o2 / other~e.17,22)))
                        :time (d2 / date-entity :year "2004"))
                  :op3 (p8 / publication-91
                        :ARG0 (a4 / and~e.16,21,26
                              :op1 (p9 / person
                                    :name (n4 / name :op1 "Tunggal"~e.25))
                              :op2 (p10 / person
                                    :mod (o3 / other~e.17,22,27)))
                        :time (d3 / date-entity :year "2005"~e.29)))))

# ::tok E @-@ cadherinknockout epidermis displays some hyperproliferation , which however appears to be limited due to compensatory upregulation of P @-@ cadherin ( Young et al. , 2003; Tinkle et al. , 2004; Tunggal et al. , 2005 )
# ::alignments 0-1.1.1.1.1.1 3-1.1.1 4-1.1 5-1.1.2.1 9-1 10-1.2 13-1.2.1.1 17-1.2.1.1.1 18-1.2.1.1.1.1.r 19-1.2.1.1.1.1.1.1 21-1.2.1.1.1.1.1.1 23-1.3.1.1.1.1.1.1 24-1.3.1 24-1.3.1.1.1 24-1.3.1.2.1 24-1.3.1.3.1 25-1.3.1.1.1.2.1 25-1.3.1.2.1.2.1 25-1.3.1.3.1.2.1 28-1.3.1.2.1.1.1.1 29-1.3.1 29-1.3.1.1.1 29-1.3.1.2.1 29-1.3.1.3.1 30-1.3.1.1.1.2.1 30-1.3.1.2.1.2.1 30-1.3.1.3.1.2.1 33-1.3.1.3.1.1.1.1 34-1.3.1.3.1 35-1.3.1.3.1.2.1 37-1.3.1.3.2.1
# ::id bel_pmid_1826_8536_25890
(c2 / contrast-01~e.9
      :ARG1 (d4 / display-01~e.4
            :ARG0 (e / epidermis~e.3
                  :mod (p / protein
                        :name (n / name :op1 "E-cadherin"~e.0)
                        :ARG2-of (m / mutate-01 :mod "-/-")))
            :ARG1 (h / hyperproliferate-00
                  :degree (s / some~e.5)))
      :ARG2 (a / appear-02~e.10
            :ARG1 (h2 / hyperproliferate-00
                  :ARG1-of (l / limit-01~e.13
                        :ARG0 (u / upregulate-01~e.17
                              :ARG1~e.18 (p2 / protein
                                    :name (n2 / name :op1 "P-cadherin"~e.19,21))
                              :ARG0-of (c / compensate-01)))))
      :ARG1-of (d5 / describe-01
            :ARG0 (a2 / and~e.24,29
                  :op1 (p3 / publication-91
                        :ARG0 (a3 / and~e.24,29
                              :op1 (p4 / person
                                    :name (n3 / name :op1 "Young"~e.23))
                              :op2 (p5 / person
                                    :mod (o / other~e.25,30)))
                        :time (d / date-entity :year "2003"))
                  :op2 (p6 / publication-91
                        :ARG0 (a4 / and~e.24,29
                              :op1 (p7 / person
                                    :name (n4 / name :op1 "Tinkle"~e.28))
                              :op2 (p8 / person
                                    :mod (o2 / other~e.25,30)))
                        :time (d2 / date-entity :year "2004"))
                  :op3 (p9 / publication-91
                        :ARG0 (a5 / and~e.24,29,34
                              :op1 (p10 / person
                                    :name (n5 / name :op1 "Tunggal"~e.33))
                              :op2 (p11 / person
                                    :mod (o3 / other~e.25,30,35)))
                        :time (d3 / date-entity :year "2005"~e.37)))))

# ::tok Recently reported in A431 cells , this can occur through E @-@ cadherin @-@ mediated inhibition of transphosphorylation on Tyr845EGF @-@ R ( Perrais et al. , 2007 ) , the site , which catalyzes EGF @-@ induced mitogenesis ( Ishizawar and Parsons , 2004 ) .
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1.1.2.r 3-1.1.1.2.1.1 4-1.1.1.2 6-1.1 7-1 10-1.2.2.1.1.1 12-1.2.2.1.1.1 14-1.2.2 15-1.2 21-1.2.1.1.3.1.1 23-1.3.1.1.1.1.1 24-1.3.1.1 25-1.3.1.1.2.1 27-1.3.1.2.1 34-1.2.1.1 34-1.2.1.1.4 34-1.2.1.1.4.r 35-1.2.1.1.4.1.1.1.1.1 37-1.2.1.1.4.1.1 38-1.2.1.1.4.1 40-1.2.1.1.4.2.1.1.1.1.1 41-1.2.1.1.4.2.1.1 42-1.2.1.1.4.2.1.1.2.1.1 44-1.2.1.1.4.2.1.2.1
# ::id bel_pmid_1826_8536_25892
(p / possible~e.7
      :domain (t / this~e.6
            :ARG1-of (r / report-01~e.1
                  :time (r2 / recent~e.0)
                  :location~e.2 (c2 / cell-line~e.4
                        :name (n8 / name :op1 "A431"~e.3))))
      :manner (i / inhibit-01~e.15
            :ARG1 (t2 / transphosphorylate-00
                  :ARG1 (a3 / amino-acid~e.34
                        :mod "845"
                        :name (n3 / name :op1 "tyrosine")
                        :part-of (e / enzyme
                              :name (n2 / name :op1 "EGF-R"~e.21))
                        :ARG0-of~e.34 (c / catalyze-01~e.34
                              :ARG1 (m2 / mitogenesis~e.38
                                    :ARG1-of (i2 / induce-01~e.37
                                          :ARG0 (s / small-molecule
                                                :name (n4 / name :op1 "EGF"~e.35))))
                              :ARG1-of (d3 / describe-01
                                    :ARG0 (p5 / publication-91
                                          :ARG0 (a / and~e.41
                                                :op1 (p6 / person
                                                      :name (n5 / name :op1 "Ishizawar"~e.40))
                                                :op2 (p7 / person
                                                      :name (n6 / name :op1 "Parsons"~e.42)))
                                          :time (d2 / date-entity :year "2004"~e.44))))))
            :ARG1-of (m / mediate-01~e.14
                  :ARG0 (p2 / protein
                        :name (n / name :op1 "E-cadherin"~e.10,12))))
      :ARG1-of (d4 / describe-01
            :ARG0 (p8 / publication-91
                  :ARG0 (a2 / and~e.24
                        :op1 (p9 / person
                              :name (n7 / name :op1 "Perrais"~e.23))
                        :op2 (p10 / person
                              :mod (o2 / other~e.25)))
                  :time (d / date-entity :year "2007"~e.27))))

# ::tok In mouse keratinocytes , Src kinase @-@ mediated phosphorylation was found to generate a docking site for PI3K ( p85 ) on plakoglobin in an EGF @-@ R @-@ dependent manner , to a minor extent on p120 cnt , but not on b @-@ catenin , which apparently lacks a PI3K ( p85 )-docking motive ( Calautti et al. , 2005 ) .
# ::alignments 1-1.2.2 4-1.1.1.1.1.1.1 5-1.1.1.1.1 7-1.1.1.1 8-1.1.1 10-1 12-1.1 14-1.1.2.1 15-1.1.2 16-1.1.2.1.1.r 17-1.1.2.1.1.2.1.1 19-1.1.2.1.1.1.1 21-1.1.2.2.r 22-1.1.2.2.1.1.1 25-1.1.3.1.1.1 27-1.1.3.1.1.1 29-1.1.3 30-1.1.3.r 34-1.1.2.2.2.2 35-1.1.2.2.2.2.r 40-1.1.2.2.3 42-1.1.2.2.3.1.r 43-1.1.2.2.3.1.1.1 45-1.1.2.2.3.1.1.1 48-1.1.2.2.3.1.2.2 49-1.1.2.2.3.1 49-1.1.2.2.3.1.2 49-1.1.2.2.3.1.2.r 51-1.1.2.2.3.1.2.1.1 52-1.1.2.2.3.1.2.1.1 53-1.1.2.2.3.1.2.1.1 55-1.1.2.2.3.1.2.1 57-1.3.1.1.1.1.1 58-1.1.2.2 58-1.3.1.1 59-1.3.1.1.2.1 61-1.3.1.2.1
# ::id bel_pmid_1826_8536_26244
(f / find-01~e.10
      :ARG1 (g / generate-01~e.12
            :ARG0 (p / phosphorylate-01~e.8
                  :ARG1-of (m2 / mediate-01~e.7
                        :ARG0 (k / kinase~e.5
                              :name (n2 / name :op1 "Src"~e.4))))
            :ARG1 (s / site~e.15
                  :ARG2-of (d2 / dock-01~e.14
                        :ARG1~e.16 (p2 / protein-segment
                              :name (n4 / name :op1 "p85"~e.19)
                              :part-of (e / enzyme
                                    :name (n3 / name :op1 "PI3K"~e.17))))
                  :location~e.21 (a / and~e.58
                        :op1 (p3 / protein
                              :name (n5 / name :op1 "plakoglobin"~e.22))
                        :op2 (p5 / protein
                              :name (n7 / name :op1 "p120cnt")
                              :extent~e.35 (m3 / minor~e.34))
                        :ARG1-of (c2 / contrast-01~e.40
                              :ARG2~e.42 (p6 / protein~e.49
                                    :name (n8 / name :op1 "b-catenin"~e.43,45)
                                    :ARG0-of~e.49 (l / lack-01~e.49
                                          :ARG1 (m4 / motive~e.55
                                                :ARG2-of d2~e.51,52,53)
                                          :ARG1-of (a2 / appear-02~e.48))))))
            :manner~e.30 (d3 / depend-01~e.29
                  :ARG1 (e2 / enzyme
                        :name (n6 / name :op1 "EGF-R"~e.25,27))))
      :location (c / cell
            :name (n / name :op1 "keratinocyte")
            :source (m / mouse~e.1))
      :ARG1-of (d4 / describe-01
            :ARG0 (p7 / publication-91
                  :ARG0 (a3 / and~e.58
                        :op1 (p8 / person
                              :name (n9 / name :op1 "Calautti"~e.57))
                        :op2 (p9 / person
                              :mod (o / other~e.59)))
                  :time (d / date-entity :year "2005"~e.61))))

# ::tok Transgenic mice ( both newborn and adult ) expressing the signalingdefective b4 @-@ integrin mutant showed a twofold decrease in the epidermal proliferative index , confirming that b4 @-@ integrin actually contributes to proliferation ( Nikolopoulos et al. , 2005 ) .
# ::alignments 0-1.1.1.1 1-1.1.1 1-1.1.2 4-1.1.1.2 5-1.1 6-1.1.2.2 8-1.1.2.3 9-1.1.2.3 10-1.1.2.3 11-1.1.2.3 12-1.1.2.3 13-1.1.2.3 14-1.1.2.3 15-1 18-1.2 23-1.2.1 25-1.3 26-1.3.1.r 27-1.3.1.1 28-1.3.1.1 29-1.3.1.1 30-1.3.1.3 30-1.3.1.3.r 31-1.3.1 32-1.2.1.1.r 33-1.2.1.1 35-1.4.1.1.1.1.1 36-1.4.1.1 37-1.4.1.1.2.1 39-1.4.1.2.1
# ::id bel_pmid_1826_8536_28578
(s / show-01~e.15
      :ARG0 (a4 / and~e.5
            :op1 (m / mouse~e.1
                  :mod (t / transgenic~e.0)
                  :mod (n / newborn~e.4)
                  :ARG3-of (e / express-03
                        :ARG2 (p / protein
                              :name (n2 / name :op1 "b4-integrin")
                              :ARG2-of (m2 / mutate-01)
                              :ARG0-of (d2 / defect-01
                                    :ARG1 (s2 / signal-07)))))
            :op2 (m3 / mouse~e.1
                  :mod t
                  :mod (a / adult~e.6)
                  :ARG3-of e~e.8,9,10,11,12,13,14))
      :ARG1 (d3 / decrease-01~e.18
            :ARG1 (i / index~e.23
                  :mod~e.32 (p3 / proliferate-01~e.33
                        :ARG0 (e2 / epidermis)))
            :ARG2 (p2 / product-of :op1 "2"))
      :ARG0-of (c / confirm-01~e.25
            :ARG1~e.26 (c2 / contribute-01~e.31
                  :ARG0 p~e.27,28,29
                  :ARG2 p3
                  :manner~e.30 (a2 / actual~e.30)))
      :ARG1-of (d4 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a3 / and~e.36
                        :op1 (p5 / person
                              :name (n3 / name :op1 "Nikolopoulos"~e.35))
                        :op2 (p6 / person
                              :mod (o / other~e.37)))
                  :time (d / date-entity :year "2005"~e.39))))

# ::tok b4 @-@ integrin mediates the phosphorylation of ErbB2 on Tyr877 by a Src @-@ family kinase....( Ishizawar and Parsons , 2004 ) .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1 5-1.2 6-1.2.1.r 7-1.2.1.3.1.1 12-1.2.2.1.1.1.1.1 14-1.2.2.1.1 16-1.3.1.1.1.1.1 17-1.3.1.1 18-1.3.1.1.2.1.1 20-1.3.1.2.1
# ::id bel_pmid_1826_8536_28582
(m / mediate-01~e.3
      :ARG0 (p2 / protein
            :name (n / name :op1 "b4-integrin"~e.0,2))
      :ARG1 (p / phosphorylate-01~e.5
            :ARG1~e.6 (a2 / amino-acid
                  :mod "877"
                  :name (n2 / name :op1 "tyrosine")
                  :part-of (p4 / protein
                        :name (n3 / name :op1 "ErbB2"~e.7)))
            :ARG2 (k / kinase
                  :ARG1-of (i / include-91
                        :ARG2 (f / family~e.14
                              :mod (k2 / kinase
                                    :name (n4 / name :op1 "Src"~e.12))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a / and~e.17
                        :op1 (p6 / person
                              :name (n5 / name :op1 "Ishizawar"~e.16))
                        :op2 (p7 / person
                              :name (n6 / name :op1 "Parsons"~e.18)))
                  :time (d / date-entity :year "2004"~e.20))))

# ::tok In parallel to JNK , two other MAPKs , ERK1 and ERK2 , were also found to be targeted to the nucleus in a b4 @-@ integrindependent manner in keratinocytes ( Nikolopoulos et al. , 2005 ) .
# ::alignments 1-1.1.2 1-1.1.2.4 1-1.1.2.4.r 2-1.1.2.4.1.r 3-1.1.2.4.1.1.1 5-1.1.2.2.1 6-1.1.2.2 9-1.1.2.3.1.1.1.1 10-1.1.2.3.1 11-1.1.2.3.1.2.1.1 14-1.2 15-1 18-1.1 19-1.1.1.r 21-1.1.1 24-1.1.3.1.1.1 27-1.1.3.r 31-1.3.1.1.1.1.1 32-1.3.1.1 33-1.3.1.1.2.1 35-1.3.1.2.1
# ::id bel_pmid_1826_8536_28586
(f / find-01~e.15
      :ARG1 (t / target-01~e.18
            :ARG0~e.19 (n4 / nucleus~e.21)
            :ARG1 (e3 / enzyme~e.1
                  :name (n3 / name :op1 "MAPK")
                  :mod (o / other~e.6 :quant "2"~e.5)
                  :ARG1-of (m / mean-01
                        :ARG2 (a / and~e.10
                              :op1 (e / enzyme
                                    :name (n / name :op1 "ERK1"~e.9))
                              :op2 (e2 / enzyme
                                    :name (n2 / name :op1 "ERK2"~e.11))))
                  :ARG0-of~e.1 (p2 / parallel-01~e.1
                        :ARG1~e.2 (e4 / enzyme
                              :name (n7 / name :op1 "JNK"~e.3))))
            :manner~e.27 (d2 / depend-01
                  :ARG1 (p / protein
                        :name (n5 / name :op1 "b4-integrin"~e.24)))
            :location (c / cell
                  :name (n6 / name :op1 "keratinocyte")))
      :mod (a2 / also~e.14)
      :ARG1-of (d3 / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a3 / and~e.32
                        :op1 (p4 / person
                              :name (n8 / name :op1 "Nikolopoulos"~e.31))
                        :op2 (p5 / person
                              :mod (o2 / other~e.33)))
                  :time (d / date-entity :year "2005"~e.35))))

# ::tok plakoglobin @-@ mediated suppression of the pro @-@ proliferative proto @-@ oncogene c @-@ Myc , which is critical for growth inhibition in these cells ( Arnold and Watt , 2001; Waikel et al. , 2001; Kolly et al. , 2005; Figure 2 ) .
# ::alignments 0-1.1.2.1.1.1 2-1.1.2 3-1.1 4-1.1.1.r 6-1.1.1.2 9-1.1.1.3 11-1.1.1 12-1.1.1.1.1 14-1.1.1.1.1 17-1.1.r 18-1 19-1.2.r 20-1.2.1 21-1.2 22-1.2.2.r 23-1.2.2.1 24-1.2.2 26-1.3.1.1.1.1.1.1 27-1.3.1.1.1 28-1.3.1.1.1.2.1.1 31-1.3.1.2.1.1.1.1 32-1.3.1 32-1.3.1.1.1 32-1.3.1.2.1 32-1.3.1.3.1 33-1.3.1.2.1.2.1 33-1.3.1.3.1.2.1 36-1.3.1.3.1.1.1.1 37-1.3.1 37-1.3.1.1.1 37-1.3.1.2.1 37-1.3.1.3.1 38-1.3.1.2.1.2.1 38-1.3.1.3.1.2.1 41-1.3.1.4 42-1.3.1.4.1
# ::id bel_pmid_1826_8536_28670
(c / critical~e.18
      :domain~e.17 (s / suppress-01~e.3
            :ARG1~e.4 (o / oncogene~e.11
                  :name (n2 / name :op1 "c-Myc"~e.12,14)
                  :ARG0-of (f / favor-01~e.6
                        :ARG1 (p2 / proliferate-01))
                  :mod (p3 / proto~e.9))
            :ARG1-of (m / mediate-01~e.2
                  :ARG0 (p / protein
                        :name (n / name :op1 "plakoglobin"~e.0))))
      :purpose~e.19 (i / inhibit-01~e.21
            :ARG1 (g / grow-01~e.20)
            :location~e.22 (c2 / cell~e.24
                  :mod (t / this~e.23)))
      :ARG1-of (d2 / describe-01
            :ARG0 (a / and~e.32,37
                  :op1 (p4 / publication-91
                        :ARG0 (a2 / and~e.27,32,37
                              :op1 (p7 / person
                                    :name (n3 / name :op1 "Arnold"~e.26))
                              :op2 (p8 / person
                                    :name (n4 / name :op1 "Watt"~e.28)))
                        :time (d / date-entity :year "2001"))
                  :op2 (p5 / publication-91
                        :ARG0 (a3 / and~e.32,37
                              :op1 (p9 / person
                                    :name (n5 / name :op1 "Waikel"~e.31))
                              :op2 (p10 / person
                                    :mod (o2 / other~e.33,38)))
                        :time d)
                  :op3 (p6 / publication-91
                        :ARG0 (a4 / and~e.32,37
                              :op1 (p11 / person
                                    :name (n6 / name :op1 "Kolly"~e.36))
                              :op2 (p12 / person
                                    :mod (o3 / other~e.33,38)))
                        :time (d3 / date-entity :year "2005"))
                  :op4 (f2 / figure~e.41 :mod "2"~e.42))))

# ::tok JNK2 was found to be necessary for cell @-@ cycle arrest in keratinocytes , as exemplified by hyperproliferation of JNK2 @-@ knockout epidermis ( Sabapathy and Wagner , 2004; Weston et al. , 2004 ) .
# ::alignments 0-1.1.2.1.1 2-1 5-1.1 6-1.1.1.r 7-1.1.1.1.1 9-1.1.1.1 10-1.1.1 14-1.2.r 14-1.3.1.2.2.r 15-1.2 19-1.2.1.1.1.1.1 22-1.2.1.1 24-1.3.1.1.1.1.1.1 25-1.3.1.1.1 26-1.3.1.1.1.2.1.1 29-1.3.1.2.1.1.1.1 30-1.3.1 30-1.3.1.2.1 31-1.3.1.2.1.2.1 33-1.3.1.1.2.1
# ::id bel_pmid_1826_8536_29114
(f / find-01~e.2
      :ARG1 (n3 / need-01~e.5
            :ARG0~e.6 (a / arrest-02~e.10
                  :ARG1 (c / cycle~e.9
                        :mod (c2 / cell~e.7))
                  :location (c3 / cell
                        :name (n4 / name :op1 "keratinocyte")))
            :ARG1 (e / enyzme
                  :name (n2 / name :op1 "JNK2"~e.0)))
      :ARG1-of~e.14 (e2 / exemplify-01~e.15
            :ARG0 (h / hyperproliferate-00
                  :ARG0 (e3 / epidermis~e.22
                        :mod (e4 / enzyme
                              :name (n5 / name :op1 "JNK2"~e.19)
                              :ARG2-of (m / mutate-01 :mod "-/-")))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a2 / and~e.30
                  :op1 (p / publication-91
                        :ARG0 (a3 / and~e.25
                              :op1 (p2 / person
                                    :name (n / name :op1 "Sabapathy"~e.24))
                              :op2 (p3 / person
                                    :name (n6 / name :op1 "Wagner"~e.26)))
                        :time (d / date-entity :year "2004"~e.33))
                  :op2 (p4 / publication-91
                        :ARG0 (a4 / and~e.30
                              :op1 (p5 / person
                                    :name (n7 / name :op1 "Weston"~e.29))
                              :op2 (p6 / person
                                    :mod (o / other~e.31)))
                        :time~e.14 d))))

# ::tok In mouse keratinocytes , it was however shown to result in Src kinase @-@ mediated phosphorylation of EGF @-@ R , presumably on Tyr920 ( Calautti et al. , 2005 ) .
# ::alignments 1-1.1.2.2 4-1.1.1.1 6-1 7-1.1 9-1.1.1 10-1.1.1.2.r 11-1.1.1.2.2.1.1.1 12-1.1.1.2.2.1 14-1.1.1.2.2 15-1.1.1.2 16-1.1.1.2.1.r 17-1.1.1.2.1.4.1.1 19-1.1.1.2.1.4.1.1 21-1.1.1.2.1 21-1.1.1.2.1.3 21-1.1.1.2.1.3.r 25-1.2.1.1.1.1.1 26-1.2.1.1 27-1.2.1.1.2.1 29-1.2.1.2.1
# ::id bel_pmid_1826_8536_32064
(c / contrast-01~e.6
      :ARG2 (s / show-01~e.7
            :ARG1 (r / result-01~e.9
                  :ARG1 (i / it~e.4)
                  :ARG2~e.10 (p / phosphorylate-01~e.15
                        :ARG1~e.16 (a2 / amino-acid~e.21
                              :mod "920"
                              :name (n2 / name :op1 "tyrosine")
                              :ARG1-of~e.21 (p3 / presume-01~e.21)
                              :part-of (e / enzyme
                                    :name (n3 / name :op1 "EGF-R"~e.17,19)))
                        :ARG1-of (m / mediate-01~e.14
                              :ARG0 (k / kinase~e.12
                                    :name (n / name :op1 "Src"~e.11)))))
            :location (c2 / cell
                  :name (n5 / name :op1 "keratinocyte")
                  :source (m2 / mouse~e.1)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication-91
                  :ARG0 (a / and~e.26
                        :op1 (p6 / person
                              :name (n4 / name :op1 "Calautti"~e.25))
                        :op2 (p7 / person
                              :mod (o / other~e.27)))
                  :time (d / date-entity :year "2005"~e.29))))

# ::tok In human HaCaT keratinocytes for instance , ERK1 @/@ 2 phosphorylation increases in dependence of EGF @-@ R recruitment to transadhering E @-@ cadherin , and E @-@ cadherin @-@ mediated activation of MAPK was also reported in intestinal epithelial cells ( Pece and Gutkind , 2000; Laprise et al. , 2004 ) .
# ::alignments 1-1.1.3.3 2-1.1.3.1.1 4-1.1.3 4-1.1.3.2 4-1.1.3.2.r 5-1.1.3 5-1.1.3.2 5-1.1.3.2.r 7-1.1.1.1.1.1.1 10-1.1.1 11-1.1 12-1.1.2.r 13-1.1.2 14-1.1.2.1.r 15-1.1.2.1.1.1.1 17-1.1.2.1.1.1.1 18-1.1.2.1 21-1.1.2.1.2.1.1 23-1.1.2.1.2.1.1 26-1.1.2.1.2.1.1 28-1.1.2.1.2.1.1 30-1.2.1.2 31-1.2.1 32-1.2.1.1.r 33-1.2.1.1.1.1 35-1.2.2 36-1.2 37-1.2.3.r 38-1.2.3.1.1 39-1.2.3.1 40-1.2.3 42-1.3.1.1.1.1.1.1 43-1.3.1.1.1 44-1.3.1.1.1.2.1.1 47-1.3.1.2.1.1.1.1 48-1 48-1.3.1 48-1.3.1.2.1 49-1.3.1.2.1.2.1 51-1.3.1.2.2.1
# ::id bel_pmid_1826_8536_36030
(a / and~e.48
      :op1 (i / increase-01~e.11
            :ARG1 (p / phosphorylate-01~e.10
                  :ARG1 (s / slash
                        :op1 (e2 / enzyme
                              :name (n2 / name :op1 "ERK1"~e.7))
                        :op2 (e3 / enzyme
                              :name (n3 / name :op1 "ERK2"))))
            :ARG0-of~e.12 (d3 / depend-01~e.13
                  :ARG1~e.14 (r / recruit-01~e.18
                        :ARG1 (e4 / enzyme
                              :name (n4 / name :op1 "EGF-R"~e.15,17))
                        :ARG2 (p3 / protein
                              :name (n5 / name :op1 "E-cadherin"~e.21,23,26,28)
                              :ARG0-of (t / transadhere-00))))
            :location (c / cell-line~e.4,5
                  :name (n6 / name :op1 "HaCaT"~e.2)
                  :ARG0-of~e.4,5 (e / exemplify-01~e.4,5)
                  :mod (h / human~e.1)
                  :part-of (c3 / cell
                        :name (n10 / name :op1 "keratinocyte"))))
      :op2 (r2 / report-01~e.36
            :ARG1 (a4 / activate-01~e.31
                  :ARG1~e.32 (p2 / pathway
                        :name (n / name :op1 "MAPK"~e.33))
                  :ARG1-of (m / mediate-01~e.30
                        :ARG0 p3))
            :mod (a3 / also~e.35)
            :location~e.37 (c2 / cell~e.40
                  :part-of (e5 / epithelium~e.39
                        :part-of (i2 / intestine~e.38))))
      :ARG1-of (d4 / describe-01
            :ARG0 (a5 / and~e.48
                  :op1 (p4 / publication-91
                        :ARG0 (a6 / and~e.43
                              :op1 (p5 / person
                                    :name (n7 / name :op1 "Pece"~e.42))
                              :op2 (p6 / person
                                    :name (n8 / name :op1 "Gutkind"~e.44)))
                        :time (d / date-entity :year "2000"))
                  :op2 (p7 / publication-91
                        :ARG0 (a7 / and~e.48
                              :op1 (p8 / person
                                    :name (n9 / name :op1 "Laprise"~e.47))
                              :op2 (p9 / person
                                    :mod (o / other~e.49)))
                        :time (d2 / date-entity :year "2004"~e.51)))))

# ::tok Similar to AlkB , ABH2 and ABH3 have the ability to repair 1 meA and 3 meC residues . However , whereas ABH2 prefers double @-@ stranded DNA , ABH3 and AlkB favour single @-@ stranded DNA and RNA ( Aas et al , 2003; Falnes et al , 2004 ) .
# ::alignments 0-1.1.1.3 1-1.1.1.3.1.r 2-1.1.1.3.1.1.1 4-1.1.1.1.1.1 5-1.1.1 6-1.1.1.2.1.1 9-1.1 11-1.1.2 14-1.1.2.2 19-1.2 19-1.2.1 19-1.2.1.r 21-1.2.1 22-1.2.1.1.1.1.1 23-1.2.1.1 24-1.2.1.1.2.1 26-1.2.1.1.2.1 26-1.2.1.2.2.1.1 27-1.2.1.1.2 27-1.2.1.2.2.1 29-1.2.1.2.1.1.1.1 30-1.2.1.2.1 30-1.2.1.2.2 30-1.2.1.3.1 30-1.2.1.3.1.1.1 31-1.2.1.2.1.2.1.1 33-1.2.1.2.2.1.1 35-1.2.1.2.2.1.1 36-1.2.1.2.2.1 37-1.2.1.2.2 38-1.2.1.2.2.2.1.1 40-1.2.1.3.1.1.1.1.1.1 41-1.2.1.3.1 41-1.2.1.3.1.1.1 41-1.2.1.3.1.2.1 45-1.2.1.3.1.2.1.1.1.1 46-1.2.1.3.1.2.1 49-1.2.1.3.1.2.2.1
# ::id bel_pmid_1828_5820_25080
(m / multi-sentence
      :snt1 (c / capable-01~e.9
            :ARG1 (a / and~e.5
                  :op1 (p / protein
                        :name (n / name :op1 "ABH2"~e.4))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "ABH3"~e.6))
                  :ARG1-of (r3 / resemble-01~e.0
                        :ARG2~e.1 (p5 / protein
                              :name (n5 / name :op1 "AlkB"~e.2))))
            :ARG2 (r2 / repair-01~e.11
                  :ARG0 a
                  :ARG1 (a2 / and~e.14
                        :op1 (p3 / protein-segment
                              :name (n3 / name :op1 "1meA"))
                        :op2 (p4 / protein-segment
                              :name (n4 / name :op1 "3meC")))))
      :snt2 (h / have-concession-91~e.19
            :ARG1~e.19 (c2 / contrast-01~e.19,21
                  :ARG1 (p6 / prefer-01~e.23
                        :ARG0 (p7 / protein
                              :name (n6 / name :op1 "ABH2"~e.22))
                        :ARG1 (d3 / DNA~e.27
                              :mod (d4 / double-stranded~e.24,26)))
                  :ARG2 (f / favor-01
                        :ARG0 (a3 / and~e.30
                              :op1 (p8 / protein
                                    :name (n7 / name :op1 "ABH3"~e.29))
                              :op2 (p9 / protein
                                    :name (n8 / name :op1 "AlkB"~e.31)))
                        :ARG1 (a4 / and~e.30,37
                              :op1 (d5 / DNA~e.27,36
                                    :mod (s / single-stranded~e.26,33,35))
                              :op2 (r4 / rna
                                    :name (n11 / name :op1 "RNA"~e.38)
                                    :mod s)))
                  :ARG1-of (d6 / describe-01
                        :ARG0 (a5 / and~e.30,41
                              :op1 (p10 / publication-91
                                    :ARG0 (a6 / and~e.30,41
                                          :op1 (p11 / person
                                                :name (n9 / name :op1 "Aas"~e.40))
                                          :op2 (p12 / person
                                                :mod (o / other)))
                                    :time (d / date-entity :year "2003"))
                              :op2 (p13 / publication-91
                                    :ARG0 (a7 / and~e.41,46
                                          :op1 (p14 / person
                                                :name (n10 / name :op1 "Falnes"~e.45))
                                          :op2 (p15 / person
                                                :mod (o2 / other)))
                                    :time (d2 / date-entity :year "2004"~e.49)))))))

# ::tok A targeted Brca1 @-@ null mutation to the T @-@ cell lineage resulted in increased genomic instability , apoptosis , cell @-@ cycle arrest , and a drastic depletion of the T @-@ cell lineage ( Mak et al , 2000 ) .
# ::alignments 1-1.1.3 2-1.1.2.1.1 5-1.1 8-1.1.2.2.1.1 10-1.1.2.2.1.1 12-1 13-1.2.r 14-1.2.1 16-1.2.1.1 18-1.2.2 20-1.2.3.1.1 22-1.2.3.1 23-1.2.3 25-1.2 27-1.2.4.2 28-1.2.4 29-1.2.4.1.r 31-1.2.4.1 32-1.2.4.1 33-1.2.4.1 36-1.3.1.1.1.1.1 37-1.3.1.1 40-1.3.1.2.1
# ::id bel_pmid_1828_5820_25550
(r / result-01~e.12
      :ARG1 (m / mutate-01~e.5
            :mod "-/-"
            :ARG1 (p / protein
                  :name (n / name :op1 "Brca1"~e.2)
                  :part-of (c / cell-line
                        :name (n2 / name :op1 "T-cell"~e.8,10)))
            :ARG1-of (t / target-01~e.1))
      :ARG2~e.13 (a / and~e.25
            :op1 (i / increase-01~e.14
                  :ARG1 (i2 / instability~e.16
                        :mod (g / genome)))
            :op2 (a2 / apoptosis~e.18)
            :op3 (a3 / arrest-02~e.23
                  :ARG1 (c2 / cycle~e.22
                        :mod (c3 / cell~e.20)))
            :op4 (d2 / deplete-01~e.28
                  :ARG2~e.29 c~e.31,32,33
                  :degree (d3 / drastic~e.27)))
      :ARG1-of (d4 / describe-01
            :ARG0 (p2 / publication-91
                  :ARG0 (a4 / and~e.37
                        :op1 (p3 / person
                              :name (n3 / name :op1 "Mak"~e.36))
                        :op2 (p4 / person
                              :mod (o / other)))
                  :time (d / date-entity :year "2000"~e.40))))

# ::tok null mutations for Brca2 result in early mouse embryonic lethality and impaired HR ( Ludwig et al , 1997; Suzuki et al , 1997; Moynahan et al , 2001 ) . Furthermore , loss of Brca2 in murine cells resulted in increased genomic instability and activation of p53 .
# ::alignments 1-1.1.1 2-1.1.1.2.r 3-1.1.1.2.1.1 4-1.1 5-1.1.2.r 6-1.1.2.1.2 7-1.1.2.1.1.1 10-1.1.2 11-1.1.2.2 12-1.1.2.2.1.1.1 14-1.1.3.1.1.1.1.1.1 15-1.1.3.1 15-1.1.3.1.1.1 15-1.1.3.1.2.1 15-1.1.3.1.3.1 19-1.1.3.1.2.1.1.1.1 20-1.1.3.1 20-1.1.3.1.1.1 20-1.1.3.1.2.1 20-1.1.3.1.3.1 24-1.1.3.1.3.1.1.1.1 25-1.1.3.1.3.1 28-1.1.3.1.3.2.1 33-1.2.1.1 34-1.2.1.1.1.r 35-1.2.1.1.1.1.1 38-1.2.1.1.2 39-1.2.1 40-1.2.1.2.r 41-1.2.1.2.1 43-1.2.1.2.1.1 44-1.2.1.2 45-1.2.1.2.2 46-1.2.1.2.2.1.r 47-1.2.1.2.2.1.1.1
# ::id bel_pmid_1828_5820_25554
(m / multi-sentence
      :snt1 (r / result-01~e.4
            :ARG1 (m2 / mutate-01~e.1
                  :mod "-/-"
                  :ARG1~e.2 (p / protein
                        :name (n / name :op1 "Brca2"~e.3)))
            :ARG2~e.5 (a / and~e.10
                  :op1 (d2 / die-01
                        :ARG1 (e / embryo
                              :mod (m3 / mouse~e.7))
                        :time (e2 / early~e.6))
                  :op2 (i / impair-01~e.11
                        :ARG1 (t / thing
                              :name (n2 / name :op1 "HR"~e.12))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (a2 / and~e.15,20
                        :op1 (p2 / publication-91
                              :ARG0 (a3 / and~e.15,20
                                    :op1 (p3 / person
                                          :name (n3 / name :op1 "Ludwig"~e.14))
                                    :op2 (p4 / person
                                          :mod (o / other)))
                              :time (d / date-entity :year "1997"))
                        :op2 (p5 / publication-91
                              :ARG0 (a4 / and~e.15,20
                                    :op1 (p6 / person
                                          :name (n4 / name :op1 "Suzuki"~e.19))
                                    :op2 (p7 / person
                                          :mod (o2 / other)))
                              :time d)
                        :op3 (p8 / publication-91
                              :ARG0 (a5 / and~e.15,20,25
                                    :op1 (p9 / person
                                          :name (n5 / name :op1 "Moynahan"~e.24))
                                    :op2 (p10 / person
                                          :mod (o3 / other)))
                              :time (d3 / date-entity :year "2001"~e.28)))))
      :snt2 (a6 / and
            :op2 (r2 / result-01~e.39
                  :ARG1 (l / lose-01~e.33
                        :ARG1~e.34 (p11 / protein
                              :name (n6 / name :op1 "Brca2"~e.35))
                        :location (c / cell~e.38
                              :part-of (o4 / organism
                                    :name (n8 / name :op1 "Murinae"))))
                  :ARG2~e.40 (a7 / and~e.44
                        :op1 (i2 / increase-01~e.41
                              :ARG1 (i3 / instability~e.43
                                    :mod (g / genome)))
                        :op2 (a8 / activate-01~e.45
                              :ARG1~e.46 (p12 / protein
                                    :name (n7 / name :op1 "p53"~e.47)))))))

# ::tok BRCA2 functions in the loading of the HR protein RAD51 during filament formation . It directly binds to RAD51 and its phosphorylation on Ser3291 inhibits this binding ( Esashi et al , 2005 ) .
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2.r 4-1.1.2 5-1.1.2.1.r 7-1.1.2.1.2.1.1.1 8-1.1.1 8-1.1.2.1 8-1.2.1.2 9-1.1.2.1.1.1 10-1.1.3.r 11-1.1.3.1 12-1.1.3 14-1.2.2.2 15-1.2.2.2 16-1.2.2.2 17-1.2.2.2 18-1.2.2.2 19-1.2.2.2 20-1.2.2.2 21-1.2.2.1 24-1.2.2 26-1.2.2.2 28-1.2.3.1.1.1.1.1 29-1.2 29-1.2.3.1.1 32-1.2.3.1.2.1
# ::id bel_pmid_1828_5820_25556
(m / multi-sentence
      :snt1 (f / function-01~e.1
            :ARG0 (p2 / protein~e.8
                  :name (n / name :op1 "BRCA2"~e.0))
            :ARG1~e.2 (l / load-01~e.4
                  :ARG2~e.5 (p3 / protein~e.8
                        :name (n2 / name :op1 "RAD51"~e.9)
                        :ARG0-of (c / cause-01
                              :ARG1 (t / thing
                                    :name (n3 / name :op1 "HR"~e.7)))))
            :time~e.10 (f2 / form-01~e.12
                  :ARG1 (f3 / filament~e.11)))
      :snt2 (a / and~e.29
            :op1 (b / bind-01
                  :ARG1 (i2 / it)
                  :ARG2 (p5 / protein~e.8
                        :name (n5 / name :op1 "RAD51"))
                  :manner (d2 / direct))
            :op2 (i / inhibit-01~e.24
                  :ARG0 (p / phosphorylate-01~e.21
                        :ARG1 (a3 / amino-acid
                              :mod "3291"
                              :name (n6 / name :op1 "serine")
                              :part-of i2))
                  :ARG1 b~e.14,15,16,17,18,19,20,26)
            :ARG1-of (d3 / describe-01
                  :ARG0 (p7 / publication-91
                        :ARG0 (a2 / and~e.29
                              :op1 (p8 / person
                                    :name (n7 / name :op1 "Esashi"~e.28))
                              :op2 (p9 / person
                                    :mod (o / other)))
                        :time (d / date-entity :year "2005"~e.32)))))

# ::tok The death of mutants such as Xrcc1/, LigIII/ and Polb/ was preceded by elevated levels of apoptosis ( Gu et al , 1994; Tebbs et al , 1999; Sugo et al , 2000; Puebla @-@ Osorio et al , 2006 ) .
# ::alignments 1-1.2 2-1.2.1.r 3-1.2.1 3-1.2.1.1 3-1.2.1.1.r 4-1.2.1.2.r 5-1.2.1.2.r 5-1.3.1.1.2.r 8-1.2.1.2 8-1.3.1 8-1.3.1.1.1 11-1 12-1.1.r 13-1.1.1 14-1.1 15-1.1.2.r 16-1.1.2 18-1.3.1.1.1.1.1.1 19-1.3.1 19-1.3.1.1.1 19-1.3.1.2.1 19-1.3.1.3.1 19-1.3.1.4.1 23-1.3.1.2.1.1.1.1 24-1.3.1 24-1.3.1.1.1 24-1.3.1.2.1 24-1.3.1.3.1 24-1.3.1.4.1 28-1.3.1.3.1.1.1.1 29-1.3.1 29-1.3.1.1.1 29-1.3.1.2.1 29-1.3.1.3.1 29-1.3.1.4.1 33-1.3.1.4.1.1.1.1 35-1.3.1.4.1.1.1.1 36-1.3.1.4.1 39-1.3.1.4.2.1
# ::id bel_pmid_1828_5820_28866
(p / precede-01~e.11
      :ARG1~e.12 (l / level~e.14
            :ARG1-of (e / elevate-01~e.13)
            :degree-of~e.15 (a2 / apoptosis~e.16))
      :ARG2 (d5 / die-01~e.1
            :ARG1~e.2 (p2 / protein~e.3
                  :ARG2-of~e.3 (m / mutate-01~e.3)
                  :example~e.4,5 (a / and~e.8
                        :op1 (p3 / protein
                              :name (n / name :op1 "Xrcc1"))
                        :op2 (p4 / protein
                              :name (n2 / name :op1 "LigIII"))
                        :op3 (p5 / protein
                              :name (n3 / name :op1 "Polb")))))
      :ARG1-of (d6 / describe-01
            :ARG0 (a3 / and~e.8,19,24,29
                  :op1 (p6 / publication-91
                        :ARG0 (a4 / and~e.8,19,24,29
                              :op1 (p10 / person
                                    :name (n4 / name :op1 "Gu"~e.18))
                              :op2 (p11 / person
                                    :mod (o / other)))
                        :time~e.5 (d / date-entity :year "1994"))
                  :op2 (p7 / publication-91
                        :ARG0 (a5 / and~e.19,24,29
                              :op1 (p12 / person
                                    :name (n5 / name :op1 "Tebbs"~e.23))
                              :op2 (p13 / person
                                    :mod (o2 / other)))
                        :time (d2 / date-entity :year "1999"))
                  :op3 (p8 / publication-91
                        :ARG0 (a6 / and~e.19,24,29
                              :op1 (p14 / person
                                    :name (n6 / name :op1 "Sugo"~e.28))
                              :op2 (p15 / person
                                    :mod (o3 / other)))
                        :time (d3 / date-entity :year "2000"))
                  :op4 (p9 / publication-91
                        :ARG0 (a7 / and~e.19,24,29,36
                              :op1 (p16 / person
                                    :name (n7 / name :op1 "Puebla-Osorio"~e.33,35))
                              :op2 (p17 / person
                                    :mod (o4 / other)))
                        :time (d4 / date-entity :year "2006"~e.39)))))

# ::tok ( McPherson et al , 2004a ) . Heterozygous and homozygous Mus81 mutants show cancer predisposition , particularly to T @- and B @-@ cell lymphomas .
# ::alignments 1-1.3.1.1.1.1.1 2-1.1 2-1.3.1.1 8-1.1.1.3 9-1.1 10-1.1.2.3 11-1.1.1.1.1 11-1.1.2.1.1 12-1.1.1 12-1.1.1.2 12-1.1.1.2.r 13-1 14-1.2.1.2 15-1.2.1 15-1.2.2 17-1.2.2.3 18-1.2.2.2.r 19-1.2.2.2.1.1.1.1 21-1.2.2.2 22-1.2.2.2.2.1.1.1 24-1.2.2.2.1.1.1.1 24-1.2.2.2.2.1.1.1 25-1.2.2.2.1 25-1.2.2.2.2
# ::id bel_pmid_1828_5820_29340
(s / show-01~e.13
      :ARG0 (a / and~e.2,9
            :op1 (e / enzyme~e.12
                  :name (n2 / name :op1 "Mus81"~e.11)
                  :ARG2-of~e.12 (m / mutate-01~e.12)
                  :mod (h / heterozygous~e.8))
            :op2 (e2 / enzyme
                  :name (n3 / name :op1 "Mus81"~e.11)
                  :ARG2-of m
                  :mod (h2 / homozygous~e.10)))
      :ARG1 (a2 / and
            :op1 (p / predispose-01~e.15
                  :ARG1 a
                  :ARG2 (c / cancer~e.14))
            :op2 (p2 / predispose-01~e.15
                  :ARG1 a
                  :ARG2~e.18 (a3 / and~e.21
                        :op1 (l / lymphoma~e.25
                              :mod (c2 / cell
                                    :name (n4 / name :op1 "T-cell"~e.19,24)))
                        :op2 (l2 / lymphoma~e.25
                              :mod (c3 / cell
                                    :name (n5 / name :op1 "B-cell"~e.22,24))))
                  :mod (p6 / particular~e.17)))
      :ARG1-of (d3 / describe-01
            :ARG0 (p3 / publication-91
                  :ARG0 (a4 / and~e.2
                        :op1 (p4 / person
                              :name (n6 / name :op1 "McPherson"~e.1))
                        :op2 (p5 / person
                              :mod (o / other)))
                  :time (d / date-entity :year "2004"))))

# ::tok after a long latency , Ung/ and Mutyh/ mice developed B @-@ cell lymphomas and intestinal tumors , respectively ( Nilsen et al , 2003; Sakamoto et al , 2007 ) .
# ::alignments 0-1.4 2-1.4.1.1 3-1.4.1 6-1 6-1.5.1 6-1.5.1.1.1 8-1.1.1 8-1.2.1 9-1.1 9-1.2 10-1.1.2.1.1.1 12-1.1.2.1.1.1 13-1.1.2 14-1 14-1.5.1 14-1.5.1.1.1 15-1.2.2.1 16-1.2.2 18-1.3 18-1.3.r 20-1.5.1.1.1.1.1.1 21-1.5.1 21-1.5.1.1.1 21-1.5.1.2.1 25-1.5.1.2.1.1.1.1 26-1.5.1.2.1 29-1.5.1.2.2.1
# ::id bel_pmid_1828_5820_29342
(a / and~e.6,14
      :op1 (d3 / develop-01~e.9
            :ARG1 (m / mouse~e.8
                  :mod (g / gene
                        :name (n / name :op1 "Ung")))
            :ARG2 (l / lymphoma~e.13
                  :mod (c / cell
                        :name (n3 / name :op1 "B-cell"~e.10,12))))
      :op2 (d4 / develop-01~e.9
            :ARG1 (m2 / mouse~e.8
                  :mod (g2 / gene
                        :name (n2 / name :op1 "Mutyh")))
            :ARG2 (t / tumor~e.16
                  :mod (i / intestine~e.15)))
      :manner~e.18 (r / respective~e.18)
      :time (a2 / after~e.0
            :op1 (l2 / latency~e.3
                  :mod (l3 / long~e.2)))
      :ARG1-of (d5 / describe-01
            :ARG0 (a3 / and~e.6,14,21
                  :op1 (p / publication-91
                        :ARG0 (a4 / and~e.6,14,21
                              :op1 (p3 / person
                                    :name (n4 / name :op1 "Nilsen"~e.20))
                              :op2 (p4 / person
                                    :mod (o / other)))
                        :time (d / date-entity :year "2003"))
                  :op2 (p2 / publication-91
                        :ARG0 (a5 / and~e.21,26
                              :op1 (p5 / person
                                    :name (n5 / name :op1 "Sakamoto"~e.25))
                              :op2 (p6 / person
                                    :mod (o2 / other)))
                        :time (d2 / date-entity :year "2007"~e.29)))))

# ::tok Increased apoptosis and proliferative arrest of pro @-@ B cells in Ku80/ mice were rescued by a p53 @-@ null background ( Difilippantonio et al , 2000 ) .
# ::alignments 0-1.2.1.1 1-1.2.1 2-1.2 4-1.2.2 5-1.2.2.1.r 6-1.2.2.1.3 8-1.2.2.1.1.1 9-1.2.2.1 12-1.2.2.1.2 14-1 15-1.1.r 17-1.1.1.1.1 20-1.1 22-1.3.1.1.1.1.1 23-1.3.1.1 26-1.3.1.2.1
# ::id bel_pmid_1828_5820_31706
(r / rescue-01~e.14
      :ARG0~e.15 (b / background~e.20
            :mod (p3 / protein
                  :name (n3 / name :op1 "p53"~e.17)
                  :ARG2-of (m2 / mutate-01 :mod "-/-")))
      :ARG1 (a / and~e.2
            :op1 (a2 / apoptosis~e.1
                  :ARG1-of (i / increase-01~e.0))
            :op2 (a3 / arrest-02~e.4
                  :ARG1~e.5 (c / cell~e.9
                        :name (n / name :op1 "B"~e.8)
                        :part-of (m / mouse~e.12
                              :mod (p2 / protein
                                    :name (n2 / name :op1 "Ku80")))
                        :mod (p7 / pro~e.6))
                  :ARG0-of (p / proliferate-01)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication-91
                  :ARG0 (a4 / and~e.23
                        :op1 (p5 / person
                              :name (n4 / name :op1 "Difilippantonio"~e.22))
                        :op2 (p6 / person
                              :mod (o / other)))
                  :time (d / date-entity :year "2000"~e.26))))

# ::tok The consequential loss of CDC25A results in G1/S arrest , due to the inefficient loading of CDC45 at the origin of replication . In addition , activated ATM , ATR , DNA–PK , Chk2 , and Chk1 all aid in the phosphorylation and activation of p53 , a key player in DNA @-@ damage checkpoints . Activated p53 transactivates p21 , which inhibits two G1/S @-@ promoting cyclin @-@ dependent kinases ( CDKs ) , CDK2 and CDK4 .
# ::alignments 1-1.1.1.2 2-1.1.1 3-1.1.1.1.r 4-1.1.1.1.1.1 5-1.1 6-1.1.2.r 7-1.1.2.1.1.1 8-1.1.2 10-1.1.2.2 11-1.1.2.2 13-1.1.2.2.1.2 13-1.1.2.2.1.2.1 13-1.1.2.2.1.2.1.r 14-1.1.2.2.1 15-1.1.2.2.1.1.r 16-1.1.2.2.1.1.1.1 17-1.1.2.2.1.3.r 19-1.1.2.2.1.3 20-1.1.2.2.1.3.1.r 21-1.1.2.2.1.3.1 23-1.2.1.1 24-1.2.1.1 26-1.2.1.1.7 27-1.2.1.1.1.1.1 29-1.2.1.1.2.1.1 31-1.2.1.1.3.1.1 33-1.2.1.1.4.1.1 35-1.2.1.1 36-1.2.1.1.5.1.1 37-1.2.1.1.6 38-1.2.1 39-1.2.1.2.r 41-1.2.1.2.1 42-1.2.1.2 43-1.2.1.2.2 44-1.2.1.2.1.1.r 45-1.2.1.2.1.1.1.1 48-1.2.1.2.1.1.2.2 51-1.2.1.2.1.1.2.1.1.1 53-1.2.1.2.1.1.2.1.1 54-1.2.1.2.1.1.2.1 56-1.3.1.2 57-1.2.1.2.1.1.1.1 57-1.3.1.1.1 58-1.3 59-1.3.2.1.1 62-1.3.2 62-1.3.2.2 62-1.3.2.2.r 63-1.3.2.2.1.1 64-1.3.2.2.1.3.1.1.1 66-1.3.2.2.1.3 67-1.3.2.2.1.2.1 69-1.3.2.2.1.2.1 70-1.3.2.2.1 70-1.3.2.2.1.4.1.1 70-1.3.2.2.1.4.1.2 75-1.3.2.2.1.4.1.1.1.1 76-1.3.2.2.1.4.1 77-1.3.2.2.1.4.1.2.1.1
# ::id bel_pmid_1828_5820_36136
(m / multi-sentence
      :snt1 (r / result-01~e.5
            :ARG1 (l / lose-01~e.2
                  :ARG1~e.3 (p4 / protein
                        :name (n / name :op1 "CDC25A"~e.4))
                  :mod (c / consequential~e.1))
            :ARG2~e.6 (a / arrest-02~e.8
                  :ARG1 (e6 / event
                        :name (n15 / name :op1 "G1/S"~e.7))
                  :ARG1-of (c2 / cause-01~e.10,11
                        :ARG0 (l2 / load-01~e.14
                              :ARG2~e.15 (p5 / protein
                                    :name (n2 / name :op1 "CDC45"~e.16))
                              :ARG1-of (e / efficient-01~e.13 :polarity~e.13 "-"~e.13)
                              :time~e.17 (o / origin~e.19
                                    :mod~e.20 (r2 / replicate-01~e.21))))))
      :snt2 (a3 / and
            :op2 (a4 / aid-01~e.38
                  :ARG0 (a5 / and~e.23,24,35
                        :op1 (e2 / enzyme
                              :name (n3 / name :op1 "ATM"~e.27))
                        :op2 (p6 / protein
                              :name (n4 / name :op1 "ATR"~e.29))
                        :op3 (e3 / enzyme
                              :name (n5 / name :op1 "DNA–PK"~e.31))
                        :op4 (e4 / enzyme
                              :name (n6 / name :op1 "Chk2"~e.33))
                        :op5 (e5 / enzyme
                              :name (n7 / name :op1 "Chk1"~e.36))
                        :mod (a6 / all~e.37)
                        :ARG1-of (a2 / activate-01~e.26))
                  :ARG1~e.39 (a7 / and~e.42
                        :op1 (p / phosphorylate-01~e.41
                              :ARG1~e.44 (p7 / protein
                                    :name (n8 / name :op1 "p53"~e.45,57)
                                    :ARG0-of (p2 / play-08
                                          :ARG1 (c3 / checkpoint~e.54
                                                :mod (d / damage-01~e.53
                                                      :ARG1 (d2 / DNA~e.51)))
                                          :mod (k / key~e.48))))
                        :op2 (a8 / activate-01~e.43
                              :ARG1 p7))))
      :snt3 (t / transactivate-00~e.58
            :ARG0 (p8 / protein
                  :name (n9 / name :op1 "p53"~e.57)
                  :ARG1-of (a9 / activate-01~e.56))
            :ARG1 (p9 / protein~e.62
                  :name (n10 / name :op1 "p21"~e.59)
                  :ARG0-of~e.62 (i / inhibit-01~e.62
                        :ARG1 (k2 / kinase~e.70
                              :quant "2"~e.63
                              :name (n11 / name :op1 "cyclin-dependent"~e.67,69)
                              :ARG0-of (p10 / promote-02~e.66
                                    :ARG1 (e7 / event
                                          :name (n16 / name :op1 "G1/S"~e.64)))
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (a11 / and~e.76
                                          :op1 (k4 / kinase~e.70
                                                :name (n13 / name :op1 "CDK2"~e.75))
                                          :op2 (k5 / kinase~e.70
                                                :name (n14 / name :op1 "CDK4"~e.77)))))))))

# ::tok Activated ATM and ATR mediate the phosphorylation and subsequent activation of Chk2 and Chk1 , respectively ; this process is necessary in the induction of phosphorylation of CDC25A , marking it for proteosomal degradation ( Su , 2006 ) .
# ::alignments 0-1.1.1.1.2 0-1.1.1.2.2 1-1.1.1.1.1.1 2-1.1 2-1.1.1.2 3-1.1.2.1.1.1 4-1.1.1 4-1.1.2 6-1.1.1.2.1 6-1.1.2.2.1 7-1.1.1.2 7-1.1.2.2 8-1.1.1.2.2.2 9-1.1.1.1.2 9-1.1.1.2.2 9-1.1.2.2.2 10-1.1.1.2.1.1.r 11-1.1.1.2.1.1.1.1 12-1.1.1.2 13-1.1.2.2.1.1.1.1 15-1.1.3 15-1.1.3.r 17-1.2.2.1 18-1.2.2 20-1.2 21-1.2.1.r 23-1.2.1 24-1.2.1.1.r 25-1.2.1.1 26-1.2.1.1.1.r 27-1.2.1.1.1.1.1 29-1.2.1.1.2 33-1.2.1.1.2.2 35-1.2.3.1.1.1.1 37-1.2.3.1.2.1
# ::id bel_pmid_1828_5820_36694
(m / multi-sentence
      :snt1 (a5 / and~e.2
            :op1 (m2 / mediate-01~e.4
                  :ARG0 (e / enzyme
                        :name (n2 / name :op1 "ATM"~e.1)
                        :ARG1-of (a / activate-01~e.0,9))
                  :ARG1 (a2 / and~e.2,7,12
                        :op1 (p / phosphorylate-01~e.6
                              :ARG1~e.10 (e2 / enzyme
                                    :name (n4 / name :op1 "Chk2"~e.11)))
                        :op2 (a3 / activate-01~e.0,9
                              :ARG1 e2
                              :mod (s / subsequent~e.8))))
            :op2 (m3 / mediate-01~e.4
                  :ARG0 (p2 / protein
                        :name (n3 / name :op1 "ATR"~e.3)
                        :ARG1-of a)
                  :ARG1 (a6 / and~e.7
                        :op1 (p3 / phosphorylate-01~e.6
                              :ARG1 (e3 / enzyme
                                    :name (n5 / name :op1 "Chk1"~e.13)))
                        :op2 (a7 / activate-01~e.9
                              :ARG1 e3
                              :mod s)))
            :manner~e.15 (r / respective~e.15))
      :snt2 (n / need-01~e.20
            :ARG0~e.21 (i / induce-01~e.23
                  :ARG1~e.24 (p5 / phosphorylate-01~e.25
                        :ARG1~e.26 (e4 / enzyme
                              :name (n6 / name :op1 "CDC25A"~e.27))
                        :ARG0-of (m4 / mark-02~e.29
                              :ARG1 e4
                              :purpose (d3 / degrade-01~e.33
                                    :ARG1 e4
                                    :ARG2 (p8 / protein
                                          :name (n8 / name :op1 "proteosome"))))))
            :ARG1 (p4 / process~e.18
                  :mod (t / this~e.17))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p6 / publication-91
                        :ARG0 (p7 / person
                              :name (n7 / name :op1 "Su"~e.35))
                        :time (d / date-entity :year "2006"~e.37)))))

# ::tok Phosphorylation of 4E @-@ BP1 , S6k1( Thr( 389 )), and Erk 1 @/@ 2 was reduced 2 h following IP injection of alcohol .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1 4-1.1.1.1.1.1 8-1.1.1.2.1 10-1.1.1 14-1.2.2.1 16-1 17-1.2.2.1 20-1.2.1.2 21-1.2.1 22-1.2.1.1.r 23-1.2.1.1
# ::id bel_pmid_1831_7950_3272
(r / reduce-01~e.16
      :ARG1 (p / phosphorylate-01~e.0
            :ARG1~e.1 (a / and~e.10
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "4E-BP1"~e.2,4))
                  :op2 (a4 / amino-acid
                        :mod "389"~e.8
                        :name (n3 / name :op1 "tyrosine")
                        :part-of (e2 / enzyme
                              :name (n4 / name :op1 "S6k1")))
                  :op3 (e3 / enzyme
                        :name (n5 / name :op1 "Erk1"))
                  :op4 (e4 / enzyme
                        :name (n6 / name :op1 "Erk2"))))
      :time (a2 / after
            :op1 (i / inject-01~e.21
                  :ARG1~e.22 (a3 / alcohol~e.23)
                  :ARG2 (i2 / IP~e.20))
            :quant (t / temporal-quantity
                  :quant "2"~e.14,17
                  :unit (h / hour))))

# ::tok TGF @-@ beta @-@ induced Foxp3 expression is inhibited by IL @-@ 6 ( ref . 17 ) , IL @-@ 21 ( ref . 10 ) and IL @-@ 23 ( Supplementary Fig. 8 ) .
# ::alignments 0-1.2.2.1.1.1 2-1.2.2.1.1.1 4-1.2.2 5-1.2.1.1.1 6-1.2 8-1 9-1.1.r 10-1.1.1.1.1 10-1.1.2.1.1 10-1.1.3.1.1 12-1.1.1.1.1 16-1.1.1.2.1.1.1 19-1.1.2.1.1 19-1.1.3.1.1 21-1.1.2.1.1 25-1.1.2.2.1.1.1 27-1.1 28-1.1.3.1.1 30-1.1.3.1.1 34-1.1.3.2.1.1
# ::id bel_pmid_1836_8049_20310
(i / inhibit-01~e.8
      :ARG0~e.9 (a / and~e.27
            :op1 (p3 / protein
                  :name (n3 / name :op1 "IL-6"~e.10,12)
                  :ARG1-of (d / describe-01
                        :ARG0 (p6 / publication
                              :ARG1-of (c / cite-01 :ARG2 "17"~e.16))))
            :op2 (p4 / protein
                  :name (n4 / name :op1 "IL-21"~e.10,19,21)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (p7 / publication
                              :ARG1-of (c2 / cite-01 :ARG2 "10"~e.25))))
            :op3 (p5 / protein
                  :name (n5 / name :op1 "IL-23"~e.10,19,28,30)
                  :ARG1-of (d3 / describe-01
                        :ARG0 (f / figure
                              :mod "8"~e.34
                              :ARG2-of (s / supplement-01)))))
      :ARG1 (e / express-03~e.6
            :ARG2 (p / protein
                  :name (n / name :op1 "Foxp3"~e.5))
            :ARG1-of (i2 / induce-01~e.4
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "TGF-beta"~e.0,2)))))

# ::tok Forced expression of wild @-@ type mouse Foxp3 inhibited IL @-@ 6/IL @-@ 21 @-@ induced Il23r expression , whereas Foxp3DeltaEx2 had less inhibitory activity ( Fig . 4a )
# ::alignments 0-1.1.1.3 1-1.1.1 2-1.1.1.2.r 3-1.1.1.2.1 5-1.1.1.2.1 6-1.1.1.2 7-1.1.1.1.1.1 8-1.1 8-1.2.2 9-1.1.2.1.1.1 9-1.1.2.2.1.1.1.1 9-1.1.2.2.1.2.1.1 13-1.1.2.2.1.2.1.1 15-1.1.2.2 17-1.1.2 19-1 22-1.2.3 28-1.3.1.1
# ::id bel_pmid_1836_8049_27060
(c / contrast-01~e.19
      :ARG1 (i / inhibit-01~e.8
            :ARG0 (e / express-03~e.1
                  :ARG2 (p / protein
                        :name (n / name :op1 "Foxp3"~e.7))
                  :ARG3~e.2 (m / mouse~e.6
                        :mod (w / wild-type~e.3,5))
                  :ARG1-of (f / force-02~e.0))
            :ARG1 (e2 / express-03~e.17
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "IL-23-R"~e.9))
                  :ARG1-of (i2 / induce-01~e.15
                        :ARG0 (s / slash
                              :op1 (p3 / protein
                                    :name (n3 / name :op1 "IL-6"~e.9))
                              :op2 (p4 / protein
                                    :name (n4 / name :op1 "IL-21"~e.9,13))))))
      :ARG2 (a2 / act-01
            :ARG0 (p5 / protein
                  :name (n5 / name :op1 "Foxp3ΔEx2"))
            :ARG1 (i3 / inhibit-01~e.8)
            :degree (l / less~e.22))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "4a"~e.28)))

# ::tok Both mouse and human Foxp3 blocked RORgammat @-@ directed IL @-@ 17 expression , but full suppression required the presence of the exon 2 @-@ encoded sequence in Foxp3 , suggesting that the interaction between Foxp3 and RORgammat is essential ( Fig . 3c and Supplementary Fig. 5 ) .
# ::alignments 1-1.1.1.1.2 2-1.1.1 3-1.1.1.2.2 4-1.1.1.1.1.1 4-1.1.1.2.1.1 5-1.1 6-1.1.2.2.1.1.1 8-1.1.2.2 9-1.1.2.1.1.1 11-1.1.2.1.1.1 12-1.1.2 14-1 15-1.2.1.2 16-1.2.1 17-1.2 22-1.2.2.1.1.1 23-1.2.2.1.1.2 25-1.2.2.1.2 28-1.2.2.1.3.1.1 30-1.2.3 31-1.2.3.1.r 33-1.2.3.1.1 35-1.1.1.2.1.1 35-1.2.2.1.3.1.1 36-1.1.1 36-1.3.1 37-1.1.2.2.1.1.1 38-1.2.2 38-1.2.3.1.1.r 39-1.2.3.1 43-1.3.1.1.1 44-1.3.1 47-1.3.1.2.1
# ::id bel_pmid_1836_8049_27066
(c / contrast-01~e.14
      :ARG1 (b / block-01~e.5
            :ARG0 (a / and~e.2,36
                  :op1 (p / protein
                        :name (n / name :op1 "Foxp3"~e.4)
                        :mod (m / mouse~e.1))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "Foxp3"~e.4,35)
                        :mod (h / human~e.3)))
            :ARG1 (e / express-03~e.12
                  :ARG2 (p3 / protein
                        :name (n3 / name :op1 "IL-17"~e.9,11))
                  :ARG1-of (d / direct-01~e.8
                        :ARG0 (p4 / protein
                              :name (n4 / name :op1 "RORgammat"~e.6,37)))))
      :ARG2 (r / require-01~e.17
            :ARG0 (s / suppress-01~e.16
                  :ARG1 e
                  :mod (f / full~e.15))
            :ARG1 (b2 / be-located-at-91~e.38
                  :ARG1 (p5 / protein-segment
                        :name (n5 / name :op1 "exon"~e.22 :op2 "2"~e.23)
                        :ARG1-of (e2 / encode-01~e.25)
                        :part-of (p6 / protein
                              :name (n6 / name :op1 "Foxp3"~e.28,35))))
            :ARG0-of (s3 / suggest-01~e.30
                  :ARG1~e.31 (e3 / essential~e.39
                        :domain~e.38 (i / interact-01~e.33
                              :ARG0 p6
                              :ARG1 p4))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a2 / and~e.36,44
                  :op1 (f2 / figure :mod "3c"~e.43)
                  :op2 (f3 / figure
                        :mod "5"~e.47
                        :ARG2-of (s4 / supplement-01)))))

# ::tok Examination of IL @-@ 17 expression in heterozygous RORgammat–GFP knock @-@ in mice revealed that RORgammat+Foxp3+ lamina propria T cells produced much less IL @-@ 17 than RORgammat+Foxp3 @- cells , suggesting that Foxp3 may interfere with the ability of RORgammat to induce IL @-@ 17 ( Fig . 1c ) .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1 3-1.1.1.1 4-1.1.1.1 5-1.1.1 5-1.1.1.2.2 6-1.1.1.2.r 7-1.1.1.2.1 12-1.1.1.2 13-1 16-1.2.1.2 17-1.2.1.2 18-1.2.1.1.1 19-1.2.3 20-1.2 21-1.2.2.2.1 22-1.2.2.2 23-1.2.2.1.1 25-1.2.2.1.1 26-1.2.3.r 29-1.2.1 31-1.3 32-1.3.1.r 33-1.3.1.1.1.1.1 34-1.3.1 35-1.3.1.1 36-1.3.1.1.2.r 38-1.3.1.1.2 39-1.1.1.2.2.1.r 40-1.1.1.2.2.1.1.1.1 42-1.3.1.1.2.2 43-1.3.1.1.2.2.2 44-1.3.1.1.2.2.2 45-1.3.1.1.2.2.2 49-1.4.1.1
# ::id bel_pmid_1836_8049_33032
(r / reveal-01~e.13
      :ARG0 (e / examine-01~e.0
            :ARG1~e.1 (e2 / express-03~e.5
                  :ARG2 p~e.2,3,4
                  :ARG3~e.6 (m / mouse~e.12
                        :mod (h / heterozygous~e.7)
                        :ARG3-of (e3 / express-03~e.5
                              :ARG2~e.39 (a / and
                                    :op1 (p2 / protein
                                          :name (n2 / name :op1 "RORgammat"~e.40))
                                    :op2 (p3 / protein
                                          :name (n3 / name :op1 "GFP")))))))
      :ARG1 (p4 / produce-01~e.20
            :ARG0 (c / cell~e.29
                  :name (n4 / name :op1 "T"~e.18)
                  :part-of (l / lamina-propria~e.16,17)
                  :mod (p5 / protein
                        :name (n5 / name :op1 "RORgammat+"))
                  :mod (p6 / protein
                        :name (n6 / name :op1 "Foxp3+")))
            :ARG1 (p / protein
                  :name (n / name :op1 "IL-17"~e.23,25)
                  :quant (l2 / less~e.22
                        :degree (m2 / much~e.21)))
            :compared-to~e.26 (c2 / cell~e.19
                  :mod (p7 / protein
                        :name (n7 / name :op1 "Foxp3-"))
                  :mod p5))
      :ARG0-of (s / suggest-01~e.31
            :ARG1~e.32 (p8 / possible~e.34
                  :domain (i / interfere-01~e.35
                        :ARG0 (p9 / protein
                              :name (n8 / name :op1 "Foxp3"~e.33))
                        :ARG1~e.36 (c3 / capable-01~e.38
                              :ARG1 p2
                              :ARG2 (i2 / induce-01~e.42
                                    :ARG0 p2
                                    :ARG1 p~e.43,44,45)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "1c"~e.49)))

# ::tok A ) Increase in IL @-@ 6 production from baseline in WT , tlr4/, myd88/, and trif/ alveolar macrophages treated with LPS , BAL fluid from normal control , or BAL fluid from acid @-@ treated WT mice . **p < 0.01. Data are from four separate experiments .
# ::alignments 0-1.1.3 2-1.1 3-1.1.1.r 4-1.1.1.1.1.1 6-1.1.1.1.1.1 7-1.1.1 8-1.1.2.1.1.r 9-1.1.2.1 11-1.1.2.1.1.1 17-1.1.2.1.1.2 18-1.1.2.1.1 18-1.1.2.2 18-1.1.2.3 18-1.1.2.4 19-1.1.2.5 20-1.1.2.5.1.r 21-1.1.2.5.1.1.1.1 23-1.1.2.5.1.2.1.1 23-1.1.2.5.1.3.1.1 25-1.1.2.5.1.2.2.r 26-1.1.2.5.1.2.2.1 27-1.1.2.5.1.2.2 29-1.1.2.5.1 30-1.1.2.5.1.2.1.1 30-1.1.2.5.1.3.1.1 32-1.1.2.5.1.2.2.r 32-1.1.2.5.1.3.2.r 33-1.1.2.5.1.3.2.2.1 35-1.1.2.5.1.3.2.2 36-1.1.2.5.1.3.2.1 37-1.1.2.5.1.3.2 42-1.2 44-1.2.1.r 45-1.2.1.1 47-1.2.1
# ::id bel_pmid_1842_3196_15956
(m / multi-sentence
      :snt1 (i / increase-01~e.2
            :ARG1~e.3 (p / produce-01~e.7
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "IL-6"~e.4,6)))
            :location (a / and
                  :op1 (b / baseline~e.9
                        :source~e.8 (m2 / macrophage~e.18
                              :mod (w / wild-type~e.11)
                              :mod (a2 / alveolus~e.17)))
                  :op2 (m3 / macrophage~e.18
                        :mod a2
                        :mod (p3 / protein
                              :name (n2 / name :op1 "tlr4")
                              :ARG2-of (m4 / mutate-01 :mod "-/-")))
                  :op3 (m5 / macrophage~e.18
                        :mod a2
                        :mod (p4 / protein
                              :name (n3 / name :op1 "myd88")
                              :ARG2-of m4))
                  :op4 (m6 / macrophage~e.18
                        :mod a2
                        :mod (p5 / protein
                              :name (n4 / name :op1 "trif")
                              :ARG2-of m4))
                  :ARG1-of (t / treat-03~e.19
                        :ARG3~e.20 (o / or~e.29
                              :op1 (m7 / molecular-physical-entity
                                    :name (n5 / name :op1 "LPS"~e.21))
                              :op2 (m8 / molecular-physical-entity
                                    :name (n6 / name :op1 "BAL"~e.23,30 :op2 "liquid")
                                    :source~e.25,32 (c / control~e.27
                                          :mod (n7 / normal~e.26)))
                              :op3 (m9 / molecular-physical-entity
                                    :name (n8 / name :op1 "BAL"~e.23,30 :op2 "liquid")
                                    :source~e.32 (m10 / mouse~e.37
                                          :mod w~e.36
                                          :ARG1-of (t2 / treat-03~e.35
                                                :ARG3 (a3 / acid~e.33)))))))
            :li (a4 / A~e.0))
      :snt3 (d / data~e.42
            :source~e.44 (e / experiment~e.47
                  :quant "4"~e.45
                  :ARG1-of (d2 / differ-02)))
      :snt2 (p6 / probability
            :quant (l / less-than :op1 "0.01")))

# ::tok By contrast , LPS @-@ induced IL @-@ 6 production in alveolar macrophages was dependent on TLR4 , MyD88 , and TRIF ( Figure 3A ) .
# ::alignments 1-1 3-1.1.1.2.1.1.1 5-1.1.1.2 6-1.1.1.1.1.1 8-1.1.1.1.1.1 9-1.1.1 10-1.1.1.3.r 11-1.1.1.3.1 12-1.1.1.3 14-1.1 15-1.1.2.r 16-1.1.2.1.1.1 18-1.1.2.2.1.1 20-1.1.2 21-1.1.2.3.1.1 23-1.2.1 24-1.2.1.1
# ::id bel_pmid_1842_3196_15958
(c / contrast-01~e.1
      :ARG2 (d / depend-01~e.14
            :ARG0 (p / produce-01~e.9
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "IL-6"~e.6,8))
                  :ARG1-of (i / induce-01~e.5
                        :ARG0 (m / molecular-physical-entity
                              :name (n2 / name :op1 "LPS"~e.3)))
                  :location~e.10 (m2 / macrophage~e.12
                        :mod (a / alveolus~e.11)))
            :ARG1~e.15 (a2 / and~e.20
                  :op1 (p3 / protein
                        :name (n3 / name :op1 "TLR4"~e.16))
                  :op2 (p4 / protein
                        :name (n4 / name :op1 "MyD88"~e.18))
                  :op3 (p5 / protein
                        :name (n5 / name :op1 "TRIF"~e.21))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.23 :mod "3A"~e.24)))

# ::tok IL @-@ 6 reduced the expression levels of Foxp3 at 48–72 h . This is probably a direct effect of IL @-@ 6 on the Foxp3 promoter because IL @-@ 6 suppressed TGF-?1 @-@ mediated Foxp3 promoter activity in primary T cells ( data not shown ) .
# ::alignments 0-1.1.1.1.1 0-1.2.1.1.1.1 2-1.1.1.1.1 2-1.2.1.1.1.1 3-1.1 5-1.1.2.1 6-1.1.2 8-1.1.2.1.1.1.1 8-1.2.1.2.1.1 13-1.2.1.4 14-1.2.1.4.r 14-1.2.1.r 15-1.2 17-1.2.1.3 18-1.2.1 19-1.2.1.1.r 20-1.2.1.1.1.1 22-1.2.1.1.1.1 23-1.2.1.2.r 25-1.2.1.2.1.1 27-1.2.1.5 28-1.2.1.5.1.1 29-1.2.1.5.1.1 30-1.2.1.5.1.1 31-1.2.1.5.1 34-1.2.1.5.1.2.3 35-1.2.1.5.1.2.1 37-1.2.1.5.1.2 38-1.2.1.5.1.3.r 39-1.2.1.5.1.3.2 40-1.2.1.5.1.3.1.1 41-1.2.1.5.1.3 43-1.2.1.6.1 44-1.2.1.6.1.1.1 44-1.2.1.6.1.1.1.r 45-1.2.1.6.1.1
# ::id bel_pmid_1843_4325_28378
(m / multi-sentence
      :snt1 (r / reduce-01~e.3
            :ARG0 (p / protein
                  :name (n / name :op1 "IL-6"~e.0,2))
            :ARG1 (l / level~e.6
                  :degree-of (e / express-03~e.5
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "Foxp3"~e.8))))
            :time (b / between
                  :op1 (t / temporal-quantity
                        :quant "48"
                        :unit (h / hour))
                  :op2 (t2 / temporal-quantity
                        :quant "72"
                        :unit h)))
      :snt2 (p8 / probable~e.15
            :domain~e.14 (a / affect-01~e.18
                  :ARG0~e.19 (p3 / protein
                        :name (n3 / name :op1 "IL-6"~e.0,2,20,22))
                  :ARG1~e.23 (p5 / protein
                        :name (n4 / name :op1 "Foxp3"~e.8,25)
                        :ARG0-of (p4 / promote-02))
                  :mod (d / direct~e.17)
                  :domain~e.14 (t3 / this~e.13)
                  :ARG1-of (c / cause-01~e.27
                        :ARG0 (s2 / suppress-01~e.31
                              :ARG0 p3~e.28,29,30
                              :ARG1 (a2 / act-02~e.37
                                    :ARG0 p5~e.35
                                    :ARG1 p4
                                    :ARG1-of (m2 / mediate-01~e.34
                                          :ARG0 (p6 / protein
                                                :name (n5 / name :op1 "TGF-beta1"))))
                              :location~e.38 (c2 / cell~e.41
                                    :name (n6 / name :op1 "T"~e.40)
                                    :mod (p7 / primary~e.39))))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (d3 / data~e.43
                              :ARG1-of (s3 / show-01~e.45 :polarity~e.44 "-"~e.44))))))

# ::tok As shown in Fig. 4C , transient overexpression of WT Foxp3 , but not {Delta}2 or {Delta}FKH , inhibited induction of IL @-@ 17A transcription ( Fig . 4C ) . Taken together , these observations suggest that Foxp3 interacts with ROR{gamma}t in the exon 2 region and that the FKH domain plays a critical role in the suppression of ROR{gamma}t @-@ mediated IL @-@ 17A transcription .
# ::alignments 1-1.1.3 4-1.1.3.1.1 6-1.1.1.1.2 9-1.1.1.1.1.2 10-1.1.1.1.1.1.1 12-1.1 13-1.1.2.1 13-1.1.2.1.r 15-1.1.2.2.1 18-1.1.1 18-1.1.2 19-1.1.1.2 20-1.1.1.2.1.r 21-1.1.1.2.1.1.1.1 23-1.1.1.2.1.1.1.1 24-1.1.1.2.1 28-1.1.3.1.1 34-1.2.1.1.2 35-1.2.1.1 35-1.2.1.1.1 35-1.2.1.1.1.r 36-1.2.1 37-1.2.1.2.r 38-1.2.1.2.1.1.2.1.1 39-1.2.1.2.1 44-1.2.1.2.1.1.1.1 45-1.2.1.2.1.1.1.2 47-1.2.1.2 48-1.2.1.2.r 50-1.2.1.2.2.1.1.1 52-1.2.1.2.2 54-1.2.1.2.2.3 56-1.2.1.2.2.2.r 58-1.2.1.2.2.2 62-1.2.1.2.2.2.1.2 63-1.2.1.2.2.2.1.1.1.1 65-1.2.1.2.2.2.1.1.1.1 66-1.2.1.2.2.2.1
# ::id bel_pmid_1843_4325_33034
(m / multi-sentence
      :snt1 (c / contrast-01~e.12
            :ARG1 (i / inhibit-01~e.18
                  :ARG0 (o / overexpress-00
                        :ARG2 (p / protein
                              :name (n / name :op1 "Foxp3"~e.10)
                              :mod (w / wild-type~e.9))
                        :mod (t / transient~e.6))
                  :ARG1 (i2 / induce-01~e.19
                        :ARG1~e.20 (t2 / transcribe-01~e.24
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "IL-17A"~e.21,23)))))
            :ARG2 (i3 / inhibit-01~e.18
                  :polarity~e.13 "-"~e.13
                  :ARG0 (o2 / overexpress-00
                        :ARG2 (o3 / or~e.15
                              :op1 (p3 / protein
                                    :name (n3 / name :op1 "Foxp3Δ2"))
                              :op2 (p4 / protein
                                    :name (n4 / name :op1 "Foxp3ΔFNK")))
                        :mod t)
                  :ARG1 i2)
            :ARG1-of (s / show-01~e.1
                  :medium (f / figure :mod "4C"~e.4,28))
            :ARG1-of (d / describe-01
                  :ARG0 f))
      :snt2 (h / have-condition-91
            :ARG1 (s2 / suggest-01~e.36
                  :ARG0 (t3 / thing~e.35
                        :ARG1-of~e.35 (o4 / observe-02~e.35)
                        :mod (t4 / this~e.34))
                  :ARG1~e.37,48 (a / and~e.47
                        :op1 (i4 / interact-01~e.39
                              :ARG0 (p7 / protein-segment
                                    :name (n7 / name :op1 "exon"~e.44 :op2 "2"~e.45)
                                    :part-of (p5 / protein
                                          :name (n5 / name :op1 "Foxp3"~e.38)))
                              :ARG1 (p6 / protein
                                    :name (n6 / name :op1 "RORgammat")))
                        :op2 (p8 / play-08~e.52
                              :ARG0 (p9 / protein-segment
                                    :name (n8 / name :op1 "FKH"~e.50)
                                    :part-of p5)
                              :ARG1~e.56 (s3 / suppress-01~e.58
                                    :ARG1 (t5 / transcribe-01~e.66
                                          :ARG1 (p10 / protein
                                                :name (n9 / name :op1 "IL-17A"~e.63,65))
                                          :ARG1-of (m2 / mediate-01~e.62
                                                :ARG0 p6)))
                              :mod (c2 / critical~e.54))))))

# ::tok Then , IL @-@ 17A promoter activity was examined with or without an ROR{gamma}t expression vector in the HEK 293T cells in which ROR{gamma}t was not expressed . In the presence of ROR{gamma}t , the promoter activity was significantly increased ( Fig . 2A ) .
# ::alignments 0-1.1.4 2-1.1.1.1.1.1 4-1.1.1.1.1.1 6-1.1.1 8-1.1 9-1.1.2.r 10-1.1.2 11-1.1.2.2.1 11-1.1.2.2.1.r 14-1.1.2.1.1 15-1.1.2.1 15-1.1.2.2 16-1.1.3.r 18-1.1.3.1.1 19-1.1.3.1.2 20-1.1.3 25-1.1.3.2.1 25-1.1.3.2.1.r 26-1.1.3.2 36-1.2.1 37-1.2.3 38-1.2.2 39-1.2 43-1.2.4.1.1
# ::id bel_pmid_1843_4325_33936
(m / multi-sentence
      :snt1 (e / examine-01~e.8
            :ARG1 (a / act-02~e.6
                  :ARG0 (p2 / protein
                        :name (n / name :op1 "IL-17A"~e.2,4))
                  :ARG1 (p / promote-02))
            :manner~e.9 (o / or~e.10
                  :op1 (v / vector~e.15
                        :mod (e2 / express-03~e.14
                              :ARG2 (p3 / protein
                                    :name (n2 / name :op1 "RORgammat"))))
                  :op2 (v2 / vector~e.15
                        :polarity~e.11 "-"~e.11
                        :mod e2))
            :location~e.16 (c / cell~e.20
                  :name (n3 / name :op1 "HEK"~e.18 :op2 "293T"~e.19)
                  :ARG3-of (e3 / express-03~e.26
                        :polarity~e.25 "-"~e.25
                        :ARG2 p3))
            :time (t / then~e.0))
      :snt2 (i / increase-01~e.39
            :ARG1 (a2 / act-02~e.36
                  :ARG1 (p4 / promote-02))
            :degree (s2 / significant~e.38)
            :condition (b / be-located-at-91~e.37
                  :ARG1 (p5 / protein
                        :name (n4 / name :op1 "RORgammat")))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "2A"~e.43))))

# ::tok Germline expression of the endogenous H @-@ RasG12V oncogene , even in homozygosis , resulted in hyperplasia of the mammary gland .
# ::alignments 0-1.1.2.1.1 1-1.1 2-1.1.1.r 4-1.1.1.3 5-1.1.1.1.1 8-1.1.1 10-1.3.1 12-1.3 14-1 15-1.2.r 16-1.2 17-1.2.1.r 19-1.2.1.1 20-1.2.1
# ::id bel_pmid_1848_3625_9006
(r / result-01~e.14
      :ARG1 (e / express-03~e.1
            :ARG1~e.2 (o / oncogene~e.8
                  :name (n2 / name :op1 "H-Ras"~e.5)
                  :ARG2-of (m / mutate-01 :value "G12V")
                  :mod (e2 / endogenous~e.4))
            :ARG3 (c / cell-line
                  :name (n / name :op1 "germline"~e.0)))
      :ARG2~e.15 (h / hyperplasia~e.16
            :mod~e.17 (g / gland~e.20
                  :mod (m2 / mammary~e.19)))
      :location (h2 / homozygosis~e.12
            :mod (e3 / even~e.10)))

# ::tok gAd induced the phosphorylation of MEK1 @/@ 2 and ERK1 @/@ 2 in RAW264 cells . In addition , the gAd @-@ induced phosphorylation of MEK1 @/@ 2 and ERK1 @/@ 2 was dramatically reduced by PD98059 and U0126 , respectively .
# ::alignments 0-1.1.1.1.1 0-1.2.1.2.2.1.1.1 1-1.2.1.2.2 3-1.2.1.2 5-1.2.1.2.1.1.1.1 8-1.2.1.2.1 9-1.2.1.2.1.3.1.1 13-1.1.3.1.1 14-1.1.3 16-1.1.2.1 17-1.1.2.1 20-1.1.1.1.1 22-1.1 23-1.1.2 23-1.2.1.2 25-1.1.2.1.1.1.1 25-1.2.1.2.1.1.1.1 28-1.1.2.1 28-1.2.1.2.1 29-1.1.2.1.3.1.1 29-1.2.1.2.1.3.1.1 33-1.2.1.3 34-1.2.1 35-1.2.1.1.r 36-1.2.1.1.1.1.1 37-1.2.1.1 38-1.2.1.1.2.1.1 40-1.2.1.1.3 40-1.2.1.1.3.r
# ::id bel_pmid_1855_5587_24926
(m / multi-sentence
      :snt1 (i / induce-01~e.22
            :ARG0 (p2 / protein
                  :name (n2 / name :op1 "gAd"~e.0,20))
            :ARG1 (p / phosphorylate-01~e.23
                  :ARG1 (a / and~e.16,17,28
                        :op1 (e / enzyme
                              :name (n3 / name :op1 "MEK1"~e.25))
                        :op2 (e2 / enzyme
                              :name (n4 / name :op1 "MEK2"))
                        :op3 (e3 / enzyme
                              :name (n5 / name :op1 "ERK1"~e.29))
                        :op4 (e4 / enzyme
                              :name (n6 / name :op1 "ERK2"))))
            :location (c / cell~e.14
                  :name (n7 / name :op1 "RAW264"~e.13)))
      :snt2 (a2 / and
            :op2 (r / reduce-01~e.34
                  :ARG0~e.35 (a3 / and~e.37
                        :op1 (s2 / small-molecule
                              :name (n8 / name :op1 "PD98059"~e.36))
                        :op2 (s / small-molecule
                              :name (n / name :op1 "U0126"~e.38))
                        :manner~e.40 (r2 / respective~e.40))
                  :ARG1 (p3 / phosphorylate-01~e.3,23
                        :ARG1 (a4 / and~e.8,28
                              :op1 (e5 / enzyme
                                    :name (n9 / name :op1 "MEK1"~e.5,25))
                              :op2 (e6 / enzyme
                                    :name (n10 / name :op1 "MEK2"))
                              :op3 (e7 / enzyme
                                    :name (n11 / name :op1 "ERK1"~e.9,29))
                              :op4 (e8 / enzyme
                                    :name (n12 / name :op1 "ERK2")))
                        :ARG1-of (i2 / induce-01~e.1
                              :ARG0 (p4 / protein
                                    :name (n13 / name :op1 "gAd"~e.0))))
                  :manner (d / dramatic~e.33))))

# ::tok We investigated whether globular adiponectin ( gAd ) affects the expression of inflammation @-@ related genes in murine macrophages ( RAW264 cells ) . DNA microarray analysis indicated that granulocyte colony @-@ stimulating factor ( G @-@ CSF ) showed the largest increase in expression in gAd @-@ stimulated RAW264 cells . The gAd @-@ induced secretion of G @-@ CSF increased in a time @- and dose @-@ dependent manner .
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.1 2-1.1.2.1.r 3-1.1.2.2.1.1 4-1.1.2.2.1.2 6-1.3.1.2.1.1.1 8-1.1.2 10-1.1.2.3 14-1.1.2.3.1.1 15-1.1.2.3.1 18-1.1.2.3.2 20-1.1.2.3.2.1.1.1.1 21-1.1.2.3.2.1.1 24-1.2.1.1.1 25-1.2.1.1.2 26-1.2.1.1.3 27-1.2 28-1.2.2.r 29-1.2.2.1.1.1 30-1.2.2.1.1.2 32-1.2.2.1.1.2 33-1.2.2.1.1.3 35-1.3.1.1.1.1 37-1.3.1.1.1.1 39-1.2.2 41-1.2.2.2.2 41-1.2.2.2.2.1 41-1.2.2.2.2.1.r 42-1.2.2.2 43-1.2.2.2.1.r 44-1.2.2.2.1 46-1.2.2.2.1.1.2.1.1.1 48-1.2.2.2.1.1.2 49-1.1.2.3.2.1.1.1.1 49-1.2.2.2.1.1.1.1 50-1.1.2.3.2.1.1 50-1.2.2.2.1.1 53-1.2.2.2.1.1.2.1.1.1 53-1.3.1.2.1.1.1 55-1.3.1.2 56-1.3.1 58-1.3.1.1.1.1 60-1.3.1.1.1.1 61-1.3 64-1.3.2.1.1 66-1.3.2.1 67-1.3.2.1.2 69-1.3.2 70-1.3.2.r
# ::id bel_pmid_1855_5587_7928
(m2 / multi-sentence
      :snt1 (i / investigate-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (a / affect-01~e.8
                  :mode~e.2 "interrogative"~e.2
                  :ARG0 (p / protein
                        :name (n / name :op1 "globular"~e.3 :op2 "adiponectin"~e.4))
                  :ARG1 (e / express-03~e.10
                        :ARG1 (g / gene~e.15
                              :ARG1-of (r / relate-01~e.14
                                    :ARG2 (i2 / inflame-01)))
                        :ARG3 (m3 / macrophage~e.18
                              :ARG1-of (m5 / mean-01
                                    :ARG2 (c / cell~e.21,50
                                          :name (n3 / name :op1 "RAW264"~e.20,49)))
                              :part-of (o / organism
                                    :name (n2 / name :op1 "Murinae"))))))
      :snt2 (i3 / indicate-01~e.27
            :ARG0 (t / thing
                  :name (n4 / name
                        :op1 "DNA"~e.24
                        :op2 "microarray"~e.25
                        :op3 "analysis"~e.26))
            :ARG1~e.28 (s / show-01~e.39
                  :ARG0 (p3 / protein
                        :name (n5 / name
                              :op1 "granulocyte"~e.29
                              :op2 "colony-stimulating"~e.30,32
                              :op3 "factor"~e.33))
                  :ARG1 (i4 / increase-01~e.42
                        :ARG1~e.43 (e2 / express-03~e.44
                              :ARG3 (c2 / cell~e.50
                                    :name (n7 / name :op1 "RAW264"~e.49)
                                    :ARG1-of (s2 / stimulate-01~e.48
                                          :ARG2 (p5 / protein
                                                :name (n8 / name :op1 "gAd"~e.46,53)))))
                        :ARG2 (l / large~e.41
                              :degree~e.41 (m / most~e.41)))))
      :snt3 (i5 / increase-01~e.61
            :ARG1 (s3 / secrete-01~e.56
                  :ARG1 (p7 / protein
                        :name (n10 / name :op1 "G-CSF"~e.35,37,58,60))
                  :ARG1-of (i6 / induce-01~e.55
                        :ARG0 (p6 / protein
                              :name (n9 / name :op1 "gAd"~e.6,53))))
            :manner~e.70 (d3 / depend-01~e.69
                  :ARG1 (a2 / and~e.66
                        :op1 (t2 / time~e.64)
                        :op2 (d4 / dose~e.67)))))

# ::tok from full text - An inactivation of IL @-@ 10 in mice results in an increased production of IL @-@ 12 and IFN @-@ gamma [42,43]. Inflamed tissues and granulomas of CD show low IL @-@ 10[44]. Melgar et al[45] reported a highly significant increase in IL @-@ 10 mRNA levels in T lymphocytes and in IL @-@ 10 @-@ positive cells in the colons of UC patients .
# ::alignments 5-1.1.1 5-1.1.1.1 5-1.1.1.1.r 6-1.1.1.2.r 7-1.1.1.2.1.1 9-1.1.1.2.1.1 11-1.1.1.3.1.1 12-1.1 15-1.3.2 16-1.1.2 17-1.1.2.1.r 18-1.1.2.1.1.1.1 20-1.1.2.1.1.1.1 21-1.1.2.1 21-1.1.2.1.2.2.1.1.1 22-1.1.2.1.2.1.1 24-1.1.2.1.2.1.1 26-1.2.1 27-1.2.1.1.1 28-1.2.1.1 30-1.2.1.1.r 31-1.2.1.1.3.1.1 32-1.2 33-1.2.2.2 34-1.2.2.1.1 34-1.3.2.1.1.1.1 37-1.3.1.1.1.1 38-1.3.1 40-1.3 42-1.3.2.2.1 43-1.3.2.2 44-1.3.2 45-1.3.2.1.r 46-1.3.2.1.1.1.1 48-1.3.2.1.1.1.1 49-1.3.2.1.1.1.2 50-1.3.2.1 51-1.3.2.3.r 52-1.3.2.3.1.1.1 53-1.3.2.3.1.1.2 54-1.3.2.3 56-1.3.2.1.1.1.1 58-1.3.2.1.1.1.1 60-1.3.2.3.2.1 61-1.3.2.3.2 64-1.3.2.3.3 67-1.3.2.3.3.1
# ::id bel_pmid_1866_6314_27860
(m / multi-sentence
      :snt1 (r / result-01~e.12
            :ARG1 (a / activate-01~e.5
                  :polarity~e.5 "-"~e.5
                  :ARG1~e.6 (g / gene
                        :name (n / name :op1 "IL-10"~e.7,9))
                  :location (o / organism
                        :name (n2 / name :op1 "mouse"~e.11)))
            :ARG2 (p / produce-01~e.16
                  :ARG1~e.17 (a2 / and~e.21
                        :op1 (p2 / protein
                              :name (n3 / name :op1 "IL-12"~e.18,20))
                        :op2 (p3 / protein
                              :name (n4 / name :op1 "IFN-gamma"~e.22,24)
                              :ARG1-of (d / describe-01
                                    :ARG0 (p4 / publication
                                          :ARG1-of (c / cite-01
                                                :ARG2 (a3 / and~e.21 :op1 "42" :op2 "43"))))))))
      :snt2 (s / show-01~e.32
            :ARG0 (i / inflame-01~e.26
                  :ARG1~e.30 (a4 / and~e.28
                        :op1 (t / tissue~e.27)
                        :op2 (g2 / granuloma)
                        :part-of (d2 / disease
                              :name (n5 / name :op1 "CD"~e.31))))
            :ARG1 (p11 / protein
                  :name (n6 / name :op1 "IL-10"~e.34)
                  :quant (l / low~e.33)
                  :ARG1-of (d3 / describe-01
                        :ARG0 (p5 / publication
                              :ARG1-of (c2 / cite-01 :ARG2 "44")))))
      :snt3 (r2 / report-01~e.40
            :ARG0 (a5 / and~e.38
                  :op1 (p6 / person
                        :name (n7 / name :op1 "Melgar"~e.37))
                  :op2 (p7 / person
                        :name (n8 / name :op1 "other")
                        :ARG1-of (d5 / describe-01
                              :ARG0 (p9 / publication
                                    :ARG1-of (c6 / cite-01 :ARG2 "45")))))
            :ARG1 (i2 / increase-01~e.15,44
                  :ARG1~e.45 (l2 / level~e.50
                        :mod (r3 / rna
                              :name (n9 / name :op1 "IL-10"~e.34,46,48,56,58 :op2 "mRNA"~e.49)))
                  :ARG2 (s2 / significant~e.43
                        :degree (h / high~e.42))
                  :location~e.51 (a6 / and~e.54
                        :op1 (c3 / cell
                              :name (n10 / name :op1 "T"~e.52 :op2 "lymphocyte"~e.53))
                        :op2 (c4 / cell~e.61
                              :mod (p10 / positive~e.60
                                    :mod (p12 / protein
                                          :name (n12 / name :op1 "IL10"))))
                        :location (c5 / colon~e.64
                              :poss-of (p8 / patient~e.67
                                    :mod (d4 / disease
                                          :name (n11 / name :op1 "ulcerative colitis"))))))))

# ::tok from full text - in a murine model of UC , Sugimoto et al demonstrated a novel protective role for IL @-@ 22 , in which IL @-@ 22 attenuates in the intestine inflammation
# ::alignments 6-1.3.1.1.1 7-1.3 8-1.3.2.r 9-1.3.2.1.1 11-1.1.1.1.1 12-1.1 14-1 16-1.2.2 17-1.2.1 18-1.2 19-1.2.3.r 20-1.2.3.1.1 22-1.2.3.1.1 26-1.2.3.1.1 28-1.2.3.1.1 29-1.2.4 32-1.2.4.2.1
# ::id bel_pmid_1866_6314_28188
(d / demonstrate-01~e.14
      :ARG0 (a / and~e.12
            :op1 (p / person
                  :name (n / name :op1 "Sugimoto"~e.11))
            :op2 (p2 / person
                  :name (n2 / name :op1 "other")))
      :ARG1 (r / role~e.18
            :ARG0-of (p3 / protect-01~e.17)
            :mod (n3 / novel~e.16)
            :beneficiary~e.19 (p4 / protein
                  :name (n6 / name :op1 "IL-22"~e.20,22,26,28))
            :location-of (a3 / attenuate-01~e.29
                  :ARG0 p4
                  :location (i / inflamation
                        :mod (i2 / intestine~e.32))))
      :location (m / model~e.7
            :mod (o / organism
                  :name (n4 / name :op1 "Muridae"~e.6))
            :mod~e.8 (d2 / disease
                  :name (n5 / name :op1 "UC"~e.9))))

# ::tok from full text - T @-@ cell receptor alpha chain @-@ deficient mice ( TCR -/-) treated with anti @-@ IL @-@ 4 monoclonal antibody showed a decrease in Th2 @-@ type mRNA cytokine production and an increase in expression of IFN @-@ gamma , suggesting that IL @-@ 4 plays a major role in inducing Th2 @-@ type CD4+ cells in the gut to shift towards a Th1 response[51].
# ::alignments 4-1.1.1.2.1.1.1.1 6-1.1.1.2.1.1.1.1 7-1.1.1.2.1.1.1.2 8-1.1.1.2.1 9-1.1.1.2.1 11-1.1.1.2 12-1.1.1.1.1 14-1.1.1.3.1.1 16-1.1.1.4 20-1.1.1.4.1.1.1 22-1.1.1.4.1.1.1 23-1.1.1.4.1.1.2 24-1.1.1.4.1.1.3 25-1.1 27-1.1.2.1 28-1.1.2.1.1.r 29-1.1.2.1.1.1.1.1 31-1.1.2.1.1.1.1.1 32-1.1.2.1.1.1.1.2 33-1.1.2.1.1.1.1.3 34-1.1.2.1.1 35-1.1.2 37-1.1.2.2 38-1.1.2.2.1.r 39-1.1.2.2.1 40-1.1.2.2.1.1.r 41-1.1.2.2.1.1.1.1 43-1.1.2.2.1.1.1.1 45-1.2 46-1.2.1.r 47-1.2.1.1.1.1 49-1.2.1.1.1.1 50-1.2.1 54-1.2.1.2.r 55-1.2.1.2 56-1.2.1.2.1.1.1.1 58-1.1.1.3.2 58-1.2.1.2.1.1.1.1 59-1.2.1.2.1.1.1.2 60-1.2.1.2.1.1.1.3 63-1.2.1.2.1.1.2 65-1.2.1.2.1 68-1.2.1.2.1.2.1.1.1
# ::id bel_pmid_1866_6314_28300
(a / and
      :op1 (s / show-01~e.25
            :ARG0 (o / organism
                  :name (n / name :op1 "mouse"~e.12)
                  :mod (d / deficient~e.11
                        :mod (a2 / alpha-chain~e.8,9
                              :mod (p / protein
                                    :name (n2 / name :op1 "T-cell"~e.4,6 :op2 "receptor"~e.7))))
                  :example (p2 / protein
                        :name (n3 / name :op1 "TCR"~e.14)
                        :mod (w / wild-type~e.58))
                  :ARG1-of (t / treat-03~e.16
                        :ARG3 (p3 / protein
                              :name (n4 / name
                                    :op1 "IL-4"~e.20,22
                                    :op2 "monoclonal"~e.23
                                    :op3 "antibody"~e.24))))
            :ARG1 (a3 / and~e.35
                  :op1 (d2 / decrease-01~e.27
                        :ARG1~e.28 (p4 / produce-01~e.34
                              :ARG1 (p8 / protein
                                    :name (n6 / name
                                          :op1 "Th2-type"~e.29,31
                                          :op2 "mRNA"~e.32
                                          :op3 "cytokine"~e.33))))
                  :op2 (i / increase-01~e.37
                        :ARG1~e.38 (e / express-03~e.39
                              :ARG2~e.40 (p5 / protein
                                    :name (n5 / name :op1 "IFN-gamma"~e.41,43))))))
      :op2 (s2 / suggest-01~e.45
            :ARG1~e.46 (p6 / play-08~e.50
                  :ARG0 (p7 / protein
                        :name (n7 / name :op1 "IL-4"~e.47,49))
                  :ARG1~e.54 (i2 / induce-01~e.55
                        :ARG1 (s3 / shift-01~e.65
                              :ARG1 (c / cell
                                    :name (n8 / name
                                          :op1 "Th2-type"~e.56,58
                                          :op2 "CD4+"~e.59
                                          :op3 "cell"~e.60)
                                    :location (g / gut~e.63))
                              :ARG2 (r / respond-01
                                    :ARG0 (c3 / cell
                                          :name (n9 / name :op1 "Th1"~e.68))
                                    :ARG1-of (d3 / describe
                                          :ARG0 (p10 / publication
                                                :ARG1-of (c2 / cite-01 :ARG2 "51")))))))))

# ::tok from full text - anti @-@ IL @-@ 6 receptor monoclonal antibody to a murine colitis model and found that the treatment with this antibody reduced IFN @-@ gamma , TNF @-@ alpha , and IL @-@ 1 beta mRNA , and suppressed expression of several intracellular adhesion molecules in the colonic vascular endothelium .
# ::alignments 6-1.1.1.2.1.1.3.1.1 11-1.1.1.1 17-1.1.1.2.1.1 18-1.1 21-1.1.1 23-1.1.1.1.1 24-1.1.1.1 25-1.1.1.2.1 26-1.1.1.2.1.1.1.1.1 28-1.1.1.2.1.1.1.1.1 30-1.1.1.2.1.1.2.1.1 32-1.1.1.2.1.1.2.1.1 35-1.1.1.2.1.1.3.1.1 39-1.1.1.2.1.1.3.1.2 41-1.1.1.2 42-1.1.1.2.2 43-1.1.1.2.2.1 44-1.1.1.2.2.1.1.r 45-1.1.1.2.2.1.1.2 46-1.1.1.2.2.1.1.1.1 47-1.1.1.2.2.1.1.1.2 48-1.1.1.2.2.1.1.1.3 49-1.1.1.2.2.2.r 51-1.1.1.2.2.2.1 53-1.1.1.2.2.2
# ::id bel_pmid_1866_6314_28380
(a / and
      :op2 (f / find-01~e.18
            :ARG1 (t / treat-03~e.21
                  :ARG3 (a2 / antibody~e.11,24
                        :mod (t2 / this~e.23))
                  :ARG0-of (a3 / and~e.41
                        :op1 (r / reduce-01~e.25
                              :ARG1 (a4 / and~e.17
                                    :op1 (r2 / rna
                                          :name (n / name :op1 "IFN-gamma"~e.26,28))
                                    :op2 (r3 / rna
                                          :name (n2 / name :op1 "TNF-alpha"~e.30,32))
                                    :op3 (r4 / rna
                                          :name (n3 / name :op1 "IL-1beta"~e.6,35 :op2 "mRNA"~e.39))))
                        :op2 (s / suppress-01~e.42
                              :ARG1 (e / express-03~e.43
                                    :ARG2~e.44 (p / protein
                                          :name (n4 / name
                                                :op1 "intracellular"~e.46
                                                :op2 "adhesion"~e.47
                                                :op3 "molecule"~e.48)
                                          :quant (s2 / several~e.45)))
                              :location~e.49 (e2 / endothelium~e.53
                                    :mod (c / colon~e.51)
                                    :mod (v / vesel)))))))

# ::tok from full text - STAT @-@ 3 itself induces the anti @-@ apoptotic factors Bcl @-@ 2 and Bcl @-@ xL
# ::alignments 4-1.1.1.1 6-1.1.1.1 7-1.1.2 8-1 10-1.2.2 12-1.2.2.1 13-1.2 14-1.2.1.1.1.1 14-1.2.1.2.1.1 16-1.2.1.1.1.1 17-1.2.1 18-1.2.1.1.1.1 18-1.2.1.2.1.1 20-1.2.1.2.1.1
# ::id bel_pmid_1866_6314_35398
(i / induce-01~e.8
      :ARG0 (p / protein
            :name (n / name :op1 "STAT-3"~e.4,6)
            :mod (i2 / it~e.7))
      :ARG1 (f / factor~e.13
            :example (a / and~e.17
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "Bcl-2"~e.14,16,18))
                  :op2 (p3 / protein
                        :name (n3 / name :op1 "Bcl-xL"~e.14,18,20)))
            :ARG0-of (o / oppose-01~e.10
                  :ARG1 (a2 / apoptosis~e.12))))

# ::tok from full text - Increased levels of IL @-@ 1 in IBD may be result of stimulation of colonic macrophages that can activate interleukin ( IL )-1 converting enzyme ( ICE ) and hence release mature IL @-@ 1 beta into the colonic mucosa[20].
# ::alignments 4-1.1.2 5-1.1.2.1 6-1.1.2.1.1.r 7-1.1.2.1.1.1.1 9-1.1.2.1.1.1.1 12-1 13-1.1.r 14-1.1 15-1.1.1.r 16-1.1.1 17-1.1.1.1.r 18-1.1.1.1.2 19-1.1.1.1.1.1 21-1.1.1.2 22-1.1.1.2.1.1 23-1.1.1.2.1.1.1.1.1 25-1.1.2.1.1.1.1 27-1.1.1.2.1.1.1.1.2 28-1.1.1.2.1.1.1.1.3 32-1.1.1.2.1 33-1.1.1.2.1.2.2 34-1.1.1.2.1.2 35-1.1.1.2.1.2.1.2 36-1.1.1.2.1.2.1.1.1 38-1.1.2.1.1.1.1 42-1.1.1.1.2 42-1.1.1.2.1.2.3.1
# ::id bel_pmid_1866_6314_35432
(p / possible~e.12
      :domain~e.13 (r / result-01~e.14
            :ARG1~e.15 (s / stimulate-01~e.16
                  :ARG1~e.17 (c / cell
                        :name (n / name :op1 "macrophage"~e.19)
                        :mod (c2 / colon~e.18,42))
                  :ARG0-of (p3 / possible~e.21
                        :domain (a2 / and~e.32
                              :op1 (a3 / activate-01~e.22
                                    :ARG1 (e / enzyme
                                          :name (n4 / name
                                                :op1 "interleukin-1"~e.23
                                                :op2 "converting"~e.27
                                                :op3 "enzyme"~e.28)))
                              :op2 (r2 / release-01~e.34
                                    :ARG1 (p4 / protein
                                          :name (n5 / name :op1 "IL-1beta"~e.36)
                                          :mod (m / mature~e.35))
                                    :ARG0-of (c3 / cause-01~e.33)
                                    :location (m2 / mucosa
                                          :mod (c4 / colon~e.42
                                                :ARG1-of (d3 / describe-01
                                                      :ARG0 (p5 / publication
                                                            :ARG1-of (c5 / cite-01 :ARG2 "20")))))))))
            :ARG2 (i / increase-01~e.4
                  :ARG1 (l / level~e.5
                        :mod~e.6 (p2 / protein
                              :name (n2 / name :op1 "IL-1"~e.7,9,25,38)))))
      :location (d2 / disease
            :name (n3 / name
                  :op1 "inflammatory"
                  :op2 "bowel"
                  :op3 "disease")))

# ::tok from full text - Both cytokines ( IL @-@ 12 and IL @-@ 23 ) activate TYK2 and JAK2 as well as STAT1 , STAT3 , STAT4 , and STAT5 [60].
# ::alignments 4-1.1.3 7-1.1.2.1.1.1 7-1.1.2.2.1.1 9-1.1.2.1.1.1 10-1.1.2 11-1.1.2.1.1.1 11-1.1.2.2.1.1 13-1.1.2.2.1.1 15-1 16-1.2.1.1.1 17-1.2 18-1.2.2.1.1 21-1.2.r 22-1.2.3.1.1 24-1.2.4.1.1 26-1.2.5.1.1 28-1.2 29-1.2.6.1.1
# ::id bel_pmid_1866_6314_36060
(a / activate-01~e.15
      :ARG0 (p / protein
            :name (n / name :op1 "cytokine")
            :example (a2 / and~e.10
                  :op1 (p2 / protein
                        :name (n2 / name :op1 "IL-12"~e.7,9,11))
                  :op2 (p3 / protein
                        :name (n3 / name :op1 "IL-23"~e.7,11,13)))
            :mod (b / both~e.4))
      :ARG1~e.21 (a3 / and~e.17,28
            :op1 (e / enzyme
                  :name (n4 / name :op1 "TYK2"~e.16))
            :op2 (e2 / enzyme
                  :name (n5 / name :op1 "JAK2"~e.18))
            :op3 (p5 / protein
                  :name (n6 / name :op1 "STAT1"~e.22))
            :op4 (p6 / protein
                  :name (n7 / name :op1 "STAT3"~e.24))
            :op5 (p7 / protein
                  :name (n8 / name :op1 "STAT4"~e.26))
            :op6 (p8 / protein
                  :name (n9 / name :op1 "STAT5"~e.29)
                  :ARG1-of (d / describe-01
                        :ARG0 (p4 / publication
                              :ARG1-of (c / cite-01 :ARG2 "60"))))))

# ::tok from full text - IL @-@ 6 signalling through signal transducer and activator of transcription @- 3 ( STAT3 )
# ::alignments 4-1.1.1.1 6-1.1.1.1 7-1 8-1.2.r 9-1 18-1.2.1.1
# ::id bel_pmid_1866_6314_38544
(s / signal-01~e.7,9
      :ARG0 (p / protein
            :name (n / name :op1 "IL-6"~e.4,6))
      :path~e.8 (p2 / protein
            :name (n2 / name :op1 "STAT3"~e.18)))

# ::tok from full text - TNF @-@ alpha exerts its pro @-@ inflammatory effects through increased production of IL @-@ 1 beta and IL @-@ 6 , expression of adhesion molecules , proliferation of fibroblasts and procoagulant factors , as well as initiation of cytotoxic , apoptotic , acute @-@ phase responses , and inhibition of apoptosis [8,9].
# ::alignments 4-1.1.1.1 6-1.1.1.1 7-1 11-1.2.1 12-1.2 13-1.3.r 14-1.3.1.2 15-1.3.1 16-1.3.1.1.r 17-1.3.1.1.1.1.1 17-1.3.1.1.2.1.1 21-1.3.1.1 22-1.3.1.1.1.1.1 22-1.3.1.1.2.1.1 24-1.3.1.1.2.1.1 26-1.3.2 29-1.3.2.1 31-1.3.3 32-1.3.3.1.r 33-1.3.3.1.1 34-1.3.3.1 34-1.3.5.1.1.1.1.1 41-1.3.4 42-1.3.4.1.r 43-1.3.4.1.1 45-1.3.4.1.2 47-1.3.4.1.3 49-1.3.4.1.3 50-1.3.4.1 52-1.3 52-1.3.5.1.1.1.1.1 53-1.3.5 54-1.3.5.1.r 55-1.3.5.1
# ::id bel_pmid_1866_6314_39148
(e / exert-01~e.7
      :ARG0 (p / protein
            :name (n / name :op1 "TNF-alpha"~e.4,6))
      :ARG1 (e2 / effect-01~e.12
            :ARG0-of (i / inflame-01~e.11
                  :ARG0-of (f2 / favor)))
      :path~e.13 (a / and~e.52
            :op1 (p3 / produce-01~e.15
                  :ARG1~e.16 (a2 / and~e.21
                        :op1 (p4 / protein
                              :name (n2 / name :op1 "IL-1beta"~e.17,22))
                        :op2 (p5 / protein
                              :name (n3 / name :op1 "IL-6"~e.17,22,24)))
                  :ARG1-of (i2 / increase-01~e.14))
            :op2 (e3 / express-03~e.26
                  :ARG2 (m / molecule~e.29
                        :ARG0-of (a3 / adhere-01)))
            :op3 (p6 / proliferate-01~e.31
                  :ARG0~e.32 (a4 / and~e.34
                        :op1 (f / fibroblast~e.33)
                        :op2 (c / coagulate-01
                              :ARG0-of (f3 / favor))))
            :op4 (i3 / initiate-01~e.41
                  :ARG1~e.42 (r / response~e.50
                        :mod (c2 / cytotoxic~e.43)
                        :mod (a5 / apoptosis~e.45)
                        :mod (a6 / acute-phase~e.47,49)))
            :op5 (i4 / inhibit-01~e.53
                  :ARG1~e.54 (a7 / apoptosis~e.55
                        :ARG1-of (d / describe-01
                              :ARG0 (p8 / publication
                                    :ARG1-of (c3 / cite-01
                                          :ARG2 (a8 / and~e.34,52 :op1 "8" :op2 "9"))))))))

# ::tok from full text - Defective transforming growth factor TGF @-@ beta1 signaling due to high levels of Smad7 is a feature of IBD[55]. UC patients have exhibited increased production of TGF @-@ beta1 by LPMC as compared with both CD patients and controls
# ::alignments 4-1.1.1.2 5-1.1.1.1.1.1 6-1.1.1.1.1.2 7-1.1.1.1.1.3 8-1.2.2.1.2.1.1 10-1.1.1.1.1.4 10-1.2.2.1.2.1.1 11-1.1.1 12-1.1.1.3 13-1.1.1.3 14-1.1.1.3.1.2.1 15-1.1.1.3.1.2 16-1.1.1.3.1.2.r 17-1.1.1.3.1.1.1 18-1.1.1.r 20-1.1 24-1.2.1 26-1.2 27-1.2.2 28-1.2.2.1 30-1.2.2.1.2.1.1 32-1.2.2.1.2.1.1 33-1.2.2.1.1.r 34-1.2.2.1.1.1.1 36-1.2.2.2.r 40-1.2.2.2.1 41-1.2.2.2 42-1.2.2.2.2
# ::id bel_pmid_1866_6314_39746
(m / multi-sentence
      :snt1 (f / feature~e.20
            :domain~e.18 (s2 / signal-07~e.11
                  :ARG0 (s3 / small-molecule
                        :name (n2 / name
                              :op1 "transforming"~e.5
                              :op2 "growth"~e.6
                              :op3 "factor"~e.7
                              :op4 "beta1"~e.10))
                  :mod (d / defective~e.4)
                  :ARG1-of (c4 / cause-01~e.12,13
                        :ARG0 (p5 / protein
                              :name (n / name :op1 "Smad7"~e.17)
                              :quant~e.16 (l / level~e.15
                                    :mod (h / high~e.14)))))
            :poss (d2 / disease
                  :name (n3 / name
                        :op1 "inflammatory"
                        :op2 "bowel"
                        :op3 "disease")
                  :ARG0-of (d3 / describe-01
                        :ARG0 (p / publication
                              :ARG1-of (c / cite-01 :ARG2 "55")))))
      :snt2 (e / exhibit-01~e.26
            :ARG0 (p2 / patient~e.24
                  :mod (d4 / disease
                        :name (n4 / name :op1 "ulcerative" :op2 "colitis")))
            :ARG1 (i / increase-01~e.27
                  :ARG1 (p3 / produce-01~e.28
                        :ARG0~e.33 (c2 / cell
                              :name (n5 / name :op1 "LPMC"~e.34))
                        :ARG1 (s4 / small-molecule
                              :name (n6 / name :op1 "TGF-beta1"~e.8,10,30,32)))
                  :compared-to~e.36 (a / and~e.41
                        :op1 (p4 / patient~e.40
                              :mod (d5 / disease
                                    :name (n7 / name :op1 "Crohn’s" :op2 "disease")))
                        :op2 (c3 / control~e.42)))))

# ::tok To determine if XIAP enhanced proinflammatory gene expression in vivo , we performed qRT @-@ PCR analysis on splenic RNA from WT and XIAP knockout mice . RNA was isolated from splenocytes harvested from uninfected animals or animals infected with L. monocytogenes for 48 h ( Figure 6 ) {to activate XIAP}. The expression of il6 and ifng mRNAs were significantly enhanced in the presence of XIAP during infection .
# ::alignments 1-1.1.3 2-1.3.3.r 3-1.3.3.1.1.1 4-1.1.3.2 6-1.1.3.2.2.1 7-1.1.3.2.2 8-1.1.3.2.2.3 9-1.1.3.2.2.3 11-1.1.1 12-1.1 13-1.1.2.2.1.1 15-1.1.2.2.1.1 16-1.1.2 18-1.1.2.1.2 19-1.1.2.1.1.1 20-1.1.2.1.3.r 21-1.1.2.1.3.1.2 22-1.1.2.1.3 23-1.1.2.1.3.2.2.1.1 24-1.1.2.1.3.3 25-1.1.2.1.3.1.1.1 25-1.1.2.1.3.2.1.1 27-1.1.2.1.1.1 27-1.2.1.1.1 28-1.3.3.1.r 29-1.2 30-1.2.2.r 32-1.2.2.2 33-1.2.2.2.1.r 34-1.2.2.2.1.1 34-1.2.2.2.1.1.1 34-1.2.2.2.1.1.1.r 34-1.2.2.2.1.2 35-1.2.2.2.1.1.2 35-1.2.2.2.1.2.1 36-1.2.2.2.1 37-1.2.2.2.1.1.2 37-1.2.2.2.1.2.1 38-1.2.2.2.1.1 38-1.2.2.2.1.2 39-1.1.2.2.r 39-1.2.2.2.1.2.2.r 40-1.2.2.2.1.2.2.1.1 41-1.2.2.2.1.2.2.1.2 42-1.2.3.r 43-1.2.3.1 46-1.2.3.2.1.1 47-1.2.3.2.1.1.1 50-1.2.4 53-1.3.1 54-1.3.1.1.r 55-1.3.1.1.1.1.1 56-1.3.1.1 57-1.3.1.1.2.1.1 58-1.3.1.1.1.1.2 58-1.3.1.1.2.1.2 59-1.3.3.1.r 60-1.3.2 61-1.3 62-1.1.3.2.2.3 64-1.3.3 65-1.2.4.1.r 66-1.2.4.1.1.1 67-1.3.4.r 68-1.3.4
# ::id bel_pmid_1876_9721_19816
(m / multi-sentence
      :snt1 (p / perform-01~e.12
            :ARG0 (w / we~e.11)
            :ARG1 (a / analyze-01~e.16
                  :ARG1 (r / rna
                        :name (n / name :op1 "RNA"~e.19,27)
                        :mod (s / spleen~e.18)
                        :source~e.20 (a2 / and~e.22
                              :op1 (o / organism
                                    :name (n3 / name :op1 "mouse"~e.25)
                                    :mod (w2 / wild-type~e.21))
                              :op2 (o2 / organism
                                    :name (n4 / name :op1 "mouse"~e.25)
                                    :mod (p3 / protein
                                          :name (n5 / name :op1 "XIAP"~e.23)))
                              :location-of (k / knockout-00~e.24)))
                  :instrument~e.39 (m2 / molecular-physical-entity
                        :name (n2 / name :op1 "qRT-PCR"~e.13,15)))
            :purpose (d / determine-01~e.1
                  :ARG0 w
                  :ARG1 (e / enhance-01~e.4
                        :ARG0 p3
                        :ARG1 (e2 / express-03~e.7
                              :ARG1 (g2 / gene~e.6)
                              :ARG1-of (i / inflame-01
                                    :ARG0-of (f / favor-01))
                              :location (i2 / in-vivo~e.8,9,62)))))
      :snt2 (i3 / isolate-01~e.29
            :ARG1 (r2 / rna
                  :name (n6 / name :op1 "RNA"~e.27))
            :source~e.30 (c / cell
                  :name (n7 / name :op1 "splenocyte")
                  :ARG1-of (h / harvest-01~e.32
                        :source~e.33 (o3 / or~e.36
                              :op1 (i4 / infect-01~e.34,38
                                    :polarity~e.34 "-"~e.34
                                    :ARG1 (a3 / animal~e.35,37))
                              :op2 (i5 / infect-01~e.34,38
                                    :ARG1 (a4 / animal~e.35,37)
                                    :ARG3~e.39 (t / thing
                                          :name (n8 / name :op1 "L."~e.40 :op2 "monocytogenes"~e.41))))))
            :duration~e.42 (t2 / temporal-quantity
                  :quant "48"~e.43
                  :unit (h2 / hour
                        :ARG1-of (d2 / describe-01
                              :ARG0 (f2 / figure~e.46 :mod "6"~e.47))))
            :purpose (a5 / activate-01~e.50
                  :ARG1~e.65 (p4 / protein
                        :name (n9 / name :op1 "XIAP"~e.66))))
      :snt3 (e3 / enhance-01~e.61
            :ARG1 (e4 / express-03~e.53
                  :ARG1~e.54 (a6 / and~e.56
                        :op1 (g / gene
                              :name (n10 / name :op1 "il6"~e.55 :op2 "mRNA"~e.58))
                        :op2 (g3 / gene
                              :name (n11 / name :op1 "ifng"~e.57 :op2 "mRNA"~e.58))))
            :ARG3 (s2 / significant~e.60)
            :condition~e.2 (p2 / present~e.64
                  :domain~e.28,59 (p5 / protein
                        :name (n12 / name :op1 "XIAP"~e.3)))
            :time~e.67 (i6 / infect-01~e.68)))

# ::tok Furthermore , the hydroxyproline content was significantly reduced in the anti @-@ CD154 mAb–treated group compared with the control IgG– treated group ( Figure 5c ) .
# ::alignments 3-1.1.1.1.1.1 4-1.1.1 6-1.1.2 7-1.1 8-1.1.3.r 10-1.1.3.1.1.1.1 12-1.1.3.1.1.1.1 14-1.1.3 15-1.1.4.r 20-1.1.3.1 20-1.1.4 21-1.1.4.1 23-1.1.4.1.1.1 24-1.1.4.1.1.1.1
# ::id bel_pmid_1897_5310_25820
(a / and
      :op2 (r / reduce-01~e.7
            :ARG1 (c / contain-01~e.4
                  :ARG1 (a2 / amino-acid
                        :name (n / name :op1 "hydroxyproline"~e.3)))
            :ARG2 (s / significant-02~e.6)
            :location~e.8 (g / group~e.14
                  :ARG1-of (t / treat-03~e.20
                        :ARG3 (p / protein
                              :name (n2 / name :op1 "anti-CD154"~e.10,12 :op2 "mAb"))))
            :compared-to~e.15 (t2 / treat-03~e.20
                  :ARG1 (g2 / group~e.21
                        :ARG1-of (d / describe
                              :ARG0 (f / figure~e.23 :mod "5c"~e.24)))
                  :ARG3 (p2 / protein
                        :name (n3 / name :op1 "IgG")))))

# ::tok In contrast , the number of BrdU @-@ positive proliferating dermal fibroblasts at 1 week was significantly reduced in the anti @-@ CD154 mAb–treated group compared with the control IgG–treated group
# ::alignments 1-1 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1.3.1.1.1 8-1.1.1.1.3 9-1.1.1.1.2 10-1.1.1.1.1 11-1.1.1.1 12-1.1.3 13-1.1.3.1.1 14-1.1.3.1.2 16-1.1.2 17-1.1 20-1.1.4.1.1.1.1 22-1.1.4.1.1.1.1 24-1.1.4 24-1.1.5 25-1.1.5.r 28-1.1.5.1 30-1.1.5
# ::id bel_pmid_1897_5310_25824
(c / contrast-01~e.1
      :ARG2 (r / reduce-01~e.17
            :ARG1 (n / number~e.4
                  :quant-of~e.5 (f / fibroblast~e.11
                        :mod (d / dermis~e.10)
                        :ARG0-of (p / proliferate-01~e.9)
                        :mod (p2 / positive~e.8
                              :mod (p3 / protein
                                    :name (n2 / name :op1 "BrdU"~e.6)))))
            :ARG2 (s / significant~e.16)
            :time (a / at~e.12
                  :op1 (t / temporal-quantity
                        :quant "1"~e.13
                        :unit (w / week~e.14)))
            :location (g / group~e.24
                  :ARG1-of (t2 / treat-03
                        :ARG3 (p4 / protein
                              :name (n3 / name :op1 "anti-CD154"~e.20,22 :op2 "mAb"))))
            :compared-to~e.25 (g2 / group~e.24,30
                  :mod (c2 / control~e.28)
                  :ARG1-of (t3 / treat-03
                        :ARG3 (p5 / protein
                              :name (n4 / name :op1 "IgG"))))))

# ::tok In addition , the anti @-@ CD154 mAb treatment suppressed the up @-@ regulated expression of COL1A1 , RANTES , and MCP @-@ 1 mRNA ( Figure 5g ) .
# ::alignments 0-1 1-1 4-1.1.1.1.1.1 6-1.1.1.1.1.1 7-1.1.1.1.1.2 8-1.1.1 9-1.1 14-1.1.2 15-1.1.2.1.r 16-1.1.2.1.1.1.1 18-1.1.2.1.2.1.1 20-1.1.2.1 21-1.1.2.1.3.1.1 23-1.1.2.1.3.1.1 24-1.1.2.1.3.1.2 26-1.1.2.1.4.1 27-1.1.2.1.4.1.1
# ::id bel_pmid_1897_5310_25836
(a / and~e.0,1
      :op2 (s / suppress-01~e.9
            :ARG0 (t / treat-03~e.8
                  :ARG3 (p / protein
                        :name (n / name :op1 "anti-CD154"~e.4,6 :op2 "mAb"~e.7)))
            :ARG1 (e / express-03~e.14
                  :ARG2~e.15 (a2 / and~e.20
                        :op1 (g / gene
                              :name (n2 / name :op1 "COL1A1"~e.16))
                        :op2 (g2 / gene
                              :name (n3 / name :op1 "RANTES"~e.18))
                        :op3 (g3 / gene
                              :name (n4 / name :op1 "MCP-1"~e.21,23 :op2 "mRNA"~e.24))
                        :ARG1-of (d / describe-01
                              :ARG0 (f / figure~e.26 :mod "5g"~e.27)))
                  :ARG1-of (u / upregulate-01))))

# ::tok Upon stimulation with soluble CD154 , cultured fibroblasts induced to express CD40 by adenoviral gene transfer proliferated and showed up @-@ regulation of the genes for intercellular adhesion molecule 1 , interleukin @-@ 6 ( IL @-@ 6 ) , IL @-@ 8 , monocyte chemoattractant protein 1 ( MCP @-@ 1 ) , and RANTES , as well as up @-@ regulation of their proteins .
# ::alignments 1-1.3 2-1.3.1.r 3-1.3.1.2 4-1.3.1.1.1 6-1.1.1.1 7-1.1.1 8-1.1.1.2 10-1.1.1.2.1 11-1.1.1.2.1.1.1.1 12-1.1.1.2.1.2.r 13-1.1.1.2.1.2.1.1 14-1.1.1.2.1.2.1 15-1.1.1.2.1.2 16-1.1 17-1 18-1.2 24-1.2.2.1.1 25-1.2.2.1.1.1.r 26-1.2.2.1.1.1.1.1.1 27-1.2.2.1.1.1.1.1.2 28-1.2.2.1.1.1.1.1.3 29-1.2.2.1.1.1.1.1.4 31-1.2.2.1.1.1.2.1.1 33-1.2.2.1.1.1.2.1.1 37-1.2.2.1.1.1.2.1.1 44-1.2.2.1.1.1.3.1.1 45-1.2.2.1.1.1.3.1.2 46-1.2.2.1.1.1.3.1.3 54-1.2.2.1.1.1 55-1.2.2.1.1.1.4.1.1 65-1.2.2.1.1.1.1
# ::id bel_pmid_1897_5310_36028
(a / and~e.17
      :op1 (p / proliferate-01~e.16
            :ARG0 (f / fibroblast~e.7
                  :mod (c / cultured~e.6)
                  :ARG1-of (i / induce-01~e.8
                        :purpose (e / express-03~e.10
                              :ARG2 (p2 / protein
                                    :name (n / name :op1 "CD40"~e.11))
                              :path~e.12 (t / transfer-01~e.15
                                    :ARG1 (g / gene~e.14
                                          :mod (a2 / adenoviral~e.13)))))))
      :op2 (s3 / show-01~e.18
            :ARG0 f
            :ARG1 (a3 / and
                  :op1 (u / upregulate-01
                        :ARG1 (g2 / gene~e.24
                              :purpose~e.25 (a4 / and~e.54
                                    :op1 (p4 / protein~e.65
                                          :name (n3 / name
                                                :op1 "intercellular"~e.26
                                                :op2 "adhesion"~e.27
                                                :op3 "molecule"~e.28
                                                :op4 "1"~e.29))
                                    :op2 (p5 / protein
                                          :name (n4 / name :op1 "interleukin-6"~e.31,33,37))
                                    :op3 (p6 / protein
                                          :name (n5 / name
                                                :op1 "monocyte"~e.44
                                                :op2 "chemoattractant"~e.45
                                                :op3 "protein"~e.46))
                                    :op4 (p7 / protein
                                          :name (n6 / name :op1 "RANTES"~e.55)))))
                  :op2 (u2 / upregulate-01
                        :ARG1 (p8 / protein
                              :poss g2))))
      :condition (s / stimulate-01~e.1
            :ARG2~e.2 (p3 / protein
                  :name (n2 / name :op1 "CD154"~e.4)
                  :mod (s2 / soluble~e.3))))

# ::tok Consistent with diminished numbers of squamous type I cells in epFoxm1-/- lungs , mRNA levels of T1 @-@ alpha and aquaporin 5 were significantly decreased as demonstrated by quantitative real @-@ time ( RT @-@ PCR ) ( qRT @-@ PCR ) analysis ( Fig . 3B ) .
# ::alignments 0-1.4 1-1.4.1.r 2-1.4.1 3-1.4.1.1.2 5-1.4.1.1.1.1 6-1.4.1.1.1.2 7-1.4.1.1.1.3 8-1.4.1.1.1.4 11-1.4.1.1.3 13-1.1.1.1 14-1.1.2 16-1.1.3.1.1.1 18-1.1.3.1.1.1 19-1.1.3 20-1.1.3.2.1.1 21-1.1.3.2.1.2 23-1.2 24-1 25-1.3.r 26-1.3 27-1.3.1.r 28-1.3.1.1 29-1.3.1.2 31-1.3.1.2 33-1.3.1.3.1.1.1 35-1.3.1.3.1.1.1 35-1.3.1.3.2.1.1 38-1.3.1.3.2.1.1 40-1.3.1.3.1.1.1 40-1.3.1.3.2.1.1 42-1.3.1 46-1.3.1.4.1.1
# ::id bel_pmid_1903_3457_27030
(d / decrease-01~e.24
      :ARG1 (r / rna
            :name (n / name :op1 "mRNA"~e.13)
            :mod (l / level~e.14)
            :location (a / and~e.19
                  :op1 (p / protein
                        :name (n2 / name :op1 "T1-alpha"~e.16,18))
                  :op2 (p2 / protein
                        :name (n3 / name :op1 "aquaporin"~e.20 :op2 "5"~e.21))))
      :ARG2 (s / significant~e.23)
      :ARG1-of~e.25 (d2 / demonstrate-01~e.26
            :ARG0~e.27 (a2 / analysis~e.42
                  :mod (q / quantity~e.28)
                  :mod (r2 / real-time~e.29,31)
                  :example (a3 / and
                        :op1 (m / molecular-physical-entity
                              :name (n4 / name :op1 "RT-PCR"~e.33,35,40))
                        :op2 (m2 / molecular-physical-entity
                              :name (n5 / name :op1 "qRT-PCR"~e.35,38,40)))
                  :ARG1-of (d3 / describe
                        :ARG0 (f / figure :mod "3B"~e.46))))
      :ARG1-of (c / consistent-01~e.0
            :ARG2~e.1 (d4 / diminish-01~e.2
                  :ARG1 (c2 / cell
                        :name (n6 / name
                              :op1 "squamous"~e.5
                              :op2 "type"~e.6
                              :op3 "I"~e.7
                              :op4 "cell"~e.8)
                        :mod (n7 / number~e.3)
                        :location (l2 / lung~e.11
                              :mod (p3 / protein
                                    :name (n8 / name :op1 "epFoxm1")
                                    :ARG2-of (m3 / mutate-01 :mod "-/-")))))))

# ::tok Significantly decreased mRNA levels of M @-@ phase @-@ promoting Cdc25B phosphatase ( Fig . 3B ) , a known transcriptional target of Foxm1 ( 15 ) , were observed in the lungs of epFoxm1-/- mice .
# ::alignments 0-1.1.2 1-1.1 2-1.1.1.1.1 3-1.1.1.2 5-1.1.1.3.1.1 7-1.1.1.3.1.1 9-1.1.1.3.1.1 10-1.1.1.3.1.2 11-1.1.1.3.1.3 15-1.1.1.3.2.1.1 19-1.1.1.3.3.2 20-1.1.1.3.3.3 21-1.1.1.3 21-1.1.1.3.3 21-1.1.1.3.3.r 22-1.1.1.3.3.1.r 23-1.1.1.3.3.1.1.1 29-1
# ::id bel_pmid_1903_3457_27038
(o / observe-01~e.29
      :ARG1 (d / decrease-01~e.1
            :ARG1 (r / rna
                  :name (n / name :op1 "mRNA"~e.2)
                  :mod (l / level~e.3)
                  :location (e / enzyme~e.21
                        :name (n2 / name
                              :op1 "M-phase-promoting"~e.5,7,9
                              :op2 "Cdc25B"~e.10
                              :op3 (p / phosphatase~e.11))
                        :ARG1-of (d2 / describe
                              :ARG0 (f / figure :mod "3B"~e.15))
                        :ARG1-of~e.21 (t / target-01~e.21
                              :ARG0~e.22 (p2 / protein
                                    :name (n3 / name :op1 "Foxm1"~e.23))
                              :ARG1-of (k / know-01~e.19)
                              :mod (t2 / transcriptional~e.20))))
            :ARG2 (s / significant~e.0)))

# ::tok The authors demonstrate that HMGB1 binds to TLR4 and that HMGB1 , which is released by chemotherapy @-@ induced cell death , can activate TLR4 and induce anti @-@ tumour T @-@ cell immunity79 .
# ::alignments 1-1.1 2-1 3-1.2.r 4-1.2.1.1.1.1 5-1.2.1 6-1.2.1.2.r 7-1.2.1.2.1.1 10-1.2.1.1.1.1 14-1.2.1.1.2 15-1.2.1.1.2.1.r 16-1.2.1.1.2.1.2.1 18-1.2.1.1.2.1.2 19-1.2.1.1.2.1.1 20-1.2.1.1.2.1 22-1.2.2 23-1.2.2.1.1 24-1.2.2.1.1.2 25-1.2.2.1 26-1.2.2.1.2 27-1.2.2.1.2.2.2 29-1.2.2.1.2.2.2.1 30-1.2.2.1.2.2.1.1.1 32-1.2.2.1.2.2.1.1.1
# ::id bel_pmid_1905_2556_19692
(d / demonstrate-01~e.2
      :ARG0 (a / author~e.1)
      :ARG1~e.3 (a2 / and
            :op1 (b / bind-01~e.5
                  :ARG1 (p / protein
                        :name (n / name :op1 "HMGB1"~e.4,10)
                        :ARG1-of (r / release-01~e.14
                              :ARG0~e.15 (d2 / die-01~e.20
                                    :ARG1 (c / cell~e.19)
                                    :ARG1-of (i2 / induce-01~e.18
                                          :ARG0 (c2 / chemotherapy~e.16)))))
                  :ARG2~e.6 (p3 / protein
                        :name (n2 / name :op1 "TLR4"~e.7)))
            :op2 (p2 / possible~e.22
                  :domain (a3 / and~e.25
                        :op1 (a4 / activate-01~e.23
                              :ARG0 p
                              :ARG1 p3~e.24)
                        :op2 (i / induce-01~e.26
                              :ARG0 p
                              :ARG1 (i3 / immunity
                                    :mod (c3 / cell
                                          :name (n3 / name :op1 "T-cell"~e.30,32))
                                    :ARG0-of (c4 / counter-01~e.27
                                          :ARG1 (t / tumour~e.29))
                                    :ARG1-of (d3 / describe-01
                                          :ARG0 (p4 / publication
                                                :ARG1-of (c5 / cite-01 :ARG2 "79")))))))))

# ::tok In response to hepatocyte cell death , MyD88 signalling was responsible for the activation of NF-?B and for the production of factors such as IL @-@ 6 ( ReF . 122 ) .
# ::alignments 1-1.3 2-1.3.1.r 3-1.3.1.1.1.1 4-1.3.1.1.1.2 5-1.3.1 7-1.1.1.1.1 8-1.1 10-1 11-1.2.r 13-1.2.1 16-1.2 19-1.2.2 20-1.2.2.1.r 21-1.2.2.1 22-1.2.2.1.1.r 23-1.2.2.1.1.r 24-1.2.2.1.1.1.1 26-1.2.2.1.1.1.1 30-1.2.2.1.1.2.1.1.1
# ::id bel_pmid_1905_2556_29386
(r / responsible-01~e.10
      :ARG0 (s / signal-07~e.8
            :ARG0 (p / protein
                  :name (n / name :op1 "MyD88"~e.7)))
      :ARG1~e.11 (a / and~e.16
            :op1 (a2 / activate-01~e.13
                  :ARG1 (p2 / protein
                        :name (n2 / name :op1 "NF-kB")))
            :op2 (p3 / produce-01~e.19
                  :ARG1~e.20 (f / factor~e.21
                        :example~e.22,23 (p4 / protein
                              :name (n3 / name :op1 "IL-6"~e.24,26)
                              :ARG1-of (d2 / describe-01
                                    :ARG0 (p5 / publication
                                          :ARG1-of (c2 / cite-01 :ARG2 "122"~e.30)))))))
      :ARG2-of (r2 / respond-01~e.1
            :ARG1~e.2 (d / die-01~e.5
                  :ARG1 (c / cell
                        :name (n4 / name :op1 "hepatocyte"~e.3 :op2 "cell"~e.4)))))

# ::tok All TLRs ( except for TLR3 ) and IL @-@ 1 receptor family members signal through MyD88 .
# ::alignments 0-1.1.1.2 3-1.1.1 3-1.1.1.3 3-1.1.1.3.r 4-1.1.1.3.1.r 5-1.1.1.3.1.1.1 7-1.1 8-1.1.2.1.1 10-1.1.2.1.1 11-1.1.2.1.2 12-1.1.2.2.1 13-1.1.2.2.2 14-1 15-1.2.r 16-1.2.1.1
# ::id bel_pmid_1905_2556_35940
(s / signal-07~e.14
      :ARG0 (a2 / and~e.7
            :op1 (p / protein~e.3
                  :name (n / name :op1 "TLR")
                  :mod (a / all~e.0)
                  :ARG2-of~e.3 (e / except-01~e.3
                        :ARG1~e.4 (p2 / protein
                              :name (n2 / name :op1 "TLR3"~e.5))))
            :op2 (p3 / protein
                  :name (n3 / name :op1 "IL-1"~e.8,10 :op2 "receptor"~e.11)
                  :ARG0-of (h / have-org-role-91
                        :ARG1 (f / family~e.12)
                        :ARG2 (m / member~e.13))))
      :path~e.15 (p4 / protein
            :name (n4 / name :op1 "MyD88"~e.16)))

# ::tok We veri ? ed the secretion levels of several SASP proteins by ELISAs ( Figure S1 and Text S1 ) . Further , because secretion increased greater than 10 @-@ fold for some SASP factors , we could verify up @-@ regulation by intracellular immunostaining . For example , IL @-@ 6 and IL @-@ 8 were barely visible in PRE cells but clearly detectable in SEN cells ( Figure 1B , Figure S2 , and Text S1 ) .
# ::alignments 0-1.1.1 5-1.1.2.1 6-1.1.2 7-1.1.2.1.1.r 8-1.1.2.1.1.1 9-1.1.2.1.1.2.1.1 10-1.1.2.1.1 14-1.1.4.1.1 15-1.1.4.1.1.1 16-1.1.4.1 17-1.1.4.1.2 18-1.1.4.1.2.1 21-1.2.2 23-1.2.1.3 24-1.2.1.3.1.1 25-1.2.1.3.1 26-1.2.1.3.1.2 27-1.2.1.3.1.2 28-1.2.1.3.1.2.1.1 31-1.2.1.3.1.1.1.r 32-1.2.1.3.1.1.1.2 33-1.2.1.3.1.1.1.1.1 34-1.2.1.3.1.1.1 36-1.2.1.1 37-1.2 37-1.3.1.1 37-1.3.1.2 38-1.1 38-1.2.1 39-1.2.1.3.1 43-1.2.1.4.1 46-1.3 47-1.3 49-1.3.1.1.1.1.1.1.1 49-1.3.1.1.1.1.2.1.1 51-1.3.1.1.1.1.1.1.1 52-1.3.1.1.1.1 53-1.3.1.1.1.1.1.1.1 53-1.3.1.1.1.1.2.1.1 55-1.3.1.1.1.1.2.1.1 56-1.3.1.1.1.r 57-1.3.1.1.1.2 58-1.3.1.1.1 61-1.3.1.1.1.3 61-1.3.1.2.1.3 62-1.3.1 63-1.3.1.2.1.2 67-1.3.1.1.1.3 67-1.3.1.2.1.3 69-1.3.2.1.1 70-1.3.2.1.1.1 72-1.3.2.1.2 73-1.3.2.1.2.1 75-1.3.2.1 76-1.3.2.1.3 77-1.3.2.1.3.1
# ::id bel_pmid_1905_3174_34990
(m / multi-sentence
      :snt1 (v / verify-01~e.38
            :ARG0 (w / we~e.0)
            :ARG1 (l / level~e.6
                  :degree-of (s / secrete-01~e.5
                        :ARG1~e.7 (p / protein~e.10
                              :quant (s2 / several~e.8)
                              :mod (t5 / thing
                                    :name (n2 / name :op1 "SASP"~e.9)))))
            :instrument (t / thing
                  :name (n / name :op1 "ELISA"))
            :ARG1-of (d / describe-01
                  :ARG0 (a / and~e.16
                        :op1 (f / figure~e.14 :mod "S1"~e.15)
                        :op2 (t2 / text~e.17 :mod "S1"~e.18))))
      :snt2 (p2 / possible~e.37
            :domain (v2 / verify-01~e.38
                  :ARG0 (w2 / we~e.36)
                  :ARG1 (u / upregulate-01)
                  :ARG1-of (c / cause-01~e.23
                        :ARG0 (i / increase-01~e.25,39
                              :ARG1 (s3 / secrete-01~e.24
                                    :ARG1~e.31 (f2 / factor~e.34
                                          :name (n3 / name :op1 "SASP"~e.33)
                                          :mod (s4 / some~e.32)))
                              :ARG2 (g / greater-than~e.26,27
                                    :mod (p4 / product-of :op1 "10"~e.28))))
                  :manner (i2 / immunostain-00
                        :manner (i3 / intracellular~e.43)))
            :mod (f5 / further~e.21))
      :snt3 (e / exemplify-01~e.46,47
            :ARG0 (c2 / contrast-01~e.62
                  :ARG1 (p5 / possible~e.37
                        :domain~e.56 (s5 / see-01~e.58
                              :ARG1 (a2 / and~e.52
                                    :op1 (p6 / protein
                                          :name (n5 / name :op1 "IL-6"~e.49,51,53))
                                    :op2 (p7 / protein
                                          :name (n6 / name :op1 "IL-8"~e.49,53,55)))
                              :degree (b / bare~e.57)
                              :location (c3 / cell~e.61,67
                                    :mod (p8 / presenescent))))
                  :ARG2 (p9 / possible~e.37
                        :domain (d2 / detect-01
                              :ARG1 a2
                              :mod (c4 / clear~e.63)
                              :location (c5 / cell~e.61,67
                                    :mod (s6 / senescent)))))
            :ARG1-of (d3 / describe-01
                  :ARG0 (a3 / and~e.75
                        :op1 (f3 / figure~e.69 :mod "1B"~e.70)
                        :op2 (f4 / figure~e.72 :mod "S2"~e.73)
                        :op3 (t4 / text~e.76 :mod "S1"~e.77)))))

# ::tok SASP components included inflammatory and immune @-@ modulatory cytokines and chemokines ( e.g . , IL @-@ 6 , ?7 , and ?8 , MCP @-@ 2 , and MIP @-@ 3a ) . They also included growth factors ( e.g . , GRO , HGF , and IGFBPs ) , shed cell surface molecules ( e.g . , ICAMs , uPAR , and TNF receptors ) , and survival factors ( Figure 1A and Table S2 )
# ::alignments 0-1.1.2.1.1.1 1-1.1.2 2-1.1 3-1.1.1.3 4-1.1.1 4-1.1.1.5.1 5-1.1.1.4.1 9-1.1.1 9-1.1.1.5.1 15-1.1.1.5.1.1.1.1 15-1.1.1.5.1.2.1.1 15-1.1.1.5.1.3.1.1 17-1.1.1.5.1.1.1.1 21-1.1.1.5.1 24-1.1.1.5.1.4.1.1 26-1.1.1.5.1.4.1.1 28-1.1.1.5.1 29-1.1.1.5.1.5.1.1 31-1.1.1.5.1.5.1.1 34-1.2.2 35-1.2.3 36-1.2 37-1.2.1.1.1 38-1.2.1.1 43-1.2.1.1.2.1.1.1.1 45-1.2.1.1.2.1.2.1.1 47-1.2.1 51-1.2.1.2.2.1 52-1.2.1.2.2 53-1.2.1.2.1 54-1.2.1.2 61-1.2.1.2.3.1.2.1.1 63-1.2.1.2.3.1 64-1.2.1.2.3.1.3.1.1 65-1.2.1.2.3.1.3.1.2 68-1.2.1 68-1.2.1.1.2.1 68-1.2.1.2.3.1 69-1.2.1.3.1 70-1.2.1.1.2.1.1 70-1.2.1.1.2.1.2 70-1.2.1.1.2.1.3 70-1.2.1.3 72-1.3.1.1 73-1.3.1.1.1 74-1.3.1 75-1.3.1.2 76-1.3.1.2.1
# ::id bel_pmid_1905_3174_35034
(m / multi-sentence
      :snt1 (i / include-01~e.2
            :ARG1 (a / and~e.4,9
                  :op1 (c2 / cytokine)
                  :op2 (c3 / chemokine)
                  :ARG0-of (i4 / inflame-01~e.3)
                  :ARG0-of (m2 / modulate-01
                        :mod (i2 / immune~e.5))
                  :ARG1-of (e / exemplify-01
                        :ARG0 (a2 / and~e.4,9,21,28
                              :op1 (c4 / cytokine
                                    :name (n2 / name :op1 "IL-6"~e.15,17))
                              :op2 (c5 / cytokine
                                    :name (n3 / name :op1 "IL-7"~e.15))
                              :op3 (c6 / chemokine
                                    :name (n4 / name :op1 "IL-8"~e.15))
                              :op4 (c7 / chemokine
                                    :name (n5 / name :op1 "MCP-2"~e.24,26))
                              :op5 (c8 / chemokine
                                    :name (n6 / name :op1 "MIP-3a"~e.29,31)))))
            :ARG2 (c / component~e.1
                  :mod (t / thing
                        :name (n / name :op1 "SASP"~e.0))))
      :snt2 (i3 / include-01~e.36
            :ARG1 (a3 / and~e.47,68
                  :op1 (f / factor~e.38
                        :mod (g / growth~e.37)
                        :ARG1-of (e2 / exemplify-01
                              :ARG0 (a4 / and~e.68
                                    :op1 (g2 / growth-factor~e.70
                                          :name (n7 / name :op1 "GRO"~e.43))
                                    :op2 (g3 / growth-factor~e.70
                                          :name (n8 / name :op1 "HGF"~e.45))
                                    :op3 (g4 / growth-factor~e.70
                                          :name (n9 / name :op1 "IGFBP")))))
                  :op2 (m3 / molecule~e.54
                        :mod (s / surface~e.53)
                        :source (c9 / cell~e.52
                              :ARG1-of (s2 / shed-01~e.51))
                        :ARG1-of (e3 / exemplify-01
                              :ARG0 (a5 / and~e.63,68
                                    :op1 (p / protein
                                          :name (n10 / name :op1 "ICAM"))
                                    :op2 (p3 / protein
                                          :name (n11 / name :op1 "uPAR"~e.61))
                                    :op3 (p2 / protein
                                          :name (n12 / name :op1 "TNF"~e.64 :op2 "receptor"~e.65)))))
                  :op3 (f2 / factor~e.70
                        :mod (s3 / survive-01~e.69)))
            :ARG2 (t2 / they~e.34)
            :mod (a6 / also~e.35))
      :ARG1-of (d / describe-01
            :ARG0 (a7 / and~e.74
                  :op1 (f3 / figure~e.72 :mod "1A"~e.73)
                  :op2 (t3 / table~e.75 :mod "S2"~e.76))))

# ::tok Hypoxia exposure of IL @-@ 6+/+ mice led to marked increases in IL @-@ 6 mRNA and protein levels within the first week , with positive IL @-@ 6 immunostaining in the pulmonary vessel walls ...In vitro studies of cultured human pulmonary @-@ artery smooth @-@ muscle @-@ cells ( PA @-@ SMCs ) and microvascular endothelial cells revealed prominent synthesis of IL @-@ 6 by PA @-@ SMCs , with further stimulation by hypoxia .
# ::alignments 0-1.1.1.2 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1.1 6-1.1.1.1 7-1.1 8-1.1.2.r 9-1.1.2.2 10-1.1.2 11-1.2.1.2 12-1.1.1.1.1.1.1 12-1.1.2.1.1.1.2.1.1.1 12-1.2.2.2.1.1 14-1.1.1.1.1.1.1 14-1.1.2.1.1.1.2.1.1.1 14-1.2.2.2.1.1 15-1.1.2.1.1.1.1.1 16-1.1.2.1 17-1.1.1.1.1 17-1.1.2.1.1.1.2.1 17-1.2.2.2 18-1.1.2.1.1 18-1.1.2.1.2 21-1.1.2.3.1 21-1.1.2.3.1.1 21-1.1.2.3.1.1.r 22-1.1.2.3 24-1.1.3.r 25-1.1.3.2 26-1.1.1.1.1.1.1 26-1.2.2.2.1.1 28-1.1.1.1.1.1.1 28-1.2.2.2.1.1 30-1.2.1.2 32-1.1.3.3.1.1 33-1.1.3.3.1 34-1.1.3.3 36-1.2.1.2 37-1.2.1 38-1.2.1.1.r 39-1.2.1.1.1.2 40-1.2.1.1.1.1.1 41-1.2.1.1.1.1.2 43-1.2.1.1.1.1.2 44-1.2.1.1.1.1.3 46-1.2.1.1.1.1.3 48-1.2.1.1.1.1.3 48-1.2.1.1.2.1.3 54-1.2.1.1 55-1.2.1.1.2.1.1 56-1.2.1.1.2.1.2 57-1.2.1.1.1.1.3 57-1.2.1.1.2.1.3 58-1.2 59-1.2.2.3 62-1.1.1.1.1.1.1 62-1.2.2.2.1.1 64-1.1.1.1.1.1.1 64-1.2.2.2.1.1 70-1.1.3.r 71-1.2.2.4.2 72-1.2.2.4 73-1.2.2.4.1.r 74-1.2.2.4.1
# ::id bel_pmid_1917_3740_18146
(m / multi-sentence
      :snt1 (l / lead-01~e.7
            :ARG0 (e / expose-01~e.1
                  :ARG1~e.2 (m2 / mouse~e.6
                        :mod (p / protein~e.17
                              :name (n / name :op1 "IL-6"~e.3,12,14,26,28,62,64)
                              :mod (w / wild-type)))
                  :ARG2 (h / hypoxia~e.0))
            :ARG4~e.8 (i / increase-01~e.10
                  :ARG1 (a / and~e.16
                        :op1 (l2 / level~e.18
                              :quant-of (r / rna
                                    :name (n2 / name :op1 "mRNA"~e.15)
                                    :ARG0-of (e2 / encode-01
                                          :ARG1 (p2 / protein~e.17
                                                :name (n3 / name :op1 "IL-6"~e.12,14)))))
                        :op2 (l3 / level~e.18
                              :quant-of p2))
                  :ARG1-of (m3 / mark-01~e.9)
                  :time (w2 / week~e.22
                        :ord (o / ordinal-entity~e.21 :value~e.21 "1"~e.21)))
            :accompanier~e.24,70 (i2 / immunostain-00
                  :ARG1 p2
                  :mod (p3 / positive~e.25)
                  :location (w3 / wall~e.34
                        :mod (v / vessel~e.33
                              :mod (p4 / pulmonary~e.32)))))
      :snt2 (r2 / reveal-01~e.58
            :ARG0 (s / study-01~e.37
                  :ARG1~e.38 (a2 / and~e.54
                        :op1 (c / cell-line
                              :name (n4 / name
                                    :op1 "human"~e.40
                                    :op2 "pulmonary-artery"~e.41,43
                                    :op3 "smooth-muscle-cell"~e.44,46,48,57)
                              :ARG1-of (c2 / culture-01~e.39))
                        :op2 (c3 / cell-line
                              :name (n5 / name
                                    :op1 "microvascular"~e.55
                                    :op2 "endothelial"~e.56
                                    :op3 "cell"~e.48,57)))
                  :manner (i3 / in-vitro~e.11,30,36))
            :ARG1 (s2 / synthesize-01
                  :ARG0 c
                  :ARG1 (p5 / protein~e.17
                        :name (n6 / name :op1 "IL-6"~e.12,14,26,28,62,64))
                  :mod (p6 / prominent~e.59)
                  :ARG1-of (s3 / stimulate-01~e.72
                        :ARG0~e.73 (h2 / hypoxia~e.74)
                        :mod (f / further~e.71)))))

# ::tok In CIA synoviocytes , IL @-@ 17 increased the expression of TLR @-@ 2 , 4, and 9 , and this effect was significantly alleviated by neutralizing antibodies to IL @-@ 17 , IL @-@ 1 beta , and IL @-@ 6 .
# ::alignments 1-1.2.2 2-1.2.2 3-1.2.2 4-1.2.2 5-1.2.2 6-1.2.2 7-1.2.2 8-1.2.2 9-1.2.2 10-1.2.2 11-1.2.2 12-1.2.2 13-1.2.2 14-1.2.2 15-1.2.2 16-1.2.2 17-1.2.2 19-1 23-1.2.3 24-1.2 25-1.2.1.r 26-1.2.1 27-1.2.1.1.1 27-1.2.1.1.2 27-1.2.1.1.3 29-1.1.1.1.1 29-1.2.1.1.2.1.1.1.1 29-1.2.1.1.3.1.1.1.1 31-1.1.1.1.1 33-1.1.1.1.1 33-1.2.1.1.2.1.1.1.1 33-1.2.1.1.3.1.1.1.1 38-1.2.1.1 39-1.2.1.1.2.1.1.1.1 39-1.2.1.1.3.1.1.1.1 41-1.2.1.1.3.1.1.1.1
# ::id bel_pmid_1922_8664_9182
(a / and~e.19
      :op1 (i / increase-01
            :ARG0 (p / protein
                  :name (n / name :op1 "IL-17"~e.29,31,33))
            :ARG1 (e / express-03
                  :ARG2 (a2 / and
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "TLR-2"))
                        :op2 (p3 / protein
                              :name (n3 / name :op1 "TLR-4"))
                        :op3 (p4 / protein
                              :name (n4 / name :op1 "TLR-9"))))
            :location (s / synoviocyte
                  :source (c / cell-line
                        :name (n5 / name :op1 "CIA"))))
      :op2 (a3 / alleviate-01~e.24
            :ARG0~e.25 (n6 / neutralize-01~e.26
                  :ARG0 (a4 / and~e.38
                        :op1 (a5 / antibody~e.27
                              :ARG0-of (c2 / counter-01
                                    :ARG1 p))
                        :op2 (a6 / antibody~e.27
                              :ARG0-of (c3 / counter-01
                                    :ARG1 (p5 / protein
                                          :name (n7 / name :op1 "IL-1beta"~e.29,33,39))))
                        :op3 (a7 / antibody~e.27
                              :ARG0-of (c4 / counter-01
                                    :ARG1 (p6 / protein
                                          :name (n8 / name :op1 "IL-6"~e.29,33,39,41))))))
            :ARG1 i~e.1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17
            :degree (s2 / significant~e.23)))

# ::tok CX3CR1 may also be of importance as it confers a survival signal , which prevents cell death of monocytes and foam cells [52].
# ::alignments 0-1.1.1.1.1 1-1 2-1.1.2 3-1.1.1.r 3-1.1.r 5-1.1 7-1.2.1.1 8-1.2.1 10-1.2.1.2.1 11-1.2.1.2 14-1.2.1.2.2 15-1.2.1.2.2.1.1.2 16-1.2.1.2.2.1 17-1.2.1.2.2.1.1.r 18-1.2.1.2.2.1.1.1 19-1.2.1.2.2.1.1 20-1.2.1.2.2.1.1.2.1 21-1.2.1.2.2.1.1.2
# ::id bel_pmid_1923_8385_18998
(p / possible~e.1
      :domain~e.3 (i / important~e.5
            :domain~e.3 (p2 / protein
                  :name (n / name :op1 "CX3CR1"~e.0))
            :mod (a2 / also~e.2))
      :ARG1-of (c / cause-01
            :ARG0 (c2 / confer-02~e.8
                  :ARG0 p2~e.7
                  :ARG1 (s / signal~e.11
                        :mod (s2 / survive-01~e.10)
                        :ARG0-of (p3 / prevent-01~e.14
                              :ARG1 (d / die-01~e.16
                                    :ARG1~e.17 (a / and~e.19
                                          :op1 (m / monocyte~e.18)
                                          :op2 (c3 / cell~e.15,21
                                                :mod (f / foam~e.20))))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c4 / cite-01 :ARG2 "52"))))

# ::tok The same group demonstrated just recently that mast cells actively participate in the formation of aortic aneurysms by release of IL @-@ 6 and IFN ? , which induced apoptosis of smooth muscle cells and protease expression [111].
# ::alignments 1-1.1.1 2-1.1 3-1 4-1.3.1 5-1.3 6-1.2.r 7-1.2.1.1 8-1.2.1 9-1.2.3 9-1.2.3.r 10-1.2 11-1.2.2.r 13-1.2.2 16-1.2.2.1 17-1.2.4.r 18-1.2.4 19-1.2.4.1.r 20-1.2.4.1.1.1.1 22-1.2.4.1.1.1.1 23-1.2.4.1 24-1.2.4.1.2.1.1 28-1.2.4.1.3 29-1.2.4.1.3.1.1 30-1.2.4.1.3.1.1.1.r 31-1.2.4.1.3.1.1.1.2 32-1.2.4.1.3.1.1.1.1 33-1.2.4.1.3.1.1.1 34-1.2.4.1.3.1 35-1.2.4.1.3.1.2.1.1.1 36-1.2.4.1.3.1.2
# ::id bel_pmid_1923_8385_27652
(d / demonstrate-01~e.3
      :ARG0 (g / group~e.2
            :mod (s / same~e.1))
      :ARG1~e.6 (p / participate-01~e.10
            :ARG0 (c / cell~e.8
                  :mod (m / mast~e.7))
            :ARG1~e.11 (f / form-01~e.13
                  :ARG1 (a2 / aneurysm~e.16
                        :mod (a3 / aorta)))
            :manner~e.9 (a / active~e.9)
            :manner~e.17 (r / release-01~e.18
                  :ARG1~e.19 (a4 / and~e.23
                        :op1 (p2 / protein
                              :name (n / name :op1 "IL-6"~e.20,22))
                        :op2 (p3 / protein
                              :name (n2 / name :op1 "IFN-γ"~e.24))
                        :ARG0-of (i / induce-01~e.28
                              :ARG1 (a6 / and~e.34
                                    :op1 (a5 / apoptosis~e.29
                                          :mod~e.30 (c2 / cell~e.33
                                                :part-of (m2 / muscle~e.32)
                                                :mod (s2 / smooth~e.31)))
                                    :op2 (e / express-03~e.36
                                          :ARG2 (e2 / enzyme
                                                :name (n3 / name :op1 "protease"~e.35))))))))
      :time (r2 / recent~e.5
            :mod (j / just~e.4))
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "111"))))

# ::tok Several receptor tyrosine kinases exhibit stimulated activity upon peroxynitrite exposure , triggering downstream phosphotyrosine @-@ dependent signalling , as shown for the platelet @-@ derived growth factor receptor ( PDGFR ) and the receptor for brain @-@ derived neurotrophic factor ( TrkB ) in murine fibroblasts ( 24,25 ) , as well as the Epidermal Growth Factor Receptor ( EGFR ) in rat lung myofibroblasts ( 26 ) .
# ::alignments 0-1.1.2 1-1.1.1.1 2-1.1.3.1.2.1.1.1 3-1.1.1.3 4-1 5-1.2.1 6-1.2 8-1.3.1.1.1 9-1.3 11-1.1.3 12-1.1.3.1.1 15-1.1.3.1.2 16-1.1.3.1 19-1.1.3.2 19-1.1.3.3 20-1.1.3.2.1.r 22-1.1.3.2.1.1.1.1 24-1.1.3.2.1.1.1.1 24-1.1.3.2.1.2.1.1 25-1.1.3.2.1.1.1.2 26-1.1.3.2.1.1.1.3 26-1.1.3.2.1.2.1.3 27-1.1.3.2.1.1.1.4 27-1.1.3.2.1.2.1.4 31-1.1.3.2.1 33-1.1.3.2.1.1.1.4 33-1.1.3.2.1.2.1.4 35-1.1.3.2.1.2.1.1 37-1.1.3.2.1.1.1.1 37-1.1.3.2.1.2.1.1 43-1.1.3.2.2.r 44-1.1.3.2.2.1.1.1 45-1.1.3.2.2 52-1.1.3.3.1.r 54-1.1.3.3.1.1.1 55-1.1.3.3.1.1.2 56-1.1.3.3.1.1.3 57-1.1.3.3.1.1.4 62-1.1.3.3.2.1.1 63-1.1.3.3.2.1 66-1.1.3.3.3.1.1.1
# ::id bel_pmid_1927_3391_16158
(e2 / exhibit-01~e.4
      :ARG0 (p / protein
            :name (n3 / name
                  :op1 "receptor"~e.1
                  :op2 "tyrosine"
                  :op3 "kinase"~e.3)
            :quant (s2 / several~e.0)
            :ARG0-of (t / trigger-01~e.11
                  :ARG1 (s / signal-07~e.16
                        :location (d / downstream~e.12)
                        :ARG0-of (d2 / depend-01~e.15
                              :ARG1 (a2 / amino-acid
                                    :name (n5 / name :op1 "tyrosine"~e.2)
                                    :ARG3-of (p2 / phosphorylate-01))))
                  :ARG1-of (s6 / show-01~e.19
                        :topic~e.20 (a3 / and~e.31
                              :op1 (p3 / protein
                                    :name (n6 / name
                                          :op1 "platelet-derived"~e.22,24,37
                                          :op2 "growth"~e.25
                                          :op3 "factor"~e.26
                                          :op4 "receptor"~e.27,33))
                              :op2 (p4 / protein
                                    :name (n7 / name
                                          :op1 "brain-derived"~e.24,35,37
                                          :op2 "neutrophic"
                                          :op3 "factor"~e.26
                                          :op4 "receptor"~e.27,33)))
                        :location~e.43 (f / fibroblast~e.45
                              :part-of (a4 / animal
                                    :name (n8 / name :op1 "Muridae"~e.44)))
                        :ARG1-of (d3 / describe-01
                              :ARG0 (p6 / publication
                                    :ARG1-of (c / cite-01
                                          :ARG2 (a5 / and :op1 "24" :op2 "25")))))
                  :ARG1-of (s7 / show-01~e.19
                        :topic~e.52 (p5 / protein
                              :name (n9 / name
                                    :op1 "Epidermal"~e.54
                                    :op2 "Growth"~e.55
                                    :op3 "Factor"~e.56
                                    :op4 "Receptor"~e.57))
                        :location (m / myofibroblast
                              :source (l / lung~e.63
                                    :part-of (r / rat~e.62)))
                        :ARG1-of (d4 / describe-01
                              :ARG0 (p7 / publication
                                    :ARG1-of (c2 / cite-01 :ARG2 "26"~e.66))))))
      :ARG1 (a / act-02~e.6
            :ARG1-of (s3 / stimulate-01~e.5))
      :condition (e3 / expose-01~e.9
            :ARG2 (s4 / small-molecule
                  :name (n4 / name :op1 "peroxynitrite"~e.8))))

# ::tok Peroxynitrite @-@ mediated JNK activation has been associated with apoptotic cell death in murine alveolar C10 cells , in which JNK was activated upon the oxidation of the death receptor Fas .
# ::alignments 0-1.1.2.1.1.1 2-1.1.2 3-1.1.1.1.1 4-1.1 7-1 8-1.2.r 9-1.2.2 10-1.2.1 11-1.2 12-1.3.r 13-1.3.3.1.1 14-1.3.2 15-1.3.1.1 16-1.3 20-1.3.4.1 22-1.3.4 28-1.3.4.2.1.1.1 29-1.3.4.2.1.1.2 30-1.3.4.2.1.1.3
# ::id bel_pmid_1927_3391_16160
(a / associate-01~e.7
      :ARG1 (a2 / activate-01~e.4
            :ARG1 (e / enzyme
                  :name (n / name :op1 "JNK"~e.3))
            :ARG1-of (m / mediate-01~e.2
                  :ARG0 (s / small-molecule
                        :name (n2 / name :op1 "peroxynitrite"~e.0))))
      :ARG2~e.8 (d / die-01~e.11
            :ARG1 (c / cell~e.10)
            :mod (a3 / apoptosis~e.9))
      :location~e.12 (c2 / cell-line~e.16
            :name (n3 / name :op1 "C10"~e.15)
            :mod (a4 / alveolus~e.14)
            :part-of (a5 / animal
                  :name (n4 / name :op1 "Muridae"~e.13))
            :location-of (a6 / activate-01~e.22
                  :ARG1 e~e.20
                  :condition (o / oxidize-01
                        :ARG1 (p / protein
                              :name (n6 / name
                                    :op1 "death"~e.28
                                    :op2 "receptor"~e.29
                                    :op3 "Fas"~e.30))))))

# ::tok Nomiyama et al , who reported that peroxynitrite inhibited insulin @-@ stimulated glucose uptake in preadipocyte @-@ derived 3T3 @-@ L1 cells by reducing insulin receptor substrate @-@ 1 ( IRS @-@ 1 ) protein levels and associated PI3K activity , upstream of Akt @/@ PKB ( 122 ) .
# ::alignments 0-1.1.1.1.1 1-1.1 5-1 6-1.2.r 7-1.2.1.1.1 8-1.2 9-1.2.2.2.1.1.1 11-1.2.2.2 12-1.2.2.1.1.1 13-1.2.2 14-1.2.3.r 15-1.2.3.2.1 17-1.2.3.2 18-1.2.3.1.1 20-1.2.3.1.1 21-1.2.3 22-1.2.4.r 23-1.2.4 24-1.2.4.2.1.1.1.1 25-1.2.4.2.1.1.1.2 26-1.2.4.2.1.1.1.3 28-1.2.4.2.1.1.1.3 32-1.2.4.2.1.1.1.3 34-1.2.2.2.1 34-1.2.4.2.1.1 35-1.2.4.2.1 36-1.2.4.2 37-1.2.4.2.2.2 38-1.2.4.2.2.1.1.1 39-1.2.4.2.2 41-1.2.4.3.2 43-1.2.4.3.1.1.1 45-1.2.4.3.1.1.1 47-1.3.1.1.1
# ::id bel_pmid_1927_3391_16162
(r / report-01~e.5
      :ARG0 (a / and~e.1
            :op1 (p2 / person
                  :name (n2 / name :op1 "Nomiyama"~e.0))
            :op2 (p / person
                  :mod (o2 / other)))
      :ARG1~e.6 (i / inhibit-01~e.8
            :ARG0 (s / small-molecule
                  :name (n3 / name :op1 "peroxynitrite"~e.7))
            :ARG1 (u / uptake-00~e.13
                  :ARG1 (s2 / small-molecule
                        :name (n4 / name :op1 "glucose"~e.12))
                  :ARG1-of (s3 / stimulate-01~e.11
                        :ARG0 (p7 / protein~e.34
                              :name (n5 / name :op1 "insulin"~e.9))))
            :location~e.14 (c / cell-line~e.21
                  :name (n6 / name :op1 "3T3-L1"~e.18,20)
                  :ARG1-of (d / derive-01~e.17
                        :ARG2 (p3 / preadipocyte~e.15)))
            :manner~e.22 (r2 / reduce-01~e.23
                  :ARG0 s
                  :ARG1 (a2 / and~e.36
                        :op1 (l / level~e.35
                              :quant-of (p4 / protein~e.34
                                    :name (n7 / name
                                          :op1 "insulin"~e.24
                                          :op2 "receptor"~e.25
                                          :op3 "substrate-1"~e.26,28,32)))
                        :op2 (a3 / act-02~e.39
                              :ARG0 (e / enzyme
                                    :name (n8 / name :op1 "PI3K"~e.38))
                              :ARG1-of (a4 / associate-01~e.37)))
                  :location (r3 / relative-position
                        :op1 (p5 / pathway
                              :name (n9 / name :op1 "Akt/PKB"~e.43,45))
                        :direction (u2 / upstream~e.41))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "122"~e.47))))

# ::tok Administration of PTEN @-@ specific siRNA reversed PKB @/@ Akt inhibition and mitigated apoptosis in diabetic mouse aortas . These findings therefore suggest that hyperglycaemia may promote apoptosis in endothelial cells through PKB @/@ Akt downregulation , via a peroxynitrite @-@ mediated , LKB1 @-@ dependent PTEN activation ( 46 ) .
# ::alignments 0-1.1.1.1 2-1.1.1.1.1.2.1.1.1 4-1.1.1.1.1.2 5-1.1.1.1.1.1.1 6-1.1.1 7-1.1.1.2.1.1.1 9-1.1.1.2.1.1.1 10-1.1.1.2 11-1.1 12-1.1.2 13-1.1.2.2 15-1.1.3.1.1 16-1.1.3.1 17-1.1.3 19-1.2.1.1.2 20-1.2.1.1 20-1.2.1.1.1 20-1.2.1.1.1.r 21-1.2 22-1.2.1 23-1.2.1.2.r 24-1.2.1.2.1.1 25-1.2.1.2 26-1.2.1.2.1 27-1.2.1.2.1.2 28-1.2.1.2.1.3.r 29-1.2.1.2.1.3.1 30-1.2.1.2.1.3 32-1.2.1.2.1.4.1.1.1 34-1.2.1.2.1.4.1.1.1 35-1.2.1.2.1.4 39-1.2.1.2.1.4.2.2.1.1.1 41-1.2.1.2.1.4.2.2 43-1.2.1.2.1.4.2.3.1.1.1 45-1.2.1.2.1.4.2.3 46-1.2.1.2.1.4.2.1.1.1 47-1.2.1.2.1.4.2 49-1.2.2.1.1.1
# ::id bel_pmid_1927_3391_30174
(m / multi-sentence
      :snt1 (a2 / and~e.11
            :op1 (r / reverse-01~e.6
                  :ARG0 (a3 / administer-01~e.0
                        :ARG1 (r2 / rna
                              :name (n / name :op1 "siRNA"~e.5)
                              :mod (s / specific~e.4
                                    :topic (p / protein
                                          :name (n2 / name :op1 "PTEN"~e.2)))))
                  :ARG1 (i / inhibit-01~e.10
                        :ARG1 (p2 / pathway
                              :name (n3 / name :op1 "PKB/Akt"~e.7,9))))
            :op2 (m2 / mitigate-01~e.12
                  :ARG0 a3
                  :ARG1 (a4 / apoptosis~e.13))
            :location (a5 / aorta~e.17
                  :part-of (m3 / mouse~e.16
                        :mod (d2 / diabetes~e.15))))
      :snt2 (i2 / infer-01~e.21
            :ARG1 (s2 / suggest-01~e.22
                  :ARG0 (t2 / thing~e.20
                        :ARG1-of~e.20 (f / find-01~e.20)
                        :mod (t / this~e.19))
                  :ARG1~e.23 (p3 / possible~e.25
                        :domain (p4 / promote-01~e.26
                              :ARG0 (h / hyperglycaemia~e.24)
                              :ARG1 (a6 / apoptosis~e.27)
                              :location~e.28 (c / cell~e.30
                                    :mod (e / endothelium~e.29))
                              :manner (d3 / downregulate-01~e.35
                                    :ARG1 (p5 / pathway
                                          :name (n4 / name :op1 "PKB/Akt"~e.32,34))
                                    :manner (a7 / activate-01~e.47
                                          :ARG1 (p6 / protein
                                                :name (n5 / name :op1 "PTEN"~e.46))
                                          :ARG1-of (m4 / mediate-01~e.41
                                                :ARG0 (s3 / small-molecule
                                                      :name (n7 / name :op1 "peroxynitrite"~e.39)))
                                          :ARG0-of (d4 / depend-01~e.45
                                                :ARG1 (e2 / enzyme
                                                      :name (n6 / name :op1 "LKB1"~e.43))))))))
            :ARG1-of (d5 / describe-01
                  :ARG0 (p8 / publication
                        :ARG1-of (c2 / cite-01 :ARG2 "46"~e.49)))))

# ::tok activation of ERK depended on EGFR , Src tyrosine kinase and calcium calmodulin in PC12 cells ( 31 ) , while requiring ras @/@ Raf @-@ 1/MEK activation in human neutrophils ( 58 ) .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1.1 3-1.1 4-1.1.2.r 5-1.1.2.1.1.1 7-1.1.2.2.1.1 8-1.1.2.2 9-1.1.2.2 10-1.1.2 11-1.1.2.3.1.1 12-1.1.2.3.1.2 13-1.1.3.r 14-1.1.3.1.1 15-1.1.3 17-1.1.4.1.1.1 20-1 21-1.2 22-1.2.2.1.1.1 24-1.2.2.1.1.1 27-1.2.2 28-1.2.3.r 29-1.2.3.1 30-1.2.3 32-1.2.4.1.1.1
# ::id bel_pmid_1927_3391_36758
(c / contrast-01~e.20
      :ARG1 (d / depend-01~e.3
            :ARG0 (a / activate-01~e.0
                  :ARG1~e.1 (e / enzyme
                        :name (n / name :op1 "ERK"~e.2)))
            :ARG1~e.4 (a2 / and~e.10
                  :op1 (e2 / enzyme
                        :name (n2 / name :op1 "EGFR"~e.5))
                  :op2 (t / tyrosine-kinase~e.8,9
                        :name (n3 / name :op1 "Src"~e.7))
                  :op3 (p / protein
                        :name (n4 / name :op1 "calcium"~e.11 :op2 "calmodulin"~e.12)))
            :location~e.13 (c2 / cell-line~e.15
                  :name (n5 / name :op1 "PC12"~e.14))
            :ARG1-of (d2 / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c3 / cite-01 :ARG2 "31"~e.17))))
      :ARG2 (r / require-01~e.21
            :ARG0 a
            :ARG1 (a3 / activate-01~e.27
                  :ARG1 (p2 / pathway
                        :name (n6 / name :op1 "ras/Raf-1/MEK"~e.22,24)))
            :location~e.28 (n7 / neutrophil~e.30
                  :mod (h / human~e.29))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p4 / publication
                        :ARG1-of (c4 / cite-01 :ARG2 "58"~e.32)))))

# ::tok we reported in H9C2 cardiomyocytes that peroxynitritemediated activation of ERK , although dependent on Raf @-@ 1 and MEK , was not due to upstream activation of p21 ras ( 63 ) .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.3.3.1.1.1 7-1.2.3 9-1.2.3.1.1.1 11-1.2.4.r 12-1.2.4 13-1.2.4.2.r 14-1.2.4.2.1.1.1 16-1.2.4.2.1.1.1 17-1.2.4.2 18-1.2.4.2.2.1.1 21-1.2.1 21-1.2.1.r 22-1.2 23-1.2 24-1.2.2.2 25-1.2.2 25-1.2.3 30-1.3.1.1.1
# ::id bel_pmid_1927_3391_37186
(r / report-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (c3 / cause-01~e.22,23
            :polarity~e.21 "-"~e.21
            :ARG0 (a3 / activate-01~e.25
                  :ARG1 (p2 / protein
                        :name (n7 / name :op1 "p21ras"))
                  :location (u / upstream~e.24))
            :ARG1 (a / activate-01~e.7,25
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "ERK"~e.9))
                  :ARG1-of (m / mediate-01
                        :ARG0 (s / small-molecule
                              :name (n4 / name :op1 "peroxynitrite")))
                  :location (c / cardiomyocyte
                        :source (c2 / cell-line
                              :name (n6 / name :op1 "H9C2"~e.3))))
            :concession~e.11 (d / depend-01~e.12
                  :ARG0 a
                  :ARG1~e.13 (a2 / and~e.17
                        :op1 (p / protein
                              :name (n5 / name :op1 "Raf-1"~e.14,16))
                        :op2 (e2 / enzyme
                              :name (n2 / name :op1 "MEK"~e.18)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c4 / cite-01 :ARG2 "63"~e.30))))

# ::tok we found that IL6 effectively inhibited LIF signalling , repressing transcription of the LIF receptor gp190 , and strongly inducing axotrophin @/@ MARCH @-@ 7 , a novel E3 ubitquitin ligase that we discovered to be active in degradation of gp190 protein .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1 4-1.2.4 4-1.2.4.r 5-1.2 6-1.2.2.1.1.1 7-1.2.2 9-1.2.3.1 10-1.2.3.1.1 11-1.2.3.1.1.1.r 13-1.2.3.1.1.1.2 14-1.2.3.1.1.1 15-1.2.3.1.1.1.1.1 17-1.2.3 18-1.2.3.2.2 18-1.2.3.2.2.r 19-1.2.3.2 20-1.2.3.2.1.1.1 22-1.2.3.2.1.1.1 24-1.2.3.2.1.1.1 27-1.2.3.2.1.2.1.2 28-1.2.3.2.1.2.1.1.1 30-1.2.3.2.1.2.1.1.3 32-1.2.3.2.1.3.2.1 33-1.2.3.2.1.3.2 38-1.2.3.2.1.3.1 40-1.2.3.1.1.1.1.1 40-1.2.3.2.1.3.1.1.1.1 41-1.2.1 41-1.2.2.1 41-1.2.3.2.1 41-1.2.3.2.1.2.1 41-1.2.3.2.1.3.1.1
# ::id bel_pmid_1934_2884_19318
(f / find-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (i / inhibit-01~e.5
            :ARG0 (p / protein~e.41
                  :name (n / name :op1 "IL6"~e.3))
            :ARG1 (s / signal-07~e.7
                  :ARG0 (p2 / protein~e.41
                        :name (n2 / name :op1 "LIF"~e.6)))
            :manner (a2 / and~e.17
                  :op1 (r / repress-01~e.9
                        :ARG1 (t / transcribe-01~e.10
                              :ARG1~e.11 (r2 / receptor~e.14
                                    :name (n3 / name :op1 "gp190"~e.15,40)
                                    :mod p2~e.13)))
                  :op2 (i2 / induce-01~e.19
                        :ARG1 (p4 / protein~e.41
                              :name (n6 / name :op1 "axotrophin/MARCH-7"~e.20,22,24)
                              :ARG1-of (m / mean-01
                                    :ARG2 (p5 / protein~e.41
                                          :name (n7 / name
                                                :op1 "E3"~e.28
                                                :op2 "ubiquitin"
                                                :op3 "ligase"~e.30)
                                          :mod (n4 / novel~e.27)))
                              :ARG1-of (a3 / activate-01
                                    :topic (d / degrade-01~e.38
                                          :ARG1 (p3 / protein~e.41
                                                :name (n5 / name :op1 "gp190"~e.40)))
                                    :ARG1-of (d2 / discover-01~e.33
                                          :ARG0 (w2 / we~e.32))))
                        :manner~e.18 (s2 / strong~e.18)))
            :manner~e.4 (e / effective~e.4)))

# ::tok Unlike IL6 , LIF supported expression of Foxp3 , the Treg lineage transcription factor , and LIF opposed IL6 by suppressing IL @-@ 6 @-@ induced IL @-@ 17A protein release .
# ::alignments 0-1.1.3 0-1.1.3.1 0-1.1.3.1.r 3-1.1.1.1.1 4-1.1 5-1.1.2 7-1.1.2.1.1.1 10-1.1.2.1.2.1.1.1.1.1.1 11-1.1.2.1.2.1.1.1 12-1.1.2.1.2.1.1 13-1.1.2.1.2.1 16-1.1.1.1.1 17-1.2 19-1.2.3.r 20-1.2.3 21-1.2.2.1.1 23-1.2.2.1.1 25-1.2.3.1.2 26-1.2.3.1.1.1.1 28-1.2.3.1.1.1.1 29-1.1.1 29-1.1.2.1 29-1.2.2 29-1.2.3.1.1 30-1.2.3.1
# ::id bel_pmid_1934_2884_27058
(a / and
      :op1 (s / support-01~e.4
            :ARG0 (p2 / protein~e.29
                  :name (n3 / name :op1 "LIF"~e.3,16))
            :ARG1 (e / express-03~e.5
                  :ARG2 (p / protein~e.29
                        :name (n / name :op1 "Foxp3"~e.7)
                        :ARG1-of (m / mean-01
                              :ARG2 (f / factor~e.13
                                    :ARG0-of (t / transcribe-01~e.12
                                          :ARG1 (l / lineage~e.11
                                                :mod (c / cell
                                                      :name (n2 / name :op1 "Treg"~e.10))))))))
            :ARG1-of (r / resemble-01~e.0
                  :polarity~e.0 "-"~e.0
                  :ARG2 (p3 / protein~e.29
                        :name (n4 / name :op1 "IL-6"~e.21,23))))
      :op2 (o / oppose-01~e.17
            :ARG0 p2
            :ARG1 p3
            :manner~e.19 (s2 / suppress-01~e.20
                  :ARG1 (r2 / release-01~e.30
                        :ARG1 (p4 / protein~e.29
                              :name (n5 / name :op1 "IL-17A"~e.26,28))
                        :ARG1-of (i / induce-01~e.25
                              :ARG0 p3)))))

# ::tok Macrophages from PC Tg mice can express high level of human PON2 besides intrinsic mouse PON2 and PON3 ... PC Tg macrophages maintained significantly lower levels of ROS for at least 2 hours than macrophages from Wt mice ... Inflammatory factors such as TNF @-@ alpha and IL @-@ 6 are expressed at lower levels in PC Tg MPMs compared with Wt MPMs .
# ::alignments 0-1.1.1.2 1-1.1.1.2.1.r 2-1.1.1.2.1.1.1.1 4-1.1.1.2.1 5-1.1 6-1.1.1 7-1.1.1.1.1.2 8-1.1.1.1.1 9-1.1.1.1.1.1.r 10-1.1.1.1.1.1.2 11-1.1.1.1.1.1.1.1 11-1.1.1.1.2.1.1 13-1.1.1.1.2.2 14-1.1.1.1.2.3 15-1.1.1.1.1.1.1.1 15-1.1.1.1.2.1.1 16-1.1.1.1 17-1.1.1.1.3.1.1 19-1.2.1.1.1.1 19-1.3.2.2.1.1 21-1.2.1 22-1.2 23-1.2.2.2.2 24-1.2.2.2 24-1.2.2.2.1 24-1.2.2.2.1.r 25-1.2.2 26-1.2.2.1.r 27-1.2.2.1.1.1 28-1.2.3.r 29-1.2.3 30-1.2.3 31-1.2.3.1.1 32-1.2.3.1.2 33-1.2.2.2.3.r 34-1.2.2.2.3 35-1.2.2.2.3.1.r 37-1.2.2.2.3.1 39-1.3.1.1 40-1.3.1 43-1.3.1.2.1.1.1.1 45-1.3.1.2.1.1.1.1 46-1.3.1.2.1 47-1.3.1.2.1.2.1.1 49-1.3.1.2.1.2.1.1 51-1.3 52-1.2.3 52-1.3.3.r 53-1.3.3.1 53-1.3.3.1.1 53-1.3.3.1.1.r 54-1.3.3 55-1.3.2.r 56-1.3.2.2.1.1 59-1.3.3.1.2.r
# ::id bel_pmid_1935_9600_29984
(m2 / multi-sentence
      :snt1 (p / possible~e.5
            :domain (e / express-03~e.6
                  :ARG2 (a3 / and~e.16
                        :op1 (l / level~e.8
                              :quant-of~e.9 (p2 / protein
                                    :name (n2 / name :op1 "PON2"~e.11,15)
                                    :mod (h3 / human~e.10))
                              :mod (h2 / high~e.7))
                        :op2 (p3 / protein
                              :name (n3 / name :op1 "PON2"~e.11,15)
                              :mod (i / intrinsic~e.13)
                              :mod (m7 / mouse~e.14))
                        :op3 (p4 / protein
                              :name (n4 / name :op1 "PON3"~e.17)
                              :mod i
                              :mod m7))
                  :ARG3 (m3 / macrophage~e.0
                        :source~e.1 (m4 / mouse~e.4
                              :mod (m6 / molecular-physical-entity
                                    :name (n / name :op1 "PC"~e.2)
                                    :mod (t2 / transgenic))))))
      :snt2 (m8 / maintain-01~e.22
            :ARG0 (m9 / macrophage~e.21
                  :mod (m12 / molecular-physical-entity
                        :name (n5 / name :op1 "PC"~e.19)
                        :mod (t3 / transgenic)))
            :ARG1 (l3 / level~e.25
                  :quant-of~e.26 (s / small-molecule
                        :name (n6 / name :op1 "ROS"~e.27))
                  :mod (l2 / low~e.24
                        :degree~e.24 (m / more~e.24)
                        :mod (s2 / significant~e.23)
                        :compared-to~e.33 (m5 / macrophage~e.34
                              :source~e.35 (m10 / mouse~e.37
                                    :mod (w / wild-type)))))
            :duration~e.28 (a / at-least~e.29,30,52
                  :op1 (t / temporal-quantity
                        :quant "2"~e.31
                        :unit (h / hour~e.32))))
      :snt3 (e2 / express-03~e.51
            :ARG2 (f / factor~e.40
                  :ARG0-of (i2 / inflame-01~e.39)
                  :ARG1-of (e3 / exemplify-01
                        :ARG0 (a4 / and~e.46
                              :op1 (p5 / protein
                                    :name (n7 / name :op1 "TNF-alpha"~e.43,45))
                              :op2 (p6 / protein
                                    :name (n8 / name :op1 "IL-6"~e.47,49)
                                    :mod f))))
            :ARG3~e.55 (c / cell-line
                  :name (n9 / name :op1 "MPM")
                  :mod (m13 / molecular-physical-entity
                        :name (n10 / name :op1 "PC"~e.19,56)
                        :mod (t4 / transgenic)))
            :degree~e.52 (l4 / level~e.54
                  :mod (l5 / low~e.53
                        :degree~e.53 (m11 / more~e.53)
                        :compared-to~e.59 (c2 / cell-line
                              :name (n11 / name :op1 "MPM")
                              :mod (w2 / wild-type))))))

# ::tok ATP @-@ mediated ADAM17 activation was also suppressed by the EGFR kinase inhibitor AG1478 and , to a lesser extent , by preincubation with ?-EGFR antibody ( Fig . 6B ) , indicating a role for EGFR in ADAM17 activation .
# ::alignments 0-1.1.2.2.1.1.1 2-1.1.2.2 3-1.1.2.1.1.1 4-1.1.2 6-1.1.3 7-1.1 7-1.2 8-1.1.1.r 10-1.1.1.2.1.1.1 11-1.1.1.2.1 12-1.1.1 12-1.1.1.2 12-1.1.1.2.r 13-1.1.1.1.1 14-1 18-1.2.1.2 18-1.2.3 18-1.2.3.1 18-1.2.3.1.r 25-1.2.1.1 29-1.4.1.1 32-1.3 34-1.3.1 35-1.3.1.1.r 36-1.3.1.1 37-1.3.1.2.r 38-1.3.1.2.1 39-1.3.1.2
# ::id bel_pmid_1938_6603_36754
(a6 / and~e.14
      :op1 (s / suppress-01~e.7
            :ARG0~e.8 (s3 / small-molecule~e.12
                  :name (n4 / name :op1 "AG1478"~e.13)
                  :ARG0-of~e.12 (i3 / inhibit-01~e.12
                        :ARG1 (k / kinase~e.11
                              :name (n5 / name :op1 "EGFR"~e.10))))
            :ARG1 (a / activate-01~e.4
                  :ARG1 (p / protein
                        :name (n2 / name :op1 "ADAM17"~e.3))
                  :ARG1-of (m / mediate-01~e.2
                        :ARG0 (s2 / small-molecule
                              :name (n3 / name :op1 "ATP"~e.0))))
            :mod (a2 / also~e.6))
      :op2 (s4 / suppress-01~e.7
            :ARG0 (p2 / preincubate-00
                  :ARG2 (a4 / antibody~e.25
                        :ARG0-of (c / counter-01
                              :ARG1 k))
                  :degree (l / less~e.18
                        :mod (m2 / more)))
            :ARG1 a
            :degree (l2 / less~e.18
                  :degree~e.18 (m3 / more~e.18)))
      :ARG0-of (i5 / indicate-01~e.32
            :ARG1 (r / role~e.34
                  :mod~e.35 k~e.36
                  :prep-in~e.37 (a5 / activate-01~e.39
                        :ARG1 p~e.38)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6B"~e.29)))

# ::tok addition of AG1478 also suppressed ATP @-@ mediated phosphorylation of ERK1 @/@ 2 and I-?B ? ( Fig . 4A ) , indicating the involvement of EGFR activation in these signaling events .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1 3-1.3 4-1 5-1.2.2.1.1.1 7-1.2.2 8-1.2 9-1.2.1.r 10-1.2.1.1.1.1 12-1.2.1.1.1.1 13-1.2.1 19-1.4.1.1 22-1.5 24-1.5.1 25-1.5.1.1.r 26-1.5.1.1.1.1.1 27-1.5.1.1 28-1.5.1.2.r 29-1.5.1.2.1 30-1.5.1.2.2 31-1.5.1.2
# ::id bel_pmid_1938_6603_36760
(s / suppress-01~e.4
      :ARG0 (a / add-02~e.0
            :ARG1~e.1 (s2 / small-molecule
                  :name (n2 / name :op1 "AG1478"~e.2)))
      :ARG1 (p2 / phosphorylate-01~e.8
            :ARG1~e.9 (a3 / and~e.13
                  :op1 (e3 / enzyme
                        :name (n3 / name :op1 "ERK1/2"~e.10,12))
                  :op2 (p4 / protein
                        :name (n4 / name :op1 "I-κBα")))
            :ARG1-of (m / mediate-01~e.7
                  :ARG0 (s3 / small-molecule
                        :name (n5 / name :op1 "ATP"~e.5))))
      :mod (a2 / also~e.3)
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4A"~e.19))
      :ARG0-of (i / indicate-01~e.22
            :ARG1 (i2 / involve-01~e.24
                  :ARG1~e.25 (a4 / activate-01~e.27
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "EGFR"~e.26)))
                  :ARG2~e.28 (e2 / event~e.31
                        :mod (t / this~e.29)
                        :mod (s4 / signal-07~e.30)))))

# ::tok As shown in Fig. 6A , both ATP and ?-ASGM1 indeed resulted in enhanced ADAM17 activity , measured by increased cleavage of a fluorogenic ADAM17 substrate , and this was attenuated after siRNA silencing of DUOX1 ( Fig . 6A
# ::alignments 0-1.2.2.r 1-1.3 4-1.3.1.1 7-1.1.1.1.1.1 8-1.1.1 10-1.1.3 11-1.1 12-1.1.2.r 13-1.1.2.2 14-1.1.2.1.1.1 15-1.1.2 17-1.1.2.3 19-1.1.2.3.1.2 23-1.1.2.3.1.1.2 24-1.1.2.3.1.1.1 25-1.1.2.3.1.1 27-1 30-1.2 31-1.2.2 32-1.2.2.1.1.1.1 33-1.2.2.1 34-1.2.2.1.2.r 35-1.2.2.1.2.1.1 39-1.3.1.1
# ::id bel_pmid_1938_6603_38056
(a / and~e.27
      :op1 (r / result-01~e.11
            :ARG1 (a2 / and~e.8
                  :op1 (s2 / small-molecule
                        :name (n / name :op1 "ATP"~e.7))
                  :op2 (a3 / antibody
                        :ARG0-of (c / counter-01
                              :ARG1 (p / protein
                                    :name (n2 / name :op1 "ASGM1")))))
            :ARG2~e.12 (a4 / act-02~e.15
                  :ARG0 (p2 / protein
                        :name (n3 / name :op1 "ADAM17"~e.14))
                  :ARG1-of (e / enhance-01~e.13)
                  :ARG1-of (m / measure-01~e.17
                        :ARG2 (c2 / cleave-01
                              :ARG1 (s3 / substrate~e.25
                                    :mod p2~e.24
                                    :mod (f2 / fluorogenic~e.23))
                              :ARG1-of (i / increase-01~e.19))))
            :mod (i2 / indeed~e.10))
      :op2 (a5 / attenuate-01~e.30
            :ARG1 a4
            :time~e.0 (a6 / after~e.31
                  :op1 (s4 / silence-01~e.33
                        :ARG0 (r2 / rna
                              :name (n5 / name :op1 "siRNA"~e.32))
                        :ARG1~e.34 (e2 / enzyme
                              :name (n4 / name :op1 "DUOX1"~e.35)))))
      :ARG1-of (s / show-01~e.1
            :ARG0 (f / figure :mod "6A"~e.4,39)))

# ::tok Silencing of DUOX1 attenuated the ATP @- and ?-ASGM1 @-@ induced TGF-? production observed in the presence of EGFR mAb ( Fig . 5B ) , indicating the involvement of DUOX1 activation in ATP @-@ induced TGF-? production and EGFR activation .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1 3-1 5-1.2.2.1.1.1.1 7-1.2.2.1 10-1.2.2 12-1.2 13-1.2.3 14-1.2.3.1.r 16-1.2.3.1 18-1.2.3.1.1.2.1.1.1 23-1.3.1.1 26-1.4 28-1.4.1 29-1.4.1.1.r 30-1.4.1.1.1 31-1.4.1.1 32-1.4.1.2.r 33-1.4.1.2.1.2.1 35-1.4.1.2.1.2 37-1.4.1.2.1 38-1.4.1.2 39-1.4.1.2.2.1 40-1.4.1.2.2
# ::id bel_pmid_1938_6603_38058
(a / attenuate-01~e.3
      :ARG0 (s / silence-01~e.0
            :ARG1~e.1 (e2 / enzyme
                  :name (n2 / name :op1 "DUOX1"~e.2)))
      :ARG1 (p2 / produce-01~e.12
            :ARG1 (p3 / protein
                  :name (n4 / name :op1 "TGF-α"))
            :ARG1-of (i / induce-01~e.10
                  :ARG0 (a7 / and~e.7
                        :op1 (s2 / small-molecule
                              :name (n5 / name :op1 "ATP"~e.5))
                        :op2 (a2 / antibody
                              :ARG0-of (c / counter-01
                                    :ARG1 (p / protein
                                          :name (n3 / name :op1 "ASGM1"))))))
            :ARG1-of (o / observe-01~e.13
                  :condition~e.14 (p4 / presence~e.16
                        :poss (a3 / antibody
                              :mod (m / monoclonal)
                              :ARG0-of (c2 / counter-01
                                    :ARG1 (e / enzyme
                                          :name (n / name :op1 "EGFR"~e.18)))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "5B"~e.23))
      :ARG0-of (i2 / indicate-01~e.26
            :ARG1 (i3 / involve-01~e.28
                  :ARG1~e.29 (a4 / activate-01~e.31
                        :ARG1 e2~e.30)
                  :ARG2~e.32 (a5 / and~e.38
                        :op1 (p5 / produce-01~e.37
                              :ARG1 p3
                              :ARG1-of (i4 / induce-01~e.35
                                    :ARG0 s2~e.33))
                        :op2 (a6 / activate-01~e.40
                              :ARG1 e~e.39)))))

# ::tok As shown in Fig. 1A , the HO @-@ 1 level in Bach1-/- mouse lungs was significantly higher than that of WT mice even before hyperoxic exposure , and the time @-@ dependent increase in HO @-@ 1 expression in Bach1-/- mouse lungs was much greater than that ofWT mice during hyperoxic exposure .
# ::alignments 0-1.2.1.4.r 1-1 4-1.1.1 7-1.2.2.3.1.1.1.1 9-1.2.2.3.1.1.1.1 10-1.2.1.3 13-1.2.1.3.1.2.1 14-1.2.1.3.1.2 15-1.2.1.3.r 16-1.2.1.2 17-1.2.1 17-1.2.1.1 17-1.2.1.1.r 18-1.2.1.5.r 21-1.2.1.5.1 22-1.2.1.5 23-1.2.1.4.2 24-1.2.1.4 26-1.2.1.4.1 28-1.2 30-1.2.1.4.r 30-1.2.2.2.2.1 32-1.2.2.2.2 33-1.2.2.2 33-1.2.2.3 35-1.2.1.3.1.1.1 35-1.2.2.3.1.1.1.1 37-1.2.1.3.1.1.1 37-1.2.2.3.1.1.1.1 38-1.2.1.3.1.2.1.1 38-1.2.2.2.1 38-1.2.2.3.1 41-1.2.1.3.1.2.1 42-1.2.1.3.1.2 43-1.2.2.2.r 44-1.2.2.1.1 45-1.2.2 45-1.2.2.1 45-1.2.2.1.r 46-1.2.2.3.r 49-1.2.1.3.1.2.1 50-1.2.2.3.2.r 52-1.2.2.3.2
# ::id bel_pmid_1943_9223_25342
(s / show-01~e.1
      :ARG0 (f / figure :mod "1A"~e.4)
      :ARG1 (a / and~e.28
            :op1 (h / high~e.17
                  :degree~e.17 (m / more~e.17)
                  :mod (s2 / significant~e.16)
                  :domain~e.15 (l / level~e.10
                        :quant-of (p / protein
                              :name (n / name :op1 "HO-1"~e.35,37)
                              :location (l2 / lung~e.14,42
                                    :part-of (m3 / mouse~e.13,41,49
                                          :ARG3-of (e / express-03~e.38
                                                :ARG1 (g3 / gene
                                                      :name (n2 / name :op1 "Bach1")
                                                      :ARG2-of (m4 / mutate-01 :mod "-/-")))))))
                  :time~e.0,30 (b / before~e.24
                        :op1 (e3 / expose-01~e.26
                              :ARG2 (h2 / hyperoxia))
                        :mod (e2 / even~e.23))
                  :compared-to~e.18 (m5 / mouse~e.22
                        :mod (w / wild-type~e.21)))
            :op2 (g / great~e.45
                  :degree~e.45 (m2 / more~e.45
                        :degree (m6 / much~e.44))
                  :domain~e.43 (i / increase-01~e.33
                        :ARG1 (e4 / express-03~e.38
                              :ARG1 p
                              :ARG3 l2)
                        :ARG0-of (d / depend-01~e.32
                              :ARG1 (t / time~e.30)))
                  :compared-to~e.46 (i2 / increase-01~e.33
                        :ARG1 (e5 / express-03~e.38
                              :ARG2 (p2 / protein
                                    :name (n3 / name :op1 "HO-1"~e.7,9,35,37))
                              :ARG3 m5)
                        :time~e.50 e3~e.52))))

# ::tok unexpectedly , however , the levels of IL @-@ 6 in bronchoalveolar lavage ( BAL ) fluid from Bach1(-/-) mice were significantly higher than those of WT mice . ..... In addition , a chromatin immunoprecipitation analysis revealed the binding of Bach1 to the IL @-@ 6 promoter and its detachment after oxidative stress .
# ::alignments 0-1.2.1.4.1 2-1.2 5-1.2.1.3 5-1.2.1.5 6-1.2.1.3.1.r 7-1.2.1.3.1.1.1 9-1.2.1.3.1.1.1 10-1.2.1.3.2.r 11-1.2.1.3.2.1.1 12-1.2.1.3.2.1.2 16-1.2.1.3.2.1.3 17-1.2.1.3.2.2.r 19-1.2.1.3.2.2 20-1.2.1.3.r 21-1.2.1.2 22-1.2.1 22-1.2.1.1 22-1.2.1.1.r 23-1.2.1.5.r 25-1.2.1.5.1.r 26-1.2.1.5.1.1 27-1.2.1.5.1 30-1.1.1.2 31-1.1 31-1.1.1.2 34-1.1.1.1.1.1 36-1.1.1.1 37-1.1.1 39-1.1.1.2.1 41-1.1.1.2.1.1.1.1 41-1.2.1.3.2.2.1.1.1.1 42-1.1.1.2.1.2.r 44-1.1.1.2.1.2.1.1.1.1 46-1.1.1.2.1.2.1.1.1.1 48-1.1.1.2 50-1.1.1.2.2 51-1.1.1.2.2.3 53-1.1.1.2.2.3.1
# ::id bel_pmid_1943_9223_32684
(m2 / multi-sentence
      :snt2 (a / and~e.31
            :op2 (r / reveal-01~e.37
                  :ARG0 (a2 / analysis~e.36
                        :name (n4 / name :op1 "chromatin"~e.34 :op2 "immunprecipitation"))
                  :ARG1 (a3 / and~e.30,31,48
                        :op1 (b / bind-01~e.39
                              :ARG1 (g2 / gene
                                    :name (n6 / name :op1 "Bach1"~e.41))
                              :ARG2~e.42 (m7 / molecular-physical-entity
                                    :ARG0-of (p2 / promote-01
                                          :ARG1 (p3 / protein
                                                :name (n5 / name :op1 "IL-6"~e.44,46)))))
                        :op2 (d / detach-01~e.50
                              :ARG1 g2
                              :ARG2 m7
                              :time (a4 / after~e.51
                                    :op1 (s2 / stress~e.53
                                          :mod (o / oxidize-01)))))))
      :snt1 (c / contrast-01~e.2
            :ARG2 (h / high~e.22
                  :degree~e.22 (m / more~e.22)
                  :mod (s / significant~e.21)
                  :domain~e.20 (l / level~e.5
                        :quant-of~e.6 (p / protein
                              :name (n / name :op1 "IL-6"~e.7,9))
                        :location~e.10 (m3 / molecular-physical-entity
                              :name (n2 / name
                                    :op1 "bronchoalveolar"~e.11
                                    :op2 "lavage"~e.12
                                    :op3 "fluid"~e.16)
                              :source~e.17 (m4 / mouse~e.19
                                    :ARG3-of (e / express-03
                                          :ARG1 (g / gene
                                                :name (n3 / name :op1 "Bach1"~e.41)
                                                :ARG2-of (m5 / mutate-01 :mod "-/-"))))))
                  :ARG1-of (e2 / expect-01 :polarity "-"~e.0)
                  :compared-to~e.23 (l2 / level~e.5
                        :mod~e.25 (m6 / mouse~e.27
                              :mod (w / wild-type~e.26))
                        :quant-of p))))

# ::tok Inhibition of COX2 markedly reduced both IL @-@ 1 beta and IL @-@ 6 release .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1 3-1.3 3-1.3.r 4-1 6-1.2.1.1.1.1 6-1.2.1.2.1.1 8-1.2.1.1.1.1 9-1.2.1.1.1.2 10-1.2.1 11-1.2.1.2.1.1 13-1.2.1.2.1.1 14-1.2
# ::id bel_pmid_1958_0863_2728
(r / reduce-01~e.4
      :ARG0 (i / inhibit-01~e.0
            :ARG1~e.1 (e / enzyme
                  :name (n / name :op1 "COX2"~e.2)))
      :ARG1 (r2 / release-01~e.14
            :ARG1 (a / and~e.10
                  :op1 (p / protein
                        :name (n2 / name :op1 "IL-1"~e.6,8 :op2 "beta"~e.9))
                  :op2 (p2 / protein
                        :name (n3 / name :op1 "IL-6"~e.6,11,13))))
      :manner~e.3 (m / marked~e.3))

# ::tok The addition of IL @-@ 1b ( 100 pg/ml ) alone significantly increased the levels of IL @-@ 6 , and approximately to the same level as 160 lg @/@ cm2 silica .
# ::alignments 1-1.1 1-1.2.2.1.1.1 2-1.1.1.r 3-1.1.1.1.1 5-1.1.1.1.1 7-1.1.1.2.1 10-1.1.1.3 11-1.3 12-1 12-1.2.2.1.1 14-1.2 14-1.2.2.1 16-1.2.1.1.1 18-1.2.1.1.1 21-1.2.2 25-1.2 26-1.2.2.1.1.1.1.r 27-1.2.2.1.1.1.1.1.1 31-1.2.2.1.1.1.1
# ::id bel_pmid_1958_0863_38416
(i / increase-01~e.12
      :ARG0 (a / add-02~e.1
            :ARG1~e.2 (p / protein
                  :name (n / name :op1 "IL-1b"~e.3,5)
                  :quant (c / concentration-quantity
                        :quant "100"~e.7
                        :unit (p2 / picogram-per-milliliter))
                  :mod (a2 / alone~e.10)))
      :ARG1 (l / level~e.14,25
            :quant-of (p3 / protein
                  :name (n2 / name :op1 "IL-6"~e.16,18))
            :ARG0-of (a4 / approximate-01~e.21
                  :ARG1 (l2 / level~e.14
                        :ARG4-of (i2 / increase-01~e.12
                              :ARG0 (a3 / add-02~e.1
                                    :ARG1~e.26 (s2 / silica~e.31
                                          :quant (c2 / concentration-quantity
                                                :quant "160"~e.27
                                                :unit (m / microgram-per-square-centimeter))))))))
      :degree (s / significant~e.11))

# ::tok In TNBS colitis , no differences were found in interleukin ( IL )-18 and tumor necrosis factor ( TNF )-alpha expression between IRF4 knockout and wild @-@ type mice . However , significant differences were detected in IL @-@ 6 and IL @-@ 17 production .
# ::alignments 0-1.1.1.4.r 1-1.1.1.4.1.1 2-1.1.1.4.1.2 4-1.1.1.1 4-1.1.1.1.r 5-1.1.1 7-1.1 8-1.1.1.4.r 9-1.1.1.2.1.1.1.1 11-1.2.1.1.1.1.1.1.1 11-1.2.1.1.1.1.2.1.1 13-1.1.1.3.1 14-1.1.1.3.1 15-1.1.1.3.1 16-1.1.1.3.1 17-1.1.1.3.1 18-1.1.1.3.1 19-1.1.1.3.1 20-1.1.1.3.1 21-1.1.1.3.1 22-1.1.1.3.1 23-1.1.1.3.1 24-1.1.1.3.1 25-1.1.1.3.2.1 27-1.1.1.3.2.1 28-1.1.1.2.2 28-1.1.1.3.2 30-1.2 32-1.2.1.1.2 33-1.2.1.1 35-1.2.1 36-1.1.1.4.r 37-1.2.1.1.1.1.1.1.1 37-1.2.1.1.1.1.2.1.1 39-1.2.1.1.1.1.1.1.1 40-1.2.1.1.1.1 41-1.2.1.1.1.1.1.1.1 41-1.2.1.1.1.1.2.1.1 43-1.2.1.1.1.1.2.1.1 44-1.2.1.1.1
# ::id bel_pmid_1969_3649_9324
(m / multi-sentence
      :snt1 (f / find-01~e.7
            :ARG1 (d5 / differ-02~e.5
                  :polarity~e.4 "-"~e.4
                  :ARG1 (e / express-03
                        :ARG2 (a / and
                              :op1 (p / protein
                                    :name (n / name :op1 "interleukin"~e.9 :op2 "18"))
                              :op2 (p2 / protein
                                    :name (n2 / name
                                          :op1 "tumor"
                                          :op2 "necrosis"
                                          :op3 "factor"
                                          :op4 "alpha")))
                        :ARG3 (m2 / mouse~e.28
                              :ARG3-of (e2 / express-03
                                    :ARG1 (g / gene
                                          :name (n3 / name :op1 "IRF4")
                                          :ARG1-of (k / knockout-00)))))
                  :ARG2 (e3 / express-03
                        :ARG1 e~e.13,14,15,16,17,18,19,20,21,22,23,24
                        :ARG3 (m4 / mouse~e.28
                              :mod (w / wild-type~e.25,27)))
                  :prep-in~e.0,8,36 (d2 / disease
                        :name (n4 / name :op1 "TNBS"~e.1 :op2 "colitis"~e.2))))
      :snt2 (h / have-concession-91~e.30
            :ARG2 (d3 / detect-01~e.35
                  :ARG1 (d4 / differ-02~e.33
                        :ARG1 (p3 / produce-01~e.44
                              :ARG1 (a3 / and~e.40
                                    :op1 (p4 / protein
                                          :name (n5 / name :op1 "IL-6"~e.11,37,39,41))
                                    :op2 (p5 / protein
                                          :name (n6 / name :op1 "IL-17"~e.11,37,41,43))))
                        :mod (s / significant~e.32)))))

# ::tok More importantly , persistent activation of IL @-@ 6 downstream Stat3 in AT II epithelial cellsdirec tly induced lung inflammation and bronchioalveolar adenocarcinoma ( 22 ) .
# ::alignments 0-1.4.1 1-1.4 3-1.1.2 4-1.1 5-1.1.1.r 6-1.1.1.1.1 8-1.1.1.1.1 9-1.1.1.2.2 10-1.1.1.2.1.1.1 11-1.1.3.r 12-1.1.3.1.1 13-1.1.3.1.2 14-1.1.3.2 17-1 18-1.2.1.1 20-1.2 21-1.2.2.1 22-1.2.2 24-1.5.1.1.1
# ::id bel_pmid_1970_6765_28338
(i / induce-01~e.17
      :ARG0 (a / activate-01~e.4
            :ARG1~e.5 (p / protein
                  :name (n / name :op1 "IL-6"~e.6,8)
                  :location (r / relative-position
                        :op1 (p2 / protein
                              :name (n2 / name :op1 "Stat3"~e.10))
                        :direction (d4 / downstream~e.9)))
            :ARG1-of (p3 / persist-01~e.3)
            :location~e.11 (c / cell-line
                  :name (n3 / name :op1 "AT"~e.12 :op2 "II"~e.13)
                  :mod (e / epithelium~e.14)))
      :ARG1 (a2 / and~e.20
            :op1 (i2 / inflame-01
                  :ARG1 (l / lung~e.18))
            :op2 (a3 / adenocarcinoma~e.22
                  :mod (b / bronchioalveolar~e.21)))
      :manner (d2 / direct)
      :mod (i3 / important~e.1
            :degree (m / more~e.0))
      :ARG1-of (d3 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01 :ARG2 "22"~e.24))))

# ::tok As shown in Fig. 3A , there was a steady increase of BrdUrd pulse @-@ labeled AT II epithelial cells in the doxycycline @-@ treated bitransgenic mice compared with untreated littermates . The increase of MMP12 @-@ induced cell proliferation wastime dependent .
# ::alignments 1-1.1.3 4-1.1.3.1.1 9-1.1.2 10-1.1 11-1.1.1.r 12-1.1.1.3.1.1.1.1 13-1.1.1.3.1 15-1.1.1.3 16-1.1.1.1.1 17-1.1.1.1.2 18-1.1.1.2 19-1.1.1 20-1.1.4.r 22-1.1.4.2.1.1.1 24-1.1.4.2 24-1.1.5.1 25-1.1.4.1 26-1.1.4 27-1.1.5.r 33-1.2.1 34-1.2.1.1.r 35-1.2.1.1.2.1.1.1 37-1.2.1.1.2 38-1.2.1.1.1 39-1.2.1.1 41-1.2
# ::id bel_pmid_1970_6765_29240
(m / multi-sentence
      :snt1 (i / increase-01~e.10
            :ARG1~e.11 (c / cell~e.19
                  :name (n2 / name :op1 "AT"~e.16 :op2 "II"~e.17)
                  :mod (e / epithelium~e.18)
                  :ARG1-of (l / label-01~e.15
                        :ARG0 (p / pulse-01~e.13
                              :ARG1 (m2 / molecular-physical-entity
                                    :name (n / name :op1 "BrdUrd"~e.12)))))
            :ARG1-of (s / steady-01~e.9)
            :ARG1-of (s2 / show-01~e.1
                  :ARG0 (f / figure :mod "3A"~e.4))
            :location~e.20 (m3 / mouse~e.26
                  :mod (b / bitransgenic~e.25)
                  :ARG1-of (t2 / treat-04~e.24
                        :ARG2 (s3 / small-molecule
                              :name (n3 / name :op1 "doxycycline"~e.22))))
            :compared-to~e.27 (l2 / littermate
                  :ARG1-of (t3 / treat-04~e.24 :polarity "-")))
      :snt2 (d / depend-01~e.41
            :ARG0 (i2 / increase-01~e.33
                  :ARG1~e.34 (p2 / proliferate-01~e.39
                        :ARG0 (c2 / cell~e.38)
                        :ARG1-of (i3 / induce-01~e.37
                              :ARG0 (e2 / enzyme
                                    :name (n4 / name :op1 "MMP12"~e.35)))))
            :ARG1 (t4 / time)))

# ::tok MMP12 overexpression in lung epithelial cells , bitransgenic mice were treated with doxycycline for various time lengths . Histopathologic analyses revealed lung abnormalities in bitransgenic mice beginning at 6 weeks of doxycycline treatment . At this stage , marked inflammatory cell infiltration and emphysema were readily detectable ( Fig . 2A , +Dox 6W ) .
# ::alignments 0-1.1.1.1.1.1 3-1.1.1.2.2 4-1.1.1.2.1 5-1.1.1.2 7-1.1.2.1.1 8-1.1.2.1 10-1.1.2 12-1.1.2.2.1.1 14-1.1.2.3.2 15-1.1.2.3.1 15-1.2.2.3.1.2 16-1.1.2.3 19-1.2.1 20-1.2 21-1.2.2.1 22-1.2.2 23-1.2.2.2.r 24-1.2.2.2.1 25-1.2.2.2 26-1.2.2.3 28-1.2.2.3.1.2.1 29-1.2.2.3.1.2.2 31-1.1.2.2.1.1 31-1.2.2.3.1.1.1.1.1 32-1.1.2 32-1.2.2.3.1.1 35-1.3.4.1 36-1.3.4 38-1.3.1.1.2 39-1.3.1.1.1.1 40-1.3.1.1.1 41-1.3.1.1 42-1.3.1 43-1.3.1.2 45-1.3.3 45-1.3.3.r 50-1.3.5.1.1.1 52-1.3.5.1.2.1.1 53-1.3.5.1.2.1.2
# ::id bel_pmid_1970_6765_29242
(m / multi-sentence
      :snt1 (a / and
            :op1 (o / overexpress-00
                  :ARG2 (e / enzyme
                        :name (n / name :op1 "MMP12"~e.0))
                  :ARG3 (c / cell~e.5
                        :mod (e2 / epithelium~e.4)
                        :mod (l / lung~e.3)))
            :op2 (t2 / treat-04~e.10,32
                  :ARG1 (m2 / mouse~e.8
                        :mod (b / bitransgenic~e.7))
                  :ARG2 (s3 / small-molecule
                        :name (n2 / name :op1 "doxycycline"~e.12,31))
                  :duration (l2 / length~e.16
                        :mod (t4 / time~e.15)
                        :mod (v / various~e.14))))
      :snt2 (r / reveal-01~e.20
            :ARG0 (a2 / analyze-01~e.19
                  :mod (h / histopahtology))
            :ARG1 (a3 / abnormality~e.22
                  :mod (l3 / lung~e.21)
                  :location~e.23 (m3 / mouse~e.25
                        :mod (b2 / bitransgenic~e.24))
                  :ARG1-of (b3 / begin-01~e.26
                        :time (a4 / after
                              :op1 (t5 / treat-04~e.32
                                    :ARG2 (s2 / small-molecule
                                          :name (n3 / name :op1 "doxycycline"~e.31)))
                              :quant (t / temporal-quantity~e.15
                                    :quant "6"~e.28
                                    :unit (w / week~e.29))))))
      :snt3 (d / detect-01
            :ARG1 (a5 / and~e.42
                  :op1 (i / infiltrate-01~e.41
                        :ARG0 (c2 / cell~e.40
                              :ARG0-of (i2 / inflame-01~e.39))
                        :ARG1-of (m4 / mark-01~e.38))
                  :op2 (e3 / emphysema~e.43))
            :mod (p / possible)
            :manner~e.45 (r2 / ready~e.45)
            :time (s / stage~e.36
                  :mod (t7 / this~e.35))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a6 / and
                        :op1 (f / figure :mod "2A"~e.50)
                        :op2 (t3 / thing
                              :name (n4 / name :op1 "+Dox"~e.52 :op2 "6W"~e.53))))))

# ::tok FACS analysis showed a more than 5 @-@ fold decrease of Annexin V–labeled AT II epithelial cellsin 9 @-@ month doxycyclinetreated bitransgenic mice compared with untreated littermates ( 21.41 % versus 4.91 %).
# ::alignments 0-1.1.1.1.1 1-1.1 2-1 4-1.2.2 5-1.2.2 6-1.2.2.1.1 9-1.2 9-1.2.5 10-1.2.1.r 10-1.2.2.1 11-1.2.1.3.1.1.1 13-1.2.1.1.1 14-1.2.1.1.2 15-1.2.1.2 17-1.2.3.1 19-1.2.3 19-1.2.3.2 19-1.2.3.2.r 21-1.2.4.1 22-1.2.4 23-1.2.5.r 28-1.2.2.2.1.1 29-1.2.2.2.1 29-1.2.5.2 31-1.2.5.2.1
# ::id bel_pmid_1970_6765_29244
(s2 / show-01~e.2
      :ARG0 (a / analyze-01~e.1
            :mod (t4 / thing
                  :name (n3 / name :op1 "FACS"~e.0)))
      :ARG1 (d / decrease-01~e.9
            :ARG1~e.10 (c / cell-line
                  :name (n2 / name :op1 "AT"~e.13 :op2 "II"~e.14)
                  :mod (e / epithelium~e.15)
                  :ARG1-of (l / label-01
                        :ARG0 (p3 / protein
                              :name (n / name :op1 "Annexin"~e.11 :op2 "V"))))
            :ARG2 (m2 / more-than~e.4,5
                  :op1 (p4 / product-of~e.10 :value "5"~e.6)
                  :ARG1-of (m4 / mean-01
                        :ARG2 (p / percentage-entity~e.29 :value "21.41"~e.28)))
            :duration (t / temporal-quantity~e.19
                  :quant "9"~e.17
                  :unit~e.19 (m / month~e.19))
            :location (m3 / mouse~e.22
                  :mod (b / bitransgenic~e.21)
                  :ARG1-of (t2 / treat-04
                        :ARG2 (d2 / doxycycline)))
            :compared-to~e.23 (d3 / decrease-01~e.9
                  :ARG1 p3
                  :ARG2 (p2 / percentage-entity~e.29 :value "4.91"~e.31)
                  :location (l2 / littermate
                        :ARG1-of (t3 / treat-04 :polarity "-")))))

# ::tok Bronchioalveolar adenocarcinomas were observed in the lungs of bitransgenic mice after doxycycline treatment asearly as16 weeks ( Fig . 2A , +Dox 16W ) .
# ::alignments 0-1.1.1 1-1.1 3-1 4-1.2.r 6-1.2 7-1.2.1.r 8-1.2.1.1 9-1.2.1 10-1.3 11-1.3.1.1.1.1 12-1.3.1 15-1.3.1.2.2 19-1.4.1.1.1 21-1.4.1.2.1.1 22-1.4.1.2.1.2
# ::id bel_pmid_1970_6765_29246
(o / observe-01~e.3
      :ARG1 (a / adenocarcinoma~e.1
            :mod (b / bronchioalveolar~e.0))
      :location~e.4 (l / lung~e.6
            :part-of~e.7 (m / mouse~e.9
                  :mod (b2 / bitransgenic~e.8)))
      :time (a2 / after~e.10
            :op1 (t / treat-04~e.12
                  :ARG2 (m2 / molecular-physical-entity
                        :name (n / name :op1 "doxycycline"~e.11))
                  :quant (t2 / temporal-quantity
                        :quant "16"
                        :unit (w / week~e.15)
                        :mod (e / early))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a4 / and
                  :op1 (f / figure :mod "2A"~e.19)
                  :op2 (t3 / thing
                        :name (n2 / name :op1 "+Dox"~e.21 :op2 "16W"~e.22)))))

# ::tok After 10 to 15 weeksof doxycycline treatment , the bitransgenic mice began to develop adenomatoid hyperplasia in both parenchyma and small conducting airways( F ig . 2A , +Dox 10W ) , which resembles to the histopathologic feature of dysplasia in clinical lesions .
# ::alignments 0-1.4 1-1.4.1.3.1.1 3-1.4.1.3.1.2 5-1.4.1.2.1.1 6-1.4.1 9-1.1.1 10-1.1 11-1 13-1.2 14-1.2.2.1 15-1.2.2 18-1.2.1.1 19-1.2.1 20-1.2.1.2.1 21-1.2.1.2.2 26-1.3.1.1.1 28-1.3.1.2.1.1 29-1.3.1.2.1.2 33-1.2.2.2 34-1.2.2.2.1.r 36-1.2.2.2.1.2 37-1.2.2.2.1 38-1.2.2.2.1.1.r 39-1.2.2.2.1.1 40-1.2.2.2.1.3.r 41-1.2.2.2.1.3.1 42-1.2.2.2.1.3
# ::id bel_pmid_1970_6765_29248
(b2 / begin-01~e.11
      :ARG0 (m / mouse~e.10
            :mod (b3 / bitransgenic~e.9))
      :ARG1 (d / develop-01~e.13
            :ARG1 (a2 / and~e.19
                  :op1 (p / parenchyma~e.18)
                  :op2 (a3 / airway
                        :mod (s / small~e.20)
                        :ARG0-of (c / conduct-01~e.21))
                  :part-of m)
            :ARG2 (h / hyperplasia~e.15
                  :mod (a / adenomatoid~e.14)
                  :ARG1-of (r / resemble-01~e.33
                        :ARG2~e.34 (f2 / feature~e.37
                              :poss~e.38 (d5 / dysplasia~e.39)
                              :mod (h2 / histopathologic~e.36)
                              :location~e.40 (l / lesion~e.42
                                    :mod (c2 / clinic~e.41))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a4 / and
                  :op1 (f / figure :mod "2A"~e.26)
                  :op2 (t3 / thing
                        :name (n2 / name :op1 "+Dox"~e.28 :op2 "10W"~e.29))))
      :time (a5 / after~e.0
            :op1 (t / treat-04~e.6
                  :ARG1 m
                  :ARG2 (s2 / small-molecule
                        :name (n / name :op1 "doxycycline"~e.5))
                  :duration (t2 / temporal-quantity
                        :quant (b / between :op1 "10"~e.1 :op2 "15"~e.3)
                        :unit (w / week)))))

# ::tok In addition , Stat3 @-@ induced downstream developmental gene HNF4a wasup @-@ regulated to 78.6 @-@ fold , Foxa3 to 9.3 @-@ fold , and SHH to 3.3 @-@ fold ( Fig . 4D ) .
# ::alignments 0-1 0-1.1 0-1.1.r 1-1 1-1.1 1-1.1.r 3-1.1.1.1.4.1.1.1 5-1.1.1.1.4 6-1.1.1.1.3 7-1.1.1.1.2 8-1.1.1.1 8-1.1.2.1 8-1.1.3.1 9-1.1.1.1.1.1 14-1.1.1.2.1 18-1.1.2.1.1.1 20-1.1.2.2.1 24-1.1 25-1.1.3.1.1.1 27-1.1.3.2.1 33-1.1.4.1.1
# ::id bel_pmid_1970_6765_29250
(a / and~e.0,1
      :op2~e.0,1 (a3 / and~e.0,1,24
            :op1 (u / upregulate-01
                  :ARG1 (g / gene~e.8
                        :name (n2 / name :op1 "HNF4a"~e.9)
                        :mod (g2 / growth~e.7)
                        :location (d / downstream~e.6)
                        :ARG1-of (i / induce-01~e.5
                              :ARG0 (p / protein
                                    :name (n / name :op1 "Stat3"~e.3))))
                  :degree (p2 / product-of :value "78.6"~e.14))
            :op2 (u2 / upregulate-01
                  :ARG1 (g3 / gene~e.8
                        :name (n3 / name :op1 "Foxa3"~e.18))
                  :degree (p4 / product-of :value "9.3"~e.20))
            :op3 (u3 / upregulate-01
                  :ARG1 (g4 / gene~e.8
                        :name (n4 / name :op1 "SHH"~e.25))
                  :degree (p6 / product-of :value "3.3"~e.27))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "4D"~e.33))))

# ::tok As shown in Fig. 4A , IL @-@ 6 concentration in BALF of doxycycline @-@ treated mice was steadily increased compared with those in untreated bitransgenic mice in a time @-@ dependent fashion ,
# ::alignments 1-1.3 4-1.3.1.1 6-1.1.1.1.1 8-1.1.1.1.1 9-1.1 9-1.4 10-1.1.2.r 11-1.1.2.1.1 13-1.1.2.2.1.1.1.1 15-1.1.2.2.1 15-1.4.2.1 16-1.1.2.2 18-1.2 18-1.2.r 19-1 20-1.4.r 25-1.4.2.2 26-1.4.2 27-1.5.r 29-1.5.2 31-1.5
# ::id bel_pmid_1970_6765_29252
(i / increase-01~e.19
      :ARG1 (c / concentrate-02~e.9
            :ARG1 (p / protein
                  :name (n / name :op1 "IL-6"~e.6,8))
            :location~e.10 (t5 / thing
                  :name (n2 / name :op1 "BALF"~e.11)
                  :mod (m / mouse~e.16
                        :ARG1-of (t / treat-04~e.15
                              :ARG2 (s3 / small-molecule
                                    :name (n3 / name :op1 "doxycycline"~e.13))))))
      :manner~e.18 (s / steady~e.18)
      :ARG1-of (s2 / show-01~e.1
            :ARG0 (f / figure :mod "4A"~e.4))
      :compared-to~e.20 (c2 / concentrate-01~e.9
            :ARG1 p
            :location (m3 / mouse~e.26
                  :ARG1-of (t3 / treat-04~e.15 :polarity "-")
                  :mod (b3 / bitransgenic~e.25)))
      :manner~e.27 (d2 / depend-01~e.31
            :ARG0 i
            :ARG1 (t4 / time~e.29)))

# ::tok increased expression of several other MMPs was also observed in doxycycline @-@ treated bitransgenic mice compared with untreated mice . ( Fig 4D )
# ::alignments 0-1.1 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.2 4-1.1.1.1.3 7-1.2 8-1 9-1.4.r 10-1.4.2.1.1.1 12-1.1.2.1 12-1.4.2 13-1.4.1 14-1.1.2 14-1.4 15-1.1.2.r 18-1.4 22-1.3.1.1
# ::id bel_pmid_1970_6765_29260
(o2 / observe-01~e.8
      :ARG1 (i / increase-01~e.0
            :ARG1 (e / express-03~e.1
                  :ARG2~e.2 (e2 / enzyme
                        :name (n / name :op1 "MMP")
                        :quant (s / several~e.3)
                        :mod (o / other~e.4)))
            :compared-to~e.15 (m2 / mouse~e.14
                  :ARG1-of (t2 / treat-04~e.12 :polarity "-")))
      :mod (a / also~e.7)
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4D"~e.22))
      :location~e.9 (m / mouse~e.14,18
            :mod (b / bitransgenic~e.13)
            :ARG1-of (t / treat-04~e.12
                  :ARG2 (s2 / small-molecule
                        :name (n2 / name :op1 "doxycycline"~e.10)))))

# ::tok Because PDGFRb activation , through transphosphorylation of tyrosine residues in its cytoplasmic domain , triggers a cascade of phosphorylation events which eventually lead to the activation of extracellular regulated @-@ protein kinases ( Erks ) , phosphorylated @- Erk1 @/@ 2 was used as an indicator of PDGFRb activation [7].
# ::alignments 0-1 1-1.1.1.1.1.1 2-1.1.1 7-1.1.1.2.1.1.1.1 8-1.1.1.2.1 10-1.1.1.2.1.1.2.2 10-1.1.1.2.1.1.2.2.r 11-1.1.1.2.1.1.2.1 12-1.1.1.2.1.1.2 14-1.1 16-1.1.2 18-1.1.2.1 21-1.1.3.2 22-1.1.3 23-1.1.3.1.r 25-1.1.3.1 26-1.1.3.1.1.r 27-1.1.3.1.1.1.1 28-1.1.3.1.1.1.2 30-1.1.3.1.1.1.2 31-1.1.3.1.1.1.3 36-1.1.2.1 36-1.2.1.2 38-1.2.1.1.1 40-1.2.1.1.1 42-1.2 43-1.1.3.2.r 43-1.2.2.r 45-1.2.2 45-1.2.2.1 45-1.2.2.1.r 46-1.2.2.1.1.r 47-1.2.2.1.1 48-1.2.2.1.1
# ::id bel_pmid_1974_2316_22040
(c / cause-01~e.0
      :ARG0 (t2 / trigger-01~e.14
            :ARG0 (a / activate-01~e.2
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "PDGFRb"~e.1))
                  :manner (t3 / transphosphorylate-00
                        :ARG1 (r / residue~e.8
                              :mod (a2 / amino-acid
                                    :name (n2 / name :op1 "tyrosine"~e.7)
                                    :part-of (d / domain~e.12
                                          :mod (c2 / cytoplasm~e.11)
                                          :part-of~e.10 p2~e.10)))))
            :ARG1 (c3 / cascade-01~e.16
                  :subevent (p / phosphorylate-01~e.18,36))
            :ARG0-of (l / lead-01~e.22
                  :ARG4~e.23 (a3 / activate-01~e.25
                        :ARG1~e.26 (e2 / enzyme
                              :name (n3 / name
                                    :op1 "extracellular"~e.27
                                    :op2 "regulated-protein"~e.28,30
                                    :op3 "kinases"~e.31)))
                  :time~e.43 (e / eventual~e.21)))
      :ARG1 (u / use-01~e.42
            :ARG1 (e3 / enzyme
                  :name (n4 / name :op1 "Erk1/2"~e.38,40)
                  :ARG1-of (p3 / phosphorylate-01~e.36))
            :ARG2~e.43 (t / thing~e.45
                  :ARG0-of~e.45 (i / indicate-01~e.45
                        :ARG1~e.46 a~e.47,48)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c4 / cite-01 :ARG2 "7"))))

# ::tok An approximately 2.5 @-@ fold increase of Smad2 phosphorylation at Ser 465 @/@ 467 was also detected in LDLR expressing , LRP1 @-@ deficient SMCs ( Figure 6B , C ) .
# ::alignments 1-1.1.2 2-1.1.2.1.1 5-1.1 6-1.1.1.r 6-1.1.2.1 7-1.1.1.1.1.3.1.1 8-1.1.1 11-1.1.1.1.1.1 13-1.1.1.1.2.1 15-1.2 16-1 17-1.4.r 18-1.4.3.1.1.1 19-1.4.3 21-1.4.2.1.1 26-1.3.1.1 26-1.3.1.2 27-1.3.1.1.1
# ::id bel_pmid_1974_2316_28806
(d / detect-01~e.16
      :ARG1 (i / increase-01~e.5
            :ARG1~e.6 (p / phosphorylate-01~e.8
                  :ARG1 (a5 / and
                        :op1 (a2 / amino-acid
                              :mod "465"~e.11
                              :name (n / name :op1 "serine")
                              :part-of (p2 / protein
                                    :name (n2 / name :op1 "Smad2"~e.7)))
                        :op2 (a6 / amino-acid
                              :mod "467"~e.13
                              :name (n6 / name :op1 "serine")
                              :part-of p2)))
            :ARG2 (a3 / approximately~e.1
                  :op1 (p3 / product-of~e.6 :value "2.5"~e.2)))
      :mod (a / also~e.15)
      :ARG1-of (d2 / describe-01
            :ARG0 (a4 / and
                  :op1 (f / figure~e.26 :mod "6B"~e.27)
                  :op2 (f2 / figure~e.26 :mod "6C")))
      :location~e.17 (c / cell
            :name (n4 / name :op1 "SMC")
            :mod (p5 / protein
                  :name (n5 / name :op1 "LRP1"~e.21)
                  :ARG2-of (m / mutate-01 :mod "-/-"))
            :ARG3-of (e / express-03~e.19
                  :ARG2 (p4 / protein
                        :name (n3 / name :op1 "LDLR"~e.18)))))

# ::tok About a two @-@ fold increase of PDGFRb expression was detected in smLRP1-/- mice regardless of LDLR genotype ( Figure 2A , C ) . Increased Erk1 @/@ 2 phosphorylation was also observed in these aortas ( Figure 2A ) . These data suggest that the expression and activation of PDGFRb is only regulated by LRP1 , not LDLR .
# ::alignments 0-1.1.1.2 2-1.1.1.2.1.1 5-1.1.1 6-1.1.1.1.r 6-1.1.1.2.1 7-1.1.1.1.1.1.1 8-1.1.1.1 10-1.1 13-1.1.2 15-1.1.1.2.1 16-1.1.3.1.1.1.1 17-1.1.3.1 19-1.1.4.1.1 19-1.2.3.1 20-1.1.4.1.1.1 20-1.2.3.1.1 25-1.2.1.2 26-1.2.1.1.1.1 28-1.2.1.1.1.1 29-1.2.1 31-1.2.2 32-1.2 33-1.2.1.3.r 34-1.2.1.3.1 35-1.2.1.3 37-1.1.4.1.1 37-1.1.4.1.2 37-1.2.3.1 38-1.1.4.1.1.1 38-1.2.3.1.1 41-1.3.1.1 42-1.3.1 43-1.3 46-1.3.2.1.2.1 47-1.3.2.1.2 48-1.3.2.1.2.2 49-1.3.2.1.2.1.1.r 50-1.3.2.1.2.1.1.1.1 52-1.3.2.1.3 53-1.3.2.1 53-1.3.2.2 54-1.3.2.1.1.r 55-1.3.2.1.1.1.1 57-1.3.2.2.1 57-1.3.2.2.1.r 58-1.1.3.1.1.1.1 58-1.3.2.2.2.1.1
# ::id bel_pmid_1974_2316_28914
(m / multi-sentence
      :snt1 (d / detect-01~e.10
            :ARG1 (i / increase-01~e.5
                  :ARG1~e.6 (e / express-03~e.8
                        :ARG2 (p2 / protein
                              :name (n / name :op1 "PDGFRb"~e.7)))
                  :ARG2 (a / about~e.0
                        :op1 (p3 / product-of~e.6,15 :value "2"~e.2)))
            :location (m2 / mouse~e.13
                  :mod (p4 / protein
                        :name (n2 / name :op1 "smLRP1")
                        :ARG2-of (m3 / mutate-01 :mod "-/-")))
            :ARG1-of (h / have-concession-91
                  :ARG2 (g / genotype~e.17
                        :mod (p5 / protein
                              :name (n3 / name :op1 "LDLR"~e.16,58))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a2 / and
                        :op1 (f / figure~e.19,37 :mod "2A"~e.20,38)
                        :op2 (f2 / figure~e.37 :mod "2C"))))
      :snt2 (o / observe-01~e.32
            :ARG1 (p / phosphorylate-01~e.29
                  :ARG1 (e2 / enzyme
                        :name (n4 / name :op1 "Erk1/2"~e.26,28))
                  :ARG1-of (i2 / increase-01~e.25)
                  :location~e.33 (a4 / aorta~e.35
                        :mod (t / this~e.34)))
            :mod (a3 / also~e.31)
            :ARG1-of (d3 / describe-01
                  :ARG0 (f3 / figure~e.19,37 :mod "2A"~e.20,38)))
      :snt3 (s / suggest-01~e.43
            :ARG0 (d4 / data~e.42
                  :mod (t2 / this~e.41))
            :ARG1 (c / contrast-01
                  :ARG1 (r / regulate-01~e.53
                        :ARG0~e.54 (p6 / protein
                              :name (n5 / name :op1 "LRP1"~e.55))
                        :ARG1 (a5 / and~e.47
                              :op1 (e3 / express-03~e.46
                                    :ARG2~e.49 (p7 / protein
                                          :name (n6 / name :op1 "PDGFRb"~e.50)))
                              :op2 (a6 / activate-01~e.48
                                    :ARG1 p7))
                        :mod (o2 / only~e.52))
                  :ARG2 (r2 / regulate-01~e.53
                        :polarity~e.57 "-"~e.57
                        :ARG0 (p8 / protein
                              :name (n7 / name :op1 "LDLR"~e.58))
                        :ARG1 a5))))

# ::tok Studies from our laboratory have shown that LRP1 suppresses PDGF receptor b ( PDGFRb ) activation and protects against atherosclerosis .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1 2-1.1.1.1.r 3-1.1.1 5-1 6-1.2.r 7-1.2.1.1.1.1 8-1.2.1 9-1.2.1.2.1.1.1 10-1.2.1.2.1.1.2 11-1.2.1.2.1.1.3 15-1.2.1.2 16-1.2 17-1.2.2 18-1.2.2.2.r 19-1.2.2.2
# ::id bel_pmid_1974_2316_28918
(s / show-01~e.5
      :ARG0 (s2 / study-01~e.0
            :source~e.1 (l / laboratory~e.3
                  :poss-of~e.2 (w / we~e.2)))
      :ARG1~e.6 (a / and~e.16
            :op1 (s3 / suppress-01~e.8
                  :ARG0 (p / protein
                        :name (n / name :op1 "LRP1"~e.7))
                  :ARG1 (a2 / activate-01~e.15
                        :ARG1 (p2 / protein
                              :name (n2 / name
                                    :op1 "PDGF"~e.9
                                    :op2 "receptor"~e.10
                                    :op3 "b"~e.11))))
            :op2 (p3 / protect-01~e.17
                  :ARG0 p
                  :ARG2~e.18 (a3 / atherosclerosis~e.19))))

# ::tok In this study , we found disorganized actin in the form of membrane ruffling and enhanced cell migration in LRP1 @-@ deficient ( LRP1-/-) SMCs .
# ::alignments 1-1.3.1 2-1.3 4-1.1 5-1 6-1.2.1.1 7-1.2.1 8-1.2.1.1.1.r 10-1.2.1.1.1 11-1.2.1.1.1.1.r 12-1.2.1.1.1.1 13-1.2.1.1.1.1.1 14-1.2 15-1.2.2.3 16-1.2.2.1 17-1.2.2 18-1.2.2.2.r 19-1.2.2.2.2.1.1
# ::id bel_pmid_1974_2316_9502
(f / find-01~e.5
      :ARG0 (w / we~e.4)
      :ARG1 (a / and~e.14
            :op1 (a2 / actin~e.7
                  :ARG1-of (d / disorganize-01~e.6
                        :manner~e.8 (f2 / form~e.10
                              :mod~e.11 (m / membrane~e.12
                                    :ARG1-of (r / ruffle-02~e.13)))))
            :op2 (m2 / migrate-01~e.17
                  :ARG0 (c / cell~e.16)
                  :ARG1~e.18 (c2 / cell-line
                        :name (n / name :op1 "SMC")
                        :mod (p / protein
                              :name (n2 / name :op1 "LRP1"~e.19)
                              :ARG2-of (m3 / mutate-01 :mod "-/-")))
                  :ARG1-of (e / enhance-01~e.15)))
      :medium (s / study~e.2
            :mod (t / this~e.1)))

# ::tok deletion of two CREB @-@ binding sites from the Cebpb promoter abrogates Cebpb induction upon macrophage activation . This blocks the downstream induction of M2 @-@ specific Msr1 , Il10 , II13 ra , and Arg @-@ 1 genes , whereas the inflammatory ( M1 ) genes Il1 , Il6 , Tnfa , and Il12 are not affected
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1 3-1.1.1.1.2.1.1.1 5-1.1.1.1.2 6-1.1.1.1 7-1.1.1.1.3.r 9-1.1.1.1.3.1.1.1.1 11-1.1 12-1.1.2.1 13-1.1.2 15-1.1.3.1 16-1.1.3 18-1.2.1 19-1.2 21-1.2.2.2 22-1.2.2 23-1.2.2.1.r 24-1.2.2.1.2.1.1.1 26-1.2.2.1.2 27-1.2.2.1.1.1.1.1.1 29-1.2.2.1.1.1.2.1.1 34-1.2.2.1.1.1 35-1.2.2.1.1.1.4.1.1 37-1.2.2.1.1.1.4.1.1 38-1.2.2.1 40-1.2.3 42-1.2.3.1.2.2 46-1.2.3.1.2 47-1.2.3.1.2.1.1.1.1.1 49-1.2.3.1.2.1.1.2.1.1 51-1.2.3.1.2.1.1.3.1.1 54-1.2.3.1.2.1.1.4.1.1 56-1.2.3.1.1 56-1.2.3.1.1.r 57-1.2.3.1
# ::id bel_pmid_1980_5133_25992
(m / multi-sentence
      :snt1 (a / abrogate-01~e.11
            :ARG0 (d / delete-01~e.0
                  :ARG1~e.1 (p / protein-segment~e.6
                        :quant "2"~e.2
                        :ARG1-of (b / bind-01~e.5
                              :ARG2 (p2 / protein
                                    :name (n / name :op1 "CREB"~e.3)))
                        :part-of~e.7 (m3 / molecular-physical-entity
                              :ARG0-of (p3 / promote-01
                                    :ARG1 (p4 / protein
                                          :name (n2 / name :op1 "Cebpb"~e.9))))))
            :ARG1 (i / induce-01~e.13
                  :ARG1 p4~e.12)
            :time (a2 / activate-01~e.16
                  :ARG1 (m2 / macrophage~e.15)))
      :snt2 (b2 / block-01~e.19
            :ARG0 (t2 / this~e.18)
            :ARG1 (i2 / induce-01~e.22
                  :ARG1~e.23 (g / gene~e.38
                        :ARG2-of (i3 / include-91
                              :ARG1 (a3 / and~e.34
                                    :op1 (g2 / gene
                                          :name (n5 / name :op1 "Msr1"~e.27))
                                    :op2 (g3 / gene
                                          :name (n6 / name :op1 "Il10"~e.29))
                                    :op3 (g4 / gene
                                          :name (n7 / name :op1 "II13ra"))
                                    :op4 (g5 / gene
                                          :name (n8 / name :op1 "Arg-1"~e.35,37))))
                        :mod (s / specific~e.26
                              :topic (c2 / cell
                                    :name (n4 / name :op1 "M2"~e.24))))
                  :mod (d2 / downstream~e.21))
            :ARG1-of (c / contrast-01~e.40
                  :ARG2 (a4 / affect-01~e.57
                        :polarity~e.56 "-"~e.56
                        :ARG1 (g11 / gene~e.46
                              :ARG2-of (i4 / include-91
                                    :ARG1 (a5 / and
                                          :op1 (g7 / gene
                                                :name (n10 / name :op1 "Il1"~e.47))
                                          :op2 (g8 / gene
                                                :name (n11 / name :op1 "Il6"~e.49))
                                          :op3 (g9 / gene
                                                :name (n12 / name :op1 "Tnfa"~e.51))
                                          :op4 (g10 / gene
                                                :name (n13 / name :op1 "Il12"~e.54))))
                              :ARG0-of (i5 / inflame-01~e.42))))))

# ::tok Cebpb expression is therefore required in infiltrating macrophages for upregulation of M2 @-@ specific genes
# ::alignments 0-1.1.2.1.1.1 1-1.1.2 3-1 4-1.1 5-1.1.3.r 6-1.1.3 7-1.1.4 8-1.1.1.r 9-1.1.1 10-1.1.1.1.r 11-1.1.1.1.1.1.1.1 13-1.1.1.1.1 14-1.1.1.1
# ::id bel_pmid_1980_5133_8276
(c2 / cause-01~e.3
      :ARG1 (r / require-01~e.4
            :ARG0~e.8 (u / upregulate-01~e.9
                  :ARG1~e.10 (g2 / gene~e.14
                        :mod (s / specific~e.13
                              :topic (c / cell
                                    :name (n2 / name :op1 "M2"~e.11)))))
            :ARG1 (e2 / express-03~e.1
                  :ARG2 (p / protein
                        :name (n / name :op1 "Cebpb"~e.0)))
            :purpose~e.5 (i / infiltrate-01~e.6)
            :location (m / macrophage~e.7)))

# ::tok Studies using TLR @-@ 4 -/- mice have demonstrated that induction of MCP @-@ 1 in BAL fluid upon exposure of mice to subacute ( exposed for a period of 5 weeks ) levels of CS depends on the presence of wild @-@ type TLR @-@ 4 , whereas TLR @-@ 4 plays a minor role in MCP @-@ 1 induction in the presence of chronic smoke exposure ( 26 weeks ) [45].
# ::alignments 0-1.1 1-1.1.1 2-1.1.1.1.1.1.1 4-1.1.1.1.1.1.1 5-1.1.1.1.1.2.1 6-1.1.1.1 8-1 9-1.2.r 10-1.2.1 11-1.2.1.1.r 12-1.2.1.1.1.1 14-1.2.1.1.1.1 15-1.2.1.2.r 16-1.2.1.2.1.1 17-1.2.1.2.1.2 19-1.2.1.3 21-1.2.1.3.1 23-1.2.1.3.2.2 25-1.2.1.3 26-1.2.1.3.3.r 28-1.2.1.3.3 29-1.2.1.3.3.1.r 30-1.2.1.3.3.1.1 31-1.2.1.3.3.1.2 33-1.2.1.3.2 34-1.2.1.3.2.1.r 35-1.2.1.3.2.1.1.1 36-1.2 37-1.2.2.r 39-1.2.2 40-1.2.2.1.r 41-1.2.2.1.2 43-1.2.2.1.2 44-1.2.2.1.1.1 46-1.2.2.1.1.1 48-1.2.3 49-1.2.3.1.1 50-1.2.3.1.1 51-1.2.3.1.1 52-1.2.3.1 54-1.2.3.1.2.1 55-1.2.3.1.2 56-1.2.3.1.2.2.r 57-1.2.3.1.2.2.1 58-1.2.3.1.2.2.1 59-1.2.3.1.2.2.1 60-1.2.3.1.2.2 61-1.2.3.1.2.2.2.r 63-1.2.3.1.2.2.2 64-1.2.3.1.2.2.2.1.r 65-1.2.3.1.2.2.2.1.1.1 66-1.2.3.1.2.2.2.1.1 67-1.2.3.1.2.2.2.1 69-1.2.3.1.2.2.2.1.2.1 70-1.2.3.1.2.2.2.1.2.2
# ::id bel_pmid_1984_2832_19720
(d / demonstrate-01~e.8
      :ARG0 (s / study-01~e.0
            :ARG0-of (u / use-01~e.1
                  :ARG1 (m / mouse~e.6
                        :mod (p / protein
                              :name (n / name :op1 "TLR-4"~e.2,4)
                              :ARG2-of (m2 / mutate-01 :mod "-/-"~e.5)))))
      :ARG1~e.9 (d2 / depend-01~e.36
            :ARG0 (i / induce-01~e.10
                  :ARG1~e.11 (p2 / protein
                        :name (n2 / name :op1 "MCP-1"~e.12,14))
                  :location~e.15 (t3 / thing
                        :name (n3 / name :op1 "BAL"~e.16 :op2 "fluid"~e.17))
                  :time (e / expose-01~e.19,25
                        :ARG1 (m3 / mouse~e.21)
                        :ARG2 (l / level~e.33
                              :quant-of~e.34 (p4 / protein
                                    :name (n4 / name :op1 "CS"~e.35))
                              :mod (s2 / subacute~e.23))
                        :duration~e.26 (p3 / period~e.28
                              :mod~e.29 (t / temporal-quantity
                                    :quant "5"~e.30
                                    :unit (w / week~e.31)))))
            :ARG1~e.37 (p5 / present-01~e.39
                  :ARG1~e.40 (p6 / protein
                        :name (n5 / name :op1 "TLR-4"~e.44,46)
                        :mod (w3 / wild-type~e.41,43)))
            :ARG1-of (c / contrast-01~e.48
                  :ARG2 (p7 / play-02~e.52
                        :ARG0 p6~e.49,50,51
                        :ARG1 (r / role~e.55
                              :degree (m4 / minor~e.54)
                              :domain~e.56 (i2 / induce-01~e.60
                                    :ARG1 p2~e.57,58,59
                                    :condition~e.61 (p9 / present-01~e.63
                                          :ARG1~e.64 (e2 / expose-01~e.67
                                                :ARG2 (s3 / smoke~e.66
                                                      :mod (c2 / chronic~e.65))
                                                :duration (t2 / temporal-quantity
                                                      :quant "26"~e.69
                                                      :unit (w2 / week~e.70)))))))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p10 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "45"))))

# ::tok LPS stimulated pulmonary neutrophil recruitment , NF @-@ kB promoter activity , and TNF @-@ a secretion are found to be severely impaired in GM @-@ CSF-/- mice .
# ::alignments 0-1.1.1.1.2.1.1.1 1-1.1.1.1.2 2-1.1.1.1.1.2 3-1.1.1.1.1.1.1 4-1.1.1.1 6-1.1.1.2.1.1.1.1.1 8-1.1.1.2.1.1.1.1.1 12-1.1.1 13-1.1.1.3.1.1.1 15-1.1.1.3.1.1.1 16-1.1.1.3 18-1 21-1.1.2 21-1.1.2.r 22-1.1 23-1.1.3.r 24-1.1.3.1.1.1 27-1.1.3
# ::id bel_pmid_1984_2832_26184
(f / find-01~e.18
      :ARG1 (i / impair-01~e.22
            :ARG1 (a / and~e.12
                  :op1 (r / recruit-01~e.4
                        :ARG1 (c / cell
                              :name (n2 / name :op1 "neutrophil"~e.3)
                              :mod (p / pulmonary~e.2))
                        :ARG1-of (s / stimulate-01~e.1
                              :ARG0 (m / molecular-physical-entity
                                    :name (n / name :op1 "LPS"~e.0))))
                  :op2 (a2 / act-01
                        :ARG0 (t / thing
                              :ARG0-of (p2 / promote-01
                                    :ARG1 (p3 / protein
                                          :name (n3 / name :op1 "NF-kB"~e.6,8)))))
                  :op3 (s2 / secrete-01~e.16
                        :ARG1 (p4 / protein
                              :name (n4 / name :op1 "TNF-a"~e.13,15))))
            :manner~e.21 (s3 / severe~e.21)
            :location~e.23 (m2 / mouse~e.27
                  :mod (p5 / protein
                        :name (n5 / name :op1 "GM-CSF"~e.24)
                        :ARG2-of (m3 / mutate-01 :mod "-/-")))))

# ::tok IL @-@ 1b increased the production of neutrophil chemoattractants such as Gro @-@ alpha ( CXCL1 ) and MIP @-@ 2 ( CXCL2 ) in lungs .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1 5-1.2 6-1.2.1.r 7-1.2.1.1 8-1.2.1 9-1.2.1.2.r 10-1.2.1.2.r 11-1.2.1.2.1.1.1 13-1.2.1.2.1.1.1 15-1.2.1.2.1.2.1.1.1 17-1.2.1.2 18-1.2.1.2.2.1.1 20-1.2.1.2.2.1.1 22-1.2.1.2.2.2.1.1.1 24-1.2.1.3.r 25-1.2.1.3
# ::id bel_pmid_1984_2832_28124
(i / increase-01~e.3
      :ARG0 (p / protein
            :name (n / name :op1 "IL-1b"~e.0,2))
      :ARG1 (p2 / produce-01~e.5
            :ARG1~e.6 (c / chemoattractants~e.8
                  :mod (n2 / neutrophil~e.7)
                  :example~e.9,10 (a / and~e.17
                        :op1 (p3 / protein
                              :name (n3 / name :op1 "Gro-alpha"~e.11,13)
                              :ARG1-of (m / mean-01
                                    :ARG2 (p5 / protein
                                          :name (n5 / name :op1 "CXCL1"~e.15))))
                        :op2 (p4 / protein
                              :name (n4 / name :op1 "MIP-2"~e.18,20)
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (p6 / protein
                                          :name (n6 / name :op1 "CXCL2"~e.22)))))
                  :location~e.24 (l / lung~e.25))))

# ::tok Tollip has been shown to associate directly with TLR @-@ 4 and inhibit TLR @-@ 4 @-@ mediated activation of NF @- kB luciferase reporter vectors in a mouse macrophage cell line ( RAW @-@ 264.7 ) .
# ::alignments 0-1.1.1.1.1.1 3-1 5-1.1.1 6-1.1.1.3 6-1.1.1.3.r 7-1.1.1.2.r 8-1.1.1.2.1.1 10-1.1.1.2.1.1 11-1.1 12-1.1.2 13-1.1.2.2.2.1 14-1.1.2.2.2.1 15-1.1.2.2.2.1 17-1.1.2.2.2 18-1.1.2.2 19-1.1.2.2.1.r 20-1.1.2.2.1.1.1.1 22-1.1.2.2.1.1.1.2 23-1.1.2.2.1.1.1.3 24-1.1.2.2.1.1.1.4 25-1.1.2.2.1 26-1.1.2.3.r 28-1.1.2.3.2 29-1.1.2.3.3 30-1.1.2.3 31-1.1.2.3 33-1.1.2.3.1.1 35-1.1.2.3.1.1
# ::id bel_pmid_1984_2832_31640
(s / show-01~e.3
      :ARG1 (a3 / and~e.11
            :op1 (a / associate-01~e.5
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "Tollip"~e.0))
                  :ARG2~e.7 (p3 / protein
                        :name (n2 / name :op1 "TLR-4"~e.8,10))
                  :manner~e.6 (d / direct~e.6))
            :op2 (i / inhibit-01~e.12
                  :ARG0 p2
                  :ARG1 (a2 / activate-01~e.18
                        :ARG1~e.19 (v / vector~e.25
                              :mod (e / enzyme
                                    :name (n3 / name
                                          :op1 "NF-"~e.20
                                          :op2 "kB"~e.22
                                          :op3 "luciferase"~e.23
                                          :op4 "reporter"~e.24)))
                        :ARG1-of (m / mediate-01~e.17
                              :ARG0 p3~e.13,14,15))
                  :location~e.26 (c / cell-line~e.30,31
                        :name (n4 / name :op1 "RAW-264.7"~e.33,35)
                        :mod (m2 / mouse~e.28)
                        :mod (m3 / macrophage~e.29)))))

# ::tok Treatment of sputum cells from COPD patients with acetylcholine produced increased amounts of LTB4 , which was sensitive both to treatment with a muscarinic receptor antagonist and to the inhibition of ERK @- 1 @/@ 2 phosphorylation . This increased LTB4 synthesis also directly correlated with increased neutrophil chemotaxis .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1.1 3-1.1.1.1 4-1.1.1.1.2.r 5-1.1.1.1.2.1.1.1 6-1.1.1.1.2 7-1.1.1.2.r 8-1.1.1.2.1.1 9-1.1 10-1.1.2.1 11-1.1.2 12-1.1.2.2.r 13-1.1.2.2.1.1 17-1.1.2.2 17-1.1.2.2.2 17-1.1.2.2.2.r 19-1.1.2.2.2.1.r 20-1.1.2.2.2.1.1 21-1.1.2.2.2.1.1.1.r 23-1.1.2.2.2.1.1.1.1.1 24-1.1.2.2.2.1.1.1.1.2 25-1.1.2.2.2.1.1.1.1.3 26-1.1.2.2.2.1 29-1.1.2.2.2.1.2 30-1.1.2.2.2.1.2.1.r 31-1.1.2.2.2.1.2.1.1.1.1 33-1.1.2.2.2.1.2.1.1.1.1 35-1.1.2.2.2.1.2.1.1.1.1 36-1.1.2.2.2.1.2.1 38-1.2.1.3 39-1.2.1.2 39-1.2.2.2 40-1.2.1.1.1.1 42-1.2.3 43-1.2.4 43-1.2.4.r 44-1.2 46-1.2.1.2 46-1.2.2.2 47-1.2.2.1 48-1.2.2
# ::id bel_pmid_1984_2832_34344
(m / multi-sentence
      :snt1 (p2 / produce-01~e.9
            :ARG0 (t / treat-04~e.0
                  :ARG1~e.1 (c / cell~e.3
                        :mod (s / sputum~e.2)
                        :source~e.4 (p3 / patient~e.6
                              :mod (d / disease
                                    :name (n2 / name :op1 "COPD"~e.5))))
                  :ARG2~e.7 (m2 / molecular-physical-entity
                        :name (n / name :op1 "acetylcholine"~e.8)))
            :ARG1 (a / amount~e.11
                  :ARG1-of (i / increase-01~e.10)
                  :quant-of~e.12 (p4 / protein~e.17
                        :name (n3 / name :op1 "LTB4"~e.13)
                        :ARG0-of~e.17 (s2 / sensitive-03~e.17
                              :ARG1~e.19 (a3 / and~e.26
                                    :op1 (t2 / treat-04~e.20
                                          :ARG2~e.21 (p5 / protein
                                                :name (n4 / name
                                                      :op1 "muscarinic"~e.23
                                                      :op2 "receptor"~e.24
                                                      :op3 "antagonist"~e.25)))
                                    :op2 (i2 / inhibit-01~e.29
                                          :ARG1~e.30 (p / phosphorylate-01~e.36
                                                :ARG1 (e2 / enzyme
                                                      :name (n5 / name :op1 "ERK-1/2"~e.31,33,35)))))))))
      :snt2 (c2 / correlate-01~e.44
            :ARG1 (s3 / synthesize-01
                  :ARG1 (p6 / protein
                        :name (n6 / name :op1 "LTB4"~e.40))
                  :ARG1-of (i3 / increase-01~e.39,46)
                  :mod (t3 / this~e.38))
            :ARG2 (c3 / chemotaxis~e.48
                  :mod (n7 / neutrophil~e.47)
                  :ARG1-of (i4 / increase-01~e.39,46))
            :mod (a4 / also~e.42)
            :manner~e.43 (d2 / direct~e.43)))

# ::tok IRAK @-@ 1 activation and recruitment is essential for activation of TRAF6 ( TNF @-@ associated factor 6 ) , which is an essential adaptor for MyD88 @-@ dependent NF @-@ kB activation .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.1.1 3-1.1.3 4-1.1 5-1.1.2 6-1.1.r 7-1 9-1.1.1 10-1.1.3.1.r 11-1.1.3.1.1.1 23-1.1.3.1.2.2 26-1.1.3.1.2.1.2.1.1.1 28-1.1.3.1.2.1.2 29-1.1.3.1.2.1.1.1.1 31-1.1.3.1.2.1.1.1.1 32-1.1.3.1.2.1
# ::id bel_pmid_1984_2832_36854
(e / essential~e.7
      :domain~e.6 (a / and~e.4
            :op1 (a2 / activate-01~e.3,9
                  :ARG1 (e2 / enzyme
                        :name (n / name :op1 "IRAK-1"~e.0,2)))
            :op2 (r / recruit-01~e.5
                  :ARG1 e2)
            :purpose (a3 / activate-01~e.3
                  :ARG1~e.10 (p / protein
                        :name (n2 / name :op1 "TRAF6"~e.11)
                        :ARG0-of (a4 / adapt-01
                              :ARG1 (a5 / activate-01~e.32
                                    :ARG1 (p2 / protein
                                          :name (n3 / name :op1 "NF-kB"~e.29,31))
                                    :ARG0-of (d / depend-01~e.28
                                          :ARG1 (p3 / protein
                                                :name (n4 / name :op1 "MyD88"~e.26))))
                              :mod (e3 / essential~e.23))))))

# ::tok It has also been shown that IL @-@ 1b stimulates the release and activity of MMP @-@ 9 ( matrix metalloproteinase @-@ 9 ) from AM obtained from COPD smokers , which is significantly higher in comparison with those obtained from healthy smokers and non @-@ smokers [155].
# ::alignments 2-1.2 4-1 5-1.1.r 6-1.1.1.1.1 8-1.1.1.1.1 9-1.1 11-1.1.2.1 11-1.1.2.4.3.1 12-1.1.2 14-1.1.2.1.1.r 15-1.1.2.1.1.1.1 17-1.1.2.1.1.1.1 22-1.1.2.1.1.1.1 24-1.1.2.3.r 25-1.1.2.3.1.1 26-1.1.2.3.2 27-1.1.2.3.r 28-1.1.2.3.2.1.2.1.1 29-1.1.2.3.2.1 29-1.1.2.3.2.1.1 29-1.1.2.3.2.1.1.r 33-1.1.2.4.2 34-1.1.2.4 34-1.1.2.4.1 34-1.1.2.4.1.r 36-1.1.2.4.3.r 39-1.1.2.3.2 39-1.1.2.4.3.3 40-1.1.2.3.r 40-1.1.2.4.3.3.1.r 41-1.1.2.4.3.3.1.1.2 42-1.1.2.4.3.3.1.1 42-1.1.2.4.3.3.1.1.1 42-1.1.2.4.3.3.1.1.1.r 42-1.1.2.4.3.3.1.2 42-1.1.2.4.3.3.1.2.1 42-1.1.2.4.3.3.1.2.1.r 43-1.1.2.4.3.3.1 44-1.1.2.4.3.3.1.2.1.1 44-1.1.2.4.3.3.1.2.1.1.r 46-1.1.2.3.2.1.1.r
# ::id bel_pmid_1984_2832_38430
(s2 / show-01~e.4
      :ARG1~e.5 (s3 / stimulate-01~e.9
            :ARG0 (p2 / protein
                  :name (n / name :op1 "IL-1b"~e.6,8))
            :ARG1 (a2 / and~e.12
                  :op1 (r / release-01~e.11
                        :ARG1~e.14 (e / enzyme
                              :name (n2 / name :op1 "MMP-9"~e.15,17,22)))
                  :op2 (a3 / act-01
                        :ARG0 e)
                  :source~e.24,27,40 (m2 / molecular-physical-entity
                        :name (n3 / name :op1 "AM"~e.25)
                        :ARG1-of (o / obtain-01~e.26,39
                              :ARG2 (p / person~e.29
                                    :ARG0-of~e.29,46 (s / smoke-02~e.29)
                                    :mod (d / disease
                                          :name (n4 / name :op1 "COPD"~e.28)))))
                  :degree (h / high~e.34
                        :degree~e.34 (m / more~e.34)
                        :mod (s4 / significant~e.33)
                        :compared-to~e.36 (a5 / and
                              :op1 (r2 / release-01~e.11
                                    :ARG1 e)
                              :op2 (a6 / act-01
                                    :ARG0 e)
                              :ARG1-of (o2 / obtain-01~e.39
                                    :ARG2~e.40 (a4 / and~e.43
                                          :op1 (p3 / person~e.42
                                                :ARG0-of~e.42 (s5 / smoke-02~e.42)
                                                :mod (h2 / healthy~e.41))
                                          :op2 (p4 / person~e.42
                                                :ARG0-of~e.42 (s6 / smoke-02~e.42 :polarity~e.44 "-"~e.44)
                                                :mod h2)))))))
      :mod (a / also~e.2)
      :ARG1-of (d2 / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c / cite-01 :ARG2 "155"))))

# ::tok Similarly , preincubation with F( ab ')2 fragments of a monoclonal anti @-@ human IL @-@ 8 antibody inhibited neutrophil chemotaxis to CB sputum supernatants by 75 % [30].
# ::alignments 0-1.6 10-1.1.1.2.1.1 11-1.1.1.2.1.2 13-1.1.1.2.1.2 14-1.1.1.2.1.3 16-1.1.1.2.1.3 17-1.1.1.2.1.4 18-1 19-1.2.1 20-1.2 21-1.3.r 22-1.3.1.1.1.1 23-1.3.1 24-1.3 25-1.4.r 26-1.4.1 27-1.4
# ::id bel_pmid_1984_2832_38592
(i / inhibit-01~e.18
      :ARG0 (p2 / preincubate-00
            :ARG2 (p4 / protein-segment
                  :name (n3 / name :op1 "F(ab')2")
                  :part-of (m / molecular-physical-entity
                        :name (n4 / name
                              :op1 "monoclonal"~e.10
                              :op2 "anti-human"~e.11,13
                              :op3 "IL-8"~e.14,16
                              :op4 "antibody"~e.17))))
      :ARG1 (c / chemotaxis~e.20
            :mod (n2 / neutrophil~e.19))
      :location~e.21 (s / supernatant~e.24
            :mod (s2 / sputum~e.23
                  :mod (d2 / disease
                        :name (n / name :op1 "CB"~e.22))))
      :quant~e.25 (p / percentage-entity~e.27 :value "75"~e.26)
      :ARG1-of (d / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01 :ARG2 "30")))
      :ARG1-of (r / resemble-01~e.0))

# ::tok Including adenosine with IFN @-@ gamma treatment delayed any measureable increase in STAT1 activation by >60 min , and led to significantly reduced STAT1 activity at 60 , 120 , and 240 min post @-@ stimulation compared with cells treated with IFN @-@ gamma alone ( p < 0.05; Fig. 4 ) .
# ::alignments 0-1.1.1 1-1.1.1.1.1.1 2-1.1.1.2.r 3-1.1.1.2.1.1.1 5-1.1.1.2.1.1.1 6-1.1.1.2 7-1.1 10-1.1.2 11-1.1.2.1.r 12-1.1.2.1.1.1.1 13-1.1.2.1 18-1 18-1.3.1 19-1.2 20-1.2.2.r 21-1.2.2.2 22-1.2.2 23-1.1.2.1.1.1.1 26-1.1.3.1.1 26-1.2.2.3.1.1.1.1 28-1.2.2.3.1.1.2.1 30-1.2.2.3.1.1 31-1.2.2.3.1.1.3.1 35-1.2.2.3.1 36-1.2.2.4.r 38-1.2.2.4 39-1.2.2.4.1 40-1.2.2.4.1.1.r 41-1.2.2.4.1.1 42-1.2.2.4.1.1 43-1.2.2.4.1.1 44-1.2.2.4.1.2 50-1.3.1.1.1
# ::id bel_pmid_1984_6878_15410
(a / and~e.18
      :op1 (d / delay-01~e.7
            :ARG0 (i / include-01~e.0
                  :ARG1 (m7 / molecular-physical-entity
                        :name (n4 / name :op1 "adenosine"~e.1))
                  :ARG2~e.2 (t / treat-04~e.6
                        :ARG2 (p / protein
                              :name (n / name :op1 "IFN-gamma"~e.3,5))))
            :ARG1 (i2 / increase-01~e.10
                  :ARG1~e.11 (a3 / activate-01~e.13
                        :ARG1 (p2 / protein
                              :name (n2 / name :op1 "STAT1"~e.12,23)))
                  :ARG1-of (m / measure-01
                        :mod (p5 / possible)))
            :ARG2 (m2 / more-than
                  :op1 (t2 / temporal-quantity
                        :quant "60"~e.26
                        :unit (m3 / minute))))
      :op2 (l / lead-03~e.19
            :ARG0 i
            :ARG2~e.20 (r / reduce-01~e.22
                  :ARG1 (a4 / act-01
                        :ARG0 p2)
                  :mod (s / significant~e.21)
                  :time (a2 / after
                        :op1 (s2 / stimulate-01~e.35
                              :quant (a5 / and~e.30
                                    :op1 (t3 / temporal-quantity
                                          :quant "60"~e.26
                                          :unit m3)
                                    :op2 (t4 / temporal-quantity
                                          :quant "120"~e.28
                                          :unit m3)
                                    :op3 (t5 / temporal-quantity
                                          :quant "240"~e.31
                                          :unit m3))))
                  :compared-to~e.36 (c / cell~e.38
                        :ARG1-of (t6 / treat-04~e.39
                              :ARG2~e.40 p~e.41,42,43
                              :manner (a6 / alone~e.44)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a7 / and~e.18
                  :op1 (f / figure :mod "4"~e.50)
                  :op2 (n3 / net-power-radiated
                        :value (l2 / less-than :op1 "0.05")))))

# ::tok Pretreatment with CCPA ( A1 receptor agonist ) , NECA ( non @-@ specific A1 and A2 receptor agonist ) , and CGS21680 ( A2A receptor agonist ) all resulted in a 14 @- to 15 @-@ fold increase in STAT1 activity over control cells , levels comparable to what was observed in cells treated with IFN @-@ gamma alone ( Fig . 6 , A ? C )
# ::alignments 2-1.1.1.1.1.1.1 4-1.1.1.1.1.2.1.1.1 5-1.1.1.1.1.2.1.1.2 6-1.1.1.1.1.2.1.1.3 9-1.1.1.1.2.1.1 11-1.1.1.1.2.2.1.1.1.1 11-1.1.1.1.2.2.1.2.1.1 13-1.1.1.1.2.2.1.1.1.1 13-1.1.1.1.2.2.1.2.1.1 14-1.1.1.1.2.2.1.1.1.2 15-1.1.1.1.2.2.1 16-1.1.1.1.2.2.1.2.1.2 17-1.1.1.1.2.2.1.1.1.3 17-1.1.1.1.2.2.1.2.1.3 18-1.1.1.1.1 18-1.1.1.1.2 18-1.1.1.1.2.2.1.1.1.4 18-1.1.1.1.2.2.1.2.1.4 18-1.1.1.1.3 21-1.1.1.1 21-1.1.1.1.2.2.1 22-1.1.1.1.3.1.1 24-1.1.1.1.3.2.1.1.1 25-1.1.1.1.3.2.1.1.2 26-1.1.1.1.3.2.1.1.3 29-1.1 30-1.1.2.r 32-1.1.2.2.1.1 35-1.1.2.2.2.1 38-1.1.2 40-1.1.2.1.1.1.1 43-1.1.2.3.1 44-1.1.2.3 46-1.1.2.2.3.1 51-1.1.2.2.3.1.1 52-1.1.2.2.3.1.1.1.r 53-1.1.2.2.3.1.1.1 54-1.1.2.2.3.1.1.1.1 55-1.1.2.2.3.1.1.1.1.1.r 56-1.1.2.2.3.1.1.1.1.1.1.1 58-1.1.2.2.3.1.1.1.1.1.1.1 59-1.1.2.2.3.1.1.1.1.1.2
# ::id bel_pmid_1984_6878_18750
(a / and
      :op1 (r / result-01~e.29
            :ARG1 (p / pretreat-00
                  :ARG2 (a2 / and~e.21
                        :op1 (a3 / agonist~e.18
                              :name (n / name :op1 "CCPA"~e.2)
                              :ARG1-of (m / mean-01
                                    :ARG2 (m4 / molecular-physical-entity
                                          :name (n10 / name
                                                :op1 "A1"~e.4
                                                :op2 "receptor"~e.5
                                                :op3 "agonist"~e.6))))
                        :op2 (a4 / agonist~e.18
                              :name (n2 / name :op1 "NECA"~e.9)
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (a10 / and~e.15,21
                                          :op1 (m5 / molecular-physical-entity
                                                :name (n6 / name
                                                      :op1 "non-specific"~e.11,13
                                                      :op2 "A1"~e.14
                                                      :op3 "receptor"~e.17
                                                      :op4 "agonist"~e.18))
                                          :op2 (m6 / molecular-physical-entity
                                                :name (n11 / name
                                                      :op1 "non-specific"~e.11,13
                                                      :op2 "A2"~e.16
                                                      :op3 "receptor"~e.17
                                                      :op4 "agonist"~e.18)))))
                        :op3 (a5 / agonist~e.18
                              :name (n3 / name :op1 "CGS21680"~e.22)
                              :ARG1-of (m3 / mean-01
                                    :ARG2 (m7 / molecular-physical-entity
                                          :name (n7 / name
                                                :op1 "A2A"~e.24
                                                :op2 "receptor"~e.25
                                                :op3 "agonist"~e.26))))))
            :ARG2~e.30 (i / increase-01~e.38
                  :ARG1 (a6 / act-01
                        :ARG0 (p2 / protein
                              :name (n4 / name :op1 "STAT1"~e.40)))
                  :ARG2 (b / between
                        :op1 (p3 / product-of :value "14"~e.32)
                        :op2 (p4 / product-of :value "15"~e.35)
                        :ARG1-of (c3 / compare-01
                              :ARG2 (l2 / level~e.46
                                    :ARG1-of (o / observe-01~e.51
                                          :location~e.52 (c4 / cell~e.53
                                                :ARG1-of (t2 / treat-04~e.54
                                                      :ARG2~e.55 (p5 / protein
                                                            :name (n5 / name :op1 "IFN-gamma"~e.56,58)
                                                            :mod (a7 / alone~e.59))))))))
                  :location (c / cell~e.44
                        :mod (c2 / control-01~e.43))))
      :ARG1-of (d / describe-01
            :ARG0 (a8 / and
                  :op1 (f / figure :mod "6A")
                  :op2 (f2 / figure :mod "6C"))))

# ::tok As expected , we found that IFN @-@ gamma led to a rapid rise in both JAK1 and JAK2 phosphorylation band density above baseline levels , and this IFN @-@ gamma @-@ induced JAK activation was not altered by adenosine treatment at any time point ( data not shown ) .
# ::alignments 0-1.2.4.r 1-1.4 3-1.1.1 4-1.1 5-1.1.2.r 6-1.1.2.1.1.1 8-1.1.2.1.1.1 9-1.1.2 12-1.1.2.2.3 13-1.1.2.2 16-1.1.2.2.1.1.1.1.1.1.1 17-1.1.2.2.1.1.1.1 18-1.1.2.2.1.1.1.1.2.1.1 19-1.1.2.2.1.1.1 20-1.1.2.2.1.1 21-1.1.2.2.1 22-1.1.2.2.2 23-1.1.2.2.2.1.1 24-1.1.2.2.2.1 28-1.1.2.1.1.1 30-1.1.2.1.1.1 32-1.2.3.2 33-1.2.3.1.1.1 34-1.2.3 36-1.2.1 36-1.2.1.r 37-1.2 38-1.2.2.r 39-1.2.2.1.1.1 40-1.2.2 42-1.2.4.1 43-1.2.4.r 44-1.2.4 46-1.3.1 47-1.3.1.1.1 47-1.3.1.1.1.r 48-1.3.1.1
# ::id bel_pmid_1984_6878_27666
(a / and
      :op1 (f / find-01~e.4
            :ARG0 (w / we~e.3)
            :ARG1~e.5 (l / lead-03~e.9
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "IFN-gamma"~e.6,8,28,30))
                  :ARG2 (r / rise-01~e.13
                        :ARG1 (d / density~e.21
                              :poss (b / band~e.20
                                    :mod (p / phosphorylate-01~e.19
                                          :ARG1 (a2 / and~e.17
                                                :op1 (p3 / protein
                                                      :name (n2 / name :op1 "JAK1"~e.16))
                                                :op2 (p4 / protein
                                                      :name (n3 / name :op1 "JAK2"~e.18))))))
                        :ARG4 (a7 / above~e.22
                              :op1 (l2 / level~e.24
                                    :mod (b2 / baseline~e.23)))
                        :mod (r2 / rapid~e.12))))
      :op2 (a3 / alter-01~e.37
            :polarity~e.36 "-"~e.36
            :ARG0~e.38 (t / treat-04~e.40
                  :ARG1 (m / molecular-physical-entity
                        :name (n5 / name :op1 "adenosine"~e.39)))
            :ARG1 (a4 / activate-01~e.34
                  :ARG1 (p5 / protein
                        :name (n4 / name :op1 "JAK"~e.33))
                  :ARG1-of (i / induce-01~e.32
                        :ARG0 p2))
            :time~e.0,43 (p6 / point~e.44
                  :mod (a6 / any~e.42)))
      :ARG1-of (d2 / describe-01
            :ARG0 (d3 / data~e.46
                  :ARG1-of (s / show-01~e.48 :polarity~e.47 "-"~e.47)))
      :ARG1-of (e / expect-01~e.1))

# ::tok Mechanistically , endothelial a6 @-@ integrin deficiency elevated significantly VEGF @-@ mediated angiogenesis both in vivo and ex vivo .
# ::alignments 0-1.4 2-1.1.1.2 3-1.1.1.1.1 5-1.1.1.1.1 7-1 8-1.3 8-1.3.r 9-1.2.1.1.1.1 11-1.2.1 12-1.2 13-1.5.3 14-1.5.1 15-1.5.1 15-1.5.2 16-1.5 17-1.5.2 18-1.5.1
# ::id bel_pmid_1996_7723_42048
(e / elevate-01~e.7
      :ARG0 (l / lack-01
            :ARG1 (p / protein
                  :name (n / name :op1 "a6-integrin"~e.3,5)
                  :mod (e2 / endothelium~e.2)))
      :ARG1 (a / angiogenesis~e.12
            :ARG1-of (m2 / mediate-01~e.11
                  :ARG0 (p2 / protein
                        :name (n2 / name :op1 "VEGF"~e.9))))
      :manner~e.8 (s / significant~e.8)
      :manner (m / mechanistic~e.0)
      :manner (a2 / and~e.16
            :op2 (i / in-vivo~e.14,15,18)
            :op2 (e3 / ex-vivo~e.15,17)
            :mod (b / both~e.13)))

# ::tok In particular , a6 @-@ integrin @-@ deficient endothelial cells displayed increased levels of VEGF @-@ receptor 2 ( VEGFR2 ) and VEGF @-@ mediated downstream ERK1 @/@ 2 activation .
# ::alignments 1-1.3 3-1.1.2.1.1.1 5-1.1.2.1.1.1 8-1.1.1 9-1.1 10-1 11-1.2.1.2 12-1.2.1 13-1.2.1.1.r 14-1.2.1.1.1.1 16-1.2.1.1.1.1 17-1.2.1.1.1.2 21-1.2 22-1.2.2.3.1.1.1 24-1.2.2.3 25-1.2.2.2 26-1.2.2.1.1.1 28-1.2.2.1.1.1 29-1.2.2
# ::id bel_pmid_1996_7723_42050
(d / display-01~e.10
      :ARG0 (c / cell~e.9
            :mod (e / endothelium~e.8)
            :ARG0-of (l / lack-01
                  :ARG1 (p / protein
                        :name (n / name :op1 "a6-integrin"~e.3,5))))
      :ARG1 (a / and~e.21
            :op1 (l2 / level~e.12
                  :quant-of~e.13 (p2 / protein
                        :name (n2 / name :op1 "VEGF-receptor"~e.14,16 :op2 "2"~e.17))
                  :ARG1-of (i / increase-01~e.11))
            :op2 (a2 / activate-01~e.29
                  :ARG1 (e2 / enzyme
                        :name (n3 / name :op1 "ERK1/2"~e.26,28))
                  :location (d2 / downstream~e.25)
                  :ARG1-of (m / mediate-01~e.24
                        :ARG0 (p3 / protein
                              :name (n4 / name :op1 "VEGF"~e.22)))))
      :mod (p4 / particular~e.1))

# ::tok Blood vessels associated with IDC showed a significant reduction in mean a6 @-@ integrin pixel intensity when compared with blood vessels from normal breast tissue (**p < 0.0001 , Figure 1b ) .
# ::alignments 0-1.1.1 1-1.1 2-1.1.2 3-1.1.2.1.r 4-1.1.2.1.1.1 5-1 7-1.2.2 8-1.2 10-1.2.1.2 10-1.4 11-1.2.1.1.1.1.1 13-1.2.1.1.1.1.1 14-1.2.1.1 17-1.2.3.r 19-1.2.3.1 20-1.2.3 21-1.2.3.2.r 22-1.2.3.2.2 23-1.2.3.2.1 24-1.2.3.2 27-1.4.1.1.1 29-1.3.1 30-1.3.1.1
# ::id bel_pmid_1996_7723_42052
(s / show-01~e.5
      :ARG0 (v / vessel~e.1
            :mod (b / blood~e.0)
            :ARG1-of (a / associate-01~e.2
                  :ARG2~e.3 (d / disease
                        :name (n3 / name :op1 "IDC"~e.4))))
      :ARG1 (r / reduce-01~e.8
            :ARG1 (i2 / intensify-01
                  :ARG1 (p / pixel~e.14
                        :mod (p4 / protein
                              :name (n / name :op1 "a6-integrin"~e.11,13)))
                  :mod (m / mean~e.10))
            :mod (s2 / significant~e.7)
            :compared-to~e.17 (v2 / vessel~e.20
                  :mod (b2 / blood~e.19)
                  :location~e.21 (t / tissue~e.24
                        :mod (b3 / breast~e.23)
                        :mod (n2 / normal~e.22))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.29 :mod "1b"~e.30))
      :ARG1-of (m2 / mean-01~e.10
            :ARG2 (n4 / net-power-radiated
                  :value (l / less-than :op1 "0.0001"~e.27))))

# ::tok The results showed that there was a significant increase in tumour blood vessel density in a6 fl @/@ fl @-@ Tie1Cre+ mice compared with a6 fl @/@ fl @-@ Tie1Cre @- controls (*p < 0.02 , Figure 3b ) .
# ::alignments 1-1.1 1-1.1.1 1-1.1.1.r 2-1 7-1.2.2 8-1.2 11-1.2.1.1.1 12-1.2.1.1 13-1.2.1 16-1.2.3.1.1.1 18-1.2.3.1.1.1 21-1.2.3 22-1.2.4 25-1.2.4.1.1.1.1 27-1.2.4.1.1.1.1 29-1.2.4.1.1.1.1 31-1.2.4.1 34-1.4.1.1.1 36-1.3.1 37-1.3.1.1
# ::id bel_pmid_1996_7723_42058
(s / show-01~e.2
      :ARG0 (t2 / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1))
      :ARG1 (i / increase-01~e.8
            :ARG1 (d / density~e.13
                  :poss (v / vessel~e.12
                        :mod (b / blood~e.11)
                        :mod (t / tumor)))
            :ARG1-of (s2 / significant-02~e.7)
            :location (m / mouse~e.21
                  :mod (g / gene
                        :name (n / name :op1 "a6fl/fl-Tie1Cre"~e.16,18)
                        :mod (w / wild-type)))
            :ARG1-of (c / compare-01~e.22
                  :ARG2 (c2 / control~e.31
                        :mod (g2 / gene
                              :name (n2 / name :op1 "a6fl/fl-Tie1Cre"~e.25,27,29)
                              :ARG2-of (m2 / mutate-01 :mod "-/-")))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.36 :mod "3b"~e.37))
      :ARG1-of (m3 / mean-01
            :ARG2 (n3 / net-power-radiated
                  :value (l2 / less-than :op1 "0.02"~e.34))))

# ::tok As predicted , the absence of a6 @-@ integrin reduced the ability of the a6-/— cells to adhere and migrate to Lm but did not affect the ability of these cells to adhere or migrate on Fn , Col or Vn (*p < 0.05 , Figures 5c and 5d ) .
# ::alignments 1-1.5 4-1.1 5-1.1.1.r 6-1.1.1.1.1 8-1.1.1.1.1 8-1.2.1.1.1.1 9-1 11-1.2 15-1.2.2.1.1 17-1.2.2.1 18-1.2.2 19-1.2.2.2 22-1.3 24-1.3.1.1 24-1.3.1.1.r 25-1.3.1 27-1.3.1.3 30-1.3.1.3.2.1.1 32-1.3.1.3.2.1 33-1.3.1.3.2.1.2 34-1.3.1.3.2.2 39-1.3.1.3.2.2.2 43-1.6.1.1.1 45-1.4.1.1 45-1.4.1.2 46-1.4.1.1.1 47-1.4.1 48-1.4.1.2.1
# ::id bel_pmid_1996_7723_42064
(r / reduce-01~e.9
      :ARG0 (a / absent-01~e.4
            :ARG1~e.5 (p / protein
                  :name (n / name :op1 "a6-integrin"~e.6,8)))
      :ARG1 (c / capable-01~e.11
            :ARG1 (c2 / cell
                  :mod (p2 / protein
                        :name (n2 / name :op1 "a6-integrin"~e.8)
                        :ARG2-of (m / mutate-01 :mod "-/-")))
            :ARG2 (a2 / and~e.18
                  :op1 (a3 / adhere-01~e.17
                        :ARG1 c2~e.15
                        :ARG2 (p3 / protein
                              :name (n3 / name :op1 "laminin")))
                  :op2 (m2 / migrate-01~e.19
                        :ARG0 c2
                        :ARG1 p3)))
      :ARG1-of (c3 / contrast-01~e.22
            :ARG2 (a4 / affect-01~e.25
                  :polarity~e.24 "-"~e.24
                  :ARG0 a
                  :ARG1 (c4 / capable-01~e.27
                        :ARG1 c2
                        :ARG2 (a5 / and
                              :op1 (a6 / adhere-01~e.32
                                    :ARG1 c2~e.30
                                    :ARG2 (o / or~e.33
                                          :op1 (p4 / protein
                                                :name (n4 / name :op1 "fibronectin"))
                                          :op2 (p5 / protein
                                                :name (n5 / name :op1 "collagen"))
                                          :op3 (p6 / protein
                                                :name (n6 / name :op1 "vitronectin"))))
                              :op2 (m3 / migrate-01~e.34
                                    :ARG0 c2
                                    :ARG1 (o2 / or~e.39
                                          :op1 p4
                                          :op2 p5
                                          :op2 p6))))))
      :ARG1-of (d / describe-01
            :ARG0 (a7 / and~e.47
                  :op1 (f / figure~e.45 :mod "5c"~e.46)
                  :op2 (f2 / figure~e.45 :mod "5d"~e.48)))
      :ARG1-of (p9 / predict-01~e.1)
      :ARG1-of (m4 / mean-01
            :ARG2 (n7 / net-power-radiated
                  :value (l / less-than :op1 "0.05"~e.43))))

# ::tok Western blot analysis revealed that VEGF stimulated the phosphorylation of ERK1 @/@ 2 in both a6 fl @/@ fl @-@ Tie1Cre @-@ and a6 fl @/@ fl @-@ Tie1Cre+ endothelial cells and that the levels of phosphorylated ERK1 @/@ 2 ( pERK1 @/@ 2 ) detected in a6 fl @/@ fl @-@ Cre+ endothelial cells after a VEGF stimulus were dramatically higher than those detected in a6 fl @/@ flTie1Cre @- endothelial cells ( Figure 6b ) .
# ::alignments 0-1.1.1.1 1-1.1.1.2 2-1.1 3-1 4-1.2.r 5-1.2.1.1.1.1 6-1.2.1 8-1.2.1.2 9-1.2.1.2.1.r 10-1.2.1.2.1.1.1 12-1.2.1.2.1.1.1 16-1.2.1.3.1.1.1.1 16-1.2.1.3.2.1.1.1 18-1.2.1.3.1.1.1.1 18-1.2.1.3.2.1.1.1 20-1.2.1.3.1.1.1.1 20-1.2.1.3.2.1.1.1 22-1.2.1.3 24-1.2.1.3.1.1.1.1 24-1.2.1.3.2.1.1.1 26-1.2.1.3.1.1.1.1 26-1.2.1.3.2.1.1.1 29-1.2.1.3.1.2 30-1.2.1.3.1 30-1.2.1.3.2 31-1.2.1.3 32-1.2.r 34-1.2.2.1 34-1.2.2.5.1 35-1.2.2.1.1.r 36-1.2.2.1.1.2 37-1.2.2.1.1.1.1 39-1.2.2.1.1.1.1 43-1.2.2.1.1.1.1 45-1.2.2.5.1.1 48-1.2.1.3.1.1.1.1 48-1.2.1.3.2.1.1.1 50-1.2.1.3.1.1.1.1 50-1.2.1.3.2.1.1.1 53-1.2.1.3.1.2 54-1.2.1.3.1 55-1.2.2.3 57-1.2.2.3.1.1 58-1.2.2.3.1 59-1.2.2.1.r 60-1.2.2.2 61-1.2.2 61-1.2.2.4 61-1.2.2.4.r 64-1.2.2.1.1.3 67-1.2.1.3.1.1.1.1 67-1.2.1.3.2.1.1.1 71-1.2.1.3.1.2 72-1.2.1.3.1 74-1.3.1 75-1.3.1.1
# ::id bel_pmid_1996_7723_42068
(r / reveal-01~e.3
      :ARG0 (a5 / analyze-01~e.2
            :name (n6 / name :op1 "western"~e.0 :op2 "blot"~e.1))
      :ARG1~e.4,32 (a2 / and
            :op1 (s / stimulate-01~e.6
                  :ARG0 (p / protein
                        :name (n / name :op1 "VEGF"~e.5))
                  :ARG1 (p2 / phosphorylate-01~e.8
                        :ARG1~e.9 (e / enzyme
                              :name (n2 / name :op1 "ERK1/2"~e.10,12)))
                  :location (a3 / and~e.22,31
                        :op1 (c / cell~e.30,54,72
                              :mod (p3 / pathway
                                    :name (n3 / name :op1 "a6fl/fl-Tie1Cre"~e.16,18,20,24,26,48,50,67)
                                    :ARG2-of (m / mutate-01 :mod "-/-"))
                              :mod (e2 / endothelium~e.29,53,71))
                        :op2 (c2 / cell~e.30
                              :mod (p4 / pathway
                                    :name (n4 / name :op1 "a6fl/fl-Tie1Cre"~e.16,18,20,24,26,48,50,67)
                                    :mod (w2 / wild-type))
                              :mod e2)))
            :op2 (h / high~e.61
                  :domain~e.59 (l / level~e.34
                        :quant-of~e.35 (e3 / enzyme
                              :name (n5 / name :op1 "ERK1/2"~e.37,39,43)
                              :ARG3-of (p5 / phosphorylate-01~e.36)
                              :ARG1-of (d2 / detect-01~e.64
                                    :location c)))
                  :mod (d / dramatic~e.60)
                  :time (a4 / after~e.55
                        :op1 (s2 / stimulus~e.58
                              :mod p~e.57))
                  :degree~e.61 (m2 / more~e.61)
                  :ARG1-of (c3 / compare-01
                        :ARG2 (l2 / level~e.34
                              :ARG1-of (d3 / detect-01~e.45
                                    :location c2)))))
      :ARG1-of (d4 / describe-01
            :ARG0 (f / figure~e.74 :mod "6b"~e.75)))

# ::tok Furthermore , blockade of VEGFR2 using the function blocking monoclonal antibody to VEGFR2 , DC101 [26], ablated these enhanced VEGF @-@ mediated responses , demonstrating that the enhanced ERK1 @/@ 2 phosphorylation was via VEGFR2 ( Figure 6b ) .
# ::alignments 4-1.1.1.1.1.1 5-1.1.1.3 7-1.1.1.3.1.3.1.2.1 8-1.1.1 8-1.1.1.3.1.3.1.2 9-1.1.1.3.1.3.1.1 10-1.1.1.3.1.3.1 12-1.1.1.1.1.1 14-1.1.1.3.1.1.1 16-1.1 17-1.1.2.2 18-1.1.2.3 19-1.1.2.4.1.1.1 21-1.1.2.4 22-1.1.2 22-1.1.2.1 22-1.1.2.1.r 24-1.1.3 25-1.1.3.1.r 27-1.1.3.1.3 28-1.1.3.1.1.1.1 30-1.1.3.1.1.1.1 31-1.1.3.1 34-1.1.3.1.2 36-1.1.4.1 37-1.1.4.1.1
# ::id bel_pmid_1996_7723_42070
(a / and
      :op2 (a2 / ablate-00~e.16
            :ARG0 (b / block-01~e.8
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "VEGFR2"~e.4,12))
                  :ARG1-of (d / describe-01
                        :ARG0 (p2 / publication
                              :ARG1-of (c2 / cite-01 :ARG2 "26")))
                  :ARG0-of (u / use-01~e.5
                        :ARG1 (s / small-molecule
                              :name (n7 / name :op1 "DC101"~e.14)
                              :ARG0-of (c3 / counter-01
                                    :ARG1 e)
                              :ARG1-of (m / mean-01
                                    :ARG2 (a3 / antibody~e.10
                                          :mod (m3 / monoclonal~e.9)
                                          :ARG0-of (b2 / block-01~e.8
                                                :ARG1 (f2 / function-01~e.7)))))))
            :ARG1 (t / thing~e.22
                  :ARG2-of~e.22 (r / respond-01~e.22)
                  :mod (t2 / this~e.17)
                  :ARG1-of (e2 / enhance-01~e.18)
                  :ARG1-of (m2 / mediate-01~e.21
                        :ARG0 (e5 / enzyme
                              :name (n5 / name :op1 "VEGF"~e.19))))
            :ARG0-of (d2 / demonstrate-01~e.24
                  :ARG1~e.25 (p4 / phosphorylate-01~e.31
                        :ARG1 (e3 / enzyme
                              :name (n6 / name :op1 "ERK1/2"~e.28,30))
                        :ARG2 e~e.34
                        :ARG1-of (e4 / enhance-01~e.27)))
            :ARG1-of (d3 / describe-01
                  :ARG0 (f / figure~e.36 :mod "6b"~e.37))))

# ::tok The mouse tumors mimic molecular hallmarks of their human tumor counterparts , including elevated IL @-@ 6/Stat3/Bcl @-@ X( L ) signaling . The newly developed mouse strains may provide a good preclinical research tool for the design and testing of new approaches to target IL @-@ 6 in treatment and prevention of human PCNs .
# ::alignments 1-1.1.1.1 2-1.1.1 3-1.1 4-1.1.2.1 5-1.1.2 8-1.1.2.2.1.1 9-1.1.2.2.1 10-1.1.2.2 12-1.1.2.3 13-1.1.2.3.1.2 14-1.1.2.3.1.1.1.1 21-1.1.2.3.1 24-1.2.1.1.2.1 25-1.2.1.1.2 26-1.2.1.1.1 27-1.2.1.1 28-1.2 29-1.2.1 31-1.2.1.2.1 32-1.2.1.2.2 33-1.2.1.2.3 34-1.2.1.2 35-1.2.1.2.4.r 37-1.2.1.2.4.1 38-1.2.1.2.4 39-1.2.1.2.4.2 40-1.2.1.2.4.1.1.r 41-1.2.1.2.4.1.1.2 42-1.2.1.2.4.1.1 44-1.2.1.2.4.1.1.1 45-1.2.1.2.4.1.1.1.1.1.1 47-1.2.1.2.4.1.1.1.1.1.1 48-1.2.1.2.4.1.1.1.2.r 49-1.2.1.2.4.1.1.1.2.1 50-1.2.1.2.4.1.1.1.2 51-1.2.1.2.4.1.1.1.2.2 52-1.2.1.2.4.1.1.1.2.1.1.r 53-1.2.1.2.4.1.1.1.2.1.1.2
# ::id bel_pmid_2001_8915_2588
(m / multi-sentence
      :snt1 (m2 / mimic-01~e.3
            :ARG0 (t / tumor~e.2
                  :mod (m3 / mouse~e.1))
            :ARG1 (h / hallmark~e.5
                  :mod (m4 / molecule~e.4)
                  :poss (c / counterpart~e.10
                        :mod (t2 / tumor~e.9
                              :mod (h2 / human~e.8))
                        :poss m3)
                  :ARG2-of (i / include-01~e.12
                        :ARG1 (s / signal-07~e.21
                              :ARG1 (p / pathway
                                    :name (n / name :op1 "IL-6/Stat3/Bcl-X(L)"~e.14))
                              :ARG1-of (e / elevate-01~e.13)))))
      :snt2 (p2 / possible~e.28
            :domain (p3 / provide-01~e.29
                  :ARG0 (s2 / strain~e.27
                        :mod (m5 / mouse~e.26)
                        :ARG1-of (d / develop-02~e.25
                              :mod (n2 / new~e.24)))
                  :ARG1 (t4 / tool~e.34
                        :mod (g / good~e.31)
                        :mod (p4 / preclinical~e.32)
                        :mod (r / research-01~e.33)
                        :purpose~e.35 (a / and~e.38
                              :op1 (d2 / design-01~e.37
                                    :ARG1~e.40 (a2 / approach-02~e.42
                                          :ARG1 (t6 / target-01~e.44
                                                :ARG1 (p5 / protein
                                                      :name (n4 / name :op1 "IL-6"~e.45,47))
                                                :purpose~e.48 (a3 / and~e.50
                                                      :op1 (t7 / treat-03~e.49
                                                            :ARG1~e.52 (d3 / disease
                                                                  :name (n5 / name :op1 "PCN")
                                                                  :mod (h3 / human~e.53)))
                                                      :op2 (p6 / prevent-01~e.51
                                                            :ARG1 d3)))
                                          :mod (n3 / new~e.41)))
                              :op2 (t5 / test-01~e.39
                                    :ARG1 a2))))))

# ::tok However , in CD4+ T cells from naive mice , IL @-@ 23 significantly increased the TGFbeta1 @/@ IL @-@ 6 @-@ induced Th17 polarization , including elevated levels of IL @-@ 17A and IL @-@ 17F and decreased expression of T @-@ bet and FoxP3. Of note , the IL @-@ 23 @-@ induced increase in IL @-@ 17A and IL @-@ 17F levels was prevented in T @-@ bet @-@ deficient mice .
# ::alignments 0-1.1 4-1.1.2.1.1 5-1.1.1.2.1 5-1.1.2 6-1.1.2.3.r 7-1.1.2.3.1 8-1.1.2.3 10-1.1.1.1.1.1 12-1.1.1.1.1.1 13-1.1.1.3 13-1.1.1.3.r 14-1.1.1 16-1.1.1.2.2.1.1.1.1 18-1.1.1.2.2.1.2.1.1 20-1.1.1.2.2.1.2.1.1 22-1.1.1.2.2 23-1.1.1.2.1.1.1 24-1.1.1.2 26-1.1.1.4 27-1.1.1.4.1.1.2 28-1.1.1.4.1.1 28-1.1.1.4.1.2 30-1.1.1.4.1.1.1.1.1 30-1.1.1.4.1.2.1.1.1 32-1.1.1.4.1.1.1.1.1 33-1.1.1.4.1 34-1.1.1.4.1.1.1.1.1 34-1.1.1.4.1.2.1.1.1 36-1.1.1.4.1.2.1.1.1 37-1.1.1.4.1 37-1.1.1.4.1.3.1 38-1.1.1.4.1.3.2 39-1.1.1.4.1.3 40-1.1.1.4.1.3.1.r 41-1.1.1.4.1.3.1.1.1.1 43-1.1.1.4.1.3.1.1.1.1 44-1.1.1.4.1 47-1.2.3 50-1.2.1.2.1.1.1 52-1.2.1.2.1.1.1 54-1.2.1.2 55-1.2.1 57-1.2.1.1.1.1.1.1 57-1.2.1.1.2.1.1.1 57-1.2.1.2.1.1.1 59-1.2.1.1.1.1.1.1 60-1.2.1.1 61-1.2.1.1.1.1.1.1 61-1.2.1.1.2.1.1.1 63-1.2.1.1.2.1.1.1 64-1.2.1.1.1 64-1.2.1.1.2 66-1.2 67-1.2.2.r 68-1.2.2.1.1.1.1 70-1.2.2.1.1.1.1 73-1.2.2
# ::id bel_pmid_2013_1264_20312
(m / multi-sentence
      :snt1 (c / contrast-01~e.0
            :ARG2 (i / increase-01~e.14
                  :ARG0 (p / protein
                        :name (n / name :op1 "IL-23"~e.10,12))
                  :ARG1 (p2 / polarize-01~e.24
                        :ARG1 (c2 / cell~e.5
                              :name (n2 / name :op1 "Th17"~e.23))
                        :ARG1-of (i2 / induce-01~e.22
                              :ARG0 (m2 / macro-molecular-complex
                                    :part (p3 / protein
                                          :name (n3 / name :op1 "TGFbeta1"~e.16))
                                    :part (p4 / protein
                                          :name (n4 / name :op1 "IL-6"~e.18,20)))))
                  :manner~e.13 (s / significant~e.13)
                  :ARG2-of (i3 / include-01~e.26
                        :ARG1 (a / and~e.33,37,44
                              :op1 (l / level~e.28
                                    :quant-of (p5 / protein
                                          :name (n5 / name :op1 "IL-17A"~e.30,32,34))
                                    :ARG1-of (e / elevate-01~e.27))
                              :op2 (l2 / level~e.28
                                    :quant-of (p6 / protein
                                          :name (n6 / name :op1 "IL-17F"~e.30,34,36))
                                    :ARG1-of e)
                              :op3 (e2 / express-03~e.39
                                    :ARG2~e.40 (a2 / and~e.37
                                          :op1 (p7 / protein
                                                :name (n7 / name :op1 "T-bet"~e.41,43))
                                          :op2 (p8 / protein
                                                :name (n8 / name :op1 "FoxP3")))
                                    :ARG1-of (d / decrease-01~e.38)))))
            :location (c3 / cell~e.5
                  :name (n9 / name :op1 "T"~e.4)
                  :mod (p9 / protein
                        :name (n10 / name :op1 "CD4")
                        :mod (w / wild-type))
                  :source~e.6 (m4 / mouse~e.8
                        :mod (n11 / naive~e.7))))
      :snt2 (p10 / prevent-01~e.66
            :ARG1 (i4 / increase-01~e.55
                  :ARG1 (a3 / and~e.60
                        :op1 (l3 / level~e.64
                              :quant-of (p12 / protein
                                    :name (n13 / name :op1 "IL-17A"~e.57,59,61)))
                        :op2 (l4 / level~e.64
                              :quant-of (p13 / protein
                                    :name (n14 / name :op1 "IL-17F"~e.57,61,63))))
                  :ARG1-of (i5 / induce-01~e.54
                        :ARG0 (p11 / protein
                              :name (n12 / name :op1 "IL-23"~e.50,52,57))))
            :location~e.67 (m5 / mouse~e.73
                  :ARG0-of (l5 / lack-01
                        :ARG1 (p14 / protein
                              :name (n15 / name :op1 "T-bet"~e.68,70))))
            :ARG1-of (n16 / note-01~e.47)))

# ::tok In contrast to TGFbeta1 @/@ IL @-@ 6 , IL @-@ 23 was critical for the induction of IL @-@ 22 in CD4+ T cells from both naive and CII @-@ immunized DBA/1 mice .
# ::alignments 1-1.1 1-1.1.2 1-1.1.2.r 2-1.1.2.1.r 3-1.1.2.1.1.1.1 5-1.1.2.1.2.1.1 7-1.1.2.1.2.1.1 9-1.1.1.1 9-1.1.2.1.2.1.1 11-1.1.1.1 12-1.1.r 13-1 14-1.2.r 16-1.2 17-1.2.1.r 18-1.2.1.1.1 20-1.2.1.1.1 23-1.2.2.1.1 24-1.2.2 25-1.2.2.3.r 26-1.2.2.3.3 27-1.2.2.3.1.2 28-1.2.2.3 31-1.2.2.3.2.2 32-1.2.2.3.1.1.1 32-1.2.2.3.2.1.1 33-1.2.2.3.1.1.2 33-1.2.2.3.2.1.2
# ::id bel_pmid_2013_1264_5500
(c / critical~e.13
      :domain~e.12 (p / protein~e.1
            :name (n / name :op1 "IL-23"~e.9,11)
            :ARG1-of~e.1 (c3 / contrast-01~e.1
                  :ARG2~e.2 (m4 / macro-molecular-complex
                        :part (p5 / protein
                              :name (n8 / name :op1 "TGFbeta1"~e.3))
                        :part (p6 / protein
                              :name (n9 / name :op1 "IL-6"~e.5,7,9)))))
      :purpose~e.14 (i / induce-01~e.16
            :ARG1~e.17 (p2 / protein
                  :name (n2 / name :op1 "IL-22"~e.18,20))
            :location (c2 / cell~e.24
                  :name (n3 / name :op1 "T"~e.23)
                  :mod (p3 / protein
                        :name (n4 / name :op1 "CD4")
                        :mod (w / wild-type))
                  :source~e.25 (a / and~e.28
                        :op1 (o / organism
                              :name (n5 / name :op1 "DBA/1"~e.32 :op2 "mouse"~e.33)
                              :mod (n7 / naive~e.27))
                        :op2 (o2 / organism
                              :name (n6 / name :op1 "DBA/1"~e.32 :op2 "mouse"~e.33)
                              :ARG1-of (i2 / immunize-01~e.31
                                    :ARG0 (p4 / protein
                                          :name (n10 / name :op1 "collagen" :op2 "II"))))
                        :mod (b / both~e.26)))))

# ::tok : In CD4+ T cells from naive DBA/1 mice , IL @-@ 23 alone hardly induced retinoic acid @-@ related orphan receptor gammat ( RORgammat ) , Th17 polarization , and Th17 cytokines , but it inhibited T @-@ bet expression .
# ::alignments 3-1.3.1.1 4-1.1.2.2.1 4-1.3 5-1.3.3.r 7-1.3.3.1.1 8-1.3.3.1.2 10-1.1.1.1.1 12-1.1.1.1.1 13-1.1.1.2 14-1.1.3 15-1.1 16-1.1.2.1.1.1 17-1.1.2.1.1.2 19-1.1.2.1.1.2 20-1.1.2.1.1.3 21-1.1.2.1.1.4 22-1.1.2.1.1.5 27-1.1.2.2.1.1.1 28-1.1.2.2 31-1.1.2.2.1.1.1 34-1 35-1.2.1 36-1.2 37-1.2.2.1.1.1 39-1.2.2.1.1.1 40-1.2.2
# ::id bel_pmid_2013_1264_5504
(c / contrast-01~e.34
      :ARG1 (i / induce-01~e.15
            :ARG0 (p / protein
                  :name (n / name :op1 "IL-23"~e.10,12)
                  :mod (a / alone~e.13))
            :ARG1 (a2 / and
                  :op1 (p2 / protein
                        :name (n2 / name
                              :op1 "retinoic"~e.16
                              :op2 "acid-related"~e.17,19
                              :op3 "orphan"~e.20
                              :op4 "receptor"~e.21
                              :op5 "gammat"~e.22))
                  :op2 (p3 / polarize-01~e.28
                        :ARG1 (c2 / cell~e.4
                              :name (n3 / name :op1 "Th17"~e.27,31)))
                  :op3 (c3 / cytokine
                        :mod c2))
            :manner (h / hardly~e.14))
      :ARG2 (i2 / inhibit-01~e.36
            :ARG0 p~e.35
            :ARG1 (e / express-03~e.40
                  :ARG1 (p4 / protein
                        :name (n4 / name :op1 "T-bet"~e.37,39))))
      :location (c4 / cell~e.4
            :name (n5 / name :op1 "T"~e.3)
            :mod (p5 / protein
                  :name (n6 / name :op1 "CD4")
                  :mod (w / wild-type))
            :source~e.5 (o / organism
                  :name (n8 / name :op1 "DBA/1"~e.7 :op2 "mouse"~e.8))))

# ::tok However , on stimulation with R848 or CpG DNA , B cells from both young and old Irf5 -/- mice produced lower levels of IL @-@ 6 than the B cells from C57BL/6 mice .
# ::alignments 0-1 4-1.1.r 5-1.1.3.1.1.1.1 6-1.1.3.1 7-1.1.3.1.2.1.1 8-1.1.3.1.2.1.2 10-1.1.1.1.1 11-1.1.1 12-1.1.1.2.r 13-1.1.1.2.3 14-1.1.1.2.1.1 15-1.1.1.2 16-1.1.1.2.2.1 17-1.1.1.2.1.2.1.1 18-1.1.1.2.1.2.2.1 19-1.1.1.2.1 20-1.1 21-1.1.2.2 21-1.1.2.2.1 21-1.1.2.2.1.r 22-1.1.2 23-1.1.2.1.r 24-1.1.2.1.1.1 26-1.1.2.1.1.1 27-1.1.2.3.r 29-1.1.2.3.1.1 30-1.1.2.3 31-1.1.2.3.2.r 32-1.1.2.3.2.1.1 33-1.1.1.2.2 33-1.1.2.3.2.1.2
# ::id bel_pmid_2017_6957_28510
(c / contrast-01~e.0
      :ARG2~e.4 (p / produce-01~e.20
            :ARG0 (c4 / cell-line~e.11
                  :name (n6 / name :op1 "B"~e.10)
                  :source~e.12 (a / and~e.15
                        :op1 (m / mouse~e.19
                              :mod (y / young~e.14)
                              :mod (p3 / protein
                                    :name (n2 / name :op1 "Irf5"~e.17)
                                    :ARG2-of (m2 / mutate-01 :mod "-/-"~e.18)))
                        :op2 (m3 / mouse~e.33
                              :mod (o / old~e.16)
                              :mod p3)
                        :mod (b / both~e.13)))
            :ARG1 (l / level~e.22
                  :quant-of~e.23 (p2 / protein
                        :name (n / name :op1 "IL-6"~e.24,26))
                  :mod (l2 / low~e.21
                        :degree~e.21 (m4 / more~e.21))
                  :compared-to~e.27 (c3 / cell-line~e.30
                        :name (n5 / name :op1 "B"~e.29)
                        :source~e.31 (o3 / organism
                              :name (n7 / name :op1 "C57BL/6"~e.32 :op2 "mouse"~e.33))))
            :time (s / simulate-01
                  :ARG2 (o2 / or~e.6
                        :op1 (s2 / small-molecule
                              :name (n3 / name :op1 "R848"~e.5))
                        :op2 (d / dna-sequence
                              :name (n4 / name :op1 "CpG"~e.7 :op2 "DNA"~e.8))))))

# ::tok There was also a decrease in IRF @-@ 4 expression in Irf5 -/- B cells , seen both on RNA and protein levels ( Fig . 4 A and B ) .
# ::alignments 2-1.2 4-1 5-1.1.r 6-1.1.1.1.1 8-1.1.1.1.1 9-1.1 10-1.1.2.r 11-1.1.2.2.1.1 12-1.1.2.2.2.1 13-1.1.2.1.1 14-1.1.2 16-1.3 18-1.3.1.r 19-1.3.1.1.1 20-1.3.1 21-1.3.1.2.1 22-1.3.1.1 22-1.3.1.2 26-1.1.1.1.1 29-1.1.2.1.1
# ::id bel_pmid_2017_6957_28512
(d / decrease-01~e.4
      :ARG1~e.5 (e / express-03~e.9
            :ARG2 (p / protein
                  :name (n / name :op1 "IRF-4"~e.6,8,26))
            :ARG3~e.10 (c2 / cell-line~e.14
                  :name (n3 / name :op1 "B"~e.13,29)
                  :mod (p2 / protein
                        :name (n2 / name :op1 "Irf5"~e.11)
                        :ARG2-of (m / mutate-01 :mod "-/-"~e.12))))
      :mod (a / also~e.2)
      :ARG1-of (s / see-01~e.16
            :location~e.18 (a2 / and~e.20
                  :op1 (l2 / level~e.22
                        :quant-of (r / RNA~e.19))
                  :op2 (l / level~e.22
                        :quant-of (p3 / protein~e.21))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a3 / and
                  :op1 (f / figure :mod "4A")
                  :op2 (f2 / figure :mod "4B"))))

# ::tok Analysis of the expression of these factors by semiquantitative RT @-@ PCR shows that purified B cells from both young and old Irf5 -/- mice exhibit significantly lower levels of Blimp @-@ 1 mRNA than B cells from the age @-@ matched C57BL/6 mice ( Fig . 4A ) .
# ::alignments 0-1.1 1-1.1.1.r 3-1.1.1 4-1.1.1.1.r 5-1.1.1.1.1 6-1.1.1.1 9-1.1.2.1.1 11-1.1.2.1.1 12-1 13-1.2.r 14-1.2.1.2 15-1.2.1.1.1 16-1.2.1 17-1.2.1.3.r 18-1.2.1.3.3 19-1.2.1.3.1.1 20-1.2.1.3 21-1.2.1.3.2.1 22-1.2.1.3.1.2.1.1 23-1.2.1.3.1.2.2.1 24-1.2.1.3.1 25-1.2 27-1.2.2.2 27-1.2.2.2.1 27-1.2.2.2.1.r 28-1.2.2 30-1.2.2.1.2.1.1.1 32-1.2.2.1.2.1.1.1 33-1.2.2.1.1.1 34-1.2.2.2.2.r 35-1.2.2.2.2.1.1 36-1.2.2.2.2 37-1.2.2.2.2.2.r 39-1.2.2.2.2.2.2.1 41-1.2.2.2.2.2.2 42-1.2.2.2.2.2.1.1 43-1.2.1.3.2 43-1.2.2.2.2.2.1.2
# ::id bel_pmid_2017_6957_28516
(s / show-01~e.12
      :ARG0 (a / analyze-01~e.0
            :ARG1~e.1 (e / express-03~e.3
                  :ARG2~e.4 (f / factor~e.6
                        :mod (t / this~e.5)))
            :manner (t2 / thing
                  :name (n4 / name :op1 "RT-PCR"~e.9,11)
                  :mod (q / quantity
                        :degree (s2 / semi))))
      :ARG1~e.13 (e2 / exhibit-01~e.25
            :ARG0 (c3 / cell-line~e.16
                  :name (n6 / name :op1 "B"~e.15)
                  :ARG1-of (p / purify-01~e.14)
                  :source~e.17 (a2 / and~e.20
                        :op1 (m / mouse~e.24
                              :mod (y / young~e.19)
                              :mod (p2 / protein
                                    :name (n / name :op1 "Irf5"~e.22)
                                    :ARG2-of (m2 / mutate-01 :mod "-/-"~e.23)))
                        :op2 (m3 / mouse~e.43
                              :mod (o / old~e.21)
                              :mod p2)
                        :mod (b / both~e.18)))
            :ARG1 (l / level~e.28
                  :quant-of (r / rna
                        :name (n2 / name :op1 "mRNA"~e.33)
                        :ARG0-of (e3 / encode-01
                              :ARG1 (p3 / protein
                                    :name (n3 / name :op1 "Blimp-1"~e.30,32))))
                  :mod (l2 / low~e.27
                        :degree~e.27 (m5 / more~e.27)
                        :compared-to~e.34 (c2 / cell-line~e.36
                              :name (n5 / name :op1 "B"~e.35)
                              :source~e.37 (o2 / organism
                                    :name (n7 / name :op1 "C57BL/6"~e.42 :op2 "mouse"~e.43)
                                    :ARG1-of (m6 / match-01~e.41
                                          :ARG1 (a3 / age~e.39)))))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "A4")))

# ::tok we found that IL @-@ 33R signaling induced a time @-@ dependent activation of Erk1 @/@ 2 , protein kinase B ( PKB ) , JNK1 @/@ 2 , NF @-@ kB , and p38 , and degradation of IkB ( supplemental Figure 1B ) .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1.1 5-1.2.1.1.1.1 6-1.2.1 7-1.2 9-1.2.2.1.2.1 11-1.2.2.1.2 12-1.2.2.1 13-1.2.2.1.1.r 14-1.2.2.1.1.1.1.1 16-1.2.2.1.1.1.1.1 16-1.2.2.1.1.3.1.1 18-1.2.2.1.1.2.1.1 19-1.2.2.1.1.2.1.2 20-1.2.2.1.1.2.1.3 25-1.2.2.1.1.3.1.1 27-1.2.2.1.1.1.1.1 27-1.2.2.1.1.3.1.1 29-1.2.2.1.1.4.1.1 31-1.2.2.1.1.4.1.1 33-1.2.2.1.1 34-1.2.2.1.1.5.1.1 36-1.2.2 37-1.2.2.2 38-1.2.2.2.1.r 39-1.2.2.2.1.1.1 41-1.3.1.2 42-1.3.1 43-1.3.1.1
# ::id bel_pmid_2020_0353_35654
(f / find-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (i2 / induce-01~e.7
            :ARG0 (s / signal-07~e.6
                  :ARG0 (p / protein
                        :name (n / name :op1 "IL-33R"~e.3,5)))
            :ARG1 (a3 / and~e.36
                  :op1 (a / activate-01~e.12
                        :ARG1~e.13 (a2 / and~e.33
                              :op1 (e / enzyme
                                    :name (n2 / name :op1 "Erk1/2"~e.14,16,27))
                              :op2 (e2 / enzyme
                                    :name (n3 / name
                                          :op1 "protein"~e.18
                                          :op2 "kinase"~e.19
                                          :op3 "B"~e.20))
                              :op3 (e3 / enzyme
                                    :name (n4 / name :op1 "JNK1/2"~e.16,25,27))
                              :op4 (p2 / protein
                                    :name (n5 / name :op1 "NF-kB"~e.29,31))
                              :op5 (p3 / protein
                                    :name (n6 / name :op1 "p38"~e.34)))
                        :ARG0-of (d / depend-01~e.11
                              :ARG1 (t / time~e.9)))
                  :op2 (d2 / degrade-01~e.37
                        :ARG1~e.38 (p4 / protein
                              :name (n7 / name :op1 "IkB"~e.39)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (f2 / figure~e.42
                  :mod "1B"~e.43
                  :mod (s2 / supplement~e.41))))

# ::tok Y721 @-@ c @-@ Kit is autophosphorylated in response to stem cell factor ( SCF ) .
# ::alignments 2-1.1.3.1.1 4-1.1.3.1.1 8-1.3 9-1.3.1.r 10-1.3.1.1.1 11-1.3.1.1.2 12-1.3.1.1.3
# ::id bel_pmid_2020_0353_38622
(p / phosphorylate-01
      :ARG1 (a / amino-acid
            :mod "721"
            :name (n / name :op1 "tyrosine")
            :part-of (p2 / protein
                  :name (n2 / name :op1 "c-Kit"~e.2,4)))
      :ARG2 a
      :ARG2-of (r / respond-01~e.8
            :ARG1~e.9 (p3 / protein
                  :name (n3 / name
                        :op1 "stem"~e.10
                        :op2 "cell"~e.11
                        :op3 "factor"~e.12))))

# ::tok The supernatants from cultured LN cells were also collected and the production of various cytokines ( TNF @-@ alpha , IFN @-@ gamma , IL @-@ 6 , and IL @-@ 17 ) was measured ( Fig . 3B ) . The cytokine levels in BLT1-/- cells were significantly lower than those in BLT1+/+ cells
# ::alignments 1-1.1.1.1 2-1.1.1.1.1.r 3-1.1.1.1.1.1 5-1.1.1.1.1 7-1.1.1.2 8-1.1.1 9-1.1 11-1.1.2.1 13-1.1.2.1.1.1 16-1.1.2.1.1.2.1.1.1.1 18-1.1.2.1.1.2.1.1.1.1 20-1.1.2.1.1.2.1.2.1.1 22-1.1.2.1.1.2.1.2.1.1 24-1.1.2.1.1.2.1.3.1.1 24-1.1.2.1.1.2.1.4.1.1 26-1.1.2.1.1.2.1.3.1.1 28-1.1.2.1.1.2.1 29-1.1.2.1.1.2.1.3.1.1 29-1.1.2.1.1.2.1.4.1.1 31-1.1.2.1.1.2.1.4.1.1 34-1.1.2 38-1.1.3.1.1 42-1.1.2.1.1 42-1.2.1.1 43-1.2.1 43-1.2.4 46-1.2.1.2 46-1.2.4.1 47-1.2.1.r 48-1.2.3 49-1.2 49-1.2.2 49-1.2.2.r 50-1.2.4.r 54-1.2.1.2
# ::id bel_pmid_2022_6760_28942
(m / multi-sentence
      :snt1 (a / and~e.9
            :op1 (c / collect-01~e.8
                  :ARG1 (s / supernatant~e.1
                        :source~e.2 (c2 / cell~e.5
                              :ARG1-of (c3 / culture-01~e.3)
                              :mod (p8 / protein
                                    :name (n7 / name :op1 "laminin"))))
                  :mod (a3 / also~e.7))
            :op2 (m2 / measure-01~e.34
                  :ARG1 (p / produce-01~e.11
                        :ARG1 (c4 / cytokine~e.42
                              :mod (v / various~e.13)
                              :ARG2-of (i / include-91
                                    :ARG1 (a2 / and~e.28
                                          :op1 (p2 / protein
                                                :name (n / name :op1 "TNF-alpha"~e.16,18))
                                          :op2 (p3 / protein
                                                :name (n2 / name :op1 "IFN-gamma"~e.20,22))
                                          :op3 (p4 / protein
                                                :name (n3 / name :op1 "IL-6"~e.24,26,29))
                                          :op4 (p5 / protein
                                                :name (n4 / name :op1 "IL-17"~e.24,29,31)))))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "3B"~e.38)))
      :snt2 (l2 / low~e.49
            :domain~e.47 (l3 / level~e.43
                  :quant-of (c5 / cytokine~e.42)
                  :location (c6 / cell~e.46,54
                        :mod (p6 / protein
                              :name (n5 / name :op1 "BLT1")
                              :ARG2-of (m5 / mutate-01 :mod "-/-"))))
            :degree~e.49 (m4 / more~e.49)
            :mod (s2 / significant~e.48)
            :compared-to~e.50 (l4 / level~e.43
                  :location (c7 / cell~e.46
                        :mod (p7 / protein
                              :name (n6 / name :op1 "BLT1")
                              :mod (w / wild-type))))))

# ::tok Table 2 Comparison of expression ratios between microarray and RT @-@ qPCR , lipid and mixed annotated genes ## WT vs Tyk2-/- peritoneal macrophages ##
# ::alignments 0-1.3.1 1-1.3.1.1 2-1.1 3-1.1.1 3-1.1.2 4-1.1.1.1 5-1.1.1 7-1.1.1.2 8-1.1.1.1.1 9-1.1.2.2.1.1 11-1.1.2.2.1.1 13-1.1.2.1 14-1.1.2.1 15-1.1.2.1 16-1.1.2.1 17-1.1.2.1 19-1.2.1.1 22-1.2.1.2 23-1.2.1
# ::id bel_pmid_2033_8026_31778
(m / multi-sentence
      :snt1 (c / compare-01~e.2
            :ARG1 (r / ratio-of~e.3,5
                  :op1 (e / express-03~e.4
                        :ARG1 (a / and~e.8
                              :op1 (g / gene
                                    :mod (l / lipid))
                              :op2 (g2 / gene
                                    :mod (m3 / mixed))
                              :ARG1-of (a2 / annotate-01)))
                  :mod (m2 / microarray~e.7))
            :ARG2 (r2 / ratio-of~e.3
                  :op1 e~e.13,14,15,16,17
                  :mod (t / thing
                        :name (n / name :op1 "RT-qPCR"~e.9,11))))
      :snt2 (c2 / contrast-01
            :ARG1 (m4 / macrophage~e.23
                  :mod (w / wild-type~e.19)
                  :mod (p / peritoneum~e.22))
            :ARG2 (p2 / protein
                  :name (n2 / name :op1 "Tyk2")
                  :ARG2-of (m5 / mutate-01 :mod "-/-")
                  :mod p))
      :ARG1-of (d / describe-01
            :ARG0 (t2 / table~e.0 :mod "2"~e.1)))

# ::tok Leptin @-@ induced MUC5B expression was blocked by the ERK1 @/@ 2 and p38 pathway inhibitors , but not by the JAK2 @/@ STAT3 pathway inhibitor .
# ::alignments 0-1.2.2.1.1.1 2-1.2.2 3-1.2.1.1.1 4-1.2 6-1 6-1.3.1 7-1.1.r 9-1.1.1.1.1.1.1 11-1.1.1.1.1.1.1 12-1.1.1.1 13-1.1.1.1.2.1.1 14-1.1.1.1.1 14-1.1.1.1.2 15-1.1 15-1.1.1 15-1.1.1.r 17-1.3 18-1.3.1.1 18-1.3.1.1.r 19-1.3.1.2.r 21-1.3.1.2.1.1.1.1 23-1.3.1.2.1.1.1.1 24-1.3.1.2.1.1 25-1.3.1.2 25-1.3.1.2.1 25-1.3.1.2.1.r
# ::id bel_pmid_2049_7020_1770
(b / block-01~e.6
      :ARG0~e.7 (m / molecular-physical-entity~e.15
            :ARG0-of~e.15 (i2 / inhibit-01~e.15
                  :ARG1 (a2 / and~e.12
                        :op1 (p5 / pathway~e.14
                              :name (n3 / name :op1 "ERK1/2"~e.9,11))
                        :op2 (p3 / pathway~e.14
                              :name (n4 / name :op1 "p38"~e.13)))))
      :ARG1 (e / express-03~e.4
            :ARG1 (p / protein
                  :name (n / name :op1 "MUC5B"~e.3))
            :ARG1-of (i / induce-01~e.2
                  :ARG0 (s / small-molecule
                        :name (n2 / name :op1 "leptin"~e.0))))
      :ARG1-of (c / contrast-01~e.17
            :ARG2 (b2 / block-01~e.6
                  :polarity~e.18 "-"~e.18
                  :ARG0~e.19 (m3 / molecular-physical-entity~e.25
                        :ARG0-of~e.25 (i3 / inhibit-01~e.25
                              :ARG1 (p4 / pathway~e.24
                                    :name (n5 / name :op1 "JAK2/STAT3"~e.21,23))))
                  :ARG1 e)))

# ::tok Both IL @-@ 6 and G @-@ CSF treatment did not markedly change surface IL @-@ 4Ra amounts on BM cells ; moreover , IL @-@ 6 had a detrimental effect on cell viability , thereby preventing any further functional characterization .
# ::alignments 0-1.1.2.1.3 1-1.1.2.1.1.1.1 3-1.1.2.1.1.1.1 4-1.1.2.1 5-1.1.2.1.2.1.1 7-1.1.2.1.2.1.1 8-1.1.2 10-1.1.1 10-1.1.1.r 11-1.1.4 12-1.1 13-1.1.3.1.2 14-1.1.3.1.1.1 16-1.1.3.1.1.1 17-1.1.3 20-1.1.5 24-1.2.1.1.1.1 26-1.2.1.1.1.1 29-1.2.1.3 30-1.2.1 31-1.2.1.2.r 32-1.2.1.2.1 33-1.2.1.2 35-1.1.4.r 36-1.2.1.4 37-1.2.1.4.1.3 38-1.2.1.4.1.2 39-1.2.1.4.1.1 40-1.2.1.4.1
# ::id bel_pmid_2060_5485_40420
(m / multi-sentence
      :snt1 (c / change-01~e.12
            :polarity~e.10 "-"~e.10
            :ARG0 (t / treat-04~e.8
                  :ARG2 (a / and~e.4
                        :op1 (p / protein
                              :name (n / name :op1 "IL-6"~e.1,3))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "G-CSF"~e.5,7))
                        :mod (b2 / both~e.0)))
            :ARG1 (a2 / amount~e.17
                  :quant-of (p3 / protein
                        :name (n3 / name :op1 "IL-4Ra"~e.14,16)
                        :mod (s / surface~e.13)))
            :manner~e.35 (m2 / marked~e.11)
            :location (c2 / cell~e.20)
            :mod (b / bone-marrow))
      :snt2 (a3 / and
            :op2 (a4 / affect-01~e.30
                  :ARG0 (p4 / protein
                        :name (n4 / name :op1 "IL-6"~e.24,26))
                  :ARG1~e.31 (v / viability~e.33
                        :mod (c3 / cell~e.32))
                  :mod (d / detrimental~e.29)
                  :ARG0-of (p5 / prevent-01~e.36
                        :ARG1 (c4 / characterize-01~e.40
                              :ARG0-of (f / function-01~e.39)
                              :mod (f2 / further~e.38)
                              :mod (a5 / any~e.37))))))

# ::tok Despite the increased IL @-@ 4Ra expression following G @-@ CSF treatment , this cytokine did not induce any appreciable imunosuppressive function in BM cells .
# ::alignments 0-1.5.r 2-1.5 3-1.5.1.1.1.1 5-1.5.1.1.1.1 6-1.5.1 7-1.5.1.2 8-1.5.1.2.1.1.1.1 10-1.5.1.2.1.1.1.1 11-1.5.1.2.1 13-1.2.1 14-1.2 16-1.1 16-1.1.r 17-1 18-1.3.3 19-1.3.1 19-1.3.1.1 19-1.3.1.1.r 20-1.3.2 21-1.3 24-1.4
# ::id bel_pmid_2060_5485_40422
(i / induce-01~e.17
      :polarity~e.16 "-"~e.16
      :ARG0 (c / cytokine~e.14
            :mod (t / this~e.13))
      :ARG1 (f / function~e.21
            :ARG1-of (a / appreciate-02~e.19
                  :mod~e.19 (p / possible~e.19))
            :mod (i2 / imunosuppressive~e.20)
            :mod (a2 / any~e.18))
      :location (c2 / cell~e.24
            :mod (b / bone-marrow))
      :concession~e.0 (i3 / increase-01~e.2
            :ARG1 (e / express-03~e.6
                  :ARG2 (p2 / protein
                        :name (n / name :op1 "IL-4Ra"~e.3,5))
                  :ARG1-of (f2 / follow-01~e.7
                        :ARG2 (t2 / treat-04~e.11
                              :ARG2 (p3 / protein
                                    :name (n2 / name :op1 "G-CSF"~e.8,10)))))))

# ::tok GM @-@ CSF induced a significant increase ( p = 0.028 versus untreated BM ) of IL @-@ 4Ra expression , and BM cells cultured with this cytokine inhibited CTL activity in a dose @-@ dependent fashion ( Figures 1A and 1B ) .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 3-1.1 5-1.1.2.2 6-1.1.2 10-1.1.2.3.1.1.1 15-1.1.2.1.r 16-1.1.2.1.1.1.1 18-1.1.2.1.1.1.1 19-1.1.2.1 21-1 23-1.1.2.3.1.2 23-1.2.1 24-1.2.1.2 25-1.2.1.2.1.r 26-1.2.1.2.1.1 27-1.2.1.2.1 28-1.2 29-1.2.2.1.1.1 30-1.2.2 31-1.2.3.r 33-1.2.3.2 35-1.2.3 38-1.3.1.1 38-1.3.1.2 39-1.3.1.1.1 40-1.3.1 41-1.3.1.2.1
# ::id bel_pmid_2060_5485_40424
(a / and~e.21
      :op1 (i / induce-01~e.3
            :ARG0 (p / protein
                  :name (n / name :op1 "GM-CSF"~e.0,2))
            :ARG1 (i2 / increase-01~e.6
                  :ARG1~e.15 (e2 / express-03~e.19
                        :ARG2 (p4 / protein
                              :name (n2 / name :op1 "IL-4Ra"~e.16,18)))
                  :mod (s / significant~e.5)
                  :ARG1-of (m / mean-01
                        :ARG2 (c / contrast-01
                              :ARG1 (n4 / net-power-radiated :value "0.028"~e.10)
                              :ARG2 (c6 / cell-line~e.23
                                    :mod (b2 / bone-marrow)
                                    :ARG1-of (t / treat-04 :polarity "-"))))))
      :op2 (i3 / inhibit-01~e.28
            :ARG0 (c3 / cell-line~e.23
                  :mod b2
                  :ARG1-of (c4 / culture-01~e.24
                        :instrument~e.25 (c5 / cytokine~e.27
                              :mod (t2 / this~e.26))))
            :ARG1 (a2 / act-02~e.30
                  :ARG0 (c2 / cell
                        :name (n3 / name :op1 "CTL"~e.29)))
            :manner~e.31 (d / depend-01~e.35
                  :ARG0 a2
                  :ARG1 (d2 / dose~e.33)))
      :ARG1-of (d3 / describe-01
            :ARG0 (a3 / and~e.40
                  :op1 (f / figure~e.38 :mod "1A"~e.39)
                  :op2 (f2 / figure~e.38 :mod "1B"~e.41))))

# ::tok When we analyzed the percentage of the different subsets of CD11b+Gr @-@ 1+ cells , percentages of CD11 bhiGr @-@ 1 hi and CD11 bhiGr @-@ 1 @- cells were decreased in both C/EBPp @-@ deficient strains , but subsets characterized by low and intermediate expression of the Gr @-@ 1 marker were significantly decreased only in fully ablated mice ( Figure 3D ) .
# ::alignments 0-1.3.r 1-1.3.1 2-1.3 4-1.3.2 5-1.3.2.1.r 7-1.3.2.1.2 8-1.3.2.1 10-1.3.2.1.1.1.1 12-1.3.2.1.1.1.1 13-1.1.2.1 13-1.3.2.1.1 15-1.1.1 15-1.1.2 20-1.1.2.1.1.1 22-1.1 26-1.1.2.1.1.1 28-1.1.1.1 30-1 31-1.2.r 32-1.2.2 33-1.2.1.1.1.1 36-1.2 38-1.4 39-1.4.1.1 40-1.4.1.1.1 41-1.4.1.1.1.1.r 42-1.4.1.1.1.1.1.2 43-1.4.1.1.1.1 44-1.4.1.1.1.1.2.2 45-1.4.1.1.1.1.1 45-1.4.1.1.1.1.2 46-1.4.1.1.1.1.1.1.r 48-1.4.1.1.1.1.1.1.1.1.1 50-1.4.1.1.1.1.1.1.1.1.1 51-1.4.1.1.1.1.1.1 53-1.4.1.2 54-1.4.1 55-1.4.1.4 56-1.4.1.3.r 57-1.4.1.3.1.1 58-1.4.1.3.1 59-1.4.1.3 61-1.5.1 62-1.5.1.1
# ::id bel_pmid_2060_5485_40432
(d / decrease-01~e.30
      :ARG1 (a / and~e.22
            :op1 (p / percentage~e.15
                  :quant-of (c / cell~e.28
                        :name (n / name :op1 "CD11bhiGr-1hi")))
            :op2 (p2 / percentage~e.15
                  :quant-of (c2 / cell~e.13
                        :name (n2 / name :op1 "CD11bhiGr-1-"~e.20,26))))
      :location~e.31 (s / strain~e.36
            :ARG0-of (l / lack-01
                  :ARG1 (p3 / protein
                        :name (n3 / name :op1 "C/EBPp"~e.33)))
            :mod (b / both~e.32))
      :time~e.0 (a2 / analyze-01~e.2
            :ARG0 (w / we~e.1)
            :ARG1 (p4 / percentage~e.4
                  :quant-of~e.5 (s2 / subset~e.8
                        :poss (c3 / cell~e.13
                              :name (n4 / name :op1 "CD11b+Gr-1+"~e.10,12))
                        :ARG1-of (d4 / differ-02~e.7))))
      :ARG1-of (c4 / contrast-01~e.38
            :ARG2 (d2 / decrease-01~e.54
                  :ARG1 (s3 / subset~e.39
                        :ARG1-of (c5 / characterize-01~e.40
                              :ARG2~e.41 (a3 / and~e.43
                                    :op1 (e / express-03~e.45
                                          :ARG2~e.46 (m / marker~e.51
                                                :mod (p5 / protein
                                                      :name (n5 / name :op1 "Gr-1"~e.48,50)))
                                          :mod (l2 / low~e.42))
                                    :op2 (e2 / express-03~e.45
                                          :ARG2 m
                                          :mod (i / intermediate~e.44)))))
                  :ARG2 (s4 / significant~e.53)
                  :location~e.56 (m2 / mouse~e.59
                        :ARG1-of (a4 / ablate-00~e.58
                              :manner (f / full~e.57)))
                  :mod (o / only~e.55)))
      :ARG1-of (d3 / describe-01
            :ARG0 (f2 / figure~e.61 :mod "3D"~e.62)))

# ::tok Following separation of CD11b+ cells from MCA203 tumor infiltrate , we found that loss of C/EBPp caused a significant reduction in both arginase 1 ( Arg1 ) and nitric oxide synthase 2 ( Nos2 ) proteins ( Figure 6A ) , two enzymes that were described as crucial components of MDSC inhibitory machinery ( Bronte and Zanovello , 2005; Gabrilovich and Nagaraj , 2009 ) .
# ::alignments 0-1.3 1-1.3.1 3-1.3.1.1.1.1 4-1.2.2.1.4.1.2.2 4-1.3.1.1 5-1.3.1.2.r 6-1.3.1.2.1.1.1 7-1.3.1.2.2 8-1.3.1.2 10-1.1 11-1 12-1.2.r 13-1.2.1 15-1.2.1.1.1.1 16-1.2 18-1.2.2.2 19-1.2.2 20-1.2.2.1.r 21-1.2.2.1.3 22-1.2.2.1.1.1.1 23-1.2.2.1.1.1.2 27-1.2.2.1 28-1.2.2.1.2.1.1 29-1.2.2.1.2.1.2 30-1.2.2.1.2.1.3 31-1.2.2.1.2.1.4 35-1.2.1.1 35-1.3.1.2.1 37-1.2.2.3.1 38-1.2.2.3.1.1 42-1.2.2.1.1 42-1.2.2.1.2 45-1.2.2.1.4 45-1.2.2.1.4.2 45-1.2.2.1.4.2.r 45-1.2.2.3 46-1.2.2.1.4.1.r 46-1.2.2.1.4.2.1.1.2.r 47-1.2.2.1.4.1.1 48-1.2.2.1.4.1 49-1.2.2.1.4.1.2.r 50-1.2.2.1.4.1.2.2.1.1 52-1.2.2.1.4.1.2 54-1.2.2.1.4.2.1.1.1.1.1.1 55-1.2.2.1.4.2.1.1.1 56-1.2.2.1.4.2.1.1.1.2.1.1 59-1.2.2.1.4.2.1.2.1.1.1.1 60-1.2.2.1.4.2.1.2.1 61-1.2.2.1.4.2.1.2.1.2.1.1 63-1.2.2.1.4.2.1.2.2.1
# ::id bel_pmid_2060_5485_40442
(f / find-01~e.11
      :ARG0 (w / we~e.10)
      :ARG1~e.12 (c / cause-01~e.16
            :ARG0 (l / lose-02~e.13
                  :ARG1 (p / protein~e.35
                        :name (n / name :op1 "C/EBPp"~e.15)))
            :ARG1 (r / reduce-01~e.19
                  :ARG1~e.20 (a / and~e.27
                        :op1 (e / enzyme~e.42
                              :name (n2 / name :op1 "arginase"~e.22 :op2 "1"~e.23))
                        :op2 (e2 / enzyme~e.42
                              :name (n3 / name
                                    :op1 "nitric"~e.28
                                    :op2 "oxide"~e.29
                                    :op3 "synthase"~e.30
                                    :op4 "2"~e.31))
                        :mod (b / both~e.21)
                        :ARG1-of (d2 / describe-01~e.45
                              :ARG2~e.46 (c3 / component~e.48
                                    :mod (c4 / crucial~e.47)
                                    :part-of~e.49 (m / machinery~e.52
                                          :ARG0-of (i2 / inhibit-01)
                                          :mod (c5 / cell-line~e.4
                                                :name (n6 / name :op1 "MDSC"~e.50))))
                              :ARG1-of~e.45 (d3 / describe-01~e.45
                                    :ARG0 (a2 / and
                                          :op1 (p3 / publication-91
                                                :ARG0 (a3 / and~e.55
                                                      :op1 (p4 / person
                                                            :name (n7 / name :op1 "Bronte"~e.54))
                                                      :op2 (p5 / person
                                                            :name (n8 / name :op1 "Zanovello"~e.56)))
                                                :time~e.46 (d4 / date-entity :year "2015"))
                                          :op2 (p6 / publication-91
                                                :ARG0 (a4 / and~e.60
                                                      :op1 (p7 / person
                                                            :name (n9 / name :op1 "Gabrilovich"~e.59))
                                                      :op2 (p8 / person
                                                            :name (n10 / name :op1 "Nagaraj"~e.61)))
                                                :time (d5 / date-entity :year "2009"~e.63))))))
                  :ARG2 (s2 / significant~e.18)
                  :ARG1-of (d / describe-01~e.45
                        :ARG0 (f2 / figure~e.37 :mod "6A"~e.38))))
      :ARG1-of (f3 / follow-01~e.0
            :ARG2 (s / separate-01~e.1
                  :ARG1 (c2 / cell~e.4
                        :name (n4 / name :op1 "CD11b+"~e.3))
                  :ARG2~e.5 (i / infiltrate-01~e.8
                        :ARG0 (p2 / protein~e.35
                              :name (n5 / name :op1 "MCA203"~e.6))
                        :mod (t / tumor~e.7)))))

# ::tok Cytokines were able to upregulate IL @-@ 4Ra expression , but a more pronounced effect was obtained by G @-@ CSF+GM @-@ CSF combination ( Figure 7B and Figure S6B ) .
# ::alignments 1-1.1.r 2-1 4-1.1 5-1.1.2.1.1.1 7-1.1.2.1.1.1 8-1.1.2 10-1.2 12-1.2.1.1.1.1 13-1.2.1.1.1 14-1.2.1.1 16-1.2.1 17-1.2.1.2.r 18-1.2.1.2.1.1.1 22-1.2.1.2.1.1.1 22-1.2.1.2.2.1.1 23-1.2.1.2 25-1.3.1.1 26-1.3.1.1.1 27-1.3.1 28-1.3.1.1 28-1.3.1.2 29-1.3.1.2.1
# ::id bel_pmid_2060_5485_40446
(p / possible~e.2
      :domain~e.1 (u / upregulate-01~e.4
            :ARG0 (c / cytokine)
            :ARG1 (e / express-03~e.8
                  :ARG1 (p2 / protein
                        :name (n / name :op1 "IL-4Ra"~e.5,7))))
      :ARG1-of (c2 / contrast-01~e.10
            :ARG2 (o / obtain-01~e.16
                  :ARG1 (e2 / effect~e.14
                        :ARG1-of (p5 / pronounce-01~e.13
                              :degree (m / more~e.12)))
                  :ARG2~e.17 (c3 / combine-01~e.23
                        :ARG1 (p3 / protein
                              :name (n2 / name :op1 "G-CSF"~e.18,22))
                        :ARG2 (p4 / protein
                              :name (n3 / name :op1 "GM-CSF"~e.22)))))
      :ARG1-of (d / describe-01
            :ARG0 (a / and~e.27
                  :op1 (f / figure~e.25,28 :mod "7B"~e.26)
                  :op2 (f2 / figure~e.28 :mod "S6B"~e.29))))

# ::tok These results indicate that the endogenous IL @-@ 33 @/@ ST2 signaling pathway enhances the expression of CCR3 on eosinophils .
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 3-1.2.r 5-1.2.1.3 6-1.2.1.1.1 8-1.2.1.1.1 10-1.2.1.1.1 11-1.2.1.2 12-1.2.1 13-1.2 15-1.2.2 16-1.2.2.1.r 17-1.2.2.1.1.1 18-1.2.2.2.r 19-1.2.2.2.1.1
# ::id bel_pmid_2069_3421_19238
(i / indicate-01~e.2
      :ARG0 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t2 / this~e.0))
      :ARG1~e.3 (e / enhance-01~e.13
            :ARG0 (p / pathway~e.12
                  :name (n / name :op1 "IL-33/ST2"~e.6,8,10)
                  :ARG0-of (s / signal-07~e.11)
                  :mod (e2 / endogenous~e.5))
            :ARG1 (e3 / express-03~e.15
                  :ARG2~e.16 (p2 / protein
                        :name (n2 / name :op1 "CCR3"~e.17))
                  :ARG3~e.18 (c / cell
                        :name (n3 / name :op1 "eosinophil"~e.19)))))

# ::tok IL @-@ 33 triggered the production of IL @-@ 13 and IL @-@ 6 and strongly increased the production of CCL17 and TGF @-@ b from WT eosinophils , but not ST2-/- eosinophils , in a dosedependent manner ( Fig . 5A ) .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 3-1.1 5-1.1.2 6-1.1.2.1.r 7-1.1.2.1.1.1.1 9-1.1.2.1.1.1.1 10-1.1.2.1 11-1.1.2.1.1.1.1 11-1.1.2.1.2.1.1 13-1.1.2.1.2.1.1 14-1.2.1.2.1 15-1.2.1.3 16-1.2.1 16-1.2.2 18-1.2.1.2 18-1.2.2.3 20-1.2.1.2.1.1.1.1 20-1.2.2.3.1.1.1.1 21-1.2.1.2.1 22-1.2.1.2.1.2.1.1 24-1.2.1.2.1.2.1.1 24-1.2.2.3.1.2.1.1 25-1.2.1.2.2.r 26-1.2.1.2.2.2 27-1.2.1.2.2.1.1 27-1.2.2.3.1.3.1.1 29-1.2 30-1.2.2.1 30-1.2.2.1.r 32-1.2.1.2.2.1.1 32-1.2.2.3.1.3.1.1 37-1.2.1.3.r 37-1.2.1.4.r 41-1.3.1.1
# ::id bel_pmid_2069_3421_19240
(a / and
      :op1 (t / trigger-01~e.3
            :ARG0 (p3 / protein
                  :name (n / name :op1 "IL-33"~e.0,2))
            :ARG1 (p4 / produce-01~e.5
                  :ARG1~e.6 (a2 / and~e.10
                        :op1 (p5 / protein
                              :name (n2 / name :op1 "IL-13"~e.7,9,11))
                        :op2 (p6 / protein
                              :name (n3 / name :op1 "IL-6"~e.11,13)))))
      :op2 (c / contrast-01~e.29
            :ARG1 (i / increase-01~e.16
                  :ARG0 p3
                  :ARG1 (p / produce-01~e.18
                        :ARG1 (a3 / and~e.14,21
                              :op1 (p7 / protein
                                    :name (n4 / name :op1 "CCL17"~e.20))
                              :op2 (p8 / protein
                                    :name (n5 / name :op1 "TGF-b"~e.22,24)))
                        :source~e.25 (c2 / cell
                              :name (n6 / name :op1 "eosinophil"~e.27,32)
                              :mod (w / wild-type~e.26)))
                  :manner~e.37 (s / strong~e.15)
                  :manner~e.37 (d / depend-01
                        :ARG1 (d2 / dose)))
            :ARG2 (i2 / increase-01~e.16
                  :polarity~e.30 "-"~e.30
                  :ARG0 p3
                  :ARG1 (p2 / produce-01~e.18
                        :ARG1 (a4 / and
                              :op1 (p9 / protein
                                    :name (n9 / name :op1 "CCL17"~e.20))
                              :op2 (p10 / protein
                                    :name (n10 / name :op1 "TGF-b"~e.24))
                              :source (c3 / cell
                                    :name (n7 / name :op1 "eosinophil"~e.27,32)
                                    :mod (g / gene
                                          :name (n8 / name :op1 "ST2")
                                          :ARG2-of (m / mutate-01 :mod "-/-")))))))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "5A"~e.41)))

# ::tok Pharmacological intervention with a VEGFR @-@ 2 @-@ neutralizing Ab ( anti @-@ Flk1 mAb ) abolished the production of IL @-@ 6 ( but not IL @-@ 12p70 ) and the subsequent development of allergen @-@ specific Th17 cell response .
# ::alignments 0-1.1.1.1 1-1.1.1 2-1.1.1.2.r 4-1.1.1.2.1.1.1.1 6-1.1.1.2.1.1.1.1 8-1.1.1.2.1 16-1.1 16-1.2 18-1.1.2.1.1 18-1.2.2 19-1.1.2.1.1.1.r 19-1.1.2.r 20-1.1.2.1.1.1.1.1 22-1.1.2.1.1.1.1.1 24-1 24-1.1.2.1 25-1.2.1 25-1.2.1.r 26-1.2.2.1.1.1 28-1.2.2.1.1.1 30-1.1.2 32-1.1.2.2.2 33-1.1.2.2 34-1.1.2.2.1.r 35-1.1.2.2.1.2.1 37-1.1.2.2.1.2 38-1.1.2.2.1.1.1.1 39-1.1.2.2.1.1 40-1.1.2.2.1
# ::id bel_pmid_2092_1519_3016
(c3 / contrast-01~e.24
      :ARG1 (a / abolish-01~e.16
            :ARG0 (i / intervene-01~e.1
                  :mod (p2 / pharmacology~e.0)
                  :instrument~e.2 (a3 / antibody
                        :ARG0-of (n / neutralize-01~e.8
                              :ARG1 (a4 / antibody
                                    :name (n2 / name :op1 "VEGFR-2"~e.4,6)))))
            :ARG1~e.19 (a2 / and~e.30
                  :op1 (c / contrast-01~e.24
                        :ARG1 (p / produce-01~e.18
                              :ARG1~e.19 (p3 / protein
                                    :name (n3 / name :op1 "IL-6"~e.20,22))))
                  :op2 (d / develop-01~e.33
                        :ARG1~e.34 (r / respond-01~e.40
                              :ARG0 (c2 / cell~e.39
                                    :name (n5 / name :op1 "Th17"~e.38))
                              :mod (s2 / specific~e.37
                                    :topic (a5 / allergen~e.35)))
                        :mod (s / subsequent~e.32))))
      :ARG2 (a6 / abolish-01~e.16
            :polarity~e.25 "-"~e.25
            :ARG1 (p4 / produce-01~e.18
                  :ARG1 (p5 / protein
                        :name (n4 / name :op1 "IL-12p70"~e.26,28)))))

# ::tok In vivo production of VEGF and Th1 @- and Th17 @-@ polarizing cytokines ( IL @-@ 12p70 and IL @-@ 6 , respectively ) were upregulated by airway exposure to LPS .
# ::alignments 0-1.2.2 1-1.2.2 2-1.2 3-1.2.1.r 4-1.2.1.1.1.1 5-1.2.1 6-1.2.1.2.2.1.1.1.1 8-1.2.1.2.2.1 9-1.2.1.2.2.1.2.1.1 11-1.2.1.2.2 14-1.2.1.2.1.1 16-1.2.1.2.1.1 18-1.2.1.3.1.1 20-1.2.1.3.1.1 27-1.1.2 28-1.1 29-1.1.1.r 30-1.1.1.1.1
# ::id bel_pmid_2092_1519_3466
(u / upregulate-01
      :ARG0 (e / expose-01~e.28
            :ARG2~e.29 (m2 / molecular-physical-entity
                  :name (n6 / name :op1 "LPS"~e.30))
            :mod (a3 / airway~e.27))
      :ARG1 (p / produce-01~e.2
            :ARG1~e.3 (a / and~e.5
                  :op1 (p3 / protein
                        :name (n3 / name :op1 "VEGF"~e.4))
                  :op2 (c / cytokine
                        :name (n / name :op1 "IL-12p70"~e.14,16)
                        :ARG0-of (p2 / polarize-01~e.11
                              :ARG1 (a2 / and~e.8
                                    :op2 (c3 / cell
                                          :name (n4 / name :op1 "Th1"~e.6))
                                    :op3 (c4 / cell
                                          :name (n5 / name :op1 "Th17"~e.9)))))
                  :op3 (c2 / cytokine
                        :name (n2 / name :op1 "IL-6"~e.18,20)
                        :ARG0-of p2))
            :manner (i / in-vivo~e.0,1)))

# ::tok Both Fyn and Hck phosphorylate the adaptor protein Gab2 to activate PI3K signaling and promote microtubule formation that is important for granule translocation to the plasma membrane ( 9 , 11 ) .
# ::alignments 0-1.2.3 1-1.2.1.1.1 2-1.2 3-1.2.2.1.1 4-1 6-1.1.2 7-1.1 8-1.1.1.1 9-1.3.r 10-1.3.1 12-1.3.1.2 13-1.3 14-1.3.2 15-1.3.2.2.1.1.1 16-1.3.2.2 19-1.3.2.2.2 20-1.3.2.2.2.1.r 21-1.3.2.2.2.1.1 22-1.3.2.2.2.1 23-1.3.2.2.2.1.2.r 25-1.3.2.2.2.1.2.1 26-1.3.2.2.2.1.2 28-1.4.1.1.1.1 30-1.4.1.1.1.2
# ::id bel_pmid_2094_4008_19124
(p4 / phosphorylate-01~e.4
      :ARG1 (p3 / protein~e.7
            :name (n3 / name :op1 "Gab2"~e.8)
            :mod (a3 / adaptor~e.6))
      :ARG2 (a2 / and~e.2
            :op1 (g / gene
                  :name (n / name :op1 "Fyn"~e.1))
            :op2 (g2 / gene
                  :name (n2 / name :op1 "Hck"~e.3))
            :mod (b / both~e.0))
      :purpose~e.9 (a4 / and~e.13
            :op1 (a5 / activate-01~e.10
                  :ARG0 a2
                  :ARG1 (s / signal-07~e.12
                        :ARG0 (e / enzyme
                              :name (n4 / name :op1 "P13K"))))
            :op2 (p2 / promote-01~e.14
                  :ARG0 a2
                  :ARG1 (f / form-01~e.16
                        :ARG1 (m / molecular-physical-entity
                              :name (n5 / name :op1 "microtubule"~e.15))
                        :mod (i / important~e.19
                              :purpose~e.20 (t / translocate-00~e.22
                                    :path (g3 / granule~e.21)
                                    :destination~e.23 (m2 / membrane~e.26
                                          :poss (p / plasma~e.25)))))))
      :ARG1-of (d / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (v / value-interval :op1 "9"~e.28 :op2 "11"~e.30)))))

# ::tok PTP ? is required for SCF @-@ induced c @-@ Kit and Fyn activation , and in this way regulates a Fyn @-@ based c @-@ Kit signaling axis ( Fyn/Gab2/Shp2/Vav/PAK/Rac/JNK ) that mediates mast cell migration .
# ::alignments 3-1.1 4-1.1.2.r 5-1.1.2.2.1.1.1 7-1.1.2.2 8-1.1.2.1.1.1.1 10-1.1.2.1.1.1.1 11-1.1.2.1 12-1.1.2.1.2.1.1 13-1.1.2 15-1 15-1.1.2.1 17-1.2.3.1 18-1.2.3 18-1.2.3.r 19-1.2 21-1.2.2.2.1 23-1.2.2.2 24-1.2.2.1.1 25-1.2.2.1.1 26-1.2.2.1.1 27-1.2.2.1 28-1.2.2 33-1.2.2.3 34-1.2.2.3.1.1.1 35-1.2.2.3.1.1 36-1.2.2.3.1
# ::id bel_pmid_2094_4008_19126
(a3 / and~e.15
      :op1 (r / require-01~e.3
            :ARG1 (e / enzyme
                  :name (n / name :op1 "PTPβ"))
            :purpose~e.4 (a / activate-01~e.13
                  :ARG1 (a2 / and~e.11,15
                        :op1 (e2 / enzyme
                              :name (n2 / name :op1 "c-Kit"~e.8,10))
                        :op2 (e3 / enzyme
                              :name (n3 / name :op1 "Fyn"~e.12)))
                  :ARG1-of (i / induce-01~e.7
                        :ARG0 (e4 / enzyme
                              :name (n4 / name :op1 "SCF"~e.5)))))
      :op2 (r2 / regulate-01~e.19
            :ARG0 e
            :ARG1 (a4 / axis~e.28
                  :ARG0-of (s / signal-07~e.27
                        :ARG1 e2~e.24,25,26)
                  :ARG1-of (b / base-02~e.23
                        :ARG2 e3~e.21)
                  :ARG0-of (m / mediate-01~e.33
                        :ARG1 (m2 / migrate-01~e.36
                              :ARG0 (c / cell~e.35
                                    :mod (m3 / mast~e.34))))
                  :consist-of (a5 / and
                        :op1 e2
                        :op2 (p / protein
                              :name (n6 / name :op1 "Gab2"))
                        :op3 (e6 / enzyme
                              :name (n7 / name :op1 "Shp2"))
                        :op4 (p2 / protein
                              :name (n8 / name :op1 "Vav"))
                        :op5 (e7 / enzyme
                              :name (n9 / name :op1 "PAK"))
                        :op6 (e8 / enzyme
                              :name (n10 / name :op1 "Rac"))
                        :op7 (e9 / enzyme
                              :name (n11 / name :op1 "JNK"))))
            :manner~e.18 (w / way~e.18
                  :mod (t / this~e.17))))

# ::tok Furthermore , we find that basal arginase 1 expression and associated arginase activity is markedly increased in MKP @-@ 2 deletion mice , a response which would also mediate a reduction in NO formation , this is again different to the findings in MKP @-@ 1?/? macrophages .
# ::alignments 2-1.1.1 3-1.1 4-1.1.2.r 5-1.1.2.1.1.1.2 6-1.1.2.1.1.1.1.1 7-1.1.2.1.1.1.1.1 8-1.1.2.1.1 9-1.1.2.1 10-1.1.2.1.2.2 11-1.1.2.1.2.1.1.1 12-1.1.2.1.2 14-1.1.2.2 15-1.1.2 16-1.1.2.3.r 17-1.1.2.3.1.1.1.1 19-1.1.2.3.1.1.1.1 20-1.1.2.3.1 21-1.1.2.3 24-1.1.2.4 28-1.1.2.4.1 30-1.1.2.4.1.1 31-1.1.2.4.1.1.1.r 32-1.1.2.4.1.1.1.1.1.1 33-1.1.2.4.1.1.1 38-1.1.2.5 39-1.1.2.5.1.r 41-1.1.2.5.1 41-1.1.2.5.1.1 41-1.1.2.5.1.1.r 42-1.1.2.5.1.1.1.r 43-1.1.2.5.1.1.1.2.2.1 46-1.1.2.5.1.1.1.1.1
# ::id bel_pmid_2108_5614_26518
(a / and
      :op2 (f / find-01~e.3
            :ARG0 (w / we~e.2)
            :ARG1~e.4 (i / increase-01~e.15
                  :ARG1 (a2 / and~e.9
                        :op1 (e / express-03~e.8
                              :ARG2 (e2 / enzyme
                                    :name (n / name :op1 "arginase-1"~e.6,7)
                                    :mod (b / basal~e.5)))
                        :op2 (a3 / act-02~e.12
                              :ARG0 (e3 / enzyme
                                    :name (n2 / name :op1 "arginase"~e.11))
                              :ARG1-of (a4 / associate-01~e.10)))
                  :ARG1-of (m / mark-01~e.14)
                  :location~e.16 (m2 / mouse~e.21
                        :ARG2-of (d / delete-01~e.20
                              :ARG1 (g2 / gene
                                    :name (n3 / name :op1 "MKP-2"~e.17,19))))
                  :ARG2-of (r / respond-01~e.24
                        :ARG0-of (m3 / mediate-01~e.28
                              :ARG1 (r2 / reduce-01~e.30
                                    :ARG1~e.31 (f2 / form-01~e.33
                                          :ARG1 (s / small-molecule
                                                :name (n4 / name :op1 "NO"~e.32))))))
                  :ARG0-of (d2 / differ-01~e.38
                        :ARG1~e.39 (t / thing~e.41
                              :ARG1-of~e.41 (f3 / find-01~e.41
                                    :location~e.42 (c / cell
                                          :name (n5 / name :op1 "macrophage"~e.46)
                                          :part (g / gene
                                                :mode "interrogative"
                                                :name (n6 / name :op1 "MKP-1"~e.43)))))))))

# ::tok MKP @-@ 2 negatively regulated IL @-@ 12 , IL @-@ 6 and TNF @-@ a expression and positively regulates IL @-@ 10 confirming this hypothesis .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 5-1.1.2.1.1.1.1 7-1.1.2.1.1.1.1 9-1.1.2.1.1.1.1 9-1.1.2.1.2.1.1 11-1.1.2.1.2.1.1 12-1.1.2.1 13-1.1.2.1.3.1.1 16-1.1.2 17-1 20-1.2.2.1.1 22-1.2.2.1.1 23-1.3 24-1.3.1.1.1 25-1.3.1 25-1.3.1.1 25-1.3.1.1.r
# ::id bel_pmid_2108_5614_26520
(a / and~e.17
      :op1 (d / downregulate-01
            :ARG0 (e2 / enzyme
                  :name (n / name :op1 "MKP-2"~e.0,2))
            :ARG1 (e / express-03~e.16
                  :ARG2 (a2 / and~e.12
                        :op1 (p / protein
                              :name (n2 / name :op1 "IL-12"~e.5,7,9))
                        :op2 (p2 / protein
                              :name (n3 / name :op1 "IL-6"~e.9,11))
                        :op3 (p3 / protein
                              :name (n4 / name :op1 "TNF"~e.13)))))
      :op2 (u / upregulate-01
            :ARG0 e2
            :ARG1 (p4 / protein
                  :name (n5 / name :op1 "IL-10"~e.20,22)))
      :ARG0-of (c / confirm-01~e.23
            :ARG1 (t2 / thing~e.25
                  :ARG1-of~e.25 (h / hypothesize-01~e.25
                        :mod (t / this~e.24)))))

# ::tok Like pDC @-@ depleted mice , IFN @-@ alpha @/@ beta receptor @-@ deficient mice showed a significant delay in wound reepithelization ( Fig . 5 E ) and displayed a profound deficiency in IL @-@ 6 , IL @-@ 17 , and IL @-@ 22 expression levels in injured skin , without affecting the expression of IFN @-@ gamma ( Fig . 5 F ) .
# ::alignments 0-1.1.3 1-1.1.3.1.1.1.1.1 3-1.1.3.1.1 4-1.1.3.1 6-1.1.1.1.1.1.1 8-1.1.1.1.1.1.1 10-1.1.1.1.1.1.1 11-1.1.1.1.1 14-1.1.1 15-1.1 17-1.1.2.2 18-1.1.2 20-1.1.2.1.1 28-1 29-1.2 31-1.2.2.2 34-1.2.2.1.1.1.1.1.1 34-1.2.2.1.1.1.2.1.1 34-1.2.2.1.1.1.3.1.1 36-1.2.2.1.1.1.1.1.1 38-1.2.2.1.1.1.1.1.1 38-1.2.2.1.1.1.2.1.1 38-1.2.2.1.1.1.3.1.1 40-1.2.2.1.1.1.2.1.1 42-1.2.2.1.1.1 43-1.2.2.1.1.1.1.1.1 43-1.2.2.1.1.1.2.1.1 43-1.2.2.1.1.1.3.1.1 45-1.2.2.1.1.1.3.1.1 46-1.2.2.1.1 47-1.2.2.1 48-1.2.2.1.2.r 49-1.2.2.1.2.1 50-1.2.2.1.2 52-1.2.3.1 52-1.2.3.1.r 53-1.2.3 55-1.2.3.2 56-1.2.3.2.1.r 57-1.2.3.2.1.1.1 59-1.2.3.2.1.1.1
# ::id bel_pmid_2111_5688_27614
(a / and~e.28
      :op1 (s / show-01~e.15
            :ARG0 (m2 / mouse~e.14
                  :consist-of (d6 / deficit
                        :consist-of (r2 / receptor~e.11
                              :name (n2 / name :op1 "IFN-alpha/beta"~e.6,8,10))))
            :ARG1 (d3 / delay-01~e.18
                  :ARG1 (r3 / reepithelize-00
                        :ARG1 (w / wound~e.20))
                  :ARG1-of (s3 / significant-02~e.17))
            :ARG1-of (r / resemble-01~e.0
                  :ARG2 (m / mouse~e.4
                        :ARG2-of (d2 / deplete-01~e.3
                              :ARG1 (e / enzyme
                                    :name (n / name :op1 "pDC"~e.1)))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (f / figure :mod "5E")))
      :op2 (d / display-01~e.29
            :ARG0 m2
            :ARG1 (l2 / lack-01
                  :ARG1 (l3 / level~e.47
                        :degree-of (e2 / express-03~e.46
                              :ARG2 (a2 / and~e.42
                                    :op1 (p / protein
                                          :name (n3 / name :op1 "IL-6"~e.34,36,38,43))
                                    :op2 (p2 / protein
                                          :name (n4 / name :op1 "IL-17"~e.34,38,40,43))
                                    :op3 (p3 / protein
                                          :name (n5 / name :op1 "IL-22"~e.34,38,43,45))))
                        :location~e.48 (s2 / skin~e.50
                              :ARG1-of (i / injure-01~e.49)))
                  :mod (p5 / profound~e.31))
            :ARG0-of (a3 / affect-01~e.53
                  :polarity~e.52 "-"~e.52
                  :ARG1 (e3 / express-03~e.55
                        :ARG2~e.56 (p4 / protein
                              :name (n6 / name :op1 "IFN-gamma"~e.57,59))))
            :ARG1-of (d5 / describe-01
                  :ARG0 (f2 / figure :mod "5F"))))

# ::tok Expression of both IFN @-@ a2 and IFN @-@ b mRNA was found to be profoundly abrogated in TLR7 @-@ deficient mice
# ::alignments 0-1.1 3-1.1.1.1.2.1.1 3-1.1.1.2.2.1.1 5-1.1.1.1.2.1.1 6-1.1.1 7-1.1.1.1.2.1.1 7-1.1.1.2.2.1.1 9-1.1.1.2.2.1.1 10-1.1.1.1.1.1 10-1.1.1.2.1.1 12-1.4 15-1.2 15-1.2.r 16-1 17-1.3.r 18-1.3.1.1.1.1 21-1.3
# ::id bel_pmid_2111_5688_31368
(a / abrogate-01~e.16
      :ARG1 (e / express-03~e.0
            :ARG2 (a3 / and~e.6
                  :op1 (r2 / rna
                        :name (n5 / name :op1 "mRNA"~e.10)
                        :poss (p / protein
                              :name (n / name :op1 "IFN-a2"~e.3,5,7)))
                  :op2 (r3 / rna
                        :name (n6 / name :op1 "mRNA"~e.10)
                        :poss (p2 / protein
                              :name (n3 / name :op1 "IFN-b"~e.3,7,9)))))
      :manner~e.15 (p3 / profound~e.15)
      :location~e.17 (m / mouse~e.21
            :ARG0-of (l / lack-01
                  :ARG1 (p4 / protein
                        :name (n4 / name :op1 "TLR7"~e.18))))
      :ARG1-of (f / find-01~e.12))

# ::tok pDCs were found to rapidly infiltrate both murine and human skin wounds and to transiently produce type I IFNs via TLR7 @- and TLR9 @-@ dependent recognition of nucleic acids .
# ::alignments 2-1.3 4-1.1.3 4-1.1.3.r 5-1.1 7-1.1.2.2.1.1 8-1.1.2 9-1.1.2.1.1.1 10-1.1.2.1.1 10-1.1.2.2.1 11-1.1.2.1 11-1.1.2.2 12-1.1.2 14-1.2.3 14-1.2.3.r 15-1.2 16-1.2.2.2 17-1.2.2.2.1 22-1.2.4.2.1 25-1.2.4.2 26-1.2.4 29-1.2.4.1
# ::id bel_pmid_2111_5688_4192
(a / and
      :op1 (i / infiltrate-01~e.5
            :ARG0 (e / enzyme
                  :name (n / name :op1 "pDC"))
            :ARG1 (a2 / and~e.8,12
                  :op1 (w / wound~e.11
                        :mod (s / skin~e.10
                              :mod (h / human~e.9)))
                  :op2 (w2 / wound-01~e.11
                        :ARG1 (s2 / skin~e.10
                              :mod (m / murine~e.7))))
            :manner~e.4 (r / rapid~e.4))
      :op2 (p / produce-01~e.15
            :ARG0 e
            :ARG1 (p2 / protein
                  :name (n2 / name :op1 "IFN")
                  :mod (t2 / type~e.16 :mod "I"~e.17))
            :manner~e.14 (t / transient~e.14)
            :instrument (r2 / recognize-02~e.26
                  :ARG1 (a4 / acid~e.29
                        :mod (n5 / nucleus))
                  :ARG0-of (d / depend-01~e.25
                        :ARG1 (a3 / and~e.22
                              :op1 (p3 / protein
                                    :name (n3 / name :op1 "TLR-7"))
                              :op2 (p4 / protein
                                    :name (n4 / name :op1 "TLR-9"))))))
      :ARG1-of (f / find-01~e.2))

# ::tok In the present study , we found that when RSK4 is inhibited in vitro using short hairpin RNA technology , cells can bypass stress @-@ induced senescence and oncogene @-@ induced senescence : normal human fibroblasts grew following oxidative stress , induction of DNA damage and KRAS( V12 ) or BRAF( E600 ) overexpression .
# ::alignments 0-1.2.3 2-1.3.2.1 3-1.3.2 5-1.3.1 6-1.3 8-1.2.r 9-1.2.1.1.1 11-1.2 12-1.2.3 13-1.2.3 15-1.2.2.1.1.1 16-1.2.2.1.1.1 17-1.2.2.1 17-1.2.2.1.1.1 18-1.2.2 20-1.1.1 21-1 22-1.1 23-1.1.2.1.1.1 25-1.1.2.1.1 25-1.1.2.2.1 26-1.1.2.1 26-1.1.2.2 27-1.1.2 28-1.1.2.2.1.1 30-1.1.2.1.1 31-1.1.2.1 33-1.1.3.1.2 34-1.1.3.1.1 35-1.1.3.1 36-1.1.3 38-1.1.3.2.1.1 39-1.1.3.2.1 41-1.1.3.2.2 42-1.1.3.2.2.1.r 43-1.1.3.2.2.1.1 44-1.1.3.2.2.1 45-1.1.3.2.3.1 47-1.1.3.2.3.1.1.2.1 51-1.1.3.2.3.1.2.2.1
# ::id bel_pmid_2123_9520_35054
(p / possible~e.21
      :domain (b / bypass-01~e.22
            :ARG0 (c / cell~e.20)
            :ARG1 (a / and~e.27
                  :op1 (s / senescence~e.26,31
                        :ARG1-of (i / induce-01~e.25,30
                              :ARG0 (s2 / stress~e.23)))
                  :op2 (s3 / senescence~e.26
                        :ARG1-of (i2 / induce-01~e.25
                              :ARG0 (o / oncogene~e.28))))
            :manner (g / grow-01~e.36
                  :ARG1 (f2 / fibroblast~e.35
                        :mod (h / human~e.34)
                        :mod (n4 / normal~e.33))
                  :time (a2 / after
                        :op1 (s6 / stress~e.39
                              :mod (o2 / oxidative~e.38))
                        :op2 (i5 / induce-01~e.41
                              :ARG1~e.42 (d / damage-01~e.44
                                    :ARG1 (d2 / DNA~e.43)))
                        :op3 (o3 / overexpress-00
                              :ARG2 (a3 / and~e.45
                                    :op1 (p3 / protein
                                          :name (n5 / name :op1 "KRAS")
                                          :ARG2-of (m2 / mutate-01 :value "V12"~e.47))
                                    :op2 (g2 / gene
                                          :name (n6 / name :op1 "BRAF")
                                          :ARG2-of (m3 / mutate-01 :value "E600"~e.51)))))))
      :time~e.8 (i3 / inhibit-01~e.11
            :ARG1 (e / enzyme
                  :name (n / name :op1 "RSK4"~e.9))
            :instrument (t / technology~e.18
                  :mod (r / rna~e.17
                        :name (n2 / name :op1 "short-hairpin-RNA"~e.15,16,17)))
            :manner (i4 / in-vitro~e.0,12,13))
      :ARG1-of (f / find-01~e.6
            :ARG0 (w / we~e.5)
            :medium (s5 / study~e.3
                  :mod (p2 / present~e.2))))

# ::tok Two days after BRAFE600 selection , we seeded cells at low density and performed growth curves . RSK4 inhibition partially rescued BRAFE600 @-@ induced senescence in both TIG3 and TIG3 p16 @-@ null ( Figure 4A ) .
# ::alignments 0-1.1.3.2.1 1-1.1.3.2.2 2-1.1.3 4-1.1.3.1 6-1.1.1.1 7-1.1.1 8-1.1.1.2 9-1.1.1.3.r 10-1.1.1.3.1 11-1.1.1.3 12-1.1 13-1.1.2 14-1.1.2.2.1 15-1.1.2.2 17-1.2.1.1.1.1 18-1.2.1 19-1.2.1.2 20-1.2 23-1.2.2.1 24-1.2.2 27-1.2.3.1.1.1 27-1.2.3.2.1.1 28-1.2.3 29-1.2.3.1.1.1 29-1.2.3.2.1.1 30-1.2.3.2.2.1.1 34-1.2.4.1 35-1.2.4.1.1
# ::id bel_pmid_2123_9520_37214
(m / multi-sentence
      :snt1 (a / and~e.12
            :op1 (s / seed-02~e.7
                  :ARG0 (w / we~e.6)
                  :ARG2 (c / cell~e.8)
                  :mod~e.9 (d2 / dense~e.11
                        :degree (l / low~e.10)))
            :op2 (p / perform-01~e.13
                  :ARG0 w
                  :ARG1 (c2 / curve~e.15
                        :topic (g / grow-01~e.14)))
            :time (a2 / after~e.2
                  :op1 (s2 / select-01~e.4
                        :ARG1 (g2 / gene
                              :name (n / name :op1 "BRAF")
                              :ARG2-of (m2 / mutate-01 :value "E600")))
                  :duration (t2 / temporal-quantity
                        :quant "2"~e.0
                        :unit (d3 / day~e.1))))
      :snt2 (r / rescue-01~e.20
            :ARG0 (i / inhibit-01~e.18
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "RSK4"~e.17))
                  :degree (p2 / partial~e.19))
            :ARG1 (s3 / senescence~e.24
                  :ARG1-of (i2 / induce-01~e.23
                        :ARG0 (g3 / gene
                              :name (n3 / name :op1 "BRAF")
                              :ARG2-of (m3 / mutate-01 :value "E600"))))
            :location (a3 / and~e.28
                  :op1 (p3 / protein
                        :name (n4 / name :op1 "TIG3"~e.27,29))
                  :op2 (p4 / protein
                        :name (n5 / name :op1 "TIG3"~e.27,29)
                        :mod (p5 / protein
                              :name (n6 / name :op1 "p16"~e.30)
                              :ARG2-of (m4 / mutate-01 :mod "-/-"))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (f / figure~e.34 :mod "4A"~e.35))))

# ::tok This IFNg @-@ stimulated expression of T @-@ bet is dependent on signaling through JAK2 and signal transducers and activators of transcription 1 ( STAT1 ) and activates T @-@ bet @-@ dependent DNA binding activity
# ::alignments 0-1.1.1.3 1-1.1.1.2.1.1.1 3-1.1.1.2 4-1.1.1 5-1.1.1.1.r 6-1.1.1.1.1.1 8-1.1.1.1.1.1 10-1.1 11-1.1.2.r 12-1.1.2.1 12-1.1.2.2.1.1 14-1.1.2.1.1.1.1 15-1.1.2 15-1.1.2.2.1.1 16-1.1.2.1 16-1.1.2.2.1.1 17-1.1.2.2.1.1 18-1.1.2.2.1.1 19-1.1.2.2.1.1 20-1.1.2.2.1.1 21-1.1.2.2.1.1 22-1.1.2.2.1.1 26-1 26-1.1.2.2.1.1 27-1.2 28-1.2.2.2.1 29-1.2.2.2.1 30-1.2.2.2.1 32-1.2.2.2 33-1.2.2.1.1 34-1.2.2.1 35-1.2.2
# ::id bel_pmid_2123_9533_1678
(a3 / and~e.26
      :op1 (d / depend-01~e.10
            :ARG0 (e / express-03~e.4
                  :ARG2~e.5 (p3 / protein
                        :name (n2 / name :op1 "T-bet"~e.6,8))
                  :ARG1-of (s / stimulate-01~e.3
                        :ARG0 (p / protein
                              :name (n / name :op1 "IFNg"~e.1)))
                  :mod (t4 / this~e.0))
            :ARG1~e.11 (a2 / and~e.15
                  :op1 (s2 / signal-07~e.12,16
                        :instrument (e2 / enzyme
                              :name (n3 / name :op1 "JAK2"~e.14)))
                  :op2 (p2 / protein
                        :name (n4 / name :op1 "signal-transducers-and-activators-of-transcription-1"~e.12,15,16,17,18,19,20,21,22,26))))
      :op2 (a4 / activate-01~e.27
            :ARG0 e
            :ARG1 (a5 / act-02~e.35
                  :mod (b / bind-01~e.34
                        :ARG1 (d2 / DNA~e.33))
                  :ARG0-of (d3 / depend-01~e.32
                        :ARG1 p3~e.28,29,30))))

# ::tok In the lung , the concentration of IL @-@ 6 was increased , which aberrantly activated oncogenic Stat3 and increased expression of Stat3 downstream genes in epithelial tumor progenitor cells .
# ::alignments 2-1.2 5-1.1 6-1.1.1.r 7-1.1.1.1.1 9-1.1.1.1.1 11-1 15-1.3 16-1.3.1.2 17-1.3.1.1.1 19-1 19-1.4 19-1.4.r 20-1.4.1 21-1.4.1.1.r 22-1.4.1.1.1.1 23-1.4.1.1.2 24-1.4.1.1 25-1.4.2.r 26-1.4.2.1.1.1 27-1.4.2.1.1 29-1.4.2
# ::id bel_pmid_2137_8275_40580
(i / increase-01~e.11,19
      :ARG1 (c / concentrate-02~e.5
            :ARG1~e.6 (p / protein
                  :name (n / name :op1 "IL-6"~e.7,9)))
      :location (l / lung~e.2)
      :ARG0-of (a / activate-01~e.15
            :ARG1 (p2 / protein
                  :name (n2 / name :op1 "Stat3"~e.17)
                  :mod (o / oncogenic~e.16))
            :manner (a2 / aberrant))
      :ARG0-of~e.19 (i2 / increase-01~e.19
            :ARG1 (e / express-03~e.20
                  :ARG2~e.21 (g / gene~e.24
                        :name (n3 / name :op1 "Stat3"~e.22)
                        :location (d / downstream~e.23)))
            :location~e.25 (c2 / cell~e.29
                  :ARG0-of (b / bear-02
                        :ARG1 (t / tumor~e.27
                              :mod (e2 / epithelium~e.26))))))

# ::tok Spontaneous emphysema and lung adenocarcinoma were sequentially developed after MMP12 overexpression .
# ::alignments 0-1.1.1.2 1-1.1.1.1.1 2-1.1 3-1.1.2.2 4-1.1.2.1.1 6-1.2 6-1.2.r 7-1 8-1.3 9-1.3.1.1.1.1
# ::id bel_pmid_2137_8275_40582
(d / develop-01~e.7
      :ARG2 (a / and~e.2
            :op1 (d2 / disease
                  :name (n / name :op1 "emphysema"~e.1)
                  :mod (s2 / spontaneous~e.0))
            :op2 (d3 / disease
                  :name (n2 / name :op1 "adenocarcinoma"~e.4)
                  :mod (l / lung~e.3)))
      :manner~e.6 (s / sequential~e.6)
      :time (a2 / after~e.8
            :op1 (o / overexpress-00
                  :ARG2 (e / enzyme
                        :name (n3 / name :op1 "MMP12"~e.9)))))

# ::tok MMP12 suppresses T @-@ cell proliferation and function in vivo The CD4+ T @-@ lymphocyte population was significantly decreased in the spleen of doxycycline @-@ treated bitransgenic mice ( 5.58 %) compared with that in untreated ones ( 21.14 %), while the CD8+ T @-@ lymphocyte population was less affected ( Figure 2A ) .
# ::alignments 0-1.1.1.1.1 1-1.1 2-1.1.2.1.1.1.1 4-1.1.2.1.1.1.1 5-1.1.2.1 6-1.1.2 7-1.1.2.2 8-1.1.3 9-1.1.3 11-1.2.1.1.2.1.1.1 11-1.2.5.1.1.2.1.1.1 12-1.2.1.1.1.1 12-1.2.5.1.1.1.1 12-1.2.6.1.1.1 14-1.2.1.1.1.1 14-1.2.5.1.1.1.1 14-1.2.6.1.1.1 15-1.2.1 15-1.2.5.1 15-1.2.6 17-1.2.3 18-1.2 18-1.2.5 19-1.1.3 19-1.2.4.r 21-1.2.4 23-1.2.4.1.1.1 25-1.2.4.1.1 26-1.2.4.1.2 27-1.2.4.1 27-1.2.5.3 29-1.2.2.1 31-1.2.5.r 31-1.2.6.r 34-1.1.3 38-1.2.5.2.1 42-1.2.6.1.2.1.1.1 43-1.2.6.1.1.1 45-1.2.6.1.1.1 46-1.2.6 48-1.2.6.2.1 49-1.2.6.2 51-1.2.7.1 52-1.2.7.1.1
# ::id bel_pmid_2137_8275_40590
(m2 / multi-sentence
      :snt1 (s / suppress-01~e.1
            :ARG0 (e / enzyme
                  :name (n / name :op1 "MMP12"~e.0))
            :ARG1 (a / and~e.6
                  :op1 (p3 / proliferate-01~e.5
                        :ARG0 (c / cell
                              :name (n2 / name :op1 "T-cell"~e.2,4)))
                  :op2 (f / function-01~e.7
                        :ARG0 c))
            :manner (i / in-vivo~e.8,9,19,34))
      :snt2 (d / decrease-01~e.18
            :ARG1 (p4 / population~e.15
                  :quant-of (c2 / cell
                        :name (n3 / name :op1 "T-lymphocyte"~e.12,14)
                        :ARG1-of (e2 / express-03
                              :ARG2 (e3 / enzyme
                                    :name (n4 / name :op1 "CD4+"~e.11)))))
            :ARG2 (p5 / percentage-entity :value "5.58"~e.29)
            :ARG1-of (s2 / significant-02~e.17)
            :location~e.19 (s3 / spleen~e.21
                  :part-of (m3 / mouse~e.27
                        :ARG1-of (t / treat-03~e.25
                              :ARG3 (d2 / doxycycline~e.23))
                        :mod (b / bitransgenic~e.26)))
            :compared-to~e.31 (d3 / decrease-01~e.18
                  :ARG1 (p6 / population~e.15
                        :quant-of (c3 / cell
                              :name (n5 / name :op1 "T-lymphocyte"~e.12,14)
                              :ARG3-of (e4 / express-03
                                    :ARG2 (e5 / enzyme
                                          :name (n6 / name :op1 "CD4+"~e.11)))))
                  :ARG2 (p7 / percentage-entity :value "21.14"~e.38)
                  :location (m4 / mouse~e.27
                        :ARG1-of (a2 / alter-01 :polarity "-")))
            :compared-to~e.31 (p8 / population~e.15,46
                  :quant-of (c4 / cell
                        :name (n7 / name :op1 "T-lymphocyte"~e.12,14,43,45)
                        :ARG1-of (e6 / express-03
                              :ARG2 (e7 / enzyme
                                    :name (n8 / name :op1 "CD8+"~e.42))))
                  :ARG1-of (a3 / affect-01~e.49
                        :mod (l / less~e.48)))
            :ARG1-of (d4 / describe-01
                  :ARG0 (f2 / figure~e.51 :mod "2A"~e.52))))

# ::tok The culture medium showed decreased secretion of IL @-@ 2 , IL @-@ 4 , and IFN7 in the activated MMP12 @-@ treated samples ( Figure 2F ) .
# ::alignments 1-1.1.1 2-1.1 3-1 4-1.2.2 5-1.2 6-1.2.1.r 7-1.2.1.1.1.1 7-1.2.1.2.1.1 9-1.2.1.1.1.1 11-1.2.1.1.1.1 11-1.2.1.2.1.1 13-1.2.1.2.1.1 15-1.2.1 16-1.2.1.3.1.1 17-1.3.r 19-1.3.1.1.2 20-1.3.1.1.1.1 22-1.3.1 23-1.3 25-1.4.1 26-1.4.1.1
# ::id bel_pmid_2137_8275_40594
(s / show-01~e.3
      :ARG0 (m / medium~e.2
            :mod (c / culture~e.1))
      :ARG1 (s2 / secrete-01~e.5
            :ARG1~e.6 (a / and~e.15
                  :op1 (p / protein
                        :name (n / name :op1 "IL-2"~e.7,9,11))
                  :op2 (p2 / protein
                        :name (n2 / name :op1 "IL-4"~e.7,11,13))
                  :op3 (p3 / protein
                        :name (n3 / name :op1 "IFN7"~e.16)))
            :ARG1-of (d2 / decrease-01~e.4))
      :location~e.17 (s3 / sample~e.23
            :ARG1-of (t / treat-04~e.22
                  :ARG2 (e / enzyme
                        :name (n4 / name :op1 "MMP12"~e.20)
                        :ARG1-of (a2 / activate-01~e.19))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.25 :mod "2F"~e.26)))

# ::tok CD11b+/Gr @-@ 1+ cells from doxcycline @-@ treated bitransgenic mice showed the strongest inhibition on proliferation of wild @-@ type CD4+ T cells ( Figure 3C ) .
# ::alignments 2-1.1.1.2.1.1 3-1.1 4-1.1.2.r 7-1.1.2.2 8-1.1.2.1 9-1.1.2 10-1 12-1.2.2 12-1.2.2.1 12-1.2.2.1.r 13-1.2 14-1.2.1.r 15-1.2.1 16-1.2.1.1.r 17-1.2.1.1.3 19-1.2.1.1.3 20-1.2.1.1.2.1.1.1 21-1.2.1.1.1.1 22-1.2.1.1.1.1 24-1.3.1 25-1.3.1.1
# ::id bel_pmid_2137_8275_40598
(s / show-01~e.10
      :ARG0 (c / cell~e.3
            :part (s2 / slash
                  :op1 (p2 / protein
                        :name (n / name :op1 "CD11b+"))
                  :op2 (p3 / protein
                        :name (n2 / name :op1 "Gr-1+"~e.2)))
            :source~e.4 (m / mouse~e.9
                  :mod (b / bitransgenic~e.8)
                  :ARG1-of (t / treat-03~e.7
                        :ARG3 (d / doxycycline))))
      :ARG1 (i / inhibit-01~e.13
            :ARG1~e.14 (p / proliferate-01~e.15
                  :ARG0~e.16 (c2 / cell
                        :name (n3 / name :op1 "T-cell"~e.21,22)
                        :ARG3-of (e / express-03
                              :ARG2 (e2 / enzyme
                                    :name (n4 / name :op1 "CD4+"~e.20)))
                        :mod (w / wild-type~e.17,19)))
            :mod (s3 / strong~e.12
                  :degree~e.12 (m2 / most~e.12)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.24 :mod "3C"~e.25)))

# ::tok This inhibition was further confirmed by a significant reduction of IL @-@ 2 and IL @-@ 4 secretion , implicating a functional impairment of CD4+ T cells by CD11b+/Gr @-@ 1+ cells from doxcycline @-@ treated bitransgenic mice ( Figure 3D ) .
# ::alignments 0-1.2.1 1-1.2 3-1.3 4-1 5-1.1.r 7-1.1.2 8-1.1 9-1.1.1.r 10-1.1.1.1.1.1.1 10-1.1.1.1.2.1.1 12-1.1.1.1.1.1.1 13-1.1.1.1 14-1.1.1.1.1.1.1 14-1.1.1.1.2.1.1 16-1.1.1.1.2.1.1 17-1.1.1 19-1.4 21-1.4.1.2 22-1.4.1 23-1.4.1.2.1.r 24-1.4.1.2.1.2.1.1.1 25-1.4.1.2.1.1.1 26-1.4.1.1 26-1.4.1.2.1.1.1 30-1.4.1.1.1.2.1.1 31-1.4.1.1 32-1.4.1.1.2.r 35-1.4.1.1.2.2 36-1.4.1.1.2.1 37-1.4.1.1.2 39-1.5.1 40-1.5.1.1
# ::id bel_pmid_2137_8275_40600
(c / confirm-01~e.4
      :ARG0~e.5 (r / reduce-01~e.8
            :ARG1~e.9 (s / secrete-01~e.17
                  :ARG1 (a / and~e.13
                        :op1 (p / protein
                              :name (n / name :op1 "IL-2"~e.10,12,14))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "IL-4"~e.10,14,16))))
            :ARG1-of (s3 / significant-02~e.7))
      :ARG1 (i / inhibit-01~e.1
            :mod (t / this~e.0))
      :degree (f / further~e.3)
      :ARG0-of (i2 / implicate-01~e.19
            :ARG1 (i3 / impair-01~e.22
                  :ARG0 (c3 / cell~e.26,31
                        :part (s2 / slash
                              :op1 (p3 / protein
                                    :name (n5 / name :op1 "CD11b+"))
                              :op2 (p4 / protein
                                    :name (n6 / name :op1 "Gr-1+"~e.30)))
                        :source~e.32 (m / mouse~e.37
                              :mod (b / bitransgenic~e.36)
                              :ARG1-of (t2 / treat-03~e.35
                                    :ARG3 (d / doxycycline))))
                  :ARG1 (f2 / function-01~e.21
                        :ARG0~e.23 (c2 / cell
                              :name (n3 / name :op1 "T-cell"~e.25,26)
                              :ARG3-of (e / express-03
                                    :ARG2 (e2 / enzyme
                                          :name (n4 / name :op1 "CD4+"~e.24)))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f3 / figure~e.39 :mod "3D"~e.40)))

# ::tok Compared with doxycycline @-@ untreated bitransgenic mice , the expression levels of IL @-@ 1p , IL @-@ 6 , MIP @-@ 2 , and TNF @-@ a were abnormally increased in the plasma of doxycycline @-@ treated bitransgenic mice ( Figure 4A ) .
# ::alignments 0-1.4.r 2-1.3.1.2.1 5-1.4.1 6-1.4 9-1.1.1 10-1.1 11-1.1.1.1.r 12-1.1.1.1.1.1.1 12-1.1.1.1.2.1.1 14-1.1.1.1.1.1.1 16-1.1.1.1.1.1.1 16-1.1.1.1.2.1.1 18-1.1.1.1.2.1.1 20-1.1.1.1.3.1.1 22-1.1.1.1.3.1.1 24-1.1.1.1 25-1.1.1.1.4.1.1 27-1.1.1.1.4.1.1 29-1.2 29-1.2.1 29-1.2.1.r 29-1.2.r 29-1.4.2.1 30-1 33-1.3 35-1.4.2.2 37-1.3.1.2 37-1.4.2 38-1.3.1.1 39-1.3.1 39-1.4 41-1.5.1 42-1.5.1.1
# ::id bel_pmid_2137_8275_40608
(i / increase-01~e.30
      :ARG1 (l / level~e.10
            :degree-of (e / express-03~e.9
                  :ARG2~e.11 (a2 / and~e.24
                        :op1 (p / protein
                              :name (n / name :op1 "IL-1p"~e.12,14,16))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "IL-6"~e.12,16,18))
                        :op3 (p3 / protein
                              :name (n3 / name :op1 "MIP-2"~e.20,22))
                        :op4 (p4 / protein
                              :name (n4 / name :op1 "TNF-a"~e.25,27)))))
      :manner~e.29 (n5 / normal~e.29 :polarity~e.29 "-"~e.29)
      :location (p5 / plasma~e.33
            :part-of (m / mouse~e.39
                  :mod (b / bitransgenic~e.38)
                  :ARG1-of (t / treat-03~e.37
                        :ARG3 (d / doxycycline~e.2))))
      :compared-to~e.0 (m2 / mouse~e.6,39
            :mod (b2 / bitransgenic~e.5)
            :ARG1-of (t2 / treat-03~e.37
                  :polarity "-"~e.29
                  :ARG3 (d2 / doxycycline~e.35)))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure~e.41 :mod "4A"~e.42)))

# ::tok To determine if the ERK @-@ MAPK pathway was also activated by TLR2 in megakaryocytes , lysates of Meg @-@ 01 cells were treated with 1 ?g/mL Pam3CSK4 for up to 1 hour and were immunoblotted for phosphorylated ERK1 @/@ 2. As shown in Figure 1A , there was an increase in the phosphorylation of ERK beginning at 5 minutes that peaks at 30 minutes ( 105.8 % ±3.9 ) .
# ::alignments 1-1.1.3 4-1.1.3.1.3.1.1 6-1.1.3.1.3.1.1 7-1.1.3.1.3 10-1.1.3.1 11-1.1.3.1.2.r 12-1.1.3.1.2.1.1 14-1.1.3.1.4.1.1 18-1.1.1.1.1.1.1 20-1.1.1.1.1.1.1 20-1.1.1.2.1 20-1.1.1.2.3.1 21-1.1.1.1.1 21-1.1.3.1.4 23-1.1.1 24-1.1.1.2.r 25-1.1.1.2.1 25-1.1.1.2.3.1 27-1.1.1.2.2.1 28-1.1.1.3.r 29-1.1.1.3 30-1.1.1.3 31-1.1.1.3.1.1 32-1.1.1.3.1.2 33-1.1 37-1.1.2.1.1.3 37-1.2.1 42-1.2.4 43-1.2.4.1.r 44-1.2.4.1 45-1.2.4.1.1 50-1.2 53-1.2.1 54-1.2.1.1.r 55-1.2.1.1.1.1 56-1.2.2 58-1.2.2.1.1.1 59-1.2.2.1.1.2 61-1.2.3 63-1.2.3.2.1.1 64-1.2.3.2.1.2 66-1.2.3.1.1 67-1.2.3.1 67-1.2.3.1.2.1.1 67-1.2.3.1.2.2.1
# ::id bel_pmid_2145_4454_35882
(m4 / multi-sentence
      :snt1 (a / and~e.33
            :op1 (t4 / treat-04~e.23
                  :ARG1 (l / lysate
                        :source (c / cell-line~e.21
                              :name (n2 / name :op1 "Meg-01"~e.18,20)))
                  :ARG2~e.24 (p3 / protein
                        :quant "1"~e.20,25
                        :name (n3 / name :op1 "Pam3CSK4"~e.27)
                        :quant (c3 / concentration-quantity
                              :quant "1"~e.20,25
                              :unit (g / gram-per-mililiter)))
                  :duration~e.28 (u / up-to~e.29,30
                        :op1 (t6 / temporal-quantity
                              :quant "1"~e.31
                              :unit (h2 / hour~e.32))))
            :op2 (i / immunoblot-00
                  :purpose (f / find-01
                        :ARG1 (s / slash
                              :op1 (e2 / enzyme
                                    :name (n4 / name :op1 "ERK-1"))
                              :op2 (e3 / enzyme
                                    :name (n5 / name :op1 "ERK-2"))
                              :ARG1-of (p4 / phosphorylate-01~e.37))))
            :purpose (d / determine-01~e.1
                  :ARG1 (a2 / activate-01~e.10
                        :mode "interrogative"
                        :ARG0~e.11 (p6 / protein
                              :name (n7 / name :op1 "TLR2"~e.12))
                        :ARG1 (p5 / pathway~e.7
                              :name (n6 / name :op1 "ERK-MAPK"~e.4,6))
                        :location (c2 / cell~e.21
                              :name (n8 / name :op1 "megakaryocyte"~e.14)))))
      :snt2 (i2 / increase-01~e.50
            :ARG1 (p7 / phosphorylate-01~e.37,53
                  :ARG1~e.54 (e4 / enzyme
                        :name (n9 / name :op1 "ERK"~e.55)))
            :ARG0-of (b / begin-01~e.56
                  :time (a6 / after
                        :op1 (t3 / temporal-quantity
                              :quant "5"~e.58
                              :unit (m3 / minute~e.59))))
            :ARG1-of (p8 / peak-01~e.61
                  :ARG2 (p9 / percentage-entity~e.67
                        :value "105.8"~e.66
                        :ARG2-of (s4 / slash
                              :op1 (a4 / add-02
                                    :ARG1 (p / percentage-entity~e.67 :value "3.9"))
                              :op2 (s3 / subtract-01
                                    :ARG1 (p2 / percentage-entity~e.67 :value "3.9"))))
                  :time (a3 / after
                        :op1 (t / temporal-quantity
                              :quant "30"~e.63
                              :unit (m2 / minute~e.64))))
            :ARG1-of (s2 / show-01~e.42
                  :location~e.43 (f2 / figure~e.44 :mod "1A"~e.45))))

# ::tok GP1b is part of the GPIb @-@ IX @-@ V complex that binds vWF and thrombin . Its expression level was significantly increased by 162 % and cell surface expression , as determined by flow cytometry , was also increased by 114 % with Pam3CSK4 treatment ( Figure 5A and Supplemental Figure 4C ) .
# ::alignments 0-1.1.1.1.1.1.1.1 0-1.2.2.1.1 2-1.2 5-1.2.1.1.1 7-1.2.1.1.1 9-1.2.1.1.1 10-1.2.1 12-1.2.1.2 13-1.2.1.2.1.1.1.1 14-1.2.1.2.1 15-1.2.1.2.1.2.1.1 18-1.1.1.1.1 19-1.1.1.1 21-1.1.1.3 22-1.1.1 23-1.1.1.2.r 24-1.1.1.2.1 25-1.1.1.2 26-1.1 27-1.1.2.1.2.1 28-1.1.2.1.2 29-1.1.2.1 31-1.1.2.1.3.r 32-1.1.2.1.3 33-1.1.2.1.3.1.r 34-1.1.2.1.3.1.1 35-1.1.2.1.3.1 38-1.1.2.3 39-1.1.2 40-1.1.2.2.r 41-1.1.2.2.1 42-1.1.2.2 43-1.1.2.4.r 44-1.1.2.4.1.1.1 45-1.1.2.4 47-1.1.3.1.1 48-1.1.3.1.1.1 49-1.1.3.1 50-1.1.3.1.2.2 51-1.1.3.1.2 52-1.1.3.1.2.1
# ::id bel_pmid_2145_4454_35884
(m / multi-sentence
      :snt2 (a / and~e.26
            :op1 (i / increase-01~e.22
                  :ARG1 (l / level~e.19
                        :degree-of (e2 / express-03~e.18
                              :ARG2 (p6 / protein
                                    :name (n6 / name :op1 "GP1b"~e.0))))
                  :ARG2~e.23 (p / percentage-entity~e.25 :value "162"~e.24)
                  :ARG1-of (s / significant-02~e.21))
            :op2 (i2 / increase-01~e.39
                  :ARG1 (e3 / express-03~e.29
                        :ARG2 p6
                        :location (s2 / surface~e.28
                              :poss (c2 / cell~e.27))
                        :ARG1-of~e.31 (d / determine-01~e.32
                              :ARG0~e.33 (c3 / cytometry~e.35
                                    :mod (f / flow~e.34))))
                  :ARG2~e.40 (p2 / percentage-entity~e.42 :value "114"~e.41)
                  :mod (a2 / also~e.38)
                  :instrument~e.43 (t / treat-04~e.45
                        :ARG2 (p5 / protein
                              :name (n5 / name :op1 "Pam3CSK4"~e.44))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a3 / and~e.49
                        :op1 (f2 / figure~e.47 :mod "5A"~e.48)
                        :op2 (f3 / figure~e.51
                              :mod "4C"~e.52
                              :ARG2-of (s3 / supplement-01~e.50)))))
      :snt1 (h / have-part-91~e.2
            :ARG1 (c / complex~e.10
                  :name (n2 / name :op1 "GPIb-IX-V"~e.5,7,9)
                  :ARG1-of (b / bind-01~e.12
                        :ARG2 (a4 / and~e.14
                              :op1 (p4 / protein
                                    :name (n3 / name :op1 "vWF"~e.13))
                              :op2 (e / enzyme
                                    :name (n4 / name :op1 "thrombin"~e.15)))))
            :ARG2 (p3 / protein
                  :name (n / name :op1 "GP1b"~e.0))))

# ::tok CD41 , also known as integrin ?IIb , part of the ?IIb ? III receptor that binds fibrinogen , was also significantly increased in the presence of Pam3CSK4 by 123 % ( Figure 5B ) . Surface expression of CD41 was increased by 125 % as shown by flow cytometry ( Supplemental Figure 4D ) .
# ::alignments 0-1.1.1.1.1 0-1.2.1.1.1.1 2-1.1.1.2.2 3-1.1.1 3-1.1.1.2 3-1.1.1.2.1.2.r 3-1.1.1.2.r 4-1.1.1.2.1.2.r 5-1.1.1.2.1.2.1 8-1.1.1.3.r 12-1.1.1.2.1.1 12-1.1.1.2.1.1.r 14-1.1.1.3 16-1.1.1.3.2 17-1.1.1.3.2.1.1.1 20-1.1.1.3.2.1.2.3 21-1.1.1.3.2.1.2.2 21-1.1.2 22-1.1 22-1.1.1.3.2.1.2 23-1.1.1.3.2.1.2.4.r 25-1.1.1.3.2.1.2.4 26-1.1.1.3.2.1.2.4.1.r 27-1.1.1.3.2.1.2.4.1.1.1 28-1.1.1.3.2.1.2.1.r 29-1.1.1.3.2.1.2.1.1 30-1.1.1.3.2.1.2.1 32-1.1.3.1 33-1.1.3.1.1 36-1.2.1.2 37-1.2.1 38-1.2.1.1.r 39-1.2.1.1.1.1 41-1.2 42-1.2.2.r 43-1.2.2.1 44-1.2.2 45-1.2.3.r 46-1.2.3 47-1.2.3.1.r 48-1.2.3.1.1 49-1.2.3.1 51-1.2.4.1.2 52-1.2.4.1 53-1.2.4.1.1
# ::id bel_pmid_2145_4454_35890
(m / multi-sentence
      :snt1 (i / increase-01~e.22
            :ARG1 (p3 / protein~e.3
                  :name (n / name :op1 "CD41"~e.0)
                  :ARG1-of~e.3 (k / know-02~e.3
                        :ARG2 (p4 / protein
                              :mode~e.12 "interrogative"~e.12
                              :name~e.3,4 (n2 / name :op1 "integrin-IIb"~e.5))
                        :mod (a / also~e.2))
                  :part-of~e.8 (r / receptor~e.14
                        :name (n3 / name :op1 "IIb/IIIa")
                        :ARG0-of (b / bind-01~e.16
                              :ARG1 (p5 / protein
                                    :name (n4 / name :op1 "fibrinogen"~e.17)
                                    :ARG1-of (i2 / increase-01~e.22
                                          :ARG2~e.28 (p / percentage-entity~e.30 :value "123"~e.29)
                                          :ARG1-of (s2 / significant-02~e.21)
                                          :mod (a2 / also~e.20)
                                          :condition~e.23 (p6 / present~e.25
                                                :domain~e.26 (p7 / protein
                                                      :name (n5 / name :op1 "Pam3CSK4"~e.27))))))))
            :ARG1-of (s / significant-02~e.21)
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure~e.32 :mod "5B"~e.33)))
      :snt2 (i3 / increase-01~e.41
            :ARG1 (e / express-03~e.37
                  :ARG2~e.38 (p8 / protein
                        :name (n6 / name :op1 "CD41"~e.0,39))
                  :location (s3 / surface~e.36))
            :ARG2~e.42 (p2 / percentage-entity~e.44 :value "125"~e.43)
            :ARG1-of~e.45 (s4 / show-01~e.46
                  :ARG0~e.47 (c / cytometry~e.49
                        :mod (f2 / flow~e.48)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f3 / figure~e.52
                        :mod "4D"~e.53
                        :ARG2-of (s5 / supplement-01~e.51)))))

# ::tok Unexpectedly , TGF @-@ beta treatment also induced increased IL @-@ 6 production by pDC .
# ::alignments 0-1.3.1 2-1.1.1.1.1 4-1.1.1.1.1 5-1.1 6-1.4 7-1 8-1.2.3 9-1.2.2.1.1 11-1.2.2.1.1 12-1.2 13-1.2.1.r 14-1.2.1.1.1
# ::id bel_pmid_2151_8970_1890
(i / induce-01~e.7
      :ARG0 (t / treat-04~e.5
            :ARG2 (p / protein
                  :name (n / name :op1 "TGF-beta"~e.2,4)))
      :ARG1 (p2 / produce-01~e.12
            :ARG0~e.13 (e / enzyme
                  :name (n3 / name :op1 "pDC"~e.14))
            :ARG1 (p3 / protein
                  :name (n2 / name :op1 "IL-6"~e.9,11))
            :ARG1-of (i2 / increase-01~e.8))
      :ARG1-of (e2 / expect-01 :polarity "-"~e.0)
      :mod (a / also~e.6))

# ::tok Api6 overexpression in lung epithelial cells only caused regional inflammation , not systemic inflammation .
# ::alignments 0-1.1.1.1.1.1 3-1.1.1.2.1.1 4-1.1.1.2.1 5-1.1.1.2 6-1.1.3 7-1.1 7-1.2 8-1.1.2.1 11-1.2.1 11-1.2.1.r
# ::id bel_pmid_2169_7282_25874
(c3 / contrast-01
      :ARG1 (c / cause-01~e.7
            :ARG0 (o / overexpress-00
                  :ARG2 (p / protein
                        :name (n / name :op1 "Api6"~e.0))
                  :location (c2 / cell~e.5
                        :part-of (e / epithelium~e.4
                              :mod (l / lung~e.3))))
            :ARG1 (i / inflame-01
                  :mod (r / region~e.8))
            :mod (o2 / only~e.6))
      :ARG2 (c4 / cause-01~e.7
            :polarity~e.11 "-"~e.11
            :ARG0 o
            :ARG1 (i2 / inflame-01
                  :ARG1 (s / system))))

# ::tok At the gene transcriptional level , Api6 overexpression stimulated mRNA expression of Stat3 and its upstream stimuli IL @-@ 6 in whole lung cells , AT II epithelial cells , and alveolar macrophages ( Fig . 4A ) .
# ::alignments 2-1.3.1.1 4-1.3 6-1.1.1.1.1 7-1.2.1 8-1 8-1.2.2.2.2 9-1.2.1.1.1.1 10-1.2.1 10-1.2.2 11-1.2.1.2.r 12-1.2.1.2.1.1 13-1.2 14-1.2.2.1 14-1.2.2.1.r 15-1.2.2.2.3 17-1.2.2.2.1.1 19-1.2.2.2.1.1 20-1.4.r 21-1.4.1.2 22-1.4.1.1 23-1.4.1 25-1.4.2.1.1.1.1 26-1.4.2.1.1.1.1 27-1.4.2.1 28-1.4.2 30-1.4 31-1.4.3.2 32-1.4.3.1.1 36-1.5.1.1
# ::id bel_pmid_2169_7282_25878
(s / stimulate-01~e.8
      :ARG0 (o / overexpress-00
            :ARG2 (p / protein
                  :name (n / name :op1 "Api6"~e.6)))
      :ARG1 (a / and~e.13
            :op1 (e / express-03~e.7,10
                  :ARG1 (r / rna
                        :name (n3 / name :op1 "mRNA"~e.9))
                  :ARG2~e.11 (p2 / protein
                        :name (n2 / name :op1 "Stat3"~e.12)))
            :op2 (e2 / express-03~e.10
                  :ARG1~e.14 r~e.14
                  :ARG2 (p3 / protein
                        :name (n4 / name :op1 "IL-6"~e.17,19)
                        :ARG0-of (s2 / stimulate-01~e.8
                              :ARG1 p2)
                        :location (u / upstream~e.15))))
      :location (l / level~e.4
            :ARG0-of (t / transcribe-01
                  :ARG1 (g / gene~e.2)))
      :location~e.20 (a2 / and~e.30
            :op1 (c / cell~e.23
                  :mod (l2 / lung~e.22)
                  :mod (w / whole~e.21))
            :op2 (c2 / cell~e.28
                  :part-of (e3 / epithelium~e.27
                        :part (p4 / protein
                              :name (n5 / name :op1 "AT-II"~e.25,26))))
            :op3 (c3 / cell
                  :name (n6 / name :op1 "macrophage"~e.32)
                  :mod (a3 / alveolus~e.31)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4A"~e.36)))

# ::tok Significant reductions in brain levels of early cytokines , including IL @-@ 1 beta and IL @-@ 6 mRNA expression , and late cytokine high mobility group box @-@ 1 protein ( HMGB1 ) , were found in the gelsolin @-@ treated group compared to the placebo group at all time points ( Figure 4 ) .
# ::alignments 0-1.1.2 1-1.1 2-1.1.3.r 3-1.1.3.1 4-1.1.3 5-1.1.1.r 6-1.1.1.1.2 9-1.1.1.1.1 10-1.1.1.1.1.1.1.1.2.1.1.1 10-1.1.1.1.1.1.1.2.2.1.1.1 12-1.1.1.2.1.1.4 14-1.1.1.1.1.1.1 15-1.1.1.1.1.1.1.1.2.1.1.1 15-1.1.1.1.1.1.1.2.2.1.1.1 17-1.1.1.1.1.1.1.2.2.1.1.1 18-1.1.1.1.1.1.1.1.1.1 18-1.1.1.1.1.1.1.2.1.1 19-1.1.1.1.1.1 21-1.1.1 22-1.1.1.2.2 23-1.1.1.1 23-1.1.1.2 24-1.1.1.2.1.1.1 25-1.1.1.2.1.1.2 26-1.1.1.2.1.1.3 27-1.1.1.2.1.1.4 29-1.1.1.2.1.1.4 30-1.1.1.1.1.1.1.1.2.1 30-1.1.1.1.1.1.1.2.2.1 30-1.1.1.2.1 30-1.2.1.1 35-1.1.1.2.1.r 36-1 37-1.2.r 39-1.2.1.1.1.1 41-1.2.1 42-1.2 43-1.1.4.r 46-1.1.4.1 47-1.1.4 48-1.3.r 49-1.3.1.1 50-1.3.1 51-1.3 53-1.4.1 54-1.4.1.1
# ::id bel_pmid_2193_6896_27282
(f / find-01~e.36
      :ARG1 (r / reduce-01~e.1
            :ARG1~e.5 (a / and~e.21
                  :op1 (c / cytokine~e.23
                        :ARG2-of (i / include-91~e.9
                              :ARG1 (e / express-03~e.19
                                    :ARG2 (a2 / and~e.14
                                          :op1 (r2 / rna
                                                :name (n / name :op1 "mRNA"~e.18)
                                                :ARG0-of (e2 / encode-01
                                                      :ARG1 (p / protein~e.30
                                                            :name (n2 / name :op1 "IL-1β"~e.10,15))))
                                          :op2 (r3 / rna
                                                :name (n3 / name :op1 "mRNA"~e.18)
                                                :ARG0-of (e3 / encode-01
                                                      :ARG1 (p2 / protein~e.30
                                                            :name (n4 / name :op1 "IL-6"~e.10,15,17)))))))
                        :mod (e4 / early~e.6))
                  :op2 (c2 / cytokine~e.23
                        :domain~e.35 (p3 / protein~e.30
                              :name (n5 / name
                                    :op1 "high"~e.24
                                    :op2 "mobility"~e.25
                                    :op3 "group"~e.26
                                    :op4 "box-1"~e.12,27,29))
                        :mod (l / late~e.22)))
            :ARG2 (s / significant-02~e.0)
            :location~e.2 (l2 / level~e.4
                  :mod (b / brain~e.3))
            :compared-to~e.43 (g / group~e.47
                  :mod (p4 / placebo~e.46)))
      :location~e.37 (g2 / group~e.42
            :ARG1-of (t / treat-04~e.41
                  :ARG2 (p5 / protein~e.30
                        :name (n6 / name :op1 "gelsolin"~e.39))))
      :time~e.48 (p6 / point~e.51
            :mod (t2 / time~e.50
                  :mod (a3 / all~e.49)))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.53 :mod "4"~e.54)))

# ::tok Factors from murine pancreatic cancer cells cause the down @-@ regulation of SHIP @-@ 1 expression , which may potentially contribute to MDSC expansion , and the suppression of CD8+ T cell immune responses .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.2.1.1 3-1.1.1.1.2 4-1.1.1.1.1.1 5-1.1.1 6-1 12-1.2.2.1.1.1 14-1.2.2.1.1.1 15-1.2.2 18-1.2.3.3 19-1.2.3.2 20-1.2.3 21-1.2.3.1.r 22-1.2.3.1.1.2.1.1 23-1.2.3.1.1 25-1.2.3.1 27-1.2.3.1.2 30-1.2.3.1.2.2.1.1.1.1 31-1.2.3.1.1.2 31-1.2.3.1.2.2.1.1 32-1.2.3.1.2.2.2 33-1.2.3.1.2.2 33-1.2.3.1.2.2.1 33-1.2.3.1.2.2.1.r
# ::id bel_pmid_2213_2131_40908
(c / cause-01~e.6
      :ARG0 (f / factor~e.0
            :source~e.1 (c2 / cell~e.5
                  :mod (d / disease
                        :name (n / name :op1 "cancer"~e.4)
                        :mod (p / pancreas~e.3))
                  :part-of (o / organism
                        :name (n2 / name :op1 "Muridae"~e.2))))
      :ARG1 (d2 / downregulate-01
            :ARG0 f
            :ARG1 (e / express-03~e.15
                  :ARG2 (p2 / protein
                        :name (n3 / name :op1 "SHIP-1"~e.12,14)))
            :ARG0-of (c3 / contribute-01~e.20
                  :ARG2~e.21 (a / and~e.25
                        :op1 (e2 / expand-01~e.23
                              :ARG0 d2
                              :ARG1 (c4 / cell~e.31
                                    :name (n4 / name :op1 "MDSC"~e.22)))
                        :op2 (s / suppress-01~e.27
                              :ARG0 d2
                              :ARG1 (t / thing~e.33
                                    :ARG2-of~e.33 (r / respond-01~e.33
                                          :ARG0 (c5 / cell~e.31
                                                :name (n5 / name :op1 "T"~e.30)
                                                :mod (p3 / protein
                                                      :name (n6 / name :op1 "CD8"))))
                                    :mod (i / immune~e.32))))
                  :mod (p4 / potential~e.19)
                  :mod (p5 / possible~e.18))))

# ::tok qRT @-@ PCR and Western blot analyses revealed the in vivo down @-@ regulation of SHIP @-@ 1 expression in splenocytes from TB mice .
# ::alignments 0-1.1.1.1.1 2-1.1.1.1.1 3-1.1 4-1.1.2.1.1 5-1.1.2.1.2 6-1.1.1 6-1.1.2 7-1 9-1.2.2 10-1.2.2 15-1.2.1.1.1.1 17-1.2.1.1.1.1 18-1.2.1 19-1.2.2 21-1.2.3.1.r 23-1.2.3.1
# ::id bel_pmid_2213_2131_40910
(r / reveal-01~e.7
      :ARG0 (a / and~e.3
            :op1 (a2 / analysis~e.6
                  :name (n / name :op1 "qRT-PCR"~e.0,2))
            :op2 (a3 / analysis~e.6
                  :name (n2 / name :op1 "Western"~e.4 :op2 "blot"~e.5)))
      :ARG1 (d / downregulate-01
            :ARG1 (e / express-03~e.18
                  :ARG2 (p / protein
                        :name (n3 / name :op1 "SHIP-1"~e.15,17)))
            :manner (i / in-vivo~e.9,10,19)
            :location (s / splenocyte
                  :source~e.21 (m / mouse~e.23
                        :ARG0-of (b / bear-01
                              :ARG1 (t / tumor))))))

# ::tok Western blot analyses also detected reduced SHIP @-@ 1 activity , increased AKT @-@ 1 and BAD hyper @-@ phosphorylation and up @-@ regulation of BCL @-@ 2 expression in splenocytes from TB mice .
# ::alignments 0-1.1.1.1 1-1.1.1.2 2-1.1 3-1.3 4-1 5-1.2.1.2 6-1.2.1.1.1.1 8-1.2.1.1.1.1 9-1.2.1 11-1.2.2.1.2 12-1.2.2.1.1.1.1.1 14-1.2.2.1.1.1.1.1 16-1.2.2.1.1.2.1.1 17-1.2.2.1 19-1.2.2.1 20-1.2.2.1.1 21-1.2.2.1.2 25-1.2.3.1.1.1.1 27-1.2.3.1.1.1.1 28-1.2.3.1 31-1.4.1.r 33-1.4.1
# ::id bel_pmid_2213_2131_40912
(d / detect-01~e.4
      :ARG0 (a / analysis~e.2
            :name (n / name :op1 "Western"~e.0 :op2 "blot"~e.1))
      :ARG1 (a2 / and
            :op1 (a3 / act-02~e.9
                  :ARG0 (e / enzyme
                        :name (n2 / name :op1 "SHIP-1"~e.6,8))
                  :ARG1-of (r / reduce-01~e.5))
            :op2 (a4 / and
                  :op1 (h / hyper-phosphorylate-00~e.17,19
                        :ARG1 (a5 / and~e.20
                              :op1 (e2 / enzyme
                                    :name (n3 / name :op1 "AKT-1"~e.12,14))
                              :op2 (p / protein
                                    :name (n4 / name :op1 "BAD"~e.16)))
                        :ARG1-of (i / increase-01~e.11,21)))
            :op3 (u / upregulate-01
                  :ARG1 (e3 / express-03~e.28
                        :ARG2 (p2 / protein
                              :name (n5 / name :op1 "BCL-2"~e.25,27)))))
      :mod (a6 / also~e.3)
      :location (s / splenocyte
            :source~e.31 (m / mouse~e.33
                  :ARG0-of (b / bear-01
                        :ARG1 (t / tumor)))))

# ::tok In vitro , qRT @-@ PCR and Western blot analyses detected reduced SHIP @-@ 1 mRNA and protein expression in control splenocytes co @-@ cultured with Panc 02.03 cells .
# ::alignments 0-1.4 1-1.4 3-1.1.1.1.1 5-1.1.1.1.1 6-1.1 7-1.1.2.1.1 8-1.1.2.1.2 9-1.1.1 9-1.1.2 10-1 11-1.2.3 12-1.2.1.1.2.1.1.1 14-1.2.1.1.2.1.1.1 15-1.2.1.1.1.1 17-1.2.1.1.2.1 18-1.2.1 18-1.2.2 19-1.4 20-1.3.1 22-1.3.2 24-1.3.2 25-1.3.2.1.r 26-1.3.2.1.1.1 27-1.3.2.1.1.2 28-1.3.2.1
# ::id bel_pmid_2213_2131_40914
(d / detect-01~e.10
      :ARG0 (a / and~e.6
            :op1 (a2 / analysis~e.9
                  :name (n / name :op1 "qRT-PCR"~e.3,5))
            :op2 (a3 / analysis~e.9
                  :name (n2 / name :op1 "Western"~e.7 :op2 "blot"~e.8)))
      :ARG1 (a4 / and
            :op1 (e / express-03~e.18
                  :ARG1 (r / rna
                        :name (n3 / name :op1 "mRNA"~e.15)
                        :ARG0-of (e2 / encode-01
                              :ARG1 (p / protein~e.17
                                    :name (n4 / name :op1 "SHIP-1"~e.12,14)))))
            :op2 (e3 / express-03~e.18
                  :ARG2 p)
            :ARG1-of (r2 / reduce-01~e.11))
      :location (s / splenocyte
            :ARG2-of (c / control-01~e.20)
            :ARG1-of (c2 / co-culture-00~e.22,24
                  :accompanier~e.25 (c3 / cell~e.28
                        :name (n5 / name :op1 "Panc"~e.26 :op2 "02.03"~e.27))))
      :manner (i / in-vitro~e.0,1,19))

# ::tok Results from the Inflammatory Cytometric Bead Analysis ( CBA ) Kit detected pro @-@ inflammatory factors Interleukin @-@ 6 ( IL @-@ 6 ) , Interleukin @-@ 10 ( IL @-@ 10 ) and Monocyte Chemoattractant Protein @-@ 1 ( MCP @-@ 1 ) to a greater extent than Tumor Necrosis Factor ( TNF ) , Interferon gamma ( IFN @-@ y and Interleukin @-@ 12p 70 ( IL @-@ 12p70 ) in the supernatants of cultured murine Panc 02.03 cells ( Figure 1a ) .
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 1-1.1.2.r 3-1.1.2.1.1 4-1.1.2.1.2 5-1.1.2.1.3 6-1.1.2.1.4 10-1.1.2 11-1 12-1.2.2.4 14-1.2.2.4.1 15-1.2.2.1 16-1.2.2.1.1.1 16-1.2.2.2.1.1 18-1.2.2.1.1.1 22-1.2.2.1.1.1 25-1.2.2.1.1.1 25-1.2.2.2.1.1 27-1.2.2.2.1.1 31-1.2.2.2.1.1 33-1.2.2 34-1.2.2.3.1.1 35-1.2.2.3.1.2 36-1.2.2.3.1.3 38-1.2.2.3.1.3 42-1.2.2.3.1.3 46-1.2.1 46-1.2.1.1 46-1.2.1.1.r 47-1.2 48-1.2.3.r 49-1.2.3.1.1.1 50-1.2.3.1.1.2 51-1.2.3.1.1.3 56-1.2.3.2.1.1 57-1.2.3.2.1.2 62-1.2.3 63-1.2.3.3.1.1 65-1.2.3.3.1.1 66-1.2.3.3.1.1 72-1.3.r 74-1.3 75-1.3.1.r 76-1.3.1.3 77-1.3.1.2.1.1 78-1.3.1.1.1 79-1.3.1.1.2 80-1.3.1 82-1.4.1 83-1.4.1.1
# ::id bel_pmid_2213_2131_40918
(d / detect-01~e.11
      :ARG0 (t / thing~e.0
            :ARG2-of~e.0 (r / result-01~e.0)
            :source~e.1 (k / kit~e.10
                  :name (n / name
                        :op1 "Inflammatory"~e.3
                        :op2 "Cytometric"~e.4
                        :op3 "Bead"~e.5
                        :op4 "Analysis"~e.6)))
      :ARG1 (e / extent~e.47
            :mod (g / great~e.46
                  :degree~e.46 (m / more~e.46))
            :domain (a / and~e.33
                  :op1 (f / factor~e.15
                        :name (n2 / name :op1 "Interleukin-6"~e.16,18,22,25))
                  :op2 (f2 / factor
                        :name (n3 / name :op1 "Interleukin-10"~e.16,25,27,31))
                  :op3 (f3 / factor
                        :name (n4 / name
                              :op1 "Monocyte"~e.34
                              :op2 "Chemoattractant"~e.35
                              :op3 "Protein-1"~e.36,38,42))
                  :ARG0-of (f8 / favor-01~e.12
                        :ARG1 (i2 / inflame-01~e.14)))
            :compared-to~e.48 (a2 / and~e.62
                  :op1 (f4 / factor
                        :name (n5 / name
                              :op1 "Tumor"~e.49
                              :op2 "Necrosis"~e.50
                              :op3 "Factor"~e.51))
                  :op2 (f5 / factor
                        :name (n6 / name :op1 "Interferon"~e.56 :op2 "gamma"~e.57))
                  :op3 (f6 / factor
                        :name (n7 / name :op1 "Interleukin-12p-70"~e.63,65,66))))
      :location~e.72 (s / supernatant~e.74
            :part-of~e.75 (c / cell~e.80
                  :name (n8 / name :op1 "Panc"~e.78 :op2 "02.03"~e.79)
                  :part-of (o / organism
                        :name (n9 / name :op1 "Muridae"~e.77))
                  :ARG1-of (c2 / culture-01~e.76)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f7 / figure~e.82 :mod "1a"~e.83)))

# ::tok TB splenocytes have a reduction in SHIP @-@ 1 expression .
# ::alignments 2-1 4-1.2 5-1.2.1.r 6-1.2.1.1.1.1 8-1.2.1.1.1.1 9-1.2.1
# ::id bel_pmid_2213_2131_40920
(h / have-03~e.2
      :ARG0 (s / splenocyte
            :ARG0-of (b / bear-01
                  :ARG1 (t / tumor)))
      :ARG1 (r / reduce-01~e.4
            :ARG1~e.5 (e / express-03~e.9
                  :ARG2 (p / protein
                        :name (n / name :op1 "SHIP-1"~e.6,8)))))

# ::tok Quantitative Reverse Transcription Polymerase Chain Reaction ( qRT @-@ PCR ) results detected a decrease in SHIP @-@ 1 mRNA expression in TB compared to control splenocytes ( Figure 3b ) .
# ::alignments 0-1.1.2.1.1 1-1.1.2.1.2 2-1.1.2.1.3 3-1.1.2.1.4 4-1.1.2.1.5 5-1.1.2.1.6 11-1.1 11-1.1.1 11-1.1.1.r 12-1 14-1.2 15-1.2.1.r 16-1.2.1.1.2.1.1.1 18-1.2.1.1.2.1.1.1 19-1.2.1.1.1.1 20-1.2.1 23-1.2.3.r 25-1.2.3.1 28-1.3.1 29-1.3.1.1
# ::id bel_pmid_2213_2131_40922
(d / detect-01~e.12
      :ARG0 (t / thing~e.11
            :ARG2-of~e.11 (r / result-01~e.11)
            :source (t2 / thing
                  :name (n / name
                        :op1 "Quantitative"~e.0
                        :op2 "Reverse"~e.1
                        :op3 "Transcription"~e.2
                        :op4 "Polymerase"~e.3
                        :op5 "Chain"~e.4
                        :op6 "Reaction"~e.5)))
      :ARG1 (d2 / decrease-01~e.14
            :ARG1~e.15 (e / express-03~e.20
                  :ARG1 (r2 / rna
                        :name (n2 / name :op1 "mRNA"~e.19)
                        :ARG0-of (e2 / encode-01
                              :ARG1 (p / protein
                                    :name (n3 / name :op1 "SHIP-1"~e.16,18)))))
            :location (s / splenocyte
                  :ARG0-of (b / bear-01
                        :ARG1 (t3 / tumor)))
            :compared-to~e.23 (s2 / splenocyte
                  :ARG2-of (c / control-01~e.25)))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure~e.28 :mod "3b"~e.29)))

# ::tok TB splenocytes have reduced SHIP @-@ 1 activity .
# ::alignments 2-1 3-1.2.2 4-1.2.1.1.1 6-1.2.1.1.1 7-1.2
# ::id bel_pmid_2213_2131_40924
(h / have-03~e.2
      :ARG0 (s / splenocyte
            :ARG0-of (b / bear-01
                  :ARG1 (t / tumor)))
      :ARG1 (a / act-02~e.7
            :ARG1 (e / enzyme
                  :name (n / name :op1 "SHIP-1"~e.4,6))
            :ARG1-of (r / reduce-01~e.3)))

# ::tok Western blot analyses did not detect phosphorylation of tyrosine 1020 on SHIP @-@ 1 , in splenocytes from TB compared to control mice ( Figure 4a ) .
# ::alignments 0-1.2.1.1 1-1.2.1.2 2-1.2 4-1.1 4-1.1.r 5-1 6-1.3 7-1.3.1.r 8-1.3.1.2.1 9-1.3.1.1 11-1.3.1.3.1.1 13-1.3.1.3.1.1 17-1.3.2.1.r 19-1.3.2.2.r 21-1.3.2.2.1.1 22-1.3.2.1 22-1.3.2.2.1 24-1.4.1 25-1.4.1.1
# ::id bel_pmid_2213_2131_40926
(d / detect-01~e.5
      :polarity~e.4 "-"~e.4
      :ARG0 (a / analysis~e.2
            :name (n / name :op1 "Western"~e.0 :op2 "blot"~e.1))
      :ARG1 (p / phosphorylate-01~e.6
            :ARG1~e.7 (a2 / amino-acid
                  :mod "1020"~e.9
                  :name (n2 / name :op1 "tyrosine"~e.8)
                  :part-of (p2 / protein
                        :name (n3 / name :op1 "SHIP-1"~e.11,13)))
            :location (s / splenocyte
                  :source~e.17 (m / mouse~e.22
                        :ARG0-of (b / bear-01
                              :ARG1 (t / tumor)))
                  :compared-to~e.19 (s2 / splenocyte
                        :source (m2 / mouse~e.22
                              :ARG2-of (c / control-01~e.21)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.24 :mod "4a"~e.25)))

# ::tok TB splenocytes have increased AKT activity .
# ::alignments 2-1 3-1.2.2 4-1.2.1.1.1 5-1.2
# ::id bel_pmid_2213_2131_40928
(h / have-03~e.2
      :ARG0 (s / splenocyte
            :ARG0-of (b / bear-01
                  :ARG1 (t / tumor)))
      :ARG1 (a / act-02~e.5
            :ARG1 (e / enzyme
                  :name (n / name :op1 "AKT"~e.4))
            :ARG1-of (i / increase-01~e.3)))

# ::tok Western Blot results revealed hyper @-@ phosphorylation of AKT @-@ 1 at Ser473 in whole splenocytes from TB compared to control mice ( Figure 4b ) .
# ::alignments 0-1.1.2.1.1 1-1.1.2.1.2 2-1.1 2-1.1.1 2-1.1.1.r 3-1 4-1.2 6-1.2 7-1.2.1.r 8-1.2.1.1.1 10-1.2.1.1.1 14-1.2.2.1 16-1.2.2.2.r 18-1.2.3.r 20-1.2.3.1.1 21-1.2.2.2 21-1.2.3.1 23-1.3.1 24-1.3.1.1
# ::id bel_pmid_2213_2131_40930
(r / reveal-01~e.3
      :ARG0 (t / thing~e.2
            :ARG2-of~e.2 (r2 / result-01~e.2)
            :source (t2 / thing
                  :name (n / name :op1 "Western"~e.0 :op2 "Blot"~e.1)))
      :ARG1 (h / hyper-phosphorylate-00~e.4,6
            :ARG1~e.7 (e / enzyme
                  :name (n3 / name :op1 "AKT-1"~e.8,10)
                  :part (a / amino-acid
                        :mod "473"
                        :name (n2 / name :op1 "serine")))
            :location (s / splenocyte
                  :mod (w / whole~e.14)
                  :source~e.16 (m / mouse~e.21
                        :ARG0-of (b / bear-01
                              :ARG1 (t3 / tumor))))
            :compared-to~e.18 (s2 / splenocyte
                  :source (m2 / mouse~e.21
                        :ARG2-of (c / control-01~e.20))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.23 :mod "4b"~e.24)))

# ::tok TB splenocytes have increased BCL @-@ 2 expression .
# ::alignments 2-1 3-1.2.2 4-1.2.1.1.1 6-1.2.1.1.1 7-1.2
# ::id bel_pmid_2213_2131_40932
(h / have-03~e.2
      :ARG0 (s / splenocyte
            :ARG0-of (b / bear-01
                  :ARG1 (t / tumor)))
      :ARG1 (e / express-03~e.7
            :ARG2 (p / protein
                  :name (n / name :op1 "BCL-2"~e.4,6))
            :ARG1-of (i / increase-01~e.3)))

# ::tok Western Blot results showed hyperphosphorylation of BAD at Ser112 in splenocytes from TB mice compared to control mice ( Figure 4c ) .
# ::alignments 0-1.1.2.1.1 1-1.1.2.1.2 2-1.1 2-1.1.1 2-1.1.1.r 3-1 6-1.2.1.1.1 11-1.2.2.1.r 13-1.2.2.1 14-1.2.3.r 16-1.2.3.1.1 17-1.2.2.1 17-1.2.3.1 19-1.3.1 20-1.3.1.1
# ::id bel_pmid_2213_2131_40934
(s / show-01~e.3
      :ARG0 (t / thing~e.2
            :ARG2-of~e.2 (r / result-01~e.2)
            :source (t2 / thing
                  :name (n3 / name :op1 "Western"~e.0 :op2 "Blot"~e.1)))
      :ARG1 (h / hyper-phosphorylate-00
            :ARG1 (p / protein
                  :name (n / name :op1 "BAD"~e.6)
                  :part (a / amino-acid
                        :mod "112"
                        :name (n2 / name :op1 "serine")))
            :location (s2 / splenocyte
                  :source~e.11 (m / mouse~e.13,17
                        :ARG0-of (b / bear-01
                              :ARG1 (t3 / tumor))))
            :compared-to~e.14 (s3 / splenocyte
                  :source (m2 / mouse~e.17
                        :ARG2-of (c / control-01~e.16))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.19 :mod "4c"~e.20)))

# ::tok Western blot results revealed an up @-@ regulation in BCL @-@ 2 expression in splenocytes from TB mice ( Figure 4d ) compared to control .
# ::alignments 0-1.1.2.1.1 1-1.1.2.1.2 2-1.1 2-1.1.1 2-1.1.1.r 3-1 9-1.2.1.1.1.1 11-1.2.1.1.1.1 12-1.2.1 15-1.2.2.1.r 17-1.2.2.1 17-1.2.3.1 19-1.2.2.2.1 20-1.2.2.2.1.1 22-1.2.3.r 24-1.2.3.1.1
# ::id bel_pmid_2213_2131_40936
(r / reveal-01~e.3
      :ARG0 (t / thing~e.2
            :ARG2-of~e.2 (r2 / result-01~e.2)
            :source (t2 / thing
                  :name (n / name :op1 "Western"~e.0 :op2 "blot"~e.1)))
      :ARG1 (u / upregulate-01
            :ARG1 (e / express-03~e.12
                  :ARG2 (p / protein
                        :name (n2 / name :op1 "BCL-2"~e.9,11)))
            :location (s / splenocyte
                  :source~e.15 (m / mouse~e.17
                        :ARG0-of (b / bear-01
                              :ARG1 (t3 / tumor)))
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure~e.19 :mod "4d"~e.20)))
            :compared-to~e.22 (s2 / splenocyte
                  :source (m2 / mouse~e.17
                        :ARG2-of (c / control-01~e.24)))))

# ::tok Murine Panc 02.03 cells down @-@ regulate SHIP @-@ 1 expression in vitro .
# ::alignments 0-1.1.2.1.1 1-1.1.1.1 2-1.1.1.2 3-1.1 7-1.2.1.1.1 9-1.2.1.1.1 10-1.2 11-1.3 12-1.3
# ::id bel_pmid_2213_2131_40938
(d / downregulate-01
      :ARG0 (c / cell~e.3
            :name (n / name :op1 "Panc"~e.1 :op2 "02.03"~e.2)
            :part-of (o / organism
                  :name (n2 / name :op1 "Muridae"~e.0)))
      :ARG1 (e / express-03~e.10
            :ARG2 (p / protein
                  :name (n3 / name :op1 "SHIP-1"~e.7,9)))
      :manner (i / in-vitro~e.11,12))

# ::tok qRT @-@ PCR analysis revealed a significant decrease in SHIP @-@ 1 mRNA expression in control splenocytes co @-@ cultured with Panc 02.03 cells compared to control splenocytes cultured alone ( Figure 5a ) .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1.1 4-1 6-1.2.2 7-1.2 8-1.2.1.r 9-1.2.1.1.2.1.1.1 11-1.2.1.1.2.1.1.1 12-1.2.1.1.1.1 13-1.2.1 15-1.2.3.1 17-1.2.3.2 19-1.2.3.2 20-1.2.3.2.1.r 21-1.2.3.2.1.1.1 22-1.2.3.2.1.1.2 23-1.2.3.2.1 24-1.2.4.r 26-1.2.4.1 28-1.2.4.2 29-1.2.4.2.1 31-1.3.1 32-1.3.1.1
# ::id bel_pmid_2213_2131_40940
(r / reveal-01~e.4
      :ARG0 (a / analysis~e.3
            :name (n / name :op1 "qRT-PCR"~e.0,2))
      :ARG1 (d / decrease-01~e.7
            :ARG1~e.8 (e / express-03~e.13
                  :ARG1 (r2 / rna
                        :name (n2 / name :op1 "mRNA"~e.12)
                        :ARG0-of (e2 / encode-01
                              :ARG1 (p / protein
                                    :name (n3 / name :op1 "SHIP-1"~e.9,11)))))
            :ARG2 (s / significant-02~e.6)
            :location (s2 / splenocyte
                  :ARG2-of (c / control-01~e.15)
                  :ARG1-of (c2 / co-culture-00~e.17,19
                        :accompanier~e.20 (c3 / cell~e.23
                              :name (n4 / name :op1 "Panc"~e.21 :op2 "02.03"~e.22))))
            :compared-to~e.24 (s3 / splenocyte
                  :ARG2-of c~e.26
                  :ARG1-of (c4 / culture-01~e.28
                        :manner (a2 / alone~e.29))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure~e.31 :mod "5a"~e.32)))

# ::tok In addition , western blot results revealed greater than a a 2 @-@ fold reduction in SHIP @-@ 1 protein expression in control splenocytes cocultured with Panc 02.03 cells compared to control splenocytes cultured alone ( Figure 5b ) .
# ::alignments 0-1 1-1 3-1.1.1.2.1.1 4-1.1.1.2.1.2 5-1.1.1 5-1.1.1.1 5-1.1.1.1.r 6-1.1 7-1.1.2.2 7-1.1.2.2.1 7-1.1.2.2.1.r 8-1.1.2.2.2.r 11-1.1.2.2.2.1 14-1.1.2 15-1.1.2.1.r 16-1.1.2.1.1.1.1 18-1.1.2.1.1.1.1 19-1.1.2.1.1 20-1.1.2.1 22-1.1.2.3.1 25-1.1.2.3.2.1.r 26-1.1.2.3.2.1.1.1 27-1.1.2.3.2.1.1.2 28-1.1.2.3.2.1 29-1.1.2.3.3.r 31-1.1.2.3.1 33-1.1.2.3.2 33-1.1.2.3.3.1 34-1.1.2.3.3.1.1 36-1.2.1 37-1.2.1.1
# ::id bel_pmid_2213_2131_40942
(a / and~e.0,1
      :op2 (r / reveal-01~e.6
            :ARG0 (t / thing~e.5
                  :ARG2-of~e.5 (r2 / result-01~e.5)
                  :source (t2 / thing
                        :name (n / name :op1 "western"~e.3 :op2 "blot"~e.4)))
            :ARG1 (r3 / reduce-01~e.14
                  :ARG1~e.15 (e / express-03~e.20
                        :ARG2 (p / protein~e.19
                              :name (n2 / name :op1 "SHIP-1"~e.16,18)))
                  :ARG2 (g / great~e.7
                        :degree~e.7 (m / more~e.7)
                        :compared-to~e.8 (p2 / product-of :op1 "2"~e.11))
                  :location (s / splenocyte
                        :ARG2-of (c / control-01~e.22,31)
                        :ARG1-of (c2 / co-culture-00~e.33
                              :accompanier~e.25 (c3 / cell~e.28
                                    :name (n3 / name :op1 "Panc"~e.26 :op2 "02.03"~e.27)))
                        :compared-to~e.29 (s2 / splenocyte
                              :ARG1-of (c4 / culture-01~e.33
                                    :manner (a2 / alone~e.34))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure~e.36 :mod "5b"~e.37)))

# ::tok These results correlate with our in vivo data and show that Panc 02.03 cells are able to suppress SHIP @-@ 1 mRNA and protein expression in vitro .
# ::alignments 0-1.1.1.2 1-1.1.1 1-1.1.1.1 1-1.1.1.1.r 2-1.1 3-1.1.2.r 4-1.1.2.2 4-1.1.2.2.r 5-1.1.2.1 6-1.1.2.1 7-1.1.2 8-1 9-1.2 10-1.2.2.r 11-1.2.2.1.1.1.1 12-1.2.2.1.1.1.2 13-1.2.2.1.1 14-1.2.2.1.r 15-1.2.2 17-1.2.2.1 18-1.2.2.1.2.1.1.2.1.1.1 20-1.2.2.1.2.1.1.2.1.1.1 21-1.2.2.1.2.1.1.1.1 23-1.2.2.1.2.1.1.2.1 24-1.2.2.1.2.1 24-1.2.2.1.2.2 25-1.2.2.1.3 26-1.2.2.1.3
# ::id bel_pmid_2213_2131_40944
(a / and~e.8
      :op1 (c / correlate-01~e.2
            :ARG1 (t / thing~e.1
                  :ARG2-of~e.1 (r / result-01~e.1)
                  :mod (t2 / this~e.0))
            :ARG2~e.3 (d / data~e.7
                  :manner (i / in-vivo~e.5,6)
                  :poss~e.4 (w / we~e.4)))
      :op2 (s / show-01~e.9
            :ARG0 t
            :ARG1~e.10 (p / possible~e.15
                  :domain~e.14 (s2 / suppress-01~e.17
                        :ARG0 (c2 / cell~e.13
                              :name (n / name :op1 "Panc"~e.11 :op2 "02.03"~e.12))
                        :ARG1 (a2 / and
                              :op1 (e / express-03~e.24
                                    :ARG2 (r2 / rna
                                          :name (n2 / name :op1 "mRNA"~e.21)
                                          :ARG0-of (e2 / encode-01
                                                :ARG1 (p2 / protein~e.23
                                                      :name (n3 / name :op1 "SHIP-1"~e.18,20)))))
                              :op2 (e3 / express-03~e.24
                                    :ARG2 p2))
                        :manner (i2 / in-vitro~e.25,26)))))

# ::tok In WT mice CH induced an approximate 2 @-@ fold increase in IL @-@ 6 mRNA at three weeks that was abrogated in C3 -/- mice... We observed increases in lung intracellular adhesion molecule 1 ( ICAM @-@ 1 ) ...the increase in ICAM @-@ 1 was abrogated in C3 -/- mice ( Fig . 7 ) .
# ::alignments 1-1.1.3.1 2-1.1.3 3-1.1.1.1.1 4-1.1 7-1.1.2.1.1 10-1.1.2.2 12-1.1.2.2.1.2.1.1.1 14-1.1.2.2.1.2.1.1.1 15-1.1.2.2.1.1.1 17-1.1.2.2.3.1.1 18-1.1.2.2.3.1.2 21-1.1.2.2.2 23-1.1.2.2.2.1.1.1.1 23-1.3.2.1.1.1 24-1.1.2.2.2.1.1.2.1 24-1.3.2.1.2.1 26-1.2.1 27-1.2 28-1.2.2 29-1.2.2.1.r 30-1.2.2.1.2 31-1.2.2.1.1.1 32-1.2.2.1.1.2 33-1.2.2.1.1.3 34-1.2.2.1.1.3 34-1.3.1.1.1.1 36-1.3.1.1.1.1 38-1.3.1.1.1.1 41-1.3.1 43-1.3.1.1.1.1 45-1.2.2.1.1.3 45-1.3.1.1.1.1 47-1.1.2.2.2 47-1.3 49-1.1.2.2.2.1.1.1.1 49-1.3.2.1.1.1 50-1.1.2.2.2.1.1.2.1 50-1.3.2.1.2.1 51-1.1.2.2.2.1 51-1.3.2 55-1.4.1.1
# ::id bel_pmid_2219_4859_25580
(m / multi-sentence
      :snt1 (i / induce-01~e.4
            :ARG0 (d / disease
                  :name (n / name :op1 "CH"~e.3))
            :ARG1 (a / approximately
                  :op1 (p / product-of :op1 "2"~e.7)
                  :op2 (i2 / increase-01~e.10
                        :ARG1 (r / rna
                              :name (n2 / name :op1 "mRNA"~e.15)
                              :ARG0-of (e / encode-01
                                    :ARG1 (p2 / protein
                                          :name (n3 / name :op1 "IL-6"~e.12,14))))
                        :ARG1-of (a2 / abrogate-01~e.21,47
                              :location (m2 / mouse~e.51
                                    :mod (p3 / protein
                                          :name (n4 / name :op1 "C3"~e.23,49)
                                          :ARG2-of (m3 / mutate-01 :mod "-/-"~e.24,50))))
                        :time (a4 / after
                              :op1 (t / temporal-quantity
                                    :quant "3"~e.17
                                    :unit (w / week~e.18)))))
            :location (m4 / mouse~e.2
                  :mod (w2 / wild-type~e.1)))
      :snt2 (o / observe-01~e.27
            :ARG0 (w3 / we~e.26)
            :ARG1 (i3 / increase-01~e.28
                  :ARG1~e.29 (p4 / protein
                        :name (n5 / name
                              :op1 "intracellular"~e.31
                              :op2 "adhesion"~e.32
                              :op3 "molecule-1"~e.33,34,45)
                        :part-of (l / lung~e.30))))
      :snt3 (a3 / abrogate-01~e.47
            :ARG1 (i4 / increase-01~e.41
                  :ARG1 (p5 / protein
                        :name (n6 / name :op1 "ICAM-1"~e.34,36,38,43,45)))
            :location (m5 / mouse~e.51
                  :mod (p6 / protein
                        :name (n7 / name :op1 "C3"~e.23,49)
                        :ARG2-of (m6 / mutate-01 :mod "-/-"~e.24,50))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "7"~e.55)))

# ::tok This Raf @-@ 1 @-@ mediated fine tuning of Rok @-@ a signaling allows the activation of junctional myosin and the timely maturation of AJ essential for maintaining cell cohesion during sprouting angiogenesis
# ::alignments 0-1.1.4 1-1.1.3.1.1.1 3-1.1.3.1.1.1 5-1.1.3 6-1.1.2 7-1.1 8-1.1.1.r 9-1.1.1.1.1.1 12-1.1.1 13-1 15-1.2.1 16-1.2.1.1.r 17-1.2.1.1.2 18-1.2.1.1.1.1 19-1.2 21-1.2.2.2 22-1.2.2 23-1.2.2.1.r 24-1.2.2.1.1.1 25-1.2.3 26-1.2.3.1.r 27-1.2.3.1 28-1.2.3.1.1.1 30-1.2.3.1.2.r 31-1.2.3.1.2.1 32-1.2.3.1.2
# ::id bel_pmid_2220_9329_1840
(a / allow-01~e.13
      :ARG0 (t / tune-01~e.7
            :ARG1~e.8 (s / signal-07~e.12
                  :ARG0 (e / enzyme
                        :name (n / name :op1 "Rok-α"~e.9)))
            :mod (f / fine~e.6)
            :ARG1-of (m / mediate-01~e.5
                  :ARG0 (e2 / enzyme
                        :name (n2 / name :op1 "Raf-1"~e.1,3)))
            :mod (t2 / this~e.0))
      :ARG1 (a2 / and~e.19
            :op1 (a3 / activate-01~e.15
                  :ARG1~e.16 (p / protein
                        :name (n3 / name :op1 "myosin"~e.18)
                        :mod (j / junctional~e.17)))
            :op2 (m2 / maturate-03~e.22
                  :ARG1~e.23 (p2 / protein
                        :name (n4 / name :op1 "AJ"~e.24))
                  :manner (t3 / timely~e.21))
            :mod (e3 / essential~e.25
                  :purpose~e.26 (m3 / maintain-01~e.27
                        :ARG1 (c / cohere-01
                              :ARG1 (c2 / cell~e.28))
                        :time~e.30 (a4 / angiogenesis~e.32
                              :ARG1-of (s2 / sprout-01~e.31))))))

# ::tok In TLR2 agonist , heat @-@ killed Listeria monocytogenes @-@ activated human monocytes , NA reduced secretion of TNF-? ( by 48.6±7.1 %), interleukin @-@ 6 ( by 60.9±1.6 %), and monocyte chemoattractant protein @-@ 1 ( by 59.3±5.3 %)
# ::alignments 1-1.4.1.1 2-1.4 4-1.4.2.3.1.2.1 6-1.4.2.3.1.2 7-1.4.2.3.1.1.1 8-1.4.2.3.1.1.2 10-1.4.2.3 11-1.4.2.2 12-1.3.2.1.1.1 14-1.1.1.1.1 15-1.1 15-1.2 15-1.3 16-1.1.2 16-1.2.2 16-1.3.2 23-1.2.2.1.1.1 25-1.2.2.1.1.1 30-1 31-1.4.2.1.1 32-1.3.2.1.1.2 33-1.3.2.1.1.3 35-1.3.2.1.1.3
# ::id bel_pmid_2226_7479_1138
(a / and~e.30
      :op1 (r / reduce-01~e.15
            :ARG0 (m / molecular-physical-entity
                  :name (n / name :op1 "NA"~e.14))
            :ARG1 (s / secrete-01~e.16
                  :ARG1 (p / protein
                        :name (n2 / name :op1 "TNF-α")))
            :ARG2 (o / or
                  :op1 (p4 / percentage-entity
                        :value "48.6"
                        :ARG2-of (a3 / add-02
                              :ARG1 (p5 / percentage-entity :value "7.1")))
                  :op2 (p6 / percentage-entity
                        :value "48.6"
                        :ARG2-of (s2 / subtract-01
                              :ARG1 p5))))
      :op2 (r2 / reduce-01~e.15
            :ARG0 m
            :ARG1 (s5 / secrete-01~e.16
                  :ARG1 (p2 / protein
                        :name (n3 / name :op1 "interleukin-6"~e.23,25)))
            :ARG2 (o3 / or
                  :op1 (p7 / percentage-entity
                        :value "60.9"
                        :ARG2-of (a4 / add-02
                              :ARG1 (p8 / percentage-entity :value "1.6")))
                  :op2 (p9 / percentage-entity
                        :value "60.9"
                        :ARG2-of (s3 / subtract-01
                              :ARG1 p8))))
      :op3 (r3 / reduce-01~e.15
            :ARG0 m
            :ARG1 (s6 / secrete-01~e.16
                  :ARG1 (p3 / protein
                        :name (n4 / name
                              :op1 "monocyte"~e.12
                              :op2 "chemoattractant"~e.32
                              :op3 "protein-1"~e.33,35)))
            :ARG2 (o4 / or
                  :op1 (p10 / percentage-entity
                        :value "59.3"
                        :ARG2-of (a5 / add-02
                              :ARG1 (p11 / percentage-entity :value "5.3")))
                  :op2 (p12 / percentage-entity
                        :value "59.3"
                        :ARG2-of (s4 / subtract-01
                              :ARG1 p11))))
      :location (a6 / agonist~e.2
            :name (n5 / name :op1 "TLR2"~e.1)
            :mod (c / cell
                  :name (n6 / name :op1 "monocyte"~e.31)
                  :part-of (h / human~e.11)
                  :ARG1-of (a7 / activate-01~e.10
                        :ARG0 (o2 / organism
                              :name (n7 / name :op1 "Listeria"~e.7 :op2 "monocytogenes"~e.8)
                              :ARG1-of (k / kill-01~e.6
                                    :ARG0 (h2 / heat-01~e.4)))))))

# ::tok Cytokine determination within BAL fluid revealed that LPS challenged Tie2 @-@ adam17 -/- mice showed reduced release of IL @-@ 6 ( Fig 7A , 3.9 @-@ fold ) and TNF @-@ a ( Fig 7B , 1.6 @-@ fold ) , whereas no effect was observed in PBS @-@ challenged mice .
# ::alignments 0-1.1.1 1-1.1 3-1.1.2.1.1 4-1.1.2 5-1 6-1.2.r 7-1.2.1.1.2.1.1.1 8-1.2.1.1.2 9-1.2.1.1.1.1.1 11-1.2.1.1.1.1.1 12-1.2.1.1.1.2.1 13-1.2.1.1 14-1.2.1 15-1.2.1.2.1.1.2 15-1.2.1.2.1.2.2 16-1.2.1.2 17-1.2.1.2.1.r 18-1.2.1.2.1.1.1.1 20-1.2.1.2.1.1.1.1 23-1.2.1.2.1.1.3.1.1 25-1.2.1.2.1.1.2.1.1 29-1.2.1.2.1 30-1.2.1.2.1.2.1.1 35-1.2.1.2.1.2.3.1.1 37-1.2.1.2.1.2.2.1.1 42-1.2 43-1.2.2.1 43-1.2.2.1.r 44-1.2.2.2 46-1.2.2 47-1.2.2.3.r 48-1.2.2.3.1.1.1.1 50-1.2.2.3.1 51-1.2.2.3
# ::id bel_pmid_2236_7719_24892
(r / reveal-01~e.5
      :ARG0 (d / determine-01~e.1
            :ARG1 (c / cytokine~e.0)
            :location (f / fluid~e.4
                  :name (n / name :op1 "BAL"~e.3)))
      :ARG1~e.6 (c2 / contrast-01~e.42
            :ARG1 (s / show-01~e.14
                  :ARG0 (m / mouse~e.13
                        :mod (e / enzyme
                              :name (n2 / name :op1 "Tie2-adam17"~e.9,11)
                              :ARG2-of (m2 / mutate-01 :mod "-/-"~e.12))
                        :ARG1-of (c3 / challenge-01~e.8
                              :ARG0 (m3 / molecular-physical-entity
                                    :name (n3 / name :op1 "LPS"~e.7))))
                  :ARG1 (r2 / release-01~e.16
                        :ARG1~e.17 (a / and~e.29
                              :op1 (p / protein
                                    :name (n4 / name :op1 "IL-6"~e.18,20)
                                    :ARG1-of (r3 / reduce-01~e.15
                                          :ARG2 (p2 / product-of :op1 "3.9"~e.25))
                                    :ARG1-of (d2 / describe-01
                                          :ARG0 (f2 / figure :mod "7A"~e.23)))
                              :op2 (p3 / protein
                                    :name (n5 / name :op1 "TNF-α"~e.30)
                                    :ARG1-of (r4 / reduce-01~e.15
                                          :ARG2 (p4 / product-of :op1 "1.6"~e.37))
                                    :ARG1-of (d3 / describe-01
                                          :ARG0 (f3 / figure :mod "7B"~e.35))))))
            :ARG2 (o / observe-01~e.46
                  :polarity~e.43 "-"~e.43
                  :ARG1 (a2 / affect-01~e.44)
                  :location~e.47 (m4 / mouse~e.51
                        :ARG1-of (c4 / challenge-01~e.50
                              :ARG0 (m5 / molecular-physical-entity
                                    :name (n6 / name :op1 "PBS"~e.48)))))))

# ::tok . The concentration of IL @-@ 6 , IL @-@ 13 and IL @-@ 17 was significantly higher in KO mice relative to wild @-@ type mice , while that of IL @-@ 12 was significantly higher in wild @-@ type mice relative to KO mice .
# ::alignments 2-1.1.1 2-1.2.1 4-1.1.1.1.1.1.1 4-1.2.1.1.1.1 6-1.1.1.1.1.1.1 8-1.1.1.1.1.1.1 8-1.1.1.1.2.1.1 8-1.1.1.1.3.1.1 10-1.1.1.1.2.1.1 11-1.1.1.1 12-1.1.1.1.1.1.1 12-1.1.1.1.2.1.1 12-1.1.1.1.3.1.1 14-1.1.1.1.3.1.1 15-1.1.1.r 16-1.1.2.1 17-1.1 17-1.1.2 17-1.1.2.r 17-1.2 20-1.1.3 20-1.1.4.1 21-1.1.4 21-1.2.4 23-1.1.4.1.1 25-1.1.4.1.1 26-1.1.4.1 28-1 31-1.1.1.1.3.1.1 31-1.2.1.1.1.1 33-1.2.1.1.1.1 34-1.1.1.r 35-1.2.2 36-1.1 36-1.1.2 36-1.1.2.r 38-1.1.4.1.1 40-1.1.4.1.1 41-1.1.4.1 42-1.1.4 45-1.1.4.1
# ::id bel_pmid_2243_8032_25776
(c / contrast-01~e.28
      :ARG1 (h / high~e.17,36
            :domain~e.15,34 (c2 / concentrate-02~e.2
                  :ARG1 (a / and~e.11
                        :op1 (p / protein
                              :name (n / name :op1 "IL-6"~e.4,6,8,12))
                        :op2 (p2 / protein
                              :name (n2 / name :op1 "IL-13"~e.8,10,12))
                        :op3 (p3 / protein
                              :name (n3 / name :op1 "IL-17"~e.8,12,14,31))))
            :degree~e.17,36 (m / more~e.17,36
                  :degree (s / significant-02~e.16))
            :location (m2 / mouse~e.20
                  :location-of (k / knockout-00))
            :ARG1-of (r / relative-05~e.21,42
                  :ARG3 (m3 / mouse~e.20,26,41,45
                        :mod (w / wild-type~e.23,25,38,40))))
      :ARG2 (h2 / high~e.17
            :domain (c3 / concentrate-02~e.2
                  :ARG1 (p4 / protein
                        :name (n4 / name :op1 "IL-12"~e.4,31,33)))
            :degree m~e.35
            :location m3
            :ARG1-of (r2 / relative-05~e.21
                  :ARG3 m2)))

# ::tok the expression of tissue damage @-@ related proteins , TGF-? and mesothelin was more markedly increased in the lungs of KO mice relative to wild @-@ type mice .
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.3.1.1 4-1.1.1.3.1 6-1.1.1.3 7-1.1.1.1 7-1.1.1.2 10-1.1.1 11-1.1.1.2.1.1 13-1.2.1 14-1.2 15-1 16-1.3.r 18-1.3 21-1.3.1 22-1.4 23-1.4.1.r 24-1.4.1.1 26-1.4.1.1 27-1.4.1
# ::id bel_pmid_2243_8032_25784
(i / increase-01~e.15
      :ARG1 (e / express-03~e.1
            :ARG2~e.2 (a / and~e.10
                  :op1 (p / protein~e.7
                        :name (n / name :op1 "TGF-βl"))
                  :op2 (p2 / protein~e.7
                        :name (n2 / name :op1 "mesothelin"~e.11))
                  :ARG1-of (r / relate-01~e.6
                        :ARG2 (d / damage-01~e.4
                              :ARG1 (t / tissue~e.3)))))
      :ARG2 (m / marked~e.14
            :degree (m2 / more~e.13))
      :location~e.16 (l / lung~e.18
            :part-of (m3 / mouse~e.21
                  :location-of (k / knockout-00)))
      :ARG1-of (r2 / relative-05~e.22
            :ARG3~e.23 (m4 / mouse~e.27
                  :mod (w / wild-type~e.24,26))))

# ::tok In this study , we identified microRNA @-@ 494 ( miR @-@ 494 ) , whose expression was dramatically induced by tumor @-@ derived factors , as an essential player in regulating the accumulation and activity of MDSCs by targeting of phosphatase and tensin homolog ( PTEN ) and activation of the Akt pathway .
# ::alignments 1-1.3.1 2-1.3 4-1.1 5-1 8-1.2.1.1 12-1.2.1.1 16-1.2.3 18-1.2.3.1.2 18-1.2.3.1.3 19-1.2.3.1 20-1.2.3.1.1.r 21-1.2.3.1.1.1.1 23-1.2.3.1.1.1 24-1.2.3.1.1 26-1.2.3.1.3.3.r 26-1.3.r 28-1.2.3.1.3.3 30-1.2.3.1.3.2.r 31-1.2.3.1.3.2 33-1.2.3.1.3.2.1.1 34-1.2.3.1.3.2.1 35-1.2.3.1.3.2.1.2 38-1.2.3.1.3.2.1.2.2.r 39-1.2.3.1.3.2.1.2.2.1 40-1.2.3.1.3.2.1.2.2.1.2.r 41-1.2.3.1.3.2.1.2.2.1.2.1.1 42-1.2.3.1.3.2.1.2.2.1.2.1.2 43-1.2.3.1.3.2.1.2.2.1.2.1.3 44-1.2.3.1.3.2.1.2.2.1.2.1.4 46-1.2.3.1.3.2.1.2.2.1.2.2.1.1.1 48-1.2.3.1.3.2.1.2.2 49-1.2.3.1.3.2.1.2.2.2 50-1.2.3.1.3.2.1.2.2.2.2.r 52-1.2.3.1.3.2.1.2.2.2.2.1.1 53-1.2.3.1.3.2.1.2.2.2.2
# ::id bel_pmid_2254_4933_40994
(i / identify-01~e.5
      :ARG0 (w / we~e.4)
      :ARG1 (r / rna
            :name (n / name :op1 "RNA-494"~e.8,12)
            :mod (m / micro)
            :ARG2-of (e / express-03~e.16
                  :ARG1-of (i2 / induce-01~e.19
                        :ARG0~e.20 (f / factor~e.24
                              :ARG1-of (d2 / derive-01~e.23
                                    :ARG2 (t3 / tumor~e.21)))
                        :manner (d / dramatic~e.18)
                        :manner (p4 / play-02~e.18
                              :ARG0 e
                              :ARG1~e.30 (r2 / regulate-01~e.31
                                    :ARG1 (a / and~e.34
                                          :op1 (a2 / accumulate-01~e.33
                                                :ARG1 (c / cell
                                                      :name (n3 / name :op1 "MDSC")))
                                          :op2 (a3 / act-02~e.35
                                                :ARG0 c
                                                :ARG1~e.38 (a5 / and~e.48
                                                      :op1 (t2 / target-01~e.39
                                                            :ARG0 e
                                                            :ARG1~e.40 (p3 / protein
                                                                  :name (n2 / name
                                                                        :op1 "phosphatase"~e.41
                                                                        :op2 "and"~e.42
                                                                        :op3 "tensin"~e.43
                                                                        :op4 "homolog"~e.44)
                                                                  :ARG1-of (m2 / mean-01
                                                                        :ARG2 (p5 / protein
                                                                              :name (n7 / name :op1 "PTEN"~e.46)))))
                                                      :op2 (a6 / activate-01~e.49
                                                            :ARG0 e
                                                            :ARG1~e.50 (p2 / pathway~e.53
                                                                  :name (n6 / name :op1 "Akt"~e.52)))))))
                              :mod~e.26 (e3 / essential~e.28)))))
      :time~e.26 (s / study-01~e.2
            :mod (t / this~e.1)))

# ::tok miR @-@ 494 is highly expressed in tumor @-@ expanded MDSCs .
# ::alignments 0-1.1.1.1 2-1.1.1.1 4-1.3 4-1.3.r 5-1 6-1.2.r 7-1.2.2.1 9-1.2.2
# ::id bel_pmid_2254_4933_41002
(e / express-03~e.5
      :ARG2 (r / rna
            :name (n / name :op1 "miR-494"~e.0,2))
      :ARG3~e.6 (c / cell
            :name (n2 / name :op1 "MDSC")
            :ARG1-of (e2 / expand-01~e.9
                  :ARG0 (t / tumor~e.7)))
      :manner~e.4 (h / high~e.4))

# ::tok As shown in Fig. 1C , significantly increased expression of miR @-@ 494 was detected in both subpopulations compared with their counterpart from tumor @-@ free mice ( granulocytic MDSCs , p < 0.01; monocytic MDSCs , p < 0.001 ) .
# ::alignments 1-1.2 4-1.2.1.1 6-1.1.2.1 6-1.1.2.1.r 7-1.1.2 8-1.1 10-1.1.1.1.1 12-1.1.1.1.1 14-1 16-1.3.1 18-1.4.r 20-1.4.1 20-1.4.1.r 21-1.4 22-1.4.2.r 23-1.4.2.1.1 25-1.4.2.1 26-1.4.2 28-1.4.3.1.1.2 34-1.4.3.1.2.2 39-1.4.3.1.2.3.1.1
# ::id bel_pmid_2254_4933_41006
(d / detect-01~e.14
      :ARG1 (e / express-03~e.8
            :ARG2 (r / rna
                  :name (n / name :op1 "miR-494"~e.10,12))
            :ARG1-of (i / increase-01~e.7
                  :manner~e.6 (s2 / significant~e.6)))
      :ARG1-of (s / show-01~e.1
            :ARG0 (f / figure :mod "1C"~e.4))
      :location (s3 / subpopulation
            :mod (b / both~e.16))
      :compared-to~e.18 (c / counterpart~e.21
            :poss~e.20 s3~e.20
            :location~e.22 (m / mouse~e.26
                  :ARG1-of (f2 / free-04~e.25
                        :ARG2 (t / tumor~e.23)))
            :ARG1-of (m2 / mean-01
                  :ARG2 (a / and
                        :op1 (c2 / cell
                              :name (n2 / name :op1 "MDSC")
                              :mod (g / granulocytic~e.28)
                              :mod (p / probability
                                    :quant (l / less-than :op1 "0.01")))
                        :op3 (c3 / cell
                              :name (n3 / name :op1 "MDSC")
                              :mod (m3 / monocytic~e.34)
                              :mod (p2 / probability
                                    :quant (l2 / less-than :op1 "0.001"~e.39)))))))

# ::tok Tumor @-@ derived factors , especially TG'F @-@ fH , markedly induce the upregulation of miR @-@ 494 in MDSCs .
# ::alignments 0-1.1.2.1 2-1.1.2 3-1.1 5-1.1.1.2 6-1.1.1.1.1 8-1.1.1.1.1 10-1.3 10-1.3.r 11-1 13-1.2 15-1.2.1.1.1 17-1.2.1.1.1
# ::id bel_pmid_2254_4933_41010
(i / induce-01~e.11
      :ARG0 (f / factor~e.3
            :example (p2 / protein
                  :name (n2 / name :op1 "TG'F-fH"~e.6,8)
                  :manner (e / especially~e.5))
            :ARG1-of (d / derive-01~e.2
                  :ARG2 (t / tumor~e.0)))
      :ARG1 (u / upregulate-01~e.13
            :ARG1 (r / rna
                  :name (n3 / name :op1 "miR-494"~e.15,17))
            :location (c / cell
                  :name (n4 / name :op1 "MDSC")))
      :manner~e.10 (m / marked~e.10))

# ::tok As expected , we found that miR @-@ 494 expression was significantly induced by TCCM in a dose @-@ dependent manner ( Fig . 2A ) .
# ::alignments 1-1.3 3-1.1 4-1 5-1.2.r 6-1.2.1.2.1.1 8-1.2.1.2.1.1 9-1.2.1 11-1.2.3 12-1.2 13-1.2.1.1.r 14-1.2.1.1.1.1 15-1.2.2.r 17-1.2.2.1 19-1.2.2 20-1.2.3.r 24-1.4.1.1
# ::id bel_pmid_2254_4933_41012
(f / find-01~e.4
      :ARG0 (w / we~e.3)
      :ARG1~e.5 (i / induce-01~e.12
            :ARG1 (e2 / express-03~e.9
                  :ARG1~e.13 (t / thing
                        :name (n2 / name :op1 "TCCM"~e.14))
                  :ARG2 (r / rna
                        :name (n / name :op1 "miR-494"~e.6,8)))
            :manner~e.15 (d / depend-01~e.19
                  :ARG1 (d2 / dose~e.17))
            :manner~e.20 (s / significant~e.11))
      :ARG1-of (e / expect-01~e.1)
      :ARG1-of (d3 / describe-01
            :ARG0 (f2 / figure :mod "2A"~e.24)))

# ::tok As shown in Fig. 2B , we found that the expression of miR @-@ 494 in Gr @-@ 1+ CD11b+ cells was not affected by GM @-@ CSF and IL @-@ 6 , but interestingly , miR @-@ 494 expression was significantly induced by TGF @-@ b1 treatment ( p < 0.001 ) .
# ::alignments 1-1.3 4-1.3.1.1 6-1.1 7-1 8-1.2.r 10-1.2.1.3 12-1.2.1.3.1.1.1 14-1.2.1.3.1.1.1 15-1.2.1.3.2.r 16-1.2.1.3.2.1.1.1 18-1.2.1.3.2.1.1.1 19-1.2.1.3.2.2.1.1 20-1.2.1.3.2 22-1.2.1.1 22-1.2.1.1.r 23-1.2.1 24-1.2.1.2.r 25-1.2.1.2.1.1.1 27-1.2.1.2.1.1.1 28-1.2.1.2 29-1.2.1.2.2.1.1 31-1.2.1.2.2.1.1 33-1.2 34-1.2.2.4 34-1.2.2.4.r 36-1.2.2.2 37-1.2.2.2 38-1.2.2.2 39-1.2.2.2 41-1.2.2.3 41-1.2.2.3.r 42-1.2.2 43-1.2.2.1.r 44-1.2.2.1.1.1.1 46-1.2.2.1.1.1.1 47-1.2.2.1 51-1.2.2.1.2.1.1
# ::id bel_pmid_2254_4933_41014
(f / find-01~e.7
      :ARG0 (w / we~e.6)
      :ARG1~e.8 (c / contrast-01~e.33
            :ARG1 (a / affect-01~e.23
                  :polarity~e.22 "-"~e.22
                  :ARG0~e.24 (a2 / and~e.28
                        :op1 (p3 / protein
                              :name (n4 / name :op1 "GM-CSF"~e.25,27))
                        :op2 (p4 / protein
                              :name (n5 / name :op1 "IL-6"~e.29,31)))
                  :ARG1 (e / express-03~e.10
                        :ARG2 (r / rna
                              :name (n / name :op1 "miR-494"~e.12,14))
                        :ARG3~e.15 (c2 / cell~e.20
                              :mod (p / protein
                                    :name (n2 / name :op1 "Gr-1+"~e.16,18))
                              :mod (p2 / protein
                                    :name (n3 / name :op1 "CD11b+"~e.19)))))
            :ARG2 (i / induce-01~e.42
                  :ARG0~e.43 (t / treat-04~e.47
                        :ARG2 (p5 / protein
                              :name (n6 / name :op1 "TGF-b1"~e.44,46))
                        :mod (p6 / probability
                              :quant (l / less-than :op1 "0.001"~e.51)))
                  :ARG1 e~e.36,37,38,39
                  :manner~e.41 (s2 / significant~e.41)
                  :manner~e.34 (i2 / interesting~e.34)))
      :ARG1-of (s / show-01~e.1
            :ARG0 (f2 / figure :mod "2B"~e.4)))

# ::tok Moreover , the induction of miR @-@ 494 was partially blocked by anti @-@ TGF @-@ p1 mAb in cells stimulated with 4T1 TCCM ( Fig . 2C ) , and the upregulation of miR @-@ 494 was impaired in Smad 3 @-@ deficient Gr @-@ 1+ CD11b+ cells isolated from the spleen of Smad 3_/_ mice ( Fig . 2D ) .
# ::alignments 5-1.1.1.2.1.1.1 7-1.1.1.2.1.1.1 9-1.1.1.3 9-1.1.1.3.r 10-1.1.1 11-1.1.1.1.r 12-1.1.1.1 12-1.1.1.1.2 12-1.1.1.1.2.r 14-1.1.1.1.1.1 16-1.1.1.1.1.1 17-1.1.1.1.2.1.1.1 18-1.1.1.4.r 19-1.1.1.4 20-1.1.1.4.1 21-1.1.1.4.1.1.r 22-1.1.1.4.1.1.1.1 23-1.1.1.4.1.1.2.1.1 27-1.1.1.5.1.1 30-1.1 32-1.1.2.1 33-1.1.2.1.1.r 34-1.1.2.1.1 35-1.1.2.1.1 36-1.1.2.1.1 38-1.1.2 39-1.1.2.2.r 40-1.1.2.2.1.1.1.1.1.1 41-1.1.2.2.1.1.1.1.1.2 44-1.1.2.4.1.1.1 46-1.1.2.4.1.1.1 47-1.1.2.4.2.1.1 48-1.1.2.2 49-1.1.2.2.1 52-1.1.2.2.1.1 56-1.1.2.2.1.1.1 60-1.1.2.3.1.1
# ::id bel_pmid_2254_4933_41016
(a / and
      :op2 (a2 / and~e.30
            :op1 (b / block-01~e.10
                  :ARG0~e.11 (p2 / protein~e.12
                        :name (n2 / name :op1 "TGF-p1"~e.14,16)
                        :ARG1-of~e.12 (c / counter-01~e.12
                              :ARG0 (e / enzyme
                                    :name (n3 / name :op1 "mAb"~e.17))))
                  :ARG1 (i2 / induct-02
                        :ARG1 (r / rna
                              :name (n / name :op1 "miR-494"~e.5,7)))
                  :manner~e.9 (p / partial~e.9)
                  :location~e.18 (c2 / cell~e.19
                        :ARG1-of (s / stimulate-01~e.20
                              :ARG2~e.21 (c5 / cell-line
                                    :name (n8 / name :op1 "4T1"~e.22)
                                    :part-of (t / thing
                                          :name (n4 / name :op1 "TCCM"~e.23)))))
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure :mod "2C"~e.27)))
            :op2 (i / impair-01~e.38
                  :ARG1 (u / upregulate-01~e.32
                        :ARG1~e.33 r~e.34,35,36)
                  :location~e.39 (c3 / cell~e.48
                        :ARG1-of (i3 / isolate-01~e.49
                              :ARG2 (s2 / spleen~e.52
                                    :part-of (m2 / mouse~e.56
                                          :mod (p6 / protein
                                                :name (n5 / name :op1 "Smad"~e.40 :op2 "3"~e.41)
                                                :ARG2-of (m3 / mutate-01 :mod "-/-"))))))
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f2 / figure :mod "2D"~e.60))
                  :location (a3 / and
                        :op1 (c6 / cell
                              :name (n6 / name :op1 "Gr-1+"~e.44,46))
                        :op2 (c7 / cell
                              :name (n7 / name :op1 "CD11b+"~e.47))
                        :ARG0-of (l / lack-01
                              :ARG1 p6)))))

# ::tok As expected , the expression levels of ARG1 , MMP2 , MMP13 , and MMP14 were significantly upregulated in lv @-@ 494 @-@ infected MDSCs compared with those in lv @-@ ctrl @-@ infected MDSCs ( Fig . 4B ) ; moreover , lv @-@ sponge overtly blocked the induction in the expression of these molecules .
# ::alignments 1-1.1.2 4-1.1.1.1 5-1.1.1 5-1.1.5 6-1.1.1.1.1.r 7-1.1.1.1.1.1.1.1 9-1.1.1.1.1.2.1.1 11-1.1.1.1.1.3.1.1 13-1.1.1.1.1 14-1.1.1.1.1.4.1.1 16-1.1.3 16-1.1.3.r 19-1.1.4.2.1.1.1 21-1.1.4.2.1.1.1 23-1.1.4.2 25-1.1.5.r 28-1.1.5.1.r 29-1.1.5.1.2.1.1.1 31-1.1.5.1.2.1.1.1 33-1.1.4.2 33-1.1.5.1.2 38-1.1.6.1.1 43-1.2.1.1.1.1 45-1.2.1.1.1.1 46-1.2.1.3 46-1.2.1.3.r 47-1.2.1 49-1.2.1.2 50-1.2.1.2.1.r 52-1.2.1.2.1 55-1.1.4.2.1 55-1.1.5.1.2.1 55-1.2.1.1
# ::id bel_pmid_2254_4933_41022
(a / and
      :op1 (u / upregulate-01
            :ARG1 (l2 / level~e.5
                  :degree-of (e3 / express-03~e.4
                        :ARG2~e.6 (a3 / and~e.13
                              :op1 (e4 / enzyme
                                    :name (n / name :op1 "ARG1"~e.7))
                              :op2 (e5 / enzyme
                                    :name (n2 / name :op1 "MMP2"~e.9))
                              :op3 (e6 / enzyme
                                    :name (n3 / name :op1 "MMP13"~e.11))
                              :op4 (e7 / enzyme
                                    :name (n4 / name :op1 "MMP14"~e.14)))))
            :ARG1-of (e2 / expect-01~e.1)
            :manner~e.16 (s2 / significant~e.16)
            :location (c / cell
                  :name (n5 / name :op1 "MDSC")
                  :ARG1-of (i2 / infect-01~e.23,33
                        :ARG0 (m / molecular-physical-entity~e.55
                              :name (n6 / name :op1 "lv-494"~e.19,21))))
            :compared-to~e.25 (l4 / level~e.5
                  :location~e.28 (c2 / cell
                        :name (n7 / name :op1 "MDSC")
                        :ARG1-of (i3 / infect-01~e.33
                              :ARG0 (m2 / molecular-physical-entity~e.55
                                    :name (n8 / name :op1 "lv-ctrl"~e.29,31))))
                  :degree-of e3)
            :ARG1-of (d3 / describe-01
                  :ARG0 (f / figure :mod "4B"~e.38)))
      :op2 (a2 / and
            :op2 (b / block-01~e.47
                  :ARG0 (m3 / molecular-physical-entity~e.55
                        :name (n9 / name :op1 "lv-sponge"~e.43,45))
                  :ARG1 (i / induce-01~e.49
                        :ARG1~e.50 (e / express-03~e.52
                              :ARG1 a3))
                  :manner~e.46 (o / overt~e.46))))

# ::tok As shown in Fig. 4G , OT @-@ 1 CD8+ T cell proliferation was significantly suppressed by lv @-@ 494 @-@ infected MDSCs in comparison with lv @-@ ctrl @-@ infected MDSCs , and this suppressive activity could be partially blocked by an ARG1 inhibitor nor @-@ NOHA .
# ::alignments 1-1.3 4-1.3.1.1 11-1.1.1 11-1.1.2.1 11-1.1.4 12-1.1.2 14-1.1.3 14-1.1.3.r 15-1.1 16-1.1.1.2.r 17-1.1.1.2.1.1.1 19-1.1.1.2.1.1.1 21-1.1.1.2 21-1.1.4.2 24-1.1.4.r 25-1.1.4.2.1.r 26-1.1.4.2.1.1.1 28-1.1.4.2.1.1.1 30-1.1.1.2 33-1 37-1.2 38-1.2.1.r 39-1.2.1.3 39-1.2.1.3.r 40-1.2.1 41-1.2.1.1.r 43-1.2.1.1.2.1.1.1 44-1.2.1.1 44-1.2.1.1.2 44-1.2.1.1.2.r 47-1.2.1.1.1.1
# ::id bel_pmid_2254_4933_41028
(a / and~e.33
      :op1 (s / suppress-01~e.15
            :ARG0 (c4 / cell~e.11
                  :name (n6 / name :op1 "MDSC")
                  :ARG1-of~e.16 (i2 / infect-01~e.21,30
                        :ARG0 (m / molecular-physical-entity
                              :name (n7 / name :op1 "lv-494"~e.17,19))))
            :ARG1 (p2 / proliferate-01~e.12
                  :ARG0 (c2 / cell~e.11
                        :name (n4 / name :op1 "OT - 1 CD8+ T")))
            :manner~e.14 (s2 / significant~e.14)
            :compared-to~e.24 (c5 / cell~e.11
                  :name (n8 / name :op1 "MDSC")
                  :ARG1-of (i3 / infect-01~e.21
                        :ARG0~e.25 (d2 / disease
                              :name (n9 / name :op1 "lv-ctrl"~e.26,28)))))
      :op2 (p3 / possible~e.37
            :domain~e.38 (b / block-01~e.40
                  :ARG0~e.41 (m2 / molecular-physical-entity~e.44
                        :name (n / name :op1 "Nor-NOHA"~e.47)
                        :ARG0-of~e.44 (i / inhibit-01~e.44
                              :ARG1 (e / enzyme
                                    :name (n2 / name :op1 "ARG1"~e.43))))
                  :ARG1 s
                  :manner~e.39 (p / partial~e.39)))
      :ARG1-of (s3 / show-01~e.1
            :ARG0 (f / figure :mod "4G"~e.4)))

# ::tok Notably , the PTEN protein level was significantly downregulated in tumor @-@ expanded MDSCs compared with that in Gr @-@ 1+ CD11b+ cells from tumor @-@ free mice , whereas PTEN mRNA expression showed no difference ( Fig . 6A ) .
# ::alignments 0-1.4 3-1.1.1.1.1.1 4-1.1.1.1 4-1.1.4.1.2.1.1 4-1.1.4.1.2.1.2 5-1.1.1 5-1.1.4 7-1.1.2 7-1.1.2.r 10-1.1.3.2.1 12-1.1.3.2 14-1.1.4.r 17-1.1.4.1.r 18-1.1.4.1.2.1.1.1.1 20-1.1.4.1.2.1.1.1.1 21-1.1.4.1.2.1.2.1.1 22-1.1.4.1 23-1.1.4.1.1.r 24-1.1.4.1.1.1.1 26-1.1.4.1.1.1 27-1.1.4.1.1 29-1 30-1.2.2.1.2 31-1.2.2.1.1.1 32-1.2.2 33-1.2 34-1.2.1 34-1.2.1.r 35-1.2.1.r 35-1.2.3 39-1.3.1.1
# ::id bel_pmid_2254_4933_41038
(c / contrast-01~e.29
      :ARG1 (d2 / downregulate-01
            :ARG1 (l / level~e.5
                  :quant-of (p / protein~e.4
                        :name (n / name :op1 "PTEN"~e.3)))
            :manner~e.7 (s / significant~e.7)
            :location (c2 / cell
                  :name (n2 / name :op1 "MDSC")
                  :ARG1-of (e / expand-01~e.12
                        :ARG0 (t / tumor~e.10)))
            :compared-to~e.14 (l2 / level~e.5
                  :location~e.17 (c3 / cell~e.22
                        :source~e.23 (m / mouse~e.27
                              :ARG1-of (f2 / free-04~e.26
                                    :ARG2 t~e.24))
                        :ARG1-of (m2 / mutate-01
                              :ARG2 (a / and
                                    :op1 (p2 / protein~e.4
                                          :name (n3 / name :op1 "Gr-1+"~e.18,20))
                                    :op2 (p3 / protein~e.4
                                          :name (n4 / name :op1 "CD11b+"~e.21)))))
                  :degree-of p))
      :ARG2 (s2 / show-01~e.33
            :polarity~e.34,35 "-"~e.34
            :ARG0 (e2 / express-03~e.32
                  :ARG2 (r / rna
                        :name (n5 / name :op1 "mRNA"~e.31)
                        :mod p~e.30))
            :ARG1 (d3 / differ-02~e.35))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6A"~e.39))
      :mod (n6 / notable~e.0))

# ::tok When the reporter plasmids with miR @-@ 494 mimics or the scrambled oligonucleotide were cotransfected to HEK @-@ 293 cells , we observed that the miR @-@ 494 mimics markedly decreased the luciferase activity ( Fig . 6B ) .
# ::alignments 0-1.4.r 2-1.4.1.1.2 4-1.4.1.1.1.r 5-1.4.1.1.1 6-1.4.1.1.1 7-1.4.1.1.1 8-1.4.1.1.1 9-1.4.1 11-1.4.1.2.1 12-1.4.1.2 16-1.4.2.1.1 18-1.4.2.1.1 19-1.4.2 21-1.1 22-1 23-1.2.r 25-1.2.1.1.1.1 27-1.2.1.1.1.1 28-1.2.1 29-1.2.3 29-1.2.3.r 30-1.2 32-1.2.2.1 33-1.2.2 37-1.3.1.1
# ::id bel_pmid_2254_4933_41040
(o / observe-01~e.22
      :ARG0 (w / we~e.21)
      :ARG1~e.23 (d / decrease-01~e.30
            :ARG0 (m2 / mimic-01~e.28
                  :ARG1 (r / rna
                        :name (n / name :op1 "miR-494"~e.25,27)))
            :ARG1 (a / act-02~e.33
                  :ARG0 (l / luciferase~e.32))
            :manner~e.29 (m / marked~e.29))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "6B"~e.37))
      :time~e.0 (c / cotransfect-00
            :ARG1 (o2 / or~e.9
                  :op1 (p / plasmid
                        :instrument~e.4 m2~e.5,6,7,8
                        :ARG0-of (r2 / report-01~e.2))
                  :op2 (o3 / oligonucleotide~e.12
                        :ARG1-of (s / scramble-02~e.11)))
            :location (c2 / cell~e.19
                  :name (n2 / name :op1 "HEK-293"~e.16,18))))

# ::tok Furthermore , transfection of lv @-@ 494 significantly decreased PTEN expression in MDSCs , thus suggesting that endogenous PTEN is targeted and regulated by miR @-@ 494 ( Fig . 6C ) .. To confirm whether miR @-@ 494 @-@ induced activation of MDSCs was mediated by targeting of PTEN expression , we designed a lentiviral vector encoding 39 @-@ UTR @-@ depleted PTEN to enforce the expression of PTEN in MDSCs .
# ::alignments 2-1.1.1.1 3-1.1.1.1.1.r 4-1.1.1.1.1.1.1 6-1.1.1.1.1.1.1 6-1.1.1.4.1.1.1.1.1 7-1.1.1.3 7-1.1.1.3.r 8-1.1.1 9-1.2.2.2.1.1.1 10-1.1.1.2 15-1.1.1.4 17-1.1.1.4.1.1.2.2 18-1.1.1.4.1.1.2.1.1 20-1.1.1.4.1.1 21-1.1.1.4.1 22-1.1.1.4.1.2 24-1.2.4.2.1.2.1.1.1 26-1.2.4.2.1.2.1.1.1 30-1.1.2.1.1 34-1.2.4 36-1.2.4.2.1.2.1.1.1 38-1.2.4.2.1.2.1.1.1 40-1.2.4.2.1.2 41-1.2.4.2.1 45-1.2.4.2 46-1.2.4.2.2.r 47-1.2.4.2.2 49-1.2.2.2.1.1.1 50-1.2.4.2.2.1 52-1.2.1 53-1.2 55-1.2.3.1 56-1.2.3.1 57-1.2.3.1 58-1.2.3.1 59-1.2.3.1 60-1.2.3.1 61-1.2.3.1 62-1.2.3.1 63-1.2.3.1 65-1.2.3 67-1.2.3.2 68-1.2.3.2.1.r 69-1.2.3.2.1
# ::id bel_pmid_2254_4933_41042
(m / multi-sentence
      :snt1 (a / and
            :op2 (d2 / decrease-01~e.8
                  :ARG0 (t / transfect-00~e.2
                        :ARG1~e.3 (m3 / molecular-physical-entity
                              :name (n / name :op1 "lv-494"~e.4,6)))
                  :ARG1 (e / express-03~e.10
                        :ARG2 (p2 / protein
                              :name (n5 / name :op1 "PTEN"~e.18)
                              :mod (m2 / monocot~e.17))
                        :ARG3 (c / cell
                              :name (n3 / name :op1 "MDSC")))
                  :manner~e.7 (s / significant~e.7)
                  :ARG1-of (s2 / suggest-01~e.15
                        :ARG2 (a2 / and~e.21
                              :op1 (t2 / target-01~e.20
                                    :ARG0 (r2 / rna
                                          :name (n4 / name :op1 "miR-494"~e.6))
                                    :ARG1 p2)
                              :op2 (r / regulate-01~e.22
                                    :ARG0 r2
                                    :ARG1 p2))))
            :ARG1-of (d4 / describe-01
                  :ARG0 (f / figure :mod "6C"~e.30)))
      :snt2 (d / design-01~e.53
            :ARG0 (w / we~e.52)
            :ARG1 (v / vector
                  :mod (l2 / lentiviral)
                  :ARG0-of (e2 / encode-01
                        :ARG1 (p / protein
                              :name (n2 / name :op1 "PTEN"~e.9,49)
                              :ARG1-of (d5 / deplete-01
                                    :ARG2 (e3 / enzyme
                                          :name (n6 / name :op1 "39-UTR"))))))
            :purpose (e4 / enforce-01~e.65
                  :ARG0 v~e.55,56,57,58,59,60,61,62,63
                  :ARG1 (e5 / express-03~e.67
                        :ARG2~e.68 p~e.69
                        :ARG3 (c2 / cell
                              :name (n7 / name :op1 "MDSC"))))
            :purpose (c3 / confirm-01~e.34
                  :ARG0 w
                  :ARG1 (m4 / mediate-01~e.45
                        :ARG0 (a3 / activate-01~e.41
                              :ARG1 c2
                              :ARG1-of (i / induce-01~e.40
                                    :ARG0 (r3 / rna
                                          :name (n8 / name :op1 "miR-494"~e.24,26,36,38))))
                        :ARG1~e.46 (t3 / target-01~e.47
                              :ARG1 (e6 / express-03~e.50))))))

# ::tok Overexpression of PTEN in Gr @-@ 1+ CD11b+ cells did not affect the TDF @-@ induced miR @-@ 494 up @-@ regulation , whereas the increased expression of MMPs induced by TCCM were significantly blocked ( Fig . 6D ) , and SDF @-@ 1/CXCL12 @-@ mediated MDSC migration was abrogated ( Fig . 6E ) .
# ::alignments 0-1.2.1.1 2-1.1.2.1.1.1 4-1.1.2.2.1.1.1.1.1 6-1.1.2.2.1.1.1.1.1 7-1.1.2.2.1.1.2.1.1 8-1.1.2.2 10-1.1.1 10-1.1.1.r 11-1.1 13-1.1.3.2.1.1.1 15-1.1.3.2 16-1.1.3.1.1.1 18-1.1.3.1.1.1 19-1.2.1.1.2 23-1 25-1.2.1.1.2 26-1.2.1.1 29-1.2.1.1.3 30-1.2.1.1.3.1.r 31-1.2.1.1.3.1.1.1 33-1.2.1.2 33-1.2.1.2.r 34-1.2.1 38-1.2.1.3.1.1 41-1.2 41-1.2.2.1.2.1 42-1.2.2.1.2.1.1.1.1 46-1.2.2.1.2 47-1.2.2.1.1.1.1 48-1.2.2.1 50-1.2.2 54-1.3.1.1
# ::id bel_pmid_2254_4933_41044
(c / contrast-01~e.23
      :ARG1 (a / affect-01~e.11
            :polarity~e.10 "-"~e.10
            :ARG0 (o / overexpress-00
                  :ARG1 (p3 / protein
                        :name (n3 / name :op1 "PTEN"~e.2))
                  :ARG3 (c2 / cell~e.8
                        :ARG1-of (m / mutate-01
                              :ARG0 (a3 / and
                                    :op1 (p / protein
                                          :name (n / name :op1 "Gr-1+"~e.4,6))
                                    :op2 (p2 / protein
                                          :name (n2 / name :op1 "CD11b+"~e.7))))))
            :ARG1 (u / upregulate-01
                  :ARG1 (r / rna
                        :name (n5 / name :op1 "miR-494"~e.16,18))
                  :ARG1-of (i / induce-01~e.15
                        :ARG0 (p4 / protein
                              :name (n4 / name :op1 "TDF"~e.13)))))
      :ARG2 (a4 / and~e.41
            :op1 (b / block-01~e.34
                  :ARG1 (e / express-03~e.0,26
                        :ARG2 (p5 / protein
                              :name (n6 / name :op1 "MMP"))
                        :ARG1-of (i2 / increase-01~e.19,25)
                        :ARG1-of (i3 / induce-01~e.29
                              :ARG0~e.30 (t / thing
                                    :name (n7 / name :op1 "TCCM"~e.31))))
                  :manner~e.33 (s / significant~e.33)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f2 / figure :mod "6D"~e.38)))
            :op2 (a5 / abrogate-01~e.50
                  :ARG1 (m2 / migrate-01~e.48
                        :ARG0 (c3 / cell
                              :name (n8 / name :op1 "MDSC"~e.47))
                        :ARG1-of (m3 / mediate-01~e.46
                              :ARG0 (a6 / and~e.41
                                    :op1 (p7 / protein
                                          :name (n9 / name :op1 "SDF-1"~e.42))
                                    :op2 (p8 / protein
                                          :name (n10 / name :op1 "/CXCL12")))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6E"~e.54)))

# ::tok Significantly reduced PTEN expression was also detected in Gr @-@ 1+ CD11b+ cells after TCCM stimulation ( Fig . 6G ) ; this was inversely correlated with the phosphorylation levels of mTOR and NF @-@ kB .
# ::alignments 0-1.1.1.2.1 0-1.1.1.2.1.r 1-1.1.1.2 2-1.1.1.1.1.1 3-1.1.1 5-1.1.2 6-1.1 7-1.1.3.r 8-1.1.3.1.1.1.1.1 10-1.1.3.1.1.1.1.1 11-1.1.3.1.1.2.1.1 12-1.1.3 13-1.1.4 14-1.1.4.1.1.1.1 15-1.1.4.1 19-1.1.5.1.1 22-1.2.1 24-1.2.3 24-1.2.3.r 25-1.2 26-1.2.2.r 28-1.2.2.1 29-1.2.2 29-1.2.2.1.1 30-1.2.2.1.1.1.r 31-1.2.2.1.1.1.1.1.1 32-1.2.2.1.1.1 33-1.2.2.1.1.1.2.1.1 35-1.2.2.1.1.1.2.1.1
# ::id bel_pmid_2254_4933_41046
(m / multi-sentence
      :snt1 (d / detect-01~e.6
            :ARG1 (e / express-03~e.3
                  :ARG2 (p / protein
                        :name (n / name :op1 "PTEN"~e.2))
                  :ARG1-of (r / reduce-01~e.1
                        :manner~e.0 (s / significant~e.0)))
            :mod (a / also~e.5)
            :location~e.7 (c / cell~e.12
                  :ARG1-of (m2 / mutate-01
                        :ARG0 (a2 / and
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "Gr-1+"~e.8,10))
                              :op2 (p3 / protein
                                    :name (n3 / name :op1 "CD11b+"~e.11)))))
            :time (a3 / after~e.13
                  :op1 (s2 / stimulate-01~e.15
                        :ARG0 (t2 / thing
                              :name (n4 / name :op1 "TCCM"~e.14))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "6G"~e.19)))
      :snt2 (c2 / correlate-01~e.25
            :ARG1 (t / this~e.22)
            :ARG2~e.26 (l2 / level~e.29
                  :degree-of (p5 / phosphorylate-01~e.28
                        :ARG1 (l / level~e.29
                              :quant-of~e.30 (a4 / and~e.32
                                    :op1 (p6 / protein
                                          :name (n5 / name :op1 "mTOR"~e.31))
                                    :op2 (p7 / protein
                                          :name (n6 / name :op1 "NF-kB"~e.33,35))))))
            :manner~e.24 (i / inverse~e.24)))

# ::tok As shown in Fig. 6H , the increased levels of MMPs induced by TCCM were completely abolished by LY294002 , suggesting that the Akt activity is indispensable for the activation of MDSCs .
# ::alignments 1-1.3 4-1.3.1.1 7-1.2.1 8-1.2 11-1.2.3 12-1.2.3.1.r 13-1.2.3.1.1.1 15-1.4 15-1.4.r 16-1 17-1.1.r 18-1.1.1.1 20-1.5 23-1.5.1.1.1.1.1.1 24-1.5.1.1.1 25-1.5.1.1.r 26-1.5.1.1 27-1.5.1.1.2.r 29-1.5.1.1.2
# ::id bel_pmid_2254_4933_41048
(a / abolish-01~e.16
      :ARG0~e.17 (m / molecular-physical-entity
            :name (n / name :op1 "LY294002"~e.18))
      :ARG1 (l / level~e.8
            :ARG1-of (i / increase-01~e.7)
            :quant-of (e / enzyme
                  :name (n2 / name :op1 "MMP"))
            :ARG1-of (i2 / induce-01~e.11
                  :ARG0~e.12 (t / thing
                        :name (n3 / name :op1 "TCCM"~e.13))))
      :ARG1-of (s2 / show-01~e.1
            :ARG0 (f / figure :mod "6H"~e.4))
      :manner~e.15 (c / complete~e.15)
      :ARG0-of (s / suggest-01~e.20
            :ARG1 (p2 / possible
                  :domain~e.25 (i3 / indispensable-01~e.26
                        :ARG1 (a2 / act-02~e.24
                              :ARG0 (p3 / pathway
                                    :name (n5 / name :op1 "Akt"~e.23)))
                        :ARG2~e.27 (a3 / activate-01~e.29
                              :ARG1 (c2 / cell
                                    :name (n6 / name :op1 "MDSC")))))))

# ::tok BAY @-@ 117802 significantly blocked MMP13 expression but had a limited effect on the upregulation of MMP2 and MMP14 , whereas rapamycin eliminated the expression of all MMPs .
# ::alignments 0-1.1.1.1.1.1 2-1.1.1.1.1.1 3-1.1.1.3 3-1.1.1.3.r 4-1.1.1 5-1.1.1.2.1.1.1 6-1.1.1.2 7-1.1 10-1.1.2.3 11-1.1.2 12-1.1.2.2.r 14-1.1.2.2 15-1.1.2.2.1.r 16-1.1.2.2.1.1.1.1 17-1.1.2.2.1 18-1.1.2.2.1.2.1.1 20-1 20-1.1 20-1.1.r 21-1.2.1 22-1.2 24-1.2.2 25-1.2.2.1.r 26-1.2.2.1.2
# ::id bel_pmid_2254_4933_41050
(c / contrast-01~e.20
      :ARG1~e.20 (c2 / contrast-01~e.7,20
            :ARG1 (b / block-01~e.4
                  :ARG0 (m / molecular-physical-entity
                        :name (n3 / name :op1 "BAY-117802"~e.0,2))
                  :ARG1 (e4 / express-03~e.6
                        :ARG2 (p2 / protein
                              :name (n2 / name :op1 "MMP13"~e.5)))
                  :manner~e.3 (s / significant~e.3))
            :ARG2 (a3 / affect-01~e.11
                  :ARG0 m
                  :ARG1~e.12 (u / upregulate-01~e.14
                        :ARG1~e.15 (a2 / and~e.17
                              :op1 (p3 / protein
                                    :name (n4 / name :op1 "MMP2"~e.16))
                              :op2 (p4 / protein
                                    :name (n5 / name :op1 "MMP14"~e.18))))
                  :ARG1-of (l / limit-01~e.10)))
      :ARG2 (e / eliminate-01~e.22
            :ARG0 (r / rapamycin~e.21)
            :ARG1 (e2 / express-03~e.24
                  :ARG2~e.25 (p / protein
                        :name (n / name :op1 "MMP")
                        :mod (a / all~e.26)))))

# ::tok TGF @-@ p1 @-@ induced miR @-@ 494 was involved in the negative regulation of PTEN expression .
# ::alignments 0-1.1.2.1.1.1 2-1.1.2.1.1.1 4-1.1.2 5-1.1.1.1 7-1.1.1.1 9-1 15-1.2.1.1.1.1 16-1.2.1
# ::id bel_pmid_2254_4933_41052
(i / involve-01~e.9
      :ARG1 (r / rna
            :name (n / name :op1 "miR-494"~e.5,7)
            :ARG1-of (i2 / induce-01~e.4
                  :ARG0 (p / protein
                        :name (n2 / name :op1 "TGF-p1"~e.0,2))))
      :ARG2 (d / downregulate-01
            :ARG1 (e / express-03~e.16
                  :ARG2 (p2 / protein
                        :name (n3 / name :op1 "PTEN"~e.15)))))

# ::tok Transcriptional reprogramming of tumors via DmiR @-@ 580 , 588 or 190 over @-@ expression resulted in downregulation of pro @-@ angiogenic factors such as TIMP @-@ 3 , bFGF and TGFalpha .
# ::alignments 3-1.1.1 4-1.1.3.r 5-1.1.3.1.1.1.1 5-1.1.3.1.2.1.1 5-1.1.3.1.3.1.1 7-1.1.3.1.1.1.1 9-1.1.3.1.2.1.1 11-1.1.3.1.3.1.1 15-1 16-1.2.r 17-1.2 18-1.2.1.r 19-1.2.1.1 22-1.2.1 23-1.2.1.2.r 24-1.2.1.2.r 25-1.2.1.2.1.1.1 27-1.2.1.2.1.1.1 29-1.2.1.2.2.1.1 30-1.2.1.2 31-1.2.1.2.3.1.1
# ::id bel_pmid_2295_2847_42202
(r / result-01~e.15
      :ARG1 (r2 / reprogram-00
            :ARG1 (t2 / tumor~e.3)
            :mod (t / transcribe-01)
            :path~e.4 (o / overexpress-00
                  :ARG1 (a2 / and
                        :op1 (r3 / rna
                              :name (n4 / name :op1 "DmiR-580"~e.5,7))
                        :op2 (r4 / rna
                              :name (n5 / name :op1 "DmiR-588"~e.5,9))
                        :op3 (r5 / rna
                              :name (n6 / name :op1 "DmiR-190"~e.5,11)))))
      :ARG2~e.16 (d / downregulate-01~e.17
            :ARG1~e.18 (f / factor~e.22
                  :ARG0-of (f2 / favor-01~e.19
                        :ARG1 (a3 / angiogenesis))
                  :example~e.23,24 (a / and~e.30
                        :op1 (p / protein
                              :name (n / name :op1 "TIMP-3"~e.25,27))
                        :op2 (p3 / protein
                              :name (n2 / name :op1 "bFGF"~e.29))
                        :op3 (p4 / protein
                              :name (n3 / name :op1 "TGFalpha"~e.31))))))

# ::tok Figure 2D shows the high rate of proliferative Ki67+ cells in a representative dormant miR @-@ 588 expressing A @-@ GBM tumor at day 113 post injection .
# ::alignments 0-1.1 1-1.1.1 2-1 4-1.2.1 5-1.2 8-1.2.2.1.1 9-1.2.2 9-1.3.2.1 12-1.3.4 13-1.3.3 14-1.3.1.1 16-1.3.1.1 17-1.3.2 18-1.3.2.1.1.1 20-1.3.2.1.1.1 23-1.3.2.2.2.2 24-1.3.2.2.2.1 26-1.3.2.2.1
# ::id bel_pmid_2295_2847_42206
(s / show-01~e.2
      :ARG0 (f / figure~e.0 :mod "2D"~e.1)
      :ARG1 (r / rate~e.5
            :mod (h / high~e.4)
            :degree-of (c / cell~e.9
                  :name (n / name :op1 "Ki67+"~e.8)))
      :location (r2 / rna
            :name (n3 / name :op1 "miR-588"~e.14,16)
            :ARG1-of (e / express-03~e.17
                  :ARG2 (c2 / cell~e.9
                        :name (n2 / name :op1 "A-GBM"~e.18,20))
                  :time (a / after
                        :op1 (i / inject-01~e.26)
                        :quant (t2 / temporal-quantity
                              :quant "113"~e.24
                              :unit (d2 / day~e.23))))
            :mod (d / dormant~e.13)
            :ARG0-of (r3 / represent-01~e.12)))

# ::tok We found that antiangiogenic and dormancy promoting genes , Angiomotin ( AMOT @-@ 1 ) and Eph receptor A5 ( EphA5 ) , were both upregulated in all DmiR expressing A @-@ GBM tumors as compared to the GFP @-@ vector @- control A @-@ GBM cells ( Figure 4 ) .
# ::alignments 0-1.1 1-1 3-1.2.1.1.2.1 4-1.2.1 5-1.2.1.2.2.1 6-1.2.1.1.2 6-1.2.1.2.2 7-1.2.1.1 7-1.2.1.2 9-1.2.1.1.1.1 9-1.2.1.2.1.1 15-1.2.1 16-1.2.1.3.1.1 17-1.2.1.3.1.2 18-1.2.1.3.1.3 27-1.2.2.2 28-1.2.2.3.1.1.1 29-1.2.2.3 30-1.2.2.1.1 32-1.2.2.1.1 35-1.2.3.r 38-1.2.3.1.1 40-1.2.3.1.1 42-1.2.3.1.1 43-1.2.2.1.1 43-1.2.3.1.2 45-1.2.2.1.1 45-1.2.3.1.2 46-1.2.2 46-1.2.3 48-1.3.1 49-1.3.1.1
# ::id bel_pmid_2295_2847_42214
(f / find-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1 (u / upregulate-01
            :ARG1 (a / and~e.4,15
                  :op1 (g / gene~e.7
                        :name (n / name :op1 "Angiomotin"~e.9)
                        :ARG0-of (p2 / promote-02~e.6
                              :ARG1 (a2 / antiangiogenic~e.3)))
                  :op2 (g2 / gene~e.7
                        :name (n2 / name :op1 "Angiomotin"~e.9)
                        :ARG0-of (p3 / promote-02~e.6
                              :ARG1 (d3 / dormancy~e.5)))
                  :op3 (p / protein
                        :name (n3 / name
                              :op1 "Eph"~e.16
                              :op2 "receptor"~e.17
                              :op3 "A5"~e.18)))
            :location (c2 / cell~e.46
                  :name (n4 / name :op1 "A-GBM"~e.30,32,43,45)
                  :mod (a3 / all~e.27)
                  :ARG3-of (e / express-03~e.29
                        :ARG1 (r / rna
                              :name (n5 / name :op1 "Dmir"~e.28))))
            :compared-to~e.35 (c / cell~e.46
                  :name (n6 / name :op1 "GFP-vector-control"~e.38,40,42 :op2 "A-GBM"~e.43,45)))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.48 :mod "4"~e.49)))

# ::tok In contrast , genes involved in pro @-@ angiogenic signaling , including tissue inhibitor of metalloprotei @-@ nases 3 ( TIMP @-@ 3 ) , hypoxia @-@ induced factor 1 alpha ( HIF @-@ 1 @-@ alpha ) , basic fibroblast growth factor ( bFGF , FGF2 ) , and the K @-@ ras tumor oncogene , were consistently downregulated in DmiR expressing A @-@ GBM .
# ::alignments 1-1 3-1.1.1 4-1.1.1.1 5-1.1.1.1.1.r 6-1.1.1.1.1.1 9-1.1.1.1.1 11-1.1.1.2 12-1.1.1.2.1.1.1.1 13-1.1.1.2.1.1.1.2 14-1.1.1.2.1.1.1.3 15-1.1.1.2.1.1.1.4 18-1.1.1.2.1.1.1.5 22-1.1.1.2.1.1.1.5 25-1.1.1.2.1.2.1.1 27-1.1.1.2.1.2.1.1 28-1.1.1.2.1.2.1.2 29-1.1.1.2.1.2.1.3 34-1.1.1.2.1.2.1.3 39-1.1.1.2.1.3.1.1 40-1.1.1.2.1.3.1.2 41-1.1.1.2.1.3.1.3 42-1.1.1.2.1.3.1.4 49-1.1.1.2.1 51-1.1.1.2.1.4.1.1.1 53-1.1.1.2.1.4.1.1.1 54-1.1.1.2.1.4.2 55-1.1.1.2.1.4 58-1.1.3 58-1.1.3.r 61-1.1.2.2.1.1.1 62-1.1.2.2 63-1.1.2.1.1 65-1.1.2.1.1
# ::id bel_pmid_2295_2847_42216
(c / contrast-01~e.1
      :ARG2 (d / downregulate-01
            :ARG1 (g2 / gene~e.3
                  :ARG1-of (i / involve-01~e.4
                        :ARG2~e.5 (s / signal-07~e.9
                              :ARG0-of (f / favor-01~e.6
                                    :ARG1 (a2 / angiogenesis))))
                  :ARG2-of (i2 / include-91~e.11
                        :ARG1 (a / and~e.49
                              :op1 (p / protein
                                    :name (n / name
                                          :op1 "tissue"~e.12
                                          :op2 "inhibitor"~e.13
                                          :op3 "of"~e.14
                                          :op4 "metalloprotei-nase"~e.15
                                          :op5 "3"~e.18,22))
                              :op2 (p3 / protein
                                    :name (n2 / name
                                          :op1 "hypoxia-induced"~e.25,27
                                          :op2 "factor"~e.28
                                          :op3 "1"~e.29,34))
                              :op3 (p4 / protein
                                    :name (n5 / name
                                          :op1 "basic"~e.39
                                          :op2 "fibroblast"~e.40
                                          :op3 "growth"~e.41
                                          :op4 "factor"~e.42))
                              :op4 (o / oncogene~e.55
                                    :mod (e / enzyme
                                          :name (n6 / name :op1 "K-ras"~e.51,53))
                                    :mod (t / tumor~e.54)))))
            :ARG2 (c3 / cell
                  :name (n3 / name :op1 "A-GBM"~e.63,65)
                  :ARG3-of (e2 / express-03~e.62
                        :ARG1 (g / gene
                              :name (n4 / name :op1 "DmiR"~e.61))))
            :manner~e.58 (c2 / consistent~e.58)))

# ::tok Importantly , we found Bv8 also known as prokineticin 2 ( Prok2 ) to be markedly downregulated in all three DmiR expressing A @-@ GBM ( Figure 5A ) .
# ::alignments 0-1.4 0-1.4.r 2-1.1 3-1 4-1.2.1.1.1 5-1.2.1.2.2 6-1.2.1 6-1.2.1.2 6-1.2.1.2.1.1.r 6-1.2.1.2.r 7-1.2.1.2.1.1.r 8-1.2.1.2.1.1.1 9-1.2.1.2.1.1.2 11-1.2.1.2.1.2.1.1.1 15-1.2.2 15-1.2.2.r 18-1.2.3.3 19-1.2.3.1 20-1.2.3.2.1 21-1.2.3.4 22-1.2.3.4.1.1.1 24-1.2.3.4.1.1.1 26-1.3.1 27-1.3.1.1
# ::id bel_pmid_2295_2847_42218
(f / find-01~e.3
      :ARG0 (w / we~e.2)
      :ARG1 (d2 / downregulate-01
            :ARG1 (p / protein~e.6
                  :name (n / name :op1 "Bv8"~e.4)
                  :ARG1-of~e.6 (k / know-02~e.6
                        :ARG2 (p2 / protein
                              :name~e.6,7 (n5 / name :op1 "prokineticin"~e.8 :op2 "2"~e.9)
                              :ARG1-of (m / mean-01
                                    :ARG2 (p3 / protein
                                          :name (n2 / name :op1 "Prok2"~e.11))))
                        :mod (a2 / also~e.5)))
            :manner~e.15 (m2 / marked~e.15)
            :location (r / rna
                  :quant "3"~e.19
                  :name (n3 / name :op1 "DmiR"~e.20)
                  :mod (a / all~e.18)
                  :ARG1-of (e / express-03~e.21
                        :ARG2 (c / cell
                              :name (n4 / name :op1 "A-GBM"~e.22,24)))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure~e.26 :mod "5A"~e.27))
      :manner~e.0 (i / important~e.0))

# ::tok Over @-@ expression of miR @-@ 580 , miR @-@ 588 and miR @-@ 190 in fast @-@ growing angiogenic glioblastoma .
# ::alignments 4-1.1.1.1.1 4-1.1.2.1.1 4-1.1.3.1.1 6-1.1.1.1.1 8-1.1.1.1.1 8-1.1.2.1.1 8-1.1.3.1.1 10-1.1.2.1.1 11-1.1 12-1.1.1.1.1 12-1.1.2.1.1 12-1.1.3.1.1 14-1.1.3.1.1 16-1.2.2.1 18-1.2.2 19-1.2.1 20-1.2
# ::id bel_pmid_2295_2847_42226
(o / overexpress-00
      :ARG2 (a / and~e.11
            :op1 (r / rna
                  :name (n / name :op1 "miR-580"~e.4,6,8,12))
            :op2 (r2 / rna
                  :name (n2 / name :op1 "miR-588"~e.4,8,10,12))
            :op3 (r3 / rna
                  :name (n3 / name :op1 "miR-190"~e.4,8,12,14)))
      :ARG3 (g / glioblastoma~e.20
            :mod (a2 / angiogenic~e.19)
            :ARG1-of (g2 / grow-01~e.18
                  :ARG2 (f / fast~e.16))))

# ::tok In contrast , VEGF plugs in Pld1~-~ mice exhibited almost no vascularization ( Fig . 2 , A and B ) .
# ::alignments 1-1 3-1.1.1.1.1.1 4-1.1.1 7-1.1.1.2 8-1.1 9-1.1.2.1 10-1.1.2.1.1 10-1.1.2.1.1.r 18-1.2.1
# ::id bel_pmid_2313_1846_42236
(c / contrast-01~e.1
      :ARG2 (e / exhibit-01~e.8
            :ARG0 (p / plug~e.4
                  :poss (p2 / protein
                        :name (n / name :op1 "VEGF"~e.3))
                  :location (m / mouse~e.7
                        :mod (g / gene
                              :name (n2 / name :op1 "Pld1")
                              :ARG2-of (m2 / mutate-01 :mod "-/-"))))
            :ARG1 (v / vascularize-00
                  :mod (a2 / almost~e.9 :polarity~e.10 "-"~e.10)))
      :ARG1-of (d / describe-01
            :ARG0 (a / and~e.18
                  :op1 (f / figure :mod "2A")
                  :op2 (f2 / figure :mod "2B"))))

# ::tok PLD1 deficiency reduced basal phosphorylation of Ser473 in Akt and prevented VEGF @-@ induced phosphorylation of Akt at Ser473 ( Fig . 3 , C and D ) .
# ::alignments 0-1.1.1.1.1.1 2-1.1 3-1.1.2.2 4-1.1.2 5-1.1.2.1.r 6-1.1.2.1.1.1 8-1.1.2.1.2.1.1 9-1 9-1.3.1 10-1.2 11-1.2.2.2.1.1.1 13-1.2.2.2 14-1.2.2 15-1.2.2.1.r 16-1.2.2.1 18-1.1.2.1.1.1 25-1 25-1.3.1
# ::id bel_pmid_2313_1846_42240
(a / and~e.9,25
      :op1 (r / reduce-01~e.2
            :ARG0 (l / lack-01
                  :ARG1 (p / protein
                        :name (n / name :op1 "PLD1"~e.0)))
            :ARG1 (p3 / phosphorylate-01~e.4
                  :ARG1~e.5 (a3 / amino-acid
                        :name (n2 / name :op1 "Ser473"~e.6,18)
                        :part-of (e / enzyme
                              :name (n4 / name :op1 "Akt"~e.8)))
                  :mod (b / basal~e.3)))
      :op2 (p2 / prevent-01~e.10
            :ARG0 l
            :ARG1 (p5 / phosphorylate-01~e.14
                  :ARG1~e.15 e~e.16
                  :ARG1-of (i / induce-01~e.13
                        :ARG0 (p6 / protein
                              :name (n3 / name :op1 "VEGF"~e.11)))))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and~e.9,25
                  :op1 (f / figure :mod "3C")
                  :op2 (f2 / figure :mod "3D"))))

# ::tok Pldl-- endothelial cells similarly exhibited a 50 % reduction in basal phosphorylation of ERK1 @/@ 2 but otherwise exhibited similar kinetics to wild @-@ type cells for VEGF @-@ induced phosphorylation of ERK1 @/@ 2 .
# ::alignments 1-1.1.1.1 2-1.1.1 3-1.1.3 4-1.1 6-1.1.2.2.1 7-1.1.2.2 8-1.1.2 9-1.1.2.1.r 10-1.1.2.1.2 11-1.1.2.1 12-1.1.2.1.1.r 13-1.1.2.1.1.1.1 15-1.1.2.1.1.1.1 16-1 18-1.1 18-1.2 19-1.1.3 19-1.2.1.1.1 20-1.2.1.1 21-1.2.1.r 22-1.2.1.2.1 24-1.2.1.2.1 25-1.2.1.2 27-1.2.1.3.2.1.1.1 29-1.2.1.3.2 30-1.2.1.3 31-1.2.1.3.1.r 32-1.2.1.3.1 33-1.2.1.3.1 34-1.2.1.3.1
# ::id bel_pmid_2313_1846_42242
(c / contrast-01~e.16
      :ARG1 (e / exhibit-01~e.4,18
            :ARG0 (c2 / cell~e.2
                  :mod (e2 / endothelium~e.1)
                  :mod (p3 / protein
                        :name (n / name :op1 "Pldl")
                        :ARG2-of (m / mutate-01 :mod "-/-")))
            :ARG1 (r2 / reduce-01~e.8
                  :ARG1~e.9 (p2 / phosphorylate-01~e.11
                        :ARG1~e.12 (e4 / enzyme
                              :name (n2 / name :op1 "ERK1/2"~e.13,15))
                        :mod (b / basal~e.10))
                  :ARG2 (p / percentage-entity~e.7 :value "50"~e.6))
            :manner (r / resemble-01~e.3,19))
      :ARG2 (e3 / exhibit-01~e.18
            :ARG1~e.21 (a / and
                  :op1 (k / kinetics~e.20
                        :mod (r3 / resemble-01~e.19))
                  :op2 (c3 / cell~e.25
                        :mod (w / wild-type~e.22,24))
                  :purpose (p5 / phosphorylate-01~e.30
                        :ARG1~e.31 e4~e.32,33,34
                        :ARG1-of (i / induce-01~e.29
                              :ARG0 (p6 / protein
                                    :name (n3 / name :op1 "VEGF"~e.27)))))))

# ::tok Histological and quantitative analyses of the tumors revealed a 79 % decrease in microvessels in the tumors that formed in FIPI @-@ treated mice ( Fig . 4C ) .
# ::alignments 0-1.1.1.2 1-1.1 2-1.1.2.2 3-1.1.1 3-1.1.2 4-1.1.1.1.r 6-1.1.1.1 7-1 9-1.2.2.1 10-1.2.2 11-1.2 16-1.2.1.1 18-1.2.1.1.1 19-1.2.1.1.1.1.r 20-1.2.1.1.1.1.1.1.1.1 22-1.2.1.1.1.1.1 23-1.2.1.1.1.1 27-1.3.1.1
# ::id bel_pmid_2313_1846_42248
(r / reveal-01~e.7
      :ARG0 (a / and~e.1
            :op1 (a2 / analyze-01~e.3
                  :ARG1~e.4 (t / tumor~e.6)
                  :mod (h / histology~e.0))
            :op2 (a3 / analyze-01~e.3
                  :ARG1 t
                  :mod (q / quantitative~e.2)))
      :ARG1 (d2 / decrease-01~e.11
            :ARG1 (m / microvessel
                  :part-of (t2 / tumor~e.16
                        :ARG0-of (f2 / form-01~e.18
                              :location~e.19 (m2 / mouse~e.23
                                    :ARG1-of (t3 / treat-04~e.22
                                          :ARG2 (s / small-molecule
                                                :name (n / name :op1 "FIPI"~e.20)))))))
            :ARG2 (p / percentage-entity~e.10 :value "79"~e.9))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4C"~e.27)))

# ::tok Engagement of Gi @- and Gq @-@ protein @-@ coupled ETB receptors by ET @-@ 1 led to phosphorylation of ERK1 @/@ 2 , p38 MAPK , and JNK1 @/@ 2 and then activated transcription factor NF-?B .
# ::alignments 0-1.1.1 1-1.1.1.2.r 2-1.1.1.2.2.1.1.1.1 4-1.1.1.2.2.1 5-1.1.1.2.2.1.2.1.1 7-1.1.1.1 7-1.1.1.2.2.1.1 7-1.1.1.2.2.1.2 9-1.1.1.2.2 10-1.1.1.2.1.1 11-1.1.1.2 13-1.1.1.1.1.1 13-1.1.2.1 15-1.1.1.1.1.1 16-1.1 17-1.1.2.r 18-1.1.2 19-1.1.2.1.r 20-1.1.2.1.1.1.1 24-1.1.2.1.3.1.1 25-1.1.2.1.3.1.2 28-1.1.2.1.4.1.1 31-1 32-1.2.3 33-1.2 34-1.2.2.2.1 35-1.2.2.2
# ::id bel_pmid_2334_3326_26540
(a4 / and~e.31
      :op1 (l / lead-03~e.16
            :ARG0 (e / engage-01~e.0
                  :ARG0 (p / protein~e.7
                        :name (n / name :op1 "ET-1"~e.13,15))
                  :ARG1~e.1 (r / receptor~e.11
                        :name (n2 / name :op1 "ETB"~e.10)
                        :ARG1-of (c / couple-01~e.9
                              :ARG2 (a / and~e.4
                                    :op1 (p2 / protein~e.7
                                          :name (n3 / name :op1 "Gi"~e.2))
                                    :op2 (p3 / protein~e.7
                                          :name (n4 / name :op1 "Gq"~e.5))))))
            :ARG2~e.17 (p4 / phosphorylate-01~e.18
                  :ARG1~e.19 (a2 / and~e.13
                        :op1 (e2 / enzyme
                              :name (n5 / name :op1 "ERK1"~e.20))
                        :op2 (e3 / enzyme
                              :name (n6 / name :op1 "ERK2"))
                        :op3 (e4 / enzyme
                              :name (n8 / name :op1 "p38"~e.24 :op2 "MAPK"~e.25))
                        :op4 (e6 / enzyme
                              :name (n9 / name :op1 "JNK1"~e.28))
                        :op5 (e7 / enzyme
                              :name (n10 / name :op1 "JNK2")))))
      :op2 (a3 / activate-01~e.33
            :ARG0 e
            :ARG1 (m / macro-molecular-complex
                  :name (n11 / name :op1 "NF-kappaB")
                  :mod (f / factor~e.35
                        :ARG0-of (t2 / transcribe-01~e.34)))
            :time (t / then~e.32)))

# ::tok Engagement of Gi @- and Gq @-@ protein @-@ coupled ETB receptors by ET @-@ 1 led to phosphorylation of ERK1 @/@ 2 , p38 MAPK , and JNK1 @/@ 2 and then activated transcription factor NF-?B .
# ::alignments 0-1.1.1 1-1.1.1.3.r 2-1.1.1.3.1.1.1.1 4-1.1.1.3.1 5-1.1.1.3.1.2.1.1 7-1.1.1.1 7-1.1.1.3.1.1 7-1.1.1.3.1.2 9-1.1.1.3 10-1.1.1.2.1.1 11-1.1.1.2 13-1.1.1.1.1.1 13-1.1.2.1 15-1.1.1.1.1.1 16-1.1 17-1.1.2.r 18-1.1.2 19-1.1.2.1.r 20-1.1.2.1.1.1.1 24-1.1.2.1.3.1.1 25-1.1.2.1.3.1.2 28-1.1.2.1.4.1.1 31-1 32-1.2.3 33-1.2 34-1.2.2.2.1 35-1.2.2.2
# ::id bel_pmid_2334_3326_38068
(a4 / and~e.31
      :op1 (l / lead-03~e.16
            :ARG0 (e / engage-01~e.0
                  :ARG0 (p / protein~e.7
                        :name (n / name :op1 "ET-1"~e.13,15))
                  :ARG1 (r / receptor~e.11
                        :name (n2 / name :op1 "ETB"~e.10))
                  :ARG1-of~e.1 (c / couple-01~e.9
                        :ARG2 (a / and~e.4
                              :op1 (p2 / protein~e.7
                                    :name (n3 / name :op1 "Gi"~e.2))
                              :op2 (p3 / protein~e.7
                                    :name (n4 / name :op1 "Gq"~e.5)))))
            :ARG2~e.17 (p4 / phosphorylate-01~e.18
                  :ARG1~e.19 (a2 / and~e.13
                        :op1 (e2 / enzyme
                              :name (n5 / name :op1 "ERK1"~e.20))
                        :op2 (e3 / enzyme
                              :name (n6 / name :op1 "ERK2"))
                        :op3 (e4 / enzyme
                              :name (n7 / name :op1 "p38"~e.24 :op2 "MAPK"~e.25))
                        :op4 (e5 / enzyme
                              :name (n8 / name :op1 "JNK1"~e.28))
                        :op5 (e6 / enzyme
                              :name (n9 / name :op1 "JNK2")))))
      :op2 (a3 / activate-01~e.33
            :ARG0 e
            :ARG1 (m / macro-molecular-complex
                  :name (n10 / name :op1 "NF-kappaB")
                  :mod (f / factor~e.35
                        :ARG0-of (t2 / transcribe-01~e.34)))
            :time (t / then~e.32)))

# ::tok Against this background , we conducted in vitro phosphorylation studies of the phosphorylation of in @-@ tegrin avp3 dimer with activated ERK1 and found phosphorylation of the dimer ( Fig . 3A ) that was inhibited by the ERK inhibitor , FR180204 .
# ::alignments 1-1.1.1 2-1.1 4-1.2.1.1 5-1.2.1 6-1.2.1.3 7-1.2.1.3 8-1.2.1.2.1 9-1.2.1.2 12-1.2.1.2.1 14-1.2.1.3 18-1.2.1.2.1.1 19-1.2.1.2.1.2.r 20-1.2.1.2.1.2.2 21-1.2.1.2.1.2.1.1 22-1.2 23-1.2.2 24-1.2.1.2.1 27-1.2.1.2.1.1 31-1.2.2.3.1.1 35-1.2.2.2 35-1.2.2.2.1.2 36-1.2.2.2.1.r 38-1.2.2.2.1.2.1.1.1 39-1.2.2.2.1.2 41-1.2.2.2.1.1.1
# ::id bel_pmid_2364_0055_42272
(c2 / contrast-01
      :ARG1 (b / background~e.2
            :mod (t / this~e.1))
      :ARG2 (a / and~e.22
            :op1 (c / conduct-01~e.5
                  :ARG0 (w / we~e.4)
                  :ARG1 (s / study-01~e.9
                        :ARG1 (p / phosphorylate-01~e.8,12,24
                              :ARG1 (d / dimer~e.18,27
                                    :name (n / name :op1 "integrin" :op2 "αVβ3"))
                              :ARG2~e.19 (e / enzyme
                                    :name (n3 / name :op1 "ERK1"~e.21)
                                    :ARG1-of (a2 / activate-01~e.20))))
                  :manner (i / in-vitro~e.6,7,14))
            :op2 (f / find-01~e.23
                  :ARG0 w
                  :ARG1 (i2 / inhibit-01~e.35
                        :ARG0~e.36 (m / molecular-physical-entity
                              :name (n4 / name :op1 "FR180204"~e.41)
                              :ARG0-of (i3 / inhibit-01~e.35,39
                                    :ARG1 (e2 / enzyme
                                          :name (n2 / name :op1 "ERK"~e.38))))
                        :ARG1 p)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f2 / figure :mod "3A"~e.31)))))

# ::tok Integrin av bound to the COX @-@ 2 promoter in both OVCAR @-@ 3 and H522 cells in response to T4 ( Fig . 4A )
# ::alignments 0-1.1.1.1 1-1.1.1.2 2-1 3-1.2.r 5-1.2.1.1.1.1 7-1.2.1.1.1.1 11-1.3.1.1.1 13-1.3.1.1.1 14-1.3 15-1.3.2.1.1 16-1.3.1 16-1.3.2 17-1.4.r 18-1.4 19-1.4.1.r 20-1.4.1.1.1 24-1.5.1.1
# ::id bel_pmid_2364_0055_42278
(b / bind-01~e.2
      :ARG1 (p / protein
            :name (n / name :op1 "integrin"~e.0 :op2 "av"~e.1))
      :ARG2~e.3 (m / molecular-physical-entity
            :ARG0-of (p2 / promote-02
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "COX-2"~e.5,7))))
      :location (a / and~e.14
            :op1 (c / cell-line~e.16
                  :name (n3 / name :op1 "OVCAR-3"~e.11,13))
            :op2 (c2 / cell-line~e.16
                  :name (n4 / name :op1 "H522"~e.15)))
      :ARG2-of~e.17 (r / respond-01~e.18
            :ARG1~e.19 (s / small-molecule
                  :name (n5 / name :op1 "T4"~e.20)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4A"~e.24)))

# ::tok These results suggest that although T4 increased complex formation between integrin av and NCoR/SMRT , the association between NCoR @/@ SMRT and DNA was unchanged .
# ::alignments 0-1.1.2 1-1.1 1-1.1.1 1-1.1.1.r 2-1 4-1.2 5-1.2.2.1.1.1 6-1.2.2 7-1.2.2.2.1 8-1.2.2.2 10-1.2.2.2.1.1.1.1 11-1.2.2.2.1.1.1.2 13-1.2.2.2.1.2.1.1 16-1.2.1.2 18-1.2.1.2.1 19-1.2.1.2.1 20-1.2.1.2.1 22-1.2.1.2.2 24-1.2.1.1
# ::id bel_pmid_2364_0055_42282
(s / suggest-01~e.2
      :ARG0 (t / thing~e.1
            :ARG2-of~e.1 (r / result-01~e.1)
            :mod (t2 / this~e.0))
      :ARG1 (h / have-concession-91~e.4
            :ARG1 (c / change-01
                  :polarity "-"~e.24
                  :ARG1 (a / associate-01~e.16
                        :ARG1 m~e.18,19,20
                        :ARG2 (d / DNA~e.22)))
            :ARG2 (i / increase-01~e.6
                  :ARG0 (s2 / small-molecule
                        :name (n / name :op1 "T4"~e.5))
                  :ARG1 (f / form-01~e.8
                        :ARG1 (m2 / macro-molecular-complex~e.7
                              :part (p / protein
                                    :name (n2 / name :op1 "integrin"~e.10 :op2 "av"~e.11))
                              :part (m / macro-molecular-complex
                                    :name (n3 / name :op1 "NCoR/SMRT"~e.13)))))))

# ::tok The transcription of COX @-@ 2 , ERa , HIF @-@ la , and TR $ 1 was increased in thyroid hormone @-@ treated cells ( Fig . 4B ) .
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.1.1.1 5-1.1.1.1.1.1 9-1.1.1.3.1.1 13-1.1.1 18-1 19-1.2.r 20-1.2.1.1.1 21-1.2.1.1 23-1.2.1 24-1.2 28-1.3.1.1
# ::id bel_pmid_2364_0055_42284
(i / increase-01~e.18
      :ARG1 (t / transcribe-01~e.1
            :ARG1~e.2 (a / and~e.13
                  :op1 (e / enzyme
                        :name (n / name :op1 "COX-2"~e.3,5))
                  :op2 (p / protein
                        :name (n2 / name :op1 "ERalpha"))
                  :op3 (p2 / protein
                        :name (n3 / name :op1 "HIF-1alpha"~e.9))
                  :op4 (p3 / protein
                        :name (n4 / name :op1 "TRbeta1"))))
      :location~e.19 (c / cell~e.24
            :ARG1-of (t2 / treat-04~e.23
                  :ARG2 (h / hormone~e.21
                        :source (t3 / thyroid~e.20))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "4B"~e.28)))

# ::tok Abundant autophagosomes in K @-@ rasG12D/+;atg7+/+ but not in K @-@ rasG12D/+;atg7 -/- tumors were confirmed by electron microscopy ( Fig . 2B ) .
# ::alignments 0-1.1.2.2 3-1.1.3.1.1.1.1 6-1 7-1.2.1 7-1.2.1.r 9-1.2.4.1.1 12-1.2.4.1.2.2.1 13-1.1.3 13-1.2.4 15-1.1 15-1.2 16-1.1.1.r 17-1.1.1.1 18-1.1.1 22-1.3.1.1
# ::id bel_pmid_2382_4538_18804
(c3 / contrast-01~e.6
      :ARG1 (c / confirm-01~e.15
            :ARG0~e.16 (m4 / microscopy~e.18
                  :mod (e2 / electron~e.17))
            :ARG1 (s / small-molecule
                  :name (n / name :op1 "autophagosome")
                  :mod (a / abundant~e.0))
            :location (t / tumor~e.13
                  :mod (s2 / slash
                        :op1 (e / enzyme
                              :name (n2 / name :op1 "K-ras"~e.3)
                              :ARG2-of (m / mutate-01 :value "G12D")
                              :mod (w / wild-type))
                        :op2 (p2 / protein
                              :name (n3 / name :op1 "atg7")
                              :ARG2-of (m2 / mutate-01 :mod "+/+")))))
      :ARG2 (c4 / confirm-01~e.15
            :polarity~e.7 "-"~e.7
            :ARG0 m4
            :ARG1 s
            :location (t2 / tumor~e.13
                  :mod (s3 / slash
                        :op1 e~e.9
                        :op2 (p3 / protein
                              :name (n4 / name :op1 "atg7")
                              :ARG2-of (m3 / mutate-01 :mod "-/-"~e.12)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2B"~e.22)))

# ::tok Reduction of atg7 @-@ deficient tumor burden was coincident with reduced proliferation ( Ki67 ) and decreased levels of phospho @-@ MEK1 @/@ 2 ( P @-@ MEK1 @/@ 2 ) and P @-@ ERK1 @/@ 2 and p53 and p21 induction , compared with wild @-@ type tumors ( Fig . 1I ; Supplemental Figs . S4A–C , S5A–C ) , suggesting that inhibition of tumor cell proliferation upon atg7 deletion is the main cause of reduced tumor burden .
# ::alignments 0-1.1.1 2-1.1.1.1.1.1.1.1.1 5-1.3.1.2.1 6-1.3.1.2 10-1.1.2.1.1 11-1.1.2.1 13-1.1.2.1.2.1.1.1 15-1.1.2 16-1.1.2.2.1 17-1.1.2.2 21-1.1.2.2.2.1.1.1 27-1.1.2.2.2.1.1.1 34-1.1.2.2.2.3.1.1 37-1.1.2 38-1.1.2.3.1.1.1.1 39-1.1.2.3.1 40-1.1.2.3.1.2.1.1 41-1.1.2.3 43-1.1.2.4.r 45-1.1.2.4.1 47-1.1.2.4.1 48-1.1.2.4 52-1.2.1.1.1 54-1.2.1.2.1 62-1.3 64-1.3.1.1 66-1.1.1.1.1 67-1.3.1.1.2.1 68-1.3.1.1.2 70-1.3.1.1.1.1 71-1.3.1.1.1 74-1.3.1.3 75-1.3.1 77-1.1.1 77-1.3.1.2.2 78-1.1.1.1.1 79-1.1.1.1
# ::id bel_pmid_2382_4538_18808
(c / coincide-01
      :ARG1 (a5 / and
            :op1 (r / reduce-01~e.0,77
                  :ARG1 (b / burden-01~e.79
                        :ARG2 (t / tumor~e.66,78
                              :ARG0-of (l / lack-01
                                    :ARG1 (p / protein
                                          :name (n / name :op1 "atg7"~e.2))))))
            :op2 (a / and~e.15,37
                  :op1 (p2 / proliferate-01~e.11
                        :ARG1-of (r2 / reduce-01~e.10)
                        :ARG1-of (m2 / measure-01
                              :ARG2 (p3 / protein
                                    :name (n2 / name :op1 "Ki67"~e.13))))
                  :op2 (l2 / level~e.17
                        :ARG1-of (d / decrease-01~e.16)
                        :quant-of (a2 / and
                              :op1 (e / enzyme
                                    :name (n3 / name :op1 "MEK1"~e.21,27))
                              :op2 (e2 / enzyme
                                    :name (n4 / name :op1 "MEK2"))
                              :op3 (e3 / enzyme
                                    :name (n5 / name :op1 "ERK1"~e.34))
                              :op4 (e4 / enzyme
                                    :name (n6 / name :op1 "ERK2"))
                              :ARG1-of (p4 / phosphorylate-01)))
                  :op3 (i / induce-01~e.41
                        :ARG1 (a3 / and~e.39
                              :op1 (p5 / protein
                                    :name (n7 / name :op1 "p53"~e.38))
                              :op2 (p6 / protein
                                    :name (n8 / name :op1 "p21"~e.40))))
                  :compared-to~e.43 (t2 / tumor~e.48
                        :mod (w / wild-type~e.45,47))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a4 / and
                  :op1 (f / figure :mod "1I"~e.52)
                  :op2 (f2 / figure
                        :ARG2-of (s / supplement-01~e.54)
                        :mod (v / value-interval :op1 "S4A" :op2 "S4C"))
                  :op3 (f3 / figure
                        :ARG2-of s
                        :mod (v2 / value-interval :op1 "S5A" :op2 "S5C"))))
      :ARG0-of (s2 / suggest-01~e.62
            :ARG1 (c2 / cause-01~e.75
                  :ARG0 (i2 / inhibit-01~e.64
                        :ARG0 (d3 / delete-01~e.71
                              :ARG1 p~e.70)
                        :ARG1 (p7 / proliferate-01~e.68
                              :ARG0 (c3 / cell~e.67
                                    :mod (t3 / tumor~e.5))))
                  :ARG1 (b2 / burden-01~e.6
                        :ARG2 t3
                        :ARG1-of (r3 / reduce-01~e.77))
                  :mod (m / main~e.74))))

# ::tok atg7 deficiency in tumors prevented LC3 @-@ I processing to LC3 @-@ II and caused accumulation of LC3 @-@ I and autophagy substrate p62 in large aggregates apparent at 6 wk that increased throughout tumorigenesis
# ::alignments 0-1.1.1.2.1.1 3-1.1.1.1 4-1.1 5-1.1.2.1.1.1 5-1.1.2.2.1.1 7-1.1.2.1.1.1 8-1.1.2 10-1.1.2.1.1.1 10-1.1.2.2.1.1 12-1.1.2.2.1.1 13-1 14-1.2 15-1.2.2 17-1.1.2.1.1.1 17-1.1.2.2.1.1 19-1.1.2.1.1.1 20-1.2.2.1 21-1.2.2.1.2.3 22-1.2.2.1.2.1.1 23-1.2.2.1.2.2.1.1 24-1.2.2.2.r 25-1.2.2.2.1 26-1.2.2.2 29-1.2.2.2.2.1.2.1 32-1.2.2.2.3 34-1.2.2.2.3.1
# ::id bel_pmid_2382_4538_18812
(a / and~e.13
      :op1 (p2 / prevent-01~e.4
            :ARG0 (l / lack-01
                  :ARG0 (t / tumor~e.3)
                  :ARG1 (p / protein
                        :name (n / name :op1 "atg7"~e.0)))
            :ARG1 (p3 / process-01~e.8
                  :ARG1 (p4 / protein
                        :name (n2 / name :op1 "LC3-I"~e.5,7,10,17,19))
                  :ARG2 (p5 / protein
                        :name (n3 / name :op1 "LC3-II"~e.5,10,12,17))))
      :op2 (c / cause-01~e.14
            :ARG0 l
            :ARG1 (a3 / accumulate-01~e.15
                  :ARG1 (a2 / and~e.20
                        :op1 p4
                        :op2 (m2 / molecular-physical-entity
                              :name (n5 / name :op1 "substrate"~e.22)
                              :consist-of (m / macro-molecular-complex
                                    :name (n4 / name :op1 "p62"~e.23))
                              :mod (a4 / autophagy~e.21)))
                  :ARG1-of~e.24 (a5 / aggregate-01~e.26
                        :mod (l2 / large~e.25)
                        :ARG1-of (a6 / appear-01
                              :time (a7 / after
                                    :op1 a3
                                    :quant (t2 / temporal-quantity
                                          :quant "6"~e.29
                                          :unit (w / week))))
                        :ARG1-of (i / increase-01~e.32
                              :duration (t3 / tumorigenesis~e.34))))))

# ::tok e ALDH1 activity in human PC ( N = 11 ) ; representative flow cytometry plot of human PC tumor gated on live EpCAM+ cells using Aldefluor assay .
# ::alignments 1-1.1.1.1.1 2-1.1 3-1.1.2.r 4-1.1.2.2 5-1.1.2.1.1 9-1.1.2.3.1 12-1.2.2.2 13-1.2.2.1 14-1.2.2 15-1.2 16-1.2.1.r 17-1.2.1.2 18-1.2.1.1.1 20-1.2.1.3 21-1.2.1.3.2.r 22-1.2.1.3.2.2 23-1.2.1.3.2.1.1.1 24-1.2.1.3.2 25-1.2.1.3.1 26-1.2.1.3.1.1.1 27-1.2.1.3.1.1
# ::id bel_pmid_2465_2403_41226
(m / multi-sentence
      :snt1 (a / act-02~e.2
            :ARG0 (e / enzyme
                  :name (n / name :op1 "ALDH1"~e.1))
            :ARG1~e.3 (d / disease
                  :name (n2 / name :op1 "PC"~e.5)
                  :mod (h / human~e.4)
                  :ARG1-of (s / sample-01 :quant "11"~e.9))
            :li e)
      :snt2 (p2 / plot~e.15
            :topic~e.16 (d2 / disease
                  :name (n3 / name :op1 "PC"~e.18)
                  :mod (h2 / human~e.17)
                  :ARG1-of (g / gate-01~e.20
                        :ARG0 (u / use-01~e.25
                              :ARG1 (a2 / assay-00~e.27 :mod "Aldefluor"~e.26))
                        :location~e.21 (c / cell~e.24
                              :mod (p3 / protein
                                    :name (n4 / name :op1 "EpCAM+"~e.23))
                              :ARG0-of (l / live-01~e.22))))
            :mod (c2 / cytometry~e.14
                  :mod (f / flow-01~e.13)
                  :mod (r / represent-01~e.12))))

# ::tok Furthermore , GCSFR-/- mice exhibit a shift in the immune profile of PC tumors from a TH @-@ 2 to TH @-@ 1 immune response , characterized by increased expression of IFN @-@ y , TNF @-@ a and IL @-@ 12 with decreased expression of arginase @-@ 1 , IL @-@ 6 , TGF @-@ P , IL @-@ 10 compared to WT mice ( Fig . 2d ) .
# ::alignments 3-1.1.1 4-1.1 5-1.1.2.1.2.1.1.1.2.1.1 6-1.1.2 9-1.1.2.1.1 10-1.1.2.1 11-1.1.2.1.3.r 12-1.1.2.1.3.1.1 15-1.1.2.1.2.1.1.1.2.1.1 16-1.1.2.2.1.1 16-1.1.2.3.1.1 18-1.1.2.3.1.1 20-1.1.2.2.1.1 20-1.1.2.3.1.1 22-1.1.2.2.1.1 23-1.1.2.3.2.1 24-1.1.2.3 24-1.1.2.3.2 24-1.1.2.3.2.r 26-1.1.2.1.2 28-1.1.2.1.2.1.1.2 29-1.1.2.1.2.1.1 30-1.1.2.1.2.1.1.1.r 31-1.1.2.1.2.1.1.1.1.1.1 33-1.1.2.1.2.1.1.1.1.1.1 35-1.1.2.1.2.1.1.1.2.1.1 37-1.1.2.1.2.1.1.1.2.1.1 38-1.1.2.1.2.1.1.1 39-1.1.2.1.2.1.1.1.3.1.1 41-1.1.2.1.2.1.1.1.3.1.1 42-1.1.2.1.2.1.r 43-1.1.2.1.2.1.2.2 44-1.1.2.1.2.1.2 44-1.1.2.1.2.1.2.2.1 45-1.1.2.1.2.1.2.1.r 46-1.1.2.1.2.1.2.1.1.1.1 48-1.1.2.1.2.1.2.1.1.1.1 50-1.1.2.1.2.1.2.1.2.1.1 50-1.1.2.1.2.1.2.1.4.1.1 52-1.1.2.1.2.1.2.1.2.1.1 54-1.1.2.1.2.1.2.1.3.1.1 56-1.1.2.1.2.1.2.1.3.1.1 58-1.1.2.1.2.1.2.1.2.1.1 58-1.1.2.1.2.1.2.1.4.1.1 60-1.1.2.1.2.1.2.1.4.1.1 61-1.1.2.1.2.1.2.2.1.r 62-1.1.2.1.2.1.2.2.1.2.r 63-1.1.2.1.2.1.2.2.1.2.1 64-1.1.2.1.2.1.2.2.1.2 68-1.2.1.1
# ::id bel_pmid_2465_2403_41228
(a / and
      :op2 (e / exhibit-01~e.4
            :ARG0 (m / mouse~e.3
                  :mod (p / protein
                        :name (n / name :op1 "GCSFR")
                        :ARG2-of (m2 / mutate-01 :mod "-/-")))
            :ARG1 (s / shift-01~e.6
                  :ARG1 (p2 / profile~e.10
                        :mod (i / immune~e.9)
                        :ARG1-of (c3 / characterize-01~e.26
                              :ARG2~e.42 (a2 / and
                                    :op1 (e2 / express-03~e.29
                                          :ARG2~e.30 (a3 / and~e.38
                                                :op1 (p3 / protein
                                                      :name (n4 / name :op1 "IFN-y"~e.31,33))
                                                :op2 (p4 / protein
                                                      :name (n5 / name :op1 "TNF-a"~e.5,15,35,37))
                                                :op3 (p5 / protein
                                                      :name (n6 / name :op1 "IL-12"~e.39,41)))
                                          :ARG1-of (i2 / increase-01~e.28))
                                    :op2 (e3 / express-03~e.44
                                          :ARG2~e.45 (a4 / and
                                                :op1 (e4 / enzyme
                                                      :name (n7 / name :op1 "arginase-1"~e.46,48))
                                                :op2 (p6 / protein
                                                      :name (n8 / name :op1 "IL-6"~e.50,52,58))
                                                :op3 (p7 / protein
                                                      :name (n9 / name :op1 "TGF-P"~e.54,56))
                                                :op4 (p8 / protein
                                                      :name (n10 / name :op1 "IL-10"~e.50,58,60)))
                                          :ARG1-of (d / decrease-01~e.43
                                                :compared-to~e.61 (e5 / express-03~e.44
                                                      :ARG2 a4
                                                      :ARG3~e.62 (m3 / mouse~e.64
                                                            :mod (w / wild-type~e.63)))))))
                        :mod~e.11 (d3 / disease
                              :name (n11 / name :op1 "PC"~e.12)))
                  :ARG2 (c2 / cell
                        :name (n3 / name :op1 "TH-1"~e.16,20,22)
                        :ARG2-of (r / respond-01~e.24
                              :mod i~e.23))
                  :ARG3 (c / cell~e.24
                        :name (n2 / name :op1 "TH-2"~e.16,18,20)
                        :ARG2-of~e.24 r)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "2d"~e.68)))

# ::tok These monocytes acquired a Mo @-@ MDSC phenotype characterized by a significantly decreased expression of HLA @-@ DR and increased expression of arginase @-@ 1 as well as the ability to suppress CD8+ T cell proliferation in vitro [29 @-@ 32] ( Fig . 4a @-@ c ) .
# ::alignments 0-1.1.2 1-1.1.1.1 2-1 4-1.2.1.1.1 6-1.2.1.1.1 7-1.2 8-1.2.2 9-1.2.2.1.r 11-1.2.2.1.1.2.1 12-1.2.2.1.1.2 13-1.2.2.1.1 14-1.2.2.1.1.1.r 15-1.2.2.1.1.1.1.1 17-1.2.2.1.1.1.1.1 18-1.2.2.1 19-1.2.2.1.2.2 20-1.2.2.1.2 21-1.2.2.1.2.1.r 22-1.2.2.1.2.1.1.1 24-1.2.2.1.2.1.1.1 29-1.2.2.1.3 31-1.2.2.1.3.2 32-1.2.2.1.3.2.2.1.1.1 33-1.2.2.1.3.2.2.1.1.2 34-1.1 34-1.2.1 34-1.2.2.1.3.2.2.1 35-1.2.2.1.3.2.2 36-1.2.2.1.3.2.3 37-1.2.2.1.3.2.3 44-1.3.1.2.1.1
# ::id bel_pmid_2465_2403_41236
(a / acquire-01~e.2
      :ARG0 (c / cell~e.34
            :name (n / name :op1 "monocyte"~e.1)
            :mod (t / this~e.0))
      :ARG1 (p / phenotype~e.7
            :mod (c2 / cell~e.34
                  :name (n2 / name :op1 "Mo-MDSC"~e.4,6))
            :ARG1-of (c3 / characterize-01~e.8
                  :ARG0~e.9 (a2 / and~e.18
                        :op1 (e / express-03~e.13
                              :ARG2~e.14 (p2 / protein
                                    :name (n3 / name :op1 "HLA-DR"~e.15,17))
                              :ARG1-of (d / decrease-01~e.12
                                    :degree (s / significant~e.11)))
                        :op2 (e2 / express-03~e.20
                              :ARG2~e.21 (e3 / enzyme
                                    :name (n4 / name :op1 "arginase-1"~e.22,24))
                              :ARG1-of (i / increase-01~e.19))
                        :op3 (c4 / capable-01~e.29
                              :ARG1 c
                              :ARG2 (s2 / suppress-01~e.31
                                    :ARG0 c
                                    :ARG1 (p3 / proliferate-01~e.35
                                          :ARG0 (c5 / cell~e.34
                                                :name (n5 / name :op1 "CD8+"~e.32 :op2 "T"~e.33)))
                                    :manner (i2 / in-vitro~e.36,37))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (a3 / and
                  :op1 (p4 / publication
                        :ARG1-of (c6 / cite-01
                              :ARG2 (v2 / value-interval :op1 "29" :op2 "32")))
                  :op2 (f / figure
                        :mod (v / value-interval :op1 "4a"~e.44 :op2 "4c")))))

# ::tok While we found that IL @-@ 6 mRNA gene expression was significantly downregulated by STAT3 inhibition ( Supplementary figure 11 ) , IL @-@ 6 blockade using anti @-@ IL @-@ 6 antibodies decreased but did not fully reverse the effect of Mo @-@ MDSC on increasing the prevalence of ALDH1Bright CSCs .
# ::alignments 0-1 1-1.1.1 2-1.1 4-1.1.2.1.2.2.1.1.1 6-1.1.2.1.2.2.1.1.1 7-1.1.2.1.2.1.1 8-1.1.2.1.1 9-1.1.2.1 11-1.1.2.3 15-1.1.2.2 18-1.1.3.1 19-1.1.3.1.1 22-1.2.1.1.2.1.1 23-1.2.1.1.2.1.1 24-1.2.1.1.2.1.1 27-1.2.1.1.2.1 29-1.2.1.1.2.1.1 30-1.2.1.1.2.1.1 31-1.2.1.1.2.1.1 32-1.2.1.1.2 33-1.2.1 34-1.2 36-1.2.2.1 36-1.2.2.1.r 37-1.2.2.4 38-1.2.2 40-1.2.1.2 41-1.2.1.2.1.r 42-1.2.1.2.1.1.1 44-1.2.1.2.1.1.1 45-1.2.1.2.2.r 46-1.2.1.2.2
# ::id bel_pmid_2465_2403_41248
(c / contrast-01~e.0
      :ARG1 (f / find-01~e.2
            :ARG0 (w / we~e.1)
            :ARG1 (d / downregulate-01
                  :ARG1 (e / express-03~e.9
                        :ARG1 (g / gene~e.8)
                        :ARG2 (r / rna
                              :name (n / name :op1 "mRNA"~e.7)
                              :ARG0-of (e2 / encode-01
                                    :ARG1 (p / protein
                                          :name (n2 / name :op1 "IL-6"~e.4,6)))))
                  :ARG2 (i / inhibit-01~e.15
                        :ARG1 (p2 / protein
                              :name (n3 / name :op1 "STAT-3")))
                  :degree (s / significant~e.11))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f2 / figure~e.18
                        :mod "11"~e.19
                        :ARG2-of (s2 / supplement-01))))
      :ARG2 (c2 / contrast-01~e.34
            :ARG1 (d3 / decrease-01~e.33
                  :ARG0 (b / block-01
                        :ARG1 p
                        :ARG3 (a / antibody~e.32
                              :ARG0-of (c3 / counter-01~e.27
                                    :ARG1 p~e.22,23,24,29,30,31)))
                  :ARG1 (a2 / affect-01~e.40
                        :ARG0~e.41 (c4 / cell
                              :name (n4 / name :op1 "Mo-MDSC"~e.42,44))
                        :ARG1~e.45 (i2 / increase-01~e.46
                              :ARG1 (p4 / prevail-01
                                    :ARG0 (c5 / cell
                                          :name (n5 / name
                                                :op1 "ALDH1"
                                                :op2 "Bright"
                                                :op3 "CSC"))))))
            :ARG2 (r2 / reverse-01~e.38
                  :polarity~e.36 "-"~e.36
                  :ARG0 b
                  :ARG1 a2
                  :degree (f3 / full~e.37))))

# ::tok the 2 cytokines most intensively involved in eliciting the acute phase response are IL6 and IL1
# ::alignments 1-1.1 3-1.3.2.1 4-1.3.2 4-1.3.2.r 5-1.3 6-1.3.1.r 7-1.3.1 9-1.3.1.1.1.1.1 10-1.3.1.1.1.1 11-1.3.1.1 11-1.3.1.1.1 11-1.3.1.1.1.r 12-1.2.r 14-1.2
# ::id bel_pmid_247_2096_38400
(c4 / cytokine
      :quant "2"~e.1
      :domain~e.12 (a3 / and~e.14
            :op1 (c / cytokine
                  :name (n / name :op1 "IL-6"))
            :op2 (c2 / cytokine
                  :name (n2 / name :op1 "IL-1")))
      :ARG1-of (i2 / involve-01~e.5
            :ARG2~e.6 (e / elicit-01~e.7
                  :ARG1 (t / thing~e.11
                        :ARG2-of~e.11 (r / respond-01~e.11
                              :ARG1 (p / phase~e.10
                                    :mod (a2 / acute~e.9)))))
            :manner~e.4 (i / intensive~e.4
                  :degree (m / most~e.3))))

# ::tok alpha 2 @-@ macroglobulin , alpha 1 @-@ antichymotrypsin ( = contrapsin ) , cysteine protease inhibitor ( = thiostatin ) , alpha 1 @-@ antitrypsin , ceruloplasmin and fibrinogens are predominantly regulated by the keratinocyte @-@ derived HSF @-@ III/-II or IL @-@ 6
# ::alignments 0-1.2.1.1.1 0-1.2.2.1.1 0-1.2.4.1.1 1-1.2.1.1.1 3-1.2.1.1.1 5-1.2.1.1.1 5-1.2.2.1.1 5-1.2.4.1.1 6-1.2.2.1.2 6-1.2.4.1.2 8-1.2.2.1.2 11-1.2.2.2.1.1.1 14-1.2.3.2.1.1.1 15-1.2.3.2.1.1.2 16-1.2.3 16-1.2.3.2 16-1.2.3.2.r 19-1.2.3.1.1 22-1.2.1.1.1 22-1.2.4.1.1 23-1.2.4.1.2 25-1.2.4.1.2 27-1.2.5.1.1 28-1.2 29-1.2.6.1.1 31-1.3 31-1.3.r 32-1 33-1.1.r 35-1.1.3.1.1.1 37-1.1.3 38-1.1.1.1.1.1 38-1.1.1.2.1.1 41-1.1 42-1.1.2.1.1 44-1.1.2.1.1
# ::id bel_pmid_248_3767_28356
(r / regulate-01~e.32
      :ARG0~e.33 (o / or~e.41
            :op1 (s / slash
                  :op1 (p3 / protein
                        :name (n2 / name :op1 "HSF-III"~e.38))
                  :op2 (p4 / protein
                        :name (n3 / name :op1 "HSF-II"~e.38)))
            :op2 (p2 / protein
                  :name (n / name :op1 "IL-6"~e.42,44))
            :ARG1-of (d / derive-01~e.37
                  :ARG2 (c / cell
                        :name (n4 / name :op1 "keratinocyte"~e.35))))
      :ARG1 (a / and~e.28
            :op1 (p5 / protein
                  :name (n5 / name :op1 "alpha-2-macroglobulin"~e.0,1,3,5,22))
            :op2 (p6 / protein
                  :name (n6 / name :op1 "alpha"~e.0,5 :op2 "1-antichymotrypsin"~e.6,8)
                  :ARG1-of (m2 / mean-01
                        :ARG2 (p9 / protein
                              :name (n11 / name :op1 "contrapsin"~e.11))))
            :op3 (p10 / protein~e.16
                  :name (n12 / name :op1 "thiostatin"~e.19)
                  :ARG0-of~e.16 (i / inhibit-01~e.16
                        :ARG1 (e / enzyme
                              :name (n7 / name :op1 "cysteine"~e.14 :op2 "protease"~e.15))))
            :op4 (p7 / protein
                  :name (n8 / name :op1 "alpha"~e.0,5,22 :op2 "1-antitrypsin"~e.6,23,25))
            :op5 (e2 / enzyme
                  :name (n9 / name :op1 "ceruloplasmin"~e.27))
            :op6 (p8 / protein
                  :name (n10 / name :op1 "fibrinogen"~e.29)))
      :manner~e.31 (p / predominant~e.31))

# ::tok The mRNA expression of Foxp3 and RORyt in the spleen was very low in the normal control group but significantly higher in the model control group ( P < 0.05 ) .
# ::alignments 1-1.1.1.2.1.1.1 2-1.1.1.2 4-1.1.1.2.1.2.1.1.1.1 5-1.1.1.2.1.2.1 6-1.1.1.2.1.2.1.2.1.1 7-1.1.1.2.2.r 9-1.1.1.2.2 10-1.1.1.2.r 11-1.1.1.1 12-1.1.1 13-1.1.1.3.r 15-1.1.1.3.1.1 16-1.1.1.3.1 17-1.1.1.3 18-1.1 19-1.1.2.2 19-1.1.2.2.r 20-1.1.2 20-1.1.2.1 20-1.1.2.1.r 21-1.1.2.4.r 23-1.1.2.4.1.1 24-1.1.2.4.1 25-1.1.2.4 29-1.2.1.1
# ::id bel_pmid_2494_9077_41642
(m3 / multi-sentence
      :snt1 (c / contrast-01~e.18
            :ARG1 (l / low~e.12
                  :degree (v / very~e.11)
                  :domain~e.10 (e / express-03~e.2
                        :ARG2 (r / rna
                              :name (n / name :op1 "mRNA"~e.1)
                              :ARG0-of (e2 / encode-01
                                    :ARG1 (a / and~e.5
                                          :op1 (p / protein
                                                :name (n2 / name :op1 "Foxp3"~e.4))
                                          :op2 (p2 / protein
                                                :name (n3 / name :op1 "RORyt"~e.6)))))
                        :ARG3~e.7 (s / spleen~e.9))
                  :location~e.13 (g / group~e.17
                        :mod (c2 / control-01~e.16
                              :mod (n4 / normal~e.15))))
            :ARG2 (h / high~e.20
                  :degree~e.20 (m / more~e.20)
                  :manner~e.19 (s2 / significant~e.19)
                  :domain e
                  :location~e.21 (g2 / group~e.25
                        :mod (c3 / control-01~e.24
                              :mod (m2 / model~e.23)))))
      :snt2 (p3 / probability
            :quant (l2 / less-than :op1 "0.05"~e.29)))

# ::tok SOCS3 protein expression was significantly downregulated in all groups except for the normal control group ( P < 0.05 ) .
# ::alignments 0-1.1.1.1.1.1 1-1.1.1.1 2-1.1.1 4-1.1.2 7-1.1.3.1 8-1.1.3 9-1.1.3.2 10-1.1.3.2.1.r 12-1.1.3.2.1.1.1 13-1.1.3.2.1.1 14-1.1.3.2.1 18-1.2.1.1
# ::id bel_pmid_2494_9077_41646
(m / multi-sentence
      :snt1 (d / downregulate-01
            :ARG1 (e / express-03~e.2
                  :ARG2 (p / protein~e.1
                        :name (n / name :op1 "SOCS3"~e.0)))
            :degree (s / significant~e.4)
            :location (g / group~e.8
                  :mod (a / all~e.7)
                  :ARG2-of (e2 / except-01~e.9
                        :ARG1~e.10 (g2 / group~e.14
                              :mod (c / control-01~e.13
                                    :mod (n2 / normal~e.12))))))
      :snt2 (p2 / probability
            :quant (l / less-than :op1 "0.05"~e.18)))

# ::tok Jak2 and STAT3 protein expression was significantly higher in the model control group than in all other groups ( P < 0.05 ) .
# ::alignments 0-1.1.3.1.1.1.1 1-1.1.3.1 2-1.1.3.1.2.1.1 3-1.1.3.1.2 4-1.1.3 5-1.1.3.r 6-1.1.2 6-1.1.2.r 7-1.1 7-1.1.1 7-1.1.1.r 8-1.1.4.r 10-1.1.4.1.1 11-1.1.4.1 12-1.1.4 13-1.2.1 14-1.1.5.r 15-1.1.5.1 16-1.1.5.2 17-1.1.5 21-1.2.1.1
# ::id bel_pmid_2494_9077_41648
(m2 / multi-sentence
      :snt1 (h / high~e.7
            :degree~e.7 (m / more~e.7)
            :manner~e.6 (s / significant~e.6)
            :domain~e.5 (e / express-03~e.4
                  :ARG2 (a / and~e.1
                        :op1 (e2 / enzyme
                              :name (n / name :op1 "Jak2"~e.0))
                        :op2 (p2 / protein~e.3
                              :name (n2 / name :op1 "STAT3"~e.2))))
            :location~e.8 (g / group~e.12
                  :mod (c / control-01~e.11
                        :mod (m3 / model~e.10)))
            :compared-to~e.14 (g2 / group~e.17
                  :mod (a2 / all~e.15)
                  :mod (o / other~e.16)))
      :snt2 (p3 / probability
            :quant (l / less-than~e.13 :op1 "0.05"~e.21)))

# ::tok Blocking STAT3 activation with the small molecule inhibitor JSI @-@ 124 significantly inhibited the accumulation of NIK and IDO expression in MDSCs .
# ::alignments 0-1.1 1-1.1.1.1.1.1 2-1.1.1 3-1.1.2.r 5-1.1.2 6-1.1.2 7-1.1.2.2 8-1.1.2.1.1 10-1.1.2.1.1 11-1.3 12-1 14-1.2.1 15-1.2.1.2.r 16-1.2.1.2.1.1 17-1.2 18-1.2.2.1.1.1 19-1.2.2
# ::id bel_pmid_2506_3873_41328
(i2 / inhibit-01~e.12
      :ARG0 (b / block-01~e.0
            :ARG1 (a / activate-01~e.2
                  :ARG1 (p / protein
                        :name (n / name :op1 "STAT3"~e.1)))
            :ARG3~e.3 (s / small-molecule~e.5,6
                  :name (n2 / name :op1 "JSI-124"~e.8,10)
                  :ARG0-of (i / inhibit-01~e.7)))
      :ARG1 (a2 / and~e.17
            :op1 (a3 / accumulate-01~e.14
                  :ARG0 (c / cell
                        :name (n5 / name :op1 "MDSC"))
                  :ARG1~e.15 (e / enzyme
                        :name (n3 / name :op1 "NIK"~e.16)))
            :op2 (e2 / express-03~e.19
                  :ARG2 (e3 / enzyme
                        :name (n4 / name :op1 "IDO"~e.18))
                  :ARG3 c))
      :degree (s2 / significant~e.11))

# ::tok Knockdown of NIK in MDSCs suppressed IDO expression but not STAT3 activation .
# ::alignments 2-1.1.1.1.1.1 5-1.1 5-1.2 6-1.1.2.1.1.1 7-1.1.2 8-1 9-1.2.1 9-1.2.1.r 10-1.2.3.1.1.1 11-1.2.3
# ::id bel_pmid_2506_3873_41330
(c / contrast-01~e.8
      :ARG1 (s / suppress-01~e.5
            :ARG0 (k / knock-02
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "NIK"~e.2))
                  :location (c2 / cell
                        :name (n2 / name :op1 "MDSC")))
            :ARG1 (e2 / express-03~e.7
                  :ARG2 (e3 / enzyme
                        :name (n3 / name :op1 "IDO"~e.6))))
      :ARG2 (s2 / suppress-01~e.5
            :polarity~e.9 "-"~e.9
            :ARG0 k
            :ARG1 (a / activate-01~e.11
                  :ARG1 (p / protein
                        :name (n4 / name :op1 "STAT3"~e.10)))))

# ::tok RelB @-@ p52 dimers were found to directly bind to the IDO promoter , leading to IDO expression in MDSCs .
# ::alignments 0-1.1.1.2.1.1 2-1.1.1.1.1.1 3-1.1.1 5-1 7-1.1.3 7-1.1.3.r 8-1.1 9-1.1.2.r 11-1.1.2.1.1.1.1 14-1.1.4 15-1.1.4.1.r 16-1.1.4.1.1 17-1.1.4.1
# ::id bel_pmid_2506_3873_41332
(f / find-01~e.5
      :ARG1 (b / bind-01~e.8
            :ARG1 (d2 / dimer~e.3
                  :part (p3 / protein
                        :name (n / name :op1 "p52"~e.2))
                  :part (p / protein
                        :name (n2 / name :op1 "RelB"~e.0)))
            :ARG2~e.9 (m / molecular-physical-entity
                  :ARG0-of (p2 / promote-01
                        :ARG1 (e / enzyme
                              :name (n3 / name :op1 "IDO"~e.11))))
            :manner~e.7 (d / direct~e.7)
            :ARG0-of (l / lead-03~e.14
                  :ARG2~e.15 (e2 / express-03~e.17
                        :ARG2 e~e.16
                        :ARG3 (c / cell
                              :name (n4 / name :op1 "MDSC"))))))

# ::tok STAT3 activation @-@ induced IDO expression is independent of direct binding of STAT3 to the promoter region of IDO gene .
# ::alignments 0-1.2.2.1.1.1.1 1-1.2.2.1 3-1.2.2 4-1.2.1.1.1 5-1.2 7-1 7-1.1 7-1.1.r 8-1.3.r 9-1.3.3 10-1.3 11-1.3.1.r 12-1.3.1 16-1.3.2 17-1.3.2.2.r 18-1.3.2.2.1.1 19-1.3.2.2
# ::id bel_pmid_2506_3873_41334
(d / depend-01~e.7
      :polarity~e.7 "-"~e.7
      :ARG0 (e / express-03~e.5
            :ARG2 (e2 / enzyme
                  :name (n / name :op1 "IDO"~e.4))
            :ARG1-of (i / induce-01~e.3
                  :ARG0 (a / activate-01~e.1
                        :ARG1 (p / protein
                              :name (n2 / name :op1 "STAT3"~e.0)))))
      :ARG1~e.8 (b / bind-01~e.10
            :ARG1~e.11 p~e.12
            :ARG2 (r / region~e.16
                  :ARG0-of (p2 / promote-01)
                  :part-of~e.17 (g / gene~e.19
                        :ARG0-of (e3 / encode-01
                              :ARG1 e2~e.18)))
            :manner (d2 / direct~e.9)))

# ::tok Blocking STAT3 activation by JSI @-@ 124 dramatically decreased the levels of p52 and RelB in nuclei ( Fig . 2C , p < 0.05 ) .
# ::alignments 0-1.1 1-1.1.1.1.1.1 2-1.1.1 3-1.1.2.r 4-1.1.2.1.1 6-1.1.2.1.1 7-1.3 8-1 10-1.2 11-1.2.1.r 12-1.2.1.1.1.1 13-1.2.1 14-1.2.1.2.1.1 15-1.4.r 16-1.4 20-1.5.1.1 24-1.5.1.2.1.1
# ::id bel_pmid_2506_3873_41344
(d / decrease-01~e.8
      :ARG0 (b / block-01~e.0
            :ARG1 (a / activate-01~e.2
                  :ARG1 (p / protein
                        :name (n / name :op1 "STAT3"~e.1)))
            :ARG3~e.3 (s / small-molecule
                  :name (n2 / name :op1 "JSI-124"~e.4,6)))
      :ARG1 (l / level~e.10
            :quant-of~e.11 (a2 / and~e.13
                  :op1 (p2 / protein
                        :name (n3 / name :op1 "p52"~e.12))
                  :op2 (p3 / protein
                        :name (n4 / name :op1 "RelB"~e.14))))
      :degree (d2 / dramatic~e.7)
      :location~e.15 (n5 / nucleus~e.16)
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure
                  :mod "2C"~e.20
                  :mod (p4 / probability
                        :quant (l2 / less-than :op1 "0.05"~e.24)))))

# ::tok The level of STAT3 phosphorylation in MDSCs was reduced at 30 min and completely suppressed at 4 h after treatment with JSI @-@ 124 .
# ::alignments 1-1.1.1 2-1.1.1.1.r 3-1.1.1.1.1.1.1 4-1.1.1.1 8-1.1 9-1.1.2.r 10-1.1.2.2.1 12-1 13-1.2.2 14-1.2 16-1.2.3.2.1 18-1.1.2 18-1.2.3 19-1.1.2.1 20-1.1.2.1.1.r 21-1.1.2.1.1.1.1 23-1.1.2.1.1.1.1
# ::id bel_pmid_2506_3873_41346
(a / and~e.12
      :op1 (r / reduce-01~e.8
            :ARG1 (l / level~e.1
                  :degree-of~e.2 (p / phosphorylate-01~e.4
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "STAT3"~e.3)))
                  :location (c / cell
                        :name (n2 / name :op1 "MDSC")))
            :time~e.9 (a2 / after~e.18
                  :op1 (t / treat-04~e.19
                        :ARG2~e.20 (s / small-molecule
                              :name (n3 / name :op1 "JSI-124"~e.21,23)))
                  :quant (t2 / temporal-quantity
                        :quant "30"~e.10
                        :unit (m / minute))))
      :op2 (s2 / suppress-01~e.14
            :ARG1 l
            :degree (c2 / complete~e.13)
            :time (a3 / after~e.18
                  :op1 t
                  :quant (t3 / temporal-quantity
                        :quant "4"~e.16
                        :unit (h / hour)))))

# ::tok Consistently , the level of NIK in MDSCs started to decline at 1 h and was completely blocked at 8 h after JSI @-@ 124 treatment .
# ::alignments 0-1 3-1.1.1.1 4-1.1.1.1.1.r 5-1.1.1.1.1.1.1 8-1.1.1 10-1.1.1.2 11-1.1.1.3.r 12-1.1.1.3.2.1 14-1.1 16-1.1.2.2 17-1.1.2 19-1.1.2.3.2.1 21-1.1.1.3 21-1.1.2.3 22-1.1.1.3.1.1.1.1 24-1.1.1.3.1.1.1.1 25-1.1.1.3.1
# ::id bel_pmid_2506_3873_41348
(c4 / consistent-01~e.0
      :ARG1 (a / and~e.14
            :op1 (s / start-01~e.8
                  :ARG0 (l / level~e.3
                        :quant-of~e.4 (e / enzyme
                              :name (n / name :op1 "NIK"~e.5))
                        :location (c / cell
                              :name (n2 / name :op1 "MDSC")))
                  :ARG1 (d / decline-01~e.10
                        :ARG1 l)
                  :time~e.11 (a2 / after~e.21
                        :op1 (t / treat-04~e.25
                              :ARG2 (s2 / small-molecule
                                    :name (n3 / name :op1 "JSI-124"~e.22,24)))
                        :quant (t2 / temporal-quantity
                              :quant "1"~e.12
                              :unit (h / hour))))
            :op2 (b / block-01~e.17
                  :ARG1 l
                  :degree (c2 / complete~e.16)
                  :time (a3 / after~e.21
                        :op1 t
                        :quant (t3 / temporal-quantity
                              :quant "8"~e.19
                              :unit h)))))

# ::tok The level of IDO significantly decreased at 4 h after JSI @-@ 124 treatment ( Fig . 3A ) .
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.1.1 4-1.2 5-1 6-1.3.r 7-1.3.2.1 9-1.3 10-1.3.1.1.1.1 12-1.3.1.1.1.1 13-1.3.1 17-1.4.1.1
# ::id bel_pmid_2506_3873_41350
(d / decrease-01~e.5
      :ARG1 (l / level~e.1
            :quant-of~e.2 (e / enzyme
                  :name (n / name :op1 "IDO"~e.3)))
      :degree (s / significant~e.4)
      :time~e.6 (a / after~e.9
            :op1 (t / treat-04~e.13
                  :ARG2 (s2 / small-molecule
                        :name (n2 / name :op1 "JSI-124"~e.10,12)))
            :quant (t2 / temporal-quantity
                  :quant "4"~e.7
                  :unit (h / hour)))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "3A"~e.17)))

# ::tok In NIK knockdown MDSCs , the level of IDO protein was reduced significantly , but the level of pSTAT3 protein was not affected ( Fig . 3B , 3C ) .
# ::alignments 1-1.3.2.1.1.1 6-1.1.1 6-1.2.2 7-1.1.1.1.r 8-1.1.1.1.1.1 9-1.2.2.1 11-1.1 12-1.1.2 14-1 16-1.2.2 19-1.2.2.1 21-1.2.1 21-1.2.1.r 22-1.2 26-1.4.1.1.1 28-1.4.1.2.1
# ::id bel_pmid_2506_3873_41352
(c / contrast-01~e.14
      :ARG1 (r / reduce-01~e.11
            :ARG1 (l / level~e.6
                  :quant-of~e.7 (e2 / enzyme
                        :name (n3 / name :op1 "IDO"~e.8)))
            :degree (s / significant~e.12))
      :ARG2 (a / affect-01~e.22
            :polarity~e.21 "-"~e.21
            :ARG1 (l2 / level~e.6,16
                  :quant-of (p2 / protein~e.9,19
                        :name (n4 / name :op1 "STAT3"))))
      :location (c2 / cell
            :name (n / name :op1 "MDSC")
            :mod (k / knock-02
                  :ARG1 (e / enzyme
                        :name (n2 / name :op1 "NIK"~e.1))))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and
                  :op1 (f / figure :mod "3B"~e.26)
                  :op2 (f2 / figure :mod "3C"~e.28))))

# ::tok In contrast , both IDO and NIK expression were reduced by JSI @-@ 124 treatment in MDSCs ( Fig . 3A ) .
# ::alignments 1-1 4-1.1.2.1.1.1.1 5-1.1.2 6-1.1.2.2.1.1.1 7-1.1.2.1 7-1.1.2.2 9-1.1 10-1.1.1.r 11-1.1.1.1.1.1 13-1.1.1.1.1.1 14-1.1.1 20-1.2.1.1
# ::id bel_pmid_2506_3873_41354
(c / contrast-01~e.1
      :ARG2 (r / reduce-01~e.9
            :ARG0~e.10 (t / treat-04~e.14
                  :ARG2 (s / small-molecule
                        :name (n3 / name :op1 "JSI-124"~e.11,13)))
            :ARG1 (a / and~e.5
                  :op1 (e / express-03~e.7
                        :ARG2 (e4 / enzyme
                              :name (n / name :op1 "IDO"~e.4))
                        :ARG3 (c2 / cell
                              :name (n4 / name :op1 "MDSC")))
                  :op2 (e2 / express-03~e.7
                        :ARG2 (e3 / enzyme
                              :name (n2 / name :op1 "NIK"~e.6))
                        :ARG3 c2)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "3A"~e.20)))

# ::tok RelB @/@ p52 dimers directly bind to the IDO promoter to regulate IDO expression in MDSCs .
# ::alignments 0-1.1.2.1.1 2-1.1.1.1.1 3-1.1 4-1.3 4-1.3.r 5-1 6-1.2.r 8-1.2.1.1.1.1 11-1.4 12-1.4.2.1 13-1.4.2
# ::id bel_pmid_2506_3873_41356
(b / bind-01~e.5
      :ARG1 (d3 / dimer~e.3
            :part (p4 / protein
                  :name (n / name :op1 "p52"~e.2))
            :part (p / protein
                  :name (n2 / name :op1 "RelB"~e.0)))
      :ARG2~e.6 (m / molecular-physical-entity
            :ARG0-of (p2 / promote-01
                  :ARG1 (e2 / enzyme
                        :name (n3 / name :op1 "IDO"~e.8))))
      :manner~e.4 (d / direct~e.4)
      :purpose (r / regulate-01~e.11
            :ARG0 d3
            :ARG1 (e / express-03~e.13
                  :ARG2 e2~e.12
                  :ARG3 (c / cell
                        :name (n4 / name :op1 "MDSC")))))

# ::tok We isolated CD11b+ MDSCs from the spleen of JSI @-@ 124 @-@ treated mice and found decreased expression of p @-@ STAT3 , NIK , and IDO protein in CD11b+ MDSCs compared with those isolated from the controls ( Fig . 6D ) .
# ::alignments 0-1.1.1 1-1.1 2-1.1.2.2.1.1 4-1.1.3.r 6-1.1.3 7-1.1.3.1.r 8-1.1.3.1.1.1.1.1 10-1.1.3.1.1.1.1.1 12-1.1.3.1.1 13-1.1.3.1 14-1 15-1.2 16-1.2.2.3 17-1.2.2 17-1.2.2.4 21-1.2.2.1.1.1.1 23-1.2.2.1.2.1.1 25-1.2.2.1 26-1.2.2.1.3.1.1 27-1.1.2.2 27-1.2.2.1.1 28-1.2.2.2.r 29-1.2.2.2 31-1.2.2.4.r 34-1.2.2.4.2.3 35-1.2.2.4.2.3.1.r 37-1.2.2.4.2.3.1 41-1.3.1.1
# ::id bel_pmid_2506_3873_41366
(a / and~e.14
      :op1 (i / isolate-01~e.1
            :ARG0 (w / we~e.0)
            :ARG1 (c / cell
                  :name (n / name :op1 "MDSC")
                  :mod (p / protein~e.27
                        :name (n2 / name :op1 "CD11b+"~e.2)))
            :ARG2~e.4 (s / spleen~e.6
                  :poss~e.7 (m / mouse~e.13
                        :ARG1-of (t / treat-03~e.12
                              :ARG3 (s2 / small-molecule
                                    :name (n3 / name :op1 "JSI-124"~e.8,10))))))
      :op2 (f / find-01~e.15
            :ARG0 w
            :ARG1 (e / express-03~e.17
                  :ARG2 (a2 / and~e.25
                        :op1 (p2 / protein~e.27
                              :name (n4 / name :op1 "STAT3"~e.21)
                              :ARG1-of (p3 / phosphorylate-01))
                        :op2 (e3 / enzyme
                              :name (n5 / name :op1 "NIK"~e.23))
                        :op3 (e4 / enzyme
                              :name (n6 / name :op1 "IDO"~e.26)))
                  :ARG3~e.28 c~e.29
                  :ARG1-of (d / decrease-01~e.16)
                  :compared-to~e.31 (e2 / express-03~e.17
                        :ARG2 a2
                        :ARG3 (c2 / cell
                              :name (n7 / name :op1 "MDSC")
                              :mod p
                              :ARG1-of (i2 / isolate-01~e.34
                                    :ARG2~e.35 (c3 / control~e.37))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure :mod "6D"~e.41)))

# ::tok Furthermore , a specific IL @-@ 6 @-@ neutralizing Ab significantly decreased the levels of p @-@ STAT3 , NIK , and IDO in MDSCs ( Fig . 7E , p < 0.05 ) .
# ::alignments 3-1.1.1.2 4-1.1.1.1.1.1.1 6-1.1.1.1.1.1.1 8-1.1.1.1 10-1.1.3 11-1.1 13-1.1.2 19-1.1.2.1.2.1.1 21-1.1.2.1 22-1.1.2.1.3.1.1 28-1.2.1.1 32-1.2.1.2.1.1
# ::id bel_pmid_2506_3873_41374
(a / and
      :op2 (d / decrease-01~e.11
            :ARG0 (a2 / antibody
                  :ARG0-of (n / neutralize-01~e.8
                        :ARG1 (p / protein
                              :name (n2 / name :op1 "IL-6"~e.4,6)))
                  :mod (s2 / specific~e.3))
            :ARG1 (l / level~e.13
                  :quant-of (a3 / and~e.21
                        :op1 (p2 / protein
                              :name (n3 / name :op1 "STAT-3")
                              :ARG1-of (p3 / phosphorylate-01))
                        :op2 (e / enzyme
                              :name (n4 / name :op1 "NIK"~e.19))
                        :op3 (e2 / enzyme
                              :name (n5 / name :op1 "IDO"~e.22))))
            :degree (s / significant~e.10)
            :location (c / cell
                  :name (n6 / name :op1 "MDSC")))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure
                  :mod "7E"~e.28
                  :mod (p6 / probability
                        :quant (l2 / less-than :op1 "0.05"~e.32)))))

# ::tok Mitogen @-@ activated protein ( MAP ) kinase is central to a signal transduction pathway that triggers cell proliferation or differentiation . Activation of the p42 mapk isoform requires its phosphorylation at two residues , Thr 183 and Tyr 185 , and this phosphorylation is catalysed by MAP kinase kinase ( MAPKK ) .
# ::alignments 0-1.1.1.3.1 2-1.1.1.3 8-1.1.1.r 9-1.1 12-1.1.1.2 14-1.1.1 16-1.1.1.4 17-1.1.1.4.1.1.1 18-1.1.1.4.1.1 19-1.1.1.4.1 20-1.1.1.4.1.2 22-1.2.1 25-1.2.1.1.1.1 26-1.1.1.1.1 26-1.2.1.1.1.2 27-1.2.1.1 27-1.2.2.1.2 28-1.2 30-1.2.2 32-1.2.2.1.1 33-1.2.2.1 36-1.2.2.1.3.1 39-1.2.2.1.4.1 43-1.2.2 51-1.2.2.2.1.1.1
# ::id bel_pmid_778_0739_6222
(m / multi-sentence
      :snt1 (c / central~e.9
            :domain~e.8 (p3 / pathway~e.14
                  :name (n3 / name :op1 "MAPK"~e.26)
                  :ARG0-of (s / signal-01~e.12
                        :ARG1-of (t3 / transduct-00))
                  :ARG1-of (a / activate-01~e.2
                        :ARG0 (m2 / mitogen~e.0))
                  :ARG0-of (t2 / trigger-01~e.16
                        :ARG1 (o / or~e.19
                              :op1 (p / proliferate-01~e.18
                                    :ARG0 (c2 / cell~e.17))
                              :op2 (d / differentiate-01~e.20
                                    :ARG1 c2)))))
      :snt2 (r / require-01~e.28
            :ARG0 (a2 / activate-01~e.22
                  :ARG0 (i2 / isoform~e.27
                        :name (n7 / name :op1 "p42"~e.25 :op2 "MAPK"~e.26)))
            :ARG1 (p4 / phosphorylate-01~e.30,43
                  :ARG1 (r2 / residue~e.33
                        :quant "2"~e.32
                        :part-of (i / isoform~e.27)
                        :mod (a4 / amino-acid
                              :mod "183"~e.36
                              :name (n4 / name :op1 "threonine"))
                        :mod (a5 / amino-acid
                              :mod "185"~e.39
                              :name (n5 / name :op1 "tyrosine")))
                  :ARG1-of (c3 / catalyse-00
                        :ARG0 (e2 / enzyme
                              :name (n6 / name :op1 "MAPKK"~e.51))))))

# ::tok Stable transfection of activated Ha @-@ ras into a number of murine cells correlated with a down @-@ regulation of the expression of the NF1 genes NF1 @/@ CTF and NF1/X .
# ::alignments 0-1.1.3 1-1.1 3-1.1.1.2 4-1.1.1.1.1 6-1.1.1.1.1 7-1.1.2.r 9-1.1.2.1 10-1.1.2.1.r 11-1.1.2.2 12-1.1.2 13-1 21-1.2.1 22-1.2.1.1.r 24-1.2.1.1.1.1.1 25-1.1.1 25-1.2.1.1.1 25-1.2.1.1.2 26-1.2.1.1.1.1.1 28-1.2.1.1.1.1.1 29-1.2.1.1 30-1.2.1.1.2.1.1
# ::id bel_pmid_812_5955_5778
(c / correlate-01~e.13
      :ARG1 (t / transfect-00~e.1
            :ARG1 (g4 / gene~e.25
                  :name (n3 / name :op1 "Ha-ras"~e.4,6)
                  :ARG1-of (a2 / activate-01~e.3))
            :ARG2~e.7 (c2 / cell~e.12
                  :quant~e.10 (n4 / number~e.9)
                  :mod (m / murine~e.11))
            :mod (s / stable~e.0))
      :ARG2 (d / downregulate-01
            :ARG1 (e / express-03~e.21
                  :ARG1~e.22 (a / and~e.29
                        :op1 (g / gene~e.25
                              :name (n / name :op1 "NF1/CTF"~e.24,26,28))
                        :op2 (g2 / gene~e.25
                              :name (n2 / name :op1 "NF1/X"~e.30))))))

# ::tok The level of the DNA binding activity of the NF1 proteins was also reduced in Ha @-@ v @-@ ras @-@ transformed cells , and the expression of a gene that depends on this family of transcription factors was specifically repressed .
# ::alignments 1-1.1.1 4-1.1.1.1.2.2 5-1.1.1.1.2 9-1.1.1.1.1.1.1 10-1.1.1.1.1 12-1.1.3 13-1.1 14-1.1.2.r 15-1.1.2.1.1.1.1 17-1.1.2.1.1.1.1 19-1.1.2.1.1.1.1 21-1.1.2.1 22-1.1.2 24-1 26-1.2.1 27-1.2.1.1.r 29-1.2.1.1 31-1.2.1.1.1 34-1.2.1.1.1.1 35-1.2.1.1.1.1.1.r 36-1.2.1.1.1.1.1.1 37-1.2.1.1.1.1.1 39-1.2.2 40-1.2
# ::id bel_pmid_812_5955_9008
(a / and~e.24
      :op1 (r / reduce-01~e.13
            :ARG1 (l / level~e.1
                  :degree-of (a3 / act-01
                        :ARG0 (p / protein~e.10
                              :name (n / name :op1 "NF1"~e.9))
                        :ARG1 (b / bind-01~e.5
                              :ARG0 p
                              :ARG1 (d / DNA~e.4))))
            :location~e.14 (c / cell~e.22
                  :ARG2-of (t / transform-01~e.21
                        :ARG0 (g / gene
                              :name (n2 / name :op1 "Ha-v-ras"~e.15,17,19))))
            :mod (a2 / also~e.12))
      :op2 (r2 / repress-01~e.40
            :ARG1 (e / express-03~e.26
                  :ARG1~e.27 (g2 / gene~e.29
                        :ARG0-of (d2 / depend-01~e.31
                              :ARG1 (f / family~e.34
                                    :consist-of~e.35 (f2 / factors~e.37
                                          :ARG0-of (t3 / transcribe-01~e.36))
                                    :mod p))))
            :manner (s / specific~e.39)))

# ::tok MEK1 and MEK2 can also be activated by autophosphorylation . Autophosphorylation of MEKs correlates with their ability to phosphorylate and activate ERKs .
# ::alignments 0-1.1.1.2.1.1.1 2-1.1.1.2.2.1.1 3-1.1 4-1.1.1.3 5-1.1.1.r 6-1.1.1 13-1.2 14-1.2.2.r 15-1.2.2.1 15-1.2.2.1.r 16-1.2.2 18-1.1.1.1 18-1.2.1 18-1.2.2.2.1 20-1.1.1 20-1.2.2.2.2
# ::id bel_pmid_822_6933_9532
(m / multi-sentence
      :snt1 (p / possible~e.3
            :domain~e.5 (a / activate-01~e.6,20
                  :ARG0 (p2 / phosphorylate-01~e.18
                        :ARG1 (a2 / and
                              :op1 (e / enzyme
                                    :name (n / name :op1 "MEK1"~e.0))
                              :op2 (e2 / enzyme
                                    :name (n2 / name :op1 "MEK2"~e.2)))
                        :ARG2 a2)
                  :ARG1 a2
                  :mod (a5 / also~e.4)))
      :snt2 (c / correlate-01~e.13
            :ARG1 (p3 / phosphorylate-01~e.18
                  :ARG1 (e3 / enzyme
                        :name (n3 / name :op1 "MEK"))
                  :ARG2 e3)
            :ARG2~e.14 (c2 / capable-01~e.16
                  :ARG1~e.15 e3~e.15
                  :ARG2 (a3 / and
                        :op1 (p4 / phosphorylate-01~e.18
                              :ARG2 (e4 / enzyme
                                    :name (n4 / name :op1 "ERK")))
                        :op2 (a4 / activate-01~e.20
                              :ARG1 e4)))))

# ::tok The two SAPK isoforms are 46 and 54 kDa . A 46 kDa kinase activity was induced in response to anisomycin but not in response to TPA .
# ::alignments 1-1.1.3.1 2-1.1.3.2.1 4-1.1.3.r 6-1.1 7-1.1.2.1.1 8-1.1.2.1.2 11-1.1.1.1.1 11-1.2.1.1.1.1 12-1.1.1.1.2 12-1.2.1.1.1.2 13-1.2.1.1 16-1.2 16-1.2.3.1 18-1.2.2 18-1.2.3.1.2 20-1.2.2.1.1.1 21-1.2.3 22-1.2.3.1.1 22-1.2.3.1.1.r 24-1.2.2 25-1.2.3.1.2.1.r 26-1.2.3.1.2.1.1.1
# ::id bel_pmid_854_8291_16558
(m / multi-sentence
      :snt1 (a / and~e.6
            :op1 (e / enzyme
                  :name (n / name :op1 "46"~e.11 :op2 "kDa"~e.12))
            :op2 (e2 / enzyme
                  :name (n2 / name :op1 "54"~e.7 :op2 "kDa"~e.8))
            :domain~e.4 (i3 / isoform
                  :quant "2"~e.1
                  :name (n3 / name :op1 "SAPK"~e.2)))
      :snt2 (i / induce-01~e.16
            :ARG1 (a2 / act-01
                  :ARG0 (k2 / kinase~e.13
                        :name (n7 / name :op1 "46"~e.11 :op2 "kDa"~e.12)))
            :ARG2-of (r / respond-01~e.18,24
                  :ARG1 (s / small-molecule
                        :name (n6 / name :op1 "anisomycin"~e.20)))
            :ARG1-of (c / contrast-01~e.21
                  :ARG2 (i2 / induce-01~e.16
                        :polarity~e.22 "-"~e.22
                        :ARG2-of (r2 / respond-01~e.18
                              :ARG1~e.25 (e4 / enzyme
                                    :name (n4 / name :op1 "TPA"~e.26)))))))

# ::tok In NIH3T3 cells , co @-@ transfection of an expression vector for Gal @-@ Elk mediates expression from a transfected GAL @-@ CAT reporter gene , which , as shown in Figure 6a , b, is potentiated upon treatment of serum @-@ starved cells with anisomycin . Replacement of the major SAPK phosphorylation site in Gal @-@ Elk , Ser383 , with alanine ( Gal @-@ Elks 383 A ) abrogates induction of reporter gene expression .
# ::alignments 1-1.1.3.1.1 2-1.1.3 6-1.1.2.1.3 9-1.1.1.1.1 10-1.1.1.1 12-1.2.1.1.1.3.1.1 14-1.2.1.1.1.3.1.1 15-1.1 16-1.1.2 19-1.1.2.1.3 20-1.1.2.1.1.1 22-1.1.2.1.1.1 23-1.1.2.1.2 24-1.1.2.1 29-1.1.2.2.2 31-1.1.2.2.2.1.1 31-1.1.2.2.2.1.2 32-1.1.2.2.2.1.1.1 38-1.1.2.2.1 39-1.1.2.2.1.1.r 40-1.1.2.2.1.1.1.1 42-1.1.2.2.1.1.1 43-1.1.2.2.1.1 44-1.1.2.2.1.2.r 45-1.1.2.2.1.2.1.1 47-1.2.1 50-1.2.1.1.2 51-1.2.1.1.1.4.1.1.1 52-1.2.1.1.1 52-1.2.1.1.1.4 52-1.2.1.1.1.4.r 53-1.2.1.1 54-1.2.1.2.r 55-1.2.1.2.3 56-1.2.1.2.3 57-1.2.1.2.3 62-1.2.1.2.2.1 64-1.1.1.1.1.1.1.1 67-1.2.1.1.1.1 67-1.2.1.2.1 70-1.2 71-1.2.2 72-1.2.2.2.r 73-1.2.2.2.1.1 74-1.2.2.2.1 75-1.2.2.2
# ::id bel_pmid_854_8291_16560
(m2 / multi-sentence
      :snt1 (m / mediate-01~e.15
            :ARG0 (c2 / cotransfect-00
                  :ARG1 (v / vector~e.10
                        :ARG1-of (e / express-03~e.9
                              :ARG2 (p / protein
                                    :name (n2 / name :op1 "Gal-Elk"~e.64)))))
            :ARG1 (e2 / express-03~e.16
                  :ARG1 (g / gene~e.24
                        :name (n3 / name :op1 "GAL-CAT"~e.20,22)
                        :ARG0-of (r / report-01~e.23)
                        :ARG1-of (t / transfect-00~e.6,19))
                  :ARG1-of (p2 / potentiate-00
                        :ARG2 (t2 / treat-04~e.38
                              :ARG1~e.39 (c3 / cell~e.43
                                    :ARG1-of (s / starve-01~e.42
                                          :ARG2 (s2 / serum~e.40)))
                              :ARG2~e.44 (s4 / small-molecule
                                    :name (n7 / name :op1 "anisomycin"~e.45)))
                        :ARG1-of (s3 / show-01~e.29
                              :ARG0 (a2 / and
                                    :op1 (f / figure~e.31 :mod "6a"~e.32)
                                    :op2 (f2 / figure~e.31 :mod "6b")))))
            :location (c / cell~e.2
                  :name (n / name :op1 "NIH3T3"~e.1)))
      :snt2 (a3 / abrogate-01~e.70
            :ARG0 (r2 / replace-01~e.47
                  :ARG1 (p5 / protein-segment~e.53
                        :mod (a / amino-acid~e.52
                              :mod "383"~e.67
                              :name (n5 / name :op1 "serine")
                              :part-of (p4 / protein
                                    :name (n6 / name :op1 "Gal-Elk"~e.12,14))
                              :ARG1-of~e.52 (p3 / phosphorylate-01~e.52
                                    :ARG2 (e4 / enzyme
                                          :name (n8 / name :op1 "SAPK"~e.51))))
                        :mod (m3 / major~e.50))
                  :ARG2~e.54 (a5 / amino-acid
                        :mod "383"~e.67
                        :name (n4 / name :op1 "alanine"~e.62)
                        :part-of p4~e.55,56,57))
            :ARG1 (i / induce-01~e.71
                  :ARG0 r2
                  :ARG1~e.72 (e3 / express-03~e.75
                        :ARG1 (g2 / gene~e.74
                              :ARG0-of (r3 / report-01~e.73))))))

# ::tok Elk @-@ 1 is phosphorylated by both kinases ( MAPK8 and MAPK9 ) , each of which is strongly stimulated by pre @-@ treatment of cells with ultraviolet light .
# ::alignments 0-1.1.1.1 2-1.1.1.1 4-1 5-1.2.r 6-1.2.4 7-1.2.1 7-1.2.2 9-1.2.1.1.1 10-1.2 11-1.2.2.1.1 18-1.2.3.2 18-1.2.3.2.r 19-1.2.3 23-1.2.3.1 24-1.2.3.1.1.r 25-1.2.3.1.1 26-1.2.3.1.2.r 27-1.2.3.1.2.1 28-1.2.3.1.2
# ::id bel_pmid_854_8291_18250
(p / phosphorylate-01~e.4
      :ARG1 (p2 / protein
            :name (n / name :op1 "Elk-1"~e.0,2))
      :ARG2~e.5 (a / and~e.10
            :op1 (k / kinase~e.7
                  :name (n2 / name :op1 "MAPK8"~e.9))
            :op2 (k2 / kinase~e.7
                  :name (n3 / name :op1 "MAPK9"~e.11))
            :ARG1-of (s / stimulate-01~e.19
                  :ARG0 (t / treat-04~e.23
                        :ARG1~e.24 (c / cell~e.25)
                        :ARG2~e.26 (l / light~e.28
                              :mod (u / ultraviolet~e.27))
                        :time (b / before))
                  :manner~e.18 (s2 / strong~e.18))
            :mod (b2 / both~e.6)))

# ::tok Figure 3b shows that activated SAPKs isolated from cells stimulate the formation of a ternary complex by Elk @-@ 1 ( Fig . 3b , lanes 8 and 10 ) .
# ::alignments 0-1.1 1-1.1.1 2-1 3-1.2.r 4-1.2.2 6-1.2.3 7-1.2.3.1.r 8-1.2.3.1 9-1.2 9-1.2.4 9-1.2.4.r 11-1.2.4.1 12-1.2.4.1.2.r 14-1.2.4.1.2.1 15-1.2.4.1.2 16-1.2.4.1.1.r 17-1.2.4.1.1.1.1 19-1.2.4.1.1.1.1 23-1.3.1.2 25-1.3.1 26-1.3.1.1.1.1 27-1.3.1.1.1 28-1.3.1.1.1.2
# ::id bel_pmid_854_8291_21982
(s / show-01~e.2
      :ARG0 (f / figure~e.0 :mod "3b"~e.1)
      :ARG1~e.3 (e / enzyme~e.9
            :name (n / name :op1 "SAPK")
            :ARG1-of (a / activate-01~e.4)
            :ARG1-of (i / isolate-01~e.6
                  :ARG2~e.7 (c / cell~e.8))
            :ARG0-of~e.9 (s2 / stimulate-01~e.9
                  :ARG1 (f2 / form-01~e.11
                        :ARG0~e.16 (p / protein
                              :name (n2 / name :op1 "Elk-1"~e.17,19))
                        :ARG1~e.12 (c2 / complex~e.15
                              :mod (t / ternary~e.14)))))
      :ARG1-of (d / describe-01
            :ARG0 (l / lane~e.25
                  :ARG1-of (l2 / label-01
                        :ARG2 (a2 / and~e.27 :op1 "8"~e.26 :op2 "10"~e.28))
                  :part-of f~e.23)))

# ::tok As shown in Figure 6e , expression of MEKK1 fails to activate either ERK1 or ERK2 , whereas both p46 SAPK and p54SAPK are activated at expression levels that result in reporter gene expression .
# ::alignments 1-1.4 2-1.4.1.r 3-1.4.1 4-1.4.1.1 6-1.1 7-1.1.1.r 8-1.1.1.1.1 9-1 11-1.2 13-1.2.2.1.1.1 14-1.2.2 15-1.2.2.2.1.1 17-1.3 18-1.3.1.2.3 19-1.3.1.2.1.1.1 20-1.3.1.2.1.1.2 21-1.3.1.2 24-1.2 24-1.3.1 25-1.3.1.1.r 26-1.3.1.1.2 27-1.3.1.1 29-1.3.1.1.1 30-1.3.1.1.1.1.r 31-1.3.1.1.1.1.1.1 32-1.3.1.1.1.1.1 33-1.3.1.1.1.1
# ::id bel_pmid_854_8291_22000
(f2 / fail-01~e.9
      :ARG1 (e / express-03~e.6
            :ARG2~e.7 (e2 / enzyme
                  :name (n / name :op1 "MEKK1"~e.8)))
      :ARG2 (a / activate-01~e.11,24
            :ARG0 e
            :ARG1 (o / or~e.14
                  :op1 (e3 / enzyme
                        :name (n2 / name :op1 "ERK1"~e.13))
                  :op2 (e4 / enzyme
                        :name (n3 / name :op1 "ERK2"~e.15))))
      :ARG1-of (c / contrast-01~e.17
            :ARG2 (a2 / activate-01~e.24
                  :ARG0~e.25 (l / level~e.27
                        :ARG1-of (r / result-01~e.29
                              :ARG2~e.30 (e8 / express-03~e.33
                                    :ARG1 (g / gene~e.32
                                          :ARG0-of (r2 / report-01~e.31))))
                        :degree-of e~e.26)
                  :ARG1 (a3 / and~e.21
                        :op1 (e5 / enzyme
                              :name (n4 / name :op1 "p46"~e.19 :op2 "SAPK"~e.20))
                        :op2 (e6 / enzyme
                              :name (n5 / name :op1 "p54" :op2 "SAPK"))
                        :mod (b / both~e.18))))
      :ARG1-of (s / show-01~e.1
            :ARG0~e.2 (f / figure~e.3 :mod "6e"~e.4)))

# ::tok Co @-@ transfection of 1.25 ug MEKK1 expression vector elicited a 24 @-@ fold activation of Gal @-@ Elk @-@ dependent reporter expression in serum @-@ starved NIH3T3 cells ( Fig . 6c , d ) .
# ::alignments 3-1.2.3 4-1.1.1.1.1.2.1 6-1.1.1.1.1.1.1 7-1.1.1.1 8-1.1.1 9-1 11-1.2.3.1 14-1.2 15-1.2.2.r 15-1.2.3 16-1.2.2.1.2.1.1.1 18-1.2.2.1.2.1.1.1 20-1.2.2.1.2 21-1.2.2.1 21-1.2.2.1.1 21-1.2.2.1.1.r 22-1.2.2 23-1.2.2.2.r 24-1.2.2.2.2.1 26-1.2.2.2.2 27-1.2.2.2.1.1 28-1.2.2.2 32-1.3.1.1.1
# ::id bel_pmid_854_8291_29024
(e / elicit-01~e.9
      :ARG0 (c / cotransfect-00
            :ARG1 (v / vector~e.8
                  :ARG1-of (e2 / express-03~e.7
                        :ARG2 (e3 / enzyme
                              :name (n / name :op1 "MEKK1"~e.6)
                              :quant (m / mass-quantity
                                    :quant "1.25"~e.4
                                    :unit (m2 / microgram))))))
      :ARG1 (a / activate-01~e.14
            :ARG0 c
            :ARG1~e.15 (e4 / express-03~e.22
                  :ARG1 (g / gene~e.21
                        :ARG0-of~e.21 (r / report-01~e.21)
                        :ARG0-of (d / depend-01~e.20
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "Gal-Elk"~e.16,18))))
                  :ARG3~e.23 (c2 / cell~e.28
                        :name (n3 / name :op1 "NIH3T3"~e.27)
                        :ARG1-of (s / starve-01~e.26
                              :ARG2 (s2 / serum~e.24))))
            :quant (p / product-of~e.3,15 :op1 "24"~e.11))
      :ARG1-of (d2 / describe-01
            :ARG0 (a2 / and
                  :op1 (f / figure :mod "6c"~e.32)
                  :op2 (f2 / figure :mod "6d"))))

# ::tok The observation that Elk @-@ 1 is phosphorylated directly and activated by p46SAPK and p54SAPK further implicates it in the stress @-@ response induction of the c @-@ fos gene .
# ::alignments 1-1.1 2-1.1.1.r 3-1.1.1.1.1.1.1 5-1.1.1.1.1.1.1 7-1.1.1.1 8-1.1.1.1.3 8-1.1.1.1.3.r 9-1.1.1 9-1.1.1.1.2 10-1.1.1.2 13-1.1.1 15-1.4 16-1 17-1.2 18-1.3.r 20-1.3.2.1 22-1.3.2 23-1.3 24-1.3.1.r 26-1.3.1.1.1 28-1.3.1.1.1 29-1.3.1
# ::id bel_pmid_854_8291_32900
(i / implicate-01~e.16
      :ARG0 (o / observe-01~e.1
            :ARG1~e.2 (a / and~e.9,13
                  :op1 (p / phosphorylate-01~e.7
                        :ARG1 (p2 / protein
                              :name (n / name :op1 "Elk-1"~e.3,5))
                        :ARG2 (a3 / and~e.9
                              :op1 (e / enzyme
                                    :name (n2 / name :op1 "p46" :op2 "SAPK"))
                              :op2 (e2 / enzyme
                                    :name (n3 / name :op1 "p54" :op2 "SAPK")))
                        :manner~e.8 (d / direct~e.8))
                  :op2 (a2 / activate-01~e.10
                        :ARG0 a3
                        :ARG1 p2)))
      :ARG1 p2~e.17
      :ARG2~e.18 (i2 / induce-01~e.23
            :ARG1~e.24 (g / gene~e.29
                  :name (n4 / name :op1 "c-fos"~e.26,28))
            :ARG2-of (r / respond-01~e.22
                  :ARG1 (s / stress~e.20)))
      :degree (f / further~e.15))

# ::tok For comparison , ElkC was also phosphorylated using recombinant ERK1 that had been activated by phosphorylation with a constitutively active mutant of the MAPK @/@ ERK kinase MKK1 [23].
# ::alignments 1-1.3 3-1.1.1.1 5-1.4 6-1 7-1.2 7-1.3.r 9-1.2.1.1.1 13-1.2.1.3 13-1.2.1.3.1.2.2.2 14-1.2.1.3.1.r 15-1.2.1.3.1 16-1.2.1.3.1.2.r 18-1.2.1.3.1.2.2.3 20-1.2.1.3.1.2 20-1.2.1.3.1.2.2 20-1.2.1.3.1.2.2.r 21-1.2.1.3.1.2.2.1.r 23-1.2.1.3.1.2.2.1.1.1 25-1.2.1.3.1.2.2.1.1.1 26-1.2.1.3.1.2.2.1 27-1.2.1.3.1.2.1.1
# ::id bel_pmid_854_8291_36930
(p / phosphorylate-01~e.6
      :ARG1 (p2 / protein
            :name (n / name :op1 "ElkC"~e.3))
      :ARG2 (u / use-01~e.7
            :ARG1 (e / enzyme
                  :name (n2 / name :op1 "ERK1"~e.9)
                  :ARG0-of (r / recombine-01)
                  :ARG1-of (a2 / activate-01~e.13
                        :ARG0~e.14 (p3 / phosphorylate-01~e.15
                              :ARG1 e
                              :ARG2~e.16 (e2 / enzyme~e.20
                                    :name (n3 / name :op1 "MKK1"~e.27)
                                    :ARG2-of~e.20 (m / mutate-01~e.20
                                          :ARG1~e.21 (k / kinase~e.26
                                                :name (n4 / name :op1 "MAPK/ERK"~e.23,25))
                                          :ARG1-of (a4 / activate-01~e.13)
                                          :mod (c2 / constitutive~e.18)))))))
      :purpose~e.7 (c / compare-01~e.1)
      :mod (a / also~e.5)
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication-91
                  :ARG1-of (c3 / cite-01 :ARG2 "23"))))

# ::tok In the case of Th2 @-@ type cytokines , enhanced production of IL @-@ 4 and IL @-@ 6 was reduced by treatment with anti @-@ TGF-/3 or anti @-@ IL @- IO ( Fig . 5B ) .
# ::alignments 4-1.1.1.1.1 6-1.1.1.2 9-1.2.2 10-1.2 11-1.2.1.r 12-1.2.1.1.1.1 14-1.2.1.1.1.1 15-1.2.1 16-1.2.1.1.1.1 16-1.2.1.2.1.1 18-1.2.1.2.1.1 20-1 22-1.1 23-1.1.2.r 24-1.1.2.1.1 24-1.1.2.2.1 26-1.1.2.1.1.1.1.1 27-1.1.2 28-1.1.2.1.1 28-1.1.2.2.1 30-1.1.2.2.1.1.1.1 32-1.1.2.2.1.1.1.1 36-1.3.1.1
# ::id bel_pmid_859_8496_27892
(r / reduce-01~e.20
      :ARG0 (t / treat-04~e.22
            :ARG1 (c4 / cytokine
                  :name (n4 / name :op1 "Th2"~e.4)
                  :mod (t3 / type~e.6))
            :ARG2~e.23 (o / or~e.27
                  :op1 (a2 / antibody
                        :ARG0-of (c3 / counter-01~e.24,28
                              :ARG1 (p4 / protein
                                    :name (n3 / name :op1 "TGF-/3"~e.26))))
                  :op2 (a3 / antibody
                        :ARG0-of (c / counter-01~e.24,28
                              :ARG1 (p7 / protein
                                    :name (n5 / name :op1 "IL-IO"~e.30,32))))))
      :ARG1 (p / produce-01~e.10
            :ARG1~e.11 (a / and~e.15
                  :op1 (p2 / protein
                        :name (n / name :op1 "IL-4"~e.12,14,16))
                  :op2 (p3 / protein
                        :name (n2 / name :op1 "IL-6"~e.16,18)))
            :ARG1-of (e / enhance-01~e.9))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "5B"~e.36)))

# ::tok As shown in Figure 5A , reduced production of Th I -@ type cytokines ( IFN @-@ y , not detected ; IL @-@ 2 , 38.0 -@ t 10.0 %) by EL4 @-@ T was significantly rcstored by treatmcnt with anti @-@ TGF @-@ P ( IFN @-@ y , 191.0 i 21.9 % ; IL @-@ 2 , 8 I . 1 i 17.5 %), while anti @-@ IL @- IO treatment had little etfect
# ::alignments 1-1.5 2-1.5.1.r 3-1.5.1 4-1.5.1.1 6-1.1.2 7-1.1 10-1.3.2.1.1.2.1.1.1.3 10-1.3.2.1.1.2.1.2.1.3 10-1.3.2.1.1.2.1.2.1.6 12-1.1.1.2 15-1.1.1.3.1.1.1.1 17-1.1.1.3.1.1.1.1 19-1.1.1.3.1.1.2.1 19-1.1.1.3.1.1.2.1.r 20-1.1.1.3.1.1.2 22-1.1.1.3.1.2.1.1 26-1.1.1.3.1.2.1.2 28-1.1.1.3.1.2.1.3 29-1.1.1.3.1.2.2.1 31-1.1.2.1.r 32-1.1.2.1.1.1 34-1.1.2.1.1.1 36-1.2 41-1.3.2.1 43-1.3.2.1.1.1.1 45-1.3.2.1.1.1.1 47-1.1.1.3.1.1.1.1 47-1.3.2.1.1.2.1.1.1.1 49-1.1.1.3.1.1.1.1 51-1.3.2.1.1.2.1.1.1.2 52-1.3.2.1.1.2.1.1.1.3 53-1.3.2.1.1.2.1.1.2.1 54-1.1.1.3.1.2.2 54-1.3.2.1.1.2.1.1.2 54-1.3.2.1.1.2.1.2.2 56-1.3.2.1.1.2.1.2.1.1 60-1.3.2.1.1.2.1.2.1.2 61-1.3.2.1.1.2.1.2.1.3 61-1.3.2.1.1.2.1.2.1.5 61-1.3.2.1.1.2.1.2.1.6 62-1.3.2.1.1.2.1.2.1.4 63-1.3.2.1.1.2.1.2.1.5 64-1.3.2.1.1.2.1.2.1.3 64-1.3.2.1.1.2.1.2.1.5 64-1.3.2.1.1.2.1.2.1.6 65-1.3.2.1.1.2.1.2.2.1 67-1.4 68-1.4.1.1.2.1 70-1.4.1.1.2.1.1.1.1 72-1.4.1.1.2.1.1.1.1 73-1.3 73-1.4.1.1 75-1.4.1.3
# ::id bel_pmid_859_8496_31126
(r / restore-01
      :ARG1 (p / produce-01~e.7
            :ARG1 (c3 / cytokine
                  :name (n8 / name :op1 "Th1")
                  :mod (t4 / type~e.12)
                  :ARG1-of (e / exemplify-01
                        :ARG0 (a / and
                              :op1 (p2 / protein
                                    :name (n2 / name :op1 "IFN-y"~e.15,17,47,49)
                                    :ARG1-of (d / detect-01~e.20 :polarity~e.19 "-"~e.19))
                              :op2 (p6 / protein
                                    :name (n5 / name
                                          :op1 "IL-2,"~e.22
                                          :op2 "38.0"~e.26
                                          :op3 "-t"~e.28)
                                    :mod (p7 / percentage-entity~e.54 :value "10.0"~e.29)))))
            :ARG1-of (r2 / reduce-01~e.6
                  :ARG0~e.31 (c2 / cell
                        :name (n / name :op1 "EL4-T"~e.32,34))))
      :degree (s2 / significant~e.36)
      :manner (t / treat-04~e.73
            :ARG1 c2
            :ARG2 (a4 / antibody
                  :ARG0-of (c6 / counter-01~e.41
                        :ARG1 (p5 / protein
                              :name (n4 / name :op1 "TGF-P"~e.43,45)
                              :ARG1-of (e2 / exemplify-01
                                    :ARG0 (a3 / and
                                          :op1 (p8 / protein
                                                :name (n6 / name
                                                      :op1 "IFN-y,"~e.47
                                                      :op2 "191.0"~e.51
                                                      :op3 "i"~e.10,52)
                                                :mod (p9 / percentage-entity~e.54 :value "21.9"~e.53))
                                          :op2 (p10 / protein
                                                :name (n7 / name
                                                      :op1 "IL-2,"~e.56
                                                      :op2 "8"~e.60
                                                      :op3 "I"~e.10,61,64
                                                      :op4 "."~e.62
                                                      :op5 "1"~e.61,63,64
                                                      :op6 "i"~e.10,61,64)
                                                :mod (p11 / percentage-entity~e.54 :value "17.5"~e.65))))))))
      :ARG1-of (c4 / contrast-01~e.67
            :ARG2 (a2 / affect-01
                  :ARG0 (t2 / treat-04~e.73
                        :ARG1 c2
                        :ARG2 (a5 / antibody
                              :ARG0-of (c5 / counter-01~e.68
                                    :ARG1 (p4 / protein
                                          :name (n3 / name :op1 "IL-IO"~e.70,72)))))
                  :ARG1 c2
                  :degree (l / little~e.75)))
      :ARG1-of (s / show-01~e.1
            :ARG0~e.2 (f / figure~e.3 :mod "5A"~e.4)))

# ::tok Similar observation that immunoprecipitated B @-@ Raf from EGF @-@ stimulated Swiss3T3 cells could activate both MEK1 and MEK2 was also obtained ( data not shown ) .
# ::alignments 0-1.1.2 1-1.1 4-1.1.1.1.1.1.1 6-1.1.1.1.1.1.1 7-1.1.1.1.1.3.r 8-1.1.1.1.1.3.2.1.1.1 10-1.1.1.1.1.3.2 11-1.1.1.1.1.3.1.1 12-1.1.1.1.1.3 13-1.1.1 14-1.1.1.1 15-1.1.1.1.2.3 16-1.1.1.1.2.1.1.1 17-1.1.1.1.2 18-1.1.1.1.2.2.1.1 19-1.1.1.1.r 20-1.2 21-1 24-1.3.1 24-1.3.1.r 25-1.3
# ::id bel_pmid_862_1729_21570
(o / obtain-01~e.21
      :ARG1 (o2 / observe-01~e.1
            :ARG1 (p / possible~e.13
                  :domain~e.19 (a / activate-01~e.14
                        :ARG0 (e / enzyme
                              :name (n / name :op1 "B-Raf"~e.4,6)
                              :ARG1-of (i / immunoprecipitate-00)
                              :source~e.7 (c / cell-line~e.12
                                    :name (n2 / name :op1 "Swiss3T3"~e.11)
                                    :ARG1-of (s / stimulate-01~e.10
                                          :ARG0 (p2 / protein
                                                :name (n3 / name :op1 "EGF"~e.8)))))
                        :ARG1 (a2 / and~e.17
                              :op1 (e2 / enzyme
                                    :name (n4 / name :op1 "MEK1"~e.16))
                              :op2 (e3 / enzyme
                                    :name (n5 / name :op1 "MEK2"~e.18))
                              :mod (b / both~e.15))))
            :ARG1-of (r / resemble-01~e.0))
      :mod (a3 / also~e.20)
      :ARG1-of (s2 / show-01~e.25 :polarity~e.24 "-"~e.24))

# ::tok The activated GST @-@ MEK1 was then used to activate the purified recombinant extracellular signal @-@ regulated kinase 1 , whose activity was measured by the [32P @-@ g]ATP incorporation into MBP , an extracellular signal @-@ regulated kinase 1 substrate .
# ::alignments 1-1.1.2 1-1.2 2-1.1.1.1 4-1.1.1.1 6-1.3 7-1 9-1.1.2 9-1.2 11-1.2.2.3 13-1.2.2.1.1 14-1.2.2.1.2 16-1.2.2.1.2 17-1.2.2.1.3 18-1.2.2.1.4 23-1.2.2.4.1 23-1.2.2.4.2 29-1.2.2.4.1.1 30-1.2.2.4.1.1.2.r 31-1.2.2.4.1.1.2.1.1 34-1.2.2.1.1 35-1.2.2.1.2 37-1.2.2.1.2 38-1.2.2.1.3 39-1.2.2.1.4 40-1.2.2.4.1.1.2.2.1
# ::id bel_pmid_862_1729_36932
(u / use-01~e.7
      :ARG1 (e / enzyme
            :name (n / name :op1 "GST-MEK1"~e.2,4)
            :ARG1-of (a / activate-01~e.1,9))
      :ARG2 (a2 / activate-01~e.1,9
            :ARG0 e
            :ARG1 (e2 / enzyme
                  :name (n2 / name
                        :op1 "extracellular"~e.13,34
                        :op2 "signal-regulated"~e.14,16,35,37
                        :op3 "kinase"~e.17,38
                        :op4 "1"~e.18,39)
                  :ARG0-of (r / recombine-01)
                  :ARG1-of (p / purify-01~e.11)
                  :ARG0-of (a3 / act-01
                        :ARG1-of (m / measure-01~e.23
                              :ARG2 (i / incorporate-02~e.29
                                    :ARG1 (s / small-molecule
                                          :name (n3 / name :op1 "ATP")
                                          :part (g / gamma-phosphorus
                                                :mod (m2 / molecular-mass :value "32")))
                                    :ARG2~e.30 (p2 / protein
                                          :name (n4 / name :op1 "MBP"~e.31)
                                          :ARG1-of (m4 / mean-01
                                                :ARG2 (s2 / substrate~e.40
                                                      :poss e2)))))
                        :ARG1-of (m3 / measure-01~e.23))))
      :time (t / then~e.6))

# ::tok c @-@ Raf activates MEK1 by phosphorylating at serine residues 218 and 222 ( 30–32 ) .
# ::alignments 2-1.1.1.1 3-1 4-1.3.1.3.2.1.1 6-1.3 8-1.3.1.3.1.1 9-1.3.1 10-1.3.1.1 11-1.3.1.3.3 12-1.3.1.2
# ::id bel_pmid_862_1729_37176
(a / activate-01~e.3
      :ARG0 (e / enzyme
            :name (n / name :op1 "C-Raf"~e.2))
      :ARG1 (e3 / enzyme
            :name (n4 / name :op1 "MEK1"~e.4))
      :manner (p / phosphorylate-01~e.6
            :ARG1 (r / residue~e.9
                  :mod "218"~e.10
                  :mod "222"~e.12
                  :mod (a2 / amino-acid
                        :name (n3 / name :op1 "serine"~e.8)
                        :part-of e3
                        :mod (b / between~e.11
                              :op1 (a3 / amino-acid :mod "30")
                              :op2 (a4 / amino-acid :mod "32"))))))

# ::tok activated MEK1 increased Elk @-@ 1 @- and c @-@ Jun @-@ dependent gene expression but not ATF2 @-@ dependent gene expression ( Fig . 4 ) .
# ::alignments 0-1.1.2 1-1.1.1.1 2-1 2-1.3.1 3-1.2.1.1.1.1.1.1 5-1.2.1.1.1.1.1.1 7-1.2.1.1.1 8-1.2.1.1.1.2.1.1 10-1.2.1.1.1.2.1.1 12-1.2.1.1 12-1.3.1.3.1.1 13-1.2.1 13-1.3.1.3.1 14-1.2 14-1.3.1.3 15-1.3 16-1.3.1.1 16-1.3.1.1.r 17-1.3.1.3.1.1.1.1.1 19-1.2.1.1 20-1.2.1 21-1.2 25-1.4.1.1
# ::id bel_pmid_862_2669_21840
(i / increase-01~e.2
      :ARG0 (e / enzyme
            :name (n / name :op1 "MEK1"~e.1)
            :ARG1-of (a / activate-01~e.0))
      :ARG1 (e2 / express-03~e.14,21
            :ARG1 (g / gene~e.13,20
                  :ARG0-of (d / depend-01~e.12,19
                        :ARG1 (a2 / and~e.7
                              :op1 (p / protein
                                    :name (n2 / name :op1 "Elk-1"~e.3,5))
                              :op2 (p2 / protein
                                    :name (n3 / name :op1 "c-Jun"~e.8,10))))))
      :ARG1-of (c / contrast-01~e.15
            :ARG2 (i2 / increase-01~e.2
                  :polarity~e.16 "-"~e.16
                  :ARG0 e
                  :ARG1 (e3 / express-03~e.14
                        :ARG1 (g2 / gene~e.13
                              :ARG0-of (d2 / depend-01~e.12
                                    :ARG1 (p3 / protein
                                          :name (n4 / name :op1 "ATF2"~e.17)))))))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "4"~e.25)))

# ::tok MKK3( Glu ) increased ATF2 @- and Elk @-@ 1 @-@ dependent reporter gene expression but caused only a small increase in Jun @-@ dependent gene expression ( Fig . 4 ) .
# ::alignments 3-1.1 4-1.1.2.1.2.1.1.1.1 6-1.1.2.1.2.1 7-1.1.2.1.2.1.2.1.1 9-1.1.2.1.2.1.2.1.1 11-1.1.2.1.2 12-1.1.2.1.1 13-1.1.2.1 14-1.1.2 15-1 16-1.2 17-1.2.2.2.1 19-1.2.2.2 20-1.2.2 22-1.2.2.1.1.1.1.1.1 24-1.2.2.1.1.1 25-1.2.2.1.1 26-1.1.2 26-1.2.2.1 30-1.3.1.1
# ::id bel_pmid_862_2669_21852
(c / contrast-01~e.15
      :ARG1 (i / increase-01~e.3
            :ARG0 (e / enzyme
                  :name (n / name :op1 "MKK3(Glu)"))
            :ARG1 (e2 / express-03~e.14,26
                  :ARG1 (g / gene~e.13
                        :ARG0-of (r / report-01~e.12)
                        :ARG0-of (d / depend-01~e.11
                              :ARG1 (a / and~e.6
                                    :op1 (p2 / protein
                                          :name (n2 / name :op1 "ATF2"~e.4))
                                    :op2 (p / protein
                                          :name (n3 / name :op1 "Elk-1"~e.7,9)))))))
      :ARG2 (c2 / cause-01~e.16
            :ARG0 e
            :ARG1 (i2 / increase-01~e.20
                  :ARG1 (e4 / express-03~e.26
                        :ARG1 (g2 / gene~e.25
                              :ARG0-of (d2 / depend-01~e.24
                                    :ARG1 (p3 / protein
                                          :name (n4 / name :op1 "Jun"~e.22)))))
                  :degree (s / small~e.19
                        :mod (o / only~e.17))))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "4"~e.30)))

# ::tok In contrast , the effect of MKK6( Glu ) was markedly reduced in experiments using phosphorylation @-@ defective ( Ala @-@ 69 , Ala @-@ 71 ) ATF2 .
# ::alignments 1-1.2 4-1.1 10-1.3 10-1.3.r 11-1 12-1.4.r 13-1.4 14-1.4.1 15-1.4.1.1 15-1.4.1.1.2 15-1.4.1.1.2.r 17-1.4.1.1.2.1 21-1.4.1.1.3.1 25-1.4.1.1.3.2 27-1.4.1.1.1.1
# ::id bel_pmid_862_2669_21858
(r / reduce-01~e.11
      :ARG1 (e / effect-01~e.4
            :ARG0 (e2 / enzyme
                  :name (n / name :op1 "MKK6(Glu)")))
      :ARG2-of (c / contrast-01~e.1)
      :manner~e.10 (m / marked~e.10)
      :manner~e.12 (e3 / experiment-01~e.13
            :ARG2 (u / use-01~e.14
                  :ARG1 (p2 / protein~e.15
                        :name (n2 / name :op1 "ATF2"~e.27)
                        :ARG2-of~e.15 (p / phosphorylate-01~e.15
                              :mod (d / defective~e.17))
                        :part (a4 / amino-acid
                              :mod "69"~e.21
                              :mod "71"~e.25
                              :name (n5 / name :op1 "alanine"))))))

# ::tok Increased ATF2 @-@ dependent gene expression was observed in cells transfected with MKK6( Glu ) . In contrast , MKK3( Glu ) did not increase ATF2 @-@ dependent gene expression in the absence of overexpression of p38 MAP kinase ( Fig . 8A ) .
# ::alignments 0-1.2 1-1.2.3.1.1.1.1.1 3-1.1.1.1.1 3-1.2.3.1.1 4-1.1.1.1 4-1.2.3.1 5-1.1.1 5-1.2.3 7-1.1 8-1.1.1.2.r 9-1.1.1.2 10-1.1.1.2.1 17-1.2.4 23-1.2.1 23-1.2.1.r 24-1.1.1.3 24-1.2 25-1.1.1.1.1.1.1.1 25-1.2.3.1.1.1.1.1 27-1.2.3.1.1 28-1.2.3.1 29-1.2.3 30-1.2.5.r 32-1.2.5 33-1.2.5.1.r 34-1.2.5.1 35-1.2.5.1.1.r 36-1.2.5.1.1.1.1 42-1.2.6.1.1
# ::id bel_pmid_862_2669_21860
(m / multi-sentence
      :snt1 (o / observe-01~e.7
            :ARG1 (e / express-03~e.5
                  :ARG1 (g / gene~e.4
                        :ARG0-of (d / depend-01~e.3
                              :ARG1 (p / protein
                                    :name (n / name :op1 "ATF2"~e.25))))
                  :ARG3~e.8 (c / cell~e.9
                        :ARG1-of (t / transfect-00~e.10
                              :ARG2 (e3 / enzyme
                                    :name (n2 / name :op1 "MKK6(Glu)"))))
                  :ARG1-of (i / increase-01~e.24)))
      :snt2 (i2 / increase-01~e.0,24
            :polarity~e.23 "-"~e.23
            :ARG0 (e4 / enzyme
                  :name (n3 / name :op1 "MKK3(Glu)"))
            :ARG1 (e5 / express-03~e.5,29
                  :ARG1 (g2 / gene~e.4,28
                        :ARG0-of (d2 / depend-01~e.3,27
                              :ARG1 (e6 / enzyme
                                    :name (n4 / name :op1 "ATF2"~e.1,25)))))
            :ARG2-of (c2 / contrast-01~e.17)
            :condition~e.30 (a / absent-01~e.32
                  :ARG1~e.33 (e8 / express-03~e.34
                        :ARG2~e.35 (e7 / enzyme
                              :name (n5 / name :op1 "p38"~e.36 :op2 "MAPK"))
                        :degree (t2 / too)))
            :ARG1-of (d3 / describe-01
                  :ARG0 (f / figure :mod "8A"~e.42))))

# ::tok Specifically , PTH and PTHrP rapidly and transiently induce expression of the mRNAs encoding IL @-@ 6 and LIF .
# ::alignments 0-1.3 2-1.1.1.1.1 3-1.1 4-1.1.2.1.1 5-1.4 5-1.4.r 6-1.1 7-1.5 8-1 9-1.2 13-1.2.1.2 14-1.2.1.2.1.1.1.1 16-1.2.1.2.1.1.1.1 17-1.2.1.2.1 18-1.2.1.2.1.2.1.1
# ::id bel_pmid_872_5172_30236
(i / induce-01~e.8
      :ARG0 (a / and~e.3,6
            :op1 (e / enzyme
                  :name (n / name :op1 "PTH"~e.2))
            :op2 (e2 / enzyme
                  :name (n2 / name :op1 "PTHrP"~e.4)))
      :ARG1 (e3 / express-03~e.9
            :ARG1 (r3 / rna
                  :name (n6 / name :op1 "messenger" :op2 "RNA")
                  :ARG0-of (e4 / encode-01~e.13
                        :ARG1 (a2 / and~e.17
                              :op1 (p / protein
                                    :name (n3 / name :op1 "IL-6"~e.14,16))
                              :op2 (p2 / protein
                                    :name (n4 / name :op1 "LIF"~e.18))))))
      :mod (s / specific~e.0)
      :manner~e.5 (r / rapid~e.5)
      :mod (t / transient~e.7))

# ::tok intracellular interaction of PKA , GMF , and p38 is supported by the phosphorylation of GMF upon cellular stimulation by forskolin ( blocked by PKA inhibitor ) and by the co @-@ immunoprecipitation of p38 with GMF from cell lysates . Withdrawal of nerve growth factor from PC12 leads to increased GMF phosphorylation with a time course similar to that reported for p38 activation .
# ::alignments 1-1.1.2 3-1.1.1.1.2.1.2.1.1.1.1.1 5-1.1.1.2.2.1.1 7-1.1.1 7-1.1.2.1 8-1.1.1.2.1.1.1 10-1.1 13-1.1.1.1 15-1.1.1.2.2.1.1 17-1.1.1.1.2.2 17-1.1.1.2.2.2.1 18-1.1.1.1.2 20-1.1.1.1.2.1.1.1 22-1.1.1.1.2.1.2 24-1.1.1.1.2.1.2.1.1.1.1.1 25-1.1.1.1.2.1.2.1 25-1.1.1.1.2.1.2.1.1 25-1.1.1.1.2.1.2.1.1.r 27-1.1.1 34-1.1.1.2.1.1.1 36-1.1.1.2.2.1.1 37-1.1.1.2.2.2.r 38-1.1.1.2.2.2.1 41-1.2.1 42-1.2.1.1.r 43-1.2.1.1.2 44-1.2.1.1.1.1 45-1.2.1.1.1.2 46-1.1.1.2.2.2.r 46-1.2.1.2.r 47-1.2.1.2.1.1 48-1.2 49-1.2.2.r 50-1.2.2.1.2 51-1.2.2.1.1.1 52-1.2.2 53-1.2.2.2.r 55-1.2.2.2.1 55-1.2.2.2.2.1.1 56-1.2.2.2 56-1.2.2.2.2.1 57-1.2.2.2.2 60-1.2.2.2.2.1.2 61-1.2.2.2.2.1.2.1.r 62-1.2.2.2.2.1.2.1.1.1.1 63-1.2.2.2.2.1.2.1
# ::id bel_pmid_879_8479_16716
(m / multi-sentence
      :snt1 (s / support-01~e.10
            :ARG0 (a2 / and~e.7,27
                  :op1 (p / phosphorylate-01~e.13
                        :ARG1 (p5 / protein
                              :name (n3 / name :op1 "GMF"~e.5,15,36)
                              :source~e.37,46 (l / lysate
                                    :part-of (c3 / cell~e.17,38
                                          :ARG0-of (c4 / contain-01
                                                :ARG1 (p3 / protein)))))
                        :ARG2 (s2 / stimulate-01~e.18
                              :ARG0 (s3 / small-molecule
                                    :name (n8 / name :op1 "forskolin"~e.20)
                                    :ARG1-of (b / block-01~e.22
                                          :ARG0 (m2 / molecular-physical-entity~e.25
                                                :ARG0-of~e.25 (i4 / inhibit-01~e.25
                                                      :ARG1 (e4 / enzyme
                                                            :name (n9 / name :op1 "PKA"~e.3,24))))))
                              :ARG1 (c / cell~e.17)))
                  :op2 (c2 / coimmunoprecipitate-00
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "p38"~e.8,34 :op2 "MAPK"))
                        :ARG2 p5))
            :ARG1 (i / interact-01~e.1
                  :ARG0 (a / and~e.7
                        :op1 (e3 / enzyme)
                        :op2 p3)
                  :ARG1 e))
      :snt2 (l2 / lead-03~e.48
            :ARG1 (w / withdraw-01~e.41
                  :ARG1~e.42 (s4 / small-molecule
                        :name (n5 / name :op1 "growth"~e.44 :op2 "factor"~e.45)
                        :mod (n2 / nerve~e.43))
                  :ARG2~e.46 (c5 / cell-line
                        :name (n4 / name :op1 "PC12"~e.47)))
            :ARG2~e.49 (p2 / phosphorylate-01~e.52
                  :ARG1 (p4 / protein
                        :name (n6 / name :op1 "GMF"~e.51)
                        :ARG1-of (i3 / increase-01~e.50))
                  :duration~e.53 (c6 / course~e.56
                        :mod (t / time~e.55)
                        :ARG1-of (r / resemble-01~e.57
                              :ARG2 (c7 / course~e.56
                                    :mod (t2 / time~e.55)
                                    :ARG1-of (r2 / report-01~e.60
                                          :topic~e.61 (a3 / activate-01~e.63
                                                :ARG1 (e2 / enzyme
                                                      :name (n7 / name :op1 "p38"~e.62 :op2 "MAPK"))))))))))

# ::tok endogenous GMF is rapidly phosphorylated upon stimulation of astrocytes by phorbol 12 @-@ myristate 13 @-@ acetate We further observed that protein kinase A ( PKA )-phosphorylated GMF is a potent inhibitor ( IC50 = 3 nM ) of the ERK1 @/@ ERK2 ( p44/p42 ) subfamily of mitogen @-@ activated protein ( MAP ) kinase .
# ::alignments 0-1.1.1.2 1-1.1.1.1.1 3-1.1.3 3-1.1.3.r 4-1.1 4-1.2.2.1.2 6-1.1.2 7-1.1.2.2.r 8-1.1.2.2 9-1.1.2.1.r 10-1.1.2.1.1.1 11-1.1.2.1.1.2 13-1.1.2.1.1.2 14-1.1.2.1.1.3 16-1.1.2.1.1.3 17-1.2.1 18-1.2.3 19-1.2 21-1.1.1 22-1.2.2.1.2.1.1.2 23-1.2.2.1.2.1.1.3 27-1.2.2.1.1.1 29-1.2.2.1.2.1.1.3 30-1.2.2.3 31-1.2.2 33-1.2.2.4.1 35-1.2.2.4.2.1.1 40-1.2.2.2.1.1.2 42-1.2.2.2.2.1.2 46-1.2.2.2.3 47-1.2.2.2.3.1.r 48-1.2.2.2.3.1.1.1 50-1.2.2.2.3.1.1.1 51-1.2.2.1.2.1.1.1 51-1.2.2.2.3.1.1.2 55-1.2.2.1.2.1.1.2 55-1.2.2.2.3.1.1.3
# ::id bel_pmid_879_8479_3974
(m / multi-sentence
      :snt1 (p / phosphorylate-01~e.4
            :ARG1 (p2 / protein~e.21
                  :name (n / name :op1 "GMF"~e.1)
                  :mod (e / endogenous~e.0))
            :ARG2 (s / stimulate-01~e.6
                  :ARG0~e.9 (s3 / small-molecule
                        :name (n2 / name
                              :op1 "phorbol"~e.10
                              :op2 "12-myristate"~e.11,13
                              :op3 "13-acetate"~e.14,16))
                  :ARG1~e.7 (a / astrocyte~e.8))
            :manner~e.3 (r / rapid~e.3))
      :snt2 (o / observe-01~e.19
            :ARG0 (w / we~e.17)
            :ARG1 (i / inhibit-01~e.31
                  :ARG0 (p3 / protein
                        :name (n3 / name :op1 "GMF"~e.27)
                        :ARG1-of (p4 / phosphorylate-01~e.4
                              :ARG2 (e2 / enzyme
                                    :name (n10 / name
                                          :op1 "protein"~e.51
                                          :op2 "kinase"~e.22,55
                                          :op3 "A"~e.23,29))))
                  :ARG1 (s2 / slash
                        :op1 (e6 / enzyme
                              :name (n4 / name :op1 "p44" :op2 "ERK1"~e.40))
                        :op2 (e7 / enzyme
                              :name (n11 / name :op1 "p42" :op2 "ERK2"~e.42))
                        :part-of (s4 / subfamily~e.46
                              :consist-of~e.47 (e5 / enzyme
                                    :name (n9 / name
                                          :op1 "mitogen-activated"~e.48,50
                                          :op2 "protein"~e.51
                                          :op3 "kinase"~e.55))))
                  :mod (p6 / potent~e.30)
                  :mod (t / thing
                        :mod "IC50"~e.33
                        :ARG1-of (e3 / equal-01
                              :ARG2 (u / unit
                                    :quant "3"~e.35
                                    :name (n7 / name :op1 "nanomolar")))))
            :degree (f / further~e.18)))

# ::tok PKA @-@ phosphorylated GMF strongly enhances the activity of a related but distinct subfamily of MAP kinase , the p38 MAP kinase , showing an increase of 60 @-@ fold over baseline and an EC50 of 7 nM .
# ::alignments 0-1.1.1.2.1.1.1 2-1.1.1.2 3-1.1.1.1.1 4-1.1.3 4-1.1.3.r 5-1.1 10-1.1.2.1.3 11-1.1.2.1.3.2.r 12-1.1.2.1.3.2 15-1.1.2.1.2.1.1.1 16-1.1.2.1 16-1.1.2.1.2.1 19-1.1.2.1.1.1 20-1.1.2.1.1.2 20-1.1.2.1.2.1.1.1 21-1.1.2.1 21-1.1.2.1.2.1 23-1.2 25-1.2.2.1 26-1.2.2.1.2 27-1.2.2.1.2.1 30-1.2.2.1.3 31-1.2.2.1.3.1 32-1.2.2 34-1.2.2.2.1.1 36-1.2.2.2.2.1
# ::id bel_pmid_879_8479_8862
(a / and
      :op1 (e / enhance-01~e.5
            :ARG0 (p / protein
                  :name (n / name :op1 "GMF"~e.3)
                  :ARG1-of (p2 / phosphorylate-01~e.2
                        :ARG2 (e2 / enzyme
                              :name (n2 / name :op1 "PKA"~e.0))))
            :ARG1 (a2 / act-01
                  :ARG0 (k / kinase~e.16,21
                        :name (n4 / name :op1 "p38"~e.19 :op2 "MAP"~e.20)
                        :part-of (f / family
                              :consist-of (k2 / kinase~e.16,21
                                    :name (n3 / name :op1 "MAP"~e.15,20)))
                        :ARG1-of (r / relate-01~e.10
                              :ARG2 f
                              :concession-of~e.11 (d / distinct~e.12
                                    :compared-to f))))
            :manner~e.4 (s2 / strong~e.4))
      :op2 (s / show-01~e.23
            :ARG0 p
            :ARG1 (a3 / and~e.32
                  :op1 (i / increase-01~e.25
                        :ARG1 k
                        :ARG2 (p3 / product-of~e.26 :op1 "60"~e.27)
                        :manner (o / over~e.30
                              :op1 (b / baseline~e.31)))
                  :op2 (t / thing
                        :name (n6 / name :op1 "EC50"~e.34)
                        :mod (c3 / concentration-quantity
                              :quant "7"~e.36
                              :unit (n5 / nanomolar))))))

# ::tok In addition , SHP @-@ 1 and its mutants showed similar association and dephosphorylation of the other Jak family members ( JAK1 , Tyk2 , and JAK3 ) but not c @-@ fes when coexpressed in Cos @-@ 7 cells ( data not shown ) .
# ::alignments 0-1.1.2 1-1.1.2 3-1.1.1.1.1.1 3-1.1.1.2.1.1 5-1.1.1.1.1.1 5-1.1.1.2.1.1 8-1.1.1.2 8-1.1.1.2.2 8-1.1.1.2.2.r 9-1.1 10-1.1.2.3 11-1.1.2.1 12-1.1.2 13-1.1.2.2 14-1.1.2.2.1.r 16-1.1.2.2.1 17-1.1.2.2.1 18-1.1.2.2.1 19-1.1.2.2.1 20-1.1.2.2.1 21-1.1.2.2.1 22-1.1.2.2.1 23-1.1.2.2.1 24-1.1.2.2.1 25-1.1.2.2.1 26-1.1.2.2.1 27-1.1.2.2.1 28-1.1.2.2.1 29-1.2.1.1.1.r 30-1.1.2.1.2.3.1.1.1 32-1.1.2.1.2.3.1.1.1 33-1.1.3.r 36-1.1.3.2.1.1 38-1.1.3.2.1.1 39-1.1.3.2 41-1.2.1 42-1.2.1.1.1 42-1.2.1.1.1.r 43-1.2.1.1
# ::id bel_pmid_894_3354_24786
(a / and
      :op2 (s / show-01~e.9
            :ARG0 (a2 / and
                  :op1 (e / enzyme
                        :name (n / name :op1 "SHP-1"~e.3,5))
                  :op2 (e2 / enzyme~e.8
                        :name (n8 / name :op1 "SHP-1"~e.3,5)
                        :ARG2-of~e.8 (m / mutate-01~e.8)))
            :ARG1 (a3 / and~e.0,1,12
                  :op1 (a4 / associate-01~e.11
                        :ARG1 a2
                        :ARG2 (m2 / member
                              :mod (o / other)
                              :ARG1-of (m3 / mean-01
                                    :ARG2 (a5 / and
                                          :op1 (e3 / enzyme
                                                :name (n3 / name :op1 "JAK1"))
                                          :op2 (e4 / enzyme
                                                :name (n4 / name :op1 "Tyk2"))
                                          :op3 (e5 / enzyme
                                                :name (n5 / name :op1 "JAK3"))))
                              :ARG1-of (c / contrast-01
                                    :ARG2 (e8 / enzyme
                                          :name (n2 / name :op1 "c-fes"~e.30,32)))
                              :ARG1-of (i2 / include-91
                                    :ARG2 (f / family
                                          :mod (e7 / enzyme
                                                :name (n6 / name :op1 "Jak"))))))
                  :op2 (d / dephosphorylate-01~e.13
                        :ARG1~e.14 m2~e.16,17,18,19,20,21,22,23,24,25,26,27,28
                        :ARG2 a2)
                  :ARG1-of (r / resemble-01~e.10))
            :time~e.33 (c4 / coexpress-00
                  :ARG2 a2
                  :ARG3 (c3 / cell-line~e.39
                        :name (n7 / name :op1 "Cos-7"~e.36,38))))
      :ARG1-of (d2 / describe-01
            :ARG0 (d3 / data~e.41
                  :ARG1-of (s2 / show-01~e.43 :polarity~e.29,42 "-"~e.42))))

# ::tok Hypoxia was capable of inducing VEGF mRNA in both immortalized and transformed endothelial cells ( 4.5 @-@ fold in cells expressing SV40 large T antigen alone or in combination with H @-@ ras ) , but both baseline and induced VEGF mRNA expression was increased in cells containing activated ras ( Fig . 4 ) .
# ::alignments 0-1.1.1 2-1.1 3-1.1.2.3.1 4-1.1.2 5-1.1.2.1.2.1.1.1 6-1.1.2.1.1.1 8-1.1.2.2.4 9-1.1.2.2.1.1 10-1.1.2.2 11-1.1.2.2.2.1 12-1.1.2.2.3 13-1.1.2.2.1 13-1.1.2.2.2 15-1.1.2.3.1.1 19-1.1.2.3.2 20-1.1.2.3.2.1 21-1.1.2.3.2.1.1.1.1.1 22-1.1.2.3.2.1.1.1.1.2 23-1.1.2.3.2.1.1.1.1.3 24-1.1.2.3.2.1.1.1.1.4 25-1.1.2.3.2.1.1.1.2 26-1.1.2.3.2.1.1 27-1.1.2.3.2.1.1.r 28-1.1.2.3.2.1.1.2 29-1.1.2.3.2.1.1.2.2.r 30-1.1.2.3.2.1.1.2.2.1.1 32-1.2.2.1.1.1.1 35-1 36-1.2.1.3 37-1.2.1.1.2 38-1.1.2.2 38-1.2.1 39-1.1.2 40-1.1.2.1.2.1.1.1 41-1.1.2.1.1.1 42-1.2.1.1 42-1.2.1.2 44-1.2 46-1.2.2 47-1.2.2.1 48-1.2.2.1.1.2 49-1.2.2.1.1.1.1 53-1.3.1.1
# ::id bel_pmid_902_3347_41730
(c8 / contrast-01~e.35
      :ARG1 (c / capable-01~e.2
            :ARG1 (h / hypoxia~e.0)
            :ARG2 (i2 / induce-01~e.4,39
                  :ARG1 (r2 / rna
                        :name (n6 / name :op1 "mRNA"~e.6,41)
                        :ARG0-of (e3 / encode-01
                              :ARG1 (p / protein
                                    :name (n4 / name :op1 "VEGF"~e.5,40))))
                  :location (a / and~e.10,38
                        :op1 (c2 / cell~e.13
                              :ARG1-of (i3 / immortalize-00~e.9))
                        :op2 (c3 / cell~e.13
                              :ARG1-of (t / transform-01~e.11))
                        :part-of (e4 / endothelium~e.12)
                        :mod (b3 / both~e.8))
                  :ARG1-of (m2 / mean-01
                        :ARG2 (p2 / product-of~e.3 :op1 "4.5"~e.15)
                        :location (c6 / cell~e.19
                              :ARG3-of (e7 / express-03~e.20
                                    :ARG1~e.27 (o / or~e.26
                                          :op1 (p3 / protein
                                                :name (n5 / name
                                                      :op1 "SV40"~e.21
                                                      :op2 "large"~e.22
                                                      :op3 "T"~e.23
                                                      :op4 "antigen"~e.24)
                                                :mod (a4 / alone~e.25))
                                          :op2 (c7 / combine-01~e.28
                                                :ARG1 p3
                                                :ARG2~e.29 (e / enzyme
                                                      :name (n / name :op1 "H-Ras"~e.30)))))))))
      :ARG2 (i4 / increase-01~e.44
            :ARG1 (a3 / and~e.38
                  :op1 (e5 / express-03~e.42
                        :ARG2 r2
                        :mod (b / baseline~e.37))
                  :op2 (e6 / express-03~e.42
                        :ARG2 r2
                        :ARG1-of i2)
                  :mod (b2 / both~e.36))
            :location (c4 / cell~e.46
                  :ARG0-of (c5 / contain-01~e.47
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "Ras"~e.32,49)
                              :ARG1-of (a2 / activate-01~e.48)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "4"~e.53)))

# ::tok Treatment of cells with wortmannin , a steroidal inhibitor of phosphatidylinositol @-@ 3 @-@ kinase ( 15 ) , resulted in a decreased level of VEGF under hypoxic conditions but the fold stimulation of VEGF mRNA was not changed ( Fig . 5 ) .
# ::alignments 0-1.1.1 1-1.1.1.1.r 2-1.1.1.1 3-1.1.1.2.r 4-1.1.1.2.1.1 8-1.1.1.2 8-1.1.1.2.2 8-1.1.1.2.2.r 9-1.1.1.2.2.1.r 10-1.1.1.2.2.1.1.1 12-1.1.1.2.2.1.1.1 14-1.1.1.2.2.1.1.1 16-1.1.1.2.4.1.1.1 19-1.1 20-1.1.2.r 22-1.1.2.2 23-1.1.2 24-1.1.2.1.r 25-1.1.2.1.1.1 28-1.1.3.r 29-1 31-1.2.2.2 32-1.2.2 34-1.1.2.1.1.1 35-1.2.2.1.1.1 37-1.2.1 37-1.2.1.r 38-1.2 42-1.3.1.1
# ::id bel_pmid_902_3347_41732
(c3 / contrast-01~e.29
      :ARG1 (r / result-01~e.19
            :ARG1 (t / treat-04~e.0
                  :ARG1~e.1 (c / cell~e.2)
                  :ARG2~e.3 (s3 / small-molecule~e.8
                        :name (n / name :op1 "wortmannin"~e.4)
                        :ARG0-of~e.8 (i3 / inhibit-01~e.8
                              :ARG1~e.9 (e / enzyme
                                    :name (n2 / name :op1 "phosphatidylinositol-3-kinase"~e.10,12,14)))
                        :mod (s / steroid)
                        :ARG1-of (d / describe-01
                              :ARG0 (p / publication
                                    :ARG1-of (c2 / cite-01 :ARG2 "15"~e.16)))))
            :ARG2~e.20 (l / level~e.23
                  :quant-of~e.24 (p2 / protein
                        :name (n3 / name :op1 "VEGF"~e.25,34))
                  :ARG1-of (d2 / decrease-01~e.22))
            :condition~e.28 (h / hypoxia))
      :ARG2 (c4 / change-01~e.38
            :polarity~e.37 "-"~e.37
            :ARG1 (s2 / stimulate-01~e.32
                  :ARG1 (r2 / rna
                        :name (n5 / name :op1 "mRNA"~e.35)
                        :ARG0-of (e2 / encode-01
                              :ARG1 p2))
                  :extent (f / fold~e.31)))
      :ARG1-of (d4 / describe-01
            :ARG0 (f2 / figure :mod "5"~e.42)))

# ::tok Cells with activated ras demonstrated high level of expression of 72 @-@ kDa metalloproteinase ( MMP @-@ 2 , gelatinase A ) , and 92 @-@ kDa metalloproteinase ( MMP @-@ 9 , gelatinase B ) compared with cells containing SV40 large T antigen alone .
# ::alignments 0-1.1 2-1.1.1.1.2 3-1.1.1.1.1.1 4-1 5-1.2.1 6-1.2 7-1.2.2.r 8-1.2.2 9-1.2.2.1.r 10-1.2.2.1.1.1.1 12-1.2.2.1.1.1.1 13-1.2.2.1.1.1.2 15-1.2.2.1.1.2.1.1.1.1 17-1.2.2.1.1.2.1.1.1.1 19-1.2.2.1.1.2.1.2.1.1 20-1.2.2.1.1.2.1.2.1.2 23-1.2.2.1 23-1.2.2.1.1.2.1 24-1.2.2.1.2.1.1 26-1.2.2.1.2.1.1 27-1.2.2.1.2.1.2 29-1.2.2.1.2.2.1.1.1.1 31-1.2.2.1.2.2.1.1.1.1 33-1.2.2.1.2.2.1.2.1.1 34-1.2.2.1.2.2.1.2.1.2 36-1.2.1.1.r 38-1.2.1.1 39-1.1.1 39-1.2.1.1.1 40-1.2.1.1.1.1.1.1 41-1.2.1.1.1.1.1.2 42-1.2.1.1.1.1.1.3 43-1.2.1.1.1.1.1.4 44-1.2.1.1.1.1.2
# ::id bel_pmid_902_3347_41734
(d / demonstrate-01~e.4
      :ARG0 (c / cell~e.0
            :ARG0-of (c2 / contain-01~e.39
                  :ARG1 (e / enzyme
                        :name (n / name :op1 "Ras"~e.3)
                        :ARG1-of (a / activate-01~e.2))))
      :ARG1 (l / level~e.6
            :mod (h / high~e.5
                  :compared-to~e.36 (c3 / cell~e.38
                        :ARG0-of (c4 / contain-01~e.39
                              :ARG1 (p / protein
                                    :name (n8 / name
                                          :op1 "SV40"~e.40
                                          :op2 "large"~e.41
                                          :op3 "T"~e.42
                                          :op4 "antigen"~e.43)
                                    :mod (a5 / alone~e.44)))))
            :degree-of~e.7 (e2 / express-03~e.8
                  :ARG2~e.9 (a2 / and~e.23
                        :op1 (e3 / enzyme
                              :name (n2 / name :op1 "72-kDa"~e.10,12 :op2 "metalloproteinase"~e.13)
                              :ARG1-of (m / mean-01
                                    :ARG2 (a3 / and~e.23
                                          :op1 (e5 / enzyme
                                                :name (n4 / name :op1 "MMP-2"~e.15,17))
                                          :op2 (e6 / enzyme
                                                :name (n5 / name :op1 "gelatinase"~e.19 :op2 "A"~e.20)))))
                        :op2 (e4 / enzyme
                              :name (n3 / name :op1 "92-kDa"~e.24,26 :op2 "metalloproteinase"~e.27)
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (a4 / and
                                          :op1 (e7 / enzyme
                                                :name (n6 / name :op1 "MMP-9"~e.29,31))
                                          :op2 (e8 / enzyme
                                                :name (n7 / name :op1 "gelatinase"~e.33 :op2 "B"~e.34)))))))))

# ::tok Treatment of ras @-@ containing cells with wortmannin resulted in a decrease in MMP expression ( Fig . 6 ) .
# ::alignments 0-1.1 1-1.1.1.r 2-1.1.1.1.1.1.1 4-1.1.1.1 5-1.1.1 6-1.1.2.r 7-1.1.2.1.1 8-1 9-1.2.r 11-1.2 12-1.2.1.r 13-1.2.1.1.1.1 14-1.2.1 18-1.3.1.1
# ::id bel_pmid_902_3347_41736
(r / result-01~e.8
      :ARG1 (t / treat-04~e.0
            :ARG1~e.1 (c / cell~e.5
                  :ARG0-of (c2 / contain-01~e.4
                        :ARG1 (e / enzyme
                              :name (n / name :op1 "Ras"~e.2))))
            :ARG2~e.6 (s / small-molecule
                  :name (n2 / name :op1 "wortmannin"~e.7)))
      :ARG2~e.9 (d / decrease-01~e.11
            :ARG1~e.12 (e2 / express-03~e.14
                  :ARG2 (e3 / enzyme
                        :name (n3 / name :op1 "MMP"~e.13))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "6"~e.18)))

# ::tok Since wortmannin inhibits VEGF and MMP activity , but does not restore TIMP activity , tumor @-@ igenesis is not expected to be fully suppressed .
# ::alignments 0-1.3 1-1.3.1.1.1.1.1 2-1.3.1.1 3-1.3.1.1.2.1.1.1.1 4-1.3.1.1.2.1 5-1.3.1.1.2.1.2.1.1 8-1.3.1 10-1.3.1.2.1 10-1.3.1.2.1.r 11-1.3.1.2 12-1.3.1.2.3.1.1.1 15-1.2.1.1 19-1.1 19-1.1.r 20-1 21-1.3 23-1.2.2 24-1.2
# ::id bel_pmid_902_3347_41744
(e / expect-01~e.20
      :polarity~e.19 "-"~e.19
      :ARG1 (s / suppress-01~e.24
            :ARG1 (c3 / create-01
                  :ARG1 (t / tumor~e.15))
            :degree (f / full~e.23))
      :ARG1-of (c / cause-01~e.0,21
            :ARG0 (c2 / contrast-01~e.8
                  :ARG1 (i / inhibit-01~e.2
                        :ARG0 (s2 / small-molecule
                              :name (n / name :op1 "wortmannin"~e.1))
                        :ARG1 (a / act-01
                              :ARG0 (a2 / and~e.4
                                    :op1 (p / protein
                                          :name (n2 / name :op1 "VEGF"~e.3))
                                    :op2 (e2 / enzyme
                                          :name (n3 / name :op1 "MMP"~e.5)))))
                  :ARG2 (r / restore-01~e.11
                        :polarity~e.10 "-"~e.10
                        :ARG0 s2
                        :ARG1 (a3 / act-01
                              :ARG0 (p2 / protein
                                    :name (n4 / name :op1 "TIMP"~e.12)))))))

# ::tok Wortmannin could inhibit ras @-@ mediated induction of VEGF , but it did not inhibit the hypoxic regulation of VEGF .
# ::alignments 0-1.1.1.1.1.1 1-1.1 2-1.1.1 3-1.1.1.2.2.1.1.1 5-1.1.1.2.2 6-1.1.1.2 7-1.1.1.2.1.r 8-1.1.1.2.1.1.1 10-1 11-1.2.2 13-1.2.1 13-1.2.1.r 14-1.2 17-1.2.3 18-1.2.3.1.r 19-1.2.3.1
# ::id bel_pmid_902_3347_41748
(c / contrast-01~e.10
      :ARG1 (p / possible~e.1
            :domain (i / inhibit-01~e.2
                  :ARG0 (s / small-molecule
                        :name (n / name :op1 "wortmannin"~e.0))
                  :ARG1 (i2 / induce-01~e.6
                        :ARG1~e.7 (p2 / protein
                              :name (n2 / name :op1 "VEGF"~e.8))
                        :ARG1-of (m2 / mediate-01~e.5
                              :ARG0 (e / enzyme
                                    :name (n3 / name :op1 "Ras"~e.3))))))
      :ARG2 (i3 / inhibit-01~e.14
            :polarity~e.13 "-"~e.13
            :ARG0 s~e.11
            :ARG1 (r / regulate-01~e.17
                  :ARG1~e.18 p2~e.19
                  :mod (h / hypoxia))))

# ::tok This suggests that the hypoxic regulation of VEGF is independent of phosphatidylinositol @-@ 3 @-@ kinase .
# ::alignments 0-1.1 1-1 5-1.2.2 6-1.2.2.1.r 7-1.2.2.1.1.1 9-1.2 9-1.2.1 9-1.2.1.r 10-1.2.3.r 11-1.2.3.1.1 13-1.2.3.1.1 15-1.2.3.1.1
# ::id bel_pmid_902_3347_41750
(s / suggest-01~e.1
      :ARG0 (t / this~e.0)
      :ARG1 (d / depend-01~e.9
            :polarity~e.9 "-"~e.9
            :ARG0 (r / regulate-01~e.5
                  :ARG1~e.6 (p / protein
                        :name (n / name :op1 "VEGF"~e.7))
                  :mod (h / hypoxia))
            :ARG1~e.10 (e / enzyme
                  :name (n2 / name :op1 "phosphatidylinositol-3-kinase"~e.11,13,15))))

# ::tok PITSLRE kinases are a superfamily of Cdc2 @-@ like kinases that have been implicated in apoptotic signaling and tumorigenesis . In this paper we report that tumor necrosis factor ( TNF )-mediated apoptosis is associated with a CrmA @- and Bcl @-@ 2 @-@ inhibitable cleavage of PITSLRE kinases , indicating a role for CASPs .
# ::alignments 0-1.1.1.1.1 1-1.1.1 2-1.1.1.r 4-1.1 6-1.1.3.1.1.1.1.1 8-1.1.3.1.1 9-1.1.3.1 12-1.1.1.r 13-1.1.2 14-1.1.2.1.r 15-1.1.2.1.1.1 16-1.1.2.1.1 17-1.1.2.1 21-1.2.3.1 22-1.2.3 23-1.2.1 24-1.2 26-1.1.2.1.2.1 30-1.2.2.1.1.1.1.1 32-1.2.2.1 34-1.2.2 37-1.2.2.2.2.1.1.1.1 39-1.2.2.2.2.1 40-1.2.2.2.2.1.2.1.1 42-1.2.2.2.2.1.2.1.1 47-1.2.2.2.1.1.1 48-1.2.2.2.1 50-1.2.4 52-1.2.4.1
# ::id bel_pmid_911_5219_31418
(m / multi-sentence
      :snt1 (s / superfamily~e.4
            :domain~e.2,12 (k2 / kinase~e.1
                  :name (n / name :op1 "PITSLRE"~e.0))
            :ARG1-of (i / implicate-01~e.13
                  :ARG2~e.14 (a / and~e.17
                        :op1 (s2 / signal-01~e.16
                              :mod (a2 / apoptosis~e.15))
                        :op2 (c2 / create-01
                              :ARG1 (t / tumor~e.26))))
            :ARG2-of (i4 / include-91
                  :ARG1 (k / kinase~e.9
                        :ARG1-of (r / resemble-01~e.8
                              :ARG2 (e3 / enzyme
                                    :name (n2 / name :op1 "Cdc2"~e.6))))))
      :snt2 (r2 / report-01~e.24
            :ARG0 (w / we~e.23)
            :ARG1 (a3 / associate-01~e.34
                  :ARG1 (a4 / apoptosis~e.32
                        :ARG1-of (m2 / mediate-01
                              :ARG0 (p4 / protein
                                    :name (n3 / name :op1 "TNF"~e.30))))
                  :ARG2 (c / cleave-01
                        :ARG1 (k3 / kinase~e.48
                              :name (n6 / name :op1 "PITSLRE"~e.47))
                        :ARG1-of (i2 / inhibit-01
                              :ARG0 (a5 / and~e.39
                                    :op1 (p6 / protein
                                          :name (n4 / name :op1 "CrmA"~e.37))
                                    :op1 (p7 / protein
                                          :name (n5 / name :op1 "Bcl-2"~e.40,42)))
                              :mod (p5 / possible))))
            :medium (p3 / paper~e.22
                  :mod (t2 / this~e.21))
            :ARG0-of (i3 / indicate-01~e.50
                  :ARG1 (r3 / role~e.52
                        :poss (t3 / thing
                              :name (n7 / name :op1 "CASP"))))))

# ::tok Elevated levels of human TNF @-@ alpha were accompanied by increases in synovial cell expression of murine IL @-@ 1 beta and IL @-@ 6
# ::alignments 0-1.2.1 1-1.2 2-1.2.2.r 3-1.2.2.2 4-1.2.2.1.1 6-1.2.2.1.1 8-1 9-1.1.r 10-1.1 11-1.1.1.r 12-1.1.1.2.1 13-1.1.1.2 14-1.1.1 15-1.1.1.1.r 16-1.1.1.1.3 17-1.1.1.1.1.1.1 17-1.1.1.1.2.1.1 21-1.1.1.1 22-1.1.1.1.1.1.1 22-1.1.1.1.2.1.1 24-1.1.1.1.2.1.1
# ::id bel_pmid_930_0710_10502
(a / accompany-01~e.8
      :ARG0~e.9 (i / increase-01~e.10
            :ARG1~e.11 (e2 / express-03~e.14
                  :ARG2~e.15 (a2 / and~e.21
                        :op1 (p / protein
                              :name (n / name :op1 "IL-1beta"~e.17,22))
                        :op2 (p3 / protein
                              :name (n3 / name :op1 "IL-6"~e.17,22,24))
                        :mod (m / murine~e.16))
                  :ARG3 (c / cell~e.13
                        :mod (s / synovial~e.12))))
      :ARG1 (l / level~e.1
            :mod (e / elevated~e.0)
            :quant-of~e.2 (p2 / protein
                  :name (n2 / name :op1 "TNF-alpha"~e.4,6)
                  :mod (h / human~e.3))))

# ::tok e show here that oncogenic forms of Ha @-@ Ras activate NF @-@ kappaB , not through induced nuclear translocation , but rather through the activation of the transcriptional function of the NF @-@ kappaB RelA @/@ p65 subunit .
# ::alignments 1-1 2-1.3 3-1.2.r 4-1.2.1 4-1.2.1.2 4-1.2.1.2.1 4-1.2.1.2.1.r 4-1.2.1.2.r 7-1.2.1.1.1 9-1.2.1.1.1 10-1.2 11-1.2.2.1.1 17-1.2.3.2.1 18-1.2.3.2.2 19-1.2.3.2 22-1.2.3.1.2 25-1.2.3.1 29-1.2.3.1.1 30-1.2.3 30-1.2.3.1.1.1.r 32-1.2.3.1.1.1.2 35-1.2.3.1.1.1.1.1 37-1.2.3.1.1.1.1.1 38-1.2.3.1.1.1.1.2
# ::id bel_pmid_930_5854_5780
(s / show-01~e.1
      :ARG0 (w / we)
      :ARG1~e.3 (a / activate-01~e.10
            :ARG0 (p / protein~e.4
                  :name (n / name :op1 "Ha-Ras"~e.7,9)
                  :ARG0-of~e.4 (c / cause-01~e.4
                        :ARG1~e.4 (c2 / cancer~e.4)))
            :ARG1 (m / macro-molecular-complex
                  :name (n2 / name :op1 "NF-kB"~e.11))
            :manner (i / instead-of-91~e.30
                  :ARG1 (a2 / activate-01~e.25
                        :ARG1 (f2 / function-01~e.29
                              :ARG0~e.30 (p2 / protein
                                    :name (n5 / name :op1 "RelA/p65"~e.35,37 :op2 "subunit"~e.38)
                                    :part-of m~e.32)
                              :ARG1 (t2 / transcribe-01))
                        :mod (r / rather~e.22))
                  :ARG2 (t / translocate-00~e.19
                        :ARG1-of (i2 / induce-01~e.17)
                        :mod (n3 / nucleus~e.18))))
      :medium (h / here~e.2))

# ::tok 1 ) STAT proteins play an essential role in angiotensin II @-@ induced vascular smooth muscle cell proliferation , 2 ) JAK2 plays an essential role in the tyrosine phosphorylation of Raf @-@ 1 , and 3 ) convergent mitogenic signaling cascades involving the cytosolic kinases JAK2 , MEK1 , and ERK1 mediate vascular smooth muscle cell proliferation
# ::alignments 0-1.1.1 2-1.1.2.1.1 3-1.1.2 4-1.1 6-1.1.4 8-1.1.3.r 9-1.1.3.2.1.1.1 10-1.1.3.2.1.1.2 12-1.1.3.2 13-1.1.3.1.1.2 14-1.1.3.1.1.1 15-1.1.3.1.1 16-1.1.3.1 17-1.1.3 19-1.2.1 21-1.2.2.1.1 22-1.2 24-1.1.4 26-1.2.3.r 28-1.2.3.1.1.1 29-1.2.3 31-1.2.3.1.2.1.1 33-1.1.1 33-1.2.3.1.2.1.1 35-1 36-1.3.1 38-1.3.2.2 39-1.3.2.1 40-1.3.2.3 41-1.3.2 42-1.3.2.4 44-1.3.2.4.1.1 45-1.3.2.4.1 46-1.3.2.4.1.2.1.1 48-1.3.2.4.1.2.1.2.1.1 50-1.3.2.4.1.2.1 51-1.3.2.4.1.2.1.3.1.1 52-1.3 53-1.3.3 54-1.3.3 55-1.3.3 56-1.3.3 57-1.3.3
# ::id bel_pmid_930_5939_36880
(a / and~e.35
      :op1 (p2 / play-08~e.4
            :li "1"~e.0,33
            :ARG0 (p3 / protein~e.3
                  :name (n / name :op1 "STAT"~e.2))
            :ARG1~e.8 (p4 / proliferate-01~e.17
                  :ARG0 (c / cell~e.16
                        :part-of (m / muscle~e.15
                              :mod (s / smooth~e.14)
                              :mod (v / vascular~e.13)))
                  :ARG1-of (i / induce-01~e.12
                        :ARG0 (s2 / small-molecule
                              :name (n2 / name :op1 "angiotensin"~e.9 :op2 "II"~e.10))))
            :mod (e / essential~e.6,24))
      :op2 (p5 / play-08~e.22
            :li "2"~e.19
            :ARG0 (e2 / enzyme
                  :name (n3 / name :op1 "JAK2"~e.21))
            :ARG1~e.26 (p / phosphorylate-01~e.29
                  :ARG1 (a2 / amino-acid
                        :name (n4 / name :op1 "tyrosine"~e.28)
                        :part-of (e4 / enzyme
                              :name (n5 / name :op1 "Raf-1"~e.31,33))))
            :mod e)
      :op3 (m2 / mediate-01~e.52
            :li "3"~e.36
            :ARG0 (c2 / cascade~e.41
                  :mod (m3 / mitogenic~e.39)
                  :ARG0-of (c3 / converge-01~e.38)
                  :ARG0-of (s3 / signal-01~e.40)
                  :ARG2-of (i2 / involve-01~e.42
                        :ARG1 (k / kinase~e.45
                              :part-of (c4 / cytosol~e.44)
                              :ARG1-of (m4 / mean-01
                                    :ARG2 (a3 / and~e.50
                                          :op1 e2~e.46
                                          :op2 (e3 / enzyme
                                                :name (n6 / name :op1 "MEK1"~e.48))
                                          :op3 (e5 / enzyme
                                                :name (n7 / name :op1 "ERK1"~e.51)))))))
            :ARG1 p4~e.53,54,55,56,57))

# ::tok The present study demonstrates that erythropoietin ( Epo ) and IL @-@ 3 induce tyrosine phosphorylation of the SH2 @/@ SH3 @-@ containing adapter protein CrkL and its transient association with tyrosine @-@ phosphorylated SHP @-@ 2 , Shc , and Cbl in a murine IL @-@ 3 @-@ dependent cell line , 32D , expressing the Epo receptor ( EpoR ) .
# ::alignments 1-1.1.1 2-1.1 3-1 4-1.2.r 5-1.2.1.1.1.1 7-1.2.1.1.2.1.1.1 10-1.2.1.2.1.1 12-1.2.1.2.1.1 13-1.2 14-1.2.2.1.1.1.1 15-1.2.2.1 18-1.2.2.1.1.2.3.1.1.1.1 20-1.2.2.1.1.2.3.1.2.1.1 22-1.2.2.1.1.2.3 24-1.2.1.2 24-1.2.2.1.1.2 24-1.2.2.1.1.2.3.1.1 24-1.2.2.1.1.2.3.1.2 24-1.2.3.4.1 24-1.2.3.4.1.2.1 25-1.2.2.1.1.2.1.1 26-1.2.2 27-1.2.2.2.1 27-1.2.2.2.1.r 28-1.2.2.2.3 29-1.2.2.2 31-1.2.2.2.2.1.1.1 31-1.2.2.2.2.2.1.1 31-1.2.2.2.2.3.1.1 33-1.2.2.2.2.1.3 34-1.2.2.2.2.1.2.1.1 36-1.2.2.2.2.1.2.1.1 38-1.2.2.2.2.2.2.1.1 41-1.2.2.2.2.3.2.1.1 42-1.2.3.r 44-1.2.3.2 45-1.2.3.3.1 46-1.2.3.3.1 47-1.2.3.3.1 49-1.2.3.3 50-1.2.3 51-1.2.3 53-1.2.3.1.1 55-1.2.3.4 57-1.2.3.4.1.1.1 58-1.2.3.4.1.1.2 60-1.2.3.4.1.2.1.1.1
# ::id bel_pmid_934_4843_8622
(d / demonstrate-01~e.3
      :ARG0 (s / study-01~e.2
            :mod (p3 / present~e.1))
      :ARG1~e.4 (i / induce-01~e.13
            :ARG0 (a / and
                  :op1 (s2 / small-molecule
                        :name (n2 / name :op1 "erythropoietin"~e.5)
                        :ARG1-of (d2 / describe-01
                              :ARG2 (s3 / small-molecule
                                    :name (n3 / name :op1 "Epo"~e.7))))
                  :op2 (p4 / protein~e.24
                        :name (n4 / name :op1 "IL-3"~e.10,12)))
            :ARG1 (a5 / and~e.26
                  :op1 (p2 / phosphorylate-01~e.15
                        :ARG1 (a2 / amino-acid
                              :name (n / name :op1 "tyrosine"~e.14)
                              :part-of (p / protein~e.24
                                    :name (n5 / name :op1 "CrkL"~e.25)
                                    :ARG0-of (a3 / adapt-01)
                                    :ARG0-of (c / contain-01~e.22
                                          :ARG1 (a4 / and
                                                :op1 (p5 / protein-segment~e.24
                                                      :name (n6 / name :op1 "SH2"~e.18))
                                                :op2 (p6 / protein-segment~e.24
                                                      :name (n7 / name :op1 "SH3"~e.20)))))))
                  :op2 (a6 / associate-01~e.29
                        :ARG1~e.27 p~e.27
                        :ARG2 (a7 / and
                              :op1 (a8 / amino-acid
                                    :name (n14 / name :op1 "tyrosine"~e.31)
                                    :part-of (e / enzyme
                                          :name (n8 / name :op1 "SHP-2"~e.34,36))
                                    :ARG1-of (p8 / phosphorylate-01~e.33))
                              :op2 (a9 / amino-acid
                                    :name (n15 / name :op1 "tyrosine"~e.31)
                                    :part-of (e3 / enzyme
                                          :name (n9 / name :op1 "Shc"~e.38))
                                    :ARG1-of p8)
                              :op3 (a10 / amino-acid
                                    :name (n16 / name :op1 "tyrosine"~e.31)
                                    :part-of (e4 / enzyme
                                          :name (n10 / name :op1 "Cbl"~e.41))
                                    :ARG1-of p8))
                        :manner (t / transient~e.28)))
            :location~e.42 (c3 / cell-line~e.50,51
                  :name (n12 / name :op1 "32D"~e.53)
                  :mod (m / murine~e.44)
                  :ARG0-of (d3 / depend-01~e.49
                        :ARG1 p4~e.45,46,47)
                  :ARG3-of (e2 / express-03~e.55
                        :ARG2 (p7 / protein~e.24
                              :name (n11 / name :op1 "Epo"~e.57 :op2 "receptor"~e.58)
                              :ARG1-of (d4 / describe-01
                                    :ARG2 (p9 / protein~e.24
                                          :name (n13 / name :op1 "EpoR"~e.60))))))))

# ::tok The hsp90 beta gene promoter contains binding sites for the transcription factors nuclear factor IL @-@ 6 (\" NF @-@ IL6\") and signal transducer and activator of transcription 3 ( STAT @-@ 3 ) , which are activated respectively by the mitogen @-@ activated @-@ protein @-@ kinase and Jak @-@ kinase pathways following IL @-@ 6 treatment .
# ::alignments 3-1.1.2.1 5-1 6-1.2.1 7-1.2 8-1.2.1.1.r 10-1.2.1.1.1 11-1.2.1.1 11-1.2.1.1.2.1.1.1.2 12-1.2.1.1.2.1.1.1.1 13-1.2.1.1.2.1.1.1.2 14-1.2.1.1.2.1.1.1.3 16-1.2.1.1.2.1.1.1.3 18-1.2.1.1.2.1.1.2.1.1.1 22-1.2.1.1.2.1.2.1.1 23-1.2.1.1.2.1.2.1.2 24-1.2.1.1.2.1.2.1.3 25-1.2.1.1.2.1.2.1.4 26-1.2.1.1.2.1.2.1.5 27-1.2.1.1.2.1.2.1.6 28-1.2.1.1.2.1.2.1.7 30-1.2.1.1.2.1.2.2.1.1.1 32-1.2.1.1.2.1.2.2.1.1.1 37-1.2.1.1.3 37-1.2.1.1.3.1.1.1.1 38-1.2.1.1.3.2 38-1.2.1.1.3.2.r 41-1.2.1.1.3.1.1.1.1 43-1.2.1.1.3.1.1.1.1 45-1.2.1.1.3.1.1.1.1 47-1.2.1.1.3.1.1.1.1 47-1.2.1.1.3.1.2.1.1 49-1.2.1.1.3.1.2.1.1 51-1.2.1.1.3.1.1.1.1 51-1.2.1.1.3.1.2.1.1 52-1.2.1.1.3.1.1 52-1.2.1.1.3.1.2 53-1.2.1.1.3.3 54-1.2.1.1.3.3.1.1.1.1 56-1.2.1.1.3.3.1.1.1.1 57-1.2.1.1.3.3.1
# ::id bel_pmid_946_1509_18046
(c / contain-01~e.5
      :ARG0 (p8 / protein
            :name (n / name :op1 "hsp90beta")
            :ARG0-of (p / promote-01
                  :ARG1 (g / gene~e.3)))
      :ARG1 (p2 / protein-segment~e.7
            :ARG2-of (b / bind-01~e.6
                  :ARG1~e.8 (f4 / factor~e.11
                        :ARG0-of (t2 / transcribe-01~e.10)
                        :ARG1-of (m2 / mean-01
                              :ARG2 (a2 / and
                                    :op1 (p5 / protein
                                          :name (n2 / name
                                                :op1 "nuclear"~e.12
                                                :op2 "factor"~e.11,13
                                                :op3 "IL-6"~e.14,16)
                                          :ARG1-of (d / describe-01
                                                :ARG2 (p9 / protein
                                                      :name (n7 / name :op1 "NF-IL6"~e.18))))
                                    :op2 (p6 / protein
                                          :name (n3 / name
                                                :op1 "signal"~e.22
                                                :op2 "transducer"~e.23
                                                :op3 "and"~e.24
                                                :op4 "activator"~e.25
                                                :op5 "of"~e.26
                                                :op6 "transcription"~e.27
                                                :op7 "3"~e.28)
                                          :ARG1-of (d2 / describe-01
                                                :ARG2 (p10 / protein
                                                      :name (n8 / name :op1 "STAT-3"~e.30,32))))))
                        :ARG1-of (a3 / activate-01~e.37
                              :ARG0 (a4 / and
                                    :op1 (p3 / pathway~e.52
                                          :name (n4 / name :op1 "mitogen-activated-protein-kinase"~e.37,41,43,45,47,51))
                                    :op2 (p4 / pathway~e.52
                                          :name (n5 / name :op1 "Jak-kinase"~e.47,49,51)))
                              :manner~e.38 (r / respective~e.38)
                              :ARG1-of (f / follow-01~e.53
                                    :ARG2 (t / treat-04~e.57
                                          :ARG2 (p7 / protein
                                                :name (n6 / name :op1 "IL-6"~e.54,56)))))))))

# ::tok In contrast , IL @-@ 1 , which activates only the \" NF @-@ IL6\" pathway , synergizes with heat shock to produce strong activation of hsp90 .
# ::alignments 1-1 3-1.1.1.1.1 5-1.1.1.1.1 8-1.1.1 8-1.1.1.2 8-1.1.1.2.r 9-1.1.1.2.2 12-1.1.1.2.1.1.1 15-1.1.1.2.1 19-1.1.2.1 20-1.1.2 22-1.1.3 23-1.1.3.1.2 24-1.1.3.1 25-1.1.3.1.1.r 26-1.1.3.1.1.1.1
# ::id bel_pmid_946_1509_22508
(c / contrast-01~e.1
      :ARG2 (s / synergize-00
            :ARG0 (p / protein~e.8
                  :name (n / name :op1 "IL-1"~e.3,5)
                  :ARG0-of~e.8 (a / activate-01~e.8
                        :ARG1 (p2 / pathway~e.15
                              :name (n2 / name :op1 "NF-IL6"~e.12))
                        :mod (o / only~e.9)))
            :ARG1 (s2 / shock~e.20
                  :mod (h / heat~e.19))
            :purpose (p3 / produce-01~e.22
                  :ARG1 (a2 / activate-01~e.24
                        :ARG1~e.25 (p4 / protein
                              :name (n3 / name :op1 "hsp90"~e.26))
                        :mod (s3 / strong~e.23)))))

# ::tok formation of the hCAF @-@ 1/BTG1 complex is driven by phosphorylation at BTG1 ( Ser @-@ 159 ) and implicates this complex in the signalling events of cell division that lead to changes in cellular proliferation associated with cell @-@ cell contact .
# ::alignments 0-1.1.2 1-1.1.2.1.r 3-1.1.2.1.1.1.1 6-1.1.2.1 8-1.1 9-1.1.1.r 10-1.1.1 11-1.1.2.1.2.r 12-1.1.2.1.2.1.1 16-1.1.1.1.1 18-1 19-1.2 21-1.2.2 22-1.2.3.r 24-1.2.3.1 25-1.2.3 26-1.2.3.2.r 27-1.2.3.2.1 28-1.2.3.2 30-1.2.3.3 31-1.2.3.3.1.r 32-1.2.3.3.1 33-1.2.3.3.1.1.r 34-1.2.3.3.1.1.1 35-1.2.3.3.1.1 36-1.2.3.3.1.1.2 38-1.2.3.2.1 40-1.2.3.2.1 40-1.2.3.3.1.1.2.1.1 41-1.2.3.3.1.1.2.1
# ::id bel_pmid_982_0826_5420
(a2 / and~e.18
      :op1 (d / drive-02~e.8
            :ARG0~e.9 (p / phosphorylate-01~e.10
                  :ARG1 (a / amino-acid
                        :mod "159"~e.16
                        :name (n3 / name :op1 "serine")
                        :part-of (p3 / protein
                              :name (n2 / name :op1 "BTG1"~e.12))))
            :ARG1 (f / form-01~e.0
                  :ARG1~e.1 (m / macro-molecular-complex~e.6
                        :part (p2 / protein
                              :name (n / name :op1 "hCAF-1"~e.3))
                        :part~e.11 p3)))
      :op2 (i / implicate-01~e.19
            :ARG0 f
            :ARG1 m~e.21
            :ARG2~e.22 (e / event~e.25
                  :ARG0-of (s / signal-01~e.24)
                  :subevent-of~e.26 (d2 / divide-02~e.28
                        :ARG1 (c / cell~e.27,38,40))
                  :ARG0-of (l / lead-03~e.30
                        :ARG2~e.31 (c2 / change-01~e.32
                              :ARG1~e.33 (p4 / proliferate-01~e.35
                                    :ARG0 c~e.34
                                    :ARG1-of (a3 / associate-01~e.36
                                          :ARG2 (c3 / contact-01~e.41
                                                :ARG0 (c4 / cell~e.40)
                                                :ARG1 c))))))))

# ::tok in vitro the hCAF @-@ 1/BTG1 complex formation was dependent on the phosphorylation of a putative p34 cdc2 kinase site on BTG1 ( Ser @-@ 159 ) .
# ::alignments 0-1.3 1-1.3 3-1.1.1.1.1.1 6-1.1.1 7-1.1 9-1 10-1.2.r 12-1.2 13-1.2.1.r 15-1.2.1.1 18-1.2.1.3 19-1.2.1 20-1.1.1.2.r 21-1.1.1.2.1.1 25-1.2.1.4.1.1
# ::id bel_pmid_982_0826_5840
(d / depend-01~e.9
      :ARG0 (f / form-01~e.7
            :ARG1 (m / macro-molecular-complex~e.6
                  :part (p2 / protein
                        :name (n / name :op1 "hCAF-1"~e.3))
                  :part~e.20 (p3 / protein
                        :name (n2 / name :op1 "BTG1"~e.21))))
      :ARG1~e.10 (p / phosphorylate-01~e.12
            :ARG1~e.13 (p4 / protein-segment~e.19
                  :ARG1-of (t / think-01~e.15)
                  :part-of p3
                  :mod (k / kinase~e.18
                        :name (n5 / name :op1 "p34cdc2"))
                  :ARG1-of (m2 / mean-01
                        :ARG2 (a / amino-acid
                              :mod "159"~e.25
                              :name (n4 / name :op1 "serine")))))
      :manner (i / in-vitro~e.0,1))

# ::tok The human BTG1 protein is thought to be a potential tumour suppressor because its overexpression inhibits NIH 3T3 cell proliferation .
# ::alignments 1-1.1.1.2 2-1.1.1.1.1 3-1.1.1 5-1 6-1.2 9-1.1.3 10-1.1.2 12-1.2 15-1.2.1 16-1.2.1.2.1.1.1 17-1.2.1.2.1.1.2 18-1.2.1.2.1 19-1.2.1.2
# ::id bel_pmid_982_0826_8154
(t / think-01~e.5
      :ARG1 (s / suppress-01
            :ARG0 (p / protein~e.3
                  :name (n / name :op1 "BTG1"~e.2)
                  :mod (h / human~e.1))
            :ARG1 (t2 / tumour~e.10)
            :mod (p2 / potential~e.9))
      :ARG1-of (c / cause-01~e.6,12
            :ARG0 (i / inhibit-01~e.15
                  :ARG0 (o / overexpress-00
                        :ARG2 p)
                  :ARG1 (p3 / proliferate-01~e.19
                        :ARG0 (c2 / cell-line~e.18
                              :name (n2 / name :op1 "NIH"~e.16 :op2 "3T3"~e.17))))))

# ::tok Pak3 phosphorylates Raf @-@ 1 on serine 338 in vitro and in vivo . The p21 @-@ activated protein kinases are regulated by the Rho @-@ family GTPases Rac and Cdc42 .
# ::alignments 1-1.1 2-1.1.1.1.1 4-1.1.1.1.1 5-1.1.3.r 6-1.1.3.2.1 7-1.1.3.1 8-1.1.4.1 9-1.1.4.1 10-1.1.4 11-1.1.4.1 11-1.1.4.2 12-1.1.4.2 15-1.2.2.1.1.1.1 17-1.2.2.1 18-1.2.2.2 19-1.2.2 21-1.2 22-1.2.1.r 24-1.2.1.3.1.1.1.1 26-1.2.1.3.1 28-1.2.1.1.1.1 29-1.2.1 30-1.2.1.2.1.1
# ::id bel_pmid_982_3899_2738
(m / multi-sentence
      :snt1 (p / phosphorylate-01~e.1
            :ARG1 (e2 / enzyme
                  :name (n3 / name :op1 "Raf-1"~e.2,4))
            :ARG2 (e / enzyme
                  :name (n2 / name :op1 "Pak-3"))
            :location~e.5 (a / amino-acid
                  :mod "338"~e.7
                  :name (n / name :op1 "serine"~e.6)
                  :part-of e2)
            :manner (a2 / and~e.10
                  :op1 (i / in-vitro~e.8,9,11)
                  :op2 (i2 / in-vivo~e.11,12)))
      :snt2 (r / regulate-01~e.21
            :ARG0~e.22 (a4 / and~e.29
                  :op1 (e5 / enzyme
                        :name (n7 / name :op1 "Rac"~e.28))
                  :op2 (e6 / enzyme
                        :name (n8 / name :op1 "Cdc42"~e.30))
                  :ARG1-of (i3 / include-91
                        :ARG2 (f / family~e.26
                              :mod (p5 / protein
                                    :name (n4 / name :op1 "Rho"~e.24 :op2 "GTPase")))))
            :ARG1 (k / kinase~e.19
                  :ARG1-of (a3 / activate-01~e.17
                        :ARG0 (p2 / protein
                              :name (n5 / name :op1 "p21"~e.15)))
                  :mod (p3 / protein~e.18))))

# ::tok We next examined the mechanisms accounting for the increase in HER3 by MAPK pathway inhibitors in BRAF mutant thyroid cell lines .
# ::alignments 0-1.1 1-1.3 2-1 4-1.2 5-1.2.1 6-1.2.1.1.r 8-1.2.1.1 9-1.2.1.1.2.r 10-1.2.1.1.2.1.1 11-1.2.1.1.1.r 12-1.2.1.1.1.1.1.1.1 13-1.2.1.1.1.1.1.1.2 14-1.2.1.1.1 14-1.2.1.1.1.1 14-1.2.1.1.1.1.r 15-1.2.1.1.3.r 16-1.2.1.1.3.2.1.1 17-1.2.1.1.3.2 17-1.2.1.1.3.2.2 17-1.2.1.1.3.2.2.r 18-1.2.1.1.3.1 19-1.2.1.1.3 20-1.2.1.1.3
# ::id bio-bel_0001_1
(e / examine-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (m / mechanism~e.4
            :ARG0-of (a / account-01~e.5
                  :ARG1~e.6 (i / increase-01~e.8
                        :ARG0~e.11 (m3 / molecular-physical-entity~e.14
                              :ARG0-of~e.14 (i2 / inhibit-01~e.14
                                    :ARG1 (p3 / pathway
                                          :name (n3 / name :op1 "MAPK"~e.12 :op2 "pathway"~e.13))))
                        :ARG1~e.9 (p / protein
                              :name (n2 / name :op1 "HER3"~e.10))
                        :location~e.15 (c2 / cell-line~e.19,20
                              :mod (t / thyroid~e.18)
                              :part (g / gene~e.17
                                    :name (n4 / name :op1 "BRAF"~e.16)
                                    :ARG1-of~e.17 (m2 / mutate-01~e.17))))))
      :time (n / next~e.1))

# ::tok Upregulation of HER3 has been found to mediate resistance to PI3K @/@ AKT ( 26 ) or HER2 ( 27 ) inhibitors in HER2 @-@ amplified breast cancer cell lines , which is caused in part through a FoxO3A @-@ dependent induction of HER3 gene transcription .
# ::alignments 2-1.1.1.1.1.1 5-1 7-1.1 8-1.1.2 9-1.1.2.1.r 9-1.1.2.3 10-1.1.2.1.1.1.1.1.1.1 12-1.1.2.1.1.1.1.2.1.1 16-1.1.2.1 17-1.1.2.1.2.1.1.1.1 21-1.1.2.1.1 21-1.1.2.1.1.1 21-1.1.2.1.1.1.r 21-1.1.2.1.2 21-1.1.2.1.2.1 21-1.1.2.1.2.1.r 23-1.1.2.1.2.1.1.1.1 26-1.1.2.2.1.1 27-1.1.2.2.1 28-1.1.2.2 29-1.1.2.2 33-1.1.2.2.1.2 33-1.1.2.3 34-1.1.2.3.2.r 35-1.1.2.3.2 38-1.1.2.3.1.2.1.1.1 40-1.1.2.3.1.2 41-1.1.2.3.1 43-1.1.2.3.1.1.1.1.1 44-1.1.2.3.1.1.1
# ::id bio-bel_0001_2
(f / find-01~e.5
      :ARG1 (m / mediate-00~e.7
            :ARG0 (u / upregulate-00
                  :ARG1 (p / protein
                        :name (n / name :op1 "HER3"~e.2)))
            :ARG1 (r / resist-01~e.8
                  :ARG1~e.9 (o2 / or~e.16
                        :op1 (s2 / small-molecule~e.21
                              :ARG0-of~e.21 (i / inhibit-01~e.21
                                    :ARG1 (s / slash
                                          :op1 (p3 / protein
                                                :name (n2 / name :op1 "PI3K"~e.10))
                                          :op2 (p4 / protein
                                                :name (n3 / name :op1 "AKT"~e.12)))))
                        :op2 (s3 / small-molecule~e.21
                              :ARG0-of~e.21 (i3 / inhibit-01~e.21
                                    :ARG1 (p5 / protein
                                          :name (n4 / name :op1 "HER2"~e.17,23)))))
                  :location (c5 / cell-line~e.28,29
                        :part-of (c2 / cancer~e.27
                              :mod (b / breast~e.26)
                              :ARG1-of (c3 / cause-01~e.33
                                    :ARG0 (a / amplify-01
                                          :ARG1 p5))))
                  :ARG1-of (c4 / cause-01~e.9,33
                        :ARG0 (i2 / induce-01~e.41
                              :ARG1 (t / transcribe-00
                                    :ARG1 (g / gene~e.44
                                          :name (n5 / name :op1 "HER3"~e.43)))
                              :ARG0-of (d / depend-01~e.40
                                    :ARG1 (p6 / protein
                                          :name (n6 / name :op1 "FoxO3A"~e.38))))
                        :degree~e.34 (p2 / part~e.35)))))

# ::tok As shown in Fig. 5A , PLX4032 treatment increased HER3 and HER2 mRNAs in all six BRAF @-@ mutant thyroid cancer cell lines tested .
# ::alignments 1-1 4-1.1.1 6-1.2.1.1.1.1 7-1.2.1 8-1.2 9-1.2.2.1.2.1.1 10-1.2.2 11-1.2.2.2.2.1.1 12-1.2.2.1.1.1 12-1.2.2.2.1.1 16-1.2.3.1.2.1.1.1 18-1.2.3.1.2.1 18-1.2.3.1.2.1.2 18-1.2.3.1.2.1.2.r 20-1.2.3.1 21-1.2.3 22-1.2.3
# ::id bio-bel_0001_3
(s / show-01~e.1
      :ARG0 (f / figure :mod "5A"~e.4)
      :ARG1 (i / increase-01~e.8
            :ARG0 (t / treat-03~e.7
                  :ARG3 (s2 / small-molecule
                        :name (n / name :op1 "PLX4032"~e.6)))
            :ARG1 (a / and~e.10
                  :op1 (r / rna-region
                        :name (n2 / name :op1 "mRNA"~e.12)
                        :mod (p / protein
                              :name (n3 / name :op1 "HER3"~e.9)))
                  :op2 (r2 / rna-region
                        :name (n4 / name :op1 "mRNA"~e.12)
                        :mod (p2 / protein
                              :name (n5 / name :op1 "HER2"~e.11))))
            :location (c / cell-line~e.21,22
                  :part-of (c2 / cancer~e.20
                        :mod (t2 / tyroid)
                        :ARG1-of (c3 / cause-01
                              :ARG0 (g / gene~e.18
                                    :name (n6 / name :op1 "BRAF"~e.16)
                                    :ARG1-of~e.18 (m / mutate-01~e.18)))))))

# ::tok The most frequently mutated oncogenes in the deadliest cancers responsible for human mortality are KRAS , PIK3CA and BRAF .
# ::alignments 2-1.1.1 3-1.1 4-1
# ::id bio-dummy_2015_1
(o / oncogene~e.4
      :ARG1-of (m / mutate-01~e.3
            :frequency (f / frequent~e.2)))

# ::tok Ras acts as a molecular switch that is activated upon GTP loading and deactivated upon hydrolysis of GTP to GDP .
# ::alignments 4-1.1 5-1
# ::id bio-dummy_2015_2
(s / switch~e.5
      :mod (m / molecule~e.4))

# ::tok The most frequently mutated oncogenes in the deadliest cancers responsible for human mortality are KRAS , PIK3CA and BRAF .
# ::alignments 1-1.1.1.1 2-1.1.1 3-1.1 4-1 4-1.4.1 4-1.4.2 4-1.4.3 5-1.2.r 7-1.2.1 8-1.3.1.1 9-1.2 10-1.2.1.1.r 11-1.2.1.1 13-1.4.r 14-1.4.1.1.1 16-1.4.2.1.1 17-1.4 18-1.4.3.1.1
# ::id bio-trainingset_2014_1
(o / oncogene~e.4
      :ARG0-of (m / mutate-01~e.3
            :frequency (f / frequent~e.2
                  :degree (m2 / most~e.1)))
      :ARG0-of~e.5 (r / responsible-01~e.9
            :ARG1 (k / kill-01~e.7
                  :ARG1~e.10 (h / human~e.11)))
      :location (d / disease
            :name (n / name :op1 "cancer"~e.8))
      :domain~e.13 (a2 / and~e.17
            :op1 (o2 / oncogene~e.4
                  :name (n3 / name :op1 "KRAS"~e.14))
            :op2 (o3 / oncogene~e.4
                  :name (n4 / name :op1 "PIK3CA"~e.16))
            :op3 (o4 / oncogene~e.4
                  :name (n5 / name :op1 "BRAF"~e.18))))

# ::tok Previous studies have found that both the C @-@ Raf and B @-@ Raf proteins are targets of ERK @-@ dependent feedback phosphorylation .
# ::alignments 0-1.1.1 1-1.1 3-1 7-1.2.1.1.1.1 9-1.2.1.1.1.1 9-1.2.1.2.1.1 10-1.2.1 11-1.2.1.2.1.1 13-1.2.1.1.1.1 13-1.2.1.2.1.1 14-1.2.1.1 14-1.2.1.2 15-1.2.1.r 16-1.2 17-1.2.2.r 18-1.2.2.1.1.1.1 20-1.2.2.1.1 20-1.2.2.1.1.2 20-1.2.2.1.1.2.r 21-1.2.2.1 22-1.2.2
# ::id bio-trainingset_2014_10
(f / find-01~e.3
      :ARG0 (s / study~e.1
            :mod (p / previous~e.0))
      :ARG1 (t / target~e.16
            :domain~e.15 (a / and~e.10
                  :op1 (p2 / protein~e.14
                        :name (n / name :op1 "C-Raf"~e.7,9,13))
                  :op2 (p3 / protein~e.14
                        :name (n2 / name :op1 "B-Raf"~e.9,11,13)))
            :ARG1-of~e.17 (p4 / phosphorylate-01~e.22
                  :mod (f2 / feedback~e.21
                        :mod (p5 / pathway~e.20
                              :name (n3 / name :op1 "ERK"~e.18)
                              :ARG0-of~e.20 (d / depend-01~e.20))))))

# ::tok These findings are similar to what has been observed for C @-@ Raf ( 8 ) and suggest that feedback phosphorylation is a conserved mechanism used to disrupt the Ras @/@ Raf interaction .
# ::alignments 0-1.1.1.1 1-1.1.1 3-1.1 8-1.1.2 9-1.1.2.1.r 10-1.1.2.1.1.1 12-1.1.2.1.1.1 16-1 17-1.2 18-1.2.2.r 19-1.2.2.2.1 20-1.2.2.2 21-1.2.2.2.r 23-1.2.2.1 24-1.2.2 25-1.2.2.3 27-1.2.2.3.1 29-1.2.2.3.1.1.1.1.1 31-1.2.2.3.1.1.2.1.1 32-1.2.2.3.1.1
# ::id bio-trainingset_2014_11
(a / and~e.16
      :op1 (r / resemble-01~e.3
            :ARG1 (f / finding~e.1
                  :mod (t / this~e.0))
            :ARG2 (o / observe-01~e.8
                  :ARG1~e.9 (e / enzyme
                        :name (n / name :op1 "C-Raf"~e.10,12)
                        :ARG1-of (d / describe-01
                              :ARG0 (p / publication
                                    :ARG1-of (c / cite-01 :ARG2 "7"))))))
      :op2 (s / suggest-01~e.17
            :ARG0 f
            :ARG1~e.18 (m / mechanism~e.24
                  :mod (c2 / conserved~e.23)
                  :domain~e.21 (p2 / phosphorylate-01~e.20
                        :mod (f2 / feedback~e.19))
                  :ARG0-of (u / use-01~e.25
                        :ARG2 (d2 / disrupt-01~e.27
                              :ARG1 (i / interact-01~e.32
                                    :ARG1 (p3 / protein
                                          :name (n2 / name :op1 "Ras"~e.29))
                                    :ARG2 (p4 / protein
                                          :name (n3 / name :op1 "Raf"~e.31))))))))

# ::tok In the case of C @-@ Raf , six sites of feedback phosphorylation have been identified , five of which are direct targets of activated ERK ( 8 ) .
# ::alignments 4-1.1.1.1 6-1.1.1.1 8-1.2.1.1.1 9-1.2.1.1 11-1.2.1.2 12-1.2.1 15-1.2 17-1.2.1.3.1 22-1.2.1.3.3 25-1.2.1.3.3.1.1.1 27-1.2.1.3.3.1.2.1.1.1
# ::id bio-trainingset_2014_12
(e / exemplify-01
      :ARG0 (e2 / enzyme
            :name (n / name :op1 "C-Raf"~e.4,6))
      :ARG1 (i / identify-01~e.15
            :ARG1 (p / phosphorylate-01~e.12
                  :ARG1 (s / sites~e.9 :quant "6"~e.8)
                  :mod (f / feedback~e.11)
                  :ARG1-of (i2 / include-91
                        :quant "5"~e.17
                        :ARG2 s
                        :ARG0-of (t / target-01~e.22
                              :ARG0 (m / macro-molecular-complex
                                    :name (n2 / name :op1 "ERK"~e.25)
                                    :ARG1-of (d / describe-01
                                          :ARG0 (p2 / publication
                                                :ARG1-of (c / cite-01 :ARG2 "8"~e.27)))))))))

# ::tok Ras acts as a molecular switch that is activated upon GTP loading and deactivated upon hydrolysis of GTP to GDP .
# ::alignments 0-1.1.1.1 4-1.2 5-1 7-1.1.r 8-1.3 10-1.3.1.1.1.1 11-1.3.1 13-1.4 15-1.4.1 16-1.4.1.1.r 17-1.4.1.1 18-1.4.1.2.r 19-1.4.1.2.1.1
# ::id bio-trainingset_2014_2
(s3 / switch~e.5
      :domain~e.7 (e / enzyme
            :name (n / name :op1 "Ras"~e.0))
      :mod (m / molecule~e.4)
      :ARG1-of (a / activate-01~e.8
            :time (l / load-01~e.11
                  :ARG2 (s / small-molecule
                        :name (n2 / name :op1 "GTP"~e.10))))
      :ARG1-of (d / deactivate-01~e.13
            :time (h / hydrolyze-01~e.15
                  :ARG1~e.16 s~e.17
                  :ARG3~e.18 (s2 / small-molecule
                        :name (n3 / name :op1 "GDP"~e.19)))))

# ::tok We show that wild @-@ type B @-@ RAF forms a complex with C @-@ RAF in a RAS @-@ dependent manner , whereas the mutants bind independently of RAS .
# ::alignments 0-1.1 1-1 2-1.2.r 3-1.2.1.1.1.2 5-1.2.1.1.1.2 6-1.2.1.1.1.1.1 8-1.2.1.1.1.1.1 8-1.2.1.1.2.1.1 8-1.2.2.1.1.1 9-1.2.1 11-1.2.1.2 12-1.2.1.1.r 13-1.2.1.1.2.1.1 15-1.2.1.1.2.1.1 18-1.2.1.3.2.1.1 20-1.2.1.3 20-1.2.2.2 21-1.2.1.3.r 23-1.2 25-1.2.2.1 25-1.2.2.1.2 25-1.2.2.1.2.r 26-1.2.2 27-1.2.2.2.1 28-1.2.2.2.3.r 29-1.2.2.2.3
# ::id bio-trainingset_2014_3
(s / show-01~e.1
      :ARG0 (w / we~e.0)
      :ARG1~e.2 (c / contrast-01~e.23
            :ARG1 (f / form-01~e.9
                  :ARG0~e.12 (a / and
                        :op1 (e / enzyme
                              :name (n / name :op1 "B-RAF"~e.6,8)
                              :mod (w2 / wild-type~e.3,5))
                        :op2 (e3 / enzyme
                              :name (n3 / name :op1 "C-RAF"~e.8,13,15)))
                  :ARG1 (c2 / complex~e.11)
                  :manner~e.21 (d / depend-01~e.20
                        :ARG0 e
                        :ARG1 (e5 / enzyme
                              :name (n5 / name :op1 "Ras"~e.18))))
            :ARG2 (b / bind-01~e.26
                  :ARG1 (e2 / enzyme~e.25
                        :name (n2 / name :op1 "B-RAF"~e.8)
                        :ARG1-of~e.25 (m / mutate-01~e.25))
                  :manner (d2 / depend-01~e.20
                        :polarity "-"~e.27
                        :ARG0 e2
                        :ARG1~e.28 e5~e.29))))

# ::tok In addition , introduction of B @-@ Raf enhances and sustains integrin @-@ mediated activation of ERK in wild @-@ type primary fibroblasts .
# ::alignments 0-1 0-1.1 0-1.1.r 1-1 1-1.1 1-1.1.r 3-1.1.1.1 4-1.1.1.1.1.r 5-1.1.1.1.1.1.1 7-1.1.1.1.1.1.1 8-1.1.1 9-1.1 10-1.1.2 11-1.1.1.2.3.1.1.1 13-1.1.1.2.3 14-1.1.1.2 15-1.1.1.2.1.r 16-1.1.1.2.1.1.1 17-1.1.1.2.2.r 18-1.1.1.2.2.1 20-1.1.1.2.2.1 21-1.1.1.2.2.2 22-1.1.1.2.2
# ::id bio-trainingset_2014_4
(a / and~e.0,1
      :op2~e.0,1 (a2 / and~e.0,1,9
            :op1 (e / enhance-01~e.8
                  :ARG0 (i / introduce-02~e.3
                        :ARG1~e.4 (e2 / enzyme
                              :name (n / name :op1 "B-Raf"~e.5,7)))
                  :ARG1 (a4 / activate-01~e.14
                        :ARG1~e.15 (e3 / enzyme
                              :name (n2 / name :op1 "ERK"~e.16))
                        :location~e.17 (f / fibroblast~e.22
                              :mod (w / wild-type~e.18,20)
                              :mod (p / primary~e.21))
                        :ARG1-of (m / mediate-01~e.13
                              :ARG0 (p2 / protein
                                    :name (n3 / name :op1 "integrin"~e.11)))))
            :op2 (s / sustain-01~e.10
                  :ARG0 i
                  :ARG1 a4)))

# ::tok hKSR @-@ 2 selectively inhibited the Cot @-@ mediated activation of MEK by 60 % .
# ::alignments 0-1.1.1.1 2-1.1.1.1 3-1.3 3-1.3.r 4-1 6-1.2.2.1.1.1 8-1.2.2 9-1.2 10-1.2.1.r 11-1.2.1.1.1 12-1.4.r 13-1.4.1 14-1.4
# ::id bio-trainingset_2014_5
(i / inhibit-01~e.4
      :ARG0 (e / enzyme
            :name (n / name :op1 "hKSR-2"~e.0,2))
      :ARG1 (a / activate-01~e.9
            :ARG1~e.10 (e2 / enzyme
                  :name (n2 / name :op1 "MEK"~e.11))
            :ARG1-of (m / mediate-01~e.8
                  :ARG0 (e3 / enzyme
                        :name (n3 / name :op1 "Cot"~e.6))))
      :manner~e.3 (s / selective~e.3)
      :quant~e.12 (p / percentage-entity~e.14 :value "60"~e.13))

# ::tok Of the three Raf kinases , only B @-@ Raf is able to function as an allosteric activator in the context of the Raf heterodimers , a role independent of B @-@ Raf kinase activity .
# ::alignments 2-1.1.1.3.1.1 3-1.1.1.3.1.2.1 4-1.1.1 4-1.1.1.3.1 6-1.1.1.2 7-1.1.1.1.1 9-1.1.1.3.1.2.1 9-1.1.2.1.1.1 10-1.1.r 11-1 16-1.1.3 17-1.1 23-1.1.1.3.1.2.1 23-1.1.2.1.1.1 24-1.1.2 28-1.1.4 28-1.1.4.1 28-1.1.4.1.r 29-1.1.4.2.r 30-1.1.4.2.1 31-1.1.4.2.1 32-1.1.4.2.1 33-1.1.4.2.1 34-1.1.4.2
# ::id bio-trainingset_2014_6
(p2 / possible~e.11
      :domain~e.10 (a3 / activate-01~e.17
            :ARG0 (k / kinase~e.4
                  :name (n3 / name :op1 "B-Raf"~e.7)
                  :mod (o / only~e.6)
                  :ARG1-of (i / include-91
                        :ARG2 (k2 / kinase~e.4
                              :quant "3"~e.2
                              :name (n2 / name :op1 "Raf"~e.3,9,23))))
            :condition (h / heterodimer~e.24
                  :mod (e / enzyme
                        :name (n / name :op1 "Raf"~e.9,23)))
            :mod (a2 / allosteric~e.16)
            :ARG0-of (d / depend-01~e.28
                  :polarity~e.28 "-"~e.28
                  :ARG1~e.29 (a / act-02~e.34
                        :ARG0 k~e.30,31,32,33))))

# ::tok In addition to promoting C @-@ Raf activation , PP2A is also able to dephosphorylate Erk @-@ dependent sites on C @-@ Raf .
# ::alignments 0-1.1 1-1.1 3-1.1.1 4-1.1.1.2.1.1.1 6-1.1.1.2.1.1.1 7-1.1.1.2 9-1.1.1.1.1.1 10-1.1.r 12-1 14-1.1.2 15-1.1.2.1.1.1.1.1 17-1.1.2.1.1 18-1.1.2.1 19-1.1.2.1.2.r 20-1.1.2.1.2 21-1.1.2.1.2 22-1.1.2.1.2
# ::id bio-trainingset_2014_7
(p2 / possible~e.12
      :domain~e.10 (a / and~e.0,1
            :op1 (p / promote-00~e.3
                  :ARG0 (e3 / enzyme
                        :name (n3 / name :op1 "PP2A"~e.9))
                  :ARG1 (a2 / activate-01~e.7
                        :ARG1 (e2 / enzyme
                              :name (n2 / name :op1 "C-Raf"~e.4,6))))
            :op2 (d / dephosphorylate-01~e.14
                  :ARG1 (s / site~e.18
                        :ARG0-of (d2 / depend-01~e.17
                              :ARG1 (e4 / enzyme
                                    :name (n4 / name :op1 "Erk"~e.15)))
                        :location~e.19 e2~e.20,21,22)
                  :ARG2 e3)))

# ::tok Similar results were found following treatment with the MEK inhibitor AZD6244 ( not shown ) .
# ::alignments 0-1.2 1-1 3-1.1 4-1.1.1 5-1.1.1.1 6-1.1.1.1.1.r 8-1.1.1.1.1.2.1.1.1 9-1.1.1.1.1 9-1.1.1.1.1.2 9-1.1.1.1.1.2.r 10-1.1.1.1.1.1.1
# ::id bio-trainingset_2014_8
(r / result-01~e.1
      :ARG1 (f / find-01~e.3
            :ARG2 (f2 / follow-01~e.4
                  :ARG1 (t / treat-04~e.5
                        :ARG0~e.6 (m / molecular-physical-entity~e.9
                              :name (n / name :op1 "AZD6244"~e.10)
                              :ARG0-of~e.9 (i / inhibit-01~e.9
                                    :ARG1 (m2 / macro-molecular-complex
                                          :name (n2 / name :op1 "MEK"~e.8)))))))
      :mod (s / similar~e.0))

# ::tok We next examined the mechanisms accounting for the increase in HER3 by MAPK pathway inhibitors in BRAF mutant thyroid cell lines .
# ::alignments 0-1.1 1-1.3 2-1 4-1.2 5-1.2.1 6-1.2.1.1.r 8-1.2.1.1 9-1.2.1.1.2.r 10-1.2.1.1.2.1.1 11-1.2.1.1.1.r 12-1.2.1.1.1.1.1.1.1 13-1.2.1.1.1.1.1 14-1.2.1.1.1 14-1.2.1.1.1.1 14-1.2.1.1.1.1.r 15-1.2.1.1.3.r 16-1.2.1.1.3.2.1.1.1 17-1.2.1.1.3.2.1 17-1.2.1.1.3.2.1.2 17-1.2.1.1.3.2.1.2.r 18-1.2.1.1.3.1 19-1.2.1.1.3 20-1.2.1.1.3
# ::id bio-trainingset_2014_9
(e2 / examine-01~e.2
      :ARG0 (w / we~e.0)
      :ARG1 (m / mechanism~e.4
            :ARG0-of (a / account-01~e.5
                  :ARG1~e.6 (i2 / increase-01~e.8
                        :ARG0~e.11 (m3 / molecular-physical-entity~e.14
                              :ARG0-of~e.14 (i / inhibit-01~e.14
                                    :ARG1 (p / pathway~e.13
                                          :name (n2 / name :op1 "MAPK"~e.12))))
                        :ARG1~e.9 (e / enzyme
                              :name (n / name :op1 "HER3"~e.10))
                        :location~e.15 (c / cell-line~e.19,20
                              :source (t2 / thyroid~e.18)
                              :ARG2-of (i3 / include-01
                                    :ARG1 (g / gene~e.17
                                          :name (n4 / name :op1 "BRAF"~e.16)
                                          :ARG1-of~e.17 (m2 / mutate-01~e.17)))))))
      :time (n3 / next~e.1))

# ::tok protein @-@ segment of protein
# ::alignments 0-1 0-1.1 0-1.1.r 2-1 4-1 4-1.1 4-1.1.r
# ::id bio.isi_0012_1
(p / protein-segment~e.0,2,4
      :part-of~e.0,4 (p2 / protein~e.0,4))

# ::tok acid @-@ free
# ::alignments 0-1.1 2-1
# ::id bio.isi_0012_112
(f / free-41~e.2
      :ARG2 (a / acid~e.0))

# ::tok non @-@ ubiquitinated protein
# ::alignments 0-1.1.1 0-1.1.1.r 2-1.1 3-1
# ::id bio.isi_0012_113
(p / protein~e.3
      :ARG3-of (u / ubiquitinate-01~e.2 :polarity~e.0 "-"~e.0))

# ::tok His @-@ ubiquitinated protein
# ::alignments 2-1.1 3-1
# ::id bio.isi_0012_114
(p / protein~e.3
      :ARG3-of (u / ubiquitinate-01~e.2
            :mod (a / amino-acid
                  :name (n / name :op1 "histidine"))))

# ::tok mono @-@ ubiquitination
# ::alignments 0-1.1 0-1.1.r 2-1
# ::id bio.isi_0012_115
(u / ubiquitinate-01~e.2 :quant~e.0 "1"~e.0)

# ::tok di @-@ ubiquitination
# ::alignments 0-1.1 0-1.1.r 2-1
# ::id bio.isi_0012_116
(u / ubiquitinate-01~e.2 :quant~e.0 "2"~e.0)

# ::tok poly @-@ ubiquitination
# ::alignments 0-1.1.r 2-1
# ::id bio.isi_0012_117
(u / ubiquitinate-01~e.2
      :quant~e.0 (m / multiple))

# ::tok protein @-@ segment on protein
# ::alignments 0-1 0-1.1 0-1.1.r 2-1 4-1 4-1.1 4-1.1.r
# ::id bio.isi_0012_2
(p / protein-segment~e.0,2,4
      :part-of~e.0,4 (p2 / protein~e.0,4))

# ::tok ERK protein
# ::alignments 0-1.1.1
# ::id bio.isi_0012_20
(e / enzyme
      :name (n / name :op1 "ERK"~e.0))

# ::tok NF1 protein
# ::alignments 0-1.1.1 1-1
# ::id bio.isi_0012_21
(p / protein~e.1
      :name (n / name :op1 "NF1"~e.0))

# ::tok amino @-@ acid of protein
# ::alignments 0-1 2-1 3-1.1.r 4-1.1
# ::id bio.isi_0012_22
(a / amino-acid~e.0,2
      :part-of~e.3 (p / protein~e.4))

# ::tok amino @-@ acid on protein
# ::alignments 0-1 2-1 3-1.1.r 4-1.1
# ::id bio.isi_0012_23
(a / amino-acid~e.0,2
      :part-of~e.3 (p / protein~e.4))

# ::tok residue of protein
# ::alignments 0-1 1-1.1.r 2-1.1
# ::id bio.isi_0012_24
(r / residue~e.0
      :part-of~e.1 (p / protein~e.2))

# ::tok residue on protein
# ::alignments 0-1 1-1.1.r 2-1.1
# ::id bio.isi_0012_25
(r / residue~e.0
      :part-of~e.1 (p / protein~e.2))

# ::tok oncogenic protein
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 1-1
# ::id bio.isi_0012_26
(p / protein~e.1
      :ARG0-of (c / cause-01~e.0
            :ARG1~e.0 (c2 / cancer~e.0)))

# ::tok oncogenic enzyme
# ::alignments 0-1.1 0-1.1.1 0-1.1.1.r 1-1
# ::id bio.isi_0012_27
(e / enzyme~e.1
      :ARG0-of (c / cause-01~e.0
            :ARG1~e.0 (c2 / cancer~e.0)))

# ::tok wild @-@ type
# ::alignments 0-1 2-1
# ::id bio.isi_0012_28
(w / wild-type~e.0,2)

# ::tok wildtype
# ::alignments 
# ::id bio.isi_0012_29
(w / wild-type)

# ::tok WT
# ::alignments 0-1
# ::id bio.isi_0012_30
(w / wild-type~e.0)

# ::tok wild @-@ type protein
# ::alignments 0-1.1 2-1.1 3-1
# ::id bio.isi_0012_31
(p / protein~e.3
      :mod (w / wild-type~e.0,2))

# ::tok <sup> 1 </sup>@ H @-@ molecule
# ::alignments 1-1.1.1.1 5-1 5-1.1.1
# ::id bio.isi_0012_32
(m / molecule~e.5
      :part (h / hydrogen
            :mod (m2 / molecular-mass~e.5 :value "1"~e.1)))

# ::tok <sup> 15 </sup>@ N @-@ molecule
# ::alignments 1-1.1.1.1 5-1 5-1.1.1
# ::id bio.isi_0012_33
(m / molecule~e.5
      :part (n / nitrogen
            :mod (m2 / molecular-mass~e.5 :value "15"~e.1)))

# ::tok <sup> 32 </sup>@ P @-@ molecule
# ::alignments 1-1.1.1.1 5-1 5-1.1.1
# ::id bio.isi_0012_34
(m / molecule~e.5
      :part (p / phosphorus
            :mod (m2 / molecular-mass~e.5 :value "32"~e.1)))

# ::tok protein phosphorylation
# ::alignments 0-1.1 1-1
# ::id bio.isi_0012_35
(p / phosphorylate-01~e.1
      :ARG1 (p2 / protein~e.0))

# ::tok protein @-@ segment phosphorylation
# ::alignments 0-1.1 2-1.1 3-1
# ::id bio.isi_0012_36
(p / phosphorylate-01~e.3
      :ARG1 (p2 / protein-segment~e.0,2))

# ::tok residue phosphorylation
# ::alignments 0-1.1 1-1
# ::id bio.isi_0012_37
(p / phosphorylate-01~e.1
      :ARG1 (r / residue~e.0))

# ::tok amino @-@ acid phosphorylation
# ::alignments 0-1.1 2-1.1 3-1
# ::id bio.isi_0012_38
(p / phosphorylate-01~e.3
      :ARG1 (a / amino-acid~e.0,2))

# ::tok amino @-@ acid phosphorylation on protein @-@ segment
# ::alignments 0-1.1 2-1.1 3-1 4-1.1.1.r 5-1.1.1 7-1.1.1
# ::id bio.isi_0012_39
(p / phosphorylate-01~e.3
      :ARG1 (a / amino-acid~e.0,2
            :part-of~e.4 (p2 / protein-segment~e.5,7)))

# ::tok amino @-@ acid phosphorylation of protein @-@ segment
# ::alignments 0-1.1 2-1.1 3-1 4-1.1.1.r 5-1.1.1 7-1.1.1
# ::id bio.isi_0012_40
(p / phosphorylate-01~e.3
      :ARG1 (a / amino-acid~e.0,2
            :part-of~e.4 (p2 / protein-segment~e.5,7)))

# ::tok residue phosphorylation on protein @-@ segment
# ::alignments 0-1.1 1-1 2-1.1.1.r 3-1.1.1 5-1.1.1
# ::id bio_isi_0012_41
(p / phosphorylate-01~e.1
      :ARG1 (r / residue~e.0
            :part-of~e.2 (p2 / protein-segment~e.3,5)))

# ::tok ubiquitinated protein
# ::alignments 0-1.1 1-1
# ::id bio.isi_0012_62
(p / protein~e.1
      :ARG3-of (u / ubiquitinate-01~e.0))

# ::tok ubiquitinated enzyme
# ::alignments 0-1.1 1-1
# ::id bio.isi_0012_63
(e / enzyme~e.1
      :ARG3-of (u / ubiquitinate-01~e.0))

# ::tok ubiquitination site
# ::alignments 0-1.1 1-1
# ::id bio.isi_0012_64
(p / protein-segment~e.1
      :ARG1-of (u / ubiquitinate-01~e.0))

# ::tok ubiquitination of protein
# ::alignments 0-1 1-1.1.r 2-1.1
# ::id bio.isi_0012_65
(u / ubiquitinate-01~e.0
      :ARG1~e.1 (p / protein~e.2))

# ::tok ubiquitination of protein @-@ segment
# ::alignments 0-1 1-1.1.r 2-1.1 4-1.1
# ::id bio.isi_0012_66
(u / ubiquitinate-01~e.0
      :ARG1~e.1 (p / protein-segment~e.2,4))

# ::tok ubiquitination of amino @-@ acid
# ::alignments 0-1 1-1.1.r 2-1.1 4-1.1
# ::id bio.isi_0012_67
(u / ubiquitinate-01~e.0
      :ARG1~e.1 (a / amino-acid~e.2,4))

# ::tok ubiquitination of residue
# ::alignments 0-1 1-1.1.r 2-1.1
# ::id bio.isi_0012_68
(u / ubiquitinate-01~e.0
      :ARG1~e.1 (r / residue~e.2))

# ::tok mono @-@ ubiquitinated protein
# ::alignments 0-1.1.1 0-1.1.1.r 2-1.1 3-1
# ::id bio.isi_0012_69
(p / protein~e.3
      :ARG3-of (u / ubiquitinate-01~e.2 :quant~e.0 "1"~e.0))

# ::tok di @-@ ubiquitinated protein
# ::alignments 0-1.1.1 0-1.1.1.r 2-1.1 3-1
# ::id bio.isi_0012_70
(p / protein~e.3
      :ARG3-of (u / ubiquitinate-01~e.2 :quant~e.0 "2"~e.0))

# ::tok poly @-@ ubiquitinated protein
# ::alignments 0-1.1.1.r 2-1.1 3-1
# ::id bio.isi_0012_71
(p / protein~e.3
      :ARG3-of (u / ubiquitinate-01~e.2
            :quant~e.0 (m / multiple)))

# ::tok monoubiquitinated protein
# ::alignments 1-1
# ::id bio.isi_0012_72
(p / protein~e.1
      :ARG3-of (u / ubiquitinate-01 :quant "1"))

# ::tok diubiquitinated protein
# ::alignments 1-1
# ::id bio.isi_0012_73
(p / protein~e.1
      :ARG3-of (u / ubiquitinate-01 :quant "2"))

# ::tok polyubiquitinated protein
# ::alignments 1-1
# ::id bio.isi_0012_74
(p / protein~e.1
      :ARG3-of (u / ubiquitinate-01
            :quant (m / multiple)))

# ::tok monoubiquitination
# ::alignments 
# ::id bio.isi_0012_75
(u / ubiquitinate-01 :quant "1")

# ::tok monoubiquitination of protein
# ::alignments 2-1.2
# ::id bio.isi_0012_76
(u / ubiquitinate-01
      :quant "1"
      :ARG1 (p / protein~e.2))

# ::tok monoubiquitinated
# ::alignments 
# ::id bio.isi_0012_77
(u / ubiquitinate-01 :quant "1")

# ::tok monoubiquitinated protein
# ::alignments 1-1
# ::id bio.isi_0012_78
(p / protein~e.1
      :ARG3-of (u / ubiquitinate-01 :quant "1"))

# ::tok protein monoubiquitination
# ::alignments 0-1.2
# ::id bio.isi_0012_79
(u / ubiquitinate-01
      :quant "1"
      :ARG1 (p / protein~e.0))

# ::tok putative thing
# ::alignments 0-1.1 1-1
# ::id bio.isi_0012_80
(t / thing~e.1
      :ARG1-of (t2 / think-01~e.0))

# ::tok enzyme inhibition
# ::alignments 0-1.1 1-1
# ::id bio.isi_0012_81
(i / inhibit-01~e.1
      :ARG1 (e / enzyme~e.0))

# ::tok pathway inhibition
# ::alignments 0-1.1 1-1
# ::id bio.isi_0012_82
(i / inhibit-01~e.1
      :ARG1 (p / pathway~e.0))

# ::tok inhibition of enzyme
# ::alignments 0-1 1-1.1.r 2-1.1
# ::id bio.isi_0012_83
(i / inhibit-01~e.0
      :ARG1~e.1 (e / enzyme~e.2))

# ::tok inhibition of pathway
# ::alignments 0-1 1-1.1.r 2-1.1
# ::id bio.isi_0012_84
(i / inhibit-01~e.0
      :ARG1~e.1 (p / pathway~e.2))

# ::tok HBP1 is a repressor of the cyclin D1 gene and inhibits the Wnt signaling pathway . The inhibition of Wnt signaling and growth requires a common domain of HBP1 . The apparent mechanism is an inhibition of TCF @/@ LEF DNA binding through physical interaction with HBP1 .
# ::alignments 0-1.1.1.1.1.1 3-1.1.1 3-1.1.1.1.r 4-1.1.1.2.r 6-1.1.1.2.1.1.1.1 7-1.1.1.2.1.1.1.2 8-1.1.1.2 9-1.1 10-1.1.2 12-1.1.2.2.1.1 13-1.1.2.2.1.2 14-1.1.2.2.1.3 17-1.1.2 17-1.2.2.1 21-1.2 22-1.2.2.1.2 23-1.2.1 23-1.2.2 26-1.2.1.2 27-1.2.1.2.1.r 28-1.2.1.2.1 31-1.3 35-1.3.1.2 36-1.3.1.2.1.r 37-1.3.1.2.1.1.1.1 39-1.3.1.2.1.1.1.1 41-1.3.1.2.1 43-1.3.1.2.2.3 44-1.3.1.2.2 45-1.3.1.2.2.2.r 46-1.3.1.2.2.2
# ::id biomed_0001_1
(m / multi-sentence
      :snt1 (a / and~e.9
            :op1 (r / repress-01~e.3
                  :ARG0~e.3 (p / protein
                        :name (n / name :op1 "HBP1"~e.0))
                  :ARG1~e.4 (g / gene~e.8
                        :ARG0-of (e / encode-01
                              :ARG1 (p2 / protein
                                    :name (n2 / name :op1 "cyclin"~e.6 :op2 "D1"~e.7)))))
            :op2 (i / inhibit-01~e.10,17
                  :ARG0 p
                  :ARG1 (p3 / pathway
                        :name (n3 / name
                              :op1 "Wnt"~e.12
                              :op2 "signaling"~e.13
                              :op3 "pathway"~e.14))))
      :snt2 (a2 / and~e.21
            :op1 (r2 / require-01~e.23
                  :ARG0 i
                  :ARG1 (d / domain~e.26
                        :part-of~e.27 p~e.28))
            :op2 (r3 / require-01~e.23
                  :ARG0 (i4 / inhibit-01~e.17
                        :ARG0 p
                        :ARG1 (g2 / grow-01~e.22))
                  :ARG1 d))
      :snt3 (a3 / appear-02~e.31
            :ARG1 (h2 / have-manner-91
                  :ARG1 i
                  :ARG2 (i2 / inhibit-01~e.35
                        :ARG1~e.36 (b / bind-01~e.41
                              :ARG1 (p4 / protein
                                    :name (n4 / name :op1 "TCF/LEF"~e.37,39))
                              :ARG2 g)
                        :manner (i3 / interact-01~e.44
                              :ARG0 p4
                              :ARG1~e.45 p~e.46
                              :manner (p5 / physical~e.43))))))

# ::tok HBP1 represses the DNMT1 promoter through sequence @-@ specific binding ( of the type TTCATTCATTCA ) and the activity of HBP1 itself is regulated through acetylation at any of 5 sites in the protein . Mutation of any acetylation sites abrogates the HBP1 repression activity . The HBP1 @-@ mediated repression of the DNMT1 gene then decreases overall DNA methylation . On the p16 gene , HBP1 expression leads to a similar DNA hypomethylation , but HBP1 instead binds to putative HBP1 activation element ( of the type GGGTAGGG ) to give activation .
# ::alignments 0-1.1.1.1.1.1 1-1.1.1 3-1.1.1.2.1.1.1.1.1 4-1.1.1.2 4-1.4.2.2.2 6-1.1.1.3.2 6-1.1.1.3.2.2.1 6-1.4.2.2 6-1.4.2.2.1.1 8-1.1.1.3.2.1 9-1.1.1.3 13-1.1.1.3.2.2 13-1.4.2.2.1 14-1.1.1.3.2.2.1.1 16-1.1 18-1.1.2.2 20-1.1.2.2.1 23-1.1.2 25-1.1.2.1 27-1.1.2.1.2.2 29-1.1.2.1.2.1.1.1 30-1.1.2.1.2.1.1 33-1.2.2 35-1.2.1 37-1.1.2.1.2.2 38-1.1.2.1 39-1.1.2.1.2 40-1.2 42-1.2.2 43-1.2.2 44-1.1.2.2 47-1.1.2.2.1 50-1.1.1 53-1.1.1.2.1.1.1.1.1 54-1.1.1.2.1 56-1.3 56-1.4.1.2 57-1.3.2.2 58-1.3.2.1 58-1.4.1.2.1.1 59-1.3.2 59-1.4.1.2.1 63-1.4.3.1.1 64-1.4.3 66-1.4.1.1.1 67-1.4.1.1 68-1.4.1 69-1.4.1.2.2.r 71-1.4.1.2.2 72-1.4.1.2.2.1 73-1.4.1.2.2.1 75-1.4 76-1.4.2.1 78-1.4.2 79-1.4.2.2.2.2.r 80-1.4.2.2.2.2 81-1.1.1.1.1.1 82-1.4.2.3 87-1.1.1.3.2.2 88-1.4.2.2.1.1.1 92-1.4.2.3
# ::id biomed_0001_2
(m / multi-sentence
      :snt1 (a / and~e.16
            :op1 (r / repress-01~e.1,50
                  :ARG0 (p / protein
                        :name (n / name :op1 "HBP1"~e.0,81))
                  :ARG1 (p2 / promoter~e.4
                        :poss (g / gene~e.54
                              :ARG0-of (e / encode-01
                                    :ARG1 (p3 / protein
                                          :name (n2 / name :op1 "DNMT1"~e.3,53)))))
                  :manner (b / bind-01~e.9
                        :ARG1 p
                        :ARG2 (d2 / dna-sequence~e.6
                              :mod (s2 / specific~e.8)
                              :mod (t / type~e.13,87
                                    :mod (d / dna-sequence~e.6 :value "TTCATTCATTCA"~e.14)))))
            :op2 (r2 / regulate-01~e.23
                  :ARG0 (a3 / acetylate-01~e.25,38
                        :ARG1 p
                        :location (s / site~e.39
                              :ARG1-of (i / include-01
                                    :ARG2 (s3 / site~e.30
                                          :quant "5"~e.29
                                          :part-of p))
                              :mod (a4 / any~e.27,37)))
                  :ARG1 (a2 / act-02~e.18,44
                        :ARG0 p~e.20,47
                        :ARG2-of (i2 / include-01
                              :ARG1 r))))
      :snt2 (a5 / abrogate-01~e.40
            :ARG0 (m2 / mutate-01~e.35
                  :ARG1 s)
            :ARG1 r~e.33,42,43)
      :snt3 (d3 / decrease-01~e.56
            :ARG0 r
            :ARG1 (m3 / methylate-01~e.59
                  :ARG1 (d4 / DNA~e.58)
                  :mod (o / overall~e.57)))
      :snt4 (c / contrast-01~e.75
            :ARG1 (l / lead-03~e.68
                  :ARG0 (e2 / express-00~e.67
                        :ARG1 p~e.66)
                  :ARG2 (d5 / decrease-01~e.56
                        :ARG1 (m4 / methylate-01~e.59
                              :ARG1 (d6 / DNA~e.58))
                        :ARG1-of~e.69 (r3 / resemble-01~e.71
                              :ARG2 d3~e.72,73)))
            :ARG2 (b2 / bind-01~e.78
                  :ARG1 p~e.76
                  :ARG2 (d7 / dna-sequence~e.6
                        :mod (t3 / type~e.13
                              :mod (d8 / dna-sequence~e.6 :value "GGGTAGGG"~e.88))
                        :mod (p4 / promoter~e.4
                              :poss (g2 / gene~e.64
                                    :name (n3 / name :op1 "p16"~e.63))
                              :ARG1-of~e.79 (t2 / think-01~e.80)))
                  :ARG0-of (a6 / activate-01~e.82,92
                        :ARG1 g2))
            :location g2))

# ::tok One is that the HBP1 DNA binding domain was not required for repression , despite the apparent similarity in the HMG domains of LEF and HBP1 .
# ::alignments 4-1.1.2.2.1.1 5-1.1.2.3.1 6-1.1.2.3 7-1.1.2 10-1.1 11-1.1.1.r 12-1.1.1 14-1.1.3.r 16-1.1.3.3 17-1.1.3 18-1.1.3.1.r 20-1.1.3.1 21-1.1.2 21-1.1.3.2 22-1.1.3.2.2.r 23-1.1.3.2.2.1.1 25-1.1.3.1
# ::id biomed_0002_2
(r4 / result-01
      :ARG2 (r / require-01~e.10
            :ARG0~e.11 (r2 / repress-01~e.12)
            :ARG1 (d / domain~e.7,21
                  :name (n2 / name :op1 "HMG-box")
                  :part-of (p / protein
                        :name (n / name :op1 "HBP1"~e.4))
                  :ARG0-of (b / bind-01~e.6
                        :ARG1 (d2 / DNA~e.5)))
            :concession~e.14 (r3 / resemble-01~e.17
                  :ARG1~e.18 d~e.20,25
                  :ARG2 (d3 / domain~e.21
                        :name n2
                        :part-of~e.22 (p2 / protein
                              :name (n3 / name :op1 "LEF"~e.23)))
                  :ARG1-of (a / appear-02~e.16))))

